PMID,Title,Abstract,Date,Cleaned_abstract,Tokenized_abstract,Processed_abstract,Molecules,Novel_Molecules,Has_Positive_Effect,Associated_Diseases
40229415,A novel peptide RR-171 derived from human umbilical cord serum induces apoptosis and pyroptosis in pancreatic cancer cells.,"Human umbilical cord serum is full of molecules that play vital roles in foetal development. This study aimed to explore the effects of RR-171, a novel peptide derived from umbilical cord serum, on pancreatic cancer cells and to elucidate its mechanisms. The anti-pancreatic cancer properties of RR-171 were detected by a cell counting kit-8, colony formation, flow cytometry, LDH release and EdU incorporation assays. RNA sequencing and gene enrichment analysis were applied to identify the differentially expressed genes and enriched pathways. Western blotting analysis was used to detect the expression of proteins. A subcutaneous xenograft model was used to examine the effect of RR-171 on pancreatic cancer cells in vivo. The results demonstrated that RR-171 inhibited the viability, proliferation and colony formation of pancreatic cancer cells in a dose-dependent manner. Gene enrichment analysis revealed that RR-171 inhibits the Wnt signaling pathway. Moreover, RR-171 significantly induced apoptosis and pyroptosis in pancreatic cancer cells in a dose-dependent manner. Z-VAD-FMK partly reversed the proapoptotic effect of RR-171, and VX-765 partly reversed the pro-pyroptotic effect of RR-171. Finally, RR-171 inhibited the growth of pancreatic cancer cells in a subcutaneous xenograft mice model and suppressed the expression of Ki-67 and PCNA in tumors. In conclusion, RR-171 induces apoptosis and pyroptosis through multiple pathways and inhibits pancreatic cancer growth, suggesting that RR-171 might be a potential agent for the treatment of pancreatic cancer.",2025-04-14,human umbilical cord serum is full of molecules that play vital roles in foetal development this study aimed to explore the effects of rr171 a novel peptide derived from umbilical cord serum on pancreatic cancer cells and to elucidate its mechanisms the antipancreatic cancer properties of rr171 were detected by a cell counting kit8 colony formation flow cytometry ldh release and edu incorporation assays rna sequencing and gene enrichment analysis were applied to identify the differentially expressed genes and enriched pathways western blotting analysis was used to detect the expression of proteins a subcutaneous xenograft model was used to examine the effect of rr171 on pancreatic cancer cells in vivo the results demonstrated that rr171 inhibited the viability proliferation and colony formation of pancreatic cancer cells in a dosedependent manner gene enrichment analysis revealed that rr171 inhibits the wnt signaling pathway moreover rr171 significantly induced apoptosis and pyroptosis in pancreatic cancer cells in a dosedependent manner zvadfmk partly reversed the proapoptotic effect of rr171 and vx765 partly reversed the propyroptotic effect of rr171 finally rr171 inhibited the growth of pancreatic cancer cells in a subcutaneous xenograft mice model and suppressed the expression of ki67 and pcna in tumors in conclusion rr171 induces apoptosis and pyroptosis through multiple pathways and inhibits pancreatic cancer growth suggesting that rr171 might be a potential agent for the treatment of pancreatic cancer,"['human', 'umbilical', 'cord', 'serum', 'is', 'full', 'of', 'molecules', 'that', 'play', 'vital', 'roles', 'in', 'foetal', 'development', 'this', 'study', 'aimed', 'to', 'explore', 'the', 'effects', 'of', 'rr171', 'a', 'novel', 'peptide', 'derived', 'from', 'umbilical', 'cord', 'serum', 'on', 'pancreatic', 'cancer', 'cells', 'and', 'to', 'elucidate', 'its', 'mechanisms', 'the', 'antipancreatic', 'cancer', 'properties', 'of', 'rr171', 'were', 'detected', 'by', 'a', 'cell', 'counting', 'kit8', 'colony', 'formation', 'flow', 'cytometry', 'ldh', 'release', 'and', 'edu', 'incorporation', 'assays', 'rna', 'sequencing', 'and', 'gene', 'enrichment', 'analysis', 'were', 'applied', 'to', 'identify', 'the', 'differentially', 'expressed', 'genes', 'and', 'enriched', 'pathways', 'western', 'blotting', 'analysis', 'was', 'used', 'to', 'detect', 'the', 'expression', 'of', 'proteins', 'a', 'subcutaneous', 'xenograft', 'model', 'was', 'used', 'to', 'examine', 'the', 'effect', 'of', 'rr171', 'on', 'pancreatic', 'cancer', 'cells', 'in', 'vivo', 'the', 'results', 'demonstrated', 'that', 'rr171', 'inhibited', 'the', 'viability', 'proliferation', 'and', 'colony', 'formation', 'of', 'pancreatic', 'cancer', 'cells', 'in', 'a', 'dosedependent', 'manner', 'gene', 'enrichment', 'analysis', 'revealed', 'that', 'rr171', 'inhibits', 'the', 'wnt', 'signaling', 'pathway', 'moreover', 'rr171', 'significantly', 'induced', 'apoptosis', 'and', 'pyroptosis', 'in', 'pancreatic', 'cancer', 'cells', 'in', 'a', 'dosedependent', 'manner', 'zvadfmk', 'partly', 'reversed', 'the', 'proapoptotic', 'effect', 'of', 'rr171', 'and', 'vx765', 'partly', 'reversed', 'the', 'propyroptotic', 'effect', 'of', 'rr171', 'finally', 'rr171', 'inhibited', 'the', 'growth', 'of', 'pancreatic', 'cancer', 'cells', 'in', 'a', 'subcutaneous', 'xenograft', 'mice', 'model', 'and', 'suppressed', 'the', 'expression', 'of', 'ki67', 'and', 'pcna', 'in', 'tumors', 'in', 'conclusion', 'rr171', 'induces', 'apoptosis', 'and', 'pyroptosis', 'through', 'multiple', 'pathways', 'and', 'inhibits', 'pancreatic', 'cancer', 'growth', 'suggesting', 'that', 'rr171', 'might', 'be', 'a', 'potential', 'agent', 'for', 'the', 'treatment', 'of', 'pancreatic', 'cancer']","['human', 'umbilical', 'cord', 'serum', 'full', 'molecules', 'play', 'vital', 'roles', 'foetal', 'development', 'study', 'aimed', 'explore', 'effects', 'rr171', 'novel', 'peptide', 'derived', 'umbilical', 'cord', 'serum', 'pancreatic', 'cancer', 'cells', 'elucidate', 'mechanisms', 'antipancreatic', 'cancer', 'properties', 'rr171', 'detected', 'cell', 'counting', 'kit8', 'colony', 'formation', 'flow', 'cytometry', 'ldh', 'release', 'edu', 'incorporation', 'assays', 'rna', 'sequencing', 'gene', 'enrichment', 'analysis', 'applied', 'identify', 'differentially', 'expressed', 'genes', 'enriched', 'pathways', 'western', 'blotting', 'analysis', 'used', 'detect', 'expression', 'proteins', 'subcutaneous', 'xenograft', 'model', 'used', 'examine', 'effect', 'rr171', 'pancreatic', 'cancer', 'cells', 'vivo', 'results', 'demonstrated', 'rr171', 'inhibited', 'viability', 'proliferation', 'colony', 'formation', 'pancreatic', 'cancer', 'cells', 'dosedependent', 'manner', 'gene', 'enrichment', 'analysis', 'revealed', 'rr171', 'inhibits', 'wnt', 'signaling', 'pathway', 'moreover', 'rr171', 'significantly', 'induced', 'apoptosis', 'pyroptosis', 'pancreatic', 'cancer', 'cells', 'dosedependent', 'manner', 'zvadfmk', 'partly', 'reversed', 'proapoptotic', 'effect', 'rr171', 'vx765', 'partly', 'reversed', 'propyroptotic', 'effect', 'rr171', 'finally', 'rr171', 'inhibited', 'growth', 'pancreatic', 'cancer', 'cells', 'subcutaneous', 'xenograft', 'mice', 'model', 'suppressed', 'expression', 'ki67', 'pcna', 'tumors', 'conclusion', 'rr171', 'induces', 'apoptosis', 'pyroptosis', 'multiple', 'pathways', 'inhibits', 'pancreatic', 'cancer', 'growth', 'suggesting', 'rr171', 'might', 'potential', 'agent', 'treatment', 'pancreatic', 'cancer']","['wnt', 'ki67', 'pcna']","['ki67', 'pcna']",True,"['tumor', 'cancer']"
40207083,Effects of the number of ethylene glycol units on the efficacy of novel complex I inhibitor 9bw.,"4'-Iodobiphenyl nonaethylene glycol ether (9bw) is a novel small molecule, composed of a biphenyl unit and 9 ethylene glycol (EG) units. Recently, we found that 9bw induces apoptosis in cancer cells by inhibiting mitochondrial respiratory complex I (CI) and accordingly reducing cellular ATP level. In addition, 9bw shows little effect on normal cells, suggesting that 9bw is a potential antitumor agent with few adverse effects. However, the exact molecular mechanisms by which 9bw acts on CI are still elusive. To clarify the molecular structure critical for 9bw's function, we tested the function of 9bw analogues on human oral squamous cell carcinoma lines HSC4 and Ca9-22. The analogues were 4-hydroxy-4'-iodobiphenyl (HIOP), I-BP-EG3, I-BP-EG6, and I-BP-EG12 containing 0, 3, 6, and 12 EG units, respectively. Our results demonstrated that I-BP-EG6 and I-BP-EG12 inhibited CI to a similar extent as 9bw, whereas I-BP3 and HIOP showed no effect on CI activity. These observations indicate that the number of EG units is crucial for the activity of 9bw and its analogues. As high-performance liquid chromatography (HPLC) analysis demonstrated that both HIOP and I-BP-EG3 could be incorporated into mitochondria abundantly, the number of EG units probably affects CI inhibitory function of 9bw and its analogues rather than their efficacy to enter cell and mitochondria.",2025-03-20,4iodobiphenyl nonaethylene glycol ether 9bw is a novel small molecule composed of a biphenyl unit and 9 ethylene glycol eg units recently we found that 9bw induces apoptosis in cancer cells by inhibiting mitochondrial respiratory complex i ci and accordingly reducing cellular atp level in addition 9bw shows little effect on normal cells suggesting that 9bw is a potential antitumor agent with few adverse effects however the exact molecular mechanisms by which 9bw acts on ci are still elusive to clarify the molecular structure critical for 9bws function we tested the function of 9bw analogues on human oral squamous cell carcinoma lines hsc4 and ca922 the analogues were 4hydroxy4iodobiphenyl hiop ibpeg3 ibpeg6 and ibpeg12 containing 0 3 6 and 12 eg units respectively our results demonstrated that ibpeg6 and ibpeg12 inhibited ci to a similar extent as 9bw whereas ibp3 and hiop showed no effect on ci activity these observations indicate that the number of eg units is crucial for the activity of 9bw and its analogues as highperformance liquid chromatography hplc analysis demonstrated that both hiop and ibpeg3 could be incorporated into mitochondria abundantly the number of eg units probably affects ci inhibitory function of 9bw and its analogues rather than their efficacy to enter cell and mitochondria,"['4iodobiphenyl', 'nonaethylene', 'glycol', 'ether', '9bw', 'is', 'a', 'novel', 'small', 'molecule', 'composed', 'of', 'a', 'biphenyl', 'unit', 'and', '9', 'ethylene', 'glycol', 'eg', 'units', 'recently', 'we', 'found', 'that', '9bw', 'induces', 'apoptosis', 'in', 'cancer', 'cells', 'by', 'inhibiting', 'mitochondrial', 'respiratory', 'complex', 'i', 'ci', 'and', 'accordingly', 'reducing', 'cellular', 'atp', 'level', 'in', 'addition', '9bw', 'shows', 'little', 'effect', 'on', 'normal', 'cells', 'suggesting', 'that', '9bw', 'is', 'a', 'potential', 'antitumor', 'agent', 'with', 'few', 'adverse', 'effects', 'however', 'the', 'exact', 'molecular', 'mechanisms', 'by', 'which', '9bw', 'acts', 'on', 'ci', 'are', 'still', 'elusive', 'to', 'clarify', 'the', 'molecular', 'structure', 'critical', 'for', '9bws', 'function', 'we', 'tested', 'the', 'function', 'of', '9bw', 'analogues', 'on', 'human', 'oral', 'squamous', 'cell', 'carcinoma', 'lines', 'hsc4', 'and', 'ca922', 'the', 'analogues', 'were', '4hydroxy4iodobiphenyl', 'hiop', 'ibpeg3', 'ibpeg6', 'and', 'ibpeg12', 'containing', '0', '3', '6', 'and', '12', 'eg', 'units', 'respectively', 'our', 'results', 'demonstrated', 'that', 'ibpeg6', 'and', 'ibpeg12', 'inhibited', 'ci', 'to', 'a', 'similar', 'extent', 'as', '9bw', 'whereas', 'ibp3', 'and', 'hiop', 'showed', 'no', 'effect', 'on', 'ci', 'activity', 'these', 'observations', 'indicate', 'that', 'the', 'number', 'of', 'eg', 'units', 'is', 'crucial', 'for', 'the', 'activity', 'of', '9bw', 'and', 'its', 'analogues', 'as', 'highperformance', 'liquid', 'chromatography', 'hplc', 'analysis', 'demonstrated', 'that', 'both', 'hiop', 'and', 'ibpeg3', 'could', 'be', 'incorporated', 'into', 'mitochondria', 'abundantly', 'the', 'number', 'of', 'eg', 'units', 'probably', 'affects', 'ci', 'inhibitory', 'function', 'of', '9bw', 'and', 'its', 'analogues', 'rather', 'than', 'their', 'efficacy', 'to', 'enter', 'cell', 'and', 'mitochondria']","['4iodobiphenyl', 'nonaethylene', 'glycol', 'ether', '9bw', 'novel', 'small', 'molecule', 'composed', 'biphenyl', 'unit', '9', 'ethylene', 'glycol', 'eg', 'units', 'recently', 'found', '9bw', 'induces', 'apoptosis', 'cancer', 'cells', 'inhibiting', 'mitochondrial', 'respiratory', 'complex', 'ci', 'accordingly', 'reducing', 'cellular', 'atp', 'level', 'addition', '9bw', 'shows', 'little', 'effect', 'normal', 'cells', 'suggesting', '9bw', 'potential', 'antitumor', 'agent', 'adverse', 'effects', 'however', 'exact', 'molecular', 'mechanisms', '9bw', 'acts', 'ci', 'still', 'elusive', 'clarify', 'molecular', 'structure', 'critical', '9bws', 'function', 'tested', 'function', '9bw', 'analogues', 'human', 'oral', 'squamous', 'cell', 'carcinoma', 'lines', 'hsc4', 'ca922', 'analogues', '4hydroxy4iodobiphenyl', 'hiop', 'ibpeg3', 'ibpeg6', 'ibpeg12', 'containing', '0', '3', '6', '12', 'eg', 'units', 'respectively', 'results', 'demonstrated', 'ibpeg6', 'ibpeg12', 'inhibited', 'ci', 'similar', 'extent', '9bw', 'whereas', 'ibp3', 'hiop', 'showed', 'effect', 'ci', 'activity', 'observations', 'indicate', 'number', 'eg', 'units', 'crucial', 'activity', '9bw', 'analogues', 'highperformance', 'liquid', 'chromatography', 'hplc', 'analysis', 'demonstrated', 'hiop', 'ibpeg3', 'could', 'incorporated', 'mitochondria', 'abundantly', 'number', 'eg', 'units', 'probably', 'affects', 'ci', 'inhibitory', 'function', '9bw', 'analogues', 'rather', 'efficacy', 'enter', 'cell', 'mitochondria']",['hsc4'],['hsc4'],True,"['tumor', 'cancer']"
40168838,pACPs-DNN: Predicting anticancer peptides using novel peptide transformation into evolutionary and structure matrix-based images with self-attention deep learning model.,"Globally, cancer remains a major health challenge due to its high mortality rates. Traditional experimental approaches and therapies are resource-intensive and often cause significant side effects. Anticancer peptides (ACPs) have emerged as alternative therapeutic agents owing to their selectivity, safety, and potential to mitigate drug resistance. In this paper, we propose pACPs-DNN, a novel attention mechanism-based deep learning model developed for the accurate prediction of ACPs and non-ACPs. The pACPs-DNN model transforms input peptides into image representations using residue-wise energy contact matrix (RECM), substitution Matrix Representation (SMR), and Position Specific Scoring Matrix (PSSM) embeddings, followed by local binary pattern (LBP)-based decomposition to capture enhanced structural and local semantic features. These transformations generate novel feature sets, including RECM_LBP, LBP_SMR, and LBP_PSSM. Subsequently, a two-tier feature selection approach is employed to identify a high-ranking optimal feature set, which is then used to train an attention-based deep neural network. The proposed pACPs-DNN model achieves an impressive training accuracy of 96.91 % and an AUC of 0.98. To evaluate its generalization capability, the model was validated on independent datasets, demonstrating significant improvements of 5 % and 3.5 % in accuracy over existing models on the Ind-I and Ind-II datasets, respectively. The demonstrated efficacy and robustness of pACPs-DNN highlight its potential as a valuable tool for advancing drug discovery and academic research in cancer-related therapeutic development.",2025-03-28,globally cancer remains a major health challenge due to its high mortality rates traditional experimental approaches and therapies are resourceintensive and often cause significant side effects anticancer peptides acps have emerged as alternative therapeutic agents owing to their selectivity safety and potential to mitigate drug resistance in this paper we propose pacpsdnn a novel attention mechanismbased deep learning model developed for the accurate prediction of acps and nonacps the pacpsdnn model transforms input peptides into image representations using residuewise energy contact matrix recm substitution matrix representation smr and position specific scoring matrix pssm embeddings followed by local binary pattern lbpbased decomposition to capture enhanced structural and local semantic features these transformations generate novel feature sets including recm_lbp lbp_smr and lbp_pssm subsequently a twotier feature selection approach is employed to identify a highranking optimal feature set which is then used to train an attentionbased deep neural network the proposed pacpsdnn model achieves an impressive training accuracy of 9691  and an auc of 098 to evaluate its generalization capability the model was validated on independent datasets demonstrating significant improvements of 5  and 35  in accuracy over existing models on the indi and indii datasets respectively the demonstrated efficacy and robustness of pacpsdnn highlight its potential as a valuable tool for advancing drug discovery and academic research in cancerrelated therapeutic development,"['globally', 'cancer', 'remains', 'a', 'major', 'health', 'challenge', 'due', 'to', 'its', 'high', 'mortality', 'rates', 'traditional', 'experimental', 'approaches', 'and', 'therapies', 'are', 'resourceintensive', 'and', 'often', 'cause', 'significant', 'side', 'effects', 'anticancer', 'peptides', 'acps', 'have', 'emerged', 'as', 'alternative', 'therapeutic', 'agents', 'owing', 'to', 'their', 'selectivity', 'safety', 'and', 'potential', 'to', 'mitigate', 'drug', 'resistance', 'in', 'this', 'paper', 'we', 'propose', 'pacpsdnn', 'a', 'novel', 'attention', 'mechanismbased', 'deep', 'learning', 'model', 'developed', 'for', 'the', 'accurate', 'prediction', 'of', 'acps', 'and', 'nonacps', 'the', 'pacpsdnn', 'model', 'transforms', 'input', 'peptides', 'into', 'image', 'representations', 'using', 'residuewise', 'energy', 'contact', 'matrix', 'recm', 'substitution', 'matrix', 'representation', 'smr', 'and', 'position', 'specific', 'scoring', 'matrix', 'pssm', 'embeddings', 'followed', 'by', 'local', 'binary', 'pattern', 'lbpbased', 'decomposition', 'to', 'capture', 'enhanced', 'structural', 'and', 'local', 'semantic', 'features', 'these', 'transformations', 'generate', 'novel', 'feature', 'sets', 'including', 'recm_lbp', 'lbp_smr', 'and', 'lbp_pssm', 'subsequently', 'a', 'twotier', 'feature', 'selection', 'approach', 'is', 'employed', 'to', 'identify', 'a', 'highranking', 'optimal', 'feature', 'set', 'which', 'is', 'then', 'used', 'to', 'train', 'an', 'attentionbased', 'deep', 'neural', 'network', 'the', 'proposed', 'pacpsdnn', 'model', 'achieves', 'an', 'impressive', 'training', 'accuracy', 'of', '9691', 'and', 'an', 'auc', 'of', '098', 'to', 'evaluate', 'its', 'generalization', 'capability', 'the', 'model', 'was', 'validated', 'on', 'independent', 'datasets', 'demonstrating', 'significant', 'improvements', 'of', '5', 'and', '35', 'in', 'accuracy', 'over', 'existing', 'models', 'on', 'the', 'indi', 'and', 'indii', 'datasets', 'respectively', 'the', 'demonstrated', 'efficacy', 'and', 'robustness', 'of', 'pacpsdnn', 'highlight', 'its', 'potential', 'as', 'a', 'valuable', 'tool', 'for', 'advancing', 'drug', 'discovery', 'and', 'academic', 'research', 'in', 'cancerrelated', 'therapeutic', 'development']","['globally', 'cancer', 'remains', 'major', 'health', 'challenge', 'due', 'high', 'mortality', 'rates', 'traditional', 'experimental', 'approaches', 'therapies', 'resourceintensive', 'often', 'cause', 'significant', 'side', 'effects', 'anticancer', 'peptides', 'acps', 'emerged', 'alternative', 'therapeutic', 'agents', 'owing', 'selectivity', 'safety', 'potential', 'mitigate', 'drug', 'resistance', 'paper', 'propose', 'pacpsdnn', 'novel', 'attention', 'mechanismbased', 'deep', 'learning', 'model', 'developed', 'accurate', 'prediction', 'acps', 'nonacps', 'pacpsdnn', 'model', 'transforms', 'input', 'peptides', 'image', 'representations', 'using', 'residuewise', 'energy', 'contact', 'matrix', 'recm', 'substitution', 'matrix', 'representation', 'smr', 'position', 'specific', 'scoring', 'matrix', 'pssm', 'embeddings', 'followed', 'local', 'binary', 'pattern', 'lbpbased', 'decomposition', 'capture', 'enhanced', 'structural', 'local', 'semantic', 'features', 'transformations', 'generate', 'novel', 'feature', 'sets', 'including', 'recm_lbp', 'lbp_smr', 'lbp_pssm', 'subsequently', 'twotier', 'feature', 'selection', 'approach', 'employed', 'identify', 'highranking', 'optimal', 'feature', 'set', 'used', 'train', 'attentionbased', 'deep', 'neural', 'network', 'proposed', 'pacpsdnn', 'model', 'achieves', 'impressive', 'training', 'accuracy', '9691', 'auc', '098', 'evaluate', 'generalization', 'capability', 'model', 'validated', 'independent', 'datasets', 'demonstrating', 'significant', 'improvements', '5', '35', 'accuracy', 'existing', 'models', 'indi', 'indii', 'datasets', 'respectively', 'demonstrated', 'efficacy', 'robustness', 'pacpsdnn', 'highlight', 'potential', 'valuable', 'tool', 'advancing', 'drug', 'discovery', 'academic', 'research', 'cancerrelated', 'therapeutic', 'development']",['smr'],['smr'],True,['cancer']
40150858,AZP2006 (Ezeprogind<sup>®</sup>): a Promising New Drug Candidate in the Battle Against Neurodegenerative Diseases.,"Progressive Supranuclear Palsy (PSP) is a rare neurodegenerative disorder characterized by abnormal tau protein accumulation. This perspective article explores AZP2006 (INN: Ezeprogind), a novel small molecule targeting the Progranulin (PGRN) and Prosaposin (PSAP) axis to enhance lysosomal health in PSP treatment. AZP2006 stabilizes the PGRN-PSAP complex, improving lysosomal function and reducing tau pathology. Preclinical studies in tauopathy models demonstrated AZP2006's ability to decrease tau hyperphosphorylation, enhance neuronal survival, mitigate neuroinflammation and promote synaptogenesis. Clinical trials have shown AZP2006 to be well-tolerated in healthy volunteers and PSP patients. A Phase 2a study met its primary endpoints, as it provided valuable safety data and even encouraged further investigation of its efficacy in a larger clinical study. An upcoming Phase 2b/3 trial aims to assess long-term safety and efficacy in a larger PSP cohort. AZP2006's mechanism of action strongly suggests potential applications in other tauopathies, including Alzheimer's and Parkinson's diseases. By addressing lysosomal dysfunction and tau pathology, AZP2006 represents a promising disease-modifying approach for PSP and other neurodegenerative disorders.",2025-03-27,progressive supranuclear palsy psp is a rare neurodegenerative disorder characterized by abnormal tau protein accumulation this perspective article explores azp2006 inn ezeprogind a novel small molecule targeting the progranulin pgrn and prosaposin psap axis to enhance lysosomal health in psp treatment azp2006 stabilizes the pgrnpsap complex improving lysosomal function and reducing tau pathology preclinical studies in tauopathy models demonstrated azp2006s ability to decrease tau hyperphosphorylation enhance neuronal survival mitigate neuroinflammation and promote synaptogenesis clinical trials have shown azp2006 to be welltolerated in healthy volunteers and psp patients a phase 2a study met its primary endpoints as it provided valuable safety data and even encouraged further investigation of its efficacy in a larger clinical study an upcoming phase 2b3 trial aims to assess longterm safety and efficacy in a larger psp cohort azp2006s mechanism of action strongly suggests potential applications in other tauopathies including alzheimers and parkinsons diseases by addressing lysosomal dysfunction and tau pathology azp2006 represents a promising diseasemodifying approach for psp and other neurodegenerative disorders,"['progressive', 'supranuclear', 'palsy', 'psp', 'is', 'a', 'rare', 'neurodegenerative', 'disorder', 'characterized', 'by', 'abnormal', 'tau', 'protein', 'accumulation', 'this', 'perspective', 'article', 'explores', 'azp2006', 'inn', 'ezeprogind', 'a', 'novel', 'small', 'molecule', 'targeting', 'the', 'progranulin', 'pgrn', 'and', 'prosaposin', 'psap', 'axis', 'to', 'enhance', 'lysosomal', 'health', 'in', 'psp', 'treatment', 'azp2006', 'stabilizes', 'the', 'pgrnpsap', 'complex', 'improving', 'lysosomal', 'function', 'and', 'reducing', 'tau', 'pathology', 'preclinical', 'studies', 'in', 'tauopathy', 'models', 'demonstrated', 'azp2006s', 'ability', 'to', 'decrease', 'tau', 'hyperphosphorylation', 'enhance', 'neuronal', 'survival', 'mitigate', 'neuroinflammation', 'and', 'promote', 'synaptogenesis', 'clinical', 'trials', 'have', 'shown', 'azp2006', 'to', 'be', 'welltolerated', 'in', 'healthy', 'volunteers', 'and', 'psp', 'patients', 'a', 'phase', '2a', 'study', 'met', 'its', 'primary', 'endpoints', 'as', 'it', 'provided', 'valuable', 'safety', 'data', 'and', 'even', 'encouraged', 'further', 'investigation', 'of', 'its', 'efficacy', 'in', 'a', 'larger', 'clinical', 'study', 'an', 'upcoming', 'phase', '2b3', 'trial', 'aims', 'to', 'assess', 'longterm', 'safety', 'and', 'efficacy', 'in', 'a', 'larger', 'psp', 'cohort', 'azp2006s', 'mechanism', 'of', 'action', 'strongly', 'suggests', 'potential', 'applications', 'in', 'other', 'tauopathies', 'including', 'alzheimers', 'and', 'parkinsons', 'diseases', 'by', 'addressing', 'lysosomal', 'dysfunction', 'and', 'tau', 'pathology', 'azp2006', 'represents', 'a', 'promising', 'diseasemodifying', 'approach', 'for', 'psp', 'and', 'other', 'neurodegenerative', 'disorders']","['progressive', 'supranuclear', 'palsy', 'psp', 'rare', 'neurodegenerative', 'disorder', 'characterized', 'abnormal', 'tau', 'protein', 'accumulation', 'perspective', 'article', 'explores', 'azp2006', 'inn', 'ezeprogind', 'novel', 'small', 'molecule', 'targeting', 'progranulin', 'pgrn', 'prosaposin', 'psap', 'axis', 'enhance', 'lysosomal', 'health', 'psp', 'treatment', 'azp2006', 'stabilizes', 'pgrnpsap', 'complex', 'improving', 'lysosomal', 'function', 'reducing', 'tau', 'pathology', 'preclinical', 'studies', 'tauopathy', 'models', 'demonstrated', 'azp2006s', 'ability', 'decrease', 'tau', 'hyperphosphorylation', 'enhance', 'neuronal', 'survival', 'mitigate', 'neuroinflammation', 'promote', 'synaptogenesis', 'clinical', 'trials', 'shown', 'azp2006', 'welltolerated', 'healthy', 'volunteers', 'psp', 'patients', 'phase', '2a', 'study', 'met', 'primary', 'endpoints', 'provided', 'valuable', 'safety', 'data', 'even', 'encouraged', 'investigation', 'efficacy', 'larger', 'clinical', 'study', 'upcoming', 'phase', '2b3', 'trial', 'aims', 'assess', 'longterm', 'safety', 'efficacy', 'larger', 'psp', 'cohort', 'azp2006s', 'mechanism', 'action', 'strongly', 'suggests', 'potential', 'applications', 'tauopathies', 'including', 'alzheimers', 'parkinsons', 'diseases', 'addressing', 'lysosomal', 'dysfunction', 'tau', 'pathology', 'azp2006', 'represents', 'promising', 'diseasemodifying', 'approach', 'psp', 'neurodegenerative', 'disorders']","['psp', 'tau', 'progranulin', 'pgrn', 'psp', 'tau', 'tau', 'psp', 'psp', 'tau', 'psp']","['psp', 'progranulin', 'pgrn', 'psp', 'psp', 'psp', 'psp']",True,"['parkinson', 'alzheimer']"
40122070,A patent review of CXCR7 modulators (2019-present).,"Atypical chemokine receptor 3 (ACKR3) (formerly CXCR7) regulates various biological processes through its ligands and is closely associated with numerous diseases, including inflammation, cancer, cardiovascular diseases (CVDs), pain, and neurological disorders. Therefore, ACKR3 has emerged as a potential target for disease treatment.",2025-04-04,atypical chemokine receptor 3 ackr3 formerly cxcr7 regulates various biological processes through its ligands and is closely associated with numerous diseases including inflammation cancer cardiovascular diseases cvds pain and neurological disorders therefore ackr3 has emerged as a potential target for disease treatment,"['atypical', 'chemokine', 'receptor', '3', 'ackr3', 'formerly', 'cxcr7', 'regulates', 'various', 'biological', 'processes', 'through', 'its', 'ligands', 'and', 'is', 'closely', 'associated', 'with', 'numerous', 'diseases', 'including', 'inflammation', 'cancer', 'cardiovascular', 'diseases', 'cvds', 'pain', 'and', 'neurological', 'disorders', 'therefore', 'ackr3', 'has', 'emerged', 'as', 'a', 'potential', 'target', 'for', 'disease', 'treatment']","['atypical', 'chemokine', 'receptor', '3', 'ackr3', 'formerly', 'cxcr7', 'regulates', 'various', 'biological', 'processes', 'ligands', 'closely', 'associated', 'numerous', 'diseases', 'including', 'inflammation', 'cancer', 'cardiovascular', 'diseases', 'cvds', 'pain', 'neurological', 'disorders', 'therefore', 'ackr3', 'emerged', 'potential', 'target', 'disease', 'treatment']",['cxcr7'],['cxcr7'],True,['cancer']
40105966,A novel peptide targeting CCR7 inhibits tumor cell lymph node metastasis.,"Lymph nodes are the most common metastasis sites for tumor cells, which are intimately linked to patient prognosis. It has been reported that cancer cells can upregulate CC Chemokine Receptor 7 (CCR7) expression and hijack its normal functions, enabling them to migrate along the gradient of CCL19 and CCL21 toward the lymph nodes and colonies as the initial stage of distant metastasis. In tumor patients, the metastatic tumor in the lymph nodes exhibited higher expression of CCR7, as well as inhibitory immune checkpoints PD-1, LAG-3, and TIM-3 compared to the primary tumors with the analysis of TCGA and GEO databases. Also, in mouse tumor model, tumor cells with elevated CCR7 expression were more susceptible to develop popliteal lymph node metastasis. Subsequently, we successfully identified a CCR7 binding peptide TC6 by phage display biopanning, which specifically blocks the interaction of CCR7/CCL19 and CCR7/CCL21. Further, the D-amino acids were introduced to substitute the N- and C-terminus of TC6 peptide to obtain the proteolysis-resistant TC6-D3 peptide, which decreased tumor cell migration in vitro via ERK1/2 pathway and inhibited tumor growth and lymph nodes metastasis in vivo, as well as effectively restored T cells cytotoxicity in both primary tumors and lymph nodes. In conclusion, CCR7 promoted tumor cell metastasis to lymph node and inhibited the anti-tumor immune responses in lymph nodes. Specific blockade of the CCR7 pathway with TC6-D3 peptide can significantly reduce lymph node tumor burden, promoting CD8<sup>+</sup> T cell infiltration in primary tumors, meanwhile, enhancing anti-tumor immune responses in lymph nodes.",2025-03-19,lymph nodes are the most common metastasis sites for tumor cells which are intimately linked to patient prognosis it has been reported that cancer cells can upregulate cc chemokine receptor 7 ccr7 expression and hijack its normal functions enabling them to migrate along the gradient of ccl19 and ccl21 toward the lymph nodes and colonies as the initial stage of distant metastasis in tumor patients the metastatic tumor in the lymph nodes exhibited higher expression of ccr7 as well as inhibitory immune checkpoints pd1 lag3 and tim3 compared to the primary tumors with the analysis of tcga and geo databases also in mouse tumor model tumor cells with elevated ccr7 expression were more susceptible to develop popliteal lymph node metastasis subsequently we successfully identified a ccr7 binding peptide tc6 by phage display biopanning which specifically blocks the interaction of ccr7ccl19 and ccr7ccl21 further the damino acids were introduced to substitute the n and cterminus of tc6 peptide to obtain the proteolysisresistant tc6d3 peptide which decreased tumor cell migration in vitro via erk12 pathway and inhibited tumor growth and lymph nodes metastasis in vivo as well as effectively restored t cells cytotoxicity in both primary tumors and lymph nodes in conclusion ccr7 promoted tumor cell metastasis to lymph node and inhibited the antitumor immune responses in lymph nodes specific blockade of the ccr7 pathway with tc6d3 peptide can significantly reduce lymph node tumor burden promoting cd8supsup t cell infiltration in primary tumors meanwhile enhancing antitumor immune responses in lymph nodes,"['lymph', 'nodes', 'are', 'the', 'most', 'common', 'metastasis', 'sites', 'for', 'tumor', 'cells', 'which', 'are', 'intimately', 'linked', 'to', 'patient', 'prognosis', 'it', 'has', 'been', 'reported', 'that', 'cancer', 'cells', 'can', 'upregulate', 'cc', 'chemokine', 'receptor', '7', 'ccr7', 'expression', 'and', 'hijack', 'its', 'normal', 'functions', 'enabling', 'them', 'to', 'migrate', 'along', 'the', 'gradient', 'of', 'ccl19', 'and', 'ccl21', 'toward', 'the', 'lymph', 'nodes', 'and', 'colonies', 'as', 'the', 'initial', 'stage', 'of', 'distant', 'metastasis', 'in', 'tumor', 'patients', 'the', 'metastatic', 'tumor', 'in', 'the', 'lymph', 'nodes', 'exhibited', 'higher', 'expression', 'of', 'ccr7', 'as', 'well', 'as', 'inhibitory', 'immune', 'checkpoints', 'pd1', 'lag3', 'and', 'tim3', 'compared', 'to', 'the', 'primary', 'tumors', 'with', 'the', 'analysis', 'of', 'tcga', 'and', 'geo', 'databases', 'also', 'in', 'mouse', 'tumor', 'model', 'tumor', 'cells', 'with', 'elevated', 'ccr7', 'expression', 'were', 'more', 'susceptible', 'to', 'develop', 'popliteal', 'lymph', 'node', 'metastasis', 'subsequently', 'we', 'successfully', 'identified', 'a', 'ccr7', 'binding', 'peptide', 'tc6', 'by', 'phage', 'display', 'biopanning', 'which', 'specifically', 'blocks', 'the', 'interaction', 'of', 'ccr7ccl19', 'and', 'ccr7ccl21', 'further', 'the', 'damino', 'acids', 'were', 'introduced', 'to', 'substitute', 'the', 'n', 'and', 'cterminus', 'of', 'tc6', 'peptide', 'to', 'obtain', 'the', 'proteolysisresistant', 'tc6d3', 'peptide', 'which', 'decreased', 'tumor', 'cell', 'migration', 'in', 'vitro', 'via', 'erk12', 'pathway', 'and', 'inhibited', 'tumor', 'growth', 'and', 'lymph', 'nodes', 'metastasis', 'in', 'vivo', 'as', 'well', 'as', 'effectively', 'restored', 't', 'cells', 'cytotoxicity', 'in', 'both', 'primary', 'tumors', 'and', 'lymph', 'nodes', 'in', 'conclusion', 'ccr7', 'promoted', 'tumor', 'cell', 'metastasis', 'to', 'lymph', 'node', 'and', 'inhibited', 'the', 'antitumor', 'immune', 'responses', 'in', 'lymph', 'nodes', 'specific', 'blockade', 'of', 'the', 'ccr7', 'pathway', 'with', 'tc6d3', 'peptide', 'can', 'significantly', 'reduce', 'lymph', 'node', 'tumor', 'burden', 'promoting', 'cd8supsup', 't', 'cell', 'infiltration', 'in', 'primary', 'tumors', 'meanwhile', 'enhancing', 'antitumor', 'immune', 'responses', 'in', 'lymph', 'nodes']","['lymph', 'nodes', 'common', 'metastasis', 'sites', 'tumor', 'cells', 'intimately', 'linked', 'patient', 'prognosis', 'reported', 'cancer', 'cells', 'upregulate', 'cc', 'chemokine', 'receptor', '7', 'ccr7', 'expression', 'hijack', 'normal', 'functions', 'enabling', 'migrate', 'along', 'gradient', 'ccl19', 'ccl21', 'toward', 'lymph', 'nodes', 'colonies', 'initial', 'stage', 'distant', 'metastasis', 'tumor', 'patients', 'metastatic', 'tumor', 'lymph', 'nodes', 'exhibited', 'higher', 'expression', 'ccr7', 'well', 'inhibitory', 'immune', 'checkpoints', 'pd1', 'lag3', 'tim3', 'compared', 'primary', 'tumors', 'analysis', 'tcga', 'geo', 'databases', 'also', 'mouse', 'tumor', 'model', 'tumor', 'cells', 'elevated', 'ccr7', 'expression', 'susceptible', 'develop', 'popliteal', 'lymph', 'node', 'metastasis', 'subsequently', 'successfully', 'identified', 'ccr7', 'binding', 'peptide', 'tc6', 'phage', 'display', 'biopanning', 'specifically', 'blocks', 'interaction', 'ccr7ccl19', 'ccr7ccl21', 'damino', 'acids', 'introduced', 'substitute', 'n', 'cterminus', 'tc6', 'peptide', 'obtain', 'proteolysisresistant', 'tc6d3', 'peptide', 'decreased', 'tumor', 'cell', 'migration', 'vitro', 'via', 'erk12', 'pathway', 'inhibited', 'tumor', 'growth', 'lymph', 'nodes', 'metastasis', 'vivo', 'well', 'effectively', 'restored', 'cells', 'cytotoxicity', 'primary', 'tumors', 'lymph', 'nodes', 'conclusion', 'ccr7', 'promoted', 'tumor', 'cell', 'metastasis', 'lymph', 'node', 'inhibited', 'antitumor', 'immune', 'responses', 'lymph', 'nodes', 'specific', 'blockade', 'ccr7', 'pathway', 'tc6d3', 'peptide', 'significantly', 'reduce', 'lymph', 'node', 'tumor', 'burden', 'promoting', 'cd8supsup', 'cell', 'infiltration', 'primary', 'tumors', 'meanwhile', 'enhancing', 'antitumor', 'immune', 'responses', 'lymph', 'nodes']","['ccr7', 'ccl19', 'ccr7', 'geo', 'ccr7', 'ccr7', 'ccr7', 'ccr7']","['ccr7', 'ccl19', 'ccr7', 'geo', 'ccr7', 'ccr7', 'ccr7', 'ccr7']",True,"['tumor', 'cancer']"
40096611,Embryonic reprogramming of the tumor vasculature reveals targets for cancer therapy.,"A sustained blood supply is critical for tumor growth, as it delivers the nutrients and oxygen required for development. Targeting of blood vessel formation via immunotherapies is an area of great importance. Knowing that certain embryonic genes, such as carcinoembryonic antigens (CEA) and oncofetal fibronectin, become reexpressed in malignant transformation, we hypothesized that a similar phenomenon holds true for tumor endothelial cells (TECs) as well. An approach for identification of highly selective tumor endothelial markers was conducted to develop targeted antiangiogenic immunotherapies. We first queried the transcriptome that is present during embryo development. We then performed a systematic search for genes selectively expressed in the mouse embryo at days E11 and E18, as compared to the transcriptome of the adult mouse. Subsequently, we queried for expression of these embryonic genes in sorted murine TECs. This approach identified among others the tumor endothelial antigens fibrillin-2 (Fbn2), elastin microfibril interface-located protein 2 (Emilin2) as well as the tumor endothelial antigens lysyl oxidase (Lox) and serine/cysteine protease inhibitor, clade E, member 1 (Serpine1; Pai-1). For these selected genes, functional involvement in angiogenesis was confirmed in in vitro bioassays. We subsequently used iBoost conjugate vaccine technology to develop vaccines against the selected targets. For all four targets, vaccination readily induced target-specific antibody responses in mice, resulting in inhibition of tumor growth. Access to highly specific tumor endothelial markers provides opportunities for direct targeting of the tumor vasculature with high specificity, without affecting healthy vasculature.",2025-03-17,a sustained blood supply is critical for tumor growth as it delivers the nutrients and oxygen required for development targeting of blood vessel formation via immunotherapies is an area of great importance knowing that certain embryonic genes such as carcinoembryonic antigens cea and oncofetal fibronectin become reexpressed in malignant transformation we hypothesized that a similar phenomenon holds true for tumor endothelial cells tecs as well an approach for identification of highly selective tumor endothelial markers was conducted to develop targeted antiangiogenic immunotherapies we first queried the transcriptome that is present during embryo development we then performed a systematic search for genes selectively expressed in the mouse embryo at days e11 and e18 as compared to the transcriptome of the adult mouse subsequently we queried for expression of these embryonic genes in sorted murine tecs this approach identified among others the tumor endothelial antigens fibrillin2 fbn2 elastin microfibril interfacelocated protein 2 emilin2 as well as the tumor endothelial antigens lysyl oxidase lox and serinecysteine protease inhibitor clade e member 1 serpine1 pai1 for these selected genes functional involvement in angiogenesis was confirmed in in vitro bioassays we subsequently used iboost conjugate vaccine technology to develop vaccines against the selected targets for all four targets vaccination readily induced targetspecific antibody responses in mice resulting in inhibition of tumor growth access to highly specific tumor endothelial markers provides opportunities for direct targeting of the tumor vasculature with high specificity without affecting healthy vasculature,"['a', 'sustained', 'blood', 'supply', 'is', 'critical', 'for', 'tumor', 'growth', 'as', 'it', 'delivers', 'the', 'nutrients', 'and', 'oxygen', 'required', 'for', 'development', 'targeting', 'of', 'blood', 'vessel', 'formation', 'via', 'immunotherapies', 'is', 'an', 'area', 'of', 'great', 'importance', 'knowing', 'that', 'certain', 'embryonic', 'genes', 'such', 'as', 'carcinoembryonic', 'antigens', 'cea', 'and', 'oncofetal', 'fibronectin', 'become', 'reexpressed', 'in', 'malignant', 'transformation', 'we', 'hypothesized', 'that', 'a', 'similar', 'phenomenon', 'holds', 'true', 'for', 'tumor', 'endothelial', 'cells', 'tecs', 'as', 'well', 'an', 'approach', 'for', 'identification', 'of', 'highly', 'selective', 'tumor', 'endothelial', 'markers', 'was', 'conducted', 'to', 'develop', 'targeted', 'antiangiogenic', 'immunotherapies', 'we', 'first', 'queried', 'the', 'transcriptome', 'that', 'is', 'present', 'during', 'embryo', 'development', 'we', 'then', 'performed', 'a', 'systematic', 'search', 'for', 'genes', 'selectively', 'expressed', 'in', 'the', 'mouse', 'embryo', 'at', 'days', 'e11', 'and', 'e18', 'as', 'compared', 'to', 'the', 'transcriptome', 'of', 'the', 'adult', 'mouse', 'subsequently', 'we', 'queried', 'for', 'expression', 'of', 'these', 'embryonic', 'genes', 'in', 'sorted', 'murine', 'tecs', 'this', 'approach', 'identified', 'among', 'others', 'the', 'tumor', 'endothelial', 'antigens', 'fibrillin2', 'fbn2', 'elastin', 'microfibril', 'interfacelocated', 'protein', '2', 'emilin2', 'as', 'well', 'as', 'the', 'tumor', 'endothelial', 'antigens', 'lysyl', 'oxidase', 'lox', 'and', 'serinecysteine', 'protease', 'inhibitor', 'clade', 'e', 'member', '1', 'serpine1', 'pai1', 'for', 'these', 'selected', 'genes', 'functional', 'involvement', 'in', 'angiogenesis', 'was', 'confirmed', 'in', 'in', 'vitro', 'bioassays', 'we', 'subsequently', 'used', 'iboost', 'conjugate', 'vaccine', 'technology', 'to', 'develop', 'vaccines', 'against', 'the', 'selected', 'targets', 'for', 'all', 'four', 'targets', 'vaccination', 'readily', 'induced', 'targetspecific', 'antibody', 'responses', 'in', 'mice', 'resulting', 'in', 'inhibition', 'of', 'tumor', 'growth', 'access', 'to', 'highly', 'specific', 'tumor', 'endothelial', 'markers', 'provides', 'opportunities', 'for', 'direct', 'targeting', 'of', 'the', 'tumor', 'vasculature', 'with', 'high', 'specificity', 'without', 'affecting', 'healthy', 'vasculature']","['sustained', 'blood', 'supply', 'critical', 'tumor', 'growth', 'delivers', 'nutrients', 'oxygen', 'required', 'development', 'targeting', 'blood', 'vessel', 'formation', 'via', 'immunotherapies', 'area', 'great', 'importance', 'knowing', 'certain', 'embryonic', 'genes', 'carcinoembryonic', 'antigens', 'cea', 'oncofetal', 'fibronectin', 'become', 'reexpressed', 'malignant', 'transformation', 'hypothesized', 'similar', 'phenomenon', 'holds', 'true', 'tumor', 'endothelial', 'cells', 'tecs', 'well', 'approach', 'identification', 'highly', 'selective', 'tumor', 'endothelial', 'markers', 'conducted', 'develop', 'targeted', 'antiangiogenic', 'immunotherapies', 'first', 'queried', 'transcriptome', 'present', 'embryo', 'development', 'performed', 'systematic', 'search', 'genes', 'selectively', 'expressed', 'mouse', 'embryo', 'days', 'e11', 'e18', 'compared', 'transcriptome', 'adult', 'mouse', 'subsequently', 'queried', 'expression', 'embryonic', 'genes', 'sorted', 'murine', 'tecs', 'approach', 'identified', 'among', 'others', 'tumor', 'endothelial', 'antigens', 'fibrillin2', 'fbn2', 'elastin', 'microfibril', 'interfacelocated', 'protein', '2', 'emilin2', 'well', 'tumor', 'endothelial', 'antigens', 'lysyl', 'oxidase', 'lox', 'serinecysteine', 'protease', 'inhibitor', 'clade', 'e', 'member', '1', 'serpine1', 'pai1', 'selected', 'genes', 'functional', 'involvement', 'angiogenesis', 'confirmed', 'vitro', 'bioassays', 'subsequently', 'used', 'iboost', 'conjugate', 'vaccine', 'technology', 'develop', 'vaccines', 'selected', 'targets', 'four', 'targets', 'vaccination', 'readily', 'induced', 'targetspecific', 'antibody', 'responses', 'mice', 'resulting', 'inhibition', 'tumor', 'growth', 'access', 'highly', 'specific', 'tumor', 'endothelial', 'markers', 'provides', 'opportunities', 'direct', 'targeting', 'tumor', 'vasculature', 'high', 'specificity', 'without', 'affecting', 'healthy', 'vasculature']","['carcinoembryonic', 'fibronectin', 'e18', 'fibrillin2', 'elastin', 'oxidase', 'serpine1']","['fibrillin2', 'serpine1']",True,['tumor']
40088962,Dual targeting of the mitochondrial Lon peptidase 1 and the chymotrypsin-like proteasome activity as a potential therapeutic strategy in malignant astrocytoma models.,"Malignant astrocytomas are aggressive primary brain tumors characterized by extensive hypoxia-induced, mitochondria-dependent changes such as altered respiration, increased chymotrypsin-like (CT-L) proteasome activity, decreased apoptosis, drug resistance, stemness, and increased invasiveness. Mitochondrial Lon Peptidase 1 (LonP1) overexpression and increased CT-L proteasome activity are biomarkers of an aggressive high-grade phenotype and found to be associated with recurrence and poor patient survival. In preclinical models, small molecule agents targeting either LonP1 or the proteasome CT-L activity have anti-astrocytoma activity. Here, we present evidence that the dual inhibition of LonP1 and CT-L proteasome activity effectively induces ROS production, leading to apoptosis in malignant astrocytoma established cell lines and patient-derived glioma stem cell-like cultures. We also evaluated a novel small molecule, BT317, derived from the coumarinic compound 4 (CC4) using structure-activity modeling, which we found to inhibit both LonP1 and CT-L proteasome activity. Using gain- and loss-of-function genetic models, we discovered that LonP1 is both necessary and sufficient to drive BT317 drug sensitivity in established and patient-derived glioma stem-like cells by generating ROS and inducing apoptosis. In vitro, BT317 had activity as a single agent but, more importantly, enhanced synergy with the standard of care commonly used chemotherapeutic temozolomide (TMZ). In an orthotopic xenograft astrocytoma model, BT317 crossed the blood-brain barrier, showed selective activity at the tumor site, and demonstrated therapeutic efficacy as a single agent and combined with TMZ. BT317 defines an emerging class of LonP1 and CT-L inhibitors that exhibited promising anti-tumor activity and could be a potential candidate for malignant astrocytoma therapeutics. SIMPLE SUMMARY: Malignant astrocytoma patients have poor clinical outcomes, and novel treatments are needed to limit tumor recurrence and improve their overall survival. These tumors have a malignant phenotype mediated by altered mitochondrial metabolism, abnormal protein processing, and adaptation to hypoxia. We have previously published that astrocytomas are especially vulnerable to proteasome inhibitors as well as to inhibitors of the mitochondrial Lon Peptidase 1 (LonP1), but the effect of combining the two strategies has not been reported. Here, we present evidence that the dual inhibition of LonP1 and Chymotrypsin-like (CT-L) proteasome activity effectively induces cellular reactive oxygen species (ROS) production, leading to apoptosis in malignant astrocytoma established cell lines and patient-derived glioma stem cell-like cultures. We developed BT317, a small molecule dual inhibitor, which crosses the blood-brain barrier and shows strong synergy with the standard of care, temozolomide (TMZ), in the astrocytoma cell lines independent of their isocitrate dehydrogenase (IDH) profile and in an orthotopic glioma murine model. This preclinical study demonstrated the potential of dual LonP1 and CT-L proteasome inhibition as a novel therapeutic strategy for malignant astrocytoma and provides insight for future clinical translational studies alone or in combination with other chemotherapies.",2025-03-13,malignant astrocytomas are aggressive primary brain tumors characterized by extensive hypoxiainduced mitochondriadependent changes such as altered respiration increased chymotrypsinlike ctl proteasome activity decreased apoptosis drug resistance stemness and increased invasiveness mitochondrial lon peptidase 1 lonp1 overexpression and increased ctl proteasome activity are biomarkers of an aggressive highgrade phenotype and found to be associated with recurrence and poor patient survival in preclinical models small molecule agents targeting either lonp1 or the proteasome ctl activity have antiastrocytoma activity here we present evidence that the dual inhibition of lonp1 and ctl proteasome activity effectively induces ros production leading to apoptosis in malignant astrocytoma established cell lines and patientderived glioma stem celllike cultures we also evaluated a novel small molecule bt317 derived from the coumarinic compound 4 cc4 using structureactivity modeling which we found to inhibit both lonp1 and ctl proteasome activity using gain and lossoffunction genetic models we discovered that lonp1 is both necessary and sufficient to drive bt317 drug sensitivity in established and patientderived glioma stemlike cells by generating ros and inducing apoptosis in vitro bt317 had activity as a single agent but more importantly enhanced synergy with the standard of care commonly used chemotherapeutic temozolomide tmz in an orthotopic xenograft astrocytoma model bt317 crossed the bloodbrain barrier showed selective activity at the tumor site and demonstrated therapeutic efficacy as a single agent and combined with tmz bt317 defines an emerging class of lonp1 and ctl inhibitors that exhibited promising antitumor activity and could be a potential candidate for malignant astrocytoma therapeutics simple summary malignant astrocytoma patients have poor clinical outcomes and novel treatments are needed to limit tumor recurrence and improve their overall survival these tumors have a malignant phenotype mediated by altered mitochondrial metabolism abnormal protein processing and adaptation to hypoxia we have previously published that astrocytomas are especially vulnerable to proteasome inhibitors as well as to inhibitors of the mitochondrial lon peptidase 1 lonp1 but the effect of combining the two strategies has not been reported here we present evidence that the dual inhibition of lonp1 and chymotrypsinlike ctl proteasome activity effectively induces cellular reactive oxygen species ros production leading to apoptosis in malignant astrocytoma established cell lines and patientderived glioma stem celllike cultures we developed bt317 a small molecule dual inhibitor which crosses the bloodbrain barrier and shows strong synergy with the standard of care temozolomide tmz in the astrocytoma cell lines independent of their isocitrate dehydrogenase idh profile and in an orthotopic glioma murine model this preclinical study demonstrated the potential of dual lonp1 and ctl proteasome inhibition as a novel therapeutic strategy for malignant astrocytoma and provides insight for future clinical translational studies alone or in combination with other chemotherapies,"['malignant', 'astrocytomas', 'are', 'aggressive', 'primary', 'brain', 'tumors', 'characterized', 'by', 'extensive', 'hypoxiainduced', 'mitochondriadependent', 'changes', 'such', 'as', 'altered', 'respiration', 'increased', 'chymotrypsinlike', 'ctl', 'proteasome', 'activity', 'decreased', 'apoptosis', 'drug', 'resistance', 'stemness', 'and', 'increased', 'invasiveness', 'mitochondrial', 'lon', 'peptidase', '1', 'lonp1', 'overexpression', 'and', 'increased', 'ctl', 'proteasome', 'activity', 'are', 'biomarkers', 'of', 'an', 'aggressive', 'highgrade', 'phenotype', 'and', 'found', 'to', 'be', 'associated', 'with', 'recurrence', 'and', 'poor', 'patient', 'survival', 'in', 'preclinical', 'models', 'small', 'molecule', 'agents', 'targeting', 'either', 'lonp1', 'or', 'the', 'proteasome', 'ctl', 'activity', 'have', 'antiastrocytoma', 'activity', 'here', 'we', 'present', 'evidence', 'that', 'the', 'dual', 'inhibition', 'of', 'lonp1', 'and', 'ctl', 'proteasome', 'activity', 'effectively', 'induces', 'ros', 'production', 'leading', 'to', 'apoptosis', 'in', 'malignant', 'astrocytoma', 'established', 'cell', 'lines', 'and', 'patientderived', 'glioma', 'stem', 'celllike', 'cultures', 'we', 'also', 'evaluated', 'a', 'novel', 'small', 'molecule', 'bt317', 'derived', 'from', 'the', 'coumarinic', 'compound', '4', 'cc4', 'using', 'structureactivity', 'modeling', 'which', 'we', 'found', 'to', 'inhibit', 'both', 'lonp1', 'and', 'ctl', 'proteasome', 'activity', 'using', 'gain', 'and', 'lossoffunction', 'genetic', 'models', 'we', 'discovered', 'that', 'lonp1', 'is', 'both', 'necessary', 'and', 'sufficient', 'to', 'drive', 'bt317', 'drug', 'sensitivity', 'in', 'established', 'and', 'patientderived', 'glioma', 'stemlike', 'cells', 'by', 'generating', 'ros', 'and', 'inducing', 'apoptosis', 'in', 'vitro', 'bt317', 'had', 'activity', 'as', 'a', 'single', 'agent', 'but', 'more', 'importantly', 'enhanced', 'synergy', 'with', 'the', 'standard', 'of', 'care', 'commonly', 'used', 'chemotherapeutic', 'temozolomide', 'tmz', 'in', 'an', 'orthotopic', 'xenograft', 'astrocytoma', 'model', 'bt317', 'crossed', 'the', 'bloodbrain', 'barrier', 'showed', 'selective', 'activity', 'at', 'the', 'tumor', 'site', 'and', 'demonstrated', 'therapeutic', 'efficacy', 'as', 'a', 'single', 'agent', 'and', 'combined', 'with', 'tmz', 'bt317', 'defines', 'an', 'emerging', 'class', 'of', 'lonp1', 'and', 'ctl', 'inhibitors', 'that', 'exhibited', 'promising', 'antitumor', 'activity', 'and', 'could', 'be', 'a', 'potential', 'candidate', 'for', 'malignant', 'astrocytoma', 'therapeutics', 'simple', 'summary', 'malignant', 'astrocytoma', 'patients', 'have', 'poor', 'clinical', 'outcomes', 'and', 'novel', 'treatments', 'are', 'needed', 'to', 'limit', 'tumor', 'recurrence', 'and', 'improve', 'their', 'overall', 'survival', 'these', 'tumors', 'have', 'a', 'malignant', 'phenotype', 'mediated', 'by', 'altered', 'mitochondrial', 'metabolism', 'abnormal', 'protein', 'processing', 'and', 'adaptation', 'to', 'hypoxia', 'we', 'have', 'previously', 'published', 'that', 'astrocytomas', 'are', 'especially', 'vulnerable', 'to', 'proteasome', 'inhibitors', 'as', 'well', 'as', 'to', 'inhibitors', 'of', 'the', 'mitochondrial', 'lon', 'peptidase', '1', 'lonp1', 'but', 'the', 'effect', 'of', 'combining', 'the', 'two', 'strategies', 'has', 'not', 'been', 'reported', 'here', 'we', 'present', 'evidence', 'that', 'the', 'dual', 'inhibition', 'of', 'lonp1', 'and', 'chymotrypsinlike', 'ctl', 'proteasome', 'activity', 'effectively', 'induces', 'cellular', 'reactive', 'oxygen', 'species', 'ros', 'production', 'leading', 'to', 'apoptosis', 'in', 'malignant', 'astrocytoma', 'established', 'cell', 'lines', 'and', 'patientderived', 'glioma', 'stem', 'celllike', 'cultures', 'we', 'developed', 'bt317', 'a', 'small', 'molecule', 'dual', 'inhibitor', 'which', 'crosses', 'the', 'bloodbrain', 'barrier', 'and', 'shows', 'strong', 'synergy', 'with', 'the', 'standard', 'of', 'care', 'temozolomide', 'tmz', 'in', 'the', 'astrocytoma', 'cell', 'lines', 'independent', 'of', 'their', 'isocitrate', 'dehydrogenase', 'idh', 'profile', 'and', 'in', 'an', 'orthotopic', 'glioma', 'murine', 'model', 'this', 'preclinical', 'study', 'demonstrated', 'the', 'potential', 'of', 'dual', 'lonp1', 'and', 'ctl', 'proteasome', 'inhibition', 'as', 'a', 'novel', 'therapeutic', 'strategy', 'for', 'malignant', 'astrocytoma', 'and', 'provides', 'insight', 'for', 'future', 'clinical', 'translational', 'studies', 'alone', 'or', 'in', 'combination', 'with', 'other', 'chemotherapies']","['malignant', 'astrocytomas', 'aggressive', 'primary', 'brain', 'tumors', 'characterized', 'extensive', 'hypoxiainduced', 'mitochondriadependent', 'changes', 'altered', 'respiration', 'increased', 'chymotrypsinlike', 'ctl', 'proteasome', 'activity', 'decreased', 'apoptosis', 'drug', 'resistance', 'stemness', 'increased', 'invasiveness', 'mitochondrial', 'lon', 'peptidase', '1', 'lonp1', 'overexpression', 'increased', 'ctl', 'proteasome', 'activity', 'biomarkers', 'aggressive', 'highgrade', 'phenotype', 'found', 'associated', 'recurrence', 'poor', 'patient', 'survival', 'preclinical', 'models', 'small', 'molecule', 'agents', 'targeting', 'either', 'lonp1', 'proteasome', 'ctl', 'activity', 'antiastrocytoma', 'activity', 'present', 'evidence', 'dual', 'inhibition', 'lonp1', 'ctl', 'proteasome', 'activity', 'effectively', 'induces', 'ros', 'production', 'leading', 'apoptosis', 'malignant', 'astrocytoma', 'established', 'cell', 'lines', 'patientderived', 'glioma', 'stem', 'celllike', 'cultures', 'also', 'evaluated', 'novel', 'small', 'molecule', 'bt317', 'derived', 'coumarinic', 'compound', '4', 'cc4', 'using', 'structureactivity', 'modeling', 'found', 'inhibit', 'lonp1', 'ctl', 'proteasome', 'activity', 'using', 'gain', 'lossoffunction', 'genetic', 'models', 'discovered', 'lonp1', 'necessary', 'sufficient', 'drive', 'bt317', 'drug', 'sensitivity', 'established', 'patientderived', 'glioma', 'stemlike', 'cells', 'generating', 'ros', 'inducing', 'apoptosis', 'vitro', 'bt317', 'activity', 'single', 'agent', 'importantly', 'enhanced', 'synergy', 'standard', 'care', 'commonly', 'used', 'chemotherapeutic', 'temozolomide', 'tmz', 'orthotopic', 'xenograft', 'astrocytoma', 'model', 'bt317', 'crossed', 'bloodbrain', 'barrier', 'showed', 'selective', 'activity', 'tumor', 'site', 'demonstrated', 'therapeutic', 'efficacy', 'single', 'agent', 'combined', 'tmz', 'bt317', 'defines', 'emerging', 'class', 'lonp1', 'ctl', 'inhibitors', 'exhibited', 'promising', 'antitumor', 'activity', 'could', 'potential', 'candidate', 'malignant', 'astrocytoma', 'therapeutics', 'simple', 'summary', 'malignant', 'astrocytoma', 'patients', 'poor', 'clinical', 'outcomes', 'novel', 'treatments', 'needed', 'limit', 'tumor', 'recurrence', 'improve', 'overall', 'survival', 'tumors', 'malignant', 'phenotype', 'mediated', 'altered', 'mitochondrial', 'metabolism', 'abnormal', 'protein', 'processing', 'adaptation', 'hypoxia', 'previously', 'published', 'astrocytomas', 'especially', 'vulnerable', 'proteasome', 'inhibitors', 'well', 'inhibitors', 'mitochondrial', 'lon', 'peptidase', '1', 'lonp1', 'effect', 'combining', 'two', 'strategies', 'reported', 'present', 'evidence', 'dual', 'inhibition', 'lonp1', 'chymotrypsinlike', 'ctl', 'proteasome', 'activity', 'effectively', 'induces', 'cellular', 'reactive', 'oxygen', 'species', 'ros', 'production', 'leading', 'apoptosis', 'malignant', 'astrocytoma', 'established', 'cell', 'lines', 'patientderived', 'glioma', 'stem', 'celllike', 'cultures', 'developed', 'bt317', 'small', 'molecule', 'dual', 'inhibitor', 'crosses', 'bloodbrain', 'barrier', 'shows', 'strong', 'synergy', 'standard', 'care', 'temozolomide', 'tmz', 'astrocytoma', 'cell', 'lines', 'independent', 'isocitrate', 'dehydrogenase', 'idh', 'profile', 'orthotopic', 'glioma', 'murine', 'model', 'preclinical', 'study', 'demonstrated', 'potential', 'dual', 'lonp1', 'ctl', 'proteasome', 'inhibition', 'novel', 'therapeutic', 'strategy', 'malignant', 'astrocytoma', 'provides', 'insight', 'future', 'clinical', 'translational', 'studies', 'alone', 'combination', 'chemotherapies']","['lon', 'ros', 'ros', 'lon', 'ros']","['lon', 'lon']",True,['tumor']
40014878,An evaluation of vimseltinib for treatment of tenosynovial giant cell tumors.,"Tenosynovial giant cell tumor (TGCT) is a rare soft tissue neoplasm with aggressive local growth. The disease is driven by excessive CSF1 expression in tumor cells, leading to increased recruitment of monocytes and macrophages, cytokine production, and tumor development. Targeted therapy against CSF1R is an effective treatment approach for unresectable, symptomatic TGCT. Vimseltinib, a novel, small-molecule tyrosine kinase inhibitor of CSF1R, has shown clinical efficacy in patients with TGCT.",2025-03-05,tenosynovial giant cell tumor tgct is a rare soft tissue neoplasm with aggressive local growth the disease is driven by excessive csf1 expression in tumor cells leading to increased recruitment of monocytes and macrophages cytokine production and tumor development targeted therapy against csf1r is an effective treatment approach for unresectable symptomatic tgct vimseltinib a novel smallmolecule tyrosine kinase inhibitor of csf1r has shown clinical efficacy in patients with tgct,"['tenosynovial', 'giant', 'cell', 'tumor', 'tgct', 'is', 'a', 'rare', 'soft', 'tissue', 'neoplasm', 'with', 'aggressive', 'local', 'growth', 'the', 'disease', 'is', 'driven', 'by', 'excessive', 'csf1', 'expression', 'in', 'tumor', 'cells', 'leading', 'to', 'increased', 'recruitment', 'of', 'monocytes', 'and', 'macrophages', 'cytokine', 'production', 'and', 'tumor', 'development', 'targeted', 'therapy', 'against', 'csf1r', 'is', 'an', 'effective', 'treatment', 'approach', 'for', 'unresectable', 'symptomatic', 'tgct', 'vimseltinib', 'a', 'novel', 'smallmolecule', 'tyrosine', 'kinase', 'inhibitor', 'of', 'csf1r', 'has', 'shown', 'clinical', 'efficacy', 'in', 'patients', 'with', 'tgct']","['tenosynovial', 'giant', 'cell', 'tumor', 'tgct', 'rare', 'soft', 'tissue', 'neoplasm', 'aggressive', 'local', 'growth', 'disease', 'driven', 'excessive', 'csf1', 'expression', 'tumor', 'cells', 'leading', 'increased', 'recruitment', 'monocytes', 'macrophages', 'cytokine', 'production', 'tumor', 'development', 'targeted', 'therapy', 'csf1r', 'effective', 'treatment', 'approach', 'unresectable', 'symptomatic', 'tgct', 'vimseltinib', 'novel', 'smallmolecule', 'tyrosine', 'kinase', 'inhibitor', 'csf1r', 'shown', 'clinical', 'efficacy', 'patients', 'tgct']","['csf1', 'csf1r', 'csf1r']","['csf1r', 'csf1r']",True,['tumor']
39995466,Efficacy of <i>Larimichthys crocea</i> TASOR protein-derived peptide FAM286 against <i>Staphylococcus aureus</i>.,"<i>Staphylococcus aureus</i> (<i>S. aureus</i>) is a major foodborne pathogen, could lead cause of intestinal infections in humans. Antimicrobial peptides, as emerging antimicrobial agents, are gradually replacing traditional agents due to their highly effective and safe antimicrobial activity. In this study, a novel peptide, designated as FAM286, was identified from TASOR protein of <i>Larimichthys crocea</i>, which had a strong antimicrobial activity against <i>S. aureus</i> with a minimum bactericidal concentration (MBC) of 3.9 μg/mL and completed bacteria killing by treatment for 1.5 h. The FAM286 could increase the permeability and disrupt the integrity of cell membranes. The cell showed aggregation phenomenon and entered the apoptosis stage. In addition, the non-bactericidal concentration of FAM286 could effectively inhibit the formation of biofilm and remove mature biofilm. Molecular docking experiments further verified the binding sites of FAM286 to <i>S. aureus</i> biofilm proteins SarA, AgrA, and Hld. FAM286 could also bind the bacterial DNA in an embedded manner, disrupting the structure of DNA and leading to the death of bacteria. This study comprehensively evaluated the antimicrobial mechanism of the FAM286 against <i>S. aureus</i> and provided a theoretical basis for the prevention and control of <i>S. aureus</i>.",2025-02-03,istaphylococcus aureusi is aureusi is a major foodborne pathogen could lead cause of intestinal infections in humans antimicrobial peptides as emerging antimicrobial agents are gradually replacing traditional agents due to their highly effective and safe antimicrobial activity in this study a novel peptide designated as fam286 was identified from tasor protein of ilarimichthys croceai which had a strong antimicrobial activity against is aureusi with a minimum bactericidal concentration mbc of 39 μgml and completed bacteria killing by treatment for 15 h the fam286 could increase the permeability and disrupt the integrity of cell membranes the cell showed aggregation phenomenon and entered the apoptosis stage in addition the nonbactericidal concentration of fam286 could effectively inhibit the formation of biofilm and remove mature biofilm molecular docking experiments further verified the binding sites of fam286 to is aureusi biofilm proteins sara agra and hld fam286 could also bind the bacterial dna in an embedded manner disrupting the structure of dna and leading to the death of bacteria this study comprehensively evaluated the antimicrobial mechanism of the fam286 against is aureusi and provided a theoretical basis for the prevention and control of is aureusi,"['istaphylococcus', 'aureusi', 'is', 'aureusi', 'is', 'a', 'major', 'foodborne', 'pathogen', 'could', 'lead', 'cause', 'of', 'intestinal', 'infections', 'in', 'humans', 'antimicrobial', 'peptides', 'as', 'emerging', 'antimicrobial', 'agents', 'are', 'gradually', 'replacing', 'traditional', 'agents', 'due', 'to', 'their', 'highly', 'effective', 'and', 'safe', 'antimicrobial', 'activity', 'in', 'this', 'study', 'a', 'novel', 'peptide', 'designated', 'as', 'fam286', 'was', 'identified', 'from', 'tasor', 'protein', 'of', 'ilarimichthys', 'croceai', 'which', 'had', 'a', 'strong', 'antimicrobial', 'activity', 'against', 'is', 'aureusi', 'with', 'a', 'minimum', 'bactericidal', 'concentration', 'mbc', 'of', '39', 'μgml', 'and', 'completed', 'bacteria', 'killing', 'by', 'treatment', 'for', '15', 'h', 'the', 'fam286', 'could', 'increase', 'the', 'permeability', 'and', 'disrupt', 'the', 'integrity', 'of', 'cell', 'membranes', 'the', 'cell', 'showed', 'aggregation', 'phenomenon', 'and', 'entered', 'the', 'apoptosis', 'stage', 'in', 'addition', 'the', 'nonbactericidal', 'concentration', 'of', 'fam286', 'could', 'effectively', 'inhibit', 'the', 'formation', 'of', 'biofilm', 'and', 'remove', 'mature', 'biofilm', 'molecular', 'docking', 'experiments', 'further', 'verified', 'the', 'binding', 'sites', 'of', 'fam286', 'to', 'is', 'aureusi', 'biofilm', 'proteins', 'sara', 'agra', 'and', 'hld', 'fam286', 'could', 'also', 'bind', 'the', 'bacterial', 'dna', 'in', 'an', 'embedded', 'manner', 'disrupting', 'the', 'structure', 'of', 'dna', 'and', 'leading', 'to', 'the', 'death', 'of', 'bacteria', 'this', 'study', 'comprehensively', 'evaluated', 'the', 'antimicrobial', 'mechanism', 'of', 'the', 'fam286', 'against', 'is', 'aureusi', 'and', 'provided', 'a', 'theoretical', 'basis', 'for', 'the', 'prevention', 'and', 'control', 'of', 'is', 'aureusi']","['istaphylococcus', 'aureusi', 'aureusi', 'major', 'foodborne', 'pathogen', 'could', 'lead', 'cause', 'intestinal', 'infections', 'humans', 'antimicrobial', 'peptides', 'emerging', 'antimicrobial', 'agents', 'gradually', 'replacing', 'traditional', 'agents', 'due', 'highly', 'effective', 'safe', 'antimicrobial', 'activity', 'study', 'novel', 'peptide', 'designated', 'fam286', 'identified', 'tasor', 'protein', 'ilarimichthys', 'croceai', 'strong', 'antimicrobial', 'activity', 'aureusi', 'minimum', 'bactericidal', 'concentration', 'mbc', '39', 'μgml', 'completed', 'bacteria', 'killing', 'treatment', '15', 'h', 'fam286', 'could', 'increase', 'permeability', 'disrupt', 'integrity', 'cell', 'membranes', 'cell', 'showed', 'aggregation', 'phenomenon', 'entered', 'apoptosis', 'stage', 'addition', 'nonbactericidal', 'concentration', 'fam286', 'could', 'effectively', 'inhibit', 'formation', 'biofilm', 'remove', 'mature', 'biofilm', 'molecular', 'docking', 'experiments', 'verified', 'binding', 'sites', 'fam286', 'aureusi', 'biofilm', 'proteins', 'sara', 'agra', 'hld', 'fam286', 'could', 'also', 'bind', 'bacterial', 'dna', 'embedded', 'manner', 'disrupting', 'structure', 'dna', 'leading', 'death', 'bacteria', 'study', 'comprehensively', 'evaluated', 'antimicrobial', 'mechanism', 'fam286', 'aureusi', 'provided', 'theoretical', 'basis', 'prevention', 'control', 'aureusi']",['hld'],['hld'],True,['infection']
39933078,Preliminary Study of a Novel <sup>68</sup>Ga-Labeled Probe Targeting Neuropilin-1 for Tumor Diagnosis.,"Neuropilin-1 (NRP-1), a transmembrane protein related to tumor progression and invasion, presents potential as a prospective biomarker for tumor diagnosis and therapy. Positron emission tomography (PET) is acknowledged as an ideal modality for accurately monitoring NRP-1 expression <i>in vivo</i> due to its superior sensitivity and resolution. In this study, a novel peptide-based PET imaging probe, [<sup>68</sup>Ga]Ga-DOTA-NEP, was successfully developed for specifically visualizing NRP-1 expression in tumors. The probe was prepared with a radiochemical yield (RCY) and radiochemical purity (RCP) greater than 95%, a molar activity of 13.28 ± 0.97 GBq/μmol, and a lipid-water partition coefficient (log <i>P</i>) of -2.20 ± 0.13. <i>In vitro</i> stability assay showed that the probe possessed sufficient stability for biological evaluation. The cellular uptake of the probe in U87 and A549 cells (4.91 ± 0.14 and 4.58 ± 0.40%AD) with high expression of NRP-1 was higher than that observed in NRP-1 negative cells HCT116 and NCI-H1299 (2.84 ± 0.23 and 1.76 ± 0.25%AD) at 1 h. <i>In vivo</i> PET imaging revealed that the maximum tumor uptake of the probe in U87 (7.20 ± 1.03%ID/mL) and A549 (5.90 ± 0.57%ID/mL) tumor-bearing mice was also markedly higher compared to that in HCT116 (3.09 ± 0.43%ID/mL) and NCI-H1299 (2.90 ± 0.70%ID/mL) tumor-bearing mice. <i>Ex vivo</i> analysis further confirmed the targeting specificity of the probe [<sup>68</sup>Ga]Ga-DOTA-NEP for NRP-1. These results suggest that [<sup>68</sup>Ga]Ga-DOTA-NEP could serve as a promising PET imaging probe for the diagnosis of NRP-1 positive tumors.",2025-02-11,neuropilin1 nrp1 a transmembrane protein related to tumor progression and invasion presents potential as a prospective biomarker for tumor diagnosis and therapy positron emission tomography pet is acknowledged as an ideal modality for accurately monitoring nrp1 expression iin vivoi due to its superior sensitivity and resolution in this study a novel peptidebased pet imaging probe sup68supgagadotanep was successfully developed for specifically visualizing nrp1 expression in tumors the probe was prepared with a radiochemical yield rcy and radiochemical purity rcp greater than 95 a molar activity of 1328  097 gbqμmol and a lipidwater partition coefficient log ipi of 220  013 iin vitroi stability assay showed that the probe possessed sufficient stability for biological evaluation the cellular uptake of the probe in u87 and a549 cells 491  014 and 458  040ad with high expression of nrp1 was higher than that observed in nrp1 negative cells hct116 and ncih1299 284  023 and 176  025ad at 1 h iin vivoi pet imaging revealed that the maximum tumor uptake of the probe in u87 720  103idml and a549 590  057idml tumorbearing mice was also markedly higher compared to that in hct116 309  043idml and ncih1299 290  070idml tumorbearing mice iex vivoi analysis further confirmed the targeting specificity of the probe sup68supgagadotanep for nrp1 these results suggest that sup68supgagadotanep could serve as a promising pet imaging probe for the diagnosis of nrp1 positive tumors,"['neuropilin1', 'nrp1', 'a', 'transmembrane', 'protein', 'related', 'to', 'tumor', 'progression', 'and', 'invasion', 'presents', 'potential', 'as', 'a', 'prospective', 'biomarker', 'for', 'tumor', 'diagnosis', 'and', 'therapy', 'positron', 'emission', 'tomography', 'pet', 'is', 'acknowledged', 'as', 'an', 'ideal', 'modality', 'for', 'accurately', 'monitoring', 'nrp1', 'expression', 'iin', 'vivoi', 'due', 'to', 'its', 'superior', 'sensitivity', 'and', 'resolution', 'in', 'this', 'study', 'a', 'novel', 'peptidebased', 'pet', 'imaging', 'probe', 'sup68supgagadotanep', 'was', 'successfully', 'developed', 'for', 'specifically', 'visualizing', 'nrp1', 'expression', 'in', 'tumors', 'the', 'probe', 'was', 'prepared', 'with', 'a', 'radiochemical', 'yield', 'rcy', 'and', 'radiochemical', 'purity', 'rcp', 'greater', 'than', '95', 'a', 'molar', 'activity', 'of', '1328', '097', 'gbqμmol', 'and', 'a', 'lipidwater', 'partition', 'coefficient', 'log', 'ipi', 'of', '220', '013', 'iin', 'vitroi', 'stability', 'assay', 'showed', 'that', 'the', 'probe', 'possessed', 'sufficient', 'stability', 'for', 'biological', 'evaluation', 'the', 'cellular', 'uptake', 'of', 'the', 'probe', 'in', 'u87', 'and', 'a549', 'cells', '491', '014', 'and', '458', '040ad', 'with', 'high', 'expression', 'of', 'nrp1', 'was', 'higher', 'than', 'that', 'observed', 'in', 'nrp1', 'negative', 'cells', 'hct116', 'and', 'ncih1299', '284', '023', 'and', '176', '025ad', 'at', '1', 'h', 'iin', 'vivoi', 'pet', 'imaging', 'revealed', 'that', 'the', 'maximum', 'tumor', 'uptake', 'of', 'the', 'probe', 'in', 'u87', '720', '103idml', 'and', 'a549', '590', '057idml', 'tumorbearing', 'mice', 'was', 'also', 'markedly', 'higher', 'compared', 'to', 'that', 'in', 'hct116', '309', '043idml', 'and', 'ncih1299', '290', '070idml', 'tumorbearing', 'mice', 'iex', 'vivoi', 'analysis', 'further', 'confirmed', 'the', 'targeting', 'specificity', 'of', 'the', 'probe', 'sup68supgagadotanep', 'for', 'nrp1', 'these', 'results', 'suggest', 'that', 'sup68supgagadotanep', 'could', 'serve', 'as', 'a', 'promising', 'pet', 'imaging', 'probe', 'for', 'the', 'diagnosis', 'of', 'nrp1', 'positive', 'tumors']","['neuropilin1', 'nrp1', 'transmembrane', 'protein', 'related', 'tumor', 'progression', 'invasion', 'presents', 'potential', 'prospective', 'biomarker', 'tumor', 'diagnosis', 'therapy', 'positron', 'emission', 'tomography', 'pet', 'acknowledged', 'ideal', 'modality', 'accurately', 'monitoring', 'nrp1', 'expression', 'iin', 'vivoi', 'due', 'superior', 'sensitivity', 'resolution', 'study', 'novel', 'peptidebased', 'pet', 'imaging', 'probe', 'sup68supgagadotanep', 'successfully', 'developed', 'specifically', 'visualizing', 'nrp1', 'expression', 'tumors', 'probe', 'prepared', 'radiochemical', 'yield', 'rcy', 'radiochemical', 'purity', 'rcp', 'greater', '95', 'molar', 'activity', '1328', '097', 'gbqμmol', 'lipidwater', 'partition', 'coefficient', 'log', 'ipi', '220', '013', 'iin', 'vitroi', 'stability', 'assay', 'showed', 'probe', 'possessed', 'sufficient', 'stability', 'biological', 'evaluation', 'cellular', 'uptake', 'probe', 'u87', 'a549', 'cells', '491', '014', '458', '040ad', 'high', 'expression', 'nrp1', 'higher', 'observed', 'nrp1', 'negative', 'cells', 'hct116', 'ncih1299', '284', '023', '176', '025ad', '1', 'h', 'iin', 'vivoi', 'pet', 'imaging', 'revealed', 'maximum', 'tumor', 'uptake', 'probe', 'u87', '720', '103idml', 'a549', '590', '057idml', 'tumorbearing', 'mice', 'also', 'markedly', 'higher', 'compared', 'hct116', '309', '043idml', 'ncih1299', '290', '070idml', 'tumorbearing', 'mice', 'iex', 'vivoi', 'analysis', 'confirmed', 'targeting', 'specificity', 'probe', 'sup68supgagadotanep', 'nrp1', 'results', 'suggest', 'sup68supgagadotanep', 'could', 'serve', 'promising', 'pet', 'imaging', 'probe', 'diagnosis', 'nrp1', 'positive', 'tumors']","['neuropilin1', 'nrp1', 'nrp1', 'nrp1', 'nrp1', 'nrp1', 'iex', 'nrp1', 'nrp1']","['neuropilin1', 'nrp1', 'nrp1', 'nrp1', 'nrp1', 'nrp1', 'iex', 'nrp1', 'nrp1']",False,['tumor']
39911136,Relocating NSAIDs into the endoplasmic reticulum induces ER stress-mediated apoptosis in cancer cells.,"The endoplasmic reticulum (ER) is a vital subcellular organelle that orchestrates numerous essential biological processes, including protein synthesis and processing. Disruption of ER function can lead to ER stress, a condition closely associated with the progression and development of cancer. Consequently, inducing ER stress in cancer cells has emerged as an unconventional yet promising therapeutic approach. However, selectively targeting the ER within cancer cells remains a significant challenge. To address this, we have designed and synthesized a novel small-molecule library composed of non-steroidal anti-inflammatory drugs (NSAIDs), fluorescent probes, and ER-targeting moieties. Through screening the library in cancer cells, we identified a promising compound: an ibuprofen derivative conjugated with a dansyl group as a dual fluorescence tag and ER-targeting moiety. This ibuprofen derivative successfully localized into the ER of HCT-116 colon cancer cells within 3 h, induced ER stress by upregulating key stress markers such as CHOP, GRP94, IRE-1α, PERK, and Cas-12, while simultaneously inhibiting Cox-2. The resulting ER stress triggered autophagy by upregulating Beclin and LC3-II/LC3-I as autophagy markers, followed by apoptosis, culminating in significant cancer cell death, particularly when combined with bafilomycin A, 10-hydroxycamptothecin and obatoclax. This NSAID-based ER stress inducer provides a powerful tool for exploring the chemical biology of NSAIDs in the ER and holds great potential for advancing ER-targeted cancer therapies in combination with other anti-cancer drugs.",2025-01-23,the endoplasmic reticulum er is a vital subcellular organelle that orchestrates numerous essential biological processes including protein synthesis and processing disruption of er function can lead to er stress a condition closely associated with the progression and development of cancer consequently inducing er stress in cancer cells has emerged as an unconventional yet promising therapeutic approach however selectively targeting the er within cancer cells remains a significant challenge to address this we have designed and synthesized a novel smallmolecule library composed of nonsteroidal antiinflammatory drugs nsaids fluorescent probes and ertargeting moieties through screening the library in cancer cells we identified a promising compound an ibuprofen derivative conjugated with a dansyl group as a dual fluorescence tag and ertargeting moiety this ibuprofen derivative successfully localized into the er of hct116 colon cancer cells within 3 h induced er stress by upregulating key stress markers such as chop grp94 ire1α perk and cas12 while simultaneously inhibiting cox2 the resulting er stress triggered autophagy by upregulating beclin and lc3iilc3i as autophagy markers followed by apoptosis culminating in significant cancer cell death particularly when combined with bafilomycin a 10hydroxycamptothecin and obatoclax this nsaidbased er stress inducer provides a powerful tool for exploring the chemical biology of nsaids in the er and holds great potential for advancing ertargeted cancer therapies in combination with other anticancer drugs,"['the', 'endoplasmic', 'reticulum', 'er', 'is', 'a', 'vital', 'subcellular', 'organelle', 'that', 'orchestrates', 'numerous', 'essential', 'biological', 'processes', 'including', 'protein', 'synthesis', 'and', 'processing', 'disruption', 'of', 'er', 'function', 'can', 'lead', 'to', 'er', 'stress', 'a', 'condition', 'closely', 'associated', 'with', 'the', 'progression', 'and', 'development', 'of', 'cancer', 'consequently', 'inducing', 'er', 'stress', 'in', 'cancer', 'cells', 'has', 'emerged', 'as', 'an', 'unconventional', 'yet', 'promising', 'therapeutic', 'approach', 'however', 'selectively', 'targeting', 'the', 'er', 'within', 'cancer', 'cells', 'remains', 'a', 'significant', 'challenge', 'to', 'address', 'this', 'we', 'have', 'designed', 'and', 'synthesized', 'a', 'novel', 'smallmolecule', 'library', 'composed', 'of', 'nonsteroidal', 'antiinflammatory', 'drugs', 'nsaids', 'fluorescent', 'probes', 'and', 'ertargeting', 'moieties', 'through', 'screening', 'the', 'library', 'in', 'cancer', 'cells', 'we', 'identified', 'a', 'promising', 'compound', 'an', 'ibuprofen', 'derivative', 'conjugated', 'with', 'a', 'dansyl', 'group', 'as', 'a', 'dual', 'fluorescence', 'tag', 'and', 'ertargeting', 'moiety', 'this', 'ibuprofen', 'derivative', 'successfully', 'localized', 'into', 'the', 'er', 'of', 'hct116', 'colon', 'cancer', 'cells', 'within', '3', 'h', 'induced', 'er', 'stress', 'by', 'upregulating', 'key', 'stress', 'markers', 'such', 'as', 'chop', 'grp94', 'ire1α', 'perk', 'and', 'cas12', 'while', 'simultaneously', 'inhibiting', 'cox2', 'the', 'resulting', 'er', 'stress', 'triggered', 'autophagy', 'by', 'upregulating', 'beclin', 'and', 'lc3iilc3i', 'as', 'autophagy', 'markers', 'followed', 'by', 'apoptosis', 'culminating', 'in', 'significant', 'cancer', 'cell', 'death', 'particularly', 'when', 'combined', 'with', 'bafilomycin', 'a', '10hydroxycamptothecin', 'and', 'obatoclax', 'this', 'nsaidbased', 'er', 'stress', 'inducer', 'provides', 'a', 'powerful', 'tool', 'for', 'exploring', 'the', 'chemical', 'biology', 'of', 'nsaids', 'in', 'the', 'er', 'and', 'holds', 'great', 'potential', 'for', 'advancing', 'ertargeted', 'cancer', 'therapies', 'in', 'combination', 'with', 'other', 'anticancer', 'drugs']","['endoplasmic', 'reticulum', 'er', 'vital', 'subcellular', 'organelle', 'orchestrates', 'numerous', 'essential', 'biological', 'processes', 'including', 'protein', 'synthesis', 'processing', 'disruption', 'er', 'function', 'lead', 'er', 'stress', 'condition', 'closely', 'associated', 'progression', 'development', 'cancer', 'consequently', 'inducing', 'er', 'stress', 'cancer', 'cells', 'emerged', 'unconventional', 'yet', 'promising', 'therapeutic', 'approach', 'however', 'selectively', 'targeting', 'er', 'within', 'cancer', 'cells', 'remains', 'significant', 'challenge', 'address', 'designed', 'synthesized', 'novel', 'smallmolecule', 'library', 'composed', 'nonsteroidal', 'antiinflammatory', 'drugs', 'nsaids', 'fluorescent', 'probes', 'ertargeting', 'moieties', 'screening', 'library', 'cancer', 'cells', 'identified', 'promising', 'compound', 'ibuprofen', 'derivative', 'conjugated', 'dansyl', 'group', 'dual', 'fluorescence', 'tag', 'ertargeting', 'moiety', 'ibuprofen', 'derivative', 'successfully', 'localized', 'er', 'hct116', 'colon', 'cancer', 'cells', 'within', '3', 'h', 'induced', 'er', 'stress', 'upregulating', 'key', 'stress', 'markers', 'chop', 'grp94', 'ire1α', 'perk', 'cas12', 'simultaneously', 'inhibiting', 'cox2', 'resulting', 'er', 'stress', 'triggered', 'autophagy', 'upregulating', 'beclin', 'lc3iilc3i', 'autophagy', 'markers', 'followed', 'apoptosis', 'culminating', 'significant', 'cancer', 'cell', 'death', 'particularly', 'combined', 'bafilomycin', '10hydroxycamptothecin', 'obatoclax', 'nsaidbased', 'er', 'stress', 'inducer', 'provides', 'powerful', 'tool', 'exploring', 'chemical', 'biology', 'nsaids', 'er', 'holds', 'great', 'potential', 'advancing', 'ertargeted', 'cancer', 'therapies', 'combination', 'anticancer', 'drugs']","['grp94', 'beclin']","['grp94', 'beclin']",True,['cancer']
39844192,A novel peptide encoded by circSRCAP confers resistance to enzalutamide by inhibiting the ubiquitin-dependent degradation of AR-V7 in castration-resistant prostate cancer.,"The sustained activation of androgen receptor splice variant-7 (AR-V7) is a key factor in the resistance of castration-resistant prostate cancer (CRPC) to second-generation anti-androgens such as enzalutamide (ENZ). The AR/AR-V7 protein is regulated by the E3 ubiquitin ligase STUB1 and a complex involving HSP70, but the precise mechanism remains unclear.",2025-01-23,the sustained activation of androgen receptor splice variant7 arv7 is a key factor in the resistance of castrationresistant prostate cancer crpc to secondgeneration antiandrogens such as enzalutamide enz the ararv7 protein is regulated by the e3 ubiquitin ligase stub1 and a complex involving hsp70 but the precise mechanism remains unclear,"['the', 'sustained', 'activation', 'of', 'androgen', 'receptor', 'splice', 'variant7', 'arv7', 'is', 'a', 'key', 'factor', 'in', 'the', 'resistance', 'of', 'castrationresistant', 'prostate', 'cancer', 'crpc', 'to', 'secondgeneration', 'antiandrogens', 'such', 'as', 'enzalutamide', 'enz', 'the', 'ararv7', 'protein', 'is', 'regulated', 'by', 'the', 'e3', 'ubiquitin', 'ligase', 'stub1', 'and', 'a', 'complex', 'involving', 'hsp70', 'but', 'the', 'precise', 'mechanism', 'remains', 'unclear']","['sustained', 'activation', 'androgen', 'receptor', 'splice', 'variant7', 'arv7', 'key', 'factor', 'resistance', 'castrationresistant', 'prostate', 'cancer', 'crpc', 'secondgeneration', 'antiandrogens', 'enzalutamide', 'enz', 'ararv7', 'protein', 'regulated', 'e3', 'ubiquitin', 'ligase', 'stub1', 'complex', 'involving', 'hsp70', 'precise', 'mechanism', 'remains', 'unclear']","['enz', 'ubiquitin', 'hsp70']",['hsp70'],False,['cancer']
39832444,An overview of small-molecule agents for the treatment of psoriasis.,"Psoriasis is a prevalent, chronic inflammatory disease characterized by abnormal skin plaques. To date, physical therapy, topical therapy, systemic therapy and biologic drugs are the most commonly employed strategies for treating psoriasis. Recently, many agents have advanced to clinical trials, and some anti-psoriasis drugs have been approved, including antibody drugs and small-molecule drugs. Many antibody drugs targeting cytokines and receptors, such as interleukin (IL-17 and IL-23) and tumor necrosis factor-α (TNF-α), have been approved for the treatment of psoriasis. And numerous small-molecule agents have displayed promising activities in the treatment of psoriasis. The targets of anti-psoriasis drugs encompass phosphodiesterase IV (PDE4), Janus kinase (JAK), tyrosine kinase (TYK), retinoic acid-related orphan receptors (ROR), vitamin D receptor (VDR), Interleukin (IL), Aryl hydrocarbon receptor (AhR), Interleukin-1 receptor-associated kinase 4 (IRAK), chemoattractant-like receptor 1 (ChemR23), Sphingosine-1-phosphate receptor (S1P), A3 adenosine receptor (A3AR), Heat shock protein 90 (HSP90), The Rho-associated protein kinases (ROCK), The bromodomain and extra-terminal domain (BET), FMS-like tyrosine kinase 3 (FLT3), Tumor Necrosis Factor α Converting Enzyme (TACE), Toll-like receptors (TLR), NF-κB inducing kinase (NIK), DNA topoisomerase I (Topo I), among others. Herein, this review mainly recapitulates the advancements in the structure and enzyme activity of small-molecule anti-psoriasis agents over the last ten years, and their binding modes were also explored. Hopefully, this review will facilitate the development of novel small-molecule agents as potential anti-psoriasis drugs.",2025-01-15,psoriasis is a prevalent chronic inflammatory disease characterized by abnormal skin plaques to date physical therapy topical therapy systemic therapy and biologic drugs are the most commonly employed strategies for treating psoriasis recently many agents have advanced to clinical trials and some antipsoriasis drugs have been approved including antibody drugs and smallmolecule drugs many antibody drugs targeting cytokines and receptors such as interleukin il17 and il23 and tumor necrosis factorα tnfα have been approved for the treatment of psoriasis and numerous smallmolecule agents have displayed promising activities in the treatment of psoriasis the targets of antipsoriasis drugs encompass phosphodiesterase iv pde4 janus kinase jak tyrosine kinase tyk retinoic acidrelated orphan receptors ror vitamin d receptor vdr interleukin il aryl hydrocarbon receptor ahr interleukin1 receptorassociated kinase 4 irak chemoattractantlike receptor 1 chemr23 sphingosine1phosphate receptor s1p a3 adenosine receptor a3ar heat shock protein 90 hsp90 the rhoassociated protein kinases rock the bromodomain and extraterminal domain bet fmslike tyrosine kinase 3 flt3 tumor necrosis factor α converting enzyme tace tolllike receptors tlr nfκb inducing kinase nik dna topoisomerase i topo i among others herein this review mainly recapitulates the advancements in the structure and enzyme activity of smallmolecule antipsoriasis agents over the last ten years and their binding modes were also explored hopefully this review will facilitate the development of novel smallmolecule agents as potential antipsoriasis drugs,"['psoriasis', 'is', 'a', 'prevalent', 'chronic', 'inflammatory', 'disease', 'characterized', 'by', 'abnormal', 'skin', 'plaques', 'to', 'date', 'physical', 'therapy', 'topical', 'therapy', 'systemic', 'therapy', 'and', 'biologic', 'drugs', 'are', 'the', 'most', 'commonly', 'employed', 'strategies', 'for', 'treating', 'psoriasis', 'recently', 'many', 'agents', 'have', 'advanced', 'to', 'clinical', 'trials', 'and', 'some', 'antipsoriasis', 'drugs', 'have', 'been', 'approved', 'including', 'antibody', 'drugs', 'and', 'smallmolecule', 'drugs', 'many', 'antibody', 'drugs', 'targeting', 'cytokines', 'and', 'receptors', 'such', 'as', 'interleukin', 'il17', 'and', 'il23', 'and', 'tumor', 'necrosis', 'factorα', 'tnfα', 'have', 'been', 'approved', 'for', 'the', 'treatment', 'of', 'psoriasis', 'and', 'numerous', 'smallmolecule', 'agents', 'have', 'displayed', 'promising', 'activities', 'in', 'the', 'treatment', 'of', 'psoriasis', 'the', 'targets', 'of', 'antipsoriasis', 'drugs', 'encompass', 'phosphodiesterase', 'iv', 'pde4', 'janus', 'kinase', 'jak', 'tyrosine', 'kinase', 'tyk', 'retinoic', 'acidrelated', 'orphan', 'receptors', 'ror', 'vitamin', 'd', 'receptor', 'vdr', 'interleukin', 'il', 'aryl', 'hydrocarbon', 'receptor', 'ahr', 'interleukin1', 'receptorassociated', 'kinase', '4', 'irak', 'chemoattractantlike', 'receptor', '1', 'chemr23', 'sphingosine1phosphate', 'receptor', 's1p', 'a3', 'adenosine', 'receptor', 'a3ar', 'heat', 'shock', 'protein', '90', 'hsp90', 'the', 'rhoassociated', 'protein', 'kinases', 'rock', 'the', 'bromodomain', 'and', 'extraterminal', 'domain', 'bet', 'fmslike', 'tyrosine', 'kinase', '3', 'flt3', 'tumor', 'necrosis', 'factor', 'α', 'converting', 'enzyme', 'tace', 'tolllike', 'receptors', 'tlr', 'nfκb', 'inducing', 'kinase', 'nik', 'dna', 'topoisomerase', 'i', 'topo', 'i', 'among', 'others', 'herein', 'this', 'review', 'mainly', 'recapitulates', 'the', 'advancements', 'in', 'the', 'structure', 'and', 'enzyme', 'activity', 'of', 'smallmolecule', 'antipsoriasis', 'agents', 'over', 'the', 'last', 'ten', 'years', 'and', 'their', 'binding', 'modes', 'were', 'also', 'explored', 'hopefully', 'this', 'review', 'will', 'facilitate', 'the', 'development', 'of', 'novel', 'smallmolecule', 'agents', 'as', 'potential', 'antipsoriasis', 'drugs']","['psoriasis', 'prevalent', 'chronic', 'inflammatory', 'disease', 'characterized', 'abnormal', 'skin', 'plaques', 'date', 'physical', 'therapy', 'topical', 'therapy', 'systemic', 'therapy', 'biologic', 'drugs', 'commonly', 'employed', 'strategies', 'treating', 'psoriasis', 'recently', 'many', 'agents', 'advanced', 'clinical', 'trials', 'antipsoriasis', 'drugs', 'approved', 'including', 'antibody', 'drugs', 'smallmolecule', 'drugs', 'many', 'antibody', 'drugs', 'targeting', 'cytokines', 'receptors', 'interleukin', 'il17', 'il23', 'tumor', 'necrosis', 'factorα', 'tnfα', 'approved', 'treatment', 'psoriasis', 'numerous', 'smallmolecule', 'agents', 'displayed', 'promising', 'activities', 'treatment', 'psoriasis', 'targets', 'antipsoriasis', 'drugs', 'encompass', 'phosphodiesterase', 'iv', 'pde4', 'janus', 'kinase', 'jak', 'tyrosine', 'kinase', 'tyk', 'retinoic', 'acidrelated', 'orphan', 'receptors', 'ror', 'vitamin', 'receptor', 'vdr', 'interleukin', 'il', 'aryl', 'hydrocarbon', 'receptor', 'ahr', 'interleukin1', 'receptorassociated', 'kinase', '4', 'irak', 'chemoattractantlike', 'receptor', '1', 'chemr23', 'sphingosine1phosphate', 'receptor', 's1p', 'a3', 'adenosine', 'receptor', 'a3ar', 'heat', 'shock', 'protein', '90', 'hsp90', 'rhoassociated', 'protein', 'kinases', 'rock', 'bromodomain', 'extraterminal', 'domain', 'bet', 'fmslike', 'tyrosine', 'kinase', '3', 'flt3', 'tumor', 'necrosis', 'factor', 'α', 'converting', 'enzyme', 'tace', 'tolllike', 'receptors', 'tlr', 'nfκb', 'inducing', 'kinase', 'nik', 'dna', 'topoisomerase', 'topo', 'among', 'others', 'herein', 'review', 'mainly', 'recapitulates', 'advancements', 'structure', 'enzyme', 'activity', 'smallmolecule', 'antipsoriasis', 'agents', 'last', 'ten', 'years', 'binding', 'modes', 'also', 'explored', 'hopefully', 'review', 'facilitate', 'development', 'novel', 'smallmolecule', 'agents', 'potential', 'antipsoriasis', 'drugs']","['interleukin', 'il17', 'vdr', 'interleukin', 'interleukin1', 's1p', 'hsp90', 'flt3', 'tlr', 'topoisomerase', 'topo']",['vdr'],True,['tumor']
39829820,"Preclinical and Toxicology Assessment of ISFP10, an Inhibitor of Fungal Phosphoglucomutase (PGM).","Previously, the novel small molecule ISFP10 has been shown to inhibit fungal phosphoglucomutase (PGM) activity in <i>Aspergillus fumigatus</i> and <i>Pneumocystis</i> spp. With 50-fold selectivity over the human PGM molecule due to the presence of a unique yet conserved cysteine residue present in a number pathogenic fungal PGMs, use of this compound may provide a novel broad-spectrum approach to treating fungal infections. Accordingly, we sought to determine the tolerability in test animals receiving this compound, as well as the potential antifungal activity of ISFP10 on cultures of the common fungal pathogens <i>Candida albicans</i> and <i>Candida glabrata</i> .",2025-01-10,previously the novel small molecule isfp10 has been shown to inhibit fungal phosphoglucomutase pgm activity in iaspergillus fumigatusi and ipneumocystisi spp with 50fold selectivity over the human pgm molecule due to the presence of a unique yet conserved cysteine residue present in a number pathogenic fungal pgms use of this compound may provide a novel broadspectrum approach to treating fungal infections accordingly we sought to determine the tolerability in test animals receiving this compound as well as the potential antifungal activity of isfp10 on cultures of the common fungal pathogens icandida albicansi and icandida glabratai ,"['previously', 'the', 'novel', 'small', 'molecule', 'isfp10', 'has', 'been', 'shown', 'to', 'inhibit', 'fungal', 'phosphoglucomutase', 'pgm', 'activity', 'in', 'iaspergillus', 'fumigatusi', 'and', 'ipneumocystisi', 'spp', 'with', '50fold', 'selectivity', 'over', 'the', 'human', 'pgm', 'molecule', 'due', 'to', 'the', 'presence', 'of', 'a', 'unique', 'yet', 'conserved', 'cysteine', 'residue', 'present', 'in', 'a', 'number', 'pathogenic', 'fungal', 'pgms', 'use', 'of', 'this', 'compound', 'may', 'provide', 'a', 'novel', 'broadspectrum', 'approach', 'to', 'treating', 'fungal', 'infections', 'accordingly', 'we', 'sought', 'to', 'determine', 'the', 'tolerability', 'in', 'test', 'animals', 'receiving', 'this', 'compound', 'as', 'well', 'as', 'the', 'potential', 'antifungal', 'activity', 'of', 'isfp10', 'on', 'cultures', 'of', 'the', 'common', 'fungal', 'pathogens', 'icandida', 'albicansi', 'and', 'icandida', 'glabratai']","['previously', 'novel', 'small', 'molecule', 'isfp10', 'shown', 'inhibit', 'fungal', 'phosphoglucomutase', 'pgm', 'activity', 'iaspergillus', 'fumigatusi', 'ipneumocystisi', 'spp', '50fold', 'selectivity', 'human', 'pgm', 'molecule', 'due', 'presence', 'unique', 'yet', 'conserved', 'cysteine', 'residue', 'present', 'number', 'pathogenic', 'fungal', 'pgms', 'use', 'compound', 'may', 'provide', 'novel', 'broadspectrum', 'approach', 'treating', 'fungal', 'infections', 'accordingly', 'sought', 'determine', 'tolerability', 'test', 'animals', 'receiving', 'compound', 'well', 'potential', 'antifungal', 'activity', 'isfp10', 'cultures', 'common', 'fungal', 'pathogens', 'icandida', 'albicansi', 'icandida', 'glabratai']",['phosphoglucomutase'],['phosphoglucomutase'],False,['infection']
39818012,Design and synthesis of isatin derivative payloaded peptide-drug conjugate as tubulin inhibitor against colorectal cancer.,"A series of isatin derivatives which could inhibit colorectal cancer (CRC) were synthesized. Among those compounds, 5B exhibited good inhibitory activity of CRC through the inhibition of tubulin expression, inducing apoptosis, and causing G2/M phase cell cycle arrest pathway, which suggested that 5B could be a potential tubulin inhibitor. Based on that, a novel peptide-drug conjugate (PDC), which employed the CRC cells related receptor CD44 ligand peptide A6 coupling to 5B to accomplish A6-5B. The in vitro and in vivo studies showed that A6-5B could significantly inhibit the tumor growth and metastasis in CRC cells. Mechanistic studies revealed that both 5B and A6-5B exert their antitumor effects by inhibiting tubulin, demonstrating that 5B might play a payload role and A6 could act as a targeting moiety for selective drug delivery to tumor cells.",2025-01-12,a series of isatin derivatives which could inhibit colorectal cancer crc were synthesized among those compounds 5b exhibited good inhibitory activity of crc through the inhibition of tubulin expression inducing apoptosis and causing g2m phase cell cycle arrest pathway which suggested that 5b could be a potential tubulin inhibitor based on that a novel peptidedrug conjugate pdc which employed the crc cells related receptor cd44 ligand peptide a6 coupling to 5b to accomplish a65b the in vitro and in vivo studies showed that a65b could significantly inhibit the tumor growth and metastasis in crc cells mechanistic studies revealed that both 5b and a65b exert their antitumor effects by inhibiting tubulin demonstrating that 5b might play a payload role and a6 could act as a targeting moiety for selective drug delivery to tumor cells,"['a', 'series', 'of', 'isatin', 'derivatives', 'which', 'could', 'inhibit', 'colorectal', 'cancer', 'crc', 'were', 'synthesized', 'among', 'those', 'compounds', '5b', 'exhibited', 'good', 'inhibitory', 'activity', 'of', 'crc', 'through', 'the', 'inhibition', 'of', 'tubulin', 'expression', 'inducing', 'apoptosis', 'and', 'causing', 'g2m', 'phase', 'cell', 'cycle', 'arrest', 'pathway', 'which', 'suggested', 'that', '5b', 'could', 'be', 'a', 'potential', 'tubulin', 'inhibitor', 'based', 'on', 'that', 'a', 'novel', 'peptidedrug', 'conjugate', 'pdc', 'which', 'employed', 'the', 'crc', 'cells', 'related', 'receptor', 'cd44', 'ligand', 'peptide', 'a6', 'coupling', 'to', '5b', 'to', 'accomplish', 'a65b', 'the', 'in', 'vitro', 'and', 'in', 'vivo', 'studies', 'showed', 'that', 'a65b', 'could', 'significantly', 'inhibit', 'the', 'tumor', 'growth', 'and', 'metastasis', 'in', 'crc', 'cells', 'mechanistic', 'studies', 'revealed', 'that', 'both', '5b', 'and', 'a65b', 'exert', 'their', 'antitumor', 'effects', 'by', 'inhibiting', 'tubulin', 'demonstrating', 'that', '5b', 'might', 'play', 'a', 'payload', 'role', 'and', 'a6', 'could', 'act', 'as', 'a', 'targeting', 'moiety', 'for', 'selective', 'drug', 'delivery', 'to', 'tumor', 'cells']","['series', 'isatin', 'derivatives', 'could', 'inhibit', 'colorectal', 'cancer', 'crc', 'synthesized', 'among', 'compounds', '5b', 'exhibited', 'good', 'inhibitory', 'activity', 'crc', 'inhibition', 'tubulin', 'expression', 'inducing', 'apoptosis', 'causing', 'g2m', 'phase', 'cell', 'cycle', 'arrest', 'pathway', 'suggested', '5b', 'could', 'potential', 'tubulin', 'inhibitor', 'based', 'novel', 'peptidedrug', 'conjugate', 'pdc', 'employed', 'crc', 'cells', 'related', 'receptor', 'cd44', 'ligand', 'peptide', 'a6', 'coupling', '5b', 'accomplish', 'a65b', 'vitro', 'vivo', 'studies', 'showed', 'a65b', 'could', 'significantly', 'inhibit', 'tumor', 'growth', 'metastasis', 'crc', 'cells', 'mechanistic', 'studies', 'revealed', '5b', 'a65b', 'exert', 'antitumor', 'effects', 'inhibiting', 'tubulin', 'demonstrating', '5b', 'might', 'play', 'payload', 'role', 'a6', 'could', 'act', 'targeting', 'moiety', 'selective', 'drug', 'delivery', 'tumor', 'cells']","['crc', 'crc', 'tubulin', 'tubulin', 'pdc', 'crc', 'cd44', 'crc', 'tubulin']",['cd44'],True,"['tumor', 'cancer']"
39770478,Identification of a Potential PGK1 Inhibitor with the Suppression of Breast Cancer Cells Using Virtual Screening and Molecular Docking.,"Breast cancer is the second most common malignancy worldwide and poses a significant threat to women's health. However, the prognostic biomarkers and therapeutic targets of breast cancer are unclear. A prognostic model can help in identifying biomarkers and targets for breast cancer. In this study, a novel prognostic model was developed to optimize treatment, improve clinical prognosis, and screen potential phosphoglycerate kinase 1 (PGK1) inhibitors for breast cancer treatment.",2024-12-05,breast cancer is the second most common malignancy worldwide and poses a significant threat to womens health however the prognostic biomarkers and therapeutic targets of breast cancer are unclear a prognostic model can help in identifying biomarkers and targets for breast cancer in this study a novel prognostic model was developed to optimize treatment improve clinical prognosis and screen potential phosphoglycerate kinase 1 pgk1 inhibitors for breast cancer treatment,"['breast', 'cancer', 'is', 'the', 'second', 'most', 'common', 'malignancy', 'worldwide', 'and', 'poses', 'a', 'significant', 'threat', 'to', 'womens', 'health', 'however', 'the', 'prognostic', 'biomarkers', 'and', 'therapeutic', 'targets', 'of', 'breast', 'cancer', 'are', 'unclear', 'a', 'prognostic', 'model', 'can', 'help', 'in', 'identifying', 'biomarkers', 'and', 'targets', 'for', 'breast', 'cancer', 'in', 'this', 'study', 'a', 'novel', 'prognostic', 'model', 'was', 'developed', 'to', 'optimize', 'treatment', 'improve', 'clinical', 'prognosis', 'and', 'screen', 'potential', 'phosphoglycerate', 'kinase', '1', 'pgk1', 'inhibitors', 'for', 'breast', 'cancer', 'treatment']","['breast', 'cancer', 'second', 'common', 'malignancy', 'worldwide', 'poses', 'significant', 'threat', 'womens', 'health', 'however', 'prognostic', 'biomarkers', 'therapeutic', 'targets', 'breast', 'cancer', 'unclear', 'prognostic', 'model', 'help', 'identifying', 'biomarkers', 'targets', 'breast', 'cancer', 'study', 'novel', 'prognostic', 'model', 'developed', 'optimize', 'treatment', 'improve', 'clinical', 'prognosis', 'screen', 'potential', 'phosphoglycerate', 'kinase', '1', 'pgk1', 'inhibitors', 'breast', 'cancer', 'treatment']",['pgk1'],['pgk1'],True,['cancer']
39766503,PA-Win2: In Silico-Based Discovery of a Novel Peptide with Dual Antibacterial and Anti-Biofilm Activity.,"<b>Background:</b> The emergence and prevalence of antibiotic-resistant bacteria (ARBs) have become a serious global threat, as the morbidity and mortality associated with ARB infections are continuously rising. The activation of quorum sensing (QS) genes can promote biofilm formation, which contributes to the acquisition of drug resistance and increases virulence. Therefore, there is an urgent need to develop new antimicrobial agents to control ARB and prevent further development. Antimicrobial peptides (AMPs) are naturally occurring defense molecules in organisms known to suppress pathogens through a broad range of antimicrobial mechanisms. <b>Methods:</b> In this study, we utilized a previously developed deep-learning model to identify AMP candidates from the venom gland transcriptome of the spider <i>Pardosa astrigera</i>, followed by experimental validation. <b>Results:</b> PA-Win2 was among the top-scoring predicted peptides and was selected based on physiochemical features. Subsequent experimental validation demonstrated that PA-Win2 inhibits the growth of <i>Bacillus subtilis</i>, <i>Escherichia coli</i>, <i>Staphylococcus aureus</i>, <i>Staphylococcus epidermidis</i>, <i>Pseudomonas aeruginosa</i>, and multidrug-resistant <i>P</i>. <i>aeruginosa</i> (MRPA) strain CCARM 2095. The peptide exhibited strong bactericidal activity against <i>P</i>. <i>aeruginosa</i>, and MRPA CCARM 2095 through the depolarization of bacterial cytoplasmic membranes and alteration of gene expression associated with bacterial survival. In addition, PA-Win2 effectively inhibited biofilm formation and degraded pre-formed biofilms of <i>P</i>. <i>aeruginosa</i>. The gene expression study showed that the peptide treatment led to the downregulation of QS genes in the Las, Pqs, and Rhl systems. <b>Conclusions:</b> These findings suggest PA-Win2 as a promising drug candidate against ARB and demonstrate the potential of in silico methods in discovering functional peptides from biological data.",2024-11-21,bbackgroundb the emergence and prevalence of antibioticresistant bacteria arbs have become a serious global threat as the morbidity and mortality associated with arb infections are continuously rising the activation of quorum sensing qs genes can promote biofilm formation which contributes to the acquisition of drug resistance and increases virulence therefore there is an urgent need to develop new antimicrobial agents to control arb and prevent further development antimicrobial peptides amps are naturally occurring defense molecules in organisms known to suppress pathogens through a broad range of antimicrobial mechanisms bmethodsb in this study we utilized a previously developed deeplearning model to identify amp candidates from the venom gland transcriptome of the spider ipardosa astrigerai followed by experimental validation bresultsb pawin2 was among the topscoring predicted peptides and was selected based on physiochemical features subsequent experimental validation demonstrated that pawin2 inhibits the growth of ibacillus subtilisi iescherichia colii istaphylococcus aureusi istaphylococcus epidermidisi ipseudomonas aeruginosai and multidrugresistant ipi iaeruginosai mrpa strain ccarm 2095 the peptide exhibited strong bactericidal activity against ipi iaeruginosai and mrpa ccarm 2095 through the depolarization of bacterial cytoplasmic membranes and alteration of gene expression associated with bacterial survival in addition pawin2 effectively inhibited biofilm formation and degraded preformed biofilms of ipi iaeruginosai the gene expression study showed that the peptide treatment led to the downregulation of qs genes in the las pqs and rhl systems bconclusionsb these findings suggest pawin2 as a promising drug candidate against arb and demonstrate the potential of in silico methods in discovering functional peptides from biological data,"['bbackgroundb', 'the', 'emergence', 'and', 'prevalence', 'of', 'antibioticresistant', 'bacteria', 'arbs', 'have', 'become', 'a', 'serious', 'global', 'threat', 'as', 'the', 'morbidity', 'and', 'mortality', 'associated', 'with', 'arb', 'infections', 'are', 'continuously', 'rising', 'the', 'activation', 'of', 'quorum', 'sensing', 'qs', 'genes', 'can', 'promote', 'biofilm', 'formation', 'which', 'contributes', 'to', 'the', 'acquisition', 'of', 'drug', 'resistance', 'and', 'increases', 'virulence', 'therefore', 'there', 'is', 'an', 'urgent', 'need', 'to', 'develop', 'new', 'antimicrobial', 'agents', 'to', 'control', 'arb', 'and', 'prevent', 'further', 'development', 'antimicrobial', 'peptides', 'amps', 'are', 'naturally', 'occurring', 'defense', 'molecules', 'in', 'organisms', 'known', 'to', 'suppress', 'pathogens', 'through', 'a', 'broad', 'range', 'of', 'antimicrobial', 'mechanisms', 'bmethodsb', 'in', 'this', 'study', 'we', 'utilized', 'a', 'previously', 'developed', 'deeplearning', 'model', 'to', 'identify', 'amp', 'candidates', 'from', 'the', 'venom', 'gland', 'transcriptome', 'of', 'the', 'spider', 'ipardosa', 'astrigerai', 'followed', 'by', 'experimental', 'validation', 'bresultsb', 'pawin2', 'was', 'among', 'the', 'topscoring', 'predicted', 'peptides', 'and', 'was', 'selected', 'based', 'on', 'physiochemical', 'features', 'subsequent', 'experimental', 'validation', 'demonstrated', 'that', 'pawin2', 'inhibits', 'the', 'growth', 'of', 'ibacillus', 'subtilisi', 'iescherichia', 'colii', 'istaphylococcus', 'aureusi', 'istaphylococcus', 'epidermidisi', 'ipseudomonas', 'aeruginosai', 'and', 'multidrugresistant', 'ipi', 'iaeruginosai', 'mrpa', 'strain', 'ccarm', '2095', 'the', 'peptide', 'exhibited', 'strong', 'bactericidal', 'activity', 'against', 'ipi', 'iaeruginosai', 'and', 'mrpa', 'ccarm', '2095', 'through', 'the', 'depolarization', 'of', 'bacterial', 'cytoplasmic', 'membranes', 'and', 'alteration', 'of', 'gene', 'expression', 'associated', 'with', 'bacterial', 'survival', 'in', 'addition', 'pawin2', 'effectively', 'inhibited', 'biofilm', 'formation', 'and', 'degraded', 'preformed', 'biofilms', 'of', 'ipi', 'iaeruginosai', 'the', 'gene', 'expression', 'study', 'showed', 'that', 'the', 'peptide', 'treatment', 'led', 'to', 'the', 'downregulation', 'of', 'qs', 'genes', 'in', 'the', 'las', 'pqs', 'and', 'rhl', 'systems', 'bconclusionsb', 'these', 'findings', 'suggest', 'pawin2', 'as', 'a', 'promising', 'drug', 'candidate', 'against', 'arb', 'and', 'demonstrate', 'the', 'potential', 'of', 'in', 'silico', 'methods', 'in', 'discovering', 'functional', 'peptides', 'from', 'biological', 'data']","['bbackgroundb', 'emergence', 'prevalence', 'antibioticresistant', 'bacteria', 'arbs', 'become', 'serious', 'global', 'threat', 'morbidity', 'mortality', 'associated', 'arb', 'infections', 'continuously', 'rising', 'activation', 'quorum', 'sensing', 'qs', 'genes', 'promote', 'biofilm', 'formation', 'contributes', 'acquisition', 'drug', 'resistance', 'increases', 'virulence', 'therefore', 'urgent', 'need', 'develop', 'new', 'antimicrobial', 'agents', 'control', 'arb', 'prevent', 'development', 'antimicrobial', 'peptides', 'amps', 'naturally', 'occurring', 'defense', 'molecules', 'organisms', 'known', 'suppress', 'pathogens', 'broad', 'range', 'antimicrobial', 'mechanisms', 'bmethodsb', 'study', 'utilized', 'previously', 'developed', 'deeplearning', 'model', 'identify', 'amp', 'candidates', 'venom', 'gland', 'transcriptome', 'spider', 'ipardosa', 'astrigerai', 'followed', 'experimental', 'validation', 'bresultsb', 'pawin2', 'among', 'topscoring', 'predicted', 'peptides', 'selected', 'based', 'physiochemical', 'features', 'subsequent', 'experimental', 'validation', 'demonstrated', 'pawin2', 'inhibits', 'growth', 'ibacillus', 'subtilisi', 'iescherichia', 'colii', 'istaphylococcus', 'aureusi', 'istaphylococcus', 'epidermidisi', 'ipseudomonas', 'aeruginosai', 'multidrugresistant', 'ipi', 'iaeruginosai', 'mrpa', 'strain', 'ccarm', '2095', 'peptide', 'exhibited', 'strong', 'bactericidal', 'activity', 'ipi', 'iaeruginosai', 'mrpa', 'ccarm', '2095', 'depolarization', 'bacterial', 'cytoplasmic', 'membranes', 'alteration', 'gene', 'expression', 'associated', 'bacterial', 'survival', 'addition', 'pawin2', 'effectively', 'inhibited', 'biofilm', 'formation', 'degraded', 'preformed', 'biofilms', 'ipi', 'iaeruginosai', 'gene', 'expression', 'study', 'showed', 'peptide', 'treatment', 'led', 'downregulation', 'qs', 'genes', 'las', 'pqs', 'rhl', 'systems', 'bconclusionsb', 'findings', 'suggest', 'pawin2', 'promising', 'drug', 'candidate', 'arb', 'demonstrate', 'potential', 'silico', 'methods', 'discovering', 'functional', 'peptides', 'biological', 'data']","['pawin2', 'pawin2', 'pawin2', 'pawin2']","['pawin2', 'pawin2', 'pawin2', 'pawin2']",True,['infection']
39759328,Design and in silico analysis of a novel peptide-based multiepitope vaccine against glioblastoma multiforme by targeting tumor-associated macrophage.,"CD204 is a distinct indicator for tumor-associated macrophages (TAMs) in glioma. Evidence indicates that CD204-positive TAMs are involved in the aggressive behavior of various types of cancers. This study was conducted to develop a new and effective peptide-based vaccine for GBM, specifically targeting CD204. Epitopes of the target protein were identified using NetMHCpan 4.1a, NetMHCIIpan-4.0, and ABCpred tools. Subsequently, the predicted epitopes were evaluated using bioinformatics tools to assess their antigenicity, non-allergenicity, immunogenicity, non-toxicity, and potential to stimulate the production of IL-4 and IFN-γ in HTL epitopes. Selected T-cell epitopes demonstrated a robust binding affinity with the particular HLA alleles. Finally, four HTL epitopes, three CTL epitopes, and two B-cell epitopes, jointed via linkers and adjuvant, were used for the final vaccine construct design. Analysis disclosed that the developed vaccine demonstrated robust antigenic properties while proving soluble, stable, non-toxic, and non-allergenic. Additionally, molecular docking studies and molecular dynamics simulations confirmed a robust correlation between the designed vaccine and TLR-2 and TLR-4 immune receptors. The molecular docking results demonstrated a strong interaction between the newly developed vaccine and TLR2 (-895.1 kcal/mol) and TLR4 (-881.0 kcal/mol) receptors. During the simulation, the vaccine-TLR2 and vaccine-TLR4 complexes exhibited binding energies of -113.41 and -106.61 kcal/mol, respectively. Analysis by different bioinformatic tools indicated the potential of the designed vaccine in immune stimulation and a significant elevation in IgG and IgM antibodies, T-helper cells, T-cytotoxic cells, INF-γ, IL-2, and IL-4. Research findings show that the newly designed multi-epitope vaccine is promising in providing long-term immunity against GBM and offers a promising therapeutic alternative.",2024-11-28,cd204 is a distinct indicator for tumorassociated macrophages tams in glioma evidence indicates that cd204positive tams are involved in the aggressive behavior of various types of cancers this study was conducted to develop a new and effective peptidebased vaccine for gbm specifically targeting cd204 epitopes of the target protein were identified using netmhcpan 41a netmhciipan40 and abcpred tools subsequently the predicted epitopes were evaluated using bioinformatics tools to assess their antigenicity nonallergenicity immunogenicity nontoxicity and potential to stimulate the production of il4 and ifnγ in htl epitopes selected tcell epitopes demonstrated a robust binding affinity with the particular hla alleles finally four htl epitopes three ctl epitopes and two bcell epitopes jointed via linkers and adjuvant were used for the final vaccine construct design analysis disclosed that the developed vaccine demonstrated robust antigenic properties while proving soluble stable nontoxic and nonallergenic additionally molecular docking studies and molecular dynamics simulations confirmed a robust correlation between the designed vaccine and tlr2 and tlr4 immune receptors the molecular docking results demonstrated a strong interaction between the newly developed vaccine and tlr2 8951 kcalmol and tlr4 8810 kcalmol receptors during the simulation the vaccinetlr2 and vaccinetlr4 complexes exhibited binding energies of 11341 and 10661 kcalmol respectively analysis by different bioinformatic tools indicated the potential of the designed vaccine in immune stimulation and a significant elevation in igg and igm antibodies thelper cells tcytotoxic cells infγ il2 and il4 research findings show that the newly designed multiepitope vaccine is promising in providing longterm immunity against gbm and offers a promising therapeutic alternative,"['cd204', 'is', 'a', 'distinct', 'indicator', 'for', 'tumorassociated', 'macrophages', 'tams', 'in', 'glioma', 'evidence', 'indicates', 'that', 'cd204positive', 'tams', 'are', 'involved', 'in', 'the', 'aggressive', 'behavior', 'of', 'various', 'types', 'of', 'cancers', 'this', 'study', 'was', 'conducted', 'to', 'develop', 'a', 'new', 'and', 'effective', 'peptidebased', 'vaccine', 'for', 'gbm', 'specifically', 'targeting', 'cd204', 'epitopes', 'of', 'the', 'target', 'protein', 'were', 'identified', 'using', 'netmhcpan', '41a', 'netmhciipan40', 'and', 'abcpred', 'tools', 'subsequently', 'the', 'predicted', 'epitopes', 'were', 'evaluated', 'using', 'bioinformatics', 'tools', 'to', 'assess', 'their', 'antigenicity', 'nonallergenicity', 'immunogenicity', 'nontoxicity', 'and', 'potential', 'to', 'stimulate', 'the', 'production', 'of', 'il4', 'and', 'ifnγ', 'in', 'htl', 'epitopes', 'selected', 'tcell', 'epitopes', 'demonstrated', 'a', 'robust', 'binding', 'affinity', 'with', 'the', 'particular', 'hla', 'alleles', 'finally', 'four', 'htl', 'epitopes', 'three', 'ctl', 'epitopes', 'and', 'two', 'bcell', 'epitopes', 'jointed', 'via', 'linkers', 'and', 'adjuvant', 'were', 'used', 'for', 'the', 'final', 'vaccine', 'construct', 'design', 'analysis', 'disclosed', 'that', 'the', 'developed', 'vaccine', 'demonstrated', 'robust', 'antigenic', 'properties', 'while', 'proving', 'soluble', 'stable', 'nontoxic', 'and', 'nonallergenic', 'additionally', 'molecular', 'docking', 'studies', 'and', 'molecular', 'dynamics', 'simulations', 'confirmed', 'a', 'robust', 'correlation', 'between', 'the', 'designed', 'vaccine', 'and', 'tlr2', 'and', 'tlr4', 'immune', 'receptors', 'the', 'molecular', 'docking', 'results', 'demonstrated', 'a', 'strong', 'interaction', 'between', 'the', 'newly', 'developed', 'vaccine', 'and', 'tlr2', '8951', 'kcalmol', 'and', 'tlr4', '8810', 'kcalmol', 'receptors', 'during', 'the', 'simulation', 'the', 'vaccinetlr2', 'and', 'vaccinetlr4', 'complexes', 'exhibited', 'binding', 'energies', 'of', '11341', 'and', '10661', 'kcalmol', 'respectively', 'analysis', 'by', 'different', 'bioinformatic', 'tools', 'indicated', 'the', 'potential', 'of', 'the', 'designed', 'vaccine', 'in', 'immune', 'stimulation', 'and', 'a', 'significant', 'elevation', 'in', 'igg', 'and', 'igm', 'antibodies', 'thelper', 'cells', 'tcytotoxic', 'cells', 'infγ', 'il2', 'and', 'il4', 'research', 'findings', 'show', 'that', 'the', 'newly', 'designed', 'multiepitope', 'vaccine', 'is', 'promising', 'in', 'providing', 'longterm', 'immunity', 'against', 'gbm', 'and', 'offers', 'a', 'promising', 'therapeutic', 'alternative']","['cd204', 'distinct', 'indicator', 'tumorassociated', 'macrophages', 'tams', 'glioma', 'evidence', 'indicates', 'cd204positive', 'tams', 'involved', 'aggressive', 'behavior', 'various', 'types', 'cancers', 'study', 'conducted', 'develop', 'new', 'effective', 'peptidebased', 'vaccine', 'gbm', 'specifically', 'targeting', 'cd204', 'epitopes', 'target', 'protein', 'identified', 'using', 'netmhcpan', '41a', 'netmhciipan40', 'abcpred', 'tools', 'subsequently', 'predicted', 'epitopes', 'evaluated', 'using', 'bioinformatics', 'tools', 'assess', 'antigenicity', 'nonallergenicity', 'immunogenicity', 'nontoxicity', 'potential', 'stimulate', 'production', 'il4', 'ifnγ', 'htl', 'epitopes', 'selected', 'tcell', 'epitopes', 'demonstrated', 'robust', 'binding', 'affinity', 'particular', 'hla', 'alleles', 'finally', 'four', 'htl', 'epitopes', 'three', 'ctl', 'epitopes', 'two', 'bcell', 'epitopes', 'jointed', 'via', 'linkers', 'adjuvant', 'used', 'final', 'vaccine', 'construct', 'design', 'analysis', 'disclosed', 'developed', 'vaccine', 'demonstrated', 'robust', 'antigenic', 'properties', 'proving', 'soluble', 'stable', 'nontoxic', 'nonallergenic', 'additionally', 'molecular', 'docking', 'studies', 'molecular', 'dynamics', 'simulations', 'confirmed', 'robust', 'correlation', 'designed', 'vaccine', 'tlr2', 'tlr4', 'immune', 'receptors', 'molecular', 'docking', 'results', 'demonstrated', 'strong', 'interaction', 'newly', 'developed', 'vaccine', 'tlr2', '8951', 'kcalmol', 'tlr4', '8810', 'kcalmol', 'receptors', 'simulation', 'vaccinetlr2', 'vaccinetlr4', 'complexes', 'exhibited', 'binding', 'energies', '11341', '10661', 'kcalmol', 'respectively', 'analysis', 'different', 'bioinformatic', 'tools', 'indicated', 'potential', 'designed', 'vaccine', 'immune', 'stimulation', 'significant', 'elevation', 'igg', 'igm', 'antibodies', 'thelper', 'cells', 'tcytotoxic', 'cells', 'infγ', 'il2', 'il4', 'research', 'findings', 'show', 'newly', 'designed', 'multiepitope', 'vaccine', 'promising', 'providing', 'longterm', 'immunity', 'gbm', 'offers', 'promising', 'therapeutic', 'alternative']","['htl', 'hla', 'htl', 'tlr2', 'tlr4', 'tlr2', 'tlr4']","['tlr2', 'tlr4', 'tlr2', 'tlr4']",True,"['tumor', 'cancer']"
39755244,"A novel peptide CP29L, selected from the phage displayed cyclic random heptapeptide library, demonstrates its potent inhibitory effects to liver cancer HCCLM3 cells by targeting FOXM1.","FOXM1 is the ""Achilles' heel"" of cancers and hence the potential therapeutic target for anticancer drug discovery. In this work, we selected high affinity peptides against the protein of human DNA binding domain of FOXM1 (FOXM1-DBD) from the disulfide-constrained, phage displayed random cyclic heptapeptide library Ph.D.-C7C. We obtained a novel peptide, 9 R-CP29L, which was identified to be a potent anticancer peptide with IC<sub>50</sub> values of 9.0 and 11.1 μM at 24 h for HCCLM3 and MD-MBA-231 cells respectively. Molecular docking, CETSA, ITC and immunoblot assays demonstrated that 9 R-CP29L can potentially specifically bind to FOXM1-DBD with a K<sub>d</sub> value of 1.25 μM and reduced the expression of FOXM1. In addition, Annexin V/PI flow cytometry, AO/EB staining, PI flow cytometry, clone formation and Transwell assays revealed that 9 R-CP29L also induced cell apoptosis and cell cycle arrest while inhibited the proliferation and migration of HCCLM3 cells. The findings were further supported by the results of qRT-PCR and immunoblot assays for the associated gene (CMYC, CDC25B, BAX, CASPASE3 and MMP2, etc) expression in HCCLM3 cells. Finally, in vivo experiment showed that 9 R-CP29 significantly reduced the tumor growth and downregulated the expression of FOXM1 in HCCLM3 xenograft nude mouse models. Taking together, our work provides a novel FOXM1 targeted peptide which has potential in both anticancer drug development and scientific researches.",2025-01-02,foxm1 is the achilles heel of cancers and hence the potential therapeutic target for anticancer drug discovery in this work we selected high affinity peptides against the protein of human dna binding domain of foxm1 foxm1dbd from the disulfideconstrained phage displayed random cyclic heptapeptide library phdc7c we obtained a novel peptide 9 rcp29l which was identified to be a potent anticancer peptide with icsub50sub values of 90 and 111 μm at 24 h for hcclm3 and mdmba231 cells respectively molecular docking cetsa itc and immunoblot assays demonstrated that 9 rcp29l can potentially specifically bind to foxm1dbd with a ksubdsub value of 125 μm and reduced the expression of foxm1 in addition annexin vpi flow cytometry aoeb staining pi flow cytometry clone formation and transwell assays revealed that 9 rcp29l also induced cell apoptosis and cell cycle arrest while inhibited the proliferation and migration of hcclm3 cells the findings were further supported by the results of qrtpcr and immunoblot assays for the associated gene cmyc cdc25b bax caspase3 and mmp2 etc expression in hcclm3 cells finally in vivo experiment showed that 9 rcp29 significantly reduced the tumor growth and downregulated the expression of foxm1 in hcclm3 xenograft nude mouse models taking together our work provides a novel foxm1 targeted peptide which has potential in both anticancer drug development and scientific researches,"['foxm1', 'is', 'the', 'achilles', 'heel', 'of', 'cancers', 'and', 'hence', 'the', 'potential', 'therapeutic', 'target', 'for', 'anticancer', 'drug', 'discovery', 'in', 'this', 'work', 'we', 'selected', 'high', 'affinity', 'peptides', 'against', 'the', 'protein', 'of', 'human', 'dna', 'binding', 'domain', 'of', 'foxm1', 'foxm1dbd', 'from', 'the', 'disulfideconstrained', 'phage', 'displayed', 'random', 'cyclic', 'heptapeptide', 'library', 'phdc7c', 'we', 'obtained', 'a', 'novel', 'peptide', '9', 'rcp29l', 'which', 'was', 'identified', 'to', 'be', 'a', 'potent', 'anticancer', 'peptide', 'with', 'icsub50sub', 'values', 'of', '90', 'and', '111', 'μm', 'at', '24', 'h', 'for', 'hcclm3', 'and', 'mdmba231', 'cells', 'respectively', 'molecular', 'docking', 'cetsa', 'itc', 'and', 'immunoblot', 'assays', 'demonstrated', 'that', '9', 'rcp29l', 'can', 'potentially', 'specifically', 'bind', 'to', 'foxm1dbd', 'with', 'a', 'ksubdsub', 'value', 'of', '125', 'μm', 'and', 'reduced', 'the', 'expression', 'of', 'foxm1', 'in', 'addition', 'annexin', 'vpi', 'flow', 'cytometry', 'aoeb', 'staining', 'pi', 'flow', 'cytometry', 'clone', 'formation', 'and', 'transwell', 'assays', 'revealed', 'that', '9', 'rcp29l', 'also', 'induced', 'cell', 'apoptosis', 'and', 'cell', 'cycle', 'arrest', 'while', 'inhibited', 'the', 'proliferation', 'and', 'migration', 'of', 'hcclm3', 'cells', 'the', 'findings', 'were', 'further', 'supported', 'by', 'the', 'results', 'of', 'qrtpcr', 'and', 'immunoblot', 'assays', 'for', 'the', 'associated', 'gene', 'cmyc', 'cdc25b', 'bax', 'caspase3', 'and', 'mmp2', 'etc', 'expression', 'in', 'hcclm3', 'cells', 'finally', 'in', 'vivo', 'experiment', 'showed', 'that', '9', 'rcp29', 'significantly', 'reduced', 'the', 'tumor', 'growth', 'and', 'downregulated', 'the', 'expression', 'of', 'foxm1', 'in', 'hcclm3', 'xenograft', 'nude', 'mouse', 'models', 'taking', 'together', 'our', 'work', 'provides', 'a', 'novel', 'foxm1', 'targeted', 'peptide', 'which', 'has', 'potential', 'in', 'both', 'anticancer', 'drug', 'development', 'and', 'scientific', 'researches']","['foxm1', 'achilles', 'heel', 'cancers', 'hence', 'potential', 'therapeutic', 'target', 'anticancer', 'drug', 'discovery', 'work', 'selected', 'high', 'affinity', 'peptides', 'protein', 'human', 'dna', 'binding', 'domain', 'foxm1', 'foxm1dbd', 'disulfideconstrained', 'phage', 'displayed', 'random', 'cyclic', 'heptapeptide', 'library', 'phdc7c', 'obtained', 'novel', 'peptide', '9', 'rcp29l', 'identified', 'potent', 'anticancer', 'peptide', 'icsub50sub', 'values', '90', '111', 'μm', '24', 'h', 'hcclm3', 'mdmba231', 'cells', 'respectively', 'molecular', 'docking', 'cetsa', 'itc', 'immunoblot', 'assays', 'demonstrated', '9', 'rcp29l', 'potentially', 'specifically', 'bind', 'foxm1dbd', 'ksubdsub', 'value', '125', 'μm', 'reduced', 'expression', 'foxm1', 'addition', 'annexin', 'vpi', 'flow', 'cytometry', 'aoeb', 'staining', 'pi', 'flow', 'cytometry', 'clone', 'formation', 'transwell', 'assays', 'revealed', '9', 'rcp29l', 'also', 'induced', 'cell', 'apoptosis', 'cell', 'cycle', 'arrest', 'inhibited', 'proliferation', 'migration', 'hcclm3', 'cells', 'findings', 'supported', 'results', 'qrtpcr', 'immunoblot', 'assays', 'associated', 'gene', 'cmyc', 'cdc25b', 'bax', 'caspase3', 'mmp2', 'etc', 'expression', 'hcclm3', 'cells', 'finally', 'vivo', 'experiment', 'showed', '9', 'rcp29', 'significantly', 'reduced', 'tumor', 'growth', 'downregulated', 'expression', 'foxm1', 'hcclm3', 'xenograft', 'nude', 'mouse', 'models', 'taking', 'together', 'work', 'provides', 'novel', 'foxm1', 'targeted', 'peptide', 'potential', 'anticancer', 'drug', 'development', 'scientific', 'researches']","['foxm1', 'foxm1', 'foxm1', 'annexin', 'cdc25b', 'bax', 'caspase3', 'mmp2', 'foxm1', 'foxm1']","['foxm1', 'foxm1', 'foxm1', 'cdc25b', 'caspase3', 'mmp2', 'foxm1', 'foxm1']",True,"['tumor', 'cancer']"
39723566,"Nuclear Factor Erythroid 2-Related Factor 2 Activator DDO-1039 Ameliorates Podocyte Injury in Diabetic Kidney Disease via Suppressing Oxidative Stress, Inflammation, and Ferroptosis.","<b><i>Aims:</i></b> Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease, and podocyte injury is one of the major contributors to DKD. As a crucial transcriptional factor that regulates cellular response to oxidative stress, nuclear factor erythroid 2-related factor 2 (Nrf2) is an attractive therapeutic target for DKD. In this study, we evaluated the therapeutic potential of DDO-1039, a novel small-molecule Nrf2 activator developed with protein-protein interaction strategy, on podocyte injury in DKD. <b><i>Results:</i></b> DDO-1039 treatment significantly increased Nrf2 protein level and Nrf2 nuclear translocation, thereby upregulating Nrf2 target genes [heme oxygenase 1, NAD(P)H quinone dehydrogenase 1, glutamate-cysteine ligase modifier, and tyrosine-protein kinase receptor] both <i>in vitro</i> and <i>in vivo</i>. DDO-1039 attenuated glomerular sclerosis and podocyte injury in the high-fat diet/streptozotocin-induced (HFD/STZ) diabetic mice and db/db diabetic mice. It also significantly improved hyperglycemia in both diabetic mice and mitigated proteinuria in HFD/STZ mice. Meanwhile, DDO-1039 attenuated oxidative stress and inflammation as well as apoptosis <i>in vivo</i> and in podocytes stimulated with palmitic acid and high glucose. Interestingly, we identified podocyte protective factor Tyro3 as a novel Nrf2-regulated gene. In addition, podocyte ferroptosis is reduced <i>via</i> activation of glutathione peroxidase 4 by the novel Nrf2 activator. <b><i>Innovation and conclusion:</i></b> DDO-1039 activates the Nrf2-based cytoprotective system to mitigate podocyte injury in the context of diabetes, suggesting the potential of DDO-1039 in the treatment of DKD. <i>Antioxid. Redox Signal.</i> 00, 000-000.",2024-12-24,biaimsib diabetic kidney disease dkd is the leading cause of endstage kidney disease and podocyte injury is one of the major contributors to dkd as a crucial transcriptional factor that regulates cellular response to oxidative stress nuclear factor erythroid 2related factor 2 nrf2 is an attractive therapeutic target for dkd in this study we evaluated the therapeutic potential of ddo1039 a novel smallmolecule nrf2 activator developed with proteinprotein interaction strategy on podocyte injury in dkd biresultsib ddo1039 treatment significantly increased nrf2 protein level and nrf2 nuclear translocation thereby upregulating nrf2 target genes heme oxygenase 1 nadph quinone dehydrogenase 1 glutamatecysteine ligase modifier and tyrosineprotein kinase receptor both iin vitroi and iin vivoi ddo1039 attenuated glomerular sclerosis and podocyte injury in the highfat dietstreptozotocininduced hfdstz diabetic mice and dbdb diabetic mice it also significantly improved hyperglycemia in both diabetic mice and mitigated proteinuria in hfdstz mice meanwhile ddo1039 attenuated oxidative stress and inflammation as well as apoptosis iin vivoi and in podocytes stimulated with palmitic acid and high glucose interestingly we identified podocyte protective factor tyro3 as a novel nrf2regulated gene in addition podocyte ferroptosis is reduced iviai activation of glutathione peroxidase 4 by the novel nrf2 activator biinnovation and conclusionib ddo1039 activates the nrf2based cytoprotective system to mitigate podocyte injury in the context of diabetes suggesting the potential of ddo1039 in the treatment of dkd iantioxid redox signali 00 000000,"['biaimsib', 'diabetic', 'kidney', 'disease', 'dkd', 'is', 'the', 'leading', 'cause', 'of', 'endstage', 'kidney', 'disease', 'and', 'podocyte', 'injury', 'is', 'one', 'of', 'the', 'major', 'contributors', 'to', 'dkd', 'as', 'a', 'crucial', 'transcriptional', 'factor', 'that', 'regulates', 'cellular', 'response', 'to', 'oxidative', 'stress', 'nuclear', 'factor', 'erythroid', '2related', 'factor', '2', 'nrf2', 'is', 'an', 'attractive', 'therapeutic', 'target', 'for', 'dkd', 'in', 'this', 'study', 'we', 'evaluated', 'the', 'therapeutic', 'potential', 'of', 'ddo1039', 'a', 'novel', 'smallmolecule', 'nrf2', 'activator', 'developed', 'with', 'proteinprotein', 'interaction', 'strategy', 'on', 'podocyte', 'injury', 'in', 'dkd', 'biresultsib', 'ddo1039', 'treatment', 'significantly', 'increased', 'nrf2', 'protein', 'level', 'and', 'nrf2', 'nuclear', 'translocation', 'thereby', 'upregulating', 'nrf2', 'target', 'genes', 'heme', 'oxygenase', '1', 'nadph', 'quinone', 'dehydrogenase', '1', 'glutamatecysteine', 'ligase', 'modifier', 'and', 'tyrosineprotein', 'kinase', 'receptor', 'both', 'iin', 'vitroi', 'and', 'iin', 'vivoi', 'ddo1039', 'attenuated', 'glomerular', 'sclerosis', 'and', 'podocyte', 'injury', 'in', 'the', 'highfat', 'dietstreptozotocininduced', 'hfdstz', 'diabetic', 'mice', 'and', 'dbdb', 'diabetic', 'mice', 'it', 'also', 'significantly', 'improved', 'hyperglycemia', 'in', 'both', 'diabetic', 'mice', 'and', 'mitigated', 'proteinuria', 'in', 'hfdstz', 'mice', 'meanwhile', 'ddo1039', 'attenuated', 'oxidative', 'stress', 'and', 'inflammation', 'as', 'well', 'as', 'apoptosis', 'iin', 'vivoi', 'and', 'in', 'podocytes', 'stimulated', 'with', 'palmitic', 'acid', 'and', 'high', 'glucose', 'interestingly', 'we', 'identified', 'podocyte', 'protective', 'factor', 'tyro3', 'as', 'a', 'novel', 'nrf2regulated', 'gene', 'in', 'addition', 'podocyte', 'ferroptosis', 'is', 'reduced', 'iviai', 'activation', 'of', 'glutathione', 'peroxidase', '4', 'by', 'the', 'novel', 'nrf2', 'activator', 'biinnovation', 'and', 'conclusionib', 'ddo1039', 'activates', 'the', 'nrf2based', 'cytoprotective', 'system', 'to', 'mitigate', 'podocyte', 'injury', 'in', 'the', 'context', 'of', 'diabetes', 'suggesting', 'the', 'potential', 'of', 'ddo1039', 'in', 'the', 'treatment', 'of', 'dkd', 'iantioxid', 'redox', 'signali', '00', '000000']","['biaimsib', 'diabetic', 'kidney', 'disease', 'dkd', 'leading', 'cause', 'endstage', 'kidney', 'disease', 'podocyte', 'injury', 'one', 'major', 'contributors', 'dkd', 'crucial', 'transcriptional', 'factor', 'regulates', 'cellular', 'response', 'oxidative', 'stress', 'nuclear', 'factor', 'erythroid', '2related', 'factor', '2', 'nrf2', 'attractive', 'therapeutic', 'target', 'dkd', 'study', 'evaluated', 'therapeutic', 'potential', 'ddo1039', 'novel', 'smallmolecule', 'nrf2', 'activator', 'developed', 'proteinprotein', 'interaction', 'strategy', 'podocyte', 'injury', 'dkd', 'biresultsib', 'ddo1039', 'treatment', 'significantly', 'increased', 'nrf2', 'protein', 'level', 'nrf2', 'nuclear', 'translocation', 'thereby', 'upregulating', 'nrf2', 'target', 'genes', 'heme', 'oxygenase', '1', 'nadph', 'quinone', 'dehydrogenase', '1', 'glutamatecysteine', 'ligase', 'modifier', 'tyrosineprotein', 'kinase', 'receptor', 'iin', 'vitroi', 'iin', 'vivoi', 'ddo1039', 'attenuated', 'glomerular', 'sclerosis', 'podocyte', 'injury', 'highfat', 'dietstreptozotocininduced', 'hfdstz', 'diabetic', 'mice', 'dbdb', 'diabetic', 'mice', 'also', 'significantly', 'improved', 'hyperglycemia', 'diabetic', 'mice', 'mitigated', 'proteinuria', 'hfdstz', 'mice', 'meanwhile', 'ddo1039', 'attenuated', 'oxidative', 'stress', 'inflammation', 'well', 'apoptosis', 'iin', 'vivoi', 'podocytes', 'stimulated', 'palmitic', 'acid', 'high', 'glucose', 'interestingly', 'identified', 'podocyte', 'protective', 'factor', 'tyro3', 'novel', 'nrf2regulated', 'gene', 'addition', 'podocyte', 'ferroptosis', 'reduced', 'iviai', 'activation', 'glutathione', 'peroxidase', '4', 'novel', 'nrf2', 'activator', 'biinnovation', 'conclusionib', 'ddo1039', 'activates', 'nrf2based', 'cytoprotective', 'system', 'mitigate', 'podocyte', 'injury', 'context', 'diabetes', 'suggesting', 'potential', 'ddo1039', 'treatment', 'dkd', 'iantioxid', 'redox', 'signali', '00', '000000']","['nrf2', 'nrf2', 'nrf2', 'nrf2', 'nrf2', 'tyro3', 'peroxidase', 'nrf2']","['tyro3', 'peroxidase']",True,['diabetes']
39679370,Discovery of novel PARP1/NRP1 dual-targeting inhibitors with strong antitumor potency.,"Given that overexpression of Poly (ADP-ribose) polymerase-1 (PARP1) and Neuropilin-1 (NRP1) is implicated in the pathogenesis of human breast cancer, the design of dual PARP1/NRP1 inhibitors has wide therapeutic prospect. However, there have been no reports of such inhibitors so far. Herein, we discovered novel small molecule inhibitors that simultaneously target PARP1 and NRP1 using structure-based virtual screening for the treatment of breast cancer. Notably, PPNR-4 was the most potent inhibitor targeting PARP1 (IC<sub>50</sub> = 7.71 ± 0.39 nM) and NRP1 (IC<sub>50</sub> = 24.48 ± 2.16 nM). PPNR-4 showed high affinity and binding stability to PARP1 and NRP1. The cytotoxicity assays showed that PPNR-4 demonstrated significant antiproliferative activity on MDA-MB-231 cells (IC<sub>50</sub> = 0.21 μM) without effect on normal human cells. <i>In vivo</i> experiments exhibited that PPNR-4 showed more effective than the positive controls in inhibiting the growth of tumors. Overall, these data suggest that PPNR-4 is an effective antitumor candidate and deserves further research.",2024-11-29,given that overexpression of poly adpribose polymerase1 parp1 and neuropilin1 nrp1 is implicated in the pathogenesis of human breast cancer the design of dual parp1nrp1 inhibitors has wide therapeutic prospect however there have been no reports of such inhibitors so far herein we discovered novel small molecule inhibitors that simultaneously target parp1 and nrp1 using structurebased virtual screening for the treatment of breast cancer notably ppnr4 was the most potent inhibitor targeting parp1 icsub50sub  771  039 nm and nrp1 icsub50sub  2448  216 nm ppnr4 showed high affinity and binding stability to parp1 and nrp1 the cytotoxicity assays showed that ppnr4 demonstrated significant antiproliferative activity on mdamb231 cells icsub50sub  021 μm without effect on normal human cells iin vivoi experiments exhibited that ppnr4 showed more effective than the positive controls in inhibiting the growth of tumors overall these data suggest that ppnr4 is an effective antitumor candidate and deserves further research,"['given', 'that', 'overexpression', 'of', 'poly', 'adpribose', 'polymerase1', 'parp1', 'and', 'neuropilin1', 'nrp1', 'is', 'implicated', 'in', 'the', 'pathogenesis', 'of', 'human', 'breast', 'cancer', 'the', 'design', 'of', 'dual', 'parp1nrp1', 'inhibitors', 'has', 'wide', 'therapeutic', 'prospect', 'however', 'there', 'have', 'been', 'no', 'reports', 'of', 'such', 'inhibitors', 'so', 'far', 'herein', 'we', 'discovered', 'novel', 'small', 'molecule', 'inhibitors', 'that', 'simultaneously', 'target', 'parp1', 'and', 'nrp1', 'using', 'structurebased', 'virtual', 'screening', 'for', 'the', 'treatment', 'of', 'breast', 'cancer', 'notably', 'ppnr4', 'was', 'the', 'most', 'potent', 'inhibitor', 'targeting', 'parp1', 'icsub50sub', '771', '039', 'nm', 'and', 'nrp1', 'icsub50sub', '2448', '216', 'nm', 'ppnr4', 'showed', 'high', 'affinity', 'and', 'binding', 'stability', 'to', 'parp1', 'and', 'nrp1', 'the', 'cytotoxicity', 'assays', 'showed', 'that', 'ppnr4', 'demonstrated', 'significant', 'antiproliferative', 'activity', 'on', 'mdamb231', 'cells', 'icsub50sub', '021', 'μm', 'without', 'effect', 'on', 'normal', 'human', 'cells', 'iin', 'vivoi', 'experiments', 'exhibited', 'that', 'ppnr4', 'showed', 'more', 'effective', 'than', 'the', 'positive', 'controls', 'in', 'inhibiting', 'the', 'growth', 'of', 'tumors', 'overall', 'these', 'data', 'suggest', 'that', 'ppnr4', 'is', 'an', 'effective', 'antitumor', 'candidate', 'and', 'deserves', 'further', 'research']","['given', 'overexpression', 'poly', 'adpribose', 'polymerase1', 'parp1', 'neuropilin1', 'nrp1', 'implicated', 'pathogenesis', 'human', 'breast', 'cancer', 'design', 'dual', 'parp1nrp1', 'inhibitors', 'wide', 'therapeutic', 'prospect', 'however', 'reports', 'inhibitors', 'far', 'herein', 'discovered', 'novel', 'small', 'molecule', 'inhibitors', 'simultaneously', 'target', 'parp1', 'nrp1', 'using', 'structurebased', 'virtual', 'screening', 'treatment', 'breast', 'cancer', 'notably', 'ppnr4', 'potent', 'inhibitor', 'targeting', 'parp1', 'icsub50sub', '771', '039', 'nm', 'nrp1', 'icsub50sub', '2448', '216', 'nm', 'ppnr4', 'showed', 'high', 'affinity', 'binding', 'stability', 'parp1', 'nrp1', 'cytotoxicity', 'assays', 'showed', 'ppnr4', 'demonstrated', 'significant', 'antiproliferative', 'activity', 'mdamb231', 'cells', 'icsub50sub', '021', 'μm', 'without', 'effect', 'normal', 'human', 'cells', 'iin', 'vivoi', 'experiments', 'exhibited', 'ppnr4', 'showed', 'effective', 'positive', 'controls', 'inhibiting', 'growth', 'tumors', 'overall', 'data', 'suggest', 'ppnr4', 'effective', 'antitumor', 'candidate', 'deserves', 'research']","['polymerase1', 'parp1', 'neuropilin1', 'nrp1', 'parp1', 'nrp1', 'parp1', 'nrp1', 'parp1', 'nrp1']","['polymerase1', 'neuropilin1', 'nrp1', 'nrp1', 'nrp1', 'nrp1']",True,"['tumor', 'cancer']"
39643141,Pleiotropic anti-cancer activities of novel non-covalent thioredoxin reductase inhibitors against triple negative breast cancer.,"Mounting evidence shows that tumor growth and progression rely on thioredoxin reductase 1 (TXNRD1)-mediated detoxification of oxidative stress that results from deregulated metabolism and mitogenic signaling in tumors. TXNRD1 levels are significant higher in triple negative breast cancer (TNBC) compared to normal tissue, making TXNRD1 a compelling TNBC therapeutic target. Despite the many attempts to generate TXNRD1 inhibitors, all known and reported compounds inhibiting TXNRD1 are problematic; they interact with TXNRD1 irreversibly and non-specifically resulting in numerous adverse side effects. Recently, a series of breakthrough studies identified a novel regulatory site, the 'doorstop pocket', in Schistosoma mansoni thioredoxin glutathione reductase, a TXNRD-like enzyme and an established drug target for the human parasitic infection, schistosomiasis. This discovery underpins the development of new first-in-class non-covalent inhibitors for this family of enzymes. Our data show that novel non-covalent TXNRD inhibitors (TXNRD(i)s) are potent dose-dependent inhibitors of viability in cellular models of TNBC. TXNRD(i)s attenuate several aggressive cancer phenotypes such as, clonogenic survival, mammosphere forming efficiency, invasion, and TXNRD-related gene expression in TNBC cells. TXNRD(i)s engage and inhibit TXNRD1 in live TNBC cells and xenograft tumors, thus supporting the mechanism of action at a cellular level. More importantly, TXNRD(i)s attenuated tumor growth in a preclinical MDA-MB-231 TNBC xenograft mouse model. Although additional optimization for TXNRD(i)s' potency is warranted, these results may open a new avenue for the development of novel small molecule therapeutics for TNBC.",2024-12-04,mounting evidence shows that tumor growth and progression rely on thioredoxin reductase 1 txnrd1mediated detoxification of oxidative stress that results from deregulated metabolism and mitogenic signaling in tumors txnrd1 levels are significant higher in triple negative breast cancer tnbc compared to normal tissue making txnrd1 a compelling tnbc therapeutic target despite the many attempts to generate txnrd1 inhibitors all known and reported compounds inhibiting txnrd1 are problematic they interact with txnrd1 irreversibly and nonspecifically resulting in numerous adverse side effects recently a series of breakthrough studies identified a novel regulatory site the doorstop pocket in schistosoma mansoni thioredoxin glutathione reductase a txnrdlike enzyme and an established drug target for the human parasitic infection schistosomiasis this discovery underpins the development of new firstinclass noncovalent inhibitors for this family of enzymes our data show that novel noncovalent txnrd inhibitors txnrdis are potent dosedependent inhibitors of viability in cellular models of tnbc txnrdis attenuate several aggressive cancer phenotypes such as clonogenic survival mammosphere forming efficiency invasion and txnrdrelated gene expression in tnbc cells txnrdis engage and inhibit txnrd1 in live tnbc cells and xenograft tumors thus supporting the mechanism of action at a cellular level more importantly txnrdis attenuated tumor growth in a preclinical mdamb231 tnbc xenograft mouse model although additional optimization for txnrdis potency is warranted these results may open a new avenue for the development of novel small molecule therapeutics for tnbc,"['mounting', 'evidence', 'shows', 'that', 'tumor', 'growth', 'and', 'progression', 'rely', 'on', 'thioredoxin', 'reductase', '1', 'txnrd1mediated', 'detoxification', 'of', 'oxidative', 'stress', 'that', 'results', 'from', 'deregulated', 'metabolism', 'and', 'mitogenic', 'signaling', 'in', 'tumors', 'txnrd1', 'levels', 'are', 'significant', 'higher', 'in', 'triple', 'negative', 'breast', 'cancer', 'tnbc', 'compared', 'to', 'normal', 'tissue', 'making', 'txnrd1', 'a', 'compelling', 'tnbc', 'therapeutic', 'target', 'despite', 'the', 'many', 'attempts', 'to', 'generate', 'txnrd1', 'inhibitors', 'all', 'known', 'and', 'reported', 'compounds', 'inhibiting', 'txnrd1', 'are', 'problematic', 'they', 'interact', 'with', 'txnrd1', 'irreversibly', 'and', 'nonspecifically', 'resulting', 'in', 'numerous', 'adverse', 'side', 'effects', 'recently', 'a', 'series', 'of', 'breakthrough', 'studies', 'identified', 'a', 'novel', 'regulatory', 'site', 'the', 'doorstop', 'pocket', 'in', 'schistosoma', 'mansoni', 'thioredoxin', 'glutathione', 'reductase', 'a', 'txnrdlike', 'enzyme', 'and', 'an', 'established', 'drug', 'target', 'for', 'the', 'human', 'parasitic', 'infection', 'schistosomiasis', 'this', 'discovery', 'underpins', 'the', 'development', 'of', 'new', 'firstinclass', 'noncovalent', 'inhibitors', 'for', 'this', 'family', 'of', 'enzymes', 'our', 'data', 'show', 'that', 'novel', 'noncovalent', 'txnrd', 'inhibitors', 'txnrdis', 'are', 'potent', 'dosedependent', 'inhibitors', 'of', 'viability', 'in', 'cellular', 'models', 'of', 'tnbc', 'txnrdis', 'attenuate', 'several', 'aggressive', 'cancer', 'phenotypes', 'such', 'as', 'clonogenic', 'survival', 'mammosphere', 'forming', 'efficiency', 'invasion', 'and', 'txnrdrelated', 'gene', 'expression', 'in', 'tnbc', 'cells', 'txnrdis', 'engage', 'and', 'inhibit', 'txnrd1', 'in', 'live', 'tnbc', 'cells', 'and', 'xenograft', 'tumors', 'thus', 'supporting', 'the', 'mechanism', 'of', 'action', 'at', 'a', 'cellular', 'level', 'more', 'importantly', 'txnrdis', 'attenuated', 'tumor', 'growth', 'in', 'a', 'preclinical', 'mdamb231', 'tnbc', 'xenograft', 'mouse', 'model', 'although', 'additional', 'optimization', 'for', 'txnrdis', 'potency', 'is', 'warranted', 'these', 'results', 'may', 'open', 'a', 'new', 'avenue', 'for', 'the', 'development', 'of', 'novel', 'small', 'molecule', 'therapeutics', 'for', 'tnbc']","['mounting', 'evidence', 'shows', 'tumor', 'growth', 'progression', 'rely', 'thioredoxin', 'reductase', '1', 'txnrd1mediated', 'detoxification', 'oxidative', 'stress', 'results', 'deregulated', 'metabolism', 'mitogenic', 'signaling', 'tumors', 'txnrd1', 'levels', 'significant', 'higher', 'triple', 'negative', 'breast', 'cancer', 'tnbc', 'compared', 'normal', 'tissue', 'making', 'txnrd1', 'compelling', 'tnbc', 'therapeutic', 'target', 'despite', 'many', 'attempts', 'generate', 'txnrd1', 'inhibitors', 'known', 'reported', 'compounds', 'inhibiting', 'txnrd1', 'problematic', 'interact', 'txnrd1', 'irreversibly', 'nonspecifically', 'resulting', 'numerous', 'adverse', 'side', 'effects', 'recently', 'series', 'breakthrough', 'studies', 'identified', 'novel', 'regulatory', 'site', 'doorstop', 'pocket', 'schistosoma', 'mansoni', 'thioredoxin', 'glutathione', 'reductase', 'txnrdlike', 'enzyme', 'established', 'drug', 'target', 'human', 'parasitic', 'infection', 'schistosomiasis', 'discovery', 'underpins', 'development', 'new', 'firstinclass', 'noncovalent', 'inhibitors', 'family', 'enzymes', 'data', 'show', 'novel', 'noncovalent', 'txnrd', 'inhibitors', 'txnrdis', 'potent', 'dosedependent', 'inhibitors', 'viability', 'cellular', 'models', 'tnbc', 'txnrdis', 'attenuate', 'several', 'aggressive', 'cancer', 'phenotypes', 'clonogenic', 'survival', 'mammosphere', 'forming', 'efficiency', 'invasion', 'txnrdrelated', 'gene', 'expression', 'tnbc', 'cells', 'txnrdis', 'engage', 'inhibit', 'txnrd1', 'live', 'tnbc', 'cells', 'xenograft', 'tumors', 'thus', 'supporting', 'mechanism', 'action', 'cellular', 'level', 'importantly', 'txnrdis', 'attenuated', 'tumor', 'growth', 'preclinical', 'mdamb231', 'tnbc', 'xenograft', 'mouse', 'model', 'although', 'additional', 'optimization', 'txnrdis', 'potency', 'warranted', 'results', 'may', 'open', 'new', 'avenue', 'development', 'novel', 'small', 'molecule', 'therapeutics', 'tnbc']","['txnrd1', 'txnrd1', 'txnrd1', 'txnrd1', 'txnrd1', 'txnrd1']","['txnrd1', 'txnrd1', 'txnrd1', 'txnrd1', 'txnrd1', 'txnrd1']",True,"['tumor', 'infection', 'cancer']"
39625835,Determination of QLNC-3A6 in canine plasma by UHPLC-MS/MS and its application in pharmacokinetic studies.,"Multi-targeted tyrosine kinase inhibitor QLNC-3A6 Di-maleate, a structurally novel small molecule compound, has therapeutic efficacy for the treatment of canine cutaneous mast cell tumor (CMCT) caused by mutations in the c-Kit gene. Since pharmacokinetic (PK) information plays an important role in the development and application of new drugs, etc., a rapid, highly sensitive and selective UHPLC-MS/MS analytical method was developed and validated for the first time in this study for the quantitative detection of QLNC-3A6 in canine plasma. 100 µL of plasma was precipitated using 350 µL of acetonitrile, and Chromatographic separation was performed on a Phenomenex Kinetex C18 column (50 × 2.1 mm, 2.6 µm) at a flow rate of 0.4 mL/min, the mobile phases were set to 0.1% formic acid aqueous solution (A) and 0.1% formic acid acetonitrile (B). The calibration curve linear range was 0.5-100 ng/mL (<i>R</i><sup>2</sup>>0.99). The intraday and interday precision values (relative standard deviation, RSD) were 2.06-13.57% and 6.90-9.14%. Intraday and interday accuracies were -10.73 to 9.54% and -3.86 to 0.70% respectively. The dilution integrity RSD value and stability RSD value were less than 3.77 and 7.45%, respectively. Subsequently, the pharmacokinetics were investigated in canine after oral administration of QLNC-3A6 Di-maleate tablets at a dose of 3 mg/kg BW using this method. The results showed that QLNC-3A6 showed fast absorption rate, rapid distribution and slow metabolic elimination in canine plasma. The results of the main PK parameters including <i>λ</i>z, <i>T</i><sub>1/2λz</sub>, <i>C</i><sub>max</sub>, <i>T</i><sub>max</sub> and <i>AUC</i><sub>last</sub> were 0.07 ± 0.01/h, 11.00 ± 2.57 h, 50.88 ± 31.94 ng/mL, 9.08 ± 11.57 h and 836.48 ± 230.53 ng h/mL, respectively.",2024-10-10,multitargeted tyrosine kinase inhibitor qlnc3a6 dimaleate a structurally novel small molecule compound has therapeutic efficacy for the treatment of canine cutaneous mast cell tumor cmct caused by mutations in the ckit gene since pharmacokinetic pk information plays an important role in the development and application of new drugs etc a rapid highly sensitive and selective uhplcmsms analytical method was developed and validated for the first time in this study for the quantitative detection of qlnc3a6 in canine plasma 100 µl of plasma was precipitated using 350 µl of acetonitrile and chromatographic separation was performed on a phenomenex kinetex c18 column 50  21 mm 26 µm at a flow rate of 04 mlmin the mobile phases were set to 01 formic acid aqueous solution a and 01 formic acid acetonitrile b the calibration curve linear range was 05100 ngml irisup2sup099 the intraday and interday precision values relative standard deviation rsd were 2061357 and 690914 intraday and interday accuracies were 1073 to 954 and 386 to 070 respectively the dilution integrity rsd value and stability rsd value were less than 377 and 745 respectively subsequently the pharmacokinetics were investigated in canine after oral administration of qlnc3a6 dimaleate tablets at a dose of 3 mgkg bw using this method the results showed that qlnc3a6 showed fast absorption rate rapid distribution and slow metabolic elimination in canine plasma the results of the main pk parameters including iλiz itisub12λzsub icisubmaxsub itisubmaxsub and iaucisublastsub were 007  001h 1100  257 h 5088  3194 ngml 908  1157 h and 83648  23053 ng hml respectively,"['multitargeted', 'tyrosine', 'kinase', 'inhibitor', 'qlnc3a6', 'dimaleate', 'a', 'structurally', 'novel', 'small', 'molecule', 'compound', 'has', 'therapeutic', 'efficacy', 'for', 'the', 'treatment', 'of', 'canine', 'cutaneous', 'mast', 'cell', 'tumor', 'cmct', 'caused', 'by', 'mutations', 'in', 'the', 'ckit', 'gene', 'since', 'pharmacokinetic', 'pk', 'information', 'plays', 'an', 'important', 'role', 'in', 'the', 'development', 'and', 'application', 'of', 'new', 'drugs', 'etc', 'a', 'rapid', 'highly', 'sensitive', 'and', 'selective', 'uhplcmsms', 'analytical', 'method', 'was', 'developed', 'and', 'validated', 'for', 'the', 'first', 'time', 'in', 'this', 'study', 'for', 'the', 'quantitative', 'detection', 'of', 'qlnc3a6', 'in', 'canine', 'plasma', '100', 'µl', 'of', 'plasma', 'was', 'precipitated', 'using', '350', 'µl', 'of', 'acetonitrile', 'and', 'chromatographic', 'separation', 'was', 'performed', 'on', 'a', 'phenomenex', 'kinetex', 'c18', 'column', '50', '21', 'mm', '26', 'µm', 'at', 'a', 'flow', 'rate', 'of', '04', 'mlmin', 'the', 'mobile', 'phases', 'were', 'set', 'to', '01', 'formic', 'acid', 'aqueous', 'solution', 'a', 'and', '01', 'formic', 'acid', 'acetonitrile', 'b', 'the', 'calibration', 'curve', 'linear', 'range', 'was', '05100', 'ngml', 'irisup2sup099', 'the', 'intraday', 'and', 'interday', 'precision', 'values', 'relative', 'standard', 'deviation', 'rsd', 'were', '2061357', 'and', '690914', 'intraday', 'and', 'interday', 'accuracies', 'were', '1073', 'to', '954', 'and', '386', 'to', '070', 'respectively', 'the', 'dilution', 'integrity', 'rsd', 'value', 'and', 'stability', 'rsd', 'value', 'were', 'less', 'than', '377', 'and', '745', 'respectively', 'subsequently', 'the', 'pharmacokinetics', 'were', 'investigated', 'in', 'canine', 'after', 'oral', 'administration', 'of', 'qlnc3a6', 'dimaleate', 'tablets', 'at', 'a', 'dose', 'of', '3', 'mgkg', 'bw', 'using', 'this', 'method', 'the', 'results', 'showed', 'that', 'qlnc3a6', 'showed', 'fast', 'absorption', 'rate', 'rapid', 'distribution', 'and', 'slow', 'metabolic', 'elimination', 'in', 'canine', 'plasma', 'the', 'results', 'of', 'the', 'main', 'pk', 'parameters', 'including', 'iλiz', 'itisub12λzsub', 'icisubmaxsub', 'itisubmaxsub', 'and', 'iaucisublastsub', 'were', '007', '001h', '1100', '257', 'h', '5088', '3194', 'ngml', '908', '1157', 'h', 'and', '83648', '23053', 'ng', 'hml', 'respectively']","['multitargeted', 'tyrosine', 'kinase', 'inhibitor', 'qlnc3a6', 'dimaleate', 'structurally', 'novel', 'small', 'molecule', 'compound', 'therapeutic', 'efficacy', 'treatment', 'canine', 'cutaneous', 'mast', 'cell', 'tumor', 'cmct', 'caused', 'mutations', 'ckit', 'gene', 'since', 'pharmacokinetic', 'pk', 'information', 'plays', 'important', 'role', 'development', 'application', 'new', 'drugs', 'etc', 'rapid', 'highly', 'sensitive', 'selective', 'uhplcmsms', 'analytical', 'method', 'developed', 'validated', 'first', 'time', 'study', 'quantitative', 'detection', 'qlnc3a6', 'canine', 'plasma', '100', 'µl', 'plasma', 'precipitated', 'using', '350', 'µl', 'acetonitrile', 'chromatographic', 'separation', 'performed', 'phenomenex', 'kinetex', 'c18', 'column', '50', '21', 'mm', '26', 'µm', 'flow', 'rate', '04', 'mlmin', 'mobile', 'phases', 'set', '01', 'formic', 'acid', 'aqueous', 'solution', '01', 'formic', 'acid', 'acetonitrile', 'b', 'calibration', 'curve', 'linear', 'range', '05100', 'ngml', 'irisup2sup099', 'intraday', 'interday', 'precision', 'values', 'relative', 'standard', 'deviation', 'rsd', '2061357', '690914', 'intraday', 'interday', 'accuracies', '1073', '954', '386', '070', 'respectively', 'dilution', 'integrity', 'rsd', 'value', 'stability', 'rsd', 'value', 'less', '377', '745', 'respectively', 'subsequently', 'pharmacokinetics', 'investigated', 'canine', 'oral', 'administration', 'qlnc3a6', 'dimaleate', 'tablets', 'dose', '3', 'mgkg', 'bw', 'using', 'method', 'results', 'showed', 'qlnc3a6', 'showed', 'fast', 'absorption', 'rate', 'rapid', 'distribution', 'slow', 'metabolic', 'elimination', 'canine', 'plasma', 'results', 'main', 'pk', 'parameters', 'including', 'iλiz', 'itisub12λzsub', 'icisubmaxsub', 'itisubmaxsub', 'iaucisublastsub', '007', '001h', '1100', '257', 'h', '5088', '3194', 'ngml', '908', '1157', 'h', '83648', '23053', 'ng', 'hml', 'respectively']","['ckit', 'hml']",['ckit'],True,['tumor']
39622844,A novel small molecule Enpp1 inhibitor improves tumor control following radiation therapy by targeting stromal Enpp1 expression.,"The uniqueness in each person's cancer cells and variation in immune infiltrates means that each tumor represents a unique problem, but therapeutic targets can be found among their shared features. Radiation therapy alters the interaction between the cancer cells and the stroma through release of innate adjuvants. The extranuclear DNA that can result from radiation damage of cells can result in production of the second messenger cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) by cyclic GMP-AMP synthase (cGAS). In turn, cGAMP can activate the innate sensor stimulator of interferon genes (STING), resulting in innate immune activation. Ectonucleotide pyrophosphatase/phosphodiesterase 1 (Enpp1) is a phosphodiesterase that can be expressed by cancer cells that can degrade cGAMP, thus can decrease or block STING activation following radiation therapy, impairing the innate immunity that is critical to support adaptive immune control of tumors. We observed that many human and murine cancer cells lack Enpp1 expression, but that Enpp1 is expressed in cells of the tumor stroma where it limits tumor control by radiation therapy. We demonstrate in preclinical models the efficacy of a novel Enpp1 inhibitor and show that this inhibitor improves tumor control by radiation even where the cancer cells lack Enpp1. This mechanism requires STING and type I interferon (IFN) receptor expression by non-cancer cells and is dependent on CD8 T cells as a final effector mechanism of tumor control. This suggests that Enpp1 inhibition may be an effective partner for radiation therapy regardless of whether cancer cells express Enpp1. This broadens the potential patient base for whom Enpp1 inhibitors can be applied to improve innate immune responses following radiation therapy.",2024-12-02,the uniqueness in each persons cancer cells and variation in immune infiltrates means that each tumor represents a unique problem but therapeutic targets can be found among their shared features radiation therapy alters the interaction between the cancer cells and the stroma through release of innate adjuvants the extranuclear dna that can result from radiation damage of cells can result in production of the second messenger cyclic guanosine monophosphateadenosine monophosphate cgamp by cyclic gmpamp synthase cgas in turn cgamp can activate the innate sensor stimulator of interferon genes sting resulting in innate immune activation ectonucleotide pyrophosphatasephosphodiesterase 1 enpp1 is a phosphodiesterase that can be expressed by cancer cells that can degrade cgamp thus can decrease or block sting activation following radiation therapy impairing the innate immunity that is critical to support adaptive immune control of tumors we observed that many human and murine cancer cells lack enpp1 expression but that enpp1 is expressed in cells of the tumor stroma where it limits tumor control by radiation therapy we demonstrate in preclinical models the efficacy of a novel enpp1 inhibitor and show that this inhibitor improves tumor control by radiation even where the cancer cells lack enpp1 this mechanism requires sting and type i interferon ifn receptor expression by noncancer cells and is dependent on cd8 t cells as a final effector mechanism of tumor control this suggests that enpp1 inhibition may be an effective partner for radiation therapy regardless of whether cancer cells express enpp1 this broadens the potential patient base for whom enpp1 inhibitors can be applied to improve innate immune responses following radiation therapy,"['the', 'uniqueness', 'in', 'each', 'persons', 'cancer', 'cells', 'and', 'variation', 'in', 'immune', 'infiltrates', 'means', 'that', 'each', 'tumor', 'represents', 'a', 'unique', 'problem', 'but', 'therapeutic', 'targets', 'can', 'be', 'found', 'among', 'their', 'shared', 'features', 'radiation', 'therapy', 'alters', 'the', 'interaction', 'between', 'the', 'cancer', 'cells', 'and', 'the', 'stroma', 'through', 'release', 'of', 'innate', 'adjuvants', 'the', 'extranuclear', 'dna', 'that', 'can', 'result', 'from', 'radiation', 'damage', 'of', 'cells', 'can', 'result', 'in', 'production', 'of', 'the', 'second', 'messenger', 'cyclic', 'guanosine', 'monophosphateadenosine', 'monophosphate', 'cgamp', 'by', 'cyclic', 'gmpamp', 'synthase', 'cgas', 'in', 'turn', 'cgamp', 'can', 'activate', 'the', 'innate', 'sensor', 'stimulator', 'of', 'interferon', 'genes', 'sting', 'resulting', 'in', 'innate', 'immune', 'activation', 'ectonucleotide', 'pyrophosphatasephosphodiesterase', '1', 'enpp1', 'is', 'a', 'phosphodiesterase', 'that', 'can', 'be', 'expressed', 'by', 'cancer', 'cells', 'that', 'can', 'degrade', 'cgamp', 'thus', 'can', 'decrease', 'or', 'block', 'sting', 'activation', 'following', 'radiation', 'therapy', 'impairing', 'the', 'innate', 'immunity', 'that', 'is', 'critical', 'to', 'support', 'adaptive', 'immune', 'control', 'of', 'tumors', 'we', 'observed', 'that', 'many', 'human', 'and', 'murine', 'cancer', 'cells', 'lack', 'enpp1', 'expression', 'but', 'that', 'enpp1', 'is', 'expressed', 'in', 'cells', 'of', 'the', 'tumor', 'stroma', 'where', 'it', 'limits', 'tumor', 'control', 'by', 'radiation', 'therapy', 'we', 'demonstrate', 'in', 'preclinical', 'models', 'the', 'efficacy', 'of', 'a', 'novel', 'enpp1', 'inhibitor', 'and', 'show', 'that', 'this', 'inhibitor', 'improves', 'tumor', 'control', 'by', 'radiation', 'even', 'where', 'the', 'cancer', 'cells', 'lack', 'enpp1', 'this', 'mechanism', 'requires', 'sting', 'and', 'type', 'i', 'interferon', 'ifn', 'receptor', 'expression', 'by', 'noncancer', 'cells', 'and', 'is', 'dependent', 'on', 'cd8', 't', 'cells', 'as', 'a', 'final', 'effector', 'mechanism', 'of', 'tumor', 'control', 'this', 'suggests', 'that', 'enpp1', 'inhibition', 'may', 'be', 'an', 'effective', 'partner', 'for', 'radiation', 'therapy', 'regardless', 'of', 'whether', 'cancer', 'cells', 'express', 'enpp1', 'this', 'broadens', 'the', 'potential', 'patient', 'base', 'for', 'whom', 'enpp1', 'inhibitors', 'can', 'be', 'applied', 'to', 'improve', 'innate', 'immune', 'responses', 'following', 'radiation', 'therapy']","['uniqueness', 'persons', 'cancer', 'cells', 'variation', 'immune', 'infiltrates', 'means', 'tumor', 'represents', 'unique', 'problem', 'therapeutic', 'targets', 'found', 'among', 'shared', 'features', 'radiation', 'therapy', 'alters', 'interaction', 'cancer', 'cells', 'stroma', 'release', 'innate', 'adjuvants', 'extranuclear', 'dna', 'result', 'radiation', 'damage', 'cells', 'result', 'production', 'second', 'messenger', 'cyclic', 'guanosine', 'monophosphateadenosine', 'monophosphate', 'cgamp', 'cyclic', 'gmpamp', 'synthase', 'cgas', 'turn', 'cgamp', 'activate', 'innate', 'sensor', 'stimulator', 'interferon', 'genes', 'sting', 'resulting', 'innate', 'immune', 'activation', 'ectonucleotide', 'pyrophosphatasephosphodiesterase', '1', 'enpp1', 'phosphodiesterase', 'expressed', 'cancer', 'cells', 'degrade', 'cgamp', 'thus', 'decrease', 'block', 'sting', 'activation', 'following', 'radiation', 'therapy', 'impairing', 'innate', 'immunity', 'critical', 'support', 'adaptive', 'immune', 'control', 'tumors', 'observed', 'many', 'human', 'murine', 'cancer', 'cells', 'lack', 'enpp1', 'expression', 'enpp1', 'expressed', 'cells', 'tumor', 'stroma', 'limits', 'tumor', 'control', 'radiation', 'therapy', 'demonstrate', 'preclinical', 'models', 'efficacy', 'novel', 'enpp1', 'inhibitor', 'show', 'inhibitor', 'improves', 'tumor', 'control', 'radiation', 'even', 'cancer', 'cells', 'lack', 'enpp1', 'mechanism', 'requires', 'sting', 'type', 'interferon', 'ifn', 'receptor', 'expression', 'noncancer', 'cells', 'dependent', 'cd8', 'cells', 'final', 'effector', 'mechanism', 'tumor', 'control', 'suggests', 'enpp1', 'inhibition', 'may', 'effective', 'partner', 'radiation', 'therapy', 'regardless', 'whether', 'cancer', 'cells', 'express', 'enpp1', 'broadens', 'potential', 'patient', 'base', 'enpp1', 'inhibitors', 'applied', 'improve', 'innate', 'immune', 'responses', 'following', 'radiation', 'therapy']",['ectonucleotide'],['ectonucleotide'],True,"['tumor', 'cancer']"
39578293,Identification and interaction mechanism of novel small molecule antagonists targeting CC chemokine receptor 1/3/5 for treatment of non-small cell lung cancer.,"Non-Small Cell Lung Cancer (NSCLC) was one of the most prevalent forms of lung cancer. Due to its ease of invasion and migration, the five-year survival rate was relatively low. Therefore, new strategies for NSCLC treatment were needed. CC chemokine receptor 1/3/5 (CCR1/CCR3/CCR5), a member of the G-protein coupled receptor family, could promote the migration and invasion of NSCLC cells by binding to related chemokines. Consequently, targeting CCR1, CCR3 and CCR5 might prevent the progression of the disease. So far, no compound had been reported as a common antagonist for CCR1, CCR3, and CCR5. In this research, we utilized virtual screening and structural optimization to obtain compound 5, which effectively inhibited the migration and invasion of NSCLC cells. Meanwhile, Western Blot and Enzyme linked immunosorbent assay (ELISA) manifested that compound 5 suppressed migration and invasion of NSCLC cells by suppressing the nuclear factor κB (NF-κB) and the consequently decreased Matrix Metalloproteinase-9(MMP-9) secretion. Moreover, drug affinity responsive target stability (DARTS) experiment and molecular simulations confirmed that compound 5 was capable of binding with CCR1/CCR3/CCR5, and Van der Waals forces were instrumental in the binding process. Ile91, Tyr113, Gln284, and Ser184(CCR1-ligand5), Ile189, Met213, and Leu209(CCR3-ligand5), Phe109, Gln194, and Thr195(CCR5-ligand5) had Van der Waals interactions with ligand 5. Dynamic cross-correlation matrix (DCCM) and free energy landscape (FEL) showed that compound 5 could stably bind to CCR1/CCR3/CCR5 to change conformation of the protein and the tendency of residue movements, leading to a persistent inhibitory effect. This study aimed to provide assistance in the rational design of common antagonists for CCR1, CCR3, and CCR5.",2024-11-22,nonsmall cell lung cancer nsclc was one of the most prevalent forms of lung cancer due to its ease of invasion and migration the fiveyear survival rate was relatively low therefore new strategies for nsclc treatment were needed cc chemokine receptor 135 ccr1ccr3ccr5 a member of the gprotein coupled receptor family could promote the migration and invasion of nsclc cells by binding to related chemokines consequently targeting ccr1 ccr3 and ccr5 might prevent the progression of the disease so far no compound had been reported as a common antagonist for ccr1 ccr3 and ccr5 in this research we utilized virtual screening and structural optimization to obtain compound 5 which effectively inhibited the migration and invasion of nsclc cells meanwhile western blot and enzyme linked immunosorbent assay elisa manifested that compound 5 suppressed migration and invasion of nsclc cells by suppressing the nuclear factor κb nfκb and the consequently decreased matrix metalloproteinase9mmp9 secretion moreover drug affinity responsive target stability darts experiment and molecular simulations confirmed that compound 5 was capable of binding with ccr1ccr3ccr5 and van der waals forces were instrumental in the binding process ile91 tyr113 gln284 and ser184ccr1ligand5 ile189 met213 and leu209ccr3ligand5 phe109 gln194 and thr195ccr5ligand5 had van der waals interactions with ligand 5 dynamic crosscorrelation matrix dccm and free energy landscape fel showed that compound 5 could stably bind to ccr1ccr3ccr5 to change conformation of the protein and the tendency of residue movements leading to a persistent inhibitory effect this study aimed to provide assistance in the rational design of common antagonists for ccr1 ccr3 and ccr5,"['nonsmall', 'cell', 'lung', 'cancer', 'nsclc', 'was', 'one', 'of', 'the', 'most', 'prevalent', 'forms', 'of', 'lung', 'cancer', 'due', 'to', 'its', 'ease', 'of', 'invasion', 'and', 'migration', 'the', 'fiveyear', 'survival', 'rate', 'was', 'relatively', 'low', 'therefore', 'new', 'strategies', 'for', 'nsclc', 'treatment', 'were', 'needed', 'cc', 'chemokine', 'receptor', '135', 'ccr1ccr3ccr5', 'a', 'member', 'of', 'the', 'gprotein', 'coupled', 'receptor', 'family', 'could', 'promote', 'the', 'migration', 'and', 'invasion', 'of', 'nsclc', 'cells', 'by', 'binding', 'to', 'related', 'chemokines', 'consequently', 'targeting', 'ccr1', 'ccr3', 'and', 'ccr5', 'might', 'prevent', 'the', 'progression', 'of', 'the', 'disease', 'so', 'far', 'no', 'compound', 'had', 'been', 'reported', 'as', 'a', 'common', 'antagonist', 'for', 'ccr1', 'ccr3', 'and', 'ccr5', 'in', 'this', 'research', 'we', 'utilized', 'virtual', 'screening', 'and', 'structural', 'optimization', 'to', 'obtain', 'compound', '5', 'which', 'effectively', 'inhibited', 'the', 'migration', 'and', 'invasion', 'of', 'nsclc', 'cells', 'meanwhile', 'western', 'blot', 'and', 'enzyme', 'linked', 'immunosorbent', 'assay', 'elisa', 'manifested', 'that', 'compound', '5', 'suppressed', 'migration', 'and', 'invasion', 'of', 'nsclc', 'cells', 'by', 'suppressing', 'the', 'nuclear', 'factor', 'κb', 'nfκb', 'and', 'the', 'consequently', 'decreased', 'matrix', 'metalloproteinase9mmp9', 'secretion', 'moreover', 'drug', 'affinity', 'responsive', 'target', 'stability', 'darts', 'experiment', 'and', 'molecular', 'simulations', 'confirmed', 'that', 'compound', '5', 'was', 'capable', 'of', 'binding', 'with', 'ccr1ccr3ccr5', 'and', 'van', 'der', 'waals', 'forces', 'were', 'instrumental', 'in', 'the', 'binding', 'process', 'ile91', 'tyr113', 'gln284', 'and', 'ser184ccr1ligand5', 'ile189', 'met213', 'and', 'leu209ccr3ligand5', 'phe109', 'gln194', 'and', 'thr195ccr5ligand5', 'had', 'van', 'der', 'waals', 'interactions', 'with', 'ligand', '5', 'dynamic', 'crosscorrelation', 'matrix', 'dccm', 'and', 'free', 'energy', 'landscape', 'fel', 'showed', 'that', 'compound', '5', 'could', 'stably', 'bind', 'to', 'ccr1ccr3ccr5', 'to', 'change', 'conformation', 'of', 'the', 'protein', 'and', 'the', 'tendency', 'of', 'residue', 'movements', 'leading', 'to', 'a', 'persistent', 'inhibitory', 'effect', 'this', 'study', 'aimed', 'to', 'provide', 'assistance', 'in', 'the', 'rational', 'design', 'of', 'common', 'antagonists', 'for', 'ccr1', 'ccr3', 'and', 'ccr5']","['nonsmall', 'cell', 'lung', 'cancer', 'nsclc', 'one', 'prevalent', 'forms', 'lung', 'cancer', 'due', 'ease', 'invasion', 'migration', 'fiveyear', 'survival', 'rate', 'relatively', 'low', 'therefore', 'new', 'strategies', 'nsclc', 'treatment', 'needed', 'cc', 'chemokine', 'receptor', '135', 'ccr1ccr3ccr5', 'member', 'gprotein', 'coupled', 'receptor', 'family', 'could', 'promote', 'migration', 'invasion', 'nsclc', 'cells', 'binding', 'related', 'chemokines', 'consequently', 'targeting', 'ccr1', 'ccr3', 'ccr5', 'might', 'prevent', 'progression', 'disease', 'far', 'compound', 'reported', 'common', 'antagonist', 'ccr1', 'ccr3', 'ccr5', 'research', 'utilized', 'virtual', 'screening', 'structural', 'optimization', 'obtain', 'compound', '5', 'effectively', 'inhibited', 'migration', 'invasion', 'nsclc', 'cells', 'meanwhile', 'western', 'blot', 'enzyme', 'linked', 'immunosorbent', 'assay', 'elisa', 'manifested', 'compound', '5', 'suppressed', 'migration', 'invasion', 'nsclc', 'cells', 'suppressing', 'nuclear', 'factor', 'κb', 'nfκb', 'consequently', 'decreased', 'matrix', 'metalloproteinase9mmp9', 'secretion', 'moreover', 'drug', 'affinity', 'responsive', 'target', 'stability', 'darts', 'experiment', 'molecular', 'simulations', 'confirmed', 'compound', '5', 'capable', 'binding', 'ccr1ccr3ccr5', 'van', 'der', 'waals', 'forces', 'instrumental', 'binding', 'process', 'ile91', 'tyr113', 'gln284', 'ser184ccr1ligand5', 'ile189', 'met213', 'leu209ccr3ligand5', 'phe109', 'gln194', 'thr195ccr5ligand5', 'van', 'der', 'waals', 'interactions', 'ligand', '5', 'dynamic', 'crosscorrelation', 'matrix', 'dccm', 'free', 'energy', 'landscape', 'fel', 'showed', 'compound', '5', 'could', 'stably', 'bind', 'ccr1ccr3ccr5', 'change', 'conformation', 'protein', 'tendency', 'residue', 'movements', 'leading', 'persistent', 'inhibitory', 'effect', 'study', 'aimed', 'provide', 'assistance', 'rational', 'design', 'common', 'antagonists', 'ccr1', 'ccr3', 'ccr5']","['ccr3', 'ccr3', 'ccr3']","['ccr3', 'ccr3', 'ccr3']",True,['cancer']
39562696,The antitumor peptide M1-20 induced the degradation of CDK1 through CUL4-DDB1-DCAF1-involved ubiquitination.,"CDK1 is an oncogenic serine/threonine kinase known to play an important role in the regulation of the cell cycle. FOXM1, as one of the CDK1 substrates, requires binding of CDK1/CCNB1 complex for phosphorylation-dependent recruitment of p300/CBP coactivators to mediate transcriptional activity. Previous studies from our laboratory found that a novel peptide (M1-20) derived from the C-terminus of FOXM1 exhibited potent inhibitory effects for cancer cells. Based on these proofs and to explore the inhibitory mechanism of M1-20, we designed experiments and found that CDK1 served as an important target of M1-20. M1-20 enhanced the ubiquitination and degradation of CDK1 by CUL4-DDB1-DCAF1 complexes through the proteasome pathway. M1-20 could also affect the formation of CDK1/CCNB1 complexes. In addition, compared to RO3306, a CDK1 inhibitor, M1-20 exhibited excellent inhibitory effects in FVB/N MMTV-PyVT murine model of spontaneous breast cancer. These results suggested that M1-20 was a potential CDK1 inhibitor for the treatment of cancer.",2024-11-20,cdk1 is an oncogenic serinethreonine kinase known to play an important role in the regulation of the cell cycle foxm1 as one of the cdk1 substrates requires binding of cdk1ccnb1 complex for phosphorylationdependent recruitment of p300cbp coactivators to mediate transcriptional activity previous studies from our laboratory found that a novel peptide m120 derived from the cterminus of foxm1 exhibited potent inhibitory effects for cancer cells based on these proofs and to explore the inhibitory mechanism of m120 we designed experiments and found that cdk1 served as an important target of m120 m120 enhanced the ubiquitination and degradation of cdk1 by cul4ddb1dcaf1 complexes through the proteasome pathway m120 could also affect the formation of cdk1ccnb1 complexes in addition compared to ro3306 a cdk1 inhibitor m120 exhibited excellent inhibitory effects in fvbn mmtvpyvt murine model of spontaneous breast cancer these results suggested that m120 was a potential cdk1 inhibitor for the treatment of cancer,"['cdk1', 'is', 'an', 'oncogenic', 'serinethreonine', 'kinase', 'known', 'to', 'play', 'an', 'important', 'role', 'in', 'the', 'regulation', 'of', 'the', 'cell', 'cycle', 'foxm1', 'as', 'one', 'of', 'the', 'cdk1', 'substrates', 'requires', 'binding', 'of', 'cdk1ccnb1', 'complex', 'for', 'phosphorylationdependent', 'recruitment', 'of', 'p300cbp', 'coactivators', 'to', 'mediate', 'transcriptional', 'activity', 'previous', 'studies', 'from', 'our', 'laboratory', 'found', 'that', 'a', 'novel', 'peptide', 'm120', 'derived', 'from', 'the', 'cterminus', 'of', 'foxm1', 'exhibited', 'potent', 'inhibitory', 'effects', 'for', 'cancer', 'cells', 'based', 'on', 'these', 'proofs', 'and', 'to', 'explore', 'the', 'inhibitory', 'mechanism', 'of', 'm120', 'we', 'designed', 'experiments', 'and', 'found', 'that', 'cdk1', 'served', 'as', 'an', 'important', 'target', 'of', 'm120', 'm120', 'enhanced', 'the', 'ubiquitination', 'and', 'degradation', 'of', 'cdk1', 'by', 'cul4ddb1dcaf1', 'complexes', 'through', 'the', 'proteasome', 'pathway', 'm120', 'could', 'also', 'affect', 'the', 'formation', 'of', 'cdk1ccnb1', 'complexes', 'in', 'addition', 'compared', 'to', 'ro3306', 'a', 'cdk1', 'inhibitor', 'm120', 'exhibited', 'excellent', 'inhibitory', 'effects', 'in', 'fvbn', 'mmtvpyvt', 'murine', 'model', 'of', 'spontaneous', 'breast', 'cancer', 'these', 'results', 'suggested', 'that', 'm120', 'was', 'a', 'potential', 'cdk1', 'inhibitor', 'for', 'the', 'treatment', 'of', 'cancer']","['cdk1', 'oncogenic', 'serinethreonine', 'kinase', 'known', 'play', 'important', 'role', 'regulation', 'cell', 'cycle', 'foxm1', 'one', 'cdk1', 'substrates', 'requires', 'binding', 'cdk1ccnb1', 'complex', 'phosphorylationdependent', 'recruitment', 'p300cbp', 'coactivators', 'mediate', 'transcriptional', 'activity', 'previous', 'studies', 'laboratory', 'found', 'novel', 'peptide', 'm120', 'derived', 'cterminus', 'foxm1', 'exhibited', 'potent', 'inhibitory', 'effects', 'cancer', 'cells', 'based', 'proofs', 'explore', 'inhibitory', 'mechanism', 'm120', 'designed', 'experiments', 'found', 'cdk1', 'served', 'important', 'target', 'm120', 'm120', 'enhanced', 'ubiquitination', 'degradation', 'cdk1', 'cul4ddb1dcaf1', 'complexes', 'proteasome', 'pathway', 'm120', 'could', 'also', 'affect', 'formation', 'cdk1ccnb1', 'complexes', 'addition', 'compared', 'ro3306', 'cdk1', 'inhibitor', 'm120', 'exhibited', 'excellent', 'inhibitory', 'effects', 'fvbn', 'mmtvpyvt', 'murine', 'model', 'spontaneous', 'breast', 'cancer', 'results', 'suggested', 'm120', 'potential', 'cdk1', 'inhibitor', 'treatment', 'cancer']","['cdk1', 'foxm1', 'cdk1', 'coactivators', 'foxm1', 'cdk1', 'cdk1', 'cdk1', 'cdk1']","['foxm1', 'coactivators', 'foxm1']",True,['cancer']
39521064,Enhanced CRISPR-Cas9 RNA system delivery using cell penetrating peptides-based nanoparticles for efficient in vitro and in vivo applications.,"CRISPR-Cas9 system has emerged as a revolutionary gene-editing tool with huge therapeutic potential for addressing the underlying genetic causes of various diseases, including cancer. However, there are challenges such as the delivery method that must be overcome for its clinical application. In addition to the risk of nuclease degradation and rapid clearance of the CRISPR-Cas9 system by macrophages, the large size of Cas9, the high anionic charge density and hydrophilic nature of the RNA hinder their intracellular delivery and overall gene transfection efficiency. In this study, we engineered a novel Peptide-Based Nanoparticles ADGN for the delivery of long RNA. ADGN peptides can form stable self-assembled nanoparticles with CRISPR-Cas9 RNA. They have the ability to cross the cell membrane of various cell types, exhibiting a preference for cancer cells that overexpress laminin receptor and safeguard RNA prior their delivery into the cytoplasm. We demonstrate that ADGN peptides significantly promote CRISPR-Cas9 mediated knockout of the luciferase gene in vitro achieving 60 % efficiency with a preference for G insertion at the targeted site of luciferase gene. Moreover, we have provided evidence that these nanoparticles can also be systemically intravenously administrated in vivo in mice to deliver a functional CRISPR-Cas9 system to tumoral lung cells orthotopically implanted in the mouse, resulting in an effective gene knockout in mice. We also demonstrated that the in vivo distribution of ADGN-RNA is influenced by its peptides to RNA molar ratio. This study introduces a promising new Peptide-Based Nanoparticles for delivering CRISPR-Cas9 system in its RNA form applicable in both in vitro and in vivo models.",2024-11-11,crisprcas9 system has emerged as a revolutionary geneediting tool with huge therapeutic potential for addressing the underlying genetic causes of various diseases including cancer however there are challenges such as the delivery method that must be overcome for its clinical application in addition to the risk of nuclease degradation and rapid clearance of the crisprcas9 system by macrophages the large size of cas9 the high anionic charge density and hydrophilic nature of the rna hinder their intracellular delivery and overall gene transfection efficiency in this study we engineered a novel peptidebased nanoparticles adgn for the delivery of long rna adgn peptides can form stable selfassembled nanoparticles with crisprcas9 rna they have the ability to cross the cell membrane of various cell types exhibiting a preference for cancer cells that overexpress laminin receptor and safeguard rna prior their delivery into the cytoplasm we demonstrate that adgn peptides significantly promote crisprcas9 mediated knockout of the luciferase gene in vitro achieving 60  efficiency with a preference for g insertion at the targeted site of luciferase gene moreover we have provided evidence that these nanoparticles can also be systemically intravenously administrated in vivo in mice to deliver a functional crisprcas9 system to tumoral lung cells orthotopically implanted in the mouse resulting in an effective gene knockout in mice we also demonstrated that the in vivo distribution of adgnrna is influenced by its peptides to rna molar ratio this study introduces a promising new peptidebased nanoparticles for delivering crisprcas9 system in its rna form applicable in both in vitro and in vivo models,"['crisprcas9', 'system', 'has', 'emerged', 'as', 'a', 'revolutionary', 'geneediting', 'tool', 'with', 'huge', 'therapeutic', 'potential', 'for', 'addressing', 'the', 'underlying', 'genetic', 'causes', 'of', 'various', 'diseases', 'including', 'cancer', 'however', 'there', 'are', 'challenges', 'such', 'as', 'the', 'delivery', 'method', 'that', 'must', 'be', 'overcome', 'for', 'its', 'clinical', 'application', 'in', 'addition', 'to', 'the', 'risk', 'of', 'nuclease', 'degradation', 'and', 'rapid', 'clearance', 'of', 'the', 'crisprcas9', 'system', 'by', 'macrophages', 'the', 'large', 'size', 'of', 'cas9', 'the', 'high', 'anionic', 'charge', 'density', 'and', 'hydrophilic', 'nature', 'of', 'the', 'rna', 'hinder', 'their', 'intracellular', 'delivery', 'and', 'overall', 'gene', 'transfection', 'efficiency', 'in', 'this', 'study', 'we', 'engineered', 'a', 'novel', 'peptidebased', 'nanoparticles', 'adgn', 'for', 'the', 'delivery', 'of', 'long', 'rna', 'adgn', 'peptides', 'can', 'form', 'stable', 'selfassembled', 'nanoparticles', 'with', 'crisprcas9', 'rna', 'they', 'have', 'the', 'ability', 'to', 'cross', 'the', 'cell', 'membrane', 'of', 'various', 'cell', 'types', 'exhibiting', 'a', 'preference', 'for', 'cancer', 'cells', 'that', 'overexpress', 'laminin', 'receptor', 'and', 'safeguard', 'rna', 'prior', 'their', 'delivery', 'into', 'the', 'cytoplasm', 'we', 'demonstrate', 'that', 'adgn', 'peptides', 'significantly', 'promote', 'crisprcas9', 'mediated', 'knockout', 'of', 'the', 'luciferase', 'gene', 'in', 'vitro', 'achieving', '60', 'efficiency', 'with', 'a', 'preference', 'for', 'g', 'insertion', 'at', 'the', 'targeted', 'site', 'of', 'luciferase', 'gene', 'moreover', 'we', 'have', 'provided', 'evidence', 'that', 'these', 'nanoparticles', 'can', 'also', 'be', 'systemically', 'intravenously', 'administrated', 'in', 'vivo', 'in', 'mice', 'to', 'deliver', 'a', 'functional', 'crisprcas9', 'system', 'to', 'tumoral', 'lung', 'cells', 'orthotopically', 'implanted', 'in', 'the', 'mouse', 'resulting', 'in', 'an', 'effective', 'gene', 'knockout', 'in', 'mice', 'we', 'also', 'demonstrated', 'that', 'the', 'in', 'vivo', 'distribution', 'of', 'adgnrna', 'is', 'influenced', 'by', 'its', 'peptides', 'to', 'rna', 'molar', 'ratio', 'this', 'study', 'introduces', 'a', 'promising', 'new', 'peptidebased', 'nanoparticles', 'for', 'delivering', 'crisprcas9', 'system', 'in', 'its', 'rna', 'form', 'applicable', 'in', 'both', 'in', 'vitro', 'and', 'in', 'vivo', 'models']","['crisprcas9', 'system', 'emerged', 'revolutionary', 'geneediting', 'tool', 'huge', 'therapeutic', 'potential', 'addressing', 'underlying', 'genetic', 'causes', 'various', 'diseases', 'including', 'cancer', 'however', 'challenges', 'delivery', 'method', 'must', 'overcome', 'clinical', 'application', 'addition', 'risk', 'nuclease', 'degradation', 'rapid', 'clearance', 'crisprcas9', 'system', 'macrophages', 'large', 'size', 'cas9', 'high', 'anionic', 'charge', 'density', 'hydrophilic', 'nature', 'rna', 'hinder', 'intracellular', 'delivery', 'overall', 'gene', 'transfection', 'efficiency', 'study', 'engineered', 'novel', 'peptidebased', 'nanoparticles', 'adgn', 'delivery', 'long', 'rna', 'adgn', 'peptides', 'form', 'stable', 'selfassembled', 'nanoparticles', 'crisprcas9', 'rna', 'ability', 'cross', 'cell', 'membrane', 'various', 'cell', 'types', 'exhibiting', 'preference', 'cancer', 'cells', 'overexpress', 'laminin', 'receptor', 'safeguard', 'rna', 'prior', 'delivery', 'cytoplasm', 'demonstrate', 'adgn', 'peptides', 'significantly', 'promote', 'crisprcas9', 'mediated', 'knockout', 'luciferase', 'gene', 'vitro', 'achieving', '60', 'efficiency', 'preference', 'g', 'insertion', 'targeted', 'site', 'luciferase', 'gene', 'moreover', 'provided', 'evidence', 'nanoparticles', 'also', 'systemically', 'intravenously', 'administrated', 'vivo', 'mice', 'deliver', 'functional', 'crisprcas9', 'system', 'tumoral', 'lung', 'cells', 'orthotopically', 'implanted', 'mouse', 'resulting', 'effective', 'gene', 'knockout', 'mice', 'also', 'demonstrated', 'vivo', 'distribution', 'adgnrna', 'influenced', 'peptides', 'rna', 'molar', 'ratio', 'study', 'introduces', 'promising', 'new', 'peptidebased', 'nanoparticles', 'delivering', 'crisprcas9', 'system', 'rna', 'form', 'applicable', 'vitro', 'vivo', 'models']","['cas9', 'laminin', 'luciferase', 'luciferase', 'rna']","['luciferase', 'luciferase']",True,"['tumor', 'cancer']"
39519786,Discovery of Cyclic Peptide Inhibitors Targeted on TNFα-TNFR1 from Computational Design and Bioactivity Verification.,"Activating tumor necrosis factor receptor 1 (TNFR1) with tumor necrosis factor alpha (TNFα) is one of the key pathological mechanisms resulting in the exacerbation of rheumatoid arthritis (RA) immune response. Despite various types of drugs being available for the treatment of RA, a series of shortcomings still limits their application. Therefore, developing novel peptide drugs that target TNFα-TNFR1 interaction is expected to expand therapeutic drug options. In this study, the detailed interaction mechanism between TNFα and TNFR1 was elucidated, based on which, a series of linear peptides were initially designed. To overcome its large conformational flexibility, two different head-to-tail cyclization strategies were adopted by adding a proline-glycine (GP) or cysteine-cysteine (CC) to form an amide or disulfide bond between the N-C terminal. The results indicate that two cyclic peptides, R1_CC4 and α_CC8, exhibit the strongest binding free energies. α_CC8 was selected for further optimization using virtual mutations through in vitro activity and toxicity experiments due to its optimal biological activity. The L16R mutant was screened, and its binding affinity to TNFR1 was validated using ELISA assays. This study designed a novel cyclic peptide structure with potential anti-inflammatory properties, possibly bringing an additional choice for the treatment of RA in the future.",2024-10-31,activating tumor necrosis factor receptor 1 tnfr1 with tumor necrosis factor alpha tnfα is one of the key pathological mechanisms resulting in the exacerbation of rheumatoid arthritis ra immune response despite various types of drugs being available for the treatment of ra a series of shortcomings still limits their application therefore developing novel peptide drugs that target tnfαtnfr1 interaction is expected to expand therapeutic drug options in this study the detailed interaction mechanism between tnfα and tnfr1 was elucidated based on which a series of linear peptides were initially designed to overcome its large conformational flexibility two different headtotail cyclization strategies were adopted by adding a prolineglycine gp or cysteinecysteine cc to form an amide or disulfide bond between the nc terminal the results indicate that two cyclic peptides r1_cc4 and α_cc8 exhibit the strongest binding free energies α_cc8 was selected for further optimization using virtual mutations through in vitro activity and toxicity experiments due to its optimal biological activity the l16r mutant was screened and its binding affinity to tnfr1 was validated using elisa assays this study designed a novel cyclic peptide structure with potential antiinflammatory properties possibly bringing an additional choice for the treatment of ra in the future,"['activating', 'tumor', 'necrosis', 'factor', 'receptor', '1', 'tnfr1', 'with', 'tumor', 'necrosis', 'factor', 'alpha', 'tnfα', 'is', 'one', 'of', 'the', 'key', 'pathological', 'mechanisms', 'resulting', 'in', 'the', 'exacerbation', 'of', 'rheumatoid', 'arthritis', 'ra', 'immune', 'response', 'despite', 'various', 'types', 'of', 'drugs', 'being', 'available', 'for', 'the', 'treatment', 'of', 'ra', 'a', 'series', 'of', 'shortcomings', 'still', 'limits', 'their', 'application', 'therefore', 'developing', 'novel', 'peptide', 'drugs', 'that', 'target', 'tnfαtnfr1', 'interaction', 'is', 'expected', 'to', 'expand', 'therapeutic', 'drug', 'options', 'in', 'this', 'study', 'the', 'detailed', 'interaction', 'mechanism', 'between', 'tnfα', 'and', 'tnfr1', 'was', 'elucidated', 'based', 'on', 'which', 'a', 'series', 'of', 'linear', 'peptides', 'were', 'initially', 'designed', 'to', 'overcome', 'its', 'large', 'conformational', 'flexibility', 'two', 'different', 'headtotail', 'cyclization', 'strategies', 'were', 'adopted', 'by', 'adding', 'a', 'prolineglycine', 'gp', 'or', 'cysteinecysteine', 'cc', 'to', 'form', 'an', 'amide', 'or', 'disulfide', 'bond', 'between', 'the', 'nc', 'terminal', 'the', 'results', 'indicate', 'that', 'two', 'cyclic', 'peptides', 'r1_cc4', 'and', 'α_cc8', 'exhibit', 'the', 'strongest', 'binding', 'free', 'energies', 'α_cc8', 'was', 'selected', 'for', 'further', 'optimization', 'using', 'virtual', 'mutations', 'through', 'in', 'vitro', 'activity', 'and', 'toxicity', 'experiments', 'due', 'to', 'its', 'optimal', 'biological', 'activity', 'the', 'l16r', 'mutant', 'was', 'screened', 'and', 'its', 'binding', 'affinity', 'to', 'tnfr1', 'was', 'validated', 'using', 'elisa', 'assays', 'this', 'study', 'designed', 'a', 'novel', 'cyclic', 'peptide', 'structure', 'with', 'potential', 'antiinflammatory', 'properties', 'possibly', 'bringing', 'an', 'additional', 'choice', 'for', 'the', 'treatment', 'of', 'ra', 'in', 'the', 'future']","['activating', 'tumor', 'necrosis', 'factor', 'receptor', '1', 'tnfr1', 'tumor', 'necrosis', 'factor', 'alpha', 'tnfα', 'one', 'key', 'pathological', 'mechanisms', 'resulting', 'exacerbation', 'rheumatoid', 'arthritis', 'ra', 'immune', 'response', 'despite', 'various', 'types', 'drugs', 'available', 'treatment', 'ra', 'series', 'shortcomings', 'still', 'limits', 'application', 'therefore', 'developing', 'novel', 'peptide', 'drugs', 'target', 'tnfαtnfr1', 'interaction', 'expected', 'expand', 'therapeutic', 'drug', 'options', 'study', 'detailed', 'interaction', 'mechanism', 'tnfα', 'tnfr1', 'elucidated', 'based', 'series', 'linear', 'peptides', 'initially', 'designed', 'overcome', 'large', 'conformational', 'flexibility', 'two', 'different', 'headtotail', 'cyclization', 'strategies', 'adopted', 'adding', 'prolineglycine', 'gp', 'cysteinecysteine', 'cc', 'form', 'amide', 'disulfide', 'bond', 'nc', 'terminal', 'results', 'indicate', 'two', 'cyclic', 'peptides', 'r1_cc4', 'α_cc8', 'exhibit', 'strongest', 'binding', 'free', 'energies', 'α_cc8', 'selected', 'optimization', 'using', 'virtual', 'mutations', 'vitro', 'activity', 'toxicity', 'experiments', 'due', 'optimal', 'biological', 'activity', 'l16r', 'mutant', 'screened', 'binding', 'affinity', 'tnfr1', 'validated', 'using', 'elisa', 'assays', 'study', 'designed', 'novel', 'cyclic', 'peptide', 'structure', 'potential', 'antiinflammatory', 'properties', 'possibly', 'bringing', 'additional', 'choice', 'treatment', 'ra', 'future']","['tnfr1', 'ra', 'ra', 'tnfr1', 'tnfr1', 'ra']","['tnfr1', 'ra', 'ra', 'tnfr1', 'tnfr1', 'ra']",True,"['tumor', 'arthritis']"
39519378,"Development and Evaluation of ABI-171, a New Fluoro-Catechin Derivative, for the Treatment of Idiopathic Pulmonary Fibrosis.","The persistent challenge of idiopathic pulmonary fibrosis (IPF), characterized by disease progression and high mortality, underscores the urgent need for innovative therapeutic strategies. We have developed a novel small molecule-catechin derivative ABI-171-selectively targeting dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) and proviral integration site for Moloney murine leukemia virus 1 (PIM1) kinases, crucial in the pathogenesis of fibrotic processes. We employed the Bleomycin-induced (intratracheal) mouse model of pulmonary fibrosis (PF) to evaluate the therapeutic efficacy of ABI-171. Mice with induced PF were treated QD with ABI-171, either prophylactically or therapeutically, using oral and intranasal routes. Pirfenidone (100 mg/kg, TID) and Epigallocatechin gallate (EGCG, 100 mg/kg, QD), a natural catechin currently in a Phase 1 clinical trial, were used as reference compounds. ABI-171, administered prophylactically, led to a significant reduction in hydroxyproline levels and fibrotic tissue formation compared to the control group. Treatment with ABI-171 improved body weight, indicating mitigation of disease-related weight loss. Additionally, ABI-171 demonstrated anti-inflammatory activity, reducing lymphocyte and neutrophil infiltration. In the therapeutic setting, ABI-171, administered 7 days post-induction, reduced mortality rates (<i>p</i> = 0.04) compared with the bleomycin and EGCG control groups. ABI-171 also ameliorated the severity of lung injuries assessed by improved Masson's trichrome scores when administered both orally and intranasally. ABI-171 significantly decreases bleomycin-induced PF and improves survival in mice, showcasing promising therapeutic potential beyond current medications like pirfenidone and EGCG for patients with IPF. Based on these results, further studies with ABI-171 are ongoing in preclinical studies.",2024-11-04,the persistent challenge of idiopathic pulmonary fibrosis ipf characterized by disease progression and high mortality underscores the urgent need for innovative therapeutic strategies we have developed a novel small moleculecatechin derivative abi171selectively targeting dualspecificity tyrosinephosphorylationregulated kinase 1a dyrk1a and proviral integration site for moloney murine leukemia virus 1 pim1 kinases crucial in the pathogenesis of fibrotic processes we employed the bleomycininduced intratracheal mouse model of pulmonary fibrosis pf to evaluate the therapeutic efficacy of abi171 mice with induced pf were treated qd with abi171 either prophylactically or therapeutically using oral and intranasal routes pirfenidone 100 mgkg tid and epigallocatechin gallate egcg 100 mgkg qd a natural catechin currently in a phase 1 clinical trial were used as reference compounds abi171 administered prophylactically led to a significant reduction in hydroxyproline levels and fibrotic tissue formation compared to the control group treatment with abi171 improved body weight indicating mitigation of diseaserelated weight loss additionally abi171 demonstrated antiinflammatory activity reducing lymphocyte and neutrophil infiltration in the therapeutic setting abi171 administered 7 days postinduction reduced mortality rates ipi  004 compared with the bleomycin and egcg control groups abi171 also ameliorated the severity of lung injuries assessed by improved massons trichrome scores when administered both orally and intranasally abi171 significantly decreases bleomycininduced pf and improves survival in mice showcasing promising therapeutic potential beyond current medications like pirfenidone and egcg for patients with ipf based on these results further studies with abi171 are ongoing in preclinical studies,"['the', 'persistent', 'challenge', 'of', 'idiopathic', 'pulmonary', 'fibrosis', 'ipf', 'characterized', 'by', 'disease', 'progression', 'and', 'high', 'mortality', 'underscores', 'the', 'urgent', 'need', 'for', 'innovative', 'therapeutic', 'strategies', 'we', 'have', 'developed', 'a', 'novel', 'small', 'moleculecatechin', 'derivative', 'abi171selectively', 'targeting', 'dualspecificity', 'tyrosinephosphorylationregulated', 'kinase', '1a', 'dyrk1a', 'and', 'proviral', 'integration', 'site', 'for', 'moloney', 'murine', 'leukemia', 'virus', '1', 'pim1', 'kinases', 'crucial', 'in', 'the', 'pathogenesis', 'of', 'fibrotic', 'processes', 'we', 'employed', 'the', 'bleomycininduced', 'intratracheal', 'mouse', 'model', 'of', 'pulmonary', 'fibrosis', 'pf', 'to', 'evaluate', 'the', 'therapeutic', 'efficacy', 'of', 'abi171', 'mice', 'with', 'induced', 'pf', 'were', 'treated', 'qd', 'with', 'abi171', 'either', 'prophylactically', 'or', 'therapeutically', 'using', 'oral', 'and', 'intranasal', 'routes', 'pirfenidone', '100', 'mgkg', 'tid', 'and', 'epigallocatechin', 'gallate', 'egcg', '100', 'mgkg', 'qd', 'a', 'natural', 'catechin', 'currently', 'in', 'a', 'phase', '1', 'clinical', 'trial', 'were', 'used', 'as', 'reference', 'compounds', 'abi171', 'administered', 'prophylactically', 'led', 'to', 'a', 'significant', 'reduction', 'in', 'hydroxyproline', 'levels', 'and', 'fibrotic', 'tissue', 'formation', 'compared', 'to', 'the', 'control', 'group', 'treatment', 'with', 'abi171', 'improved', 'body', 'weight', 'indicating', 'mitigation', 'of', 'diseaserelated', 'weight', 'loss', 'additionally', 'abi171', 'demonstrated', 'antiinflammatory', 'activity', 'reducing', 'lymphocyte', 'and', 'neutrophil', 'infiltration', 'in', 'the', 'therapeutic', 'setting', 'abi171', 'administered', '7', 'days', 'postinduction', 'reduced', 'mortality', 'rates', 'ipi', '004', 'compared', 'with', 'the', 'bleomycin', 'and', 'egcg', 'control', 'groups', 'abi171', 'also', 'ameliorated', 'the', 'severity', 'of', 'lung', 'injuries', 'assessed', 'by', 'improved', 'massons', 'trichrome', 'scores', 'when', 'administered', 'both', 'orally', 'and', 'intranasally', 'abi171', 'significantly', 'decreases', 'bleomycininduced', 'pf', 'and', 'improves', 'survival', 'in', 'mice', 'showcasing', 'promising', 'therapeutic', 'potential', 'beyond', 'current', 'medications', 'like', 'pirfenidone', 'and', 'egcg', 'for', 'patients', 'with', 'ipf', 'based', 'on', 'these', 'results', 'further', 'studies', 'with', 'abi171', 'are', 'ongoing', 'in', 'preclinical', 'studies']","['persistent', 'challenge', 'idiopathic', 'pulmonary', 'fibrosis', 'ipf', 'characterized', 'disease', 'progression', 'high', 'mortality', 'underscores', 'urgent', 'need', 'innovative', 'therapeutic', 'strategies', 'developed', 'novel', 'small', 'moleculecatechin', 'derivative', 'abi171selectively', 'targeting', 'dualspecificity', 'tyrosinephosphorylationregulated', 'kinase', '1a', 'dyrk1a', 'proviral', 'integration', 'site', 'moloney', 'murine', 'leukemia', 'virus', '1', 'pim1', 'kinases', 'crucial', 'pathogenesis', 'fibrotic', 'processes', 'employed', 'bleomycininduced', 'intratracheal', 'mouse', 'model', 'pulmonary', 'fibrosis', 'pf', 'evaluate', 'therapeutic', 'efficacy', 'abi171', 'mice', 'induced', 'pf', 'treated', 'qd', 'abi171', 'either', 'prophylactically', 'therapeutically', 'using', 'oral', 'intranasal', 'routes', 'pirfenidone', '100', 'mgkg', 'tid', 'epigallocatechin', 'gallate', 'egcg', '100', 'mgkg', 'qd', 'natural', 'catechin', 'currently', 'phase', '1', 'clinical', 'trial', 'used', 'reference', 'compounds', 'abi171', 'administered', 'prophylactically', 'led', 'significant', 'reduction', 'hydroxyproline', 'levels', 'fibrotic', 'tissue', 'formation', 'compared', 'control', 'group', 'treatment', 'abi171', 'improved', 'body', 'weight', 'indicating', 'mitigation', 'diseaserelated', 'weight', 'loss', 'additionally', 'abi171', 'demonstrated', 'antiinflammatory', 'activity', 'reducing', 'lymphocyte', 'neutrophil', 'infiltration', 'therapeutic', 'setting', 'abi171', 'administered', '7', 'days', 'postinduction', 'reduced', 'mortality', 'rates', 'ipi', '004', 'compared', 'bleomycin', 'egcg', 'control', 'groups', 'abi171', 'also', 'ameliorated', 'severity', 'lung', 'injuries', 'assessed', 'improved', 'massons', 'trichrome', 'scores', 'administered', 'orally', 'intranasally', 'abi171', 'significantly', 'decreases', 'bleomycininduced', 'pf', 'improves', 'survival', 'mice', 'showcasing', 'promising', 'therapeutic', 'potential', 'beyond', 'current', 'medications', 'like', 'pirfenidone', 'egcg', 'patients', 'ipf', 'based', 'results', 'studies', 'abi171', 'ongoing', 'preclinical', 'studies']","['dyrk1a', 'pim1']",['dyrk1a'],True,['leukemia']
39513867,p70S6K as a Potential Anti-COVID-19 Target: Insights from Wet Bench and In Silico Studies.,"The onset of SARS-CoV-2 infection in 2019 sparked a global COVID-19 pandemic. This infection is marked by a significant rise in both viral and host kinase activity. Our primary objective was to identify a pivotal host kinase essential for COVID-19 infection and the associated phenomenon of the cytokine storm, which may lead to long-term COVID-19 complications irrespective of viral genetic variations. To achieve this, our study tracked kinase phosphorylation dynamics in RAW264.7 macrophages following SPIKE transfection over time. Among the kinases surveyed, p70S6K (RPS6KB1) exhibited a 3.5-fold increase in phosphorylation at S418. This significant change prompted the selection of p70S6K for in silico investigation, utilizing its structure bound to M2698 (PDB: 7N93). M2698, an oral dual Akt/p70S6K inhibitor with an IC<sub>50</sub> of 1.1 nM, exhibited psychosis side effects in phase I clinical trials, potentially linked to its interaction with Akt2. Our secondary objective was to discover a small-molecule analogue of M2698 that exhibits a distinct binding preference for p70S6K over Akt2 through computational modeling and analysis. The in silico part of our project began with validating the prediction accuracy of the docking algorithm, followed by an OCA analysis pinpointing specific atoms on M2698 that could be modified to enhance selectivity. Subsequently, our investigation led to the identification of an analog of M2698, designated as S34, that showed a superior docking score towards p70S6K compared to Akt2. To further assess the stability of S34 in its protein-ligand (PL) complexes with p70S6K and Akt2, MD simulations were conducted. These simulations suggest that S34, on average, forms two hydrogen bond interactions with p70S6K, whereas it only forms one hydrogen bond interaction with Akt2. This difference in hydrogen bond interactions likely contributed to the observed larger root mean square deviation (RMSD) of 0.3 nm in the S34-Akt2 complex, compared to 0.1 nm in the S34-p70S6K complex. Additionally, we calculated free binding energy to predict the strength of the binding interactions of S34 to p70S6K and Akt2, which showed ~2-fold favorable binding affinity of S34 in the p70S6K binding pocket compared to that in the Akt2 binding pocket. These observations may suggest that the S34-p70S6K complex is more stable than the S34-Akt2 complex. Our work focused on identifying a host kinase target and predicting the binding affinity of a novel small molecule to accelerate the development of effective treatments. The wet bench results specifically highlight p70S6K as a compelling anti-COVID-19 target. Meanwhile, our in silico investigations address the known off-target effects associated with M2698 by identifying a close analog called S34. In conclusion, this study presents novel and intriguing findings that could potentially lead to clinical applications with further investigations.",2024-10-24,the onset of sarscov2 infection in 2019 sparked a global covid19 pandemic this infection is marked by a significant rise in both viral and host kinase activity our primary objective was to identify a pivotal host kinase essential for covid19 infection and the associated phenomenon of the cytokine storm which may lead to longterm covid19 complications irrespective of viral genetic variations to achieve this our study tracked kinase phosphorylation dynamics in raw2647 macrophages following spike transfection over time among the kinases surveyed p70s6k rps6kb1 exhibited a 35fold increase in phosphorylation at s418 this significant change prompted the selection of p70s6k for in silico investigation utilizing its structure bound to m2698 pdb 7n93 m2698 an oral dual aktp70s6k inhibitor with an icsub50sub of 11 nm exhibited psychosis side effects in phase i clinical trials potentially linked to its interaction with akt2 our secondary objective was to discover a smallmolecule analogue of m2698 that exhibits a distinct binding preference for p70s6k over akt2 through computational modeling and analysis the in silico part of our project began with validating the prediction accuracy of the docking algorithm followed by an oca analysis pinpointing specific atoms on m2698 that could be modified to enhance selectivity subsequently our investigation led to the identification of an analog of m2698 designated as s34 that showed a superior docking score towards p70s6k compared to akt2 to further assess the stability of s34 in its proteinligand pl complexes with p70s6k and akt2 md simulations were conducted these simulations suggest that s34 on average forms two hydrogen bond interactions with p70s6k whereas it only forms one hydrogen bond interaction with akt2 this difference in hydrogen bond interactions likely contributed to the observed larger root mean square deviation rmsd of 03 nm in the s34akt2 complex compared to 01 nm in the s34p70s6k complex additionally we calculated free binding energy to predict the strength of the binding interactions of s34 to p70s6k and akt2 which showed 2fold favorable binding affinity of s34 in the p70s6k binding pocket compared to that in the akt2 binding pocket these observations may suggest that the s34p70s6k complex is more stable than the s34akt2 complex our work focused on identifying a host kinase target and predicting the binding affinity of a novel small molecule to accelerate the development of effective treatments the wet bench results specifically highlight p70s6k as a compelling anticovid19 target meanwhile our in silico investigations address the known offtarget effects associated with m2698 by identifying a close analog called s34 in conclusion this study presents novel and intriguing findings that could potentially lead to clinical applications with further investigations,"['the', 'onset', 'of', 'sarscov2', 'infection', 'in', '2019', 'sparked', 'a', 'global', 'covid19', 'pandemic', 'this', 'infection', 'is', 'marked', 'by', 'a', 'significant', 'rise', 'in', 'both', 'viral', 'and', 'host', 'kinase', 'activity', 'our', 'primary', 'objective', 'was', 'to', 'identify', 'a', 'pivotal', 'host', 'kinase', 'essential', 'for', 'covid19', 'infection', 'and', 'the', 'associated', 'phenomenon', 'of', 'the', 'cytokine', 'storm', 'which', 'may', 'lead', 'to', 'longterm', 'covid19', 'complications', 'irrespective', 'of', 'viral', 'genetic', 'variations', 'to', 'achieve', 'this', 'our', 'study', 'tracked', 'kinase', 'phosphorylation', 'dynamics', 'in', 'raw2647', 'macrophages', 'following', 'spike', 'transfection', 'over', 'time', 'among', 'the', 'kinases', 'surveyed', 'p70s6k', 'rps6kb1', 'exhibited', 'a', '35fold', 'increase', 'in', 'phosphorylation', 'at', 's418', 'this', 'significant', 'change', 'prompted', 'the', 'selection', 'of', 'p70s6k', 'for', 'in', 'silico', 'investigation', 'utilizing', 'its', 'structure', 'bound', 'to', 'm2698', 'pdb', '7n93', 'm2698', 'an', 'oral', 'dual', 'aktp70s6k', 'inhibitor', 'with', 'an', 'icsub50sub', 'of', '11', 'nm', 'exhibited', 'psychosis', 'side', 'effects', 'in', 'phase', 'i', 'clinical', 'trials', 'potentially', 'linked', 'to', 'its', 'interaction', 'with', 'akt2', 'our', 'secondary', 'objective', 'was', 'to', 'discover', 'a', 'smallmolecule', 'analogue', 'of', 'm2698', 'that', 'exhibits', 'a', 'distinct', 'binding', 'preference', 'for', 'p70s6k', 'over', 'akt2', 'through', 'computational', 'modeling', 'and', 'analysis', 'the', 'in', 'silico', 'part', 'of', 'our', 'project', 'began', 'with', 'validating', 'the', 'prediction', 'accuracy', 'of', 'the', 'docking', 'algorithm', 'followed', 'by', 'an', 'oca', 'analysis', 'pinpointing', 'specific', 'atoms', 'on', 'm2698', 'that', 'could', 'be', 'modified', 'to', 'enhance', 'selectivity', 'subsequently', 'our', 'investigation', 'led', 'to', 'the', 'identification', 'of', 'an', 'analog', 'of', 'm2698', 'designated', 'as', 's34', 'that', 'showed', 'a', 'superior', 'docking', 'score', 'towards', 'p70s6k', 'compared', 'to', 'akt2', 'to', 'further', 'assess', 'the', 'stability', 'of', 's34', 'in', 'its', 'proteinligand', 'pl', 'complexes', 'with', 'p70s6k', 'and', 'akt2', 'md', 'simulations', 'were', 'conducted', 'these', 'simulations', 'suggest', 'that', 's34', 'on', 'average', 'forms', 'two', 'hydrogen', 'bond', 'interactions', 'with', 'p70s6k', 'whereas', 'it', 'only', 'forms', 'one', 'hydrogen', 'bond', 'interaction', 'with', 'akt2', 'this', 'difference', 'in', 'hydrogen', 'bond', 'interactions', 'likely', 'contributed', 'to', 'the', 'observed', 'larger', 'root', 'mean', 'square', 'deviation', 'rmsd', 'of', '03', 'nm', 'in', 'the', 's34akt2', 'complex', 'compared', 'to', '01', 'nm', 'in', 'the', 's34p70s6k', 'complex', 'additionally', 'we', 'calculated', 'free', 'binding', 'energy', 'to', 'predict', 'the', 'strength', 'of', 'the', 'binding', 'interactions', 'of', 's34', 'to', 'p70s6k', 'and', 'akt2', 'which', 'showed', '2fold', 'favorable', 'binding', 'affinity', 'of', 's34', 'in', 'the', 'p70s6k', 'binding', 'pocket', 'compared', 'to', 'that', 'in', 'the', 'akt2', 'binding', 'pocket', 'these', 'observations', 'may', 'suggest', 'that', 'the', 's34p70s6k', 'complex', 'is', 'more', 'stable', 'than', 'the', 's34akt2', 'complex', 'our', 'work', 'focused', 'on', 'identifying', 'a', 'host', 'kinase', 'target', 'and', 'predicting', 'the', 'binding', 'affinity', 'of', 'a', 'novel', 'small', 'molecule', 'to', 'accelerate', 'the', 'development', 'of', 'effective', 'treatments', 'the', 'wet', 'bench', 'results', 'specifically', 'highlight', 'p70s6k', 'as', 'a', 'compelling', 'anticovid19', 'target', 'meanwhile', 'our', 'in', 'silico', 'investigations', 'address', 'the', 'known', 'offtarget', 'effects', 'associated', 'with', 'm2698', 'by', 'identifying', 'a', 'close', 'analog', 'called', 's34', 'in', 'conclusion', 'this', 'study', 'presents', 'novel', 'and', 'intriguing', 'findings', 'that', 'could', 'potentially', 'lead', 'to', 'clinical', 'applications', 'with', 'further', 'investigations']","['onset', 'sarscov2', 'infection', '2019', 'sparked', 'global', 'covid19', 'pandemic', 'infection', 'marked', 'significant', 'rise', 'viral', 'host', 'kinase', 'activity', 'primary', 'objective', 'identify', 'pivotal', 'host', 'kinase', 'essential', 'covid19', 'infection', 'associated', 'phenomenon', 'cytokine', 'storm', 'may', 'lead', 'longterm', 'covid19', 'complications', 'irrespective', 'viral', 'genetic', 'variations', 'achieve', 'study', 'tracked', 'kinase', 'phosphorylation', 'dynamics', 'raw2647', 'macrophages', 'following', 'spike', 'transfection', 'time', 'among', 'kinases', 'surveyed', 'p70s6k', 'rps6kb1', 'exhibited', '35fold', 'increase', 'phosphorylation', 's418', 'significant', 'change', 'prompted', 'selection', 'p70s6k', 'silico', 'investigation', 'utilizing', 'structure', 'bound', 'm2698', 'pdb', '7n93', 'm2698', 'oral', 'dual', 'aktp70s6k', 'inhibitor', 'icsub50sub', '11', 'nm', 'exhibited', 'psychosis', 'side', 'effects', 'phase', 'clinical', 'trials', 'potentially', 'linked', 'interaction', 'akt2', 'secondary', 'objective', 'discover', 'smallmolecule', 'analogue', 'm2698', 'exhibits', 'distinct', 'binding', 'preference', 'p70s6k', 'akt2', 'computational', 'modeling', 'analysis', 'silico', 'part', 'project', 'began', 'validating', 'prediction', 'accuracy', 'docking', 'algorithm', 'followed', 'oca', 'analysis', 'pinpointing', 'specific', 'atoms', 'm2698', 'could', 'modified', 'enhance', 'selectivity', 'subsequently', 'investigation', 'led', 'identification', 'analog', 'm2698', 'designated', 's34', 'showed', 'superior', 'docking', 'score', 'towards', 'p70s6k', 'compared', 'akt2', 'assess', 'stability', 's34', 'proteinligand', 'pl', 'complexes', 'p70s6k', 'akt2', 'md', 'simulations', 'conducted', 'simulations', 'suggest', 's34', 'average', 'forms', 'two', 'hydrogen', 'bond', 'interactions', 'p70s6k', 'whereas', 'forms', 'one', 'hydrogen', 'bond', 'interaction', 'akt2', 'difference', 'hydrogen', 'bond', 'interactions', 'likely', 'contributed', 'observed', 'larger', 'root', 'mean', 'square', 'deviation', 'rmsd', '03', 'nm', 's34akt2', 'complex', 'compared', '01', 'nm', 's34p70s6k', 'complex', 'additionally', 'calculated', 'free', 'binding', 'energy', 'predict', 'strength', 'binding', 'interactions', 's34', 'p70s6k', 'akt2', 'showed', '2fold', 'favorable', 'binding', 'affinity', 's34', 'p70s6k', 'binding', 'pocket', 'compared', 'akt2', 'binding', 'pocket', 'observations', 'may', 'suggest', 's34p70s6k', 'complex', 'stable', 's34akt2', 'complex', 'work', 'focused', 'identifying', 'host', 'kinase', 'target', 'predicting', 'binding', 'affinity', 'novel', 'small', 'molecule', 'accelerate', 'development', 'effective', 'treatments', 'wet', 'bench', 'results', 'specifically', 'highlight', 'p70s6k', 'compelling', 'anticovid19', 'target', 'meanwhile', 'silico', 'investigations', 'address', 'known', 'offtarget', 'effects', 'associated', 'm2698', 'identifying', 'close', 'analog', 'called', 's34', 'conclusion', 'study', 'presents', 'novel', 'intriguing', 'findings', 'could', 'potentially', 'lead', 'clinical', 'applications', 'investigations']","['p70s6k', 'p70s6k', 'akt2', 'p70s6k', 'akt2', 'p70s6k', 'akt2', 'p70s6k', 'akt2', 'p70s6k', 'akt2', 'p70s6k', 'akt2', 'p70s6k', 'akt2', 'p70s6k', 'offtarget']","['p70s6k', 'p70s6k', 'akt2', 'p70s6k', 'akt2', 'p70s6k', 'akt2', 'p70s6k', 'akt2', 'p70s6k', 'akt2', 'p70s6k', 'akt2', 'p70s6k', 'akt2', 'p70s6k', 'offtarget']",True,['infection']
39485774,A novel small molecule screening assay using normal human chondrocytes toward osteoarthritis drug discovery.,"Osteoarthritis (OA) is the most common form of arthritis and a leading cause of pain and disability in adults. A central feature is progressive cartilage degradation and matrix fragment formation driven by the excessive production of matrix metalloproteinases (MMPs), such as MMP-13, by articular chondrocytes. Inflammatory factors, including interleukin 6 (IL-6), are secreted into the joint by synovial fibroblasts, and can contribute to pain and inflammation. No therapeutic exists that addresses the underlying loss of joint tissue in OA. To address this, we developed and utilized a cell-based high-throughput OA drug discovery platform using normal human chondrocytes treated with a recombinant fragment of the matrix protein fibronectin (FN-f) as a catabolic stimulus relevant to OA pathogenesis and a readout using a fluorescent MMP-13 responsive probe. The goal was to test this screening platform by identifying compounds that inhibited FN-f-induced MMP-13 production and determine if these compounds also inhibited catabolic signaling in OA chondrocytes and synovial fibroblasts. Two pilot screens of 1344 small molecules revealed five ""hits"" that strongly inhibited FN-f induced MMP-13 production with low cytotoxicity. These included RO-3306 (CDK1 inhibitor (i)), staurosporine (PKCi), trametinib (MEK1 and MEK2i), GSK-626616 (DYRK3i), and edicotinib (CSF-1Ri). Secondary testing using immunoblots and cells derived from OA joint tissues confirmed the ability of selected compounds to inhibit chondrocyte MMP-13 production and FN-f stimulated IL-6 production by synovial fibroblasts. These findings support the use of this high throughput screening assay for discovery of disease-modifying osteoarthritis drugs.",2024-11-01,osteoarthritis oa is the most common form of arthritis and a leading cause of pain and disability in adults a central feature is progressive cartilage degradation and matrix fragment formation driven by the excessive production of matrix metalloproteinases mmps such as mmp13 by articular chondrocytes inflammatory factors including interleukin 6 il6 are secreted into the joint by synovial fibroblasts and can contribute to pain and inflammation no therapeutic exists that addresses the underlying loss of joint tissue in oa to address this we developed and utilized a cellbased highthroughput oa drug discovery platform using normal human chondrocytes treated with a recombinant fragment of the matrix protein fibronectin fnf as a catabolic stimulus relevant to oa pathogenesis and a readout using a fluorescent mmp13 responsive probe the goal was to test this screening platform by identifying compounds that inhibited fnfinduced mmp13 production and determine if these compounds also inhibited catabolic signaling in oa chondrocytes and synovial fibroblasts two pilot screens of 1344 small molecules revealed five hits that strongly inhibited fnf induced mmp13 production with low cytotoxicity these included ro3306 cdk1 inhibitor i staurosporine pkci trametinib mek1 and mek2i gsk626616 dyrk3i and edicotinib csf1ri secondary testing using immunoblots and cells derived from oa joint tissues confirmed the ability of selected compounds to inhibit chondrocyte mmp13 production and fnf stimulated il6 production by synovial fibroblasts these findings support the use of this high throughput screening assay for discovery of diseasemodifying osteoarthritis drugs,"['osteoarthritis', 'oa', 'is', 'the', 'most', 'common', 'form', 'of', 'arthritis', 'and', 'a', 'leading', 'cause', 'of', 'pain', 'and', 'disability', 'in', 'adults', 'a', 'central', 'feature', 'is', 'progressive', 'cartilage', 'degradation', 'and', 'matrix', 'fragment', 'formation', 'driven', 'by', 'the', 'excessive', 'production', 'of', 'matrix', 'metalloproteinases', 'mmps', 'such', 'as', 'mmp13', 'by', 'articular', 'chondrocytes', 'inflammatory', 'factors', 'including', 'interleukin', '6', 'il6', 'are', 'secreted', 'into', 'the', 'joint', 'by', 'synovial', 'fibroblasts', 'and', 'can', 'contribute', 'to', 'pain', 'and', 'inflammation', 'no', 'therapeutic', 'exists', 'that', 'addresses', 'the', 'underlying', 'loss', 'of', 'joint', 'tissue', 'in', 'oa', 'to', 'address', 'this', 'we', 'developed', 'and', 'utilized', 'a', 'cellbased', 'highthroughput', 'oa', 'drug', 'discovery', 'platform', 'using', 'normal', 'human', 'chondrocytes', 'treated', 'with', 'a', 'recombinant', 'fragment', 'of', 'the', 'matrix', 'protein', 'fibronectin', 'fnf', 'as', 'a', 'catabolic', 'stimulus', 'relevant', 'to', 'oa', 'pathogenesis', 'and', 'a', 'readout', 'using', 'a', 'fluorescent', 'mmp13', 'responsive', 'probe', 'the', 'goal', 'was', 'to', 'test', 'this', 'screening', 'platform', 'by', 'identifying', 'compounds', 'that', 'inhibited', 'fnfinduced', 'mmp13', 'production', 'and', 'determine', 'if', 'these', 'compounds', 'also', 'inhibited', 'catabolic', 'signaling', 'in', 'oa', 'chondrocytes', 'and', 'synovial', 'fibroblasts', 'two', 'pilot', 'screens', 'of', '1344', 'small', 'molecules', 'revealed', 'five', 'hits', 'that', 'strongly', 'inhibited', 'fnf', 'induced', 'mmp13', 'production', 'with', 'low', 'cytotoxicity', 'these', 'included', 'ro3306', 'cdk1', 'inhibitor', 'i', 'staurosporine', 'pkci', 'trametinib', 'mek1', 'and', 'mek2i', 'gsk626616', 'dyrk3i', 'and', 'edicotinib', 'csf1ri', 'secondary', 'testing', 'using', 'immunoblots', 'and', 'cells', 'derived', 'from', 'oa', 'joint', 'tissues', 'confirmed', 'the', 'ability', 'of', 'selected', 'compounds', 'to', 'inhibit', 'chondrocyte', 'mmp13', 'production', 'and', 'fnf', 'stimulated', 'il6', 'production', 'by', 'synovial', 'fibroblasts', 'these', 'findings', 'support', 'the', 'use', 'of', 'this', 'high', 'throughput', 'screening', 'assay', 'for', 'discovery', 'of', 'diseasemodifying', 'osteoarthritis', 'drugs']","['osteoarthritis', 'oa', 'common', 'form', 'arthritis', 'leading', 'cause', 'pain', 'disability', 'adults', 'central', 'feature', 'progressive', 'cartilage', 'degradation', 'matrix', 'fragment', 'formation', 'driven', 'excessive', 'production', 'matrix', 'metalloproteinases', 'mmps', 'mmp13', 'articular', 'chondrocytes', 'inflammatory', 'factors', 'including', 'interleukin', '6', 'il6', 'secreted', 'joint', 'synovial', 'fibroblasts', 'contribute', 'pain', 'inflammation', 'therapeutic', 'exists', 'addresses', 'underlying', 'loss', 'joint', 'tissue', 'oa', 'address', 'developed', 'utilized', 'cellbased', 'highthroughput', 'oa', 'drug', 'discovery', 'platform', 'using', 'normal', 'human', 'chondrocytes', 'treated', 'recombinant', 'fragment', 'matrix', 'protein', 'fibronectin', 'fnf', 'catabolic', 'stimulus', 'relevant', 'oa', 'pathogenesis', 'readout', 'using', 'fluorescent', 'mmp13', 'responsive', 'probe', 'goal', 'test', 'screening', 'platform', 'identifying', 'compounds', 'inhibited', 'fnfinduced', 'mmp13', 'production', 'determine', 'compounds', 'also', 'inhibited', 'catabolic', 'signaling', 'oa', 'chondrocytes', 'synovial', 'fibroblasts', 'two', 'pilot', 'screens', '1344', 'small', 'molecules', 'revealed', 'five', 'hits', 'strongly', 'inhibited', 'fnf', 'induced', 'mmp13', 'production', 'low', 'cytotoxicity', 'included', 'ro3306', 'cdk1', 'inhibitor', 'staurosporine', 'pkci', 'trametinib', 'mek1', 'mek2i', 'gsk626616', 'dyrk3i', 'edicotinib', 'csf1ri', 'secondary', 'testing', 'using', 'immunoblots', 'cells', 'derived', 'oa', 'joint', 'tissues', 'confirmed', 'ability', 'selected', 'compounds', 'inhibit', 'chondrocyte', 'mmp13', 'production', 'fnf', 'stimulated', 'il6', 'production', 'synovial', 'fibroblasts', 'findings', 'support', 'use', 'high', 'throughput', 'screening', 'assay', 'discovery', 'diseasemodifying', 'osteoarthritis', 'drugs']","['metalloproteinases', 'mmp13', 'interleukin', 'fibronectin', 'mmp13', 'mmp13', 'mmp13', 'cdk1', 'mmp13']","['mmp13', 'mmp13', 'mmp13', 'mmp13', 'mmp13']",True,['arthritis']
39426685,Effects of phospholipase D1-inhibitory peptide on the growth and metastasis of gastric cancer cells.,"Phospholipase D1 (PLD1) contributes to cancer development and progression through its effects on cell proliferation, survival, invasion, metastasis, angiogenesis, drug resistance, and modulation of the tumor microenvironment. Its central role in these processes makes it a promising target for novel cancer treatments aimed at inhibiting its activity and disrupting the signaling pathways it regulates. In this study, we aimed to investigate the effect of PLD1 inhibition on gastric cancer cell growth using a novel peptide inhibitor, TAT-TVTSP. PLD1, which plays a role in cancer progression, catalyzes the conversion of phosphatidylcholine into choline and phosphatidic acid through hydrolysis. To effectively target PLD1 in cells, we engineered TAT-TVTSP by fusing a PLD1-inhibitory peptide (TVTSP) with a cell-penetrating peptide (TAT). We observed that TAT-TVTSP effectively inhibited PLD1 activity in AGS gastric cancer cells. Moreover, TAT-TVTSP significantly inhibited the mammalian target of the rapamycin signaling pathway, including the phosphorylation of key downstream targets such as S6K1, AKT, S473, glycogen synthase kinase-3b, and forkhead box O1. TAT-TVTSP did not induce cell death, but it triggered cell cycle arrest by activating p21 and p27 via AKT phosphorylation. Functional assays revealed that TAT-TVTSP significantly impaired the colony-forming ability of AGS cells, thus inhibiting cell proliferation. Transwell and wound-healing assays revealed that this peptide disrupted the cellular behaviors critical to cancer progression, such as migration and invasion. In vivo, TAT-TVTSP significantly reduced tumor growth in the xenograft model of gastric cancer without any toxicity. Overall, our results suggest that TAT-TVTSP is a novel therapeutic agent for PLD1-mediated cancers.",2024-10-18,phospholipase d1 pld1 contributes to cancer development and progression through its effects on cell proliferation survival invasion metastasis angiogenesis drug resistance and modulation of the tumor microenvironment its central role in these processes makes it a promising target for novel cancer treatments aimed at inhibiting its activity and disrupting the signaling pathways it regulates in this study we aimed to investigate the effect of pld1 inhibition on gastric cancer cell growth using a novel peptide inhibitor tattvtsp pld1 which plays a role in cancer progression catalyzes the conversion of phosphatidylcholine into choline and phosphatidic acid through hydrolysis to effectively target pld1 in cells we engineered tattvtsp by fusing a pld1inhibitory peptide tvtsp with a cellpenetrating peptide tat we observed that tattvtsp effectively inhibited pld1 activity in ags gastric cancer cells moreover tattvtsp significantly inhibited the mammalian target of the rapamycin signaling pathway including the phosphorylation of key downstream targets such as s6k1 akt s473 glycogen synthase kinase3b and forkhead box o1 tattvtsp did not induce cell death but it triggered cell cycle arrest by activating p21 and p27 via akt phosphorylation functional assays revealed that tattvtsp significantly impaired the colonyforming ability of ags cells thus inhibiting cell proliferation transwell and woundhealing assays revealed that this peptide disrupted the cellular behaviors critical to cancer progression such as migration and invasion in vivo tattvtsp significantly reduced tumor growth in the xenograft model of gastric cancer without any toxicity overall our results suggest that tattvtsp is a novel therapeutic agent for pld1mediated cancers,"['phospholipase', 'd1', 'pld1', 'contributes', 'to', 'cancer', 'development', 'and', 'progression', 'through', 'its', 'effects', 'on', 'cell', 'proliferation', 'survival', 'invasion', 'metastasis', 'angiogenesis', 'drug', 'resistance', 'and', 'modulation', 'of', 'the', 'tumor', 'microenvironment', 'its', 'central', 'role', 'in', 'these', 'processes', 'makes', 'it', 'a', 'promising', 'target', 'for', 'novel', 'cancer', 'treatments', 'aimed', 'at', 'inhibiting', 'its', 'activity', 'and', 'disrupting', 'the', 'signaling', 'pathways', 'it', 'regulates', 'in', 'this', 'study', 'we', 'aimed', 'to', 'investigate', 'the', 'effect', 'of', 'pld1', 'inhibition', 'on', 'gastric', 'cancer', 'cell', 'growth', 'using', 'a', 'novel', 'peptide', 'inhibitor', 'tattvtsp', 'pld1', 'which', 'plays', 'a', 'role', 'in', 'cancer', 'progression', 'catalyzes', 'the', 'conversion', 'of', 'phosphatidylcholine', 'into', 'choline', 'and', 'phosphatidic', 'acid', 'through', 'hydrolysis', 'to', 'effectively', 'target', 'pld1', 'in', 'cells', 'we', 'engineered', 'tattvtsp', 'by', 'fusing', 'a', 'pld1inhibitory', 'peptide', 'tvtsp', 'with', 'a', 'cellpenetrating', 'peptide', 'tat', 'we', 'observed', 'that', 'tattvtsp', 'effectively', 'inhibited', 'pld1', 'activity', 'in', 'ags', 'gastric', 'cancer', 'cells', 'moreover', 'tattvtsp', 'significantly', 'inhibited', 'the', 'mammalian', 'target', 'of', 'the', 'rapamycin', 'signaling', 'pathway', 'including', 'the', 'phosphorylation', 'of', 'key', 'downstream', 'targets', 'such', 'as', 's6k1', 'akt', 's473', 'glycogen', 'synthase', 'kinase3b', 'and', 'forkhead', 'box', 'o1', 'tattvtsp', 'did', 'not', 'induce', 'cell', 'death', 'but', 'it', 'triggered', 'cell', 'cycle', 'arrest', 'by', 'activating', 'p21', 'and', 'p27', 'via', 'akt', 'phosphorylation', 'functional', 'assays', 'revealed', 'that', 'tattvtsp', 'significantly', 'impaired', 'the', 'colonyforming', 'ability', 'of', 'ags', 'cells', 'thus', 'inhibiting', 'cell', 'proliferation', 'transwell', 'and', 'woundhealing', 'assays', 'revealed', 'that', 'this', 'peptide', 'disrupted', 'the', 'cellular', 'behaviors', 'critical', 'to', 'cancer', 'progression', 'such', 'as', 'migration', 'and', 'invasion', 'in', 'vivo', 'tattvtsp', 'significantly', 'reduced', 'tumor', 'growth', 'in', 'the', 'xenograft', 'model', 'of', 'gastric', 'cancer', 'without', 'any', 'toxicity', 'overall', 'our', 'results', 'suggest', 'that', 'tattvtsp', 'is', 'a', 'novel', 'therapeutic', 'agent', 'for', 'pld1mediated', 'cancers']","['phospholipase', 'd1', 'pld1', 'contributes', 'cancer', 'development', 'progression', 'effects', 'cell', 'proliferation', 'survival', 'invasion', 'metastasis', 'angiogenesis', 'drug', 'resistance', 'modulation', 'tumor', 'microenvironment', 'central', 'role', 'processes', 'makes', 'promising', 'target', 'novel', 'cancer', 'treatments', 'aimed', 'inhibiting', 'activity', 'disrupting', 'signaling', 'pathways', 'regulates', 'study', 'aimed', 'investigate', 'effect', 'pld1', 'inhibition', 'gastric', 'cancer', 'cell', 'growth', 'using', 'novel', 'peptide', 'inhibitor', 'tattvtsp', 'pld1', 'plays', 'role', 'cancer', 'progression', 'catalyzes', 'conversion', 'phosphatidylcholine', 'choline', 'phosphatidic', 'acid', 'hydrolysis', 'effectively', 'target', 'pld1', 'cells', 'engineered', 'tattvtsp', 'fusing', 'pld1inhibitory', 'peptide', 'tvtsp', 'cellpenetrating', 'peptide', 'tat', 'observed', 'tattvtsp', 'effectively', 'inhibited', 'pld1', 'activity', 'ags', 'gastric', 'cancer', 'cells', 'moreover', 'tattvtsp', 'significantly', 'inhibited', 'mammalian', 'target', 'rapamycin', 'signaling', 'pathway', 'including', 'phosphorylation', 'key', 'downstream', 'targets', 's6k1', 'akt', 's473', 'glycogen', 'synthase', 'kinase3b', 'forkhead', 'box', 'o1', 'tattvtsp', 'induce', 'cell', 'death', 'triggered', 'cell', 'cycle', 'arrest', 'activating', 'p21', 'p27', 'via', 'akt', 'phosphorylation', 'functional', 'assays', 'revealed', 'tattvtsp', 'significantly', 'impaired', 'colonyforming', 'ability', 'ags', 'cells', 'thus', 'inhibiting', 'cell', 'proliferation', 'transwell', 'woundhealing', 'assays', 'revealed', 'peptide', 'disrupted', 'cellular', 'behaviors', 'critical', 'cancer', 'progression', 'migration', 'invasion', 'vivo', 'tattvtsp', 'significantly', 'reduced', 'tumor', 'growth', 'xenograft', 'model', 'gastric', 'cancer', 'without', 'toxicity', 'overall', 'results', 'suggest', 'tattvtsp', 'novel', 'therapeutic', 'agent', 'pld1mediated', 'cancers']","['tat', 'akt', 's473', 'p21', 'p27', 'akt']",['s473'],True,"['tumor', 'cancer']"
39287420,Identification of AS1842856 as a novel small-molecule GSK3α/β inhibitor against Tauopathy by accelerating GSK3α/β exocytosis.,"Glycogen synthase kinase-3α/β (GSK3α/β) is a critical kinase for Tau hyperphosphorylation which contributes to neurodegeneration. Despite the termination of clinical trials for GSK3α/β inhibitors in Alzheimer's disease (AD) treatment, there is a pressing need for novel therapeutic strategies targeting GSK3α/β. Here, we identified the compound AS1842856 (AS), a specific forkhead box protein O1 (FOXO1) inhibitor, reduced intracellular GSK3α/β content in a FOXO1-independent manner. Specifically, AS directly bound to GSK3α/β, promoting its translocation to the multivesicular bodies (MVBs) and accelerating exocytosis, ultimately decreasing intracellular GSK3α/β content. Expectedly, AS treatment effectively suppressed Tau hyperphosphorylation in cells exposed to okadaic acid or expressing the Tau<sup>P301S</sup> mutant. Furthermore, AS was visualized to penetrate the blood-brain barrier (BBB) using an imaging mass microscope. Long-term treatment of AS enhanced cognitive function in P301S transgenic mice by mitigating Tau hyperphosphorylation through downregulation of GSK3α/β expression in the brain. Altogether, AS represents a novel small-molecule GSK3α/β inhibitor that facilitates GSK3α/β exocytosis, holding promise as a therapeutic agent for GSK3α/β hyperactivation-associated disorders.",2024-09-17,glycogen synthase kinase3αβ gsk3αβ is a critical kinase for tau hyperphosphorylation which contributes to neurodegeneration despite the termination of clinical trials for gsk3αβ inhibitors in alzheimers disease ad treatment there is a pressing need for novel therapeutic strategies targeting gsk3αβ here we identified the compound as1842856 as a specific forkhead box protein o1 foxo1 inhibitor reduced intracellular gsk3αβ content in a foxo1independent manner specifically as directly bound to gsk3αβ promoting its translocation to the multivesicular bodies mvbs and accelerating exocytosis ultimately decreasing intracellular gsk3αβ content expectedly as treatment effectively suppressed tau hyperphosphorylation in cells exposed to okadaic acid or expressing the tausupp301ssup mutant furthermore as was visualized to penetrate the bloodbrain barrier bbb using an imaging mass microscope longterm treatment of as enhanced cognitive function in p301s transgenic mice by mitigating tau hyperphosphorylation through downregulation of gsk3αβ expression in the brain altogether as represents a novel smallmolecule gsk3αβ inhibitor that facilitates gsk3αβ exocytosis holding promise as a therapeutic agent for gsk3αβ hyperactivationassociated disorders,"['glycogen', 'synthase', 'kinase3αβ', 'gsk3αβ', 'is', 'a', 'critical', 'kinase', 'for', 'tau', 'hyperphosphorylation', 'which', 'contributes', 'to', 'neurodegeneration', 'despite', 'the', 'termination', 'of', 'clinical', 'trials', 'for', 'gsk3αβ', 'inhibitors', 'in', 'alzheimers', 'disease', 'ad', 'treatment', 'there', 'is', 'a', 'pressing', 'need', 'for', 'novel', 'therapeutic', 'strategies', 'targeting', 'gsk3αβ', 'here', 'we', 'identified', 'the', 'compound', 'as1842856', 'as', 'a', 'specific', 'forkhead', 'box', 'protein', 'o1', 'foxo1', 'inhibitor', 'reduced', 'intracellular', 'gsk3αβ', 'content', 'in', 'a', 'foxo1independent', 'manner', 'specifically', 'as', 'directly', 'bound', 'to', 'gsk3αβ', 'promoting', 'its', 'translocation', 'to', 'the', 'multivesicular', 'bodies', 'mvbs', 'and', 'accelerating', 'exocytosis', 'ultimately', 'decreasing', 'intracellular', 'gsk3αβ', 'content', 'expectedly', 'as', 'treatment', 'effectively', 'suppressed', 'tau', 'hyperphosphorylation', 'in', 'cells', 'exposed', 'to', 'okadaic', 'acid', 'or', 'expressing', 'the', 'tausupp301ssup', 'mutant', 'furthermore', 'as', 'was', 'visualized', 'to', 'penetrate', 'the', 'bloodbrain', 'barrier', 'bbb', 'using', 'an', 'imaging', 'mass', 'microscope', 'longterm', 'treatment', 'of', 'as', 'enhanced', 'cognitive', 'function', 'in', 'p301s', 'transgenic', 'mice', 'by', 'mitigating', 'tau', 'hyperphosphorylation', 'through', 'downregulation', 'of', 'gsk3αβ', 'expression', 'in', 'the', 'brain', 'altogether', 'as', 'represents', 'a', 'novel', 'smallmolecule', 'gsk3αβ', 'inhibitor', 'that', 'facilitates', 'gsk3αβ', 'exocytosis', 'holding', 'promise', 'as', 'a', 'therapeutic', 'agent', 'for', 'gsk3αβ', 'hyperactivationassociated', 'disorders']","['glycogen', 'synthase', 'kinase3αβ', 'gsk3αβ', 'critical', 'kinase', 'tau', 'hyperphosphorylation', 'contributes', 'neurodegeneration', 'despite', 'termination', 'clinical', 'trials', 'gsk3αβ', 'inhibitors', 'alzheimers', 'disease', 'ad', 'treatment', 'pressing', 'need', 'novel', 'therapeutic', 'strategies', 'targeting', 'gsk3αβ', 'identified', 'compound', 'as1842856', 'specific', 'forkhead', 'box', 'protein', 'o1', 'foxo1', 'inhibitor', 'reduced', 'intracellular', 'gsk3αβ', 'content', 'foxo1independent', 'manner', 'specifically', 'directly', 'bound', 'gsk3αβ', 'promoting', 'translocation', 'multivesicular', 'bodies', 'mvbs', 'accelerating', 'exocytosis', 'ultimately', 'decreasing', 'intracellular', 'gsk3αβ', 'content', 'expectedly', 'treatment', 'effectively', 'suppressed', 'tau', 'hyperphosphorylation', 'cells', 'exposed', 'okadaic', 'acid', 'expressing', 'tausupp301ssup', 'mutant', 'furthermore', 'visualized', 'penetrate', 'bloodbrain', 'barrier', 'bbb', 'using', 'imaging', 'mass', 'microscope', 'longterm', 'treatment', 'enhanced', 'cognitive', 'function', 'p301s', 'transgenic', 'mice', 'mitigating', 'tau', 'hyperphosphorylation', 'downregulation', 'gsk3αβ', 'expression', 'brain', 'altogether', 'represents', 'novel', 'smallmolecule', 'gsk3αβ', 'inhibitor', 'facilitates', 'gsk3αβ', 'exocytosis', 'holding', 'promise', 'therapeutic', 'agent', 'gsk3αβ', 'hyperactivationassociated', 'disorders']","['tau', 'foxo1', 'tau', 'tau']",['foxo1'],True,['alzheimer']
39194017,Identification and Characterization of Novel Small-Molecule Enhancers of the CUL3<sup>LZTR1</sup> E3 Ligase KRAS Complex.,"The RAS family of GTPases is among the most frequently mutated proteins in human cancer, creating a high clinical demand for therapies that counteract their signaling activity. An important layer of regulation that could be therapeutically exploited is the proteostatic regulation of the main RAS GTPases KRAS, NRAS, and HRAS, as well as the closely related members, MRAS and RIT1, by the leucine zipper-like transcriptional regulator 1 cullin 3 RING E3 ubiquitin ligase complex (CUL3<sup>LZTR1</sup>). Genetic inactivation of <i>LZTR1</i>, as observed in different cancer entities and Noonan syndrome leads to enhanced RAS GTPase abundance and altered MAPK pathway activation state. Novel therapeutic approaches to interfere with hyperactive RAS signaling, thereby complementing existing treatments, are highly sought after. Motivated by the growing arsenal of molecular glue degraders, we report the identification of novel chemical fragments that enhance the protein-protein interaction (PPI) of the KRAS-LZTR1 complex. We established a split-luciferase-based reporter assay that monitors the RAS GTPase-LZTR1 interaction in a scalable format, capable of capturing chemical, as well as mutational perturbations. Using this screening system, in combination with a small fragment library, we identified two fragments, C53 and Z86, that enhance the interaction of the KRAS-LZTR1 complex in a dose-dependent manner. Further orthogonal validation experiments using proximity biotinylation (BioID), thermal shift assays, and NMR spectroscopy demonstrated fragment-dependent enhanced recruitment of endogenous LZTR1 and physical engagement of KRAS. The two fragments, which potentiate the KRAS-LZTR1 interaction, serve as starting points for fragment-based drug discovery. Additionally, the assay we introduced is amenable to high-throughput screening to further explore the pharmacological modulation of the CUL3<sup>LZTR1</sup>-RAS GTPase complex.",2024-08-28,the ras family of gtpases is among the most frequently mutated proteins in human cancer creating a high clinical demand for therapies that counteract their signaling activity an important layer of regulation that could be therapeutically exploited is the proteostatic regulation of the main ras gtpases kras nras and hras as well as the closely related members mras and rit1 by the leucine zipperlike transcriptional regulator 1 cullin 3 ring e3 ubiquitin ligase complex cul3suplztr1sup genetic inactivation of ilztr1i as observed in different cancer entities and noonan syndrome leads to enhanced ras gtpase abundance and altered mapk pathway activation state novel therapeutic approaches to interfere with hyperactive ras signaling thereby complementing existing treatments are highly sought after motivated by the growing arsenal of molecular glue degraders we report the identification of novel chemical fragments that enhance the proteinprotein interaction ppi of the kraslztr1 complex we established a splitluciferasebased reporter assay that monitors the ras gtpaselztr1 interaction in a scalable format capable of capturing chemical as well as mutational perturbations using this screening system in combination with a small fragment library we identified two fragments c53 and z86 that enhance the interaction of the kraslztr1 complex in a dosedependent manner further orthogonal validation experiments using proximity biotinylation bioid thermal shift assays and nmr spectroscopy demonstrated fragmentdependent enhanced recruitment of endogenous lztr1 and physical engagement of kras the two fragments which potentiate the kraslztr1 interaction serve as starting points for fragmentbased drug discovery additionally the assay we introduced is amenable to highthroughput screening to further explore the pharmacological modulation of the cul3suplztr1supras gtpase complex,"['the', 'ras', 'family', 'of', 'gtpases', 'is', 'among', 'the', 'most', 'frequently', 'mutated', 'proteins', 'in', 'human', 'cancer', 'creating', 'a', 'high', 'clinical', 'demand', 'for', 'therapies', 'that', 'counteract', 'their', 'signaling', 'activity', 'an', 'important', 'layer', 'of', 'regulation', 'that', 'could', 'be', 'therapeutically', 'exploited', 'is', 'the', 'proteostatic', 'regulation', 'of', 'the', 'main', 'ras', 'gtpases', 'kras', 'nras', 'and', 'hras', 'as', 'well', 'as', 'the', 'closely', 'related', 'members', 'mras', 'and', 'rit1', 'by', 'the', 'leucine', 'zipperlike', 'transcriptional', 'regulator', '1', 'cullin', '3', 'ring', 'e3', 'ubiquitin', 'ligase', 'complex', 'cul3suplztr1sup', 'genetic', 'inactivation', 'of', 'ilztr1i', 'as', 'observed', 'in', 'different', 'cancer', 'entities', 'and', 'noonan', 'syndrome', 'leads', 'to', 'enhanced', 'ras', 'gtpase', 'abundance', 'and', 'altered', 'mapk', 'pathway', 'activation', 'state', 'novel', 'therapeutic', 'approaches', 'to', 'interfere', 'with', 'hyperactive', 'ras', 'signaling', 'thereby', 'complementing', 'existing', 'treatments', 'are', 'highly', 'sought', 'after', 'motivated', 'by', 'the', 'growing', 'arsenal', 'of', 'molecular', 'glue', 'degraders', 'we', 'report', 'the', 'identification', 'of', 'novel', 'chemical', 'fragments', 'that', 'enhance', 'the', 'proteinprotein', 'interaction', 'ppi', 'of', 'the', 'kraslztr1', 'complex', 'we', 'established', 'a', 'splitluciferasebased', 'reporter', 'assay', 'that', 'monitors', 'the', 'ras', 'gtpaselztr1', 'interaction', 'in', 'a', 'scalable', 'format', 'capable', 'of', 'capturing', 'chemical', 'as', 'well', 'as', 'mutational', 'perturbations', 'using', 'this', 'screening', 'system', 'in', 'combination', 'with', 'a', 'small', 'fragment', 'library', 'we', 'identified', 'two', 'fragments', 'c53', 'and', 'z86', 'that', 'enhance', 'the', 'interaction', 'of', 'the', 'kraslztr1', 'complex', 'in', 'a', 'dosedependent', 'manner', 'further', 'orthogonal', 'validation', 'experiments', 'using', 'proximity', 'biotinylation', 'bioid', 'thermal', 'shift', 'assays', 'and', 'nmr', 'spectroscopy', 'demonstrated', 'fragmentdependent', 'enhanced', 'recruitment', 'of', 'endogenous', 'lztr1', 'and', 'physical', 'engagement', 'of', 'kras', 'the', 'two', 'fragments', 'which', 'potentiate', 'the', 'kraslztr1', 'interaction', 'serve', 'as', 'starting', 'points', 'for', 'fragmentbased', 'drug', 'discovery', 'additionally', 'the', 'assay', 'we', 'introduced', 'is', 'amenable', 'to', 'highthroughput', 'screening', 'to', 'further', 'explore', 'the', 'pharmacological', 'modulation', 'of', 'the', 'cul3suplztr1supras', 'gtpase', 'complex']","['ras', 'family', 'gtpases', 'among', 'frequently', 'mutated', 'proteins', 'human', 'cancer', 'creating', 'high', 'clinical', 'demand', 'therapies', 'counteract', 'signaling', 'activity', 'important', 'layer', 'regulation', 'could', 'therapeutically', 'exploited', 'proteostatic', 'regulation', 'main', 'ras', 'gtpases', 'kras', 'nras', 'hras', 'well', 'closely', 'related', 'members', 'mras', 'rit1', 'leucine', 'zipperlike', 'transcriptional', 'regulator', '1', 'cullin', '3', 'ring', 'e3', 'ubiquitin', 'ligase', 'complex', 'cul3suplztr1sup', 'genetic', 'inactivation', 'ilztr1i', 'observed', 'different', 'cancer', 'entities', 'noonan', 'syndrome', 'leads', 'enhanced', 'ras', 'gtpase', 'abundance', 'altered', 'mapk', 'pathway', 'activation', 'state', 'novel', 'therapeutic', 'approaches', 'interfere', 'hyperactive', 'ras', 'signaling', 'thereby', 'complementing', 'existing', 'treatments', 'highly', 'sought', 'motivated', 'growing', 'arsenal', 'molecular', 'glue', 'degraders', 'report', 'identification', 'novel', 'chemical', 'fragments', 'enhance', 'proteinprotein', 'interaction', 'ppi', 'kraslztr1', 'complex', 'established', 'splitluciferasebased', 'reporter', 'assay', 'monitors', 'ras', 'gtpaselztr1', 'interaction', 'scalable', 'format', 'capable', 'capturing', 'chemical', 'well', 'mutational', 'perturbations', 'using', 'screening', 'system', 'combination', 'small', 'fragment', 'library', 'identified', 'two', 'fragments', 'c53', 'z86', 'enhance', 'interaction', 'kraslztr1', 'complex', 'dosedependent', 'manner', 'orthogonal', 'validation', 'experiments', 'using', 'proximity', 'biotinylation', 'bioid', 'thermal', 'shift', 'assays', 'nmr', 'spectroscopy', 'demonstrated', 'fragmentdependent', 'enhanced', 'recruitment', 'endogenous', 'lztr1', 'physical', 'engagement', 'kras', 'two', 'fragments', 'potentiate', 'kraslztr1', 'interaction', 'serve', 'starting', 'points', 'fragmentbased', 'drug', 'discovery', 'additionally', 'assay', 'introduced', 'amenable', 'highthroughput', 'screening', 'explore', 'pharmacological', 'modulation', 'cul3suplztr1supras', 'gtpase', 'complex']","['ras', 'ras', 'mras', 'cullin', 'ubiquitin', 'ras', 'gtpase', 'ras', 'ras', 'c53', 'gtpase']","['cullin', 'gtpase', 'gtpase']",True,['cancer']
39143566,"Does rAj-Tspin, a novel peptide from A. japonicus, exert antihepatocellular carcinoma effects via the ITGB1/ZYX/FAK/AKT signaling pathway?","rAj-Tspin, a soluble recombinant peptide from Apostichopus japonicus, can inhibit the integrin β1 (ITGB1)/FAK/AKT signaling pathway in hepatocellular carcinoma (HCC) via cell epithelial-mesenchymal transition (EMT) and apoptosis. Zyxin (ZYX) is a focal adhesion protein that is considered a novel mediator of EMT and apoptosis. However, the inhibitory mechanisms of rAj-Tspin in HCC and whether it is related to ZYX are unclear. We examined the antitumor effect of rAj-Tspin on the Huh7 human HCC cell line and on a nude mouse model generated via subcutaneous injection or orthotopic intrahepatic transplantation of Huh7 cells. Our results revealed that rAj-Tspin strikingly reduced the viability and promoted the apoptosis of Huh7 cells and inhibited HCC tumor growth in nude mice. rAj-Tspin inhibited ITGB1 and ZYX protein expression in vivo and in vitro in a dose-dependent manner. Mechanistically, the FAK/AKT signaling pathway and the proliferation and invasion of HCC cells were suppressed upon ITGB1 and ZYX knockdown. Moreover, the effect of ITGB1 overexpression on the growth of HCC cells was inhibited by rAj-Tspin. In contrast, the promoting effect of ITGB1 overexpression could be inhibited by ZYX knockdown. ZYX knockdown had no effect on ITGB1 expression. These findings suggest that ZYX is required for the indispensable role of ITGB1 in rAj-Tspin-alleviated HCC and provide an important therapeutic target for HCC. In summary, the anti-HCC effect of rAj-Tspin potentially involves the regulation of the ITGB1/ZYX/FAK/AKT pathway, which in turn impacts EMT and apoptosis.",2024-08-14,rajtspin a soluble recombinant peptide from apostichopus japonicus can inhibit the integrin β1 itgb1fakakt signaling pathway in hepatocellular carcinoma hcc via cell epithelialmesenchymal transition emt and apoptosis zyxin zyx is a focal adhesion protein that is considered a novel mediator of emt and apoptosis however the inhibitory mechanisms of rajtspin in hcc and whether it is related to zyx are unclear we examined the antitumor effect of rajtspin on the huh7 human hcc cell line and on a nude mouse model generated via subcutaneous injection or orthotopic intrahepatic transplantation of huh7 cells our results revealed that rajtspin strikingly reduced the viability and promoted the apoptosis of huh7 cells and inhibited hcc tumor growth in nude mice rajtspin inhibited itgb1 and zyx protein expression in vivo and in vitro in a dosedependent manner mechanistically the fakakt signaling pathway and the proliferation and invasion of hcc cells were suppressed upon itgb1 and zyx knockdown moreover the effect of itgb1 overexpression on the growth of hcc cells was inhibited by rajtspin in contrast the promoting effect of itgb1 overexpression could be inhibited by zyx knockdown zyx knockdown had no effect on itgb1 expression these findings suggest that zyx is required for the indispensable role of itgb1 in rajtspinalleviated hcc and provide an important therapeutic target for hcc in summary the antihcc effect of rajtspin potentially involves the regulation of the itgb1zyxfakakt pathway which in turn impacts emt and apoptosis,"['rajtspin', 'a', 'soluble', 'recombinant', 'peptide', 'from', 'apostichopus', 'japonicus', 'can', 'inhibit', 'the', 'integrin', 'β1', 'itgb1fakakt', 'signaling', 'pathway', 'in', 'hepatocellular', 'carcinoma', 'hcc', 'via', 'cell', 'epithelialmesenchymal', 'transition', 'emt', 'and', 'apoptosis', 'zyxin', 'zyx', 'is', 'a', 'focal', 'adhesion', 'protein', 'that', 'is', 'considered', 'a', 'novel', 'mediator', 'of', 'emt', 'and', 'apoptosis', 'however', 'the', 'inhibitory', 'mechanisms', 'of', 'rajtspin', 'in', 'hcc', 'and', 'whether', 'it', 'is', 'related', 'to', 'zyx', 'are', 'unclear', 'we', 'examined', 'the', 'antitumor', 'effect', 'of', 'rajtspin', 'on', 'the', 'huh7', 'human', 'hcc', 'cell', 'line', 'and', 'on', 'a', 'nude', 'mouse', 'model', 'generated', 'via', 'subcutaneous', 'injection', 'or', 'orthotopic', 'intrahepatic', 'transplantation', 'of', 'huh7', 'cells', 'our', 'results', 'revealed', 'that', 'rajtspin', 'strikingly', 'reduced', 'the', 'viability', 'and', 'promoted', 'the', 'apoptosis', 'of', 'huh7', 'cells', 'and', 'inhibited', 'hcc', 'tumor', 'growth', 'in', 'nude', 'mice', 'rajtspin', 'inhibited', 'itgb1', 'and', 'zyx', 'protein', 'expression', 'in', 'vivo', 'and', 'in', 'vitro', 'in', 'a', 'dosedependent', 'manner', 'mechanistically', 'the', 'fakakt', 'signaling', 'pathway', 'and', 'the', 'proliferation', 'and', 'invasion', 'of', 'hcc', 'cells', 'were', 'suppressed', 'upon', 'itgb1', 'and', 'zyx', 'knockdown', 'moreover', 'the', 'effect', 'of', 'itgb1', 'overexpression', 'on', 'the', 'growth', 'of', 'hcc', 'cells', 'was', 'inhibited', 'by', 'rajtspin', 'in', 'contrast', 'the', 'promoting', 'effect', 'of', 'itgb1', 'overexpression', 'could', 'be', 'inhibited', 'by', 'zyx', 'knockdown', 'zyx', 'knockdown', 'had', 'no', 'effect', 'on', 'itgb1', 'expression', 'these', 'findings', 'suggest', 'that', 'zyx', 'is', 'required', 'for', 'the', 'indispensable', 'role', 'of', 'itgb1', 'in', 'rajtspinalleviated', 'hcc', 'and', 'provide', 'an', 'important', 'therapeutic', 'target', 'for', 'hcc', 'in', 'summary', 'the', 'antihcc', 'effect', 'of', 'rajtspin', 'potentially', 'involves', 'the', 'regulation', 'of', 'the', 'itgb1zyxfakakt', 'pathway', 'which', 'in', 'turn', 'impacts', 'emt', 'and', 'apoptosis']","['rajtspin', 'soluble', 'recombinant', 'peptide', 'apostichopus', 'japonicus', 'inhibit', 'integrin', 'β1', 'itgb1fakakt', 'signaling', 'pathway', 'hepatocellular', 'carcinoma', 'hcc', 'via', 'cell', 'epithelialmesenchymal', 'transition', 'emt', 'apoptosis', 'zyxin', 'zyx', 'focal', 'adhesion', 'protein', 'considered', 'novel', 'mediator', 'emt', 'apoptosis', 'however', 'inhibitory', 'mechanisms', 'rajtspin', 'hcc', 'whether', 'related', 'zyx', 'unclear', 'examined', 'antitumor', 'effect', 'rajtspin', 'huh7', 'human', 'hcc', 'cell', 'line', 'nude', 'mouse', 'model', 'generated', 'via', 'subcutaneous', 'injection', 'orthotopic', 'intrahepatic', 'transplantation', 'huh7', 'cells', 'results', 'revealed', 'rajtspin', 'strikingly', 'reduced', 'viability', 'promoted', 'apoptosis', 'huh7', 'cells', 'inhibited', 'hcc', 'tumor', 'growth', 'nude', 'mice', 'rajtspin', 'inhibited', 'itgb1', 'zyx', 'protein', 'expression', 'vivo', 'vitro', 'dosedependent', 'manner', 'mechanistically', 'fakakt', 'signaling', 'pathway', 'proliferation', 'invasion', 'hcc', 'cells', 'suppressed', 'upon', 'itgb1', 'zyx', 'knockdown', 'moreover', 'effect', 'itgb1', 'overexpression', 'growth', 'hcc', 'cells', 'inhibited', 'rajtspin', 'contrast', 'promoting', 'effect', 'itgb1', 'overexpression', 'could', 'inhibited', 'zyx', 'knockdown', 'zyx', 'knockdown', 'effect', 'itgb1', 'expression', 'findings', 'suggest', 'zyx', 'required', 'indispensable', 'role', 'itgb1', 'rajtspinalleviated', 'hcc', 'provide', 'important', 'therapeutic', 'target', 'hcc', 'summary', 'antihcc', 'effect', 'rajtspin', 'potentially', 'involves', 'regulation', 'itgb1zyxfakakt', 'pathway', 'turn', 'impacts', 'emt', 'apoptosis']","['integrin', 'zyxin']",['zyxin'],True,['tumor']
39123210,"Efficacy and safety of chiauranib in a combination therapy in platinum-resistant or refractory ovarian cancer: a multicenter, open-label, phase Ib and II study.","Platinum-resistant or refractory ovarian cancer is a highly lethal gynecologic disease with limited treatment options. Chiauranib is a novel small-molecule selective inhibitor, which could effectively target multiple pathways including Aurora B and CSF-1R to inhibit cell cycle process and improve anti-tumor immune function, as long as VEGF pathway for tumor extinction.",2024-08-09,platinumresistant or refractory ovarian cancer is a highly lethal gynecologic disease with limited treatment options chiauranib is a novel smallmolecule selective inhibitor which could effectively target multiple pathways including aurora b and csf1r to inhibit cell cycle process and improve antitumor immune function as long as vegf pathway for tumor extinction,"['platinumresistant', 'or', 'refractory', 'ovarian', 'cancer', 'is', 'a', 'highly', 'lethal', 'gynecologic', 'disease', 'with', 'limited', 'treatment', 'options', 'chiauranib', 'is', 'a', 'novel', 'smallmolecule', 'selective', 'inhibitor', 'which', 'could', 'effectively', 'target', 'multiple', 'pathways', 'including', 'aurora', 'b', 'and', 'csf1r', 'to', 'inhibit', 'cell', 'cycle', 'process', 'and', 'improve', 'antitumor', 'immune', 'function', 'as', 'long', 'as', 'vegf', 'pathway', 'for', 'tumor', 'extinction']","['platinumresistant', 'refractory', 'ovarian', 'cancer', 'highly', 'lethal', 'gynecologic', 'disease', 'limited', 'treatment', 'options', 'chiauranib', 'novel', 'smallmolecule', 'selective', 'inhibitor', 'could', 'effectively', 'target', 'multiple', 'pathways', 'including', 'aurora', 'b', 'csf1r', 'inhibit', 'cell', 'cycle', 'process', 'improve', 'antitumor', 'immune', 'function', 'long', 'vegf', 'pathway', 'tumor', 'extinction']","['csf1r', 'vegf']",['csf1r'],True,"['tumor', 'cancer']"
39106256,A High-Throughput Screening Platform Identifies FDA-Approved Drugs That Inhibit SREBP Pathway Activation.,"Sterol regulatory element-binding protein (SREBP) transcription factors are central regulators of lipid homeostasis and are essential for lipid metabolic reprogramming that supports tumor growth in multiple cancers. SREBP pathway inhibitors have been identified, but bioavailable compounds are lacking. To address this need, we designed a novel approach for screening a collection of 4,474 FDA-approved drugs. SREBPs are conditionally essential and required under low lipid conditions. Leveraging this property, we screened for drugs that inhibited pancreatic cancer cell growth in lipid-poor, but not lipid-rich, medium. The primary screen identified 83 drugs that inhibited cell growth in a lipid-dependent manner. Secondary assays examining SREBP target gene expression, SREBP proteolytic cleavage, and effects on human breast cancer cells identified 13 FDA-approved drugs that inhibit SREBP pathway activation. Taken together, we demonstrated that our screening approach can identify SREBP inhibitors from a small library of compounds. This high-throughput screening platform enables screening of large compound collections to discover novel small molecule SREBP inhibitors.",2024-08-06,sterol regulatory elementbinding protein srebp transcription factors are central regulators of lipid homeostasis and are essential for lipid metabolic reprogramming that supports tumor growth in multiple cancers srebp pathway inhibitors have been identified but bioavailable compounds are lacking to address this need we designed a novel approach for screening a collection of 4474 fdaapproved drugs srebps are conditionally essential and required under low lipid conditions leveraging this property we screened for drugs that inhibited pancreatic cancer cell growth in lipidpoor but not lipidrich medium the primary screen identified 83 drugs that inhibited cell growth in a lipiddependent manner secondary assays examining srebp target gene expression srebp proteolytic cleavage and effects on human breast cancer cells identified 13 fdaapproved drugs that inhibit srebp pathway activation taken together we demonstrated that our screening approach can identify srebp inhibitors from a small library of compounds this highthroughput screening platform enables screening of large compound collections to discover novel small molecule srebp inhibitors,"['sterol', 'regulatory', 'elementbinding', 'protein', 'srebp', 'transcription', 'factors', 'are', 'central', 'regulators', 'of', 'lipid', 'homeostasis', 'and', 'are', 'essential', 'for', 'lipid', 'metabolic', 'reprogramming', 'that', 'supports', 'tumor', 'growth', 'in', 'multiple', 'cancers', 'srebp', 'pathway', 'inhibitors', 'have', 'been', 'identified', 'but', 'bioavailable', 'compounds', 'are', 'lacking', 'to', 'address', 'this', 'need', 'we', 'designed', 'a', 'novel', 'approach', 'for', 'screening', 'a', 'collection', 'of', '4474', 'fdaapproved', 'drugs', 'srebps', 'are', 'conditionally', 'essential', 'and', 'required', 'under', 'low', 'lipid', 'conditions', 'leveraging', 'this', 'property', 'we', 'screened', 'for', 'drugs', 'that', 'inhibited', 'pancreatic', 'cancer', 'cell', 'growth', 'in', 'lipidpoor', 'but', 'not', 'lipidrich', 'medium', 'the', 'primary', 'screen', 'identified', '83', 'drugs', 'that', 'inhibited', 'cell', 'growth', 'in', 'a', 'lipiddependent', 'manner', 'secondary', 'assays', 'examining', 'srebp', 'target', 'gene', 'expression', 'srebp', 'proteolytic', 'cleavage', 'and', 'effects', 'on', 'human', 'breast', 'cancer', 'cells', 'identified', '13', 'fdaapproved', 'drugs', 'that', 'inhibit', 'srebp', 'pathway', 'activation', 'taken', 'together', 'we', 'demonstrated', 'that', 'our', 'screening', 'approach', 'can', 'identify', 'srebp', 'inhibitors', 'from', 'a', 'small', 'library', 'of', 'compounds', 'this', 'highthroughput', 'screening', 'platform', 'enables', 'screening', 'of', 'large', 'compound', 'collections', 'to', 'discover', 'novel', 'small', 'molecule', 'srebp', 'inhibitors']","['sterol', 'regulatory', 'elementbinding', 'protein', 'srebp', 'transcription', 'factors', 'central', 'regulators', 'lipid', 'homeostasis', 'essential', 'lipid', 'metabolic', 'reprogramming', 'supports', 'tumor', 'growth', 'multiple', 'cancers', 'srebp', 'pathway', 'inhibitors', 'identified', 'bioavailable', 'compounds', 'lacking', 'address', 'need', 'designed', 'novel', 'approach', 'screening', 'collection', '4474', 'fdaapproved', 'drugs', 'srebps', 'conditionally', 'essential', 'required', 'low', 'lipid', 'conditions', 'leveraging', 'property', 'screened', 'drugs', 'inhibited', 'pancreatic', 'cancer', 'cell', 'growth', 'lipidpoor', 'lipidrich', 'medium', 'primary', 'screen', 'identified', '83', 'drugs', 'inhibited', 'cell', 'growth', 'lipiddependent', 'manner', 'secondary', 'assays', 'examining', 'srebp', 'target', 'gene', 'expression', 'srebp', 'proteolytic', 'cleavage', 'effects', 'human', 'breast', 'cancer', 'cells', 'identified', '13', 'fdaapproved', 'drugs', 'inhibit', 'srebp', 'pathway', 'activation', 'taken', 'together', 'demonstrated', 'screening', 'approach', 'identify', 'srebp', 'inhibitors', 'small', 'library', 'compounds', 'highthroughput', 'screening', 'platform', 'enables', 'screening', 'large', 'compound', 'collections', 'discover', 'novel', 'small', 'molecule', 'srebp', 'inhibitors']","['srebp', 'srebp', 'srebp', 'srebp', 'srebp', 'srebp', 'srebp']","['srebp', 'srebp', 'srebp', 'srebp', 'srebp', 'srebp', 'srebp']",True,"['tumor', 'cancer']"
39067438,A peptide-salinomycin conjugate with a bystander effect reduces the stemness characteristics of ovarian cancer cells and enhances drug sensitivity.,"Salinomycin (Sal) has attracted considerable attention in the field of tumor treatment, especially for its inhibitory effect on cancer stem cells (CSCs) and drug-resistant tumor cells. However, its solubility and targeting specificity pose significant challenges to its pharmaceutical development. Sal-A6, a novel peptide-drug conjugate (PDC), was formed by linking the peptide A6 targeting the CSC marker CD44 with Sal using a specific linker. This conjugation markedly enhances the physicochemical properties of Sal and compared to Sal, Sal-A6 demonstrated a significantly increased activity against ovarian cancer. Furthermore, Sal-A6, employing a disulfide bond as a linker, exhibited bystander killing effect. Moreover, it induces substantial cytotoxic effect on both cancer stem cells and drug-resistant cells in addition to enhance chemosensitivity of resistant ovarian cancer cells. In summary, the results indicated that Sal-A6, a novel PDC derived from Sal, has potential therapeutic applications in the treatment of ovarian cancer and drug-resistant patients. Additionally, this discovery offers insights for developing PDC-type drugs using Sal as a foundation.",2024-07-20,salinomycin sal has attracted considerable attention in the field of tumor treatment especially for its inhibitory effect on cancer stem cells cscs and drugresistant tumor cells however its solubility and targeting specificity pose significant challenges to its pharmaceutical development sala6 a novel peptidedrug conjugate pdc was formed by linking the peptide a6 targeting the csc marker cd44 with sal using a specific linker this conjugation markedly enhances the physicochemical properties of sal and compared to sal sala6 demonstrated a significantly increased activity against ovarian cancer furthermore sala6 employing a disulfide bond as a linker exhibited bystander killing effect moreover it induces substantial cytotoxic effect on both cancer stem cells and drugresistant cells in addition to enhance chemosensitivity of resistant ovarian cancer cells in summary the results indicated that sala6 a novel pdc derived from sal has potential therapeutic applications in the treatment of ovarian cancer and drugresistant patients additionally this discovery offers insights for developing pdctype drugs using sal as a foundation,"['salinomycin', 'sal', 'has', 'attracted', 'considerable', 'attention', 'in', 'the', 'field', 'of', 'tumor', 'treatment', 'especially', 'for', 'its', 'inhibitory', 'effect', 'on', 'cancer', 'stem', 'cells', 'cscs', 'and', 'drugresistant', 'tumor', 'cells', 'however', 'its', 'solubility', 'and', 'targeting', 'specificity', 'pose', 'significant', 'challenges', 'to', 'its', 'pharmaceutical', 'development', 'sala6', 'a', 'novel', 'peptidedrug', 'conjugate', 'pdc', 'was', 'formed', 'by', 'linking', 'the', 'peptide', 'a6', 'targeting', 'the', 'csc', 'marker', 'cd44', 'with', 'sal', 'using', 'a', 'specific', 'linker', 'this', 'conjugation', 'markedly', 'enhances', 'the', 'physicochemical', 'properties', 'of', 'sal', 'and', 'compared', 'to', 'sal', 'sala6', 'demonstrated', 'a', 'significantly', 'increased', 'activity', 'against', 'ovarian', 'cancer', 'furthermore', 'sala6', 'employing', 'a', 'disulfide', 'bond', 'as', 'a', 'linker', 'exhibited', 'bystander', 'killing', 'effect', 'moreover', 'it', 'induces', 'substantial', 'cytotoxic', 'effect', 'on', 'both', 'cancer', 'stem', 'cells', 'and', 'drugresistant', 'cells', 'in', 'addition', 'to', 'enhance', 'chemosensitivity', 'of', 'resistant', 'ovarian', 'cancer', 'cells', 'in', 'summary', 'the', 'results', 'indicated', 'that', 'sala6', 'a', 'novel', 'pdc', 'derived', 'from', 'sal', 'has', 'potential', 'therapeutic', 'applications', 'in', 'the', 'treatment', 'of', 'ovarian', 'cancer', 'and', 'drugresistant', 'patients', 'additionally', 'this', 'discovery', 'offers', 'insights', 'for', 'developing', 'pdctype', 'drugs', 'using', 'sal', 'as', 'a', 'foundation']","['salinomycin', 'sal', 'attracted', 'considerable', 'attention', 'field', 'tumor', 'treatment', 'especially', 'inhibitory', 'effect', 'cancer', 'stem', 'cells', 'cscs', 'drugresistant', 'tumor', 'cells', 'however', 'solubility', 'targeting', 'specificity', 'pose', 'significant', 'challenges', 'pharmaceutical', 'development', 'sala6', 'novel', 'peptidedrug', 'conjugate', 'pdc', 'formed', 'linking', 'peptide', 'a6', 'targeting', 'csc', 'marker', 'cd44', 'sal', 'using', 'specific', 'linker', 'conjugation', 'markedly', 'enhances', 'physicochemical', 'properties', 'sal', 'compared', 'sal', 'sala6', 'demonstrated', 'significantly', 'increased', 'activity', 'ovarian', 'cancer', 'furthermore', 'sala6', 'employing', 'disulfide', 'bond', 'linker', 'exhibited', 'bystander', 'killing', 'effect', 'moreover', 'induces', 'substantial', 'cytotoxic', 'effect', 'cancer', 'stem', 'cells', 'drugresistant', 'cells', 'addition', 'enhance', 'chemosensitivity', 'resistant', 'ovarian', 'cancer', 'cells', 'summary', 'results', 'indicated', 'sala6', 'novel', 'pdc', 'derived', 'sal', 'potential', 'therapeutic', 'applications', 'treatment', 'ovarian', 'cancer', 'drugresistant', 'patients', 'additionally', 'discovery', 'offers', 'insights', 'developing', 'pdctype', 'drugs', 'using', 'sal', 'foundation']","['sal', 'pdc', 'cd44', 'sal', 'sal', 'sal', 'pdc', 'sal', 'sal']",['cd44'],True,"['tumor', 'cancer']"
39053726,An MDM2 degrader shows potent cytotoxicity to MDM2-overexpressing acute lymphoblastic leukemia cells with minimal toxicity to normal cells/tissues.,"The MDM2 oncogene is amplified and/or overexpressed in various human cancers and elevated expression of MDM2 protein acts as a survival factor promoting cancer progression through both p53-dependent and -independent pathways. Here, we report a novel small-molecule chemical compound (MX69-102) that we identified to induce MDM2 protein degradation, resulting in reactivation of p53, inhibition of XIAP, and potent cell growth inhibition and apoptosis in MDM2-overexpressing acute lymphoblastic leukemia (ALL) in vitro and in vivo. We have previously identified a compound (MX69) that binds to the MDM2 C-terminal RING domain and induces MDM2 protein degradation. In the present study, we performed structural modifications of MX69 and selected analog MX69-102, showing increased MDM2-targeting activity. MX69-102 exhibited significantly enhanced inhibitory and apoptotic effects on a group of MDM2-overexpressing ALL cell lines in vitro with IC<sub>50</sub> values of about 0.2 μM, representing an approximately 38-fold increase in activity compared to MX69. MX69-102 also showed effective inhibition on xenografted human MDM2-overexpressing ALL in SCID mice. Importantly, MX69-102 had minimal or no inhibitory effect on normal human hematopoiesis in vitro and was very well tolerated in vivo in animal models. Based on the strong inhibitory and apoptotic activity against MDM2-overexpressing ALL, along with minimal or no toxicity to normal cells/tissues, MX69-102 is a candidate for further development as a novel MDM2-targeted therapeutic drug for refractory/MDM2-overexpressing ALL.",2024-07-23,the mdm2 oncogene is amplified andor overexpressed in various human cancers and elevated expression of mdm2 protein acts as a survival factor promoting cancer progression through both p53dependent and independent pathways here we report a novel smallmolecule chemical compound mx69102 that we identified to induce mdm2 protein degradation resulting in reactivation of p53 inhibition of xiap and potent cell growth inhibition and apoptosis in mdm2overexpressing acute lymphoblastic leukemia all in vitro and in vivo we have previously identified a compound mx69 that binds to the mdm2 cterminal ring domain and induces mdm2 protein degradation in the present study we performed structural modifications of mx69 and selected analog mx69102 showing increased mdm2targeting activity mx69102 exhibited significantly enhanced inhibitory and apoptotic effects on a group of mdm2overexpressing all cell lines in vitro with icsub50sub values of about 02 μm representing an approximately 38fold increase in activity compared to mx69 mx69102 also showed effective inhibition on xenografted human mdm2overexpressing all in scid mice importantly mx69102 had minimal or no inhibitory effect on normal human hematopoiesis in vitro and was very well tolerated in vivo in animal models based on the strong inhibitory and apoptotic activity against mdm2overexpressing all along with minimal or no toxicity to normal cellstissues mx69102 is a candidate for further development as a novel mdm2targeted therapeutic drug for refractorymdm2overexpressing all,"['the', 'mdm2', 'oncogene', 'is', 'amplified', 'andor', 'overexpressed', 'in', 'various', 'human', 'cancers', 'and', 'elevated', 'expression', 'of', 'mdm2', 'protein', 'acts', 'as', 'a', 'survival', 'factor', 'promoting', 'cancer', 'progression', 'through', 'both', 'p53dependent', 'and', 'independent', 'pathways', 'here', 'we', 'report', 'a', 'novel', 'smallmolecule', 'chemical', 'compound', 'mx69102', 'that', 'we', 'identified', 'to', 'induce', 'mdm2', 'protein', 'degradation', 'resulting', 'in', 'reactivation', 'of', 'p53', 'inhibition', 'of', 'xiap', 'and', 'potent', 'cell', 'growth', 'inhibition', 'and', 'apoptosis', 'in', 'mdm2overexpressing', 'acute', 'lymphoblastic', 'leukemia', 'all', 'in', 'vitro', 'and', 'in', 'vivo', 'we', 'have', 'previously', 'identified', 'a', 'compound', 'mx69', 'that', 'binds', 'to', 'the', 'mdm2', 'cterminal', 'ring', 'domain', 'and', 'induces', 'mdm2', 'protein', 'degradation', 'in', 'the', 'present', 'study', 'we', 'performed', 'structural', 'modifications', 'of', 'mx69', 'and', 'selected', 'analog', 'mx69102', 'showing', 'increased', 'mdm2targeting', 'activity', 'mx69102', 'exhibited', 'significantly', 'enhanced', 'inhibitory', 'and', 'apoptotic', 'effects', 'on', 'a', 'group', 'of', 'mdm2overexpressing', 'all', 'cell', 'lines', 'in', 'vitro', 'with', 'icsub50sub', 'values', 'of', 'about', '02', 'μm', 'representing', 'an', 'approximately', '38fold', 'increase', 'in', 'activity', 'compared', 'to', 'mx69', 'mx69102', 'also', 'showed', 'effective', 'inhibition', 'on', 'xenografted', 'human', 'mdm2overexpressing', 'all', 'in', 'scid', 'mice', 'importantly', 'mx69102', 'had', 'minimal', 'or', 'no', 'inhibitory', 'effect', 'on', 'normal', 'human', 'hematopoiesis', 'in', 'vitro', 'and', 'was', 'very', 'well', 'tolerated', 'in', 'vivo', 'in', 'animal', 'models', 'based', 'on', 'the', 'strong', 'inhibitory', 'and', 'apoptotic', 'activity', 'against', 'mdm2overexpressing', 'all', 'along', 'with', 'minimal', 'or', 'no', 'toxicity', 'to', 'normal', 'cellstissues', 'mx69102', 'is', 'a', 'candidate', 'for', 'further', 'development', 'as', 'a', 'novel', 'mdm2targeted', 'therapeutic', 'drug', 'for', 'refractorymdm2overexpressing', 'all']","['mdm2', 'oncogene', 'amplified', 'andor', 'overexpressed', 'various', 'human', 'cancers', 'elevated', 'expression', 'mdm2', 'protein', 'acts', 'survival', 'factor', 'promoting', 'cancer', 'progression', 'p53dependent', 'independent', 'pathways', 'report', 'novel', 'smallmolecule', 'chemical', 'compound', 'mx69102', 'identified', 'induce', 'mdm2', 'protein', 'degradation', 'resulting', 'reactivation', 'p53', 'inhibition', 'xiap', 'potent', 'cell', 'growth', 'inhibition', 'apoptosis', 'mdm2overexpressing', 'acute', 'lymphoblastic', 'leukemia', 'vitro', 'vivo', 'previously', 'identified', 'compound', 'mx69', 'binds', 'mdm2', 'cterminal', 'ring', 'domain', 'induces', 'mdm2', 'protein', 'degradation', 'present', 'study', 'performed', 'structural', 'modifications', 'mx69', 'selected', 'analog', 'mx69102', 'showing', 'increased', 'mdm2targeting', 'activity', 'mx69102', 'exhibited', 'significantly', 'enhanced', 'inhibitory', 'apoptotic', 'effects', 'group', 'mdm2overexpressing', 'cell', 'lines', 'vitro', 'icsub50sub', 'values', '02', 'μm', 'representing', 'approximately', '38fold', 'increase', 'activity', 'compared', 'mx69', 'mx69102', 'also', 'showed', 'effective', 'inhibition', 'xenografted', 'human', 'mdm2overexpressing', 'scid', 'mice', 'importantly', 'mx69102', 'minimal', 'inhibitory', 'effect', 'normal', 'human', 'hematopoiesis', 'vitro', 'well', 'tolerated', 'vivo', 'animal', 'models', 'based', 'strong', 'inhibitory', 'apoptotic', 'activity', 'mdm2overexpressing', 'along', 'minimal', 'toxicity', 'normal', 'cellstissues', 'mx69102', 'candidate', 'development', 'novel', 'mdm2targeted', 'therapeutic', 'drug', 'refractorymdm2overexpressing']","['mdm2', 'mdm2', 'mdm2', 'p53', 'xiap', 'mdm2', 'mdm2']",['xiap'],True,"['cancer', 'leukemia']"
39048042,Novel peptide and hyaluronic acid coated biomimetic liposomes for targeting bacterial infections and sepsis.,"Sepsis is a life-threatening syndrome resulting from an imbalanced immune response to severe infections. Despite advances in nanomedicines, effective treatments for sepsis are still lacking. Herein, vancomycin free base (VCM)-loaded dual functionalized biomimetic liposomes based on a novel TLR4-targeting peptide (P3) and hyaluronic acid (HA) (HA-P3-Lipo) were developed to enhance sepsis therapy. The nanocarrier revealed appropriate physicochemical parameters, good stability, and biocompatibility. The release of VCM from HA-P3-Lipo was found to be sustained with 76 % VCM released in 48 h. The biomimicry was elucidated by in silico tools and MST and results confirmed strong binding between the system and TLR4. Furthermore, HA-P3-Lipo revealed 2-fold enhanced antibacterial activity against S. aureus, sustained antibacterial activity against MRSA over 72 h and 5-fold better MRSA biofilm inhibition compared to bare VCM. Bacterial-killing kinetics and flow cytometry confirmed the superiority of HA-P3-Lipo in eliminating MRSA faster than VCM. The in vivo potential of the nanocarrier was elucidated in an MRSA-induced sepsis mice model, and the results confirmed the superiority of HA-P3-Lipo compared to free VCM in eliminating bacteria and down-regulating the proinflammatory markers. Therefore, HA-P3-Lipo exhibits potential as a promising novel multi-functional nanosystem against sepsis and could significantly contribute to the transformation of sepsis therapy.",2024-07-22,sepsis is a lifethreatening syndrome resulting from an imbalanced immune response to severe infections despite advances in nanomedicines effective treatments for sepsis are still lacking herein vancomycin free base vcmloaded dual functionalized biomimetic liposomes based on a novel tlr4targeting peptide p3 and hyaluronic acid ha hap3lipo were developed to enhance sepsis therapy the nanocarrier revealed appropriate physicochemical parameters good stability and biocompatibility the release of vcm from hap3lipo was found to be sustained with 76  vcm released in 48 h the biomimicry was elucidated by in silico tools and mst and results confirmed strong binding between the system and tlr4 furthermore hap3lipo revealed 2fold enhanced antibacterial activity against s aureus sustained antibacterial activity against mrsa over 72 h and 5fold better mrsa biofilm inhibition compared to bare vcm bacterialkilling kinetics and flow cytometry confirmed the superiority of hap3lipo in eliminating mrsa faster than vcm the in vivo potential of the nanocarrier was elucidated in an mrsainduced sepsis mice model and the results confirmed the superiority of hap3lipo compared to free vcm in eliminating bacteria and downregulating the proinflammatory markers therefore hap3lipo exhibits potential as a promising novel multifunctional nanosystem against sepsis and could significantly contribute to the transformation of sepsis therapy,"['sepsis', 'is', 'a', 'lifethreatening', 'syndrome', 'resulting', 'from', 'an', 'imbalanced', 'immune', 'response', 'to', 'severe', 'infections', 'despite', 'advances', 'in', 'nanomedicines', 'effective', 'treatments', 'for', 'sepsis', 'are', 'still', 'lacking', 'herein', 'vancomycin', 'free', 'base', 'vcmloaded', 'dual', 'functionalized', 'biomimetic', 'liposomes', 'based', 'on', 'a', 'novel', 'tlr4targeting', 'peptide', 'p3', 'and', 'hyaluronic', 'acid', 'ha', 'hap3lipo', 'were', 'developed', 'to', 'enhance', 'sepsis', 'therapy', 'the', 'nanocarrier', 'revealed', 'appropriate', 'physicochemical', 'parameters', 'good', 'stability', 'and', 'biocompatibility', 'the', 'release', 'of', 'vcm', 'from', 'hap3lipo', 'was', 'found', 'to', 'be', 'sustained', 'with', '76', 'vcm', 'released', 'in', '48', 'h', 'the', 'biomimicry', 'was', 'elucidated', 'by', 'in', 'silico', 'tools', 'and', 'mst', 'and', 'results', 'confirmed', 'strong', 'binding', 'between', 'the', 'system', 'and', 'tlr4', 'furthermore', 'hap3lipo', 'revealed', '2fold', 'enhanced', 'antibacterial', 'activity', 'against', 's', 'aureus', 'sustained', 'antibacterial', 'activity', 'against', 'mrsa', 'over', '72', 'h', 'and', '5fold', 'better', 'mrsa', 'biofilm', 'inhibition', 'compared', 'to', 'bare', 'vcm', 'bacterialkilling', 'kinetics', 'and', 'flow', 'cytometry', 'confirmed', 'the', 'superiority', 'of', 'hap3lipo', 'in', 'eliminating', 'mrsa', 'faster', 'than', 'vcm', 'the', 'in', 'vivo', 'potential', 'of', 'the', 'nanocarrier', 'was', 'elucidated', 'in', 'an', 'mrsainduced', 'sepsis', 'mice', 'model', 'and', 'the', 'results', 'confirmed', 'the', 'superiority', 'of', 'hap3lipo', 'compared', 'to', 'free', 'vcm', 'in', 'eliminating', 'bacteria', 'and', 'downregulating', 'the', 'proinflammatory', 'markers', 'therefore', 'hap3lipo', 'exhibits', 'potential', 'as', 'a', 'promising', 'novel', 'multifunctional', 'nanosystem', 'against', 'sepsis', 'and', 'could', 'significantly', 'contribute', 'to', 'the', 'transformation', 'of', 'sepsis', 'therapy']","['sepsis', 'lifethreatening', 'syndrome', 'resulting', 'imbalanced', 'immune', 'response', 'severe', 'infections', 'despite', 'advances', 'nanomedicines', 'effective', 'treatments', 'sepsis', 'still', 'lacking', 'herein', 'vancomycin', 'free', 'base', 'vcmloaded', 'dual', 'functionalized', 'biomimetic', 'liposomes', 'based', 'novel', 'tlr4targeting', 'peptide', 'p3', 'hyaluronic', 'acid', 'ha', 'hap3lipo', 'developed', 'enhance', 'sepsis', 'therapy', 'nanocarrier', 'revealed', 'appropriate', 'physicochemical', 'parameters', 'good', 'stability', 'biocompatibility', 'release', 'vcm', 'hap3lipo', 'found', 'sustained', '76', 'vcm', 'released', '48', 'h', 'biomimicry', 'elucidated', 'silico', 'tools', 'mst', 'results', 'confirmed', 'strong', 'binding', 'system', 'tlr4', 'furthermore', 'hap3lipo', 'revealed', '2fold', 'enhanced', 'antibacterial', 'activity', 'aureus', 'sustained', 'antibacterial', 'activity', 'mrsa', '72', 'h', '5fold', 'better', 'mrsa', 'biofilm', 'inhibition', 'compared', 'bare', 'vcm', 'bacterialkilling', 'kinetics', 'flow', 'cytometry', 'confirmed', 'superiority', 'hap3lipo', 'eliminating', 'mrsa', 'faster', 'vcm', 'vivo', 'potential', 'nanocarrier', 'elucidated', 'mrsainduced', 'sepsis', 'mice', 'model', 'results', 'confirmed', 'superiority', 'hap3lipo', 'compared', 'free', 'vcm', 'eliminating', 'bacteria', 'downregulating', 'proinflammatory', 'markers', 'therefore', 'hap3lipo', 'exhibits', 'potential', 'promising', 'novel', 'multifunctional', 'nanosystem', 'sepsis', 'could', 'significantly', 'contribute', 'transformation', 'sepsis', 'therapy']",['tlr4'],['tlr4'],True,['infection']
39047262,QPH-FR: A Novel Quinoa Peptide Enhances Chemosensitivity by Targeting Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 5 in Colorectal Cancer.,"Chemoresistance is one of the difficulties in the treatment of colorectal cancer (CRC), and the enhanced stemness of tumor cells is the underlying contributing factor. Leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) is a classical marker of CRC stem cells and can be an important potential target for CRC chemotherapy. Quinoa, a protein-rich plant, offers potential as a source of high-quality active peptides. Novelly, the study obtained quinoa protein hydrolysate (QPH) from whole quinoa grains by simulated digestion. <i>In vivo</i> experiments revealed that the tumor volume in the 5-FU+QPH group decreased from 145.90 ± 13.35 to 94.49 ± 13.05 mm<sup>3</sup> in the 5-FU group, suggesting that QPH enhances the chemosensitivity of CRC. Further, the most effective peptide QPH-FR from 631 peptides in QPH was screened by activity prediction, molecular docking, and experimental validation. Mechanistically, QPH-FR competitively suppressed the formation of the LGR5/RSPO1 complex by binding to LGR5, causing RNF43/ZNRF3 to ubiquitinate the FZD receptor, thereby suppressing the Wnt/β-catenin signaling pathway and exerting stemness inhibition. In summary, the study proposes that a novel peptide QPH-FR from quinoa elucidates the mechanism by which QPH-FR targets LGR5 to enhance chemosensitivity, providing theoretical support for the development of chemotherapeutic adjuvant drugs based on plant peptides.",2024-07-24,chemoresistance is one of the difficulties in the treatment of colorectal cancer crc and the enhanced stemness of tumor cells is the underlying contributing factor leucinerich repeatcontaining gproteincoupled receptor 5 lgr5 is a classical marker of crc stem cells and can be an important potential target for crc chemotherapy quinoa a proteinrich plant offers potential as a source of highquality active peptides novelly the study obtained quinoa protein hydrolysate qph from whole quinoa grains by simulated digestion iin vivoi experiments revealed that the tumor volume in the 5fuqph group decreased from 14590  1335 to 9449  1305 mmsup3sup in the 5fu group suggesting that qph enhances the chemosensitivity of crc further the most effective peptide qphfr from 631 peptides in qph was screened by activity prediction molecular docking and experimental validation mechanistically qphfr competitively suppressed the formation of the lgr5rspo1 complex by binding to lgr5 causing rnf43znrf3 to ubiquitinate the fzd receptor thereby suppressing the wntβcatenin signaling pathway and exerting stemness inhibition in summary the study proposes that a novel peptide qphfr from quinoa elucidates the mechanism by which qphfr targets lgr5 to enhance chemosensitivity providing theoretical support for the development of chemotherapeutic adjuvant drugs based on plant peptides,"['chemoresistance', 'is', 'one', 'of', 'the', 'difficulties', 'in', 'the', 'treatment', 'of', 'colorectal', 'cancer', 'crc', 'and', 'the', 'enhanced', 'stemness', 'of', 'tumor', 'cells', 'is', 'the', 'underlying', 'contributing', 'factor', 'leucinerich', 'repeatcontaining', 'gproteincoupled', 'receptor', '5', 'lgr5', 'is', 'a', 'classical', 'marker', 'of', 'crc', 'stem', 'cells', 'and', 'can', 'be', 'an', 'important', 'potential', 'target', 'for', 'crc', 'chemotherapy', 'quinoa', 'a', 'proteinrich', 'plant', 'offers', 'potential', 'as', 'a', 'source', 'of', 'highquality', 'active', 'peptides', 'novelly', 'the', 'study', 'obtained', 'quinoa', 'protein', 'hydrolysate', 'qph', 'from', 'whole', 'quinoa', 'grains', 'by', 'simulated', 'digestion', 'iin', 'vivoi', 'experiments', 'revealed', 'that', 'the', 'tumor', 'volume', 'in', 'the', '5fuqph', 'group', 'decreased', 'from', '14590', '1335', 'to', '9449', '1305', 'mmsup3sup', 'in', 'the', '5fu', 'group', 'suggesting', 'that', 'qph', 'enhances', 'the', 'chemosensitivity', 'of', 'crc', 'further', 'the', 'most', 'effective', 'peptide', 'qphfr', 'from', '631', 'peptides', 'in', 'qph', 'was', 'screened', 'by', 'activity', 'prediction', 'molecular', 'docking', 'and', 'experimental', 'validation', 'mechanistically', 'qphfr', 'competitively', 'suppressed', 'the', 'formation', 'of', 'the', 'lgr5rspo1', 'complex', 'by', 'binding', 'to', 'lgr5', 'causing', 'rnf43znrf3', 'to', 'ubiquitinate', 'the', 'fzd', 'receptor', 'thereby', 'suppressing', 'the', 'wntβcatenin', 'signaling', 'pathway', 'and', 'exerting', 'stemness', 'inhibition', 'in', 'summary', 'the', 'study', 'proposes', 'that', 'a', 'novel', 'peptide', 'qphfr', 'from', 'quinoa', 'elucidates', 'the', 'mechanism', 'by', 'which', 'qphfr', 'targets', 'lgr5', 'to', 'enhance', 'chemosensitivity', 'providing', 'theoretical', 'support', 'for', 'the', 'development', 'of', 'chemotherapeutic', 'adjuvant', 'drugs', 'based', 'on', 'plant', 'peptides']","['chemoresistance', 'one', 'difficulties', 'treatment', 'colorectal', 'cancer', 'crc', 'enhanced', 'stemness', 'tumor', 'cells', 'underlying', 'contributing', 'factor', 'leucinerich', 'repeatcontaining', 'gproteincoupled', 'receptor', '5', 'lgr5', 'classical', 'marker', 'crc', 'stem', 'cells', 'important', 'potential', 'target', 'crc', 'chemotherapy', 'quinoa', 'proteinrich', 'plant', 'offers', 'potential', 'source', 'highquality', 'active', 'peptides', 'novelly', 'study', 'obtained', 'quinoa', 'protein', 'hydrolysate', 'qph', 'whole', 'quinoa', 'grains', 'simulated', 'digestion', 'iin', 'vivoi', 'experiments', 'revealed', 'tumor', 'volume', '5fuqph', 'group', 'decreased', '14590', '1335', '9449', '1305', 'mmsup3sup', '5fu', 'group', 'suggesting', 'qph', 'enhances', 'chemosensitivity', 'crc', 'effective', 'peptide', 'qphfr', '631', 'peptides', 'qph', 'screened', 'activity', 'prediction', 'molecular', 'docking', 'experimental', 'validation', 'mechanistically', 'qphfr', 'competitively', 'suppressed', 'formation', 'lgr5rspo1', 'complex', 'binding', 'lgr5', 'causing', 'rnf43znrf3', 'ubiquitinate', 'fzd', 'receptor', 'thereby', 'suppressing', 'wntβcatenin', 'signaling', 'pathway', 'exerting', 'stemness', 'inhibition', 'summary', 'study', 'proposes', 'novel', 'peptide', 'qphfr', 'quinoa', 'elucidates', 'mechanism', 'qphfr', 'targets', 'lgr5', 'enhance', 'chemosensitivity', 'providing', 'theoretical', 'support', 'development', 'chemotherapeutic', 'adjuvant', 'drugs', 'based', 'plant', 'peptides']","['crc', 'lgr5', 'crc', 'crc', 'crc', 'lgr5', 'fzd', 'lgr5']","['lgr5', 'lgr5', 'lgr5']",True,"['tumor', 'cancer']"
39015272,Design Principle of Heparanase Inhibitors: A Combined In Vitro and In Silico Study.,"Heparanase (HPSE) is an enzyme that cleaves heparan sulfate (HS) side chains from heparan sulfate proteoglycans (HSPGs). Overexpression of HPSE is associated with various types of cancer, inflammation, and immune disorders, making it a highly promising therapeutic target. Previously developed HPSE inhibitors that have advanced to clinical trials are polysaccharide-derived compounds or their mimetics; however, these molecules tend to suffer from poor bioavailability, side effects via targeting other saccharide binding proteins, and heterogeneity. Few small-molecule inhibitors have progressed to the preclinical or clinical stages, leaving a gap in HPSE drug discovery. In this study, a novel small molecule that can inhibit HPSE activity was discovered through high-throughput screening (HTS) using an ultrasensitive HPSE probe. Computational tools were employed to elucidate the mechanisms of inhibition. The essential structural features of the hit compound were summarized into a structure-activity relationship (SAR) theory, providing insights into the future design of HPSE small-molecule inhibitors.",2024-05-23,heparanase hpse is an enzyme that cleaves heparan sulfate hs side chains from heparan sulfate proteoglycans hspgs overexpression of hpse is associated with various types of cancer inflammation and immune disorders making it a highly promising therapeutic target previously developed hpse inhibitors that have advanced to clinical trials are polysaccharidederived compounds or their mimetics however these molecules tend to suffer from poor bioavailability side effects via targeting other saccharide binding proteins and heterogeneity few smallmolecule inhibitors have progressed to the preclinical or clinical stages leaving a gap in hpse drug discovery in this study a novel small molecule that can inhibit hpse activity was discovered through highthroughput screening hts using an ultrasensitive hpse probe computational tools were employed to elucidate the mechanisms of inhibition the essential structural features of the hit compound were summarized into a structureactivity relationship sar theory providing insights into the future design of hpse smallmolecule inhibitors,"['heparanase', 'hpse', 'is', 'an', 'enzyme', 'that', 'cleaves', 'heparan', 'sulfate', 'hs', 'side', 'chains', 'from', 'heparan', 'sulfate', 'proteoglycans', 'hspgs', 'overexpression', 'of', 'hpse', 'is', 'associated', 'with', 'various', 'types', 'of', 'cancer', 'inflammation', 'and', 'immune', 'disorders', 'making', 'it', 'a', 'highly', 'promising', 'therapeutic', 'target', 'previously', 'developed', 'hpse', 'inhibitors', 'that', 'have', 'advanced', 'to', 'clinical', 'trials', 'are', 'polysaccharidederived', 'compounds', 'or', 'their', 'mimetics', 'however', 'these', 'molecules', 'tend', 'to', 'suffer', 'from', 'poor', 'bioavailability', 'side', 'effects', 'via', 'targeting', 'other', 'saccharide', 'binding', 'proteins', 'and', 'heterogeneity', 'few', 'smallmolecule', 'inhibitors', 'have', 'progressed', 'to', 'the', 'preclinical', 'or', 'clinical', 'stages', 'leaving', 'a', 'gap', 'in', 'hpse', 'drug', 'discovery', 'in', 'this', 'study', 'a', 'novel', 'small', 'molecule', 'that', 'can', 'inhibit', 'hpse', 'activity', 'was', 'discovered', 'through', 'highthroughput', 'screening', 'hts', 'using', 'an', 'ultrasensitive', 'hpse', 'probe', 'computational', 'tools', 'were', 'employed', 'to', 'elucidate', 'the', 'mechanisms', 'of', 'inhibition', 'the', 'essential', 'structural', 'features', 'of', 'the', 'hit', 'compound', 'were', 'summarized', 'into', 'a', 'structureactivity', 'relationship', 'sar', 'theory', 'providing', 'insights', 'into', 'the', 'future', 'design', 'of', 'hpse', 'smallmolecule', 'inhibitors']","['heparanase', 'hpse', 'enzyme', 'cleaves', 'heparan', 'sulfate', 'hs', 'side', 'chains', 'heparan', 'sulfate', 'proteoglycans', 'hspgs', 'overexpression', 'hpse', 'associated', 'various', 'types', 'cancer', 'inflammation', 'immune', 'disorders', 'making', 'highly', 'promising', 'therapeutic', 'target', 'previously', 'developed', 'hpse', 'inhibitors', 'advanced', 'clinical', 'trials', 'polysaccharidederived', 'compounds', 'mimetics', 'however', 'molecules', 'tend', 'suffer', 'poor', 'bioavailability', 'side', 'effects', 'via', 'targeting', 'saccharide', 'binding', 'proteins', 'heterogeneity', 'smallmolecule', 'inhibitors', 'progressed', 'preclinical', 'clinical', 'stages', 'leaving', 'gap', 'hpse', 'drug', 'discovery', 'study', 'novel', 'small', 'molecule', 'inhibit', 'hpse', 'activity', 'discovered', 'highthroughput', 'screening', 'hts', 'using', 'ultrasensitive', 'hpse', 'probe', 'computational', 'tools', 'employed', 'elucidate', 'mechanisms', 'inhibition', 'essential', 'structural', 'features', 'hit', 'compound', 'summarized', 'structureactivity', 'relationship', 'sar', 'theory', 'providing', 'insights', 'future', 'design', 'hpse', 'smallmolecule', 'inhibitors']","['heparanase', 'sar']",['heparanase'],True,['cancer']
38968799,"Preclinical pharmacokinetics, pharmacodynamics, and toxicity of novel small-molecule GPR119 agonists to treat type-2 diabetes and obesity.","The escalating global prevalence of type-2 diabetes (T2D) and obesity necessitates the development of novel oral medications. Agonism at G-protein coupled receptor-119 (GPR119) has been recognized for modulation of metabolic homeostasis in T2D, obesity, and fatty liver disease. However, off-target effects have impeded the advancement of synthetic GPR119 agonist drug candidates. Non-systemic, gut-restricted GPR119 agonism is suggested as an alternative strategy that may locally stimulate intestinal enteroendocrine cells (EEC) for incretin secretion, without the need for systemic drug availability, consequently alleviating conventional class-related side effects. Herein, we report the preclinical acute safety, efficacy, and pharmacokinetics (PK) of novel GPR119 agonist compounds ps297 and ps318 that potentially target gut EEC for incretin secretion. In a proof-of-efficacy study, both compounds demonstrated glucagon-like peptide-1 (GLP-1) secretion capability during glucose and mixed-meal tolerance tests in healthy mice. Furthermore, co-administration of sitagliptin with investigational compounds in diabetic db/db mice resulted in synergism, with GLP-1 concentrations rising by three-fold. Both ps297 and ps318 exhibited low gut permeability assessed in the in-vitro Caco-2 cell model. A single oral dose PK study conducted on healthy mice demonstrated poor systemic bioavailability of both agents. PK measures (mean ± SD) for compound ps297 (C<sub>max</sub> 23 ± 19 ng/mL, T<sub>max</sub> range 0.5 - 1 h, AUC<sub>0-24 h</sub> 19.6 ± 21 h*ng/mL) and ps318 (C<sub>max</sub> 75 ± 22 ng/mL, T<sub>max</sub> range 0.25 - 0.5 h, AUC<sub>0-24 h</sub> 35 ± 23 h*ng/mL) suggest poor oral absorption. Additionally, examinations of drug excretion patterns in mice revealed that around 25 % (ps297) and 4 % (ps318) of the drugs were excreted through faeces as an unchanged form, while negligible drug concentrations (<0.005 %) were excreted in the urine. These acute PK/PD assessments suggest the gut is a primary site of action for both agents. Toxicity assessments conducted in the zebrafish and healthy mice models confirmed the safety and tolerability of both compounds. Future chronic in-vivo studies in relevant disease models will be essential to confirm the long-term safety and efficacy of these novel compounds.",2024-07-05,the escalating global prevalence of type2 diabetes t2d and obesity necessitates the development of novel oral medications agonism at gprotein coupled receptor119 gpr119 has been recognized for modulation of metabolic homeostasis in t2d obesity and fatty liver disease however offtarget effects have impeded the advancement of synthetic gpr119 agonist drug candidates nonsystemic gutrestricted gpr119 agonism is suggested as an alternative strategy that may locally stimulate intestinal enteroendocrine cells eec for incretin secretion without the need for systemic drug availability consequently alleviating conventional classrelated side effects herein we report the preclinical acute safety efficacy and pharmacokinetics pk of novel gpr119 agonist compounds ps297 and ps318 that potentially target gut eec for incretin secretion in a proofofefficacy study both compounds demonstrated glucagonlike peptide1 glp1 secretion capability during glucose and mixedmeal tolerance tests in healthy mice furthermore coadministration of sitagliptin with investigational compounds in diabetic dbdb mice resulted in synergism with glp1 concentrations rising by threefold both ps297 and ps318 exhibited low gut permeability assessed in the invitro caco2 cell model a single oral dose pk study conducted on healthy mice demonstrated poor systemic bioavailability of both agents pk measures mean  sd for compound ps297 csubmaxsub 23  19 ngml tsubmaxsub range 05  1 h aucsub024 hsub 196  21 hngml and ps318 csubmaxsub 75  22 ngml tsubmaxsub range 025  05 h aucsub024 hsub 35  23 hngml suggest poor oral absorption additionally examinations of drug excretion patterns in mice revealed that around 25  ps297 and 4  ps318 of the drugs were excreted through faeces as an unchanged form while negligible drug concentrations 0005  were excreted in the urine these acute pkpd assessments suggest the gut is a primary site of action for both agents toxicity assessments conducted in the zebrafish and healthy mice models confirmed the safety and tolerability of both compounds future chronic invivo studies in relevant disease models will be essential to confirm the longterm safety and efficacy of these novel compounds,"['the', 'escalating', 'global', 'prevalence', 'of', 'type2', 'diabetes', 't2d', 'and', 'obesity', 'necessitates', 'the', 'development', 'of', 'novel', 'oral', 'medications', 'agonism', 'at', 'gprotein', 'coupled', 'receptor119', 'gpr119', 'has', 'been', 'recognized', 'for', 'modulation', 'of', 'metabolic', 'homeostasis', 'in', 't2d', 'obesity', 'and', 'fatty', 'liver', 'disease', 'however', 'offtarget', 'effects', 'have', 'impeded', 'the', 'advancement', 'of', 'synthetic', 'gpr119', 'agonist', 'drug', 'candidates', 'nonsystemic', 'gutrestricted', 'gpr119', 'agonism', 'is', 'suggested', 'as', 'an', 'alternative', 'strategy', 'that', 'may', 'locally', 'stimulate', 'intestinal', 'enteroendocrine', 'cells', 'eec', 'for', 'incretin', 'secretion', 'without', 'the', 'need', 'for', 'systemic', 'drug', 'availability', 'consequently', 'alleviating', 'conventional', 'classrelated', 'side', 'effects', 'herein', 'we', 'report', 'the', 'preclinical', 'acute', 'safety', 'efficacy', 'and', 'pharmacokinetics', 'pk', 'of', 'novel', 'gpr119', 'agonist', 'compounds', 'ps297', 'and', 'ps318', 'that', 'potentially', 'target', 'gut', 'eec', 'for', 'incretin', 'secretion', 'in', 'a', 'proofofefficacy', 'study', 'both', 'compounds', 'demonstrated', 'glucagonlike', 'peptide1', 'glp1', 'secretion', 'capability', 'during', 'glucose', 'and', 'mixedmeal', 'tolerance', 'tests', 'in', 'healthy', 'mice', 'furthermore', 'coadministration', 'of', 'sitagliptin', 'with', 'investigational', 'compounds', 'in', 'diabetic', 'dbdb', 'mice', 'resulted', 'in', 'synergism', 'with', 'glp1', 'concentrations', 'rising', 'by', 'threefold', 'both', 'ps297', 'and', 'ps318', 'exhibited', 'low', 'gut', 'permeability', 'assessed', 'in', 'the', 'invitro', 'caco2', 'cell', 'model', 'a', 'single', 'oral', 'dose', 'pk', 'study', 'conducted', 'on', 'healthy', 'mice', 'demonstrated', 'poor', 'systemic', 'bioavailability', 'of', 'both', 'agents', 'pk', 'measures', 'mean', 'sd', 'for', 'compound', 'ps297', 'csubmaxsub', '23', '19', 'ngml', 'tsubmaxsub', 'range', '05', '1', 'h', 'aucsub024', 'hsub', '196', '21', 'hngml', 'and', 'ps318', 'csubmaxsub', '75', '22', 'ngml', 'tsubmaxsub', 'range', '025', '05', 'h', 'aucsub024', 'hsub', '35', '23', 'hngml', 'suggest', 'poor', 'oral', 'absorption', 'additionally', 'examinations', 'of', 'drug', 'excretion', 'patterns', 'in', 'mice', 'revealed', 'that', 'around', '25', 'ps297', 'and', '4', 'ps318', 'of', 'the', 'drugs', 'were', 'excreted', 'through', 'faeces', 'as', 'an', 'unchanged', 'form', 'while', 'negligible', 'drug', 'concentrations', '0005', 'were', 'excreted', 'in', 'the', 'urine', 'these', 'acute', 'pkpd', 'assessments', 'suggest', 'the', 'gut', 'is', 'a', 'primary', 'site', 'of', 'action', 'for', 'both', 'agents', 'toxicity', 'assessments', 'conducted', 'in', 'the', 'zebrafish', 'and', 'healthy', 'mice', 'models', 'confirmed', 'the', 'safety', 'and', 'tolerability', 'of', 'both', 'compounds', 'future', 'chronic', 'invivo', 'studies', 'in', 'relevant', 'disease', 'models', 'will', 'be', 'essential', 'to', 'confirm', 'the', 'longterm', 'safety', 'and', 'efficacy', 'of', 'these', 'novel', 'compounds']","['escalating', 'global', 'prevalence', 'type2', 'diabetes', 't2d', 'obesity', 'necessitates', 'development', 'novel', 'oral', 'medications', 'agonism', 'gprotein', 'coupled', 'receptor119', 'gpr119', 'recognized', 'modulation', 'metabolic', 'homeostasis', 't2d', 'obesity', 'fatty', 'liver', 'disease', 'however', 'offtarget', 'effects', 'impeded', 'advancement', 'synthetic', 'gpr119', 'agonist', 'drug', 'candidates', 'nonsystemic', 'gutrestricted', 'gpr119', 'agonism', 'suggested', 'alternative', 'strategy', 'may', 'locally', 'stimulate', 'intestinal', 'enteroendocrine', 'cells', 'eec', 'incretin', 'secretion', 'without', 'need', 'systemic', 'drug', 'availability', 'consequently', 'alleviating', 'conventional', 'classrelated', 'side', 'effects', 'herein', 'report', 'preclinical', 'acute', 'safety', 'efficacy', 'pharmacokinetics', 'pk', 'novel', 'gpr119', 'agonist', 'compounds', 'ps297', 'ps318', 'potentially', 'target', 'gut', 'eec', 'incretin', 'secretion', 'proofofefficacy', 'study', 'compounds', 'demonstrated', 'glucagonlike', 'peptide1', 'glp1', 'secretion', 'capability', 'glucose', 'mixedmeal', 'tolerance', 'tests', 'healthy', 'mice', 'furthermore', 'coadministration', 'sitagliptin', 'investigational', 'compounds', 'diabetic', 'dbdb', 'mice', 'resulted', 'synergism', 'glp1', 'concentrations', 'rising', 'threefold', 'ps297', 'ps318', 'exhibited', 'low', 'gut', 'permeability', 'assessed', 'invitro', 'caco2', 'cell', 'model', 'single', 'oral', 'dose', 'pk', 'study', 'conducted', 'healthy', 'mice', 'demonstrated', 'poor', 'systemic', 'bioavailability', 'agents', 'pk', 'measures', 'mean', 'sd', 'compound', 'ps297', 'csubmaxsub', '23', '19', 'ngml', 'tsubmaxsub', 'range', '05', '1', 'h', 'aucsub024', 'hsub', '196', '21', 'hngml', 'ps318', 'csubmaxsub', '75', '22', 'ngml', 'tsubmaxsub', 'range', '025', '05', 'h', 'aucsub024', 'hsub', '35', '23', 'hngml', 'suggest', 'poor', 'oral', 'absorption', 'additionally', 'examinations', 'drug', 'excretion', 'patterns', 'mice', 'revealed', 'around', '25', 'ps297', '4', 'ps318', 'drugs', 'excreted', 'faeces', 'unchanged', 'form', 'negligible', 'drug', 'concentrations', '0005', 'excreted', 'urine', 'acute', 'pkpd', 'assessments', 'suggest', 'gut', 'primary', 'site', 'action', 'agents', 'toxicity', 'assessments', 'conducted', 'zebrafish', 'healthy', 'mice', 'models', 'confirmed', 'safety', 'tolerability', 'compounds', 'future', 'chronic', 'invivo', 'studies', 'relevant', 'disease', 'models', 'essential', 'confirm', 'longterm', 'safety', 'efficacy', 'novel', 'compounds']","['fatty', 'offtarget', 'incretin', 'incretin', 'glucagonlike', 'peptide1', 'glp1', 'glp1']","['offtarget', 'incretin', 'incretin']",False,['diabetes']
38931896,Comparative Study of the Potential Cell-Penetrating Peptide ∆M4 on Apoptosis Cell Signaling in A375 and A431 Cancer Cell Lines.,"In recent yearsjajajj, peptide-based therapeutics have attracted increasing interest as a potential approach to cancer treatment. Peptides are characterized by high specificity and low cytotoxicity, but they cannot be considered universal drugs for all types of cancer. Of the numerous anticancer-reported peptides, both natural and synthetic, only a few have reached clinical applications. However, in most cases, the mechanism behind the anticancer activity of the peptide is not fully understood. For this reason, in this work, we investigated the effect of the novel peptide ∆M4, which has documented anticancer activity, on two human skin cancer cell lines. A novel approach to studying the potential induction of apoptosis by anticancer peptides is the use of protein microarrays. The results of the apoptosis protein study demonstrated that both cell types, skin malignant melanoma (A375) and epidermoid carcinoma (A431), exhibited markers associated with apoptosis and cellular response to oxidative stress. Additionally, ∆M4 induced concentration- and time-dependent moderate ROS production, triggering a defensive response from the cells, which showed decreased activation of cytoplasmic superoxide dismutase. However, the studied cells exhibited a differential response in catalase activity, with A375 cells showing greater resistance to the peptide action, possibly mediated by the Nrf2 pathway. Nevertheless, both cell types showed moderate activity of caspases 3/7, suggesting that they may undergo partial apoptosis, although another pathway of programmed death cannot be excluded. Extended analysis of the mechanisms of action of anticancer peptides may help determine their effectiveness in overcoming chemoresistance in cancerous cells.",2024-06-07,in recent yearsjajajj peptidebased therapeutics have attracted increasing interest as a potential approach to cancer treatment peptides are characterized by high specificity and low cytotoxicity but they cannot be considered universal drugs for all types of cancer of the numerous anticancerreported peptides both natural and synthetic only a few have reached clinical applications however in most cases the mechanism behind the anticancer activity of the peptide is not fully understood for this reason in this work we investigated the effect of the novel peptide m4 which has documented anticancer activity on two human skin cancer cell lines a novel approach to studying the potential induction of apoptosis by anticancer peptides is the use of protein microarrays the results of the apoptosis protein study demonstrated that both cell types skin malignant melanoma a375 and epidermoid carcinoma a431 exhibited markers associated with apoptosis and cellular response to oxidative stress additionally m4 induced concentration and timedependent moderate ros production triggering a defensive response from the cells which showed decreased activation of cytoplasmic superoxide dismutase however the studied cells exhibited a differential response in catalase activity with a375 cells showing greater resistance to the peptide action possibly mediated by the nrf2 pathway nevertheless both cell types showed moderate activity of caspases 37 suggesting that they may undergo partial apoptosis although another pathway of programmed death cannot be excluded extended analysis of the mechanisms of action of anticancer peptides may help determine their effectiveness in overcoming chemoresistance in cancerous cells,"['in', 'recent', 'yearsjajajj', 'peptidebased', 'therapeutics', 'have', 'attracted', 'increasing', 'interest', 'as', 'a', 'potential', 'approach', 'to', 'cancer', 'treatment', 'peptides', 'are', 'characterized', 'by', 'high', 'specificity', 'and', 'low', 'cytotoxicity', 'but', 'they', 'can', 'not', 'be', 'considered', 'universal', 'drugs', 'for', 'all', 'types', 'of', 'cancer', 'of', 'the', 'numerous', 'anticancerreported', 'peptides', 'both', 'natural', 'and', 'synthetic', 'only', 'a', 'few', 'have', 'reached', 'clinical', 'applications', 'however', 'in', 'most', 'cases', 'the', 'mechanism', 'behind', 'the', 'anticancer', 'activity', 'of', 'the', 'peptide', 'is', 'not', 'fully', 'understood', 'for', 'this', 'reason', 'in', 'this', 'work', 'we', 'investigated', 'the', 'effect', 'of', 'the', 'novel', 'peptide', 'm4', 'which', 'has', 'documented', 'anticancer', 'activity', 'on', 'two', 'human', 'skin', 'cancer', 'cell', 'lines', 'a', 'novel', 'approach', 'to', 'studying', 'the', 'potential', 'induction', 'of', 'apoptosis', 'by', 'anticancer', 'peptides', 'is', 'the', 'use', 'of', 'protein', 'microarrays', 'the', 'results', 'of', 'the', 'apoptosis', 'protein', 'study', 'demonstrated', 'that', 'both', 'cell', 'types', 'skin', 'malignant', 'melanoma', 'a375', 'and', 'epidermoid', 'carcinoma', 'a431', 'exhibited', 'markers', 'associated', 'with', 'apoptosis', 'and', 'cellular', 'response', 'to', 'oxidative', 'stress', 'additionally', 'm4', 'induced', 'concentration', 'and', 'timedependent', 'moderate', 'ros', 'production', 'triggering', 'a', 'defensive', 'response', 'from', 'the', 'cells', 'which', 'showed', 'decreased', 'activation', 'of', 'cytoplasmic', 'superoxide', 'dismutase', 'however', 'the', 'studied', 'cells', 'exhibited', 'a', 'differential', 'response', 'in', 'catalase', 'activity', 'with', 'a375', 'cells', 'showing', 'greater', 'resistance', 'to', 'the', 'peptide', 'action', 'possibly', 'mediated', 'by', 'the', 'nrf2', 'pathway', 'nevertheless', 'both', 'cell', 'types', 'showed', 'moderate', 'activity', 'of', 'caspases', '37', 'suggesting', 'that', 'they', 'may', 'undergo', 'partial', 'apoptosis', 'although', 'another', 'pathway', 'of', 'programmed', 'death', 'can', 'not', 'be', 'excluded', 'extended', 'analysis', 'of', 'the', 'mechanisms', 'of', 'action', 'of', 'anticancer', 'peptides', 'may', 'help', 'determine', 'their', 'effectiveness', 'in', 'overcoming', 'chemoresistance', 'in', 'cancerous', 'cells']","['recent', 'yearsjajajj', 'peptidebased', 'therapeutics', 'attracted', 'increasing', 'interest', 'potential', 'approach', 'cancer', 'treatment', 'peptides', 'characterized', 'high', 'specificity', 'low', 'cytotoxicity', 'considered', 'universal', 'drugs', 'types', 'cancer', 'numerous', 'anticancerreported', 'peptides', 'natural', 'synthetic', 'reached', 'clinical', 'applications', 'however', 'cases', 'mechanism', 'behind', 'anticancer', 'activity', 'peptide', 'fully', 'understood', 'reason', 'work', 'investigated', 'effect', 'novel', 'peptide', 'm4', 'documented', 'anticancer', 'activity', 'two', 'human', 'skin', 'cancer', 'cell', 'lines', 'novel', 'approach', 'studying', 'potential', 'induction', 'apoptosis', 'anticancer', 'peptides', 'use', 'protein', 'microarrays', 'results', 'apoptosis', 'protein', 'study', 'demonstrated', 'cell', 'types', 'skin', 'malignant', 'melanoma', 'a375', 'epidermoid', 'carcinoma', 'a431', 'exhibited', 'markers', 'associated', 'apoptosis', 'cellular', 'response', 'oxidative', 'stress', 'additionally', 'm4', 'induced', 'concentration', 'timedependent', 'moderate', 'ros', 'production', 'triggering', 'defensive', 'response', 'cells', 'showed', 'decreased', 'activation', 'cytoplasmic', 'superoxide', 'dismutase', 'however', 'studied', 'cells', 'exhibited', 'differential', 'response', 'catalase', 'activity', 'a375', 'cells', 'showing', 'greater', 'resistance', 'peptide', 'action', 'possibly', 'mediated', 'nrf2', 'pathway', 'nevertheless', 'cell', 'types', 'showed', 'moderate', 'activity', 'caspases', '37', 'suggesting', 'may', 'undergo', 'partial', 'apoptosis', 'although', 'another', 'pathway', 'programmed', 'death', 'excluded', 'extended', 'analysis', 'mechanisms', 'action', 'anticancer', 'peptides', 'may', 'help', 'determine', 'effectiveness', 'overcoming', 'chemoresistance', 'cancerous', 'cells']","['a375', 'ros', 'a375', 'nrf2']","['a375', 'a375']",True,['cancer']
38919263,Serum Spexin Level Is Negatively Associated With Peripheral Neuropathy and Sensory Pain in Type 2 Diabetes.,"<b>Background:</b> Spexin is a novel peptide hormone and has shown antinociceptive effects in experimental mice. This study is aimed at evaluating the association of serum spexin level with diabetic peripheral neuropathy (DPN) and related pain in a Chinese population. <b>Methods:</b> We enrolled 167 type 2 diabetes mellitus (T2DM) including 56 patients without DPN (non-DPN), 67 painless DPN, and 44 painful DPN. Serum spexin was measured using ELISA. Logistic regression models were performed to analyze the independent effects of spexin on prevalence of DPN and painful DPN. In streptozotocin (STZ)-induced diabetic mice, mechanical pain threshold was measured using electronic von Frey aesthesiometer. Human peripheral blood mononuclear cells (PBMCs) were isolated and further stimulated with lipopolysaccharide without or with spexin. The gene expression was assayed by qPCR. <b>Results:</b> Compared with non-DPN, serum spexin level decreased in painless DPN and further decreased in painful DPN. The odds of DPN was associated with low spexin level in T2DM, which was similar by age, sex, BMI, and diabetes duration, but attenuated in smokers. The odds of having pain was associated with decreased spexin level in DPN, which was similar by age, sex, smoking status, and diabetes duration, but attenuated in normal weight. Furthermore, we observed that mechanical pain threshold increased in spexin-treated diabetic mice. We also found that lipopolysaccharide treatment increased the mRNA level of TNF-<i>α</i>, IL-6, and MCP-1 in human PBMCs, while spexin treatment prevented this increase. <b>Conclusions:</b> These results suggested that spexin might serve as a protective factor for diabetes against neuropathology and pain-related pathogenesis.",2024-05-23,bbackgroundb spexin is a novel peptide hormone and has shown antinociceptive effects in experimental mice this study is aimed at evaluating the association of serum spexin level with diabetic peripheral neuropathy dpn and related pain in a chinese population bmethodsb we enrolled 167 type 2 diabetes mellitus t2dm including 56 patients without dpn nondpn 67 painless dpn and 44 painful dpn serum spexin was measured using elisa logistic regression models were performed to analyze the independent effects of spexin on prevalence of dpn and painful dpn in streptozotocin stzinduced diabetic mice mechanical pain threshold was measured using electronic von frey aesthesiometer human peripheral blood mononuclear cells pbmcs were isolated and further stimulated with lipopolysaccharide without or with spexin the gene expression was assayed by qpcr bresultsb compared with nondpn serum spexin level decreased in painless dpn and further decreased in painful dpn the odds of dpn was associated with low spexin level in t2dm which was similar by age sex bmi and diabetes duration but attenuated in smokers the odds of having pain was associated with decreased spexin level in dpn which was similar by age sex smoking status and diabetes duration but attenuated in normal weight furthermore we observed that mechanical pain threshold increased in spexintreated diabetic mice we also found that lipopolysaccharide treatment increased the mrna level of tnfiαi il6 and mcp1 in human pbmcs while spexin treatment prevented this increase bconclusionsb these results suggested that spexin might serve as a protective factor for diabetes against neuropathology and painrelated pathogenesis,"['bbackgroundb', 'spexin', 'is', 'a', 'novel', 'peptide', 'hormone', 'and', 'has', 'shown', 'antinociceptive', 'effects', 'in', 'experimental', 'mice', 'this', 'study', 'is', 'aimed', 'at', 'evaluating', 'the', 'association', 'of', 'serum', 'spexin', 'level', 'with', 'diabetic', 'peripheral', 'neuropathy', 'dpn', 'and', 'related', 'pain', 'in', 'a', 'chinese', 'population', 'bmethodsb', 'we', 'enrolled', '167', 'type', '2', 'diabetes', 'mellitus', 't2dm', 'including', '56', 'patients', 'without', 'dpn', 'nondpn', '67', 'painless', 'dpn', 'and', '44', 'painful', 'dpn', 'serum', 'spexin', 'was', 'measured', 'using', 'elisa', 'logistic', 'regression', 'models', 'were', 'performed', 'to', 'analyze', 'the', 'independent', 'effects', 'of', 'spexin', 'on', 'prevalence', 'of', 'dpn', 'and', 'painful', 'dpn', 'in', 'streptozotocin', 'stzinduced', 'diabetic', 'mice', 'mechanical', 'pain', 'threshold', 'was', 'measured', 'using', 'electronic', 'von', 'frey', 'aesthesiometer', 'human', 'peripheral', 'blood', 'mononuclear', 'cells', 'pbmcs', 'were', 'isolated', 'and', 'further', 'stimulated', 'with', 'lipopolysaccharide', 'without', 'or', 'with', 'spexin', 'the', 'gene', 'expression', 'was', 'assayed', 'by', 'qpcr', 'bresultsb', 'compared', 'with', 'nondpn', 'serum', 'spexin', 'level', 'decreased', 'in', 'painless', 'dpn', 'and', 'further', 'decreased', 'in', 'painful', 'dpn', 'the', 'odds', 'of', 'dpn', 'was', 'associated', 'with', 'low', 'spexin', 'level', 'in', 't2dm', 'which', 'was', 'similar', 'by', 'age', 'sex', 'bmi', 'and', 'diabetes', 'duration', 'but', 'attenuated', 'in', 'smokers', 'the', 'odds', 'of', 'having', 'pain', 'was', 'associated', 'with', 'decreased', 'spexin', 'level', 'in', 'dpn', 'which', 'was', 'similar', 'by', 'age', 'sex', 'smoking', 'status', 'and', 'diabetes', 'duration', 'but', 'attenuated', 'in', 'normal', 'weight', 'furthermore', 'we', 'observed', 'that', 'mechanical', 'pain', 'threshold', 'increased', 'in', 'spexintreated', 'diabetic', 'mice', 'we', 'also', 'found', 'that', 'lipopolysaccharide', 'treatment', 'increased', 'the', 'mrna', 'level', 'of', 'tnfiαi', 'il6', 'and', 'mcp1', 'in', 'human', 'pbmcs', 'while', 'spexin', 'treatment', 'prevented', 'this', 'increase', 'bconclusionsb', 'these', 'results', 'suggested', 'that', 'spexin', 'might', 'serve', 'as', 'a', 'protective', 'factor', 'for', 'diabetes', 'against', 'neuropathology', 'and', 'painrelated', 'pathogenesis']","['bbackgroundb', 'spexin', 'novel', 'peptide', 'hormone', 'shown', 'antinociceptive', 'effects', 'experimental', 'mice', 'study', 'aimed', 'evaluating', 'association', 'serum', 'spexin', 'level', 'diabetic', 'peripheral', 'neuropathy', 'dpn', 'related', 'pain', 'chinese', 'population', 'bmethodsb', 'enrolled', '167', 'type', '2', 'diabetes', 'mellitus', 't2dm', 'including', '56', 'patients', 'without', 'dpn', 'nondpn', '67', 'painless', 'dpn', '44', 'painful', 'dpn', 'serum', 'spexin', 'measured', 'using', 'elisa', 'logistic', 'regression', 'models', 'performed', 'analyze', 'independent', 'effects', 'spexin', 'prevalence', 'dpn', 'painful', 'dpn', 'streptozotocin', 'stzinduced', 'diabetic', 'mice', 'mechanical', 'pain', 'threshold', 'measured', 'using', 'electronic', 'von', 'frey', 'aesthesiometer', 'human', 'peripheral', 'blood', 'mononuclear', 'cells', 'pbmcs', 'isolated', 'stimulated', 'lipopolysaccharide', 'without', 'spexin', 'gene', 'expression', 'assayed', 'qpcr', 'bresultsb', 'compared', 'nondpn', 'serum', 'spexin', 'level', 'decreased', 'painless', 'dpn', 'decreased', 'painful', 'dpn', 'odds', 'dpn', 'associated', 'low', 'spexin', 'level', 't2dm', 'similar', 'age', 'sex', 'bmi', 'diabetes', 'duration', 'attenuated', 'smokers', 'odds', 'pain', 'associated', 'decreased', 'spexin', 'level', 'dpn', 'similar', 'age', 'sex', 'smoking', 'status', 'diabetes', 'duration', 'attenuated', 'normal', 'weight', 'furthermore', 'observed', 'mechanical', 'pain', 'threshold', 'increased', 'spexintreated', 'diabetic', 'mice', 'also', 'found', 'lipopolysaccharide', 'treatment', 'increased', 'mrna', 'level', 'tnfiαi', 'il6', 'mcp1', 'human', 'pbmcs', 'spexin', 'treatment', 'prevented', 'increase', 'bconclusionsb', 'results', 'suggested', 'spexin', 'might', 'serve', 'protective', 'factor', 'diabetes', 'neuropathology', 'painrelated', 'pathogenesis']","['spexin', 'spexin', 'spexin', 'spexin', 'spexin', 'spexin', 'spexin', 'spexin', 'spexin', 'spexin']","['spexin', 'spexin', 'spexin', 'spexin', 'spexin', 'spexin', 'spexin', 'spexin', 'spexin', 'spexin']",True,['diabetes']
38908201,"TMVP1448, a novel peptide improves detection of primary tumors and metastases by specifically targeting VEGFR-3.","Lymphangiogenesis at primary tumor and draining lymph nodes plays a pivotal role in tumor metastasis, which has been demonstrated to be regulated by the vascular endothelial growth factor receptor 3 (VEGFR-3) pathway. However, the effect of molecular imaging peptides, which specifically bind VEGFR-3, in tracing tumors remains unclear. We prepared a novel peptide, TMVP1448, with high-affinity to VEGFR-3. The dissociation constant (KD) of TMVP1448 with VEGFR-3 was 7.07 ×10-7 M. In vitro cellular assay showed that TMVP1448 could bind specifically with VEGFR-3. Near infrared imaging results showed that Cy7-TMVP1448 was able to accurately trace primary and metastatic cancers, and PET/CT results showed that [<sup>68</sup>Ga]Ga-DOTA-TMVP1448 was superior to commonly used radiotracers <sup>18</sup>F-FDG. Additionally, no significant negative effect of TMVP1448 was found in mice. Our results suggested that TMVP1448 had great potential for future clinical applications in fluorescence imaging and nuclear imaging of tumors.",2024-06-21,lymphangiogenesis at primary tumor and draining lymph nodes plays a pivotal role in tumor metastasis which has been demonstrated to be regulated by the vascular endothelial growth factor receptor 3 vegfr3 pathway however the effect of molecular imaging peptides which specifically bind vegfr3 in tracing tumors remains unclear we prepared a novel peptide tmvp1448 with highaffinity to vegfr3 the dissociation constant kd of tmvp1448 with vegfr3 was 707 107 m in vitro cellular assay showed that tmvp1448 could bind specifically with vegfr3 near infrared imaging results showed that cy7tmvp1448 was able to accurately trace primary and metastatic cancers and petct results showed that sup68supgagadotatmvp1448 was superior to commonly used radiotracers sup18supffdg additionally no significant negative effect of tmvp1448 was found in mice our results suggested that tmvp1448 had great potential for future clinical applications in fluorescence imaging and nuclear imaging of tumors,"['lymphangiogenesis', 'at', 'primary', 'tumor', 'and', 'draining', 'lymph', 'nodes', 'plays', 'a', 'pivotal', 'role', 'in', 'tumor', 'metastasis', 'which', 'has', 'been', 'demonstrated', 'to', 'be', 'regulated', 'by', 'the', 'vascular', 'endothelial', 'growth', 'factor', 'receptor', '3', 'vegfr3', 'pathway', 'however', 'the', 'effect', 'of', 'molecular', 'imaging', 'peptides', 'which', 'specifically', 'bind', 'vegfr3', 'in', 'tracing', 'tumors', 'remains', 'unclear', 'we', 'prepared', 'a', 'novel', 'peptide', 'tmvp1448', 'with', 'highaffinity', 'to', 'vegfr3', 'the', 'dissociation', 'constant', 'kd', 'of', 'tmvp1448', 'with', 'vegfr3', 'was', '707', '107', 'm', 'in', 'vitro', 'cellular', 'assay', 'showed', 'that', 'tmvp1448', 'could', 'bind', 'specifically', 'with', 'vegfr3', 'near', 'infrared', 'imaging', 'results', 'showed', 'that', 'cy7tmvp1448', 'was', 'able', 'to', 'accurately', 'trace', 'primary', 'and', 'metastatic', 'cancers', 'and', 'petct', 'results', 'showed', 'that', 'sup68supgagadotatmvp1448', 'was', 'superior', 'to', 'commonly', 'used', 'radiotracers', 'sup18supffdg', 'additionally', 'no', 'significant', 'negative', 'effect', 'of', 'tmvp1448', 'was', 'found', 'in', 'mice', 'our', 'results', 'suggested', 'that', 'tmvp1448', 'had', 'great', 'potential', 'for', 'future', 'clinical', 'applications', 'in', 'fluorescence', 'imaging', 'and', 'nuclear', 'imaging', 'of', 'tumors']","['lymphangiogenesis', 'primary', 'tumor', 'draining', 'lymph', 'nodes', 'plays', 'pivotal', 'role', 'tumor', 'metastasis', 'demonstrated', 'regulated', 'vascular', 'endothelial', 'growth', 'factor', 'receptor', '3', 'vegfr3', 'pathway', 'however', 'effect', 'molecular', 'imaging', 'peptides', 'specifically', 'bind', 'vegfr3', 'tracing', 'tumors', 'remains', 'unclear', 'prepared', 'novel', 'peptide', 'tmvp1448', 'highaffinity', 'vegfr3', 'dissociation', 'constant', 'kd', 'tmvp1448', 'vegfr3', '707', '107', 'vitro', 'cellular', 'assay', 'showed', 'tmvp1448', 'could', 'bind', 'specifically', 'vegfr3', 'near', 'infrared', 'imaging', 'results', 'showed', 'cy7tmvp1448', 'able', 'accurately', 'trace', 'primary', 'metastatic', 'cancers', 'petct', 'results', 'showed', 'sup68supgagadotatmvp1448', 'superior', 'commonly', 'used', 'radiotracers', 'sup18supffdg', 'additionally', 'significant', 'negative', 'effect', 'tmvp1448', 'found', 'mice', 'results', 'suggested', 'tmvp1448', 'great', 'potential', 'future', 'clinical', 'applications', 'fluorescence', 'imaging', 'nuclear', 'imaging', 'tumors']","['vegfr3', 'vegfr3', 'vegfr3', 'vegfr3', 'vegfr3']","['vegfr3', 'vegfr3', 'vegfr3', 'vegfr3', 'vegfr3']",False,"['tumor', 'cancer']"
38906029,"The Notch inhibitor, FLI-06, increases the chemosensitivity of head and neck Squamous cell carcinoma cells to taxanes-based treatment.","Aberration of Notch signaling is one of the key events involved in the development and progression of head and neck squamous cell carcinoma (HNSCC). The Notch pathway controls the tissue-specific differentiation of normal squamous epithelial cells and is frequently altered in squamous carcinomas, thus affecting their proliferation, growth, survival, and chemosensitivity or resistance against anti-cancer agents. In this study, we show that the use of novel, small-molecule inhibitors of Notch signaling, such as FLI-06, can have a beneficial effect on increasing the chemosensitivity of HNSCC to taxane-based chemotherapy. Inhibition of Notch signaling by FLI-06 alone virtually blocks the proliferation and growth of HNSCC cells in both 2D and 3D cultures and the zebrafish model, which is accompanied by down-regulation of key Notch target genes and proteins. Mechanistically, FLI-06 treatment causes cell cycle arrest in the G<sub>1</sub>-phase and induction of apoptosis in HNSCC, which is accompanied by increased c-Jun<sup>S63</sup> phosphorylation. Combining FLI-06 with Docetaxel shows a synergistic effect and partially blocks the cell growth of aggressive HNSCC cells via enhanced apoptosis and modification of c-Jun<sup>S243</sup> phosphorylation via GSK-3β inhibition. In conclusion, inhibition of Notch signaling in HNSCC cells that retain active Notch signaling significantly supports taxane-based anticancer activities via modulation of both the GSK-3β and the c-Jun.",2024-06-20,aberration of notch signaling is one of the key events involved in the development and progression of head and neck squamous cell carcinoma hnscc the notch pathway controls the tissuespecific differentiation of normal squamous epithelial cells and is frequently altered in squamous carcinomas thus affecting their proliferation growth survival and chemosensitivity or resistance against anticancer agents in this study we show that the use of novel smallmolecule inhibitors of notch signaling such as fli06 can have a beneficial effect on increasing the chemosensitivity of hnscc to taxanebased chemotherapy inhibition of notch signaling by fli06 alone virtually blocks the proliferation and growth of hnscc cells in both 2d and 3d cultures and the zebrafish model which is accompanied by downregulation of key notch target genes and proteins mechanistically fli06 treatment causes cell cycle arrest in the gsub1subphase and induction of apoptosis in hnscc which is accompanied by increased cjunsups63sup phosphorylation combining fli06 with docetaxel shows a synergistic effect and partially blocks the cell growth of aggressive hnscc cells via enhanced apoptosis and modification of cjunsups243sup phosphorylation via gsk3β inhibition in conclusion inhibition of notch signaling in hnscc cells that retain active notch signaling significantly supports taxanebased anticancer activities via modulation of both the gsk3β and the cjun,"['aberration', 'of', 'notch', 'signaling', 'is', 'one', 'of', 'the', 'key', 'events', 'involved', 'in', 'the', 'development', 'and', 'progression', 'of', 'head', 'and', 'neck', 'squamous', 'cell', 'carcinoma', 'hnscc', 'the', 'notch', 'pathway', 'controls', 'the', 'tissuespecific', 'differentiation', 'of', 'normal', 'squamous', 'epithelial', 'cells', 'and', 'is', 'frequently', 'altered', 'in', 'squamous', 'carcinomas', 'thus', 'affecting', 'their', 'proliferation', 'growth', 'survival', 'and', 'chemosensitivity', 'or', 'resistance', 'against', 'anticancer', 'agents', 'in', 'this', 'study', 'we', 'show', 'that', 'the', 'use', 'of', 'novel', 'smallmolecule', 'inhibitors', 'of', 'notch', 'signaling', 'such', 'as', 'fli06', 'can', 'have', 'a', 'beneficial', 'effect', 'on', 'increasing', 'the', 'chemosensitivity', 'of', 'hnscc', 'to', 'taxanebased', 'chemotherapy', 'inhibition', 'of', 'notch', 'signaling', 'by', 'fli06', 'alone', 'virtually', 'blocks', 'the', 'proliferation', 'and', 'growth', 'of', 'hnscc', 'cells', 'in', 'both', '2d', 'and', '3d', 'cultures', 'and', 'the', 'zebrafish', 'model', 'which', 'is', 'accompanied', 'by', 'downregulation', 'of', 'key', 'notch', 'target', 'genes', 'and', 'proteins', 'mechanistically', 'fli06', 'treatment', 'causes', 'cell', 'cycle', 'arrest', 'in', 'the', 'gsub1subphase', 'and', 'induction', 'of', 'apoptosis', 'in', 'hnscc', 'which', 'is', 'accompanied', 'by', 'increased', 'cjunsups63sup', 'phosphorylation', 'combining', 'fli06', 'with', 'docetaxel', 'shows', 'a', 'synergistic', 'effect', 'and', 'partially', 'blocks', 'the', 'cell', 'growth', 'of', 'aggressive', 'hnscc', 'cells', 'via', 'enhanced', 'apoptosis', 'and', 'modification', 'of', 'cjunsups243sup', 'phosphorylation', 'via', 'gsk3β', 'inhibition', 'in', 'conclusion', 'inhibition', 'of', 'notch', 'signaling', 'in', 'hnscc', 'cells', 'that', 'retain', 'active', 'notch', 'signaling', 'significantly', 'supports', 'taxanebased', 'anticancer', 'activities', 'via', 'modulation', 'of', 'both', 'the', 'gsk3β', 'and', 'the', 'cjun']","['aberration', 'notch', 'signaling', 'one', 'key', 'events', 'involved', 'development', 'progression', 'head', 'neck', 'squamous', 'cell', 'carcinoma', 'hnscc', 'notch', 'pathway', 'controls', 'tissuespecific', 'differentiation', 'normal', 'squamous', 'epithelial', 'cells', 'frequently', 'altered', 'squamous', 'carcinomas', 'thus', 'affecting', 'proliferation', 'growth', 'survival', 'chemosensitivity', 'resistance', 'anticancer', 'agents', 'study', 'show', 'use', 'novel', 'smallmolecule', 'inhibitors', 'notch', 'signaling', 'fli06', 'beneficial', 'effect', 'increasing', 'chemosensitivity', 'hnscc', 'taxanebased', 'chemotherapy', 'inhibition', 'notch', 'signaling', 'fli06', 'alone', 'virtually', 'blocks', 'proliferation', 'growth', 'hnscc', 'cells', '2d', '3d', 'cultures', 'zebrafish', 'model', 'accompanied', 'downregulation', 'key', 'notch', 'target', 'genes', 'proteins', 'mechanistically', 'fli06', 'treatment', 'causes', 'cell', 'cycle', 'arrest', 'gsub1subphase', 'induction', 'apoptosis', 'hnscc', 'accompanied', 'increased', 'cjunsups63sup', 'phosphorylation', 'combining', 'fli06', 'docetaxel', 'shows', 'synergistic', 'effect', 'partially', 'blocks', 'cell', 'growth', 'aggressive', 'hnscc', 'cells', 'via', 'enhanced', 'apoptosis', 'modification', 'cjunsups243sup', 'phosphorylation', 'via', 'gsk3β', 'inhibition', 'conclusion', 'inhibition', 'notch', 'signaling', 'hnscc', 'cells', 'retain', 'active', 'notch', 'signaling', 'significantly', 'supports', 'taxanebased', 'anticancer', 'activities', 'via', 'modulation', 'gsk3β', 'cjun']",['cjun'],['cjun'],True,['cancer']
38904299,Discovery of Novel Small Molecule Dual Inhibitor Targeting Toll-Like Receptors 7 and 9.,"The aberrant secretion of proinflammatory cytokines by immune cells is the principal cause of inflammatory diseases, such as systemic lupus erythematosus and rheumatoid arthritis. Toll-like receptor 7 (TLR7) and TLR9, sequestered to the endosomal compartment of dendritic cells and macrophages, are closely associated with the initiation and progression of these diseases. Therefore, the development of drugs targeting dysregulated endosomal TLRs is imperative to mitigate systemic inflammation. Here, we applied the principles of computer-aided drug discovery to identify a novel low-molecular-weight compound, TLR inhibitory compound 10 (TIC10), and its potent derivative (TIC10g), which demonstrated dual inhibition of TLR7 and TLR9 signaling pathways. Compared to TIC10, TIC10g exhibited a more pronounced inhibition of the TLR7- and TLR9-mediated secretion of the proinflammatory cytokine tumor necrosis factor-α in a mouse macrophage cell line and mouse bone marrow dendritic cells in a concentration-dependent manner. While TIC10g slightly prevented TLR3 and TLR8 activation, it had no impact on cell surface TLRs (TLR1/2, TLR2/6, TLR4, or TLR5), indicating its selectivity for TLR7 and TLR9. Additionally, mechanistic studies suggested that TIC10g interfered with TLR9 activation by CpG DNA and suppressed downstream pathways by directly binding to TLR9. Western blot analysis revealed that TIC10g downregulated the phosphorylation of the p65 subunit of nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) and mitogen-activated protein kinases (MAPKs), including extracellular-signal-regulated kinase, p38-MAPK, and c-Jun N-terminal kinase. These findings indicate that the novel ligand, TIC10g, is a specific dual inhibitor of endosomal TLRs (TLR7 and TLR9), disrupting MAPK- and NF-κB-mediated proinflammatory gene expression.",2024-06-21,the aberrant secretion of proinflammatory cytokines by immune cells is the principal cause of inflammatory diseases such as systemic lupus erythematosus and rheumatoid arthritis tolllike receptor 7 tlr7 and tlr9 sequestered to the endosomal compartment of dendritic cells and macrophages are closely associated with the initiation and progression of these diseases therefore the development of drugs targeting dysregulated endosomal tlrs is imperative to mitigate systemic inflammation here we applied the principles of computeraided drug discovery to identify a novel lowmolecularweight compound tlr inhibitory compound 10 tic10 and its potent derivative tic10g which demonstrated dual inhibition of tlr7 and tlr9 signaling pathways compared to tic10 tic10g exhibited a more pronounced inhibition of the tlr7 and tlr9mediated secretion of the proinflammatory cytokine tumor necrosis factorα in a mouse macrophage cell line and mouse bone marrow dendritic cells in a concentrationdependent manner while tic10g slightly prevented tlr3 and tlr8 activation it had no impact on cell surface tlrs tlr12 tlr26 tlr4 or tlr5 indicating its selectivity for tlr7 and tlr9 additionally mechanistic studies suggested that tic10g interfered with tlr9 activation by cpg dna and suppressed downstream pathways by directly binding to tlr9 western blot analysis revealed that tic10g downregulated the phosphorylation of the p65 subunit of nuclear factor κlightchainenhancer of activated b cells nfκb and mitogenactivated protein kinases mapks including extracellularsignalregulated kinase p38mapk and cjun nterminal kinase these findings indicate that the novel ligand tic10g is a specific dual inhibitor of endosomal tlrs tlr7 and tlr9 disrupting mapk and nfκbmediated proinflammatory gene expression,"['the', 'aberrant', 'secretion', 'of', 'proinflammatory', 'cytokines', 'by', 'immune', 'cells', 'is', 'the', 'principal', 'cause', 'of', 'inflammatory', 'diseases', 'such', 'as', 'systemic', 'lupus', 'erythematosus', 'and', 'rheumatoid', 'arthritis', 'tolllike', 'receptor', '7', 'tlr7', 'and', 'tlr9', 'sequestered', 'to', 'the', 'endosomal', 'compartment', 'of', 'dendritic', 'cells', 'and', 'macrophages', 'are', 'closely', 'associated', 'with', 'the', 'initiation', 'and', 'progression', 'of', 'these', 'diseases', 'therefore', 'the', 'development', 'of', 'drugs', 'targeting', 'dysregulated', 'endosomal', 'tlrs', 'is', 'imperative', 'to', 'mitigate', 'systemic', 'inflammation', 'here', 'we', 'applied', 'the', 'principles', 'of', 'computeraided', 'drug', 'discovery', 'to', 'identify', 'a', 'novel', 'lowmolecularweight', 'compound', 'tlr', 'inhibitory', 'compound', '10', 'tic10', 'and', 'its', 'potent', 'derivative', 'tic10g', 'which', 'demonstrated', 'dual', 'inhibition', 'of', 'tlr7', 'and', 'tlr9', 'signaling', 'pathways', 'compared', 'to', 'tic10', 'tic10g', 'exhibited', 'a', 'more', 'pronounced', 'inhibition', 'of', 'the', 'tlr7', 'and', 'tlr9mediated', 'secretion', 'of', 'the', 'proinflammatory', 'cytokine', 'tumor', 'necrosis', 'factorα', 'in', 'a', 'mouse', 'macrophage', 'cell', 'line', 'and', 'mouse', 'bone', 'marrow', 'dendritic', 'cells', 'in', 'a', 'concentrationdependent', 'manner', 'while', 'tic10g', 'slightly', 'prevented', 'tlr3', 'and', 'tlr8', 'activation', 'it', 'had', 'no', 'impact', 'on', 'cell', 'surface', 'tlrs', 'tlr12', 'tlr26', 'tlr4', 'or', 'tlr5', 'indicating', 'its', 'selectivity', 'for', 'tlr7', 'and', 'tlr9', 'additionally', 'mechanistic', 'studies', 'suggested', 'that', 'tic10g', 'interfered', 'with', 'tlr9', 'activation', 'by', 'cpg', 'dna', 'and', 'suppressed', 'downstream', 'pathways', 'by', 'directly', 'binding', 'to', 'tlr9', 'western', 'blot', 'analysis', 'revealed', 'that', 'tic10g', 'downregulated', 'the', 'phosphorylation', 'of', 'the', 'p65', 'subunit', 'of', 'nuclear', 'factor', 'κlightchainenhancer', 'of', 'activated', 'b', 'cells', 'nfκb', 'and', 'mitogenactivated', 'protein', 'kinases', 'mapks', 'including', 'extracellularsignalregulated', 'kinase', 'p38mapk', 'and', 'cjun', 'nterminal', 'kinase', 'these', 'findings', 'indicate', 'that', 'the', 'novel', 'ligand', 'tic10g', 'is', 'a', 'specific', 'dual', 'inhibitor', 'of', 'endosomal', 'tlrs', 'tlr7', 'and', 'tlr9', 'disrupting', 'mapk', 'and', 'nfκbmediated', 'proinflammatory', 'gene', 'expression']","['aberrant', 'secretion', 'proinflammatory', 'cytokines', 'immune', 'cells', 'principal', 'cause', 'inflammatory', 'diseases', 'systemic', 'lupus', 'erythematosus', 'rheumatoid', 'arthritis', 'tolllike', 'receptor', '7', 'tlr7', 'tlr9', 'sequestered', 'endosomal', 'compartment', 'dendritic', 'cells', 'macrophages', 'closely', 'associated', 'initiation', 'progression', 'diseases', 'therefore', 'development', 'drugs', 'targeting', 'dysregulated', 'endosomal', 'tlrs', 'imperative', 'mitigate', 'systemic', 'inflammation', 'applied', 'principles', 'computeraided', 'drug', 'discovery', 'identify', 'novel', 'lowmolecularweight', 'compound', 'tlr', 'inhibitory', 'compound', '10', 'tic10', 'potent', 'derivative', 'tic10g', 'demonstrated', 'dual', 'inhibition', 'tlr7', 'tlr9', 'signaling', 'pathways', 'compared', 'tic10', 'tic10g', 'exhibited', 'pronounced', 'inhibition', 'tlr7', 'tlr9mediated', 'secretion', 'proinflammatory', 'cytokine', 'tumor', 'necrosis', 'factorα', 'mouse', 'macrophage', 'cell', 'line', 'mouse', 'bone', 'marrow', 'dendritic', 'cells', 'concentrationdependent', 'manner', 'tic10g', 'slightly', 'prevented', 'tlr3', 'tlr8', 'activation', 'impact', 'cell', 'surface', 'tlrs', 'tlr12', 'tlr26', 'tlr4', 'tlr5', 'indicating', 'selectivity', 'tlr7', 'tlr9', 'additionally', 'mechanistic', 'studies', 'suggested', 'tic10g', 'interfered', 'tlr9', 'activation', 'cpg', 'dna', 'suppressed', 'downstream', 'pathways', 'directly', 'binding', 'tlr9', 'western', 'blot', 'analysis', 'revealed', 'tic10g', 'downregulated', 'phosphorylation', 'p65', 'subunit', 'nuclear', 'factor', 'κlightchainenhancer', 'activated', 'b', 'cells', 'nfκb', 'mitogenactivated', 'protein', 'kinases', 'mapks', 'including', 'extracellularsignalregulated', 'kinase', 'p38mapk', 'cjun', 'nterminal', 'kinase', 'findings', 'indicate', 'novel', 'ligand', 'tic10g', 'specific', 'dual', 'inhibitor', 'endosomal', 'tlrs', 'tlr7', 'tlr9', 'disrupting', 'mapk', 'nfκbmediated', 'proinflammatory', 'gene', 'expression']","['tlr9', 'tlr', 'tlr9', 'tlr4', 'tlr5', 'tlr9', 'tlr9', 'tlr9', 'p65', 'p38mapk', 'cjun', 'tlr9']","['tlr4', 'tlr5', 'p38mapk', 'cjun']",True,"['tumor', 'arthritis']"
38888047,Discovery and Development of NLRP3 Inhibitors Targeting the LRR Domain to Disrupt NLRP3-NEK7 Interaction for the Treatment of Rheumatoid Arthritis.,"Rheumatoid arthritis (RA) is a chronic autoimmune disease. Targeting NLRP3 inflammasome, specifically its interaction with NEK7 via the LRR domain of NLRP3, is a promising therapeutic strategy. Our research aimed to disrupt this interaction by focusing on the LRR domain. Through virtual screening, we identified five compounds with potent anti-inflammatory effects and ideal LRR binding affinity. Lead compound <b>C878-1943</b> underwent structural optimization, yielding pyridoimidazole derivatives with different anti-inflammatory activities. Compound <b>I-19</b> from the initial series effectively inhibited caspase-1 and IL-1β release in an adjuvant-induced arthritis (AIA) rat model, significantly reducing joint swelling and spleen/thymus indices. To further enhance potency and extend <i>in vivo</i> half-life, a second series including <b>II-8</b> was developed, demonstrating superior efficacy and longer half-life. Both <b>I-19</b> and <b>II-8</b> bind to the LRR domain, inhibiting NLRP3 inflammasome activation. These findings introduce novel small molecule inhibitors targeting the LRR domain of NLRP3 protein and disrupt NLRP3-NEK7 interaction, offering a novel approach for RA treatment.",2024-06-18,rheumatoid arthritis ra is a chronic autoimmune disease targeting nlrp3 inflammasome specifically its interaction with nek7 via the lrr domain of nlrp3 is a promising therapeutic strategy our research aimed to disrupt this interaction by focusing on the lrr domain through virtual screening we identified five compounds with potent antiinflammatory effects and ideal lrr binding affinity lead compound bc8781943b underwent structural optimization yielding pyridoimidazole derivatives with different antiinflammatory activities compound bi19b from the initial series effectively inhibited caspase1 and il1β release in an adjuvantinduced arthritis aia rat model significantly reducing joint swelling and spleenthymus indices to further enhance potency and extend iin vivoi halflife a second series including bii8b was developed demonstrating superior efficacy and longer halflife both bi19b and bii8b bind to the lrr domain inhibiting nlrp3 inflammasome activation these findings introduce novel small molecule inhibitors targeting the lrr domain of nlrp3 protein and disrupt nlrp3nek7 interaction offering a novel approach for ra treatment,"['rheumatoid', 'arthritis', 'ra', 'is', 'a', 'chronic', 'autoimmune', 'disease', 'targeting', 'nlrp3', 'inflammasome', 'specifically', 'its', 'interaction', 'with', 'nek7', 'via', 'the', 'lrr', 'domain', 'of', 'nlrp3', 'is', 'a', 'promising', 'therapeutic', 'strategy', 'our', 'research', 'aimed', 'to', 'disrupt', 'this', 'interaction', 'by', 'focusing', 'on', 'the', 'lrr', 'domain', 'through', 'virtual', 'screening', 'we', 'identified', 'five', 'compounds', 'with', 'potent', 'antiinflammatory', 'effects', 'and', 'ideal', 'lrr', 'binding', 'affinity', 'lead', 'compound', 'bc8781943b', 'underwent', 'structural', 'optimization', 'yielding', 'pyridoimidazole', 'derivatives', 'with', 'different', 'antiinflammatory', 'activities', 'compound', 'bi19b', 'from', 'the', 'initial', 'series', 'effectively', 'inhibited', 'caspase1', 'and', 'il1β', 'release', 'in', 'an', 'adjuvantinduced', 'arthritis', 'aia', 'rat', 'model', 'significantly', 'reducing', 'joint', 'swelling', 'and', 'spleenthymus', 'indices', 'to', 'further', 'enhance', 'potency', 'and', 'extend', 'iin', 'vivoi', 'halflife', 'a', 'second', 'series', 'including', 'bii8b', 'was', 'developed', 'demonstrating', 'superior', 'efficacy', 'and', 'longer', 'halflife', 'both', 'bi19b', 'and', 'bii8b', 'bind', 'to', 'the', 'lrr', 'domain', 'inhibiting', 'nlrp3', 'inflammasome', 'activation', 'these', 'findings', 'introduce', 'novel', 'small', 'molecule', 'inhibitors', 'targeting', 'the', 'lrr', 'domain', 'of', 'nlrp3', 'protein', 'and', 'disrupt', 'nlrp3nek7', 'interaction', 'offering', 'a', 'novel', 'approach', 'for', 'ra', 'treatment']","['rheumatoid', 'arthritis', 'ra', 'chronic', 'autoimmune', 'disease', 'targeting', 'nlrp3', 'inflammasome', 'specifically', 'interaction', 'nek7', 'via', 'lrr', 'domain', 'nlrp3', 'promising', 'therapeutic', 'strategy', 'research', 'aimed', 'disrupt', 'interaction', 'focusing', 'lrr', 'domain', 'virtual', 'screening', 'identified', 'five', 'compounds', 'potent', 'antiinflammatory', 'effects', 'ideal', 'lrr', 'binding', 'affinity', 'lead', 'compound', 'bc8781943b', 'underwent', 'structural', 'optimization', 'yielding', 'pyridoimidazole', 'derivatives', 'different', 'antiinflammatory', 'activities', 'compound', 'bi19b', 'initial', 'series', 'effectively', 'inhibited', 'caspase1', 'il1β', 'release', 'adjuvantinduced', 'arthritis', 'aia', 'rat', 'model', 'significantly', 'reducing', 'joint', 'swelling', 'spleenthymus', 'indices', 'enhance', 'potency', 'extend', 'iin', 'vivoi', 'halflife', 'second', 'series', 'including', 'bii8b', 'developed', 'demonstrating', 'superior', 'efficacy', 'longer', 'halflife', 'bi19b', 'bii8b', 'bind', 'lrr', 'domain', 'inhibiting', 'nlrp3', 'inflammasome', 'activation', 'findings', 'introduce', 'novel', 'small', 'molecule', 'inhibitors', 'targeting', 'lrr', 'domain', 'nlrp3', 'protein', 'disrupt', 'nlrp3nek7', 'interaction', 'offering', 'novel', 'approach', 'ra', 'treatment']","['ra', 'caspase1', 'ra']","['ra', 'caspase1', 'ra']",True,['arthritis']
38874005,A patent review on hypoxia-inducible factor (HIF) modulators (2021-2023).,"Hypoxia-inducible factor (HIF) is a central regulatory factor in detecting and adapting to cellular oxygen stress. Dysregulation of HIF is associated with various human diseases. Seven HIF modulators, including six prolyl hydroxylase (PHD) inhibitors and one HIF-2α inhibitor, have already been approved for the treatment of renal anemia and cancer, respectively.",2024-06-19,hypoxiainducible factor hif is a central regulatory factor in detecting and adapting to cellular oxygen stress dysregulation of hif is associated with various human diseases seven hif modulators including six prolyl hydroxylase phd inhibitors and one hif2α inhibitor have already been approved for the treatment of renal anemia and cancer respectively,"['hypoxiainducible', 'factor', 'hif', 'is', 'a', 'central', 'regulatory', 'factor', 'in', 'detecting', 'and', 'adapting', 'to', 'cellular', 'oxygen', 'stress', 'dysregulation', 'of', 'hif', 'is', 'associated', 'with', 'various', 'human', 'diseases', 'seven', 'hif', 'modulators', 'including', 'six', 'prolyl', 'hydroxylase', 'phd', 'inhibitors', 'and', 'one', 'hif2α', 'inhibitor', 'have', 'already', 'been', 'approved', 'for', 'the', 'treatment', 'of', 'renal', 'anemia', 'and', 'cancer', 'respectively']","['hypoxiainducible', 'factor', 'hif', 'central', 'regulatory', 'factor', 'detecting', 'adapting', 'cellular', 'oxygen', 'stress', 'dysregulation', 'hif', 'associated', 'various', 'human', 'diseases', 'seven', 'hif', 'modulators', 'including', 'six', 'prolyl', 'hydroxylase', 'phd', 'inhibitors', 'one', 'hif2α', 'inhibitor', 'already', 'approved', 'treatment', 'renal', 'anemia', 'cancer', 'respectively']","['hif', 'hif', 'hif', 'phd']",['phd'],True,['cancer']
38870120,A novel peptide derived from Zingiber cassumunar rhizomes exhibits anticancer activity against the colon adenocarcinoma cells (Caco-2) via the induction of intrinsic apoptosis signaling.,"This paper presents the initial exploration of the free radical scavenging capabilities of peptides derived from protein hydrolysates (PPH) obtained from Zingiber cassumunar rhizomes (Phlai). To replicate the conditions of gastrointestinal digestion, a combination of pepsin and pancreatin proteolysis was employed to generate these hydrolysates. Subsequently, the hydrolysate underwent fractionation using molecular weight cut-off membranes at 10, 5, 3, and 0.65 kDa. The fraction with a molecular weight less than 0.65 kDa exhibited the highest levels ABTS, DPPH, FRAP, and NO radical scavenging activity. Following this, RP-HPLC was used to further separate the fraction with a molecular weight less than 0.65 kDa into three sub-fractions. Among these, the F5 sub-fraction displayed the most prominent radical-scavenging properties. De novo peptide sequencing via quadrupole-time-of-flight-electron spin induction-mass spectrometry identified a pair of novel peptides: Asp-Gly-Ile-Phe-Val-Leu-Asn-Tyr (DGIFVLNY or DY-8) and Ile-Pro-Thr-Asp-Glu-Lys (IPTDEK or IK-6). Database analysis confirmed various properties, including biological activity, toxicity, hydrophilicity, solubility, and potential allergy concerns. Furthermore, when tested on the human adenocarcinoma colon (Caco-2) cell line, two synthetic peptides demonstrated cellular antioxidant activity in a concentration-dependent manner. These peptides were also assessed using the FITC Annexin V apoptosis detection kit with PI, confirming the induction of apoptosis. Notably, the DY-8 peptide induced apoptosis, upregulated mRNA levels of caspase-3, -8, and -9, and downregulated Bcl-2, as confirmed by real-time quantitative polymerase chain reaction (RT-qPCR). Western blot analysis indicated increased pro-apoptotic Bax expression and decreased anti-apoptotic Bcl-2 expression in Caco-2 cells exposed to the DY-8 peptide. Molecular docking analysis revealed that the DY-8 peptide exhibited binding affinity with Bcl-2, Bcl-xL, and Mcl-1, suggesting potential utility in combating colon cancer as functional food ingredients.",2024-06-13,this paper presents the initial exploration of the free radical scavenging capabilities of peptides derived from protein hydrolysates pph obtained from zingiber cassumunar rhizomes phlai to replicate the conditions of gastrointestinal digestion a combination of pepsin and pancreatin proteolysis was employed to generate these hydrolysates subsequently the hydrolysate underwent fractionation using molecular weight cutoff membranes at 10 5 3 and 065 kda the fraction with a molecular weight less than 065 kda exhibited the highest levels abts dpph frap and no radical scavenging activity following this rphplc was used to further separate the fraction with a molecular weight less than 065 kda into three subfractions among these the f5 subfraction displayed the most prominent radicalscavenging properties de novo peptide sequencing via quadrupoletimeofflightelectron spin inductionmass spectrometry identified a pair of novel peptides aspglyilephevalleuasntyr dgifvlny or dy8 and ileprothraspglulys iptdek or ik6 database analysis confirmed various properties including biological activity toxicity hydrophilicity solubility and potential allergy concerns furthermore when tested on the human adenocarcinoma colon caco2 cell line two synthetic peptides demonstrated cellular antioxidant activity in a concentrationdependent manner these peptides were also assessed using the fitc annexin v apoptosis detection kit with pi confirming the induction of apoptosis notably the dy8 peptide induced apoptosis upregulated mrna levels of caspase3 8 and 9 and downregulated bcl2 as confirmed by realtime quantitative polymerase chain reaction rtqpcr western blot analysis indicated increased proapoptotic bax expression and decreased antiapoptotic bcl2 expression in caco2 cells exposed to the dy8 peptide molecular docking analysis revealed that the dy8 peptide exhibited binding affinity with bcl2 bclxl and mcl1 suggesting potential utility in combating colon cancer as functional food ingredients,"['this', 'paper', 'presents', 'the', 'initial', 'exploration', 'of', 'the', 'free', 'radical', 'scavenging', 'capabilities', 'of', 'peptides', 'derived', 'from', 'protein', 'hydrolysates', 'pph', 'obtained', 'from', 'zingiber', 'cassumunar', 'rhizomes', 'phlai', 'to', 'replicate', 'the', 'conditions', 'of', 'gastrointestinal', 'digestion', 'a', 'combination', 'of', 'pepsin', 'and', 'pancreatin', 'proteolysis', 'was', 'employed', 'to', 'generate', 'these', 'hydrolysates', 'subsequently', 'the', 'hydrolysate', 'underwent', 'fractionation', 'using', 'molecular', 'weight', 'cutoff', 'membranes', 'at', '10', '5', '3', 'and', '065', 'kda', 'the', 'fraction', 'with', 'a', 'molecular', 'weight', 'less', 'than', '065', 'kda', 'exhibited', 'the', 'highest', 'levels', 'abts', 'dpph', 'frap', 'and', 'no', 'radical', 'scavenging', 'activity', 'following', 'this', 'rphplc', 'was', 'used', 'to', 'further', 'separate', 'the', 'fraction', 'with', 'a', 'molecular', 'weight', 'less', 'than', '065', 'kda', 'into', 'three', 'subfractions', 'among', 'these', 'the', 'f5', 'subfraction', 'displayed', 'the', 'most', 'prominent', 'radicalscavenging', 'properties', 'de', 'novo', 'peptide', 'sequencing', 'via', 'quadrupoletimeofflightelectron', 'spin', 'inductionmass', 'spectrometry', 'identified', 'a', 'pair', 'of', 'novel', 'peptides', 'aspglyilephevalleuasntyr', 'dgifvlny', 'or', 'dy8', 'and', 'ileprothraspglulys', 'iptdek', 'or', 'ik6', 'database', 'analysis', 'confirmed', 'various', 'properties', 'including', 'biological', 'activity', 'toxicity', 'hydrophilicity', 'solubility', 'and', 'potential', 'allergy', 'concerns', 'furthermore', 'when', 'tested', 'on', 'the', 'human', 'adenocarcinoma', 'colon', 'caco2', 'cell', 'line', 'two', 'synthetic', 'peptides', 'demonstrated', 'cellular', 'antioxidant', 'activity', 'in', 'a', 'concentrationdependent', 'manner', 'these', 'peptides', 'were', 'also', 'assessed', 'using', 'the', 'fitc', 'annexin', 'v', 'apoptosis', 'detection', 'kit', 'with', 'pi', 'confirming', 'the', 'induction', 'of', 'apoptosis', 'notably', 'the', 'dy8', 'peptide', 'induced', 'apoptosis', 'upregulated', 'mrna', 'levels', 'of', 'caspase3', '8', 'and', '9', 'and', 'downregulated', 'bcl2', 'as', 'confirmed', 'by', 'realtime', 'quantitative', 'polymerase', 'chain', 'reaction', 'rtqpcr', 'western', 'blot', 'analysis', 'indicated', 'increased', 'proapoptotic', 'bax', 'expression', 'and', 'decreased', 'antiapoptotic', 'bcl2', 'expression', 'in', 'caco2', 'cells', 'exposed', 'to', 'the', 'dy8', 'peptide', 'molecular', 'docking', 'analysis', 'revealed', 'that', 'the', 'dy8', 'peptide', 'exhibited', 'binding', 'affinity', 'with', 'bcl2', 'bclxl', 'and', 'mcl1', 'suggesting', 'potential', 'utility', 'in', 'combating', 'colon', 'cancer', 'as', 'functional', 'food', 'ingredients']","['paper', 'presents', 'initial', 'exploration', 'free', 'radical', 'scavenging', 'capabilities', 'peptides', 'derived', 'protein', 'hydrolysates', 'pph', 'obtained', 'zingiber', 'cassumunar', 'rhizomes', 'phlai', 'replicate', 'conditions', 'gastrointestinal', 'digestion', 'combination', 'pepsin', 'pancreatin', 'proteolysis', 'employed', 'generate', 'hydrolysates', 'subsequently', 'hydrolysate', 'underwent', 'fractionation', 'using', 'molecular', 'weight', 'cutoff', 'membranes', '10', '5', '3', '065', 'kda', 'fraction', 'molecular', 'weight', 'less', '065', 'kda', 'exhibited', 'highest', 'levels', 'abts', 'dpph', 'frap', 'radical', 'scavenging', 'activity', 'following', 'rphplc', 'used', 'separate', 'fraction', 'molecular', 'weight', 'less', '065', 'kda', 'three', 'subfractions', 'among', 'f5', 'subfraction', 'displayed', 'prominent', 'radicalscavenging', 'properties', 'de', 'novo', 'peptide', 'sequencing', 'via', 'quadrupoletimeofflightelectron', 'spin', 'inductionmass', 'spectrometry', 'identified', 'pair', 'novel', 'peptides', 'aspglyilephevalleuasntyr', 'dgifvlny', 'dy8', 'ileprothraspglulys', 'iptdek', 'ik6', 'database', 'analysis', 'confirmed', 'various', 'properties', 'including', 'biological', 'activity', 'toxicity', 'hydrophilicity', 'solubility', 'potential', 'allergy', 'concerns', 'furthermore', 'tested', 'human', 'adenocarcinoma', 'colon', 'caco2', 'cell', 'line', 'two', 'synthetic', 'peptides', 'demonstrated', 'cellular', 'antioxidant', 'activity', 'concentrationdependent', 'manner', 'peptides', 'also', 'assessed', 'using', 'fitc', 'annexin', 'v', 'apoptosis', 'detection', 'kit', 'pi', 'confirming', 'induction', 'apoptosis', 'notably', 'dy8', 'peptide', 'induced', 'apoptosis', 'upregulated', 'mrna', 'levels', 'caspase3', '8', '9', 'downregulated', 'bcl2', 'confirmed', 'realtime', 'quantitative', 'polymerase', 'chain', 'reaction', 'rtqpcr', 'western', 'blot', 'analysis', 'indicated', 'increased', 'proapoptotic', 'bax', 'expression', 'decreased', 'antiapoptotic', 'bcl2', 'expression', 'caco2', 'cells', 'exposed', 'dy8', 'peptide', 'molecular', 'docking', 'analysis', 'revealed', 'dy8', 'peptide', 'exhibited', 'binding', 'affinity', 'bcl2', 'bclxl', 'mcl1', 'suggesting', 'potential', 'utility', 'combating', 'colon', 'cancer', 'functional', 'food', 'ingredients']","['pph', 'pancreatin', 'annexin', 'caspase3', 'bcl2', 'bax', 'bcl2', 'bcl2', 'bclxl', 'mcl1']","['caspase3', 'bclxl']",False,['cancer']
38839973,Novel peptide inhibitor of human tumor necrosis factor-α has antiarthritic activity.,"The inhibition of tumor necrosis factor (TNF)-α trimer formation renders it inactive for binding to its receptors, thus mitigating the vicious cycle of inflammation. We designed a peptide (PIYLGGVFQ) that simulates a sequence strand of human TNFα monomer using a series of in silico methods, such as active site finding (Acsite), protein-protein interaction (PPI), docking studies (GOLD and Flex-X) followed by molecular dynamics (MD) simulation studies. The MD studies confirmed the intermolecular interaction of the peptide with the TNFα. Fluorescence-activated cell sorting and fluorescence microscopy revealed that the peptide effectively inhibited the binding of TNF to the cell surface receptors. The cell culture assays showed that the peptide significantly inhibited the TNFα-mediated cell death. In addition, the nuclear translocation of the nuclear factor kappa B (NFκB) was significantly suppressed in the peptide-treated A549 cells, as observed in immunofluorescence and gel mobility-shift assays. Furthermore, the peptide protected against joint damage in the collagen-induced arthritis (CIA) mouse model, as revealed in the micro focal-CT scans. In conclusion, this TNFα antagonist would be helpful for the prevention and repair of inflammatory bone destruction and subsequent loss in the mouse model of CIA as well as human rheumatoid arthritis (RA) patients. This calls upon further clinical investigation to utilize its potential effect as an antiarthritic drug.",2024-06-05,the inhibition of tumor necrosis factor tnfα trimer formation renders it inactive for binding to its receptors thus mitigating the vicious cycle of inflammation we designed a peptide piylggvfq that simulates a sequence strand of human tnfα monomer using a series of in silico methods such as active site finding acsite proteinprotein interaction ppi docking studies gold and flexx followed by molecular dynamics md simulation studies the md studies confirmed the intermolecular interaction of the peptide with the tnfα fluorescenceactivated cell sorting and fluorescence microscopy revealed that the peptide effectively inhibited the binding of tnf to the cell surface receptors the cell culture assays showed that the peptide significantly inhibited the tnfαmediated cell death in addition the nuclear translocation of the nuclear factor kappa b nfκb was significantly suppressed in the peptidetreated a549 cells as observed in immunofluorescence and gel mobilityshift assays furthermore the peptide protected against joint damage in the collageninduced arthritis cia mouse model as revealed in the micro focalct scans in conclusion this tnfα antagonist would be helpful for the prevention and repair of inflammatory bone destruction and subsequent loss in the mouse model of cia as well as human rheumatoid arthritis ra patients this calls upon further clinical investigation to utilize its potential effect as an antiarthritic drug,"['the', 'inhibition', 'of', 'tumor', 'necrosis', 'factor', 'tnfα', 'trimer', 'formation', 'renders', 'it', 'inactive', 'for', 'binding', 'to', 'its', 'receptors', 'thus', 'mitigating', 'the', 'vicious', 'cycle', 'of', 'inflammation', 'we', 'designed', 'a', 'peptide', 'piylggvfq', 'that', 'simulates', 'a', 'sequence', 'strand', 'of', 'human', 'tnfα', 'monomer', 'using', 'a', 'series', 'of', 'in', 'silico', 'methods', 'such', 'as', 'active', 'site', 'finding', 'acsite', 'proteinprotein', 'interaction', 'ppi', 'docking', 'studies', 'gold', 'and', 'flexx', 'followed', 'by', 'molecular', 'dynamics', 'md', 'simulation', 'studies', 'the', 'md', 'studies', 'confirmed', 'the', 'intermolecular', 'interaction', 'of', 'the', 'peptide', 'with', 'the', 'tnfα', 'fluorescenceactivated', 'cell', 'sorting', 'and', 'fluorescence', 'microscopy', 'revealed', 'that', 'the', 'peptide', 'effectively', 'inhibited', 'the', 'binding', 'of', 'tnf', 'to', 'the', 'cell', 'surface', 'receptors', 'the', 'cell', 'culture', 'assays', 'showed', 'that', 'the', 'peptide', 'significantly', 'inhibited', 'the', 'tnfαmediated', 'cell', 'death', 'in', 'addition', 'the', 'nuclear', 'translocation', 'of', 'the', 'nuclear', 'factor', 'kappa', 'b', 'nfκb', 'was', 'significantly', 'suppressed', 'in', 'the', 'peptidetreated', 'a549', 'cells', 'as', 'observed', 'in', 'immunofluorescence', 'and', 'gel', 'mobilityshift', 'assays', 'furthermore', 'the', 'peptide', 'protected', 'against', 'joint', 'damage', 'in', 'the', 'collageninduced', 'arthritis', 'cia', 'mouse', 'model', 'as', 'revealed', 'in', 'the', 'micro', 'focalct', 'scans', 'in', 'conclusion', 'this', 'tnfα', 'antagonist', 'would', 'be', 'helpful', 'for', 'the', 'prevention', 'and', 'repair', 'of', 'inflammatory', 'bone', 'destruction', 'and', 'subsequent', 'loss', 'in', 'the', 'mouse', 'model', 'of', 'cia', 'as', 'well', 'as', 'human', 'rheumatoid', 'arthritis', 'ra', 'patients', 'this', 'calls', 'upon', 'further', 'clinical', 'investigation', 'to', 'utilize', 'its', 'potential', 'effect', 'as', 'an', 'antiarthritic', 'drug']","['inhibition', 'tumor', 'necrosis', 'factor', 'tnfα', 'trimer', 'formation', 'renders', 'inactive', 'binding', 'receptors', 'thus', 'mitigating', 'vicious', 'cycle', 'inflammation', 'designed', 'peptide', 'piylggvfq', 'simulates', 'sequence', 'strand', 'human', 'tnfα', 'monomer', 'using', 'series', 'silico', 'methods', 'active', 'site', 'finding', 'acsite', 'proteinprotein', 'interaction', 'ppi', 'docking', 'studies', 'gold', 'flexx', 'followed', 'molecular', 'dynamics', 'md', 'simulation', 'studies', 'md', 'studies', 'confirmed', 'intermolecular', 'interaction', 'peptide', 'tnfα', 'fluorescenceactivated', 'cell', 'sorting', 'fluorescence', 'microscopy', 'revealed', 'peptide', 'effectively', 'inhibited', 'binding', 'tnf', 'cell', 'surface', 'receptors', 'cell', 'culture', 'assays', 'showed', 'peptide', 'significantly', 'inhibited', 'tnfαmediated', 'cell', 'death', 'addition', 'nuclear', 'translocation', 'nuclear', 'factor', 'kappa', 'b', 'nfκb', 'significantly', 'suppressed', 'peptidetreated', 'a549', 'cells', 'observed', 'immunofluorescence', 'gel', 'mobilityshift', 'assays', 'furthermore', 'peptide', 'protected', 'joint', 'damage', 'collageninduced', 'arthritis', 'cia', 'mouse', 'model', 'revealed', 'micro', 'focalct', 'scans', 'conclusion', 'tnfα', 'antagonist', 'would', 'helpful', 'prevention', 'repair', 'inflammatory', 'bone', 'destruction', 'subsequent', 'loss', 'mouse', 'model', 'cia', 'well', 'human', 'rheumatoid', 'arthritis', 'ra', 'patients', 'calls', 'upon', 'clinical', 'investigation', 'utilize', 'potential', 'effect', 'antiarthritic', 'drug']","['tnf', 'ra']",['ra'],True,"['tumor', 'arthritis']"
38690856,Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer.,"The mediator kinases CDK8 and CDK19 control the dynamic transcription of selected genes in response to various signals and have been shown to be hijacked to sustain hyperproliferation by various solid and liquid tumors. CDK8/19 is emerging as a promising anticancer therapeutic target. Here, we report the discovery of compound <b>12</b>, a novel small molecule CDK8/19 inhibitor. This molecule demonstrated not only decent enzymatic and cellular activities but also remarkable selectivity in CDK and kinome panels. Besides, compound <b>12</b> also displayed favorable ADME profiles including low CYP1A2 inhibition, acceptable clearance, and high oral bioavailability in multiple preclinical species. Robust in vivo PD and efficacy studies in mice models further demonstrated its potential use as mono- and combination therapy for the treatment of cancers.",2024-05-01,the mediator kinases cdk8 and cdk19 control the dynamic transcription of selected genes in response to various signals and have been shown to be hijacked to sustain hyperproliferation by various solid and liquid tumors cdk819 is emerging as a promising anticancer therapeutic target here we report the discovery of compound b12b a novel small molecule cdk819 inhibitor this molecule demonstrated not only decent enzymatic and cellular activities but also remarkable selectivity in cdk and kinome panels besides compound b12b also displayed favorable adme profiles including low cyp1a2 inhibition acceptable clearance and high oral bioavailability in multiple preclinical species robust in vivo pd and efficacy studies in mice models further demonstrated its potential use as mono and combination therapy for the treatment of cancers,"['the', 'mediator', 'kinases', 'cdk8', 'and', 'cdk19', 'control', 'the', 'dynamic', 'transcription', 'of', 'selected', 'genes', 'in', 'response', 'to', 'various', 'signals', 'and', 'have', 'been', 'shown', 'to', 'be', 'hijacked', 'to', 'sustain', 'hyperproliferation', 'by', 'various', 'solid', 'and', 'liquid', 'tumors', 'cdk819', 'is', 'emerging', 'as', 'a', 'promising', 'anticancer', 'therapeutic', 'target', 'here', 'we', 'report', 'the', 'discovery', 'of', 'compound', 'b12b', 'a', 'novel', 'small', 'molecule', 'cdk819', 'inhibitor', 'this', 'molecule', 'demonstrated', 'not', 'only', 'decent', 'enzymatic', 'and', 'cellular', 'activities', 'but', 'also', 'remarkable', 'selectivity', 'in', 'cdk', 'and', 'kinome', 'panels', 'besides', 'compound', 'b12b', 'also', 'displayed', 'favorable', 'adme', 'profiles', 'including', 'low', 'cyp1a2', 'inhibition', 'acceptable', 'clearance', 'and', 'high', 'oral', 'bioavailability', 'in', 'multiple', 'preclinical', 'species', 'robust', 'in', 'vivo', 'pd', 'and', 'efficacy', 'studies', 'in', 'mice', 'models', 'further', 'demonstrated', 'its', 'potential', 'use', 'as', 'mono', 'and', 'combination', 'therapy', 'for', 'the', 'treatment', 'of', 'cancers']","['mediator', 'kinases', 'cdk8', 'cdk19', 'control', 'dynamic', 'transcription', 'selected', 'genes', 'response', 'various', 'signals', 'shown', 'hijacked', 'sustain', 'hyperproliferation', 'various', 'solid', 'liquid', 'tumors', 'cdk819', 'emerging', 'promising', 'anticancer', 'therapeutic', 'target', 'report', 'discovery', 'compound', 'b12b', 'novel', 'small', 'molecule', 'cdk819', 'inhibitor', 'molecule', 'demonstrated', 'decent', 'enzymatic', 'cellular', 'activities', 'also', 'remarkable', 'selectivity', 'cdk', 'kinome', 'panels', 'besides', 'compound', 'b12b', 'also', 'displayed', 'favorable', 'adme', 'profiles', 'including', 'low', 'cyp1a2', 'inhibition', 'acceptable', 'clearance', 'high', 'oral', 'bioavailability', 'multiple', 'preclinical', 'species', 'robust', 'vivo', 'pd', 'efficacy', 'studies', 'mice', 'models', 'demonstrated', 'potential', 'use', 'mono', 'combination', 'therapy', 'treatment', 'cancers']","['cdk8', 'cdk', 'cyp1a2']",['cyp1a2'],True,"['tumor', 'cancer']"
38675451,Discovery of Small Molecule Glycolytic Stimulants for Enhanced ApoE Lipidation in Alzheimer's Disease Cell Model.,"Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by pathophysiological deposits of extracellular amyloid beta (Aβ) peptides and intracellular neurofibrillary tangles of tau. The central role of Aβ in AD pathology is well-established, with its increased deposition attributed mainly to its decreased cerebral clearance. Here, it is noteworthy that apolipoprotein E (ApoE), the most significant risk factor for AD, has been shown to play an isoform-specific role in clearing Aβ deposits (ApoE2 > ApoE3 > ApoE4), owing mainly to its lipidation status. In addition to the pathophysiological Aβ deposits, AD is also characterized by abnormal glucose metabolism, which is a distinct event preceding Aβ deposition. The present study established, for the first time, a possible link between these two major AD etiologies, with glucose metabolism directly influencing ApoE lipidation and its secretion by astrocytes expressing human ApoE4. Specifically, glucose dose-dependently activated liver X receptor (LXR), leading to elevated ABCA1 and ABCG1 protein levels and enhanced ApoE lipidation. Moreover, co-treatment with a glycolytic inhibitor significantly inhibited this LXR activation and subsequent ApoE lipidation, further supporting a central role of glucose metabolism in LXR activation leading to enhanced ApoE lipidation, which may help against AD through potential Aβ clearance. Therefore, we hypothesized that pharmacological agents that can target cellular energy metabolism, specifically aerobic glycolysis, may hold significant therapeutic potential against AD. In this context, the present study also led to the discovery of novel, small-molecule stimulants of astrocytic glucose metabolism, leading to significantly enhanced lipidation status of ApoE4 in astrocytic cells. Three such newly discovered compounds (lonidamine, phenformin, and berberine), owing to their promising cellular effect on the glycolysis-ApoE nexus, warrant further investigation in suitable in vivo models of AD.",2024-04-12,alzheimers disease ad is a progressive neurodegenerative disease characterized by pathophysiological deposits of extracellular amyloid beta aβ peptides and intracellular neurofibrillary tangles of tau the central role of aβ in ad pathology is wellestablished with its increased deposition attributed mainly to its decreased cerebral clearance here it is noteworthy that apolipoprotein e apoe the most significant risk factor for ad has been shown to play an isoformspecific role in clearing aβ deposits apoe2  apoe3  apoe4 owing mainly to its lipidation status in addition to the pathophysiological aβ deposits ad is also characterized by abnormal glucose metabolism which is a distinct event preceding aβ deposition the present study established for the first time a possible link between these two major ad etiologies with glucose metabolism directly influencing apoe lipidation and its secretion by astrocytes expressing human apoe4 specifically glucose dosedependently activated liver x receptor lxr leading to elevated abca1 and abcg1 protein levels and enhanced apoe lipidation moreover cotreatment with a glycolytic inhibitor significantly inhibited this lxr activation and subsequent apoe lipidation further supporting a central role of glucose metabolism in lxr activation leading to enhanced apoe lipidation which may help against ad through potential aβ clearance therefore we hypothesized that pharmacological agents that can target cellular energy metabolism specifically aerobic glycolysis may hold significant therapeutic potential against ad in this context the present study also led to the discovery of novel smallmolecule stimulants of astrocytic glucose metabolism leading to significantly enhanced lipidation status of apoe4 in astrocytic cells three such newly discovered compounds lonidamine phenformin and berberine owing to their promising cellular effect on the glycolysisapoe nexus warrant further investigation in suitable in vivo models of ad,"['alzheimers', 'disease', 'ad', 'is', 'a', 'progressive', 'neurodegenerative', 'disease', 'characterized', 'by', 'pathophysiological', 'deposits', 'of', 'extracellular', 'amyloid', 'beta', 'aβ', 'peptides', 'and', 'intracellular', 'neurofibrillary', 'tangles', 'of', 'tau', 'the', 'central', 'role', 'of', 'aβ', 'in', 'ad', 'pathology', 'is', 'wellestablished', 'with', 'its', 'increased', 'deposition', 'attributed', 'mainly', 'to', 'its', 'decreased', 'cerebral', 'clearance', 'here', 'it', 'is', 'noteworthy', 'that', 'apolipoprotein', 'e', 'apoe', 'the', 'most', 'significant', 'risk', 'factor', 'for', 'ad', 'has', 'been', 'shown', 'to', 'play', 'an', 'isoformspecific', 'role', 'in', 'clearing', 'aβ', 'deposits', 'apoe2', 'apoe3', 'apoe4', 'owing', 'mainly', 'to', 'its', 'lipidation', 'status', 'in', 'addition', 'to', 'the', 'pathophysiological', 'aβ', 'deposits', 'ad', 'is', 'also', 'characterized', 'by', 'abnormal', 'glucose', 'metabolism', 'which', 'is', 'a', 'distinct', 'event', 'preceding', 'aβ', 'deposition', 'the', 'present', 'study', 'established', 'for', 'the', 'first', 'time', 'a', 'possible', 'link', 'between', 'these', 'two', 'major', 'ad', 'etiologies', 'with', 'glucose', 'metabolism', 'directly', 'influencing', 'apoe', 'lipidation', 'and', 'its', 'secretion', 'by', 'astrocytes', 'expressing', 'human', 'apoe4', 'specifically', 'glucose', 'dosedependently', 'activated', 'liver', 'x', 'receptor', 'lxr', 'leading', 'to', 'elevated', 'abca1', 'and', 'abcg1', 'protein', 'levels', 'and', 'enhanced', 'apoe', 'lipidation', 'moreover', 'cotreatment', 'with', 'a', 'glycolytic', 'inhibitor', 'significantly', 'inhibited', 'this', 'lxr', 'activation', 'and', 'subsequent', 'apoe', 'lipidation', 'further', 'supporting', 'a', 'central', 'role', 'of', 'glucose', 'metabolism', 'in', 'lxr', 'activation', 'leading', 'to', 'enhanced', 'apoe', 'lipidation', 'which', 'may', 'help', 'against', 'ad', 'through', 'potential', 'aβ', 'clearance', 'therefore', 'we', 'hypothesized', 'that', 'pharmacological', 'agents', 'that', 'can', 'target', 'cellular', 'energy', 'metabolism', 'specifically', 'aerobic', 'glycolysis', 'may', 'hold', 'significant', 'therapeutic', 'potential', 'against', 'ad', 'in', 'this', 'context', 'the', 'present', 'study', 'also', 'led', 'to', 'the', 'discovery', 'of', 'novel', 'smallmolecule', 'stimulants', 'of', 'astrocytic', 'glucose', 'metabolism', 'leading', 'to', 'significantly', 'enhanced', 'lipidation', 'status', 'of', 'apoe4', 'in', 'astrocytic', 'cells', 'three', 'such', 'newly', 'discovered', 'compounds', 'lonidamine', 'phenformin', 'and', 'berberine', 'owing', 'to', 'their', 'promising', 'cellular', 'effect', 'on', 'the', 'glycolysisapoe', 'nexus', 'warrant', 'further', 'investigation', 'in', 'suitable', 'in', 'vivo', 'models', 'of', 'ad']","['alzheimers', 'disease', 'ad', 'progressive', 'neurodegenerative', 'disease', 'characterized', 'pathophysiological', 'deposits', 'extracellular', 'amyloid', 'beta', 'aβ', 'peptides', 'intracellular', 'neurofibrillary', 'tangles', 'tau', 'central', 'role', 'aβ', 'ad', 'pathology', 'wellestablished', 'increased', 'deposition', 'attributed', 'mainly', 'decreased', 'cerebral', 'clearance', 'noteworthy', 'apolipoprotein', 'e', 'apoe', 'significant', 'risk', 'factor', 'ad', 'shown', 'play', 'isoformspecific', 'role', 'clearing', 'aβ', 'deposits', 'apoe2', 'apoe3', 'apoe4', 'owing', 'mainly', 'lipidation', 'status', 'addition', 'pathophysiological', 'aβ', 'deposits', 'ad', 'also', 'characterized', 'abnormal', 'glucose', 'metabolism', 'distinct', 'event', 'preceding', 'aβ', 'deposition', 'present', 'study', 'established', 'first', 'time', 'possible', 'link', 'two', 'major', 'ad', 'etiologies', 'glucose', 'metabolism', 'directly', 'influencing', 'apoe', 'lipidation', 'secretion', 'astrocytes', 'expressing', 'human', 'apoe4', 'specifically', 'glucose', 'dosedependently', 'activated', 'liver', 'x', 'receptor', 'lxr', 'leading', 'elevated', 'abca1', 'abcg1', 'protein', 'levels', 'enhanced', 'apoe', 'lipidation', 'moreover', 'cotreatment', 'glycolytic', 'inhibitor', 'significantly', 'inhibited', 'lxr', 'activation', 'subsequent', 'apoe', 'lipidation', 'supporting', 'central', 'role', 'glucose', 'metabolism', 'lxr', 'activation', 'leading', 'enhanced', 'apoe', 'lipidation', 'may', 'help', 'ad', 'potential', 'aβ', 'clearance', 'therefore', 'hypothesized', 'pharmacological', 'agents', 'target', 'cellular', 'energy', 'metabolism', 'specifically', 'aerobic', 'glycolysis', 'may', 'hold', 'significant', 'therapeutic', 'potential', 'ad', 'context', 'present', 'study', 'also', 'led', 'discovery', 'novel', 'smallmolecule', 'stimulants', 'astrocytic', 'glucose', 'metabolism', 'leading', 'significantly', 'enhanced', 'lipidation', 'status', 'apoe4', 'astrocytic', 'cells', 'three', 'newly', 'discovered', 'compounds', 'lonidamine', 'phenformin', 'berberine', 'owing', 'promising', 'cellular', 'effect', 'glycolysisapoe', 'nexus', 'warrant', 'investigation', 'suitable', 'vivo', 'models', 'ad']","['beta', 'tau', 'apolipoprotein', 'apoe', 'isoformspecific', 'apoe', 'lxr', 'abca1', 'abcg1', 'apoe', 'lxr', 'apoe', 'lxr', 'apoe']","['apolipoprotein', 'isoformspecific', 'abca1', 'abcg1']",True,['alzheimer']
38645276,Restoring cellular copper homeostasis in Alzheimer disease: a novel peptide shuttle is internalized by an ATP-dependent endocytosis pathway involving Rab5- and Rab14-endosomes.,"CPPs, or Cell-Penetrating Peptides, offer invaluable utility in disease treatment due to their ability to transport various therapeutic molecules across cellular membranes. Their unique characteristics, such as biocompatibility and low immunogenicity, make them ideal candidates for delivering drugs, genes, or imaging agents directly into cells. This targeted delivery enhances treatment efficacy while minimizing systemic side effects. CPPs exhibit versatility, crossing biological barriers and reaching intracellular targets that conventional drugs struggle to access. This capability holds promise in treating a wide array of diseases, including cancer, neurodegenerative disorders, and infectious diseases, offering a potent avenue for innovative and targeted therapies, yet their precise mechanism of cell entry is far from being fully understood. In order to correct Cu dysregulation found in various pathologies such as Alzheimer disease, we have recently conceived a peptide Cu(II) shuttle, based on the αR5W4 CPP, which, when bound to Cu(II), is able to readily enter a neurosecretory cell model, and release bioavailable Cu in cells. Furthermore, this shuttle has the capacity to protect cells in culture against oxidative stress-induced damage which occurs when Cu binds to the Aβ peptide. The aim of this study was therefore to characterize the cell entry route used by this shuttle and determine in which compartment Cu is released. Pharmacological treatments, siRNA silencing and colocalization experiments with GFP-Rab fusion proteins, indicate that the shuttle is internalized by an ATP-dependent endocytosis pathway involving both Rab5 and Rab14 endosomes route and suggest an early release of Cu from the shuttle.",2024-04-05,cpps or cellpenetrating peptides offer invaluable utility in disease treatment due to their ability to transport various therapeutic molecules across cellular membranes their unique characteristics such as biocompatibility and low immunogenicity make them ideal candidates for delivering drugs genes or imaging agents directly into cells this targeted delivery enhances treatment efficacy while minimizing systemic side effects cpps exhibit versatility crossing biological barriers and reaching intracellular targets that conventional drugs struggle to access this capability holds promise in treating a wide array of diseases including cancer neurodegenerative disorders and infectious diseases offering a potent avenue for innovative and targeted therapies yet their precise mechanism of cell entry is far from being fully understood in order to correct cu dysregulation found in various pathologies such as alzheimer disease we have recently conceived a peptide cuii shuttle based on the αr5w4 cpp which when bound to cuii is able to readily enter a neurosecretory cell model and release bioavailable cu in cells furthermore this shuttle has the capacity to protect cells in culture against oxidative stressinduced damage which occurs when cu binds to the aβ peptide the aim of this study was therefore to characterize the cell entry route used by this shuttle and determine in which compartment cu is released pharmacological treatments sirna silencing and colocalization experiments with gfprab fusion proteins indicate that the shuttle is internalized by an atpdependent endocytosis pathway involving both rab5 and rab14 endosomes route and suggest an early release of cu from the shuttle,"['cpps', 'or', 'cellpenetrating', 'peptides', 'offer', 'invaluable', 'utility', 'in', 'disease', 'treatment', 'due', 'to', 'their', 'ability', 'to', 'transport', 'various', 'therapeutic', 'molecules', 'across', 'cellular', 'membranes', 'their', 'unique', 'characteristics', 'such', 'as', 'biocompatibility', 'and', 'low', 'immunogenicity', 'make', 'them', 'ideal', 'candidates', 'for', 'delivering', 'drugs', 'genes', 'or', 'imaging', 'agents', 'directly', 'into', 'cells', 'this', 'targeted', 'delivery', 'enhances', 'treatment', 'efficacy', 'while', 'minimizing', 'systemic', 'side', 'effects', 'cpps', 'exhibit', 'versatility', 'crossing', 'biological', 'barriers', 'and', 'reaching', 'intracellular', 'targets', 'that', 'conventional', 'drugs', 'struggle', 'to', 'access', 'this', 'capability', 'holds', 'promise', 'in', 'treating', 'a', 'wide', 'array', 'of', 'diseases', 'including', 'cancer', 'neurodegenerative', 'disorders', 'and', 'infectious', 'diseases', 'offering', 'a', 'potent', 'avenue', 'for', 'innovative', 'and', 'targeted', 'therapies', 'yet', 'their', 'precise', 'mechanism', 'of', 'cell', 'entry', 'is', 'far', 'from', 'being', 'fully', 'understood', 'in', 'order', 'to', 'correct', 'cu', 'dysregulation', 'found', 'in', 'various', 'pathologies', 'such', 'as', 'alzheimer', 'disease', 'we', 'have', 'recently', 'conceived', 'a', 'peptide', 'cuii', 'shuttle', 'based', 'on', 'the', 'αr5w4', 'cpp', 'which', 'when', 'bound', 'to', 'cuii', 'is', 'able', 'to', 'readily', 'enter', 'a', 'neurosecretory', 'cell', 'model', 'and', 'release', 'bioavailable', 'cu', 'in', 'cells', 'furthermore', 'this', 'shuttle', 'has', 'the', 'capacity', 'to', 'protect', 'cells', 'in', 'culture', 'against', 'oxidative', 'stressinduced', 'damage', 'which', 'occurs', 'when', 'cu', 'binds', 'to', 'the', 'aβ', 'peptide', 'the', 'aim', 'of', 'this', 'study', 'was', 'therefore', 'to', 'characterize', 'the', 'cell', 'entry', 'route', 'used', 'by', 'this', 'shuttle', 'and', 'determine', 'in', 'which', 'compartment', 'cu', 'is', 'released', 'pharmacological', 'treatments', 'sirna', 'silencing', 'and', 'colocalization', 'experiments', 'with', 'gfprab', 'fusion', 'proteins', 'indicate', 'that', 'the', 'shuttle', 'is', 'internalized', 'by', 'an', 'atpdependent', 'endocytosis', 'pathway', 'involving', 'both', 'rab5', 'and', 'rab14', 'endosomes', 'route', 'and', 'suggest', 'an', 'early', 'release', 'of', 'cu', 'from', 'the', 'shuttle']","['cpps', 'cellpenetrating', 'peptides', 'offer', 'invaluable', 'utility', 'disease', 'treatment', 'due', 'ability', 'transport', 'various', 'therapeutic', 'molecules', 'across', 'cellular', 'membranes', 'unique', 'characteristics', 'biocompatibility', 'low', 'immunogenicity', 'make', 'ideal', 'candidates', 'delivering', 'drugs', 'genes', 'imaging', 'agents', 'directly', 'cells', 'targeted', 'delivery', 'enhances', 'treatment', 'efficacy', 'minimizing', 'systemic', 'side', 'effects', 'cpps', 'exhibit', 'versatility', 'crossing', 'biological', 'barriers', 'reaching', 'intracellular', 'targets', 'conventional', 'drugs', 'struggle', 'access', 'capability', 'holds', 'promise', 'treating', 'wide', 'array', 'diseases', 'including', 'cancer', 'neurodegenerative', 'disorders', 'infectious', 'diseases', 'offering', 'potent', 'avenue', 'innovative', 'targeted', 'therapies', 'yet', 'precise', 'mechanism', 'cell', 'entry', 'far', 'fully', 'understood', 'order', 'correct', 'cu', 'dysregulation', 'found', 'various', 'pathologies', 'alzheimer', 'disease', 'recently', 'conceived', 'peptide', 'cuii', 'shuttle', 'based', 'αr5w4', 'cpp', 'bound', 'cuii', 'able', 'readily', 'enter', 'neurosecretory', 'cell', 'model', 'release', 'bioavailable', 'cu', 'cells', 'furthermore', 'shuttle', 'capacity', 'protect', 'cells', 'culture', 'oxidative', 'stressinduced', 'damage', 'occurs', 'cu', 'binds', 'aβ', 'peptide', 'aim', 'study', 'therefore', 'characterize', 'cell', 'entry', 'route', 'used', 'shuttle', 'determine', 'compartment', 'cu', 'released', 'pharmacological', 'treatments', 'sirna', 'silencing', 'colocalization', 'experiments', 'gfprab', 'fusion', 'proteins', 'indicate', 'shuttle', 'internalized', 'atpdependent', 'endocytosis', 'pathway', 'involving', 'rab5', 'rab14', 'endosomes', 'route', 'suggest', 'early', 'release', 'cu', 'shuttle']","['sirna', 'rab5', 'rab14']","['rab5', 'rab14']",True,"['cancer', 'alzheimer']"
38626518,Novel small molecule DMAMCL induces differentiation in rhabdomyosarcoma by downregulating of DLL1.,"Rhabdomyosarcoma (RMS), a mesenchymal tumor occurring in the soft tissue of children, is associated with a defect in differentiation. This study unveils a novel anti-tumor mechanism of dimethylaminomicheliolide (DMAMCL), which is a water-soluble derivative of Micheliolide. First, we demonstrate that DMAMCL inhibits RMS cell growth without obvious cell death, leading to morphological alterations, enhanced expression of muscle differentiation markers, and a shift from a malignant to a more benign metabolic phenotype. Second, we detected decreased expression of DLL1 in RMS cells after DMAMCL treatment, known as a pivotal ligand in the Notch signaling pathway. Downregulation of DLL1 inhibits RMS cell growth and induces morphological changes similar to the effects of DMAMCL. Furthermore, DMAMCL treatment or loss of DLL1 expression also inhibits RMS xenograft tumor growth and augmented the expression of differentiation markers. Surprisingly, in C2C12 cells DMAMCL treatment or DLL1 downregulation also induces cell growth inhibition and an elevation in muscle differentiation marker expression. These data indicated that DMAMCL induced RMS differentiation and DLL1 is an important factor for RMS differentiation, opening a new window for the clinical use of DMAMCL as an agent for differentiation-inducing therapy for RMS treatment.",2024-04-15,rhabdomyosarcoma rms a mesenchymal tumor occurring in the soft tissue of children is associated with a defect in differentiation this study unveils a novel antitumor mechanism of dimethylaminomicheliolide dmamcl which is a watersoluble derivative of micheliolide first we demonstrate that dmamcl inhibits rms cell growth without obvious cell death leading to morphological alterations enhanced expression of muscle differentiation markers and a shift from a malignant to a more benign metabolic phenotype second we detected decreased expression of dll1 in rms cells after dmamcl treatment known as a pivotal ligand in the notch signaling pathway downregulation of dll1 inhibits rms cell growth and induces morphological changes similar to the effects of dmamcl furthermore dmamcl treatment or loss of dll1 expression also inhibits rms xenograft tumor growth and augmented the expression of differentiation markers surprisingly in c2c12 cells dmamcl treatment or dll1 downregulation also induces cell growth inhibition and an elevation in muscle differentiation marker expression these data indicated that dmamcl induced rms differentiation and dll1 is an important factor for rms differentiation opening a new window for the clinical use of dmamcl as an agent for differentiationinducing therapy for rms treatment,"['rhabdomyosarcoma', 'rms', 'a', 'mesenchymal', 'tumor', 'occurring', 'in', 'the', 'soft', 'tissue', 'of', 'children', 'is', 'associated', 'with', 'a', 'defect', 'in', 'differentiation', 'this', 'study', 'unveils', 'a', 'novel', 'antitumor', 'mechanism', 'of', 'dimethylaminomicheliolide', 'dmamcl', 'which', 'is', 'a', 'watersoluble', 'derivative', 'of', 'micheliolide', 'first', 'we', 'demonstrate', 'that', 'dmamcl', 'inhibits', 'rms', 'cell', 'growth', 'without', 'obvious', 'cell', 'death', 'leading', 'to', 'morphological', 'alterations', 'enhanced', 'expression', 'of', 'muscle', 'differentiation', 'markers', 'and', 'a', 'shift', 'from', 'a', 'malignant', 'to', 'a', 'more', 'benign', 'metabolic', 'phenotype', 'second', 'we', 'detected', 'decreased', 'expression', 'of', 'dll1', 'in', 'rms', 'cells', 'after', 'dmamcl', 'treatment', 'known', 'as', 'a', 'pivotal', 'ligand', 'in', 'the', 'notch', 'signaling', 'pathway', 'downregulation', 'of', 'dll1', 'inhibits', 'rms', 'cell', 'growth', 'and', 'induces', 'morphological', 'changes', 'similar', 'to', 'the', 'effects', 'of', 'dmamcl', 'furthermore', 'dmamcl', 'treatment', 'or', 'loss', 'of', 'dll1', 'expression', 'also', 'inhibits', 'rms', 'xenograft', 'tumor', 'growth', 'and', 'augmented', 'the', 'expression', 'of', 'differentiation', 'markers', 'surprisingly', 'in', 'c2c12', 'cells', 'dmamcl', 'treatment', 'or', 'dll1', 'downregulation', 'also', 'induces', 'cell', 'growth', 'inhibition', 'and', 'an', 'elevation', 'in', 'muscle', 'differentiation', 'marker', 'expression', 'these', 'data', 'indicated', 'that', 'dmamcl', 'induced', 'rms', 'differentiation', 'and', 'dll1', 'is', 'an', 'important', 'factor', 'for', 'rms', 'differentiation', 'opening', 'a', 'new', 'window', 'for', 'the', 'clinical', 'use', 'of', 'dmamcl', 'as', 'an', 'agent', 'for', 'differentiationinducing', 'therapy', 'for', 'rms', 'treatment']","['rhabdomyosarcoma', 'rms', 'mesenchymal', 'tumor', 'occurring', 'soft', 'tissue', 'children', 'associated', 'defect', 'differentiation', 'study', 'unveils', 'novel', 'antitumor', 'mechanism', 'dimethylaminomicheliolide', 'dmamcl', 'watersoluble', 'derivative', 'micheliolide', 'first', 'demonstrate', 'dmamcl', 'inhibits', 'rms', 'cell', 'growth', 'without', 'obvious', 'cell', 'death', 'leading', 'morphological', 'alterations', 'enhanced', 'expression', 'muscle', 'differentiation', 'markers', 'shift', 'malignant', 'benign', 'metabolic', 'phenotype', 'second', 'detected', 'decreased', 'expression', 'dll1', 'rms', 'cells', 'dmamcl', 'treatment', 'known', 'pivotal', 'ligand', 'notch', 'signaling', 'pathway', 'downregulation', 'dll1', 'inhibits', 'rms', 'cell', 'growth', 'induces', 'morphological', 'changes', 'similar', 'effects', 'dmamcl', 'furthermore', 'dmamcl', 'treatment', 'loss', 'dll1', 'expression', 'also', 'inhibits', 'rms', 'xenograft', 'tumor', 'growth', 'augmented', 'expression', 'differentiation', 'markers', 'surprisingly', 'c2c12', 'cells', 'dmamcl', 'treatment', 'dll1', 'downregulation', 'also', 'induces', 'cell', 'growth', 'inhibition', 'elevation', 'muscle', 'differentiation', 'marker', 'expression', 'data', 'indicated', 'dmamcl', 'induced', 'rms', 'differentiation', 'dll1', 'important', 'factor', 'rms', 'differentiation', 'opening', 'new', 'window', 'clinical', 'use', 'dmamcl', 'agent', 'differentiationinducing', 'therapy', 'rms', 'treatment']","['dll1', 'dll1', 'dll1', 'dll1', 'dll1']","['dll1', 'dll1', 'dll1', 'dll1', 'dll1']",True,['tumor']
38611022,"The Therapeutic Efficacy and Mechanism of Action of Gnetin C, a Natural Compound from the Melinjo Plant, in a Preclinical Mouse Model of Advanced Prostate Cancer.","The metastasis-associated protein 1/protein kinase B (MTA1/AKT) signaling pathway has been shown to cooperate in promoting prostate tumor growth. Targeted interception strategies by plant-based polyphenols, specifically stilbenes, have shown great promise against MTA1-mediated prostate cancer progression. In this study, we employed a prostate-specific transgenic mouse model with MTA1 overexpression on the background of phosphatase and tensin homolog (<i>Pten</i>) null (<i>R26<sup>MTA1</sup></i>; <i>Pten<sup>f/f</sup></i>) and PC3M prostate cancer cells which recapitulate altered molecular pathways in advanced prostate cancer. Mechanistically, the MTA1 knockdown or pharmacological inhibition of MTA1 by gnetin C (dimer resveratrol) in cultured PC3M cells resulted in the marked inactivation of mammalian target of rapamycin (mTOR) signaling. In vivo, mice tolerated a daily intraperitoneal treatment of gnetin C (7 mg/kg bw) for 12 weeks without any sign of toxicity. Treatment with gnetin C markedly reduced cell proliferation and angiogenesis and promoted apoptosis in mice with advanced prostate cancer. Further, in addition to decreasing MTA1 levels in prostate epithelial cells, gnetin C significantly reduced mTOR signaling activity in prostate tissues, including the activity of mTOR-target proteins: p70 ribosomal protein S6 kinase (S6K) and eukaryotic translational initiation factor 4E (elF4E)-binding protein 1 (4EBP1). Collectively, these findings established gnetin C as a new natural compound with anticancer properties against MTA1/AKT/mTOR-activated prostate cancer, with potential as monotherapy and as a possible adjunct to clinically approved mTOR pathway inhibitors in the future.",2024-03-29,the metastasisassociated protein 1protein kinase b mta1akt signaling pathway has been shown to cooperate in promoting prostate tumor growth targeted interception strategies by plantbased polyphenols specifically stilbenes have shown great promise against mta1mediated prostate cancer progression in this study we employed a prostatespecific transgenic mouse model with mta1 overexpression on the background of phosphatase and tensin homolog ipteni null ir26supmta1supi iptensupffsupi and pc3m prostate cancer cells which recapitulate altered molecular pathways in advanced prostate cancer mechanistically the mta1 knockdown or pharmacological inhibition of mta1 by gnetin c dimer resveratrol in cultured pc3m cells resulted in the marked inactivation of mammalian target of rapamycin mtor signaling in vivo mice tolerated a daily intraperitoneal treatment of gnetin c 7 mgkg bw for 12 weeks without any sign of toxicity treatment with gnetin c markedly reduced cell proliferation and angiogenesis and promoted apoptosis in mice with advanced prostate cancer further in addition to decreasing mta1 levels in prostate epithelial cells gnetin c significantly reduced mtor signaling activity in prostate tissues including the activity of mtortarget proteins p70 ribosomal protein s6 kinase s6k and eukaryotic translational initiation factor 4e elf4ebinding protein 1 4ebp1 collectively these findings established gnetin c as a new natural compound with anticancer properties against mta1aktmtoractivated prostate cancer with potential as monotherapy and as a possible adjunct to clinically approved mtor pathway inhibitors in the future,"['the', 'metastasisassociated', 'protein', '1protein', 'kinase', 'b', 'mta1akt', 'signaling', 'pathway', 'has', 'been', 'shown', 'to', 'cooperate', 'in', 'promoting', 'prostate', 'tumor', 'growth', 'targeted', 'interception', 'strategies', 'by', 'plantbased', 'polyphenols', 'specifically', 'stilbenes', 'have', 'shown', 'great', 'promise', 'against', 'mta1mediated', 'prostate', 'cancer', 'progression', 'in', 'this', 'study', 'we', 'employed', 'a', 'prostatespecific', 'transgenic', 'mouse', 'model', 'with', 'mta1', 'overexpression', 'on', 'the', 'background', 'of', 'phosphatase', 'and', 'tensin', 'homolog', 'ipteni', 'null', 'ir26supmta1supi', 'iptensupffsupi', 'and', 'pc3m', 'prostate', 'cancer', 'cells', 'which', 'recapitulate', 'altered', 'molecular', 'pathways', 'in', 'advanced', 'prostate', 'cancer', 'mechanistically', 'the', 'mta1', 'knockdown', 'or', 'pharmacological', 'inhibition', 'of', 'mta1', 'by', 'gnetin', 'c', 'dimer', 'resveratrol', 'in', 'cultured', 'pc3m', 'cells', 'resulted', 'in', 'the', 'marked', 'inactivation', 'of', 'mammalian', 'target', 'of', 'rapamycin', 'mtor', 'signaling', 'in', 'vivo', 'mice', 'tolerated', 'a', 'daily', 'intraperitoneal', 'treatment', 'of', 'gnetin', 'c', '7', 'mgkg', 'bw', 'for', '12', 'weeks', 'without', 'any', 'sign', 'of', 'toxicity', 'treatment', 'with', 'gnetin', 'c', 'markedly', 'reduced', 'cell', 'proliferation', 'and', 'angiogenesis', 'and', 'promoted', 'apoptosis', 'in', 'mice', 'with', 'advanced', 'prostate', 'cancer', 'further', 'in', 'addition', 'to', 'decreasing', 'mta1', 'levels', 'in', 'prostate', 'epithelial', 'cells', 'gnetin', 'c', 'significantly', 'reduced', 'mtor', 'signaling', 'activity', 'in', 'prostate', 'tissues', 'including', 'the', 'activity', 'of', 'mtortarget', 'proteins', 'p70', 'ribosomal', 'protein', 's6', 'kinase', 's6k', 'and', 'eukaryotic', 'translational', 'initiation', 'factor', '4e', 'elf4ebinding', 'protein', '1', '4ebp1', 'collectively', 'these', 'findings', 'established', 'gnetin', 'c', 'as', 'a', 'new', 'natural', 'compound', 'with', 'anticancer', 'properties', 'against', 'mta1aktmtoractivated', 'prostate', 'cancer', 'with', 'potential', 'as', 'monotherapy', 'and', 'as', 'a', 'possible', 'adjunct', 'to', 'clinically', 'approved', 'mtor', 'pathway', 'inhibitors', 'in', 'the', 'future']","['metastasisassociated', 'protein', '1protein', 'kinase', 'b', 'mta1akt', 'signaling', 'pathway', 'shown', 'cooperate', 'promoting', 'prostate', 'tumor', 'growth', 'targeted', 'interception', 'strategies', 'plantbased', 'polyphenols', 'specifically', 'stilbenes', 'shown', 'great', 'promise', 'mta1mediated', 'prostate', 'cancer', 'progression', 'study', 'employed', 'prostatespecific', 'transgenic', 'mouse', 'model', 'mta1', 'overexpression', 'background', 'phosphatase', 'tensin', 'homolog', 'ipteni', 'null', 'ir26supmta1supi', 'iptensupffsupi', 'pc3m', 'prostate', 'cancer', 'cells', 'recapitulate', 'altered', 'molecular', 'pathways', 'advanced', 'prostate', 'cancer', 'mechanistically', 'mta1', 'knockdown', 'pharmacological', 'inhibition', 'mta1', 'gnetin', 'c', 'dimer', 'resveratrol', 'cultured', 'pc3m', 'cells', 'resulted', 'marked', 'inactivation', 'mammalian', 'target', 'rapamycin', 'mtor', 'signaling', 'vivo', 'mice', 'tolerated', 'daily', 'intraperitoneal', 'treatment', 'gnetin', 'c', '7', 'mgkg', 'bw', '12', 'weeks', 'without', 'sign', 'toxicity', 'treatment', 'gnetin', 'c', 'markedly', 'reduced', 'cell', 'proliferation', 'angiogenesis', 'promoted', 'apoptosis', 'mice', 'advanced', 'prostate', 'cancer', 'addition', 'decreasing', 'mta1', 'levels', 'prostate', 'epithelial', 'cells', 'gnetin', 'c', 'significantly', 'reduced', 'mtor', 'signaling', 'activity', 'prostate', 'tissues', 'including', 'activity', 'mtortarget', 'proteins', 'p70', 'ribosomal', 'protein', 's6', 'kinase', 's6k', 'eukaryotic', 'translational', 'initiation', 'factor', '4e', 'elf4ebinding', 'protein', '1', '4ebp1', 'collectively', 'findings', 'established', 'gnetin', 'c', 'new', 'natural', 'compound', 'anticancer', 'properties', 'mta1aktmtoractivated', 'prostate', 'cancer', 'potential', 'monotherapy', 'possible', 'adjunct', 'clinically', 'approved', 'mtor', 'pathway', 'inhibitors', 'future']","['mta1', 'mta1', 'mta1', 'mta1', 'p70', 's6k', '4ebp1']","['mta1', 'mta1', 'mta1', 'mta1']",True,"['tumor', 'cancer']"
38599565,Discovery and validation of a novel inhibitor of HYPE-mediated AMPylation.,"Adenosyl monophosphate (AMP)ylation (the covalent transfer of an AMP from Adenosine Triphosphate (ATP) onto a target protein) is catalyzed by the human enzyme Huntingtin Yeast Interacting Partner E (HYPE)/FicD to regulate its substrate, the heat shock chaperone binding immunoglobulin protein (BiP). HYPE-mediated AMPylation of BiP is critical for maintaining proteostasis in the endoplasmic reticulum and mounting a unfolded protein response in times of proteostatic imbalance. Thus, manipulating HYPE's enzymatic activity is a key therapeutic strategy toward the treatment of various protein misfolding diseases, including neuropathy and early-onset diabetes associated with two recently identified clinical mutations of HYPE. Herein, we present an optimized, fluorescence polarization-based, high-throughput screening (HTS) assay to discover activators and inhibitors of HYPE-mediated AMPylation. After challenging our HTS assay with over 30,000 compounds, we discovered a novel AMPylase inhibitor, I2.10. We also determined a low micromolar IC50 for I2.10 and employed biorthogonal counter-screens to validate its efficacy against HYPE's AMPylation of BiP. Further, we report low cytotoxicity of I2.10 on human cell lines. We thus established an optimized, high-quality HTS assay amenable to tracking HYPE's enzymatic activity at scale, and provided the first novel small-molecule inhibitor capable of perturbing HYPE-directed AMPylation of BiP in vitro. Our HTS assay and I2.10 compound serve as a platform for further development of HYPE-specific small-molecule therapeutics.",2024-04-09,adenosyl monophosphate ampylation the covalent transfer of an amp from adenosine triphosphate atp onto a target protein is catalyzed by the human enzyme huntingtin yeast interacting partner e hypeficd to regulate its substrate the heat shock chaperone binding immunoglobulin protein bip hypemediated ampylation of bip is critical for maintaining proteostasis in the endoplasmic reticulum and mounting a unfolded protein response in times of proteostatic imbalance thus manipulating hypes enzymatic activity is a key therapeutic strategy toward the treatment of various protein misfolding diseases including neuropathy and earlyonset diabetes associated with two recently identified clinical mutations of hype herein we present an optimized fluorescence polarizationbased highthroughput screening hts assay to discover activators and inhibitors of hypemediated ampylation after challenging our hts assay with over 30000 compounds we discovered a novel ampylase inhibitor i210 we also determined a low micromolar ic50 for i210 and employed biorthogonal counterscreens to validate its efficacy against hypes ampylation of bip further we report low cytotoxicity of i210 on human cell lines we thus established an optimized highquality hts assay amenable to tracking hypes enzymatic activity at scale and provided the first novel smallmolecule inhibitor capable of perturbing hypedirected ampylation of bip in vitro our hts assay and i210 compound serve as a platform for further development of hypespecific smallmolecule therapeutics,"['adenosyl', 'monophosphate', 'ampylation', 'the', 'covalent', 'transfer', 'of', 'an', 'amp', 'from', 'adenosine', 'triphosphate', 'atp', 'onto', 'a', 'target', 'protein', 'is', 'catalyzed', 'by', 'the', 'human', 'enzyme', 'huntingtin', 'yeast', 'interacting', 'partner', 'e', 'hypeficd', 'to', 'regulate', 'its', 'substrate', 'the', 'heat', 'shock', 'chaperone', 'binding', 'immunoglobulin', 'protein', 'bip', 'hypemediated', 'ampylation', 'of', 'bip', 'is', 'critical', 'for', 'maintaining', 'proteostasis', 'in', 'the', 'endoplasmic', 'reticulum', 'and', 'mounting', 'a', 'unfolded', 'protein', 'response', 'in', 'times', 'of', 'proteostatic', 'imbalance', 'thus', 'manipulating', 'hypes', 'enzymatic', 'activity', 'is', 'a', 'key', 'therapeutic', 'strategy', 'toward', 'the', 'treatment', 'of', 'various', 'protein', 'misfolding', 'diseases', 'including', 'neuropathy', 'and', 'earlyonset', 'diabetes', 'associated', 'with', 'two', 'recently', 'identified', 'clinical', 'mutations', 'of', 'hype', 'herein', 'we', 'present', 'an', 'optimized', 'fluorescence', 'polarizationbased', 'highthroughput', 'screening', 'hts', 'assay', 'to', 'discover', 'activators', 'and', 'inhibitors', 'of', 'hypemediated', 'ampylation', 'after', 'challenging', 'our', 'hts', 'assay', 'with', 'over', '30000', 'compounds', 'we', 'discovered', 'a', 'novel', 'ampylase', 'inhibitor', 'i210', 'we', 'also', 'determined', 'a', 'low', 'micromolar', 'ic50', 'for', 'i210', 'and', 'employed', 'biorthogonal', 'counterscreens', 'to', 'validate', 'its', 'efficacy', 'against', 'hypes', 'ampylation', 'of', 'bip', 'further', 'we', 'report', 'low', 'cytotoxicity', 'of', 'i210', 'on', 'human', 'cell', 'lines', 'we', 'thus', 'established', 'an', 'optimized', 'highquality', 'hts', 'assay', 'amenable', 'to', 'tracking', 'hypes', 'enzymatic', 'activity', 'at', 'scale', 'and', 'provided', 'the', 'first', 'novel', 'smallmolecule', 'inhibitor', 'capable', 'of', 'perturbing', 'hypedirected', 'ampylation', 'of', 'bip', 'in', 'vitro', 'our', 'hts', 'assay', 'and', 'i210', 'compound', 'serve', 'as', 'a', 'platform', 'for', 'further', 'development', 'of', 'hypespecific', 'smallmolecule', 'therapeutics']","['adenosyl', 'monophosphate', 'ampylation', 'covalent', 'transfer', 'amp', 'adenosine', 'triphosphate', 'atp', 'onto', 'target', 'protein', 'catalyzed', 'human', 'enzyme', 'huntingtin', 'yeast', 'interacting', 'partner', 'e', 'hypeficd', 'regulate', 'substrate', 'heat', 'shock', 'chaperone', 'binding', 'immunoglobulin', 'protein', 'bip', 'hypemediated', 'ampylation', 'bip', 'critical', 'maintaining', 'proteostasis', 'endoplasmic', 'reticulum', 'mounting', 'unfolded', 'protein', 'response', 'times', 'proteostatic', 'imbalance', 'thus', 'manipulating', 'hypes', 'enzymatic', 'activity', 'key', 'therapeutic', 'strategy', 'toward', 'treatment', 'various', 'protein', 'misfolding', 'diseases', 'including', 'neuropathy', 'earlyonset', 'diabetes', 'associated', 'two', 'recently', 'identified', 'clinical', 'mutations', 'hype', 'herein', 'present', 'optimized', 'fluorescence', 'polarizationbased', 'highthroughput', 'screening', 'hts', 'assay', 'discover', 'activators', 'inhibitors', 'hypemediated', 'ampylation', 'challenging', 'hts', 'assay', '30000', 'compounds', 'discovered', 'novel', 'ampylase', 'inhibitor', 'i210', 'also', 'determined', 'low', 'micromolar', 'ic50', 'i210', 'employed', 'biorthogonal', 'counterscreens', 'validate', 'efficacy', 'hypes', 'ampylation', 'bip', 'report', 'low', 'cytotoxicity', 'i210', 'human', 'cell', 'lines', 'thus', 'established', 'optimized', 'highquality', 'hts', 'assay', 'amenable', 'tracking', 'hypes', 'enzymatic', 'activity', 'scale', 'provided', 'first', 'novel', 'smallmolecule', 'inhibitor', 'capable', 'perturbing', 'hypedirected', 'ampylation', 'bip', 'vitro', 'hts', 'assay', 'i210', 'compound', 'serve', 'platform', 'development', 'hypespecific', 'smallmolecule', 'therapeutics']","['huntingtin', 'immunoglobulin', 'bip', 'bip', 'bip', 'bip']",['huntingtin'],True,['diabetes']
38583575,A novel peptide-drug conjugate for glioma-targeted drug delivery.,"The existence of the blood-brain barrier (BBB) and blood-brain tumor barrier (BBTB) greatly limits the application of chemotherapy in glioma. To address this challenge, an optimal drug delivery system must efficiently cross the BBB/BBTB and specifically deliver therapeutic drugs into glioma cells while minimizing systemic toxicity. Here we demonstrated that glucose-regulated protein 78 (GRP78) and dopamine receptor D2 were highly expressed in patient-derived glioma tissues, and dopamine receptors were highly expressed on the BBB. Subsequently, we synthesized a novel ""Y""-shaped peptide and compared the effects of different linkers on the receptor affinity and targeting ability of the peptide. A peptide-drug conjugate (pHA-AOHX-VAP-doxorubicin conjugate, pHA-AOHX-VAP-DOX) with a better affinity for glioma cells and higher solubility was derived for glioma treatment. pHA-AOHX-VAP-DOX could cross both BBB and BBTB via dopamine receptor and GRP78 receptor, and finally target glioma cells, significantly prolonging the survival time of nude mice bearing intracranial glioma. Furthermore, pHA-AOHX-VAP-DOX significantly reduced the toxicity of DOX and increased the maximum tolerated dose (MTD). Collectively, this work paves a new avenue for overcoming multiple barriers and effectively delivering chemotherapeutic agents to glioma cells while providing key evidence to identify potential receptors for glioma-targeted drug delivery.",2024-04-13,the existence of the bloodbrain barrier bbb and bloodbrain tumor barrier bbtb greatly limits the application of chemotherapy in glioma to address this challenge an optimal drug delivery system must efficiently cross the bbbbbtb and specifically deliver therapeutic drugs into glioma cells while minimizing systemic toxicity here we demonstrated that glucoseregulated protein 78 grp78 and dopamine receptor d2 were highly expressed in patientderived glioma tissues and dopamine receptors were highly expressed on the bbb subsequently we synthesized a novel yshaped peptide and compared the effects of different linkers on the receptor affinity and targeting ability of the peptide a peptidedrug conjugate phaaohxvapdoxorubicin conjugate phaaohxvapdox with a better affinity for glioma cells and higher solubility was derived for glioma treatment phaaohxvapdox could cross both bbb and bbtb via dopamine receptor and grp78 receptor and finally target glioma cells significantly prolonging the survival time of nude mice bearing intracranial glioma furthermore phaaohxvapdox significantly reduced the toxicity of dox and increased the maximum tolerated dose mtd collectively this work paves a new avenue for overcoming multiple barriers and effectively delivering chemotherapeutic agents to glioma cells while providing key evidence to identify potential receptors for gliomatargeted drug delivery,"['the', 'existence', 'of', 'the', 'bloodbrain', 'barrier', 'bbb', 'and', 'bloodbrain', 'tumor', 'barrier', 'bbtb', 'greatly', 'limits', 'the', 'application', 'of', 'chemotherapy', 'in', 'glioma', 'to', 'address', 'this', 'challenge', 'an', 'optimal', 'drug', 'delivery', 'system', 'must', 'efficiently', 'cross', 'the', 'bbbbbtb', 'and', 'specifically', 'deliver', 'therapeutic', 'drugs', 'into', 'glioma', 'cells', 'while', 'minimizing', 'systemic', 'toxicity', 'here', 'we', 'demonstrated', 'that', 'glucoseregulated', 'protein', '78', 'grp78', 'and', 'dopamine', 'receptor', 'd2', 'were', 'highly', 'expressed', 'in', 'patientderived', 'glioma', 'tissues', 'and', 'dopamine', 'receptors', 'were', 'highly', 'expressed', 'on', 'the', 'bbb', 'subsequently', 'we', 'synthesized', 'a', 'novel', 'yshaped', 'peptide', 'and', 'compared', 'the', 'effects', 'of', 'different', 'linkers', 'on', 'the', 'receptor', 'affinity', 'and', 'targeting', 'ability', 'of', 'the', 'peptide', 'a', 'peptidedrug', 'conjugate', 'phaaohxvapdoxorubicin', 'conjugate', 'phaaohxvapdox', 'with', 'a', 'better', 'affinity', 'for', 'glioma', 'cells', 'and', 'higher', 'solubility', 'was', 'derived', 'for', 'glioma', 'treatment', 'phaaohxvapdox', 'could', 'cross', 'both', 'bbb', 'and', 'bbtb', 'via', 'dopamine', 'receptor', 'and', 'grp78', 'receptor', 'and', 'finally', 'target', 'glioma', 'cells', 'significantly', 'prolonging', 'the', 'survival', 'time', 'of', 'nude', 'mice', 'bearing', 'intracranial', 'glioma', 'furthermore', 'phaaohxvapdox', 'significantly', 'reduced', 'the', 'toxicity', 'of', 'dox', 'and', 'increased', 'the', 'maximum', 'tolerated', 'dose', 'mtd', 'collectively', 'this', 'work', 'paves', 'a', 'new', 'avenue', 'for', 'overcoming', 'multiple', 'barriers', 'and', 'effectively', 'delivering', 'chemotherapeutic', 'agents', 'to', 'glioma', 'cells', 'while', 'providing', 'key', 'evidence', 'to', 'identify', 'potential', 'receptors', 'for', 'gliomatargeted', 'drug', 'delivery']","['existence', 'bloodbrain', 'barrier', 'bbb', 'bloodbrain', 'tumor', 'barrier', 'bbtb', 'greatly', 'limits', 'application', 'chemotherapy', 'glioma', 'address', 'challenge', 'optimal', 'drug', 'delivery', 'system', 'must', 'efficiently', 'cross', 'bbbbbtb', 'specifically', 'deliver', 'therapeutic', 'drugs', 'glioma', 'cells', 'minimizing', 'systemic', 'toxicity', 'demonstrated', 'glucoseregulated', 'protein', '78', 'grp78', 'dopamine', 'receptor', 'd2', 'highly', 'expressed', 'patientderived', 'glioma', 'tissues', 'dopamine', 'receptors', 'highly', 'expressed', 'bbb', 'subsequently', 'synthesized', 'novel', 'yshaped', 'peptide', 'compared', 'effects', 'different', 'linkers', 'receptor', 'affinity', 'targeting', 'ability', 'peptide', 'peptidedrug', 'conjugate', 'phaaohxvapdoxorubicin', 'conjugate', 'phaaohxvapdox', 'better', 'affinity', 'glioma', 'cells', 'higher', 'solubility', 'derived', 'glioma', 'treatment', 'phaaohxvapdox', 'could', 'cross', 'bbb', 'bbtb', 'via', 'dopamine', 'receptor', 'grp78', 'receptor', 'finally', 'target', 'glioma', 'cells', 'significantly', 'prolonging', 'survival', 'time', 'nude', 'mice', 'bearing', 'intracranial', 'glioma', 'furthermore', 'phaaohxvapdox', 'significantly', 'reduced', 'toxicity', 'dox', 'increased', 'maximum', 'tolerated', 'dose', 'mtd', 'collectively', 'work', 'paves', 'new', 'avenue', 'overcoming', 'multiple', 'barriers', 'effectively', 'delivering', 'chemotherapeutic', 'agents', 'glioma', 'cells', 'providing', 'key', 'evidence', 'identify', 'potential', 'receptors', 'gliomatargeted', 'drug', 'delivery']","['grp78', 'grp78', 'mtd']","['grp78', 'grp78', 'mtd']",True,['tumor']
38579616,Discovery of a novel small-molecule activator of SIRT3 that inhibits cell proliferation and migration by apoptosis and autophagy-dependent cell death pathways in colorectal cancer.,"Colorectal cancer (CRC) is well known as a prevalent malignancy affecting the digestive tract, yet its precise etiological determinants remain to be elusive. Accordingly, identifying specific molecular targets for colorectal cancer and predicting potential malignant tumor behavior are potential strategies for therapeutic interventions. Of note, apoptosis (type I programmed cell death) has been widely reported to play a pivotal role in tumorigenesis by exerting a suppressive effect on cancer development. Moreover, autophagy-dependent cell death (type II programmed cell death) has been implicated in different types of human cancers. Thus, investigating the molecular mechanisms underlying apoptosis and autophagy-dependent cell death is paramount in treatment modalities of colorectal cancer. In this study, we uncovered that a new small-molecule activator of SIRT3, named MY-13, triggered both autophagy-dependent cell death and apoptosis by modulating the SIRT3/Hsp90/AKT signaling pathway. Consequently, this compound inhibited tumor cell proliferation and migration in RKO and HCT-116 cell lines. Moreover, we further demonstrated that the small-molecule activator significantly suppressed tumor growth in vivo. In conclusion, these findings demonstrate that the novel small-molecule activator of SIRT3 may hold a therapeutic potential as a drug candidate in colorectal cancer.",2024-04-02,colorectal cancer crc is well known as a prevalent malignancy affecting the digestive tract yet its precise etiological determinants remain to be elusive accordingly identifying specific molecular targets for colorectal cancer and predicting potential malignant tumor behavior are potential strategies for therapeutic interventions of note apoptosis type i programmed cell death has been widely reported to play a pivotal role in tumorigenesis by exerting a suppressive effect on cancer development moreover autophagydependent cell death type ii programmed cell death has been implicated in different types of human cancers thus investigating the molecular mechanisms underlying apoptosis and autophagydependent cell death is paramount in treatment modalities of colorectal cancer in this study we uncovered that a new smallmolecule activator of sirt3 named my13 triggered both autophagydependent cell death and apoptosis by modulating the sirt3hsp90akt signaling pathway consequently this compound inhibited tumor cell proliferation and migration in rko and hct116 cell lines moreover we further demonstrated that the smallmolecule activator significantly suppressed tumor growth in vivo in conclusion these findings demonstrate that the novel smallmolecule activator of sirt3 may hold a therapeutic potential as a drug candidate in colorectal cancer,"['colorectal', 'cancer', 'crc', 'is', 'well', 'known', 'as', 'a', 'prevalent', 'malignancy', 'affecting', 'the', 'digestive', 'tract', 'yet', 'its', 'precise', 'etiological', 'determinants', 'remain', 'to', 'be', 'elusive', 'accordingly', 'identifying', 'specific', 'molecular', 'targets', 'for', 'colorectal', 'cancer', 'and', 'predicting', 'potential', 'malignant', 'tumor', 'behavior', 'are', 'potential', 'strategies', 'for', 'therapeutic', 'interventions', 'of', 'note', 'apoptosis', 'type', 'i', 'programmed', 'cell', 'death', 'has', 'been', 'widely', 'reported', 'to', 'play', 'a', 'pivotal', 'role', 'in', 'tumorigenesis', 'by', 'exerting', 'a', 'suppressive', 'effect', 'on', 'cancer', 'development', 'moreover', 'autophagydependent', 'cell', 'death', 'type', 'ii', 'programmed', 'cell', 'death', 'has', 'been', 'implicated', 'in', 'different', 'types', 'of', 'human', 'cancers', 'thus', 'investigating', 'the', 'molecular', 'mechanisms', 'underlying', 'apoptosis', 'and', 'autophagydependent', 'cell', 'death', 'is', 'paramount', 'in', 'treatment', 'modalities', 'of', 'colorectal', 'cancer', 'in', 'this', 'study', 'we', 'uncovered', 'that', 'a', 'new', 'smallmolecule', 'activator', 'of', 'sirt3', 'named', 'my13', 'triggered', 'both', 'autophagydependent', 'cell', 'death', 'and', 'apoptosis', 'by', 'modulating', 'the', 'sirt3hsp90akt', 'signaling', 'pathway', 'consequently', 'this', 'compound', 'inhibited', 'tumor', 'cell', 'proliferation', 'and', 'migration', 'in', 'rko', 'and', 'hct116', 'cell', 'lines', 'moreover', 'we', 'further', 'demonstrated', 'that', 'the', 'smallmolecule', 'activator', 'significantly', 'suppressed', 'tumor', 'growth', 'in', 'vivo', 'in', 'conclusion', 'these', 'findings', 'demonstrate', 'that', 'the', 'novel', 'smallmolecule', 'activator', 'of', 'sirt3', 'may', 'hold', 'a', 'therapeutic', 'potential', 'as', 'a', 'drug', 'candidate', 'in', 'colorectal', 'cancer']","['colorectal', 'cancer', 'crc', 'well', 'known', 'prevalent', 'malignancy', 'affecting', 'digestive', 'tract', 'yet', 'precise', 'etiological', 'determinants', 'remain', 'elusive', 'accordingly', 'identifying', 'specific', 'molecular', 'targets', 'colorectal', 'cancer', 'predicting', 'potential', 'malignant', 'tumor', 'behavior', 'potential', 'strategies', 'therapeutic', 'interventions', 'note', 'apoptosis', 'type', 'programmed', 'cell', 'death', 'widely', 'reported', 'play', 'pivotal', 'role', 'tumorigenesis', 'exerting', 'suppressive', 'effect', 'cancer', 'development', 'moreover', 'autophagydependent', 'cell', 'death', 'type', 'ii', 'programmed', 'cell', 'death', 'implicated', 'different', 'types', 'human', 'cancers', 'thus', 'investigating', 'molecular', 'mechanisms', 'underlying', 'apoptosis', 'autophagydependent', 'cell', 'death', 'paramount', 'treatment', 'modalities', 'colorectal', 'cancer', 'study', 'uncovered', 'new', 'smallmolecule', 'activator', 'sirt3', 'named', 'my13', 'triggered', 'autophagydependent', 'cell', 'death', 'apoptosis', 'modulating', 'sirt3hsp90akt', 'signaling', 'pathway', 'consequently', 'compound', 'inhibited', 'tumor', 'cell', 'proliferation', 'migration', 'rko', 'hct116', 'cell', 'lines', 'moreover', 'demonstrated', 'smallmolecule', 'activator', 'significantly', 'suppressed', 'tumor', 'growth', 'vivo', 'conclusion', 'findings', 'demonstrate', 'novel', 'smallmolecule', 'activator', 'sirt3', 'may', 'hold', 'therapeutic', 'potential', 'drug', 'candidate', 'colorectal', 'cancer']","['crc', 'sirt3', 'sirt3']","['sirt3', 'sirt3']",True,"['tumor', 'cancer']"
38567350,PCC0208057 as a small molecule inhibitor of TRPC6 in the treatment of prostate cancer.,"Prostate cancer (PCa) is a common malignant tumor, whose morbidity and mortality keep the top three in the male-related tumors in developed countries. Abnormal ion channels, such as transient receptor potential canonical 6 (TRPC6), are reported to be involved in the carcinogenesis and progress of prostate cancer and have become potential drug targets against prostate cancer. Here, we report a novel small molecule inhibitor of TRPC6, designated as PCC0208057, which can suppress the proliferation and migration of prostate cancer cells <i>in vitro</i>, and inhibit the formation of Human umbilical vein endothelial cells cell lumen. PCC0208057 can effectively inhibit the growth of xenograft tumor <i>in vivo</i>. Molecular mechanism studies revealed that PCC0208057 could directly bind and inhibit the activity of TRPC6, which then induces the prostate cancer cells arrested in G<sub>2</sub>/M phase <i>via</i> enhancing the phosphorylation of Nuclear Factor of Activated T Cells (NFAT) and Cdc2. Taken together, our study describes for the first time that PCC0208057, a novel TRPC6 inhibitor, might be a promising lead compound for treatment of prostate cancer.",2024-03-18,prostate cancer pca is a common malignant tumor whose morbidity and mortality keep the top three in the malerelated tumors in developed countries abnormal ion channels such as transient receptor potential canonical 6 trpc6 are reported to be involved in the carcinogenesis and progress of prostate cancer and have become potential drug targets against prostate cancer here we report a novel small molecule inhibitor of trpc6 designated as pcc0208057 which can suppress the proliferation and migration of prostate cancer cells iin vitroi and inhibit the formation of human umbilical vein endothelial cells cell lumen pcc0208057 can effectively inhibit the growth of xenograft tumor iin vivoi molecular mechanism studies revealed that pcc0208057 could directly bind and inhibit the activity of trpc6 which then induces the prostate cancer cells arrested in gsub2subm phase iviai enhancing the phosphorylation of nuclear factor of activated t cells nfat and cdc2 taken together our study describes for the first time that pcc0208057 a novel trpc6 inhibitor might be a promising lead compound for treatment of prostate cancer,"['prostate', 'cancer', 'pca', 'is', 'a', 'common', 'malignant', 'tumor', 'whose', 'morbidity', 'and', 'mortality', 'keep', 'the', 'top', 'three', 'in', 'the', 'malerelated', 'tumors', 'in', 'developed', 'countries', 'abnormal', 'ion', 'channels', 'such', 'as', 'transient', 'receptor', 'potential', 'canonical', '6', 'trpc6', 'are', 'reported', 'to', 'be', 'involved', 'in', 'the', 'carcinogenesis', 'and', 'progress', 'of', 'prostate', 'cancer', 'and', 'have', 'become', 'potential', 'drug', 'targets', 'against', 'prostate', 'cancer', 'here', 'we', 'report', 'a', 'novel', 'small', 'molecule', 'inhibitor', 'of', 'trpc6', 'designated', 'as', 'pcc0208057', 'which', 'can', 'suppress', 'the', 'proliferation', 'and', 'migration', 'of', 'prostate', 'cancer', 'cells', 'iin', 'vitroi', 'and', 'inhibit', 'the', 'formation', 'of', 'human', 'umbilical', 'vein', 'endothelial', 'cells', 'cell', 'lumen', 'pcc0208057', 'can', 'effectively', 'inhibit', 'the', 'growth', 'of', 'xenograft', 'tumor', 'iin', 'vivoi', 'molecular', 'mechanism', 'studies', 'revealed', 'that', 'pcc0208057', 'could', 'directly', 'bind', 'and', 'inhibit', 'the', 'activity', 'of', 'trpc6', 'which', 'then', 'induces', 'the', 'prostate', 'cancer', 'cells', 'arrested', 'in', 'gsub2subm', 'phase', 'iviai', 'enhancing', 'the', 'phosphorylation', 'of', 'nuclear', 'factor', 'of', 'activated', 't', 'cells', 'nfat', 'and', 'cdc2', 'taken', 'together', 'our', 'study', 'describes', 'for', 'the', 'first', 'time', 'that', 'pcc0208057', 'a', 'novel', 'trpc6', 'inhibitor', 'might', 'be', 'a', 'promising', 'lead', 'compound', 'for', 'treatment', 'of', 'prostate', 'cancer']","['prostate', 'cancer', 'pca', 'common', 'malignant', 'tumor', 'whose', 'morbidity', 'mortality', 'keep', 'top', 'three', 'malerelated', 'tumors', 'developed', 'countries', 'abnormal', 'ion', 'channels', 'transient', 'receptor', 'potential', 'canonical', '6', 'trpc6', 'reported', 'involved', 'carcinogenesis', 'progress', 'prostate', 'cancer', 'become', 'potential', 'drug', 'targets', 'prostate', 'cancer', 'report', 'novel', 'small', 'molecule', 'inhibitor', 'trpc6', 'designated', 'pcc0208057', 'suppress', 'proliferation', 'migration', 'prostate', 'cancer', 'cells', 'iin', 'vitroi', 'inhibit', 'formation', 'human', 'umbilical', 'vein', 'endothelial', 'cells', 'cell', 'lumen', 'pcc0208057', 'effectively', 'inhibit', 'growth', 'xenograft', 'tumor', 'iin', 'vivoi', 'molecular', 'mechanism', 'studies', 'revealed', 'pcc0208057', 'could', 'directly', 'bind', 'inhibit', 'activity', 'trpc6', 'induces', 'prostate', 'cancer', 'cells', 'arrested', 'gsub2subm', 'phase', 'iviai', 'enhancing', 'phosphorylation', 'nuclear', 'factor', 'activated', 'cells', 'nfat', 'cdc2', 'taken', 'together', 'study', 'describes', 'first', 'time', 'pcc0208057', 'novel', 'trpc6', 'inhibitor', 'might', 'promising', 'lead', 'compound', 'treatment', 'prostate', 'cancer']",['cdc2'],['cdc2'],True,"['tumor', 'cancer']"
38554143,Synthesis and Evaluation of [<sup>18</sup>F]AlF-NOTA-c-<sup>D</sup>VAP: A Novel PET Probe for Imaging GRP78 in Cancer.,"GRP78, a member of the HSP70 superfamily, is an endoplasmic reticulum chaperone protein overexpressed in various cancers, making it a promising target for cancer imaging and therapy. Positron emission tomography (PET) imaging offers unique advantages in real time, noninvasive tumor imaging, rendering it a suitable tool for targeting GRP78 in tumor imaging to guide targeted therapy. Several studies have reported successful tumor imaging using PET probes targeting GRP78. However, existing PET probes face challenges such as low tumor uptake, inadequate in vivo distribution, and high abdominal background signal. Therefore, this study introduces a novel peptide PET probe, [<sup>18</sup>F]AlF-NOTA-c-<sup>D</sup>VAP, for targeted tumor imaging of GRP78. [<sup>18</sup>F]AlF-NOTA-c-<sup>D</sup>VAP was radiolabeled with fluoride-18 using the aluminum-[<sup>18</sup>F]fluoride ([<sup>18</sup>F]AlF) method. The study assessed the partition coefficients, stability in vitro, and metabolic stability of [<sup>18</sup>F]AlF-NOTA-c-<sup>D</sup>VAP. Micro-PET imaging, pharmacokinetic analysis, and biodistribution studies were carried out in tumor-bearing mice to evaluate the probe's performance. Docking studies and pharmacokinetic analyses of [<sup>18</sup>F]AlF-NOTA-c-<sup>D</sup>VAP were also performed. Immunohistochemical and immunofluorescence analyses were conducted to confirm GRP78 expression in tumor tissues. The probe's binding affinity to GRP78 was analyzed by molecular docking simulation. [<sup>18</sup>F]AlF-NOTA-c-<sup>D</sup>VAP was radiolabeled in just 25 min with a high yield of 51 ± 16%, a radiochemical purity of 99%, and molar activity within the range of 20-50 GBq/μmol. [<sup>18</sup>F]AlF-NOTA-c-<sup>D</sup>VAP demonstrated high stability in vitro and in vivo, with a logD value of -3.41 ± 0.03. Dynamic PET imaging of [<sup>18</sup>F]AlF-NOTA-c-<sup>D</sup>VAP in tumors showed rapid uptake and sustained retention, with minimal background uptake. Biodistribution studies revealed rapid blood clearance and excretion through the kidneys following a single-compartment reversible metabolic model. In PET imaging, the T/M ratios for A549 tumors (high GRP78 expression), MDA-MB-231 tumors (medium expression), and HepG2 tumors (low expression) at 60 min postintravenous injection were 10.48 ± 1.39, 6.25 ± 0.47, and 3.15 ± 1.15% ID/g, respectively, indicating a positive correlation with GRP78 expression. This study demonstrates the feasibility of using [<sup>18</sup>F]AlF-NOTA-c-<sup>D</sup>VAP as a PET tracer for imaging GRP78 in tumors. The probe shows promising results in terms of stability, specificity, and tumor targeting. Further research may explore the clinical utility and potential therapeutic applications of this PET tracer for cancer diagnosis.",2024-03-30,grp78 a member of the hsp70 superfamily is an endoplasmic reticulum chaperone protein overexpressed in various cancers making it a promising target for cancer imaging and therapy positron emission tomography pet imaging offers unique advantages in real time noninvasive tumor imaging rendering it a suitable tool for targeting grp78 in tumor imaging to guide targeted therapy several studies have reported successful tumor imaging using pet probes targeting grp78 however existing pet probes face challenges such as low tumor uptake inadequate in vivo distribution and high abdominal background signal therefore this study introduces a novel peptide pet probe sup18supfalfnotacsupdsupvap for targeted tumor imaging of grp78 sup18supfalfnotacsupdsupvap was radiolabeled with fluoride18 using the aluminumsup18supffluoride sup18supfalf method the study assessed the partition coefficients stability in vitro and metabolic stability of sup18supfalfnotacsupdsupvap micropet imaging pharmacokinetic analysis and biodistribution studies were carried out in tumorbearing mice to evaluate the probes performance docking studies and pharmacokinetic analyses of sup18supfalfnotacsupdsupvap were also performed immunohistochemical and immunofluorescence analyses were conducted to confirm grp78 expression in tumor tissues the probes binding affinity to grp78 was analyzed by molecular docking simulation sup18supfalfnotacsupdsupvap was radiolabeled in just 25 min with a high yield of 51  16 a radiochemical purity of 99 and molar activity within the range of 2050 gbqμmol sup18supfalfnotacsupdsupvap demonstrated high stability in vitro and in vivo with a logd value of 341  003 dynamic pet imaging of sup18supfalfnotacsupdsupvap in tumors showed rapid uptake and sustained retention with minimal background uptake biodistribution studies revealed rapid blood clearance and excretion through the kidneys following a singlecompartment reversible metabolic model in pet imaging the tm ratios for a549 tumors high grp78 expression mdamb231 tumors medium expression and hepg2 tumors low expression at 60 min postintravenous injection were 1048  139 625  047 and 315  115 idg respectively indicating a positive correlation with grp78 expression this study demonstrates the feasibility of using sup18supfalfnotacsupdsupvap as a pet tracer for imaging grp78 in tumors the probe shows promising results in terms of stability specificity and tumor targeting further research may explore the clinical utility and potential therapeutic applications of this pet tracer for cancer diagnosis,"['grp78', 'a', 'member', 'of', 'the', 'hsp70', 'superfamily', 'is', 'an', 'endoplasmic', 'reticulum', 'chaperone', 'protein', 'overexpressed', 'in', 'various', 'cancers', 'making', 'it', 'a', 'promising', 'target', 'for', 'cancer', 'imaging', 'and', 'therapy', 'positron', 'emission', 'tomography', 'pet', 'imaging', 'offers', 'unique', 'advantages', 'in', 'real', 'time', 'noninvasive', 'tumor', 'imaging', 'rendering', 'it', 'a', 'suitable', 'tool', 'for', 'targeting', 'grp78', 'in', 'tumor', 'imaging', 'to', 'guide', 'targeted', 'therapy', 'several', 'studies', 'have', 'reported', 'successful', 'tumor', 'imaging', 'using', 'pet', 'probes', 'targeting', 'grp78', 'however', 'existing', 'pet', 'probes', 'face', 'challenges', 'such', 'as', 'low', 'tumor', 'uptake', 'inadequate', 'in', 'vivo', 'distribution', 'and', 'high', 'abdominal', 'background', 'signal', 'therefore', 'this', 'study', 'introduces', 'a', 'novel', 'peptide', 'pet', 'probe', 'sup18supfalfnotacsupdsupvap', 'for', 'targeted', 'tumor', 'imaging', 'of', 'grp78', 'sup18supfalfnotacsupdsupvap', 'was', 'radiolabeled', 'with', 'fluoride18', 'using', 'the', 'aluminumsup18supffluoride', 'sup18supfalf', 'method', 'the', 'study', 'assessed', 'the', 'partition', 'coefficients', 'stability', 'in', 'vitro', 'and', 'metabolic', 'stability', 'of', 'sup18supfalfnotacsupdsupvap', 'micropet', 'imaging', 'pharmacokinetic', 'analysis', 'and', 'biodistribution', 'studies', 'were', 'carried', 'out', 'in', 'tumorbearing', 'mice', 'to', 'evaluate', 'the', 'probes', 'performance', 'docking', 'studies', 'and', 'pharmacokinetic', 'analyses', 'of', 'sup18supfalfnotacsupdsupvap', 'were', 'also', 'performed', 'immunohistochemical', 'and', 'immunofluorescence', 'analyses', 'were', 'conducted', 'to', 'confirm', 'grp78', 'expression', 'in', 'tumor', 'tissues', 'the', 'probes', 'binding', 'affinity', 'to', 'grp78', 'was', 'analyzed', 'by', 'molecular', 'docking', 'simulation', 'sup18supfalfnotacsupdsupvap', 'was', 'radiolabeled', 'in', 'just', '25', 'min', 'with', 'a', 'high', 'yield', 'of', '51', '16', 'a', 'radiochemical', 'purity', 'of', '99', 'and', 'molar', 'activity', 'within', 'the', 'range', 'of', '2050', 'gbqμmol', 'sup18supfalfnotacsupdsupvap', 'demonstrated', 'high', 'stability', 'in', 'vitro', 'and', 'in', 'vivo', 'with', 'a', 'logd', 'value', 'of', '341', '003', 'dynamic', 'pet', 'imaging', 'of', 'sup18supfalfnotacsupdsupvap', 'in', 'tumors', 'showed', 'rapid', 'uptake', 'and', 'sustained', 'retention', 'with', 'minimal', 'background', 'uptake', 'biodistribution', 'studies', 'revealed', 'rapid', 'blood', 'clearance', 'and', 'excretion', 'through', 'the', 'kidneys', 'following', 'a', 'singlecompartment', 'reversible', 'metabolic', 'model', 'in', 'pet', 'imaging', 'the', 'tm', 'ratios', 'for', 'a549', 'tumors', 'high', 'grp78', 'expression', 'mdamb231', 'tumors', 'medium', 'expression', 'and', 'hepg2', 'tumors', 'low', 'expression', 'at', '60', 'min', 'postintravenous', 'injection', 'were', '1048', '139', '625', '047', 'and', '315', '115', 'idg', 'respectively', 'indicating', 'a', 'positive', 'correlation', 'with', 'grp78', 'expression', 'this', 'study', 'demonstrates', 'the', 'feasibility', 'of', 'using', 'sup18supfalfnotacsupdsupvap', 'as', 'a', 'pet', 'tracer', 'for', 'imaging', 'grp78', 'in', 'tumors', 'the', 'probe', 'shows', 'promising', 'results', 'in', 'terms', 'of', 'stability', 'specificity', 'and', 'tumor', 'targeting', 'further', 'research', 'may', 'explore', 'the', 'clinical', 'utility', 'and', 'potential', 'therapeutic', 'applications', 'of', 'this', 'pet', 'tracer', 'for', 'cancer', 'diagnosis']","['grp78', 'member', 'hsp70', 'superfamily', 'endoplasmic', 'reticulum', 'chaperone', 'protein', 'overexpressed', 'various', 'cancers', 'making', 'promising', 'target', 'cancer', 'imaging', 'therapy', 'positron', 'emission', 'tomography', 'pet', 'imaging', 'offers', 'unique', 'advantages', 'real', 'time', 'noninvasive', 'tumor', 'imaging', 'rendering', 'suitable', 'tool', 'targeting', 'grp78', 'tumor', 'imaging', 'guide', 'targeted', 'therapy', 'several', 'studies', 'reported', 'successful', 'tumor', 'imaging', 'using', 'pet', 'probes', 'targeting', 'grp78', 'however', 'existing', 'pet', 'probes', 'face', 'challenges', 'low', 'tumor', 'uptake', 'inadequate', 'vivo', 'distribution', 'high', 'abdominal', 'background', 'signal', 'therefore', 'study', 'introduces', 'novel', 'peptide', 'pet', 'probe', 'sup18supfalfnotacsupdsupvap', 'targeted', 'tumor', 'imaging', 'grp78', 'sup18supfalfnotacsupdsupvap', 'radiolabeled', 'fluoride18', 'using', 'aluminumsup18supffluoride', 'sup18supfalf', 'method', 'study', 'assessed', 'partition', 'coefficients', 'stability', 'vitro', 'metabolic', 'stability', 'sup18supfalfnotacsupdsupvap', 'micropet', 'imaging', 'pharmacokinetic', 'analysis', 'biodistribution', 'studies', 'carried', 'tumorbearing', 'mice', 'evaluate', 'probes', 'performance', 'docking', 'studies', 'pharmacokinetic', 'analyses', 'sup18supfalfnotacsupdsupvap', 'also', 'performed', 'immunohistochemical', 'immunofluorescence', 'analyses', 'conducted', 'confirm', 'grp78', 'expression', 'tumor', 'tissues', 'probes', 'binding', 'affinity', 'grp78', 'analyzed', 'molecular', 'docking', 'simulation', 'sup18supfalfnotacsupdsupvap', 'radiolabeled', '25', 'min', 'high', 'yield', '51', '16', 'radiochemical', 'purity', '99', 'molar', 'activity', 'within', 'range', '2050', 'gbqμmol', 'sup18supfalfnotacsupdsupvap', 'demonstrated', 'high', 'stability', 'vitro', 'vivo', 'logd', 'value', '341', '003', 'dynamic', 'pet', 'imaging', 'sup18supfalfnotacsupdsupvap', 'tumors', 'showed', 'rapid', 'uptake', 'sustained', 'retention', 'minimal', 'background', 'uptake', 'biodistribution', 'studies', 'revealed', 'rapid', 'blood', 'clearance', 'excretion', 'kidneys', 'following', 'singlecompartment', 'reversible', 'metabolic', 'model', 'pet', 'imaging', 'tm', 'ratios', 'a549', 'tumors', 'high', 'grp78', 'expression', 'mdamb231', 'tumors', 'medium', 'expression', 'hepg2', 'tumors', 'low', 'expression', '60', 'min', 'postintravenous', 'injection', '1048', '139', '625', '047', '315', '115', 'idg', 'respectively', 'indicating', 'positive', 'correlation', 'grp78', 'expression', 'study', 'demonstrates', 'feasibility', 'using', 'sup18supfalfnotacsupdsupvap', 'pet', 'tracer', 'imaging', 'grp78', 'tumors', 'probe', 'shows', 'promising', 'results', 'terms', 'stability', 'specificity', 'tumor', 'targeting', 'research', 'may', 'explore', 'clinical', 'utility', 'potential', 'therapeutic', 'applications', 'pet', 'tracer', 'cancer', 'diagnosis']","['grp78', 'hsp70', 'grp78', 'grp78', 'grp78', 'grp78', 'grp78', 'grp78', 'grp78', 'grp78']","['grp78', 'hsp70', 'grp78', 'grp78', 'grp78', 'grp78', 'grp78', 'grp78', 'grp78', 'grp78']",True,"['tumor', 'cancer']"
38491556,Derivation of a novel antimicrobial peptide from the Red Sea Brine Pools modified to enhance its anticancer activity against U2OS cells.,"Cancer associated drug resistance is a major cause for cancer aggravation, particularly as conventional therapies have presented limited efficiency, low specificity, resulting in long term deleterious side effects. Peptide based drugs have emerged as potential alternative cancer treatment tools due to their selectivity, ease of design and synthesis, safety profile, and low cost of manufacturing. In this study, we utilized the Red Sea metagenomics database, generated during AUC/KAUST Red Sea microbiome project, to derive a viable anticancer peptide (ACP). We generated a set of peptide hits from our library that shared similar composition to ACPs. A peptide with a homeodomain was selected, modified to improve its anticancer properties, verified to maintain high anticancer properties, and processed for further in-silico prediction of structure and function. The peptide's anticancer properties were then assessed in vitro on osteosarcoma U2OS cells, through cytotoxicity assay (MTT assay), scratch-wound healing assay, apoptosis/necrosis detection assay (Annexin/PI assay), RNA expression analysis of Caspase 3, KI67 and Survivin, and protein expression of PARP1. L929 mouse fibroblasts were also assessed for cytotoxicity treatment. In addition, the antimicrobial activity of the peptide was also examined on E coli and S. aureus, as sample representative species of the human bacterial microbiome, by examining viability, disk diffusion, morphological assessment, and hemolytic analysis. We observed a dose dependent cytotoxic response from peptide treatment of U2OS, with a higher tolerance in L929s. Wound closure was debilitated in cells exposed to the peptide, while annexin fluorescent imaging suggested peptide treatment caused apoptosis as a major mode of cell death. Caspase 3 gene expression was not altered, while KI67 and Survivin were both downregulated in peptide treated cells. Additionally, PARP-1 protein analysis showed a decrease in expression with peptide exposure. The peptide exhibited minimal antimicrobial activity on critical human microbiome species E. coli and S. aureus, with a low inhibition rate, maintenance of structural morphology and minimal hemolytic impact. These findings suggest our novel peptide displayed preliminary ACP properties against U2OS cells, through limited specificity, while triggering apoptosis as a primary mode of cell death and while having minimal impact on the microbiological species E. coli and S. aureus.",2024-03-15,cancer associated drug resistance is a major cause for cancer aggravation particularly as conventional therapies have presented limited efficiency low specificity resulting in long term deleterious side effects peptide based drugs have emerged as potential alternative cancer treatment tools due to their selectivity ease of design and synthesis safety profile and low cost of manufacturing in this study we utilized the red sea metagenomics database generated during auckaust red sea microbiome project to derive a viable anticancer peptide acp we generated a set of peptide hits from our library that shared similar composition to acps a peptide with a homeodomain was selected modified to improve its anticancer properties verified to maintain high anticancer properties and processed for further insilico prediction of structure and function the peptides anticancer properties were then assessed in vitro on osteosarcoma u2os cells through cytotoxicity assay mtt assay scratchwound healing assay apoptosisnecrosis detection assay annexinpi assay rna expression analysis of caspase 3 ki67 and survivin and protein expression of parp1 l929 mouse fibroblasts were also assessed for cytotoxicity treatment in addition the antimicrobial activity of the peptide was also examined on e coli and s aureus as sample representative species of the human bacterial microbiome by examining viability disk diffusion morphological assessment and hemolytic analysis we observed a dose dependent cytotoxic response from peptide treatment of u2os with a higher tolerance in l929s wound closure was debilitated in cells exposed to the peptide while annexin fluorescent imaging suggested peptide treatment caused apoptosis as a major mode of cell death caspase 3 gene expression was not altered while ki67 and survivin were both downregulated in peptide treated cells additionally parp1 protein analysis showed a decrease in expression with peptide exposure the peptide exhibited minimal antimicrobial activity on critical human microbiome species e coli and s aureus with a low inhibition rate maintenance of structural morphology and minimal hemolytic impact these findings suggest our novel peptide displayed preliminary acp properties against u2os cells through limited specificity while triggering apoptosis as a primary mode of cell death and while having minimal impact on the microbiological species e coli and s aureus,"['cancer', 'associated', 'drug', 'resistance', 'is', 'a', 'major', 'cause', 'for', 'cancer', 'aggravation', 'particularly', 'as', 'conventional', 'therapies', 'have', 'presented', 'limited', 'efficiency', 'low', 'specificity', 'resulting', 'in', 'long', 'term', 'deleterious', 'side', 'effects', 'peptide', 'based', 'drugs', 'have', 'emerged', 'as', 'potential', 'alternative', 'cancer', 'treatment', 'tools', 'due', 'to', 'their', 'selectivity', 'ease', 'of', 'design', 'and', 'synthesis', 'safety', 'profile', 'and', 'low', 'cost', 'of', 'manufacturing', 'in', 'this', 'study', 'we', 'utilized', 'the', 'red', 'sea', 'metagenomics', 'database', 'generated', 'during', 'auckaust', 'red', 'sea', 'microbiome', 'project', 'to', 'derive', 'a', 'viable', 'anticancer', 'peptide', 'acp', 'we', 'generated', 'a', 'set', 'of', 'peptide', 'hits', 'from', 'our', 'library', 'that', 'shared', 'similar', 'composition', 'to', 'acps', 'a', 'peptide', 'with', 'a', 'homeodomain', 'was', 'selected', 'modified', 'to', 'improve', 'its', 'anticancer', 'properties', 'verified', 'to', 'maintain', 'high', 'anticancer', 'properties', 'and', 'processed', 'for', 'further', 'insilico', 'prediction', 'of', 'structure', 'and', 'function', 'the', 'peptides', 'anticancer', 'properties', 'were', 'then', 'assessed', 'in', 'vitro', 'on', 'osteosarcoma', 'u2os', 'cells', 'through', 'cytotoxicity', 'assay', 'mtt', 'assay', 'scratchwound', 'healing', 'assay', 'apoptosisnecrosis', 'detection', 'assay', 'annexinpi', 'assay', 'rna', 'expression', 'analysis', 'of', 'caspase', '3', 'ki67', 'and', 'survivin', 'and', 'protein', 'expression', 'of', 'parp1', 'l929', 'mouse', 'fibroblasts', 'were', 'also', 'assessed', 'for', 'cytotoxicity', 'treatment', 'in', 'addition', 'the', 'antimicrobial', 'activity', 'of', 'the', 'peptide', 'was', 'also', 'examined', 'on', 'e', 'coli', 'and', 's', 'aureus', 'as', 'sample', 'representative', 'species', 'of', 'the', 'human', 'bacterial', 'microbiome', 'by', 'examining', 'viability', 'disk', 'diffusion', 'morphological', 'assessment', 'and', 'hemolytic', 'analysis', 'we', 'observed', 'a', 'dose', 'dependent', 'cytotoxic', 'response', 'from', 'peptide', 'treatment', 'of', 'u2os', 'with', 'a', 'higher', 'tolerance', 'in', 'l929s', 'wound', 'closure', 'was', 'debilitated', 'in', 'cells', 'exposed', 'to', 'the', 'peptide', 'while', 'annexin', 'fluorescent', 'imaging', 'suggested', 'peptide', 'treatment', 'caused', 'apoptosis', 'as', 'a', 'major', 'mode', 'of', 'cell', 'death', 'caspase', '3', 'gene', 'expression', 'was', 'not', 'altered', 'while', 'ki67', 'and', 'survivin', 'were', 'both', 'downregulated', 'in', 'peptide', 'treated', 'cells', 'additionally', 'parp1', 'protein', 'analysis', 'showed', 'a', 'decrease', 'in', 'expression', 'with', 'peptide', 'exposure', 'the', 'peptide', 'exhibited', 'minimal', 'antimicrobial', 'activity', 'on', 'critical', 'human', 'microbiome', 'species', 'e', 'coli', 'and', 's', 'aureus', 'with', 'a', 'low', 'inhibition', 'rate', 'maintenance', 'of', 'structural', 'morphology', 'and', 'minimal', 'hemolytic', 'impact', 'these', 'findings', 'suggest', 'our', 'novel', 'peptide', 'displayed', 'preliminary', 'acp', 'properties', 'against', 'u2os', 'cells', 'through', 'limited', 'specificity', 'while', 'triggering', 'apoptosis', 'as', 'a', 'primary', 'mode', 'of', 'cell', 'death', 'and', 'while', 'having', 'minimal', 'impact', 'on', 'the', 'microbiological', 'species', 'e', 'coli', 'and', 's', 'aureus']","['cancer', 'associated', 'drug', 'resistance', 'major', 'cause', 'cancer', 'aggravation', 'particularly', 'conventional', 'therapies', 'presented', 'limited', 'efficiency', 'low', 'specificity', 'resulting', 'long', 'term', 'deleterious', 'side', 'effects', 'peptide', 'based', 'drugs', 'emerged', 'potential', 'alternative', 'cancer', 'treatment', 'tools', 'due', 'selectivity', 'ease', 'design', 'synthesis', 'safety', 'profile', 'low', 'cost', 'manufacturing', 'study', 'utilized', 'red', 'sea', 'metagenomics', 'database', 'generated', 'auckaust', 'red', 'sea', 'microbiome', 'project', 'derive', 'viable', 'anticancer', 'peptide', 'acp', 'generated', 'set', 'peptide', 'hits', 'library', 'shared', 'similar', 'composition', 'acps', 'peptide', 'homeodomain', 'selected', 'modified', 'improve', 'anticancer', 'properties', 'verified', 'maintain', 'high', 'anticancer', 'properties', 'processed', 'insilico', 'prediction', 'structure', 'function', 'peptides', 'anticancer', 'properties', 'assessed', 'vitro', 'osteosarcoma', 'u2os', 'cells', 'cytotoxicity', 'assay', 'mtt', 'assay', 'scratchwound', 'healing', 'assay', 'apoptosisnecrosis', 'detection', 'assay', 'annexinpi', 'assay', 'rna', 'expression', 'analysis', 'caspase', '3', 'ki67', 'survivin', 'protein', 'expression', 'parp1', 'l929', 'mouse', 'fibroblasts', 'also', 'assessed', 'cytotoxicity', 'treatment', 'addition', 'antimicrobial', 'activity', 'peptide', 'also', 'examined', 'e', 'coli', 'aureus', 'sample', 'representative', 'species', 'human', 'bacterial', 'microbiome', 'examining', 'viability', 'disk', 'diffusion', 'morphological', 'assessment', 'hemolytic', 'analysis', 'observed', 'dose', 'dependent', 'cytotoxic', 'response', 'peptide', 'treatment', 'u2os', 'higher', 'tolerance', 'l929s', 'wound', 'closure', 'debilitated', 'cells', 'exposed', 'peptide', 'annexin', 'fluorescent', 'imaging', 'suggested', 'peptide', 'treatment', 'caused', 'apoptosis', 'major', 'mode', 'cell', 'death', 'caspase', '3', 'gene', 'expression', 'altered', 'ki67', 'survivin', 'downregulated', 'peptide', 'treated', 'cells', 'additionally', 'parp1', 'protein', 'analysis', 'showed', 'decrease', 'expression', 'peptide', 'exposure', 'peptide', 'exhibited', 'minimal', 'antimicrobial', 'activity', 'critical', 'human', 'microbiome', 'species', 'e', 'coli', 'aureus', 'low', 'inhibition', 'rate', 'maintenance', 'structural', 'morphology', 'minimal', 'hemolytic', 'impact', 'findings', 'suggest', 'novel', 'peptide', 'displayed', 'preliminary', 'acp', 'properties', 'u2os', 'cells', 'limited', 'specificity', 'triggering', 'apoptosis', 'primary', 'mode', 'cell', 'death', 'minimal', 'impact', 'microbiological', 'species', 'e', 'coli', 'aureus']","['caspase', 'ki67', 'survivin', 'parp1', 'annexin', 'caspase', 'ki67', 'survivin', 'parp1']","['ki67', 'survivin', 'ki67', 'survivin']",True,['cancer']
38431094,Peptide targeting improves the delivery and therapeutic index of glucocorticoids to treat rheumatoid arthritis.,"Rheumatoid arthritis (RA) is a prevalent autoimmune disease characterized by excessive inflammation in the joints. Glucocorticoid drugs are used clinically to manage RA symptoms, while their dosage and duration need to be tightly controlled due to severe adverse effects. Using dexamethasone (DEX) as a model drug, we explored here whether peptide-guided delivery could increase the safety and therapeutic index of glucocorticoids for RA treatment. Using multiple murine RA models such as collagen-induced arthritis (CIA), we found that CRV, a macrophage-targeting peptide, can selectively home to the inflammatory synovium of RA joints upon intravenous injection. The expression of the CRV receptor, retinoid X receptor beta (RXRB), was also elevated in the inflammatory synovium, likely being the basis of CRV targeting. CRV-conjugated DEX increased the accumulation of DEX in the inflamed synovium but not in healthy organs of CIA mice. Therefore, CRV-DEX demonstrated a stronger efficacy to suppress synovial inflammation and alleviate cartilage/bone destruction. Meanwhile, CRV conjugation reduced immune-related adverse effects of DEX even after a long-term use. Last, we found that RXRB expression was significantly elevated in human patient samples, demonstrating the potential of clinical translation. Taken together, we provide a novel, peptide-targeted strategy to improve the therapeutic efficacy and safety of glucocorticoids for RA treatment.",2024-03-05,rheumatoid arthritis ra is a prevalent autoimmune disease characterized by excessive inflammation in the joints glucocorticoid drugs are used clinically to manage ra symptoms while their dosage and duration need to be tightly controlled due to severe adverse effects using dexamethasone dex as a model drug we explored here whether peptideguided delivery could increase the safety and therapeutic index of glucocorticoids for ra treatment using multiple murine ra models such as collageninduced arthritis cia we found that crv a macrophagetargeting peptide can selectively home to the inflammatory synovium of ra joints upon intravenous injection the expression of the crv receptor retinoid x receptor beta rxrb was also elevated in the inflammatory synovium likely being the basis of crv targeting crvconjugated dex increased the accumulation of dex in the inflamed synovium but not in healthy organs of cia mice therefore crvdex demonstrated a stronger efficacy to suppress synovial inflammation and alleviate cartilagebone destruction meanwhile crv conjugation reduced immunerelated adverse effects of dex even after a longterm use last we found that rxrb expression was significantly elevated in human patient samples demonstrating the potential of clinical translation taken together we provide a novel peptidetargeted strategy to improve the therapeutic efficacy and safety of glucocorticoids for ra treatment,"['rheumatoid', 'arthritis', 'ra', 'is', 'a', 'prevalent', 'autoimmune', 'disease', 'characterized', 'by', 'excessive', 'inflammation', 'in', 'the', 'joints', 'glucocorticoid', 'drugs', 'are', 'used', 'clinically', 'to', 'manage', 'ra', 'symptoms', 'while', 'their', 'dosage', 'and', 'duration', 'need', 'to', 'be', 'tightly', 'controlled', 'due', 'to', 'severe', 'adverse', 'effects', 'using', 'dexamethasone', 'dex', 'as', 'a', 'model', 'drug', 'we', 'explored', 'here', 'whether', 'peptideguided', 'delivery', 'could', 'increase', 'the', 'safety', 'and', 'therapeutic', 'index', 'of', 'glucocorticoids', 'for', 'ra', 'treatment', 'using', 'multiple', 'murine', 'ra', 'models', 'such', 'as', 'collageninduced', 'arthritis', 'cia', 'we', 'found', 'that', 'crv', 'a', 'macrophagetargeting', 'peptide', 'can', 'selectively', 'home', 'to', 'the', 'inflammatory', 'synovium', 'of', 'ra', 'joints', 'upon', 'intravenous', 'injection', 'the', 'expression', 'of', 'the', 'crv', 'receptor', 'retinoid', 'x', 'receptor', 'beta', 'rxrb', 'was', 'also', 'elevated', 'in', 'the', 'inflammatory', 'synovium', 'likely', 'being', 'the', 'basis', 'of', 'crv', 'targeting', 'crvconjugated', 'dex', 'increased', 'the', 'accumulation', 'of', 'dex', 'in', 'the', 'inflamed', 'synovium', 'but', 'not', 'in', 'healthy', 'organs', 'of', 'cia', 'mice', 'therefore', 'crvdex', 'demonstrated', 'a', 'stronger', 'efficacy', 'to', 'suppress', 'synovial', 'inflammation', 'and', 'alleviate', 'cartilagebone', 'destruction', 'meanwhile', 'crv', 'conjugation', 'reduced', 'immunerelated', 'adverse', 'effects', 'of', 'dex', 'even', 'after', 'a', 'longterm', 'use', 'last', 'we', 'found', 'that', 'rxrb', 'expression', 'was', 'significantly', 'elevated', 'in', 'human', 'patient', 'samples', 'demonstrating', 'the', 'potential', 'of', 'clinical', 'translation', 'taken', 'together', 'we', 'provide', 'a', 'novel', 'peptidetargeted', 'strategy', 'to', 'improve', 'the', 'therapeutic', 'efficacy', 'and', 'safety', 'of', 'glucocorticoids', 'for', 'ra', 'treatment']","['rheumatoid', 'arthritis', 'ra', 'prevalent', 'autoimmune', 'disease', 'characterized', 'excessive', 'inflammation', 'joints', 'glucocorticoid', 'drugs', 'used', 'clinically', 'manage', 'ra', 'symptoms', 'dosage', 'duration', 'need', 'tightly', 'controlled', 'due', 'severe', 'adverse', 'effects', 'using', 'dexamethasone', 'dex', 'model', 'drug', 'explored', 'whether', 'peptideguided', 'delivery', 'could', 'increase', 'safety', 'therapeutic', 'index', 'glucocorticoids', 'ra', 'treatment', 'using', 'multiple', 'murine', 'ra', 'models', 'collageninduced', 'arthritis', 'cia', 'found', 'crv', 'macrophagetargeting', 'peptide', 'selectively', 'home', 'inflammatory', 'synovium', 'ra', 'joints', 'upon', 'intravenous', 'injection', 'expression', 'crv', 'receptor', 'retinoid', 'x', 'receptor', 'beta', 'rxrb', 'also', 'elevated', 'inflammatory', 'synovium', 'likely', 'basis', 'crv', 'targeting', 'crvconjugated', 'dex', 'increased', 'accumulation', 'dex', 'inflamed', 'synovium', 'healthy', 'organs', 'cia', 'mice', 'therefore', 'crvdex', 'demonstrated', 'stronger', 'efficacy', 'suppress', 'synovial', 'inflammation', 'alleviate', 'cartilagebone', 'destruction', 'meanwhile', 'crv', 'conjugation', 'reduced', 'immunerelated', 'adverse', 'effects', 'dex', 'even', 'longterm', 'use', 'last', 'found', 'rxrb', 'expression', 'significantly', 'elevated', 'human', 'patient', 'samples', 'demonstrating', 'potential', 'clinical', 'translation', 'taken', 'together', 'provide', 'novel', 'peptidetargeted', 'strategy', 'improve', 'therapeutic', 'efficacy', 'safety', 'glucocorticoids', 'ra', 'treatment']","['ra', 'ra', 'ra', 'ra', 'ra', 'beta', 'ra']","['ra', 'ra', 'ra', 'ra', 'ra', 'ra']",True,['arthritis']
38377719,A modified natural small molecule inhibits triple-negative breast cancer growth by interacting with Tubb3.,"Triple-negative breast cancer (TNBC) is a malignant tumor without specific therapeutic targets and a poor prognosis. Chemotherapy is currently the first-line therapeutic option for TNBC. However, due to the heterogeneity of TNBC, not all of TNBC patients are responsive to chemotherapeutic agents. Therefore, the demand for new targeted agents is critical. β-tubulin isotype III (Tubb3) is a prognostic factor associated with cancer progression, including breast cancer, and targeting Tubb3 may lead to improve TNBC disease control. Shikonin, the active compound in the roots of Lithospermun erythrorhizon suppresses the growth of various types of tumors, and its efficacy can be improved by altering its chemical structure.",2023-05-19,triplenegative breast cancer tnbc is a malignant tumor without specific therapeutic targets and a poor prognosis chemotherapy is currently the firstline therapeutic option for tnbc however due to the heterogeneity of tnbc not all of tnbc patients are responsive to chemotherapeutic agents therefore the demand for new targeted agents is critical βtubulin isotype iii tubb3 is a prognostic factor associated with cancer progression including breast cancer and targeting tubb3 may lead to improve tnbc disease control shikonin the active compound in the roots of lithospermun erythrorhizon suppresses the growth of various types of tumors and its efficacy can be improved by altering its chemical structure,"['triplenegative', 'breast', 'cancer', 'tnbc', 'is', 'a', 'malignant', 'tumor', 'without', 'specific', 'therapeutic', 'targets', 'and', 'a', 'poor', 'prognosis', 'chemotherapy', 'is', 'currently', 'the', 'firstline', 'therapeutic', 'option', 'for', 'tnbc', 'however', 'due', 'to', 'the', 'heterogeneity', 'of', 'tnbc', 'not', 'all', 'of', 'tnbc', 'patients', 'are', 'responsive', 'to', 'chemotherapeutic', 'agents', 'therefore', 'the', 'demand', 'for', 'new', 'targeted', 'agents', 'is', 'critical', 'βtubulin', 'isotype', 'iii', 'tubb3', 'is', 'a', 'prognostic', 'factor', 'associated', 'with', 'cancer', 'progression', 'including', 'breast', 'cancer', 'and', 'targeting', 'tubb3', 'may', 'lead', 'to', 'improve', 'tnbc', 'disease', 'control', 'shikonin', 'the', 'active', 'compound', 'in', 'the', 'roots', 'of', 'lithospermun', 'erythrorhizon', 'suppresses', 'the', 'growth', 'of', 'various', 'types', 'of', 'tumors', 'and', 'its', 'efficacy', 'can', 'be', 'improved', 'by', 'altering', 'its', 'chemical', 'structure']","['triplenegative', 'breast', 'cancer', 'tnbc', 'malignant', 'tumor', 'without', 'specific', 'therapeutic', 'targets', 'poor', 'prognosis', 'chemotherapy', 'currently', 'firstline', 'therapeutic', 'option', 'tnbc', 'however', 'due', 'heterogeneity', 'tnbc', 'tnbc', 'patients', 'responsive', 'chemotherapeutic', 'agents', 'therefore', 'demand', 'new', 'targeted', 'agents', 'critical', 'βtubulin', 'isotype', 'iii', 'tubb3', 'prognostic', 'factor', 'associated', 'cancer', 'progression', 'including', 'breast', 'cancer', 'targeting', 'tubb3', 'may', 'lead', 'improve', 'tnbc', 'disease', 'control', 'shikonin', 'active', 'compound', 'roots', 'lithospermun', 'erythrorhizon', 'suppresses', 'growth', 'various', 'types', 'tumors', 'efficacy', 'improved', 'altering', 'chemical', 'structure']","['tubb3', 'tubb3']","['tubb3', 'tubb3']",True,"['tumor', 'cancer']"
38354956,"Ebselen and TPI-1, as RecG helicase inhibitors, potently enhance the susceptibility of Pseudomonas aeruginosa to DNA damage agents.","Holliday junction (HJ) is a four-way structured DNA intermediate in processes of homologous recombination and DNA double-stranded break (DSB) repair. In bacteria, HJs are processed via either the RuvABC or RecG-dependent pathways. In addition, RecG also plays a critical role in the reactivation of stalled replication forks, making it an attractive target for antibacterial drug development. Here, we conducted a high-throughput screening targeting the RecG helicase from a common opportunistic pathogen Pseudomonas aeruginosa (Pa). From a library containing 7920 compounds, we identified Ebselen and TPI-1 (2',5'-Dichloro-[1,1'-biphenyl]-2,5-dione) as two potent PaRecG inhibitors, with IC<sub>50</sub> values of 0.31 ± 0.02 μM and 1.16 ± 0.06 μM, respectively. Further biochemical analyses suggested that both Ebselen and TPI-1 inhibited the ATPase activity of PaRecG, and hindered its binding to HJ DNA with high selectivity. These compounds, when combined with our previously reported RuvAB inhibitors, resulted in more severe DNA repair defects than the individual treatment, and potently enhanced the susceptibility of P. aeruginosa to the DNA damage agents. This work reports novel small molecule inhibitors of RecG, offering valuable chemical tools for advancing our understanding of RecG's function and mechanism. Additionally, these inhibitors might be further developed as promising antibacterial agents in the fight against P. aeruginosa infections.",2024-02-12,holliday junction hj is a fourway structured dna intermediate in processes of homologous recombination and dna doublestranded break dsb repair in bacteria hjs are processed via either the ruvabc or recgdependent pathways in addition recg also plays a critical role in the reactivation of stalled replication forks making it an attractive target for antibacterial drug development here we conducted a highthroughput screening targeting the recg helicase from a common opportunistic pathogen pseudomonas aeruginosa pa from a library containing 7920 compounds we identified ebselen and tpi1 25dichloro11biphenyl25dione as two potent parecg inhibitors with icsub50sub values of 031  002 μm and 116  006 μm respectively further biochemical analyses suggested that both ebselen and tpi1 inhibited the atpase activity of parecg and hindered its binding to hj dna with high selectivity these compounds when combined with our previously reported ruvab inhibitors resulted in more severe dna repair defects than the individual treatment and potently enhanced the susceptibility of p aeruginosa to the dna damage agents this work reports novel small molecule inhibitors of recg offering valuable chemical tools for advancing our understanding of recgs function and mechanism additionally these inhibitors might be further developed as promising antibacterial agents in the fight against p aeruginosa infections,"['holliday', 'junction', 'hj', 'is', 'a', 'fourway', 'structured', 'dna', 'intermediate', 'in', 'processes', 'of', 'homologous', 'recombination', 'and', 'dna', 'doublestranded', 'break', 'dsb', 'repair', 'in', 'bacteria', 'hjs', 'are', 'processed', 'via', 'either', 'the', 'ruvabc', 'or', 'recgdependent', 'pathways', 'in', 'addition', 'recg', 'also', 'plays', 'a', 'critical', 'role', 'in', 'the', 'reactivation', 'of', 'stalled', 'replication', 'forks', 'making', 'it', 'an', 'attractive', 'target', 'for', 'antibacterial', 'drug', 'development', 'here', 'we', 'conducted', 'a', 'highthroughput', 'screening', 'targeting', 'the', 'recg', 'helicase', 'from', 'a', 'common', 'opportunistic', 'pathogen', 'pseudomonas', 'aeruginosa', 'pa', 'from', 'a', 'library', 'containing', '7920', 'compounds', 'we', 'identified', 'ebselen', 'and', 'tpi1', '25dichloro11biphenyl25dione', 'as', 'two', 'potent', 'parecg', 'inhibitors', 'with', 'icsub50sub', 'values', 'of', '031', '002', 'μm', 'and', '116', '006', 'μm', 'respectively', 'further', 'biochemical', 'analyses', 'suggested', 'that', 'both', 'ebselen', 'and', 'tpi1', 'inhibited', 'the', 'atpase', 'activity', 'of', 'parecg', 'and', 'hindered', 'its', 'binding', 'to', 'hj', 'dna', 'with', 'high', 'selectivity', 'these', 'compounds', 'when', 'combined', 'with', 'our', 'previously', 'reported', 'ruvab', 'inhibitors', 'resulted', 'in', 'more', 'severe', 'dna', 'repair', 'defects', 'than', 'the', 'individual', 'treatment', 'and', 'potently', 'enhanced', 'the', 'susceptibility', 'of', 'p', 'aeruginosa', 'to', 'the', 'dna', 'damage', 'agents', 'this', 'work', 'reports', 'novel', 'small', 'molecule', 'inhibitors', 'of', 'recg', 'offering', 'valuable', 'chemical', 'tools', 'for', 'advancing', 'our', 'understanding', 'of', 'recgs', 'function', 'and', 'mechanism', 'additionally', 'these', 'inhibitors', 'might', 'be', 'further', 'developed', 'as', 'promising', 'antibacterial', 'agents', 'in', 'the', 'fight', 'against', 'p', 'aeruginosa', 'infections']","['holliday', 'junction', 'hj', 'fourway', 'structured', 'dna', 'intermediate', 'processes', 'homologous', 'recombination', 'dna', 'doublestranded', 'break', 'dsb', 'repair', 'bacteria', 'hjs', 'processed', 'via', 'either', 'ruvabc', 'recgdependent', 'pathways', 'addition', 'recg', 'also', 'plays', 'critical', 'role', 'reactivation', 'stalled', 'replication', 'forks', 'making', 'attractive', 'target', 'antibacterial', 'drug', 'development', 'conducted', 'highthroughput', 'screening', 'targeting', 'recg', 'helicase', 'common', 'opportunistic', 'pathogen', 'pseudomonas', 'aeruginosa', 'pa', 'library', 'containing', '7920', 'compounds', 'identified', 'ebselen', 'tpi1', '25dichloro11biphenyl25dione', 'two', 'potent', 'parecg', 'inhibitors', 'icsub50sub', 'values', '031', '002', 'μm', '116', '006', 'μm', 'respectively', 'biochemical', 'analyses', 'suggested', 'ebselen', 'tpi1', 'inhibited', 'atpase', 'activity', 'parecg', 'hindered', 'binding', 'hj', 'dna', 'high', 'selectivity', 'compounds', 'combined', 'previously', 'reported', 'ruvab', 'inhibitors', 'resulted', 'severe', 'dna', 'repair', 'defects', 'individual', 'treatment', 'potently', 'enhanced', 'susceptibility', 'p', 'aeruginosa', 'dna', 'damage', 'agents', 'work', 'reports', 'novel', 'small', 'molecule', 'inhibitors', 'recg', 'offering', 'valuable', 'chemical', 'tools', 'advancing', 'understanding', 'recgs', 'function', 'mechanism', 'additionally', 'inhibitors', 'might', 'developed', 'promising', 'antibacterial', 'agents', 'fight', 'p', 'aeruginosa', 'infections']",['atpase'],['atpase'],True,['infection']
38328202,Increased interaction between connexin43 and microtubules is critical for glioblastoma stem-like cell maintenance and tumorigenicity.,"Glioblastoma (GBM) is the most common primary tumor of the central nervous system. One major challenge in GBM treatment is the resistance to chemotherapy and radiotherapy observed in subpopulations of cancer cells, including GBM stem-like cells (GSCs). These cells hold the ability to self-renew or differentiate following treatment, participating in tumor recurrence. The gap junction protein connexin43 (Cx43) has complex roles in oncogenesis and we have previously demonstrated an association between Cx43 and GBM chemotherapy resistance. Here, we report, for the first time, increased direct interaction between non-junctional Cx43 with microtubules in the cytoplasm of GSCs. We hypothesize that non-junctional Cx43/microtubule complexing is critical for GSC maintenance and survival and sought to specifically disrupt this interaction while maintaining other Cx43 functions, such as gap junction formation. Using a Cx43 mimetic peptide of the carboxyl terminal tubulin-binding domain of Cx43 (JM2), we successfully ablated Cx43 interaction with microtubules in GSCs. Importantly, administration of JM2 significantly decreased GSC survival <i>in vitro</i> , and limited GSC-derived tumor growth <i>in vivo</i> . Together, these results identify JM2 as a novel peptide drug to ablate GSCs in GBM treatment.",2024-01-27,glioblastoma gbm is the most common primary tumor of the central nervous system one major challenge in gbm treatment is the resistance to chemotherapy and radiotherapy observed in subpopulations of cancer cells including gbm stemlike cells gscs these cells hold the ability to selfrenew or differentiate following treatment participating in tumor recurrence the gap junction protein connexin43 cx43 has complex roles in oncogenesis and we have previously demonstrated an association between cx43 and gbm chemotherapy resistance here we report for the first time increased direct interaction between nonjunctional cx43 with microtubules in the cytoplasm of gscs we hypothesize that nonjunctional cx43microtubule complexing is critical for gsc maintenance and survival and sought to specifically disrupt this interaction while maintaining other cx43 functions such as gap junction formation using a cx43 mimetic peptide of the carboxyl terminal tubulinbinding domain of cx43 jm2 we successfully ablated cx43 interaction with microtubules in gscs importantly administration of jm2 significantly decreased gsc survival iin vitroi  and limited gscderived tumor growth iin vivoi  together these results identify jm2 as a novel peptide drug to ablate gscs in gbm treatment,"['glioblastoma', 'gbm', 'is', 'the', 'most', 'common', 'primary', 'tumor', 'of', 'the', 'central', 'nervous', 'system', 'one', 'major', 'challenge', 'in', 'gbm', 'treatment', 'is', 'the', 'resistance', 'to', 'chemotherapy', 'and', 'radiotherapy', 'observed', 'in', 'subpopulations', 'of', 'cancer', 'cells', 'including', 'gbm', 'stemlike', 'cells', 'gscs', 'these', 'cells', 'hold', 'the', 'ability', 'to', 'selfrenew', 'or', 'differentiate', 'following', 'treatment', 'participating', 'in', 'tumor', 'recurrence', 'the', 'gap', 'junction', 'protein', 'connexin43', 'cx43', 'has', 'complex', 'roles', 'in', 'oncogenesis', 'and', 'we', 'have', 'previously', 'demonstrated', 'an', 'association', 'between', 'cx43', 'and', 'gbm', 'chemotherapy', 'resistance', 'here', 'we', 'report', 'for', 'the', 'first', 'time', 'increased', 'direct', 'interaction', 'between', 'nonjunctional', 'cx43', 'with', 'microtubules', 'in', 'the', 'cytoplasm', 'of', 'gscs', 'we', 'hypothesize', 'that', 'nonjunctional', 'cx43microtubule', 'complexing', 'is', 'critical', 'for', 'gsc', 'maintenance', 'and', 'survival', 'and', 'sought', 'to', 'specifically', 'disrupt', 'this', 'interaction', 'while', 'maintaining', 'other', 'cx43', 'functions', 'such', 'as', 'gap', 'junction', 'formation', 'using', 'a', 'cx43', 'mimetic', 'peptide', 'of', 'the', 'carboxyl', 'terminal', 'tubulinbinding', 'domain', 'of', 'cx43', 'jm2', 'we', 'successfully', 'ablated', 'cx43', 'interaction', 'with', 'microtubules', 'in', 'gscs', 'importantly', 'administration', 'of', 'jm2', 'significantly', 'decreased', 'gsc', 'survival', 'iin', 'vitroi', 'and', 'limited', 'gscderived', 'tumor', 'growth', 'iin', 'vivoi', 'together', 'these', 'results', 'identify', 'jm2', 'as', 'a', 'novel', 'peptide', 'drug', 'to', 'ablate', 'gscs', 'in', 'gbm', 'treatment']","['glioblastoma', 'gbm', 'common', 'primary', 'tumor', 'central', 'nervous', 'system', 'one', 'major', 'challenge', 'gbm', 'treatment', 'resistance', 'chemotherapy', 'radiotherapy', 'observed', 'subpopulations', 'cancer', 'cells', 'including', 'gbm', 'stemlike', 'cells', 'gscs', 'cells', 'hold', 'ability', 'selfrenew', 'differentiate', 'following', 'treatment', 'participating', 'tumor', 'recurrence', 'gap', 'junction', 'protein', 'connexin43', 'cx43', 'complex', 'roles', 'oncogenesis', 'previously', 'demonstrated', 'association', 'cx43', 'gbm', 'chemotherapy', 'resistance', 'report', 'first', 'time', 'increased', 'direct', 'interaction', 'nonjunctional', 'cx43', 'microtubules', 'cytoplasm', 'gscs', 'hypothesize', 'nonjunctional', 'cx43microtubule', 'complexing', 'critical', 'gsc', 'maintenance', 'survival', 'sought', 'specifically', 'disrupt', 'interaction', 'maintaining', 'cx43', 'functions', 'gap', 'junction', 'formation', 'using', 'cx43', 'mimetic', 'peptide', 'carboxyl', 'terminal', 'tubulinbinding', 'domain', 'cx43', 'jm2', 'successfully', 'ablated', 'cx43', 'interaction', 'microtubules', 'gscs', 'importantly', 'administration', 'jm2', 'significantly', 'decreased', 'gsc', 'survival', 'iin', 'vitroi', 'limited', 'gscderived', 'tumor', 'growth', 'iin', 'vivoi', 'together', 'results', 'identify', 'jm2', 'novel', 'peptide', 'drug', 'ablate', 'gscs', 'gbm', 'treatment']","['connexin43', 'cx43', 'cx43', 'cx43', 'gsc', 'cx43', 'cx43', 'cx43', 'cx43', 'gsc']","['connexin43', 'cx43', 'cx43', 'cx43', 'cx43', 'cx43', 'cx43', 'cx43']",True,"['tumor', 'cancer']"
38299600,The <i>in vitro</i> and <i>in vivo</i> antiviral effects of IGF1R inhibitors against respiratory syncytial virus infection.,"The insulin-like growth factor 1 receptor (IGF1R) was recognized as a pivotal receptor that facilitated the cellular entry of RSV. Small molecule inhibitors designed to target IGF1R exhibited potential as potent antiviral agents. Through virtual screening, we conducted a screening process involving small molecule compounds derived from natural products, aiming to target the IGF1R protein against respiratory syncytial virus infection. The molecular dynamics simulation analysis showed that tannic acid and daptomycin interacted with the IGF1R. The experimental results <i>in vivo</i> and <i>in vitro</i> showed that tannic acid and daptomycin had anti-RSV infection potential through reducing viral loads, inflammation, airway resistance and protecting alveolar integrity. The CC50 values of tannic acid and daptomycin were 6 nM and 0.45 μM, respectively. Novel small-molecule inhibitors targeting the IGF1R, tannic acid and daptomycin, may be effective anti-RSV therapy agents. This study may in future broaden the arsenal of therapeutics for use against RSV infection and lead to more effective care against the virus.",2024-02-01,the insulinlike growth factor 1 receptor igf1r was recognized as a pivotal receptor that facilitated the cellular entry of rsv small molecule inhibitors designed to target igf1r exhibited potential as potent antiviral agents through virtual screening we conducted a screening process involving small molecule compounds derived from natural products aiming to target the igf1r protein against respiratory syncytial virus infection the molecular dynamics simulation analysis showed that tannic acid and daptomycin interacted with the igf1r the experimental results iin vivoi and iin vitroi showed that tannic acid and daptomycin had antirsv infection potential through reducing viral loads inflammation airway resistance and protecting alveolar integrity the cc50 values of tannic acid and daptomycin were 6 nm and 045 μm respectively novel smallmolecule inhibitors targeting the igf1r tannic acid and daptomycin may be effective antirsv therapy agents this study may in future broaden the arsenal of therapeutics for use against rsv infection and lead to more effective care against the virus,"['the', 'insulinlike', 'growth', 'factor', '1', 'receptor', 'igf1r', 'was', 'recognized', 'as', 'a', 'pivotal', 'receptor', 'that', 'facilitated', 'the', 'cellular', 'entry', 'of', 'rsv', 'small', 'molecule', 'inhibitors', 'designed', 'to', 'target', 'igf1r', 'exhibited', 'potential', 'as', 'potent', 'antiviral', 'agents', 'through', 'virtual', 'screening', 'we', 'conducted', 'a', 'screening', 'process', 'involving', 'small', 'molecule', 'compounds', 'derived', 'from', 'natural', 'products', 'aiming', 'to', 'target', 'the', 'igf1r', 'protein', 'against', 'respiratory', 'syncytial', 'virus', 'infection', 'the', 'molecular', 'dynamics', 'simulation', 'analysis', 'showed', 'that', 'tannic', 'acid', 'and', 'daptomycin', 'interacted', 'with', 'the', 'igf1r', 'the', 'experimental', 'results', 'iin', 'vivoi', 'and', 'iin', 'vitroi', 'showed', 'that', 'tannic', 'acid', 'and', 'daptomycin', 'had', 'antirsv', 'infection', 'potential', 'through', 'reducing', 'viral', 'loads', 'inflammation', 'airway', 'resistance', 'and', 'protecting', 'alveolar', 'integrity', 'the', 'cc50', 'values', 'of', 'tannic', 'acid', 'and', 'daptomycin', 'were', '6', 'nm', 'and', '045', 'μm', 'respectively', 'novel', 'smallmolecule', 'inhibitors', 'targeting', 'the', 'igf1r', 'tannic', 'acid', 'and', 'daptomycin', 'may', 'be', 'effective', 'antirsv', 'therapy', 'agents', 'this', 'study', 'may', 'in', 'future', 'broaden', 'the', 'arsenal', 'of', 'therapeutics', 'for', 'use', 'against', 'rsv', 'infection', 'and', 'lead', 'to', 'more', 'effective', 'care', 'against', 'the', 'virus']","['insulinlike', 'growth', 'factor', '1', 'receptor', 'igf1r', 'recognized', 'pivotal', 'receptor', 'facilitated', 'cellular', 'entry', 'rsv', 'small', 'molecule', 'inhibitors', 'designed', 'target', 'igf1r', 'exhibited', 'potential', 'potent', 'antiviral', 'agents', 'virtual', 'screening', 'conducted', 'screening', 'process', 'involving', 'small', 'molecule', 'compounds', 'derived', 'natural', 'products', 'aiming', 'target', 'igf1r', 'protein', 'respiratory', 'syncytial', 'virus', 'infection', 'molecular', 'dynamics', 'simulation', 'analysis', 'showed', 'tannic', 'acid', 'daptomycin', 'interacted', 'igf1r', 'experimental', 'results', 'iin', 'vivoi', 'iin', 'vitroi', 'showed', 'tannic', 'acid', 'daptomycin', 'antirsv', 'infection', 'potential', 'reducing', 'viral', 'loads', 'inflammation', 'airway', 'resistance', 'protecting', 'alveolar', 'integrity', 'cc50', 'values', 'tannic', 'acid', 'daptomycin', '6', 'nm', '045', 'μm', 'respectively', 'novel', 'smallmolecule', 'inhibitors', 'targeting', 'igf1r', 'tannic', 'acid', 'daptomycin', 'may', 'effective', 'antirsv', 'therapy', 'agents', 'study', 'may', 'future', 'broaden', 'arsenal', 'therapeutics', 'use', 'rsv', 'infection', 'lead', 'effective', 'care', 'virus']","['insulinlike', 'igf1r', 'igf1r', 'igf1r', 'igf1r', 'igf1r']","['igf1r', 'igf1r', 'igf1r', 'igf1r', 'igf1r']",True,['infection']
38260445,Enabling Systemic Identification and Functionality Profiling for Cdc42 Homeostatic Modulators.,"Homeostatic modulation is pivotal in modern therapeutics. However, the discovery of bioactive materials to achieve this functionality is often random and unpredictive. Here, we enabled a systemic identification and functional classification of chemicals that elicit homeostatic modulation of signaling through Cdc42, a classical small GTPase of Ras superfamily. Rationally designed for high throughput screening, the capture of homeostatic modulators (HMs) along with molecular re-docking uncovered at least five functionally distinct classes of small molecules. This enabling led to partial agonists, hormetic agonists, <i>bona fide</i> activators and inhibitors, and ligand-enhanced agonists. Novel HMs exerted striking functionality in bradykinin-Cdc42 activation of actin remodelingand modified Alzheimer's disease-like behavior in mouse model. This concurrent computer-aided and experimentally empowered HM profiling highlights a model path for predicting HM landscape.",2024-01-08,homeostatic modulation is pivotal in modern therapeutics however the discovery of bioactive materials to achieve this functionality is often random and unpredictive here we enabled a systemic identification and functional classification of chemicals that elicit homeostatic modulation of signaling through cdc42 a classical small gtpase of ras superfamily rationally designed for high throughput screening the capture of homeostatic modulators hms along with molecular redocking uncovered at least five functionally distinct classes of small molecules this enabling led to partial agonists hormetic agonists ibona fidei activators and inhibitors and ligandenhanced agonists novel hms exerted striking functionality in bradykinincdc42 activation of actin remodelingand modified alzheimers diseaselike behavior in mouse model this concurrent computeraided and experimentally empowered hm profiling highlights a model path for predicting hm landscape,"['homeostatic', 'modulation', 'is', 'pivotal', 'in', 'modern', 'therapeutics', 'however', 'the', 'discovery', 'of', 'bioactive', 'materials', 'to', 'achieve', 'this', 'functionality', 'is', 'often', 'random', 'and', 'unpredictive', 'here', 'we', 'enabled', 'a', 'systemic', 'identification', 'and', 'functional', 'classification', 'of', 'chemicals', 'that', 'elicit', 'homeostatic', 'modulation', 'of', 'signaling', 'through', 'cdc42', 'a', 'classical', 'small', 'gtpase', 'of', 'ras', 'superfamily', 'rationally', 'designed', 'for', 'high', 'throughput', 'screening', 'the', 'capture', 'of', 'homeostatic', 'modulators', 'hms', 'along', 'with', 'molecular', 'redocking', 'uncovered', 'at', 'least', 'five', 'functionally', 'distinct', 'classes', 'of', 'small', 'molecules', 'this', 'enabling', 'led', 'to', 'partial', 'agonists', 'hormetic', 'agonists', 'ibona', 'fidei', 'activators', 'and', 'inhibitors', 'and', 'ligandenhanced', 'agonists', 'novel', 'hms', 'exerted', 'striking', 'functionality', 'in', 'bradykinincdc42', 'activation', 'of', 'actin', 'remodelingand', 'modified', 'alzheimers', 'diseaselike', 'behavior', 'in', 'mouse', 'model', 'this', 'concurrent', 'computeraided', 'and', 'experimentally', 'empowered', 'hm', 'profiling', 'highlights', 'a', 'model', 'path', 'for', 'predicting', 'hm', 'landscape']","['homeostatic', 'modulation', 'pivotal', 'modern', 'therapeutics', 'however', 'discovery', 'bioactive', 'materials', 'achieve', 'functionality', 'often', 'random', 'unpredictive', 'enabled', 'systemic', 'identification', 'functional', 'classification', 'chemicals', 'elicit', 'homeostatic', 'modulation', 'signaling', 'cdc42', 'classical', 'small', 'gtpase', 'ras', 'superfamily', 'rationally', 'designed', 'high', 'throughput', 'screening', 'capture', 'homeostatic', 'modulators', 'hms', 'along', 'molecular', 'redocking', 'uncovered', 'least', 'five', 'functionally', 'distinct', 'classes', 'small', 'molecules', 'enabling', 'led', 'partial', 'agonists', 'hormetic', 'agonists', 'ibona', 'fidei', 'activators', 'inhibitors', 'ligandenhanced', 'agonists', 'novel', 'hms', 'exerted', 'striking', 'functionality', 'bradykinincdc42', 'activation', 'actin', 'remodelingand', 'modified', 'alzheimers', 'diseaselike', 'behavior', 'mouse', 'model', 'concurrent', 'computeraided', 'experimentally', 'empowered', 'hm', 'profiling', 'highlights', 'model', 'path', 'predicting', 'hm', 'landscape']","['cdc42', 'gtpase', 'ras', 'actin']","['cdc42', 'gtpase']",True,['alzheimer']
38254786,Gα<sub>i</sub>2 Protein Inhibition Blocks Chemotherapy- and Anti-Androgen-Induced Prostate Cancer Cell Migration.,"We have previously shown that heterotrimeric G-protein subunit alphai2 (Gα<sub>i</sub>2) is essential for cell migration and invasion in prostate, ovarian and breast cancer cells, and novel small molecule inhibitors targeting Gα<sub>i</sub>2 block its effects on migratory and invasive behavior. In this study, we have identified potent, metabolically stable, second generation Gα<sub>i</sub>2 inhibitors which inhibit cell migration in prostate cancer cells. Recent studies have shown that chemotherapy can induce the cancer cells to migrate to distant sites to form metastases. In the present study, we determined the effects of taxanes (docetaxel), anti-androgens (enzalutamide and bicalutamide) and histone deacetylase (HDAC) inhibitors (SAHA and SBI-I-19) on cell migration in prostate cancer cells. All treatments induced cell migration, and simultaneous treatments with new Gα<sub>i</sub>2 inhibitors blocked their effects on cell migration. We concluded that a combination treatment of Gα<sub>i</sub>2 inhibitors and chemotherapy could blunt the capability of cancer cells to migrate and form metastases.",2024-01-10,we have previously shown that heterotrimeric gprotein subunit alphai2 gαsubisub2 is essential for cell migration and invasion in prostate ovarian and breast cancer cells and novel small molecule inhibitors targeting gαsubisub2 block its effects on migratory and invasive behavior in this study we have identified potent metabolically stable second generation gαsubisub2 inhibitors which inhibit cell migration in prostate cancer cells recent studies have shown that chemotherapy can induce the cancer cells to migrate to distant sites to form metastases in the present study we determined the effects of taxanes docetaxel antiandrogens enzalutamide and bicalutamide and histone deacetylase hdac inhibitors saha and sbii19 on cell migration in prostate cancer cells all treatments induced cell migration and simultaneous treatments with new gαsubisub2 inhibitors blocked their effects on cell migration we concluded that a combination treatment of gαsubisub2 inhibitors and chemotherapy could blunt the capability of cancer cells to migrate and form metastases,"['we', 'have', 'previously', 'shown', 'that', 'heterotrimeric', 'gprotein', 'subunit', 'alphai2', 'gαsubisub2', 'is', 'essential', 'for', 'cell', 'migration', 'and', 'invasion', 'in', 'prostate', 'ovarian', 'and', 'breast', 'cancer', 'cells', 'and', 'novel', 'small', 'molecule', 'inhibitors', 'targeting', 'gαsubisub2', 'block', 'its', 'effects', 'on', 'migratory', 'and', 'invasive', 'behavior', 'in', 'this', 'study', 'we', 'have', 'identified', 'potent', 'metabolically', 'stable', 'second', 'generation', 'gαsubisub2', 'inhibitors', 'which', 'inhibit', 'cell', 'migration', 'in', 'prostate', 'cancer', 'cells', 'recent', 'studies', 'have', 'shown', 'that', 'chemotherapy', 'can', 'induce', 'the', 'cancer', 'cells', 'to', 'migrate', 'to', 'distant', 'sites', 'to', 'form', 'metastases', 'in', 'the', 'present', 'study', 'we', 'determined', 'the', 'effects', 'of', 'taxanes', 'docetaxel', 'antiandrogens', 'enzalutamide', 'and', 'bicalutamide', 'and', 'histone', 'deacetylase', 'hdac', 'inhibitors', 'saha', 'and', 'sbii19', 'on', 'cell', 'migration', 'in', 'prostate', 'cancer', 'cells', 'all', 'treatments', 'induced', 'cell', 'migration', 'and', 'simultaneous', 'treatments', 'with', 'new', 'gαsubisub2', 'inhibitors', 'blocked', 'their', 'effects', 'on', 'cell', 'migration', 'we', 'concluded', 'that', 'a', 'combination', 'treatment', 'of', 'gαsubisub2', 'inhibitors', 'and', 'chemotherapy', 'could', 'blunt', 'the', 'capability', 'of', 'cancer', 'cells', 'to', 'migrate', 'and', 'form', 'metastases']","['previously', 'shown', 'heterotrimeric', 'gprotein', 'subunit', 'alphai2', 'gαsubisub2', 'essential', 'cell', 'migration', 'invasion', 'prostate', 'ovarian', 'breast', 'cancer', 'cells', 'novel', 'small', 'molecule', 'inhibitors', 'targeting', 'gαsubisub2', 'block', 'effects', 'migratory', 'invasive', 'behavior', 'study', 'identified', 'potent', 'metabolically', 'stable', 'second', 'generation', 'gαsubisub2', 'inhibitors', 'inhibit', 'cell', 'migration', 'prostate', 'cancer', 'cells', 'recent', 'studies', 'shown', 'chemotherapy', 'induce', 'cancer', 'cells', 'migrate', 'distant', 'sites', 'form', 'metastases', 'present', 'study', 'determined', 'effects', 'taxanes', 'docetaxel', 'antiandrogens', 'enzalutamide', 'bicalutamide', 'histone', 'deacetylase', 'hdac', 'inhibitors', 'saha', 'sbii19', 'cell', 'migration', 'prostate', 'cancer', 'cells', 'treatments', 'induced', 'cell', 'migration', 'simultaneous', 'treatments', 'new', 'gαsubisub2', 'inhibitors', 'blocked', 'effects', 'cell', 'migration', 'concluded', 'combination', 'treatment', 'gαsubisub2', 'inhibitors', 'chemotherapy', 'could', 'blunt', 'capability', 'cancer', 'cells', 'migrate', 'form', 'metastases']","['alphai2', 'deacetylase']",['alphai2'],True,['cancer']
38233164,Precisely Activating cGAS-STING Pathway with a Novel Peptide-Based Nanoagonist to Potentiate Immune Checkpoint Blockade Cancer Immunotherapy.,"As an essential intracellular immune activation pathway, the cGAS-STING pathway has attracted broad attention in cancer treatment. However, low bioavailability, nonspecificity, and adverse effects of small molecule STING agonists severely limit their therapeutic efficacy and in vivo application. In this study, a peptide-based STING agonist is first proposed, and KLA is screened out to activate the cGAS-STING pathway by promoting mitochondrial DNA (mtDNA) leakage. To precisely activate the cGAS-STING pathway and block the PD-1/PD-L1 pathway, a multi-stimuli activatable peptide nanodrug (MAPN) is developed for the effective delivery of KLA and PD-L1 antagonist peptide (CVR). With rational design, MAPN achieved the site-specific release of KLA and CVR in response to multiple endogenous stimuli, simultaneously activating the cGAS-STING pathway and blocking PD-1/PD-L1 pathway, ultimately initiating robust and durable T cell anti-tumor immunity with a tumor growth inhibition rate of 78% and extending the median survival time of B16F10 tumor-bearing mice to 40 days. Overall, antimicrobial peptides, which can promote mtDNA leakage through damaging mitochondrial membranes, may be potential alternatives for small molecule STING agonists and giving a new insight for the design of novel STING agonists. Furthermore, MAPN presents a universal delivery platform for the effective synergy of multiple peptides.",2024-01-17,as an essential intracellular immune activation pathway the cgassting pathway has attracted broad attention in cancer treatment however low bioavailability nonspecificity and adverse effects of small molecule sting agonists severely limit their therapeutic efficacy and in vivo application in this study a peptidebased sting agonist is first proposed and kla is screened out to activate the cgassting pathway by promoting mitochondrial dna mtdna leakage to precisely activate the cgassting pathway and block the pd1pdl1 pathway a multistimuli activatable peptide nanodrug mapn is developed for the effective delivery of kla and pdl1 antagonist peptide cvr with rational design mapn achieved the sitespecific release of kla and cvr in response to multiple endogenous stimuli simultaneously activating the cgassting pathway and blocking pd1pdl1 pathway ultimately initiating robust and durable t cell antitumor immunity with a tumor growth inhibition rate of 78 and extending the median survival time of b16f10 tumorbearing mice to 40 days overall antimicrobial peptides which can promote mtdna leakage through damaging mitochondrial membranes may be potential alternatives for small molecule sting agonists and giving a new insight for the design of novel sting agonists furthermore mapn presents a universal delivery platform for the effective synergy of multiple peptides,"['as', 'an', 'essential', 'intracellular', 'immune', 'activation', 'pathway', 'the', 'cgassting', 'pathway', 'has', 'attracted', 'broad', 'attention', 'in', 'cancer', 'treatment', 'however', 'low', 'bioavailability', 'nonspecificity', 'and', 'adverse', 'effects', 'of', 'small', 'molecule', 'sting', 'agonists', 'severely', 'limit', 'their', 'therapeutic', 'efficacy', 'and', 'in', 'vivo', 'application', 'in', 'this', 'study', 'a', 'peptidebased', 'sting', 'agonist', 'is', 'first', 'proposed', 'and', 'kla', 'is', 'screened', 'out', 'to', 'activate', 'the', 'cgassting', 'pathway', 'by', 'promoting', 'mitochondrial', 'dna', 'mtdna', 'leakage', 'to', 'precisely', 'activate', 'the', 'cgassting', 'pathway', 'and', 'block', 'the', 'pd1pdl1', 'pathway', 'a', 'multistimuli', 'activatable', 'peptide', 'nanodrug', 'mapn', 'is', 'developed', 'for', 'the', 'effective', 'delivery', 'of', 'kla', 'and', 'pdl1', 'antagonist', 'peptide', 'cvr', 'with', 'rational', 'design', 'mapn', 'achieved', 'the', 'sitespecific', 'release', 'of', 'kla', 'and', 'cvr', 'in', 'response', 'to', 'multiple', 'endogenous', 'stimuli', 'simultaneously', 'activating', 'the', 'cgassting', 'pathway', 'and', 'blocking', 'pd1pdl1', 'pathway', 'ultimately', 'initiating', 'robust', 'and', 'durable', 't', 'cell', 'antitumor', 'immunity', 'with', 'a', 'tumor', 'growth', 'inhibition', 'rate', 'of', '78', 'and', 'extending', 'the', 'median', 'survival', 'time', 'of', 'b16f10', 'tumorbearing', 'mice', 'to', '40', 'days', 'overall', 'antimicrobial', 'peptides', 'which', 'can', 'promote', 'mtdna', 'leakage', 'through', 'damaging', 'mitochondrial', 'membranes', 'may', 'be', 'potential', 'alternatives', 'for', 'small', 'molecule', 'sting', 'agonists', 'and', 'giving', 'a', 'new', 'insight', 'for', 'the', 'design', 'of', 'novel', 'sting', 'agonists', 'furthermore', 'mapn', 'presents', 'a', 'universal', 'delivery', 'platform', 'for', 'the', 'effective', 'synergy', 'of', 'multiple', 'peptides']","['essential', 'intracellular', 'immune', 'activation', 'pathway', 'cgassting', 'pathway', 'attracted', 'broad', 'attention', 'cancer', 'treatment', 'however', 'low', 'bioavailability', 'nonspecificity', 'adverse', 'effects', 'small', 'molecule', 'sting', 'agonists', 'severely', 'limit', 'therapeutic', 'efficacy', 'vivo', 'application', 'study', 'peptidebased', 'sting', 'agonist', 'first', 'proposed', 'kla', 'screened', 'activate', 'cgassting', 'pathway', 'promoting', 'mitochondrial', 'dna', 'mtdna', 'leakage', 'precisely', 'activate', 'cgassting', 'pathway', 'block', 'pd1pdl1', 'pathway', 'multistimuli', 'activatable', 'peptide', 'nanodrug', 'mapn', 'developed', 'effective', 'delivery', 'kla', 'pdl1', 'antagonist', 'peptide', 'cvr', 'rational', 'design', 'mapn', 'achieved', 'sitespecific', 'release', 'kla', 'cvr', 'response', 'multiple', 'endogenous', 'stimuli', 'simultaneously', 'activating', 'cgassting', 'pathway', 'blocking', 'pd1pdl1', 'pathway', 'ultimately', 'initiating', 'robust', 'durable', 'cell', 'antitumor', 'immunity', 'tumor', 'growth', 'inhibition', 'rate', '78', 'extending', 'median', 'survival', 'time', 'b16f10', 'tumorbearing', 'mice', '40', 'days', 'overall', 'antimicrobial', 'peptides', 'promote', 'mtdna', 'leakage', 'damaging', 'mitochondrial', 'membranes', 'may', 'potential', 'alternatives', 'small', 'molecule', 'sting', 'agonists', 'giving', 'new', 'insight', 'design', 'novel', 'sting', 'agonists', 'furthermore', 'mapn', 'presents', 'universal', 'delivery', 'platform', 'effective', 'synergy', 'multiple', 'peptides']",['activatable'],['activatable'],True,"['tumor', 'cancer']"
38176026,Discovery of Natural Ah Receptor Antagonists from <i>Salvia miltiorrhiza</i> Bunge and Synthesis of Analogs for Tumor Immunotherapy.,"IDO/TDO/Kyn/AhR signaling plays a crucial role in regulating innate and adaptive immunity, and targeting Ah receptor (AhR) inhibition can potentially redirect immune cells toward an antitumoral phenotype. Therefore, AhR is an attractive drug target for novel small molecule cancer immunotherapies. In this study, natural products tanshinolic A-D (<b>1-4</b>), the first adducts composed of <i>ortho</i>-naphthoquinone-type tanshinone and phenolic acid featuring a unique 1,4-benzodioxan hemiacetal structure, were isolated and characterized from the roots of <i>Salvia miltiorrhiza</i> Bunge. Luciferase reporter gene assay revealed that these adducts exhibited significant AhR inhibitory activity. A linear strategy was developed to construct a <i>cis</i>-3,4-disubstituted 1,4-benzodioxan hemiacetal structure. Encouragingly, in both <i>in</i> <i>vitro</i> and <i>in</i> <i>vivo</i> experiments, (±)-<b>13e</b> demonstrated the ability to inhibit tumor cell proliferation, promote INF-γ secretion in CD8<sup>+</sup> T cells, and inhibit PD-1/PD-L1 signal transduction, which could exert tumor inhibition properties by inhibiting AhR activity, positioning it as a promising candidate for tumor immunotherapy.",2024-01-04,idotdokynahr signaling plays a crucial role in regulating innate and adaptive immunity and targeting ah receptor ahr inhibition can potentially redirect immune cells toward an antitumoral phenotype therefore ahr is an attractive drug target for novel small molecule cancer immunotherapies in this study natural products tanshinolic ad b14b the first adducts composed of iorthoinaphthoquinonetype tanshinone and phenolic acid featuring a unique 14benzodioxan hemiacetal structure were isolated and characterized from the roots of isalvia miltiorrhizai bunge luciferase reporter gene assay revealed that these adducts exhibited significant ahr inhibitory activity a linear strategy was developed to construct a icisi34disubstituted 14benzodioxan hemiacetal structure encouragingly in both iini ivitroi and iini ivivoi experiments b13eb demonstrated the ability to inhibit tumor cell proliferation promote infγ secretion in cd8supsup t cells and inhibit pd1pdl1 signal transduction which could exert tumor inhibition properties by inhibiting ahr activity positioning it as a promising candidate for tumor immunotherapy,"['idotdokynahr', 'signaling', 'plays', 'a', 'crucial', 'role', 'in', 'regulating', 'innate', 'and', 'adaptive', 'immunity', 'and', 'targeting', 'ah', 'receptor', 'ahr', 'inhibition', 'can', 'potentially', 'redirect', 'immune', 'cells', 'toward', 'an', 'antitumoral', 'phenotype', 'therefore', 'ahr', 'is', 'an', 'attractive', 'drug', 'target', 'for', 'novel', 'small', 'molecule', 'cancer', 'immunotherapies', 'in', 'this', 'study', 'natural', 'products', 'tanshinolic', 'ad', 'b14b', 'the', 'first', 'adducts', 'composed', 'of', 'iorthoinaphthoquinonetype', 'tanshinone', 'and', 'phenolic', 'acid', 'featuring', 'a', 'unique', '14benzodioxan', 'hemiacetal', 'structure', 'were', 'isolated', 'and', 'characterized', 'from', 'the', 'roots', 'of', 'isalvia', 'miltiorrhizai', 'bunge', 'luciferase', 'reporter', 'gene', 'assay', 'revealed', 'that', 'these', 'adducts', 'exhibited', 'significant', 'ahr', 'inhibitory', 'activity', 'a', 'linear', 'strategy', 'was', 'developed', 'to', 'construct', 'a', 'icisi34disubstituted', '14benzodioxan', 'hemiacetal', 'structure', 'encouragingly', 'in', 'both', 'iini', 'ivitroi', 'and', 'iini', 'ivivoi', 'experiments', 'b13eb', 'demonstrated', 'the', 'ability', 'to', 'inhibit', 'tumor', 'cell', 'proliferation', 'promote', 'infγ', 'secretion', 'in', 'cd8supsup', 't', 'cells', 'and', 'inhibit', 'pd1pdl1', 'signal', 'transduction', 'which', 'could', 'exert', 'tumor', 'inhibition', 'properties', 'by', 'inhibiting', 'ahr', 'activity', 'positioning', 'it', 'as', 'a', 'promising', 'candidate', 'for', 'tumor', 'immunotherapy']","['idotdokynahr', 'signaling', 'plays', 'crucial', 'role', 'regulating', 'innate', 'adaptive', 'immunity', 'targeting', 'ah', 'receptor', 'ahr', 'inhibition', 'potentially', 'redirect', 'immune', 'cells', 'toward', 'antitumoral', 'phenotype', 'therefore', 'ahr', 'attractive', 'drug', 'target', 'novel', 'small', 'molecule', 'cancer', 'immunotherapies', 'study', 'natural', 'products', 'tanshinolic', 'ad', 'b14b', 'first', 'adducts', 'composed', 'iorthoinaphthoquinonetype', 'tanshinone', 'phenolic', 'acid', 'featuring', 'unique', '14benzodioxan', 'hemiacetal', 'structure', 'isolated', 'characterized', 'roots', 'isalvia', 'miltiorrhizai', 'bunge', 'luciferase', 'reporter', 'gene', 'assay', 'revealed', 'adducts', 'exhibited', 'significant', 'ahr', 'inhibitory', 'activity', 'linear', 'strategy', 'developed', 'construct', 'icisi34disubstituted', '14benzodioxan', 'hemiacetal', 'structure', 'encouragingly', 'iini', 'ivitroi', 'iini', 'ivivoi', 'experiments', 'b13eb', 'demonstrated', 'ability', 'inhibit', 'tumor', 'cell', 'proliferation', 'promote', 'infγ', 'secretion', 'cd8supsup', 'cells', 'inhibit', 'pd1pdl1', 'signal', 'transduction', 'could', 'exert', 'tumor', 'inhibition', 'properties', 'inhibiting', 'ahr', 'activity', 'positioning', 'promising', 'candidate', 'tumor', 'immunotherapy']",['luciferase'],['luciferase'],True,"['tumor', 'cancer']"
38170991,SMR peptide antagonizes <i>Staphylococcus aureus</i> biofilm formation.,"The emergence and international dissemination of multi-drug resistant <i>Staphylococcus aureus</i> (<i>S. aureus</i>) strains challenge current antibiotic-based therapies, representing an urgent threat to public health worldwide. In the U.S. alone, <i>S</i>. <i>aureus</i> infections are responsible for 11,000 deaths and 500,000 hospitalizations annually. Biofilm formation is a major contributor to antibiotic tolerance and resistance-induced delays in empirical therapy with increased infection severity, frequency, treatment failure, and mortality. Developing novel treatment strategies to prevent and disrupt biofilm formation is imperative. In this article, we test the Secretion Modification Region (SMR) peptides for inhibitory effects on resistant <i>S. aureus</i> biofilm-forming capacity by targeting the molecular chaperone DnaK. The dose effect of SMR peptides on biofilm formation was assessed using microtiter plate methods and confocal microscopy. Interaction between the antagonist and DnaK was determined by immune precipitation with anti-Flag M2 Affinity and Western blot analysis. Increasing SMR peptide concentrations exhibited increasing blockade of <i>S. aureus</i> biofilm formation with significant inhibition found at 18 µM, 36 µM, and 72 µM. This work supports the potential therapeutic benefit of SMR peptides in reducing biofilm viability and could improve the susceptibility to antimicrobial agents.IMPORTANCEThe development of anti-biofilm agents is critical to restoring bacterial sensitivity, directly combating the evolution of resistance, and overall reducing the clinical burden related to pervasive biofilm-mediated infections. Thus, in this study, the SMR peptide, a novel small molecule derived from the HIV Nef protein, was preliminarily explored for anti-biofilm properties. The SMR peptide was shown to effectively target the molecular chaperone DnaK and inhibit biofilm formation in a dose-dependent manner. These results support further investigation into the mechanism of SMR peptide-mediated biofilm formation and inhibition to benefit rational drug design and the identification of therapeutic targets.",2024-01-03,the emergence and international dissemination of multidrug resistant istaphylococcus aureusi is aureusi strains challenge current antibioticbased therapies representing an urgent threat to public health worldwide in the us alone isi iaureusi infections are responsible for 11000 deaths and 500000 hospitalizations annually biofilm formation is a major contributor to antibiotic tolerance and resistanceinduced delays in empirical therapy with increased infection severity frequency treatment failure and mortality developing novel treatment strategies to prevent and disrupt biofilm formation is imperative in this article we test the secretion modification region smr peptides for inhibitory effects on resistant is aureusi biofilmforming capacity by targeting the molecular chaperone dnak the dose effect of smr peptides on biofilm formation was assessed using microtiter plate methods and confocal microscopy interaction between the antagonist and dnak was determined by immune precipitation with antiflag m2 affinity and western blot analysis increasing smr peptide concentrations exhibited increasing blockade of is aureusi biofilm formation with significant inhibition found at 18 µm 36 µm and 72 µm this work supports the potential therapeutic benefit of smr peptides in reducing biofilm viability and could improve the susceptibility to antimicrobial agentsimportancethe development of antibiofilm agents is critical to restoring bacterial sensitivity directly combating the evolution of resistance and overall reducing the clinical burden related to pervasive biofilmmediated infections thus in this study the smr peptide a novel small molecule derived from the hiv nef protein was preliminarily explored for antibiofilm properties the smr peptide was shown to effectively target the molecular chaperone dnak and inhibit biofilm formation in a dosedependent manner these results support further investigation into the mechanism of smr peptidemediated biofilm formation and inhibition to benefit rational drug design and the identification of therapeutic targets,"['the', 'emergence', 'and', 'international', 'dissemination', 'of', 'multidrug', 'resistant', 'istaphylococcus', 'aureusi', 'is', 'aureusi', 'strains', 'challenge', 'current', 'antibioticbased', 'therapies', 'representing', 'an', 'urgent', 'threat', 'to', 'public', 'health', 'worldwide', 'in', 'the', 'us', 'alone', 'isi', 'iaureusi', 'infections', 'are', 'responsible', 'for', '11000', 'deaths', 'and', '500000', 'hospitalizations', 'annually', 'biofilm', 'formation', 'is', 'a', 'major', 'contributor', 'to', 'antibiotic', 'tolerance', 'and', 'resistanceinduced', 'delays', 'in', 'empirical', 'therapy', 'with', 'increased', 'infection', 'severity', 'frequency', 'treatment', 'failure', 'and', 'mortality', 'developing', 'novel', 'treatment', 'strategies', 'to', 'prevent', 'and', 'disrupt', 'biofilm', 'formation', 'is', 'imperative', 'in', 'this', 'article', 'we', 'test', 'the', 'secretion', 'modification', 'region', 'smr', 'peptides', 'for', 'inhibitory', 'effects', 'on', 'resistant', 'is', 'aureusi', 'biofilmforming', 'capacity', 'by', 'targeting', 'the', 'molecular', 'chaperone', 'dnak', 'the', 'dose', 'effect', 'of', 'smr', 'peptides', 'on', 'biofilm', 'formation', 'was', 'assessed', 'using', 'microtiter', 'plate', 'methods', 'and', 'confocal', 'microscopy', 'interaction', 'between', 'the', 'antagonist', 'and', 'dnak', 'was', 'determined', 'by', 'immune', 'precipitation', 'with', 'antiflag', 'm2', 'affinity', 'and', 'western', 'blot', 'analysis', 'increasing', 'smr', 'peptide', 'concentrations', 'exhibited', 'increasing', 'blockade', 'of', 'is', 'aureusi', 'biofilm', 'formation', 'with', 'significant', 'inhibition', 'found', 'at', '18', 'µm', '36', 'µm', 'and', '72', 'µm', 'this', 'work', 'supports', 'the', 'potential', 'therapeutic', 'benefit', 'of', 'smr', 'peptides', 'in', 'reducing', 'biofilm', 'viability', 'and', 'could', 'improve', 'the', 'susceptibility', 'to', 'antimicrobial', 'agentsimportancethe', 'development', 'of', 'antibiofilm', 'agents', 'is', 'critical', 'to', 'restoring', 'bacterial', 'sensitivity', 'directly', 'combating', 'the', 'evolution', 'of', 'resistance', 'and', 'overall', 'reducing', 'the', 'clinical', 'burden', 'related', 'to', 'pervasive', 'biofilmmediated', 'infections', 'thus', 'in', 'this', 'study', 'the', 'smr', 'peptide', 'a', 'novel', 'small', 'molecule', 'derived', 'from', 'the', 'hiv', 'nef', 'protein', 'was', 'preliminarily', 'explored', 'for', 'antibiofilm', 'properties', 'the', 'smr', 'peptide', 'was', 'shown', 'to', 'effectively', 'target', 'the', 'molecular', 'chaperone', 'dnak', 'and', 'inhibit', 'biofilm', 'formation', 'in', 'a', 'dosedependent', 'manner', 'these', 'results', 'support', 'further', 'investigation', 'into', 'the', 'mechanism', 'of', 'smr', 'peptidemediated', 'biofilm', 'formation', 'and', 'inhibition', 'to', 'benefit', 'rational', 'drug', 'design', 'and', 'the', 'identification', 'of', 'therapeutic', 'targets']","['emergence', 'international', 'dissemination', 'multidrug', 'resistant', 'istaphylococcus', 'aureusi', 'aureusi', 'strains', 'challenge', 'current', 'antibioticbased', 'therapies', 'representing', 'urgent', 'threat', 'public', 'health', 'worldwide', 'us', 'alone', 'isi', 'iaureusi', 'infections', 'responsible', '11000', 'deaths', '500000', 'hospitalizations', 'annually', 'biofilm', 'formation', 'major', 'contributor', 'antibiotic', 'tolerance', 'resistanceinduced', 'delays', 'empirical', 'therapy', 'increased', 'infection', 'severity', 'frequency', 'treatment', 'failure', 'mortality', 'developing', 'novel', 'treatment', 'strategies', 'prevent', 'disrupt', 'biofilm', 'formation', 'imperative', 'article', 'test', 'secretion', 'modification', 'region', 'smr', 'peptides', 'inhibitory', 'effects', 'resistant', 'aureusi', 'biofilmforming', 'capacity', 'targeting', 'molecular', 'chaperone', 'dnak', 'dose', 'effect', 'smr', 'peptides', 'biofilm', 'formation', 'assessed', 'using', 'microtiter', 'plate', 'methods', 'confocal', 'microscopy', 'interaction', 'antagonist', 'dnak', 'determined', 'immune', 'precipitation', 'antiflag', 'm2', 'affinity', 'western', 'blot', 'analysis', 'increasing', 'smr', 'peptide', 'concentrations', 'exhibited', 'increasing', 'blockade', 'aureusi', 'biofilm', 'formation', 'significant', 'inhibition', 'found', '18', 'µm', '36', 'µm', '72', 'µm', 'work', 'supports', 'potential', 'therapeutic', 'benefit', 'smr', 'peptides', 'reducing', 'biofilm', 'viability', 'could', 'improve', 'susceptibility', 'antimicrobial', 'agentsimportancethe', 'development', 'antibiofilm', 'agents', 'critical', 'restoring', 'bacterial', 'sensitivity', 'directly', 'combating', 'evolution', 'resistance', 'overall', 'reducing', 'clinical', 'burden', 'related', 'pervasive', 'biofilmmediated', 'infections', 'thus', 'study', 'smr', 'peptide', 'novel', 'small', 'molecule', 'derived', 'hiv', 'nef', 'protein', 'preliminarily', 'explored', 'antibiofilm', 'properties', 'smr', 'peptide', 'shown', 'effectively', 'target', 'molecular', 'chaperone', 'dnak', 'inhibit', 'biofilm', 'formation', 'dosedependent', 'manner', 'results', 'support', 'investigation', 'mechanism', 'smr', 'peptidemediated', 'biofilm', 'formation', 'inhibition', 'benefit', 'rational', 'drug', 'design', 'identification', 'therapeutic', 'targets']","['smr', 'smr', 'smr', 'smr', 'smr', 'smr', 'smr']","['smr', 'smr', 'smr', 'smr', 'smr', 'smr', 'smr']",True,['infection']
38164158,Selective induction of Rab9-dependent alternative mitophagy using a synthetic derivative of isoquinoline alleviates mitochondrial dysfunction and cognitive deficits in Alzheimer's disease models.,"<b>Rationale:</b> Promotion of mitophagy is considered a promising strategy for the treatment of neurodegenerative diseases including Alzheimer's disease (AD). The development of mitophagy-specific inducers with low toxicity and defined molecular mechanisms is essential for the clinical application of mitophagy-based therapy. The aim of this study was to investigate the potential of a novel small-molecule mitophagy inducer, ALT001, as a treatment for AD. <b>Methods:</b> ALT001 was developed through chemical optimization of an isoquinolium scaffold, which was identified from a chemical library screening using a mitophagy reporter system. <i>In vitro</i> and <i>in vivo</i> experiments were conducted to evaluate the potential of ALT001 as a mitophagy-targeting therapeutic agent and to investigate the molecular mechanisms underlying ALT001-induced mitophagy. The therapeutic effect of ALT001 was assessed in SH-SY5Y cells expressing mutant APP and mouse models of AD (5×FAD and PS2APP) by analyzing mitochondrial dysfunction and cognitive defects. <b>Results:</b> ALT001 specifically induces mitophagy both <i>in vitro</i> and <i>in vivo</i> but is nontoxic to mitochondria. Interestingly, we found that ALT001 induces mitophagy through the ULK1-Rab9-dependent alternative mitophagy pathway independent of canonical mitophagy pathway regulators such as ATG7 and PINK1. Importantly, ALT001 reverses mitochondrial dysfunction in SH-SY5Y cells expressing mutant APP in a mitophagy-dependent manner. ALT001 induces alternative mitophagy in mice and restores the decreased mitophagy level in a 5×FAD AD model mouse. In addition, ALT001 reverses mitochondrial dysfunction and cognitive defects in the PS2APP and 5×FAD AD mouse models. AAV-mediated silencing of Rab9 in the hippocampus further confirmed that ALT001 exerts its therapeutic effect through alternative mitophagy. <b>Conclusion:</b> Our results highlight the therapeutic potential of ALT001 for AD via alleviation of mitochondrial dysfunction and indicate the usefulness of the ULK1-Rab9 alternative mitophagy pathway as a therapeutic target.",2024-01-01,brationaleb promotion of mitophagy is considered a promising strategy for the treatment of neurodegenerative diseases including alzheimers disease ad the development of mitophagyspecific inducers with low toxicity and defined molecular mechanisms is essential for the clinical application of mitophagybased therapy the aim of this study was to investigate the potential of a novel smallmolecule mitophagy inducer alt001 as a treatment for ad bmethodsb alt001 was developed through chemical optimization of an isoquinolium scaffold which was identified from a chemical library screening using a mitophagy reporter system iin vitroi and iin vivoi experiments were conducted to evaluate the potential of alt001 as a mitophagytargeting therapeutic agent and to investigate the molecular mechanisms underlying alt001induced mitophagy the therapeutic effect of alt001 was assessed in shsy5y cells expressing mutant app and mouse models of ad 5fad and ps2app by analyzing mitochondrial dysfunction and cognitive defects bresultsb alt001 specifically induces mitophagy both iin vitroi and iin vivoi but is nontoxic to mitochondria interestingly we found that alt001 induces mitophagy through the ulk1rab9dependent alternative mitophagy pathway independent of canonical mitophagy pathway regulators such as atg7 and pink1 importantly alt001 reverses mitochondrial dysfunction in shsy5y cells expressing mutant app in a mitophagydependent manner alt001 induces alternative mitophagy in mice and restores the decreased mitophagy level in a 5fad ad model mouse in addition alt001 reverses mitochondrial dysfunction and cognitive defects in the ps2app and 5fad ad mouse models aavmediated silencing of rab9 in the hippocampus further confirmed that alt001 exerts its therapeutic effect through alternative mitophagy bconclusionb our results highlight the therapeutic potential of alt001 for ad via alleviation of mitochondrial dysfunction and indicate the usefulness of the ulk1rab9 alternative mitophagy pathway as a therapeutic target,"['brationaleb', 'promotion', 'of', 'mitophagy', 'is', 'considered', 'a', 'promising', 'strategy', 'for', 'the', 'treatment', 'of', 'neurodegenerative', 'diseases', 'including', 'alzheimers', 'disease', 'ad', 'the', 'development', 'of', 'mitophagyspecific', 'inducers', 'with', 'low', 'toxicity', 'and', 'defined', 'molecular', 'mechanisms', 'is', 'essential', 'for', 'the', 'clinical', 'application', 'of', 'mitophagybased', 'therapy', 'the', 'aim', 'of', 'this', 'study', 'was', 'to', 'investigate', 'the', 'potential', 'of', 'a', 'novel', 'smallmolecule', 'mitophagy', 'inducer', 'alt001', 'as', 'a', 'treatment', 'for', 'ad', 'bmethodsb', 'alt001', 'was', 'developed', 'through', 'chemical', 'optimization', 'of', 'an', 'isoquinolium', 'scaffold', 'which', 'was', 'identified', 'from', 'a', 'chemical', 'library', 'screening', 'using', 'a', 'mitophagy', 'reporter', 'system', 'iin', 'vitroi', 'and', 'iin', 'vivoi', 'experiments', 'were', 'conducted', 'to', 'evaluate', 'the', 'potential', 'of', 'alt001', 'as', 'a', 'mitophagytargeting', 'therapeutic', 'agent', 'and', 'to', 'investigate', 'the', 'molecular', 'mechanisms', 'underlying', 'alt001induced', 'mitophagy', 'the', 'therapeutic', 'effect', 'of', 'alt001', 'was', 'assessed', 'in', 'shsy5y', 'cells', 'expressing', 'mutant', 'app', 'and', 'mouse', 'models', 'of', 'ad', '5fad', 'and', 'ps2app', 'by', 'analyzing', 'mitochondrial', 'dysfunction', 'and', 'cognitive', 'defects', 'bresultsb', 'alt001', 'specifically', 'induces', 'mitophagy', 'both', 'iin', 'vitroi', 'and', 'iin', 'vivoi', 'but', 'is', 'nontoxic', 'to', 'mitochondria', 'interestingly', 'we', 'found', 'that', 'alt001', 'induces', 'mitophagy', 'through', 'the', 'ulk1rab9dependent', 'alternative', 'mitophagy', 'pathway', 'independent', 'of', 'canonical', 'mitophagy', 'pathway', 'regulators', 'such', 'as', 'atg7', 'and', 'pink1', 'importantly', 'alt001', 'reverses', 'mitochondrial', 'dysfunction', 'in', 'shsy5y', 'cells', 'expressing', 'mutant', 'app', 'in', 'a', 'mitophagydependent', 'manner', 'alt001', 'induces', 'alternative', 'mitophagy', 'in', 'mice', 'and', 'restores', 'the', 'decreased', 'mitophagy', 'level', 'in', 'a', '5fad', 'ad', 'model', 'mouse', 'in', 'addition', 'alt001', 'reverses', 'mitochondrial', 'dysfunction', 'and', 'cognitive', 'defects', 'in', 'the', 'ps2app', 'and', '5fad', 'ad', 'mouse', 'models', 'aavmediated', 'silencing', 'of', 'rab9', 'in', 'the', 'hippocampus', 'further', 'confirmed', 'that', 'alt001', 'exerts', 'its', 'therapeutic', 'effect', 'through', 'alternative', 'mitophagy', 'bconclusionb', 'our', 'results', 'highlight', 'the', 'therapeutic', 'potential', 'of', 'alt001', 'for', 'ad', 'via', 'alleviation', 'of', 'mitochondrial', 'dysfunction', 'and', 'indicate', 'the', 'usefulness', 'of', 'the', 'ulk1rab9', 'alternative', 'mitophagy', 'pathway', 'as', 'a', 'therapeutic', 'target']","['brationaleb', 'promotion', 'mitophagy', 'considered', 'promising', 'strategy', 'treatment', 'neurodegenerative', 'diseases', 'including', 'alzheimers', 'disease', 'ad', 'development', 'mitophagyspecific', 'inducers', 'low', 'toxicity', 'defined', 'molecular', 'mechanisms', 'essential', 'clinical', 'application', 'mitophagybased', 'therapy', 'aim', 'study', 'investigate', 'potential', 'novel', 'smallmolecule', 'mitophagy', 'inducer', 'alt001', 'treatment', 'ad', 'bmethodsb', 'alt001', 'developed', 'chemical', 'optimization', 'isoquinolium', 'scaffold', 'identified', 'chemical', 'library', 'screening', 'using', 'mitophagy', 'reporter', 'system', 'iin', 'vitroi', 'iin', 'vivoi', 'experiments', 'conducted', 'evaluate', 'potential', 'alt001', 'mitophagytargeting', 'therapeutic', 'agent', 'investigate', 'molecular', 'mechanisms', 'underlying', 'alt001induced', 'mitophagy', 'therapeutic', 'effect', 'alt001', 'assessed', 'shsy5y', 'cells', 'expressing', 'mutant', 'app', 'mouse', 'models', 'ad', '5fad', 'ps2app', 'analyzing', 'mitochondrial', 'dysfunction', 'cognitive', 'defects', 'bresultsb', 'alt001', 'specifically', 'induces', 'mitophagy', 'iin', 'vitroi', 'iin', 'vivoi', 'nontoxic', 'mitochondria', 'interestingly', 'found', 'alt001', 'induces', 'mitophagy', 'ulk1rab9dependent', 'alternative', 'mitophagy', 'pathway', 'independent', 'canonical', 'mitophagy', 'pathway', 'regulators', 'atg7', 'pink1', 'importantly', 'alt001', 'reverses', 'mitochondrial', 'dysfunction', 'shsy5y', 'cells', 'expressing', 'mutant', 'app', 'mitophagydependent', 'manner', 'alt001', 'induces', 'alternative', 'mitophagy', 'mice', 'restores', 'decreased', 'mitophagy', 'level', '5fad', 'ad', 'model', 'mouse', 'addition', 'alt001', 'reverses', 'mitochondrial', 'dysfunction', 'cognitive', 'defects', 'ps2app', '5fad', 'ad', 'mouse', 'models', 'aavmediated', 'silencing', 'rab9', 'hippocampus', 'confirmed', 'alt001', 'exerts', 'therapeutic', 'effect', 'alternative', 'mitophagy', 'bconclusionb', 'results', 'highlight', 'therapeutic', 'potential', 'alt001', 'ad', 'via', 'alleviation', 'mitochondrial', 'dysfunction', 'indicate', 'usefulness', 'ulk1rab9', 'alternative', 'mitophagy', 'pathway', 'therapeutic', 'target']",['pink1'],['pink1'],True,['alzheimer']
38139260,The LIFR Inhibitor EC359 Effectively Targets Type II Endometrial Cancer by Blocking LIF/LIFR Oncogenic Signaling.,"Endometrial cancer (ECa) is the most common female gynecologic cancer. When comparing the two histological subtypes of endometrial cancer, Type II tumors are biologically more aggressive and have a worse prognosis than Type I tumors. Current treatments for Type II tumors are ineffective, and new targeted therapies are urgently needed. LIFR and its ligand, LIF, have been shown to play a critical role in the progression of multiple solid cancers and therapy resistance. The role of LIF/LIFR in the progression of Type II ECa, on the other hand, is unknown. We investigated the role of LIF/LIFR signaling in Type II ECa and tested the efficacy of EC359, a novel small-molecule LIFR inhibitor, against Type II ECa. The analysis of tumor databases has uncovered a correlation between diminished survival rates and increased expression of leukemia inhibitory factor (LIF), suggesting a potential connection between altered LIF expression and unfavorable overall survival in Type II ECa. The results obtained from cell viability and colony formation assays demonstrated a significant decrease in the growth of Type II ECa LIFR knockdown cells in comparison to vector control cells. Furthermore, in both primary and established Type II ECa cells, pharmacological inhibition of the LIF/LIFR axis with EC359 markedly decreased cell viability, long-term cell survival, and invasion, and promoted apoptosis. Additionally, EC359 treatment reduced the activation of pathways driven by LIF/LIFR, such as AKT, mTOR, and STAT3. Tumor progression was markedly inhibited by EC359 treatment in two different patient-derived xenograft models in vivo and patient-derived organoids ex vivo. Collectively, these results suggest LIFR inhibitor EC359 as a possible new small-molecule therapeutics for the management of Type II ECa.",2023-12-13,endometrial cancer eca is the most common female gynecologic cancer when comparing the two histological subtypes of endometrial cancer type ii tumors are biologically more aggressive and have a worse prognosis than type i tumors current treatments for type ii tumors are ineffective and new targeted therapies are urgently needed lifr and its ligand lif have been shown to play a critical role in the progression of multiple solid cancers and therapy resistance the role of liflifr in the progression of type ii eca on the other hand is unknown we investigated the role of liflifr signaling in type ii eca and tested the efficacy of ec359 a novel smallmolecule lifr inhibitor against type ii eca the analysis of tumor databases has uncovered a correlation between diminished survival rates and increased expression of leukemia inhibitory factor lif suggesting a potential connection between altered lif expression and unfavorable overall survival in type ii eca the results obtained from cell viability and colony formation assays demonstrated a significant decrease in the growth of type ii eca lifr knockdown cells in comparison to vector control cells furthermore in both primary and established type ii eca cells pharmacological inhibition of the liflifr axis with ec359 markedly decreased cell viability longterm cell survival and invasion and promoted apoptosis additionally ec359 treatment reduced the activation of pathways driven by liflifr such as akt mtor and stat3 tumor progression was markedly inhibited by ec359 treatment in two different patientderived xenograft models in vivo and patientderived organoids ex vivo collectively these results suggest lifr inhibitor ec359 as a possible new smallmolecule therapeutics for the management of type ii eca,"['endometrial', 'cancer', 'eca', 'is', 'the', 'most', 'common', 'female', 'gynecologic', 'cancer', 'when', 'comparing', 'the', 'two', 'histological', 'subtypes', 'of', 'endometrial', 'cancer', 'type', 'ii', 'tumors', 'are', 'biologically', 'more', 'aggressive', 'and', 'have', 'a', 'worse', 'prognosis', 'than', 'type', 'i', 'tumors', 'current', 'treatments', 'for', 'type', 'ii', 'tumors', 'are', 'ineffective', 'and', 'new', 'targeted', 'therapies', 'are', 'urgently', 'needed', 'lifr', 'and', 'its', 'ligand', 'lif', 'have', 'been', 'shown', 'to', 'play', 'a', 'critical', 'role', 'in', 'the', 'progression', 'of', 'multiple', 'solid', 'cancers', 'and', 'therapy', 'resistance', 'the', 'role', 'of', 'liflifr', 'in', 'the', 'progression', 'of', 'type', 'ii', 'eca', 'on', 'the', 'other', 'hand', 'is', 'unknown', 'we', 'investigated', 'the', 'role', 'of', 'liflifr', 'signaling', 'in', 'type', 'ii', 'eca', 'and', 'tested', 'the', 'efficacy', 'of', 'ec359', 'a', 'novel', 'smallmolecule', 'lifr', 'inhibitor', 'against', 'type', 'ii', 'eca', 'the', 'analysis', 'of', 'tumor', 'databases', 'has', 'uncovered', 'a', 'correlation', 'between', 'diminished', 'survival', 'rates', 'and', 'increased', 'expression', 'of', 'leukemia', 'inhibitory', 'factor', 'lif', 'suggesting', 'a', 'potential', 'connection', 'between', 'altered', 'lif', 'expression', 'and', 'unfavorable', 'overall', 'survival', 'in', 'type', 'ii', 'eca', 'the', 'results', 'obtained', 'from', 'cell', 'viability', 'and', 'colony', 'formation', 'assays', 'demonstrated', 'a', 'significant', 'decrease', 'in', 'the', 'growth', 'of', 'type', 'ii', 'eca', 'lifr', 'knockdown', 'cells', 'in', 'comparison', 'to', 'vector', 'control', 'cells', 'furthermore', 'in', 'both', 'primary', 'and', 'established', 'type', 'ii', 'eca', 'cells', 'pharmacological', 'inhibition', 'of', 'the', 'liflifr', 'axis', 'with', 'ec359', 'markedly', 'decreased', 'cell', 'viability', 'longterm', 'cell', 'survival', 'and', 'invasion', 'and', 'promoted', 'apoptosis', 'additionally', 'ec359', 'treatment', 'reduced', 'the', 'activation', 'of', 'pathways', 'driven', 'by', 'liflifr', 'such', 'as', 'akt', 'mtor', 'and', 'stat3', 'tumor', 'progression', 'was', 'markedly', 'inhibited', 'by', 'ec359', 'treatment', 'in', 'two', 'different', 'patientderived', 'xenograft', 'models', 'in', 'vivo', 'and', 'patientderived', 'organoids', 'ex', 'vivo', 'collectively', 'these', 'results', 'suggest', 'lifr', 'inhibitor', 'ec359', 'as', 'a', 'possible', 'new', 'smallmolecule', 'therapeutics', 'for', 'the', 'management', 'of', 'type', 'ii', 'eca']","['endometrial', 'cancer', 'eca', 'common', 'female', 'gynecologic', 'cancer', 'comparing', 'two', 'histological', 'subtypes', 'endometrial', 'cancer', 'type', 'ii', 'tumors', 'biologically', 'aggressive', 'worse', 'prognosis', 'type', 'tumors', 'current', 'treatments', 'type', 'ii', 'tumors', 'ineffective', 'new', 'targeted', 'therapies', 'urgently', 'needed', 'lifr', 'ligand', 'lif', 'shown', 'play', 'critical', 'role', 'progression', 'multiple', 'solid', 'cancers', 'therapy', 'resistance', 'role', 'liflifr', 'progression', 'type', 'ii', 'eca', 'hand', 'unknown', 'investigated', 'role', 'liflifr', 'signaling', 'type', 'ii', 'eca', 'tested', 'efficacy', 'ec359', 'novel', 'smallmolecule', 'lifr', 'inhibitor', 'type', 'ii', 'eca', 'analysis', 'tumor', 'databases', 'uncovered', 'correlation', 'diminished', 'survival', 'rates', 'increased', 'expression', 'leukemia', 'inhibitory', 'factor', 'lif', 'suggesting', 'potential', 'connection', 'altered', 'lif', 'expression', 'unfavorable', 'overall', 'survival', 'type', 'ii', 'eca', 'results', 'obtained', 'cell', 'viability', 'colony', 'formation', 'assays', 'demonstrated', 'significant', 'decrease', 'growth', 'type', 'ii', 'eca', 'lifr', 'knockdown', 'cells', 'comparison', 'vector', 'control', 'cells', 'furthermore', 'primary', 'established', 'type', 'ii', 'eca', 'cells', 'pharmacological', 'inhibition', 'liflifr', 'axis', 'ec359', 'markedly', 'decreased', 'cell', 'viability', 'longterm', 'cell', 'survival', 'invasion', 'promoted', 'apoptosis', 'additionally', 'ec359', 'treatment', 'reduced', 'activation', 'pathways', 'driven', 'liflifr', 'akt', 'mtor', 'stat3', 'tumor', 'progression', 'markedly', 'inhibited', 'ec359', 'treatment', 'two', 'different', 'patientderived', 'xenograft', 'models', 'vivo', 'patientderived', 'organoids', 'ex', 'vivo', 'collectively', 'results', 'suggest', 'lifr', 'inhibitor', 'ec359', 'possible', 'new', 'smallmolecule', 'therapeutics', 'management', 'type', 'ii', 'eca']","['lifr', 'lif', 'lifr', 'lif', 'lif', 'lifr', 'akt', 'stat3', 'lifr']","['lifr', 'lif', 'lifr', 'lif', 'lif', 'lifr', 'lifr']",True,"['tumor', 'cancer', 'leukemia']"
38043914,Release of a novel peptide from ferritin nanocages: A new tool for therapeutic applications.,"The development of new drug delivery systems for targeted chemotherapy release in cancer cells represents a very promising tool. In this contest, protein-based nanocages have considerable potential as drug delivery devices. Notably, ferritin has emerged as an excellent candidate due to its unique architecture, surface properties and high biocompatibility. A promising strategy might then involve ferritin cargos for specifical release of AntiMicrobial Peptides endowed with anticancer activity to cancer cells. In this paper, we encapsulated the TRIL analogue of Temporin-L peptide within a ferritin nanocage and evaluated the cargo biological properties. The results demonstrated a reduced haemolytic activity of the peptide and a selective cytotoxicity activity on cancer cells likely mediated by oxidative stress while having no effects on non-tumoral cells. The combination of the properties of ferritin with TRIL, might open up the way to the development of novel peptide delivery systems for future pharmaceutical applications.",2023-12-02,the development of new drug delivery systems for targeted chemotherapy release in cancer cells represents a very promising tool in this contest proteinbased nanocages have considerable potential as drug delivery devices notably ferritin has emerged as an excellent candidate due to its unique architecture surface properties and high biocompatibility a promising strategy might then involve ferritin cargos for specifical release of antimicrobial peptides endowed with anticancer activity to cancer cells in this paper we encapsulated the tril analogue of temporinl peptide within a ferritin nanocage and evaluated the cargo biological properties the results demonstrated a reduced haemolytic activity of the peptide and a selective cytotoxicity activity on cancer cells likely mediated by oxidative stress while having no effects on nontumoral cells the combination of the properties of ferritin with tril might open up the way to the development of novel peptide delivery systems for future pharmaceutical applications,"['the', 'development', 'of', 'new', 'drug', 'delivery', 'systems', 'for', 'targeted', 'chemotherapy', 'release', 'in', 'cancer', 'cells', 'represents', 'a', 'very', 'promising', 'tool', 'in', 'this', 'contest', 'proteinbased', 'nanocages', 'have', 'considerable', 'potential', 'as', 'drug', 'delivery', 'devices', 'notably', 'ferritin', 'has', 'emerged', 'as', 'an', 'excellent', 'candidate', 'due', 'to', 'its', 'unique', 'architecture', 'surface', 'properties', 'and', 'high', 'biocompatibility', 'a', 'promising', 'strategy', 'might', 'then', 'involve', 'ferritin', 'cargos', 'for', 'specifical', 'release', 'of', 'antimicrobial', 'peptides', 'endowed', 'with', 'anticancer', 'activity', 'to', 'cancer', 'cells', 'in', 'this', 'paper', 'we', 'encapsulated', 'the', 'tril', 'analogue', 'of', 'temporinl', 'peptide', 'within', 'a', 'ferritin', 'nanocage', 'and', 'evaluated', 'the', 'cargo', 'biological', 'properties', 'the', 'results', 'demonstrated', 'a', 'reduced', 'haemolytic', 'activity', 'of', 'the', 'peptide', 'and', 'a', 'selective', 'cytotoxicity', 'activity', 'on', 'cancer', 'cells', 'likely', 'mediated', 'by', 'oxidative', 'stress', 'while', 'having', 'no', 'effects', 'on', 'nontumoral', 'cells', 'the', 'combination', 'of', 'the', 'properties', 'of', 'ferritin', 'with', 'tril', 'might', 'open', 'up', 'the', 'way', 'to', 'the', 'development', 'of', 'novel', 'peptide', 'delivery', 'systems', 'for', 'future', 'pharmaceutical', 'applications']","['development', 'new', 'drug', 'delivery', 'systems', 'targeted', 'chemotherapy', 'release', 'cancer', 'cells', 'represents', 'promising', 'tool', 'contest', 'proteinbased', 'nanocages', 'considerable', 'potential', 'drug', 'delivery', 'devices', 'notably', 'ferritin', 'emerged', 'excellent', 'candidate', 'due', 'unique', 'architecture', 'surface', 'properties', 'high', 'biocompatibility', 'promising', 'strategy', 'might', 'involve', 'ferritin', 'cargos', 'specifical', 'release', 'antimicrobial', 'peptides', 'endowed', 'anticancer', 'activity', 'cancer', 'cells', 'paper', 'encapsulated', 'tril', 'analogue', 'temporinl', 'peptide', 'within', 'ferritin', 'nanocage', 'evaluated', 'cargo', 'biological', 'properties', 'results', 'demonstrated', 'reduced', 'haemolytic', 'activity', 'peptide', 'selective', 'cytotoxicity', 'activity', 'cancer', 'cells', 'likely', 'mediated', 'oxidative', 'stress', 'effects', 'nontumoral', 'cells', 'combination', 'properties', 'ferritin', 'tril', 'might', 'open', 'way', 'development', 'novel', 'peptide', 'delivery', 'systems', 'future', 'pharmaceutical', 'applications']","['ferritin', 'ferritin', 'ferritin', 'ferritin']","['ferritin', 'ferritin', 'ferritin', 'ferritin']",False,"['tumor', 'cancer']"
38035024,"A novel small molecule, CU05-1189, targeting the pleckstrin homology domain of PDK1 suppresses VEGF-mediated angiogenesis and tumor growth by blocking the Akt signaling pathway.","Inhibition of angiogenesis is considered a promising therapeutic approach for cancer treatment. Our previous genetic research showed that the use of a cell-penetrating peptide to inhibit the pleckstrin homology (PH) domain of 3-phosphoinositide-dependent kinase 1 (PDK1) was a viable approach to suppress pathological angiogenesis. Herein, we synthesized and characterized a novel small molecule, CU05-1189, based on our prior study and present evidence for the first time that this compound possesses antiangiogenic properties both <i>in vitro</i> and <i>in vivo</i>. The computational analysis showed that CU05-1189 can interact with the PH domain of PDK1, and it significantly inhibited vascular endothelial growth factor (VEGF)-induced proliferation, migration, invasion, and tube formation in human umbilical vein endothelial cells without apparent toxicity. Western blot analysis revealed that the Akt signaling pathway was specifically inhibited by CU05-1189 upon VEGF stimulation, without affecting other VEGF receptor 2 downstream molecules or cytosolic substrates of PDK1, by preventing translocation of PDK1 to the plasma membrane. We also found that CU05-1189 suppressed VEGF-mediated vascular network formation in a Matrigel plug assay. More importantly, CU05-1189 had a good pharmacokinetic profile with a bioavailability of 68%. These results led to the oral administration of CU05-1189, which resulted in reduced tumor microvessel density and growth in a xenograft mouse model. Taken together, our data suggest that CU05-1189 may have great potential and be a promising lead as a novel antiangiogenic agent for cancer treatment.",2023-11-16,inhibition of angiogenesis is considered a promising therapeutic approach for cancer treatment our previous genetic research showed that the use of a cellpenetrating peptide to inhibit the pleckstrin homology ph domain of 3phosphoinositidedependent kinase 1 pdk1 was a viable approach to suppress pathological angiogenesis herein we synthesized and characterized a novel small molecule cu051189 based on our prior study and present evidence for the first time that this compound possesses antiangiogenic properties both iin vitroi and iin vivoi the computational analysis showed that cu051189 can interact with the ph domain of pdk1 and it significantly inhibited vascular endothelial growth factor vegfinduced proliferation migration invasion and tube formation in human umbilical vein endothelial cells without apparent toxicity western blot analysis revealed that the akt signaling pathway was specifically inhibited by cu051189 upon vegf stimulation without affecting other vegf receptor 2 downstream molecules or cytosolic substrates of pdk1 by preventing translocation of pdk1 to the plasma membrane we also found that cu051189 suppressed vegfmediated vascular network formation in a matrigel plug assay more importantly cu051189 had a good pharmacokinetic profile with a bioavailability of 68 these results led to the oral administration of cu051189 which resulted in reduced tumor microvessel density and growth in a xenograft mouse model taken together our data suggest that cu051189 may have great potential and be a promising lead as a novel antiangiogenic agent for cancer treatment,"['inhibition', 'of', 'angiogenesis', 'is', 'considered', 'a', 'promising', 'therapeutic', 'approach', 'for', 'cancer', 'treatment', 'our', 'previous', 'genetic', 'research', 'showed', 'that', 'the', 'use', 'of', 'a', 'cellpenetrating', 'peptide', 'to', 'inhibit', 'the', 'pleckstrin', 'homology', 'ph', 'domain', 'of', '3phosphoinositidedependent', 'kinase', '1', 'pdk1', 'was', 'a', 'viable', 'approach', 'to', 'suppress', 'pathological', 'angiogenesis', 'herein', 'we', 'synthesized', 'and', 'characterized', 'a', 'novel', 'small', 'molecule', 'cu051189', 'based', 'on', 'our', 'prior', 'study', 'and', 'present', 'evidence', 'for', 'the', 'first', 'time', 'that', 'this', 'compound', 'possesses', 'antiangiogenic', 'properties', 'both', 'iin', 'vitroi', 'and', 'iin', 'vivoi', 'the', 'computational', 'analysis', 'showed', 'that', 'cu051189', 'can', 'interact', 'with', 'the', 'ph', 'domain', 'of', 'pdk1', 'and', 'it', 'significantly', 'inhibited', 'vascular', 'endothelial', 'growth', 'factor', 'vegfinduced', 'proliferation', 'migration', 'invasion', 'and', 'tube', 'formation', 'in', 'human', 'umbilical', 'vein', 'endothelial', 'cells', 'without', 'apparent', 'toxicity', 'western', 'blot', 'analysis', 'revealed', 'that', 'the', 'akt', 'signaling', 'pathway', 'was', 'specifically', 'inhibited', 'by', 'cu051189', 'upon', 'vegf', 'stimulation', 'without', 'affecting', 'other', 'vegf', 'receptor', '2', 'downstream', 'molecules', 'or', 'cytosolic', 'substrates', 'of', 'pdk1', 'by', 'preventing', 'translocation', 'of', 'pdk1', 'to', 'the', 'plasma', 'membrane', 'we', 'also', 'found', 'that', 'cu051189', 'suppressed', 'vegfmediated', 'vascular', 'network', 'formation', 'in', 'a', 'matrigel', 'plug', 'assay', 'more', 'importantly', 'cu051189', 'had', 'a', 'good', 'pharmacokinetic', 'profile', 'with', 'a', 'bioavailability', 'of', '68', 'these', 'results', 'led', 'to', 'the', 'oral', 'administration', 'of', 'cu051189', 'which', 'resulted', 'in', 'reduced', 'tumor', 'microvessel', 'density', 'and', 'growth', 'in', 'a', 'xenograft', 'mouse', 'model', 'taken', 'together', 'our', 'data', 'suggest', 'that', 'cu051189', 'may', 'have', 'great', 'potential', 'and', 'be', 'a', 'promising', 'lead', 'as', 'a', 'novel', 'antiangiogenic', 'agent', 'for', 'cancer', 'treatment']","['inhibition', 'angiogenesis', 'considered', 'promising', 'therapeutic', 'approach', 'cancer', 'treatment', 'previous', 'genetic', 'research', 'showed', 'use', 'cellpenetrating', 'peptide', 'inhibit', 'pleckstrin', 'homology', 'ph', 'domain', '3phosphoinositidedependent', 'kinase', '1', 'pdk1', 'viable', 'approach', 'suppress', 'pathological', 'angiogenesis', 'herein', 'synthesized', 'characterized', 'novel', 'small', 'molecule', 'cu051189', 'based', 'prior', 'study', 'present', 'evidence', 'first', 'time', 'compound', 'possesses', 'antiangiogenic', 'properties', 'iin', 'vitroi', 'iin', 'vivoi', 'computational', 'analysis', 'showed', 'cu051189', 'interact', 'ph', 'domain', 'pdk1', 'significantly', 'inhibited', 'vascular', 'endothelial', 'growth', 'factor', 'vegfinduced', 'proliferation', 'migration', 'invasion', 'tube', 'formation', 'human', 'umbilical', 'vein', 'endothelial', 'cells', 'without', 'apparent', 'toxicity', 'western', 'blot', 'analysis', 'revealed', 'akt', 'signaling', 'pathway', 'specifically', 'inhibited', 'cu051189', 'upon', 'vegf', 'stimulation', 'without', 'affecting', 'vegf', 'receptor', '2', 'downstream', 'molecules', 'cytosolic', 'substrates', 'pdk1', 'preventing', 'translocation', 'pdk1', 'plasma', 'membrane', 'also', 'found', 'cu051189', 'suppressed', 'vegfmediated', 'vascular', 'network', 'formation', 'matrigel', 'plug', 'assay', 'importantly', 'cu051189', 'good', 'pharmacokinetic', 'profile', 'bioavailability', '68', 'results', 'led', 'oral', 'administration', 'cu051189', 'resulted', 'reduced', 'tumor', 'microvessel', 'density', 'growth', 'xenograft', 'mouse', 'model', 'taken', 'together', 'data', 'suggest', 'cu051189', 'may', 'great', 'potential', 'promising', 'lead', 'novel', 'antiangiogenic', 'agent', 'cancer', 'treatment']","['pleckstrin', 'pdk1', 'pdk1', 'akt', 'vegf', 'vegf', 'pdk1', 'pdk1']",['pleckstrin'],True,"['tumor', 'cancer']"
38012755,Therapeutic effect and transcriptome-methylome characteristics of METTL3 inhibition in liver hepatocellular carcinoma.,"Methyltransferase-like 3 (METTL3) is the key subunit of methyltransferase complex responsible for catalyzing N6-methyladenosine (m<sup>6</sup>A) modification on mRNA, which is the most prevalent post-transcriptional modification in eukaryotes. In this study, we utilized online databases to analyze the association between METTL3 expression and various aspects of tumorigenesis, including gene methylation, immunity, and prognosis. Our investigation revealed that METTL3 serves as a prognostic marker and therapeutic target for liver hepatocellular carcinoma (LIHC). Through experimental studies, we observed frequent upregulation of METTL3 in LIHC tumor tissue and cells. Subsequent inhibition of METTL3 using a novel small molecule inhibitor, STM2457, significantly impeded tumor growth in LIHC cell lines, spheroids, and xenograft tumor model. Further, transcriptome and m<sup>6</sup>A sequencing of xenograft bodies unveiled that inhibition of METTL3-m<sup>6</sup>A altered genes enriched in SMAD and MAPK signaling pathways that are critical for tumorigenesis. These findings suggest that targeting METTL3 represents a promising therapeutic strategy for LIHC.",2023-11-27,methyltransferaselike 3 mettl3 is the key subunit of methyltransferase complex responsible for catalyzing n6methyladenosine msup6supa modification on mrna which is the most prevalent posttranscriptional modification in eukaryotes in this study we utilized online databases to analyze the association between mettl3 expression and various aspects of tumorigenesis including gene methylation immunity and prognosis our investigation revealed that mettl3 serves as a prognostic marker and therapeutic target for liver hepatocellular carcinoma lihc through experimental studies we observed frequent upregulation of mettl3 in lihc tumor tissue and cells subsequent inhibition of mettl3 using a novel small molecule inhibitor stm2457 significantly impeded tumor growth in lihc cell lines spheroids and xenograft tumor model further transcriptome and msup6supa sequencing of xenograft bodies unveiled that inhibition of mettl3msup6supa altered genes enriched in smad and mapk signaling pathways that are critical for tumorigenesis these findings suggest that targeting mettl3 represents a promising therapeutic strategy for lihc,"['methyltransferaselike', '3', 'mettl3', 'is', 'the', 'key', 'subunit', 'of', 'methyltransferase', 'complex', 'responsible', 'for', 'catalyzing', 'n6methyladenosine', 'msup6supa', 'modification', 'on', 'mrna', 'which', 'is', 'the', 'most', 'prevalent', 'posttranscriptional', 'modification', 'in', 'eukaryotes', 'in', 'this', 'study', 'we', 'utilized', 'online', 'databases', 'to', 'analyze', 'the', 'association', 'between', 'mettl3', 'expression', 'and', 'various', 'aspects', 'of', 'tumorigenesis', 'including', 'gene', 'methylation', 'immunity', 'and', 'prognosis', 'our', 'investigation', 'revealed', 'that', 'mettl3', 'serves', 'as', 'a', 'prognostic', 'marker', 'and', 'therapeutic', 'target', 'for', 'liver', 'hepatocellular', 'carcinoma', 'lihc', 'through', 'experimental', 'studies', 'we', 'observed', 'frequent', 'upregulation', 'of', 'mettl3', 'in', 'lihc', 'tumor', 'tissue', 'and', 'cells', 'subsequent', 'inhibition', 'of', 'mettl3', 'using', 'a', 'novel', 'small', 'molecule', 'inhibitor', 'stm2457', 'significantly', 'impeded', 'tumor', 'growth', 'in', 'lihc', 'cell', 'lines', 'spheroids', 'and', 'xenograft', 'tumor', 'model', 'further', 'transcriptome', 'and', 'msup6supa', 'sequencing', 'of', 'xenograft', 'bodies', 'unveiled', 'that', 'inhibition', 'of', 'mettl3msup6supa', 'altered', 'genes', 'enriched', 'in', 'smad', 'and', 'mapk', 'signaling', 'pathways', 'that', 'are', 'critical', 'for', 'tumorigenesis', 'these', 'findings', 'suggest', 'that', 'targeting', 'mettl3', 'represents', 'a', 'promising', 'therapeutic', 'strategy', 'for', 'lihc']","['methyltransferaselike', '3', 'mettl3', 'key', 'subunit', 'methyltransferase', 'complex', 'responsible', 'catalyzing', 'n6methyladenosine', 'msup6supa', 'modification', 'mrna', 'prevalent', 'posttranscriptional', 'modification', 'eukaryotes', 'study', 'utilized', 'online', 'databases', 'analyze', 'association', 'mettl3', 'expression', 'various', 'aspects', 'tumorigenesis', 'including', 'gene', 'methylation', 'immunity', 'prognosis', 'investigation', 'revealed', 'mettl3', 'serves', 'prognostic', 'marker', 'therapeutic', 'target', 'liver', 'hepatocellular', 'carcinoma', 'lihc', 'experimental', 'studies', 'observed', 'frequent', 'upregulation', 'mettl3', 'lihc', 'tumor', 'tissue', 'cells', 'subsequent', 'inhibition', 'mettl3', 'using', 'novel', 'small', 'molecule', 'inhibitor', 'stm2457', 'significantly', 'impeded', 'tumor', 'growth', 'lihc', 'cell', 'lines', 'spheroids', 'xenograft', 'tumor', 'model', 'transcriptome', 'msup6supa', 'sequencing', 'xenograft', 'bodies', 'unveiled', 'inhibition', 'mettl3msup6supa', 'altered', 'genes', 'enriched', 'smad', 'mapk', 'signaling', 'pathways', 'critical', 'tumorigenesis', 'findings', 'suggest', 'targeting', 'mettl3', 'represents', 'promising', 'therapeutic', 'strategy', 'lihc']",['smad'],['smad'],True,['tumor']
38006628,Development of chemical tools based on GSK-7975A to study store-operated calcium entry in cells.,"Many physiological functions, such as cell differentiation, proliferation, muscle contraction, neurotransmission and fertilisation, are regulated by changes of Ca<sup>2+</sup> levels. The major Ca<sup>2+</sup> store in cells is the endoplasmic reticulum (ER). Certain cellular processes induce ER store depletion, e.g. by activating IP<sub>3</sub> receptors, that in turn induces a store refilling process known as store-operated calcium entry (SOCE). This refilling process entails protein-protein interactions between Ca<sup>2+</sup> sensing stromal interaction molecules (STIM) in the ER membrane and Orai proteins in the plasma membrane. Fully assembled STIM/Orai complexes then form highly selective Ca<sup>2+</sup> channels called Ca<sup>2+</sup> release-activated Ca<sup>2+</sup> Channels (CRAC) through which Ca<sup>2+</sup> ions flow into the cytosol and subsequently are pumped into the ER by the sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA). Abnormal SOCE has been associated with numerous human diseases and cancers, and therefore key players STIM and Orai have attracted significant therapeutic interest. Several potent experimental and clinical candidate compounds have been developed and have helped to study SOCE in various cell types. We have synthesized multiple novel small-molecule probes based on the known SOCE inhibitor GSK-7975A. Here we present GSK-7975A derivatives, which feature photo-caging, photo-crosslinking, biotin and clickable moieties, and also contain deuterium labels. Evaluation of these GSK-7975A probes using a fluorometric imaging plate reader (FLIPR)-Tetra-based Ca<sup>2+</sup> imaging assay showed that most synthetic modifications did not have a detrimental impact on the SOCE inhibitory activity. The photo-caged GSK-7975A was also used in patch-clamp electrophysiology experiments. In summary, we have developed a number of active, GSK-7975A-based molecular probes that have interesting properties and therefore are useful experimental tools to study SOCE in various cells and settings.",2023-11-15,many physiological functions such as cell differentiation proliferation muscle contraction neurotransmission and fertilisation are regulated by changes of casup2sup levels the major casup2sup store in cells is the endoplasmic reticulum er certain cellular processes induce er store depletion eg by activating ipsub3sub receptors that in turn induces a store refilling process known as storeoperated calcium entry soce this refilling process entails proteinprotein interactions between casup2sup sensing stromal interaction molecules stim in the er membrane and orai proteins in the plasma membrane fully assembled stimorai complexes then form highly selective casup2sup channels called casup2sup releaseactivated casup2sup channels crac through which casup2sup ions flow into the cytosol and subsequently are pumped into the er by the sarcoplasmicendoplasmic reticulum calcium atpase serca abnormal soce has been associated with numerous human diseases and cancers and therefore key players stim and orai have attracted significant therapeutic interest several potent experimental and clinical candidate compounds have been developed and have helped to study soce in various cell types we have synthesized multiple novel smallmolecule probes based on the known soce inhibitor gsk7975a here we present gsk7975a derivatives which feature photocaging photocrosslinking biotin and clickable moieties and also contain deuterium labels evaluation of these gsk7975a probes using a fluorometric imaging plate reader fliprtetrabased casup2sup imaging assay showed that most synthetic modifications did not have a detrimental impact on the soce inhibitory activity the photocaged gsk7975a was also used in patchclamp electrophysiology experiments in summary we have developed a number of active gsk7975abased molecular probes that have interesting properties and therefore are useful experimental tools to study soce in various cells and settings,"['many', 'physiological', 'functions', 'such', 'as', 'cell', 'differentiation', 'proliferation', 'muscle', 'contraction', 'neurotransmission', 'and', 'fertilisation', 'are', 'regulated', 'by', 'changes', 'of', 'casup2sup', 'levels', 'the', 'major', 'casup2sup', 'store', 'in', 'cells', 'is', 'the', 'endoplasmic', 'reticulum', 'er', 'certain', 'cellular', 'processes', 'induce', 'er', 'store', 'depletion', 'eg', 'by', 'activating', 'ipsub3sub', 'receptors', 'that', 'in', 'turn', 'induces', 'a', 'store', 'refilling', 'process', 'known', 'as', 'storeoperated', 'calcium', 'entry', 'soce', 'this', 'refilling', 'process', 'entails', 'proteinprotein', 'interactions', 'between', 'casup2sup', 'sensing', 'stromal', 'interaction', 'molecules', 'stim', 'in', 'the', 'er', 'membrane', 'and', 'orai', 'proteins', 'in', 'the', 'plasma', 'membrane', 'fully', 'assembled', 'stimorai', 'complexes', 'then', 'form', 'highly', 'selective', 'casup2sup', 'channels', 'called', 'casup2sup', 'releaseactivated', 'casup2sup', 'channels', 'crac', 'through', 'which', 'casup2sup', 'ions', 'flow', 'into', 'the', 'cytosol', 'and', 'subsequently', 'are', 'pumped', 'into', 'the', 'er', 'by', 'the', 'sarcoplasmicendoplasmic', 'reticulum', 'calcium', 'atpase', 'serca', 'abnormal', 'soce', 'has', 'been', 'associated', 'with', 'numerous', 'human', 'diseases', 'and', 'cancers', 'and', 'therefore', 'key', 'players', 'stim', 'and', 'orai', 'have', 'attracted', 'significant', 'therapeutic', 'interest', 'several', 'potent', 'experimental', 'and', 'clinical', 'candidate', 'compounds', 'have', 'been', 'developed', 'and', 'have', 'helped', 'to', 'study', 'soce', 'in', 'various', 'cell', 'types', 'we', 'have', 'synthesized', 'multiple', 'novel', 'smallmolecule', 'probes', 'based', 'on', 'the', 'known', 'soce', 'inhibitor', 'gsk7975a', 'here', 'we', 'present', 'gsk7975a', 'derivatives', 'which', 'feature', 'photocaging', 'photocrosslinking', 'biotin', 'and', 'clickable', 'moieties', 'and', 'also', 'contain', 'deuterium', 'labels', 'evaluation', 'of', 'these', 'gsk7975a', 'probes', 'using', 'a', 'fluorometric', 'imaging', 'plate', 'reader', 'fliprtetrabased', 'casup2sup', 'imaging', 'assay', 'showed', 'that', 'most', 'synthetic', 'modifications', 'did', 'not', 'have', 'a', 'detrimental', 'impact', 'on', 'the', 'soce', 'inhibitory', 'activity', 'the', 'photocaged', 'gsk7975a', 'was', 'also', 'used', 'in', 'patchclamp', 'electrophysiology', 'experiments', 'in', 'summary', 'we', 'have', 'developed', 'a', 'number', 'of', 'active', 'gsk7975abased', 'molecular', 'probes', 'that', 'have', 'interesting', 'properties', 'and', 'therefore', 'are', 'useful', 'experimental', 'tools', 'to', 'study', 'soce', 'in', 'various', 'cells', 'and', 'settings']","['many', 'physiological', 'functions', 'cell', 'differentiation', 'proliferation', 'muscle', 'contraction', 'neurotransmission', 'fertilisation', 'regulated', 'changes', 'casup2sup', 'levels', 'major', 'casup2sup', 'store', 'cells', 'endoplasmic', 'reticulum', 'er', 'certain', 'cellular', 'processes', 'induce', 'er', 'store', 'depletion', 'eg', 'activating', 'ipsub3sub', 'receptors', 'turn', 'induces', 'store', 'refilling', 'process', 'known', 'storeoperated', 'calcium', 'entry', 'soce', 'refilling', 'process', 'entails', 'proteinprotein', 'interactions', 'casup2sup', 'sensing', 'stromal', 'interaction', 'molecules', 'stim', 'er', 'membrane', 'orai', 'proteins', 'plasma', 'membrane', 'fully', 'assembled', 'stimorai', 'complexes', 'form', 'highly', 'selective', 'casup2sup', 'channels', 'called', 'casup2sup', 'releaseactivated', 'casup2sup', 'channels', 'crac', 'casup2sup', 'ions', 'flow', 'cytosol', 'subsequently', 'pumped', 'er', 'sarcoplasmicendoplasmic', 'reticulum', 'calcium', 'atpase', 'serca', 'abnormal', 'soce', 'associated', 'numerous', 'human', 'diseases', 'cancers', 'therefore', 'key', 'players', 'stim', 'orai', 'attracted', 'significant', 'therapeutic', 'interest', 'several', 'potent', 'experimental', 'clinical', 'candidate', 'compounds', 'developed', 'helped', 'study', 'soce', 'various', 'cell', 'types', 'synthesized', 'multiple', 'novel', 'smallmolecule', 'probes', 'based', 'known', 'soce', 'inhibitor', 'gsk7975a', 'present', 'gsk7975a', 'derivatives', 'feature', 'photocaging', 'photocrosslinking', 'biotin', 'clickable', 'moieties', 'also', 'contain', 'deuterium', 'labels', 'evaluation', 'gsk7975a', 'probes', 'using', 'fluorometric', 'imaging', 'plate', 'reader', 'fliprtetrabased', 'casup2sup', 'imaging', 'assay', 'showed', 'synthetic', 'modifications', 'detrimental', 'impact', 'soce', 'inhibitory', 'activity', 'photocaged', 'gsk7975a', 'also', 'used', 'patchclamp', 'electrophysiology', 'experiments', 'summary', 'developed', 'number', 'active', 'gsk7975abased', 'molecular', 'probes', 'interesting', 'properties', 'therefore', 'useful', 'experimental', 'tools', 'study', 'soce', 'various', 'cells', 'settings']",['atpase'],['atpase'],True,['cancer']
38003456,NXC736 Attenuates Radiation-Induced Lung Fibrosis via Regulating NLRP3/IL-1β Signaling Pathway.,"Radiation-induced lung fibrosis (RILF) is a common complication of radiotherapy in lung cancer. However, to date no effective treatment has been developed for this condition. NXC736 is a novel small-molecule compound that inhibits NLRP3, but its effect on RILF is unknown. NLRP3 activation is an important trigger for the development of RILF. Thus, we aimed to evaluate the therapeutic effect of NXC736 on lung fibrosis inhibition using a RILF animal model and to elucidate its molecular signaling pathway. The left lungs of mice were irradiated with a single dose of 75 Gy. We observed that NXC736 treatment inhibited collagen deposition and inflammatory cell infiltration in irradiated mouse lung tissues. The damaged lung volume, evaluated by magnetic resonance imaging, was lower in NXC736-treated mice than in irradiated mice. NXC736-treated mice exhibited significant changes in lung function parameters. NXC736 inhibited inflammasome activation by interfering with the NLRP3-ASC-cleaved caspase-1 interaction, thereby reducing the expression of IL-1β and blocking the fibrotic pathway. In addition, NXC736 treatment reduced the expression of epithelial-mesenchymal transition markers such as α-SMA, vimentin, and twist by blocking the Smad 2,3,4 signaling pathway. These data suggested that NXC736 is a potent therapeutic agent against RILF.",2023-11-13,radiationinduced lung fibrosis rilf is a common complication of radiotherapy in lung cancer however to date no effective treatment has been developed for this condition nxc736 is a novel smallmolecule compound that inhibits nlrp3 but its effect on rilf is unknown nlrp3 activation is an important trigger for the development of rilf thus we aimed to evaluate the therapeutic effect of nxc736 on lung fibrosis inhibition using a rilf animal model and to elucidate its molecular signaling pathway the left lungs of mice were irradiated with a single dose of 75 gy we observed that nxc736 treatment inhibited collagen deposition and inflammatory cell infiltration in irradiated mouse lung tissues the damaged lung volume evaluated by magnetic resonance imaging was lower in nxc736treated mice than in irradiated mice nxc736treated mice exhibited significant changes in lung function parameters nxc736 inhibited inflammasome activation by interfering with the nlrp3asccleaved caspase1 interaction thereby reducing the expression of il1β and blocking the fibrotic pathway in addition nxc736 treatment reduced the expression of epithelialmesenchymal transition markers such as αsma vimentin and twist by blocking the smad 234 signaling pathway these data suggested that nxc736 is a potent therapeutic agent against rilf,"['radiationinduced', 'lung', 'fibrosis', 'rilf', 'is', 'a', 'common', 'complication', 'of', 'radiotherapy', 'in', 'lung', 'cancer', 'however', 'to', 'date', 'no', 'effective', 'treatment', 'has', 'been', 'developed', 'for', 'this', 'condition', 'nxc736', 'is', 'a', 'novel', 'smallmolecule', 'compound', 'that', 'inhibits', 'nlrp3', 'but', 'its', 'effect', 'on', 'rilf', 'is', 'unknown', 'nlrp3', 'activation', 'is', 'an', 'important', 'trigger', 'for', 'the', 'development', 'of', 'rilf', 'thus', 'we', 'aimed', 'to', 'evaluate', 'the', 'therapeutic', 'effect', 'of', 'nxc736', 'on', 'lung', 'fibrosis', 'inhibition', 'using', 'a', 'rilf', 'animal', 'model', 'and', 'to', 'elucidate', 'its', 'molecular', 'signaling', 'pathway', 'the', 'left', 'lungs', 'of', 'mice', 'were', 'irradiated', 'with', 'a', 'single', 'dose', 'of', '75', 'gy', 'we', 'observed', 'that', 'nxc736', 'treatment', 'inhibited', 'collagen', 'deposition', 'and', 'inflammatory', 'cell', 'infiltration', 'in', 'irradiated', 'mouse', 'lung', 'tissues', 'the', 'damaged', 'lung', 'volume', 'evaluated', 'by', 'magnetic', 'resonance', 'imaging', 'was', 'lower', 'in', 'nxc736treated', 'mice', 'than', 'in', 'irradiated', 'mice', 'nxc736treated', 'mice', 'exhibited', 'significant', 'changes', 'in', 'lung', 'function', 'parameters', 'nxc736', 'inhibited', 'inflammasome', 'activation', 'by', 'interfering', 'with', 'the', 'nlrp3asccleaved', 'caspase1', 'interaction', 'thereby', 'reducing', 'the', 'expression', 'of', 'il1β', 'and', 'blocking', 'the', 'fibrotic', 'pathway', 'in', 'addition', 'nxc736', 'treatment', 'reduced', 'the', 'expression', 'of', 'epithelialmesenchymal', 'transition', 'markers', 'such', 'as', 'αsma', 'vimentin', 'and', 'twist', 'by', 'blocking', 'the', 'smad', '234', 'signaling', 'pathway', 'these', 'data', 'suggested', 'that', 'nxc736', 'is', 'a', 'potent', 'therapeutic', 'agent', 'against', 'rilf']","['radiationinduced', 'lung', 'fibrosis', 'rilf', 'common', 'complication', 'radiotherapy', 'lung', 'cancer', 'however', 'date', 'effective', 'treatment', 'developed', 'condition', 'nxc736', 'novel', 'smallmolecule', 'compound', 'inhibits', 'nlrp3', 'effect', 'rilf', 'unknown', 'nlrp3', 'activation', 'important', 'trigger', 'development', 'rilf', 'thus', 'aimed', 'evaluate', 'therapeutic', 'effect', 'nxc736', 'lung', 'fibrosis', 'inhibition', 'using', 'rilf', 'animal', 'model', 'elucidate', 'molecular', 'signaling', 'pathway', 'left', 'lungs', 'mice', 'irradiated', 'single', 'dose', '75', 'gy', 'observed', 'nxc736', 'treatment', 'inhibited', 'collagen', 'deposition', 'inflammatory', 'cell', 'infiltration', 'irradiated', 'mouse', 'lung', 'tissues', 'damaged', 'lung', 'volume', 'evaluated', 'magnetic', 'resonance', 'imaging', 'lower', 'nxc736treated', 'mice', 'irradiated', 'mice', 'nxc736treated', 'mice', 'exhibited', 'significant', 'changes', 'lung', 'function', 'parameters', 'nxc736', 'inhibited', 'inflammasome', 'activation', 'interfering', 'nlrp3asccleaved', 'caspase1', 'interaction', 'thereby', 'reducing', 'expression', 'il1β', 'blocking', 'fibrotic', 'pathway', 'addition', 'nxc736', 'treatment', 'reduced', 'expression', 'epithelialmesenchymal', 'transition', 'markers', 'αsma', 'vimentin', 'twist', 'blocking', 'smad', '234', 'signaling', 'pathway', 'data', 'suggested', 'nxc736', 'potent', 'therapeutic', 'agent', 'rilf']","['collagen', 'caspase1', 'vimentin', 'smad']","['caspase1', 'vimentin', 'smad']",True,['cancer']
37998149,A Novel Combination Therapy Tβ4/VIP Protects against Hyperglycemia-Induced Changes in Human Corneal Epithelial Cells.,"Despite the prevalence of diabetic retinopathy, the majority of adult diabetic patients develop visually debilitating corneal complications, including impaired wound healing. Unfortunately, there is limited treatment for diabetes-induced corneal damage. The current project investigates a novel, peptide-based combination therapy, thymosin beta-4 and vasoactive intestinal peptide (Tβ4/VIP), against high-glucose-induced damage to the corneal epithelium. Electric cell-substrate impedance sensing (ECIS) was used for real-time monitoring of barrier function and wound healing of human corneal epithelial cells maintained in either normal glucose (5 mM) or high glucose (25 mM) ± Tβ4 (0.1%) and VIP (5 nM). Barrier integrity was assessed by resistance, impedance, and capacitance measurements. For the wound healing assay, cell migration was also monitored. Corneal epithelial tight junction proteins (ZO-1, ZO-2, occludin, and claudin-1) were assessed to confirm our findings. Barrier integrity and wound healing were significantly impaired under high-glucose conditions. However, barrier function and cell migration significantly improved with Tβ4/VIP treatment. These findings were supported by high-glucose-induced downregulation of tight junction proteins that were effectively maintained similar to normal levels when treated with Tβ4/VIP. These results strongly support the premise that Tβ4 and VIP work synergistically to protect corneal epithelial cells against hyperglycemia-induced damage. In addition, this work highlights the potential for significant translational impact regarding the treatment of diabetic patients and associated complications of the cornea.",2023-11-07,despite the prevalence of diabetic retinopathy the majority of adult diabetic patients develop visually debilitating corneal complications including impaired wound healing unfortunately there is limited treatment for diabetesinduced corneal damage the current project investigates a novel peptidebased combination therapy thymosin beta4 and vasoactive intestinal peptide tβ4vip against highglucoseinduced damage to the corneal epithelium electric cellsubstrate impedance sensing ecis was used for realtime monitoring of barrier function and wound healing of human corneal epithelial cells maintained in either normal glucose 5 mm or high glucose 25 mm  tβ4 01 and vip 5 nm barrier integrity was assessed by resistance impedance and capacitance measurements for the wound healing assay cell migration was also monitored corneal epithelial tight junction proteins zo1 zo2 occludin and claudin1 were assessed to confirm our findings barrier integrity and wound healing were significantly impaired under highglucose conditions however barrier function and cell migration significantly improved with tβ4vip treatment these findings were supported by highglucoseinduced downregulation of tight junction proteins that were effectively maintained similar to normal levels when treated with tβ4vip these results strongly support the premise that tβ4 and vip work synergistically to protect corneal epithelial cells against hyperglycemiainduced damage in addition this work highlights the potential for significant translational impact regarding the treatment of diabetic patients and associated complications of the cornea,"['despite', 'the', 'prevalence', 'of', 'diabetic', 'retinopathy', 'the', 'majority', 'of', 'adult', 'diabetic', 'patients', 'develop', 'visually', 'debilitating', 'corneal', 'complications', 'including', 'impaired', 'wound', 'healing', 'unfortunately', 'there', 'is', 'limited', 'treatment', 'for', 'diabetesinduced', 'corneal', 'damage', 'the', 'current', 'project', 'investigates', 'a', 'novel', 'peptidebased', 'combination', 'therapy', 'thymosin', 'beta4', 'and', 'vasoactive', 'intestinal', 'peptide', 'tβ4vip', 'against', 'highglucoseinduced', 'damage', 'to', 'the', 'corneal', 'epithelium', 'electric', 'cellsubstrate', 'impedance', 'sensing', 'ecis', 'was', 'used', 'for', 'realtime', 'monitoring', 'of', 'barrier', 'function', 'and', 'wound', 'healing', 'of', 'human', 'corneal', 'epithelial', 'cells', 'maintained', 'in', 'either', 'normal', 'glucose', '5', 'mm', 'or', 'high', 'glucose', '25', 'mm', 'tβ4', '01', 'and', 'vip', '5', 'nm', 'barrier', 'integrity', 'was', 'assessed', 'by', 'resistance', 'impedance', 'and', 'capacitance', 'measurements', 'for', 'the', 'wound', 'healing', 'assay', 'cell', 'migration', 'was', 'also', 'monitored', 'corneal', 'epithelial', 'tight', 'junction', 'proteins', 'zo1', 'zo2', 'occludin', 'and', 'claudin1', 'were', 'assessed', 'to', 'confirm', 'our', 'findings', 'barrier', 'integrity', 'and', 'wound', 'healing', 'were', 'significantly', 'impaired', 'under', 'highglucose', 'conditions', 'however', 'barrier', 'function', 'and', 'cell', 'migration', 'significantly', 'improved', 'with', 'tβ4vip', 'treatment', 'these', 'findings', 'were', 'supported', 'by', 'highglucoseinduced', 'downregulation', 'of', 'tight', 'junction', 'proteins', 'that', 'were', 'effectively', 'maintained', 'similar', 'to', 'normal', 'levels', 'when', 'treated', 'with', 'tβ4vip', 'these', 'results', 'strongly', 'support', 'the', 'premise', 'that', 'tβ4', 'and', 'vip', 'work', 'synergistically', 'to', 'protect', 'corneal', 'epithelial', 'cells', 'against', 'hyperglycemiainduced', 'damage', 'in', 'addition', 'this', 'work', 'highlights', 'the', 'potential', 'for', 'significant', 'translational', 'impact', 'regarding', 'the', 'treatment', 'of', 'diabetic', 'patients', 'and', 'associated', 'complications', 'of', 'the', 'cornea']","['despite', 'prevalence', 'diabetic', 'retinopathy', 'majority', 'adult', 'diabetic', 'patients', 'develop', 'visually', 'debilitating', 'corneal', 'complications', 'including', 'impaired', 'wound', 'healing', 'unfortunately', 'limited', 'treatment', 'diabetesinduced', 'corneal', 'damage', 'current', 'project', 'investigates', 'novel', 'peptidebased', 'combination', 'therapy', 'thymosin', 'beta4', 'vasoactive', 'intestinal', 'peptide', 'tβ4vip', 'highglucoseinduced', 'damage', 'corneal', 'epithelium', 'electric', 'cellsubstrate', 'impedance', 'sensing', 'ecis', 'used', 'realtime', 'monitoring', 'barrier', 'function', 'wound', 'healing', 'human', 'corneal', 'epithelial', 'cells', 'maintained', 'either', 'normal', 'glucose', '5', 'mm', 'high', 'glucose', '25', 'mm', 'tβ4', '01', 'vip', '5', 'nm', 'barrier', 'integrity', 'assessed', 'resistance', 'impedance', 'capacitance', 'measurements', 'wound', 'healing', 'assay', 'cell', 'migration', 'also', 'monitored', 'corneal', 'epithelial', 'tight', 'junction', 'proteins', 'zo1', 'zo2', 'occludin', 'claudin1', 'assessed', 'confirm', 'findings', 'barrier', 'integrity', 'wound', 'healing', 'significantly', 'impaired', 'highglucose', 'conditions', 'however', 'barrier', 'function', 'cell', 'migration', 'significantly', 'improved', 'tβ4vip', 'treatment', 'findings', 'supported', 'highglucoseinduced', 'downregulation', 'tight', 'junction', 'proteins', 'effectively', 'maintained', 'similar', 'normal', 'levels', 'treated', 'tβ4vip', 'results', 'strongly', 'support', 'premise', 'tβ4', 'vip', 'work', 'synergistically', 'protect', 'corneal', 'epithelial', 'cells', 'hyperglycemiainduced', 'damage', 'addition', 'work', 'highlights', 'potential', 'significant', 'translational', 'impact', 'regarding', 'treatment', 'diabetic', 'patients', 'associated', 'complications', 'cornea']","['beta4', 'tβ4vip', 'occludin', 'claudin1', 'tβ4vip', 'tβ4vip']","['tβ4vip', 'occludin', 'claudin1', 'tβ4vip', 'tβ4vip']",True,['diabetes']
37897912,A GPX4 non-enzymatic domain and MDM2 targeting peptide PROTAC for acute lymphoid leukemia therapy through ferroptosis induction.,"Ferroptosis, an emerging form of programmed cell death, has garnered substantial attention as a potential target for cancer therapy. However, despite the potential promise, no ferroptosis-related therapies have progressed to clinical trials. Identifying disease types sensitive to ferroptosis and developing specific ferroptosis-targeting drugs are critical focal points in the field of ferroptosis-based treatment. In this study, we conducted a comprehensive database analysis and presented compelling evidence indicating a high expression of GPX4 in patients with acute lymphoblastic leukemia (ALL), significantly correlating with poor prognosis. Notably, elevated GPX4 expression is closely associated with ALL relapse, a major challenge in the treatment of this disease. Building upon these findings, we devised a novel peptide-based Proteolysis Targeting Chimeras (PROTAC) drug targeting GPX4 through computer-aided design. In contrast to existing drugs that target the conjugative enzyme active site, our design focused on a peptide drug targeting the non-active site of GPX4. Furthermore, we strategically selected MDM2, an E3 ligase highly expressed in ALL, for the PROTAC drug design. This deliberate choice amplifies the drug's effect on cancer cells while minimizing its impact on normal cells, achieving desirable selectivity for cancer cells. Leveraging nanogold delivery, we successfully facilitated intracellular action of the GPX4-targeting peptide PROTAC drug, denoted as Au-PGPD (peptide GPX4 PROTAC drug). Au-PGPD effectively induced GPX4 degradation and inhibited ALL cell proliferation. Remarkably, Au-PGPD exhibited significantly less efficacy on normal cells, underscoring the selectivity and safety of our design.",2023-10-20,ferroptosis an emerging form of programmed cell death has garnered substantial attention as a potential target for cancer therapy however despite the potential promise no ferroptosisrelated therapies have progressed to clinical trials identifying disease types sensitive to ferroptosis and developing specific ferroptosistargeting drugs are critical focal points in the field of ferroptosisbased treatment in this study we conducted a comprehensive database analysis and presented compelling evidence indicating a high expression of gpx4 in patients with acute lymphoblastic leukemia all significantly correlating with poor prognosis notably elevated gpx4 expression is closely associated with all relapse a major challenge in the treatment of this disease building upon these findings we devised a novel peptidebased proteolysis targeting chimeras protac drug targeting gpx4 through computeraided design in contrast to existing drugs that target the conjugative enzyme active site our design focused on a peptide drug targeting the nonactive site of gpx4 furthermore we strategically selected mdm2 an e3 ligase highly expressed in all for the protac drug design this deliberate choice amplifies the drugs effect on cancer cells while minimizing its impact on normal cells achieving desirable selectivity for cancer cells leveraging nanogold delivery we successfully facilitated intracellular action of the gpx4targeting peptide protac drug denoted as aupgpd peptide gpx4 protac drug aupgpd effectively induced gpx4 degradation and inhibited all cell proliferation remarkably aupgpd exhibited significantly less efficacy on normal cells underscoring the selectivity and safety of our design,"['ferroptosis', 'an', 'emerging', 'form', 'of', 'programmed', 'cell', 'death', 'has', 'garnered', 'substantial', 'attention', 'as', 'a', 'potential', 'target', 'for', 'cancer', 'therapy', 'however', 'despite', 'the', 'potential', 'promise', 'no', 'ferroptosisrelated', 'therapies', 'have', 'progressed', 'to', 'clinical', 'trials', 'identifying', 'disease', 'types', 'sensitive', 'to', 'ferroptosis', 'and', 'developing', 'specific', 'ferroptosistargeting', 'drugs', 'are', 'critical', 'focal', 'points', 'in', 'the', 'field', 'of', 'ferroptosisbased', 'treatment', 'in', 'this', 'study', 'we', 'conducted', 'a', 'comprehensive', 'database', 'analysis', 'and', 'presented', 'compelling', 'evidence', 'indicating', 'a', 'high', 'expression', 'of', 'gpx4', 'in', 'patients', 'with', 'acute', 'lymphoblastic', 'leukemia', 'all', 'significantly', 'correlating', 'with', 'poor', 'prognosis', 'notably', 'elevated', 'gpx4', 'expression', 'is', 'closely', 'associated', 'with', 'all', 'relapse', 'a', 'major', 'challenge', 'in', 'the', 'treatment', 'of', 'this', 'disease', 'building', 'upon', 'these', 'findings', 'we', 'devised', 'a', 'novel', 'peptidebased', 'proteolysis', 'targeting', 'chimeras', 'protac', 'drug', 'targeting', 'gpx4', 'through', 'computeraided', 'design', 'in', 'contrast', 'to', 'existing', 'drugs', 'that', 'target', 'the', 'conjugative', 'enzyme', 'active', 'site', 'our', 'design', 'focused', 'on', 'a', 'peptide', 'drug', 'targeting', 'the', 'nonactive', 'site', 'of', 'gpx4', 'furthermore', 'we', 'strategically', 'selected', 'mdm2', 'an', 'e3', 'ligase', 'highly', 'expressed', 'in', 'all', 'for', 'the', 'protac', 'drug', 'design', 'this', 'deliberate', 'choice', 'amplifies', 'the', 'drugs', 'effect', 'on', 'cancer', 'cells', 'while', 'minimizing', 'its', 'impact', 'on', 'normal', 'cells', 'achieving', 'desirable', 'selectivity', 'for', 'cancer', 'cells', 'leveraging', 'nanogold', 'delivery', 'we', 'successfully', 'facilitated', 'intracellular', 'action', 'of', 'the', 'gpx4targeting', 'peptide', 'protac', 'drug', 'denoted', 'as', 'aupgpd', 'peptide', 'gpx4', 'protac', 'drug', 'aupgpd', 'effectively', 'induced', 'gpx4', 'degradation', 'and', 'inhibited', 'all', 'cell', 'proliferation', 'remarkably', 'aupgpd', 'exhibited', 'significantly', 'less', 'efficacy', 'on', 'normal', 'cells', 'underscoring', 'the', 'selectivity', 'and', 'safety', 'of', 'our', 'design']","['ferroptosis', 'emerging', 'form', 'programmed', 'cell', 'death', 'garnered', 'substantial', 'attention', 'potential', 'target', 'cancer', 'therapy', 'however', 'despite', 'potential', 'promise', 'ferroptosisrelated', 'therapies', 'progressed', 'clinical', 'trials', 'identifying', 'disease', 'types', 'sensitive', 'ferroptosis', 'developing', 'specific', 'ferroptosistargeting', 'drugs', 'critical', 'focal', 'points', 'field', 'ferroptosisbased', 'treatment', 'study', 'conducted', 'comprehensive', 'database', 'analysis', 'presented', 'compelling', 'evidence', 'indicating', 'high', 'expression', 'gpx4', 'patients', 'acute', 'lymphoblastic', 'leukemia', 'significantly', 'correlating', 'poor', 'prognosis', 'notably', 'elevated', 'gpx4', 'expression', 'closely', 'associated', 'relapse', 'major', 'challenge', 'treatment', 'disease', 'building', 'upon', 'findings', 'devised', 'novel', 'peptidebased', 'proteolysis', 'targeting', 'chimeras', 'protac', 'drug', 'targeting', 'gpx4', 'computeraided', 'design', 'contrast', 'existing', 'drugs', 'target', 'conjugative', 'enzyme', 'active', 'site', 'design', 'focused', 'peptide', 'drug', 'targeting', 'nonactive', 'site', 'gpx4', 'furthermore', 'strategically', 'selected', 'mdm2', 'e3', 'ligase', 'highly', 'expressed', 'protac', 'drug', 'design', 'deliberate', 'choice', 'amplifies', 'drugs', 'effect', 'cancer', 'cells', 'minimizing', 'impact', 'normal', 'cells', 'achieving', 'desirable', 'selectivity', 'cancer', 'cells', 'leveraging', 'nanogold', 'delivery', 'successfully', 'facilitated', 'intracellular', 'action', 'gpx4targeting', 'peptide', 'protac', 'drug', 'denoted', 'aupgpd', 'peptide', 'gpx4', 'protac', 'drug', 'aupgpd', 'effectively', 'induced', 'gpx4', 'degradation', 'inhibited', 'cell', 'proliferation', 'remarkably', 'aupgpd', 'exhibited', 'significantly', 'less', 'efficacy', 'normal', 'cells', 'underscoring', 'selectivity', 'safety', 'design']","['gpx4', 'gpx4', 'gpx4', 'gpx4', 'mdm2', 'gpx4', 'gpx4']","['gpx4', 'gpx4', 'gpx4', 'gpx4', 'gpx4', 'gpx4']",True,"['cancer', 'leukemia']"
37886595,Therapeutic Intervention of Neuroinflammatory Alzheimer Disease Model by Inhibition of Classical Complement Pathway with the Use of Anti-C1r Loaded Exosomes.,"Alzheimer's disease (AD) is a complex neurodegenerative disease associated with memory decline, cognitive impairment, amyloid plaque formation and tau tangles. Neuroinflammation has been shown to be a precursor to apparent amyloid plaque accumulation and subsequent synaptic loss and cognitive decline. In this study, the ability of a novel, small molecule, T-ALZ01, to inhibit neuroinflammatory processes was analyzed. T-ALZ01, an inhibitor of complement component C1r, demonstrated a significant reduction in the levels of the inflammatory cytokines, IL-6 and TNF-α <i>in vitro</i>. An LPS-induced animal model, whereby animals were injected intraperitoneally with 0.5 mg/kg LPS, was used to analyze the effect of T-ALZ01 on neuroinflammation <i>in vivo</i>. Moreover, exosomes (nanosized, endogenous extracellular vehicles) were used as drug delivery vehicles to facilitate intranasal administration of T-ALZ01 across the blood-brain barrier. T-ALZ01 demonstrated significant reduction in degenerating neurons and the activation of resident microglia and astrocytes, as well as inflammatory markers <i>in vivo</i>. This study demonstrates a significant use of small molecule complement inhibitors via exosome drug delivery as a possible therapeutic in disorders characterized by neuroinflammation, such AD.",2023-10-18,alzheimers disease ad is a complex neurodegenerative disease associated with memory decline cognitive impairment amyloid plaque formation and tau tangles neuroinflammation has been shown to be a precursor to apparent amyloid plaque accumulation and subsequent synaptic loss and cognitive decline in this study the ability of a novel small molecule talz01 to inhibit neuroinflammatory processes was analyzed talz01 an inhibitor of complement component c1r demonstrated a significant reduction in the levels of the inflammatory cytokines il6 and tnfα iin vitroi an lpsinduced animal model whereby animals were injected intraperitoneally with 05 mgkg lps was used to analyze the effect of talz01 on neuroinflammation iin vivoi moreover exosomes nanosized endogenous extracellular vehicles were used as drug delivery vehicles to facilitate intranasal administration of talz01 across the bloodbrain barrier talz01 demonstrated significant reduction in degenerating neurons and the activation of resident microglia and astrocytes as well as inflammatory markers iin vivoi this study demonstrates a significant use of small molecule complement inhibitors via exosome drug delivery as a possible therapeutic in disorders characterized by neuroinflammation such ad,"['alzheimers', 'disease', 'ad', 'is', 'a', 'complex', 'neurodegenerative', 'disease', 'associated', 'with', 'memory', 'decline', 'cognitive', 'impairment', 'amyloid', 'plaque', 'formation', 'and', 'tau', 'tangles', 'neuroinflammation', 'has', 'been', 'shown', 'to', 'be', 'a', 'precursor', 'to', 'apparent', 'amyloid', 'plaque', 'accumulation', 'and', 'subsequent', 'synaptic', 'loss', 'and', 'cognitive', 'decline', 'in', 'this', 'study', 'the', 'ability', 'of', 'a', 'novel', 'small', 'molecule', 'talz01', 'to', 'inhibit', 'neuroinflammatory', 'processes', 'was', 'analyzed', 'talz01', 'an', 'inhibitor', 'of', 'complement', 'component', 'c1r', 'demonstrated', 'a', 'significant', 'reduction', 'in', 'the', 'levels', 'of', 'the', 'inflammatory', 'cytokines', 'il6', 'and', 'tnfα', 'iin', 'vitroi', 'an', 'lpsinduced', 'animal', 'model', 'whereby', 'animals', 'were', 'injected', 'intraperitoneally', 'with', '05', 'mgkg', 'lps', 'was', 'used', 'to', 'analyze', 'the', 'effect', 'of', 'talz01', 'on', 'neuroinflammation', 'iin', 'vivoi', 'moreover', 'exosomes', 'nanosized', 'endogenous', 'extracellular', 'vehicles', 'were', 'used', 'as', 'drug', 'delivery', 'vehicles', 'to', 'facilitate', 'intranasal', 'administration', 'of', 'talz01', 'across', 'the', 'bloodbrain', 'barrier', 'talz01', 'demonstrated', 'significant', 'reduction', 'in', 'degenerating', 'neurons', 'and', 'the', 'activation', 'of', 'resident', 'microglia', 'and', 'astrocytes', 'as', 'well', 'as', 'inflammatory', 'markers', 'iin', 'vivoi', 'this', 'study', 'demonstrates', 'a', 'significant', 'use', 'of', 'small', 'molecule', 'complement', 'inhibitors', 'via', 'exosome', 'drug', 'delivery', 'as', 'a', 'possible', 'therapeutic', 'in', 'disorders', 'characterized', 'by', 'neuroinflammation', 'such', 'ad']","['alzheimers', 'disease', 'ad', 'complex', 'neurodegenerative', 'disease', 'associated', 'memory', 'decline', 'cognitive', 'impairment', 'amyloid', 'plaque', 'formation', 'tau', 'tangles', 'neuroinflammation', 'shown', 'precursor', 'apparent', 'amyloid', 'plaque', 'accumulation', 'subsequent', 'synaptic', 'loss', 'cognitive', 'decline', 'study', 'ability', 'novel', 'small', 'molecule', 'talz01', 'inhibit', 'neuroinflammatory', 'processes', 'analyzed', 'talz01', 'inhibitor', 'complement', 'component', 'c1r', 'demonstrated', 'significant', 'reduction', 'levels', 'inflammatory', 'cytokines', 'il6', 'tnfα', 'iin', 'vitroi', 'lpsinduced', 'animal', 'model', 'whereby', 'animals', 'injected', 'intraperitoneally', '05', 'mgkg', 'lps', 'used', 'analyze', 'effect', 'talz01', 'neuroinflammation', 'iin', 'vivoi', 'moreover', 'exosomes', 'nanosized', 'endogenous', 'extracellular', 'vehicles', 'used', 'drug', 'delivery', 'vehicles', 'facilitate', 'intranasal', 'administration', 'talz01', 'across', 'bloodbrain', 'barrier', 'talz01', 'demonstrated', 'significant', 'reduction', 'degenerating', 'neurons', 'activation', 'resident', 'microglia', 'astrocytes', 'well', 'inflammatory', 'markers', 'iin', 'vivoi', 'study', 'demonstrates', 'significant', 'use', 'small', 'molecule', 'complement', 'inhibitors', 'via', 'exosome', 'drug', 'delivery', 'possible', 'therapeutic', 'disorders', 'characterized', 'neuroinflammation', 'ad']","['tau', 'c1r']",['c1r'],True,['alzheimer']
37874823,A mechanistically novel peptide agonist of the IL-7 receptor that addresses limitations of IL-7 cytokine therapy.,"Interleukin (IL)-7 is broadly active on T-cell populations, and modified versions have been clinically evaluated for a variety of therapeutic applications, including cancer, lymphopenia, and infectious diseases; and found to be relatively well-tolerated and biologically active. Here we describe novel IL-7R agonists that are unrelated in structure to IL-7, bind to the receptor subunits differently from IL-7, but closely emulate IL-7 biology. The small size, low structural complexity, and the natural amino acid composition of the pharmacologically active peptide MDK1472 allows facile incorporation into protein structures, such as the IgG2-Fc fusion MDK-703. This molecule possesses properties potentially better suited to therapeutic applications than native IL-7 or its derivatives. We compared these compounds with IL-7 for immune cell selectivity, induction of IL-7R signaling, receptor-mediated internalization, proliferation, and generation of immune cell phenotypes in human and non-human primate (NHP) peripheral blood cells in vitro; and found them to be similar in biological activity to IL-7. In cynomolgus macaques, MDK-703 exhibits a circulating half-life of 46 hr and produces sustained T-cell expansion characteristic of IL-7 treatment. In the huCD34+-engrafted NSG mouse model of the human immune system, MDK-703 induces an immune cell profile very similar to that generated by IL-7-derived compounds; including the pronounced expansion of memory T-cells, particularly the population of stem-like memory T-cells (Tscm) which may be important for anti-tumor activities reported with IL-7 treatment. Clinical administration of IL-7 and modified variants has been reported to induce anti-drug antibodies (ADAs), including IL-7 neutralizing antibodies. The novel peptide agonist reported here scores very low in predicted immunogenicity, and because the peptide lacks sequence similarity with IL-7, the problematic immunogenic neutralization of endogenous cytokine should not occur. The properties we report here implicate MDK-703 as a candidate for clinical evaluation in oncology, anti-viral and other infectious disease, vaccine enhancement, and treatment of lymphopenia.",2023-10-24,interleukin il7 is broadly active on tcell populations and modified versions have been clinically evaluated for a variety of therapeutic applications including cancer lymphopenia and infectious diseases and found to be relatively welltolerated and biologically active here we describe novel il7r agonists that are unrelated in structure to il7 bind to the receptor subunits differently from il7 but closely emulate il7 biology the small size low structural complexity and the natural amino acid composition of the pharmacologically active peptide mdk1472 allows facile incorporation into protein structures such as the igg2fc fusion mdk703 this molecule possesses properties potentially better suited to therapeutic applications than native il7 or its derivatives we compared these compounds with il7 for immune cell selectivity induction of il7r signaling receptormediated internalization proliferation and generation of immune cell phenotypes in human and nonhuman primate nhp peripheral blood cells in vitro and found them to be similar in biological activity to il7 in cynomolgus macaques mdk703 exhibits a circulating halflife of 46 hr and produces sustained tcell expansion characteristic of il7 treatment in the hucd34engrafted nsg mouse model of the human immune system mdk703 induces an immune cell profile very similar to that generated by il7derived compounds including the pronounced expansion of memory tcells particularly the population of stemlike memory tcells tscm which may be important for antitumor activities reported with il7 treatment clinical administration of il7 and modified variants has been reported to induce antidrug antibodies adas including il7 neutralizing antibodies the novel peptide agonist reported here scores very low in predicted immunogenicity and because the peptide lacks sequence similarity with il7 the problematic immunogenic neutralization of endogenous cytokine should not occur the properties we report here implicate mdk703 as a candidate for clinical evaluation in oncology antiviral and other infectious disease vaccine enhancement and treatment of lymphopenia,"['interleukin', 'il7', 'is', 'broadly', 'active', 'on', 'tcell', 'populations', 'and', 'modified', 'versions', 'have', 'been', 'clinically', 'evaluated', 'for', 'a', 'variety', 'of', 'therapeutic', 'applications', 'including', 'cancer', 'lymphopenia', 'and', 'infectious', 'diseases', 'and', 'found', 'to', 'be', 'relatively', 'welltolerated', 'and', 'biologically', 'active', 'here', 'we', 'describe', 'novel', 'il7r', 'agonists', 'that', 'are', 'unrelated', 'in', 'structure', 'to', 'il7', 'bind', 'to', 'the', 'receptor', 'subunits', 'differently', 'from', 'il7', 'but', 'closely', 'emulate', 'il7', 'biology', 'the', 'small', 'size', 'low', 'structural', 'complexity', 'and', 'the', 'natural', 'amino', 'acid', 'composition', 'of', 'the', 'pharmacologically', 'active', 'peptide', 'mdk1472', 'allows', 'facile', 'incorporation', 'into', 'protein', 'structures', 'such', 'as', 'the', 'igg2fc', 'fusion', 'mdk703', 'this', 'molecule', 'possesses', 'properties', 'potentially', 'better', 'suited', 'to', 'therapeutic', 'applications', 'than', 'native', 'il7', 'or', 'its', 'derivatives', 'we', 'compared', 'these', 'compounds', 'with', 'il7', 'for', 'immune', 'cell', 'selectivity', 'induction', 'of', 'il7r', 'signaling', 'receptormediated', 'internalization', 'proliferation', 'and', 'generation', 'of', 'immune', 'cell', 'phenotypes', 'in', 'human', 'and', 'nonhuman', 'primate', 'nhp', 'peripheral', 'blood', 'cells', 'in', 'vitro', 'and', 'found', 'them', 'to', 'be', 'similar', 'in', 'biological', 'activity', 'to', 'il7', 'in', 'cynomolgus', 'macaques', 'mdk703', 'exhibits', 'a', 'circulating', 'halflife', 'of', '46', 'hr', 'and', 'produces', 'sustained', 'tcell', 'expansion', 'characteristic', 'of', 'il7', 'treatment', 'in', 'the', 'hucd34engrafted', 'nsg', 'mouse', 'model', 'of', 'the', 'human', 'immune', 'system', 'mdk703', 'induces', 'an', 'immune', 'cell', 'profile', 'very', 'similar', 'to', 'that', 'generated', 'by', 'il7derived', 'compounds', 'including', 'the', 'pronounced', 'expansion', 'of', 'memory', 'tcells', 'particularly', 'the', 'population', 'of', 'stemlike', 'memory', 'tcells', 'tscm', 'which', 'may', 'be', 'important', 'for', 'antitumor', 'activities', 'reported', 'with', 'il7', 'treatment', 'clinical', 'administration', 'of', 'il7', 'and', 'modified', 'variants', 'has', 'been', 'reported', 'to', 'induce', 'antidrug', 'antibodies', 'adas', 'including', 'il7', 'neutralizing', 'antibodies', 'the', 'novel', 'peptide', 'agonist', 'reported', 'here', 'scores', 'very', 'low', 'in', 'predicted', 'immunogenicity', 'and', 'because', 'the', 'peptide', 'lacks', 'sequence', 'similarity', 'with', 'il7', 'the', 'problematic', 'immunogenic', 'neutralization', 'of', 'endogenous', 'cytokine', 'should', 'not', 'occur', 'the', 'properties', 'we', 'report', 'here', 'implicate', 'mdk703', 'as', 'a', 'candidate', 'for', 'clinical', 'evaluation', 'in', 'oncology', 'antiviral', 'and', 'other', 'infectious', 'disease', 'vaccine', 'enhancement', 'and', 'treatment', 'of', 'lymphopenia']","['interleukin', 'il7', 'broadly', 'active', 'tcell', 'populations', 'modified', 'versions', 'clinically', 'evaluated', 'variety', 'therapeutic', 'applications', 'including', 'cancer', 'lymphopenia', 'infectious', 'diseases', 'found', 'relatively', 'welltolerated', 'biologically', 'active', 'describe', 'novel', 'il7r', 'agonists', 'unrelated', 'structure', 'il7', 'bind', 'receptor', 'subunits', 'differently', 'il7', 'closely', 'emulate', 'il7', 'biology', 'small', 'size', 'low', 'structural', 'complexity', 'natural', 'amino', 'acid', 'composition', 'pharmacologically', 'active', 'peptide', 'mdk1472', 'allows', 'facile', 'incorporation', 'protein', 'structures', 'igg2fc', 'fusion', 'mdk703', 'molecule', 'possesses', 'properties', 'potentially', 'better', 'suited', 'therapeutic', 'applications', 'native', 'il7', 'derivatives', 'compared', 'compounds', 'il7', 'immune', 'cell', 'selectivity', 'induction', 'il7r', 'signaling', 'receptormediated', 'internalization', 'proliferation', 'generation', 'immune', 'cell', 'phenotypes', 'human', 'nonhuman', 'primate', 'nhp', 'peripheral', 'blood', 'cells', 'vitro', 'found', 'similar', 'biological', 'activity', 'il7', 'cynomolgus', 'macaques', 'mdk703', 'exhibits', 'circulating', 'halflife', '46', 'hr', 'produces', 'sustained', 'tcell', 'expansion', 'characteristic', 'il7', 'treatment', 'hucd34engrafted', 'nsg', 'mouse', 'model', 'human', 'immune', 'system', 'mdk703', 'induces', 'immune', 'cell', 'profile', 'similar', 'generated', 'il7derived', 'compounds', 'including', 'pronounced', 'expansion', 'memory', 'tcells', 'particularly', 'population', 'stemlike', 'memory', 'tcells', 'tscm', 'may', 'important', 'antitumor', 'activities', 'reported', 'il7', 'treatment', 'clinical', 'administration', 'il7', 'modified', 'variants', 'reported', 'induce', 'antidrug', 'antibodies', 'adas', 'including', 'il7', 'neutralizing', 'antibodies', 'novel', 'peptide', 'agonist', 'reported', 'scores', 'low', 'predicted', 'immunogenicity', 'peptide', 'lacks', 'sequence', 'similarity', 'il7', 'problematic', 'immunogenic', 'neutralization', 'endogenous', 'cytokine', 'occur', 'properties', 'report', 'implicate', 'mdk703', 'candidate', 'clinical', 'evaluation', 'oncology', 'antiviral', 'infectious', 'disease', 'vaccine', 'enhancement', 'treatment', 'lymphopenia']","['interleukin', 'il7r', 'il7r']","['il7r', 'il7r']",True,"['tumor', 'cancer']"
37873470,Elucidating Compound Mechanism of Action and Polypharmacology with a Large-scale Perturbational Profile Compendium.,"The Mechanism of Action (MoA) of a drug is generally represented as a small, non-tissue-specific repertoire of high-affinity binding targets. Yet, drug activity and polypharmacology are increasingly associated with a broad range of off-target and tissue-specific effector proteins. To address this challenge, we have leveraged a microfluidics-based Plate-Seq technology to survey drug perturbational profiles representing >700 FDA-approved and experimental oncology drugs, in cell lines selected as high-fidelity models of 23 aggressive tumor subtypes. Built on this dataset, we implemented an efficient computational framework to define a tissue-specific protein activity landscape of these drugs and reported almost 50 million differential protein activities derived from drug perturbations <i>vs.</i> vehicle controls. These analyses revealed thousands of highly reproducible and novel, drug-mediated modulation of tissue-specific targets, leading to generation of a proteome-wide drug functional network, characterization of MoA-related drug clusters and off-target effects, dramatical expansion of druggable human proteome, and identification and experimental validation of novel, tissue-specific inhibitors of undruggable oncoproteins, most never reported before. The drug perturbation profile resource described here represents the first, large-scale, whole-genome-wide, RNA-Seq based dataset assembled to date, with the proposed framework, which is easily extended to elucidating the MoA of novel small-molecule libraries, facilitates mechanistic exploration of drug functions, supports systematic and quantitative approaches to precision oncology, and serves as a rich data foundation for drug discovery.",2024-06-27,the mechanism of action moa of a drug is generally represented as a small nontissuespecific repertoire of highaffinity binding targets yet drug activity and polypharmacology are increasingly associated with a broad range of offtarget and tissuespecific effector proteins to address this challenge we have leveraged a microfluidicsbased plateseq technology to survey drug perturbational profiles representing 700 fdaapproved and experimental oncology drugs in cell lines selected as highfidelity models of 23 aggressive tumor subtypes built on this dataset we implemented an efficient computational framework to define a tissuespecific protein activity landscape of these drugs and reported almost 50 million differential protein activities derived from drug perturbations ivsi vehicle controls these analyses revealed thousands of highly reproducible and novel drugmediated modulation of tissuespecific targets leading to generation of a proteomewide drug functional network characterization of moarelated drug clusters and offtarget effects dramatical expansion of druggable human proteome and identification and experimental validation of novel tissuespecific inhibitors of undruggable oncoproteins most never reported before the drug perturbation profile resource described here represents the first largescale wholegenomewide rnaseq based dataset assembled to date with the proposed framework which is easily extended to elucidating the moa of novel smallmolecule libraries facilitates mechanistic exploration of drug functions supports systematic and quantitative approaches to precision oncology and serves as a rich data foundation for drug discovery,"['the', 'mechanism', 'of', 'action', 'moa', 'of', 'a', 'drug', 'is', 'generally', 'represented', 'as', 'a', 'small', 'nontissuespecific', 'repertoire', 'of', 'highaffinity', 'binding', 'targets', 'yet', 'drug', 'activity', 'and', 'polypharmacology', 'are', 'increasingly', 'associated', 'with', 'a', 'broad', 'range', 'of', 'offtarget', 'and', 'tissuespecific', 'effector', 'proteins', 'to', 'address', 'this', 'challenge', 'we', 'have', 'leveraged', 'a', 'microfluidicsbased', 'plateseq', 'technology', 'to', 'survey', 'drug', 'perturbational', 'profiles', 'representing', '700', 'fdaapproved', 'and', 'experimental', 'oncology', 'drugs', 'in', 'cell', 'lines', 'selected', 'as', 'highfidelity', 'models', 'of', '23', 'aggressive', 'tumor', 'subtypes', 'built', 'on', 'this', 'dataset', 'we', 'implemented', 'an', 'efficient', 'computational', 'framework', 'to', 'define', 'a', 'tissuespecific', 'protein', 'activity', 'landscape', 'of', 'these', 'drugs', 'and', 'reported', 'almost', '50', 'million', 'differential', 'protein', 'activities', 'derived', 'from', 'drug', 'perturbations', 'ivsi', 'vehicle', 'controls', 'these', 'analyses', 'revealed', 'thousands', 'of', 'highly', 'reproducible', 'and', 'novel', 'drugmediated', 'modulation', 'of', 'tissuespecific', 'targets', 'leading', 'to', 'generation', 'of', 'a', 'proteomewide', 'drug', 'functional', 'network', 'characterization', 'of', 'moarelated', 'drug', 'clusters', 'and', 'offtarget', 'effects', 'dramatical', 'expansion', 'of', 'druggable', 'human', 'proteome', 'and', 'identification', 'and', 'experimental', 'validation', 'of', 'novel', 'tissuespecific', 'inhibitors', 'of', 'undruggable', 'oncoproteins', 'most', 'never', 'reported', 'before', 'the', 'drug', 'perturbation', 'profile', 'resource', 'described', 'here', 'represents', 'the', 'first', 'largescale', 'wholegenomewide', 'rnaseq', 'based', 'dataset', 'assembled', 'to', 'date', 'with', 'the', 'proposed', 'framework', 'which', 'is', 'easily', 'extended', 'to', 'elucidating', 'the', 'moa', 'of', 'novel', 'smallmolecule', 'libraries', 'facilitates', 'mechanistic', 'exploration', 'of', 'drug', 'functions', 'supports', 'systematic', 'and', 'quantitative', 'approaches', 'to', 'precision', 'oncology', 'and', 'serves', 'as', 'a', 'rich', 'data', 'foundation', 'for', 'drug', 'discovery']","['mechanism', 'action', 'moa', 'drug', 'generally', 'represented', 'small', 'nontissuespecific', 'repertoire', 'highaffinity', 'binding', 'targets', 'yet', 'drug', 'activity', 'polypharmacology', 'increasingly', 'associated', 'broad', 'range', 'offtarget', 'tissuespecific', 'effector', 'proteins', 'address', 'challenge', 'leveraged', 'microfluidicsbased', 'plateseq', 'technology', 'survey', 'drug', 'perturbational', 'profiles', 'representing', '700', 'fdaapproved', 'experimental', 'oncology', 'drugs', 'cell', 'lines', 'selected', 'highfidelity', 'models', '23', 'aggressive', 'tumor', 'subtypes', 'built', 'dataset', 'implemented', 'efficient', 'computational', 'framework', 'define', 'tissuespecific', 'protein', 'activity', 'landscape', 'drugs', 'reported', 'almost', '50', 'million', 'differential', 'protein', 'activities', 'derived', 'drug', 'perturbations', 'ivsi', 'vehicle', 'controls', 'analyses', 'revealed', 'thousands', 'highly', 'reproducible', 'novel', 'drugmediated', 'modulation', 'tissuespecific', 'targets', 'leading', 'generation', 'proteomewide', 'drug', 'functional', 'network', 'characterization', 'moarelated', 'drug', 'clusters', 'offtarget', 'effects', 'dramatical', 'expansion', 'druggable', 'human', 'proteome', 'identification', 'experimental', 'validation', 'novel', 'tissuespecific', 'inhibitors', 'undruggable', 'oncoproteins', 'never', 'reported', 'drug', 'perturbation', 'profile', 'resource', 'described', 'represents', 'first', 'largescale', 'wholegenomewide', 'rnaseq', 'based', 'dataset', 'assembled', 'date', 'proposed', 'framework', 'easily', 'extended', 'elucidating', 'moa', 'novel', 'smallmolecule', 'libraries', 'facilitates', 'mechanistic', 'exploration', 'drug', 'functions', 'supports', 'systematic', 'quantitative', 'approaches', 'precision', 'oncology', 'serves', 'rich', 'data', 'foundation', 'drug', 'discovery']","['offtarget', 'offtarget']","['offtarget', 'offtarget']",True,['tumor']
37865992,Discovery of tetrazolo-pyridazine-based small molecules as inhibitors of MACC1-driven cancer metastasis.,"Metastasis is directly linked to poor prognosis of cancer patients and warrants search for effective anti-metastatic drugs. MACC1 is a causal key molecule for metastasis. High MACC1 expression is prognostic for metastasis and poor survival. Here, we developed novel small molecule inhibitors targeting MACC1 expression to impede metastasis formation. We performed a human MACC1 promoter-driven luciferase reporter-based high-throughput screen (HTS; 118.500 compound library) to identify MACC1 transcriptional inhibitors. HTS revealed 1,2,3,4-tetrazolo[1,5-b]pyridazine-based compounds as efficient transcriptional inhibitors of MACC1 expression, able to decrease MACC1-induced cancer cell motility in vitro. Structure-activity relationships identified the essential inhibitory core structure. Best candidates were evaluated for metastasis inhibition in xenografted mouse models demonstrating metastasis restriction. ADMET showed high drug-likeness of these new candidates for cancer therapy. The NFκB pathway was identified as one mode of action targeted by these compounds. Taken together, 1,2,3,4-tetrazolo[1,5-b]pyridazine-based compounds are effective MACC1 inhibitors and pose promising candidates for anti-metastatic therapies particularly for patients with MACC1-overexpressing cancers, that are at high risk to develop metastases. Although further preclinical and clinical development is necessary, these compounds represent important building blocks for an individualized anti-metastatic therapy for solid cancers.",2023-10-21,metastasis is directly linked to poor prognosis of cancer patients and warrants search for effective antimetastatic drugs macc1 is a causal key molecule for metastasis high macc1 expression is prognostic for metastasis and poor survival here we developed novel small molecule inhibitors targeting macc1 expression to impede metastasis formation we performed a human macc1 promoterdriven luciferase reporterbased highthroughput screen hts 118500 compound library to identify macc1 transcriptional inhibitors hts revealed 1234tetrazolo15bpyridazinebased compounds as efficient transcriptional inhibitors of macc1 expression able to decrease macc1induced cancer cell motility in vitro structureactivity relationships identified the essential inhibitory core structure best candidates were evaluated for metastasis inhibition in xenografted mouse models demonstrating metastasis restriction admet showed high druglikeness of these new candidates for cancer therapy the nfκb pathway was identified as one mode of action targeted by these compounds taken together 1234tetrazolo15bpyridazinebased compounds are effective macc1 inhibitors and pose promising candidates for antimetastatic therapies particularly for patients with macc1overexpressing cancers that are at high risk to develop metastases although further preclinical and clinical development is necessary these compounds represent important building blocks for an individualized antimetastatic therapy for solid cancers,"['metastasis', 'is', 'directly', 'linked', 'to', 'poor', 'prognosis', 'of', 'cancer', 'patients', 'and', 'warrants', 'search', 'for', 'effective', 'antimetastatic', 'drugs', 'macc1', 'is', 'a', 'causal', 'key', 'molecule', 'for', 'metastasis', 'high', 'macc1', 'expression', 'is', 'prognostic', 'for', 'metastasis', 'and', 'poor', 'survival', 'here', 'we', 'developed', 'novel', 'small', 'molecule', 'inhibitors', 'targeting', 'macc1', 'expression', 'to', 'impede', 'metastasis', 'formation', 'we', 'performed', 'a', 'human', 'macc1', 'promoterdriven', 'luciferase', 'reporterbased', 'highthroughput', 'screen', 'hts', '118500', 'compound', 'library', 'to', 'identify', 'macc1', 'transcriptional', 'inhibitors', 'hts', 'revealed', '1234tetrazolo15bpyridazinebased', 'compounds', 'as', 'efficient', 'transcriptional', 'inhibitors', 'of', 'macc1', 'expression', 'able', 'to', 'decrease', 'macc1induced', 'cancer', 'cell', 'motility', 'in', 'vitro', 'structureactivity', 'relationships', 'identified', 'the', 'essential', 'inhibitory', 'core', 'structure', 'best', 'candidates', 'were', 'evaluated', 'for', 'metastasis', 'inhibition', 'in', 'xenografted', 'mouse', 'models', 'demonstrating', 'metastasis', 'restriction', 'admet', 'showed', 'high', 'druglikeness', 'of', 'these', 'new', 'candidates', 'for', 'cancer', 'therapy', 'the', 'nfκb', 'pathway', 'was', 'identified', 'as', 'one', 'mode', 'of', 'action', 'targeted', 'by', 'these', 'compounds', 'taken', 'together', '1234tetrazolo15bpyridazinebased', 'compounds', 'are', 'effective', 'macc1', 'inhibitors', 'and', 'pose', 'promising', 'candidates', 'for', 'antimetastatic', 'therapies', 'particularly', 'for', 'patients', 'with', 'macc1overexpressing', 'cancers', 'that', 'are', 'at', 'high', 'risk', 'to', 'develop', 'metastases', 'although', 'further', 'preclinical', 'and', 'clinical', 'development', 'is', 'necessary', 'these', 'compounds', 'represent', 'important', 'building', 'blocks', 'for', 'an', 'individualized', 'antimetastatic', 'therapy', 'for', 'solid', 'cancers']","['metastasis', 'directly', 'linked', 'poor', 'prognosis', 'cancer', 'patients', 'warrants', 'search', 'effective', 'antimetastatic', 'drugs', 'macc1', 'causal', 'key', 'molecule', 'metastasis', 'high', 'macc1', 'expression', 'prognostic', 'metastasis', 'poor', 'survival', 'developed', 'novel', 'small', 'molecule', 'inhibitors', 'targeting', 'macc1', 'expression', 'impede', 'metastasis', 'formation', 'performed', 'human', 'macc1', 'promoterdriven', 'luciferase', 'reporterbased', 'highthroughput', 'screen', 'hts', '118500', 'compound', 'library', 'identify', 'macc1', 'transcriptional', 'inhibitors', 'hts', 'revealed', '1234tetrazolo15bpyridazinebased', 'compounds', 'efficient', 'transcriptional', 'inhibitors', 'macc1', 'expression', 'able', 'decrease', 'macc1induced', 'cancer', 'cell', 'motility', 'vitro', 'structureactivity', 'relationships', 'identified', 'essential', 'inhibitory', 'core', 'structure', 'best', 'candidates', 'evaluated', 'metastasis', 'inhibition', 'xenografted', 'mouse', 'models', 'demonstrating', 'metastasis', 'restriction', 'admet', 'showed', 'high', 'druglikeness', 'new', 'candidates', 'cancer', 'therapy', 'nfκb', 'pathway', 'identified', 'one', 'mode', 'action', 'targeted', 'compounds', 'taken', 'together', '1234tetrazolo15bpyridazinebased', 'compounds', 'effective', 'macc1', 'inhibitors', 'pose', 'promising', 'candidates', 'antimetastatic', 'therapies', 'particularly', 'patients', 'macc1overexpressing', 'cancers', 'high', 'risk', 'develop', 'metastases', 'although', 'preclinical', 'clinical', 'development', 'necessary', 'compounds', 'represent', 'important', 'building', 'blocks', 'individualized', 'antimetastatic', 'therapy', 'solid', 'cancers']",['luciferase'],['luciferase'],True,['cancer']
37864629,AQP4 is an Emerging Regulator of Pathological Pain: A Narrative Review.,"Pathological pain presents significant challenges in clinical practice and research. Aquaporin-4 (AQP4), which is primarily found in astrocytes, is being considered as a prospective modulator of pathological pain. This review examines the association between AQP4 and pain-related diseases, including cancer pain, neuropathic pain, and inflammatory pain. In cancer pain, upregulated AQP4 expression in tumor cells is linked to increased pain severity, potentially through tumor-induced inflammation and edema. Targeting AQP4 may offer therapeutic strategies for managing cancer pain. AQP4 has also been found to play a role in nerve damage. Changes in AQP4 expression have been detected in pain-related regions of the brain and spinal cord; thus, modulating AQP4 expression or function may provide new avenues for treating neuropathic pain. Of note, AQP4-deficient mice exhibit reduced chronic pain responses, suggesting potential involvement of AQP4 in chronic pain modulation, and AQP4 is involved in pain modulation during inflammation, so understanding AQP4-mediated pain modulation may lead to novel anti-inflammatory and analgesic therapies. Recent advancements in magnetic resonance imaging (MRI) techniques enable assessment of AQP4 expression and localization, contributing to our understanding of its involvement in brain edema and clearance pathways related to pathological pain. Furthermore, targeting AQP4 through gene therapies and small-molecule modulators shows promise as a potential therapeutic intervention. Future research should focus on utilizing advanced MRI techniques to observe glymphatic system changes and the exchange of cerebrospinal fluid and interstitial fluid. Additionally, investigating the regulation of AQP4 by non-coding RNAs and exploring novel small-molecule medicines are important directions for future research. This review shed light on AQP4-based innovative therapeutic strategies for the treatment of pathological pain. Dark blue cells represent astrocytes, green cells represent microglia, and red ones represent brain microvasculature.",2023-10-21,pathological pain presents significant challenges in clinical practice and research aquaporin4 aqp4 which is primarily found in astrocytes is being considered as a prospective modulator of pathological pain this review examines the association between aqp4 and painrelated diseases including cancer pain neuropathic pain and inflammatory pain in cancer pain upregulated aqp4 expression in tumor cells is linked to increased pain severity potentially through tumorinduced inflammation and edema targeting aqp4 may offer therapeutic strategies for managing cancer pain aqp4 has also been found to play a role in nerve damage changes in aqp4 expression have been detected in painrelated regions of the brain and spinal cord thus modulating aqp4 expression or function may provide new avenues for treating neuropathic pain of note aqp4deficient mice exhibit reduced chronic pain responses suggesting potential involvement of aqp4 in chronic pain modulation and aqp4 is involved in pain modulation during inflammation so understanding aqp4mediated pain modulation may lead to novel antiinflammatory and analgesic therapies recent advancements in magnetic resonance imaging mri techniques enable assessment of aqp4 expression and localization contributing to our understanding of its involvement in brain edema and clearance pathways related to pathological pain furthermore targeting aqp4 through gene therapies and smallmolecule modulators shows promise as a potential therapeutic intervention future research should focus on utilizing advanced mri techniques to observe glymphatic system changes and the exchange of cerebrospinal fluid and interstitial fluid additionally investigating the regulation of aqp4 by noncoding rnas and exploring novel smallmolecule medicines are important directions for future research this review shed light on aqp4based innovative therapeutic strategies for the treatment of pathological pain dark blue cells represent astrocytes green cells represent microglia and red ones represent brain microvasculature,"['pathological', 'pain', 'presents', 'significant', 'challenges', 'in', 'clinical', 'practice', 'and', 'research', 'aquaporin4', 'aqp4', 'which', 'is', 'primarily', 'found', 'in', 'astrocytes', 'is', 'being', 'considered', 'as', 'a', 'prospective', 'modulator', 'of', 'pathological', 'pain', 'this', 'review', 'examines', 'the', 'association', 'between', 'aqp4', 'and', 'painrelated', 'diseases', 'including', 'cancer', 'pain', 'neuropathic', 'pain', 'and', 'inflammatory', 'pain', 'in', 'cancer', 'pain', 'upregulated', 'aqp4', 'expression', 'in', 'tumor', 'cells', 'is', 'linked', 'to', 'increased', 'pain', 'severity', 'potentially', 'through', 'tumorinduced', 'inflammation', 'and', 'edema', 'targeting', 'aqp4', 'may', 'offer', 'therapeutic', 'strategies', 'for', 'managing', 'cancer', 'pain', 'aqp4', 'has', 'also', 'been', 'found', 'to', 'play', 'a', 'role', 'in', 'nerve', 'damage', 'changes', 'in', 'aqp4', 'expression', 'have', 'been', 'detected', 'in', 'painrelated', 'regions', 'of', 'the', 'brain', 'and', 'spinal', 'cord', 'thus', 'modulating', 'aqp4', 'expression', 'or', 'function', 'may', 'provide', 'new', 'avenues', 'for', 'treating', 'neuropathic', 'pain', 'of', 'note', 'aqp4deficient', 'mice', 'exhibit', 'reduced', 'chronic', 'pain', 'responses', 'suggesting', 'potential', 'involvement', 'of', 'aqp4', 'in', 'chronic', 'pain', 'modulation', 'and', 'aqp4', 'is', 'involved', 'in', 'pain', 'modulation', 'during', 'inflammation', 'so', 'understanding', 'aqp4mediated', 'pain', 'modulation', 'may', 'lead', 'to', 'novel', 'antiinflammatory', 'and', 'analgesic', 'therapies', 'recent', 'advancements', 'in', 'magnetic', 'resonance', 'imaging', 'mri', 'techniques', 'enable', 'assessment', 'of', 'aqp4', 'expression', 'and', 'localization', 'contributing', 'to', 'our', 'understanding', 'of', 'its', 'involvement', 'in', 'brain', 'edema', 'and', 'clearance', 'pathways', 'related', 'to', 'pathological', 'pain', 'furthermore', 'targeting', 'aqp4', 'through', 'gene', 'therapies', 'and', 'smallmolecule', 'modulators', 'shows', 'promise', 'as', 'a', 'potential', 'therapeutic', 'intervention', 'future', 'research', 'should', 'focus', 'on', 'utilizing', 'advanced', 'mri', 'techniques', 'to', 'observe', 'glymphatic', 'system', 'changes', 'and', 'the', 'exchange', 'of', 'cerebrospinal', 'fluid', 'and', 'interstitial', 'fluid', 'additionally', 'investigating', 'the', 'regulation', 'of', 'aqp4', 'by', 'noncoding', 'rnas', 'and', 'exploring', 'novel', 'smallmolecule', 'medicines', 'are', 'important', 'directions', 'for', 'future', 'research', 'this', 'review', 'shed', 'light', 'on', 'aqp4based', 'innovative', 'therapeutic', 'strategies', 'for', 'the', 'treatment', 'of', 'pathological', 'pain', 'dark', 'blue', 'cells', 'represent', 'astrocytes', 'green', 'cells', 'represent', 'microglia', 'and', 'red', 'ones', 'represent', 'brain', 'microvasculature']","['pathological', 'pain', 'presents', 'significant', 'challenges', 'clinical', 'practice', 'research', 'aquaporin4', 'aqp4', 'primarily', 'found', 'astrocytes', 'considered', 'prospective', 'modulator', 'pathological', 'pain', 'review', 'examines', 'association', 'aqp4', 'painrelated', 'diseases', 'including', 'cancer', 'pain', 'neuropathic', 'pain', 'inflammatory', 'pain', 'cancer', 'pain', 'upregulated', 'aqp4', 'expression', 'tumor', 'cells', 'linked', 'increased', 'pain', 'severity', 'potentially', 'tumorinduced', 'inflammation', 'edema', 'targeting', 'aqp4', 'may', 'offer', 'therapeutic', 'strategies', 'managing', 'cancer', 'pain', 'aqp4', 'also', 'found', 'play', 'role', 'nerve', 'damage', 'changes', 'aqp4', 'expression', 'detected', 'painrelated', 'regions', 'brain', 'spinal', 'cord', 'thus', 'modulating', 'aqp4', 'expression', 'function', 'may', 'provide', 'new', 'avenues', 'treating', 'neuropathic', 'pain', 'note', 'aqp4deficient', 'mice', 'exhibit', 'reduced', 'chronic', 'pain', 'responses', 'suggesting', 'potential', 'involvement', 'aqp4', 'chronic', 'pain', 'modulation', 'aqp4', 'involved', 'pain', 'modulation', 'inflammation', 'understanding', 'aqp4mediated', 'pain', 'modulation', 'may', 'lead', 'novel', 'antiinflammatory', 'analgesic', 'therapies', 'recent', 'advancements', 'magnetic', 'resonance', 'imaging', 'mri', 'techniques', 'enable', 'assessment', 'aqp4', 'expression', 'localization', 'contributing', 'understanding', 'involvement', 'brain', 'edema', 'clearance', 'pathways', 'related', 'pathological', 'pain', 'furthermore', 'targeting', 'aqp4', 'gene', 'therapies', 'smallmolecule', 'modulators', 'shows', 'promise', 'potential', 'therapeutic', 'intervention', 'future', 'research', 'focus', 'utilizing', 'advanced', 'mri', 'techniques', 'observe', 'glymphatic', 'system', 'changes', 'exchange', 'cerebrospinal', 'fluid', 'interstitial', 'fluid', 'additionally', 'investigating', 'regulation', 'aqp4', 'noncoding', 'rnas', 'exploring', 'novel', 'smallmolecule', 'medicines', 'important', 'directions', 'future', 'research', 'review', 'shed', 'light', 'aqp4based', 'innovative', 'therapeutic', 'strategies', 'treatment', 'pathological', 'pain', 'dark', 'blue', 'cells', 'represent', 'astrocytes', 'green', 'cells', 'represent', 'microglia', 'red', 'ones', 'represent', 'brain', 'microvasculature']","['aquaporin4', 'aqp4', 'aqp4', 'aqp4', 'aqp4', 'aqp4', 'aqp4', 'aqp4', 'aqp4', 'aqp4', 'aqp4', 'aqp4', 'aqp4']","['aquaporin4', 'aqp4', 'aqp4', 'aqp4', 'aqp4', 'aqp4', 'aqp4', 'aqp4', 'aqp4', 'aqp4', 'aqp4', 'aqp4', 'aqp4']",True,"['tumor', 'cancer']"
37859283,Transcriptomic discovery of a theranostic signature (SERPINE1/MMP3/COL1A1/SPP1) for head and neck squamous cell carcinomas and identification of antrocinol as a candidate drug.,"Head and neck squamous cell carcinomas (HNSCC) are prevalent malignancies with a disappointing prognosis, necessitating the search for theranostic biomarkers for better management. Based on a meta-analysis of transcriptomic data containing ten clinical datasets of HNSCC and matched nonmalignant samples, we identified SERPINE1/MMP3/COL1A1/SPP1 as essential hub genes as the potential theranostic biomarkers. Our analysis suggests these hub genes are associated with the extracellular matrix, peptidoglycans, cell migration, wound-healing processes, complement and coagulation cascades, and the AGE-RAGE signaling pathway within the tumor microenvironment. Also, these hub genes were associated with tumor-immune infiltrating cells and immunosuppressive phenotypes of HNSCC. Further investigation of The Cancer Genome Atlas (TCGA) cohorts revealed that these hub genes were associated with staging, metastasis, and poor survival in HNSCC patients. Molecular docking simulations were performed to evaluate binding activities between the hub genes and antrocinol, a novel small-molecule derivative of an anticancer phytochemical antrocin previously discovered by our group. Antrocinol showed high affinities to MMP3 and COL1A1. Notably, antrocinol presented satisfactory drug-like and ADMET properties for therapeutic applications. These results hinted at the potential of antrocinol as an anti-HNSCC candidate via targeting MMP3 and COL1A1. In conclusion, we identified hub genes: SERPINE1/MMP3/COL1A1/SPP1 as potential diagnostic biomarkers and antrocinol as a potential new drug for HNSCC.",2022-10-17,head and neck squamous cell carcinomas hnscc are prevalent malignancies with a disappointing prognosis necessitating the search for theranostic biomarkers for better management based on a metaanalysis of transcriptomic data containing ten clinical datasets of hnscc and matched nonmalignant samples we identified serpine1mmp3col1a1spp1 as essential hub genes as the potential theranostic biomarkers our analysis suggests these hub genes are associated with the extracellular matrix peptidoglycans cell migration woundhealing processes complement and coagulation cascades and the agerage signaling pathway within the tumor microenvironment also these hub genes were associated with tumorimmune infiltrating cells and immunosuppressive phenotypes of hnscc further investigation of the cancer genome atlas tcga cohorts revealed that these hub genes were associated with staging metastasis and poor survival in hnscc patients molecular docking simulations were performed to evaluate binding activities between the hub genes and antrocinol a novel smallmolecule derivative of an anticancer phytochemical antrocin previously discovered by our group antrocinol showed high affinities to mmp3 and col1a1 notably antrocinol presented satisfactory druglike and admet properties for therapeutic applications these results hinted at the potential of antrocinol as an antihnscc candidate via targeting mmp3 and col1a1 in conclusion we identified hub genes serpine1mmp3col1a1spp1 as potential diagnostic biomarkers and antrocinol as a potential new drug for hnscc,"['head', 'and', 'neck', 'squamous', 'cell', 'carcinomas', 'hnscc', 'are', 'prevalent', 'malignancies', 'with', 'a', 'disappointing', 'prognosis', 'necessitating', 'the', 'search', 'for', 'theranostic', 'biomarkers', 'for', 'better', 'management', 'based', 'on', 'a', 'metaanalysis', 'of', 'transcriptomic', 'data', 'containing', 'ten', 'clinical', 'datasets', 'of', 'hnscc', 'and', 'matched', 'nonmalignant', 'samples', 'we', 'identified', 'serpine1mmp3col1a1spp1', 'as', 'essential', 'hub', 'genes', 'as', 'the', 'potential', 'theranostic', 'biomarkers', 'our', 'analysis', 'suggests', 'these', 'hub', 'genes', 'are', 'associated', 'with', 'the', 'extracellular', 'matrix', 'peptidoglycans', 'cell', 'migration', 'woundhealing', 'processes', 'complement', 'and', 'coagulation', 'cascades', 'and', 'the', 'agerage', 'signaling', 'pathway', 'within', 'the', 'tumor', 'microenvironment', 'also', 'these', 'hub', 'genes', 'were', 'associated', 'with', 'tumorimmune', 'infiltrating', 'cells', 'and', 'immunosuppressive', 'phenotypes', 'of', 'hnscc', 'further', 'investigation', 'of', 'the', 'cancer', 'genome', 'atlas', 'tcga', 'cohorts', 'revealed', 'that', 'these', 'hub', 'genes', 'were', 'associated', 'with', 'staging', 'metastasis', 'and', 'poor', 'survival', 'in', 'hnscc', 'patients', 'molecular', 'docking', 'simulations', 'were', 'performed', 'to', 'evaluate', 'binding', 'activities', 'between', 'the', 'hub', 'genes', 'and', 'antrocinol', 'a', 'novel', 'smallmolecule', 'derivative', 'of', 'an', 'anticancer', 'phytochemical', 'antrocin', 'previously', 'discovered', 'by', 'our', 'group', 'antrocinol', 'showed', 'high', 'affinities', 'to', 'mmp3', 'and', 'col1a1', 'notably', 'antrocinol', 'presented', 'satisfactory', 'druglike', 'and', 'admet', 'properties', 'for', 'therapeutic', 'applications', 'these', 'results', 'hinted', 'at', 'the', 'potential', 'of', 'antrocinol', 'as', 'an', 'antihnscc', 'candidate', 'via', 'targeting', 'mmp3', 'and', 'col1a1', 'in', 'conclusion', 'we', 'identified', 'hub', 'genes', 'serpine1mmp3col1a1spp1', 'as', 'potential', 'diagnostic', 'biomarkers', 'and', 'antrocinol', 'as', 'a', 'potential', 'new', 'drug', 'for', 'hnscc']","['head', 'neck', 'squamous', 'cell', 'carcinomas', 'hnscc', 'prevalent', 'malignancies', 'disappointing', 'prognosis', 'necessitating', 'search', 'theranostic', 'biomarkers', 'better', 'management', 'based', 'metaanalysis', 'transcriptomic', 'data', 'containing', 'ten', 'clinical', 'datasets', 'hnscc', 'matched', 'nonmalignant', 'samples', 'identified', 'serpine1mmp3col1a1spp1', 'essential', 'hub', 'genes', 'potential', 'theranostic', 'biomarkers', 'analysis', 'suggests', 'hub', 'genes', 'associated', 'extracellular', 'matrix', 'peptidoglycans', 'cell', 'migration', 'woundhealing', 'processes', 'complement', 'coagulation', 'cascades', 'agerage', 'signaling', 'pathway', 'within', 'tumor', 'microenvironment', 'also', 'hub', 'genes', 'associated', 'tumorimmune', 'infiltrating', 'cells', 'immunosuppressive', 'phenotypes', 'hnscc', 'investigation', 'cancer', 'genome', 'atlas', 'tcga', 'cohorts', 'revealed', 'hub', 'genes', 'associated', 'staging', 'metastasis', 'poor', 'survival', 'hnscc', 'patients', 'molecular', 'docking', 'simulations', 'performed', 'evaluate', 'binding', 'activities', 'hub', 'genes', 'antrocinol', 'novel', 'smallmolecule', 'derivative', 'anticancer', 'phytochemical', 'antrocin', 'previously', 'discovered', 'group', 'antrocinol', 'showed', 'high', 'affinities', 'mmp3', 'col1a1', 'notably', 'antrocinol', 'presented', 'satisfactory', 'druglike', 'admet', 'properties', 'therapeutic', 'applications', 'results', 'hinted', 'potential', 'antrocinol', 'antihnscc', 'candidate', 'via', 'targeting', 'mmp3', 'col1a1', 'conclusion', 'identified', 'hub', 'genes', 'serpine1mmp3col1a1spp1', 'potential', 'diagnostic', 'biomarkers', 'antrocinol', 'potential', 'new', 'drug', 'hnscc']","['antrocin', 'col1a1', 'col1a1']","['antrocin', 'col1a1', 'col1a1']",True,"['tumor', 'cancer']"
37855364,Identification of novel small molecule inhibitors for solute carrier SGLT1; a computational exploration.,"Diabetes results in substantial disabilities, diminished quality of life, and mortality that imposes a huge economic burden on societies and governments worldwide. Despite the absence of specific oral therapies at present, there exists an urgent requirement to develop a novel drug for the treatment of diabetes mellitus. The membrane protein sodium glucose co-transporters (SGLT1) present a captivating therapeutic target for diabetes, given its pivotal role in facilitating glucose absorption in the small intestine, offering immense promise for potential therapeutic intervention. In this connection, the present study is aimed at identifying potential inhibitors of SGLT1 from a small molecule database, including compounds from both natural as well as synthetic origins. A comprehensive approach was employed, by integrating homology modeling, ligand-based pharmacophore modeling, virtual screening, and molecular docking simulation. The process resulted in the identification of 16 new compounds, featuring similar attributes as observed for the documented actives. In a systematic screening procedure, five potential virtual hits were selected for simulation studies followed by subsequent binding free energy calculations, providing deeper insight into the time-dependent behavior of protein-ligand complexes in a dynamic state. In conclusion, our findings demonstrated that the identified compounds, particularly <b>compounds 81</b> and <b>91</b>, exhibit enhanced stability and favorable binding affinities with the target protein, marking them promising candidates for further investigations.Communicated by Ramaswamy H. Sarma.",2023-10-19,diabetes results in substantial disabilities diminished quality of life and mortality that imposes a huge economic burden on societies and governments worldwide despite the absence of specific oral therapies at present there exists an urgent requirement to develop a novel drug for the treatment of diabetes mellitus the membrane protein sodium glucose cotransporters sglt1 present a captivating therapeutic target for diabetes given its pivotal role in facilitating glucose absorption in the small intestine offering immense promise for potential therapeutic intervention in this connection the present study is aimed at identifying potential inhibitors of sglt1 from a small molecule database including compounds from both natural as well as synthetic origins a comprehensive approach was employed by integrating homology modeling ligandbased pharmacophore modeling virtual screening and molecular docking simulation the process resulted in the identification of 16 new compounds featuring similar attributes as observed for the documented actives in a systematic screening procedure five potential virtual hits were selected for simulation studies followed by subsequent binding free energy calculations providing deeper insight into the timedependent behavior of proteinligand complexes in a dynamic state in conclusion our findings demonstrated that the identified compounds particularly bcompounds 81b and b91b exhibit enhanced stability and favorable binding affinities with the target protein marking them promising candidates for further investigationscommunicated by ramaswamy h sarma,"['diabetes', 'results', 'in', 'substantial', 'disabilities', 'diminished', 'quality', 'of', 'life', 'and', 'mortality', 'that', 'imposes', 'a', 'huge', 'economic', 'burden', 'on', 'societies', 'and', 'governments', 'worldwide', 'despite', 'the', 'absence', 'of', 'specific', 'oral', 'therapies', 'at', 'present', 'there', 'exists', 'an', 'urgent', 'requirement', 'to', 'develop', 'a', 'novel', 'drug', 'for', 'the', 'treatment', 'of', 'diabetes', 'mellitus', 'the', 'membrane', 'protein', 'sodium', 'glucose', 'cotransporters', 'sglt1', 'present', 'a', 'captivating', 'therapeutic', 'target', 'for', 'diabetes', 'given', 'its', 'pivotal', 'role', 'in', 'facilitating', 'glucose', 'absorption', 'in', 'the', 'small', 'intestine', 'offering', 'immense', 'promise', 'for', 'potential', 'therapeutic', 'intervention', 'in', 'this', 'connection', 'the', 'present', 'study', 'is', 'aimed', 'at', 'identifying', 'potential', 'inhibitors', 'of', 'sglt1', 'from', 'a', 'small', 'molecule', 'database', 'including', 'compounds', 'from', 'both', 'natural', 'as', 'well', 'as', 'synthetic', 'origins', 'a', 'comprehensive', 'approach', 'was', 'employed', 'by', 'integrating', 'homology', 'modeling', 'ligandbased', 'pharmacophore', 'modeling', 'virtual', 'screening', 'and', 'molecular', 'docking', 'simulation', 'the', 'process', 'resulted', 'in', 'the', 'identification', 'of', '16', 'new', 'compounds', 'featuring', 'similar', 'attributes', 'as', 'observed', 'for', 'the', 'documented', 'actives', 'in', 'a', 'systematic', 'screening', 'procedure', 'five', 'potential', 'virtual', 'hits', 'were', 'selected', 'for', 'simulation', 'studies', 'followed', 'by', 'subsequent', 'binding', 'free', 'energy', 'calculations', 'providing', 'deeper', 'insight', 'into', 'the', 'timedependent', 'behavior', 'of', 'proteinligand', 'complexes', 'in', 'a', 'dynamic', 'state', 'in', 'conclusion', 'our', 'findings', 'demonstrated', 'that', 'the', 'identified', 'compounds', 'particularly', 'bcompounds', '81b', 'and', 'b91b', 'exhibit', 'enhanced', 'stability', 'and', 'favorable', 'binding', 'affinities', 'with', 'the', 'target', 'protein', 'marking', 'them', 'promising', 'candidates', 'for', 'further', 'investigationscommunicated', 'by', 'ramaswamy', 'h', 'sarma']","['diabetes', 'results', 'substantial', 'disabilities', 'diminished', 'quality', 'life', 'mortality', 'imposes', 'huge', 'economic', 'burden', 'societies', 'governments', 'worldwide', 'despite', 'absence', 'specific', 'oral', 'therapies', 'present', 'exists', 'urgent', 'requirement', 'develop', 'novel', 'drug', 'treatment', 'diabetes', 'mellitus', 'membrane', 'protein', 'sodium', 'glucose', 'cotransporters', 'sglt1', 'present', 'captivating', 'therapeutic', 'target', 'diabetes', 'given', 'pivotal', 'role', 'facilitating', 'glucose', 'absorption', 'small', 'intestine', 'offering', 'immense', 'promise', 'potential', 'therapeutic', 'intervention', 'connection', 'present', 'study', 'aimed', 'identifying', 'potential', 'inhibitors', 'sglt1', 'small', 'molecule', 'database', 'including', 'compounds', 'natural', 'well', 'synthetic', 'origins', 'comprehensive', 'approach', 'employed', 'integrating', 'homology', 'modeling', 'ligandbased', 'pharmacophore', 'modeling', 'virtual', 'screening', 'molecular', 'docking', 'simulation', 'process', 'resulted', 'identification', '16', 'new', 'compounds', 'featuring', 'similar', 'attributes', 'observed', 'documented', 'actives', 'systematic', 'screening', 'procedure', 'five', 'potential', 'virtual', 'hits', 'selected', 'simulation', 'studies', 'followed', 'subsequent', 'binding', 'free', 'energy', 'calculations', 'providing', 'deeper', 'insight', 'timedependent', 'behavior', 'proteinligand', 'complexes', 'dynamic', 'state', 'conclusion', 'findings', 'demonstrated', 'identified', 'compounds', 'particularly', 'bcompounds', '81b', 'b91b', 'exhibit', 'enhanced', 'stability', 'favorable', 'binding', 'affinities', 'target', 'protein', 'marking', 'promising', 'candidates', 'investigationscommunicated', 'ramaswamy', 'h', 'sarma']",['cotransporters'],['cotransporters'],True,['diabetes']
37829571,A Novel Peptide that Disrupts the Lck-IP<sub>3</sub>R Protein-Protein Interaction Induces Widespread Cell Death in Leukemia and Lymphoma.,"There is increasing evidence that the T-cell protein, Lck, is involved in the pathogenesis of chronic lymphocytic leukemia (CLL) as well as other leukemias and lymphomas. We previously discovered that Lck binds to domain 5 of inositol 1,4,5-trisphosphate receptors (IP<sub>3</sub>R) to regulate Ca<sup>2+</sup> homeostasis. Using bioinformatics, we targeted a region within domain 5 of IP<sub>3</sub>R-1 predicted to facilitate protein-protein interactions (PPIs). We generated a synthetic 21 amino acid peptide, KKRMDLVLELKNNASKLLLAI, which constitutes a domain 5 sub-domain (D5SD) of IP<sub>3</sub>R-1 that specifically binds Lck via its SH2 domain. With the addition of an HIV-TAT sequence to enable cell permeability of D5SD peptide, we observed wide-spread, Ca<sup>2+</sup>-dependent, cell killing of hematological cancer cells when the Lck-IP<sub>3</sub>R PPI was disrupted by TAT-D5SD. All cell lines and primary cells were sensitive to D5SD peptide, but malignant T-cells were less sensitive compared with B-cell or myeloid malignancies. Mining of RNA-seq data showed that <i>LCK</i> was expressed in primary diffuse large B-cell lymphoma (DLBCL) as well as acute myeloid leukemia (AML). In fact, <i>LCK</i> shows a similar pattern of expression as many well-characterized AML oncogenes and is part of a protein interactome that includes FLT3-ITD, Notch-1, and Kit. Consistent with these findings, our data suggest that the Lck-IP<sub>3</sub>R PPI may protect malignant hematopoietic cells from death. Importantly, TAT-D5SD showed no cytotoxicity in three different non-hematopoietic cell lines; thus its ability to induce cell death appears specific to hematopoietic cells. Together, these data show that a peptide designed to disrupt the Lck-IP<sub>3</sub>R PPI has a wide range of pre-clinical activity in leukemia and lymphoma.",2023-08-30,there is increasing evidence that the tcell protein lck is involved in the pathogenesis of chronic lymphocytic leukemia cll as well as other leukemias and lymphomas we previously discovered that lck binds to domain 5 of inositol 145trisphosphate receptors ipsub3subr to regulate casup2sup homeostasis using bioinformatics we targeted a region within domain 5 of ipsub3subr1 predicted to facilitate proteinprotein interactions ppis we generated a synthetic 21 amino acid peptide kkrmdlvlelknnasklllai which constitutes a domain 5 subdomain d5sd of ipsub3subr1 that specifically binds lck via its sh2 domain with the addition of an hivtat sequence to enable cell permeability of d5sd peptide we observed widespread casup2supdependent cell killing of hematological cancer cells when the lckipsub3subr ppi was disrupted by tatd5sd all cell lines and primary cells were sensitive to d5sd peptide but malignant tcells were less sensitive compared with bcell or myeloid malignancies mining of rnaseq data showed that ilcki was expressed in primary diffuse large bcell lymphoma dlbcl as well as acute myeloid leukemia aml in fact ilcki shows a similar pattern of expression as many wellcharacterized aml oncogenes and is part of a protein interactome that includes flt3itd notch1 and kit consistent with these findings our data suggest that the lckipsub3subr ppi may protect malignant hematopoietic cells from death importantly tatd5sd showed no cytotoxicity in three different nonhematopoietic cell lines thus its ability to induce cell death appears specific to hematopoietic cells together these data show that a peptide designed to disrupt the lckipsub3subr ppi has a wide range of preclinical activity in leukemia and lymphoma,"['there', 'is', 'increasing', 'evidence', 'that', 'the', 'tcell', 'protein', 'lck', 'is', 'involved', 'in', 'the', 'pathogenesis', 'of', 'chronic', 'lymphocytic', 'leukemia', 'cll', 'as', 'well', 'as', 'other', 'leukemias', 'and', 'lymphomas', 'we', 'previously', 'discovered', 'that', 'lck', 'binds', 'to', 'domain', '5', 'of', 'inositol', '145trisphosphate', 'receptors', 'ipsub3subr', 'to', 'regulate', 'casup2sup', 'homeostasis', 'using', 'bioinformatics', 'we', 'targeted', 'a', 'region', 'within', 'domain', '5', 'of', 'ipsub3subr1', 'predicted', 'to', 'facilitate', 'proteinprotein', 'interactions', 'ppis', 'we', 'generated', 'a', 'synthetic', '21', 'amino', 'acid', 'peptide', 'kkrmdlvlelknnasklllai', 'which', 'constitutes', 'a', 'domain', '5', 'subdomain', 'd5sd', 'of', 'ipsub3subr1', 'that', 'specifically', 'binds', 'lck', 'via', 'its', 'sh2', 'domain', 'with', 'the', 'addition', 'of', 'an', 'hivtat', 'sequence', 'to', 'enable', 'cell', 'permeability', 'of', 'd5sd', 'peptide', 'we', 'observed', 'widespread', 'casup2supdependent', 'cell', 'killing', 'of', 'hematological', 'cancer', 'cells', 'when', 'the', 'lckipsub3subr', 'ppi', 'was', 'disrupted', 'by', 'tatd5sd', 'all', 'cell', 'lines', 'and', 'primary', 'cells', 'were', 'sensitive', 'to', 'd5sd', 'peptide', 'but', 'malignant', 'tcells', 'were', 'less', 'sensitive', 'compared', 'with', 'bcell', 'or', 'myeloid', 'malignancies', 'mining', 'of', 'rnaseq', 'data', 'showed', 'that', 'ilcki', 'was', 'expressed', 'in', 'primary', 'diffuse', 'large', 'bcell', 'lymphoma', 'dlbcl', 'as', 'well', 'as', 'acute', 'myeloid', 'leukemia', 'aml', 'in', 'fact', 'ilcki', 'shows', 'a', 'similar', 'pattern', 'of', 'expression', 'as', 'many', 'wellcharacterized', 'aml', 'oncogenes', 'and', 'is', 'part', 'of', 'a', 'protein', 'interactome', 'that', 'includes', 'flt3itd', 'notch1', 'and', 'kit', 'consistent', 'with', 'these', 'findings', 'our', 'data', 'suggest', 'that', 'the', 'lckipsub3subr', 'ppi', 'may', 'protect', 'malignant', 'hematopoietic', 'cells', 'from', 'death', 'importantly', 'tatd5sd', 'showed', 'no', 'cytotoxicity', 'in', 'three', 'different', 'nonhematopoietic', 'cell', 'lines', 'thus', 'its', 'ability', 'to', 'induce', 'cell', 'death', 'appears', 'specific', 'to', 'hematopoietic', 'cells', 'together', 'these', 'data', 'show', 'that', 'a', 'peptide', 'designed', 'to', 'disrupt', 'the', 'lckipsub3subr', 'ppi', 'has', 'a', 'wide', 'range', 'of', 'preclinical', 'activity', 'in', 'leukemia', 'and', 'lymphoma']","['increasing', 'evidence', 'tcell', 'protein', 'lck', 'involved', 'pathogenesis', 'chronic', 'lymphocytic', 'leukemia', 'cll', 'well', 'leukemias', 'lymphomas', 'previously', 'discovered', 'lck', 'binds', 'domain', '5', 'inositol', '145trisphosphate', 'receptors', 'ipsub3subr', 'regulate', 'casup2sup', 'homeostasis', 'using', 'bioinformatics', 'targeted', 'region', 'within', 'domain', '5', 'ipsub3subr1', 'predicted', 'facilitate', 'proteinprotein', 'interactions', 'ppis', 'generated', 'synthetic', '21', 'amino', 'acid', 'peptide', 'kkrmdlvlelknnasklllai', 'constitutes', 'domain', '5', 'subdomain', 'd5sd', 'ipsub3subr1', 'specifically', 'binds', 'lck', 'via', 'sh2', 'domain', 'addition', 'hivtat', 'sequence', 'enable', 'cell', 'permeability', 'd5sd', 'peptide', 'observed', 'widespread', 'casup2supdependent', 'cell', 'killing', 'hematological', 'cancer', 'cells', 'lckipsub3subr', 'ppi', 'disrupted', 'tatd5sd', 'cell', 'lines', 'primary', 'cells', 'sensitive', 'd5sd', 'peptide', 'malignant', 'tcells', 'less', 'sensitive', 'compared', 'bcell', 'myeloid', 'malignancies', 'mining', 'rnaseq', 'data', 'showed', 'ilcki', 'expressed', 'primary', 'diffuse', 'large', 'bcell', 'lymphoma', 'dlbcl', 'well', 'acute', 'myeloid', 'leukemia', 'aml', 'fact', 'ilcki', 'shows', 'similar', 'pattern', 'expression', 'many', 'wellcharacterized', 'aml', 'oncogenes', 'part', 'protein', 'interactome', 'includes', 'flt3itd', 'notch1', 'kit', 'consistent', 'findings', 'data', 'suggest', 'lckipsub3subr', 'ppi', 'may', 'protect', 'malignant', 'hematopoietic', 'cells', 'death', 'importantly', 'tatd5sd', 'showed', 'cytotoxicity', 'three', 'different', 'nonhematopoietic', 'cell', 'lines', 'thus', 'ability', 'induce', 'cell', 'death', 'appears', 'specific', 'hematopoietic', 'cells', 'together', 'data', 'show', 'peptide', 'designed', 'disrupt', 'lckipsub3subr', 'ppi', 'wide', 'range', 'preclinical', 'activity', 'leukemia', 'lymphoma']","['lck', 'lck', 'lck', 'notch1']",['notch1'],False,"['cancer', 'leukemia']"
37744342,Chimeric RNAs reveal putative neoantigen peptides for developing tumor vaccines for breast cancer.,We present here a strategy to identify immunogenic neoantigen candidates from unique amino acid sequences at the junctions of fusion proteins which can serve as targets in the development of tumor vaccines for the treatment of breastcancer.,2023-09-06,we present here a strategy to identify immunogenic neoantigen candidates from unique amino acid sequences at the junctions of fusion proteins which can serve as targets in the development of tumor vaccines for the treatment of breastcancer,"['we', 'present', 'here', 'a', 'strategy', 'to', 'identify', 'immunogenic', 'neoantigen', 'candidates', 'from', 'unique', 'amino', 'acid', 'sequences', 'at', 'the', 'junctions', 'of', 'fusion', 'proteins', 'which', 'can', 'serve', 'as', 'targets', 'in', 'the', 'development', 'of', 'tumor', 'vaccines', 'for', 'the', 'treatment', 'of', 'breastcancer']","['present', 'strategy', 'identify', 'immunogenic', 'neoantigen', 'candidates', 'unique', 'amino', 'acid', 'sequences', 'junctions', 'fusion', 'proteins', 'serve', 'targets', 'development', 'tumor', 'vaccines', 'treatment', 'breastcancer']",['neoantigen'],['neoantigen'],True,"['tumor', 'cancer']"
37716621,The novel small molecule BH3 mimetic nobiletin synergizes with vorinostat to induce apoptosis and autophagy in small cell lung cancer.,"Small cell lung cancer (SCLC) is a highly lethal subtype of lung cancer with few therapeutic options; therefore, the identification of new targets and drugs with potent combination therapy is desirable. We previously screened BH3 mimetics from a natural product library, and in this study, we validated nobiletin as a BH3 mimetic. Specifically, we observed its combination potential and mechanism with vorinostat in SCLC in vitro and in vivo. The results showed that combination treatment with nobiletin and vorinostat reduced the proliferation of SCLC H82 cells and increased the levels of apoptotic proteins such as cleaved caspase-9 and cleaved PARP. The combination treatment increased LC3-II expression and induced autophagic cell death. In addition, this treatment significantly inhibited H82 cell xenograft SCLC tumor growth in nude mice. The combination treatment with nobiletin and vorinostat efficiently increased autophagy by inhibiting the PI3K-AKT-mTOR pathway and promoting dissociation of the BCL-2 and Beclin 1 complex, increasing the level of isolated Beclin 1 to stimulate autophagy. Molecular docking and surface plasmon resonance analysis showed that nobiletin stably bound to the BCL-2, BCL-XL and MCL-1 proteins with high affinity in a concentration-dependent manner. These results suggest that nobiletin is a BH3-only protein mimetic. Furthermore, the combination of nobiletin with vorinostat increased histone H3K9 and H3K27 acetylation levels in SCLC mouse tumor tissue and enhanced the expression of the BH3-only proteins BIM and BID. We conclude that nobiletin is a novel natural BH3 mimetic that can cooperate with vorinostat to induce apoptosis and autophagy in SCLC.",2023-09-15,small cell lung cancer sclc is a highly lethal subtype of lung cancer with few therapeutic options therefore the identification of new targets and drugs with potent combination therapy is desirable we previously screened bh3 mimetics from a natural product library and in this study we validated nobiletin as a bh3 mimetic specifically we observed its combination potential and mechanism with vorinostat in sclc in vitro and in vivo the results showed that combination treatment with nobiletin and vorinostat reduced the proliferation of sclc h82 cells and increased the levels of apoptotic proteins such as cleaved caspase9 and cleaved parp the combination treatment increased lc3ii expression and induced autophagic cell death in addition this treatment significantly inhibited h82 cell xenograft sclc tumor growth in nude mice the combination treatment with nobiletin and vorinostat efficiently increased autophagy by inhibiting the pi3kaktmtor pathway and promoting dissociation of the bcl2 and beclin 1 complex increasing the level of isolated beclin 1 to stimulate autophagy molecular docking and surface plasmon resonance analysis showed that nobiletin stably bound to the bcl2 bclxl and mcl1 proteins with high affinity in a concentrationdependent manner these results suggest that nobiletin is a bh3only protein mimetic furthermore the combination of nobiletin with vorinostat increased histone h3k9 and h3k27 acetylation levels in sclc mouse tumor tissue and enhanced the expression of the bh3only proteins bim and bid we conclude that nobiletin is a novel natural bh3 mimetic that can cooperate with vorinostat to induce apoptosis and autophagy in sclc,"['small', 'cell', 'lung', 'cancer', 'sclc', 'is', 'a', 'highly', 'lethal', 'subtype', 'of', 'lung', 'cancer', 'with', 'few', 'therapeutic', 'options', 'therefore', 'the', 'identification', 'of', 'new', 'targets', 'and', 'drugs', 'with', 'potent', 'combination', 'therapy', 'is', 'desirable', 'we', 'previously', 'screened', 'bh3', 'mimetics', 'from', 'a', 'natural', 'product', 'library', 'and', 'in', 'this', 'study', 'we', 'validated', 'nobiletin', 'as', 'a', 'bh3', 'mimetic', 'specifically', 'we', 'observed', 'its', 'combination', 'potential', 'and', 'mechanism', 'with', 'vorinostat', 'in', 'sclc', 'in', 'vitro', 'and', 'in', 'vivo', 'the', 'results', 'showed', 'that', 'combination', 'treatment', 'with', 'nobiletin', 'and', 'vorinostat', 'reduced', 'the', 'proliferation', 'of', 'sclc', 'h82', 'cells', 'and', 'increased', 'the', 'levels', 'of', 'apoptotic', 'proteins', 'such', 'as', 'cleaved', 'caspase9', 'and', 'cleaved', 'parp', 'the', 'combination', 'treatment', 'increased', 'lc3ii', 'expression', 'and', 'induced', 'autophagic', 'cell', 'death', 'in', 'addition', 'this', 'treatment', 'significantly', 'inhibited', 'h82', 'cell', 'xenograft', 'sclc', 'tumor', 'growth', 'in', 'nude', 'mice', 'the', 'combination', 'treatment', 'with', 'nobiletin', 'and', 'vorinostat', 'efficiently', 'increased', 'autophagy', 'by', 'inhibiting', 'the', 'pi3kaktmtor', 'pathway', 'and', 'promoting', 'dissociation', 'of', 'the', 'bcl2', 'and', 'beclin', '1', 'complex', 'increasing', 'the', 'level', 'of', 'isolated', 'beclin', '1', 'to', 'stimulate', 'autophagy', 'molecular', 'docking', 'and', 'surface', 'plasmon', 'resonance', 'analysis', 'showed', 'that', 'nobiletin', 'stably', 'bound', 'to', 'the', 'bcl2', 'bclxl', 'and', 'mcl1', 'proteins', 'with', 'high', 'affinity', 'in', 'a', 'concentrationdependent', 'manner', 'these', 'results', 'suggest', 'that', 'nobiletin', 'is', 'a', 'bh3only', 'protein', 'mimetic', 'furthermore', 'the', 'combination', 'of', 'nobiletin', 'with', 'vorinostat', 'increased', 'histone', 'h3k9', 'and', 'h3k27', 'acetylation', 'levels', 'in', 'sclc', 'mouse', 'tumor', 'tissue', 'and', 'enhanced', 'the', 'expression', 'of', 'the', 'bh3only', 'proteins', 'bim', 'and', 'bid', 'we', 'conclude', 'that', 'nobiletin', 'is', 'a', 'novel', 'natural', 'bh3', 'mimetic', 'that', 'can', 'cooperate', 'with', 'vorinostat', 'to', 'induce', 'apoptosis', 'and', 'autophagy', 'in', 'sclc']","['small', 'cell', 'lung', 'cancer', 'sclc', 'highly', 'lethal', 'subtype', 'lung', 'cancer', 'therapeutic', 'options', 'therefore', 'identification', 'new', 'targets', 'drugs', 'potent', 'combination', 'therapy', 'desirable', 'previously', 'screened', 'bh3', 'mimetics', 'natural', 'product', 'library', 'study', 'validated', 'nobiletin', 'bh3', 'mimetic', 'specifically', 'observed', 'combination', 'potential', 'mechanism', 'vorinostat', 'sclc', 'vitro', 'vivo', 'results', 'showed', 'combination', 'treatment', 'nobiletin', 'vorinostat', 'reduced', 'proliferation', 'sclc', 'h82', 'cells', 'increased', 'levels', 'apoptotic', 'proteins', 'cleaved', 'caspase9', 'cleaved', 'parp', 'combination', 'treatment', 'increased', 'lc3ii', 'expression', 'induced', 'autophagic', 'cell', 'death', 'addition', 'treatment', 'significantly', 'inhibited', 'h82', 'cell', 'xenograft', 'sclc', 'tumor', 'growth', 'nude', 'mice', 'combination', 'treatment', 'nobiletin', 'vorinostat', 'efficiently', 'increased', 'autophagy', 'inhibiting', 'pi3kaktmtor', 'pathway', 'promoting', 'dissociation', 'bcl2', 'beclin', '1', 'complex', 'increasing', 'level', 'isolated', 'beclin', '1', 'stimulate', 'autophagy', 'molecular', 'docking', 'surface', 'plasmon', 'resonance', 'analysis', 'showed', 'nobiletin', 'stably', 'bound', 'bcl2', 'bclxl', 'mcl1', 'proteins', 'high', 'affinity', 'concentrationdependent', 'manner', 'results', 'suggest', 'nobiletin', 'bh3only', 'protein', 'mimetic', 'furthermore', 'combination', 'nobiletin', 'vorinostat', 'increased', 'histone', 'h3k9', 'h3k27', 'acetylation', 'levels', 'sclc', 'mouse', 'tumor', 'tissue', 'enhanced', 'expression', 'bh3only', 'proteins', 'bim', 'bid', 'conclude', 'nobiletin', 'novel', 'natural', 'bh3', 'mimetic', 'cooperate', 'vorinostat', 'induce', 'apoptosis', 'autophagy', 'sclc']","['caspase9', 'bcl2', 'beclin', 'beclin', 'bcl2', 'bclxl', 'mcl1', 'bim']","['caspase9', 'beclin', 'beclin', 'bclxl']",True,"['tumor', 'cancer']"
37696459,Development of a novel peptide targeting GPR81 to suppress adipocyte-mediated tumor progression.,"GPR81, initially discovered in adipocytes, has been found to suppress lipolysis when activated. However, the current small molecules that target GPR81 carry the risk of off-target effects, and their impact on tumor progression remains uncertain. Here, we utilized phage display technology to screen a GPR81-targeting peptide named 7w-2 and proceeded to demonstrate its bioactivity. Although 7w-2 did not affect the proliferation of tumor cells, it effectively reduced adipocyte catabolism in vitro, consequently restraining the proliferation of co-cultured tumor cells. Furthermore, our findings revealed that 7w-2 could inhibit lipolysis in vivo, leading to a significant impediment in tumor growth and metastasis in the 4T1 murine tumor model. Additionally, 7w-2 exhibited the ability to significantly elevate the proportion and functionality of CD8<sup>+</sup> T cells. Our study introduces 7w-2 as the first peptide targeting GPR81, shedding light on its potential role in adipocytes in suppressing tumor progression.",2023-09-09,gpr81 initially discovered in adipocytes has been found to suppress lipolysis when activated however the current small molecules that target gpr81 carry the risk of offtarget effects and their impact on tumor progression remains uncertain here we utilized phage display technology to screen a gpr81targeting peptide named 7w2 and proceeded to demonstrate its bioactivity although 7w2 did not affect the proliferation of tumor cells it effectively reduced adipocyte catabolism in vitro consequently restraining the proliferation of cocultured tumor cells furthermore our findings revealed that 7w2 could inhibit lipolysis in vivo leading to a significant impediment in tumor growth and metastasis in the 4t1 murine tumor model additionally 7w2 exhibited the ability to significantly elevate the proportion and functionality of cd8supsup t cells our study introduces 7w2 as the first peptide targeting gpr81 shedding light on its potential role in adipocytes in suppressing tumor progression,"['gpr81', 'initially', 'discovered', 'in', 'adipocytes', 'has', 'been', 'found', 'to', 'suppress', 'lipolysis', 'when', 'activated', 'however', 'the', 'current', 'small', 'molecules', 'that', 'target', 'gpr81', 'carry', 'the', 'risk', 'of', 'offtarget', 'effects', 'and', 'their', 'impact', 'on', 'tumor', 'progression', 'remains', 'uncertain', 'here', 'we', 'utilized', 'phage', 'display', 'technology', 'to', 'screen', 'a', 'gpr81targeting', 'peptide', 'named', '7w2', 'and', 'proceeded', 'to', 'demonstrate', 'its', 'bioactivity', 'although', '7w2', 'did', 'not', 'affect', 'the', 'proliferation', 'of', 'tumor', 'cells', 'it', 'effectively', 'reduced', 'adipocyte', 'catabolism', 'in', 'vitro', 'consequently', 'restraining', 'the', 'proliferation', 'of', 'cocultured', 'tumor', 'cells', 'furthermore', 'our', 'findings', 'revealed', 'that', '7w2', 'could', 'inhibit', 'lipolysis', 'in', 'vivo', 'leading', 'to', 'a', 'significant', 'impediment', 'in', 'tumor', 'growth', 'and', 'metastasis', 'in', 'the', '4t1', 'murine', 'tumor', 'model', 'additionally', '7w2', 'exhibited', 'the', 'ability', 'to', 'significantly', 'elevate', 'the', 'proportion', 'and', 'functionality', 'of', 'cd8supsup', 't', 'cells', 'our', 'study', 'introduces', '7w2', 'as', 'the', 'first', 'peptide', 'targeting', 'gpr81', 'shedding', 'light', 'on', 'its', 'potential', 'role', 'in', 'adipocytes', 'in', 'suppressing', 'tumor', 'progression']","['gpr81', 'initially', 'discovered', 'adipocytes', 'found', 'suppress', 'lipolysis', 'activated', 'however', 'current', 'small', 'molecules', 'target', 'gpr81', 'carry', 'risk', 'offtarget', 'effects', 'impact', 'tumor', 'progression', 'remains', 'uncertain', 'utilized', 'phage', 'display', 'technology', 'screen', 'gpr81targeting', 'peptide', 'named', '7w2', 'proceeded', 'demonstrate', 'bioactivity', 'although', '7w2', 'affect', 'proliferation', 'tumor', 'cells', 'effectively', 'reduced', 'adipocyte', 'catabolism', 'vitro', 'consequently', 'restraining', 'proliferation', 'cocultured', 'tumor', 'cells', 'furthermore', 'findings', 'revealed', '7w2', 'could', 'inhibit', 'lipolysis', 'vivo', 'leading', 'significant', 'impediment', 'tumor', 'growth', 'metastasis', '4t1', 'murine', 'tumor', 'model', 'additionally', '7w2', 'exhibited', 'ability', 'significantly', 'elevate', 'proportion', 'functionality', 'cd8supsup', 'cells', 'study', 'introduces', '7w2', 'first', 'peptide', 'targeting', 'gpr81', 'shedding', 'light', 'potential', 'role', 'adipocytes', 'suppressing', 'tumor', 'progression']",['offtarget'],['offtarget'],True,['tumor']
37578890,Restoring connexin-36 function in diabetogenic environments precludes mouse and human islet dysfunction.,"The secretion of insulin from β-cells in the islet of Langerhans is governed by a series of metabolic and electrical events, which can fail during the progression of type 2 diabetes (T2D). β-cells are electrically coupled via connexin-36 (Cx36) gap junction channels, which coordinates the pulsatile dynamics of [Ca<sup>2+</sup> ] and insulin release across the islet. Factors such as pro-inflammatory cytokines and free fatty acids disrupt gap junction coupling under in vitro conditions. Here we test whether gap junction coupling and coordinated [Ca<sup>2+</sup> ] dynamics are disrupted in T2D, and whether recovery of gap junction coupling can recover islet function. We examine islets from donors with T2D, from db/db mice, and islets treated with pro-inflammatory cytokines (TNF-α, IL-1β, IFN-ɣ) or free fatty acids (palmitate). We modulate gap junction coupling using Cx36 over-expression or pharmacological activation via modafinil. We also develop a peptide mimetic (S293) of the c-terminal regulatory site of Cx36 designed to compete against its phosphorylation. Cx36 gap junction permeability and [Ca<sup>2+</sup> ] dynamics were disrupted in islets from both human donors with T2D and db/db mice, and in islets treated with pro-inflammatory cytokines or palmitate. Cx36 over-expression, modafinil treatment and S293 peptide all enhanced Cx36 gap junction coupling and protected against declines in coordinated [Ca<sup>2+</sup> ] dynamics. Cx36 over-expression and S293 peptide also reduced apoptosis induced by pro-inflammatory cytokines. Critically, S293 peptide rescued gap junction coupling and [Ca<sup>2+</sup> ] dynamics in islets from both db/db mice and a sub-set of T2D donors. Thus, recovering or enhancing Cx36 gap junction coupling can improve islet function in diabetes. KEY POINTS: Connexin-36 (Cx36) gap junction permeability and associated coordination of [Ca<sup>2+</sup> ] dynamics is diminished in human type 2 diabetes (T2D) and mouse models of T2D. Enhancing Cx36 gap junction permeability protects against disruptions to the coordination of [Ca<sup>2+</sup> ] dynamics. A novel peptide mimetic of the Cx36 c-terminal regulatory region protects against declines in Cx36 gap junction permeability. Pharmacological elevation in Cx36 or Cx36 peptide mimetic recovers [Ca<sup>2+</sup> ] dynamics and glucose-stimulated insulin secretion in human T2D and mouse models of T2D.",2023-08-14,the secretion of insulin from βcells in the islet of langerhans is governed by a series of metabolic and electrical events which can fail during the progression of type 2 diabetes t2d βcells are electrically coupled via connexin36 cx36 gap junction channels which coordinates the pulsatile dynamics of casup2sup  and insulin release across the islet factors such as proinflammatory cytokines and free fatty acids disrupt gap junction coupling under in vitro conditions here we test whether gap junction coupling and coordinated casup2sup  dynamics are disrupted in t2d and whether recovery of gap junction coupling can recover islet function we examine islets from donors with t2d from dbdb mice and islets treated with proinflammatory cytokines tnfα il1β ifnɣ or free fatty acids palmitate we modulate gap junction coupling using cx36 overexpression or pharmacological activation via modafinil we also develop a peptide mimetic s293 of the cterminal regulatory site of cx36 designed to compete against its phosphorylation cx36 gap junction permeability and casup2sup  dynamics were disrupted in islets from both human donors with t2d and dbdb mice and in islets treated with proinflammatory cytokines or palmitate cx36 overexpression modafinil treatment and s293 peptide all enhanced cx36 gap junction coupling and protected against declines in coordinated casup2sup  dynamics cx36 overexpression and s293 peptide also reduced apoptosis induced by proinflammatory cytokines critically s293 peptide rescued gap junction coupling and casup2sup  dynamics in islets from both dbdb mice and a subset of t2d donors thus recovering or enhancing cx36 gap junction coupling can improve islet function in diabetes key points connexin36 cx36 gap junction permeability and associated coordination of casup2sup  dynamics is diminished in human type 2 diabetes t2d and mouse models of t2d enhancing cx36 gap junction permeability protects against disruptions to the coordination of casup2sup  dynamics a novel peptide mimetic of the cx36 cterminal regulatory region protects against declines in cx36 gap junction permeability pharmacological elevation in cx36 or cx36 peptide mimetic recovers casup2sup  dynamics and glucosestimulated insulin secretion in human t2d and mouse models of t2d,"['the', 'secretion', 'of', 'insulin', 'from', 'βcells', 'in', 'the', 'islet', 'of', 'langerhans', 'is', 'governed', 'by', 'a', 'series', 'of', 'metabolic', 'and', 'electrical', 'events', 'which', 'can', 'fail', 'during', 'the', 'progression', 'of', 'type', '2', 'diabetes', 't2d', 'βcells', 'are', 'electrically', 'coupled', 'via', 'connexin36', 'cx36', 'gap', 'junction', 'channels', 'which', 'coordinates', 'the', 'pulsatile', 'dynamics', 'of', 'casup2sup', 'and', 'insulin', 'release', 'across', 'the', 'islet', 'factors', 'such', 'as', 'proinflammatory', 'cytokines', 'and', 'free', 'fatty', 'acids', 'disrupt', 'gap', 'junction', 'coupling', 'under', 'in', 'vitro', 'conditions', 'here', 'we', 'test', 'whether', 'gap', 'junction', 'coupling', 'and', 'coordinated', 'casup2sup', 'dynamics', 'are', 'disrupted', 'in', 't2d', 'and', 'whether', 'recovery', 'of', 'gap', 'junction', 'coupling', 'can', 'recover', 'islet', 'function', 'we', 'examine', 'islets', 'from', 'donors', 'with', 't2d', 'from', 'dbdb', 'mice', 'and', 'islets', 'treated', 'with', 'proinflammatory', 'cytokines', 'tnfα', 'il1β', 'ifnɣ', 'or', 'free', 'fatty', 'acids', 'palmitate', 'we', 'modulate', 'gap', 'junction', 'coupling', 'using', 'cx36', 'overexpression', 'or', 'pharmacological', 'activation', 'via', 'modafinil', 'we', 'also', 'develop', 'a', 'peptide', 'mimetic', 's293', 'of', 'the', 'cterminal', 'regulatory', 'site', 'of', 'cx36', 'designed', 'to', 'compete', 'against', 'its', 'phosphorylation', 'cx36', 'gap', 'junction', 'permeability', 'and', 'casup2sup', 'dynamics', 'were', 'disrupted', 'in', 'islets', 'from', 'both', 'human', 'donors', 'with', 't2d', 'and', 'dbdb', 'mice', 'and', 'in', 'islets', 'treated', 'with', 'proinflammatory', 'cytokines', 'or', 'palmitate', 'cx36', 'overexpression', 'modafinil', 'treatment', 'and', 's293', 'peptide', 'all', 'enhanced', 'cx36', 'gap', 'junction', 'coupling', 'and', 'protected', 'against', 'declines', 'in', 'coordinated', 'casup2sup', 'dynamics', 'cx36', 'overexpression', 'and', 's293', 'peptide', 'also', 'reduced', 'apoptosis', 'induced', 'by', 'proinflammatory', 'cytokines', 'critically', 's293', 'peptide', 'rescued', 'gap', 'junction', 'coupling', 'and', 'casup2sup', 'dynamics', 'in', 'islets', 'from', 'both', 'dbdb', 'mice', 'and', 'a', 'subset', 'of', 't2d', 'donors', 'thus', 'recovering', 'or', 'enhancing', 'cx36', 'gap', 'junction', 'coupling', 'can', 'improve', 'islet', 'function', 'in', 'diabetes', 'key', 'points', 'connexin36', 'cx36', 'gap', 'junction', 'permeability', 'and', 'associated', 'coordination', 'of', 'casup2sup', 'dynamics', 'is', 'diminished', 'in', 'human', 'type', '2', 'diabetes', 't2d', 'and', 'mouse', 'models', 'of', 't2d', 'enhancing', 'cx36', 'gap', 'junction', 'permeability', 'protects', 'against', 'disruptions', 'to', 'the', 'coordination', 'of', 'casup2sup', 'dynamics', 'a', 'novel', 'peptide', 'mimetic', 'of', 'the', 'cx36', 'cterminal', 'regulatory', 'region', 'protects', 'against', 'declines', 'in', 'cx36', 'gap', 'junction', 'permeability', 'pharmacological', 'elevation', 'in', 'cx36', 'or', 'cx36', 'peptide', 'mimetic', 'recovers', 'casup2sup', 'dynamics', 'and', 'glucosestimulated', 'insulin', 'secretion', 'in', 'human', 't2d', 'and', 'mouse', 'models', 'of', 't2d']","['secretion', 'insulin', 'βcells', 'islet', 'langerhans', 'governed', 'series', 'metabolic', 'electrical', 'events', 'fail', 'progression', 'type', '2', 'diabetes', 't2d', 'βcells', 'electrically', 'coupled', 'via', 'connexin36', 'cx36', 'gap', 'junction', 'channels', 'coordinates', 'pulsatile', 'dynamics', 'casup2sup', 'insulin', 'release', 'across', 'islet', 'factors', 'proinflammatory', 'cytokines', 'free', 'fatty', 'acids', 'disrupt', 'gap', 'junction', 'coupling', 'vitro', 'conditions', 'test', 'whether', 'gap', 'junction', 'coupling', 'coordinated', 'casup2sup', 'dynamics', 'disrupted', 't2d', 'whether', 'recovery', 'gap', 'junction', 'coupling', 'recover', 'islet', 'function', 'examine', 'islets', 'donors', 't2d', 'dbdb', 'mice', 'islets', 'treated', 'proinflammatory', 'cytokines', 'tnfα', 'il1β', 'ifnɣ', 'free', 'fatty', 'acids', 'palmitate', 'modulate', 'gap', 'junction', 'coupling', 'using', 'cx36', 'overexpression', 'pharmacological', 'activation', 'via', 'modafinil', 'also', 'develop', 'peptide', 'mimetic', 's293', 'cterminal', 'regulatory', 'site', 'cx36', 'designed', 'compete', 'phosphorylation', 'cx36', 'gap', 'junction', 'permeability', 'casup2sup', 'dynamics', 'disrupted', 'islets', 'human', 'donors', 't2d', 'dbdb', 'mice', 'islets', 'treated', 'proinflammatory', 'cytokines', 'palmitate', 'cx36', 'overexpression', 'modafinil', 'treatment', 's293', 'peptide', 'enhanced', 'cx36', 'gap', 'junction', 'coupling', 'protected', 'declines', 'coordinated', 'casup2sup', 'dynamics', 'cx36', 'overexpression', 's293', 'peptide', 'also', 'reduced', 'apoptosis', 'induced', 'proinflammatory', 'cytokines', 'critically', 's293', 'peptide', 'rescued', 'gap', 'junction', 'coupling', 'casup2sup', 'dynamics', 'islets', 'dbdb', 'mice', 'subset', 't2d', 'donors', 'thus', 'recovering', 'enhancing', 'cx36', 'gap', 'junction', 'coupling', 'improve', 'islet', 'function', 'diabetes', 'key', 'points', 'connexin36', 'cx36', 'gap', 'junction', 'permeability', 'associated', 'coordination', 'casup2sup', 'dynamics', 'diminished', 'human', 'type', '2', 'diabetes', 't2d', 'mouse', 'models', 't2d', 'enhancing', 'cx36', 'gap', 'junction', 'permeability', 'protects', 'disruptions', 'coordination', 'casup2sup', 'dynamics', 'novel', 'peptide', 'mimetic', 'cx36', 'cterminal', 'regulatory', 'region', 'protects', 'declines', 'cx36', 'gap', 'junction', 'permeability', 'pharmacological', 'elevation', 'cx36', 'cx36', 'peptide', 'mimetic', 'recovers', 'casup2sup', 'dynamics', 'glucosestimulated', 'insulin', 'secretion', 'human', 't2d', 'mouse', 'models', 't2d']","['insulin', 'connexin36', 'insulin', 'fatty', 'fatty', 'connexin36', 'insulin']","['connexin36', 'connexin36']",True,['diabetes']
37577264,Reduction of <i>Chlamydia pecorum</i> and Koala Retrovirus subtype B expression in wild koalas vaccinated with novel peptide and peptide/recombinant protein formulations.,"Koalas are an endangered species under threat of extinction from several factors, including infections agents. <i>Chlamydia pecorum</i> infection results in morbidity and mortality from ocular and urogenital diseases while Koala Retrovirus (KoRV) infection has been linked to increased rates of cancer and chlamydiosis. Both <i>C. pecorum</i> and KoRV are endemic in many wild Australian koala populations, with limited treatment options available. Fortunately, vaccines for these pathogens are under development and have generated effective immune responses in multiple trials. The current study aimed to improve vaccine formulations by testing a novel peptide version of the <i>Chlamydia</i> vaccine and a combination <i>Chlamydia</i> - KoRV vaccine. Utilising a monitored wild population in Southeast Queensland, this trial followed koalas given either a 'Chlamydia only' vaccine (utilising four peptides from the chlamydial Major Outer Membrane Protein, MOMP), a combination 'Chlamydia and KoRV' vaccine (comprised of the chlamydial peptides plus a KoRV recombinant envelope protein (rEnv)) or no treatment. Clinical observations, <i>C. pecorum</i> and KoRV gene expression, serum IgG, and mucosal immune gene expression were assessed over a 17-month period. Overall, both vaccine formulations resulted in a decrease in chlamydiosis mortality, with decreases in <i>C. pecorum</i>, CD4, CD8β and IL-17A gene expression observed. In addition, the combination vaccine group also showed an increase in anti-KoRV IgG production that corresponded to a decrease in detected KoRV-B expression. While these results are favourable, the chlamydial peptide vaccine did not appear to outperform the established recombinant chlamydial vaccine and suggests that a combination vaccine formulated with recombinant MOMP plus KoRV rEnv could capitalize on the demonstrated benefits of both for the betterment of koalas into the future.",2023-06-08,koalas are an endangered species under threat of extinction from several factors including infections agents ichlamydia pecorumi infection results in morbidity and mortality from ocular and urogenital diseases while koala retrovirus korv infection has been linked to increased rates of cancer and chlamydiosis both ic pecorumi and korv are endemic in many wild australian koala populations with limited treatment options available fortunately vaccines for these pathogens are under development and have generated effective immune responses in multiple trials the current study aimed to improve vaccine formulations by testing a novel peptide version of the ichlamydiai vaccine and a combination ichlamydiai  korv vaccine utilising a monitored wild population in southeast queensland this trial followed koalas given either a chlamydia only vaccine utilising four peptides from the chlamydial major outer membrane protein momp a combination chlamydia and korv vaccine comprised of the chlamydial peptides plus a korv recombinant envelope protein renv or no treatment clinical observations ic pecorumi and korv gene expression serum igg and mucosal immune gene expression were assessed over a 17month period overall both vaccine formulations resulted in a decrease in chlamydiosis mortality with decreases in ic pecorumi cd4 cd8β and il17a gene expression observed in addition the combination vaccine group also showed an increase in antikorv igg production that corresponded to a decrease in detected korvb expression while these results are favourable the chlamydial peptide vaccine did not appear to outperform the established recombinant chlamydial vaccine and suggests that a combination vaccine formulated with recombinant momp plus korv renv could capitalize on the demonstrated benefits of both for the betterment of koalas into the future,"['koalas', 'are', 'an', 'endangered', 'species', 'under', 'threat', 'of', 'extinction', 'from', 'several', 'factors', 'including', 'infections', 'agents', 'ichlamydia', 'pecorumi', 'infection', 'results', 'in', 'morbidity', 'and', 'mortality', 'from', 'ocular', 'and', 'urogenital', 'diseases', 'while', 'koala', 'retrovirus', 'korv', 'infection', 'has', 'been', 'linked', 'to', 'increased', 'rates', 'of', 'cancer', 'and', 'chlamydiosis', 'both', 'ic', 'pecorumi', 'and', 'korv', 'are', 'endemic', 'in', 'many', 'wild', 'australian', 'koala', 'populations', 'with', 'limited', 'treatment', 'options', 'available', 'fortunately', 'vaccines', 'for', 'these', 'pathogens', 'are', 'under', 'development', 'and', 'have', 'generated', 'effective', 'immune', 'responses', 'in', 'multiple', 'trials', 'the', 'current', 'study', 'aimed', 'to', 'improve', 'vaccine', 'formulations', 'by', 'testing', 'a', 'novel', 'peptide', 'version', 'of', 'the', 'ichlamydiai', 'vaccine', 'and', 'a', 'combination', 'ichlamydiai', 'korv', 'vaccine', 'utilising', 'a', 'monitored', 'wild', 'population', 'in', 'southeast', 'queensland', 'this', 'trial', 'followed', 'koalas', 'given', 'either', 'a', 'chlamydia', 'only', 'vaccine', 'utilising', 'four', 'peptides', 'from', 'the', 'chlamydial', 'major', 'outer', 'membrane', 'protein', 'momp', 'a', 'combination', 'chlamydia', 'and', 'korv', 'vaccine', 'comprised', 'of', 'the', 'chlamydial', 'peptides', 'plus', 'a', 'korv', 'recombinant', 'envelope', 'protein', 'renv', 'or', 'no', 'treatment', 'clinical', 'observations', 'ic', 'pecorumi', 'and', 'korv', 'gene', 'expression', 'serum', 'igg', 'and', 'mucosal', 'immune', 'gene', 'expression', 'were', 'assessed', 'over', 'a', '17month', 'period', 'overall', 'both', 'vaccine', 'formulations', 'resulted', 'in', 'a', 'decrease', 'in', 'chlamydiosis', 'mortality', 'with', 'decreases', 'in', 'ic', 'pecorumi', 'cd4', 'cd8β', 'and', 'il17a', 'gene', 'expression', 'observed', 'in', 'addition', 'the', 'combination', 'vaccine', 'group', 'also', 'showed', 'an', 'increase', 'in', 'antikorv', 'igg', 'production', 'that', 'corresponded', 'to', 'a', 'decrease', 'in', 'detected', 'korvb', 'expression', 'while', 'these', 'results', 'are', 'favourable', 'the', 'chlamydial', 'peptide', 'vaccine', 'did', 'not', 'appear', 'to', 'outperform', 'the', 'established', 'recombinant', 'chlamydial', 'vaccine', 'and', 'suggests', 'that', 'a', 'combination', 'vaccine', 'formulated', 'with', 'recombinant', 'momp', 'plus', 'korv', 'renv', 'could', 'capitalize', 'on', 'the', 'demonstrated', 'benefits', 'of', 'both', 'for', 'the', 'betterment', 'of', 'koalas', 'into', 'the', 'future']","['koalas', 'endangered', 'species', 'threat', 'extinction', 'several', 'factors', 'including', 'infections', 'agents', 'ichlamydia', 'pecorumi', 'infection', 'results', 'morbidity', 'mortality', 'ocular', 'urogenital', 'diseases', 'koala', 'retrovirus', 'korv', 'infection', 'linked', 'increased', 'rates', 'cancer', 'chlamydiosis', 'ic', 'pecorumi', 'korv', 'endemic', 'many', 'wild', 'australian', 'koala', 'populations', 'limited', 'treatment', 'options', 'available', 'fortunately', 'vaccines', 'pathogens', 'development', 'generated', 'effective', 'immune', 'responses', 'multiple', 'trials', 'current', 'study', 'aimed', 'improve', 'vaccine', 'formulations', 'testing', 'novel', 'peptide', 'version', 'ichlamydiai', 'vaccine', 'combination', 'ichlamydiai', 'korv', 'vaccine', 'utilising', 'monitored', 'wild', 'population', 'southeast', 'queensland', 'trial', 'followed', 'koalas', 'given', 'either', 'chlamydia', 'vaccine', 'utilising', 'four', 'peptides', 'chlamydial', 'major', 'outer', 'membrane', 'protein', 'momp', 'combination', 'chlamydia', 'korv', 'vaccine', 'comprised', 'chlamydial', 'peptides', 'plus', 'korv', 'recombinant', 'envelope', 'protein', 'renv', 'treatment', 'clinical', 'observations', 'ic', 'pecorumi', 'korv', 'gene', 'expression', 'serum', 'igg', 'mucosal', 'immune', 'gene', 'expression', 'assessed', '17month', 'period', 'overall', 'vaccine', 'formulations', 'resulted', 'decrease', 'chlamydiosis', 'mortality', 'decreases', 'ic', 'pecorumi', 'cd4', 'cd8β', 'il17a', 'gene', 'expression', 'observed', 'addition', 'combination', 'vaccine', 'group', 'also', 'showed', 'increase', 'antikorv', 'igg', 'production', 'corresponded', 'decrease', 'detected', 'korvb', 'expression', 'results', 'favourable', 'chlamydial', 'peptide', 'vaccine', 'appear', 'outperform', 'established', 'recombinant', 'chlamydial', 'vaccine', 'suggests', 'combination', 'vaccine', 'formulated', 'recombinant', 'momp', 'plus', 'korv', 'renv', 'could', 'capitalize', 'demonstrated', 'benefits', 'betterment', 'koalas', 'future']","['cd4', 'il17a']",['il17a'],True,"['infection', 'cancer']"
37542030,Histone acetylation by HBO1 (KAT7) activates Wnt/β-catenin signaling to promote leukemogenesis in B-cell acute lymphoblastic leukemia.,"B-cell acute lymphoblastic leukemia (B-ALL) is an aggressive hematological disorder with a dismal prognosis. The dysregulation of histone acetylation is of great significance in the pathogenesis and progression of B-ALL. Regarded as a fundamental acetyltransferase gene, the role of HBO1 (lysine acetyltransferase 7/KAT7) in B-ALL has not been investigated. Herein, we found that HBO1 expression was elevated in human B-ALL cells and associated with poor disease-free survival. Strikingly, HBO1 knockdown inhibited viability, proliferation, and G1-S cycle progression in B-ALL cells, while provoking apoptosis. In contrast, ectopic overexpression of HBO1 enhanced cell viability and proliferation but inhibited apoptotic activation. The results of in vivo experiments also certificated the inhibitory effect of HBO1 knockdown on tumor growth. Mechanistically, HBO1 acetylated histone H3K14, H4K8, and H4K12, followed by upregulating CTNNB1 expression, resulting in activation of the Wnt/β-catenin signaling pathway. Moreover, a novel small molecule inhibitor of HBO1, WM-3835, potently inhibited the progression of B-ALL. Our data identified HBO1 as an efficacious regulator of CTNNB1 with therapeutic potential in B-ALL.",2023-08-04,bcell acute lymphoblastic leukemia ball is an aggressive hematological disorder with a dismal prognosis the dysregulation of histone acetylation is of great significance in the pathogenesis and progression of ball regarded as a fundamental acetyltransferase gene the role of hbo1 lysine acetyltransferase 7kat7 in ball has not been investigated herein we found that hbo1 expression was elevated in human ball cells and associated with poor diseasefree survival strikingly hbo1 knockdown inhibited viability proliferation and g1s cycle progression in ball cells while provoking apoptosis in contrast ectopic overexpression of hbo1 enhanced cell viability and proliferation but inhibited apoptotic activation the results of in vivo experiments also certificated the inhibitory effect of hbo1 knockdown on tumor growth mechanistically hbo1 acetylated histone h3k14 h4k8 and h4k12 followed by upregulating ctnnb1 expression resulting in activation of the wntβcatenin signaling pathway moreover a novel small molecule inhibitor of hbo1 wm3835 potently inhibited the progression of ball our data identified hbo1 as an efficacious regulator of ctnnb1 with therapeutic potential in ball,"['bcell', 'acute', 'lymphoblastic', 'leukemia', 'ball', 'is', 'an', 'aggressive', 'hematological', 'disorder', 'with', 'a', 'dismal', 'prognosis', 'the', 'dysregulation', 'of', 'histone', 'acetylation', 'is', 'of', 'great', 'significance', 'in', 'the', 'pathogenesis', 'and', 'progression', 'of', 'ball', 'regarded', 'as', 'a', 'fundamental', 'acetyltransferase', 'gene', 'the', 'role', 'of', 'hbo1', 'lysine', 'acetyltransferase', '7kat7', 'in', 'ball', 'has', 'not', 'been', 'investigated', 'herein', 'we', 'found', 'that', 'hbo1', 'expression', 'was', 'elevated', 'in', 'human', 'ball', 'cells', 'and', 'associated', 'with', 'poor', 'diseasefree', 'survival', 'strikingly', 'hbo1', 'knockdown', 'inhibited', 'viability', 'proliferation', 'and', 'g1s', 'cycle', 'progression', 'in', 'ball', 'cells', 'while', 'provoking', 'apoptosis', 'in', 'contrast', 'ectopic', 'overexpression', 'of', 'hbo1', 'enhanced', 'cell', 'viability', 'and', 'proliferation', 'but', 'inhibited', 'apoptotic', 'activation', 'the', 'results', 'of', 'in', 'vivo', 'experiments', 'also', 'certificated', 'the', 'inhibitory', 'effect', 'of', 'hbo1', 'knockdown', 'on', 'tumor', 'growth', 'mechanistically', 'hbo1', 'acetylated', 'histone', 'h3k14', 'h4k8', 'and', 'h4k12', 'followed', 'by', 'upregulating', 'ctnnb1', 'expression', 'resulting', 'in', 'activation', 'of', 'the', 'wntβcatenin', 'signaling', 'pathway', 'moreover', 'a', 'novel', 'small', 'molecule', 'inhibitor', 'of', 'hbo1', 'wm3835', 'potently', 'inhibited', 'the', 'progression', 'of', 'ball', 'our', 'data', 'identified', 'hbo1', 'as', 'an', 'efficacious', 'regulator', 'of', 'ctnnb1', 'with', 'therapeutic', 'potential', 'in', 'ball']","['bcell', 'acute', 'lymphoblastic', 'leukemia', 'ball', 'aggressive', 'hematological', 'disorder', 'dismal', 'prognosis', 'dysregulation', 'histone', 'acetylation', 'great', 'significance', 'pathogenesis', 'progression', 'ball', 'regarded', 'fundamental', 'acetyltransferase', 'gene', 'role', 'hbo1', 'lysine', 'acetyltransferase', '7kat7', 'ball', 'investigated', 'herein', 'found', 'hbo1', 'expression', 'elevated', 'human', 'ball', 'cells', 'associated', 'poor', 'diseasefree', 'survival', 'strikingly', 'hbo1', 'knockdown', 'inhibited', 'viability', 'proliferation', 'g1s', 'cycle', 'progression', 'ball', 'cells', 'provoking', 'apoptosis', 'contrast', 'ectopic', 'overexpression', 'hbo1', 'enhanced', 'cell', 'viability', 'proliferation', 'inhibited', 'apoptotic', 'activation', 'results', 'vivo', 'experiments', 'also', 'certificated', 'inhibitory', 'effect', 'hbo1', 'knockdown', 'tumor', 'growth', 'mechanistically', 'hbo1', 'acetylated', 'histone', 'h3k14', 'h4k8', 'h4k12', 'followed', 'upregulating', 'ctnnb1', 'expression', 'resulting', 'activation', 'wntβcatenin', 'signaling', 'pathway', 'moreover', 'novel', 'small', 'molecule', 'inhibitor', 'hbo1', 'wm3835', 'potently', 'inhibited', 'progression', 'ball', 'data', 'identified', 'hbo1', 'efficacious', 'regulator', 'ctnnb1', 'therapeutic', 'potential', 'ball']","['acetyltransferase', 'acetyltransferase', 'ctnnb1', 'ctnnb1']","['ctnnb1', 'ctnnb1']",True,"['tumor', 'leukemia']"
37536035,Discovery of a novel small molecule with efficacy in protecting against inflammation in vitro and in vivo by enhancing macrophages activation.,"Immune response and inflammation highly contribute to many metabolic syndromes such as inflammatory bowel disease (IBD), ageing and cancer with disruption of host metabolic homeostasis and the gut microbiome. Icariin-1 (GH01), a small-molecule flavonoid derived from Epimedium, has been shown to protect against systemic inflammation. However, the molecular mechanisms by which GH01 ameliorates ulcerative colitis via regulation of microbiota-mediated macrophages polarization remain elusive. In this study, we found that GH01 effectively ameliorated dextran sulfate sodium (DSS)-induced colitis symptoms in mice. Disruption of intestinal barrier function, commensal microbiota and its metabolites were also significantly restored by GH01 in a dose-dependent manner. Of note, we also found that GH01 enhanced phagocytic ability of macrophages and switched macrophage phenotype from M1 to M2 both in vitro and in vivo. Such macrophage polarization was highly associated with intestinal barrier integrity and the gut microbial community. Consequently, GH01 exhibited strong anti-inflammatory capacity by inhibiting TLR4 and NF-κB pathways and proinflammatory factors (IL-6). These findings suggested that GH01 might be a potential nutritional intervention strategy for IBD treatment with the gut microbial community-meditated macrophage as the therapeutic targets.",2023-08-01,immune response and inflammation highly contribute to many metabolic syndromes such as inflammatory bowel disease ibd ageing and cancer with disruption of host metabolic homeostasis and the gut microbiome icariin1 gh01 a smallmolecule flavonoid derived from epimedium has been shown to protect against systemic inflammation however the molecular mechanisms by which gh01 ameliorates ulcerative colitis via regulation of microbiotamediated macrophages polarization remain elusive in this study we found that gh01 effectively ameliorated dextran sulfate sodium dssinduced colitis symptoms in mice disruption of intestinal barrier function commensal microbiota and its metabolites were also significantly restored by gh01 in a dosedependent manner of note we also found that gh01 enhanced phagocytic ability of macrophages and switched macrophage phenotype from m1 to m2 both in vitro and in vivo such macrophage polarization was highly associated with intestinal barrier integrity and the gut microbial community consequently gh01 exhibited strong antiinflammatory capacity by inhibiting tlr4 and nfκb pathways and proinflammatory factors il6 these findings suggested that gh01 might be a potential nutritional intervention strategy for ibd treatment with the gut microbial communitymeditated macrophage as the therapeutic targets,"['immune', 'response', 'and', 'inflammation', 'highly', 'contribute', 'to', 'many', 'metabolic', 'syndromes', 'such', 'as', 'inflammatory', 'bowel', 'disease', 'ibd', 'ageing', 'and', 'cancer', 'with', 'disruption', 'of', 'host', 'metabolic', 'homeostasis', 'and', 'the', 'gut', 'microbiome', 'icariin1', 'gh01', 'a', 'smallmolecule', 'flavonoid', 'derived', 'from', 'epimedium', 'has', 'been', 'shown', 'to', 'protect', 'against', 'systemic', 'inflammation', 'however', 'the', 'molecular', 'mechanisms', 'by', 'which', 'gh01', 'ameliorates', 'ulcerative', 'colitis', 'via', 'regulation', 'of', 'microbiotamediated', 'macrophages', 'polarization', 'remain', 'elusive', 'in', 'this', 'study', 'we', 'found', 'that', 'gh01', 'effectively', 'ameliorated', 'dextran', 'sulfate', 'sodium', 'dssinduced', 'colitis', 'symptoms', 'in', 'mice', 'disruption', 'of', 'intestinal', 'barrier', 'function', 'commensal', 'microbiota', 'and', 'its', 'metabolites', 'were', 'also', 'significantly', 'restored', 'by', 'gh01', 'in', 'a', 'dosedependent', 'manner', 'of', 'note', 'we', 'also', 'found', 'that', 'gh01', 'enhanced', 'phagocytic', 'ability', 'of', 'macrophages', 'and', 'switched', 'macrophage', 'phenotype', 'from', 'm1', 'to', 'm2', 'both', 'in', 'vitro', 'and', 'in', 'vivo', 'such', 'macrophage', 'polarization', 'was', 'highly', 'associated', 'with', 'intestinal', 'barrier', 'integrity', 'and', 'the', 'gut', 'microbial', 'community', 'consequently', 'gh01', 'exhibited', 'strong', 'antiinflammatory', 'capacity', 'by', 'inhibiting', 'tlr4', 'and', 'nfκb', 'pathways', 'and', 'proinflammatory', 'factors', 'il6', 'these', 'findings', 'suggested', 'that', 'gh01', 'might', 'be', 'a', 'potential', 'nutritional', 'intervention', 'strategy', 'for', 'ibd', 'treatment', 'with', 'the', 'gut', 'microbial', 'communitymeditated', 'macrophage', 'as', 'the', 'therapeutic', 'targets']","['immune', 'response', 'inflammation', 'highly', 'contribute', 'many', 'metabolic', 'syndromes', 'inflammatory', 'bowel', 'disease', 'ibd', 'ageing', 'cancer', 'disruption', 'host', 'metabolic', 'homeostasis', 'gut', 'microbiome', 'icariin1', 'gh01', 'smallmolecule', 'flavonoid', 'derived', 'epimedium', 'shown', 'protect', 'systemic', 'inflammation', 'however', 'molecular', 'mechanisms', 'gh01', 'ameliorates', 'ulcerative', 'colitis', 'via', 'regulation', 'microbiotamediated', 'macrophages', 'polarization', 'remain', 'elusive', 'study', 'found', 'gh01', 'effectively', 'ameliorated', 'dextran', 'sulfate', 'sodium', 'dssinduced', 'colitis', 'symptoms', 'mice', 'disruption', 'intestinal', 'barrier', 'function', 'commensal', 'microbiota', 'metabolites', 'also', 'significantly', 'restored', 'gh01', 'dosedependent', 'manner', 'note', 'also', 'found', 'gh01', 'enhanced', 'phagocytic', 'ability', 'macrophages', 'switched', 'macrophage', 'phenotype', 'm1', 'm2', 'vitro', 'vivo', 'macrophage', 'polarization', 'highly', 'associated', 'intestinal', 'barrier', 'integrity', 'gut', 'microbial', 'community', 'consequently', 'gh01', 'exhibited', 'strong', 'antiinflammatory', 'capacity', 'inhibiting', 'tlr4', 'nfκb', 'pathways', 'proinflammatory', 'factors', 'il6', 'findings', 'suggested', 'gh01', 'might', 'potential', 'nutritional', 'intervention', 'strategy', 'ibd', 'treatment', 'gut', 'microbial', 'communitymeditated', 'macrophage', 'therapeutic', 'targets']",['tlr4'],['tlr4'],True,['cancer']
37504963,"Machine learning and biological evaluation-based identification of a potential MMP-9 inhibitor, effective against ovarian cancer cells SKOV3.","MMP-9, also known as gelatinase B, is a zinc-metalloproteinase family protein that plays a key role in the degradation of the extracellular matrix (ECM). The normal function of MMP-9 includes the breakdown of ECM, a process that aids in normal physiological processes such as embryonic development, angiogenesis, etc. Interruptions in these processes due to the over-expression or downregulation of MMP-9 are reported to cause some pathological conditions like neurodegenerative diseases and cancer. In the present study, an integrated approach for ML-based virtual screening of the Maybridge library was carried out and their biological activity was tested in an attempt to identify novel small molecule scaffolds that can inhibit the activity of MMP-9. The top hits were identified and selected for target-based activity against MMP-9 protein using the kit (Biovision K844). Further, MTT assay was performed in various cancer cell lines such as breast (MCF-7, MDA-MB-231), colorectal (HCT119, DL-D-1), cervical (HeLa), lung (A549) and ovarian cancer (SKOV3). Interestingly, one compound viz., RJF02215 exhibited anti-cancer activity selectively in SKOV3. Wound healing assay and colony formation assay performed on SKOV3 cell line in the presence of RJF02215 confirmed that the compound had a significant inhibitory effect on this cell line. Thus, we have identified a novel molecule that can inhibit MMP-9 activity <i>in vitro</i> and inhibits the proliferation of SKOV3 cells. Novel molecules based on the structure of RJF02215 may become a good value addition for the treatment of ovarian cancer by exhibiting selective MMP-9 activity.Communicated by Ramaswamy H. Sarma.",2023-07-28,mmp9 also known as gelatinase b is a zincmetalloproteinase family protein that plays a key role in the degradation of the extracellular matrix ecm the normal function of mmp9 includes the breakdown of ecm a process that aids in normal physiological processes such as embryonic development angiogenesis etc interruptions in these processes due to the overexpression or downregulation of mmp9 are reported to cause some pathological conditions like neurodegenerative diseases and cancer in the present study an integrated approach for mlbased virtual screening of the maybridge library was carried out and their biological activity was tested in an attempt to identify novel small molecule scaffolds that can inhibit the activity of mmp9 the top hits were identified and selected for targetbased activity against mmp9 protein using the kit biovision k844 further mtt assay was performed in various cancer cell lines such as breast mcf7 mdamb231 colorectal hct119 dld1 cervical hela lung a549 and ovarian cancer skov3 interestingly one compound viz rjf02215 exhibited anticancer activity selectively in skov3 wound healing assay and colony formation assay performed on skov3 cell line in the presence of rjf02215 confirmed that the compound had a significant inhibitory effect on this cell line thus we have identified a novel molecule that can inhibit mmp9 activity iin vitroi and inhibits the proliferation of skov3 cells novel molecules based on the structure of rjf02215 may become a good value addition for the treatment of ovarian cancer by exhibiting selective mmp9 activitycommunicated by ramaswamy h sarma,"['mmp9', 'also', 'known', 'as', 'gelatinase', 'b', 'is', 'a', 'zincmetalloproteinase', 'family', 'protein', 'that', 'plays', 'a', 'key', 'role', 'in', 'the', 'degradation', 'of', 'the', 'extracellular', 'matrix', 'ecm', 'the', 'normal', 'function', 'of', 'mmp9', 'includes', 'the', 'breakdown', 'of', 'ecm', 'a', 'process', 'that', 'aids', 'in', 'normal', 'physiological', 'processes', 'such', 'as', 'embryonic', 'development', 'angiogenesis', 'etc', 'interruptions', 'in', 'these', 'processes', 'due', 'to', 'the', 'overexpression', 'or', 'downregulation', 'of', 'mmp9', 'are', 'reported', 'to', 'cause', 'some', 'pathological', 'conditions', 'like', 'neurodegenerative', 'diseases', 'and', 'cancer', 'in', 'the', 'present', 'study', 'an', 'integrated', 'approach', 'for', 'mlbased', 'virtual', 'screening', 'of', 'the', 'maybridge', 'library', 'was', 'carried', 'out', 'and', 'their', 'biological', 'activity', 'was', 'tested', 'in', 'an', 'attempt', 'to', 'identify', 'novel', 'small', 'molecule', 'scaffolds', 'that', 'can', 'inhibit', 'the', 'activity', 'of', 'mmp9', 'the', 'top', 'hits', 'were', 'identified', 'and', 'selected', 'for', 'targetbased', 'activity', 'against', 'mmp9', 'protein', 'using', 'the', 'kit', 'biovision', 'k844', 'further', 'mtt', 'assay', 'was', 'performed', 'in', 'various', 'cancer', 'cell', 'lines', 'such', 'as', 'breast', 'mcf7', 'mdamb231', 'colorectal', 'hct119', 'dld1', 'cervical', 'hela', 'lung', 'a549', 'and', 'ovarian', 'cancer', 'skov3', 'interestingly', 'one', 'compound', 'viz', 'rjf02215', 'exhibited', 'anticancer', 'activity', 'selectively', 'in', 'skov3', 'wound', 'healing', 'assay', 'and', 'colony', 'formation', 'assay', 'performed', 'on', 'skov3', 'cell', 'line', 'in', 'the', 'presence', 'of', 'rjf02215', 'confirmed', 'that', 'the', 'compound', 'had', 'a', 'significant', 'inhibitory', 'effect', 'on', 'this', 'cell', 'line', 'thus', 'we', 'have', 'identified', 'a', 'novel', 'molecule', 'that', 'can', 'inhibit', 'mmp9', 'activity', 'iin', 'vitroi', 'and', 'inhibits', 'the', 'proliferation', 'of', 'skov3', 'cells', 'novel', 'molecules', 'based', 'on', 'the', 'structure', 'of', 'rjf02215', 'may', 'become', 'a', 'good', 'value', 'addition', 'for', 'the', 'treatment', 'of', 'ovarian', 'cancer', 'by', 'exhibiting', 'selective', 'mmp9', 'activitycommunicated', 'by', 'ramaswamy', 'h', 'sarma']","['mmp9', 'also', 'known', 'gelatinase', 'b', 'zincmetalloproteinase', 'family', 'protein', 'plays', 'key', 'role', 'degradation', 'extracellular', 'matrix', 'ecm', 'normal', 'function', 'mmp9', 'includes', 'breakdown', 'ecm', 'process', 'aids', 'normal', 'physiological', 'processes', 'embryonic', 'development', 'angiogenesis', 'etc', 'interruptions', 'processes', 'due', 'overexpression', 'downregulation', 'mmp9', 'reported', 'cause', 'pathological', 'conditions', 'like', 'neurodegenerative', 'diseases', 'cancer', 'present', 'study', 'integrated', 'approach', 'mlbased', 'virtual', 'screening', 'maybridge', 'library', 'carried', 'biological', 'activity', 'tested', 'attempt', 'identify', 'novel', 'small', 'molecule', 'scaffolds', 'inhibit', 'activity', 'mmp9', 'top', 'hits', 'identified', 'selected', 'targetbased', 'activity', 'mmp9', 'protein', 'using', 'kit', 'biovision', 'k844', 'mtt', 'assay', 'performed', 'various', 'cancer', 'cell', 'lines', 'breast', 'mcf7', 'mdamb231', 'colorectal', 'hct119', 'dld1', 'cervical', 'hela', 'lung', 'a549', 'ovarian', 'cancer', 'skov3', 'interestingly', 'one', 'compound', 'viz', 'rjf02215', 'exhibited', 'anticancer', 'activity', 'selectively', 'skov3', 'wound', 'healing', 'assay', 'colony', 'formation', 'assay', 'performed', 'skov3', 'cell', 'line', 'presence', 'rjf02215', 'confirmed', 'compound', 'significant', 'inhibitory', 'effect', 'cell', 'line', 'thus', 'identified', 'novel', 'molecule', 'inhibit', 'mmp9', 'activity', 'iin', 'vitroi', 'inhibits', 'proliferation', 'skov3', 'cells', 'novel', 'molecules', 'based', 'structure', 'rjf02215', 'may', 'become', 'good', 'value', 'addition', 'treatment', 'ovarian', 'cancer', 'exhibiting', 'selective', 'mmp9', 'activitycommunicated', 'ramaswamy', 'h', 'sarma']","['mmp9', 'mmp9', 'mmp9', 'mmp9', 'mmp9', 'mmp9', 'mmp9']","['mmp9', 'mmp9', 'mmp9', 'mmp9', 'mmp9', 'mmp9', 'mmp9']",True,['cancer']
37461469,A Compound that Inhibits Glycolysis in Prostate Cancer Controls Growth of Advanced Prostate Cancer.,"Metastatic castration-resistant prostate cancer remains incurable regardless of recent therapeutic advances. Prostate cancer tumors display highly glycolytic phenotypes as the cancer progresses. Non-specific inhibitors of glycolysis have not been utilized successfully for chemotherapy, because of their penchant to cause systemic toxicity. This study reports the preclinical activity, safety, and pharmacokinetics of a novel small molecule preclinical candidate, BKIDC-1553, with antiglycolytic activity.",2024-02-13,metastatic castrationresistant prostate cancer remains incurable regardless of recent therapeutic advances prostate cancer tumors display highly glycolytic phenotypes as the cancer progresses nonspecific inhibitors of glycolysis have not been utilized successfully for chemotherapy because of their penchant to cause systemic toxicity this study reports the preclinical activity safety and pharmacokinetics of a novel small molecule preclinical candidate bkidc1553 with antiglycolytic activity,"['metastatic', 'castrationresistant', 'prostate', 'cancer', 'remains', 'incurable', 'regardless', 'of', 'recent', 'therapeutic', 'advances', 'prostate', 'cancer', 'tumors', 'display', 'highly', 'glycolytic', 'phenotypes', 'as', 'the', 'cancer', 'progresses', 'nonspecific', 'inhibitors', 'of', 'glycolysis', 'have', 'not', 'been', 'utilized', 'successfully', 'for', 'chemotherapy', 'because', 'of', 'their', 'penchant', 'to', 'cause', 'systemic', 'toxicity', 'this', 'study', 'reports', 'the', 'preclinical', 'activity', 'safety', 'and', 'pharmacokinetics', 'of', 'a', 'novel', 'small', 'molecule', 'preclinical', 'candidate', 'bkidc1553', 'with', 'antiglycolytic', 'activity']","['metastatic', 'castrationresistant', 'prostate', 'cancer', 'remains', 'incurable', 'regardless', 'recent', 'therapeutic', 'advances', 'prostate', 'cancer', 'tumors', 'display', 'highly', 'glycolytic', 'phenotypes', 'cancer', 'progresses', 'nonspecific', 'inhibitors', 'glycolysis', 'utilized', 'successfully', 'chemotherapy', 'penchant', 'cause', 'systemic', 'toxicity', 'study', 'reports', 'preclinical', 'activity', 'safety', 'pharmacokinetics', 'novel', 'small', 'molecule', 'preclinical', 'candidate', 'bkidc1553', 'antiglycolytic', 'activity']",['bkidc1553'],['bkidc1553'],True,"['tumor', 'cancer']"
37459824,Synthesis of and anti-fibrotic effect of pyrazole derivative J-1048: Inhibition of ALK5 as a novel approach to liver fibrosis targeting inflammation.,"Liver fibrosis is a worldwide challenge of health issue. Developing effective new drugs for treating liver fibrosis is of great importance. In recent years, chemically synthesized drugs have significant advantages in treating liver fibrosis. Small molecule pyrazole derivatives as activin receptor-like kinase 5 (ALK5) inhibitors have also shown anti-fibrotic and tumor growth inhibitory effects. To develop the candidate with anti-fibrotic effect, we synthesized a novel pyrazole derivative, J-1048. The inhibitory effect of J-1048 on ALK5 and p38α mitogen-activated protein (MAP) kinase activity was assessed by enzymatic assays. We established an in vivo liver fibrosis model by injecting thioacetamide (TAA) into mice and in vitro model of TGF-β stimulated hepatic stellated cells to explore the inhibition mechanisms and therapeutic potential of J-1048 as an ALK5 inhibitor in liver fibrosis. Our data showed that J-1048 inhibited TAA-induced liver fibrosis in mice by explicitly blocking the TGF-β/Smad signaling pathway. Additionally, J-1048 inhibited the production of inflammatory cytokine Interleukin-1β (IL-1β) by inhibiting the purinergic ligand-gated ion channel 7 receptor (P2X7r) -Nucleotide-binding domain-(NOD-)like receptor protein 3 (NLRP3) axis, thereby alleviating liver fibrosis. Our findings demonstrated that a novel small molecule ALK5 inhibitor, J-1048, exhibited strong potential as a clinical therapeutic candidate for liver fibrosis.",2023-07-12,liver fibrosis is a worldwide challenge of health issue developing effective new drugs for treating liver fibrosis is of great importance in recent years chemically synthesized drugs have significant advantages in treating liver fibrosis small molecule pyrazole derivatives as activin receptorlike kinase 5 alk5 inhibitors have also shown antifibrotic and tumor growth inhibitory effects to develop the candidate with antifibrotic effect we synthesized a novel pyrazole derivative j1048 the inhibitory effect of j1048 on alk5 and p38α mitogenactivated protein map kinase activity was assessed by enzymatic assays we established an in vivo liver fibrosis model by injecting thioacetamide taa into mice and in vitro model of tgfβ stimulated hepatic stellated cells to explore the inhibition mechanisms and therapeutic potential of j1048 as an alk5 inhibitor in liver fibrosis our data showed that j1048 inhibited taainduced liver fibrosis in mice by explicitly blocking the tgfβsmad signaling pathway additionally j1048 inhibited the production of inflammatory cytokine interleukin1β il1β by inhibiting the purinergic ligandgated ion channel 7 receptor p2x7r nucleotidebinding domainnodlike receptor protein 3 nlrp3 axis thereby alleviating liver fibrosis our findings demonstrated that a novel small molecule alk5 inhibitor j1048 exhibited strong potential as a clinical therapeutic candidate for liver fibrosis,"['liver', 'fibrosis', 'is', 'a', 'worldwide', 'challenge', 'of', 'health', 'issue', 'developing', 'effective', 'new', 'drugs', 'for', 'treating', 'liver', 'fibrosis', 'is', 'of', 'great', 'importance', 'in', 'recent', 'years', 'chemically', 'synthesized', 'drugs', 'have', 'significant', 'advantages', 'in', 'treating', 'liver', 'fibrosis', 'small', 'molecule', 'pyrazole', 'derivatives', 'as', 'activin', 'receptorlike', 'kinase', '5', 'alk5', 'inhibitors', 'have', 'also', 'shown', 'antifibrotic', 'and', 'tumor', 'growth', 'inhibitory', 'effects', 'to', 'develop', 'the', 'candidate', 'with', 'antifibrotic', 'effect', 'we', 'synthesized', 'a', 'novel', 'pyrazole', 'derivative', 'j1048', 'the', 'inhibitory', 'effect', 'of', 'j1048', 'on', 'alk5', 'and', 'p38α', 'mitogenactivated', 'protein', 'map', 'kinase', 'activity', 'was', 'assessed', 'by', 'enzymatic', 'assays', 'we', 'established', 'an', 'in', 'vivo', 'liver', 'fibrosis', 'model', 'by', 'injecting', 'thioacetamide', 'taa', 'into', 'mice', 'and', 'in', 'vitro', 'model', 'of', 'tgfβ', 'stimulated', 'hepatic', 'stellated', 'cells', 'to', 'explore', 'the', 'inhibition', 'mechanisms', 'and', 'therapeutic', 'potential', 'of', 'j1048', 'as', 'an', 'alk5', 'inhibitor', 'in', 'liver', 'fibrosis', 'our', 'data', 'showed', 'that', 'j1048', 'inhibited', 'taainduced', 'liver', 'fibrosis', 'in', 'mice', 'by', 'explicitly', 'blocking', 'the', 'tgfβsmad', 'signaling', 'pathway', 'additionally', 'j1048', 'inhibited', 'the', 'production', 'of', 'inflammatory', 'cytokine', 'interleukin1β', 'il1β', 'by', 'inhibiting', 'the', 'purinergic', 'ligandgated', 'ion', 'channel', '7', 'receptor', 'p2x7r', 'nucleotidebinding', 'domainnodlike', 'receptor', 'protein', '3', 'nlrp3', 'axis', 'thereby', 'alleviating', 'liver', 'fibrosis', 'our', 'findings', 'demonstrated', 'that', 'a', 'novel', 'small', 'molecule', 'alk5', 'inhibitor', 'j1048', 'exhibited', 'strong', 'potential', 'as', 'a', 'clinical', 'therapeutic', 'candidate', 'for', 'liver', 'fibrosis']","['liver', 'fibrosis', 'worldwide', 'challenge', 'health', 'issue', 'developing', 'effective', 'new', 'drugs', 'treating', 'liver', 'fibrosis', 'great', 'importance', 'recent', 'years', 'chemically', 'synthesized', 'drugs', 'significant', 'advantages', 'treating', 'liver', 'fibrosis', 'small', 'molecule', 'pyrazole', 'derivatives', 'activin', 'receptorlike', 'kinase', '5', 'alk5', 'inhibitors', 'also', 'shown', 'antifibrotic', 'tumor', 'growth', 'inhibitory', 'effects', 'develop', 'candidate', 'antifibrotic', 'effect', 'synthesized', 'novel', 'pyrazole', 'derivative', 'j1048', 'inhibitory', 'effect', 'j1048', 'alk5', 'p38α', 'mitogenactivated', 'protein', 'map', 'kinase', 'activity', 'assessed', 'enzymatic', 'assays', 'established', 'vivo', 'liver', 'fibrosis', 'model', 'injecting', 'thioacetamide', 'taa', 'mice', 'vitro', 'model', 'tgfβ', 'stimulated', 'hepatic', 'stellated', 'cells', 'explore', 'inhibition', 'mechanisms', 'therapeutic', 'potential', 'j1048', 'alk5', 'inhibitor', 'liver', 'fibrosis', 'data', 'showed', 'j1048', 'inhibited', 'taainduced', 'liver', 'fibrosis', 'mice', 'explicitly', 'blocking', 'tgfβsmad', 'signaling', 'pathway', 'additionally', 'j1048', 'inhibited', 'production', 'inflammatory', 'cytokine', 'interleukin1β', 'il1β', 'inhibiting', 'purinergic', 'ligandgated', 'ion', 'channel', '7', 'receptor', 'p2x7r', 'nucleotidebinding', 'domainnodlike', 'receptor', 'protein', '3', 'nlrp3', 'axis', 'thereby', 'alleviating', 'liver', 'fibrosis', 'findings', 'demonstrated', 'novel', 'small', 'molecule', 'alk5', 'inhibitor', 'j1048', 'exhibited', 'strong', 'potential', 'clinical', 'therapeutic', 'candidate', 'liver', 'fibrosis']","['activin', 'receptorlike', 'alk5', 'alk5', 'alk5', 'alk5']","['activin', 'receptorlike']",True,['tumor']
37406957,A novel peptide P1-121aa encoded by STK24P1 regulates vasculogenic mimicry via ELF2 phosphorylation in glioblastoma.,"Glioblastoma (GBM) is the most common malignant tumor of the central nervous system. Vasculogenic mimicry (VM) is a hematological system composed of tumor cells that exert blood perfusion without relying on vascular endothelial cells. The current poor results of anti-vascular therapy for clinical GBM are associated with the presence of VM; therefore, it is important to investigate VM formation in GBM. Our results demonstrate that STK24P1 encodes P1-121aa with a kinase structural domain, and in vitro kinase assays demonstrated that P1-121aa mediates modification of ELF2 phosphorylation. ChIP and dual luciferase reporter gene assays demonstrated that the transcription factor ELF2 binds to VE-cadherin and the VEGFR2 promoter region, thereby promoting VM formation in glioma cells. P1-121aa, encoded by the pseudogene STK24P1, phosphorylates ELF2 at S107, increasing the stability of the ELF2 protein. ELF2 promotes VEGFR2 and VE-cadherin expression at the transcriptional level, which in turn promotes VM in GBM. This study demonstrates the important roles of STK24P1, P1-121aa, and ELF2 in regulating VM in GBM, which could provide potential targets for GBM treatment.",2023-07-03,glioblastoma gbm is the most common malignant tumor of the central nervous system vasculogenic mimicry vm is a hematological system composed of tumor cells that exert blood perfusion without relying on vascular endothelial cells the current poor results of antivascular therapy for clinical gbm are associated with the presence of vm therefore it is important to investigate vm formation in gbm our results demonstrate that stk24p1 encodes p1121aa with a kinase structural domain and in vitro kinase assays demonstrated that p1121aa mediates modification of elf2 phosphorylation chip and dual luciferase reporter gene assays demonstrated that the transcription factor elf2 binds to vecadherin and the vegfr2 promoter region thereby promoting vm formation in glioma cells p1121aa encoded by the pseudogene stk24p1 phosphorylates elf2 at s107 increasing the stability of the elf2 protein elf2 promotes vegfr2 and vecadherin expression at the transcriptional level which in turn promotes vm in gbm this study demonstrates the important roles of stk24p1 p1121aa and elf2 in regulating vm in gbm which could provide potential targets for gbm treatment,"['glioblastoma', 'gbm', 'is', 'the', 'most', 'common', 'malignant', 'tumor', 'of', 'the', 'central', 'nervous', 'system', 'vasculogenic', 'mimicry', 'vm', 'is', 'a', 'hematological', 'system', 'composed', 'of', 'tumor', 'cells', 'that', 'exert', 'blood', 'perfusion', 'without', 'relying', 'on', 'vascular', 'endothelial', 'cells', 'the', 'current', 'poor', 'results', 'of', 'antivascular', 'therapy', 'for', 'clinical', 'gbm', 'are', 'associated', 'with', 'the', 'presence', 'of', 'vm', 'therefore', 'it', 'is', 'important', 'to', 'investigate', 'vm', 'formation', 'in', 'gbm', 'our', 'results', 'demonstrate', 'that', 'stk24p1', 'encodes', 'p1121aa', 'with', 'a', 'kinase', 'structural', 'domain', 'and', 'in', 'vitro', 'kinase', 'assays', 'demonstrated', 'that', 'p1121aa', 'mediates', 'modification', 'of', 'elf2', 'phosphorylation', 'chip', 'and', 'dual', 'luciferase', 'reporter', 'gene', 'assays', 'demonstrated', 'that', 'the', 'transcription', 'factor', 'elf2', 'binds', 'to', 'vecadherin', 'and', 'the', 'vegfr2', 'promoter', 'region', 'thereby', 'promoting', 'vm', 'formation', 'in', 'glioma', 'cells', 'p1121aa', 'encoded', 'by', 'the', 'pseudogene', 'stk24p1', 'phosphorylates', 'elf2', 'at', 's107', 'increasing', 'the', 'stability', 'of', 'the', 'elf2', 'protein', 'elf2', 'promotes', 'vegfr2', 'and', 'vecadherin', 'expression', 'at', 'the', 'transcriptional', 'level', 'which', 'in', 'turn', 'promotes', 'vm', 'in', 'gbm', 'this', 'study', 'demonstrates', 'the', 'important', 'roles', 'of', 'stk24p1', 'p1121aa', 'and', 'elf2', 'in', 'regulating', 'vm', 'in', 'gbm', 'which', 'could', 'provide', 'potential', 'targets', 'for', 'gbm', 'treatment']","['glioblastoma', 'gbm', 'common', 'malignant', 'tumor', 'central', 'nervous', 'system', 'vasculogenic', 'mimicry', 'vm', 'hematological', 'system', 'composed', 'tumor', 'cells', 'exert', 'blood', 'perfusion', 'without', 'relying', 'vascular', 'endothelial', 'cells', 'current', 'poor', 'results', 'antivascular', 'therapy', 'clinical', 'gbm', 'associated', 'presence', 'vm', 'therefore', 'important', 'investigate', 'vm', 'formation', 'gbm', 'results', 'demonstrate', 'stk24p1', 'encodes', 'p1121aa', 'kinase', 'structural', 'domain', 'vitro', 'kinase', 'assays', 'demonstrated', 'p1121aa', 'mediates', 'modification', 'elf2', 'phosphorylation', 'chip', 'dual', 'luciferase', 'reporter', 'gene', 'assays', 'demonstrated', 'transcription', 'factor', 'elf2', 'binds', 'vecadherin', 'vegfr2', 'promoter', 'region', 'thereby', 'promoting', 'vm', 'formation', 'glioma', 'cells', 'p1121aa', 'encoded', 'pseudogene', 'stk24p1', 'phosphorylates', 'elf2', 's107', 'increasing', 'stability', 'elf2', 'protein', 'elf2', 'promotes', 'vegfr2', 'vecadherin', 'expression', 'transcriptional', 'level', 'turn', 'promotes', 'vm', 'gbm', 'study', 'demonstrates', 'important', 'roles', 'stk24p1', 'p1121aa', 'elf2', 'regulating', 'vm', 'gbm', 'could', 'provide', 'potential', 'targets', 'gbm', 'treatment']","['luciferase', 'vegfr2', 'vegfr2']",['luciferase'],True,['tumor']
37406849,CT2-3 induces cell cycle arrest and apoptosis in rheumatoid arthritis fibroblast-like synoviocytes through regulating PI3K/AKT pathway.,"Rheumatoid arthritis (RA) is a kind of chronic autoimmune disease. The existing therapies encountered several challenges. Therefore, continued novel anti-RA drug discovery remains necessary for RA therapy. Recently, our group reported a novel compound named CT2-3, which could be realized as a hybrid of the natural product magnolol and phthalimide and exhibited anti-lung cancer activity. However, the effect of CT2-3 on RA is unclear. Here, we aim to explore the effect and potential mechanism of CT2-3 on the abnormal functions of RA-fibroblast-like synoviocytes (RA-FLSs). In this study, we identified the important role of the dysregulated cell cycle and apoptosis of RA-FLSs in RA progression. Interestingly, we found that CT2-3 inhibited the proliferation and DNA replication of primary RA-FLSs and immortalized RA-FLSs namely MH7A. In addition, CT2-3 downregulated the mRNA and protein expression of cyclin-dependent kinase 2 (CDK2), cyclin A2, and cyclin B1, resulting in cell cycle arrest of primary RA-FLSs and MH7A cells. Also, CT2-3 downregulated the level of B-cell lymphoma-2 (Bcl-2), and increased the level of Bcl-2 associated X (Bax), contributing to apoptosis of primary RA-FLSs and MH7A cells. Furthermore, differential analyses of RNA-sequencing, Western blot, and network pharmacological analysis confirmed that CT2-3 inhibited phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway of primary RA-FLSs and MH7A cells. In conclusion, CT2-3 induces cell cycle arrest and apoptosis in RA-FLSs through modulating PI3K/AKT pathway, which may serve as a potential lead compound for further novel small molecule anti-RA drug development.",2023-07-03,rheumatoid arthritis ra is a kind of chronic autoimmune disease the existing therapies encountered several challenges therefore continued novel antira drug discovery remains necessary for ra therapy recently our group reported a novel compound named ct23 which could be realized as a hybrid of the natural product magnolol and phthalimide and exhibited antilung cancer activity however the effect of ct23 on ra is unclear here we aim to explore the effect and potential mechanism of ct23 on the abnormal functions of rafibroblastlike synoviocytes raflss in this study we identified the important role of the dysregulated cell cycle and apoptosis of raflss in ra progression interestingly we found that ct23 inhibited the proliferation and dna replication of primary raflss and immortalized raflss namely mh7a in addition ct23 downregulated the mrna and protein expression of cyclindependent kinase 2 cdk2 cyclin a2 and cyclin b1 resulting in cell cycle arrest of primary raflss and mh7a cells also ct23 downregulated the level of bcell lymphoma2 bcl2 and increased the level of bcl2 associated x bax contributing to apoptosis of primary raflss and mh7a cells furthermore differential analyses of rnasequencing western blot and network pharmacological analysis confirmed that ct23 inhibited phosphoinositide 3kinase pi3kprotein kinase b akt pathway of primary raflss and mh7a cells in conclusion ct23 induces cell cycle arrest and apoptosis in raflss through modulating pi3kakt pathway which may serve as a potential lead compound for further novel small molecule antira drug development,"['rheumatoid', 'arthritis', 'ra', 'is', 'a', 'kind', 'of', 'chronic', 'autoimmune', 'disease', 'the', 'existing', 'therapies', 'encountered', 'several', 'challenges', 'therefore', 'continued', 'novel', 'antira', 'drug', 'discovery', 'remains', 'necessary', 'for', 'ra', 'therapy', 'recently', 'our', 'group', 'reported', 'a', 'novel', 'compound', 'named', 'ct23', 'which', 'could', 'be', 'realized', 'as', 'a', 'hybrid', 'of', 'the', 'natural', 'product', 'magnolol', 'and', 'phthalimide', 'and', 'exhibited', 'antilung', 'cancer', 'activity', 'however', 'the', 'effect', 'of', 'ct23', 'on', 'ra', 'is', 'unclear', 'here', 'we', 'aim', 'to', 'explore', 'the', 'effect', 'and', 'potential', 'mechanism', 'of', 'ct23', 'on', 'the', 'abnormal', 'functions', 'of', 'rafibroblastlike', 'synoviocytes', 'raflss', 'in', 'this', 'study', 'we', 'identified', 'the', 'important', 'role', 'of', 'the', 'dysregulated', 'cell', 'cycle', 'and', 'apoptosis', 'of', 'raflss', 'in', 'ra', 'progression', 'interestingly', 'we', 'found', 'that', 'ct23', 'inhibited', 'the', 'proliferation', 'and', 'dna', 'replication', 'of', 'primary', 'raflss', 'and', 'immortalized', 'raflss', 'namely', 'mh7a', 'in', 'addition', 'ct23', 'downregulated', 'the', 'mrna', 'and', 'protein', 'expression', 'of', 'cyclindependent', 'kinase', '2', 'cdk2', 'cyclin', 'a2', 'and', 'cyclin', 'b1', 'resulting', 'in', 'cell', 'cycle', 'arrest', 'of', 'primary', 'raflss', 'and', 'mh7a', 'cells', 'also', 'ct23', 'downregulated', 'the', 'level', 'of', 'bcell', 'lymphoma2', 'bcl2', 'and', 'increased', 'the', 'level', 'of', 'bcl2', 'associated', 'x', 'bax', 'contributing', 'to', 'apoptosis', 'of', 'primary', 'raflss', 'and', 'mh7a', 'cells', 'furthermore', 'differential', 'analyses', 'of', 'rnasequencing', 'western', 'blot', 'and', 'network', 'pharmacological', 'analysis', 'confirmed', 'that', 'ct23', 'inhibited', 'phosphoinositide', '3kinase', 'pi3kprotein', 'kinase', 'b', 'akt', 'pathway', 'of', 'primary', 'raflss', 'and', 'mh7a', 'cells', 'in', 'conclusion', 'ct23', 'induces', 'cell', 'cycle', 'arrest', 'and', 'apoptosis', 'in', 'raflss', 'through', 'modulating', 'pi3kakt', 'pathway', 'which', 'may', 'serve', 'as', 'a', 'potential', 'lead', 'compound', 'for', 'further', 'novel', 'small', 'molecule', 'antira', 'drug', 'development']","['rheumatoid', 'arthritis', 'ra', 'kind', 'chronic', 'autoimmune', 'disease', 'existing', 'therapies', 'encountered', 'several', 'challenges', 'therefore', 'continued', 'novel', 'antira', 'drug', 'discovery', 'remains', 'necessary', 'ra', 'therapy', 'recently', 'group', 'reported', 'novel', 'compound', 'named', 'ct23', 'could', 'realized', 'hybrid', 'natural', 'product', 'magnolol', 'phthalimide', 'exhibited', 'antilung', 'cancer', 'activity', 'however', 'effect', 'ct23', 'ra', 'unclear', 'aim', 'explore', 'effect', 'potential', 'mechanism', 'ct23', 'abnormal', 'functions', 'rafibroblastlike', 'synoviocytes', 'raflss', 'study', 'identified', 'important', 'role', 'dysregulated', 'cell', 'cycle', 'apoptosis', 'raflss', 'ra', 'progression', 'interestingly', 'found', 'ct23', 'inhibited', 'proliferation', 'dna', 'replication', 'primary', 'raflss', 'immortalized', 'raflss', 'namely', 'mh7a', 'addition', 'ct23', 'downregulated', 'mrna', 'protein', 'expression', 'cyclindependent', 'kinase', '2', 'cdk2', 'cyclin', 'a2', 'cyclin', 'b1', 'resulting', 'cell', 'cycle', 'arrest', 'primary', 'raflss', 'mh7a', 'cells', 'also', 'ct23', 'downregulated', 'level', 'bcell', 'lymphoma2', 'bcl2', 'increased', 'level', 'bcl2', 'associated', 'x', 'bax', 'contributing', 'apoptosis', 'primary', 'raflss', 'mh7a', 'cells', 'furthermore', 'differential', 'analyses', 'rnasequencing', 'western', 'blot', 'network', 'pharmacological', 'analysis', 'confirmed', 'ct23', 'inhibited', 'phosphoinositide', '3kinase', 'pi3kprotein', 'kinase', 'b', 'akt', 'pathway', 'primary', 'raflss', 'mh7a', 'cells', 'conclusion', 'ct23', 'induces', 'cell', 'cycle', 'arrest', 'apoptosis', 'raflss', 'modulating', 'pi3kakt', 'pathway', 'may', 'serve', 'potential', 'lead', 'compound', 'novel', 'small', 'molecule', 'antira', 'drug', 'development']","['ra', 'ra', 'ra', 'ra', 'cyclindependent', 'cdk2', 'cyclin', 'cyclin', 'bcl2', 'bcl2', 'bax', '3kinase', 'akt']","['ra', 'ra', 'ra', 'ra']",False,"['cancer', 'arthritis']"
37396624,Dual-targeting inhibition of TNFR1 for alleviating rheumatoid arthritis by a novel composite nucleic acid nanodrug.,"Selective suppression of tumor necrosis factor (TNF) α-TNF receptor 1 (TNFR1) signaling is a potent solution for rheumatoid arthritis (RA). Herein, novel composite nucleic acid nanodrugs that simultaneously restrain TNF α binding and TNFR1 multimerization were designed to reinforce inhibition of TNF α-TNFR1 signaling for RA therapy. Towards this end, a novel peptide Pep4-19 that suppresses TNFR1 clustering was extracted from TNFR1. The resulting peptide and a DNA aptamer Apt2-55, which inhibits TNF α binding, were integrally or separately anchored on DNA tetrahedron (TD) to obtain nanodrugs with different spatial distribution of Apt2-55 and Pep4-19 (TD-3A-3P and TD-3(A-P)). Our results showed that Pep4-19 enhanced the viability of inflammatory L929 cells. Both TD-3A-3P and TD-3(A-P) suppressed caspase 3, reduced cell apoptosis, and inhibited FLS-RA migration. Compared to TD-3(A-P), TD-3A-3P supplied sufficient flexibility for Apt2-55 and Pep4-19, and showed better anti-inflammation properties. Furthermore, TD-3A-3P significantly relieved symptoms in collagen-induced arthritis (CIA) mice, and the anti-RA efficacy through intravenous injection was comparable to transdermal administration <i>via</i> microneedles. Overall, the work provides an effective strategy for RA treatment by dual-targeting TNFR1, and demonstrates that microneedles are promising approach to drug administration in the treatment of RA.",2023-01-10,selective suppression of tumor necrosis factor tnf αtnf receptor 1 tnfr1 signaling is a potent solution for rheumatoid arthritis ra herein novel composite nucleic acid nanodrugs that simultaneously restrain tnf α binding and tnfr1 multimerization were designed to reinforce inhibition of tnf αtnfr1 signaling for ra therapy towards this end a novel peptide pep419 that suppresses tnfr1 clustering was extracted from tnfr1 the resulting peptide and a dna aptamer apt255 which inhibits tnf α binding were integrally or separately anchored on dna tetrahedron td to obtain nanodrugs with different spatial distribution of apt255 and pep419 td3a3p and td3ap our results showed that pep419 enhanced the viability of inflammatory l929 cells both td3a3p and td3ap suppressed caspase 3 reduced cell apoptosis and inhibited flsra migration compared to td3ap td3a3p supplied sufficient flexibility for apt255 and pep419 and showed better antiinflammation properties furthermore td3a3p significantly relieved symptoms in collageninduced arthritis cia mice and the antira efficacy through intravenous injection was comparable to transdermal administration iviai microneedles overall the work provides an effective strategy for ra treatment by dualtargeting tnfr1 and demonstrates that microneedles are promising approach to drug administration in the treatment of ra,"['selective', 'suppression', 'of', 'tumor', 'necrosis', 'factor', 'tnf', 'αtnf', 'receptor', '1', 'tnfr1', 'signaling', 'is', 'a', 'potent', 'solution', 'for', 'rheumatoid', 'arthritis', 'ra', 'herein', 'novel', 'composite', 'nucleic', 'acid', 'nanodrugs', 'that', 'simultaneously', 'restrain', 'tnf', 'α', 'binding', 'and', 'tnfr1', 'multimerization', 'were', 'designed', 'to', 'reinforce', 'inhibition', 'of', 'tnf', 'αtnfr1', 'signaling', 'for', 'ra', 'therapy', 'towards', 'this', 'end', 'a', 'novel', 'peptide', 'pep419', 'that', 'suppresses', 'tnfr1', 'clustering', 'was', 'extracted', 'from', 'tnfr1', 'the', 'resulting', 'peptide', 'and', 'a', 'dna', 'aptamer', 'apt255', 'which', 'inhibits', 'tnf', 'α', 'binding', 'were', 'integrally', 'or', 'separately', 'anchored', 'on', 'dna', 'tetrahedron', 'td', 'to', 'obtain', 'nanodrugs', 'with', 'different', 'spatial', 'distribution', 'of', 'apt255', 'and', 'pep419', 'td3a3p', 'and', 'td3ap', 'our', 'results', 'showed', 'that', 'pep419', 'enhanced', 'the', 'viability', 'of', 'inflammatory', 'l929', 'cells', 'both', 'td3a3p', 'and', 'td3ap', 'suppressed', 'caspase', '3', 'reduced', 'cell', 'apoptosis', 'and', 'inhibited', 'flsra', 'migration', 'compared', 'to', 'td3ap', 'td3a3p', 'supplied', 'sufficient', 'flexibility', 'for', 'apt255', 'and', 'pep419', 'and', 'showed', 'better', 'antiinflammation', 'properties', 'furthermore', 'td3a3p', 'significantly', 'relieved', 'symptoms', 'in', 'collageninduced', 'arthritis', 'cia', 'mice', 'and', 'the', 'antira', 'efficacy', 'through', 'intravenous', 'injection', 'was', 'comparable', 'to', 'transdermal', 'administration', 'iviai', 'microneedles', 'overall', 'the', 'work', 'provides', 'an', 'effective', 'strategy', 'for', 'ra', 'treatment', 'by', 'dualtargeting', 'tnfr1', 'and', 'demonstrates', 'that', 'microneedles', 'are', 'promising', 'approach', 'to', 'drug', 'administration', 'in', 'the', 'treatment', 'of', 'ra']","['selective', 'suppression', 'tumor', 'necrosis', 'factor', 'tnf', 'αtnf', 'receptor', '1', 'tnfr1', 'signaling', 'potent', 'solution', 'rheumatoid', 'arthritis', 'ra', 'herein', 'novel', 'composite', 'nucleic', 'acid', 'nanodrugs', 'simultaneously', 'restrain', 'tnf', 'α', 'binding', 'tnfr1', 'multimerization', 'designed', 'reinforce', 'inhibition', 'tnf', 'αtnfr1', 'signaling', 'ra', 'therapy', 'towards', 'end', 'novel', 'peptide', 'pep419', 'suppresses', 'tnfr1', 'clustering', 'extracted', 'tnfr1', 'resulting', 'peptide', 'dna', 'aptamer', 'apt255', 'inhibits', 'tnf', 'α', 'binding', 'integrally', 'separately', 'anchored', 'dna', 'tetrahedron', 'td', 'obtain', 'nanodrugs', 'different', 'spatial', 'distribution', 'apt255', 'pep419', 'td3a3p', 'td3ap', 'results', 'showed', 'pep419', 'enhanced', 'viability', 'inflammatory', 'l929', 'cells', 'td3a3p', 'td3ap', 'suppressed', 'caspase', '3', 'reduced', 'cell', 'apoptosis', 'inhibited', 'flsra', 'migration', 'compared', 'td3ap', 'td3a3p', 'supplied', 'sufficient', 'flexibility', 'apt255', 'pep419', 'showed', 'better', 'antiinflammation', 'properties', 'furthermore', 'td3a3p', 'significantly', 'relieved', 'symptoms', 'collageninduced', 'arthritis', 'cia', 'mice', 'antira', 'efficacy', 'intravenous', 'injection', 'comparable', 'transdermal', 'administration', 'iviai', 'microneedles', 'overall', 'work', 'provides', 'effective', 'strategy', 'ra', 'treatment', 'dualtargeting', 'tnfr1', 'demonstrates', 'microneedles', 'promising', 'approach', 'drug', 'administration', 'treatment', 'ra']","['tnf', 'tnfr1', 'ra', 'tnf', 'tnfr1', 'tnf', 'ra', 'pep419', 'tnfr1', 'tnfr1', 'tnf', 'pep419', 'pep419', 'caspase', 'pep419', 'ra', 'tnfr1', ""ra']""]","['tnfr1', 'ra', 'tnfr1', 'ra', 'pep419', 'tnfr1', 'tnfr1', 'pep419', 'pep419', 'pep419', 'ra', 'tnfr1']",True,"['tumor', 'arthritis']"
37350944,Anti-HPV16 oncoproteins siRNA therapy for cervical cancer using a novel transdermal peptide PKU12.,"In this study, an innovative transdermal peptide, #PKU12, was developed based on transdermal peptide TD-1, and the anti-tumor effect of PKU12-based siRNA against HPV was investigated <i>in vivo</i>. Furthermore, transcriptome differences between PKU12 + siRNA treatment and control groups were compared to assess treatment effects. The top five upregulated and downregulated genes identified by RNA sequencing were further subjected to survival analysis. The present study, for the first time, showed that this novel peptide could enhance the transdermal delivery of the siRNA targeting HPV16 L1, E6, and E7. PKU12-based siRNA delivery significantly repressed the mRNA expression levels of HPV16 L1, E6, and E7 in the SiHa xenograft tumors and attenuated tumor growth as well. The RNA-sequencing results showed that a total of 586 DEGs were detected in the PKU12 + siRNA-treated tumor tissues compared to the control tumor tissues. The GSEA analysis revealed that DEGs were inversely associated with the HIF-1 signaling pathway, the TNF signaling pathway, the AGE-RAGE signaling pathway, the NF-kappa B signaling pathway, ferroptosis, the IL-17 signaling pathway, ovarian steroidogenesis, and rheumatoid arthritis. Further functional enrichment analysis revealed that DEGs were significantly enriched in several key pathways, including cytokine-cytokine receptor interaction, the TNF signaling pathway, and the IL-17 signaling pathway. High expression of MYH1, MYH4, FGG, DEPP1, and ZBTB16 was associated with shorter overall survival of patients with cervical cancer; high expression of SULT1E1, RAB3C, CXCR3, and PROX2 was associated with longer overall survival of patients with cervical cancer. In conclusion, the transdermal peptide PKU12 is potentially a good candidate for a siRNA delivery vehicle for the treatment of cervical cancer.",2023-06-07,in this study an innovative transdermal peptide pku12 was developed based on transdermal peptide td1 and the antitumor effect of pku12based sirna against hpv was investigated iin vivoi furthermore transcriptome differences between pku12  sirna treatment and control groups were compared to assess treatment effects the top five upregulated and downregulated genes identified by rna sequencing were further subjected to survival analysis the present study for the first time showed that this novel peptide could enhance the transdermal delivery of the sirna targeting hpv16 l1 e6 and e7 pku12based sirna delivery significantly repressed the mrna expression levels of hpv16 l1 e6 and e7 in the siha xenograft tumors and attenuated tumor growth as well the rnasequencing results showed that a total of 586 degs were detected in the pku12  sirnatreated tumor tissues compared to the control tumor tissues the gsea analysis revealed that degs were inversely associated with the hif1 signaling pathway the tnf signaling pathway the agerage signaling pathway the nfkappa b signaling pathway ferroptosis the il17 signaling pathway ovarian steroidogenesis and rheumatoid arthritis further functional enrichment analysis revealed that degs were significantly enriched in several key pathways including cytokinecytokine receptor interaction the tnf signaling pathway and the il17 signaling pathway high expression of myh1 myh4 fgg depp1 and zbtb16 was associated with shorter overall survival of patients with cervical cancer high expression of sult1e1 rab3c cxcr3 and prox2 was associated with longer overall survival of patients with cervical cancer in conclusion the transdermal peptide pku12 is potentially a good candidate for a sirna delivery vehicle for the treatment of cervical cancer,"['in', 'this', 'study', 'an', 'innovative', 'transdermal', 'peptide', 'pku12', 'was', 'developed', 'based', 'on', 'transdermal', 'peptide', 'td1', 'and', 'the', 'antitumor', 'effect', 'of', 'pku12based', 'sirna', 'against', 'hpv', 'was', 'investigated', 'iin', 'vivoi', 'furthermore', 'transcriptome', 'differences', 'between', 'pku12', 'sirna', 'treatment', 'and', 'control', 'groups', 'were', 'compared', 'to', 'assess', 'treatment', 'effects', 'the', 'top', 'five', 'upregulated', 'and', 'downregulated', 'genes', 'identified', 'by', 'rna', 'sequencing', 'were', 'further', 'subjected', 'to', 'survival', 'analysis', 'the', 'present', 'study', 'for', 'the', 'first', 'time', 'showed', 'that', 'this', 'novel', 'peptide', 'could', 'enhance', 'the', 'transdermal', 'delivery', 'of', 'the', 'sirna', 'targeting', 'hpv16', 'l1', 'e6', 'and', 'e7', 'pku12based', 'sirna', 'delivery', 'significantly', 'repressed', 'the', 'mrna', 'expression', 'levels', 'of', 'hpv16', 'l1', 'e6', 'and', 'e7', 'in', 'the', 'siha', 'xenograft', 'tumors', 'and', 'attenuated', 'tumor', 'growth', 'as', 'well', 'the', 'rnasequencing', 'results', 'showed', 'that', 'a', 'total', 'of', '586', 'degs', 'were', 'detected', 'in', 'the', 'pku12', 'sirnatreated', 'tumor', 'tissues', 'compared', 'to', 'the', 'control', 'tumor', 'tissues', 'the', 'gsea', 'analysis', 'revealed', 'that', 'degs', 'were', 'inversely', 'associated', 'with', 'the', 'hif1', 'signaling', 'pathway', 'the', 'tnf', 'signaling', 'pathway', 'the', 'agerage', 'signaling', 'pathway', 'the', 'nfkappa', 'b', 'signaling', 'pathway', 'ferroptosis', 'the', 'il17', 'signaling', 'pathway', 'ovarian', 'steroidogenesis', 'and', 'rheumatoid', 'arthritis', 'further', 'functional', 'enrichment', 'analysis', 'revealed', 'that', 'degs', 'were', 'significantly', 'enriched', 'in', 'several', 'key', 'pathways', 'including', 'cytokinecytokine', 'receptor', 'interaction', 'the', 'tnf', 'signaling', 'pathway', 'and', 'the', 'il17', 'signaling', 'pathway', 'high', 'expression', 'of', 'myh1', 'myh4', 'fgg', 'depp1', 'and', 'zbtb16', 'was', 'associated', 'with', 'shorter', 'overall', 'survival', 'of', 'patients', 'with', 'cervical', 'cancer', 'high', 'expression', 'of', 'sult1e1', 'rab3c', 'cxcr3', 'and', 'prox2', 'was', 'associated', 'with', 'longer', 'overall', 'survival', 'of', 'patients', 'with', 'cervical', 'cancer', 'in', 'conclusion', 'the', 'transdermal', 'peptide', 'pku12', 'is', 'potentially', 'a', 'good', 'candidate', 'for', 'a', 'sirna', 'delivery', 'vehicle', 'for', 'the', 'treatment', 'of', 'cervical', 'cancer']","['study', 'innovative', 'transdermal', 'peptide', 'pku12', 'developed', 'based', 'transdermal', 'peptide', 'td1', 'antitumor', 'effect', 'pku12based', 'sirna', 'hpv', 'investigated', 'iin', 'vivoi', 'furthermore', 'transcriptome', 'differences', 'pku12', 'sirna', 'treatment', 'control', 'groups', 'compared', 'assess', 'treatment', 'effects', 'top', 'five', 'upregulated', 'downregulated', 'genes', 'identified', 'rna', 'sequencing', 'subjected', 'survival', 'analysis', 'present', 'study', 'first', 'time', 'showed', 'novel', 'peptide', 'could', 'enhance', 'transdermal', 'delivery', 'sirna', 'targeting', 'hpv16', 'l1', 'e6', 'e7', 'pku12based', 'sirna', 'delivery', 'significantly', 'repressed', 'mrna', 'expression', 'levels', 'hpv16', 'l1', 'e6', 'e7', 'siha', 'xenograft', 'tumors', 'attenuated', 'tumor', 'growth', 'well', 'rnasequencing', 'results', 'showed', 'total', '586', 'degs', 'detected', 'pku12', 'sirnatreated', 'tumor', 'tissues', 'compared', 'control', 'tumor', 'tissues', 'gsea', 'analysis', 'revealed', 'degs', 'inversely', 'associated', 'hif1', 'signaling', 'pathway', 'tnf', 'signaling', 'pathway', 'agerage', 'signaling', 'pathway', 'nfkappa', 'b', 'signaling', 'pathway', 'ferroptosis', 'il17', 'signaling', 'pathway', 'ovarian', 'steroidogenesis', 'rheumatoid', 'arthritis', 'functional', 'enrichment', 'analysis', 'revealed', 'degs', 'significantly', 'enriched', 'several', 'key', 'pathways', 'including', 'cytokinecytokine', 'receptor', 'interaction', 'tnf', 'signaling', 'pathway', 'il17', 'signaling', 'pathway', 'high', 'expression', 'myh1', 'myh4', 'fgg', 'depp1', 'zbtb16', 'associated', 'shorter', 'overall', 'survival', 'patients', 'cervical', 'cancer', 'high', 'expression', 'sult1e1', 'rab3c', 'cxcr3', 'prox2', 'associated', 'longer', 'overall', 'survival', 'patients', 'cervical', 'cancer', 'conclusion', 'transdermal', 'peptide', 'pku12', 'potentially', 'good', 'candidate', 'sirna', 'delivery', 'vehicle', 'treatment', 'cervical', 'cancer']","['sirna', 'sirna', 'sirna', 'sirna', 'hif1', 'tnf', 'il17', 'tnf', 'il17', 'myh4', 'cxcr3', 'prox2', 'sirna']","['hif1', 'myh4', 'cxcr3', 'prox2']",True,"['tumor', 'cancer', 'arthritis']"
37307715,Targeting the Hedgehog pathway with novel Gli1 hydrophobic tagging degraders.,"The Hedgehog/Glioma-associated oncogene (Hh/Gli) signaling pathway plays an essential role in embryonic development and tissue homeostasis. Aberrant regulation of this pathway has been linked to various human malignancies. Gli1, the downstream transcription factor of the Hh pathway, is the ultimate effector of the canonical Hh pathway and has been identified as a common regulator of several tumorigenic pathways prevalent in Hh-independent cancers. Thus Gli1 represents a unique and promising drug target for a wide range of cancers. However, the identification and development of small molecules that directly target Gli1 protein have progressed slowly, due to an insufficient efficacy and selectivity. Herein, we developed novel small-molecule Gli1 degraders based on the hydrophobic tagging (HyT) strategy. The Gli1 HyT degrader 8e potently inhibited the proliferation of Gli1-overexpressed HT29 colorectal cancer cells, induced Gli1 degradation with a DC<sub>50</sub> value of 5.4 μM in HT29 and achieved 70% degradation at 7.5 μM in MEF<sup>PTCH1-/-</sup> and MEF<sup>SUFU-/-</sup>cell lines, via proteasome pathway. Compared to the canonical Hh antagonist Vismodegib, 8e exhibited much stronger potency in suppressing the mRNA expression of Hh target genes in Hh-overactivated MEF<sup>PTCH1-/-</sup> and Vismodegib resistant MEF<sup>SUFU-/-</sup> cells. Our study provides small molecule Gli1 degraders effectively interfering with both canonical and noncanonical Hh signaling and overcoming current Smoothened (SMO) antagonists resistance, which might pave a new avenue for developing therapeutic modalities targeting Hh/Gli1 signaling pathway.",2023-06-07,the hedgehoggliomaassociated oncogene hhgli signaling pathway plays an essential role in embryonic development and tissue homeostasis aberrant regulation of this pathway has been linked to various human malignancies gli1 the downstream transcription factor of the hh pathway is the ultimate effector of the canonical hh pathway and has been identified as a common regulator of several tumorigenic pathways prevalent in hhindependent cancers thus gli1 represents a unique and promising drug target for a wide range of cancers however the identification and development of small molecules that directly target gli1 protein have progressed slowly due to an insufficient efficacy and selectivity herein we developed novel smallmolecule gli1 degraders based on the hydrophobic tagging hyt strategy the gli1 hyt degrader 8e potently inhibited the proliferation of gli1overexpressed ht29 colorectal cancer cells induced gli1 degradation with a dcsub50sub value of 54 μm in ht29 and achieved 70 degradation at 75 μm in mefsupptch1sup and mefsupsufusupcell lines via proteasome pathway compared to the canonical hh antagonist vismodegib 8e exhibited much stronger potency in suppressing the mrna expression of hh target genes in hhoveractivated mefsupptch1sup and vismodegib resistant mefsupsufusup cells our study provides small molecule gli1 degraders effectively interfering with both canonical and noncanonical hh signaling and overcoming current smoothened smo antagonists resistance which might pave a new avenue for developing therapeutic modalities targeting hhgli1 signaling pathway,"['the', 'hedgehoggliomaassociated', 'oncogene', 'hhgli', 'signaling', 'pathway', 'plays', 'an', 'essential', 'role', 'in', 'embryonic', 'development', 'and', 'tissue', 'homeostasis', 'aberrant', 'regulation', 'of', 'this', 'pathway', 'has', 'been', 'linked', 'to', 'various', 'human', 'malignancies', 'gli1', 'the', 'downstream', 'transcription', 'factor', 'of', 'the', 'hh', 'pathway', 'is', 'the', 'ultimate', 'effector', 'of', 'the', 'canonical', 'hh', 'pathway', 'and', 'has', 'been', 'identified', 'as', 'a', 'common', 'regulator', 'of', 'several', 'tumorigenic', 'pathways', 'prevalent', 'in', 'hhindependent', 'cancers', 'thus', 'gli1', 'represents', 'a', 'unique', 'and', 'promising', 'drug', 'target', 'for', 'a', 'wide', 'range', 'of', 'cancers', 'however', 'the', 'identification', 'and', 'development', 'of', 'small', 'molecules', 'that', 'directly', 'target', 'gli1', 'protein', 'have', 'progressed', 'slowly', 'due', 'to', 'an', 'insufficient', 'efficacy', 'and', 'selectivity', 'herein', 'we', 'developed', 'novel', 'smallmolecule', 'gli1', 'degraders', 'based', 'on', 'the', 'hydrophobic', 'tagging', 'hyt', 'strategy', 'the', 'gli1', 'hyt', 'degrader', '8e', 'potently', 'inhibited', 'the', 'proliferation', 'of', 'gli1overexpressed', 'ht29', 'colorectal', 'cancer', 'cells', 'induced', 'gli1', 'degradation', 'with', 'a', 'dcsub50sub', 'value', 'of', '54', 'μm', 'in', 'ht29', 'and', 'achieved', '70', 'degradation', 'at', '75', 'μm', 'in', 'mefsupptch1sup', 'and', 'mefsupsufusupcell', 'lines', 'via', 'proteasome', 'pathway', 'compared', 'to', 'the', 'canonical', 'hh', 'antagonist', 'vismodegib', '8e', 'exhibited', 'much', 'stronger', 'potency', 'in', 'suppressing', 'the', 'mrna', 'expression', 'of', 'hh', 'target', 'genes', 'in', 'hhoveractivated', 'mefsupptch1sup', 'and', 'vismodegib', 'resistant', 'mefsupsufusup', 'cells', 'our', 'study', 'provides', 'small', 'molecule', 'gli1', 'degraders', 'effectively', 'interfering', 'with', 'both', 'canonical', 'and', 'noncanonical', 'hh', 'signaling', 'and', 'overcoming', 'current', 'smoothened', 'smo', 'antagonists', 'resistance', 'which', 'might', 'pave', 'a', 'new', 'avenue', 'for', 'developing', 'therapeutic', 'modalities', 'targeting', 'hhgli1', 'signaling', 'pathway']","['hedgehoggliomaassociated', 'oncogene', 'hhgli', 'signaling', 'pathway', 'plays', 'essential', 'role', 'embryonic', 'development', 'tissue', 'homeostasis', 'aberrant', 'regulation', 'pathway', 'linked', 'various', 'human', 'malignancies', 'gli1', 'downstream', 'transcription', 'factor', 'hh', 'pathway', 'ultimate', 'effector', 'canonical', 'hh', 'pathway', 'identified', 'common', 'regulator', 'several', 'tumorigenic', 'pathways', 'prevalent', 'hhindependent', 'cancers', 'thus', 'gli1', 'represents', 'unique', 'promising', 'drug', 'target', 'wide', 'range', 'cancers', 'however', 'identification', 'development', 'small', 'molecules', 'directly', 'target', 'gli1', 'protein', 'progressed', 'slowly', 'due', 'insufficient', 'efficacy', 'selectivity', 'herein', 'developed', 'novel', 'smallmolecule', 'gli1', 'degraders', 'based', 'hydrophobic', 'tagging', 'hyt', 'strategy', 'gli1', 'hyt', 'degrader', '8e', 'potently', 'inhibited', 'proliferation', 'gli1overexpressed', 'ht29', 'colorectal', 'cancer', 'cells', 'induced', 'gli1', 'degradation', 'dcsub50sub', 'value', '54', 'μm', 'ht29', 'achieved', '70', 'degradation', '75', 'μm', 'mefsupptch1sup', 'mefsupsufusupcell', 'lines', 'via', 'proteasome', 'pathway', 'compared', 'canonical', 'hh', 'antagonist', 'vismodegib', '8e', 'exhibited', 'much', 'stronger', 'potency', 'suppressing', 'mrna', 'expression', 'hh', 'target', 'genes', 'hhoveractivated', 'mefsupptch1sup', 'vismodegib', 'resistant', 'mefsupsufusup', 'cells', 'study', 'provides', 'small', 'molecule', 'gli1', 'degraders', 'effectively', 'interfering', 'canonical', 'noncanonical', 'hh', 'signaling', 'overcoming', 'current', 'smoothened', 'smo', 'antagonists', 'resistance', 'might', 'pave', 'new', 'avenue', 'developing', 'therapeutic', 'modalities', 'targeting', 'hhgli1', 'signaling', 'pathway']","['gli1', 'gli1', 'gli1', 'gli1', 'gli1', 'gli1', 'gli1', 'smo']","['gli1', 'gli1', 'gli1', 'gli1', 'gli1', 'gli1', 'gli1']",True,"['tumor', 'cancer']"
37304671,"Anticancer efficacy of 3-(4-isopropyl) benzylidene-8-ethoxy, 6-methyl, chroman-4-one (SBL-060), a novel, dual, estrogen receptor-Akt kinase inhibitor in acute myeloid leukemia cells.","Estrogen receptor (ER) α is expressed in a subset of patient-derived acute myeloid leukemia (AML) cells, whereas Akt is predominantly expressed in most types of AML. Targeting AML with dual inhibitors is a novel approach to combat the disease. Herein, we examined a novel small molecule, 3-(4-isopropyl) benzylidene-8-ethoxy,6-methyl, chroman-4-one (SBL-060), capable of targeting AML cells by inhibiting ERα and Akt kinase. The chemical properties of SBL-060 were identified by proton nuclear magnetic resonance (<sup>1</sup>H-NMR), <sup>13</sup>C-NMR, and mass spectroscopy. <i>In silico</i> docking was performed using an automated protocol with AutoDock-VINA. THP-1 and HL-60 cell lines were differentiated using phorbol 12-myristate 13-acetate. ERα inhibition was assessed using ELISA. The MTT assay assessed cell viability. Flow cytometry was performed for cell cycle, apoptosis, and p-Akt analyses. Chemical analysis identified the compound as 3-(4-isopropyl) benzylidene-8-ethoxy,6-methyl, chroman-4-one, which showed high binding efficacy toward ER, with a ΔG<sub>binding</sub> score of -7.4 kcal/mol. SBL-060 inhibited ERα, exhibiting IC<sub>50</sub> values of 448 and 374.3 nM in THP-1 and HL-60 cells, respectively. Regarding inhibited cell proliferation, GI<sub>50</sub> values of SBL-060 were 244.1 and 189.9 nM for THP-1 and HL-60 cells, respectively. In addition, a dose-dependent increase in sub G<sub>0</sub>/G<sub>1</sub> phase cell cycle arrest and total apoptosis was observed after treatment with SBL-060 in both cell types. SBL-060 also dose-dependently increased the p-Akt-positive populations in both THP-1 and HL-60 cells. Our results indicate that SBL-060 has excellent efficacy against differentiated AML cell types by inhibiting ER and Akt kinase, warranting further preclinical evaluations.",2022-08-01,estrogen receptor er α is expressed in a subset of patientderived acute myeloid leukemia aml cells whereas akt is predominantly expressed in most types of aml targeting aml with dual inhibitors is a novel approach to combat the disease herein we examined a novel small molecule 34isopropyl benzylidene8ethoxy6methyl chroman4one sbl060 capable of targeting aml cells by inhibiting erα and akt kinase the chemical properties of sbl060 were identified by proton nuclear magnetic resonance sup1suphnmr sup13supcnmr and mass spectroscopy iin silicoi docking was performed using an automated protocol with autodockvina thp1 and hl60 cell lines were differentiated using phorbol 12myristate 13acetate erα inhibition was assessed using elisa the mtt assay assessed cell viability flow cytometry was performed for cell cycle apoptosis and pakt analyses chemical analysis identified the compound as 34isopropyl benzylidene8ethoxy6methyl chroman4one which showed high binding efficacy toward er with a δgsubbindingsub score of 74 kcalmol sbl060 inhibited erα exhibiting icsub50sub values of 448 and 3743 nm in thp1 and hl60 cells respectively regarding inhibited cell proliferation gisub50sub values of sbl060 were 2441 and 1899 nm for thp1 and hl60 cells respectively in addition a dosedependent increase in sub gsub0subgsub1sub phase cell cycle arrest and total apoptosis was observed after treatment with sbl060 in both cell types sbl060 also dosedependently increased the paktpositive populations in both thp1 and hl60 cells our results indicate that sbl060 has excellent efficacy against differentiated aml cell types by inhibiting er and akt kinase warranting further preclinical evaluations,"['estrogen', 'receptor', 'er', 'α', 'is', 'expressed', 'in', 'a', 'subset', 'of', 'patientderived', 'acute', 'myeloid', 'leukemia', 'aml', 'cells', 'whereas', 'akt', 'is', 'predominantly', 'expressed', 'in', 'most', 'types', 'of', 'aml', 'targeting', 'aml', 'with', 'dual', 'inhibitors', 'is', 'a', 'novel', 'approach', 'to', 'combat', 'the', 'disease', 'herein', 'we', 'examined', 'a', 'novel', 'small', 'molecule', '34isopropyl', 'benzylidene8ethoxy6methyl', 'chroman4one', 'sbl060', 'capable', 'of', 'targeting', 'aml', 'cells', 'by', 'inhibiting', 'erα', 'and', 'akt', 'kinase', 'the', 'chemical', 'properties', 'of', 'sbl060', 'were', 'identified', 'by', 'proton', 'nuclear', 'magnetic', 'resonance', 'sup1suphnmr', 'sup13supcnmr', 'and', 'mass', 'spectroscopy', 'iin', 'silicoi', 'docking', 'was', 'performed', 'using', 'an', 'automated', 'protocol', 'with', 'autodockvina', 'thp1', 'and', 'hl60', 'cell', 'lines', 'were', 'differentiated', 'using', 'phorbol', '12myristate', '13acetate', 'erα', 'inhibition', 'was', 'assessed', 'using', 'elisa', 'the', 'mtt', 'assay', 'assessed', 'cell', 'viability', 'flow', 'cytometry', 'was', 'performed', 'for', 'cell', 'cycle', 'apoptosis', 'and', 'pakt', 'analyses', 'chemical', 'analysis', 'identified', 'the', 'compound', 'as', '34isopropyl', 'benzylidene8ethoxy6methyl', 'chroman4one', 'which', 'showed', 'high', 'binding', 'efficacy', 'toward', 'er', 'with', 'a', 'δgsubbindingsub', 'score', 'of', '74', 'kcalmol', 'sbl060', 'inhibited', 'erα', 'exhibiting', 'icsub50sub', 'values', 'of', '448', 'and', '3743', 'nm', 'in', 'thp1', 'and', 'hl60', 'cells', 'respectively', 'regarding', 'inhibited', 'cell', 'proliferation', 'gisub50sub', 'values', 'of', 'sbl060', 'were', '2441', 'and', '1899', 'nm', 'for', 'thp1', 'and', 'hl60', 'cells', 'respectively', 'in', 'addition', 'a', 'dosedependent', 'increase', 'in', 'sub', 'gsub0subgsub1sub', 'phase', 'cell', 'cycle', 'arrest', 'and', 'total', 'apoptosis', 'was', 'observed', 'after', 'treatment', 'with', 'sbl060', 'in', 'both', 'cell', 'types', 'sbl060', 'also', 'dosedependently', 'increased', 'the', 'paktpositive', 'populations', 'in', 'both', 'thp1', 'and', 'hl60', 'cells', 'our', 'results', 'indicate', 'that', 'sbl060', 'has', 'excellent', 'efficacy', 'against', 'differentiated', 'aml', 'cell', 'types', 'by', 'inhibiting', 'er', 'and', 'akt', 'kinase', 'warranting', 'further', 'preclinical', 'evaluations']","['estrogen', 'receptor', 'er', 'α', 'expressed', 'subset', 'patientderived', 'acute', 'myeloid', 'leukemia', 'aml', 'cells', 'whereas', 'akt', 'predominantly', 'expressed', 'types', 'aml', 'targeting', 'aml', 'dual', 'inhibitors', 'novel', 'approach', 'combat', 'disease', 'herein', 'examined', 'novel', 'small', 'molecule', '34isopropyl', 'benzylidene8ethoxy6methyl', 'chroman4one', 'sbl060', 'capable', 'targeting', 'aml', 'cells', 'inhibiting', 'erα', 'akt', 'kinase', 'chemical', 'properties', 'sbl060', 'identified', 'proton', 'nuclear', 'magnetic', 'resonance', 'sup1suphnmr', 'sup13supcnmr', 'mass', 'spectroscopy', 'iin', 'silicoi', 'docking', 'performed', 'using', 'automated', 'protocol', 'autodockvina', 'thp1', 'hl60', 'cell', 'lines', 'differentiated', 'using', 'phorbol', '12myristate', '13acetate', 'erα', 'inhibition', 'assessed', 'using', 'elisa', 'mtt', 'assay', 'assessed', 'cell', 'viability', 'flow', 'cytometry', 'performed', 'cell', 'cycle', 'apoptosis', 'pakt', 'analyses', 'chemical', 'analysis', 'identified', 'compound', '34isopropyl', 'benzylidene8ethoxy6methyl', 'chroman4one', 'showed', 'high', 'binding', 'efficacy', 'toward', 'er', 'δgsubbindingsub', 'score', '74', 'kcalmol', 'sbl060', 'inhibited', 'erα', 'exhibiting', 'icsub50sub', 'values', '448', '3743', 'nm', 'thp1', 'hl60', 'cells', 'respectively', 'regarding', 'inhibited', 'cell', 'proliferation', 'gisub50sub', 'values', 'sbl060', '2441', '1899', 'nm', 'thp1', 'hl60', 'cells', 'respectively', 'addition', 'dosedependent', 'increase', 'sub', 'gsub0subgsub1sub', 'phase', 'cell', 'cycle', 'arrest', 'total', 'apoptosis', 'observed', 'treatment', 'sbl060', 'cell', 'types', 'sbl060', 'also', 'dosedependently', 'increased', 'paktpositive', 'populations', 'thp1', 'hl60', 'cells', 'results', 'indicate', 'sbl060', 'excellent', 'efficacy', 'differentiated', 'aml', 'cell', 'types', 'inhibiting', 'er', 'akt', 'kinase', 'warranting', 'preclinical', 'evaluations']","['akt', 'akt', 'thp1', 'thp1', 'thp1', 'thp1', 'akt']","['thp1', 'thp1', 'thp1', 'thp1']",True,['leukemia']
37244126,Development of an assay pipeline for the discovery of novel small molecule inhibitors of human glutathione peroxidases GPX1 and GPX4.,"Selenoprotein glutathione peroxidases (GPX), like ubiquitously expressed GPX1 and the ferroptosis modulator GPX4, enact antioxidant activities by reducing hydroperoxides using glutathione. Overexpression of these enzymes is common in cancer and can be associated with the development of resistance to chemotherapy. GPX1 and GPX4 inhibitors have thus shown promise as anti-cancer agents, and targeting other GPX isoforms may prove equally beneficial. Existing inhibitors are often promiscuous, or modulate GPXs only indirectly, so novel direct inhibitors identified through screening against GPX1 and GPX4 could be valuable. Here, we developed optimized glutathione reductase (GR)-coupled GPX assays for the biochemical high-throughput screen (HTS) of almost 12,000 compounds with proposed mechanisms of action. Initial hits were triaged using a GR counter-screen, assessed for isoform specificity against an additional GPX isoform, GPX2, and were assessed for general selenocysteine-targeting activity using a thioredoxin reductase (TXNRD1) assay. Importantly, 70% of the GPX1 inhibitors identified in the primary screen, including several cephalosporin antibiotics, were found to also inhibit TXNRD1, while auranofin, previously known as a TXNRD1 inhibitor, also inhibited GPX1 (but not GPX4). Additionally, every GPX1 inhibitor identified (including omapatrilat, tenatoprazole, cefoxitin and ceftibuten) showed similar inhibitory activity against GPX2. Some compounds inhibiting GPX4 but not GPX1 or GPX2, also inhibited TXNRD1 (26%). Compounds only inhibiting GPX4 included pranlukast sodium hydrate, lusutrombopag, brilanestrant, simeprevir, grazoprevir (MK-5172), paritaprevir, navitoclax, venetoclax and VU0661013. Two compounds (metamizole sodium and isoniazid sodium methanesulfate) inhibited all three GPXs but not TXNRD1, while 2,3-dimercaptopropanesulfonate, PI4KIII beta inhibitor 3, SCE-2174 and cefotetan sodium inhibited all tested selenoproteins (but not GR). The detected overlaps in chemical space suggest that the counter screens introduced here should be imperative for identification of specific GPX inhibitors. With this approach, we could indeed identify novel GPX1/GPX2- or GPX4-specific inhibitors, thus presenting a validated pipeline for future identification of specific selenoprotein-targeting agents. Our study also identified GPX1/GPX2, GPX4 and/or TXNRD1 as targets for several previously developed pharmacologically active compounds.",2023-05-16,selenoprotein glutathione peroxidases gpx like ubiquitously expressed gpx1 and the ferroptosis modulator gpx4 enact antioxidant activities by reducing hydroperoxides using glutathione overexpression of these enzymes is common in cancer and can be associated with the development of resistance to chemotherapy gpx1 and gpx4 inhibitors have thus shown promise as anticancer agents and targeting other gpx isoforms may prove equally beneficial existing inhibitors are often promiscuous or modulate gpxs only indirectly so novel direct inhibitors identified through screening against gpx1 and gpx4 could be valuable here we developed optimized glutathione reductase grcoupled gpx assays for the biochemical highthroughput screen hts of almost 12000 compounds with proposed mechanisms of action initial hits were triaged using a gr counterscreen assessed for isoform specificity against an additional gpx isoform gpx2 and were assessed for general selenocysteinetargeting activity using a thioredoxin reductase txnrd1 assay importantly 70 of the gpx1 inhibitors identified in the primary screen including several cephalosporin antibiotics were found to also inhibit txnrd1 while auranofin previously known as a txnrd1 inhibitor also inhibited gpx1 but not gpx4 additionally every gpx1 inhibitor identified including omapatrilat tenatoprazole cefoxitin and ceftibuten showed similar inhibitory activity against gpx2 some compounds inhibiting gpx4 but not gpx1 or gpx2 also inhibited txnrd1 26 compounds only inhibiting gpx4 included pranlukast sodium hydrate lusutrombopag brilanestrant simeprevir grazoprevir mk5172 paritaprevir navitoclax venetoclax and vu0661013 two compounds metamizole sodium and isoniazid sodium methanesulfate inhibited all three gpxs but not txnrd1 while 23dimercaptopropanesulfonate pi4kiii beta inhibitor 3 sce2174 and cefotetan sodium inhibited all tested selenoproteins but not gr the detected overlaps in chemical space suggest that the counter screens introduced here should be imperative for identification of specific gpx inhibitors with this approach we could indeed identify novel gpx1gpx2 or gpx4specific inhibitors thus presenting a validated pipeline for future identification of specific selenoproteintargeting agents our study also identified gpx1gpx2 gpx4 andor txnrd1 as targets for several previously developed pharmacologically active compounds,"['selenoprotein', 'glutathione', 'peroxidases', 'gpx', 'like', 'ubiquitously', 'expressed', 'gpx1', 'and', 'the', 'ferroptosis', 'modulator', 'gpx4', 'enact', 'antioxidant', 'activities', 'by', 'reducing', 'hydroperoxides', 'using', 'glutathione', 'overexpression', 'of', 'these', 'enzymes', 'is', 'common', 'in', 'cancer', 'and', 'can', 'be', 'associated', 'with', 'the', 'development', 'of', 'resistance', 'to', 'chemotherapy', 'gpx1', 'and', 'gpx4', 'inhibitors', 'have', 'thus', 'shown', 'promise', 'as', 'anticancer', 'agents', 'and', 'targeting', 'other', 'gpx', 'isoforms', 'may', 'prove', 'equally', 'beneficial', 'existing', 'inhibitors', 'are', 'often', 'promiscuous', 'or', 'modulate', 'gpxs', 'only', 'indirectly', 'so', 'novel', 'direct', 'inhibitors', 'identified', 'through', 'screening', 'against', 'gpx1', 'and', 'gpx4', 'could', 'be', 'valuable', 'here', 'we', 'developed', 'optimized', 'glutathione', 'reductase', 'grcoupled', 'gpx', 'assays', 'for', 'the', 'biochemical', 'highthroughput', 'screen', 'hts', 'of', 'almost', '12000', 'compounds', 'with', 'proposed', 'mechanisms', 'of', 'action', 'initial', 'hits', 'were', 'triaged', 'using', 'a', 'gr', 'counterscreen', 'assessed', 'for', 'isoform', 'specificity', 'against', 'an', 'additional', 'gpx', 'isoform', 'gpx2', 'and', 'were', 'assessed', 'for', 'general', 'selenocysteinetargeting', 'activity', 'using', 'a', 'thioredoxin', 'reductase', 'txnrd1', 'assay', 'importantly', '70', 'of', 'the', 'gpx1', 'inhibitors', 'identified', 'in', 'the', 'primary', 'screen', 'including', 'several', 'cephalosporin', 'antibiotics', 'were', 'found', 'to', 'also', 'inhibit', 'txnrd1', 'while', 'auranofin', 'previously', 'known', 'as', 'a', 'txnrd1', 'inhibitor', 'also', 'inhibited', 'gpx1', 'but', 'not', 'gpx4', 'additionally', 'every', 'gpx1', 'inhibitor', 'identified', 'including', 'omapatrilat', 'tenatoprazole', 'cefoxitin', 'and', 'ceftibuten', 'showed', 'similar', 'inhibitory', 'activity', 'against', 'gpx2', 'some', 'compounds', 'inhibiting', 'gpx4', 'but', 'not', 'gpx1', 'or', 'gpx2', 'also', 'inhibited', 'txnrd1', '26', 'compounds', 'only', 'inhibiting', 'gpx4', 'included', 'pranlukast', 'sodium', 'hydrate', 'lusutrombopag', 'brilanestrant', 'simeprevir', 'grazoprevir', 'mk5172', 'paritaprevir', 'navitoclax', 'venetoclax', 'and', 'vu0661013', 'two', 'compounds', 'metamizole', 'sodium', 'and', 'isoniazid', 'sodium', 'methanesulfate', 'inhibited', 'all', 'three', 'gpxs', 'but', 'not', 'txnrd1', 'while', '23dimercaptopropanesulfonate', 'pi4kiii', 'beta', 'inhibitor', '3', 'sce2174', 'and', 'cefotetan', 'sodium', 'inhibited', 'all', 'tested', 'selenoproteins', 'but', 'not', 'gr', 'the', 'detected', 'overlaps', 'in', 'chemical', 'space', 'suggest', 'that', 'the', 'counter', 'screens', 'introduced', 'here', 'should', 'be', 'imperative', 'for', 'identification', 'of', 'specific', 'gpx', 'inhibitors', 'with', 'this', 'approach', 'we', 'could', 'indeed', 'identify', 'novel', 'gpx1gpx2', 'or', 'gpx4specific', 'inhibitors', 'thus', 'presenting', 'a', 'validated', 'pipeline', 'for', 'future', 'identification', 'of', 'specific', 'selenoproteintargeting', 'agents', 'our', 'study', 'also', 'identified', 'gpx1gpx2', 'gpx4', 'andor', 'txnrd1', 'as', 'targets', 'for', 'several', 'previously', 'developed', 'pharmacologically', 'active', 'compounds']","['selenoprotein', 'glutathione', 'peroxidases', 'gpx', 'like', 'ubiquitously', 'expressed', 'gpx1', 'ferroptosis', 'modulator', 'gpx4', 'enact', 'antioxidant', 'activities', 'reducing', 'hydroperoxides', 'using', 'glutathione', 'overexpression', 'enzymes', 'common', 'cancer', 'associated', 'development', 'resistance', 'chemotherapy', 'gpx1', 'gpx4', 'inhibitors', 'thus', 'shown', 'promise', 'anticancer', 'agents', 'targeting', 'gpx', 'isoforms', 'may', 'prove', 'equally', 'beneficial', 'existing', 'inhibitors', 'often', 'promiscuous', 'modulate', 'gpxs', 'indirectly', 'novel', 'direct', 'inhibitors', 'identified', 'screening', 'gpx1', 'gpx4', 'could', 'valuable', 'developed', 'optimized', 'glutathione', 'reductase', 'grcoupled', 'gpx', 'assays', 'biochemical', 'highthroughput', 'screen', 'hts', 'almost', '12000', 'compounds', 'proposed', 'mechanisms', 'action', 'initial', 'hits', 'triaged', 'using', 'gr', 'counterscreen', 'assessed', 'isoform', 'specificity', 'additional', 'gpx', 'isoform', 'gpx2', 'assessed', 'general', 'selenocysteinetargeting', 'activity', 'using', 'thioredoxin', 'reductase', 'txnrd1', 'assay', 'importantly', '70', 'gpx1', 'inhibitors', 'identified', 'primary', 'screen', 'including', 'several', 'cephalosporin', 'antibiotics', 'found', 'also', 'inhibit', 'txnrd1', 'auranofin', 'previously', 'known', 'txnrd1', 'inhibitor', 'also', 'inhibited', 'gpx1', 'gpx4', 'additionally', 'every', 'gpx1', 'inhibitor', 'identified', 'including', 'omapatrilat', 'tenatoprazole', 'cefoxitin', 'ceftibuten', 'showed', 'similar', 'inhibitory', 'activity', 'gpx2', 'compounds', 'inhibiting', 'gpx4', 'gpx1', 'gpx2', 'also', 'inhibited', 'txnrd1', '26', 'compounds', 'inhibiting', 'gpx4', 'included', 'pranlukast', 'sodium', 'hydrate', 'lusutrombopag', 'brilanestrant', 'simeprevir', 'grazoprevir', 'mk5172', 'paritaprevir', 'navitoclax', 'venetoclax', 'vu0661013', 'two', 'compounds', 'metamizole', 'sodium', 'isoniazid', 'sodium', 'methanesulfate', 'inhibited', 'three', 'gpxs', 'txnrd1', '23dimercaptopropanesulfonate', 'pi4kiii', 'beta', 'inhibitor', '3', 'sce2174', 'cefotetan', 'sodium', 'inhibited', 'tested', 'selenoproteins', 'gr', 'detected', 'overlaps', 'chemical', 'space', 'suggest', 'counter', 'screens', 'introduced', 'imperative', 'identification', 'specific', 'gpx', 'inhibitors', 'approach', 'could', 'indeed', 'identify', 'novel', 'gpx1gpx2', 'gpx4specific', 'inhibitors', 'thus', 'presenting', 'validated', 'pipeline', 'future', 'identification', 'specific', 'selenoproteintargeting', 'agents', 'study', 'also', 'identified', 'gpx1gpx2', 'gpx4', 'andor', 'txnrd1', 'targets', 'several', 'previously', 'developed', 'pharmacologically', 'active', 'compounds']","['selenoprotein', 'peroxidases', 'gpx', 'gpx1', 'gpx4', 'gpx1', 'gpx4', 'gpx', 'gpx1', 'gpx4', 'gpx', 'gpx', 'gpx2', 'txnrd1', 'gpx1', 'txnrd1', 'txnrd1', 'gpx1', 'gpx4', 'gpx1', 'gpx2', 'gpx4', 'gpx1', 'gpx2', 'txnrd1', 'gpx4', 'txnrd1', 'beta', 'gpx', 'gpx4', 'txnrd1']","['selenoprotein', 'peroxidases', 'gpx1', 'gpx4', 'gpx1', 'gpx4', 'gpx1', 'gpx4', 'gpx2', 'txnrd1', 'gpx1', 'txnrd1', 'txnrd1', 'gpx1', 'gpx4', 'gpx1', 'gpx2', 'gpx4', 'gpx1', 'gpx2', 'txnrd1', 'gpx4', 'txnrd1', 'gpx4', 'txnrd1']",True,['cancer']
37148978,Identification of a novel small-molecule inhibitor targeting TIM-3 for cancer immunotherapy.,"PD-1/PD-L1 blockade has achieved substantial clinical results in cancer treatment. However, the expression of other immune checkpoints leads to resistance and hinders the efficacy of PD-1/PD-L1 blockade. T cell immunoglobulin and mucin domain 3 (TIM-3), a non-redundant immune checkpoint, synergizes with PD-1 to mediate T cell dysfunction in tumor microenvironment. Development of small molecules targeting TIM-3 is a promising strategy for cancer immunotherapy. Here, to identify small molecule inhibitors targeting TIM-3, the docking pocket in TIM-3 was analyzed by Molecular Operating Environment (MOE) and the Chemdiv compound database was screened. The small molecule SMI402 could bind to TIM-3 with high affinity and prevent the ligation of PtdSer, HMGB1, and CEACAM1. SMI402 reinvigorated T cell function in vitro. In the MC38-bearing mouse model, SMI402 inhibited tumor growth by increasing CD8<sup>+</sup> T and natural killing (NK) cells infiltration at the tumor site, as well as restoring the function of CD8<sup>+</sup> T and NK cells. In conclusions, the small molecule SMI402 shows promise as a leading compound which targets TIM-3 for cancer immunotherapy.",2023-05-04,pd1pdl1 blockade has achieved substantial clinical results in cancer treatment however the expression of other immune checkpoints leads to resistance and hinders the efficacy of pd1pdl1 blockade t cell immunoglobulin and mucin domain 3 tim3 a nonredundant immune checkpoint synergizes with pd1 to mediate t cell dysfunction in tumor microenvironment development of small molecules targeting tim3 is a promising strategy for cancer immunotherapy here to identify small molecule inhibitors targeting tim3 the docking pocket in tim3 was analyzed by molecular operating environment moe and the chemdiv compound database was screened the small molecule smi402 could bind to tim3 with high affinity and prevent the ligation of ptdser hmgb1 and ceacam1 smi402 reinvigorated t cell function in vitro in the mc38bearing mouse model smi402 inhibited tumor growth by increasing cd8supsup t and natural killing nk cells infiltration at the tumor site as well as restoring the function of cd8supsup t and nk cells in conclusions the small molecule smi402 shows promise as a leading compound which targets tim3 for cancer immunotherapy,"['pd1pdl1', 'blockade', 'has', 'achieved', 'substantial', 'clinical', 'results', 'in', 'cancer', 'treatment', 'however', 'the', 'expression', 'of', 'other', 'immune', 'checkpoints', 'leads', 'to', 'resistance', 'and', 'hinders', 'the', 'efficacy', 'of', 'pd1pdl1', 'blockade', 't', 'cell', 'immunoglobulin', 'and', 'mucin', 'domain', '3', 'tim3', 'a', 'nonredundant', 'immune', 'checkpoint', 'synergizes', 'with', 'pd1', 'to', 'mediate', 't', 'cell', 'dysfunction', 'in', 'tumor', 'microenvironment', 'development', 'of', 'small', 'molecules', 'targeting', 'tim3', 'is', 'a', 'promising', 'strategy', 'for', 'cancer', 'immunotherapy', 'here', 'to', 'identify', 'small', 'molecule', 'inhibitors', 'targeting', 'tim3', 'the', 'docking', 'pocket', 'in', 'tim3', 'was', 'analyzed', 'by', 'molecular', 'operating', 'environment', 'moe', 'and', 'the', 'chemdiv', 'compound', 'database', 'was', 'screened', 'the', 'small', 'molecule', 'smi402', 'could', 'bind', 'to', 'tim3', 'with', 'high', 'affinity', 'and', 'prevent', 'the', 'ligation', 'of', 'ptdser', 'hmgb1', 'and', 'ceacam1', 'smi402', 'reinvigorated', 't', 'cell', 'function', 'in', 'vitro', 'in', 'the', 'mc38bearing', 'mouse', 'model', 'smi402', 'inhibited', 'tumor', 'growth', 'by', 'increasing', 'cd8supsup', 't', 'and', 'natural', 'killing', 'nk', 'cells', 'infiltration', 'at', 'the', 'tumor', 'site', 'as', 'well', 'as', 'restoring', 'the', 'function', 'of', 'cd8supsup', 't', 'and', 'nk', 'cells', 'in', 'conclusions', 'the', 'small', 'molecule', 'smi402', 'shows', 'promise', 'as', 'a', 'leading', 'compound', 'which', 'targets', 'tim3', 'for', 'cancer', 'immunotherapy']","['pd1pdl1', 'blockade', 'achieved', 'substantial', 'clinical', 'results', 'cancer', 'treatment', 'however', 'expression', 'immune', 'checkpoints', 'leads', 'resistance', 'hinders', 'efficacy', 'pd1pdl1', 'blockade', 'cell', 'immunoglobulin', 'mucin', 'domain', '3', 'tim3', 'nonredundant', 'immune', 'checkpoint', 'synergizes', 'pd1', 'mediate', 'cell', 'dysfunction', 'tumor', 'microenvironment', 'development', 'small', 'molecules', 'targeting', 'tim3', 'promising', 'strategy', 'cancer', 'immunotherapy', 'identify', 'small', 'molecule', 'inhibitors', 'targeting', 'tim3', 'docking', 'pocket', 'tim3', 'analyzed', 'molecular', 'operating', 'environment', 'moe', 'chemdiv', 'compound', 'database', 'screened', 'small', 'molecule', 'smi402', 'could', 'bind', 'tim3', 'high', 'affinity', 'prevent', 'ligation', 'ptdser', 'hmgb1', 'ceacam1', 'smi402', 'reinvigorated', 'cell', 'function', 'vitro', 'mc38bearing', 'mouse', 'model', 'smi402', 'inhibited', 'tumor', 'growth', 'increasing', 'cd8supsup', 'natural', 'killing', 'nk', 'cells', 'infiltration', 'tumor', 'site', 'well', 'restoring', 'function', 'cd8supsup', 'nk', 'cells', 'conclusions', 'small', 'molecule', 'smi402', 'shows', 'promise', 'leading', 'compound', 'targets', 'tim3', 'cancer', 'immunotherapy']","['immunoglobulin', 'mucin', 'moe', 'hmgb1', 'ceacam1']","['hmgb1', 'ceacam1']",True,"['tumor', 'cancer']"
37119975,Effectiveness of analog of Humanin in ameliorating streptozotocin-induced diabetic nephropathy in Sprague Dawley rats.,"Diabetes mellitus (DM) is associated with numerous complications, including nephropathy, which principally occur due to hyperglycemia-induced oxidative stress and inflammation. Humanin (HN), a novel peptide generated from mitochondria, has anti-oxidant and anti-inflammatory potential as observed in different disease models. However, role of HN in diabetic nephropathy (DN) has not yet been explored. This study aimed to evaluate biochemical and molecular aspects of the effects of HN analog, Humanin-glycine ([S14G]-humanin) on streptozotocin (STZ)-induced rat model of DN. Ninety Sprague Dawley (SD) rats were randomly segregated into three groups - A (control), B (disease control) and C (treatment). DM type-I was induced in group B and C via single intra-peritoneal dose of STZ (45 mg/Kg). Seven days following STZ injection, rats were deemed diabetic if their blood glucose level was > 250 mg/dL. Subsequently, diabetic rats in group C were injected with [S14G]-humanin intra-peritoneally (0.4 mg/Kg/day) for sixteen weeks. Biochemical analysis revealed that diabetic rats had markedly elevated levels of serum glucose, creatinine, BUN, TNF-α, and kidney tissue SOD. Whereas, significant decline was detected in serum insulin and albumin levels. All these parameters were significantly reversed in group C after administering [S14G]-humanin. Moreover, qRT-PCR analysis displayed up-regulation of pro-inflammatory (IL-18, IL-6, IL-1α, IL-1β, TNF-α) and down-regulation of anti-inflammatory cytokines (IL-10, IL-1RN, IL-4) in diabetic rats (group B). [S14G]-humanin treatment significantly reversed the expression of IL-18 and IL-1α, however, change in relative expression of IL-6, IL-1β, TNF-α and anti-inflammatory cytokines was insignificant (group C). Conclusively, the findings of this study depicted potential therapeutic role of [S14G]-humanin in pre-clinical rodent model of DN.",2023-04-28,diabetes mellitus dm is associated with numerous complications including nephropathy which principally occur due to hyperglycemiainduced oxidative stress and inflammation humanin hn a novel peptide generated from mitochondria has antioxidant and antiinflammatory potential as observed in different disease models however role of hn in diabetic nephropathy dn has not yet been explored this study aimed to evaluate biochemical and molecular aspects of the effects of hn analog humaninglycine s14ghumanin on streptozotocin stzinduced rat model of dn ninety sprague dawley sd rats were randomly segregated into three groups  a control b disease control and c treatment dm typei was induced in group b and c via single intraperitoneal dose of stz 45 mgkg seven days following stz injection rats were deemed diabetic if their blood glucose level was  250 mgdl subsequently diabetic rats in group c were injected with s14ghumanin intraperitoneally 04 mgkgday for sixteen weeks biochemical analysis revealed that diabetic rats had markedly elevated levels of serum glucose creatinine bun tnfα and kidney tissue sod whereas significant decline was detected in serum insulin and albumin levels all these parameters were significantly reversed in group c after administering s14ghumanin moreover qrtpcr analysis displayed upregulation of proinflammatory il18 il6 il1α il1β tnfα and downregulation of antiinflammatory cytokines il10 il1rn il4 in diabetic rats group b s14ghumanin treatment significantly reversed the expression of il18 and il1α however change in relative expression of il6 il1β tnfα and antiinflammatory cytokines was insignificant group c conclusively the findings of this study depicted potential therapeutic role of s14ghumanin in preclinical rodent model of dn,"['diabetes', 'mellitus', 'dm', 'is', 'associated', 'with', 'numerous', 'complications', 'including', 'nephropathy', 'which', 'principally', 'occur', 'due', 'to', 'hyperglycemiainduced', 'oxidative', 'stress', 'and', 'inflammation', 'humanin', 'hn', 'a', 'novel', 'peptide', 'generated', 'from', 'mitochondria', 'has', 'antioxidant', 'and', 'antiinflammatory', 'potential', 'as', 'observed', 'in', 'different', 'disease', 'models', 'however', 'role', 'of', 'hn', 'in', 'diabetic', 'nephropathy', 'dn', 'has', 'not', 'yet', 'been', 'explored', 'this', 'study', 'aimed', 'to', 'evaluate', 'biochemical', 'and', 'molecular', 'aspects', 'of', 'the', 'effects', 'of', 'hn', 'analog', 'humaninglycine', 's14ghumanin', 'on', 'streptozotocin', 'stzinduced', 'rat', 'model', 'of', 'dn', 'ninety', 'sprague', 'dawley', 'sd', 'rats', 'were', 'randomly', 'segregated', 'into', 'three', 'groups', 'a', 'control', 'b', 'disease', 'control', 'and', 'c', 'treatment', 'dm', 'typei', 'was', 'induced', 'in', 'group', 'b', 'and', 'c', 'via', 'single', 'intraperitoneal', 'dose', 'of', 'stz', '45', 'mgkg', 'seven', 'days', 'following', 'stz', 'injection', 'rats', 'were', 'deemed', 'diabetic', 'if', 'their', 'blood', 'glucose', 'level', 'was', '250', 'mgdl', 'subsequently', 'diabetic', 'rats', 'in', 'group', 'c', 'were', 'injected', 'with', 's14ghumanin', 'intraperitoneally', '04', 'mgkgday', 'for', 'sixteen', 'weeks', 'biochemical', 'analysis', 'revealed', 'that', 'diabetic', 'rats', 'had', 'markedly', 'elevated', 'levels', 'of', 'serum', 'glucose', 'creatinine', 'bun', 'tnfα', 'and', 'kidney', 'tissue', 'sod', 'whereas', 'significant', 'decline', 'was', 'detected', 'in', 'serum', 'insulin', 'and', 'albumin', 'levels', 'all', 'these', 'parameters', 'were', 'significantly', 'reversed', 'in', 'group', 'c', 'after', 'administering', 's14ghumanin', 'moreover', 'qrtpcr', 'analysis', 'displayed', 'upregulation', 'of', 'proinflammatory', 'il18', 'il6', 'il1α', 'il1β', 'tnfα', 'and', 'downregulation', 'of', 'antiinflammatory', 'cytokines', 'il10', 'il1rn', 'il4', 'in', 'diabetic', 'rats', 'group', 'b', 's14ghumanin', 'treatment', 'significantly', 'reversed', 'the', 'expression', 'of', 'il18', 'and', 'il1α', 'however', 'change', 'in', 'relative', 'expression', 'of', 'il6', 'il1β', 'tnfα', 'and', 'antiinflammatory', 'cytokines', 'was', 'insignificant', 'group', 'c', 'conclusively', 'the', 'findings', 'of', 'this', 'study', 'depicted', 'potential', 'therapeutic', 'role', 'of', 's14ghumanin', 'in', 'preclinical', 'rodent', 'model', 'of', 'dn']","['diabetes', 'mellitus', 'dm', 'associated', 'numerous', 'complications', 'including', 'nephropathy', 'principally', 'occur', 'due', 'hyperglycemiainduced', 'oxidative', 'stress', 'inflammation', 'humanin', 'hn', 'novel', 'peptide', 'generated', 'mitochondria', 'antioxidant', 'antiinflammatory', 'potential', 'observed', 'different', 'disease', 'models', 'however', 'role', 'hn', 'diabetic', 'nephropathy', 'dn', 'yet', 'explored', 'study', 'aimed', 'evaluate', 'biochemical', 'molecular', 'aspects', 'effects', 'hn', 'analog', 'humaninglycine', 's14ghumanin', 'streptozotocin', 'stzinduced', 'rat', 'model', 'dn', 'ninety', 'sprague', 'dawley', 'sd', 'rats', 'randomly', 'segregated', 'three', 'groups', 'control', 'b', 'disease', 'control', 'c', 'treatment', 'dm', 'typei', 'induced', 'group', 'b', 'c', 'via', 'single', 'intraperitoneal', 'dose', 'stz', '45', 'mgkg', 'seven', 'days', 'following', 'stz', 'injection', 'rats', 'deemed', 'diabetic', 'blood', 'glucose', 'level', '250', 'mgdl', 'subsequently', 'diabetic', 'rats', 'group', 'c', 'injected', 's14ghumanin', 'intraperitoneally', '04', 'mgkgday', 'sixteen', 'weeks', 'biochemical', 'analysis', 'revealed', 'diabetic', 'rats', 'markedly', 'elevated', 'levels', 'serum', 'glucose', 'creatinine', 'bun', 'tnfα', 'kidney', 'tissue', 'sod', 'whereas', 'significant', 'decline', 'detected', 'serum', 'insulin', 'albumin', 'levels', 'parameters', 'significantly', 'reversed', 'group', 'c', 'administering', 's14ghumanin', 'moreover', 'qrtpcr', 'analysis', 'displayed', 'upregulation', 'proinflammatory', 'il18', 'il6', 'il1α', 'il1β', 'tnfα', 'downregulation', 'antiinflammatory', 'cytokines', 'il10', 'il1rn', 'il4', 'diabetic', 'rats', 'group', 'b', 's14ghumanin', 'treatment', 'significantly', 'reversed', 'expression', 'il18', 'il1α', 'however', 'change', 'relative', 'expression', 'il6', 'il1β', 'tnfα', 'antiinflammatory', 'cytokines', 'insignificant', 'group', 'c', 'conclusively', 'findings', 'study', 'depicted', 'potential', 'therapeutic', 'role', 's14ghumanin', 'preclinical', 'rodent', 'model', 'dn']","['humanin', 'stz', 'stz', 'sod', 'insulin', 'albumin', 'il18', 'il10', 'il1rn', 'il18']",['il1rn'],True,['diabetes']
37111759,High-Throughput/High Content Imaging Screen Identifies Novel Small Molecule Inhibitors and Immunoproteasomes as Therapeutic Targets for Chordoma.,"Chordomas account for approximately 1-4% of all malignant bone tumors and 20% of primary tumors of the spinal column. It is a rare disease, with an incidence estimated to be approximately 1 per 1,000,000 people. The underlying causative mechanism of chordoma is unknown, which makes it challenging to treat. Chordomas have been linked to the T-box transcription factor T (TBXT) gene located on chromosome 6. The TBXT gene encodes a protein transcription factor TBXT, or brachyury homolog. Currently, there is no approved targeted therapy for chordoma. Here, we performed a small molecule screening to identify small chemical molecules and therapeutic targets for treating chordoma. We screened 3730 unique compounds and selected 50 potential hits. The top three hits were Ribociclib, Ingenol-3-angelate, and Duvelisib. Among the top 10 hits, we found a novel class of small molecules, including proteasomal inhibitors, as promising molecules that reduce the proliferation of human chordoma cells. Furthermore, we discovered that proteasomal subunits PSMB5 and PSMB8 are increased in human chordoma cell lines U-CH1 and U-CH2, confirming that the proteasome may serve as a molecular target whose specific inhibition may lead to better therapeutic strategies for chordoma.",2023-04-18,chordomas account for approximately 14 of all malignant bone tumors and 20 of primary tumors of the spinal column it is a rare disease with an incidence estimated to be approximately 1 per 1000000 people the underlying causative mechanism of chordoma is unknown which makes it challenging to treat chordomas have been linked to the tbox transcription factor t tbxt gene located on chromosome 6 the tbxt gene encodes a protein transcription factor tbxt or brachyury homolog currently there is no approved targeted therapy for chordoma here we performed a small molecule screening to identify small chemical molecules and therapeutic targets for treating chordoma we screened 3730 unique compounds and selected 50 potential hits the top three hits were ribociclib ingenol3angelate and duvelisib among the top 10 hits we found a novel class of small molecules including proteasomal inhibitors as promising molecules that reduce the proliferation of human chordoma cells furthermore we discovered that proteasomal subunits psmb5 and psmb8 are increased in human chordoma cell lines uch1 and uch2 confirming that the proteasome may serve as a molecular target whose specific inhibition may lead to better therapeutic strategies for chordoma,"['chordomas', 'account', 'for', 'approximately', '14', 'of', 'all', 'malignant', 'bone', 'tumors', 'and', '20', 'of', 'primary', 'tumors', 'of', 'the', 'spinal', 'column', 'it', 'is', 'a', 'rare', 'disease', 'with', 'an', 'incidence', 'estimated', 'to', 'be', 'approximately', '1', 'per', '1000000', 'people', 'the', 'underlying', 'causative', 'mechanism', 'of', 'chordoma', 'is', 'unknown', 'which', 'makes', 'it', 'challenging', 'to', 'treat', 'chordomas', 'have', 'been', 'linked', 'to', 'the', 'tbox', 'transcription', 'factor', 't', 'tbxt', 'gene', 'located', 'on', 'chromosome', '6', 'the', 'tbxt', 'gene', 'encodes', 'a', 'protein', 'transcription', 'factor', 'tbxt', 'or', 'brachyury', 'homolog', 'currently', 'there', 'is', 'no', 'approved', 'targeted', 'therapy', 'for', 'chordoma', 'here', 'we', 'performed', 'a', 'small', 'molecule', 'screening', 'to', 'identify', 'small', 'chemical', 'molecules', 'and', 'therapeutic', 'targets', 'for', 'treating', 'chordoma', 'we', 'screened', '3730', 'unique', 'compounds', 'and', 'selected', '50', 'potential', 'hits', 'the', 'top', 'three', 'hits', 'were', 'ribociclib', 'ingenol3angelate', 'and', 'duvelisib', 'among', 'the', 'top', '10', 'hits', 'we', 'found', 'a', 'novel', 'class', 'of', 'small', 'molecules', 'including', 'proteasomal', 'inhibitors', 'as', 'promising', 'molecules', 'that', 'reduce', 'the', 'proliferation', 'of', 'human', 'chordoma', 'cells', 'furthermore', 'we', 'discovered', 'that', 'proteasomal', 'subunits', 'psmb5', 'and', 'psmb8', 'are', 'increased', 'in', 'human', 'chordoma', 'cell', 'lines', 'uch1', 'and', 'uch2', 'confirming', 'that', 'the', 'proteasome', 'may', 'serve', 'as', 'a', 'molecular', 'target', 'whose', 'specific', 'inhibition', 'may', 'lead', 'to', 'better', 'therapeutic', 'strategies', 'for', 'chordoma']","['chordomas', 'account', 'approximately', '14', 'malignant', 'bone', 'tumors', '20', 'primary', 'tumors', 'spinal', 'column', 'rare', 'disease', 'incidence', 'estimated', 'approximately', '1', 'per', '1000000', 'people', 'underlying', 'causative', 'mechanism', 'chordoma', 'unknown', 'makes', 'challenging', 'treat', 'chordomas', 'linked', 'tbox', 'transcription', 'factor', 'tbxt', 'gene', 'located', 'chromosome', '6', 'tbxt', 'gene', 'encodes', 'protein', 'transcription', 'factor', 'tbxt', 'brachyury', 'homolog', 'currently', 'approved', 'targeted', 'therapy', 'chordoma', 'performed', 'small', 'molecule', 'screening', 'identify', 'small', 'chemical', 'molecules', 'therapeutic', 'targets', 'treating', 'chordoma', 'screened', '3730', 'unique', 'compounds', 'selected', '50', 'potential', 'hits', 'top', 'three', 'hits', 'ribociclib', 'ingenol3angelate', 'duvelisib', 'among', 'top', '10', 'hits', 'found', 'novel', 'class', 'small', 'molecules', 'including', 'proteasomal', 'inhibitors', 'promising', 'molecules', 'reduce', 'proliferation', 'human', 'chordoma', 'cells', 'furthermore', 'discovered', 'proteasomal', 'subunits', 'psmb5', 'psmb8', 'increased', 'human', 'chordoma', 'cell', 'lines', 'uch1', 'uch2', 'confirming', 'proteasome', 'may', 'serve', 'molecular', 'target', 'whose', 'specific', 'inhibition', 'may', 'lead', 'better', 'therapeutic', 'strategies', 'chordoma']",['brachyury'],['brachyury'],True,['tumor']
37103357,A Novel Aldisine Derivative Exhibits Potential Antitumor Effects by Targeting JAK/STAT3 Signaling.,"The JAK/STAT3 signaling pathway is aberrantly hyperactivated in many cancers, promoting cell proliferation, survival, invasiveness, and metastasis. Thus, inhibitors targeting JAK/STAT3 have enormous potential for cancer treatment. Herein, we modified <b>aldisine</b> derivatives by introducing the isothiouronium group, which can improve the antitumor activity of the compounds. We performed a high-throughput screen of 3157 compounds and identified compounds <b>11a</b>, <b>11b</b>, and <b>11c</b>, which contain a pyrrole [2,3-c] azepine structure linked to an isothiouronium group through different lengths of carbon alkyl chains and significantly inhibited JAK/STAT3 activities. Further results showed that compound <b>11c</b> exhibited the optimal antiproliferative activity and was a pan-JAKs inhibitor capable of inhibiting constitutive and IL-6-induced STAT3 activation. In addition, compound <b>11c</b> influenced STAT3 downstream gene expression (Bcl-xl, C-Myc, and Cyclin D1) and induced the apoptosis of A549 and DU145 cells in a dose-dependent manner. The antitumor effects of <b>11c</b> were further demonstrated in an in vivo subcutaneous tumor xenograft experiment with DU145 cells. Taken together, we designed and synthesized a novel small molecule JAKs inhibitor targeting the JAK/STAT3 signaling pathway, which has predicted therapeutic potential for JAK/STAT3 overactivated cancer treatment.",2023-03-29,the jakstat3 signaling pathway is aberrantly hyperactivated in many cancers promoting cell proliferation survival invasiveness and metastasis thus inhibitors targeting jakstat3 have enormous potential for cancer treatment herein we modified baldisineb derivatives by introducing the isothiouronium group which can improve the antitumor activity of the compounds we performed a highthroughput screen of 3157 compounds and identified compounds b11ab b11bb and b11cb which contain a pyrrole 23c azepine structure linked to an isothiouronium group through different lengths of carbon alkyl chains and significantly inhibited jakstat3 activities further results showed that compound b11cb exhibited the optimal antiproliferative activity and was a panjaks inhibitor capable of inhibiting constitutive and il6induced stat3 activation in addition compound b11cb influenced stat3 downstream gene expression bclxl cmyc and cyclin d1 and induced the apoptosis of a549 and du145 cells in a dosedependent manner the antitumor effects of b11cb were further demonstrated in an in vivo subcutaneous tumor xenograft experiment with du145 cells taken together we designed and synthesized a novel small molecule jaks inhibitor targeting the jakstat3 signaling pathway which has predicted therapeutic potential for jakstat3 overactivated cancer treatment,"['the', 'jakstat3', 'signaling', 'pathway', 'is', 'aberrantly', 'hyperactivated', 'in', 'many', 'cancers', 'promoting', 'cell', 'proliferation', 'survival', 'invasiveness', 'and', 'metastasis', 'thus', 'inhibitors', 'targeting', 'jakstat3', 'have', 'enormous', 'potential', 'for', 'cancer', 'treatment', 'herein', 'we', 'modified', 'baldisineb', 'derivatives', 'by', 'introducing', 'the', 'isothiouronium', 'group', 'which', 'can', 'improve', 'the', 'antitumor', 'activity', 'of', 'the', 'compounds', 'we', 'performed', 'a', 'highthroughput', 'screen', 'of', '3157', 'compounds', 'and', 'identified', 'compounds', 'b11ab', 'b11bb', 'and', 'b11cb', 'which', 'contain', 'a', 'pyrrole', '23c', 'azepine', 'structure', 'linked', 'to', 'an', 'isothiouronium', 'group', 'through', 'different', 'lengths', 'of', 'carbon', 'alkyl', 'chains', 'and', 'significantly', 'inhibited', 'jakstat3', 'activities', 'further', 'results', 'showed', 'that', 'compound', 'b11cb', 'exhibited', 'the', 'optimal', 'antiproliferative', 'activity', 'and', 'was', 'a', 'panjaks', 'inhibitor', 'capable', 'of', 'inhibiting', 'constitutive', 'and', 'il6induced', 'stat3', 'activation', 'in', 'addition', 'compound', 'b11cb', 'influenced', 'stat3', 'downstream', 'gene', 'expression', 'bclxl', 'cmyc', 'and', 'cyclin', 'd1', 'and', 'induced', 'the', 'apoptosis', 'of', 'a549', 'and', 'du145', 'cells', 'in', 'a', 'dosedependent', 'manner', 'the', 'antitumor', 'effects', 'of', 'b11cb', 'were', 'further', 'demonstrated', 'in', 'an', 'in', 'vivo', 'subcutaneous', 'tumor', 'xenograft', 'experiment', 'with', 'du145', 'cells', 'taken', 'together', 'we', 'designed', 'and', 'synthesized', 'a', 'novel', 'small', 'molecule', 'jaks', 'inhibitor', 'targeting', 'the', 'jakstat3', 'signaling', 'pathway', 'which', 'has', 'predicted', 'therapeutic', 'potential', 'for', 'jakstat3', 'overactivated', 'cancer', 'treatment']","['jakstat3', 'signaling', 'pathway', 'aberrantly', 'hyperactivated', 'many', 'cancers', 'promoting', 'cell', 'proliferation', 'survival', 'invasiveness', 'metastasis', 'thus', 'inhibitors', 'targeting', 'jakstat3', 'enormous', 'potential', 'cancer', 'treatment', 'herein', 'modified', 'baldisineb', 'derivatives', 'introducing', 'isothiouronium', 'group', 'improve', 'antitumor', 'activity', 'compounds', 'performed', 'highthroughput', 'screen', '3157', 'compounds', 'identified', 'compounds', 'b11ab', 'b11bb', 'b11cb', 'contain', 'pyrrole', '23c', 'azepine', 'structure', 'linked', 'isothiouronium', 'group', 'different', 'lengths', 'carbon', 'alkyl', 'chains', 'significantly', 'inhibited', 'jakstat3', 'activities', 'results', 'showed', 'compound', 'b11cb', 'exhibited', 'optimal', 'antiproliferative', 'activity', 'panjaks', 'inhibitor', 'capable', 'inhibiting', 'constitutive', 'il6induced', 'stat3', 'activation', 'addition', 'compound', 'b11cb', 'influenced', 'stat3', 'downstream', 'gene', 'expression', 'bclxl', 'cmyc', 'cyclin', 'd1', 'induced', 'apoptosis', 'a549', 'du145', 'cells', 'dosedependent', 'manner', 'antitumor', 'effects', 'b11cb', 'demonstrated', 'vivo', 'subcutaneous', 'tumor', 'xenograft', 'experiment', 'du145', 'cells', 'taken', 'together', 'designed', 'synthesized', 'novel', 'small', 'molecule', 'jaks', 'inhibitor', 'targeting', 'jakstat3', 'signaling', 'pathway', 'predicted', 'therapeutic', 'potential', 'jakstat3', 'overactivated', 'cancer', 'treatment']","['stat3', 'stat3', 'bclxl', 'cyclin']",['bclxl'],True,"['tumor', 'cancer']"
37067993,"TACH101, a first-in-class pan-inhibitor of KDM4 histone demethylase.","Histone lysine demethylase 4 (KDM4) is an epigenetic regulator that facilitates the transition between transcriptionally silent and active chromatin states by catalyzing the removal of methyl groups on histones H3K9, H3K36, and H1.4K26. KDM4 overamplification or dysregulation has been reported in various cancers and has been shown to drive key processes linked to tumorigenesis, such as replicative immortality, evasion of apoptosis, metastasis, DNA repair deficiency, and genomic instability. KDM4 also plays a role in epigenetic regulation of cancer stem cell renewal and has been linked to more aggressive disease and poorer clinical outcomes. The KDM4 family is composed of four main isoforms (KDM4A-D) that demonstrate functional redundancy and cross-activity; thus, selective inhibition of one isoform appears to be ineffective and pan-inhibition targeting multiple KDM4 isoforms is required. Here, we describe TACH101, a novel, small-molecule pan-inhibitor of KDM4 that selectively targets KDM4A-D with no effect on other KDM families. TACH101 demonstrated potent antiproliferative activity in cancer cell lines and organoid models derived from various histologies, including colorectal, esophageal, gastric, breast, pancreatic, and hematological malignancies. In vivo , potent inhibition of KDM4 led to efficient tumor growth inhibition and regression in several xenograft models. A reduction in the population of tumor-initiating cells was observed following TACH101 treatment. Overall, these observations demonstrate the broad applicability of TACH101 as a potential anticancer agent and support its advancement into clinical trials.",2023-03-24,histone lysine demethylase 4 kdm4 is an epigenetic regulator that facilitates the transition between transcriptionally silent and active chromatin states by catalyzing the removal of methyl groups on histones h3k9 h3k36 and h14k26 kdm4 overamplification or dysregulation has been reported in various cancers and has been shown to drive key processes linked to tumorigenesis such as replicative immortality evasion of apoptosis metastasis dna repair deficiency and genomic instability kdm4 also plays a role in epigenetic regulation of cancer stem cell renewal and has been linked to more aggressive disease and poorer clinical outcomes the kdm4 family is composed of four main isoforms kdm4ad that demonstrate functional redundancy and crossactivity thus selective inhibition of one isoform appears to be ineffective and paninhibition targeting multiple kdm4 isoforms is required here we describe tach101 a novel smallmolecule paninhibitor of kdm4 that selectively targets kdm4ad with no effect on other kdm families tach101 demonstrated potent antiproliferative activity in cancer cell lines and organoid models derived from various histologies including colorectal esophageal gastric breast pancreatic and hematological malignancies in vivo  potent inhibition of kdm4 led to efficient tumor growth inhibition and regression in several xenograft models a reduction in the population of tumorinitiating cells was observed following tach101 treatment overall these observations demonstrate the broad applicability of tach101 as a potential anticancer agent and support its advancement into clinical trials,"['histone', 'lysine', 'demethylase', '4', 'kdm4', 'is', 'an', 'epigenetic', 'regulator', 'that', 'facilitates', 'the', 'transition', 'between', 'transcriptionally', 'silent', 'and', 'active', 'chromatin', 'states', 'by', 'catalyzing', 'the', 'removal', 'of', 'methyl', 'groups', 'on', 'histones', 'h3k9', 'h3k36', 'and', 'h14k26', 'kdm4', 'overamplification', 'or', 'dysregulation', 'has', 'been', 'reported', 'in', 'various', 'cancers', 'and', 'has', 'been', 'shown', 'to', 'drive', 'key', 'processes', 'linked', 'to', 'tumorigenesis', 'such', 'as', 'replicative', 'immortality', 'evasion', 'of', 'apoptosis', 'metastasis', 'dna', 'repair', 'deficiency', 'and', 'genomic', 'instability', 'kdm4', 'also', 'plays', 'a', 'role', 'in', 'epigenetic', 'regulation', 'of', 'cancer', 'stem', 'cell', 'renewal', 'and', 'has', 'been', 'linked', 'to', 'more', 'aggressive', 'disease', 'and', 'poorer', 'clinical', 'outcomes', 'the', 'kdm4', 'family', 'is', 'composed', 'of', 'four', 'main', 'isoforms', 'kdm4ad', 'that', 'demonstrate', 'functional', 'redundancy', 'and', 'crossactivity', 'thus', 'selective', 'inhibition', 'of', 'one', 'isoform', 'appears', 'to', 'be', 'ineffective', 'and', 'paninhibition', 'targeting', 'multiple', 'kdm4', 'isoforms', 'is', 'required', 'here', 'we', 'describe', 'tach101', 'a', 'novel', 'smallmolecule', 'paninhibitor', 'of', 'kdm4', 'that', 'selectively', 'targets', 'kdm4ad', 'with', 'no', 'effect', 'on', 'other', 'kdm', 'families', 'tach101', 'demonstrated', 'potent', 'antiproliferative', 'activity', 'in', 'cancer', 'cell', 'lines', 'and', 'organoid', 'models', 'derived', 'from', 'various', 'histologies', 'including', 'colorectal', 'esophageal', 'gastric', 'breast', 'pancreatic', 'and', 'hematological', 'malignancies', 'in', 'vivo', 'potent', 'inhibition', 'of', 'kdm4', 'led', 'to', 'efficient', 'tumor', 'growth', 'inhibition', 'and', 'regression', 'in', 'several', 'xenograft', 'models', 'a', 'reduction', 'in', 'the', 'population', 'of', 'tumorinitiating', 'cells', 'was', 'observed', 'following', 'tach101', 'treatment', 'overall', 'these', 'observations', 'demonstrate', 'the', 'broad', 'applicability', 'of', 'tach101', 'as', 'a', 'potential', 'anticancer', 'agent', 'and', 'support', 'its', 'advancement', 'into', 'clinical', 'trials']","['histone', 'lysine', 'demethylase', '4', 'kdm4', 'epigenetic', 'regulator', 'facilitates', 'transition', 'transcriptionally', 'silent', 'active', 'chromatin', 'states', 'catalyzing', 'removal', 'methyl', 'groups', 'histones', 'h3k9', 'h3k36', 'h14k26', 'kdm4', 'overamplification', 'dysregulation', 'reported', 'various', 'cancers', 'shown', 'drive', 'key', 'processes', 'linked', 'tumorigenesis', 'replicative', 'immortality', 'evasion', 'apoptosis', 'metastasis', 'dna', 'repair', 'deficiency', 'genomic', 'instability', 'kdm4', 'also', 'plays', 'role', 'epigenetic', 'regulation', 'cancer', 'stem', 'cell', 'renewal', 'linked', 'aggressive', 'disease', 'poorer', 'clinical', 'outcomes', 'kdm4', 'family', 'composed', 'four', 'main', 'isoforms', 'kdm4ad', 'demonstrate', 'functional', 'redundancy', 'crossactivity', 'thus', 'selective', 'inhibition', 'one', 'isoform', 'appears', 'ineffective', 'paninhibition', 'targeting', 'multiple', 'kdm4', 'isoforms', 'required', 'describe', 'tach101', 'novel', 'smallmolecule', 'paninhibitor', 'kdm4', 'selectively', 'targets', 'kdm4ad', 'effect', 'kdm', 'families', 'tach101', 'demonstrated', 'potent', 'antiproliferative', 'activity', 'cancer', 'cell', 'lines', 'organoid', 'models', 'derived', 'various', 'histologies', 'including', 'colorectal', 'esophageal', 'gastric', 'breast', 'pancreatic', 'hematological', 'malignancies', 'vivo', 'potent', 'inhibition', 'kdm4', 'led', 'efficient', 'tumor', 'growth', 'inhibition', 'regression', 'several', 'xenograft', 'models', 'reduction', 'population', 'tumorinitiating', 'cells', 'observed', 'following', 'tach101', 'treatment', 'overall', 'observations', 'demonstrate', 'broad', 'applicability', 'tach101', 'potential', 'anticancer', 'agent', 'support', 'advancement', 'clinical', 'trials']","['histone', 'paninhibitor']",['paninhibitor'],True,"['tumor', 'cancer']"
37044298,A novel peptide isolated from Aphonopelma chalcodes tarantula venom with benefits on pancreatic islet function and appetite control.,"Proof-of-concept for therapeutic application of venom-derived compounds in diabetes is exemplified by the incretin mimetic, exenatide, originally extracted from the saliva of the venomous Heloderma suspectum lizard. In this regard, we have isolated and sequenced a novel 28 amino acid peptide named Δ-theraphotoxin-Ac1 (Δ-TRTX-AC1) from venom of the Mexican Blond tarantula spider Aphonopelma chalcodes, with potential therapeutic benefits for diabetes. Following confirmation of the structure and safety profile of the synthetic peptide, assessment of enzymatic stability and effects of Δ-TRTX-AC1 on in vitro beta-cell function were studied, alongside potential mechanisms. Glucose homeostatic and satiety actions of Δ-TRTX-AC1 alone, and in combination with exenatide, were then assessed in C57BL/6 mice. Synthetic Δ-TRTX-AC1 was shown to adopt a characteristic inhibitor cysteine knot (ICK)-like structure and was non-toxic to beta-cells. Δ-TRTX-AC1 evoked glucose-dependent insulin secretion from BRIN BD11 cells with bioactivity confirmed in murine islets. Insulin secretory potency was established to be dependent on K<sub>ATP</sub> and Ca<sup>2+</sup> channel beta-cell signalling. In addition, Δ-TRTX-AC1 enhanced beta-cell proliferation and provided significant protection against cytokine-induced apoptosis. When injected co-jointly with glucose in mice at a dose of 250 nmol/kg, Δ-TRTX-AC1 decreased blood-glucose levels and evoked a significant satiating effect. Moreover, whilst Δ-TRTX-AC1 did not enhance exenatide induced benefits on glucose homeostasis, the peptide significantly augmented exenatide mediated suppression of appetite. Together these data highlight the therapeutic potential of tarantula spider venom-derived peptides, such as Δ-TRTX-Ac1, for diabetes and related obesity.",2023-04-11,proofofconcept for therapeutic application of venomderived compounds in diabetes is exemplified by the incretin mimetic exenatide originally extracted from the saliva of the venomous heloderma suspectum lizard in this regard we have isolated and sequenced a novel 28 amino acid peptide named δtheraphotoxinac1 δtrtxac1 from venom of the mexican blond tarantula spider aphonopelma chalcodes with potential therapeutic benefits for diabetes following confirmation of the structure and safety profile of the synthetic peptide assessment of enzymatic stability and effects of δtrtxac1 on in vitro betacell function were studied alongside potential mechanisms glucose homeostatic and satiety actions of δtrtxac1 alone and in combination with exenatide were then assessed in c57bl6 mice synthetic δtrtxac1 was shown to adopt a characteristic inhibitor cysteine knot icklike structure and was nontoxic to betacells δtrtxac1 evoked glucosedependent insulin secretion from brin bd11 cells with bioactivity confirmed in murine islets insulin secretory potency was established to be dependent on ksubatpsub and casup2sup channel betacell signalling in addition δtrtxac1 enhanced betacell proliferation and provided significant protection against cytokineinduced apoptosis when injected cojointly with glucose in mice at a dose of 250 nmolkg δtrtxac1 decreased bloodglucose levels and evoked a significant satiating effect moreover whilst δtrtxac1 did not enhance exenatide induced benefits on glucose homeostasis the peptide significantly augmented exenatide mediated suppression of appetite together these data highlight the therapeutic potential of tarantula spider venomderived peptides such as δtrtxac1 for diabetes and related obesity,"['proofofconcept', 'for', 'therapeutic', 'application', 'of', 'venomderived', 'compounds', 'in', 'diabetes', 'is', 'exemplified', 'by', 'the', 'incretin', 'mimetic', 'exenatide', 'originally', 'extracted', 'from', 'the', 'saliva', 'of', 'the', 'venomous', 'heloderma', 'suspectum', 'lizard', 'in', 'this', 'regard', 'we', 'have', 'isolated', 'and', 'sequenced', 'a', 'novel', '28', 'amino', 'acid', 'peptide', 'named', 'δtheraphotoxinac1', 'δtrtxac1', 'from', 'venom', 'of', 'the', 'mexican', 'blond', 'tarantula', 'spider', 'aphonopelma', 'chalcodes', 'with', 'potential', 'therapeutic', 'benefits', 'for', 'diabetes', 'following', 'confirmation', 'of', 'the', 'structure', 'and', 'safety', 'profile', 'of', 'the', 'synthetic', 'peptide', 'assessment', 'of', 'enzymatic', 'stability', 'and', 'effects', 'of', 'δtrtxac1', 'on', 'in', 'vitro', 'betacell', 'function', 'were', 'studied', 'alongside', 'potential', 'mechanisms', 'glucose', 'homeostatic', 'and', 'satiety', 'actions', 'of', 'δtrtxac1', 'alone', 'and', 'in', 'combination', 'with', 'exenatide', 'were', 'then', 'assessed', 'in', 'c57bl6', 'mice', 'synthetic', 'δtrtxac1', 'was', 'shown', 'to', 'adopt', 'a', 'characteristic', 'inhibitor', 'cysteine', 'knot', 'icklike', 'structure', 'and', 'was', 'nontoxic', 'to', 'betacells', 'δtrtxac1', 'evoked', 'glucosedependent', 'insulin', 'secretion', 'from', 'brin', 'bd11', 'cells', 'with', 'bioactivity', 'confirmed', 'in', 'murine', 'islets', 'insulin', 'secretory', 'potency', 'was', 'established', 'to', 'be', 'dependent', 'on', 'ksubatpsub', 'and', 'casup2sup', 'channel', 'betacell', 'signalling', 'in', 'addition', 'δtrtxac1', 'enhanced', 'betacell', 'proliferation', 'and', 'provided', 'significant', 'protection', 'against', 'cytokineinduced', 'apoptosis', 'when', 'injected', 'cojointly', 'with', 'glucose', 'in', 'mice', 'at', 'a', 'dose', 'of', '250', 'nmolkg', 'δtrtxac1', 'decreased', 'bloodglucose', 'levels', 'and', 'evoked', 'a', 'significant', 'satiating', 'effect', 'moreover', 'whilst', 'δtrtxac1', 'did', 'not', 'enhance', 'exenatide', 'induced', 'benefits', 'on', 'glucose', 'homeostasis', 'the', 'peptide', 'significantly', 'augmented', 'exenatide', 'mediated', 'suppression', 'of', 'appetite', 'together', 'these', 'data', 'highlight', 'the', 'therapeutic', 'potential', 'of', 'tarantula', 'spider', 'venomderived', 'peptides', 'such', 'as', 'δtrtxac1', 'for', 'diabetes', 'and', 'related', 'obesity']","['proofofconcept', 'therapeutic', 'application', 'venomderived', 'compounds', 'diabetes', 'exemplified', 'incretin', 'mimetic', 'exenatide', 'originally', 'extracted', 'saliva', 'venomous', 'heloderma', 'suspectum', 'lizard', 'regard', 'isolated', 'sequenced', 'novel', '28', 'amino', 'acid', 'peptide', 'named', 'δtheraphotoxinac1', 'δtrtxac1', 'venom', 'mexican', 'blond', 'tarantula', 'spider', 'aphonopelma', 'chalcodes', 'potential', 'therapeutic', 'benefits', 'diabetes', 'following', 'confirmation', 'structure', 'safety', 'profile', 'synthetic', 'peptide', 'assessment', 'enzymatic', 'stability', 'effects', 'δtrtxac1', 'vitro', 'betacell', 'function', 'studied', 'alongside', 'potential', 'mechanisms', 'glucose', 'homeostatic', 'satiety', 'actions', 'δtrtxac1', 'alone', 'combination', 'exenatide', 'assessed', 'c57bl6', 'mice', 'synthetic', 'δtrtxac1', 'shown', 'adopt', 'characteristic', 'inhibitor', 'cysteine', 'knot', 'icklike', 'structure', 'nontoxic', 'betacells', 'δtrtxac1', 'evoked', 'glucosedependent', 'insulin', 'secretion', 'brin', 'bd11', 'cells', 'bioactivity', 'confirmed', 'murine', 'islets', 'insulin', 'secretory', 'potency', 'established', 'dependent', 'ksubatpsub', 'casup2sup', 'channel', 'betacell', 'signalling', 'addition', 'δtrtxac1', 'enhanced', 'betacell', 'proliferation', 'provided', 'significant', 'protection', 'cytokineinduced', 'apoptosis', 'injected', 'cojointly', 'glucose', 'mice', 'dose', '250', 'nmolkg', 'δtrtxac1', 'decreased', 'bloodglucose', 'levels', 'evoked', 'significant', 'satiating', 'effect', 'moreover', 'whilst', 'δtrtxac1', 'enhance', 'exenatide', 'induced', 'benefits', 'glucose', 'homeostasis', 'peptide', 'significantly', 'augmented', 'exenatide', 'mediated', 'suppression', 'appetite', 'together', 'data', 'highlight', 'therapeutic', 'potential', 'tarantula', 'spider', 'venomderived', 'peptides', 'δtrtxac1', 'diabetes', 'related', 'obesity']","['incretin', 'δtheraphotoxinac1', 'insulin', 'insulin']","['incretin', 'δtheraphotoxinac1']",True,['diabetes']
36927289,Structure-based small inhibitors search combined with molecular dynamics driven energies for human programmed cell death-1 (PD-1) protein.,"Human immune system is specialized in distinguishing normal cells from foreign particles mainly through proteins expressed on immune cells called 'checkpoints'. Immune checkpoints work as a switch to activate and deactivate immune responses. T cells express one of the immune checkpoint, human programmed cell death-1 (PD-1), which normally operates as an off-switch function to protect the normal cell from T-cell attack. Binding of PD-1 to its ligand, the programmed cell death ligand (PD-L1/2) expressed on myeloid/cancer cells, induce downstream inhibitory signals, leading to tumor immune evasion. Targeting PD-1 or PD-L1 can boost the immune response against cancer cells. To design novel small molecule inhibitors for the PD-1, <i>in silico</i> structure-based screening on pharmacophoric points and molecular docking were performed. Based on the docking score and significant binding interaction with the crucial residues of PD-1 (Thr59, Glu61, Ser62, Glu84, Arg86 and Ala132), compounds were selected from the ZINC20 database, and their dynamic behavior and conformational stability were examined through molecular dynamic simulations. Besides, the Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) method was used to calculate the binding strength of each selected inhibitor complexed with PD-1. The binding energy calculations revealed that these selected inhibitors show a considerable affinity for PD-1. The selected novel inhibitors exhibit excellent drug-like and pharmacokinetic properties (absorption, distribution, metabolism, excretion and toxicity). In conclusion, the identified novel compounds (ZINC1443480030, ZINC1002854123, ZINC988238128, ZINC1481242350, ZINC1001739421, ZINC1220816434 and ZINC1167786692) from the current study can be validated <i>in-vitro</i> as potential PD-1 inhibitors and for discovery of novel drugs against PD-1 in the future.Communicated by Ramaswamy H. Sarma.",2023-03-16,human immune system is specialized in distinguishing normal cells from foreign particles mainly through proteins expressed on immune cells called checkpoints immune checkpoints work as a switch to activate and deactivate immune responses t cells express one of the immune checkpoint human programmed cell death1 pd1 which normally operates as an offswitch function to protect the normal cell from tcell attack binding of pd1 to its ligand the programmed cell death ligand pdl12 expressed on myeloidcancer cells induce downstream inhibitory signals leading to tumor immune evasion targeting pd1 or pdl1 can boost the immune response against cancer cells to design novel small molecule inhibitors for the pd1 iin silicoi structurebased screening on pharmacophoric points and molecular docking were performed based on the docking score and significant binding interaction with the crucial residues of pd1 thr59 glu61 ser62 glu84 arg86 and ala132 compounds were selected from the zinc20 database and their dynamic behavior and conformational stability were examined through molecular dynamic simulations besides the molecular mechanicsgeneralized born surface area mmgbsa method was used to calculate the binding strength of each selected inhibitor complexed with pd1 the binding energy calculations revealed that these selected inhibitors show a considerable affinity for pd1 the selected novel inhibitors exhibit excellent druglike and pharmacokinetic properties absorption distribution metabolism excretion and toxicity in conclusion the identified novel compounds zinc1443480030 zinc1002854123 zinc988238128 zinc1481242350 zinc1001739421 zinc1220816434 and zinc1167786692 from the current study can be validated iinvitroi as potential pd1 inhibitors and for discovery of novel drugs against pd1 in the futurecommunicated by ramaswamy h sarma,"['human', 'immune', 'system', 'is', 'specialized', 'in', 'distinguishing', 'normal', 'cells', 'from', 'foreign', 'particles', 'mainly', 'through', 'proteins', 'expressed', 'on', 'immune', 'cells', 'called', 'checkpoints', 'immune', 'checkpoints', 'work', 'as', 'a', 'switch', 'to', 'activate', 'and', 'deactivate', 'immune', 'responses', 't', 'cells', 'express', 'one', 'of', 'the', 'immune', 'checkpoint', 'human', 'programmed', 'cell', 'death1', 'pd1', 'which', 'normally', 'operates', 'as', 'an', 'offswitch', 'function', 'to', 'protect', 'the', 'normal', 'cell', 'from', 'tcell', 'attack', 'binding', 'of', 'pd1', 'to', 'its', 'ligand', 'the', 'programmed', 'cell', 'death', 'ligand', 'pdl12', 'expressed', 'on', 'myeloidcancer', 'cells', 'induce', 'downstream', 'inhibitory', 'signals', 'leading', 'to', 'tumor', 'immune', 'evasion', 'targeting', 'pd1', 'or', 'pdl1', 'can', 'boost', 'the', 'immune', 'response', 'against', 'cancer', 'cells', 'to', 'design', 'novel', 'small', 'molecule', 'inhibitors', 'for', 'the', 'pd1', 'iin', 'silicoi', 'structurebased', 'screening', 'on', 'pharmacophoric', 'points', 'and', 'molecular', 'docking', 'were', 'performed', 'based', 'on', 'the', 'docking', 'score', 'and', 'significant', 'binding', 'interaction', 'with', 'the', 'crucial', 'residues', 'of', 'pd1', 'thr59', 'glu61', 'ser62', 'glu84', 'arg86', 'and', 'ala132', 'compounds', 'were', 'selected', 'from', 'the', 'zinc20', 'database', 'and', 'their', 'dynamic', 'behavior', 'and', 'conformational', 'stability', 'were', 'examined', 'through', 'molecular', 'dynamic', 'simulations', 'besides', 'the', 'molecular', 'mechanicsgeneralized', 'born', 'surface', 'area', 'mmgbsa', 'method', 'was', 'used', 'to', 'calculate', 'the', 'binding', 'strength', 'of', 'each', 'selected', 'inhibitor', 'complexed', 'with', 'pd1', 'the', 'binding', 'energy', 'calculations', 'revealed', 'that', 'these', 'selected', 'inhibitors', 'show', 'a', 'considerable', 'affinity', 'for', 'pd1', 'the', 'selected', 'novel', 'inhibitors', 'exhibit', 'excellent', 'druglike', 'and', 'pharmacokinetic', 'properties', 'absorption', 'distribution', 'metabolism', 'excretion', 'and', 'toxicity', 'in', 'conclusion', 'the', 'identified', 'novel', 'compounds', 'zinc1443480030', 'zinc1002854123', 'zinc988238128', 'zinc1481242350', 'zinc1001739421', 'zinc1220816434', 'and', 'zinc1167786692', 'from', 'the', 'current', 'study', 'can', 'be', 'validated', 'iinvitroi', 'as', 'potential', 'pd1', 'inhibitors', 'and', 'for', 'discovery', 'of', 'novel', 'drugs', 'against', 'pd1', 'in', 'the', 'futurecommunicated', 'by', 'ramaswamy', 'h', 'sarma']","['human', 'immune', 'system', 'specialized', 'distinguishing', 'normal', 'cells', 'foreign', 'particles', 'mainly', 'proteins', 'expressed', 'immune', 'cells', 'called', 'checkpoints', 'immune', 'checkpoints', 'work', 'switch', 'activate', 'deactivate', 'immune', 'responses', 'cells', 'express', 'one', 'immune', 'checkpoint', 'human', 'programmed', 'cell', 'death1', 'pd1', 'normally', 'operates', 'offswitch', 'function', 'protect', 'normal', 'cell', 'tcell', 'attack', 'binding', 'pd1', 'ligand', 'programmed', 'cell', 'death', 'ligand', 'pdl12', 'expressed', 'myeloidcancer', 'cells', 'induce', 'downstream', 'inhibitory', 'signals', 'leading', 'tumor', 'immune', 'evasion', 'targeting', 'pd1', 'pdl1', 'boost', 'immune', 'response', 'cancer', 'cells', 'design', 'novel', 'small', 'molecule', 'inhibitors', 'pd1', 'iin', 'silicoi', 'structurebased', 'screening', 'pharmacophoric', 'points', 'molecular', 'docking', 'performed', 'based', 'docking', 'score', 'significant', 'binding', 'interaction', 'crucial', 'residues', 'pd1', 'thr59', 'glu61', 'ser62', 'glu84', 'arg86', 'ala132', 'compounds', 'selected', 'zinc20', 'database', 'dynamic', 'behavior', 'conformational', 'stability', 'examined', 'molecular', 'dynamic', 'simulations', 'besides', 'molecular', 'mechanicsgeneralized', 'born', 'surface', 'area', 'mmgbsa', 'method', 'used', 'calculate', 'binding', 'strength', 'selected', 'inhibitor', 'complexed', 'pd1', 'binding', 'energy', 'calculations', 'revealed', 'selected', 'inhibitors', 'show', 'considerable', 'affinity', 'pd1', 'selected', 'novel', 'inhibitors', 'exhibit', 'excellent', 'druglike', 'pharmacokinetic', 'properties', 'absorption', 'distribution', 'metabolism', 'excretion', 'toxicity', 'conclusion', 'identified', 'novel', 'compounds', 'zinc1443480030', 'zinc1002854123', 'zinc988238128', 'zinc1481242350', 'zinc1001739421', 'zinc1220816434', 'zinc1167786692', 'current', 'study', 'validated', 'iinvitroi', 'potential', 'pd1', 'inhibitors', 'discovery', 'novel', 'drugs', 'pd1', 'futurecommunicated', 'ramaswamy', 'h', 'sarma']","['glu61', 'ser62']","['glu61', 'ser62']",True,"['tumor', 'cancer']"
36893941,"Chelerythrine, a novel small molecule targeting IL-2, inhibits melanoma progression by blocking the interaction between IL-2 and its receptor.","In this study, we investigated the inhibition of IL-2 activity and anticancer efficacy of chelerythrine (CHE), a natural small molecule that targets IL-2 and inhibits CD25 binding, and elucidated the mechanism underlying the action of CHE on immune cells.",2023-03-08,in this study we investigated the inhibition of il2 activity and anticancer efficacy of chelerythrine che a natural small molecule that targets il2 and inhibits cd25 binding and elucidated the mechanism underlying the action of che on immune cells,"['in', 'this', 'study', 'we', 'investigated', 'the', 'inhibition', 'of', 'il2', 'activity', 'and', 'anticancer', 'efficacy', 'of', 'chelerythrine', 'che', 'a', 'natural', 'small', 'molecule', 'that', 'targets', 'il2', 'and', 'inhibits', 'cd25', 'binding', 'and', 'elucidated', 'the', 'mechanism', 'underlying', 'the', 'action', 'of', 'che', 'on', 'immune', 'cells']","['study', 'investigated', 'inhibition', 'il2', 'activity', 'anticancer', 'efficacy', 'chelerythrine', 'che', 'natural', 'small', 'molecule', 'targets', 'il2', 'inhibits', 'cd25', 'binding', 'elucidated', 'mechanism', 'underlying', 'action', 'che', 'immune', 'cells']",['cd25'],['cd25'],True,['cancer']
36892036,In silico and in vitro analyses of a novel FoxO1 agonist reducing Aβ levels via downregulation of BACE1.,"FoxO1 is an important target in the treatment of Alzheimer's disease (AD). However, FoxO1-specific agonists and their effects on AD have not yet been reported. This study aimed to identify small molecules that upregulate the activity of FoxO1 to attenuate the symptoms of AD.",2023-03-09,foxo1 is an important target in the treatment of alzheimers disease ad however foxo1specific agonists and their effects on ad have not yet been reported this study aimed to identify small molecules that upregulate the activity of foxo1 to attenuate the symptoms of ad,"['foxo1', 'is', 'an', 'important', 'target', 'in', 'the', 'treatment', 'of', 'alzheimers', 'disease', 'ad', 'however', 'foxo1specific', 'agonists', 'and', 'their', 'effects', 'on', 'ad', 'have', 'not', 'yet', 'been', 'reported', 'this', 'study', 'aimed', 'to', 'identify', 'small', 'molecules', 'that', 'upregulate', 'the', 'activity', 'of', 'foxo1', 'to', 'attenuate', 'the', 'symptoms', 'of', 'ad']","['foxo1', 'important', 'target', 'treatment', 'alzheimers', 'disease', 'ad', 'however', 'foxo1specific', 'agonists', 'effects', 'ad', 'yet', 'reported', 'study', 'aimed', 'identify', 'small', 'molecules', 'upregulate', 'activity', 'foxo1', 'attenuate', 'symptoms', 'ad']","['foxo1', 'foxo1']","['foxo1', 'foxo1']",True,['alzheimer']
36891498,Identification of a novel small-molecule inhibitor of miR-29b attenuates muscle atrophy.,"Muscle atrophy is debilitating and can be induced by several stressors. Unfortunately, there are no effective pharmacological treatment until now. MicroRNA (miR)-29b is an important target that we identified to be commonly involved in multiple types of muscle atrophy. Although sequence-specific inhibition of miR-29b has been developed, in this study, we report a novel small-molecule miR-29b inhibitor that targets miR-29b hairpin precursor (pre-miR-29b) (Targapremir-29b-066 [TGP-29b-066]) considering both its three-dimensional structure and the thermodynamics of interaction between pre-miR-29b and the small molecule. This novel small-molecule inhibitor has been demonstrated to attenuate muscle atrophy induced by angiotensin II (Ang II), dexamethasone (Dex), and tumor necrosis factor α (TNF-α) in C2C12 myotubes, as evidenced by increase in the diameter of myotube and decrease in the expression of Atrogin-1 and MuRF-1. Moreover, it can also attenuate Ang II-induced muscle atrophy in mice, as evidenced by a similar increase in the diameter of myotube, reduced Atrogin-1 and MuRF-1 expression, AKT-FOXO3A-mTOR signaling activation, and decreased apoptosis and autophagy. In summary, we experimentally identified and demonstrated a novel small-molecule inhibitor of miR-29b that could act as a potential therapeutic agent for muscle atrophy.",2023-02-04,muscle atrophy is debilitating and can be induced by several stressors unfortunately there are no effective pharmacological treatment until now microrna mir29b is an important target that we identified to be commonly involved in multiple types of muscle atrophy although sequencespecific inhibition of mir29b has been developed in this study we report a novel smallmolecule mir29b inhibitor that targets mir29b hairpin precursor premir29b targapremir29b066 tgp29b066 considering both its threedimensional structure and the thermodynamics of interaction between premir29b and the small molecule this novel smallmolecule inhibitor has been demonstrated to attenuate muscle atrophy induced by angiotensin ii ang ii dexamethasone dex and tumor necrosis factor α tnfα in c2c12 myotubes as evidenced by increase in the diameter of myotube and decrease in the expression of atrogin1 and murf1 moreover it can also attenuate ang iiinduced muscle atrophy in mice as evidenced by a similar increase in the diameter of myotube reduced atrogin1 and murf1 expression aktfoxo3amtor signaling activation and decreased apoptosis and autophagy in summary we experimentally identified and demonstrated a novel smallmolecule inhibitor of mir29b that could act as a potential therapeutic agent for muscle atrophy,"['muscle', 'atrophy', 'is', 'debilitating', 'and', 'can', 'be', 'induced', 'by', 'several', 'stressors', 'unfortunately', 'there', 'are', 'no', 'effective', 'pharmacological', 'treatment', 'until', 'now', 'microrna', 'mir29b', 'is', 'an', 'important', 'target', 'that', 'we', 'identified', 'to', 'be', 'commonly', 'involved', 'in', 'multiple', 'types', 'of', 'muscle', 'atrophy', 'although', 'sequencespecific', 'inhibition', 'of', 'mir29b', 'has', 'been', 'developed', 'in', 'this', 'study', 'we', 'report', 'a', 'novel', 'smallmolecule', 'mir29b', 'inhibitor', 'that', 'targets', 'mir29b', 'hairpin', 'precursor', 'premir29b', 'targapremir29b066', 'tgp29b066', 'considering', 'both', 'its', 'threedimensional', 'structure', 'and', 'the', 'thermodynamics', 'of', 'interaction', 'between', 'premir29b', 'and', 'the', 'small', 'molecule', 'this', 'novel', 'smallmolecule', 'inhibitor', 'has', 'been', 'demonstrated', 'to', 'attenuate', 'muscle', 'atrophy', 'induced', 'by', 'angiotensin', 'ii', 'ang', 'ii', 'dexamethasone', 'dex', 'and', 'tumor', 'necrosis', 'factor', 'α', 'tnfα', 'in', 'c2c12', 'myotubes', 'as', 'evidenced', 'by', 'increase', 'in', 'the', 'diameter', 'of', 'myotube', 'and', 'decrease', 'in', 'the', 'expression', 'of', 'atrogin1', 'and', 'murf1', 'moreover', 'it', 'can', 'also', 'attenuate', 'ang', 'iiinduced', 'muscle', 'atrophy', 'in', 'mice', 'as', 'evidenced', 'by', 'a', 'similar', 'increase', 'in', 'the', 'diameter', 'of', 'myotube', 'reduced', 'atrogin1', 'and', 'murf1', 'expression', 'aktfoxo3amtor', 'signaling', 'activation', 'and', 'decreased', 'apoptosis', 'and', 'autophagy', 'in', 'summary', 'we', 'experimentally', 'identified', 'and', 'demonstrated', 'a', 'novel', 'smallmolecule', 'inhibitor', 'of', 'mir29b', 'that', 'could', 'act', 'as', 'a', 'potential', 'therapeutic', 'agent', 'for', 'muscle', 'atrophy']","['muscle', 'atrophy', 'debilitating', 'induced', 'several', 'stressors', 'unfortunately', 'effective', 'pharmacological', 'treatment', 'microrna', 'mir29b', 'important', 'target', 'identified', 'commonly', 'involved', 'multiple', 'types', 'muscle', 'atrophy', 'although', 'sequencespecific', 'inhibition', 'mir29b', 'developed', 'study', 'report', 'novel', 'smallmolecule', 'mir29b', 'inhibitor', 'targets', 'mir29b', 'hairpin', 'precursor', 'premir29b', 'targapremir29b066', 'tgp29b066', 'considering', 'threedimensional', 'structure', 'thermodynamics', 'interaction', 'premir29b', 'small', 'molecule', 'novel', 'smallmolecule', 'inhibitor', 'demonstrated', 'attenuate', 'muscle', 'atrophy', 'induced', 'angiotensin', 'ii', 'ang', 'ii', 'dexamethasone', 'dex', 'tumor', 'necrosis', 'factor', 'α', 'tnfα', 'c2c12', 'myotubes', 'evidenced', 'increase', 'diameter', 'myotube', 'decrease', 'expression', 'atrogin1', 'murf1', 'moreover', 'also', 'attenuate', 'ang', 'iiinduced', 'muscle', 'atrophy', 'mice', 'evidenced', 'similar', 'increase', 'diameter', 'myotube', 'reduced', 'atrogin1', 'murf1', 'expression', 'aktfoxo3amtor', 'signaling', 'activation', 'decreased', 'apoptosis', 'autophagy', 'summary', 'experimentally', 'identified', 'demonstrated', 'novel', 'smallmolecule', 'inhibitor', 'mir29b', 'could', 'act', 'potential', 'therapeutic', 'agent', 'muscle', 'atrophy']","['microrna', 'ang', 'atrogin1', 'murf1', 'ang', 'atrogin1', 'murf1']","['microrna', 'atrogin1', 'murf1', 'atrogin1', 'murf1']",True,['tumor']
36807368,"Rice-memolin, a novel peptide derived from rice bran, improves cognitive function after oral administration in mice.","Many people eat polished rice, while rice bran, a by-product known to be rich in protein and expected to have potential functions for health benefits, has not been effectively utilized. In this study, we determined that orally administered Val-Tyr-Thr-Pro-Gly (VYTPG) derived from rice bran protein improved cognitive decline in mice fed a high-fat diet (HFD). It was demonstrated that VYTPG was released from model peptides corresponding to fragment sequences of original rice proteins (Os01g0941500, Os01g0872700, and allergenic protein) after treatment with thermolysin, a microorganism-derived enzyme often used in industrial scale processes. The thermolysin digest also improved cognitive decline after oral administration in mice. Because VYTPG (1.0 mg/kg) potently improved cognitive decline and is enzymatically produced from the rice bran, we named it rice-memolin. Next, we investigated the mechanisms underlying the cognitive decline improvement associated with rice-memolin. Methyllycaconitine, an antagonist for α7 nicotinic acetylcholine receptor, suppressed the rice-memolin-induced effect, suggesting that rice-memolin improved cognitive decline coupled to the acetylcholine system. Rice-memolin increased the number of 5-bromo-2'-deoxyuridine (BrdU)-positive cells and promoted the mRNA expression of EGF and FGF-2 in the hippocampus, implying that these neurotropic factors play a role in hippocampal neurogenesis after rice-memolin administration. Epidemiologic studies demonstrated that diabetes is a risk factor for dementia; therefore, we also examined the effect of rice-memolin on glucose metabolism. Rice-memolin improved glucose intolerance. In conclusion, we identified a novel rice-derived peptide that can improve cognitive decline. The mechanisms are associated with acetylcholine and hippocampal neurogenesis. Rice-memolin is the first rice-brain-derived peptide able to improve cognitive decline.",2023-02-18,many people eat polished rice while rice bran a byproduct known to be rich in protein and expected to have potential functions for health benefits has not been effectively utilized in this study we determined that orally administered valtyrthrprogly vytpg derived from rice bran protein improved cognitive decline in mice fed a highfat diet hfd it was demonstrated that vytpg was released from model peptides corresponding to fragment sequences of original rice proteins os01g0941500 os01g0872700 and allergenic protein after treatment with thermolysin a microorganismderived enzyme often used in industrial scale processes the thermolysin digest also improved cognitive decline after oral administration in mice because vytpg 10 mgkg potently improved cognitive decline and is enzymatically produced from the rice bran we named it ricememolin next we investigated the mechanisms underlying the cognitive decline improvement associated with ricememolin methyllycaconitine an antagonist for α7 nicotinic acetylcholine receptor suppressed the ricememolininduced effect suggesting that ricememolin improved cognitive decline coupled to the acetylcholine system ricememolin increased the number of 5bromo2deoxyuridine brdupositive cells and promoted the mrna expression of egf and fgf2 in the hippocampus implying that these neurotropic factors play a role in hippocampal neurogenesis after ricememolin administration epidemiologic studies demonstrated that diabetes is a risk factor for dementia therefore we also examined the effect of ricememolin on glucose metabolism ricememolin improved glucose intolerance in conclusion we identified a novel ricederived peptide that can improve cognitive decline the mechanisms are associated with acetylcholine and hippocampal neurogenesis ricememolin is the first ricebrainderived peptide able to improve cognitive decline,"['many', 'people', 'eat', 'polished', 'rice', 'while', 'rice', 'bran', 'a', 'byproduct', 'known', 'to', 'be', 'rich', 'in', 'protein', 'and', 'expected', 'to', 'have', 'potential', 'functions', 'for', 'health', 'benefits', 'has', 'not', 'been', 'effectively', 'utilized', 'in', 'this', 'study', 'we', 'determined', 'that', 'orally', 'administered', 'valtyrthrprogly', 'vytpg', 'derived', 'from', 'rice', 'bran', 'protein', 'improved', 'cognitive', 'decline', 'in', 'mice', 'fed', 'a', 'highfat', 'diet', 'hfd', 'it', 'was', 'demonstrated', 'that', 'vytpg', 'was', 'released', 'from', 'model', 'peptides', 'corresponding', 'to', 'fragment', 'sequences', 'of', 'original', 'rice', 'proteins', 'os01g0941500', 'os01g0872700', 'and', 'allergenic', 'protein', 'after', 'treatment', 'with', 'thermolysin', 'a', 'microorganismderived', 'enzyme', 'often', 'used', 'in', 'industrial', 'scale', 'processes', 'the', 'thermolysin', 'digest', 'also', 'improved', 'cognitive', 'decline', 'after', 'oral', 'administration', 'in', 'mice', 'because', 'vytpg', '10', 'mgkg', 'potently', 'improved', 'cognitive', 'decline', 'and', 'is', 'enzymatically', 'produced', 'from', 'the', 'rice', 'bran', 'we', 'named', 'it', 'ricememolin', 'next', 'we', 'investigated', 'the', 'mechanisms', 'underlying', 'the', 'cognitive', 'decline', 'improvement', 'associated', 'with', 'ricememolin', 'methyllycaconitine', 'an', 'antagonist', 'for', 'α7', 'nicotinic', 'acetylcholine', 'receptor', 'suppressed', 'the', 'ricememolininduced', 'effect', 'suggesting', 'that', 'ricememolin', 'improved', 'cognitive', 'decline', 'coupled', 'to', 'the', 'acetylcholine', 'system', 'ricememolin', 'increased', 'the', 'number', 'of', '5bromo2deoxyuridine', 'brdupositive', 'cells', 'and', 'promoted', 'the', 'mrna', 'expression', 'of', 'egf', 'and', 'fgf2', 'in', 'the', 'hippocampus', 'implying', 'that', 'these', 'neurotropic', 'factors', 'play', 'a', 'role', 'in', 'hippocampal', 'neurogenesis', 'after', 'ricememolin', 'administration', 'epidemiologic', 'studies', 'demonstrated', 'that', 'diabetes', 'is', 'a', 'risk', 'factor', 'for', 'dementia', 'therefore', 'we', 'also', 'examined', 'the', 'effect', 'of', 'ricememolin', 'on', 'glucose', 'metabolism', 'ricememolin', 'improved', 'glucose', 'intolerance', 'in', 'conclusion', 'we', 'identified', 'a', 'novel', 'ricederived', 'peptide', 'that', 'can', 'improve', 'cognitive', 'decline', 'the', 'mechanisms', 'are', 'associated', 'with', 'acetylcholine', 'and', 'hippocampal', 'neurogenesis', 'ricememolin', 'is', 'the', 'first', 'ricebrainderived', 'peptide', 'able', 'to', 'improve', 'cognitive', 'decline']","['many', 'people', 'eat', 'polished', 'rice', 'rice', 'bran', 'byproduct', 'known', 'rich', 'protein', 'expected', 'potential', 'functions', 'health', 'benefits', 'effectively', 'utilized', 'study', 'determined', 'orally', 'administered', 'valtyrthrprogly', 'vytpg', 'derived', 'rice', 'bran', 'protein', 'improved', 'cognitive', 'decline', 'mice', 'fed', 'highfat', 'diet', 'hfd', 'demonstrated', 'vytpg', 'released', 'model', 'peptides', 'corresponding', 'fragment', 'sequences', 'original', 'rice', 'proteins', 'os01g0941500', 'os01g0872700', 'allergenic', 'protein', 'treatment', 'thermolysin', 'microorganismderived', 'enzyme', 'often', 'used', 'industrial', 'scale', 'processes', 'thermolysin', 'digest', 'also', 'improved', 'cognitive', 'decline', 'oral', 'administration', 'mice', 'vytpg', '10', 'mgkg', 'potently', 'improved', 'cognitive', 'decline', 'enzymatically', 'produced', 'rice', 'bran', 'named', 'ricememolin', 'next', 'investigated', 'mechanisms', 'underlying', 'cognitive', 'decline', 'improvement', 'associated', 'ricememolin', 'methyllycaconitine', 'antagonist', 'α7', 'nicotinic', 'acetylcholine', 'receptor', 'suppressed', 'ricememolininduced', 'effect', 'suggesting', 'ricememolin', 'improved', 'cognitive', 'decline', 'coupled', 'acetylcholine', 'system', 'ricememolin', 'increased', 'number', '5bromo2deoxyuridine', 'brdupositive', 'cells', 'promoted', 'mrna', 'expression', 'egf', 'fgf2', 'hippocampus', 'implying', 'neurotropic', 'factors', 'play', 'role', 'hippocampal', 'neurogenesis', 'ricememolin', 'administration', 'epidemiologic', 'studies', 'demonstrated', 'diabetes', 'risk', 'factor', 'dementia', 'therefore', 'also', 'examined', 'effect', 'ricememolin', 'glucose', 'metabolism', 'ricememolin', 'improved', 'glucose', 'intolerance', 'conclusion', 'identified', 'novel', 'ricederived', 'peptide', 'improve', 'cognitive', 'decline', 'mechanisms', 'associated', 'acetylcholine', 'hippocampal', 'neurogenesis', 'ricememolin', 'first', 'ricebrainderived', 'peptide', 'able', 'improve', 'cognitive', 'decline']","['egf', 'fgf2']",['fgf2'],True,['diabetes']
36773708,Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models.,"Ubiquitin proteasome activity is suppressed in enzalutamide resistant prostate cancer cells, and the heat shock protein 70/STIP1 homology and U-box-containing protein 1 (HSP70/STUB1) machinery are involved in androgen receptor (AR) and AR variant protein stabilization. Targeting HSP70 could be a viable strategy to overcome resistance to androgen receptor signaling inhibitor (ARSI) in advanced prostate cancer. Here, we showed that a novel HSP70 allosteric inhibitor, JG98, significantly suppressed drug-resistant C4-2B MDVR and CWR22Rv1 cell growth, and enhanced enzalutamide treatment. JG98 also suppressed cell growth in conditional reprogramed cell cultures (CRCs) and organoids derived from advanced prostate cancer patient samples. Mechanistically, JG98 degraded AR/AR-V7 expression in resistant cells and promoted STUB1 nuclear translocation to bind AR-V7. Knockdown of the E3 ligase STUB1 significantly diminished the anticancer effects and partially restored AR-V7 inhibitory effects of JG98. JG231, a more potent analog developed from JG98, effectively suppressed the growth of the drug-resistant prostate cancer cells, CRCs, and organoids. Notably, the combination of JG231 and enzalutamide synergistically inhibited AR/AR-V7 expression and suppressed CWR22Rv1 xenograft tumor growth. Inhibition of HSP70 using novel small-molecule inhibitors coordinates with STUB1 to regulate AR/AR-V7 protein stabilization and ARSI resistance.",2023-02-10,ubiquitin proteasome activity is suppressed in enzalutamide resistant prostate cancer cells and the heat shock protein 70stip1 homology and uboxcontaining protein 1 hsp70stub1 machinery are involved in androgen receptor ar and ar variant protein stabilization targeting hsp70 could be a viable strategy to overcome resistance to androgen receptor signaling inhibitor arsi in advanced prostate cancer here we showed that a novel hsp70 allosteric inhibitor jg98 significantly suppressed drugresistant c42b mdvr and cwr22rv1 cell growth and enhanced enzalutamide treatment jg98 also suppressed cell growth in conditional reprogramed cell cultures crcs and organoids derived from advanced prostate cancer patient samples mechanistically jg98 degraded ararv7 expression in resistant cells and promoted stub1 nuclear translocation to bind arv7 knockdown of the e3 ligase stub1 significantly diminished the anticancer effects and partially restored arv7 inhibitory effects of jg98 jg231 a more potent analog developed from jg98 effectively suppressed the growth of the drugresistant prostate cancer cells crcs and organoids notably the combination of jg231 and enzalutamide synergistically inhibited ararv7 expression and suppressed cwr22rv1 xenograft tumor growth inhibition of hsp70 using novel smallmolecule inhibitors coordinates with stub1 to regulate ararv7 protein stabilization and arsi resistance,"['ubiquitin', 'proteasome', 'activity', 'is', 'suppressed', 'in', 'enzalutamide', 'resistant', 'prostate', 'cancer', 'cells', 'and', 'the', 'heat', 'shock', 'protein', '70stip1', 'homology', 'and', 'uboxcontaining', 'protein', '1', 'hsp70stub1', 'machinery', 'are', 'involved', 'in', 'androgen', 'receptor', 'ar', 'and', 'ar', 'variant', 'protein', 'stabilization', 'targeting', 'hsp70', 'could', 'be', 'a', 'viable', 'strategy', 'to', 'overcome', 'resistance', 'to', 'androgen', 'receptor', 'signaling', 'inhibitor', 'arsi', 'in', 'advanced', 'prostate', 'cancer', 'here', 'we', 'showed', 'that', 'a', 'novel', 'hsp70', 'allosteric', 'inhibitor', 'jg98', 'significantly', 'suppressed', 'drugresistant', 'c42b', 'mdvr', 'and', 'cwr22rv1', 'cell', 'growth', 'and', 'enhanced', 'enzalutamide', 'treatment', 'jg98', 'also', 'suppressed', 'cell', 'growth', 'in', 'conditional', 'reprogramed', 'cell', 'cultures', 'crcs', 'and', 'organoids', 'derived', 'from', 'advanced', 'prostate', 'cancer', 'patient', 'samples', 'mechanistically', 'jg98', 'degraded', 'ararv7', 'expression', 'in', 'resistant', 'cells', 'and', 'promoted', 'stub1', 'nuclear', 'translocation', 'to', 'bind', 'arv7', 'knockdown', 'of', 'the', 'e3', 'ligase', 'stub1', 'significantly', 'diminished', 'the', 'anticancer', 'effects', 'and', 'partially', 'restored', 'arv7', 'inhibitory', 'effects', 'of', 'jg98', 'jg231', 'a', 'more', 'potent', 'analog', 'developed', 'from', 'jg98', 'effectively', 'suppressed', 'the', 'growth', 'of', 'the', 'drugresistant', 'prostate', 'cancer', 'cells', 'crcs', 'and', 'organoids', 'notably', 'the', 'combination', 'of', 'jg231', 'and', 'enzalutamide', 'synergistically', 'inhibited', 'ararv7', 'expression', 'and', 'suppressed', 'cwr22rv1', 'xenograft', 'tumor', 'growth', 'inhibition', 'of', 'hsp70', 'using', 'novel', 'smallmolecule', 'inhibitors', 'coordinates', 'with', 'stub1', 'to', 'regulate', 'ararv7', 'protein', 'stabilization', 'and', 'arsi', 'resistance']","['ubiquitin', 'proteasome', 'activity', 'suppressed', 'enzalutamide', 'resistant', 'prostate', 'cancer', 'cells', 'heat', 'shock', 'protein', '70stip1', 'homology', 'uboxcontaining', 'protein', '1', 'hsp70stub1', 'machinery', 'involved', 'androgen', 'receptor', 'ar', 'ar', 'variant', 'protein', 'stabilization', 'targeting', 'hsp70', 'could', 'viable', 'strategy', 'overcome', 'resistance', 'androgen', 'receptor', 'signaling', 'inhibitor', 'arsi', 'advanced', 'prostate', 'cancer', 'showed', 'novel', 'hsp70', 'allosteric', 'inhibitor', 'jg98', 'significantly', 'suppressed', 'drugresistant', 'c42b', 'mdvr', 'cwr22rv1', 'cell', 'growth', 'enhanced', 'enzalutamide', 'treatment', 'jg98', 'also', 'suppressed', 'cell', 'growth', 'conditional', 'reprogramed', 'cell', 'cultures', 'crcs', 'organoids', 'derived', 'advanced', 'prostate', 'cancer', 'patient', 'samples', 'mechanistically', 'jg98', 'degraded', 'ararv7', 'expression', 'resistant', 'cells', 'promoted', 'stub1', 'nuclear', 'translocation', 'bind', 'arv7', 'knockdown', 'e3', 'ligase', 'stub1', 'significantly', 'diminished', 'anticancer', 'effects', 'partially', 'restored', 'arv7', 'inhibitory', 'effects', 'jg98', 'jg231', 'potent', 'analog', 'developed', 'jg98', 'effectively', 'suppressed', 'growth', 'drugresistant', 'prostate', 'cancer', 'cells', 'crcs', 'organoids', 'notably', 'combination', 'jg231', 'enzalutamide', 'synergistically', 'inhibited', 'ararv7', 'expression', 'suppressed', 'cwr22rv1', 'xenograft', 'tumor', 'growth', 'inhibition', 'hsp70', 'using', 'novel', 'smallmolecule', 'inhibitors', 'coordinates', 'stub1', 'regulate', 'ararv7', 'protein', 'stabilization', 'arsi', 'resistance']","['ubiquitin', 'hsp70', 'hsp70', 'hsp70']","['hsp70', 'hsp70', 'hsp70']",True,"['tumor', 'cancer']"
36768267,Definition and Characterization of SOX11-Derived T Cell Epitopes towards Immunotherapy of Glioma.,"The transcription factor SOX11 is a tumor-associated antigen with low expression in normal cells, but overexpression in glioblastoma (GBM). So far, conventional surgery, chemotherapy, and radiotherapy have not substantially improved the dismal prognosis of relapsed/refractory GBM patients. Immunotherapy is considered a promising strategy against GBM, but there is a fervent need for better immunotargets in GBM. To this end, we performed an in silico prediction study on SOX11, which primarily yielded ten promising HLA-A*0201-restricted peptides derived from SOX11. We defined a novel peptide FMACSPVAL, which had the highest score according to in silico prediction (6.02 nM by NetMHC-4.0) and showed an exquisite binding affinity to the HLA-A*0201 molecule in the peptide-binding assays. In the IFN-γ ELISPOT assays, FMACSPVAL demonstrated a high efficiency for generating SOX11-specific CD8<sup>+</sup> T cells. Nine out of thirty-two healthy donors showed a positive response to SOX11, as assessed by the ELISPOT assays. Therefore, this novel antigen peptide epitope seems to be promising as a target for T cell-based immunotherapy in GBM. The adoptive transfer of in vitro elicited SOX11-specific CD8<sup>+</sup> T cells constitutes a potential approach for the treatment of GBM patients.",2023-01-18,the transcription factor sox11 is a tumorassociated antigen with low expression in normal cells but overexpression in glioblastoma gbm so far conventional surgery chemotherapy and radiotherapy have not substantially improved the dismal prognosis of relapsedrefractory gbm patients immunotherapy is considered a promising strategy against gbm but there is a fervent need for better immunotargets in gbm to this end we performed an in silico prediction study on sox11 which primarily yielded ten promising hlaa0201restricted peptides derived from sox11 we defined a novel peptide fmacspval which had the highest score according to in silico prediction 602 nm by netmhc40 and showed an exquisite binding affinity to the hlaa0201 molecule in the peptidebinding assays in the ifnγ elispot assays fmacspval demonstrated a high efficiency for generating sox11specific cd8supsup t cells nine out of thirtytwo healthy donors showed a positive response to sox11 as assessed by the elispot assays therefore this novel antigen peptide epitope seems to be promising as a target for t cellbased immunotherapy in gbm the adoptive transfer of in vitro elicited sox11specific cd8supsup t cells constitutes a potential approach for the treatment of gbm patients,"['the', 'transcription', 'factor', 'sox11', 'is', 'a', 'tumorassociated', 'antigen', 'with', 'low', 'expression', 'in', 'normal', 'cells', 'but', 'overexpression', 'in', 'glioblastoma', 'gbm', 'so', 'far', 'conventional', 'surgery', 'chemotherapy', 'and', 'radiotherapy', 'have', 'not', 'substantially', 'improved', 'the', 'dismal', 'prognosis', 'of', 'relapsedrefractory', 'gbm', 'patients', 'immunotherapy', 'is', 'considered', 'a', 'promising', 'strategy', 'against', 'gbm', 'but', 'there', 'is', 'a', 'fervent', 'need', 'for', 'better', 'immunotargets', 'in', 'gbm', 'to', 'this', 'end', 'we', 'performed', 'an', 'in', 'silico', 'prediction', 'study', 'on', 'sox11', 'which', 'primarily', 'yielded', 'ten', 'promising', 'hlaa0201restricted', 'peptides', 'derived', 'from', 'sox11', 'we', 'defined', 'a', 'novel', 'peptide', 'fmacspval', 'which', 'had', 'the', 'highest', 'score', 'according', 'to', 'in', 'silico', 'prediction', '602', 'nm', 'by', 'netmhc40', 'and', 'showed', 'an', 'exquisite', 'binding', 'affinity', 'to', 'the', 'hlaa0201', 'molecule', 'in', 'the', 'peptidebinding', 'assays', 'in', 'the', 'ifnγ', 'elispot', 'assays', 'fmacspval', 'demonstrated', 'a', 'high', 'efficiency', 'for', 'generating', 'sox11specific', 'cd8supsup', 't', 'cells', 'nine', 'out', 'of', 'thirtytwo', 'healthy', 'donors', 'showed', 'a', 'positive', 'response', 'to', 'sox11', 'as', 'assessed', 'by', 'the', 'elispot', 'assays', 'therefore', 'this', 'novel', 'antigen', 'peptide', 'epitope', 'seems', 'to', 'be', 'promising', 'as', 'a', 'target', 'for', 't', 'cellbased', 'immunotherapy', 'in', 'gbm', 'the', 'adoptive', 'transfer', 'of', 'in', 'vitro', 'elicited', 'sox11specific', 'cd8supsup', 't', 'cells', 'constitutes', 'a', 'potential', 'approach', 'for', 'the', 'treatment', 'of', 'gbm', 'patients']","['transcription', 'factor', 'sox11', 'tumorassociated', 'antigen', 'low', 'expression', 'normal', 'cells', 'overexpression', 'glioblastoma', 'gbm', 'far', 'conventional', 'surgery', 'chemotherapy', 'radiotherapy', 'substantially', 'improved', 'dismal', 'prognosis', 'relapsedrefractory', 'gbm', 'patients', 'immunotherapy', 'considered', 'promising', 'strategy', 'gbm', 'fervent', 'need', 'better', 'immunotargets', 'gbm', 'end', 'performed', 'silico', 'prediction', 'study', 'sox11', 'primarily', 'yielded', 'ten', 'promising', 'hlaa0201restricted', 'peptides', 'derived', 'sox11', 'defined', 'novel', 'peptide', 'fmacspval', 'highest', 'score', 'according', 'silico', 'prediction', '602', 'nm', 'netmhc40', 'showed', 'exquisite', 'binding', 'affinity', 'hlaa0201', 'molecule', 'peptidebinding', 'assays', 'ifnγ', 'elispot', 'assays', 'fmacspval', 'demonstrated', 'high', 'efficiency', 'generating', 'sox11specific', 'cd8supsup', 'cells', 'nine', 'thirtytwo', 'healthy', 'donors', 'showed', 'positive', 'response', 'sox11', 'assessed', 'elispot', 'assays', 'therefore', 'novel', 'antigen', 'peptide', 'epitope', 'seems', 'promising', 'target', 'cellbased', 'immunotherapy', 'gbm', 'adoptive', 'transfer', 'vitro', 'elicited', 'sox11specific', 'cd8supsup', 'cells', 'constitutes', 'potential', 'approach', 'treatment', 'gbm', 'patients']","['sox11', 'sox11', 'sox11', 'sox11']","['sox11', 'sox11', 'sox11', 'sox11']",True,['tumor']
36763100,Therapeutic potential of FLT4-targeting peptide in acute myeloid leukemia.,"Previously, we found that dysfunctional natural killer (NK) cells with low interferon gamma (IFN-γ) were restored in acute myeloid leukemia (AML) by the FLT4 antagonist MAZ51. Here, we developed 12 peptides targeting FLT4 for clinical application and examined whether they restored the frequency of lymphocytes, especially T cells and NK cells, and high IFN-γ expression, as MAZ51 treatment did in our previous study. Although clinical data from using peptides are currently available, peptides targeting FLT4 to modulate immune cells have not been fully elucidated. In this study, we focus on novel peptide 4 (P4) from the intracellular domain of FLT4 because it had dominant negative activity. Similar to MAZ51, high IFN-γ levels were expressed in AML-mononuclear cells exposed to P4. Additionally, T and NK cell levels were restored, as were high IFN-γ levels, in a leukemic environment when P4 was treated. Interestingly, the regulatory T cells were significantly decreased by P4, implying the role of peptide in tumor niche. Overall, we demonstrated the therapeutic value of functionally modulating lymphocytes using a peptide targeting FLT4 and proposed the development of advanced therapeutic approaches against AML by using immune cells.",2023-02-10,previously we found that dysfunctional natural killer nk cells with low interferon gamma ifnγ were restored in acute myeloid leukemia aml by the flt4 antagonist maz51 here we developed 12 peptides targeting flt4 for clinical application and examined whether they restored the frequency of lymphocytes especially t cells and nk cells and high ifnγ expression as maz51 treatment did in our previous study although clinical data from using peptides are currently available peptides targeting flt4 to modulate immune cells have not been fully elucidated in this study we focus on novel peptide 4 p4 from the intracellular domain of flt4 because it had dominant negative activity similar to maz51 high ifnγ levels were expressed in amlmononuclear cells exposed to p4 additionally t and nk cell levels were restored as were high ifnγ levels in a leukemic environment when p4 was treated interestingly the regulatory t cells were significantly decreased by p4 implying the role of peptide in tumor niche overall we demonstrated the therapeutic value of functionally modulating lymphocytes using a peptide targeting flt4 and proposed the development of advanced therapeutic approaches against aml by using immune cells,"['previously', 'we', 'found', 'that', 'dysfunctional', 'natural', 'killer', 'nk', 'cells', 'with', 'low', 'interferon', 'gamma', 'ifnγ', 'were', 'restored', 'in', 'acute', 'myeloid', 'leukemia', 'aml', 'by', 'the', 'flt4', 'antagonist', 'maz51', 'here', 'we', 'developed', '12', 'peptides', 'targeting', 'flt4', 'for', 'clinical', 'application', 'and', 'examined', 'whether', 'they', 'restored', 'the', 'frequency', 'of', 'lymphocytes', 'especially', 't', 'cells', 'and', 'nk', 'cells', 'and', 'high', 'ifnγ', 'expression', 'as', 'maz51', 'treatment', 'did', 'in', 'our', 'previous', 'study', 'although', 'clinical', 'data', 'from', 'using', 'peptides', 'are', 'currently', 'available', 'peptides', 'targeting', 'flt4', 'to', 'modulate', 'immune', 'cells', 'have', 'not', 'been', 'fully', 'elucidated', 'in', 'this', 'study', 'we', 'focus', 'on', 'novel', 'peptide', '4', 'p4', 'from', 'the', 'intracellular', 'domain', 'of', 'flt4', 'because', 'it', 'had', 'dominant', 'negative', 'activity', 'similar', 'to', 'maz51', 'high', 'ifnγ', 'levels', 'were', 'expressed', 'in', 'amlmononuclear', 'cells', 'exposed', 'to', 'p4', 'additionally', 't', 'and', 'nk', 'cell', 'levels', 'were', 'restored', 'as', 'were', 'high', 'ifnγ', 'levels', 'in', 'a', 'leukemic', 'environment', 'when', 'p4', 'was', 'treated', 'interestingly', 'the', 'regulatory', 't', 'cells', 'were', 'significantly', 'decreased', 'by', 'p4', 'implying', 'the', 'role', 'of', 'peptide', 'in', 'tumor', 'niche', 'overall', 'we', 'demonstrated', 'the', 'therapeutic', 'value', 'of', 'functionally', 'modulating', 'lymphocytes', 'using', 'a', 'peptide', 'targeting', 'flt4', 'and', 'proposed', 'the', 'development', 'of', 'advanced', 'therapeutic', 'approaches', 'against', 'aml', 'by', 'using', 'immune', 'cells']","['previously', 'found', 'dysfunctional', 'natural', 'killer', 'nk', 'cells', 'low', 'interferon', 'gamma', 'ifnγ', 'restored', 'acute', 'myeloid', 'leukemia', 'aml', 'flt4', 'antagonist', 'maz51', 'developed', '12', 'peptides', 'targeting', 'flt4', 'clinical', 'application', 'examined', 'whether', 'restored', 'frequency', 'lymphocytes', 'especially', 'cells', 'nk', 'cells', 'high', 'ifnγ', 'expression', 'maz51', 'treatment', 'previous', 'study', 'although', 'clinical', 'data', 'using', 'peptides', 'currently', 'available', 'peptides', 'targeting', 'flt4', 'modulate', 'immune', 'cells', 'fully', 'elucidated', 'study', 'focus', 'novel', 'peptide', '4', 'p4', 'intracellular', 'domain', 'flt4', 'dominant', 'negative', 'activity', 'similar', 'maz51', 'high', 'ifnγ', 'levels', 'expressed', 'amlmononuclear', 'cells', 'exposed', 'p4', 'additionally', 'nk', 'cell', 'levels', 'restored', 'high', 'ifnγ', 'levels', 'leukemic', 'environment', 'p4', 'treated', 'interestingly', 'regulatory', 'cells', 'significantly', 'decreased', 'p4', 'implying', 'role', 'peptide', 'tumor', 'niche', 'overall', 'demonstrated', 'therapeutic', 'value', 'functionally', 'modulating', 'lymphocytes', 'using', 'peptide', 'targeting', 'flt4', 'proposed', 'development', 'advanced', 'therapeutic', 'approaches', 'aml', 'using', 'immune', 'cells']","['flt4', 'flt4', 'flt4', 'flt4', 'flt4']","['flt4', 'flt4', 'flt4', 'flt4', 'flt4']",True,"['tumor', 'leukemia']"
36696800,Identification and characterization of a first-generation inhibitor of claudin-1 in colon cancer progression and metastasis.,"Colorectal cancer (CRC) is a leading cause of the cancer-related deaths worldwide. Thus, developing novel and targeted therapies for inhibiting CRC progression and metastasis is urgent. Several studies, including ours, have reported a causal role for an upregulated claudin-1 expression in promoting CRC metastasis through the activation of the Src and β-catenin-signaling. In murine models of colon tumorigenesis, claudin-1 overexpression promotes oncogenic properties such as transformation and invasiveness. Conversely, the downregulation of claudin-1 inhibits colon tumorigenesis. Despite being a desirable target for cancer treatment, there are currently no known claudin-1 inhibitors with antitumor efficacy. Using a rigorous analytical design and implementing in- vitro and in-vivo testing and a brief medicinal chemistry campaign, we identified a claudin-1-specific inhibitor and named it I-6. Despite its high potency, I-6 was rapidly cleared in human liver microsomes. We, therefore, synthesized I-6 analogs and discovered a novel small molecule, PDS-0330. We determined that PDS0330 inhibits claudin-1-dependent CRC progression without exhibiting toxicity in in-vitro and in-vivo models of CRC and that it binds directly and specifically to claudin-1 with micromolar affinity. Further analyses revealed that PDS-0330 exhibits antitumor and chemosensitizer activities with favorable pharmacokinetic properties by inhibiting the association with metastatic oncogene Src. Overall, our data propose that PDS-0330 interferes with claudin-1/Src association to inhibit CRC progression and metastasis. Our findings are of direct clinical relevance and may open new therapeutic opportunities in colon cancer treatment and/or management by targeting claudin-1.",2023-01-23,colorectal cancer crc is a leading cause of the cancerrelated deaths worldwide thus developing novel and targeted therapies for inhibiting crc progression and metastasis is urgent several studies including ours have reported a causal role for an upregulated claudin1 expression in promoting crc metastasis through the activation of the src and βcateninsignaling in murine models of colon tumorigenesis claudin1 overexpression promotes oncogenic properties such as transformation and invasiveness conversely the downregulation of claudin1 inhibits colon tumorigenesis despite being a desirable target for cancer treatment there are currently no known claudin1 inhibitors with antitumor efficacy using a rigorous analytical design and implementing in vitro and invivo testing and a brief medicinal chemistry campaign we identified a claudin1specific inhibitor and named it i6 despite its high potency i6 was rapidly cleared in human liver microsomes we therefore synthesized i6 analogs and discovered a novel small molecule pds0330 we determined that pds0330 inhibits claudin1dependent crc progression without exhibiting toxicity in invitro and invivo models of crc and that it binds directly and specifically to claudin1 with micromolar affinity further analyses revealed that pds0330 exhibits antitumor and chemosensitizer activities with favorable pharmacokinetic properties by inhibiting the association with metastatic oncogene src overall our data propose that pds0330 interferes with claudin1src association to inhibit crc progression and metastasis our findings are of direct clinical relevance and may open new therapeutic opportunities in colon cancer treatment andor management by targeting claudin1,"['colorectal', 'cancer', 'crc', 'is', 'a', 'leading', 'cause', 'of', 'the', 'cancerrelated', 'deaths', 'worldwide', 'thus', 'developing', 'novel', 'and', 'targeted', 'therapies', 'for', 'inhibiting', 'crc', 'progression', 'and', 'metastasis', 'is', 'urgent', 'several', 'studies', 'including', 'ours', 'have', 'reported', 'a', 'causal', 'role', 'for', 'an', 'upregulated', 'claudin1', 'expression', 'in', 'promoting', 'crc', 'metastasis', 'through', 'the', 'activation', 'of', 'the', 'src', 'and', 'βcateninsignaling', 'in', 'murine', 'models', 'of', 'colon', 'tumorigenesis', 'claudin1', 'overexpression', 'promotes', 'oncogenic', 'properties', 'such', 'as', 'transformation', 'and', 'invasiveness', 'conversely', 'the', 'downregulation', 'of', 'claudin1', 'inhibits', 'colon', 'tumorigenesis', 'despite', 'being', 'a', 'desirable', 'target', 'for', 'cancer', 'treatment', 'there', 'are', 'currently', 'no', 'known', 'claudin1', 'inhibitors', 'with', 'antitumor', 'efficacy', 'using', 'a', 'rigorous', 'analytical', 'design', 'and', 'implementing', 'in', 'vitro', 'and', 'invivo', 'testing', 'and', 'a', 'brief', 'medicinal', 'chemistry', 'campaign', 'we', 'identified', 'a', 'claudin1specific', 'inhibitor', 'and', 'named', 'it', 'i6', 'despite', 'its', 'high', 'potency', 'i6', 'was', 'rapidly', 'cleared', 'in', 'human', 'liver', 'microsomes', 'we', 'therefore', 'synthesized', 'i6', 'analogs', 'and', 'discovered', 'a', 'novel', 'small', 'molecule', 'pds0330', 'we', 'determined', 'that', 'pds0330', 'inhibits', 'claudin1dependent', 'crc', 'progression', 'without', 'exhibiting', 'toxicity', 'in', 'invitro', 'and', 'invivo', 'models', 'of', 'crc', 'and', 'that', 'it', 'binds', 'directly', 'and', 'specifically', 'to', 'claudin1', 'with', 'micromolar', 'affinity', 'further', 'analyses', 'revealed', 'that', 'pds0330', 'exhibits', 'antitumor', 'and', 'chemosensitizer', 'activities', 'with', 'favorable', 'pharmacokinetic', 'properties', 'by', 'inhibiting', 'the', 'association', 'with', 'metastatic', 'oncogene', 'src', 'overall', 'our', 'data', 'propose', 'that', 'pds0330', 'interferes', 'with', 'claudin1src', 'association', 'to', 'inhibit', 'crc', 'progression', 'and', 'metastasis', 'our', 'findings', 'are', 'of', 'direct', 'clinical', 'relevance', 'and', 'may', 'open', 'new', 'therapeutic', 'opportunities', 'in', 'colon', 'cancer', 'treatment', 'andor', 'management', 'by', 'targeting', 'claudin1']","['colorectal', 'cancer', 'crc', 'leading', 'cause', 'cancerrelated', 'deaths', 'worldwide', 'thus', 'developing', 'novel', 'targeted', 'therapies', 'inhibiting', 'crc', 'progression', 'metastasis', 'urgent', 'several', 'studies', 'including', 'reported', 'causal', 'role', 'upregulated', 'claudin1', 'expression', 'promoting', 'crc', 'metastasis', 'activation', 'src', 'βcateninsignaling', 'murine', 'models', 'colon', 'tumorigenesis', 'claudin1', 'overexpression', 'promotes', 'oncogenic', 'properties', 'transformation', 'invasiveness', 'conversely', 'downregulation', 'claudin1', 'inhibits', 'colon', 'tumorigenesis', 'despite', 'desirable', 'target', 'cancer', 'treatment', 'currently', 'known', 'claudin1', 'inhibitors', 'antitumor', 'efficacy', 'using', 'rigorous', 'analytical', 'design', 'implementing', 'vitro', 'invivo', 'testing', 'brief', 'medicinal', 'chemistry', 'campaign', 'identified', 'claudin1specific', 'inhibitor', 'named', 'i6', 'despite', 'high', 'potency', 'i6', 'rapidly', 'cleared', 'human', 'liver', 'microsomes', 'therefore', 'synthesized', 'i6', 'analogs', 'discovered', 'novel', 'small', 'molecule', 'pds0330', 'determined', 'pds0330', 'inhibits', 'claudin1dependent', 'crc', 'progression', 'without', 'exhibiting', 'toxicity', 'invitro', 'invivo', 'models', 'crc', 'binds', 'directly', 'specifically', 'claudin1', 'micromolar', 'affinity', 'analyses', 'revealed', 'pds0330', 'exhibits', 'antitumor', 'chemosensitizer', 'activities', 'favorable', 'pharmacokinetic', 'properties', 'inhibiting', 'association', 'metastatic', 'oncogene', 'src', 'overall', 'data', 'propose', 'pds0330', 'interferes', 'claudin1src', 'association', 'inhibit', 'crc', 'progression', 'metastasis', 'findings', 'direct', 'clinical', 'relevance', 'may', 'open', 'new', 'therapeutic', 'opportunities', 'colon', 'cancer', 'treatment', 'andor', 'management', 'targeting', 'claudin1']","['crc', 'crc', 'claudin1', 'crc', 'src', 'claudin1', 'claudin1', 'claudin1', 'crc', 'crc', 'claudin1', 'src', 'crc', 'claudin1']","['claudin1', 'claudin1', 'claudin1', 'claudin1', 'claudin1', 'claudin1']",True,"['tumor', 'cancer']"
36685223,New natural compound inhibitors of PDGFRA (platelet-derived growth factor receptor α) based on computational study for high-grade glioma therapy.,"High-grade glioma (HGG) is a malignant brain tumor that is common and aggressive in children and adults. In the current medical paradigm, surgery and radiotherapy are the standard treatments for HGG patients. Despite this, the overall prognosis is still very bleak. Studies have shown that platelet-derived growth factor receptor α (PDGFRA) is an essential target to treat tumors and inhibiting the activity of PDGFRA can improve the prognosis of HGG. Thus, PDGFRA inhibitors are critical to developing drugs and cancer treatment.",2023-01-04,highgrade glioma hgg is a malignant brain tumor that is common and aggressive in children and adults in the current medical paradigm surgery and radiotherapy are the standard treatments for hgg patients despite this the overall prognosis is still very bleak studies have shown that plateletderived growth factor receptor α pdgfra is an essential target to treat tumors and inhibiting the activity of pdgfra can improve the prognosis of hgg thus pdgfra inhibitors are critical to developing drugs and cancer treatment,"['highgrade', 'glioma', 'hgg', 'is', 'a', 'malignant', 'brain', 'tumor', 'that', 'is', 'common', 'and', 'aggressive', 'in', 'children', 'and', 'adults', 'in', 'the', 'current', 'medical', 'paradigm', 'surgery', 'and', 'radiotherapy', 'are', 'the', 'standard', 'treatments', 'for', 'hgg', 'patients', 'despite', 'this', 'the', 'overall', 'prognosis', 'is', 'still', 'very', 'bleak', 'studies', 'have', 'shown', 'that', 'plateletderived', 'growth', 'factor', 'receptor', 'α', 'pdgfra', 'is', 'an', 'essential', 'target', 'to', 'treat', 'tumors', 'and', 'inhibiting', 'the', 'activity', 'of', 'pdgfra', 'can', 'improve', 'the', 'prognosis', 'of', 'hgg', 'thus', 'pdgfra', 'inhibitors', 'are', 'critical', 'to', 'developing', 'drugs', 'and', 'cancer', 'treatment']","['highgrade', 'glioma', 'hgg', 'malignant', 'brain', 'tumor', 'common', 'aggressive', 'children', 'adults', 'current', 'medical', 'paradigm', 'surgery', 'radiotherapy', 'standard', 'treatments', 'hgg', 'patients', 'despite', 'overall', 'prognosis', 'still', 'bleak', 'studies', 'shown', 'plateletderived', 'growth', 'factor', 'receptor', 'α', 'pdgfra', 'essential', 'target', 'treat', 'tumors', 'inhibiting', 'activity', 'pdgfra', 'improve', 'prognosis', 'hgg', 'thus', 'pdgfra', 'inhibitors', 'critical', 'developing', 'drugs', 'cancer', 'treatment']","['pdgfra', 'pdgfra', 'pdgfra']","['pdgfra', 'pdgfra', 'pdgfra']",True,"['tumor', 'cancer']"
36683422,"Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study.","Orelabrutinib is a novel, small molecule, selective irreversible Bruton's tyrosine kinase inhibitor. The aim of this study was to evaluate the efficacy and safety in patients with refractory or relapsed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). This is single-arm, multi-center, open-label, phase 2 study in 80 eligible Chinese patients, who were treated with monotherapy of orelabrutinib at 150 mg once daily. Overall response rate evaluated by an independent review committee was the primary endpoint, and secondary endpoints include progression-free survival, overall survival, and safety. Independent review committee assessed overall response rate was 92.5% (74/80); complete response 21.3% (17/80), partial response 60.0% (48/80), partial response with lymphocytosis 11.3% (9/80). At a 32.3-month median follow-up, the median progression-free survival had not been achieved, while the 30-month progression-free survival rate and overall survival rates were 70.9% (95% confidence interval [CI], 59.5-79.6) and 81.3% (95% CI, 70.8-88.2), respectively. Orelabrutinib also revealed substantial response in patients with high prognostic risks: overall response rates of patients carrying positive TP53 mutational status or del(17p), del(11q), as well as unmutated immunoglobulin heavy-chain variable region gene were 100%, 94.7%, and 93.9%, respectively. Most adverse events were in low grade, with 86.8% of AEs being Grade 1 or 2. Nearly 67% of patients were still receiving orelabrutinib after almost a 3-year follow-up. In conclusion, Orelabrutinib demonstrated compelling efficacy as well as safety profiles, with a noteworthy number of patients obtaining complete response in refractory or relapsed CLL/SLL.",2023-01-22,orelabrutinib is a novel small molecule selective irreversible brutons tyrosine kinase inhibitor the aim of this study was to evaluate the efficacy and safety in patients with refractory or relapsed chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sll this is singlearm multicenter openlabel phase 2 study in 80 eligible chinese patients who were treated with monotherapy of orelabrutinib at 150 mg once daily overall response rate evaluated by an independent review committee was the primary endpoint and secondary endpoints include progressionfree survival overall survival and safety independent review committee assessed overall response rate was 925 7480 complete response 213 1780 partial response 600 4880 partial response with lymphocytosis 113 980 at a 323month median followup the median progressionfree survival had not been achieved while the 30month progressionfree survival rate and overall survival rates were 709 95 confidence interval ci 595796 and 813 95 ci 708882 respectively orelabrutinib also revealed substantial response in patients with high prognostic risks overall response rates of patients carrying positive tp53 mutational status or del17p del11q as well as unmutated immunoglobulin heavychain variable region gene were 100 947 and 939 respectively most adverse events were in low grade with 868 of aes being grade 1 or 2 nearly 67 of patients were still receiving orelabrutinib after almost a 3year followup in conclusion orelabrutinib demonstrated compelling efficacy as well as safety profiles with a noteworthy number of patients obtaining complete response in refractory or relapsed cllsll,"['orelabrutinib', 'is', 'a', 'novel', 'small', 'molecule', 'selective', 'irreversible', 'brutons', 'tyrosine', 'kinase', 'inhibitor', 'the', 'aim', 'of', 'this', 'study', 'was', 'to', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'in', 'patients', 'with', 'refractory', 'or', 'relapsed', 'chronic', 'lymphocytic', 'leukemia', 'cllsmall', 'lymphocytic', 'lymphoma', 'sll', 'this', 'is', 'singlearm', 'multicenter', 'openlabel', 'phase', '2', 'study', 'in', '80', 'eligible', 'chinese', 'patients', 'who', 'were', 'treated', 'with', 'monotherapy', 'of', 'orelabrutinib', 'at', '150', 'mg', 'once', 'daily', 'overall', 'response', 'rate', 'evaluated', 'by', 'an', 'independent', 'review', 'committee', 'was', 'the', 'primary', 'endpoint', 'and', 'secondary', 'endpoints', 'include', 'progressionfree', 'survival', 'overall', 'survival', 'and', 'safety', 'independent', 'review', 'committee', 'assessed', 'overall', 'response', 'rate', 'was', '925', '7480', 'complete', 'response', '213', '1780', 'partial', 'response', '600', '4880', 'partial', 'response', 'with', 'lymphocytosis', '113', '980', 'at', 'a', '323month', 'median', 'followup', 'the', 'median', 'progressionfree', 'survival', 'had', 'not', 'been', 'achieved', 'while', 'the', '30month', 'progressionfree', 'survival', 'rate', 'and', 'overall', 'survival', 'rates', 'were', '709', '95', 'confidence', 'interval', 'ci', '595796', 'and', '813', '95', 'ci', '708882', 'respectively', 'orelabrutinib', 'also', 'revealed', 'substantial', 'response', 'in', 'patients', 'with', 'high', 'prognostic', 'risks', 'overall', 'response', 'rates', 'of', 'patients', 'carrying', 'positive', 'tp53', 'mutational', 'status', 'or', 'del17p', 'del11q', 'as', 'well', 'as', 'unmutated', 'immunoglobulin', 'heavychain', 'variable', 'region', 'gene', 'were', '100', '947', 'and', '939', 'respectively', 'most', 'adverse', 'events', 'were', 'in', 'low', 'grade', 'with', '868', 'of', 'aes', 'being', 'grade', '1', 'or', '2', 'nearly', '67', 'of', 'patients', 'were', 'still', 'receiving', 'orelabrutinib', 'after', 'almost', 'a', '3year', 'followup', 'in', 'conclusion', 'orelabrutinib', 'demonstrated', 'compelling', 'efficacy', 'as', 'well', 'as', 'safety', 'profiles', 'with', 'a', 'noteworthy', 'number', 'of', 'patients', 'obtaining', 'complete', 'response', 'in', 'refractory', 'or', 'relapsed', 'cllsll']","['orelabrutinib', 'novel', 'small', 'molecule', 'selective', 'irreversible', 'brutons', 'tyrosine', 'kinase', 'inhibitor', 'aim', 'study', 'evaluate', 'efficacy', 'safety', 'patients', 'refractory', 'relapsed', 'chronic', 'lymphocytic', 'leukemia', 'cllsmall', 'lymphocytic', 'lymphoma', 'sll', 'singlearm', 'multicenter', 'openlabel', 'phase', '2', 'study', '80', 'eligible', 'chinese', 'patients', 'treated', 'monotherapy', 'orelabrutinib', '150', 'mg', 'daily', 'overall', 'response', 'rate', 'evaluated', 'independent', 'review', 'committee', 'primary', 'endpoint', 'secondary', 'endpoints', 'include', 'progressionfree', 'survival', 'overall', 'survival', 'safety', 'independent', 'review', 'committee', 'assessed', 'overall', 'response', 'rate', '925', '7480', 'complete', 'response', '213', '1780', 'partial', 'response', '600', '4880', 'partial', 'response', 'lymphocytosis', '113', '980', '323month', 'median', 'followup', 'median', 'progressionfree', 'survival', 'achieved', '30month', 'progressionfree', 'survival', 'rate', 'overall', 'survival', 'rates', '709', '95', 'confidence', 'interval', 'ci', '595796', '813', '95', 'ci', '708882', 'respectively', 'orelabrutinib', 'also', 'revealed', 'substantial', 'response', 'patients', 'high', 'prognostic', 'risks', 'overall', 'response', 'rates', 'patients', 'carrying', 'positive', 'tp53', 'mutational', 'status', 'del17p', 'del11q', 'well', 'unmutated', 'immunoglobulin', 'heavychain', 'variable', 'region', 'gene', '100', '947', '939', 'respectively', 'adverse', 'events', 'low', 'grade', '868', 'aes', 'grade', '1', '2', 'nearly', '67', 'patients', 'still', 'receiving', 'orelabrutinib', 'almost', '3year', 'followup', 'conclusion', 'orelabrutinib', 'demonstrated', 'compelling', 'efficacy', 'well', 'safety', 'profiles', 'noteworthy', 'number', 'patients', 'obtaining', 'complete', 'response', 'refractory', 'relapsed', 'cllsll']","['sll', 'tp53', 'immunoglobulin']",['tp53'],True,['leukemia']
36658088,Defining the role of mTOR pathway in the regulation of stem cells of glioblastoma.,"The mechanistic target of rapamycin (mTOR), a serine/threonine kinase, functions by forming two multiprotein complexes termed mTORC1 and mTORC2. Glioblastoma (GBM) is a uniformly fatal brain tumor that remains incurable partly due to the existence of untreatable cancer stem cells (CSC). The pathogenesis of GBM is largely due to the loss of the tumor suppressor gene PTEN, which is implicated in the aberrant activation of the mTOR pathway. The major cause of tumor recurrence, growth, and invasion is the presence of the unique population of CSC. Resistance to conventional therapies appears to be caused by both extensive genetic abnormalities and dysregulation of the transcription landscape. Consequently, CSCs have emerged as targets of interest in new treatment paradigms. Evidence suggests that inhibition of the mTOR pathway can also be applied to target CSCs. Here we explored the role of the mTOR pathway in the regulation of stem cells of GBM by treating them with inhibitors of canonical PI3K/AKT/mTOR pathways such as rapamycin (mTORC1 inhibitor), PP242 (ATP binding mTORC1/2 inhibitor), LY294002 (PI3K inhibitor), and MAPK inhibitor, U0126. A significant number of GBM tumors expressed stem cell marker nestin and activated mTOR (pmTOR<sup>Ser2448</sup>), with most tumor cells co-expressing both markers. The expression of stem cell marker NANOG was suppressed following rapamycin treatment. The neurospheres were disrupted following rapamycin and LY294002 treatments. Rapamycin or PP242 along with differentiating agent All-trans-retinoic acid reduced stem cell proliferation. Treatment with novel small molecule inhibitors of mTORC1/2 demonstrated that Torin1 and Torin2 suppressed the proliferation of GBM CSC, while XL388 was less effective. Torin1 and XL388 delay the process of self-renewal as compared to controls, whereas Torin2 halted self-renewal. Torin2 was able to eradicate tumor cells. In conclusion, Torin2 effectively targeted CSCs of GBM by halting self-renewal and inhibiting cell proliferation, underscoring the use of Torin2 in the treatment of GBM.",2022-12-31,the mechanistic target of rapamycin mtor a serinethreonine kinase functions by forming two multiprotein complexes termed mtorc1 and mtorc2 glioblastoma gbm is a uniformly fatal brain tumor that remains incurable partly due to the existence of untreatable cancer stem cells csc the pathogenesis of gbm is largely due to the loss of the tumor suppressor gene pten which is implicated in the aberrant activation of the mtor pathway the major cause of tumor recurrence growth and invasion is the presence of the unique population of csc resistance to conventional therapies appears to be caused by both extensive genetic abnormalities and dysregulation of the transcription landscape consequently cscs have emerged as targets of interest in new treatment paradigms evidence suggests that inhibition of the mtor pathway can also be applied to target cscs here we explored the role of the mtor pathway in the regulation of stem cells of gbm by treating them with inhibitors of canonical pi3kaktmtor pathways such as rapamycin mtorc1 inhibitor pp242 atp binding mtorc12 inhibitor ly294002 pi3k inhibitor and mapk inhibitor u0126 a significant number of gbm tumors expressed stem cell marker nestin and activated mtor pmtorsupser2448sup with most tumor cells coexpressing both markers the expression of stem cell marker nanog was suppressed following rapamycin treatment the neurospheres were disrupted following rapamycin and ly294002 treatments rapamycin or pp242 along with differentiating agent alltransretinoic acid reduced stem cell proliferation treatment with novel small molecule inhibitors of mtorc12 demonstrated that torin1 and torin2 suppressed the proliferation of gbm csc while xl388 was less effective torin1 and xl388 delay the process of selfrenewal as compared to controls whereas torin2 halted selfrenewal torin2 was able to eradicate tumor cells in conclusion torin2 effectively targeted cscs of gbm by halting selfrenewal and inhibiting cell proliferation underscoring the use of torin2 in the treatment of gbm,"['the', 'mechanistic', 'target', 'of', 'rapamycin', 'mtor', 'a', 'serinethreonine', 'kinase', 'functions', 'by', 'forming', 'two', 'multiprotein', 'complexes', 'termed', 'mtorc1', 'and', 'mtorc2', 'glioblastoma', 'gbm', 'is', 'a', 'uniformly', 'fatal', 'brain', 'tumor', 'that', 'remains', 'incurable', 'partly', 'due', 'to', 'the', 'existence', 'of', 'untreatable', 'cancer', 'stem', 'cells', 'csc', 'the', 'pathogenesis', 'of', 'gbm', 'is', 'largely', 'due', 'to', 'the', 'loss', 'of', 'the', 'tumor', 'suppressor', 'gene', 'pten', 'which', 'is', 'implicated', 'in', 'the', 'aberrant', 'activation', 'of', 'the', 'mtor', 'pathway', 'the', 'major', 'cause', 'of', 'tumor', 'recurrence', 'growth', 'and', 'invasion', 'is', 'the', 'presence', 'of', 'the', 'unique', 'population', 'of', 'csc', 'resistance', 'to', 'conventional', 'therapies', 'appears', 'to', 'be', 'caused', 'by', 'both', 'extensive', 'genetic', 'abnormalities', 'and', 'dysregulation', 'of', 'the', 'transcription', 'landscape', 'consequently', 'cscs', 'have', 'emerged', 'as', 'targets', 'of', 'interest', 'in', 'new', 'treatment', 'paradigms', 'evidence', 'suggests', 'that', 'inhibition', 'of', 'the', 'mtor', 'pathway', 'can', 'also', 'be', 'applied', 'to', 'target', 'cscs', 'here', 'we', 'explored', 'the', 'role', 'of', 'the', 'mtor', 'pathway', 'in', 'the', 'regulation', 'of', 'stem', 'cells', 'of', 'gbm', 'by', 'treating', 'them', 'with', 'inhibitors', 'of', 'canonical', 'pi3kaktmtor', 'pathways', 'such', 'as', 'rapamycin', 'mtorc1', 'inhibitor', 'pp242', 'atp', 'binding', 'mtorc12', 'inhibitor', 'ly294002', 'pi3k', 'inhibitor', 'and', 'mapk', 'inhibitor', 'u0126', 'a', 'significant', 'number', 'of', 'gbm', 'tumors', 'expressed', 'stem', 'cell', 'marker', 'nestin', 'and', 'activated', 'mtor', 'pmtorsupser2448sup', 'with', 'most', 'tumor', 'cells', 'coexpressing', 'both', 'markers', 'the', 'expression', 'of', 'stem', 'cell', 'marker', 'nanog', 'was', 'suppressed', 'following', 'rapamycin', 'treatment', 'the', 'neurospheres', 'were', 'disrupted', 'following', 'rapamycin', 'and', 'ly294002', 'treatments', 'rapamycin', 'or', 'pp242', 'along', 'with', 'differentiating', 'agent', 'alltransretinoic', 'acid', 'reduced', 'stem', 'cell', 'proliferation', 'treatment', 'with', 'novel', 'small', 'molecule', 'inhibitors', 'of', 'mtorc12', 'demonstrated', 'that', 'torin1', 'and', 'torin2', 'suppressed', 'the', 'proliferation', 'of', 'gbm', 'csc', 'while', 'xl388', 'was', 'less', 'effective', 'torin1', 'and', 'xl388', 'delay', 'the', 'process', 'of', 'selfrenewal', 'as', 'compared', 'to', 'controls', 'whereas', 'torin2', 'halted', 'selfrenewal', 'torin2', 'was', 'able', 'to', 'eradicate', 'tumor', 'cells', 'in', 'conclusion', 'torin2', 'effectively', 'targeted', 'cscs', 'of', 'gbm', 'by', 'halting', 'selfrenewal', 'and', 'inhibiting', 'cell', 'proliferation', 'underscoring', 'the', 'use', 'of', 'torin2', 'in', 'the', 'treatment', 'of', 'gbm']","['mechanistic', 'target', 'rapamycin', 'mtor', 'serinethreonine', 'kinase', 'functions', 'forming', 'two', 'multiprotein', 'complexes', 'termed', 'mtorc1', 'mtorc2', 'glioblastoma', 'gbm', 'uniformly', 'fatal', 'brain', 'tumor', 'remains', 'incurable', 'partly', 'due', 'existence', 'untreatable', 'cancer', 'stem', 'cells', 'csc', 'pathogenesis', 'gbm', 'largely', 'due', 'loss', 'tumor', 'suppressor', 'gene', 'pten', 'implicated', 'aberrant', 'activation', 'mtor', 'pathway', 'major', 'cause', 'tumor', 'recurrence', 'growth', 'invasion', 'presence', 'unique', 'population', 'csc', 'resistance', 'conventional', 'therapies', 'appears', 'caused', 'extensive', 'genetic', 'abnormalities', 'dysregulation', 'transcription', 'landscape', 'consequently', 'cscs', 'emerged', 'targets', 'interest', 'new', 'treatment', 'paradigms', 'evidence', 'suggests', 'inhibition', 'mtor', 'pathway', 'also', 'applied', 'target', 'cscs', 'explored', 'role', 'mtor', 'pathway', 'regulation', 'stem', 'cells', 'gbm', 'treating', 'inhibitors', 'canonical', 'pi3kaktmtor', 'pathways', 'rapamycin', 'mtorc1', 'inhibitor', 'pp242', 'atp', 'binding', 'mtorc12', 'inhibitor', 'ly294002', 'pi3k', 'inhibitor', 'mapk', 'inhibitor', 'u0126', 'significant', 'number', 'gbm', 'tumors', 'expressed', 'stem', 'cell', 'marker', 'nestin', 'activated', 'mtor', 'pmtorsupser2448sup', 'tumor', 'cells', 'coexpressing', 'markers', 'expression', 'stem', 'cell', 'marker', 'nanog', 'suppressed', 'following', 'rapamycin', 'treatment', 'neurospheres', 'disrupted', 'following', 'rapamycin', 'ly294002', 'treatments', 'rapamycin', 'pp242', 'along', 'differentiating', 'agent', 'alltransretinoic', 'acid', 'reduced', 'stem', 'cell', 'proliferation', 'treatment', 'novel', 'small', 'molecule', 'inhibitors', 'mtorc12', 'demonstrated', 'torin1', 'torin2', 'suppressed', 'proliferation', 'gbm', 'csc', 'xl388', 'less', 'effective', 'torin1', 'xl388', 'delay', 'process', 'selfrenewal', 'compared', 'controls', 'whereas', 'torin2', 'halted', 'selfrenewal', 'torin2', 'able', 'eradicate', 'tumor', 'cells', 'conclusion', 'torin2', 'effectively', 'targeted', 'cscs', 'gbm', 'halting', 'selfrenewal', 'inhibiting', 'cell', 'proliferation', 'underscoring', 'use', 'torin2', 'treatment', 'gbm']","['pten', 'pi3k', 'nestin', 'nanog', 'torin1', 'torin1']","['nestin', 'nanog']",True,"['tumor', 'cancer']"
36622852,BET-HDAC Dual Inhibitors for Combinational Treatment of Breast Cancer and Concurrent Candidiasis.,"Breast cancer is susceptible to <i>Candida</i> infections, and candidiasis has an enhancing effect on the progression and metastasis of tumor. Breast cancer and concurrent candidiasis represent a significant challenge in clinical therapy. Herein, a series of novel small molecule inhibitors simultaneously targeting bromodomain and extra-terminal (BET) and histone deacetylase (HDAC) were designed for combinational treatment of breast cancer and resistant <i>Candida albicans</i> infections. Among them, compounds <b>13c</b> and <b>17b</b> exhibited excellent and balanced inhibitory activity against both BET family proteins BRD4 and HDAC1. As compared with BRD4 or HDAC1 inhibitors, dual inhibitors <b>13c</b> and <b>17b</b> displayed improved <i>in vivo</i> antitumor efficacy in MDA-MB-231 breast cancer xenograft models. Notably, they synergized with fluconazole (FLC) to effectively reduce the kidney fungal burden in a murine model of disseminated candidiasis. Thus, the BET-HDAC dual inhibitors represented a novel therapeutic strategy for combinational treatment of breast cancer and concurrent candidiasis.",2023-01-09,breast cancer is susceptible to icandidai infections and candidiasis has an enhancing effect on the progression and metastasis of tumor breast cancer and concurrent candidiasis represent a significant challenge in clinical therapy herein a series of novel small molecule inhibitors simultaneously targeting bromodomain and extraterminal bet and histone deacetylase hdac were designed for combinational treatment of breast cancer and resistant icandida albicansi infections among them compounds b13cb and b17bb exhibited excellent and balanced inhibitory activity against both bet family proteins brd4 and hdac1 as compared with brd4 or hdac1 inhibitors dual inhibitors b13cb and b17bb displayed improved iin vivoi antitumor efficacy in mdamb231 breast cancer xenograft models notably they synergized with fluconazole flc to effectively reduce the kidney fungal burden in a murine model of disseminated candidiasis thus the bethdac dual inhibitors represented a novel therapeutic strategy for combinational treatment of breast cancer and concurrent candidiasis,"['breast', 'cancer', 'is', 'susceptible', 'to', 'icandidai', 'infections', 'and', 'candidiasis', 'has', 'an', 'enhancing', 'effect', 'on', 'the', 'progression', 'and', 'metastasis', 'of', 'tumor', 'breast', 'cancer', 'and', 'concurrent', 'candidiasis', 'represent', 'a', 'significant', 'challenge', 'in', 'clinical', 'therapy', 'herein', 'a', 'series', 'of', 'novel', 'small', 'molecule', 'inhibitors', 'simultaneously', 'targeting', 'bromodomain', 'and', 'extraterminal', 'bet', 'and', 'histone', 'deacetylase', 'hdac', 'were', 'designed', 'for', 'combinational', 'treatment', 'of', 'breast', 'cancer', 'and', 'resistant', 'icandida', 'albicansi', 'infections', 'among', 'them', 'compounds', 'b13cb', 'and', 'b17bb', 'exhibited', 'excellent', 'and', 'balanced', 'inhibitory', 'activity', 'against', 'both', 'bet', 'family', 'proteins', 'brd4', 'and', 'hdac1', 'as', 'compared', 'with', 'brd4', 'or', 'hdac1', 'inhibitors', 'dual', 'inhibitors', 'b13cb', 'and', 'b17bb', 'displayed', 'improved', 'iin', 'vivoi', 'antitumor', 'efficacy', 'in', 'mdamb231', 'breast', 'cancer', 'xenograft', 'models', 'notably', 'they', 'synergized', 'with', 'fluconazole', 'flc', 'to', 'effectively', 'reduce', 'the', 'kidney', 'fungal', 'burden', 'in', 'a', 'murine', 'model', 'of', 'disseminated', 'candidiasis', 'thus', 'the', 'bethdac', 'dual', 'inhibitors', 'represented', 'a', 'novel', 'therapeutic', 'strategy', 'for', 'combinational', 'treatment', 'of', 'breast', 'cancer', 'and', 'concurrent', 'candidiasis']","['breast', 'cancer', 'susceptible', 'icandidai', 'infections', 'candidiasis', 'enhancing', 'effect', 'progression', 'metastasis', 'tumor', 'breast', 'cancer', 'concurrent', 'candidiasis', 'represent', 'significant', 'challenge', 'clinical', 'therapy', 'herein', 'series', 'novel', 'small', 'molecule', 'inhibitors', 'simultaneously', 'targeting', 'bromodomain', 'extraterminal', 'bet', 'histone', 'deacetylase', 'hdac', 'designed', 'combinational', 'treatment', 'breast', 'cancer', 'resistant', 'icandida', 'albicansi', 'infections', 'among', 'compounds', 'b13cb', 'b17bb', 'exhibited', 'excellent', 'balanced', 'inhibitory', 'activity', 'bet', 'family', 'proteins', 'brd4', 'hdac1', 'compared', 'brd4', 'hdac1', 'inhibitors', 'dual', 'inhibitors', 'b13cb', 'b17bb', 'displayed', 'improved', 'iin', 'vivoi', 'antitumor', 'efficacy', 'mdamb231', 'breast', 'cancer', 'xenograft', 'models', 'notably', 'synergized', 'fluconazole', 'flc', 'effectively', 'reduce', 'kidney', 'fungal', 'burden', 'murine', 'model', 'disseminated', 'candidiasis', 'thus', 'bethdac', 'dual', 'inhibitors', 'represented', 'novel', 'therapeutic', 'strategy', 'combinational', 'treatment', 'breast', 'cancer', 'concurrent', 'candidiasis']","['deacetylase', 'brd4', 'hdac1', 'brd4', 'hdac1']","['hdac1', 'hdac1']",True,"['tumor', 'infection', 'cancer']"
36597724,Antigen-independent tumor targeting by CBX-12 (alphalex<sup>™</sup>-exatecan) induces long-term antitumor immunity.,"<b>Aims:</b> To determine whether antigen-independent targeting of the TOP1 inhibitor exatecan to tumor with a pH-sensitive peptide (CBX-12) produces superior synergy with immunotherapy compared with unconjugated exatecan. <b>Materials & methods:</b> <i>In vitro</i> and <i>ex vivo</i> functional assays were performed via FACS and ELISA assays. <i>In vivo</i> efficacy was evaluated in the syngeneic CT26 model. <b>Results:</b> CBX-12 combined with anti-PD-1 or anti-CTLA4 results in delayed tumor growth and complete response, with cured animals displaying long-term antitumor immunity. CBX-12 stimulates expression of MHC 1 and PD-L1 and is an inducer of immunogenic cell death, producing long-term immune recognition of tumor cells and resultant antitumor immunity. <b>Conclusion:</b> The authors' data provide the rationale for exploring immunotherapy combinations with CBX-12 in clinical trials.",2023-01-04,baimsb to determine whether antigenindependent targeting of the top1 inhibitor exatecan to tumor with a phsensitive peptide cbx12 produces superior synergy with immunotherapy compared with unconjugated exatecan bmaterials  methodsb iin vitroi and iex vivoi functional assays were performed via facs and elisa assays iin vivoi efficacy was evaluated in the syngeneic ct26 model bresultsb cbx12 combined with antipd1 or antictla4 results in delayed tumor growth and complete response with cured animals displaying longterm antitumor immunity cbx12 stimulates expression of mhc 1 and pdl1 and is an inducer of immunogenic cell death producing longterm immune recognition of tumor cells and resultant antitumor immunity bconclusionb the authors data provide the rationale for exploring immunotherapy combinations with cbx12 in clinical trials,"['baimsb', 'to', 'determine', 'whether', 'antigenindependent', 'targeting', 'of', 'the', 'top1', 'inhibitor', 'exatecan', 'to', 'tumor', 'with', 'a', 'phsensitive', 'peptide', 'cbx12', 'produces', 'superior', 'synergy', 'with', 'immunotherapy', 'compared', 'with', 'unconjugated', 'exatecan', 'bmaterials', 'methodsb', 'iin', 'vitroi', 'and', 'iex', 'vivoi', 'functional', 'assays', 'were', 'performed', 'via', 'facs', 'and', 'elisa', 'assays', 'iin', 'vivoi', 'efficacy', 'was', 'evaluated', 'in', 'the', 'syngeneic', 'ct26', 'model', 'bresultsb', 'cbx12', 'combined', 'with', 'antipd1', 'or', 'antictla4', 'results', 'in', 'delayed', 'tumor', 'growth', 'and', 'complete', 'response', 'with', 'cured', 'animals', 'displaying', 'longterm', 'antitumor', 'immunity', 'cbx12', 'stimulates', 'expression', 'of', 'mhc', '1', 'and', 'pdl1', 'and', 'is', 'an', 'inducer', 'of', 'immunogenic', 'cell', 'death', 'producing', 'longterm', 'immune', 'recognition', 'of', 'tumor', 'cells', 'and', 'resultant', 'antitumor', 'immunity', 'bconclusionb', 'the', 'authors', 'data', 'provide', 'the', 'rationale', 'for', 'exploring', 'immunotherapy', 'combinations', 'with', 'cbx12', 'in', 'clinical', 'trials']","['baimsb', 'determine', 'whether', 'antigenindependent', 'targeting', 'top1', 'inhibitor', 'exatecan', 'tumor', 'phsensitive', 'peptide', 'cbx12', 'produces', 'superior', 'synergy', 'immunotherapy', 'compared', 'unconjugated', 'exatecan', 'bmaterials', 'methodsb', 'iin', 'vitroi', 'iex', 'vivoi', 'functional', 'assays', 'performed', 'via', 'facs', 'elisa', 'assays', 'iin', 'vivoi', 'efficacy', 'evaluated', 'syngeneic', 'ct26', 'model', 'bresultsb', 'cbx12', 'combined', 'antipd1', 'antictla4', 'results', 'delayed', 'tumor', 'growth', 'complete', 'response', 'cured', 'animals', 'displaying', 'longterm', 'antitumor', 'immunity', 'cbx12', 'stimulates', 'expression', 'mhc', '1', 'pdl1', 'inducer', 'immunogenic', 'cell', 'death', 'producing', 'longterm', 'immune', 'recognition', 'tumor', 'cells', 'resultant', 'antitumor', 'immunity', 'bconclusionb', 'authors', 'data', 'provide', 'rationale', 'exploring', 'immunotherapy', 'combinations', 'cbx12', 'clinical', 'trials']","['top1', 'iex']",['iex'],True,['tumor']
36589826,Urolithin B: Two-way attack on IAPP proteotoxicity with implications for diabetes.,"Diabetes is one of the major metabolic diseases worldwide. Despite being a complex systemic pathology, the aggregation and deposition of Islet Amyloid Polypeptide (IAPP), or amylin, is a recognized histopathological marker of the disease. Although IAPP proteotoxicity represents an important trigger of β-cell dysfunction and ultimately death, its exploitation as a therapeutic tool remains underdeveloped. The bioactivity of (poly)phenols towards inhibition of pathological protein aggregation is well known, however, most of the identified molecules have limited bioavailability.",2022-12-15,diabetes is one of the major metabolic diseases worldwide despite being a complex systemic pathology the aggregation and deposition of islet amyloid polypeptide iapp or amylin is a recognized histopathological marker of the disease although iapp proteotoxicity represents an important trigger of βcell dysfunction and ultimately death its exploitation as a therapeutic tool remains underdeveloped the bioactivity of polyphenols towards inhibition of pathological protein aggregation is well known however most of the identified molecules have limited bioavailability,"['diabetes', 'is', 'one', 'of', 'the', 'major', 'metabolic', 'diseases', 'worldwide', 'despite', 'being', 'a', 'complex', 'systemic', 'pathology', 'the', 'aggregation', 'and', 'deposition', 'of', 'islet', 'amyloid', 'polypeptide', 'iapp', 'or', 'amylin', 'is', 'a', 'recognized', 'histopathological', 'marker', 'of', 'the', 'disease', 'although', 'iapp', 'proteotoxicity', 'represents', 'an', 'important', 'trigger', 'of', 'βcell', 'dysfunction', 'and', 'ultimately', 'death', 'its', 'exploitation', 'as', 'a', 'therapeutic', 'tool', 'remains', 'underdeveloped', 'the', 'bioactivity', 'of', 'polyphenols', 'towards', 'inhibition', 'of', 'pathological', 'protein', 'aggregation', 'is', 'well', 'known', 'however', 'most', 'of', 'the', 'identified', 'molecules', 'have', 'limited', 'bioavailability']","['diabetes', 'one', 'major', 'metabolic', 'diseases', 'worldwide', 'despite', 'complex', 'systemic', 'pathology', 'aggregation', 'deposition', 'islet', 'amyloid', 'polypeptide', 'iapp', 'amylin', 'recognized', 'histopathological', 'marker', 'disease', 'although', 'iapp', 'proteotoxicity', 'represents', 'important', 'trigger', 'βcell', 'dysfunction', 'ultimately', 'death', 'exploitation', 'therapeutic', 'tool', 'remains', 'underdeveloped', 'bioactivity', 'polyphenols', 'towards', 'inhibition', 'pathological', 'protein', 'aggregation', 'well', 'known', 'however', 'identified', 'molecules', 'limited', 'bioavailability']","['iapp', 'amylin', 'iapp']","['iapp', 'iapp']",True,['diabetes']
36541899,"Novel Peptide from the Hydrolysate of Hybrid Sturgeon (<i>Acipenseridae</i>) Spinal Cord: Isolation, Identification, and Anti-proliferative Effects in Human Cervix Cancer Cells.","Anti-proliferative peptides have recently attracted attention for their excellent bioactivity and biocompatibility. In this paper, five novel anti-proliferative peptides were identified from the hydrolysate of hybrid sturgeon spinal cord (HSSC). In addition, the structure-activity relationship of the novel anti-proliferative peptides was explored. In vitro experiments indicated that the peptide ""VDSVLDVVRK"" presented the highest inhibition of HeLa cell growth in all samples (IC<sub>50</sub> = 2.5 μM). VDSVLDVVRK showed a random coil secondary structure and nanomicelles in the tumor microenvironment. Transmission electron microscopy results confirmed that nanomicelles disassemble as the concentration of VDSVLDVVRK decreases. Furthermore, VDSVLDVVRK could induce HeLa cell apoptosis by increasing the expression of Cyt-c (98.65 ± 1.85%, <i>p</i> < 0.01) and caspase-9 (39.85 ± 1.81%, <i>p</i> < 0.01). In this study, the anti-proliferative mechanism of the HSSC peptide was discussed, which provided a theoretical basis for the research and development of anti-proliferative functional food.",2022-12-21,antiproliferative peptides have recently attracted attention for their excellent bioactivity and biocompatibility in this paper five novel antiproliferative peptides were identified from the hydrolysate of hybrid sturgeon spinal cord hssc in addition the structureactivity relationship of the novel antiproliferative peptides was explored in vitro experiments indicated that the peptide vdsvldvvrk presented the highest inhibition of hela cell growth in all samples icsub50sub  25 μm vdsvldvvrk showed a random coil secondary structure and nanomicelles in the tumor microenvironment transmission electron microscopy results confirmed that nanomicelles disassemble as the concentration of vdsvldvvrk decreases furthermore vdsvldvvrk could induce hela cell apoptosis by increasing the expression of cytc 9865  185 ipi  001 and caspase9 3985  181 ipi  001 in this study the antiproliferative mechanism of the hssc peptide was discussed which provided a theoretical basis for the research and development of antiproliferative functional food,"['antiproliferative', 'peptides', 'have', 'recently', 'attracted', 'attention', 'for', 'their', 'excellent', 'bioactivity', 'and', 'biocompatibility', 'in', 'this', 'paper', 'five', 'novel', 'antiproliferative', 'peptides', 'were', 'identified', 'from', 'the', 'hydrolysate', 'of', 'hybrid', 'sturgeon', 'spinal', 'cord', 'hssc', 'in', 'addition', 'the', 'structureactivity', 'relationship', 'of', 'the', 'novel', 'antiproliferative', 'peptides', 'was', 'explored', 'in', 'vitro', 'experiments', 'indicated', 'that', 'the', 'peptide', 'vdsvldvvrk', 'presented', 'the', 'highest', 'inhibition', 'of', 'hela', 'cell', 'growth', 'in', 'all', 'samples', 'icsub50sub', '25', 'μm', 'vdsvldvvrk', 'showed', 'a', 'random', 'coil', 'secondary', 'structure', 'and', 'nanomicelles', 'in', 'the', 'tumor', 'microenvironment', 'transmission', 'electron', 'microscopy', 'results', 'confirmed', 'that', 'nanomicelles', 'disassemble', 'as', 'the', 'concentration', 'of', 'vdsvldvvrk', 'decreases', 'furthermore', 'vdsvldvvrk', 'could', 'induce', 'hela', 'cell', 'apoptosis', 'by', 'increasing', 'the', 'expression', 'of', 'cytc', '9865', '185', 'ipi', '001', 'and', 'caspase9', '3985', '181', 'ipi', '001', 'in', 'this', 'study', 'the', 'antiproliferative', 'mechanism', 'of', 'the', 'hssc', 'peptide', 'was', 'discussed', 'which', 'provided', 'a', 'theoretical', 'basis', 'for', 'the', 'research', 'and', 'development', 'of', 'antiproliferative', 'functional', 'food']","['antiproliferative', 'peptides', 'recently', 'attracted', 'attention', 'excellent', 'bioactivity', 'biocompatibility', 'paper', 'five', 'novel', 'antiproliferative', 'peptides', 'identified', 'hydrolysate', 'hybrid', 'sturgeon', 'spinal', 'cord', 'hssc', 'addition', 'structureactivity', 'relationship', 'novel', 'antiproliferative', 'peptides', 'explored', 'vitro', 'experiments', 'indicated', 'peptide', 'vdsvldvvrk', 'presented', 'highest', 'inhibition', 'hela', 'cell', 'growth', 'samples', 'icsub50sub', '25', 'μm', 'vdsvldvvrk', 'showed', 'random', 'coil', 'secondary', 'structure', 'nanomicelles', 'tumor', 'microenvironment', 'transmission', 'electron', 'microscopy', 'results', 'confirmed', 'nanomicelles', 'disassemble', 'concentration', 'vdsvldvvrk', 'decreases', 'furthermore', 'vdsvldvvrk', 'could', 'induce', 'hela', 'cell', 'apoptosis', 'increasing', 'expression', 'cytc', '9865', '185', 'ipi', '001', 'caspase9', '3985', '181', 'ipi', '001', 'study', 'antiproliferative', 'mechanism', 'hssc', 'peptide', 'discussed', 'provided', 'theoretical', 'basis', 'research', 'development', 'antiproliferative', 'functional', 'food']","['cytc', 'caspase9']","['cytc', 'caspase9']",False,['tumor']
36523977,Structure-based discovery of a novel small-molecule inhibitor of TEAD palmitoylation with anticancer activity.,"The paralogous oncogenic transcriptional coactivators YAP and TAZ are the distal effectors of the Hippo signaling pathway, which plays a critical role in cell proliferation, survival and cell fate specification. They are frequently deregulated in most human cancers, where they contribute to multiple aspects of tumorigenesis including growth, metabolism, metastasis and chemo/immunotherapy resistance. Thus, they provide a critical point for therapeutic intervention. However, due to their intrinsically disordered structure, they are challenging to target directly. Since YAP/TAZ exerts oncogenic activity by associating with the TEAD1-4 transcription factors, to regulate target gene expression, YAP activity can be controlled indirectly by regulating TEAD1-4. Interestingly, TEADs undergo autopalmitoylation, which is essential for their stability and function, and small-molecule inhibitors that prevent this posttranslational modification can render them unstable. In this article we report discovery of a novel small molecule inhibitor of YAP activity. We combined structure-based virtual ligand screening with biochemical and cell biological studies and identified JM7, which inhibits YAP transcriptional reporter activity with an IC50 of 972 nMoles/Ltr. Further, it inhibits YAP target gene expression, without affecting YAP/TEAD localization. Mechanistically, JM7 inhibits TEAD palmitoylation and renders them unstable. Cellular thermal shift assay revealed that JM7 directly binds to TEAD1-4 in cells. Consistent with the inhibitory effect of JM7 on YAP activity, it significantly impairs proliferation, colony-formation and migration of mesothelioma (NCI-H226), breast (MDA-MB-231) and ovarian (OVCAR-8) cancer cells that exhibit increased YAP activity. Collectively, these results establish JM7 as a novel lead compound for development of more potent inhibitors of TEAD palmitoylation for treating cancer.",2022-11-29,the paralogous oncogenic transcriptional coactivators yap and taz are the distal effectors of the hippo signaling pathway which plays a critical role in cell proliferation survival and cell fate specification they are frequently deregulated in most human cancers where they contribute to multiple aspects of tumorigenesis including growth metabolism metastasis and chemoimmunotherapy resistance thus they provide a critical point for therapeutic intervention however due to their intrinsically disordered structure they are challenging to target directly since yaptaz exerts oncogenic activity by associating with the tead14 transcription factors to regulate target gene expression yap activity can be controlled indirectly by regulating tead14 interestingly teads undergo autopalmitoylation which is essential for their stability and function and smallmolecule inhibitors that prevent this posttranslational modification can render them unstable in this article we report discovery of a novel small molecule inhibitor of yap activity we combined structurebased virtual ligand screening with biochemical and cell biological studies and identified jm7 which inhibits yap transcriptional reporter activity with an ic50 of 972 nmolesltr further it inhibits yap target gene expression without affecting yaptead localization mechanistically jm7 inhibits tead palmitoylation and renders them unstable cellular thermal shift assay revealed that jm7 directly binds to tead14 in cells consistent with the inhibitory effect of jm7 on yap activity it significantly impairs proliferation colonyformation and migration of mesothelioma ncih226 breast mdamb231 and ovarian ovcar8 cancer cells that exhibit increased yap activity collectively these results establish jm7 as a novel lead compound for development of more potent inhibitors of tead palmitoylation for treating cancer,"['the', 'paralogous', 'oncogenic', 'transcriptional', 'coactivators', 'yap', 'and', 'taz', 'are', 'the', 'distal', 'effectors', 'of', 'the', 'hippo', 'signaling', 'pathway', 'which', 'plays', 'a', 'critical', 'role', 'in', 'cell', 'proliferation', 'survival', 'and', 'cell', 'fate', 'specification', 'they', 'are', 'frequently', 'deregulated', 'in', 'most', 'human', 'cancers', 'where', 'they', 'contribute', 'to', 'multiple', 'aspects', 'of', 'tumorigenesis', 'including', 'growth', 'metabolism', 'metastasis', 'and', 'chemoimmunotherapy', 'resistance', 'thus', 'they', 'provide', 'a', 'critical', 'point', 'for', 'therapeutic', 'intervention', 'however', 'due', 'to', 'their', 'intrinsically', 'disordered', 'structure', 'they', 'are', 'challenging', 'to', 'target', 'directly', 'since', 'yaptaz', 'exerts', 'oncogenic', 'activity', 'by', 'associating', 'with', 'the', 'tead14', 'transcription', 'factors', 'to', 'regulate', 'target', 'gene', 'expression', 'yap', 'activity', 'can', 'be', 'controlled', 'indirectly', 'by', 'regulating', 'tead14', 'interestingly', 'teads', 'undergo', 'autopalmitoylation', 'which', 'is', 'essential', 'for', 'their', 'stability', 'and', 'function', 'and', 'smallmolecule', 'inhibitors', 'that', 'prevent', 'this', 'posttranslational', 'modification', 'can', 'render', 'them', 'unstable', 'in', 'this', 'article', 'we', 'report', 'discovery', 'of', 'a', 'novel', 'small', 'molecule', 'inhibitor', 'of', 'yap', 'activity', 'we', 'combined', 'structurebased', 'virtual', 'ligand', 'screening', 'with', 'biochemical', 'and', 'cell', 'biological', 'studies', 'and', 'identified', 'jm7', 'which', 'inhibits', 'yap', 'transcriptional', 'reporter', 'activity', 'with', 'an', 'ic50', 'of', '972', 'nmolesltr', 'further', 'it', 'inhibits', 'yap', 'target', 'gene', 'expression', 'without', 'affecting', 'yaptead', 'localization', 'mechanistically', 'jm7', 'inhibits', 'tead', 'palmitoylation', 'and', 'renders', 'them', 'unstable', 'cellular', 'thermal', 'shift', 'assay', 'revealed', 'that', 'jm7', 'directly', 'binds', 'to', 'tead14', 'in', 'cells', 'consistent', 'with', 'the', 'inhibitory', 'effect', 'of', 'jm7', 'on', 'yap', 'activity', 'it', 'significantly', 'impairs', 'proliferation', 'colonyformation', 'and', 'migration', 'of', 'mesothelioma', 'ncih226', 'breast', 'mdamb231', 'and', 'ovarian', 'ovcar8', 'cancer', 'cells', 'that', 'exhibit', 'increased', 'yap', 'activity', 'collectively', 'these', 'results', 'establish', 'jm7', 'as', 'a', 'novel', 'lead', 'compound', 'for', 'development', 'of', 'more', 'potent', 'inhibitors', 'of', 'tead', 'palmitoylation', 'for', 'treating', 'cancer']","['paralogous', 'oncogenic', 'transcriptional', 'coactivators', 'yap', 'taz', 'distal', 'effectors', 'hippo', 'signaling', 'pathway', 'plays', 'critical', 'role', 'cell', 'proliferation', 'survival', 'cell', 'fate', 'specification', 'frequently', 'deregulated', 'human', 'cancers', 'contribute', 'multiple', 'aspects', 'tumorigenesis', 'including', 'growth', 'metabolism', 'metastasis', 'chemoimmunotherapy', 'resistance', 'thus', 'provide', 'critical', 'point', 'therapeutic', 'intervention', 'however', 'due', 'intrinsically', 'disordered', 'structure', 'challenging', 'target', 'directly', 'since', 'yaptaz', 'exerts', 'oncogenic', 'activity', 'associating', 'tead14', 'transcription', 'factors', 'regulate', 'target', 'gene', 'expression', 'yap', 'activity', 'controlled', 'indirectly', 'regulating', 'tead14', 'interestingly', 'teads', 'undergo', 'autopalmitoylation', 'essential', 'stability', 'function', 'smallmolecule', 'inhibitors', 'prevent', 'posttranslational', 'modification', 'render', 'unstable', 'article', 'report', 'discovery', 'novel', 'small', 'molecule', 'inhibitor', 'yap', 'activity', 'combined', 'structurebased', 'virtual', 'ligand', 'screening', 'biochemical', 'cell', 'biological', 'studies', 'identified', 'jm7', 'inhibits', 'yap', 'transcriptional', 'reporter', 'activity', 'ic50', '972', 'nmolesltr', 'inhibits', 'yap', 'target', 'gene', 'expression', 'without', 'affecting', 'yaptead', 'localization', 'mechanistically', 'jm7', 'inhibits', 'tead', 'palmitoylation', 'renders', 'unstable', 'cellular', 'thermal', 'shift', 'assay', 'revealed', 'jm7', 'directly', 'binds', 'tead14', 'cells', 'consistent', 'inhibitory', 'effect', 'jm7', 'yap', 'activity', 'significantly', 'impairs', 'proliferation', 'colonyformation', 'migration', 'mesothelioma', 'ncih226', 'breast', 'mdamb231', 'ovarian', 'ovcar8', 'cancer', 'cells', 'exhibit', 'increased', 'yap', 'activity', 'collectively', 'results', 'establish', 'jm7', 'novel', 'lead', 'compound', 'development', 'potent', 'inhibitors', 'tead', 'palmitoylation', 'treating', 'cancer']","['coactivators', 'taz']",['coactivators'],True,"['tumor', 'cancer']"
36462722,Emerging insights of peptide-based nanotherapeutics for effective management of rheumatoid arthritis.,"Rheumatoid arthritis (RA) is a chronic, prevalent, immune-mediated, inflammatory, joint disorder affecting millions of people worldwide. Despite current treatment options, many patients remain unable to achieve remission and suffer from comorbidities. Because of several comorbidities as well as its chronic nature, it diminishes the quality of patients' life and intensifies socioeconomic cargo. Consolidating peptides with immensely effective drug delivery systems has the ability to alleviate adverse effects associated with conventional treatments. Peptides are widely used as targeting moieties for the delivery of nanotherapeutics. The use of novel peptide-based nanotherapeutics may open up new avenues for improving efficacy by promoting drug accumulation in inflamed joints and reducing off-target cytotoxicity. Peptide therapeutics have grabbed significant attention due to their advantages over small drug molecules as well as complex targeting moieties. In light of this, the market for peptide-based medications is growing exponentially. Peptides can provide the versatility required for the successful delivery of drugs due to their structural diversity and their capability to lead drugs at the site of inflammation while maintaining optimum therapeutic efficacy. This comprehensive review aims to provide an enhanced understanding of recent advancements in the arena of peptide-based nanotherapeutics to strengthen targeted delivery for the effective management of rheumatoid arthritis. Additionally, various peptides having therapeutic roles in rheumatoid arthritis are summarized along with regulatory considerations for peptides.",2022-11-30,rheumatoid arthritis ra is a chronic prevalent immunemediated inflammatory joint disorder affecting millions of people worldwide despite current treatment options many patients remain unable to achieve remission and suffer from comorbidities because of several comorbidities as well as its chronic nature it diminishes the quality of patients life and intensifies socioeconomic cargo consolidating peptides with immensely effective drug delivery systems has the ability to alleviate adverse effects associated with conventional treatments peptides are widely used as targeting moieties for the delivery of nanotherapeutics the use of novel peptidebased nanotherapeutics may open up new avenues for improving efficacy by promoting drug accumulation in inflamed joints and reducing offtarget cytotoxicity peptide therapeutics have grabbed significant attention due to their advantages over small drug molecules as well as complex targeting moieties in light of this the market for peptidebased medications is growing exponentially peptides can provide the versatility required for the successful delivery of drugs due to their structural diversity and their capability to lead drugs at the site of inflammation while maintaining optimum therapeutic efficacy this comprehensive review aims to provide an enhanced understanding of recent advancements in the arena of peptidebased nanotherapeutics to strengthen targeted delivery for the effective management of rheumatoid arthritis additionally various peptides having therapeutic roles in rheumatoid arthritis are summarized along with regulatory considerations for peptides,"['rheumatoid', 'arthritis', 'ra', 'is', 'a', 'chronic', 'prevalent', 'immunemediated', 'inflammatory', 'joint', 'disorder', 'affecting', 'millions', 'of', 'people', 'worldwide', 'despite', 'current', 'treatment', 'options', 'many', 'patients', 'remain', 'unable', 'to', 'achieve', 'remission', 'and', 'suffer', 'from', 'comorbidities', 'because', 'of', 'several', 'comorbidities', 'as', 'well', 'as', 'its', 'chronic', 'nature', 'it', 'diminishes', 'the', 'quality', 'of', 'patients', 'life', 'and', 'intensifies', 'socioeconomic', 'cargo', 'consolidating', 'peptides', 'with', 'immensely', 'effective', 'drug', 'delivery', 'systems', 'has', 'the', 'ability', 'to', 'alleviate', 'adverse', 'effects', 'associated', 'with', 'conventional', 'treatments', 'peptides', 'are', 'widely', 'used', 'as', 'targeting', 'moieties', 'for', 'the', 'delivery', 'of', 'nanotherapeutics', 'the', 'use', 'of', 'novel', 'peptidebased', 'nanotherapeutics', 'may', 'open', 'up', 'new', 'avenues', 'for', 'improving', 'efficacy', 'by', 'promoting', 'drug', 'accumulation', 'in', 'inflamed', 'joints', 'and', 'reducing', 'offtarget', 'cytotoxicity', 'peptide', 'therapeutics', 'have', 'grabbed', 'significant', 'attention', 'due', 'to', 'their', 'advantages', 'over', 'small', 'drug', 'molecules', 'as', 'well', 'as', 'complex', 'targeting', 'moieties', 'in', 'light', 'of', 'this', 'the', 'market', 'for', 'peptidebased', 'medications', 'is', 'growing', 'exponentially', 'peptides', 'can', 'provide', 'the', 'versatility', 'required', 'for', 'the', 'successful', 'delivery', 'of', 'drugs', 'due', 'to', 'their', 'structural', 'diversity', 'and', 'their', 'capability', 'to', 'lead', 'drugs', 'at', 'the', 'site', 'of', 'inflammation', 'while', 'maintaining', 'optimum', 'therapeutic', 'efficacy', 'this', 'comprehensive', 'review', 'aims', 'to', 'provide', 'an', 'enhanced', 'understanding', 'of', 'recent', 'advancements', 'in', 'the', 'arena', 'of', 'peptidebased', 'nanotherapeutics', 'to', 'strengthen', 'targeted', 'delivery', 'for', 'the', 'effective', 'management', 'of', 'rheumatoid', 'arthritis', 'additionally', 'various', 'peptides', 'having', 'therapeutic', 'roles', 'in', 'rheumatoid', 'arthritis', 'are', 'summarized', 'along', 'with', 'regulatory', 'considerations', 'for', 'peptides']","['rheumatoid', 'arthritis', 'ra', 'chronic', 'prevalent', 'immunemediated', 'inflammatory', 'joint', 'disorder', 'affecting', 'millions', 'people', 'worldwide', 'despite', 'current', 'treatment', 'options', 'many', 'patients', 'remain', 'unable', 'achieve', 'remission', 'suffer', 'comorbidities', 'several', 'comorbidities', 'well', 'chronic', 'nature', 'diminishes', 'quality', 'patients', 'life', 'intensifies', 'socioeconomic', 'cargo', 'consolidating', 'peptides', 'immensely', 'effective', 'drug', 'delivery', 'systems', 'ability', 'alleviate', 'adverse', 'effects', 'associated', 'conventional', 'treatments', 'peptides', 'widely', 'used', 'targeting', 'moieties', 'delivery', 'nanotherapeutics', 'use', 'novel', 'peptidebased', 'nanotherapeutics', 'may', 'open', 'new', 'avenues', 'improving', 'efficacy', 'promoting', 'drug', 'accumulation', 'inflamed', 'joints', 'reducing', 'offtarget', 'cytotoxicity', 'peptide', 'therapeutics', 'grabbed', 'significant', 'attention', 'due', 'advantages', 'small', 'drug', 'molecules', 'well', 'complex', 'targeting', 'moieties', 'light', 'market', 'peptidebased', 'medications', 'growing', 'exponentially', 'peptides', 'provide', 'versatility', 'required', 'successful', 'delivery', 'drugs', 'due', 'structural', 'diversity', 'capability', 'lead', 'drugs', 'site', 'inflammation', 'maintaining', 'optimum', 'therapeutic', 'efficacy', 'comprehensive', 'review', 'aims', 'provide', 'enhanced', 'understanding', 'recent', 'advancements', 'arena', 'peptidebased', 'nanotherapeutics', 'strengthen', 'targeted', 'delivery', 'effective', 'management', 'rheumatoid', 'arthritis', 'additionally', 'various', 'peptides', 'therapeutic', 'roles', 'rheumatoid', 'arthritis', 'summarized', 'along', 'regulatory', 'considerations', 'peptides']","['ra', 'offtarget']","['ra', 'offtarget']",True,['arthritis']
36456600,Identification of a novel peptide ligand for the cancer-specific receptor mutation EGFRvIII using high-throughput sequencing of phage-selected peptides.,"We report here the selection and characterization of a novel peptide ligand using phage display targeted against the cancer-specific epidermal growth factor tyrosine kinase receptor mutation variant III (EGFRvIII). This receptor is expressed in several kinds of cancer: ovarian cancer, breast cancer and glioblastoma, but not in normal tissues. A 12-mer random peptide library was screened against EGFRvIII. Phage-selected peptides were sequenced in high-throughput by next generation sequencing (NGS), and their diversity was studied to identify highly abundant clones expected to bind with the highest affinities to EGFRvIII. The enriched peptides were characterized and their binding capacity towards stable cell lines expressing EGFRvIII, EGFR wild type (EGFR WT), or a low endogenous level of EGFR WT was confirmed by flow cytometry analysis. The best peptide candidate, VLGREEWSTSYW, was synthesized, and its binding specificity towards EGFRvIII was validated in vitro. Additionally, computational docking analysis suggested that the identified peptide binds selectively to EGFRvIII. The novel VLGREEWSTSYW peptide is thus a promising EGFRvIII-targeting agent for future applications in cancer diagnosis and therapy.",2022-12-01,we report here the selection and characterization of a novel peptide ligand using phage display targeted against the cancerspecific epidermal growth factor tyrosine kinase receptor mutation variant iii egfrviii this receptor is expressed in several kinds of cancer ovarian cancer breast cancer and glioblastoma but not in normal tissues a 12mer random peptide library was screened against egfrviii phageselected peptides were sequenced in highthroughput by next generation sequencing ngs and their diversity was studied to identify highly abundant clones expected to bind with the highest affinities to egfrviii the enriched peptides were characterized and their binding capacity towards stable cell lines expressing egfrviii egfr wild type egfr wt or a low endogenous level of egfr wt was confirmed by flow cytometry analysis the best peptide candidate vlgreewstsyw was synthesized and its binding specificity towards egfrviii was validated in vitro additionally computational docking analysis suggested that the identified peptide binds selectively to egfrviii the novel vlgreewstsyw peptide is thus a promising egfrviiitargeting agent for future applications in cancer diagnosis and therapy,"['we', 'report', 'here', 'the', 'selection', 'and', 'characterization', 'of', 'a', 'novel', 'peptide', 'ligand', 'using', 'phage', 'display', 'targeted', 'against', 'the', 'cancerspecific', 'epidermal', 'growth', 'factor', 'tyrosine', 'kinase', 'receptor', 'mutation', 'variant', 'iii', 'egfrviii', 'this', 'receptor', 'is', 'expressed', 'in', 'several', 'kinds', 'of', 'cancer', 'ovarian', 'cancer', 'breast', 'cancer', 'and', 'glioblastoma', 'but', 'not', 'in', 'normal', 'tissues', 'a', '12mer', 'random', 'peptide', 'library', 'was', 'screened', 'against', 'egfrviii', 'phageselected', 'peptides', 'were', 'sequenced', 'in', 'highthroughput', 'by', 'next', 'generation', 'sequencing', 'ngs', 'and', 'their', 'diversity', 'was', 'studied', 'to', 'identify', 'highly', 'abundant', 'clones', 'expected', 'to', 'bind', 'with', 'the', 'highest', 'affinities', 'to', 'egfrviii', 'the', 'enriched', 'peptides', 'were', 'characterized', 'and', 'their', 'binding', 'capacity', 'towards', 'stable', 'cell', 'lines', 'expressing', 'egfrviii', 'egfr', 'wild', 'type', 'egfr', 'wt', 'or', 'a', 'low', 'endogenous', 'level', 'of', 'egfr', 'wt', 'was', 'confirmed', 'by', 'flow', 'cytometry', 'analysis', 'the', 'best', 'peptide', 'candidate', 'vlgreewstsyw', 'was', 'synthesized', 'and', 'its', 'binding', 'specificity', 'towards', 'egfrviii', 'was', 'validated', 'in', 'vitro', 'additionally', 'computational', 'docking', 'analysis', 'suggested', 'that', 'the', 'identified', 'peptide', 'binds', 'selectively', 'to', 'egfrviii', 'the', 'novel', 'vlgreewstsyw', 'peptide', 'is', 'thus', 'a', 'promising', 'egfrviiitargeting', 'agent', 'for', 'future', 'applications', 'in', 'cancer', 'diagnosis', 'and', 'therapy']","['report', 'selection', 'characterization', 'novel', 'peptide', 'ligand', 'using', 'phage', 'display', 'targeted', 'cancerspecific', 'epidermal', 'growth', 'factor', 'tyrosine', 'kinase', 'receptor', 'mutation', 'variant', 'iii', 'egfrviii', 'receptor', 'expressed', 'several', 'kinds', 'cancer', 'ovarian', 'cancer', 'breast', 'cancer', 'glioblastoma', 'normal', 'tissues', '12mer', 'random', 'peptide', 'library', 'screened', 'egfrviii', 'phageselected', 'peptides', 'sequenced', 'highthroughput', 'next', 'generation', 'sequencing', 'ngs', 'diversity', 'studied', 'identify', 'highly', 'abundant', 'clones', 'expected', 'bind', 'highest', 'affinities', 'egfrviii', 'enriched', 'peptides', 'characterized', 'binding', 'capacity', 'towards', 'stable', 'cell', 'lines', 'expressing', 'egfrviii', 'egfr', 'wild', 'type', 'egfr', 'wt', 'low', 'endogenous', 'level', 'egfr', 'wt', 'confirmed', 'flow', 'cytometry', 'analysis', 'best', 'peptide', 'candidate', 'vlgreewstsyw', 'synthesized', 'binding', 'specificity', 'towards', 'egfrviii', 'validated', 'vitro', 'additionally', 'computational', 'docking', 'analysis', 'suggested', 'identified', 'peptide', 'binds', 'selectively', 'egfrviii', 'novel', 'vlgreewstsyw', 'peptide', 'thus', 'promising', 'egfrviiitargeting', 'agent', 'future', 'applications', 'cancer', 'diagnosis', 'therapy']","['cancerspecific', 'egfr', 'egfr', 'egfr']",['cancerspecific'],False,['cancer']
36400857,Construction and validation of a prognostic model for lung adenocarcinoma based on endoplasmic reticulum stress-related genes.,"Lung adenocarcinoma (LUAD) is one of the most universal types of cancer all over the world and its morbidity continues to rise year by year. Growing evidence has demonstrated that endoplasmic reticulum stress is highly activated in cancer cells and plays a key role in regulating the fate of cancer cells. However, the role and mechanism of endoplasmic reticulum stress in lung adenocarcinoma genesis and development remains unclear. In this research, we developed a prognostic model to predict the overall survival of patients with LUAD utilizing endoplasmic reticulum stress-related genes and screened out potential small molecular compounds, which could assist the clinician in making accurate decisions and better treat LUAD patients. Firstly, we downloaded 419 endoplasmic reticulum stress-related genes (ERSRGs) from Molecular Signatures Database (MSigDB). Secondly, we obtained information about the transcriptome profiling and corresponding clinical data of 59 normal samples and 535 lung adenocarcinoma samples from The Cancer Genome Atlas (TCGA) database. Next, we used the DESeq2 package to identify differentially expressed genes related to endoplasmic reticulum stress. We performed univariate Cox, least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression analysis to establish a prognostic model for LUAD patients based on ERSRGs. Then, we carried out univariate and multivariate independent prognostic analysis of endoplasmic reticulum stress-related gene (ERSRG) score and some clinical traits of lung adenocarcinoma. Additionally, we developed a clinically applicable nomogram for predicting survival for LUAD patients over one, three, and five years. Moreover, we carried out a drug sensitivity analysis to identify novel small molecule compounds for LUAD treatment. Finally, we examined the tumor microenvironment (TME) and immune cell infiltrating analysis to explore the interactions between immune and cancer cells. 142 differentially expressed ERSRGs were identified by using the DESeq2 package. A prognostic model was built based on 7 differentially expressed ERSRGs after performing univariate Cox regression, LASSO regression, and multivariate Cox regression analysis. According to the results of univariate and multivariate independent prognostic analysis, we found ERSRG score can be used as an independent prognostic maker. Using the Kaplan-Meier curves, we found low-risk patients had higher survival probability than high-risk patients in both training set and test set. A nomogram was drawn to predict 1-, 3-, and 5-year survival probability. The calibration curves explained good performance of the model for the prediction of survival. Phenformin, OSU-03012, GSK-650394 and KIN001-135 were identified as the drugs most likely to provide important information to clinicians about the treatment of LUAD patients. A prognostic prediction model was established based on 7 differentially expressed ERSRGs (PDX1, IGFBP1, DDIT4, PPP1R3G, CFTR, DERL3 and NUPR1), which could effectively predict the prognosis of LUAD patients and give a reference for clinical doctors to help LUAD patients to make better treatment tactics. Based on the 4 small molecule compounds (Phenformin, OSU-03012, GSK-650394 and KIN001-135) we discovered, targeting endoplasmic reticulum stress-related genes may also be a therapeutic approach for LUAD patients.",2022-11-18,lung adenocarcinoma luad is one of the most universal types of cancer all over the world and its morbidity continues to rise year by year growing evidence has demonstrated that endoplasmic reticulum stress is highly activated in cancer cells and plays a key role in regulating the fate of cancer cells however the role and mechanism of endoplasmic reticulum stress in lung adenocarcinoma genesis and development remains unclear in this research we developed a prognostic model to predict the overall survival of patients with luad utilizing endoplasmic reticulum stressrelated genes and screened out potential small molecular compounds which could assist the clinician in making accurate decisions and better treat luad patients firstly we downloaded 419 endoplasmic reticulum stressrelated genes ersrgs from molecular signatures database msigdb secondly we obtained information about the transcriptome profiling and corresponding clinical data of 59 normal samples and 535 lung adenocarcinoma samples from the cancer genome atlas tcga database next we used the deseq2 package to identify differentially expressed genes related to endoplasmic reticulum stress we performed univariate cox least absolute shrinkage and selection operator lasso and multivariate cox regression analysis to establish a prognostic model for luad patients based on ersrgs then we carried out univariate and multivariate independent prognostic analysis of endoplasmic reticulum stressrelated gene ersrg score and some clinical traits of lung adenocarcinoma additionally we developed a clinically applicable nomogram for predicting survival for luad patients over one three and five years moreover we carried out a drug sensitivity analysis to identify novel small molecule compounds for luad treatment finally we examined the tumor microenvironment tme and immune cell infiltrating analysis to explore the interactions between immune and cancer cells 142 differentially expressed ersrgs were identified by using the deseq2 package a prognostic model was built based on 7 differentially expressed ersrgs after performing univariate cox regression lasso regression and multivariate cox regression analysis according to the results of univariate and multivariate independent prognostic analysis we found ersrg score can be used as an independent prognostic maker using the kaplanmeier curves we found lowrisk patients had higher survival probability than highrisk patients in both training set and test set a nomogram was drawn to predict 1 3 and 5year survival probability the calibration curves explained good performance of the model for the prediction of survival phenformin osu03012 gsk650394 and kin001135 were identified as the drugs most likely to provide important information to clinicians about the treatment of luad patients a prognostic prediction model was established based on 7 differentially expressed ersrgs pdx1 igfbp1 ddit4 ppp1r3g cftr derl3 and nupr1 which could effectively predict the prognosis of luad patients and give a reference for clinical doctors to help luad patients to make better treatment tactics based on the 4 small molecule compounds phenformin osu03012 gsk650394 and kin001135 we discovered targeting endoplasmic reticulum stressrelated genes may also be a therapeutic approach for luad patients,"['lung', 'adenocarcinoma', 'luad', 'is', 'one', 'of', 'the', 'most', 'universal', 'types', 'of', 'cancer', 'all', 'over', 'the', 'world', 'and', 'its', 'morbidity', 'continues', 'to', 'rise', 'year', 'by', 'year', 'growing', 'evidence', 'has', 'demonstrated', 'that', 'endoplasmic', 'reticulum', 'stress', 'is', 'highly', 'activated', 'in', 'cancer', 'cells', 'and', 'plays', 'a', 'key', 'role', 'in', 'regulating', 'the', 'fate', 'of', 'cancer', 'cells', 'however', 'the', 'role', 'and', 'mechanism', 'of', 'endoplasmic', 'reticulum', 'stress', 'in', 'lung', 'adenocarcinoma', 'genesis', 'and', 'development', 'remains', 'unclear', 'in', 'this', 'research', 'we', 'developed', 'a', 'prognostic', 'model', 'to', 'predict', 'the', 'overall', 'survival', 'of', 'patients', 'with', 'luad', 'utilizing', 'endoplasmic', 'reticulum', 'stressrelated', 'genes', 'and', 'screened', 'out', 'potential', 'small', 'molecular', 'compounds', 'which', 'could', 'assist', 'the', 'clinician', 'in', 'making', 'accurate', 'decisions', 'and', 'better', 'treat', 'luad', 'patients', 'firstly', 'we', 'downloaded', '419', 'endoplasmic', 'reticulum', 'stressrelated', 'genes', 'ersrgs', 'from', 'molecular', 'signatures', 'database', 'msigdb', 'secondly', 'we', 'obtained', 'information', 'about', 'the', 'transcriptome', 'profiling', 'and', 'corresponding', 'clinical', 'data', 'of', '59', 'normal', 'samples', 'and', '535', 'lung', 'adenocarcinoma', 'samples', 'from', 'the', 'cancer', 'genome', 'atlas', 'tcga', 'database', 'next', 'we', 'used', 'the', 'deseq2', 'package', 'to', 'identify', 'differentially', 'expressed', 'genes', 'related', 'to', 'endoplasmic', 'reticulum', 'stress', 'we', 'performed', 'univariate', 'cox', 'least', 'absolute', 'shrinkage', 'and', 'selection', 'operator', 'lasso', 'and', 'multivariate', 'cox', 'regression', 'analysis', 'to', 'establish', 'a', 'prognostic', 'model', 'for', 'luad', 'patients', 'based', 'on', 'ersrgs', 'then', 'we', 'carried', 'out', 'univariate', 'and', 'multivariate', 'independent', 'prognostic', 'analysis', 'of', 'endoplasmic', 'reticulum', 'stressrelated', 'gene', 'ersrg', 'score', 'and', 'some', 'clinical', 'traits', 'of', 'lung', 'adenocarcinoma', 'additionally', 'we', 'developed', 'a', 'clinically', 'applicable', 'nomogram', 'for', 'predicting', 'survival', 'for', 'luad', 'patients', 'over', 'one', 'three', 'and', 'five', 'years', 'moreover', 'we', 'carried', 'out', 'a', 'drug', 'sensitivity', 'analysis', 'to', 'identify', 'novel', 'small', 'molecule', 'compounds', 'for', 'luad', 'treatment', 'finally', 'we', 'examined', 'the', 'tumor', 'microenvironment', 'tme', 'and', 'immune', 'cell', 'infiltrating', 'analysis', 'to', 'explore', 'the', 'interactions', 'between', 'immune', 'and', 'cancer', 'cells', '142', 'differentially', 'expressed', 'ersrgs', 'were', 'identified', 'by', 'using', 'the', 'deseq2', 'package', 'a', 'prognostic', 'model', 'was', 'built', 'based', 'on', '7', 'differentially', 'expressed', 'ersrgs', 'after', 'performing', 'univariate', 'cox', 'regression', 'lasso', 'regression', 'and', 'multivariate', 'cox', 'regression', 'analysis', 'according', 'to', 'the', 'results', 'of', 'univariate', 'and', 'multivariate', 'independent', 'prognostic', 'analysis', 'we', 'found', 'ersrg', 'score', 'can', 'be', 'used', 'as', 'an', 'independent', 'prognostic', 'maker', 'using', 'the', 'kaplanmeier', 'curves', 'we', 'found', 'lowrisk', 'patients', 'had', 'higher', 'survival', 'probability', 'than', 'highrisk', 'patients', 'in', 'both', 'training', 'set', 'and', 'test', 'set', 'a', 'nomogram', 'was', 'drawn', 'to', 'predict', '1', '3', 'and', '5year', 'survival', 'probability', 'the', 'calibration', 'curves', 'explained', 'good', 'performance', 'of', 'the', 'model', 'for', 'the', 'prediction', 'of', 'survival', 'phenformin', 'osu03012', 'gsk650394', 'and', 'kin001135', 'were', 'identified', 'as', 'the', 'drugs', 'most', 'likely', 'to', 'provide', 'important', 'information', 'to', 'clinicians', 'about', 'the', 'treatment', 'of', 'luad', 'patients', 'a', 'prognostic', 'prediction', 'model', 'was', 'established', 'based', 'on', '7', 'differentially', 'expressed', 'ersrgs', 'pdx1', 'igfbp1', 'ddit4', 'ppp1r3g', 'cftr', 'derl3', 'and', 'nupr1', 'which', 'could', 'effectively', 'predict', 'the', 'prognosis', 'of', 'luad', 'patients', 'and', 'give', 'a', 'reference', 'for', 'clinical', 'doctors', 'to', 'help', 'luad', 'patients', 'to', 'make', 'better', 'treatment', 'tactics', 'based', 'on', 'the', '4', 'small', 'molecule', 'compounds', 'phenformin', 'osu03012', 'gsk650394', 'and', 'kin001135', 'we', 'discovered', 'targeting', 'endoplasmic', 'reticulum', 'stressrelated', 'genes', 'may', 'also', 'be', 'a', 'therapeutic', 'approach', 'for', 'luad', 'patients']","['lung', 'adenocarcinoma', 'luad', 'one', 'universal', 'types', 'cancer', 'world', 'morbidity', 'continues', 'rise', 'year', 'year', 'growing', 'evidence', 'demonstrated', 'endoplasmic', 'reticulum', 'stress', 'highly', 'activated', 'cancer', 'cells', 'plays', 'key', 'role', 'regulating', 'fate', 'cancer', 'cells', 'however', 'role', 'mechanism', 'endoplasmic', 'reticulum', 'stress', 'lung', 'adenocarcinoma', 'genesis', 'development', 'remains', 'unclear', 'research', 'developed', 'prognostic', 'model', 'predict', 'overall', 'survival', 'patients', 'luad', 'utilizing', 'endoplasmic', 'reticulum', 'stressrelated', 'genes', 'screened', 'potential', 'small', 'molecular', 'compounds', 'could', 'assist', 'clinician', 'making', 'accurate', 'decisions', 'better', 'treat', 'luad', 'patients', 'firstly', 'downloaded', '419', 'endoplasmic', 'reticulum', 'stressrelated', 'genes', 'ersrgs', 'molecular', 'signatures', 'database', 'msigdb', 'secondly', 'obtained', 'information', 'transcriptome', 'profiling', 'corresponding', 'clinical', 'data', '59', 'normal', 'samples', '535', 'lung', 'adenocarcinoma', 'samples', 'cancer', 'genome', 'atlas', 'tcga', 'database', 'next', 'used', 'deseq2', 'package', 'identify', 'differentially', 'expressed', 'genes', 'related', 'endoplasmic', 'reticulum', 'stress', 'performed', 'univariate', 'cox', 'least', 'absolute', 'shrinkage', 'selection', 'operator', 'lasso', 'multivariate', 'cox', 'regression', 'analysis', 'establish', 'prognostic', 'model', 'luad', 'patients', 'based', 'ersrgs', 'carried', 'univariate', 'multivariate', 'independent', 'prognostic', 'analysis', 'endoplasmic', 'reticulum', 'stressrelated', 'gene', 'ersrg', 'score', 'clinical', 'traits', 'lung', 'adenocarcinoma', 'additionally', 'developed', 'clinically', 'applicable', 'nomogram', 'predicting', 'survival', 'luad', 'patients', 'one', 'three', 'five', 'years', 'moreover', 'carried', 'drug', 'sensitivity', 'analysis', 'identify', 'novel', 'small', 'molecule', 'compounds', 'luad', 'treatment', 'finally', 'examined', 'tumor', 'microenvironment', 'tme', 'immune', 'cell', 'infiltrating', 'analysis', 'explore', 'interactions', 'immune', 'cancer', 'cells', '142', 'differentially', 'expressed', 'ersrgs', 'identified', 'using', 'deseq2', 'package', 'prognostic', 'model', 'built', 'based', '7', 'differentially', 'expressed', 'ersrgs', 'performing', 'univariate', 'cox', 'regression', 'lasso', 'regression', 'multivariate', 'cox', 'regression', 'analysis', 'according', 'results', 'univariate', 'multivariate', 'independent', 'prognostic', 'analysis', 'found', 'ersrg', 'score', 'used', 'independent', 'prognostic', 'maker', 'using', 'kaplanmeier', 'curves', 'found', 'lowrisk', 'patients', 'higher', 'survival', 'probability', 'highrisk', 'patients', 'training', 'set', 'test', 'set', 'nomogram', 'drawn', 'predict', '1', '3', '5year', 'survival', 'probability', 'calibration', 'curves', 'explained', 'good', 'performance', 'model', 'prediction', 'survival', 'phenformin', 'osu03012', 'gsk650394', 'kin001135', 'identified', 'drugs', 'likely', 'provide', 'important', 'information', 'clinicians', 'treatment', 'luad', 'patients', 'prognostic', 'prediction', 'model', 'established', 'based', '7', 'differentially', 'expressed', 'ersrgs', 'pdx1', 'igfbp1', 'ddit4', 'ppp1r3g', 'cftr', 'derl3', 'nupr1', 'could', 'effectively', 'predict', 'prognosis', 'luad', 'patients', 'give', 'reference', 'clinical', 'doctors', 'help', 'luad', 'patients', 'make', 'better', 'treatment', 'tactics', 'based', '4', 'small', 'molecule', 'compounds', 'phenformin', 'osu03012', 'gsk650394', 'kin001135', 'discovered', 'targeting', 'endoplasmic', 'reticulum', 'stressrelated', 'genes', 'may', 'also', 'therapeutic', 'approach', 'luad', 'patients']","['pdx1', 'igfbp1', 'nupr1']","['pdx1', 'igfbp1', 'nupr1']",True,"['tumor', 'cancer']"
36381330,The cancer stemness inhibitor napabucasin suppresses small cell lung cancer growth through SOX2 expression.,"Small cell lung cancer (SCLC) is a high-grade malignancy of neuroendocrine origin characterized by aggressive cell growth and a poor survival rate of patients. Currently, the treatment options for SCLC remain limited despite platinum-based chemotherapy. Systemic chemotherapy is effective for SCLC, but most patients eventually acquire drug resistance, which leads to treatment failure. Stemness-high cancer cells show characteristics of advanced tumorigenesis and metastasis and have high potential in promoting treatment resistance and disease relapse. Napabucasin (BBI608), a novel small-molecule drug targeting on signal transducer and activator of transcription 3 (STAT3), was shown to suppress the progression and metastasis of stemness-high cancer stem cells in various cancers. Here, we demonstrated that napabucasin significantly decreased viability and colony formation and induced the arrest of S-phase cell cycle and apoptosis in cisplatin-resistant SCLC cells. Findings from mechanistic studies further indicated that napabucasin directly downregulated the expression of SOX2 in cisplatin-resistant SCLC cells; however, dysfunctional SOX2 expression in SCLC cells was associated with interference in the napabucasin-mediated reduction of cell viability. In contrast, napabucasin-induced viability reduction was restored in these cells when SOX2 expression was upregulated. Furthermore, napabucasin significantly inhibited cisplatin-resistant SCLC cell xenograft growth <i>in vivo</i> by downregulating SOX2 and inducing apoptosis. These data demonstrate that napabucasin may be a novel drug for the clinical treatment of cisplatin-resistant SCLC.",2022-10-15,small cell lung cancer sclc is a highgrade malignancy of neuroendocrine origin characterized by aggressive cell growth and a poor survival rate of patients currently the treatment options for sclc remain limited despite platinumbased chemotherapy systemic chemotherapy is effective for sclc but most patients eventually acquire drug resistance which leads to treatment failure stemnesshigh cancer cells show characteristics of advanced tumorigenesis and metastasis and have high potential in promoting treatment resistance and disease relapse napabucasin bbi608 a novel smallmolecule drug targeting on signal transducer and activator of transcription 3 stat3 was shown to suppress the progression and metastasis of stemnesshigh cancer stem cells in various cancers here we demonstrated that napabucasin significantly decreased viability and colony formation and induced the arrest of sphase cell cycle and apoptosis in cisplatinresistant sclc cells findings from mechanistic studies further indicated that napabucasin directly downregulated the expression of sox2 in cisplatinresistant sclc cells however dysfunctional sox2 expression in sclc cells was associated with interference in the napabucasinmediated reduction of cell viability in contrast napabucasininduced viability reduction was restored in these cells when sox2 expression was upregulated furthermore napabucasin significantly inhibited cisplatinresistant sclc cell xenograft growth iin vivoi by downregulating sox2 and inducing apoptosis these data demonstrate that napabucasin may be a novel drug for the clinical treatment of cisplatinresistant sclc,"['small', 'cell', 'lung', 'cancer', 'sclc', 'is', 'a', 'highgrade', 'malignancy', 'of', 'neuroendocrine', 'origin', 'characterized', 'by', 'aggressive', 'cell', 'growth', 'and', 'a', 'poor', 'survival', 'rate', 'of', 'patients', 'currently', 'the', 'treatment', 'options', 'for', 'sclc', 'remain', 'limited', 'despite', 'platinumbased', 'chemotherapy', 'systemic', 'chemotherapy', 'is', 'effective', 'for', 'sclc', 'but', 'most', 'patients', 'eventually', 'acquire', 'drug', 'resistance', 'which', 'leads', 'to', 'treatment', 'failure', 'stemnesshigh', 'cancer', 'cells', 'show', 'characteristics', 'of', 'advanced', 'tumorigenesis', 'and', 'metastasis', 'and', 'have', 'high', 'potential', 'in', 'promoting', 'treatment', 'resistance', 'and', 'disease', 'relapse', 'napabucasin', 'bbi608', 'a', 'novel', 'smallmolecule', 'drug', 'targeting', 'on', 'signal', 'transducer', 'and', 'activator', 'of', 'transcription', '3', 'stat3', 'was', 'shown', 'to', 'suppress', 'the', 'progression', 'and', 'metastasis', 'of', 'stemnesshigh', 'cancer', 'stem', 'cells', 'in', 'various', 'cancers', 'here', 'we', 'demonstrated', 'that', 'napabucasin', 'significantly', 'decreased', 'viability', 'and', 'colony', 'formation', 'and', 'induced', 'the', 'arrest', 'of', 'sphase', 'cell', 'cycle', 'and', 'apoptosis', 'in', 'cisplatinresistant', 'sclc', 'cells', 'findings', 'from', 'mechanistic', 'studies', 'further', 'indicated', 'that', 'napabucasin', 'directly', 'downregulated', 'the', 'expression', 'of', 'sox2', 'in', 'cisplatinresistant', 'sclc', 'cells', 'however', 'dysfunctional', 'sox2', 'expression', 'in', 'sclc', 'cells', 'was', 'associated', 'with', 'interference', 'in', 'the', 'napabucasinmediated', 'reduction', 'of', 'cell', 'viability', 'in', 'contrast', 'napabucasininduced', 'viability', 'reduction', 'was', 'restored', 'in', 'these', 'cells', 'when', 'sox2', 'expression', 'was', 'upregulated', 'furthermore', 'napabucasin', 'significantly', 'inhibited', 'cisplatinresistant', 'sclc', 'cell', 'xenograft', 'growth', 'iin', 'vivoi', 'by', 'downregulating', 'sox2', 'and', 'inducing', 'apoptosis', 'these', 'data', 'demonstrate', 'that', 'napabucasin', 'may', 'be', 'a', 'novel', 'drug', 'for', 'the', 'clinical', 'treatment', 'of', 'cisplatinresistant', 'sclc']","['small', 'cell', 'lung', 'cancer', 'sclc', 'highgrade', 'malignancy', 'neuroendocrine', 'origin', 'characterized', 'aggressive', 'cell', 'growth', 'poor', 'survival', 'rate', 'patients', 'currently', 'treatment', 'options', 'sclc', 'remain', 'limited', 'despite', 'platinumbased', 'chemotherapy', 'systemic', 'chemotherapy', 'effective', 'sclc', 'patients', 'eventually', 'acquire', 'drug', 'resistance', 'leads', 'treatment', 'failure', 'stemnesshigh', 'cancer', 'cells', 'show', 'characteristics', 'advanced', 'tumorigenesis', 'metastasis', 'high', 'potential', 'promoting', 'treatment', 'resistance', 'disease', 'relapse', 'napabucasin', 'bbi608', 'novel', 'smallmolecule', 'drug', 'targeting', 'signal', 'transducer', 'activator', 'transcription', '3', 'stat3', 'shown', 'suppress', 'progression', 'metastasis', 'stemnesshigh', 'cancer', 'stem', 'cells', 'various', 'cancers', 'demonstrated', 'napabucasin', 'significantly', 'decreased', 'viability', 'colony', 'formation', 'induced', 'arrest', 'sphase', 'cell', 'cycle', 'apoptosis', 'cisplatinresistant', 'sclc', 'cells', 'findings', 'mechanistic', 'studies', 'indicated', 'napabucasin', 'directly', 'downregulated', 'expression', 'sox2', 'cisplatinresistant', 'sclc', 'cells', 'however', 'dysfunctional', 'sox2', 'expression', 'sclc', 'cells', 'associated', 'interference', 'napabucasinmediated', 'reduction', 'cell', 'viability', 'contrast', 'napabucasininduced', 'viability', 'reduction', 'restored', 'cells', 'sox2', 'expression', 'upregulated', 'furthermore', 'napabucasin', 'significantly', 'inhibited', 'cisplatinresistant', 'sclc', 'cell', 'xenograft', 'growth', 'iin', 'vivoi', 'downregulating', 'sox2', 'inducing', 'apoptosis', 'data', 'demonstrate', 'napabucasin', 'may', 'novel', 'drug', 'clinical', 'treatment', 'cisplatinresistant', 'sclc']","['stat3', 'sox2', 'sox2', 'sox2', 'sox2']","['sox2', 'sox2', 'sox2', 'sox2']",True,"['tumor', 'cancer']"
36335744,CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment.,"Colony-Stimulating Factor-1 Receptor (CSF1R) is a receptor tyrosine kinase that controls the differentiation and maintenance of most tissue-resident macrophages and bone-resorbing osteoclasts. Mutations of CSF1R have been implicated in neurodegeneration, skeletal anomalies, and cancers. Activation of CSF1R by endogenous cytokine ligation to the ectodomain triggers the autophosphorylation of the intracellular tyrosine kinase domain, and thereafter, activation of several downstream pro-survival kinase cascades, including PI3K, ERK1/2, and JNK. The immunological role of CSF1R in regulating tumor-associate macrophages (TAMs) have been well-documented. TAMs harboring activated CSF1R release tumorigenic cytokines, which further deconditioning tumor microenvironment to a protumoral phenotype. Pharmacological inhibition of CSF1R has emerged as a promising antitumor strategy, with PLX3397 (pexidartinib) been approved by the FDA for the treatment of tenosynovial giant cell tumor in 2019. Research around developing novel small-molecule CSF1R inhibitors, as well as expanding their potential indications, have drawn numerous attentions thenceforward. Herein, we've comprehensively reviewed the latest progression of CSF1R inhibitors under clinical and preclinical studies. Key findings of CSF1R targeted therapies either as monotherapy or combinatorial therapy have also been discussed.",2022-10-29,colonystimulating factor1 receptor csf1r is a receptor tyrosine kinase that controls the differentiation and maintenance of most tissueresident macrophages and boneresorbing osteoclasts mutations of csf1r have been implicated in neurodegeneration skeletal anomalies and cancers activation of csf1r by endogenous cytokine ligation to the ectodomain triggers the autophosphorylation of the intracellular tyrosine kinase domain and thereafter activation of several downstream prosurvival kinase cascades including pi3k erk12 and jnk the immunological role of csf1r in regulating tumorassociate macrophages tams have been welldocumented tams harboring activated csf1r release tumorigenic cytokines which further deconditioning tumor microenvironment to a protumoral phenotype pharmacological inhibition of csf1r has emerged as a promising antitumor strategy with plx3397 pexidartinib been approved by the fda for the treatment of tenosynovial giant cell tumor in 2019 research around developing novel smallmolecule csf1r inhibitors as well as expanding their potential indications have drawn numerous attentions thenceforward herein weve comprehensively reviewed the latest progression of csf1r inhibitors under clinical and preclinical studies key findings of csf1r targeted therapies either as monotherapy or combinatorial therapy have also been discussed,"['colonystimulating', 'factor1', 'receptor', 'csf1r', 'is', 'a', 'receptor', 'tyrosine', 'kinase', 'that', 'controls', 'the', 'differentiation', 'and', 'maintenance', 'of', 'most', 'tissueresident', 'macrophages', 'and', 'boneresorbing', 'osteoclasts', 'mutations', 'of', 'csf1r', 'have', 'been', 'implicated', 'in', 'neurodegeneration', 'skeletal', 'anomalies', 'and', 'cancers', 'activation', 'of', 'csf1r', 'by', 'endogenous', 'cytokine', 'ligation', 'to', 'the', 'ectodomain', 'triggers', 'the', 'autophosphorylation', 'of', 'the', 'intracellular', 'tyrosine', 'kinase', 'domain', 'and', 'thereafter', 'activation', 'of', 'several', 'downstream', 'prosurvival', 'kinase', 'cascades', 'including', 'pi3k', 'erk12', 'and', 'jnk', 'the', 'immunological', 'role', 'of', 'csf1r', 'in', 'regulating', 'tumorassociate', 'macrophages', 'tams', 'have', 'been', 'welldocumented', 'tams', 'harboring', 'activated', 'csf1r', 'release', 'tumorigenic', 'cytokines', 'which', 'further', 'deconditioning', 'tumor', 'microenvironment', 'to', 'a', 'protumoral', 'phenotype', 'pharmacological', 'inhibition', 'of', 'csf1r', 'has', 'emerged', 'as', 'a', 'promising', 'antitumor', 'strategy', 'with', 'plx3397', 'pexidartinib', 'been', 'approved', 'by', 'the', 'fda', 'for', 'the', 'treatment', 'of', 'tenosynovial', 'giant', 'cell', 'tumor', 'in', '2019', 'research', 'around', 'developing', 'novel', 'smallmolecule', 'csf1r', 'inhibitors', 'as', 'well', 'as', 'expanding', 'their', 'potential', 'indications', 'have', 'drawn', 'numerous', 'attentions', 'thenceforward', 'herein', 'weve', 'comprehensively', 'reviewed', 'the', 'latest', 'progression', 'of', 'csf1r', 'inhibitors', 'under', 'clinical', 'and', 'preclinical', 'studies', 'key', 'findings', 'of', 'csf1r', 'targeted', 'therapies', 'either', 'as', 'monotherapy', 'or', 'combinatorial', 'therapy', 'have', 'also', 'been', 'discussed']","['colonystimulating', 'factor1', 'receptor', 'csf1r', 'receptor', 'tyrosine', 'kinase', 'controls', 'differentiation', 'maintenance', 'tissueresident', 'macrophages', 'boneresorbing', 'osteoclasts', 'mutations', 'csf1r', 'implicated', 'neurodegeneration', 'skeletal', 'anomalies', 'cancers', 'activation', 'csf1r', 'endogenous', 'cytokine', 'ligation', 'ectodomain', 'triggers', 'autophosphorylation', 'intracellular', 'tyrosine', 'kinase', 'domain', 'thereafter', 'activation', 'several', 'downstream', 'prosurvival', 'kinase', 'cascades', 'including', 'pi3k', 'erk12', 'jnk', 'immunological', 'role', 'csf1r', 'regulating', 'tumorassociate', 'macrophages', 'tams', 'welldocumented', 'tams', 'harboring', 'activated', 'csf1r', 'release', 'tumorigenic', 'cytokines', 'deconditioning', 'tumor', 'microenvironment', 'protumoral', 'phenotype', 'pharmacological', 'inhibition', 'csf1r', 'emerged', 'promising', 'antitumor', 'strategy', 'plx3397', 'pexidartinib', 'approved', 'fda', 'treatment', 'tenosynovial', 'giant', 'cell', 'tumor', '2019', 'research', 'around', 'developing', 'novel', 'smallmolecule', 'csf1r', 'inhibitors', 'well', 'expanding', 'potential', 'indications', 'drawn', 'numerous', 'attentions', 'thenceforward', 'herein', 'weve', 'comprehensively', 'reviewed', 'latest', 'progression', 'csf1r', 'inhibitors', 'clinical', 'preclinical', 'studies', 'key', 'findings', 'csf1r', 'targeted', 'therapies', 'either', 'monotherapy', 'combinatorial', 'therapy', 'also', 'discussed']","['factor1', 'csf1r', 'csf1r', 'csf1r', 'pi3k', 'jnk', 'csf1r', 'csf1r', 'csf1r', 'csf1r', 'csf1r', 'csf1r']","['csf1r', 'csf1r', 'csf1r', 'csf1r', 'csf1r', 'csf1r', 'csf1r', 'csf1r', 'csf1r']",True,"['tumor', 'cancer']"
36297523,The Novel Peptide Chm-273s Has Therapeutic Potential for Metabolic Disorders: Evidence from In Vitro Studies and High-Sucrose Diet and High-Fat Diet Rodent Models.,"The aim of this study was to develop a novel peptide potentially applicable for the treatment of metabolic conditions, such as obesity and type 2 diabetes (T2D). We identified CHM-273S from the list of peptides from milk hydrolysate obtained by HPLC/MS-MS. In vitro analysis of primary murine fibroblasts indicated the potential of CHM-273S to upregulate IRS2 mRNA expression. CHM-273S showed a prominent anorexigenic effect in mice with the induction of a key mechanism of leptin signaling via STAT3 in the hypothalamus as a possible effector. In the animal model of metabolic disease, CHM-273S alleviated glucose intolerance and insulin resistance, and induced phosphorylation of Akt at Ser473 and Thr308 in the hepatocytes of high-sucrose diet-fed rats. In a murine model of T2D, CHM-273S mitigated high-fat diet-induced hyperglycemia and insulin resistance and improved low-grade inflammation by diminishing serum TNFα. Mice treated with chronic CHM-273S had a significant reduction in body weight, with a lower visceral fat pad weight and narrow adipocytes. The effects of the peptide administration were comparable to those of metformin. We show the potential of CHM-273S to alleviate diet-induced metabolic alterations in rodents, substantiating its further development as a therapeutic for obesity, T2D, and other metabolic conditions.",2022-09-30,the aim of this study was to develop a novel peptide potentially applicable for the treatment of metabolic conditions such as obesity and type 2 diabetes t2d we identified chm273s from the list of peptides from milk hydrolysate obtained by hplcmsms in vitro analysis of primary murine fibroblasts indicated the potential of chm273s to upregulate irs2 mrna expression chm273s showed a prominent anorexigenic effect in mice with the induction of a key mechanism of leptin signaling via stat3 in the hypothalamus as a possible effector in the animal model of metabolic disease chm273s alleviated glucose intolerance and insulin resistance and induced phosphorylation of akt at ser473 and thr308 in the hepatocytes of highsucrose dietfed rats in a murine model of t2d chm273s mitigated highfat dietinduced hyperglycemia and insulin resistance and improved lowgrade inflammation by diminishing serum tnfα mice treated with chronic chm273s had a significant reduction in body weight with a lower visceral fat pad weight and narrow adipocytes the effects of the peptide administration were comparable to those of metformin we show the potential of chm273s to alleviate dietinduced metabolic alterations in rodents substantiating its further development as a therapeutic for obesity t2d and other metabolic conditions,"['the', 'aim', 'of', 'this', 'study', 'was', 'to', 'develop', 'a', 'novel', 'peptide', 'potentially', 'applicable', 'for', 'the', 'treatment', 'of', 'metabolic', 'conditions', 'such', 'as', 'obesity', 'and', 'type', '2', 'diabetes', 't2d', 'we', 'identified', 'chm273s', 'from', 'the', 'list', 'of', 'peptides', 'from', 'milk', 'hydrolysate', 'obtained', 'by', 'hplcmsms', 'in', 'vitro', 'analysis', 'of', 'primary', 'murine', 'fibroblasts', 'indicated', 'the', 'potential', 'of', 'chm273s', 'to', 'upregulate', 'irs2', 'mrna', 'expression', 'chm273s', 'showed', 'a', 'prominent', 'anorexigenic', 'effect', 'in', 'mice', 'with', 'the', 'induction', 'of', 'a', 'key', 'mechanism', 'of', 'leptin', 'signaling', 'via', 'stat3', 'in', 'the', 'hypothalamus', 'as', 'a', 'possible', 'effector', 'in', 'the', 'animal', 'model', 'of', 'metabolic', 'disease', 'chm273s', 'alleviated', 'glucose', 'intolerance', 'and', 'insulin', 'resistance', 'and', 'induced', 'phosphorylation', 'of', 'akt', 'at', 'ser473', 'and', 'thr308', 'in', 'the', 'hepatocytes', 'of', 'highsucrose', 'dietfed', 'rats', 'in', 'a', 'murine', 'model', 'of', 't2d', 'chm273s', 'mitigated', 'highfat', 'dietinduced', 'hyperglycemia', 'and', 'insulin', 'resistance', 'and', 'improved', 'lowgrade', 'inflammation', 'by', 'diminishing', 'serum', 'tnfα', 'mice', 'treated', 'with', 'chronic', 'chm273s', 'had', 'a', 'significant', 'reduction', 'in', 'body', 'weight', 'with', 'a', 'lower', 'visceral', 'fat', 'pad', 'weight', 'and', 'narrow', 'adipocytes', 'the', 'effects', 'of', 'the', 'peptide', 'administration', 'were', 'comparable', 'to', 'those', 'of', 'metformin', 'we', 'show', 'the', 'potential', 'of', 'chm273s', 'to', 'alleviate', 'dietinduced', 'metabolic', 'alterations', 'in', 'rodents', 'substantiating', 'its', 'further', 'development', 'as', 'a', 'therapeutic', 'for', 'obesity', 't2d', 'and', 'other', 'metabolic', 'conditions']","['aim', 'study', 'develop', 'novel', 'peptide', 'potentially', 'applicable', 'treatment', 'metabolic', 'conditions', 'obesity', 'type', '2', 'diabetes', 't2d', 'identified', 'chm273s', 'list', 'peptides', 'milk', 'hydrolysate', 'obtained', 'hplcmsms', 'vitro', 'analysis', 'primary', 'murine', 'fibroblasts', 'indicated', 'potential', 'chm273s', 'upregulate', 'irs2', 'mrna', 'expression', 'chm273s', 'showed', 'prominent', 'anorexigenic', 'effect', 'mice', 'induction', 'key', 'mechanism', 'leptin', 'signaling', 'via', 'stat3', 'hypothalamus', 'possible', 'effector', 'animal', 'model', 'metabolic', 'disease', 'chm273s', 'alleviated', 'glucose', 'intolerance', 'insulin', 'resistance', 'induced', 'phosphorylation', 'akt', 'ser473', 'thr308', 'hepatocytes', 'highsucrose', 'dietfed', 'rats', 'murine', 'model', 't2d', 'chm273s', 'mitigated', 'highfat', 'dietinduced', 'hyperglycemia', 'insulin', 'resistance', 'improved', 'lowgrade', 'inflammation', 'diminishing', 'serum', 'tnfα', 'mice', 'treated', 'chronic', 'chm273s', 'significant', 'reduction', 'body', 'weight', 'lower', 'visceral', 'fat', 'pad', 'weight', 'narrow', 'adipocytes', 'effects', 'peptide', 'administration', 'comparable', 'metformin', 'show', 'potential', 'chm273s', 'alleviate', 'dietinduced', 'metabolic', 'alterations', 'rodents', 'substantiating', 'development', 'therapeutic', 'obesity', 't2d', 'metabolic', 'conditions']","['leptin', 'stat3', 'insulin', 'akt', 'ser473', 'thr308', 'insulin']","['ser473', 'thr308']",True,['diabetes']
36268125,Discovery of Novel Small-Molecule Scaffolds for the Inhibition and Activation of WIP1 Phosphatase from a RapidFire Mass Spectrometry High-Throughput Screen.,"Wild-type P53-induced phosphatase 1 (WIP1), also known as <i>PPM1D</i> or PP2Cδ, is a serine/threonine protein phosphatase induced by P53 after genotoxic stress. WIP1 inhibition has been proposed as a therapeutic strategy for P53 wild-type cancers in which it is overexpressed, but this approach would be ineffective in P53-negative cancers. Furthermore, there are several cancers with mutated P53 where WIP1 acts as a tumor suppressor. Therefore, activating WIP1 phosphatase might also be a therapeutic strategy, depending on the P53 status. To date, no specific, potent WIP1 inhibitors with appropriate pharmacokinetic properties have been reported, nor have WIP1-specific activators. Here, we report the discovery of new WIP1 modulators from a high-throughput screen (HTS) using previously described orthogonal biochemical assays suitable for identifying both inhibitors and activators. The primary HTS was performed against a library of 102 277 compounds at a single concentration using a RapidFire mass spectrometry assay. Hits were further evaluated over a range of 11 concentrations with both the RapidFire MS assay and an orthogonal fluorescence-based assay. Further biophysical, biochemical, and cell-based studies of confirmed hits revealed a WIP1 activator and two inhibitors, one competitive and one uncompetitive. These new scaffolds are prime candidates for optimization which might enable inhibitors with improved pharmacokinetics and a first-in-class WIP1 activator.",2022-09-28,wildtype p53induced phosphatase 1 wip1 also known as ippm1di or pp2cδ is a serinethreonine protein phosphatase induced by p53 after genotoxic stress wip1 inhibition has been proposed as a therapeutic strategy for p53 wildtype cancers in which it is overexpressed but this approach would be ineffective in p53negative cancers furthermore there are several cancers with mutated p53 where wip1 acts as a tumor suppressor therefore activating wip1 phosphatase might also be a therapeutic strategy depending on the p53 status to date no specific potent wip1 inhibitors with appropriate pharmacokinetic properties have been reported nor have wip1specific activators here we report the discovery of new wip1 modulators from a highthroughput screen hts using previously described orthogonal biochemical assays suitable for identifying both inhibitors and activators the primary hts was performed against a library of 102 277 compounds at a single concentration using a rapidfire mass spectrometry assay hits were further evaluated over a range of 11 concentrations with both the rapidfire ms assay and an orthogonal fluorescencebased assay further biophysical biochemical and cellbased studies of confirmed hits revealed a wip1 activator and two inhibitors one competitive and one uncompetitive these new scaffolds are prime candidates for optimization which might enable inhibitors with improved pharmacokinetics and a firstinclass wip1 activator,"['wildtype', 'p53induced', 'phosphatase', '1', 'wip1', 'also', 'known', 'as', 'ippm1di', 'or', 'pp2cδ', 'is', 'a', 'serinethreonine', 'protein', 'phosphatase', 'induced', 'by', 'p53', 'after', 'genotoxic', 'stress', 'wip1', 'inhibition', 'has', 'been', 'proposed', 'as', 'a', 'therapeutic', 'strategy', 'for', 'p53', 'wildtype', 'cancers', 'in', 'which', 'it', 'is', 'overexpressed', 'but', 'this', 'approach', 'would', 'be', 'ineffective', 'in', 'p53negative', 'cancers', 'furthermore', 'there', 'are', 'several', 'cancers', 'with', 'mutated', 'p53', 'where', 'wip1', 'acts', 'as', 'a', 'tumor', 'suppressor', 'therefore', 'activating', 'wip1', 'phosphatase', 'might', 'also', 'be', 'a', 'therapeutic', 'strategy', 'depending', 'on', 'the', 'p53', 'status', 'to', 'date', 'no', 'specific', 'potent', 'wip1', 'inhibitors', 'with', 'appropriate', 'pharmacokinetic', 'properties', 'have', 'been', 'reported', 'nor', 'have', 'wip1specific', 'activators', 'here', 'we', 'report', 'the', 'discovery', 'of', 'new', 'wip1', 'modulators', 'from', 'a', 'highthroughput', 'screen', 'hts', 'using', 'previously', 'described', 'orthogonal', 'biochemical', 'assays', 'suitable', 'for', 'identifying', 'both', 'inhibitors', 'and', 'activators', 'the', 'primary', 'hts', 'was', 'performed', 'against', 'a', 'library', 'of', '102', '277', 'compounds', 'at', 'a', 'single', 'concentration', 'using', 'a', 'rapidfire', 'mass', 'spectrometry', 'assay', 'hits', 'were', 'further', 'evaluated', 'over', 'a', 'range', 'of', '11', 'concentrations', 'with', 'both', 'the', 'rapidfire', 'ms', 'assay', 'and', 'an', 'orthogonal', 'fluorescencebased', 'assay', 'further', 'biophysical', 'biochemical', 'and', 'cellbased', 'studies', 'of', 'confirmed', 'hits', 'revealed', 'a', 'wip1', 'activator', 'and', 'two', 'inhibitors', 'one', 'competitive', 'and', 'one', 'uncompetitive', 'these', 'new', 'scaffolds', 'are', 'prime', 'candidates', 'for', 'optimization', 'which', 'might', 'enable', 'inhibitors', 'with', 'improved', 'pharmacokinetics', 'and', 'a', 'firstinclass', 'wip1', 'activator']","['wildtype', 'p53induced', 'phosphatase', '1', 'wip1', 'also', 'known', 'ippm1di', 'pp2cδ', 'serinethreonine', 'protein', 'phosphatase', 'induced', 'p53', 'genotoxic', 'stress', 'wip1', 'inhibition', 'proposed', 'therapeutic', 'strategy', 'p53', 'wildtype', 'cancers', 'overexpressed', 'approach', 'would', 'ineffective', 'p53negative', 'cancers', 'furthermore', 'several', 'cancers', 'mutated', 'p53', 'wip1', 'acts', 'tumor', 'suppressor', 'therefore', 'activating', 'wip1', 'phosphatase', 'might', 'also', 'therapeutic', 'strategy', 'depending', 'p53', 'status', 'date', 'specific', 'potent', 'wip1', 'inhibitors', 'appropriate', 'pharmacokinetic', 'properties', 'reported', 'wip1specific', 'activators', 'report', 'discovery', 'new', 'wip1', 'modulators', 'highthroughput', 'screen', 'hts', 'using', 'previously', 'described', 'orthogonal', 'biochemical', 'assays', 'suitable', 'identifying', 'inhibitors', 'activators', 'primary', 'hts', 'performed', 'library', '102', '277', 'compounds', 'single', 'concentration', 'using', 'rapidfire', 'mass', 'spectrometry', 'assay', 'hits', 'evaluated', 'range', '11', 'concentrations', 'rapidfire', 'ms', 'assay', 'orthogonal', 'fluorescencebased', 'assay', 'biophysical', 'biochemical', 'cellbased', 'studies', 'confirmed', 'hits', 'revealed', 'wip1', 'activator', 'two', 'inhibitors', 'one', 'competitive', 'one', 'uncompetitive', 'new', 'scaffolds', 'prime', 'candidates', 'optimization', 'might', 'enable', 'inhibitors', 'improved', 'pharmacokinetics', 'firstinclass', 'wip1', 'activator']","['wip1', 'p53', 'wip1', 'p53', 'p53', 'wip1', 'wip1', 'p53', 'wip1', 'wip1', 'wip1', 'wip1']","['wip1', 'wip1', 'wip1', 'wip1', 'wip1', 'wip1', 'wip1', 'wip1']",True,"['tumor', 'cancer']"
36185250,Chaperonin containing TCP-1 (CCT/TRiC) is a novel therapeutic and diagnostic target for neuroblastoma.,"Chaperonin containing TCP1 (CCT/TRiC) is a multi-subunit protein folding complex that enables the cancer phenotype to emerge from the mutational landscape that drives oncogenesis. We and others linked increased expression of CCT subunits to advanced tumor stage and invasiveness that inversely correlates with cancer patient outcomes. In this study, we examined the expression of the second CCT subunit, CCT2, using genomic databases of adult and pediatric tumors and normal tissues, and found that it was highly expressed in pediatric cancers, showing a significant difference compared to normal tissues. Histologic staining confirmed that CCT subunits are highly expressed in tumor tissues, which was exemplified in neuroblastoma. Using two neuroblastoma cells, MYCN-amplified, IMR-32 cells, and non-amplified, SK-N-AS cells, we assessed baseline levels for CCT subunits and found expressions comparable to the highly invasive triple-negative breast cancer (TNBC) cell line, MDA-MB-231. Exogenous expression of CCT2 in both SK-N-AS and IMR-32 cells resulted in morphological changes, such as larger cell size and increased adherence, with significant increases in the CCT substrates, actin, and tubulin, as well as increased migration. Depletion of CCT2 reversed these effects and reduced cell viability. We evaluated CCT as a therapeutic target in IMR-32 cells by testing a novel peptide CCT inhibitor, CT20p. Treatment with CT20p induced cell death in these neuroblastoma cells. The use of CCT2 as a biological indicator for detection of neuroblastoma cells shed in blood was examined by spiking IMR-32 cells into human blood and using an anti-CCT2 antibody for the identification of spiked cancer cells with the CellSearch system. Results showed that using CCT2 for the detection of neuroblastoma cells in blood was more effective than the conventional approach of using epithelial markers like cytokeratins. CCT2 plays an essential role in promoting the invasive capacity of neuroblastoma cells and thus offers the potential to act as a molecular target in the development of novel therapeutics and diagnostics for pediatric cancers.",2022-09-15,chaperonin containing tcp1 ccttric is a multisubunit protein folding complex that enables the cancer phenotype to emerge from the mutational landscape that drives oncogenesis we and others linked increased expression of cct subunits to advanced tumor stage and invasiveness that inversely correlates with cancer patient outcomes in this study we examined the expression of the second cct subunit cct2 using genomic databases of adult and pediatric tumors and normal tissues and found that it was highly expressed in pediatric cancers showing a significant difference compared to normal tissues histologic staining confirmed that cct subunits are highly expressed in tumor tissues which was exemplified in neuroblastoma using two neuroblastoma cells mycnamplified imr32 cells and nonamplified sknas cells we assessed baseline levels for cct subunits and found expressions comparable to the highly invasive triplenegative breast cancer tnbc cell line mdamb231 exogenous expression of cct2 in both sknas and imr32 cells resulted in morphological changes such as larger cell size and increased adherence with significant increases in the cct substrates actin and tubulin as well as increased migration depletion of cct2 reversed these effects and reduced cell viability we evaluated cct as a therapeutic target in imr32 cells by testing a novel peptide cct inhibitor ct20p treatment with ct20p induced cell death in these neuroblastoma cells the use of cct2 as a biological indicator for detection of neuroblastoma cells shed in blood was examined by spiking imr32 cells into human blood and using an anticct2 antibody for the identification of spiked cancer cells with the cellsearch system results showed that using cct2 for the detection of neuroblastoma cells in blood was more effective than the conventional approach of using epithelial markers like cytokeratins cct2 plays an essential role in promoting the invasive capacity of neuroblastoma cells and thus offers the potential to act as a molecular target in the development of novel therapeutics and diagnostics for pediatric cancers,"['chaperonin', 'containing', 'tcp1', 'ccttric', 'is', 'a', 'multisubunit', 'protein', 'folding', 'complex', 'that', 'enables', 'the', 'cancer', 'phenotype', 'to', 'emerge', 'from', 'the', 'mutational', 'landscape', 'that', 'drives', 'oncogenesis', 'we', 'and', 'others', 'linked', 'increased', 'expression', 'of', 'cct', 'subunits', 'to', 'advanced', 'tumor', 'stage', 'and', 'invasiveness', 'that', 'inversely', 'correlates', 'with', 'cancer', 'patient', 'outcomes', 'in', 'this', 'study', 'we', 'examined', 'the', 'expression', 'of', 'the', 'second', 'cct', 'subunit', 'cct2', 'using', 'genomic', 'databases', 'of', 'adult', 'and', 'pediatric', 'tumors', 'and', 'normal', 'tissues', 'and', 'found', 'that', 'it', 'was', 'highly', 'expressed', 'in', 'pediatric', 'cancers', 'showing', 'a', 'significant', 'difference', 'compared', 'to', 'normal', 'tissues', 'histologic', 'staining', 'confirmed', 'that', 'cct', 'subunits', 'are', 'highly', 'expressed', 'in', 'tumor', 'tissues', 'which', 'was', 'exemplified', 'in', 'neuroblastoma', 'using', 'two', 'neuroblastoma', 'cells', 'mycnamplified', 'imr32', 'cells', 'and', 'nonamplified', 'sknas', 'cells', 'we', 'assessed', 'baseline', 'levels', 'for', 'cct', 'subunits', 'and', 'found', 'expressions', 'comparable', 'to', 'the', 'highly', 'invasive', 'triplenegative', 'breast', 'cancer', 'tnbc', 'cell', 'line', 'mdamb231', 'exogenous', 'expression', 'of', 'cct2', 'in', 'both', 'sknas', 'and', 'imr32', 'cells', 'resulted', 'in', 'morphological', 'changes', 'such', 'as', 'larger', 'cell', 'size', 'and', 'increased', 'adherence', 'with', 'significant', 'increases', 'in', 'the', 'cct', 'substrates', 'actin', 'and', 'tubulin', 'as', 'well', 'as', 'increased', 'migration', 'depletion', 'of', 'cct2', 'reversed', 'these', 'effects', 'and', 'reduced', 'cell', 'viability', 'we', 'evaluated', 'cct', 'as', 'a', 'therapeutic', 'target', 'in', 'imr32', 'cells', 'by', 'testing', 'a', 'novel', 'peptide', 'cct', 'inhibitor', 'ct20p', 'treatment', 'with', 'ct20p', 'induced', 'cell', 'death', 'in', 'these', 'neuroblastoma', 'cells', 'the', 'use', 'of', 'cct2', 'as', 'a', 'biological', 'indicator', 'for', 'detection', 'of', 'neuroblastoma', 'cells', 'shed', 'in', 'blood', 'was', 'examined', 'by', 'spiking', 'imr32', 'cells', 'into', 'human', 'blood', 'and', 'using', 'an', 'anticct2', 'antibody', 'for', 'the', 'identification', 'of', 'spiked', 'cancer', 'cells', 'with', 'the', 'cellsearch', 'system', 'results', 'showed', 'that', 'using', 'cct2', 'for', 'the', 'detection', 'of', 'neuroblastoma', 'cells', 'in', 'blood', 'was', 'more', 'effective', 'than', 'the', 'conventional', 'approach', 'of', 'using', 'epithelial', 'markers', 'like', 'cytokeratins', 'cct2', 'plays', 'an', 'essential', 'role', 'in', 'promoting', 'the', 'invasive', 'capacity', 'of', 'neuroblastoma', 'cells', 'and', 'thus', 'offers', 'the', 'potential', 'to', 'act', 'as', 'a', 'molecular', 'target', 'in', 'the', 'development', 'of', 'novel', 'therapeutics', 'and', 'diagnostics', 'for', 'pediatric', 'cancers']","['chaperonin', 'containing', 'tcp1', 'ccttric', 'multisubunit', 'protein', 'folding', 'complex', 'enables', 'cancer', 'phenotype', 'emerge', 'mutational', 'landscape', 'drives', 'oncogenesis', 'others', 'linked', 'increased', 'expression', 'cct', 'subunits', 'advanced', 'tumor', 'stage', 'invasiveness', 'inversely', 'correlates', 'cancer', 'patient', 'outcomes', 'study', 'examined', 'expression', 'second', 'cct', 'subunit', 'cct2', 'using', 'genomic', 'databases', 'adult', 'pediatric', 'tumors', 'normal', 'tissues', 'found', 'highly', 'expressed', 'pediatric', 'cancers', 'showing', 'significant', 'difference', 'compared', 'normal', 'tissues', 'histologic', 'staining', 'confirmed', 'cct', 'subunits', 'highly', 'expressed', 'tumor', 'tissues', 'exemplified', 'neuroblastoma', 'using', 'two', 'neuroblastoma', 'cells', 'mycnamplified', 'imr32', 'cells', 'nonamplified', 'sknas', 'cells', 'assessed', 'baseline', 'levels', 'cct', 'subunits', 'found', 'expressions', 'comparable', 'highly', 'invasive', 'triplenegative', 'breast', 'cancer', 'tnbc', 'cell', 'line', 'mdamb231', 'exogenous', 'expression', 'cct2', 'sknas', 'imr32', 'cells', 'resulted', 'morphological', 'changes', 'larger', 'cell', 'size', 'increased', 'adherence', 'significant', 'increases', 'cct', 'substrates', 'actin', 'tubulin', 'well', 'increased', 'migration', 'depletion', 'cct2', 'reversed', 'effects', 'reduced', 'cell', 'viability', 'evaluated', 'cct', 'therapeutic', 'target', 'imr32', 'cells', 'testing', 'novel', 'peptide', 'cct', 'inhibitor', 'ct20p', 'treatment', 'ct20p', 'induced', 'cell', 'death', 'neuroblastoma', 'cells', 'use', 'cct2', 'biological', 'indicator', 'detection', 'neuroblastoma', 'cells', 'shed', 'blood', 'examined', 'spiking', 'imr32', 'cells', 'human', 'blood', 'using', 'anticct2', 'antibody', 'identification', 'spiked', 'cancer', 'cells', 'cellsearch', 'system', 'results', 'showed', 'using', 'cct2', 'detection', 'neuroblastoma', 'cells', 'blood', 'effective', 'conventional', 'approach', 'using', 'epithelial', 'markers', 'like', 'cytokeratins', 'cct2', 'plays', 'essential', 'role', 'promoting', 'invasive', 'capacity', 'neuroblastoma', 'cells', 'thus', 'offers', 'potential', 'act', 'molecular', 'target', 'development', 'novel', 'therapeutics', 'diagnostics', 'pediatric', 'cancers']","['chaperonin', 'actin', 'tubulin', 'cytokeratins']","['chaperonin', 'cytokeratins']",True,"['tumor', 'cancer']"
36145311,Evaluation of Novel Inhibitors of Tryptophan Dioxygenases for Enzyme and Species Selectivity Using Engineered Tumour Cell Lines Expressing Either Murine or Human IDO1 or TDO2.,"Indoleamine 2, 3-dioxygenase 1 (IDO1) is commonly expressed by cancers as a mechanism for evading the immune system. Preclinical and clinical studies have indicated the potential of combining IDO1 inhibitors with immune therapies for the treatment of cancer, strengthening an interest in the discovery of novel dioxygenase inhibitors for reversing tumour-mediated immune suppression. To facilitate the discovery, development and investigation of novel small molecule inhibitors of IDO1 and its hepatic isozyme tryptophan dioxygenase (TDO2), murine tumour cells were engineered to selectively express either murine or human IDO1 and TDO2 for use as tools to dissect both the species specificity and isoenzyme selectivity of newly discovered inhibitors. Lewis lung carcinoma (LLTC) lines were engineered to express either murine or human IDO1 for use to test species selectivity of the novel inhibitors; in addition, GL261 glioma lines were engineered to express either human IDO1 or human TDO2 and used to test the isoenzyme selectivity of individual inhibitors in cell-based assays. The 20 most potent inhibitors against recombinant human IDO1 enzyme, discovered from a commissioned screening of 40,000 compounds in the Australian WEHI compound library, returned comparable IC<sub>50</sub> values against murine or human IDO1 in cell-based assays using the LLTC-mIDO1 and LLTC-hIDO1 line, respectively. To test the in vivo activity of the hits, transfected lines were inoculated into syngeneic C57Bl/6 mice. Individual LLTC-hIDO1 tumours showed variable expression of human IDO1 in contrast to GL261-hIDO1 tumours which were homogenous in their IDO1 expression and were subsequently used for in vivo studies. W-0019482, the most potent IDO1 inhibitor identified from cell-based assays, reduced plasma and intratumoural ratios of kynurenine to tryptophan (K:T) and delayed the growth of subcutaneous GL261-hIDO1 tumours in mice. Synthetic modification of W-0019482 generated analogues with dual IDO1/TDO2 inhibitory activity, as well as inhibitors that were selective for either TDO2 or IDO1. These results demonstrate the versatility of W-0019482 as a lead in generating all three subclasses of tryptophan dioxygenase inhibitors which can be applied for investigating the individual roles and interactions between IDO1 and TDO2 in driving cancer-mediated immune suppression.",2022-08-31,indoleamine 2 3dioxygenase 1 ido1 is commonly expressed by cancers as a mechanism for evading the immune system preclinical and clinical studies have indicated the potential of combining ido1 inhibitors with immune therapies for the treatment of cancer strengthening an interest in the discovery of novel dioxygenase inhibitors for reversing tumourmediated immune suppression to facilitate the discovery development and investigation of novel small molecule inhibitors of ido1 and its hepatic isozyme tryptophan dioxygenase tdo2 murine tumour cells were engineered to selectively express either murine or human ido1 and tdo2 for use as tools to dissect both the species specificity and isoenzyme selectivity of newly discovered inhibitors lewis lung carcinoma lltc lines were engineered to express either murine or human ido1 for use to test species selectivity of the novel inhibitors in addition gl261 glioma lines were engineered to express either human ido1 or human tdo2 and used to test the isoenzyme selectivity of individual inhibitors in cellbased assays the 20 most potent inhibitors against recombinant human ido1 enzyme discovered from a commissioned screening of 40000 compounds in the australian wehi compound library returned comparable icsub50sub values against murine or human ido1 in cellbased assays using the lltcmido1 and lltchido1 line respectively to test the in vivo activity of the hits transfected lines were inoculated into syngeneic c57bl6 mice individual lltchido1 tumours showed variable expression of human ido1 in contrast to gl261hido1 tumours which were homogenous in their ido1 expression and were subsequently used for in vivo studies w0019482 the most potent ido1 inhibitor identified from cellbased assays reduced plasma and intratumoural ratios of kynurenine to tryptophan kt and delayed the growth of subcutaneous gl261hido1 tumours in mice synthetic modification of w0019482 generated analogues with dual ido1tdo2 inhibitory activity as well as inhibitors that were selective for either tdo2 or ido1 these results demonstrate the versatility of w0019482 as a lead in generating all three subclasses of tryptophan dioxygenase inhibitors which can be applied for investigating the individual roles and interactions between ido1 and tdo2 in driving cancermediated immune suppression,"['indoleamine', '2', '3dioxygenase', '1', 'ido1', 'is', 'commonly', 'expressed', 'by', 'cancers', 'as', 'a', 'mechanism', 'for', 'evading', 'the', 'immune', 'system', 'preclinical', 'and', 'clinical', 'studies', 'have', 'indicated', 'the', 'potential', 'of', 'combining', 'ido1', 'inhibitors', 'with', 'immune', 'therapies', 'for', 'the', 'treatment', 'of', 'cancer', 'strengthening', 'an', 'interest', 'in', 'the', 'discovery', 'of', 'novel', 'dioxygenase', 'inhibitors', 'for', 'reversing', 'tumourmediated', 'immune', 'suppression', 'to', 'facilitate', 'the', 'discovery', 'development', 'and', 'investigation', 'of', 'novel', 'small', 'molecule', 'inhibitors', 'of', 'ido1', 'and', 'its', 'hepatic', 'isozyme', 'tryptophan', 'dioxygenase', 'tdo2', 'murine', 'tumour', 'cells', 'were', 'engineered', 'to', 'selectively', 'express', 'either', 'murine', 'or', 'human', 'ido1', 'and', 'tdo2', 'for', 'use', 'as', 'tools', 'to', 'dissect', 'both', 'the', 'species', 'specificity', 'and', 'isoenzyme', 'selectivity', 'of', 'newly', 'discovered', 'inhibitors', 'lewis', 'lung', 'carcinoma', 'lltc', 'lines', 'were', 'engineered', 'to', 'express', 'either', 'murine', 'or', 'human', 'ido1', 'for', 'use', 'to', 'test', 'species', 'selectivity', 'of', 'the', 'novel', 'inhibitors', 'in', 'addition', 'gl261', 'glioma', 'lines', 'were', 'engineered', 'to', 'express', 'either', 'human', 'ido1', 'or', 'human', 'tdo2', 'and', 'used', 'to', 'test', 'the', 'isoenzyme', 'selectivity', 'of', 'individual', 'inhibitors', 'in', 'cellbased', 'assays', 'the', '20', 'most', 'potent', 'inhibitors', 'against', 'recombinant', 'human', 'ido1', 'enzyme', 'discovered', 'from', 'a', 'commissioned', 'screening', 'of', '40000', 'compounds', 'in', 'the', 'australian', 'wehi', 'compound', 'library', 'returned', 'comparable', 'icsub50sub', 'values', 'against', 'murine', 'or', 'human', 'ido1', 'in', 'cellbased', 'assays', 'using', 'the', 'lltcmido1', 'and', 'lltchido1', 'line', 'respectively', 'to', 'test', 'the', 'in', 'vivo', 'activity', 'of', 'the', 'hits', 'transfected', 'lines', 'were', 'inoculated', 'into', 'syngeneic', 'c57bl6', 'mice', 'individual', 'lltchido1', 'tumours', 'showed', 'variable', 'expression', 'of', 'human', 'ido1', 'in', 'contrast', 'to', 'gl261hido1', 'tumours', 'which', 'were', 'homogenous', 'in', 'their', 'ido1', 'expression', 'and', 'were', 'subsequently', 'used', 'for', 'in', 'vivo', 'studies', 'w0019482', 'the', 'most', 'potent', 'ido1', 'inhibitor', 'identified', 'from', 'cellbased', 'assays', 'reduced', 'plasma', 'and', 'intratumoural', 'ratios', 'of', 'kynurenine', 'to', 'tryptophan', 'kt', 'and', 'delayed', 'the', 'growth', 'of', 'subcutaneous', 'gl261hido1', 'tumours', 'in', 'mice', 'synthetic', 'modification', 'of', 'w0019482', 'generated', 'analogues', 'with', 'dual', 'ido1tdo2', 'inhibitory', 'activity', 'as', 'well', 'as', 'inhibitors', 'that', 'were', 'selective', 'for', 'either', 'tdo2', 'or', 'ido1', 'these', 'results', 'demonstrate', 'the', 'versatility', 'of', 'w0019482', 'as', 'a', 'lead', 'in', 'generating', 'all', 'three', 'subclasses', 'of', 'tryptophan', 'dioxygenase', 'inhibitors', 'which', 'can', 'be', 'applied', 'for', 'investigating', 'the', 'individual', 'roles', 'and', 'interactions', 'between', 'ido1', 'and', 'tdo2', 'in', 'driving', 'cancermediated', 'immune', 'suppression']","['indoleamine', '2', '3dioxygenase', '1', 'ido1', 'commonly', 'expressed', 'cancers', 'mechanism', 'evading', 'immune', 'system', 'preclinical', 'clinical', 'studies', 'indicated', 'potential', 'combining', 'ido1', 'inhibitors', 'immune', 'therapies', 'treatment', 'cancer', 'strengthening', 'interest', 'discovery', 'novel', 'dioxygenase', 'inhibitors', 'reversing', 'tumourmediated', 'immune', 'suppression', 'facilitate', 'discovery', 'development', 'investigation', 'novel', 'small', 'molecule', 'inhibitors', 'ido1', 'hepatic', 'isozyme', 'tryptophan', 'dioxygenase', 'tdo2', 'murine', 'tumour', 'cells', 'engineered', 'selectively', 'express', 'either', 'murine', 'human', 'ido1', 'tdo2', 'use', 'tools', 'dissect', 'species', 'specificity', 'isoenzyme', 'selectivity', 'newly', 'discovered', 'inhibitors', 'lewis', 'lung', 'carcinoma', 'lltc', 'lines', 'engineered', 'express', 'either', 'murine', 'human', 'ido1', 'use', 'test', 'species', 'selectivity', 'novel', 'inhibitors', 'addition', 'gl261', 'glioma', 'lines', 'engineered', 'express', 'either', 'human', 'ido1', 'human', 'tdo2', 'used', 'test', 'isoenzyme', 'selectivity', 'individual', 'inhibitors', 'cellbased', 'assays', '20', 'potent', 'inhibitors', 'recombinant', 'human', 'ido1', 'enzyme', 'discovered', 'commissioned', 'screening', '40000', 'compounds', 'australian', 'wehi', 'compound', 'library', 'returned', 'comparable', 'icsub50sub', 'values', 'murine', 'human', 'ido1', 'cellbased', 'assays', 'using', 'lltcmido1', 'lltchido1', 'line', 'respectively', 'test', 'vivo', 'activity', 'hits', 'transfected', 'lines', 'inoculated', 'syngeneic', 'c57bl6', 'mice', 'individual', 'lltchido1', 'tumours', 'showed', 'variable', 'expression', 'human', 'ido1', 'contrast', 'gl261hido1', 'tumours', 'homogenous', 'ido1', 'expression', 'subsequently', 'used', 'vivo', 'studies', 'w0019482', 'potent', 'ido1', 'inhibitor', 'identified', 'cellbased', 'assays', 'reduced', 'plasma', 'intratumoural', 'ratios', 'kynurenine', 'tryptophan', 'kt', 'delayed', 'growth', 'subcutaneous', 'gl261hido1', 'tumours', 'mice', 'synthetic', 'modification', 'w0019482', 'generated', 'analogues', 'dual', 'ido1tdo2', 'inhibitory', 'activity', 'well', 'inhibitors', 'selective', 'either', 'tdo2', 'ido1', 'results', 'demonstrate', 'versatility', 'w0019482', 'lead', 'generating', 'three', 'subclasses', 'tryptophan', 'dioxygenase', 'inhibitors', 'applied', 'investigating', 'individual', 'roles', 'interactions', 'ido1', 'tdo2', 'driving', 'cancermediated', 'immune', 'suppression']","['lltchido1', 'lltchido1']","['lltchido1', 'lltchido1']",True,['cancer']
36142566,Machine Learning-Based Virtual Screening for the Identification of Cdk5 Inhibitors.,"Cyclin-dependent kinase 5 (Cdk5) is an atypical proline-directed serine/threonine protein kinase well-characterized for its role in the central nervous system rather than in the cell cycle. Indeed, its dysregulation has been strongly implicated in the progression of synaptic dysfunction and neurodegenerative diseases, such as Alzheimer's disease (AD) and Parkinson's disease (PD), and also in the development and progression of a variety of cancers. For this reason, Cdk5 is considered as a promising target for drug design, and the discovery of novel small-molecule Cdk5 inhibitors is of great interest in the medicinal chemistry field. In this context, we employed a machine learning-based virtual screening protocol with subsequent molecular docking, molecular dynamics simulations and binding free energy evaluations. Our virtual screening studies resulted in the identification of two novel Cdk5 inhibitors, highlighting an experimental hit rate of 50% and thus validating the reliability of the in silico workflow. Both identified ligands, compounds <b>CPD1</b> and <b>CPD4</b>, showed a promising enzyme inhibitory activity and <b>CPD1</b> also demonstrated a remarkable antiproliferative activity in ovarian and colon cancer cells. These ligands represent a valuable starting point for structure-based hit-optimization studies aimed at identifying new potent Cdk5 inhibitors.",2022-09-13,cyclindependent kinase 5 cdk5 is an atypical prolinedirected serinethreonine protein kinase wellcharacterized for its role in the central nervous system rather than in the cell cycle indeed its dysregulation has been strongly implicated in the progression of synaptic dysfunction and neurodegenerative diseases such as alzheimers disease ad and parkinsons disease pd and also in the development and progression of a variety of cancers for this reason cdk5 is considered as a promising target for drug design and the discovery of novel smallmolecule cdk5 inhibitors is of great interest in the medicinal chemistry field in this context we employed a machine learningbased virtual screening protocol with subsequent molecular docking molecular dynamics simulations and binding free energy evaluations our virtual screening studies resulted in the identification of two novel cdk5 inhibitors highlighting an experimental hit rate of 50 and thus validating the reliability of the in silico workflow both identified ligands compounds bcpd1b and bcpd4b showed a promising enzyme inhibitory activity and bcpd1b also demonstrated a remarkable antiproliferative activity in ovarian and colon cancer cells these ligands represent a valuable starting point for structurebased hitoptimization studies aimed at identifying new potent cdk5 inhibitors,"['cyclindependent', 'kinase', '5', 'cdk5', 'is', 'an', 'atypical', 'prolinedirected', 'serinethreonine', 'protein', 'kinase', 'wellcharacterized', 'for', 'its', 'role', 'in', 'the', 'central', 'nervous', 'system', 'rather', 'than', 'in', 'the', 'cell', 'cycle', 'indeed', 'its', 'dysregulation', 'has', 'been', 'strongly', 'implicated', 'in', 'the', 'progression', 'of', 'synaptic', 'dysfunction', 'and', 'neurodegenerative', 'diseases', 'such', 'as', 'alzheimers', 'disease', 'ad', 'and', 'parkinsons', 'disease', 'pd', 'and', 'also', 'in', 'the', 'development', 'and', 'progression', 'of', 'a', 'variety', 'of', 'cancers', 'for', 'this', 'reason', 'cdk5', 'is', 'considered', 'as', 'a', 'promising', 'target', 'for', 'drug', 'design', 'and', 'the', 'discovery', 'of', 'novel', 'smallmolecule', 'cdk5', 'inhibitors', 'is', 'of', 'great', 'interest', 'in', 'the', 'medicinal', 'chemistry', 'field', 'in', 'this', 'context', 'we', 'employed', 'a', 'machine', 'learningbased', 'virtual', 'screening', 'protocol', 'with', 'subsequent', 'molecular', 'docking', 'molecular', 'dynamics', 'simulations', 'and', 'binding', 'free', 'energy', 'evaluations', 'our', 'virtual', 'screening', 'studies', 'resulted', 'in', 'the', 'identification', 'of', 'two', 'novel', 'cdk5', 'inhibitors', 'highlighting', 'an', 'experimental', 'hit', 'rate', 'of', '50', 'and', 'thus', 'validating', 'the', 'reliability', 'of', 'the', 'in', 'silico', 'workflow', 'both', 'identified', 'ligands', 'compounds', 'bcpd1b', 'and', 'bcpd4b', 'showed', 'a', 'promising', 'enzyme', 'inhibitory', 'activity', 'and', 'bcpd1b', 'also', 'demonstrated', 'a', 'remarkable', 'antiproliferative', 'activity', 'in', 'ovarian', 'and', 'colon', 'cancer', 'cells', 'these', 'ligands', 'represent', 'a', 'valuable', 'starting', 'point', 'for', 'structurebased', 'hitoptimization', 'studies', 'aimed', 'at', 'identifying', 'new', 'potent', 'cdk5', 'inhibitors']","['cyclindependent', 'kinase', '5', 'cdk5', 'atypical', 'prolinedirected', 'serinethreonine', 'protein', 'kinase', 'wellcharacterized', 'role', 'central', 'nervous', 'system', 'rather', 'cell', 'cycle', 'indeed', 'dysregulation', 'strongly', 'implicated', 'progression', 'synaptic', 'dysfunction', 'neurodegenerative', 'diseases', 'alzheimers', 'disease', 'ad', 'parkinsons', 'disease', 'pd', 'also', 'development', 'progression', 'variety', 'cancers', 'reason', 'cdk5', 'considered', 'promising', 'target', 'drug', 'design', 'discovery', 'novel', 'smallmolecule', 'cdk5', 'inhibitors', 'great', 'interest', 'medicinal', 'chemistry', 'field', 'context', 'employed', 'machine', 'learningbased', 'virtual', 'screening', 'protocol', 'subsequent', 'molecular', 'docking', 'molecular', 'dynamics', 'simulations', 'binding', 'free', 'energy', 'evaluations', 'virtual', 'screening', 'studies', 'resulted', 'identification', 'two', 'novel', 'cdk5', 'inhibitors', 'highlighting', 'experimental', 'hit', 'rate', '50', 'thus', 'validating', 'reliability', 'silico', 'workflow', 'identified', 'ligands', 'compounds', 'bcpd1b', 'bcpd4b', 'showed', 'promising', 'enzyme', 'inhibitory', 'activity', 'bcpd1b', 'also', 'demonstrated', 'remarkable', 'antiproliferative', 'activity', 'ovarian', 'colon', 'cancer', 'cells', 'ligands', 'represent', 'valuable', 'starting', 'point', 'structurebased', 'hitoptimization', 'studies', 'aimed', 'identifying', 'new', 'potent', 'cdk5', 'inhibitors']","['cyclindependent', 'cdk5', 'cdk5', 'cdk5', 'cdk5', 'cdk5']","['cdk5', 'cdk5', 'cdk5', 'cdk5', 'cdk5']",True,"['cancer', 'parkinson', 'alzheimer']"
36110371,Monomerization of Homodimeric Trefoil Factor 3 (TFF3) by an Aminonitrile Compound Inhibits TFF3-Dependent Cancer Cell Survival.,"Trefoil factor 3 (TFF3) is a secreted protein with an established oncogenic function and a highly significant association with clinical progression of various human malignancies. Herein, a novel small molecule that specifically targets TFF3 homodimeric functions was identified. Utilizing the concept of reversible covalent interaction, 2-amino-4-(4-(6-fluoro-5-methylpyridin-3-yl)phenyl)-5-oxo-4H,5H-pyrano[3,2-<i>c</i>]chromene-3-carbonitrile (AMPC) was identified as a molecule that interacted with TFF3. AMPC monomerized the cellular and secreted TFF3 homodimer at the cysteine (Cys)57-Cys57 residue with subsequent more rapid degradation of the generated TFF3 monomers. Hence, AMPC treatment also resulted in cellular depletion of TFF3 with consequent decreased cell viability in various human carcinoma-derived TFF3 expressing cell lines, including estrogen receptor positive (ER+) mammary carcinoma (MC). AMPC treatment of TFF3 expressing ER+ MC cells significantly suppressed total cell number in a dose-dependent manner. Consistently, exposure of TFF3 expressing ER+ MC cells to AMPC decreased soft agar colony formation, foci formation, and growth in suspension culture and inhibited growth of preformed colonies in 3D Matrigel. AMPC increased apoptosis in TFF3 expressing ER+ MC cells associated with decreased activity of EGFR, p38, STAT3, AKT, and ERK, decreased protein levels of CCND1, CCNE1, BCL2, and BCL-XL, and increased protein levels of TP53, CDKN1A, CASP7, and CASP9. <i>siRNA</i>-mediated depletion of <i>TFF3</i> expression in ER+ MC cells efficiently abrogated AMPC-stimulated loss of cell viability and CASPASE 3/7 activities. Furthermore, in mice bearing ER+ MC cell-generated xenografts, AMPC treatment significantly impeded xenograft growth. Hence, AMPC exemplifies a novel mechanism by which small molecule drugs may inhibit a dimeric oncogenic protein and provides a strategy to impede TFF3-dependent cancer progression.",2022-08-17,trefoil factor 3 tff3 is a secreted protein with an established oncogenic function and a highly significant association with clinical progression of various human malignancies herein a novel small molecule that specifically targets tff3 homodimeric functions was identified utilizing the concept of reversible covalent interaction 2amino446fluoro5methylpyridin3ylphenyl5oxo4h5hpyrano32icichromene3carbonitrile ampc was identified as a molecule that interacted with tff3 ampc monomerized the cellular and secreted tff3 homodimer at the cysteine cys57cys57 residue with subsequent more rapid degradation of the generated tff3 monomers hence ampc treatment also resulted in cellular depletion of tff3 with consequent decreased cell viability in various human carcinomaderived tff3 expressing cell lines including estrogen receptor positive er mammary carcinoma mc ampc treatment of tff3 expressing er mc cells significantly suppressed total cell number in a dosedependent manner consistently exposure of tff3 expressing er mc cells to ampc decreased soft agar colony formation foci formation and growth in suspension culture and inhibited growth of preformed colonies in 3d matrigel ampc increased apoptosis in tff3 expressing er mc cells associated with decreased activity of egfr p38 stat3 akt and erk decreased protein levels of ccnd1 ccne1 bcl2 and bclxl and increased protein levels of tp53 cdkn1a casp7 and casp9 isirnaimediated depletion of itff3i expression in er mc cells efficiently abrogated ampcstimulated loss of cell viability and caspase 37 activities furthermore in mice bearing er mc cellgenerated xenografts ampc treatment significantly impeded xenograft growth hence ampc exemplifies a novel mechanism by which small molecule drugs may inhibit a dimeric oncogenic protein and provides a strategy to impede tff3dependent cancer progression,"['trefoil', 'factor', '3', 'tff3', 'is', 'a', 'secreted', 'protein', 'with', 'an', 'established', 'oncogenic', 'function', 'and', 'a', 'highly', 'significant', 'association', 'with', 'clinical', 'progression', 'of', 'various', 'human', 'malignancies', 'herein', 'a', 'novel', 'small', 'molecule', 'that', 'specifically', 'targets', 'tff3', 'homodimeric', 'functions', 'was', 'identified', 'utilizing', 'the', 'concept', 'of', 'reversible', 'covalent', 'interaction', '2amino446fluoro5methylpyridin3ylphenyl5oxo4h5hpyrano32icichromene3carbonitrile', 'ampc', 'was', 'identified', 'as', 'a', 'molecule', 'that', 'interacted', 'with', 'tff3', 'ampc', 'monomerized', 'the', 'cellular', 'and', 'secreted', 'tff3', 'homodimer', 'at', 'the', 'cysteine', 'cys57cys57', 'residue', 'with', 'subsequent', 'more', 'rapid', 'degradation', 'of', 'the', 'generated', 'tff3', 'monomers', 'hence', 'ampc', 'treatment', 'also', 'resulted', 'in', 'cellular', 'depletion', 'of', 'tff3', 'with', 'consequent', 'decreased', 'cell', 'viability', 'in', 'various', 'human', 'carcinomaderived', 'tff3', 'expressing', 'cell', 'lines', 'including', 'estrogen', 'receptor', 'positive', 'er', 'mammary', 'carcinoma', 'mc', 'ampc', 'treatment', 'of', 'tff3', 'expressing', 'er', 'mc', 'cells', 'significantly', 'suppressed', 'total', 'cell', 'number', 'in', 'a', 'dosedependent', 'manner', 'consistently', 'exposure', 'of', 'tff3', 'expressing', 'er', 'mc', 'cells', 'to', 'ampc', 'decreased', 'soft', 'agar', 'colony', 'formation', 'foci', 'formation', 'and', 'growth', 'in', 'suspension', 'culture', 'and', 'inhibited', 'growth', 'of', 'preformed', 'colonies', 'in', '3d', 'matrigel', 'ampc', 'increased', 'apoptosis', 'in', 'tff3', 'expressing', 'er', 'mc', 'cells', 'associated', 'with', 'decreased', 'activity', 'of', 'egfr', 'p38', 'stat3', 'akt', 'and', 'erk', 'decreased', 'protein', 'levels', 'of', 'ccnd1', 'ccne1', 'bcl2', 'and', 'bclxl', 'and', 'increased', 'protein', 'levels', 'of', 'tp53', 'cdkn1a', 'casp7', 'and', 'casp9', 'isirnaimediated', 'depletion', 'of', 'itff3i', 'expression', 'in', 'er', 'mc', 'cells', 'efficiently', 'abrogated', 'ampcstimulated', 'loss', 'of', 'cell', 'viability', 'and', 'caspase', '37', 'activities', 'furthermore', 'in', 'mice', 'bearing', 'er', 'mc', 'cellgenerated', 'xenografts', 'ampc', 'treatment', 'significantly', 'impeded', 'xenograft', 'growth', 'hence', 'ampc', 'exemplifies', 'a', 'novel', 'mechanism', 'by', 'which', 'small', 'molecule', 'drugs', 'may', 'inhibit', 'a', 'dimeric', 'oncogenic', 'protein', 'and', 'provides', 'a', 'strategy', 'to', 'impede', 'tff3dependent', 'cancer', 'progression']","['trefoil', 'factor', '3', 'tff3', 'secreted', 'protein', 'established', 'oncogenic', 'function', 'highly', 'significant', 'association', 'clinical', 'progression', 'various', 'human', 'malignancies', 'herein', 'novel', 'small', 'molecule', 'specifically', 'targets', 'tff3', 'homodimeric', 'functions', 'identified', 'utilizing', 'concept', 'reversible', 'covalent', 'interaction', '2amino446fluoro5methylpyridin3ylphenyl5oxo4h5hpyrano32icichromene3carbonitrile', 'ampc', 'identified', 'molecule', 'interacted', 'tff3', 'ampc', 'monomerized', 'cellular', 'secreted', 'tff3', 'homodimer', 'cysteine', 'cys57cys57', 'residue', 'subsequent', 'rapid', 'degradation', 'generated', 'tff3', 'monomers', 'hence', 'ampc', 'treatment', 'also', 'resulted', 'cellular', 'depletion', 'tff3', 'consequent', 'decreased', 'cell', 'viability', 'various', 'human', 'carcinomaderived', 'tff3', 'expressing', 'cell', 'lines', 'including', 'estrogen', 'receptor', 'positive', 'er', 'mammary', 'carcinoma', 'mc', 'ampc', 'treatment', 'tff3', 'expressing', 'er', 'mc', 'cells', 'significantly', 'suppressed', 'total', 'cell', 'number', 'dosedependent', 'manner', 'consistently', 'exposure', 'tff3', 'expressing', 'er', 'mc', 'cells', 'ampc', 'decreased', 'soft', 'agar', 'colony', 'formation', 'foci', 'formation', 'growth', 'suspension', 'culture', 'inhibited', 'growth', 'preformed', 'colonies', '3d', 'matrigel', 'ampc', 'increased', 'apoptosis', 'tff3', 'expressing', 'er', 'mc', 'cells', 'associated', 'decreased', 'activity', 'egfr', 'p38', 'stat3', 'akt', 'erk', 'decreased', 'protein', 'levels', 'ccnd1', 'ccne1', 'bcl2', 'bclxl', 'increased', 'protein', 'levels', 'tp53', 'cdkn1a', 'casp7', 'casp9', 'isirnaimediated', 'depletion', 'itff3i', 'expression', 'er', 'mc', 'cells', 'efficiently', 'abrogated', 'ampcstimulated', 'loss', 'cell', 'viability', 'caspase', '37', 'activities', 'furthermore', 'mice', 'bearing', 'er', 'mc', 'cellgenerated', 'xenografts', 'ampc', 'treatment', 'significantly', 'impeded', 'xenograft', 'growth', 'hence', 'ampc', 'exemplifies', 'novel', 'mechanism', 'small', 'molecule', 'drugs', 'may', 'inhibit', 'dimeric', 'oncogenic', 'protein', 'provides', 'strategy', 'impede', 'tff3dependent', 'cancer', 'progression']","['egfr', 'p38', 'stat3', 'akt', 'erk', 'ccnd1', 'ccne1', 'bcl2', 'bclxl', 'tp53', 'cdkn1a', 'casp9', 'caspase']","['ccnd1', 'ccne1', 'bclxl', 'tp53', 'cdkn1a']",True,['cancer']
36009550,"LLL12B, a Novel Small-Molecule STAT3 Inhibitor, Induces Apoptosis and Suppresses Cell Migration and Tumor Growth in Triple-Negative Breast Cancer Cells.","Persistent STAT3 signaling plays a pivotal role in human tumor malignancy, including triple-negative breast cancer (TNBC). There are few treatment options currently available for TNBC; thus, given its importance to cancer, STAT3 is a potential cancer therapeutic target and is the focus of drug discovery efforts. In this study, we tested a novel orally bioavailable small-molecule STAT3 inhibitor, LLL12B, in human MDA-MB-231, SUM159, and murine 4T1 TNBC cell lines. TNBC cells frequently expressed persistent STAT3 phosphorylation and their cell viability was sensitive to STAT3 knockdown by siRNA. LLL12B selectively inhibited the IL-6-mediated induction of STAT3 phosphorylation, but had little effect on the IFN-γ-mediated induction of STAT1 phosphorylation nor the EGF-mediated induction of ERK phosphorylation. In addition, targeting STAT3 with LLL12B induced apoptosis, reduced colony formation ability, and inhibited cell migration in TNBC cells. Furthermore, LLL12B suppressed the tumor growth of the MDA-MB-231 TNBC cells in a mammary fat pad mouse tumor model in vivo. Together, our findings support the concept that targeting persistent STAT3 signaling using the novel small-molecule LLL12B is a potential approach for TNBC therapy.",2022-08-18,persistent stat3 signaling plays a pivotal role in human tumor malignancy including triplenegative breast cancer tnbc there are few treatment options currently available for tnbc thus given its importance to cancer stat3 is a potential cancer therapeutic target and is the focus of drug discovery efforts in this study we tested a novel orally bioavailable smallmolecule stat3 inhibitor lll12b in human mdamb231 sum159 and murine 4t1 tnbc cell lines tnbc cells frequently expressed persistent stat3 phosphorylation and their cell viability was sensitive to stat3 knockdown by sirna lll12b selectively inhibited the il6mediated induction of stat3 phosphorylation but had little effect on the ifnγmediated induction of stat1 phosphorylation nor the egfmediated induction of erk phosphorylation in addition targeting stat3 with lll12b induced apoptosis reduced colony formation ability and inhibited cell migration in tnbc cells furthermore lll12b suppressed the tumor growth of the mdamb231 tnbc cells in a mammary fat pad mouse tumor model in vivo together our findings support the concept that targeting persistent stat3 signaling using the novel smallmolecule lll12b is a potential approach for tnbc therapy,"['persistent', 'stat3', 'signaling', 'plays', 'a', 'pivotal', 'role', 'in', 'human', 'tumor', 'malignancy', 'including', 'triplenegative', 'breast', 'cancer', 'tnbc', 'there', 'are', 'few', 'treatment', 'options', 'currently', 'available', 'for', 'tnbc', 'thus', 'given', 'its', 'importance', 'to', 'cancer', 'stat3', 'is', 'a', 'potential', 'cancer', 'therapeutic', 'target', 'and', 'is', 'the', 'focus', 'of', 'drug', 'discovery', 'efforts', 'in', 'this', 'study', 'we', 'tested', 'a', 'novel', 'orally', 'bioavailable', 'smallmolecule', 'stat3', 'inhibitor', 'lll12b', 'in', 'human', 'mdamb231', 'sum159', 'and', 'murine', '4t1', 'tnbc', 'cell', 'lines', 'tnbc', 'cells', 'frequently', 'expressed', 'persistent', 'stat3', 'phosphorylation', 'and', 'their', 'cell', 'viability', 'was', 'sensitive', 'to', 'stat3', 'knockdown', 'by', 'sirna', 'lll12b', 'selectively', 'inhibited', 'the', 'il6mediated', 'induction', 'of', 'stat3', 'phosphorylation', 'but', 'had', 'little', 'effect', 'on', 'the', 'ifnγmediated', 'induction', 'of', 'stat1', 'phosphorylation', 'nor', 'the', 'egfmediated', 'induction', 'of', 'erk', 'phosphorylation', 'in', 'addition', 'targeting', 'stat3', 'with', 'lll12b', 'induced', 'apoptosis', 'reduced', 'colony', 'formation', 'ability', 'and', 'inhibited', 'cell', 'migration', 'in', 'tnbc', 'cells', 'furthermore', 'lll12b', 'suppressed', 'the', 'tumor', 'growth', 'of', 'the', 'mdamb231', 'tnbc', 'cells', 'in', 'a', 'mammary', 'fat', 'pad', 'mouse', 'tumor', 'model', 'in', 'vivo', 'together', 'our', 'findings', 'support', 'the', 'concept', 'that', 'targeting', 'persistent', 'stat3', 'signaling', 'using', 'the', 'novel', 'smallmolecule', 'lll12b', 'is', 'a', 'potential', 'approach', 'for', 'tnbc', 'therapy']","['persistent', 'stat3', 'signaling', 'plays', 'pivotal', 'role', 'human', 'tumor', 'malignancy', 'including', 'triplenegative', 'breast', 'cancer', 'tnbc', 'treatment', 'options', 'currently', 'available', 'tnbc', 'thus', 'given', 'importance', 'cancer', 'stat3', 'potential', 'cancer', 'therapeutic', 'target', 'focus', 'drug', 'discovery', 'efforts', 'study', 'tested', 'novel', 'orally', 'bioavailable', 'smallmolecule', 'stat3', 'inhibitor', 'lll12b', 'human', 'mdamb231', 'sum159', 'murine', '4t1', 'tnbc', 'cell', 'lines', 'tnbc', 'cells', 'frequently', 'expressed', 'persistent', 'stat3', 'phosphorylation', 'cell', 'viability', 'sensitive', 'stat3', 'knockdown', 'sirna', 'lll12b', 'selectively', 'inhibited', 'il6mediated', 'induction', 'stat3', 'phosphorylation', 'little', 'effect', 'ifnγmediated', 'induction', 'stat1', 'phosphorylation', 'egfmediated', 'induction', 'erk', 'phosphorylation', 'addition', 'targeting', 'stat3', 'lll12b', 'induced', 'apoptosis', 'reduced', 'colony', 'formation', 'ability', 'inhibited', 'cell', 'migration', 'tnbc', 'cells', 'furthermore', 'lll12b', 'suppressed', 'tumor', 'growth', 'mdamb231', 'tnbc', 'cells', 'mammary', 'fat', 'pad', 'mouse', 'tumor', 'model', 'vivo', 'together', 'findings', 'support', 'concept', 'targeting', 'persistent', 'stat3', 'signaling', 'using', 'novel', 'smallmolecule', 'lll12b', 'potential', 'approach', 'tnbc', 'therapy']","['stat3', 'stat3', 'stat3', 'stat3', 'stat3', 'sirna', 'stat3', 'stat1', 'erk', 'stat3', 'stat3']",['stat1'],True,"['tumor', 'cancer']"
35943255,Targeting Doublecortin-Like Kinase 1 (DCLK1)-Regulated SARS-CoV-2 Pathogenesis in COVID-19.,"Host factors play critical roles in SARS-CoV-2 infection-associated pathology and the severity of COVID-19. In this study, we systematically analyzed the roles of SARS-CoV-2-induced host factors, doublecortin-like kinase 1 (DCLK1), and S100A9 in viral pathogenesis. In autopsied subjects with COVID-19 and pre-existing chronic liver disease, we observed high levels of DCLK1 and S100A9 expression and immunosuppressive (DCLK1<sup>+</sup>S100A9<sup>+</sup>CD206<sup>+</sup>) M2-like macrophages and N2-like neutrophils in lungs and livers. DCLK1 and S100A9 expression were rarely observed in normal controls, COVID-19-negative subjects with chronic lung disease, or COVID-19 subjects without chronic liver disease. In hospitalized patients with COVID-19, we detected 2 to 3-fold increased levels of circulating DCLK1<sup>+</sup>S100A9<sup>+</sup> mononuclear cells that correlated with disease severity. We validated the SARS-CoV-2-dependent generation of these double-positive immune cells in coculture. SARS-CoV-2-induced DCLK1 expression correlated with the activation of β-catenin, a known regulator of the DCLK1 promoter. Gain and loss of function studies showed that DCLK1 kinase amplified live virus production and promoted cytokine, chemokine, and growth factor secretion by peripheral blood mononuclear cells. Inhibition of DCLK1 kinase blocked pro-inflammatory caspase-1/interleukin-1β signaling in infected cells. Treatment of SARS-CoV-2-infected cells with inhibitors of DCLK1 kinase and S100A9 normalized cytokine/chemokine profiles and attenuated DCLK1 expression and β-catenin activation. In conclusion, we report previously unidentified roles of DCLK1 in augmenting SARS-CoV-2 viremia, inflammatory cytokine expression, and dysregulation of immune cells involved in innate immunity. DCLK1 could be a potential therapeutic target for COVID-19, especially in patients with underlying comorbid diseases associated with DCLK1 expression. <b>IMPORTANCE</b> High mortality in COVID-19 is associated with underlying comorbidities such as chronic liver diseases. Successful treatment of severe/critical COVID-19 remains challenging. Herein, we report a targetable host factor, DCLK1, that amplifies SARS-CoV-2 production, cytokine secretion, and inflammatory pathways via activation of β-catenin(p65)/DCLK1/S100A9/NF-<i>κ</i>B signaling. Furthermore, we observed in the lung, liver, and blood an increased prevalence of immune cells coexpressing DCLK1 and S100A9, a myeloid-derived proinflammatory protein. These cells were associated with increased disease severity in COVID-19 patients. Finally, we used a novel small-molecule inhibitor of DCLK1 kinase (DCLK1-IN-1) and S100A9 inhibitor (tasquinimod) to decrease virus production <i>in vitro</i> and normalize hyperinflammatory responses known to contribute to disease severity in COVID-19.",2022-08-09,host factors play critical roles in sarscov2 infectionassociated pathology and the severity of covid19 in this study we systematically analyzed the roles of sarscov2induced host factors doublecortinlike kinase 1 dclk1 and s100a9 in viral pathogenesis in autopsied subjects with covid19 and preexisting chronic liver disease we observed high levels of dclk1 and s100a9 expression and immunosuppressive dclk1supsups100a9supsupcd206supsup m2like macrophages and n2like neutrophils in lungs and livers dclk1 and s100a9 expression were rarely observed in normal controls covid19negative subjects with chronic lung disease or covid19 subjects without chronic liver disease in hospitalized patients with covid19 we detected 2 to 3fold increased levels of circulating dclk1supsups100a9supsup mononuclear cells that correlated with disease severity we validated the sarscov2dependent generation of these doublepositive immune cells in coculture sarscov2induced dclk1 expression correlated with the activation of βcatenin a known regulator of the dclk1 promoter gain and loss of function studies showed that dclk1 kinase amplified live virus production and promoted cytokine chemokine and growth factor secretion by peripheral blood mononuclear cells inhibition of dclk1 kinase blocked proinflammatory caspase1interleukin1β signaling in infected cells treatment of sarscov2infected cells with inhibitors of dclk1 kinase and s100a9 normalized cytokinechemokine profiles and attenuated dclk1 expression and βcatenin activation in conclusion we report previously unidentified roles of dclk1 in augmenting sarscov2 viremia inflammatory cytokine expression and dysregulation of immune cells involved in innate immunity dclk1 could be a potential therapeutic target for covid19 especially in patients with underlying comorbid diseases associated with dclk1 expression bimportanceb high mortality in covid19 is associated with underlying comorbidities such as chronic liver diseases successful treatment of severecritical covid19 remains challenging herein we report a targetable host factor dclk1 that amplifies sarscov2 production cytokine secretion and inflammatory pathways via activation of βcateninp65dclk1s100a9nfiκib signaling furthermore we observed in the lung liver and blood an increased prevalence of immune cells coexpressing dclk1 and s100a9 a myeloidderived proinflammatory protein these cells were associated with increased disease severity in covid19 patients finally we used a novel smallmolecule inhibitor of dclk1 kinase dclk1in1 and s100a9 inhibitor tasquinimod to decrease virus production iin vitroi and normalize hyperinflammatory responses known to contribute to disease severity in covid19,"['host', 'factors', 'play', 'critical', 'roles', 'in', 'sarscov2', 'infectionassociated', 'pathology', 'and', 'the', 'severity', 'of', 'covid19', 'in', 'this', 'study', 'we', 'systematically', 'analyzed', 'the', 'roles', 'of', 'sarscov2induced', 'host', 'factors', 'doublecortinlike', 'kinase', '1', 'dclk1', 'and', 's100a9', 'in', 'viral', 'pathogenesis', 'in', 'autopsied', 'subjects', 'with', 'covid19', 'and', 'preexisting', 'chronic', 'liver', 'disease', 'we', 'observed', 'high', 'levels', 'of', 'dclk1', 'and', 's100a9', 'expression', 'and', 'immunosuppressive', 'dclk1supsups100a9supsupcd206supsup', 'm2like', 'macrophages', 'and', 'n2like', 'neutrophils', 'in', 'lungs', 'and', 'livers', 'dclk1', 'and', 's100a9', 'expression', 'were', 'rarely', 'observed', 'in', 'normal', 'controls', 'covid19negative', 'subjects', 'with', 'chronic', 'lung', 'disease', 'or', 'covid19', 'subjects', 'without', 'chronic', 'liver', 'disease', 'in', 'hospitalized', 'patients', 'with', 'covid19', 'we', 'detected', '2', 'to', '3fold', 'increased', 'levels', 'of', 'circulating', 'dclk1supsups100a9supsup', 'mononuclear', 'cells', 'that', 'correlated', 'with', 'disease', 'severity', 'we', 'validated', 'the', 'sarscov2dependent', 'generation', 'of', 'these', 'doublepositive', 'immune', 'cells', 'in', 'coculture', 'sarscov2induced', 'dclk1', 'expression', 'correlated', 'with', 'the', 'activation', 'of', 'βcatenin', 'a', 'known', 'regulator', 'of', 'the', 'dclk1', 'promoter', 'gain', 'and', 'loss', 'of', 'function', 'studies', 'showed', 'that', 'dclk1', 'kinase', 'amplified', 'live', 'virus', 'production', 'and', 'promoted', 'cytokine', 'chemokine', 'and', 'growth', 'factor', 'secretion', 'by', 'peripheral', 'blood', 'mononuclear', 'cells', 'inhibition', 'of', 'dclk1', 'kinase', 'blocked', 'proinflammatory', 'caspase1interleukin1β', 'signaling', 'in', 'infected', 'cells', 'treatment', 'of', 'sarscov2infected', 'cells', 'with', 'inhibitors', 'of', 'dclk1', 'kinase', 'and', 's100a9', 'normalized', 'cytokinechemokine', 'profiles', 'and', 'attenuated', 'dclk1', 'expression', 'and', 'βcatenin', 'activation', 'in', 'conclusion', 'we', 'report', 'previously', 'unidentified', 'roles', 'of', 'dclk1', 'in', 'augmenting', 'sarscov2', 'viremia', 'inflammatory', 'cytokine', 'expression', 'and', 'dysregulation', 'of', 'immune', 'cells', 'involved', 'in', 'innate', 'immunity', 'dclk1', 'could', 'be', 'a', 'potential', 'therapeutic', 'target', 'for', 'covid19', 'especially', 'in', 'patients', 'with', 'underlying', 'comorbid', 'diseases', 'associated', 'with', 'dclk1', 'expression', 'bimportanceb', 'high', 'mortality', 'in', 'covid19', 'is', 'associated', 'with', 'underlying', 'comorbidities', 'such', 'as', 'chronic', 'liver', 'diseases', 'successful', 'treatment', 'of', 'severecritical', 'covid19', 'remains', 'challenging', 'herein', 'we', 'report', 'a', 'targetable', 'host', 'factor', 'dclk1', 'that', 'amplifies', 'sarscov2', 'production', 'cytokine', 'secretion', 'and', 'inflammatory', 'pathways', 'via', 'activation', 'of', 'βcateninp65dclk1s100a9nfiκib', 'signaling', 'furthermore', 'we', 'observed', 'in', 'the', 'lung', 'liver', 'and', 'blood', 'an', 'increased', 'prevalence', 'of', 'immune', 'cells', 'coexpressing', 'dclk1', 'and', 's100a9', 'a', 'myeloidderived', 'proinflammatory', 'protein', 'these', 'cells', 'were', 'associated', 'with', 'increased', 'disease', 'severity', 'in', 'covid19', 'patients', 'finally', 'we', 'used', 'a', 'novel', 'smallmolecule', 'inhibitor', 'of', 'dclk1', 'kinase', 'dclk1in1', 'and', 's100a9', 'inhibitor', 'tasquinimod', 'to', 'decrease', 'virus', 'production', 'iin', 'vitroi', 'and', 'normalize', 'hyperinflammatory', 'responses', 'known', 'to', 'contribute', 'to', 'disease', 'severity', 'in', 'covid19']","['host', 'factors', 'play', 'critical', 'roles', 'sarscov2', 'infectionassociated', 'pathology', 'severity', 'covid19', 'study', 'systematically', 'analyzed', 'roles', 'sarscov2induced', 'host', 'factors', 'doublecortinlike', 'kinase', '1', 'dclk1', 's100a9', 'viral', 'pathogenesis', 'autopsied', 'subjects', 'covid19', 'preexisting', 'chronic', 'liver', 'disease', 'observed', 'high', 'levels', 'dclk1', 's100a9', 'expression', 'immunosuppressive', 'dclk1supsups100a9supsupcd206supsup', 'm2like', 'macrophages', 'n2like', 'neutrophils', 'lungs', 'livers', 'dclk1', 's100a9', 'expression', 'rarely', 'observed', 'normal', 'controls', 'covid19negative', 'subjects', 'chronic', 'lung', 'disease', 'covid19', 'subjects', 'without', 'chronic', 'liver', 'disease', 'hospitalized', 'patients', 'covid19', 'detected', '2', '3fold', 'increased', 'levels', 'circulating', 'dclk1supsups100a9supsup', 'mononuclear', 'cells', 'correlated', 'disease', 'severity', 'validated', 'sarscov2dependent', 'generation', 'doublepositive', 'immune', 'cells', 'coculture', 'sarscov2induced', 'dclk1', 'expression', 'correlated', 'activation', 'βcatenin', 'known', 'regulator', 'dclk1', 'promoter', 'gain', 'loss', 'function', 'studies', 'showed', 'dclk1', 'kinase', 'amplified', 'live', 'virus', 'production', 'promoted', 'cytokine', 'chemokine', 'growth', 'factor', 'secretion', 'peripheral', 'blood', 'mononuclear', 'cells', 'inhibition', 'dclk1', 'kinase', 'blocked', 'proinflammatory', 'caspase1interleukin1β', 'signaling', 'infected', 'cells', 'treatment', 'sarscov2infected', 'cells', 'inhibitors', 'dclk1', 'kinase', 's100a9', 'normalized', 'cytokinechemokine', 'profiles', 'attenuated', 'dclk1', 'expression', 'βcatenin', 'activation', 'conclusion', 'report', 'previously', 'unidentified', 'roles', 'dclk1', 'augmenting', 'sarscov2', 'viremia', 'inflammatory', 'cytokine', 'expression', 'dysregulation', 'immune', 'cells', 'involved', 'innate', 'immunity', 'dclk1', 'could', 'potential', 'therapeutic', 'target', 'covid19', 'especially', 'patients', 'underlying', 'comorbid', 'diseases', 'associated', 'dclk1', 'expression', 'bimportanceb', 'high', 'mortality', 'covid19', 'associated', 'underlying', 'comorbidities', 'chronic', 'liver', 'diseases', 'successful', 'treatment', 'severecritical', 'covid19', 'remains', 'challenging', 'herein', 'report', 'targetable', 'host', 'factor', 'dclk1', 'amplifies', 'sarscov2', 'production', 'cytokine', 'secretion', 'inflammatory', 'pathways', 'via', 'activation', 'βcateninp65dclk1s100a9nfiκib', 'signaling', 'furthermore', 'observed', 'lung', 'liver', 'blood', 'increased', 'prevalence', 'immune', 'cells', 'coexpressing', 'dclk1', 's100a9', 'myeloidderived', 'proinflammatory', 'protein', 'cells', 'associated', 'increased', 'disease', 'severity', 'covid19', 'patients', 'finally', 'used', 'novel', 'smallmolecule', 'inhibitor', 'dclk1', 'kinase', 'dclk1in1', 's100a9', 'inhibitor', 'tasquinimod', 'decrease', 'virus', 'production', 'iin', 'vitroi', 'normalize', 'hyperinflammatory', 'responses', 'known', 'contribute', 'disease', 'severity', 'covid19']","['s100a9', 's100a9', 's100a9', 's100a9', 's100a9', 's100a9']","['s100a9', 's100a9', 's100a9', 's100a9', 's100a9', 's100a9']",True,['infection']
35930922,Novel isatin-based hybrids as potential anti-rheumatoid arthritis drug candidates: Synthesis and biological evaluation.,"Rheumatoid arthritis (RA) is an autoimmune disease accompanied with serious symptoms, such as joint destruction and chronic synovitis. Though many anti-RA drugs could improve the outcome of RA patients to a certain extent, about 40% inefficient rate, severe side effects, and high costs have become urgent problems. Therefore, exploring new alternative drugs for RA therapy is still an urgent need so far. Isatin is an important structural motif found in numerous biologically active compounds and therapeutic agents. Herein, we aim to synthesize several novel isatin analogues for RA therapy and further explore the mechanism of the most potential anti-RA drug candidate in suppressing the pathological progress of RA in vitro and in vivo. We found that the most therapeutic potential compound, a novel small molecule isatin-honokiol hybrid named CT5-2 inhibited the viability of RA-fibroblast-like synoviocytes (FLSs), an effector cell of synovial hyperplasia in the RA synovial tissue with IC<sub>50</sub> ranging from 8.54 to 10.66 μM. In addition, CT5-2 reduced the DNA replication and triggered cell cycle arrest and apoptosis of RA-FLSs. Moreover, differential analyses of RNA-sequencing and the mechanistic studies demonstrated that CDCA7 is a key gene correlated with RA progression, and CT5-2 could inhibit the c-Myc/CDCA7/p65 pathway to regulate CDK1, Bcl-2, and vimentin in RA-FLSs. Furthermore, CT5-2 relieved collagen-induced arthritis (CIA) and reduced the level of CDCA7, CDK1, Bcl-2, and vimentin of synovial tissue in CIA mice. Taken together, the novel small molecule isatin-honokiol hybrid CT5-2 exhibits a potential anti-RA drug candidate that inhibits proliferation and triggers cell cycle arrest and apoptosis of RA-FLSs by regulating the c-Myc/CDCA7/p65 pathway. Our study lays a good foundation for further clinical research and structuralmodification of CT5-2.",2022-07-29,rheumatoid arthritis ra is an autoimmune disease accompanied with serious symptoms such as joint destruction and chronic synovitis though many antira drugs could improve the outcome of ra patients to a certain extent about 40 inefficient rate severe side effects and high costs have become urgent problems therefore exploring new alternative drugs for ra therapy is still an urgent need so far isatin is an important structural motif found in numerous biologically active compounds and therapeutic agents herein we aim to synthesize several novel isatin analogues for ra therapy and further explore the mechanism of the most potential antira drug candidate in suppressing the pathological progress of ra in vitro and in vivo we found that the most therapeutic potential compound a novel small molecule isatinhonokiol hybrid named ct52 inhibited the viability of rafibroblastlike synoviocytes flss an effector cell of synovial hyperplasia in the ra synovial tissue with icsub50sub ranging from 854 to 1066 μm in addition ct52 reduced the dna replication and triggered cell cycle arrest and apoptosis of raflss moreover differential analyses of rnasequencing and the mechanistic studies demonstrated that cdca7 is a key gene correlated with ra progression and ct52 could inhibit the cmyccdca7p65 pathway to regulate cdk1 bcl2 and vimentin in raflss furthermore ct52 relieved collageninduced arthritis cia and reduced the level of cdca7 cdk1 bcl2 and vimentin of synovial tissue in cia mice taken together the novel small molecule isatinhonokiol hybrid ct52 exhibits a potential antira drug candidate that inhibits proliferation and triggers cell cycle arrest and apoptosis of raflss by regulating the cmyccdca7p65 pathway our study lays a good foundation for further clinical research and structuralmodification of ct52,"['rheumatoid', 'arthritis', 'ra', 'is', 'an', 'autoimmune', 'disease', 'accompanied', 'with', 'serious', 'symptoms', 'such', 'as', 'joint', 'destruction', 'and', 'chronic', 'synovitis', 'though', 'many', 'antira', 'drugs', 'could', 'improve', 'the', 'outcome', 'of', 'ra', 'patients', 'to', 'a', 'certain', 'extent', 'about', '40', 'inefficient', 'rate', 'severe', 'side', 'effects', 'and', 'high', 'costs', 'have', 'become', 'urgent', 'problems', 'therefore', 'exploring', 'new', 'alternative', 'drugs', 'for', 'ra', 'therapy', 'is', 'still', 'an', 'urgent', 'need', 'so', 'far', 'isatin', 'is', 'an', 'important', 'structural', 'motif', 'found', 'in', 'numerous', 'biologically', 'active', 'compounds', 'and', 'therapeutic', 'agents', 'herein', 'we', 'aim', 'to', 'synthesize', 'several', 'novel', 'isatin', 'analogues', 'for', 'ra', 'therapy', 'and', 'further', 'explore', 'the', 'mechanism', 'of', 'the', 'most', 'potential', 'antira', 'drug', 'candidate', 'in', 'suppressing', 'the', 'pathological', 'progress', 'of', 'ra', 'in', 'vitro', 'and', 'in', 'vivo', 'we', 'found', 'that', 'the', 'most', 'therapeutic', 'potential', 'compound', 'a', 'novel', 'small', 'molecule', 'isatinhonokiol', 'hybrid', 'named', 'ct52', 'inhibited', 'the', 'viability', 'of', 'rafibroblastlike', 'synoviocytes', 'flss', 'an', 'effector', 'cell', 'of', 'synovial', 'hyperplasia', 'in', 'the', 'ra', 'synovial', 'tissue', 'with', 'icsub50sub', 'ranging', 'from', '854', 'to', '1066', 'μm', 'in', 'addition', 'ct52', 'reduced', 'the', 'dna', 'replication', 'and', 'triggered', 'cell', 'cycle', 'arrest', 'and', 'apoptosis', 'of', 'raflss', 'moreover', 'differential', 'analyses', 'of', 'rnasequencing', 'and', 'the', 'mechanistic', 'studies', 'demonstrated', 'that', 'cdca7', 'is', 'a', 'key', 'gene', 'correlated', 'with', 'ra', 'progression', 'and', 'ct52', 'could', 'inhibit', 'the', 'cmyccdca7p65', 'pathway', 'to', 'regulate', 'cdk1', 'bcl2', 'and', 'vimentin', 'in', 'raflss', 'furthermore', 'ct52', 'relieved', 'collageninduced', 'arthritis', 'cia', 'and', 'reduced', 'the', 'level', 'of', 'cdca7', 'cdk1', 'bcl2', 'and', 'vimentin', 'of', 'synovial', 'tissue', 'in', 'cia', 'mice', 'taken', 'together', 'the', 'novel', 'small', 'molecule', 'isatinhonokiol', 'hybrid', 'ct52', 'exhibits', 'a', 'potential', 'antira', 'drug', 'candidate', 'that', 'inhibits', 'proliferation', 'and', 'triggers', 'cell', 'cycle', 'arrest', 'and', 'apoptosis', 'of', 'raflss', 'by', 'regulating', 'the', 'cmyccdca7p65', 'pathway', 'our', 'study', 'lays', 'a', 'good', 'foundation', 'for', 'further', 'clinical', 'research', 'and', 'structuralmodification', 'of', 'ct52']","['rheumatoid', 'arthritis', 'ra', 'autoimmune', 'disease', 'accompanied', 'serious', 'symptoms', 'joint', 'destruction', 'chronic', 'synovitis', 'though', 'many', 'antira', 'drugs', 'could', 'improve', 'outcome', 'ra', 'patients', 'certain', 'extent', '40', 'inefficient', 'rate', 'severe', 'side', 'effects', 'high', 'costs', 'become', 'urgent', 'problems', 'therefore', 'exploring', 'new', 'alternative', 'drugs', 'ra', 'therapy', 'still', 'urgent', 'need', 'far', 'isatin', 'important', 'structural', 'motif', 'found', 'numerous', 'biologically', 'active', 'compounds', 'therapeutic', 'agents', 'herein', 'aim', 'synthesize', 'several', 'novel', 'isatin', 'analogues', 'ra', 'therapy', 'explore', 'mechanism', 'potential', 'antira', 'drug', 'candidate', 'suppressing', 'pathological', 'progress', 'ra', 'vitro', 'vivo', 'found', 'therapeutic', 'potential', 'compound', 'novel', 'small', 'molecule', 'isatinhonokiol', 'hybrid', 'named', 'ct52', 'inhibited', 'viability', 'rafibroblastlike', 'synoviocytes', 'flss', 'effector', 'cell', 'synovial', 'hyperplasia', 'ra', 'synovial', 'tissue', 'icsub50sub', 'ranging', '854', '1066', 'μm', 'addition', 'ct52', 'reduced', 'dna', 'replication', 'triggered', 'cell', 'cycle', 'arrest', 'apoptosis', 'raflss', 'moreover', 'differential', 'analyses', 'rnasequencing', 'mechanistic', 'studies', 'demonstrated', 'cdca7', 'key', 'gene', 'correlated', 'ra', 'progression', 'ct52', 'could', 'inhibit', 'cmyccdca7p65', 'pathway', 'regulate', 'cdk1', 'bcl2', 'vimentin', 'raflss', 'furthermore', 'ct52', 'relieved', 'collageninduced', 'arthritis', 'cia', 'reduced', 'level', 'cdca7', 'cdk1', 'bcl2', 'vimentin', 'synovial', 'tissue', 'cia', 'mice', 'taken', 'together', 'novel', 'small', 'molecule', 'isatinhonokiol', 'hybrid', 'ct52', 'exhibits', 'potential', 'antira', 'drug', 'candidate', 'inhibits', 'proliferation', 'triggers', 'cell', 'cycle', 'arrest', 'apoptosis', 'raflss', 'regulating', 'cmyccdca7p65', 'pathway', 'study', 'lays', 'good', 'foundation', 'clinical', 'research', 'structuralmodification', 'ct52']","['ra', 'ra', 'ra', 'ra', 'ra', 'ra', 'ra', 'cdk1', 'bcl2', 'vimentin', 'cdk1', 'bcl2', 'vimentin']","['ra', 'ra', 'ra', 'ra', 'ra', 'ra', 'ra', 'vimentin', 'vimentin']",True,['arthritis']
35894141,Cryptotanshinone suppresses tumorigenesis by inhibiting lipogenesis and promoting reactive oxygen species production in KRAS‑activated pancreatic cancer cells.,"Pyruvate dehydrogenase kinase 4 (PDK4) is an important regulator of energy metabolism. Previously, knockdown of PDK4 by specific small interfering RNAs (siRNAs) have been shown to suppress the expression of Κirsten rat sarcoma viral oncogene homolog (KRAS) and the growth of lung and colorectal cancer cells, indicating that PDK4 is an attractive target of cancer therapy by altering energy metabolism. The authors previously reported that a novel small molecule, cryptotanshinone (CPT), which inhibits PDK4 activity, suppresses the <i>in vitro</i> three‑dimensional (3D)‑spheroid formation and <i>in vivo</i> tumorigenesis of KRAS‑activated human pancreatic and colorectal cancer cells. The present study investigated the molecular mechanism of CPT‑induced tumor suppression via alteration of glutamine and lipid metabolism in human pancreatic and colon cancer cell lines with mutant and wild‑type KRAS. The antitumor effect of CPT was more pronounced in the cancer cells containing mutant KRAS compared with those containing wild‑type KRAS. CPT treatment decreased glutamine and lipid metabolism, affected redox regulation and increased reactive oxygen species (ROS) production in the pancreatic cancer cell line MIAPaCa‑2 containing mutant KRAS. Suppression of activated KRAS by specific siRNAs decreased 3D‑spheroid formation, the expression of acetyl‑CoA carboxylase 1 and fatty acid synthase (FASN) and lipid synthesis. The suppression also reduced glutathione‑SH/glutathione disulfide and increased the production of ROS. Knockdown of FASN suppressed lipid synthesis in MIAPaCa‑2 cells, partially promoted ROS production and mildly suppressed 3D‑spheroid formation. These results indicated that CPT reduced tumorigenesis by inhibiting lipid metabolism and promoting ROS production in a mutant KRAS‑dependent manner. This PDK4 inhibitor could serve as a novel therapeutic drug for KRAS‑driven intractable cancers via alteration of cell metabolism.",2022-07-27,pyruvate dehydrogenase kinase 4 pdk4 is an important regulator of energy metabolism previously knockdown of pdk4 by specific small interfering rnas sirnas have been shown to suppress the expression of κirsten rat sarcoma viral oncogene homolog kras and the growth of lung and colorectal cancer cells indicating that pdk4 is an attractive target of cancer therapy by altering energy metabolism the authors previously reported that a novel small molecule cryptotanshinone cpt which inhibits pdk4 activity suppresses the iin vitroi threedimensional 3dspheroid formation and iin vivoi tumorigenesis of krasactivated human pancreatic and colorectal cancer cells the present study investigated the molecular mechanism of cptinduced tumor suppression via alteration of glutamine and lipid metabolism in human pancreatic and colon cancer cell lines with mutant and wildtype kras the antitumor effect of cpt was more pronounced in the cancer cells containing mutant kras compared with those containing wildtype kras cpt treatment decreased glutamine and lipid metabolism affected redox regulation and increased reactive oxygen species ros production in the pancreatic cancer cell line miapaca2 containing mutant kras suppression of activated kras by specific sirnas decreased 3dspheroid formation the expression of acetylcoa carboxylase 1 and fatty acid synthase fasn and lipid synthesis the suppression also reduced glutathioneshglutathione disulfide and increased the production of ros knockdown of fasn suppressed lipid synthesis in miapaca2 cells partially promoted ros production and mildly suppressed 3dspheroid formation these results indicated that cpt reduced tumorigenesis by inhibiting lipid metabolism and promoting ros production in a mutant krasdependent manner this pdk4 inhibitor could serve as a novel therapeutic drug for krasdriven intractable cancers via alteration of cell metabolism,"['pyruvate', 'dehydrogenase', 'kinase', '4', 'pdk4', 'is', 'an', 'important', 'regulator', 'of', 'energy', 'metabolism', 'previously', 'knockdown', 'of', 'pdk4', 'by', 'specific', 'small', 'interfering', 'rnas', 'sirnas', 'have', 'been', 'shown', 'to', 'suppress', 'the', 'expression', 'of', 'κirsten', 'rat', 'sarcoma', 'viral', 'oncogene', 'homolog', 'kras', 'and', 'the', 'growth', 'of', 'lung', 'and', 'colorectal', 'cancer', 'cells', 'indicating', 'that', 'pdk4', 'is', 'an', 'attractive', 'target', 'of', 'cancer', 'therapy', 'by', 'altering', 'energy', 'metabolism', 'the', 'authors', 'previously', 'reported', 'that', 'a', 'novel', 'small', 'molecule', 'cryptotanshinone', 'cpt', 'which', 'inhibits', 'pdk4', 'activity', 'suppresses', 'the', 'iin', 'vitroi', 'threedimensional', '3dspheroid', 'formation', 'and', 'iin', 'vivoi', 'tumorigenesis', 'of', 'krasactivated', 'human', 'pancreatic', 'and', 'colorectal', 'cancer', 'cells', 'the', 'present', 'study', 'investigated', 'the', 'molecular', 'mechanism', 'of', 'cptinduced', 'tumor', 'suppression', 'via', 'alteration', 'of', 'glutamine', 'and', 'lipid', 'metabolism', 'in', 'human', 'pancreatic', 'and', 'colon', 'cancer', 'cell', 'lines', 'with', 'mutant', 'and', 'wildtype', 'kras', 'the', 'antitumor', 'effect', 'of', 'cpt', 'was', 'more', 'pronounced', 'in', 'the', 'cancer', 'cells', 'containing', 'mutant', 'kras', 'compared', 'with', 'those', 'containing', 'wildtype', 'kras', 'cpt', 'treatment', 'decreased', 'glutamine', 'and', 'lipid', 'metabolism', 'affected', 'redox', 'regulation', 'and', 'increased', 'reactive', 'oxygen', 'species', 'ros', 'production', 'in', 'the', 'pancreatic', 'cancer', 'cell', 'line', 'miapaca2', 'containing', 'mutant', 'kras', 'suppression', 'of', 'activated', 'kras', 'by', 'specific', 'sirnas', 'decreased', '3dspheroid', 'formation', 'the', 'expression', 'of', 'acetylcoa', 'carboxylase', '1', 'and', 'fatty', 'acid', 'synthase', 'fasn', 'and', 'lipid', 'synthesis', 'the', 'suppression', 'also', 'reduced', 'glutathioneshglutathione', 'disulfide', 'and', 'increased', 'the', 'production', 'of', 'ros', 'knockdown', 'of', 'fasn', 'suppressed', 'lipid', 'synthesis', 'in', 'miapaca2', 'cells', 'partially', 'promoted', 'ros', 'production', 'and', 'mildly', 'suppressed', '3dspheroid', 'formation', 'these', 'results', 'indicated', 'that', 'cpt', 'reduced', 'tumorigenesis', 'by', 'inhibiting', 'lipid', 'metabolism', 'and', 'promoting', 'ros', 'production', 'in', 'a', 'mutant', 'krasdependent', 'manner', 'this', 'pdk4', 'inhibitor', 'could', 'serve', 'as', 'a', 'novel', 'therapeutic', 'drug', 'for', 'krasdriven', 'intractable', 'cancers', 'via', 'alteration', 'of', 'cell', 'metabolism']","['pyruvate', 'dehydrogenase', 'kinase', '4', 'pdk4', 'important', 'regulator', 'energy', 'metabolism', 'previously', 'knockdown', 'pdk4', 'specific', 'small', 'interfering', 'rnas', 'sirnas', 'shown', 'suppress', 'expression', 'κirsten', 'rat', 'sarcoma', 'viral', 'oncogene', 'homolog', 'kras', 'growth', 'lung', 'colorectal', 'cancer', 'cells', 'indicating', 'pdk4', 'attractive', 'target', 'cancer', 'therapy', 'altering', 'energy', 'metabolism', 'authors', 'previously', 'reported', 'novel', 'small', 'molecule', 'cryptotanshinone', 'cpt', 'inhibits', 'pdk4', 'activity', 'suppresses', 'iin', 'vitroi', 'threedimensional', '3dspheroid', 'formation', 'iin', 'vivoi', 'tumorigenesis', 'krasactivated', 'human', 'pancreatic', 'colorectal', 'cancer', 'cells', 'present', 'study', 'investigated', 'molecular', 'mechanism', 'cptinduced', 'tumor', 'suppression', 'via', 'alteration', 'glutamine', 'lipid', 'metabolism', 'human', 'pancreatic', 'colon', 'cancer', 'cell', 'lines', 'mutant', 'wildtype', 'kras', 'antitumor', 'effect', 'cpt', 'pronounced', 'cancer', 'cells', 'containing', 'mutant', 'kras', 'compared', 'containing', 'wildtype', 'kras', 'cpt', 'treatment', 'decreased', 'glutamine', 'lipid', 'metabolism', 'affected', 'redox', 'regulation', 'increased', 'reactive', 'oxygen', 'species', 'ros', 'production', 'pancreatic', 'cancer', 'cell', 'line', 'miapaca2', 'containing', 'mutant', 'kras', 'suppression', 'activated', 'kras', 'specific', 'sirnas', 'decreased', '3dspheroid', 'formation', 'expression', 'acetylcoa', 'carboxylase', '1', 'fatty', 'acid', 'synthase', 'fasn', 'lipid', 'synthesis', 'suppression', 'also', 'reduced', 'glutathioneshglutathione', 'disulfide', 'increased', 'production', 'ros', 'knockdown', 'fasn', 'suppressed', 'lipid', 'synthesis', 'miapaca2', 'cells', 'partially', 'promoted', 'ros', 'production', 'mildly', 'suppressed', '3dspheroid', 'formation', 'results', 'indicated', 'cpt', 'reduced', 'tumorigenesis', 'inhibiting', 'lipid', 'metabolism', 'promoting', 'ros', 'production', 'mutant', 'krasdependent', 'manner', 'pdk4', 'inhibitor', 'could', 'serve', 'novel', 'therapeutic', 'drug', 'krasdriven', 'intractable', 'cancers', 'via', 'alteration', 'cell', 'metabolism']","['pdk4', 'pdk4', 'pdk4', 'pdk4', 'ros', 'fatty', 'ros', 'ros', 'ros', 'pdk4']","['pdk4', 'pdk4', 'pdk4', 'pdk4', 'pdk4']",True,"['tumor', 'cancer']"
35889210,A Novel ERK2 Degrader Z734 Induces Apoptosis of MCF-7 Cells via the HERC3/p53 Signaling Pathway.,"Breast cancer is one of the leading causes of death worldwide, and synthetic chemicals targeting specific proteins or various molecular pathways for tumor suppression, such as ERK inhibitors and degraders, have been intensively investigated. The targets of ERK participate in the regulation of critical cellular mechanisms and underpin the progression of anticancer therapy. In this study, we identified a novel small molecule, which we named Z734, as a new mitogen-activated protein kinase 1 (ERK2) degrader and demonstrated that Z734 inhibits cell growth by inducing p53-mediated apoptotic pathways in human breast cancer cells. Treatment with Z734 resulted in the inhibition of cancer cell proliferation, colony formation and migration invasion, as well as cancer cell death via apoptosis. In addition, the Co-IP and GST pulldown assays indicated that the HECT and RLD domains containing E3 ubiquitin protein ligase 3 (HERC3) could directly interact with ERK2 through the HECT domain, promoting ERK2 ubiquitination. We also observed a strong link between HERC3 and p53 for the modulation of apoptosis. HERC3 can increase the protein and phosphorylation levels of p53, which further promotes apoptotic activity. In a xenograft mouse model, the effect was obtained in a treatment group that combined Z734 with lapatinib compared with that of the single-treatment groups. In summary, our results indicated that Z734 actively controls the development of breast cancer through apoptosis, and HERC3 may mediate ERK2 and p53 signaling, which offers new potential targets for clinical therapy.",2022-07-06,breast cancer is one of the leading causes of death worldwide and synthetic chemicals targeting specific proteins or various molecular pathways for tumor suppression such as erk inhibitors and degraders have been intensively investigated the targets of erk participate in the regulation of critical cellular mechanisms and underpin the progression of anticancer therapy in this study we identified a novel small molecule which we named z734 as a new mitogenactivated protein kinase 1 erk2 degrader and demonstrated that z734 inhibits cell growth by inducing p53mediated apoptotic pathways in human breast cancer cells treatment with z734 resulted in the inhibition of cancer cell proliferation colony formation and migration invasion as well as cancer cell death via apoptosis in addition the coip and gst pulldown assays indicated that the hect and rld domains containing e3 ubiquitin protein ligase 3 herc3 could directly interact with erk2 through the hect domain promoting erk2 ubiquitination we also observed a strong link between herc3 and p53 for the modulation of apoptosis herc3 can increase the protein and phosphorylation levels of p53 which further promotes apoptotic activity in a xenograft mouse model the effect was obtained in a treatment group that combined z734 with lapatinib compared with that of the singletreatment groups in summary our results indicated that z734 actively controls the development of breast cancer through apoptosis and herc3 may mediate erk2 and p53 signaling which offers new potential targets for clinical therapy,"['breast', 'cancer', 'is', 'one', 'of', 'the', 'leading', 'causes', 'of', 'death', 'worldwide', 'and', 'synthetic', 'chemicals', 'targeting', 'specific', 'proteins', 'or', 'various', 'molecular', 'pathways', 'for', 'tumor', 'suppression', 'such', 'as', 'erk', 'inhibitors', 'and', 'degraders', 'have', 'been', 'intensively', 'investigated', 'the', 'targets', 'of', 'erk', 'participate', 'in', 'the', 'regulation', 'of', 'critical', 'cellular', 'mechanisms', 'and', 'underpin', 'the', 'progression', 'of', 'anticancer', 'therapy', 'in', 'this', 'study', 'we', 'identified', 'a', 'novel', 'small', 'molecule', 'which', 'we', 'named', 'z734', 'as', 'a', 'new', 'mitogenactivated', 'protein', 'kinase', '1', 'erk2', 'degrader', 'and', 'demonstrated', 'that', 'z734', 'inhibits', 'cell', 'growth', 'by', 'inducing', 'p53mediated', 'apoptotic', 'pathways', 'in', 'human', 'breast', 'cancer', 'cells', 'treatment', 'with', 'z734', 'resulted', 'in', 'the', 'inhibition', 'of', 'cancer', 'cell', 'proliferation', 'colony', 'formation', 'and', 'migration', 'invasion', 'as', 'well', 'as', 'cancer', 'cell', 'death', 'via', 'apoptosis', 'in', 'addition', 'the', 'coip', 'and', 'gst', 'pulldown', 'assays', 'indicated', 'that', 'the', 'hect', 'and', 'rld', 'domains', 'containing', 'e3', 'ubiquitin', 'protein', 'ligase', '3', 'herc3', 'could', 'directly', 'interact', 'with', 'erk2', 'through', 'the', 'hect', 'domain', 'promoting', 'erk2', 'ubiquitination', 'we', 'also', 'observed', 'a', 'strong', 'link', 'between', 'herc3', 'and', 'p53', 'for', 'the', 'modulation', 'of', 'apoptosis', 'herc3', 'can', 'increase', 'the', 'protein', 'and', 'phosphorylation', 'levels', 'of', 'p53', 'which', 'further', 'promotes', 'apoptotic', 'activity', 'in', 'a', 'xenograft', 'mouse', 'model', 'the', 'effect', 'was', 'obtained', 'in', 'a', 'treatment', 'group', 'that', 'combined', 'z734', 'with', 'lapatinib', 'compared', 'with', 'that', 'of', 'the', 'singletreatment', 'groups', 'in', 'summary', 'our', 'results', 'indicated', 'that', 'z734', 'actively', 'controls', 'the', 'development', 'of', 'breast', 'cancer', 'through', 'apoptosis', 'and', 'herc3', 'may', 'mediate', 'erk2', 'and', 'p53', 'signaling', 'which', 'offers', 'new', 'potential', 'targets', 'for', 'clinical', 'therapy']","['breast', 'cancer', 'one', 'leading', 'causes', 'death', 'worldwide', 'synthetic', 'chemicals', 'targeting', 'specific', 'proteins', 'various', 'molecular', 'pathways', 'tumor', 'suppression', 'erk', 'inhibitors', 'degraders', 'intensively', 'investigated', 'targets', 'erk', 'participate', 'regulation', 'critical', 'cellular', 'mechanisms', 'underpin', 'progression', 'anticancer', 'therapy', 'study', 'identified', 'novel', 'small', 'molecule', 'named', 'z734', 'new', 'mitogenactivated', 'protein', 'kinase', '1', 'erk2', 'degrader', 'demonstrated', 'z734', 'inhibits', 'cell', 'growth', 'inducing', 'p53mediated', 'apoptotic', 'pathways', 'human', 'breast', 'cancer', 'cells', 'treatment', 'z734', 'resulted', 'inhibition', 'cancer', 'cell', 'proliferation', 'colony', 'formation', 'migration', 'invasion', 'well', 'cancer', 'cell', 'death', 'via', 'apoptosis', 'addition', 'coip', 'gst', 'pulldown', 'assays', 'indicated', 'hect', 'rld', 'domains', 'containing', 'e3', 'ubiquitin', 'protein', 'ligase', '3', 'herc3', 'could', 'directly', 'interact', 'erk2', 'hect', 'domain', 'promoting', 'erk2', 'ubiquitination', 'also', 'observed', 'strong', 'link', 'herc3', 'p53', 'modulation', 'apoptosis', 'herc3', 'increase', 'protein', 'phosphorylation', 'levels', 'p53', 'promotes', 'apoptotic', 'activity', 'xenograft', 'mouse', 'model', 'effect', 'obtained', 'treatment', 'group', 'combined', 'z734', 'lapatinib', 'compared', 'singletreatment', 'groups', 'summary', 'results', 'indicated', 'z734', 'actively', 'controls', 'development', 'breast', 'cancer', 'apoptosis', 'herc3', 'may', 'mediate', 'erk2', 'p53', 'signaling', 'offers', 'new', 'potential', 'targets', 'clinical', 'therapy']","['erk', 'erk', 'erk2', 'gst', 'ubiquitin', 'erk2', 'erk2', 'p53', 'p53', 'erk2', 'p53']","['erk2', 'erk2', 'erk2', 'erk2']",True,"['tumor', 'cancer']"
35847506,Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds.,"Glioblastoma (GBM) is the most common aggressive malignant tumor in brain neuroepithelial tumors and remains incurable. A variety of treatment options are currently being explored to improve patient survival, including small molecule inhibitors, viral therapies, cancer vaccines, and monoclonal antibodies. Among them, the unique advantages of small molecule inhibitors have made them a focus of attention in the drug discovery of glioblastoma. Currently, the most used chemotherapeutic agents are small molecule inhibitors that target key dysregulated signaling pathways in glioblastoma, including receptor tyrosine kinase, PI3K/AKT/mTOR pathway, DNA damage response, TP53 and cell cycle inhibitors. This review analyzes the therapeutic benefit and clinical development of novel small molecule inhibitors discovered as promising anti-glioblastoma agents by the related targets of these major pathways. Meanwhile, the recent advances in temozolomide resistance and drug combination are also reviewed. In the last part, due to the constant clinical failure of targeted therapies, this paper reviewed the research progress of other therapeutic methods for glioblastoma, to provide patients and readers with a more comprehensive understanding of the treatment landscape of glioblastoma.",2021-12-31,glioblastoma gbm is the most common aggressive malignant tumor in brain neuroepithelial tumors and remains incurable a variety of treatment options are currently being explored to improve patient survival including small molecule inhibitors viral therapies cancer vaccines and monoclonal antibodies among them the unique advantages of small molecule inhibitors have made them a focus of attention in the drug discovery of glioblastoma currently the most used chemotherapeutic agents are small molecule inhibitors that target key dysregulated signaling pathways in glioblastoma including receptor tyrosine kinase pi3kaktmtor pathway dna damage response tp53 and cell cycle inhibitors this review analyzes the therapeutic benefit and clinical development of novel small molecule inhibitors discovered as promising antiglioblastoma agents by the related targets of these major pathways meanwhile the recent advances in temozolomide resistance and drug combination are also reviewed in the last part due to the constant clinical failure of targeted therapies this paper reviewed the research progress of other therapeutic methods for glioblastoma to provide patients and readers with a more comprehensive understanding of the treatment landscape of glioblastoma,"['glioblastoma', 'gbm', 'is', 'the', 'most', 'common', 'aggressive', 'malignant', 'tumor', 'in', 'brain', 'neuroepithelial', 'tumors', 'and', 'remains', 'incurable', 'a', 'variety', 'of', 'treatment', 'options', 'are', 'currently', 'being', 'explored', 'to', 'improve', 'patient', 'survival', 'including', 'small', 'molecule', 'inhibitors', 'viral', 'therapies', 'cancer', 'vaccines', 'and', 'monoclonal', 'antibodies', 'among', 'them', 'the', 'unique', 'advantages', 'of', 'small', 'molecule', 'inhibitors', 'have', 'made', 'them', 'a', 'focus', 'of', 'attention', 'in', 'the', 'drug', 'discovery', 'of', 'glioblastoma', 'currently', 'the', 'most', 'used', 'chemotherapeutic', 'agents', 'are', 'small', 'molecule', 'inhibitors', 'that', 'target', 'key', 'dysregulated', 'signaling', 'pathways', 'in', 'glioblastoma', 'including', 'receptor', 'tyrosine', 'kinase', 'pi3kaktmtor', 'pathway', 'dna', 'damage', 'response', 'tp53', 'and', 'cell', 'cycle', 'inhibitors', 'this', 'review', 'analyzes', 'the', 'therapeutic', 'benefit', 'and', 'clinical', 'development', 'of', 'novel', 'small', 'molecule', 'inhibitors', 'discovered', 'as', 'promising', 'antiglioblastoma', 'agents', 'by', 'the', 'related', 'targets', 'of', 'these', 'major', 'pathways', 'meanwhile', 'the', 'recent', 'advances', 'in', 'temozolomide', 'resistance', 'and', 'drug', 'combination', 'are', 'also', 'reviewed', 'in', 'the', 'last', 'part', 'due', 'to', 'the', 'constant', 'clinical', 'failure', 'of', 'targeted', 'therapies', 'this', 'paper', 'reviewed', 'the', 'research', 'progress', 'of', 'other', 'therapeutic', 'methods', 'for', 'glioblastoma', 'to', 'provide', 'patients', 'and', 'readers', 'with', 'a', 'more', 'comprehensive', 'understanding', 'of', 'the', 'treatment', 'landscape', 'of', 'glioblastoma']","['glioblastoma', 'gbm', 'common', 'aggressive', 'malignant', 'tumor', 'brain', 'neuroepithelial', 'tumors', 'remains', 'incurable', 'variety', 'treatment', 'options', 'currently', 'explored', 'improve', 'patient', 'survival', 'including', 'small', 'molecule', 'inhibitors', 'viral', 'therapies', 'cancer', 'vaccines', 'monoclonal', 'antibodies', 'among', 'unique', 'advantages', 'small', 'molecule', 'inhibitors', 'made', 'focus', 'attention', 'drug', 'discovery', 'glioblastoma', 'currently', 'used', 'chemotherapeutic', 'agents', 'small', 'molecule', 'inhibitors', 'target', 'key', 'dysregulated', 'signaling', 'pathways', 'glioblastoma', 'including', 'receptor', 'tyrosine', 'kinase', 'pi3kaktmtor', 'pathway', 'dna', 'damage', 'response', 'tp53', 'cell', 'cycle', 'inhibitors', 'review', 'analyzes', 'therapeutic', 'benefit', 'clinical', 'development', 'novel', 'small', 'molecule', 'inhibitors', 'discovered', 'promising', 'antiglioblastoma', 'agents', 'related', 'targets', 'major', 'pathways', 'meanwhile', 'recent', 'advances', 'temozolomide', 'resistance', 'drug', 'combination', 'also', 'reviewed', 'last', 'part', 'due', 'constant', 'clinical', 'failure', 'targeted', 'therapies', 'paper', 'reviewed', 'research', 'progress', 'therapeutic', 'methods', 'glioblastoma', 'provide', 'patients', 'readers', 'comprehensive', 'understanding', 'treatment', 'landscape', 'glioblastoma']",['tp53'],['tp53'],True,"['tumor', 'cancer']"
35841928,A small molecule toll-like receptor antagonist rescues α-synuclein fibril pathology.,"The propagation and accumulation of pathological α-synuclein protein is thought to underlie the clinical symptoms of the neurodegenerative movement disorder Parkinson's disease (PD). Consequently, there is significant interest in identifying the mechanisms that contribute to α-synuclein pathology, as these may inform therapeutic targets for the treatment of PD. One protein that appears to contribute to α-synuclein pathology is the innate immune pathogen recognition receptor, toll-like receptor 2 (TLR2). TLR2 is expressed on neurons, and its activation results in the accumulation of α-synuclein protein; however, the precise mechanism by which TLR2 contributes to α-synuclein pathology is unclear. Herein we demonstrate using human cell models that neuronal TLR2 activation acutely impairs the autophagy lysosomal pathway and markedly potentiates α-synuclein pathology seeded with α-synuclein preformed fibrils. Moreover, α-synuclein pathology could be ameliorated with a novel small molecule TLR2 inhibitor, including in induced pluripotent stem cell-derived neurons from a patient with PD. These results provide further insight into how TLR2 activation may promote α-synuclein pathology in PD and support that TLR2 may be a potential therapeutic target for the treatment of PD.",2022-07-13,the propagation and accumulation of pathological αsynuclein protein is thought to underlie the clinical symptoms of the neurodegenerative movement disorder parkinsons disease pd consequently there is significant interest in identifying the mechanisms that contribute to αsynuclein pathology as these may inform therapeutic targets for the treatment of pd one protein that appears to contribute to αsynuclein pathology is the innate immune pathogen recognition receptor tolllike receptor 2 tlr2 tlr2 is expressed on neurons and its activation results in the accumulation of αsynuclein protein however the precise mechanism by which tlr2 contributes to αsynuclein pathology is unclear herein we demonstrate using human cell models that neuronal tlr2 activation acutely impairs the autophagy lysosomal pathway and markedly potentiates αsynuclein pathology seeded with αsynuclein preformed fibrils moreover αsynuclein pathology could be ameliorated with a novel small molecule tlr2 inhibitor including in induced pluripotent stem cellderived neurons from a patient with pd these results provide further insight into how tlr2 activation may promote αsynuclein pathology in pd and support that tlr2 may be a potential therapeutic target for the treatment of pd,"['the', 'propagation', 'and', 'accumulation', 'of', 'pathological', 'αsynuclein', 'protein', 'is', 'thought', 'to', 'underlie', 'the', 'clinical', 'symptoms', 'of', 'the', 'neurodegenerative', 'movement', 'disorder', 'parkinsons', 'disease', 'pd', 'consequently', 'there', 'is', 'significant', 'interest', 'in', 'identifying', 'the', 'mechanisms', 'that', 'contribute', 'to', 'αsynuclein', 'pathology', 'as', 'these', 'may', 'inform', 'therapeutic', 'targets', 'for', 'the', 'treatment', 'of', 'pd', 'one', 'protein', 'that', 'appears', 'to', 'contribute', 'to', 'αsynuclein', 'pathology', 'is', 'the', 'innate', 'immune', 'pathogen', 'recognition', 'receptor', 'tolllike', 'receptor', '2', 'tlr2', 'tlr2', 'is', 'expressed', 'on', 'neurons', 'and', 'its', 'activation', 'results', 'in', 'the', 'accumulation', 'of', 'αsynuclein', 'protein', 'however', 'the', 'precise', 'mechanism', 'by', 'which', 'tlr2', 'contributes', 'to', 'αsynuclein', 'pathology', 'is', 'unclear', 'herein', 'we', 'demonstrate', 'using', 'human', 'cell', 'models', 'that', 'neuronal', 'tlr2', 'activation', 'acutely', 'impairs', 'the', 'autophagy', 'lysosomal', 'pathway', 'and', 'markedly', 'potentiates', 'αsynuclein', 'pathology', 'seeded', 'with', 'αsynuclein', 'preformed', 'fibrils', 'moreover', 'αsynuclein', 'pathology', 'could', 'be', 'ameliorated', 'with', 'a', 'novel', 'small', 'molecule', 'tlr2', 'inhibitor', 'including', 'in', 'induced', 'pluripotent', 'stem', 'cellderived', 'neurons', 'from', 'a', 'patient', 'with', 'pd', 'these', 'results', 'provide', 'further', 'insight', 'into', 'how', 'tlr2', 'activation', 'may', 'promote', 'αsynuclein', 'pathology', 'in', 'pd', 'and', 'support', 'that', 'tlr2', 'may', 'be', 'a', 'potential', 'therapeutic', 'target', 'for', 'the', 'treatment', 'of', 'pd']","['propagation', 'accumulation', 'pathological', 'αsynuclein', 'protein', 'thought', 'underlie', 'clinical', 'symptoms', 'neurodegenerative', 'movement', 'disorder', 'parkinsons', 'disease', 'pd', 'consequently', 'significant', 'interest', 'identifying', 'mechanisms', 'contribute', 'αsynuclein', 'pathology', 'may', 'inform', 'therapeutic', 'targets', 'treatment', 'pd', 'one', 'protein', 'appears', 'contribute', 'αsynuclein', 'pathology', 'innate', 'immune', 'pathogen', 'recognition', 'receptor', 'tolllike', 'receptor', '2', 'tlr2', 'tlr2', 'expressed', 'neurons', 'activation', 'results', 'accumulation', 'αsynuclein', 'protein', 'however', 'precise', 'mechanism', 'tlr2', 'contributes', 'αsynuclein', 'pathology', 'unclear', 'herein', 'demonstrate', 'using', 'human', 'cell', 'models', 'neuronal', 'tlr2', 'activation', 'acutely', 'impairs', 'autophagy', 'lysosomal', 'pathway', 'markedly', 'potentiates', 'αsynuclein', 'pathology', 'seeded', 'αsynuclein', 'preformed', 'fibrils', 'moreover', 'αsynuclein', 'pathology', 'could', 'ameliorated', 'novel', 'small', 'molecule', 'tlr2', 'inhibitor', 'including', 'induced', 'pluripotent', 'stem', 'cellderived', 'neurons', 'patient', 'pd', 'results', 'provide', 'insight', 'tlr2', 'activation', 'may', 'promote', 'αsynuclein', 'pathology', 'pd', 'support', 'tlr2', 'may', 'potential', 'therapeutic', 'target', 'treatment', 'pd']","['tlr2', 'tlr2', 'tlr2', 'tlr2', 'tlr2', 'tlr2', 'tlr2']","['tlr2', 'tlr2', 'tlr2', 'tlr2', 'tlr2', 'tlr2', 'tlr2']",True,['parkinson']
35774785,"RG100204, A Novel Aquaporin-9 Inhibitor, Reduces Septic Cardiomyopathy and Multiple Organ Failure in Murine Sepsis.","Sepsis is caused by systemic infection and is a major health concern as it is the primary cause of death from infection. It is the leading cause of mortality worldwide and there are no specific effective treatments for sepsis. Gene deletion of the neutral solute channel Aquaporin 9 (AQP9) normalizes oxidative stress and improves survival in a bacterial endotoxin induced mouse model of sepsis. In this study we described the initial characterization and effects of a novel small molecule AQP9 inhibitor, RG100204, in a cecal ligation and puncture (CLP) induced model of polymicrobial infection. <i>In vitro</i>, RG100204 blocked mouse AQP9 H<sub>2</sub>O<sub>2</sub> permeability in an ectopic CHO cell expression system and abolished the LPS induced increase in superoxide anion and nitric oxide in FaO hepatoma cells. Pre-treatment of CLP-mice with RG100204 (25 mg/kg p.o. before CLP and then again at 8 h after CLP) attenuated the hypothermia, cardiac dysfunction (systolic and diastolic), renal dysfunction and hepatocellular injury caused by CLP-induced sepsis. Post-treatment of CLP-mice with RG100204 also attenuated the cardiac dysfunction (systolic and diastolic), the renal dysfunction caused by CLP-induced sepsis, but did not significantly reduce the liver injury or hypothermia. The most striking finding was that oral administration of RG100204 as late as 3 h after the onset of polymicrobial sepsis attenuated the cardiac and renal dysfunction caused by severe sepsis. Immunoblot quantification demonstrated that RG100204 reduced activation of the NLRP3 inflammasome pathway. Moreover, myeloperoxidase activity in RG100204 treated lung tissue was reduced. Together these results indicate that AQP9 may be a novel drug target in polymicrobial sepsis.",2022-06-14,sepsis is caused by systemic infection and is a major health concern as it is the primary cause of death from infection it is the leading cause of mortality worldwide and there are no specific effective treatments for sepsis gene deletion of the neutral solute channel aquaporin 9 aqp9 normalizes oxidative stress and improves survival in a bacterial endotoxin induced mouse model of sepsis in this study we described the initial characterization and effects of a novel small molecule aqp9 inhibitor rg100204 in a cecal ligation and puncture clp induced model of polymicrobial infection iin vitroi rg100204 blocked mouse aqp9 hsub2subosub2sub permeability in an ectopic cho cell expression system and abolished the lps induced increase in superoxide anion and nitric oxide in fao hepatoma cells pretreatment of clpmice with rg100204 25 mgkg po before clp and then again at 8 h after clp attenuated the hypothermia cardiac dysfunction systolic and diastolic renal dysfunction and hepatocellular injury caused by clpinduced sepsis posttreatment of clpmice with rg100204 also attenuated the cardiac dysfunction systolic and diastolic the renal dysfunction caused by clpinduced sepsis but did not significantly reduce the liver injury or hypothermia the most striking finding was that oral administration of rg100204 as late as 3 h after the onset of polymicrobial sepsis attenuated the cardiac and renal dysfunction caused by severe sepsis immunoblot quantification demonstrated that rg100204 reduced activation of the nlrp3 inflammasome pathway moreover myeloperoxidase activity in rg100204 treated lung tissue was reduced together these results indicate that aqp9 may be a novel drug target in polymicrobial sepsis,"['sepsis', 'is', 'caused', 'by', 'systemic', 'infection', 'and', 'is', 'a', 'major', 'health', 'concern', 'as', 'it', 'is', 'the', 'primary', 'cause', 'of', 'death', 'from', 'infection', 'it', 'is', 'the', 'leading', 'cause', 'of', 'mortality', 'worldwide', 'and', 'there', 'are', 'no', 'specific', 'effective', 'treatments', 'for', 'sepsis', 'gene', 'deletion', 'of', 'the', 'neutral', 'solute', 'channel', 'aquaporin', '9', 'aqp9', 'normalizes', 'oxidative', 'stress', 'and', 'improves', 'survival', 'in', 'a', 'bacterial', 'endotoxin', 'induced', 'mouse', 'model', 'of', 'sepsis', 'in', 'this', 'study', 'we', 'described', 'the', 'initial', 'characterization', 'and', 'effects', 'of', 'a', 'novel', 'small', 'molecule', 'aqp9', 'inhibitor', 'rg100204', 'in', 'a', 'cecal', 'ligation', 'and', 'puncture', 'clp', 'induced', 'model', 'of', 'polymicrobial', 'infection', 'iin', 'vitroi', 'rg100204', 'blocked', 'mouse', 'aqp9', 'hsub2subosub2sub', 'permeability', 'in', 'an', 'ectopic', 'cho', 'cell', 'expression', 'system', 'and', 'abolished', 'the', 'lps', 'induced', 'increase', 'in', 'superoxide', 'anion', 'and', 'nitric', 'oxide', 'in', 'fao', 'hepatoma', 'cells', 'pretreatment', 'of', 'clpmice', 'with', 'rg100204', '25', 'mgkg', 'po', 'before', 'clp', 'and', 'then', 'again', 'at', '8', 'h', 'after', 'clp', 'attenuated', 'the', 'hypothermia', 'cardiac', 'dysfunction', 'systolic', 'and', 'diastolic', 'renal', 'dysfunction', 'and', 'hepatocellular', 'injury', 'caused', 'by', 'clpinduced', 'sepsis', 'posttreatment', 'of', 'clpmice', 'with', 'rg100204', 'also', 'attenuated', 'the', 'cardiac', 'dysfunction', 'systolic', 'and', 'diastolic', 'the', 'renal', 'dysfunction', 'caused', 'by', 'clpinduced', 'sepsis', 'but', 'did', 'not', 'significantly', 'reduce', 'the', 'liver', 'injury', 'or', 'hypothermia', 'the', 'most', 'striking', 'finding', 'was', 'that', 'oral', 'administration', 'of', 'rg100204', 'as', 'late', 'as', '3', 'h', 'after', 'the', 'onset', 'of', 'polymicrobial', 'sepsis', 'attenuated', 'the', 'cardiac', 'and', 'renal', 'dysfunction', 'caused', 'by', 'severe', 'sepsis', 'immunoblot', 'quantification', 'demonstrated', 'that', 'rg100204', 'reduced', 'activation', 'of', 'the', 'nlrp3', 'inflammasome', 'pathway', 'moreover', 'myeloperoxidase', 'activity', 'in', 'rg100204', 'treated', 'lung', 'tissue', 'was', 'reduced', 'together', 'these', 'results', 'indicate', 'that', 'aqp9', 'may', 'be', 'a', 'novel', 'drug', 'target', 'in', 'polymicrobial', 'sepsis']","['sepsis', 'caused', 'systemic', 'infection', 'major', 'health', 'concern', 'primary', 'cause', 'death', 'infection', 'leading', 'cause', 'mortality', 'worldwide', 'specific', 'effective', 'treatments', 'sepsis', 'gene', 'deletion', 'neutral', 'solute', 'channel', 'aquaporin', '9', 'aqp9', 'normalizes', 'oxidative', 'stress', 'improves', 'survival', 'bacterial', 'endotoxin', 'induced', 'mouse', 'model', 'sepsis', 'study', 'described', 'initial', 'characterization', 'effects', 'novel', 'small', 'molecule', 'aqp9', 'inhibitor', 'rg100204', 'cecal', 'ligation', 'puncture', 'clp', 'induced', 'model', 'polymicrobial', 'infection', 'iin', 'vitroi', 'rg100204', 'blocked', 'mouse', 'aqp9', 'hsub2subosub2sub', 'permeability', 'ectopic', 'cho', 'cell', 'expression', 'system', 'abolished', 'lps', 'induced', 'increase', 'superoxide', 'anion', 'nitric', 'oxide', 'fao', 'hepatoma', 'cells', 'pretreatment', 'clpmice', 'rg100204', '25', 'mgkg', 'po', 'clp', '8', 'h', 'clp', 'attenuated', 'hypothermia', 'cardiac', 'dysfunction', 'systolic', 'diastolic', 'renal', 'dysfunction', 'hepatocellular', 'injury', 'caused', 'clpinduced', 'sepsis', 'posttreatment', 'clpmice', 'rg100204', 'also', 'attenuated', 'cardiac', 'dysfunction', 'systolic', 'diastolic', 'renal', 'dysfunction', 'caused', 'clpinduced', 'sepsis', 'significantly', 'reduce', 'liver', 'injury', 'hypothermia', 'striking', 'finding', 'oral', 'administration', 'rg100204', 'late', '3', 'h', 'onset', 'polymicrobial', 'sepsis', 'attenuated', 'cardiac', 'renal', 'dysfunction', 'caused', 'severe', 'sepsis', 'immunoblot', 'quantification', 'demonstrated', 'rg100204', 'reduced', 'activation', 'nlrp3', 'inflammasome', 'pathway', 'moreover', 'myeloperoxidase', 'activity', 'rg100204', 'treated', 'lung', 'tissue', 'reduced', 'together', 'results', 'indicate', 'aqp9', 'may', 'novel', 'drug', 'target', 'polymicrobial', 'sepsis']","['aquaporin', 'aqp9', 'aqp9', 'clp', 'aqp9', 'cho', 'clp', 'clp', 'myeloperoxidase', 'aqp9']","['aquaporin', 'aqp9', 'aqp9', 'aqp9', 'aqp9']",True,['infection']
35766508,"MBZM-N-IBT, a Novel Small Molecule, Restricts Chikungunya Virus Infection by Targeting nsP2 Protease Activity <i>In Vitro</i>, <i>In Vivo</i>, and <i>Ex Vivo</i>.","The increase in disease incidences and persistent Chikungunya virus (CHIKV)-induced arthritis have been a huge burden on public health globally. In the absence of specific antivirals or vaccines, it is essential to continue efforts to develop effective anti-CHIKV strategies. Our previous study showing the <i>in vitro</i> anti-CHIKV potential of a novel molecule 1-[(2-methylbenzimidazol-1-yl) methyl]-2-oxo-indolin-3-ylidene] amino] thiourea (MBZM-N-IBT) encouraged us to further validate its efficacy. Here, the effect of MBZM-N-IBT was evaluated <i>in vitro</i> in RAW 264.7 cells, <i>in vivo</i> in C57BL/6 mice, and <i>ex vivo</i> in human peripheral blood mononuclear cells (hPBMCs). The study demonstrated that CHIKV infection was efficiently abrogated in RAW 264.7 cells (IC<sub>50</sub> = 22.34 μM) with significant inhibition in viral proteins. The inhibition was effective in the postentry step, and MBZM-N-IBT predominately interfered in the early stages of CHIKV life cycle. It was further supported when the protease activity of CHIKV-nsP2 was hindered by the compound. Moreover, it diminished the CHIKV-induced inflammatory responses <i>in vitro</i> through significant downregulation of all the major mitogen-activated protein kinases (MAPKs), NF-κB, cyclooxygenase (COX)-2, and cytokines. Furthermore, MBZM-N-IBT restricted CHIKV infection and inflammation <i>in vivo</i>, leading to reduced clinical scores and complete survival of C57BL/6 mice. Additionally, it has been noticed that the CHIKV infection was reduced remarkably in hPBMC-derived monocyte-macrophage populations <i>ex vivo</i> by the compound. In conclusion, it can be suggested that this novel compound MBZM-N-IBT has been demonstrated to be a potential anti-CHIKV molecule <i>in vitro</i>, <i>in vivo</i>, and <i>ex vivo</i> and fulfilled all the criteria to investigate further for successful treatment of CHIKV infection.",2022-06-29,the increase in disease incidences and persistent chikungunya virus chikvinduced arthritis have been a huge burden on public health globally in the absence of specific antivirals or vaccines it is essential to continue efforts to develop effective antichikv strategies our previous study showing the iin vitroi antichikv potential of a novel molecule 12methylbenzimidazol1yl methyl2oxoindolin3ylidene amino thiourea mbzmnibt encouraged us to further validate its efficacy here the effect of mbzmnibt was evaluated iin vitroi in raw 2647 cells iin vivoi in c57bl6 mice and iex vivoi in human peripheral blood mononuclear cells hpbmcs the study demonstrated that chikv infection was efficiently abrogated in raw 2647 cells icsub50sub  2234 μm with significant inhibition in viral proteins the inhibition was effective in the postentry step and mbzmnibt predominately interfered in the early stages of chikv life cycle it was further supported when the protease activity of chikvnsp2 was hindered by the compound moreover it diminished the chikvinduced inflammatory responses iin vitroi through significant downregulation of all the major mitogenactivated protein kinases mapks nfκb cyclooxygenase cox2 and cytokines furthermore mbzmnibt restricted chikv infection and inflammation iin vivoi leading to reduced clinical scores and complete survival of c57bl6 mice additionally it has been noticed that the chikv infection was reduced remarkably in hpbmcderived monocytemacrophage populations iex vivoi by the compound in conclusion it can be suggested that this novel compound mbzmnibt has been demonstrated to be a potential antichikv molecule iin vitroi iin vivoi and iex vivoi and fulfilled all the criteria to investigate further for successful treatment of chikv infection,"['the', 'increase', 'in', 'disease', 'incidences', 'and', 'persistent', 'chikungunya', 'virus', 'chikvinduced', 'arthritis', 'have', 'been', 'a', 'huge', 'burden', 'on', 'public', 'health', 'globally', 'in', 'the', 'absence', 'of', 'specific', 'antivirals', 'or', 'vaccines', 'it', 'is', 'essential', 'to', 'continue', 'efforts', 'to', 'develop', 'effective', 'antichikv', 'strategies', 'our', 'previous', 'study', 'showing', 'the', 'iin', 'vitroi', 'antichikv', 'potential', 'of', 'a', 'novel', 'molecule', '12methylbenzimidazol1yl', 'methyl2oxoindolin3ylidene', 'amino', 'thiourea', 'mbzmnibt', 'encouraged', 'us', 'to', 'further', 'validate', 'its', 'efficacy', 'here', 'the', 'effect', 'of', 'mbzmnibt', 'was', 'evaluated', 'iin', 'vitroi', 'in', 'raw', '2647', 'cells', 'iin', 'vivoi', 'in', 'c57bl6', 'mice', 'and', 'iex', 'vivoi', 'in', 'human', 'peripheral', 'blood', 'mononuclear', 'cells', 'hpbmcs', 'the', 'study', 'demonstrated', 'that', 'chikv', 'infection', 'was', 'efficiently', 'abrogated', 'in', 'raw', '2647', 'cells', 'icsub50sub', '2234', 'μm', 'with', 'significant', 'inhibition', 'in', 'viral', 'proteins', 'the', 'inhibition', 'was', 'effective', 'in', 'the', 'postentry', 'step', 'and', 'mbzmnibt', 'predominately', 'interfered', 'in', 'the', 'early', 'stages', 'of', 'chikv', 'life', 'cycle', 'it', 'was', 'further', 'supported', 'when', 'the', 'protease', 'activity', 'of', 'chikvnsp2', 'was', 'hindered', 'by', 'the', 'compound', 'moreover', 'it', 'diminished', 'the', 'chikvinduced', 'inflammatory', 'responses', 'iin', 'vitroi', 'through', 'significant', 'downregulation', 'of', 'all', 'the', 'major', 'mitogenactivated', 'protein', 'kinases', 'mapks', 'nfκb', 'cyclooxygenase', 'cox2', 'and', 'cytokines', 'furthermore', 'mbzmnibt', 'restricted', 'chikv', 'infection', 'and', 'inflammation', 'iin', 'vivoi', 'leading', 'to', 'reduced', 'clinical', 'scores', 'and', 'complete', 'survival', 'of', 'c57bl6', 'mice', 'additionally', 'it', 'has', 'been', 'noticed', 'that', 'the', 'chikv', 'infection', 'was', 'reduced', 'remarkably', 'in', 'hpbmcderived', 'monocytemacrophage', 'populations', 'iex', 'vivoi', 'by', 'the', 'compound', 'in', 'conclusion', 'it', 'can', 'be', 'suggested', 'that', 'this', 'novel', 'compound', 'mbzmnibt', 'has', 'been', 'demonstrated', 'to', 'be', 'a', 'potential', 'antichikv', 'molecule', 'iin', 'vitroi', 'iin', 'vivoi', 'and', 'iex', 'vivoi', 'and', 'fulfilled', 'all', 'the', 'criteria', 'to', 'investigate', 'further', 'for', 'successful', 'treatment', 'of', 'chikv', 'infection']","['increase', 'disease', 'incidences', 'persistent', 'chikungunya', 'virus', 'chikvinduced', 'arthritis', 'huge', 'burden', 'public', 'health', 'globally', 'absence', 'specific', 'antivirals', 'vaccines', 'essential', 'continue', 'efforts', 'develop', 'effective', 'antichikv', 'strategies', 'previous', 'study', 'showing', 'iin', 'vitroi', 'antichikv', 'potential', 'novel', 'molecule', '12methylbenzimidazol1yl', 'methyl2oxoindolin3ylidene', 'amino', 'thiourea', 'mbzmnibt', 'encouraged', 'us', 'validate', 'efficacy', 'effect', 'mbzmnibt', 'evaluated', 'iin', 'vitroi', 'raw', '2647', 'cells', 'iin', 'vivoi', 'c57bl6', 'mice', 'iex', 'vivoi', 'human', 'peripheral', 'blood', 'mononuclear', 'cells', 'hpbmcs', 'study', 'demonstrated', 'chikv', 'infection', 'efficiently', 'abrogated', 'raw', '2647', 'cells', 'icsub50sub', '2234', 'μm', 'significant', 'inhibition', 'viral', 'proteins', 'inhibition', 'effective', 'postentry', 'step', 'mbzmnibt', 'predominately', 'interfered', 'early', 'stages', 'chikv', 'life', 'cycle', 'supported', 'protease', 'activity', 'chikvnsp2', 'hindered', 'compound', 'moreover', 'diminished', 'chikvinduced', 'inflammatory', 'responses', 'iin', 'vitroi', 'significant', 'downregulation', 'major', 'mitogenactivated', 'protein', 'kinases', 'mapks', 'nfκb', 'cyclooxygenase', 'cox2', 'cytokines', 'furthermore', 'mbzmnibt', 'restricted', 'chikv', 'infection', 'inflammation', 'iin', 'vivoi', 'leading', 'reduced', 'clinical', 'scores', 'complete', 'survival', 'c57bl6', 'mice', 'additionally', 'noticed', 'chikv', 'infection', 'reduced', 'remarkably', 'hpbmcderived', 'monocytemacrophage', 'populations', 'iex', 'vivoi', 'compound', 'conclusion', 'suggested', 'novel', 'compound', 'mbzmnibt', 'demonstrated', 'potential', 'antichikv', 'molecule', 'iin', 'vitroi', 'iin', 'vivoi', 'iex', 'vivoi', 'fulfilled', 'criteria', 'investigate', 'successful', 'treatment', 'chikv', 'infection']","['iex', 'cyclooxygenase', 'iex', 'iex']","['iex', 'iex', 'iex']",True,"['infection', 'arthritis']"
35743155,A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic Leukemia.,"B-cell chronic lymphocytic leukemia (CLL) results from intrinsic genetic defects and complex microenvironment stimuli that fuel CLL cell growth through an array of survival signaling pathways. Novel small-molecule agents targeting the B-cell receptor pathway and anti-apoptotic proteins alone or in combination have revolutionized the management of CLL, yet combination therapy carries significant toxicity and CLL remains incurable due to residual disease and relapse. Single-molecule inhibitors that can target multiple disease-driving factors are thus an attractive approach to combat both drug resistance and combination-therapy-related toxicities. We demonstrate that SRX3305, a novel small-molecule BTK/PI3K/BRD4 inhibitor that targets three distinctive facets of CLL biology, attenuates CLL cell proliferation and promotes apoptosis in a dose-dependent fashion. SRX3305 also inhibits the activation-induced proliferation of primary CLL cells in vitro and effectively blocks microenvironment-mediated survival signals, including stromal cell contact. Furthermore, SRX3305 blocks CLL cell migration toward CXCL-12 and CXCL-13, which are major chemokines involved in CLL cell homing and retention in microenvironment niches. Importantly, SRX3305 maintains its anti-tumor effects in ibrutinib-resistant CLL cells. Collectively, this study establishes the preclinical efficacy of SRX3305 in CLL, providing significant rationale for its development as a therapeutic agent for CLL and related disorders.",2022-06-16,bcell chronic lymphocytic leukemia cll results from intrinsic genetic defects and complex microenvironment stimuli that fuel cll cell growth through an array of survival signaling pathways novel smallmolecule agents targeting the bcell receptor pathway and antiapoptotic proteins alone or in combination have revolutionized the management of cll yet combination therapy carries significant toxicity and cll remains incurable due to residual disease and relapse singlemolecule inhibitors that can target multiple diseasedriving factors are thus an attractive approach to combat both drug resistance and combinationtherapyrelated toxicities we demonstrate that srx3305 a novel smallmolecule btkpi3kbrd4 inhibitor that targets three distinctive facets of cll biology attenuates cll cell proliferation and promotes apoptosis in a dosedependent fashion srx3305 also inhibits the activationinduced proliferation of primary cll cells in vitro and effectively blocks microenvironmentmediated survival signals including stromal cell contact furthermore srx3305 blocks cll cell migration toward cxcl12 and cxcl13 which are major chemokines involved in cll cell homing and retention in microenvironment niches importantly srx3305 maintains its antitumor effects in ibrutinibresistant cll cells collectively this study establishes the preclinical efficacy of srx3305 in cll providing significant rationale for its development as a therapeutic agent for cll and related disorders,"['bcell', 'chronic', 'lymphocytic', 'leukemia', 'cll', 'results', 'from', 'intrinsic', 'genetic', 'defects', 'and', 'complex', 'microenvironment', 'stimuli', 'that', 'fuel', 'cll', 'cell', 'growth', 'through', 'an', 'array', 'of', 'survival', 'signaling', 'pathways', 'novel', 'smallmolecule', 'agents', 'targeting', 'the', 'bcell', 'receptor', 'pathway', 'and', 'antiapoptotic', 'proteins', 'alone', 'or', 'in', 'combination', 'have', 'revolutionized', 'the', 'management', 'of', 'cll', 'yet', 'combination', 'therapy', 'carries', 'significant', 'toxicity', 'and', 'cll', 'remains', 'incurable', 'due', 'to', 'residual', 'disease', 'and', 'relapse', 'singlemolecule', 'inhibitors', 'that', 'can', 'target', 'multiple', 'diseasedriving', 'factors', 'are', 'thus', 'an', 'attractive', 'approach', 'to', 'combat', 'both', 'drug', 'resistance', 'and', 'combinationtherapyrelated', 'toxicities', 'we', 'demonstrate', 'that', 'srx3305', 'a', 'novel', 'smallmolecule', 'btkpi3kbrd4', 'inhibitor', 'that', 'targets', 'three', 'distinctive', 'facets', 'of', 'cll', 'biology', 'attenuates', 'cll', 'cell', 'proliferation', 'and', 'promotes', 'apoptosis', 'in', 'a', 'dosedependent', 'fashion', 'srx3305', 'also', 'inhibits', 'the', 'activationinduced', 'proliferation', 'of', 'primary', 'cll', 'cells', 'in', 'vitro', 'and', 'effectively', 'blocks', 'microenvironmentmediated', 'survival', 'signals', 'including', 'stromal', 'cell', 'contact', 'furthermore', 'srx3305', 'blocks', 'cll', 'cell', 'migration', 'toward', 'cxcl12', 'and', 'cxcl13', 'which', 'are', 'major', 'chemokines', 'involved', 'in', 'cll', 'cell', 'homing', 'and', 'retention', 'in', 'microenvironment', 'niches', 'importantly', 'srx3305', 'maintains', 'its', 'antitumor', 'effects', 'in', 'ibrutinibresistant', 'cll', 'cells', 'collectively', 'this', 'study', 'establishes', 'the', 'preclinical', 'efficacy', 'of', 'srx3305', 'in', 'cll', 'providing', 'significant', 'rationale', 'for', 'its', 'development', 'as', 'a', 'therapeutic', 'agent', 'for', 'cll', 'and', 'related', 'disorders']","['bcell', 'chronic', 'lymphocytic', 'leukemia', 'cll', 'results', 'intrinsic', 'genetic', 'defects', 'complex', 'microenvironment', 'stimuli', 'fuel', 'cll', 'cell', 'growth', 'array', 'survival', 'signaling', 'pathways', 'novel', 'smallmolecule', 'agents', 'targeting', 'bcell', 'receptor', 'pathway', 'antiapoptotic', 'proteins', 'alone', 'combination', 'revolutionized', 'management', 'cll', 'yet', 'combination', 'therapy', 'carries', 'significant', 'toxicity', 'cll', 'remains', 'incurable', 'due', 'residual', 'disease', 'relapse', 'singlemolecule', 'inhibitors', 'target', 'multiple', 'diseasedriving', 'factors', 'thus', 'attractive', 'approach', 'combat', 'drug', 'resistance', 'combinationtherapyrelated', 'toxicities', 'demonstrate', 'srx3305', 'novel', 'smallmolecule', 'btkpi3kbrd4', 'inhibitor', 'targets', 'three', 'distinctive', 'facets', 'cll', 'biology', 'attenuates', 'cll', 'cell', 'proliferation', 'promotes', 'apoptosis', 'dosedependent', 'fashion', 'srx3305', 'also', 'inhibits', 'activationinduced', 'proliferation', 'primary', 'cll', 'cells', 'vitro', 'effectively', 'blocks', 'microenvironmentmediated', 'survival', 'signals', 'including', 'stromal', 'cell', 'contact', 'furthermore', 'srx3305', 'blocks', 'cll', 'cell', 'migration', 'toward', 'cxcl12', 'cxcl13', 'major', 'chemokines', 'involved', 'cll', 'cell', 'homing', 'retention', 'microenvironment', 'niches', 'importantly', 'srx3305', 'maintains', 'antitumor', 'effects', 'ibrutinibresistant', 'cll', 'cells', 'collectively', 'study', 'establishes', 'preclinical', 'efficacy', 'srx3305', 'cll', 'providing', 'significant', 'rationale', 'development', 'therapeutic', 'agent', 'cll', 'related', 'disorders']","['cxcl12', 'cxcl13']","['cxcl12', 'cxcl13']",True,"['tumor', 'leukemia']"
35695407,Discovery of a Novel Small-Molecule Inhibitor Disrupting TRBP-Dicer Interaction against Hepatocellular Carcinoma via the Modulation of microRNA Biogenesis.,"MicroRNAs (miRNAs) are key players in human hepatocellular carcinoma (HCC) tumorigenesis. Therefore, small molecules targeting components of miRNA biogenesis may provide new therapeutic means for HCC treatment. By a high-throughput screening and structural simplification, we identified a small molecule, CIB-3b, which suppresses the growth and metastasis of HCC <i>in vitro</i> and <i>in vivo</i> by modulating expression profiles of miRNAome and proteome in HCC cells. Mechanistically, CIB-3b physically binds to transactivation response (TAR) RNA-binding protein 2 (TRBP) and disrupts the TRBP-Dicer interaction, thereby altering the activity of Dicer and mature miRNA production. Structure-activity relationship study via the synthesis of 45 CIB-3b derivatives showed that some compounds exhibited a similar inhibitory effect on miRNA biogenesis to CIB-3b. These results support TRBP as a potential therapeutic target in HCC and warrant further development of CIB-3b along with its analogues as a novel therapeutic strategy for the treatment of HCC.",2022-06-13,micrornas mirnas are key players in human hepatocellular carcinoma hcc tumorigenesis therefore small molecules targeting components of mirna biogenesis may provide new therapeutic means for hcc treatment by a highthroughput screening and structural simplification we identified a small molecule cib3b which suppresses the growth and metastasis of hcc iin vitroi and iin vivoi by modulating expression profiles of mirnaome and proteome in hcc cells mechanistically cib3b physically binds to transactivation response tar rnabinding protein 2 trbp and disrupts the trbpdicer interaction thereby altering the activity of dicer and mature mirna production structureactivity relationship study via the synthesis of 45 cib3b derivatives showed that some compounds exhibited a similar inhibitory effect on mirna biogenesis to cib3b these results support trbp as a potential therapeutic target in hcc and warrant further development of cib3b along with its analogues as a novel therapeutic strategy for the treatment of hcc,"['micrornas', 'mirnas', 'are', 'key', 'players', 'in', 'human', 'hepatocellular', 'carcinoma', 'hcc', 'tumorigenesis', 'therefore', 'small', 'molecules', 'targeting', 'components', 'of', 'mirna', 'biogenesis', 'may', 'provide', 'new', 'therapeutic', 'means', 'for', 'hcc', 'treatment', 'by', 'a', 'highthroughput', 'screening', 'and', 'structural', 'simplification', 'we', 'identified', 'a', 'small', 'molecule', 'cib3b', 'which', 'suppresses', 'the', 'growth', 'and', 'metastasis', 'of', 'hcc', 'iin', 'vitroi', 'and', 'iin', 'vivoi', 'by', 'modulating', 'expression', 'profiles', 'of', 'mirnaome', 'and', 'proteome', 'in', 'hcc', 'cells', 'mechanistically', 'cib3b', 'physically', 'binds', 'to', 'transactivation', 'response', 'tar', 'rnabinding', 'protein', '2', 'trbp', 'and', 'disrupts', 'the', 'trbpdicer', 'interaction', 'thereby', 'altering', 'the', 'activity', 'of', 'dicer', 'and', 'mature', 'mirna', 'production', 'structureactivity', 'relationship', 'study', 'via', 'the', 'synthesis', 'of', '45', 'cib3b', 'derivatives', 'showed', 'that', 'some', 'compounds', 'exhibited', 'a', 'similar', 'inhibitory', 'effect', 'on', 'mirna', 'biogenesis', 'to', 'cib3b', 'these', 'results', 'support', 'trbp', 'as', 'a', 'potential', 'therapeutic', 'target', 'in', 'hcc', 'and', 'warrant', 'further', 'development', 'of', 'cib3b', 'along', 'with', 'its', 'analogues', 'as', 'a', 'novel', 'therapeutic', 'strategy', 'for', 'the', 'treatment', 'of', 'hcc']","['micrornas', 'mirnas', 'key', 'players', 'human', 'hepatocellular', 'carcinoma', 'hcc', 'tumorigenesis', 'therefore', 'small', 'molecules', 'targeting', 'components', 'mirna', 'biogenesis', 'may', 'provide', 'new', 'therapeutic', 'means', 'hcc', 'treatment', 'highthroughput', 'screening', 'structural', 'simplification', 'identified', 'small', 'molecule', 'cib3b', 'suppresses', 'growth', 'metastasis', 'hcc', 'iin', 'vitroi', 'iin', 'vivoi', 'modulating', 'expression', 'profiles', 'mirnaome', 'proteome', 'hcc', 'cells', 'mechanistically', 'cib3b', 'physically', 'binds', 'transactivation', 'response', 'tar', 'rnabinding', 'protein', '2', 'trbp', 'disrupts', 'trbpdicer', 'interaction', 'thereby', 'altering', 'activity', 'dicer', 'mature', 'mirna', 'production', 'structureactivity', 'relationship', 'study', 'via', 'synthesis', '45', 'cib3b', 'derivatives', 'showed', 'compounds', 'exhibited', 'similar', 'inhibitory', 'effect', 'mirna', 'biogenesis', 'cib3b', 'results', 'support', 'trbp', 'potential', 'therapeutic', 'target', 'hcc', 'warrant', 'development', 'cib3b', 'along', 'analogues', 'novel', 'therapeutic', 'strategy', 'treatment', 'hcc']",['dicer'],['dicer'],True,['tumor']
35680376,"Cardioprotective Effects of 1-(3,6-Dibromo-carbazol-9-yl)-3-Phenylamino-Propan-2-Ol in Diabetic Hearts via Nicotinamide Phosphoribosyltransferase Activation.","Diabetes is associated with increased cardiac injury and sudden death. Nicotinamide phosphoribosyltransferase (Nampt) is an essential enzyme for the NAD<sup>+</sup> salvage pathway and is dysregulated in diabetes. Nampt activation results in rescued NADH/NAD<sup>+</sup> ratios and provides pharmacological changes necessary for diabetic cardioprotection. Computer docking shows that 1-(3,6-Dibromo-carbazol-9-yl)-3-phenylamino-propan-2-ol (P7C3) allows for enhanced Nampt dimerization and association. To test the pharmacological application, we used male leptin receptor-deficient (db/db) mice and treated them with Nampt activator P7C3. The effects of 4-week P7C3 treatment on cardiac function were evaluated along with molecular signaling changes for phosphorylated protein kinase B (p-AKT), phosphorylated endothelial nitric oxide synthase (p-eNOS), and sirtuin 1 (SIRT1). The cardiac function evaluated by ECG and echocardiography were significantly improved after 4 weeks of P7C3 treatment. Biochemically, higher NADH/NAD<sup>+</sup> ratios in diabetic hearts were rescued by P7C3 treatment. Moreover, activities of Nampt and SIRT1 were significantly increased in P7C3-treated diabetic hearts. P7C3 treatment significantly decreased the blood glucose in diabetic mice with 4-week treatment as noted by glucose tolerance test and fasting blood glucose measurements compared with vehicle-treated mice. P7C3 activated Nampt enzymatic activity both in vitro and in the 4-week diabetic mouse hearts, demonstrating the specificity of the small molecule. P7C3 treatment significantly enhanced the expression of cardioprotective signaling of p-AKT, p-eNOS, and Beclin 1 in diabetic hearts. Nampt activator P7C3 allows for decreased infarct size with decreased Troponin I and lactose dehydrogenase (LDH) release, which is beneficial to the heart. Overall, the present study shows that P7C3 activates Nampt and SIRT1 activity and decreases NADH/NAD<sup>+</sup> ratio, resulting in improved biochemical signaling providing cardioprotection. SIGNIFICANCE STATEMENT: This study shows that 1-(3,6-Dibromo-carbazol-9-yl)-3-phenylamino-propan-2-ol (P7C3) is effective in treating diabetes and cardiovascular diseases. The novel small molecule is antiarrhythmic and improves the ejection fraction in diabetic hearts. The study successfully demonstrated that P7C3 decreases the infarct size in hearts during myocardial infarction and ischemia-reperfusion injury. Biochemical and cellular signaling show increased NAD<sup>+</sup> levels, along with Nampt activity involved in upregulating protective signaling in the diabetic heart. P7C3 has high therapeutic potential for rescuing heart disease.",2022-06-09,diabetes is associated with increased cardiac injury and sudden death nicotinamide phosphoribosyltransferase nampt is an essential enzyme for the nadsupsup salvage pathway and is dysregulated in diabetes nampt activation results in rescued nadhnadsupsup ratios and provides pharmacological changes necessary for diabetic cardioprotection computer docking shows that 136dibromocarbazol9yl3phenylaminopropan2ol p7c3 allows for enhanced nampt dimerization and association to test the pharmacological application we used male leptin receptordeficient dbdb mice and treated them with nampt activator p7c3 the effects of 4week p7c3 treatment on cardiac function were evaluated along with molecular signaling changes for phosphorylated protein kinase b pakt phosphorylated endothelial nitric oxide synthase penos and sirtuin 1 sirt1 the cardiac function evaluated by ecg and echocardiography were significantly improved after 4 weeks of p7c3 treatment biochemically higher nadhnadsupsup ratios in diabetic hearts were rescued by p7c3 treatment moreover activities of nampt and sirt1 were significantly increased in p7c3treated diabetic hearts p7c3 treatment significantly decreased the blood glucose in diabetic mice with 4week treatment as noted by glucose tolerance test and fasting blood glucose measurements compared with vehicletreated mice p7c3 activated nampt enzymatic activity both in vitro and in the 4week diabetic mouse hearts demonstrating the specificity of the small molecule p7c3 treatment significantly enhanced the expression of cardioprotective signaling of pakt penos and beclin 1 in diabetic hearts nampt activator p7c3 allows for decreased infarct size with decreased troponin i and lactose dehydrogenase ldh release which is beneficial to the heart overall the present study shows that p7c3 activates nampt and sirt1 activity and decreases nadhnadsupsup ratio resulting in improved biochemical signaling providing cardioprotection significance statement this study shows that 136dibromocarbazol9yl3phenylaminopropan2ol p7c3 is effective in treating diabetes and cardiovascular diseases the novel small molecule is antiarrhythmic and improves the ejection fraction in diabetic hearts the study successfully demonstrated that p7c3 decreases the infarct size in hearts during myocardial infarction and ischemiareperfusion injury biochemical and cellular signaling show increased nadsupsup levels along with nampt activity involved in upregulating protective signaling in the diabetic heart p7c3 has high therapeutic potential for rescuing heart disease,"['diabetes', 'is', 'associated', 'with', 'increased', 'cardiac', 'injury', 'and', 'sudden', 'death', 'nicotinamide', 'phosphoribosyltransferase', 'nampt', 'is', 'an', 'essential', 'enzyme', 'for', 'the', 'nadsupsup', 'salvage', 'pathway', 'and', 'is', 'dysregulated', 'in', 'diabetes', 'nampt', 'activation', 'results', 'in', 'rescued', 'nadhnadsupsup', 'ratios', 'and', 'provides', 'pharmacological', 'changes', 'necessary', 'for', 'diabetic', 'cardioprotection', 'computer', 'docking', 'shows', 'that', '136dibromocarbazol9yl3phenylaminopropan2ol', 'p7c3', 'allows', 'for', 'enhanced', 'nampt', 'dimerization', 'and', 'association', 'to', 'test', 'the', 'pharmacological', 'application', 'we', 'used', 'male', 'leptin', 'receptordeficient', 'dbdb', 'mice', 'and', 'treated', 'them', 'with', 'nampt', 'activator', 'p7c3', 'the', 'effects', 'of', '4week', 'p7c3', 'treatment', 'on', 'cardiac', 'function', 'were', 'evaluated', 'along', 'with', 'molecular', 'signaling', 'changes', 'for', 'phosphorylated', 'protein', 'kinase', 'b', 'pakt', 'phosphorylated', 'endothelial', 'nitric', 'oxide', 'synthase', 'penos', 'and', 'sirtuin', '1', 'sirt1', 'the', 'cardiac', 'function', 'evaluated', 'by', 'ecg', 'and', 'echocardiography', 'were', 'significantly', 'improved', 'after', '4', 'weeks', 'of', 'p7c3', 'treatment', 'biochemically', 'higher', 'nadhnadsupsup', 'ratios', 'in', 'diabetic', 'hearts', 'were', 'rescued', 'by', 'p7c3', 'treatment', 'moreover', 'activities', 'of', 'nampt', 'and', 'sirt1', 'were', 'significantly', 'increased', 'in', 'p7c3treated', 'diabetic', 'hearts', 'p7c3', 'treatment', 'significantly', 'decreased', 'the', 'blood', 'glucose', 'in', 'diabetic', 'mice', 'with', '4week', 'treatment', 'as', 'noted', 'by', 'glucose', 'tolerance', 'test', 'and', 'fasting', 'blood', 'glucose', 'measurements', 'compared', 'with', 'vehicletreated', 'mice', 'p7c3', 'activated', 'nampt', 'enzymatic', 'activity', 'both', 'in', 'vitro', 'and', 'in', 'the', '4week', 'diabetic', 'mouse', 'hearts', 'demonstrating', 'the', 'specificity', 'of', 'the', 'small', 'molecule', 'p7c3', 'treatment', 'significantly', 'enhanced', 'the', 'expression', 'of', 'cardioprotective', 'signaling', 'of', 'pakt', 'penos', 'and', 'beclin', '1', 'in', 'diabetic', 'hearts', 'nampt', 'activator', 'p7c3', 'allows', 'for', 'decreased', 'infarct', 'size', 'with', 'decreased', 'troponin', 'i', 'and', 'lactose', 'dehydrogenase', 'ldh', 'release', 'which', 'is', 'beneficial', 'to', 'the', 'heart', 'overall', 'the', 'present', 'study', 'shows', 'that', 'p7c3', 'activates', 'nampt', 'and', 'sirt1', 'activity', 'and', 'decreases', 'nadhnadsupsup', 'ratio', 'resulting', 'in', 'improved', 'biochemical', 'signaling', 'providing', 'cardioprotection', 'significance', 'statement', 'this', 'study', 'shows', 'that', '136dibromocarbazol9yl3phenylaminopropan2ol', 'p7c3', 'is', 'effective', 'in', 'treating', 'diabetes', 'and', 'cardiovascular', 'diseases', 'the', 'novel', 'small', 'molecule', 'is', 'antiarrhythmic', 'and', 'improves', 'the', 'ejection', 'fraction', 'in', 'diabetic', 'hearts', 'the', 'study', 'successfully', 'demonstrated', 'that', 'p7c3', 'decreases', 'the', 'infarct', 'size', 'in', 'hearts', 'during', 'myocardial', 'infarction', 'and', 'ischemiareperfusion', 'injury', 'biochemical', 'and', 'cellular', 'signaling', 'show', 'increased', 'nadsupsup', 'levels', 'along', 'with', 'nampt', 'activity', 'involved', 'in', 'upregulating', 'protective', 'signaling', 'in', 'the', 'diabetic', 'heart', 'p7c3', 'has', 'high', 'therapeutic', 'potential', 'for', 'rescuing', 'heart', 'disease']","['diabetes', 'associated', 'increased', 'cardiac', 'injury', 'sudden', 'death', 'nicotinamide', 'phosphoribosyltransferase', 'nampt', 'essential', 'enzyme', 'nadsupsup', 'salvage', 'pathway', 'dysregulated', 'diabetes', 'nampt', 'activation', 'results', 'rescued', 'nadhnadsupsup', 'ratios', 'provides', 'pharmacological', 'changes', 'necessary', 'diabetic', 'cardioprotection', 'computer', 'docking', 'shows', '136dibromocarbazol9yl3phenylaminopropan2ol', 'p7c3', 'allows', 'enhanced', 'nampt', 'dimerization', 'association', 'test', 'pharmacological', 'application', 'used', 'male', 'leptin', 'receptordeficient', 'dbdb', 'mice', 'treated', 'nampt', 'activator', 'p7c3', 'effects', '4week', 'p7c3', 'treatment', 'cardiac', 'function', 'evaluated', 'along', 'molecular', 'signaling', 'changes', 'phosphorylated', 'protein', 'kinase', 'b', 'pakt', 'phosphorylated', 'endothelial', 'nitric', 'oxide', 'synthase', 'penos', 'sirtuin', '1', 'sirt1', 'cardiac', 'function', 'evaluated', 'ecg', 'echocardiography', 'significantly', 'improved', '4', 'weeks', 'p7c3', 'treatment', 'biochemically', 'higher', 'nadhnadsupsup', 'ratios', 'diabetic', 'hearts', 'rescued', 'p7c3', 'treatment', 'moreover', 'activities', 'nampt', 'sirt1', 'significantly', 'increased', 'p7c3treated', 'diabetic', 'hearts', 'p7c3', 'treatment', 'significantly', 'decreased', 'blood', 'glucose', 'diabetic', 'mice', '4week', 'treatment', 'noted', 'glucose', 'tolerance', 'test', 'fasting', 'blood', 'glucose', 'measurements', 'compared', 'vehicletreated', 'mice', 'p7c3', 'activated', 'nampt', 'enzymatic', 'activity', 'vitro', '4week', 'diabetic', 'mouse', 'hearts', 'demonstrating', 'specificity', 'small', 'molecule', 'p7c3', 'treatment', 'significantly', 'enhanced', 'expression', 'cardioprotective', 'signaling', 'pakt', 'penos', 'beclin', '1', 'diabetic', 'hearts', 'nampt', 'activator', 'p7c3', 'allows', 'decreased', 'infarct', 'size', 'decreased', 'troponin', 'lactose', 'dehydrogenase', 'ldh', 'release', 'beneficial', 'heart', 'overall', 'present', 'study', 'shows', 'p7c3', 'activates', 'nampt', 'sirt1', 'activity', 'decreases', 'nadhnadsupsup', 'ratio', 'resulting', 'improved', 'biochemical', 'signaling', 'providing', 'cardioprotection', 'significance', 'statement', 'study', 'shows', '136dibromocarbazol9yl3phenylaminopropan2ol', 'p7c3', 'effective', 'treating', 'diabetes', 'cardiovascular', 'diseases', 'novel', 'small', 'molecule', 'antiarrhythmic', 'improves', 'ejection', 'fraction', 'diabetic', 'hearts', 'study', 'successfully', 'demonstrated', 'p7c3', 'decreases', 'infarct', 'size', 'hearts', 'myocardial', 'infarction', 'ischemiareperfusion', 'injury', 'biochemical', 'cellular', 'signaling', 'show', 'increased', 'nadsupsup', 'levels', 'along', 'nampt', 'activity', 'involved', 'upregulating', 'protective', 'signaling', 'diabetic', 'heart', 'p7c3', 'high', 'therapeutic', 'potential', 'rescuing', 'heart', 'disease']","['leptin', 'sirtuin', 'sirt1', 'sirt1', 'beclin', 'troponin', 'sirt1']","['sirtuin', 'beclin']",True,['diabetes']
35662712,A Novel Small-Molecule Inhibitor of SREBP-1 Based on Natural Product Monomers Upregulates the Sensitivity of Lung Squamous Cell Carcinoma Cells to Antitumor Drugs.,"The transcription factor, sterol regulatory element binding protein 1 (SREBP-1), plays important roles in modulating the proliferation, metastasis, or resistance to antitumor agents by promoting cellular lipid metabolism and related cellular glucose-uptake/Warburg Effect. However, the underlying mechanism of SREBP-1 regulating the proliferation or drug-resistance in lung squamous cell carcinoma (LUSC) and the therapeutic strategies targeted to SREBP-1 in LUSC remain unclear. In this study, SREBP-1 was highly expressed in LUSC tissues, compared with the paired non-tumor tissues (the para-tumor tissues). A novel small-molecule inhibitor of SREBP-1, MSI-1 (Ma's inhibitor of SREBP-1), based on natural product monomers, was identified by screening the database of natural products. Treatment with MSI-1 suppressed the activation of SREBP-1-related pathways and the Warburg effect of LUSC cells, as indicated by decreased glucose uptake or glycolysis. Moreover, treatment of MSI-1 enhanced the sensitivity of LUSC cells to antitumor agents. The specificity of MSI-1 on SREBP-1 was confirmed by molecular docking and point-mutation of SPEBP-1. Therefore, MSI-1 improved our understanding of SREBP-1 and provided additional options for the treatment of LUSC.",2022-05-18,the transcription factor sterol regulatory element binding protein 1 srebp1 plays important roles in modulating the proliferation metastasis or resistance to antitumor agents by promoting cellular lipid metabolism and related cellular glucoseuptakewarburg effect however the underlying mechanism of srebp1 regulating the proliferation or drugresistance in lung squamous cell carcinoma lusc and the therapeutic strategies targeted to srebp1 in lusc remain unclear in this study srebp1 was highly expressed in lusc tissues compared with the paired nontumor tissues the paratumor tissues a novel smallmolecule inhibitor of srebp1 msi1 mas inhibitor of srebp1 based on natural product monomers was identified by screening the database of natural products treatment with msi1 suppressed the activation of srebp1related pathways and the warburg effect of lusc cells as indicated by decreased glucose uptake or glycolysis moreover treatment of msi1 enhanced the sensitivity of lusc cells to antitumor agents the specificity of msi1 on srebp1 was confirmed by molecular docking and pointmutation of spebp1 therefore msi1 improved our understanding of srebp1 and provided additional options for the treatment of lusc,"['the', 'transcription', 'factor', 'sterol', 'regulatory', 'element', 'binding', 'protein', '1', 'srebp1', 'plays', 'important', 'roles', 'in', 'modulating', 'the', 'proliferation', 'metastasis', 'or', 'resistance', 'to', 'antitumor', 'agents', 'by', 'promoting', 'cellular', 'lipid', 'metabolism', 'and', 'related', 'cellular', 'glucoseuptakewarburg', 'effect', 'however', 'the', 'underlying', 'mechanism', 'of', 'srebp1', 'regulating', 'the', 'proliferation', 'or', 'drugresistance', 'in', 'lung', 'squamous', 'cell', 'carcinoma', 'lusc', 'and', 'the', 'therapeutic', 'strategies', 'targeted', 'to', 'srebp1', 'in', 'lusc', 'remain', 'unclear', 'in', 'this', 'study', 'srebp1', 'was', 'highly', 'expressed', 'in', 'lusc', 'tissues', 'compared', 'with', 'the', 'paired', 'nontumor', 'tissues', 'the', 'paratumor', 'tissues', 'a', 'novel', 'smallmolecule', 'inhibitor', 'of', 'srebp1', 'msi1', 'mas', 'inhibitor', 'of', 'srebp1', 'based', 'on', 'natural', 'product', 'monomers', 'was', 'identified', 'by', 'screening', 'the', 'database', 'of', 'natural', 'products', 'treatment', 'with', 'msi1', 'suppressed', 'the', 'activation', 'of', 'srebp1related', 'pathways', 'and', 'the', 'warburg', 'effect', 'of', 'lusc', 'cells', 'as', 'indicated', 'by', 'decreased', 'glucose', 'uptake', 'or', 'glycolysis', 'moreover', 'treatment', 'of', 'msi1', 'enhanced', 'the', 'sensitivity', 'of', 'lusc', 'cells', 'to', 'antitumor', 'agents', 'the', 'specificity', 'of', 'msi1', 'on', 'srebp1', 'was', 'confirmed', 'by', 'molecular', 'docking', 'and', 'pointmutation', 'of', 'spebp1', 'therefore', 'msi1', 'improved', 'our', 'understanding', 'of', 'srebp1', 'and', 'provided', 'additional', 'options', 'for', 'the', 'treatment', 'of', 'lusc']","['transcription', 'factor', 'sterol', 'regulatory', 'element', 'binding', 'protein', '1', 'srebp1', 'plays', 'important', 'roles', 'modulating', 'proliferation', 'metastasis', 'resistance', 'antitumor', 'agents', 'promoting', 'cellular', 'lipid', 'metabolism', 'related', 'cellular', 'glucoseuptakewarburg', 'effect', 'however', 'underlying', 'mechanism', 'srebp1', 'regulating', 'proliferation', 'drugresistance', 'lung', 'squamous', 'cell', 'carcinoma', 'lusc', 'therapeutic', 'strategies', 'targeted', 'srebp1', 'lusc', 'remain', 'unclear', 'study', 'srebp1', 'highly', 'expressed', 'lusc', 'tissues', 'compared', 'paired', 'nontumor', 'tissues', 'paratumor', 'tissues', 'novel', 'smallmolecule', 'inhibitor', 'srebp1', 'msi1', 'mas', 'inhibitor', 'srebp1', 'based', 'natural', 'product', 'monomers', 'identified', 'screening', 'database', 'natural', 'products', 'treatment', 'msi1', 'suppressed', 'activation', 'srebp1related', 'pathways', 'warburg', 'effect', 'lusc', 'cells', 'indicated', 'decreased', 'glucose', 'uptake', 'glycolysis', 'moreover', 'treatment', 'msi1', 'enhanced', 'sensitivity', 'lusc', 'cells', 'antitumor', 'agents', 'specificity', 'msi1', 'srebp1', 'confirmed', 'molecular', 'docking', 'pointmutation', 'spebp1', 'therefore', 'msi1', 'improved', 'understanding', 'srebp1', 'provided', 'additional', 'options', 'treatment', 'lusc']","['srebp1', 'srebp1', 'srebp1', 'srebp1', 'srebp1', 'srebp1', 'srebp1', 'srebp1']","['srebp1', 'srebp1', 'srebp1', 'srebp1', 'srebp1', 'srebp1', 'srebp1', 'srebp1']",True,['tumor']
35631512,IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma.,"High-grade gliomas (HGG) are devastating diseases in children and adults. In the pediatric population, diffuse midline gliomas (DMG) harboring H3K27 alterations are the most aggressive primary malignant brain tumors. With no effective therapies available, children typically succumb to disease within one year of diagnosis. In adults, glioblastoma (GBM) remains largely intractable, with a median survival of approximately 14 months despite standard clinical care of radiation and temozolomide. Therefore, effective therapies for these tumors remain one of the most urgent and unmet needs in modern medicine. Interleukin 13 receptor subunit alpha 2 (IL-13Rα2) is a cell-surface transmembrane protein upregulated in many HGGs, including DMG and adult GBM, posing a potentially promising therapeutic target for these tumors. In this study, we investigated the pharmacological effects of GB-13 (also known as IL13.E13K-PE4E), a novel peptide-toxin conjugate that contains a targeting moiety designed to bind IL-13Rα2 with high specificity and a point-mutant cytotoxic domain derived from Pseudomonas exotoxin A. Glioma cell lines demonstrated a spectrum of IL-13Rα2 expression at both the transcript and protein level. Anti-tumor effects of GB-13 strongly correlated with IL-13Rα2 expression and were reflected in apoptosis induction and decreased cell proliferation in vitro. Direct intratumoral administration of GB-13 via convection-enhanced delivery (CED) significantly decreased tumor burden and resulted in prolonged survival in IL-13Rα2-upregulated orthotopic xenograft models of HGG. In summary, administration of GB-13 demonstrated a promising pharmacological response in HGG models both in vitro and in vivo in a manner strongly associated with IL-13Rα2 expression, underscoring the potential of this IL-13Rα2-targeted therapy in a subset of HGG with increased IL-13Rα2 levels.",2022-04-24,highgrade gliomas hgg are devastating diseases in children and adults in the pediatric population diffuse midline gliomas dmg harboring h3k27 alterations are the most aggressive primary malignant brain tumors with no effective therapies available children typically succumb to disease within one year of diagnosis in adults glioblastoma gbm remains largely intractable with a median survival of approximately 14 months despite standard clinical care of radiation and temozolomide therefore effective therapies for these tumors remain one of the most urgent and unmet needs in modern medicine interleukin 13 receptor subunit alpha 2 il13rα2 is a cellsurface transmembrane protein upregulated in many hggs including dmg and adult gbm posing a potentially promising therapeutic target for these tumors in this study we investigated the pharmacological effects of gb13 also known as il13e13kpe4e a novel peptidetoxin conjugate that contains a targeting moiety designed to bind il13rα2 with high specificity and a pointmutant cytotoxic domain derived from pseudomonas exotoxin a glioma cell lines demonstrated a spectrum of il13rα2 expression at both the transcript and protein level antitumor effects of gb13 strongly correlated with il13rα2 expression and were reflected in apoptosis induction and decreased cell proliferation in vitro direct intratumoral administration of gb13 via convectionenhanced delivery ced significantly decreased tumor burden and resulted in prolonged survival in il13rα2upregulated orthotopic xenograft models of hgg in summary administration of gb13 demonstrated a promising pharmacological response in hgg models both in vitro and in vivo in a manner strongly associated with il13rα2 expression underscoring the potential of this il13rα2targeted therapy in a subset of hgg with increased il13rα2 levels,"['highgrade', 'gliomas', 'hgg', 'are', 'devastating', 'diseases', 'in', 'children', 'and', 'adults', 'in', 'the', 'pediatric', 'population', 'diffuse', 'midline', 'gliomas', 'dmg', 'harboring', 'h3k27', 'alterations', 'are', 'the', 'most', 'aggressive', 'primary', 'malignant', 'brain', 'tumors', 'with', 'no', 'effective', 'therapies', 'available', 'children', 'typically', 'succumb', 'to', 'disease', 'within', 'one', 'year', 'of', 'diagnosis', 'in', 'adults', 'glioblastoma', 'gbm', 'remains', 'largely', 'intractable', 'with', 'a', 'median', 'survival', 'of', 'approximately', '14', 'months', 'despite', 'standard', 'clinical', 'care', 'of', 'radiation', 'and', 'temozolomide', 'therefore', 'effective', 'therapies', 'for', 'these', 'tumors', 'remain', 'one', 'of', 'the', 'most', 'urgent', 'and', 'unmet', 'needs', 'in', 'modern', 'medicine', 'interleukin', '13', 'receptor', 'subunit', 'alpha', '2', 'il13rα2', 'is', 'a', 'cellsurface', 'transmembrane', 'protein', 'upregulated', 'in', 'many', 'hggs', 'including', 'dmg', 'and', 'adult', 'gbm', 'posing', 'a', 'potentially', 'promising', 'therapeutic', 'target', 'for', 'these', 'tumors', 'in', 'this', 'study', 'we', 'investigated', 'the', 'pharmacological', 'effects', 'of', 'gb13', 'also', 'known', 'as', 'il13e13kpe4e', 'a', 'novel', 'peptidetoxin', 'conjugate', 'that', 'contains', 'a', 'targeting', 'moiety', 'designed', 'to', 'bind', 'il13rα2', 'with', 'high', 'specificity', 'and', 'a', 'pointmutant', 'cytotoxic', 'domain', 'derived', 'from', 'pseudomonas', 'exotoxin', 'a', 'glioma', 'cell', 'lines', 'demonstrated', 'a', 'spectrum', 'of', 'il13rα2', 'expression', 'at', 'both', 'the', 'transcript', 'and', 'protein', 'level', 'antitumor', 'effects', 'of', 'gb13', 'strongly', 'correlated', 'with', 'il13rα2', 'expression', 'and', 'were', 'reflected', 'in', 'apoptosis', 'induction', 'and', 'decreased', 'cell', 'proliferation', 'in', 'vitro', 'direct', 'intratumoral', 'administration', 'of', 'gb13', 'via', 'convectionenhanced', 'delivery', 'ced', 'significantly', 'decreased', 'tumor', 'burden', 'and', 'resulted', 'in', 'prolonged', 'survival', 'in', 'il13rα2upregulated', 'orthotopic', 'xenograft', 'models', 'of', 'hgg', 'in', 'summary', 'administration', 'of', 'gb13', 'demonstrated', 'a', 'promising', 'pharmacological', 'response', 'in', 'hgg', 'models', 'both', 'in', 'vitro', 'and', 'in', 'vivo', 'in', 'a', 'manner', 'strongly', 'associated', 'with', 'il13rα2', 'expression', 'underscoring', 'the', 'potential', 'of', 'this', 'il13rα2targeted', 'therapy', 'in', 'a', 'subset', 'of', 'hgg', 'with', 'increased', 'il13rα2', 'levels']","['highgrade', 'gliomas', 'hgg', 'devastating', 'diseases', 'children', 'adults', 'pediatric', 'population', 'diffuse', 'midline', 'gliomas', 'dmg', 'harboring', 'h3k27', 'alterations', 'aggressive', 'primary', 'malignant', 'brain', 'tumors', 'effective', 'therapies', 'available', 'children', 'typically', 'succumb', 'disease', 'within', 'one', 'year', 'diagnosis', 'adults', 'glioblastoma', 'gbm', 'remains', 'largely', 'intractable', 'median', 'survival', 'approximately', '14', 'months', 'despite', 'standard', 'clinical', 'care', 'radiation', 'temozolomide', 'therefore', 'effective', 'therapies', 'tumors', 'remain', 'one', 'urgent', 'unmet', 'needs', 'modern', 'medicine', 'interleukin', '13', 'receptor', 'subunit', 'alpha', '2', 'il13rα2', 'cellsurface', 'transmembrane', 'protein', 'upregulated', 'many', 'hggs', 'including', 'dmg', 'adult', 'gbm', 'posing', 'potentially', 'promising', 'therapeutic', 'target', 'tumors', 'study', 'investigated', 'pharmacological', 'effects', 'gb13', 'also', 'known', 'il13e13kpe4e', 'novel', 'peptidetoxin', 'conjugate', 'contains', 'targeting', 'moiety', 'designed', 'bind', 'il13rα2', 'high', 'specificity', 'pointmutant', 'cytotoxic', 'domain', 'derived', 'pseudomonas', 'exotoxin', 'glioma', 'cell', 'lines', 'demonstrated', 'spectrum', 'il13rα2', 'expression', 'transcript', 'protein', 'level', 'antitumor', 'effects', 'gb13', 'strongly', 'correlated', 'il13rα2', 'expression', 'reflected', 'apoptosis', 'induction', 'decreased', 'cell', 'proliferation', 'vitro', 'direct', 'intratumoral', 'administration', 'gb13', 'via', 'convectionenhanced', 'delivery', 'ced', 'significantly', 'decreased', 'tumor', 'burden', 'resulted', 'prolonged', 'survival', 'il13rα2upregulated', 'orthotopic', 'xenograft', 'models', 'hgg', 'summary', 'administration', 'gb13', 'demonstrated', 'promising', 'pharmacological', 'response', 'hgg', 'models', 'vitro', 'vivo', 'manner', 'strongly', 'associated', 'il13rα2', 'expression', 'underscoring', 'potential', 'il13rα2targeted', 'therapy', 'subset', 'hgg', 'increased', 'il13rα2', 'levels']","['interleukin', 'cellsurface', 'exotoxin']",['cellsurface'],True,['tumor']
35594837,An all-in-one adjuvanted therapeutic cancer vaccine targeting dendritic cell cytosol induces long-lived tumor suppression through NLRC4 inflammasome activation.,"Therapeutic cancer vaccines (TCVs) should induce robust tumor-specific T cell responses. To achieve this, TCVs incorporate T cell epitopes and strong adjuvants. Here, we report an all-in-one adjuvanted cancer vaccine platform that targets the intracellular compartment of dentritic cells and subsequently induces effective cytotoxic T cell responses. We screened a novel peptide (DCpep6) that specifically binds and transmits into CD11c<sup>+</sup> cells through a novel in vivo phage biopanning. We then engineered a protein-based TCV (DEF) consisting of DCpep6 (D), an optimized HPV E7 tumor antigen (E), and a built-in flagellin adjuvant (F) as a single molecule. DEF was stably expressed, and each component was functional. In vivo-administered DEF rapidly biodistributed in draining LNs and internalized into CD11c<sup>+</sup> cells. DEF immunization elicited strong antitumor T cell responses and provided long-term survival of TC-1 tumor-implanted mice. The DEF-mediated antitumor effect was abolished in NLRC4<sup>-/-</sup> mice. Taken together, we propose a protein-based all-in-one TCV platform that intracellularly codelivers tumor antigen and inflammasome activator to DCs to induce long-lasting antitumor T cell responses.",2022-05-10,therapeutic cancer vaccines tcvs should induce robust tumorspecific t cell responses to achieve this tcvs incorporate t cell epitopes and strong adjuvants here we report an allinone adjuvanted cancer vaccine platform that targets the intracellular compartment of dentritic cells and subsequently induces effective cytotoxic t cell responses we screened a novel peptide dcpep6 that specifically binds and transmits into cd11csupsup cells through a novel in vivo phage biopanning we then engineered a proteinbased tcv def consisting of dcpep6 d an optimized hpv e7 tumor antigen e and a builtin flagellin adjuvant f as a single molecule def was stably expressed and each component was functional in vivoadministered def rapidly biodistributed in draining lns and internalized into cd11csupsup cells def immunization elicited strong antitumor t cell responses and provided longterm survival of tc1 tumorimplanted mice the defmediated antitumor effect was abolished in nlrc4supsup mice taken together we propose a proteinbased allinone tcv platform that intracellularly codelivers tumor antigen and inflammasome activator to dcs to induce longlasting antitumor t cell responses,"['therapeutic', 'cancer', 'vaccines', 'tcvs', 'should', 'induce', 'robust', 'tumorspecific', 't', 'cell', 'responses', 'to', 'achieve', 'this', 'tcvs', 'incorporate', 't', 'cell', 'epitopes', 'and', 'strong', 'adjuvants', 'here', 'we', 'report', 'an', 'allinone', 'adjuvanted', 'cancer', 'vaccine', 'platform', 'that', 'targets', 'the', 'intracellular', 'compartment', 'of', 'dentritic', 'cells', 'and', 'subsequently', 'induces', 'effective', 'cytotoxic', 't', 'cell', 'responses', 'we', 'screened', 'a', 'novel', 'peptide', 'dcpep6', 'that', 'specifically', 'binds', 'and', 'transmits', 'into', 'cd11csupsup', 'cells', 'through', 'a', 'novel', 'in', 'vivo', 'phage', 'biopanning', 'we', 'then', 'engineered', 'a', 'proteinbased', 'tcv', 'def', 'consisting', 'of', 'dcpep6', 'd', 'an', 'optimized', 'hpv', 'e7', 'tumor', 'antigen', 'e', 'and', 'a', 'builtin', 'flagellin', 'adjuvant', 'f', 'as', 'a', 'single', 'molecule', 'def', 'was', 'stably', 'expressed', 'and', 'each', 'component', 'was', 'functional', 'in', 'vivoadministered', 'def', 'rapidly', 'biodistributed', 'in', 'draining', 'lns', 'and', 'internalized', 'into', 'cd11csupsup', 'cells', 'def', 'immunization', 'elicited', 'strong', 'antitumor', 't', 'cell', 'responses', 'and', 'provided', 'longterm', 'survival', 'of', 'tc1', 'tumorimplanted', 'mice', 'the', 'defmediated', 'antitumor', 'effect', 'was', 'abolished', 'in', 'nlrc4supsup', 'mice', 'taken', 'together', 'we', 'propose', 'a', 'proteinbased', 'allinone', 'tcv', 'platform', 'that', 'intracellularly', 'codelivers', 'tumor', 'antigen', 'and', 'inflammasome', 'activator', 'to', 'dcs', 'to', 'induce', 'longlasting', 'antitumor', 't', 'cell', 'responses']","['therapeutic', 'cancer', 'vaccines', 'tcvs', 'induce', 'robust', 'tumorspecific', 'cell', 'responses', 'achieve', 'tcvs', 'incorporate', 'cell', 'epitopes', 'strong', 'adjuvants', 'report', 'allinone', 'adjuvanted', 'cancer', 'vaccine', 'platform', 'targets', 'intracellular', 'compartment', 'dentritic', 'cells', 'subsequently', 'induces', 'effective', 'cytotoxic', 'cell', 'responses', 'screened', 'novel', 'peptide', 'dcpep6', 'specifically', 'binds', 'transmits', 'cd11csupsup', 'cells', 'novel', 'vivo', 'phage', 'biopanning', 'engineered', 'proteinbased', 'tcv', 'def', 'consisting', 'dcpep6', 'optimized', 'hpv', 'e7', 'tumor', 'antigen', 'e', 'builtin', 'flagellin', 'adjuvant', 'f', 'single', 'molecule', 'def', 'stably', 'expressed', 'component', 'functional', 'vivoadministered', 'def', 'rapidly', 'biodistributed', 'draining', 'lns', 'internalized', 'cd11csupsup', 'cells', 'def', 'immunization', 'elicited', 'strong', 'antitumor', 'cell', 'responses', 'provided', 'longterm', 'survival', 'tc1', 'tumorimplanted', 'mice', 'defmediated', 'antitumor', 'effect', 'abolished', 'nlrc4supsup', 'mice', 'taken', 'together', 'propose', 'proteinbased', 'allinone', 'tcv', 'platform', 'intracellularly', 'codelivers', 'tumor', 'antigen', 'inflammasome', 'activator', 'dcs', 'induce', 'longlasting', 'antitumor', 'cell', 'responses']","['flagellin', 'lns', 'dcs']",['flagellin'],True,"['tumor', 'cancer']"
35566047,Novel Small Molecule Inhibitors Targeting the IL-6/STAT3 Pathway or IL-1β.,"Development of small molecules that inhibit inflammatory cytokines is a desirable strategy for the treatment of inflammatory diseases such as rheumatoid arthritis (RA). Following up a previous study, we synthesized 10 novel compounds with a 2,5-diaminobenzoxazole moiety and evaluated their biological activities. Among them, compound 3e showed potent inhibitory activity on Interleukin 6 (IL-6)/Signal Transducer and Activator of Transcription 3 (STAT3) signaling inhibition (71.5%), and 3a showed excellent inhibitory activity on Interleukin 1 (IL-1β) (92.1%). To test in vivo anti-inflammatory activity, compounds 3a and 3e were administered by intraperitoneal (IP) injection after subcutaneous (SC) injection of zymosan A into the right footpad of mice. Inflammation on the footpad was reduced after administration of compounds 3a and 3e. Especially, compound 3a showed a significant ameliorative effect on zymosan-induced inflammation. From the in vivo and in vitro test results, we confirmed that our synthesized compounds are effective on the RA animal model through inhibition of the IL-6/STAT3 signaling pathway. Since drugs developed with small molecule inhibitors have several advantages over biological drugs, further study on these compounds is needed for the development of potent SMI drugs on RA.",2022-04-22,development of small molecules that inhibit inflammatory cytokines is a desirable strategy for the treatment of inflammatory diseases such as rheumatoid arthritis ra following up a previous study we synthesized 10 novel compounds with a 25diaminobenzoxazole moiety and evaluated their biological activities among them compound 3e showed potent inhibitory activity on interleukin 6 il6signal transducer and activator of transcription 3 stat3 signaling inhibition 715 and 3a showed excellent inhibitory activity on interleukin 1 il1β 921 to test in vivo antiinflammatory activity compounds 3a and 3e were administered by intraperitoneal ip injection after subcutaneous sc injection of zymosan a into the right footpad of mice inflammation on the footpad was reduced after administration of compounds 3a and 3e especially compound 3a showed a significant ameliorative effect on zymosaninduced inflammation from the in vivo and in vitro test results we confirmed that our synthesized compounds are effective on the ra animal model through inhibition of the il6stat3 signaling pathway since drugs developed with small molecule inhibitors have several advantages over biological drugs further study on these compounds is needed for the development of potent smi drugs on ra,"['development', 'of', 'small', 'molecules', 'that', 'inhibit', 'inflammatory', 'cytokines', 'is', 'a', 'desirable', 'strategy', 'for', 'the', 'treatment', 'of', 'inflammatory', 'diseases', 'such', 'as', 'rheumatoid', 'arthritis', 'ra', 'following', 'up', 'a', 'previous', 'study', 'we', 'synthesized', '10', 'novel', 'compounds', 'with', 'a', '25diaminobenzoxazole', 'moiety', 'and', 'evaluated', 'their', 'biological', 'activities', 'among', 'them', 'compound', '3e', 'showed', 'potent', 'inhibitory', 'activity', 'on', 'interleukin', '6', 'il6signal', 'transducer', 'and', 'activator', 'of', 'transcription', '3', 'stat3', 'signaling', 'inhibition', '715', 'and', '3a', 'showed', 'excellent', 'inhibitory', 'activity', 'on', 'interleukin', '1', 'il1β', '921', 'to', 'test', 'in', 'vivo', 'antiinflammatory', 'activity', 'compounds', '3a', 'and', '3e', 'were', 'administered', 'by', 'intraperitoneal', 'ip', 'injection', 'after', 'subcutaneous', 'sc', 'injection', 'of', 'zymosan', 'a', 'into', 'the', 'right', 'footpad', 'of', 'mice', 'inflammation', 'on', 'the', 'footpad', 'was', 'reduced', 'after', 'administration', 'of', 'compounds', '3a', 'and', '3e', 'especially', 'compound', '3a', 'showed', 'a', 'significant', 'ameliorative', 'effect', 'on', 'zymosaninduced', 'inflammation', 'from', 'the', 'in', 'vivo', 'and', 'in', 'vitro', 'test', 'results', 'we', 'confirmed', 'that', 'our', 'synthesized', 'compounds', 'are', 'effective', 'on', 'the', 'ra', 'animal', 'model', 'through', 'inhibition', 'of', 'the', 'il6stat3', 'signaling', 'pathway', 'since', 'drugs', 'developed', 'with', 'small', 'molecule', 'inhibitors', 'have', 'several', 'advantages', 'over', 'biological', 'drugs', 'further', 'study', 'on', 'these', 'compounds', 'is', 'needed', 'for', 'the', 'development', 'of', 'potent', 'smi', 'drugs', 'on', 'ra']","['development', 'small', 'molecules', 'inhibit', 'inflammatory', 'cytokines', 'desirable', 'strategy', 'treatment', 'inflammatory', 'diseases', 'rheumatoid', 'arthritis', 'ra', 'following', 'previous', 'study', 'synthesized', '10', 'novel', 'compounds', '25diaminobenzoxazole', 'moiety', 'evaluated', 'biological', 'activities', 'among', 'compound', '3e', 'showed', 'potent', 'inhibitory', 'activity', 'interleukin', '6', 'il6signal', 'transducer', 'activator', 'transcription', '3', 'stat3', 'signaling', 'inhibition', '715', '3a', 'showed', 'excellent', 'inhibitory', 'activity', 'interleukin', '1', 'il1β', '921', 'test', 'vivo', 'antiinflammatory', 'activity', 'compounds', '3a', '3e', 'administered', 'intraperitoneal', 'ip', 'injection', 'subcutaneous', 'sc', 'injection', 'zymosan', 'right', 'footpad', 'mice', 'inflammation', 'footpad', 'reduced', 'administration', 'compounds', '3a', '3e', 'especially', 'compound', '3a', 'showed', 'significant', 'ameliorative', 'effect', 'zymosaninduced', 'inflammation', 'vivo', 'vitro', 'test', 'results', 'confirmed', 'synthesized', 'compounds', 'effective', 'ra', 'animal', 'model', 'inhibition', 'il6stat3', 'signaling', 'pathway', 'since', 'drugs', 'developed', 'small', 'molecule', 'inhibitors', 'several', 'advantages', 'biological', 'drugs', 'study', 'compounds', 'needed', 'development', 'potent', 'smi', 'drugs', 'ra']","['ra', 'interleukin', 'stat3', 'interleukin', 'ra', ""ra']""]","['ra', 'ra']",True,['arthritis']
35547769,Polymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer.,"<b>Rationale:</b> Scarce tumor mutation burden and neoantigens create tremendous obstacles for an effective immunotherapy of colorectal cancer (CRC). Oncolytic peptides rise as a promising therapeutic approach that boosts tumor-specific immune responses by inducing antigenic substances. However, the clinical application of oncolytic peptides has been hindered because of structural instability, proteolytic degradation, and undesired toxicity when administered systemically. <b>Methods:</b> Based on wasp venom peptide, an optimized stapled oncolytic peptide MP9 was developed with rigid α-helix, protease-resistance, and CRC cell cytotoxicity. By incorporating four functional motifs that include D-peptidomimetic inhibitor of PD-L1, matrix metalloproteinase-2 (MMP-2) cleavable spacer, and MP9 with 4-arm PEG, a novel peptide-polymer conjugate (PEG-MP9-aPDL1) was obtained and identified as the most promising systemic delivery vehicle with PD-L1 targeting specificity and favorable pharmacokinetic properties. <b>Results:</b> We demonstrated that PEG-MP9-aPDL1-driven oncolysis induces a panel of immunogenic cell death (ICD)-relevant damage-associated molecular patterns (DAMPs) both <i>in vitro</i> and <i>in vivo</i>, which are key elements for immunotherapy with PD-L1 inhibitor. Further, PEG-MP9-aPDL1 exhibited prominent immunotherapeutic efficacy in a CRC mouse model characterized by tumor infiltration of CD8+ T cells and induction of cytotoxic lymphocytes (CTLs) in the spleens. <b>Conclusion:</b> Our findings suggest that PEG-MP9-aPDL1 is an all-in-one platform for oncolytic immunotherapy and immune checkpoint blockade (ICB).",2022-04-24,brationaleb scarce tumor mutation burden and neoantigens create tremendous obstacles for an effective immunotherapy of colorectal cancer crc oncolytic peptides rise as a promising therapeutic approach that boosts tumorspecific immune responses by inducing antigenic substances however the clinical application of oncolytic peptides has been hindered because of structural instability proteolytic degradation and undesired toxicity when administered systemically bmethodsb based on wasp venom peptide an optimized stapled oncolytic peptide mp9 was developed with rigid αhelix proteaseresistance and crc cell cytotoxicity by incorporating four functional motifs that include dpeptidomimetic inhibitor of pdl1 matrix metalloproteinase2 mmp2 cleavable spacer and mp9 with 4arm peg a novel peptidepolymer conjugate pegmp9apdl1 was obtained and identified as the most promising systemic delivery vehicle with pdl1 targeting specificity and favorable pharmacokinetic properties bresultsb we demonstrated that pegmp9apdl1driven oncolysis induces a panel of immunogenic cell death icdrelevant damageassociated molecular patterns damps both iin vitroi and iin vivoi which are key elements for immunotherapy with pdl1 inhibitor further pegmp9apdl1 exhibited prominent immunotherapeutic efficacy in a crc mouse model characterized by tumor infiltration of cd8 t cells and induction of cytotoxic lymphocytes ctls in the spleens bconclusionb our findings suggest that pegmp9apdl1 is an allinone platform for oncolytic immunotherapy and immune checkpoint blockade icb,"['brationaleb', 'scarce', 'tumor', 'mutation', 'burden', 'and', 'neoantigens', 'create', 'tremendous', 'obstacles', 'for', 'an', 'effective', 'immunotherapy', 'of', 'colorectal', 'cancer', 'crc', 'oncolytic', 'peptides', 'rise', 'as', 'a', 'promising', 'therapeutic', 'approach', 'that', 'boosts', 'tumorspecific', 'immune', 'responses', 'by', 'inducing', 'antigenic', 'substances', 'however', 'the', 'clinical', 'application', 'of', 'oncolytic', 'peptides', 'has', 'been', 'hindered', 'because', 'of', 'structural', 'instability', 'proteolytic', 'degradation', 'and', 'undesired', 'toxicity', 'when', 'administered', 'systemically', 'bmethodsb', 'based', 'on', 'wasp', 'venom', 'peptide', 'an', 'optimized', 'stapled', 'oncolytic', 'peptide', 'mp9', 'was', 'developed', 'with', 'rigid', 'αhelix', 'proteaseresistance', 'and', 'crc', 'cell', 'cytotoxicity', 'by', 'incorporating', 'four', 'functional', 'motifs', 'that', 'include', 'dpeptidomimetic', 'inhibitor', 'of', 'pdl1', 'matrix', 'metalloproteinase2', 'mmp2', 'cleavable', 'spacer', 'and', 'mp9', 'with', '4arm', 'peg', 'a', 'novel', 'peptidepolymer', 'conjugate', 'pegmp9apdl1', 'was', 'obtained', 'and', 'identified', 'as', 'the', 'most', 'promising', 'systemic', 'delivery', 'vehicle', 'with', 'pdl1', 'targeting', 'specificity', 'and', 'favorable', 'pharmacokinetic', 'properties', 'bresultsb', 'we', 'demonstrated', 'that', 'pegmp9apdl1driven', 'oncolysis', 'induces', 'a', 'panel', 'of', 'immunogenic', 'cell', 'death', 'icdrelevant', 'damageassociated', 'molecular', 'patterns', 'damps', 'both', 'iin', 'vitroi', 'and', 'iin', 'vivoi', 'which', 'are', 'key', 'elements', 'for', 'immunotherapy', 'with', 'pdl1', 'inhibitor', 'further', 'pegmp9apdl1', 'exhibited', 'prominent', 'immunotherapeutic', 'efficacy', 'in', 'a', 'crc', 'mouse', 'model', 'characterized', 'by', 'tumor', 'infiltration', 'of', 'cd8', 't', 'cells', 'and', 'induction', 'of', 'cytotoxic', 'lymphocytes', 'ctls', 'in', 'the', 'spleens', 'bconclusionb', 'our', 'findings', 'suggest', 'that', 'pegmp9apdl1', 'is', 'an', 'allinone', 'platform', 'for', 'oncolytic', 'immunotherapy', 'and', 'immune', 'checkpoint', 'blockade', 'icb']","['brationaleb', 'scarce', 'tumor', 'mutation', 'burden', 'neoantigens', 'create', 'tremendous', 'obstacles', 'effective', 'immunotherapy', 'colorectal', 'cancer', 'crc', 'oncolytic', 'peptides', 'rise', 'promising', 'therapeutic', 'approach', 'boosts', 'tumorspecific', 'immune', 'responses', 'inducing', 'antigenic', 'substances', 'however', 'clinical', 'application', 'oncolytic', 'peptides', 'hindered', 'structural', 'instability', 'proteolytic', 'degradation', 'undesired', 'toxicity', 'administered', 'systemically', 'bmethodsb', 'based', 'wasp', 'venom', 'peptide', 'optimized', 'stapled', 'oncolytic', 'peptide', 'mp9', 'developed', 'rigid', 'αhelix', 'proteaseresistance', 'crc', 'cell', 'cytotoxicity', 'incorporating', 'four', 'functional', 'motifs', 'include', 'dpeptidomimetic', 'inhibitor', 'pdl1', 'matrix', 'metalloproteinase2', 'mmp2', 'cleavable', 'spacer', 'mp9', '4arm', 'peg', 'novel', 'peptidepolymer', 'conjugate', 'pegmp9apdl1', 'obtained', 'identified', 'promising', 'systemic', 'delivery', 'vehicle', 'pdl1', 'targeting', 'specificity', 'favorable', 'pharmacokinetic', 'properties', 'bresultsb', 'demonstrated', 'pegmp9apdl1driven', 'oncolysis', 'induces', 'panel', 'immunogenic', 'cell', 'death', 'icdrelevant', 'damageassociated', 'molecular', 'patterns', 'damps', 'iin', 'vitroi', 'iin', 'vivoi', 'key', 'elements', 'immunotherapy', 'pdl1', 'inhibitor', 'pegmp9apdl1', 'exhibited', 'prominent', 'immunotherapeutic', 'efficacy', 'crc', 'mouse', 'model', 'characterized', 'tumor', 'infiltration', 'cd8', 'cells', 'induction', 'cytotoxic', 'lymphocytes', 'ctls', 'spleens', 'bconclusionb', 'findings', 'suggest', 'pegmp9apdl1', 'allinone', 'platform', 'oncolytic', 'immunotherapy', 'immune', 'checkpoint', 'blockade', 'icb']","['crc', 'crc', 'metalloproteinase2', 'mmp2', 'crc']","['metalloproteinase2', 'mmp2']",True,"['tumor', 'cancer']"
35477128,FDFT1/FGFR2 rearrangement: A newly identified anlotinib-sensitive FGFR2 variant in cholangiocarcinoma.,"According to previous reports,10-16% of patients with clinically advanced cholangiocarcinoma develop FGFR2 fusions or rearrangements. Treatment with FGFR2-specific inhibitors (tyrosine kinase inhibitors, TKIs) has proven effective for patients with cholangiocarcinoma. In this study, we report a case of advanced cholangiocarcinoma, in which the patient was unable to tolerate the adverse effects of standard first-line chemotherapy. Genetic testing suggested the presence of a novel variant resulting from FDFT1/FGFR2 rearrangement. Owing to poor accessibility and high price, only a limited number of patients with advanced cholangiocarcinoma have access to TKIs and precision targeted therapy in China. Anlotinib is a novel small-molecule multi-target TKI developed independently in China. It has a broad target spectrum, including FGFR, and can effectively inhibit tumor angiogenesis and tumor cell proliferation, thereby achieving an anti-tumor effect. Here, the patient was prescribed anlotinib. After treatment, the tumor size continued to shrink, and no significant adverse effects were reported. The finding suggested that anlotinib may be effective in patients with FDFT1/FGFR2 rearrangement and could serve as a novel treatment option for affected patients in future.",2022-04-20,according to previous reports1016 of patients with clinically advanced cholangiocarcinoma develop fgfr2 fusions or rearrangements treatment with fgfr2specific inhibitors tyrosine kinase inhibitors tkis has proven effective for patients with cholangiocarcinoma in this study we report a case of advanced cholangiocarcinoma in which the patient was unable to tolerate the adverse effects of standard firstline chemotherapy genetic testing suggested the presence of a novel variant resulting from fdft1fgfr2 rearrangement owing to poor accessibility and high price only a limited number of patients with advanced cholangiocarcinoma have access to tkis and precision targeted therapy in china anlotinib is a novel smallmolecule multitarget tki developed independently in china it has a broad target spectrum including fgfr and can effectively inhibit tumor angiogenesis and tumor cell proliferation thereby achieving an antitumor effect here the patient was prescribed anlotinib after treatment the tumor size continued to shrink and no significant adverse effects were reported the finding suggested that anlotinib may be effective in patients with fdft1fgfr2 rearrangement and could serve as a novel treatment option for affected patients in future,"['according', 'to', 'previous', 'reports1016', 'of', 'patients', 'with', 'clinically', 'advanced', 'cholangiocarcinoma', 'develop', 'fgfr2', 'fusions', 'or', 'rearrangements', 'treatment', 'with', 'fgfr2specific', 'inhibitors', 'tyrosine', 'kinase', 'inhibitors', 'tkis', 'has', 'proven', 'effective', 'for', 'patients', 'with', 'cholangiocarcinoma', 'in', 'this', 'study', 'we', 'report', 'a', 'case', 'of', 'advanced', 'cholangiocarcinoma', 'in', 'which', 'the', 'patient', 'was', 'unable', 'to', 'tolerate', 'the', 'adverse', 'effects', 'of', 'standard', 'firstline', 'chemotherapy', 'genetic', 'testing', 'suggested', 'the', 'presence', 'of', 'a', 'novel', 'variant', 'resulting', 'from', 'fdft1fgfr2', 'rearrangement', 'owing', 'to', 'poor', 'accessibility', 'and', 'high', 'price', 'only', 'a', 'limited', 'number', 'of', 'patients', 'with', 'advanced', 'cholangiocarcinoma', 'have', 'access', 'to', 'tkis', 'and', 'precision', 'targeted', 'therapy', 'in', 'china', 'anlotinib', 'is', 'a', 'novel', 'smallmolecule', 'multitarget', 'tki', 'developed', 'independently', 'in', 'china', 'it', 'has', 'a', 'broad', 'target', 'spectrum', 'including', 'fgfr', 'and', 'can', 'effectively', 'inhibit', 'tumor', 'angiogenesis', 'and', 'tumor', 'cell', 'proliferation', 'thereby', 'achieving', 'an', 'antitumor', 'effect', 'here', 'the', 'patient', 'was', 'prescribed', 'anlotinib', 'after', 'treatment', 'the', 'tumor', 'size', 'continued', 'to', 'shrink', 'and', 'no', 'significant', 'adverse', 'effects', 'were', 'reported', 'the', 'finding', 'suggested', 'that', 'anlotinib', 'may', 'be', 'effective', 'in', 'patients', 'with', 'fdft1fgfr2', 'rearrangement', 'and', 'could', 'serve', 'as', 'a', 'novel', 'treatment', 'option', 'for', 'affected', 'patients', 'in', 'future']","['according', 'previous', 'reports1016', 'patients', 'clinically', 'advanced', 'cholangiocarcinoma', 'develop', 'fgfr2', 'fusions', 'rearrangements', 'treatment', 'fgfr2specific', 'inhibitors', 'tyrosine', 'kinase', 'inhibitors', 'tkis', 'proven', 'effective', 'patients', 'cholangiocarcinoma', 'study', 'report', 'case', 'advanced', 'cholangiocarcinoma', 'patient', 'unable', 'tolerate', 'adverse', 'effects', 'standard', 'firstline', 'chemotherapy', 'genetic', 'testing', 'suggested', 'presence', 'novel', 'variant', 'resulting', 'fdft1fgfr2', 'rearrangement', 'owing', 'poor', 'accessibility', 'high', 'price', 'limited', 'number', 'patients', 'advanced', 'cholangiocarcinoma', 'access', 'tkis', 'precision', 'targeted', 'therapy', 'china', 'anlotinib', 'novel', 'smallmolecule', 'multitarget', 'tki', 'developed', 'independently', 'china', 'broad', 'target', 'spectrum', 'including', 'fgfr', 'effectively', 'inhibit', 'tumor', 'angiogenesis', 'tumor', 'cell', 'proliferation', 'thereby', 'achieving', 'antitumor', 'effect', 'patient', 'prescribed', 'anlotinib', 'treatment', 'tumor', 'size', 'continued', 'shrink', 'significant', 'adverse', 'effects', 'reported', 'finding', 'suggested', 'anlotinib', 'may', 'effective', 'patients', 'fdft1fgfr2', 'rearrangement', 'could', 'serve', 'novel', 'treatment', 'option', 'affected', 'patients', 'future']","['fgfr2', 'fgfr']",['fgfr2'],True,['tumor']
35476173,A Novel Peptide Isolated from Microalgae Isochrysis zhanjiangensis Exhibits Anti-apoptosis and Anti-inflammation in Ox-LDL Induced HUVEC to Improve Atherosclerosis.,"In the early stage, oxidized low density lipoprotein (ox-LDL) caused atherosclerosis, followed by human umbilical vein endothelial cells (HUVEC) damage, leading to a variety of cardiovascular related diseases. This study investigated the mechanism of nonapeptide (EMFGTSSET, ETT) isolated from in vitro gastrointestinal digestion of Isochrysis zhanjiang on endothelial cell inflammation and apoptosis induced by ox-LDL in atherosclerosis. At the cellular level, the results shown that ETT inhibited the up-regulation of oxidized low-density lipoprotein receptor-1 (LOX-1) induced by ox-LDL. Furthermore, ETT inhibited the fluorescence intensity of ROS, inflammatory factors (interleukin-6, interleukin-1β, and tumor necrosis factor-α) and the expression of cell adhesion molecules (vascular cell adhesion protein 1 and intercellular cell adhesion molecule-1). In addition, it also upregulates nuclear red blood cell 2 related factor 2 (Nrf2), heme oxygenase-1 (HO -1), p-Akt, and bcl-2 levels. But down-regulated the expression of p-p65, p-IκB-α, p-p38, p-ERK, p-JNK, bax, and cleaved caspase-9/-3 (c-c-9/-3), thereby inhibited ox-LDL induction inflammation and apoptosis of atherosclerosis. Through molecular docking, it was judged that the stable interaction between ETT and LOX-1 and VCAM-1 was maintained through hydrogen bonding. These results can provide a theoretical basis for ETT as a potential substance for the prevention and treatment of atherosclerosis, and further improve the value of Isochrysis zhanjiangensis.",2022-04-27,in the early stage oxidized low density lipoprotein oxldl caused atherosclerosis followed by human umbilical vein endothelial cells huvec damage leading to a variety of cardiovascular related diseases this study investigated the mechanism of nonapeptide emfgtsset ett isolated from in vitro gastrointestinal digestion of isochrysis zhanjiang on endothelial cell inflammation and apoptosis induced by oxldl in atherosclerosis at the cellular level the results shown that ett inhibited the upregulation of oxidized lowdensity lipoprotein receptor1 lox1 induced by oxldl furthermore ett inhibited the fluorescence intensity of ros inflammatory factors interleukin6 interleukin1β and tumor necrosis factorα and the expression of cell adhesion molecules vascular cell adhesion protein 1 and intercellular cell adhesion molecule1 in addition it also upregulates nuclear red blood cell 2 related factor 2 nrf2 heme oxygenase1 ho 1 pakt and bcl2 levels but downregulated the expression of pp65 piκbα pp38 perk pjnk bax and cleaved caspase93 cc93 thereby inhibited oxldl induction inflammation and apoptosis of atherosclerosis through molecular docking it was judged that the stable interaction between ett and lox1 and vcam1 was maintained through hydrogen bonding these results can provide a theoretical basis for ett as a potential substance for the prevention and treatment of atherosclerosis and further improve the value of isochrysis zhanjiangensis,"['in', 'the', 'early', 'stage', 'oxidized', 'low', 'density', 'lipoprotein', 'oxldl', 'caused', 'atherosclerosis', 'followed', 'by', 'human', 'umbilical', 'vein', 'endothelial', 'cells', 'huvec', 'damage', 'leading', 'to', 'a', 'variety', 'of', 'cardiovascular', 'related', 'diseases', 'this', 'study', 'investigated', 'the', 'mechanism', 'of', 'nonapeptide', 'emfgtsset', 'ett', 'isolated', 'from', 'in', 'vitro', 'gastrointestinal', 'digestion', 'of', 'isochrysis', 'zhanjiang', 'on', 'endothelial', 'cell', 'inflammation', 'and', 'apoptosis', 'induced', 'by', 'oxldl', 'in', 'atherosclerosis', 'at', 'the', 'cellular', 'level', 'the', 'results', 'shown', 'that', 'ett', 'inhibited', 'the', 'upregulation', 'of', 'oxidized', 'lowdensity', 'lipoprotein', 'receptor1', 'lox1', 'induced', 'by', 'oxldl', 'furthermore', 'ett', 'inhibited', 'the', 'fluorescence', 'intensity', 'of', 'ros', 'inflammatory', 'factors', 'interleukin6', 'interleukin1β', 'and', 'tumor', 'necrosis', 'factorα', 'and', 'the', 'expression', 'of', 'cell', 'adhesion', 'molecules', 'vascular', 'cell', 'adhesion', 'protein', '1', 'and', 'intercellular', 'cell', 'adhesion', 'molecule1', 'in', 'addition', 'it', 'also', 'upregulates', 'nuclear', 'red', 'blood', 'cell', '2', 'related', 'factor', '2', 'nrf2', 'heme', 'oxygenase1', 'ho', '1', 'pakt', 'and', 'bcl2', 'levels', 'but', 'downregulated', 'the', 'expression', 'of', 'pp65', 'piκbα', 'pp38', 'perk', 'pjnk', 'bax', 'and', 'cleaved', 'caspase93', 'cc93', 'thereby', 'inhibited', 'oxldl', 'induction', 'inflammation', 'and', 'apoptosis', 'of', 'atherosclerosis', 'through', 'molecular', 'docking', 'it', 'was', 'judged', 'that', 'the', 'stable', 'interaction', 'between', 'ett', 'and', 'lox1', 'and', 'vcam1', 'was', 'maintained', 'through', 'hydrogen', 'bonding', 'these', 'results', 'can', 'provide', 'a', 'theoretical', 'basis', 'for', 'ett', 'as', 'a', 'potential', 'substance', 'for', 'the', 'prevention', 'and', 'treatment', 'of', 'atherosclerosis', 'and', 'further', 'improve', 'the', 'value', 'of', 'isochrysis', 'zhanjiangensis']","['early', 'stage', 'oxidized', 'low', 'density', 'lipoprotein', 'oxldl', 'caused', 'atherosclerosis', 'followed', 'human', 'umbilical', 'vein', 'endothelial', 'cells', 'huvec', 'damage', 'leading', 'variety', 'cardiovascular', 'related', 'diseases', 'study', 'investigated', 'mechanism', 'nonapeptide', 'emfgtsset', 'ett', 'isolated', 'vitro', 'gastrointestinal', 'digestion', 'isochrysis', 'zhanjiang', 'endothelial', 'cell', 'inflammation', 'apoptosis', 'induced', 'oxldl', 'atherosclerosis', 'cellular', 'level', 'results', 'shown', 'ett', 'inhibited', 'upregulation', 'oxidized', 'lowdensity', 'lipoprotein', 'receptor1', 'lox1', 'induced', 'oxldl', 'furthermore', 'ett', 'inhibited', 'fluorescence', 'intensity', 'ros', 'inflammatory', 'factors', 'interleukin6', 'interleukin1β', 'tumor', 'necrosis', 'factorα', 'expression', 'cell', 'adhesion', 'molecules', 'vascular', 'cell', 'adhesion', 'protein', '1', 'intercellular', 'cell', 'adhesion', 'molecule1', 'addition', 'also', 'upregulates', 'nuclear', 'red', 'blood', 'cell', '2', 'related', 'factor', '2', 'nrf2', 'heme', 'oxygenase1', 'ho', '1', 'pakt', 'bcl2', 'levels', 'downregulated', 'expression', 'pp65', 'piκbα', 'pp38', 'perk', 'pjnk', 'bax', 'cleaved', 'caspase93', 'cc93', 'thereby', 'inhibited', 'oxldl', 'induction', 'inflammation', 'apoptosis', 'atherosclerosis', 'molecular', 'docking', 'judged', 'stable', 'interaction', 'ett', 'lox1', 'vcam1', 'maintained', 'hydrogen', 'bonding', 'results', 'provide', 'theoretical', 'basis', 'ett', 'potential', 'substance', 'prevention', 'treatment', 'atherosclerosis', 'improve', 'value', 'isochrysis', 'zhanjiangensis']","['ros', 'interleukin6', 'nrf2', 'oxygenase1', 'bcl2', 'pp65', 'pp38', 'bax']",['oxygenase1'],True,['tumor']
35460923,A high-throughput screening assay for mutant isocitrate dehydrogenase 1 using acoustic droplet ejection mass spectrometry.,"Acoustic droplet ejection mass spectrometry (ADE-MS) has recently emerged as a promising label-free, MS-based readout method for high throughput screening (HTS) campaigns in early pharmaceutical drug discovery, since it enables high-speed analysis directly from 384- or 1536-well plates. In this manuscript we describe our characterization of an ADE-MS based high sample content enzymatic assay for mutant isocitrate dehydrogenase 1 (IDH1) R132H with a strong focus on assay development. IDH1 R132H has become a very attractive therapeutic target in the field of antitumor drug discovery, and several pharmaceutical companies have attempted to develop novel small molecule inhibitors against mutant IDH1. With the development of an mIDH1 ADE-MS based HTS assay and a detailed comparison of this new readout technique to the commonly used fluorescence intensity mIDH1 assay, we demonstrated good correlation of both methods and were able to identify new potent inhibitors of mIDH1.",2022-04-20,acoustic droplet ejection mass spectrometry adems has recently emerged as a promising labelfree msbased readout method for high throughput screening hts campaigns in early pharmaceutical drug discovery since it enables highspeed analysis directly from 384 or 1536well plates in this manuscript we describe our characterization of an adems based high sample content enzymatic assay for mutant isocitrate dehydrogenase 1 idh1 r132h with a strong focus on assay development idh1 r132h has become a very attractive therapeutic target in the field of antitumor drug discovery and several pharmaceutical companies have attempted to develop novel small molecule inhibitors against mutant idh1 with the development of an midh1 adems based hts assay and a detailed comparison of this new readout technique to the commonly used fluorescence intensity midh1 assay we demonstrated good correlation of both methods and were able to identify new potent inhibitors of midh1,"['acoustic', 'droplet', 'ejection', 'mass', 'spectrometry', 'adems', 'has', 'recently', 'emerged', 'as', 'a', 'promising', 'labelfree', 'msbased', 'readout', 'method', 'for', 'high', 'throughput', 'screening', 'hts', 'campaigns', 'in', 'early', 'pharmaceutical', 'drug', 'discovery', 'since', 'it', 'enables', 'highspeed', 'analysis', 'directly', 'from', '384', 'or', '1536well', 'plates', 'in', 'this', 'manuscript', 'we', 'describe', 'our', 'characterization', 'of', 'an', 'adems', 'based', 'high', 'sample', 'content', 'enzymatic', 'assay', 'for', 'mutant', 'isocitrate', 'dehydrogenase', '1', 'idh1', 'r132h', 'with', 'a', 'strong', 'focus', 'on', 'assay', 'development', 'idh1', 'r132h', 'has', 'become', 'a', 'very', 'attractive', 'therapeutic', 'target', 'in', 'the', 'field', 'of', 'antitumor', 'drug', 'discovery', 'and', 'several', 'pharmaceutical', 'companies', 'have', 'attempted', 'to', 'develop', 'novel', 'small', 'molecule', 'inhibitors', 'against', 'mutant', 'idh1', 'with', 'the', 'development', 'of', 'an', 'midh1', 'adems', 'based', 'hts', 'assay', 'and', 'a', 'detailed', 'comparison', 'of', 'this', 'new', 'readout', 'technique', 'to', 'the', 'commonly', 'used', 'fluorescence', 'intensity', 'midh1', 'assay', 'we', 'demonstrated', 'good', 'correlation', 'of', 'both', 'methods', 'and', 'were', 'able', 'to', 'identify', 'new', 'potent', 'inhibitors', 'of', 'midh1']","['acoustic', 'droplet', 'ejection', 'mass', 'spectrometry', 'adems', 'recently', 'emerged', 'promising', 'labelfree', 'msbased', 'readout', 'method', 'high', 'throughput', 'screening', 'hts', 'campaigns', 'early', 'pharmaceutical', 'drug', 'discovery', 'since', 'enables', 'highspeed', 'analysis', 'directly', '384', '1536well', 'plates', 'manuscript', 'describe', 'characterization', 'adems', 'based', 'high', 'sample', 'content', 'enzymatic', 'assay', 'mutant', 'isocitrate', 'dehydrogenase', '1', 'idh1', 'r132h', 'strong', 'focus', 'assay', 'development', 'idh1', 'r132h', 'become', 'attractive', 'therapeutic', 'target', 'field', 'antitumor', 'drug', 'discovery', 'several', 'pharmaceutical', 'companies', 'attempted', 'develop', 'novel', 'small', 'molecule', 'inhibitors', 'mutant', 'idh1', 'development', 'midh1', 'adems', 'based', 'hts', 'assay', 'detailed', 'comparison', 'new', 'readout', 'technique', 'commonly', 'used', 'fluorescence', 'intensity', 'midh1', 'assay', 'demonstrated', 'good', 'correlation', 'methods', 'able', 'identify', 'new', 'potent', 'inhibitors', 'midh1']","['idh1', 'idh1', 'idh1']","['idh1', 'idh1', 'idh1']",True,['tumor']
35359589,Mechanism of Peptide Agonist Binding in CXCR4 Chemokine Receptor.,"Chemokine receptors are key G-protein-coupled receptors (GPCRs) that control cell migration in immune system responses, development of cardiovascular and central nervous systems, and numerous diseases. In particular, the CXCR4 chemokine receptor promotes metastasis, tumor growth and angiogenesis in cancers. CXCR4 is also used as one of the two co-receptors for T-tropic HIV-1 entry into host cells. Therefore, CXCR4 serves as an important therapeutic target for treating cancers and HIV infection. Apart from the CXCL12 endogenous peptide agonist, previous studies suggested that the first 17 amino acids of CXCL12 are sufficient to activate CXCR4. Two 17-residue peptides with positions 1-4 mutated to RSVM and ASLW functioned as super and partial agonists of CXCR4, respectively. However, the mechanism of peptide agonist binding in CXCR4 remains unclear. Here, we have investigated this mechanism through all-atom simulations using a novel Peptide Gaussian accelerated molecular dynamics (Pep-GaMD) method. The Pep-GaMD simulations have allowed us to explore representative binding conformations of each peptide and identify critical low-energy states of CXCR4 activated by the super versus partial peptide agonists. Our simulations have provided important mechanistic insights into peptide agonist binding in CXCR4, which are expected to facilitate rational design of new peptide modulators of CXCR4 and other chemokine receptors.",2022-03-11,chemokine receptors are key gproteincoupled receptors gpcrs that control cell migration in immune system responses development of cardiovascular and central nervous systems and numerous diseases in particular the cxcr4 chemokine receptor promotes metastasis tumor growth and angiogenesis in cancers cxcr4 is also used as one of the two coreceptors for ttropic hiv1 entry into host cells therefore cxcr4 serves as an important therapeutic target for treating cancers and hiv infection apart from the cxcl12 endogenous peptide agonist previous studies suggested that the first 17 amino acids of cxcl12 are sufficient to activate cxcr4 two 17residue peptides with positions 14 mutated to rsvm and aslw functioned as super and partial agonists of cxcr4 respectively however the mechanism of peptide agonist binding in cxcr4 remains unclear here we have investigated this mechanism through allatom simulations using a novel peptide gaussian accelerated molecular dynamics pepgamd method the pepgamd simulations have allowed us to explore representative binding conformations of each peptide and identify critical lowenergy states of cxcr4 activated by the super versus partial peptide agonists our simulations have provided important mechanistic insights into peptide agonist binding in cxcr4 which are expected to facilitate rational design of new peptide modulators of cxcr4 and other chemokine receptors,"['chemokine', 'receptors', 'are', 'key', 'gproteincoupled', 'receptors', 'gpcrs', 'that', 'control', 'cell', 'migration', 'in', 'immune', 'system', 'responses', 'development', 'of', 'cardiovascular', 'and', 'central', 'nervous', 'systems', 'and', 'numerous', 'diseases', 'in', 'particular', 'the', 'cxcr4', 'chemokine', 'receptor', 'promotes', 'metastasis', 'tumor', 'growth', 'and', 'angiogenesis', 'in', 'cancers', 'cxcr4', 'is', 'also', 'used', 'as', 'one', 'of', 'the', 'two', 'coreceptors', 'for', 'ttropic', 'hiv1', 'entry', 'into', 'host', 'cells', 'therefore', 'cxcr4', 'serves', 'as', 'an', 'important', 'therapeutic', 'target', 'for', 'treating', 'cancers', 'and', 'hiv', 'infection', 'apart', 'from', 'the', 'cxcl12', 'endogenous', 'peptide', 'agonist', 'previous', 'studies', 'suggested', 'that', 'the', 'first', '17', 'amino', 'acids', 'of', 'cxcl12', 'are', 'sufficient', 'to', 'activate', 'cxcr4', 'two', '17residue', 'peptides', 'with', 'positions', '14', 'mutated', 'to', 'rsvm', 'and', 'aslw', 'functioned', 'as', 'super', 'and', 'partial', 'agonists', 'of', 'cxcr4', 'respectively', 'however', 'the', 'mechanism', 'of', 'peptide', 'agonist', 'binding', 'in', 'cxcr4', 'remains', 'unclear', 'here', 'we', 'have', 'investigated', 'this', 'mechanism', 'through', 'allatom', 'simulations', 'using', 'a', 'novel', 'peptide', 'gaussian', 'accelerated', 'molecular', 'dynamics', 'pepgamd', 'method', 'the', 'pepgamd', 'simulations', 'have', 'allowed', 'us', 'to', 'explore', 'representative', 'binding', 'conformations', 'of', 'each', 'peptide', 'and', 'identify', 'critical', 'lowenergy', 'states', 'of', 'cxcr4', 'activated', 'by', 'the', 'super', 'versus', 'partial', 'peptide', 'agonists', 'our', 'simulations', 'have', 'provided', 'important', 'mechanistic', 'insights', 'into', 'peptide', 'agonist', 'binding', 'in', 'cxcr4', 'which', 'are', 'expected', 'to', 'facilitate', 'rational', 'design', 'of', 'new', 'peptide', 'modulators', 'of', 'cxcr4', 'and', 'other', 'chemokine', 'receptors']","['chemokine', 'receptors', 'key', 'gproteincoupled', 'receptors', 'gpcrs', 'control', 'cell', 'migration', 'immune', 'system', 'responses', 'development', 'cardiovascular', 'central', 'nervous', 'systems', 'numerous', 'diseases', 'particular', 'cxcr4', 'chemokine', 'receptor', 'promotes', 'metastasis', 'tumor', 'growth', 'angiogenesis', 'cancers', 'cxcr4', 'also', 'used', 'one', 'two', 'coreceptors', 'ttropic', 'hiv1', 'entry', 'host', 'cells', 'therefore', 'cxcr4', 'serves', 'important', 'therapeutic', 'target', 'treating', 'cancers', 'hiv', 'infection', 'apart', 'cxcl12', 'endogenous', 'peptide', 'agonist', 'previous', 'studies', 'suggested', 'first', '17', 'amino', 'acids', 'cxcl12', 'sufficient', 'activate', 'cxcr4', 'two', '17residue', 'peptides', 'positions', '14', 'mutated', 'rsvm', 'aslw', 'functioned', 'super', 'partial', 'agonists', 'cxcr4', 'respectively', 'however', 'mechanism', 'peptide', 'agonist', 'binding', 'cxcr4', 'remains', 'unclear', 'investigated', 'mechanism', 'allatom', 'simulations', 'using', 'novel', 'peptide', 'gaussian', 'accelerated', 'molecular', 'dynamics', 'pepgamd', 'method', 'pepgamd', 'simulations', 'allowed', 'us', 'explore', 'representative', 'binding', 'conformations', 'peptide', 'identify', 'critical', 'lowenergy', 'states', 'cxcr4', 'activated', 'super', 'versus', 'partial', 'peptide', 'agonists', 'simulations', 'provided', 'important', 'mechanistic', 'insights', 'peptide', 'agonist', 'binding', 'cxcr4', 'expected', 'facilitate', 'rational', 'design', 'new', 'peptide', 'modulators', 'cxcr4', 'chemokine', 'receptors']","['cxcr4', 'cxcr4', 'cxcr4', 'cxcl12', 'cxcl12', 'cxcr4', 'cxcr4', 'cxcr4', 'cxcr4', 'cxcr4', 'cxcr4']","['cxcl12', 'cxcl12']",True,"['tumor', 'infection', 'cancer']"
35357812,O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies.,"Neurodegenerative proteinopathies are characterized by the intracellular formation of insoluble and toxic protein aggregates in the brain that are closely linked to disease progression. In Alzheimer's disease and in rare tauopathies, aggregation of the microtubule-associated tau protein leads to the formation of neurofibrillary tangles (NFT). In Parkinson's disease (PD) and other α-synucleinopathies, intracellular Lewy bodies containing aggregates of α-synuclein constitute the pathological hallmark. Inhibition of the glycoside hydrolase O-GlcNAcase (OGA) prevents the removal of O-linked <i>N</i>-acetyl-d-glucosamine (O-GlcNAc) moieties from intracellular proteins and has emerged as an attractive therapeutic approach to prevent the formation of tau pathology. Like tau, α-synuclein is known to be modified with O-GlcNAc moieties and <i>in vitro</i> these have been shown to prevent its aggregation and toxicity. Here, we report the preclinical discovery and development of a novel small molecule OGA inhibitor, ASN90. Consistent with the substantial exposure of the drug and demonstrating target engagement in the brain, the clinical OGA inhibitor ASN90 promoted the O-GlcNAcylation of tau and α-synuclein in brains of transgenic mice after daily oral dosing. Across human tauopathy mouse models, oral administration of ASN90 prevented the development of tau pathology (NFT formation), functional deficits in motor behavior and breathing, and increased survival. In addition, ASN90 slowed the progression of motor impairment and reduced astrogliosis in a frequently utilized α-synuclein-dependent preclinical rodent model of PD. These findings provide a strong rationale for the development of OGA inhibitors as disease-modifying agents in both tauopathies and α-synucleinopathies. Since tau and α-synuclein pathologies frequently co-exist in neurodegenerative diseases, OGA inhibitors represent unique, multimodal drug candidates for further clinical development.",2022-03-31,neurodegenerative proteinopathies are characterized by the intracellular formation of insoluble and toxic protein aggregates in the brain that are closely linked to disease progression in alzheimers disease and in rare tauopathies aggregation of the microtubuleassociated tau protein leads to the formation of neurofibrillary tangles nft in parkinsons disease pd and other αsynucleinopathies intracellular lewy bodies containing aggregates of αsynuclein constitute the pathological hallmark inhibition of the glycoside hydrolase oglcnacase oga prevents the removal of olinked iniacetyldglucosamine oglcnac moieties from intracellular proteins and has emerged as an attractive therapeutic approach to prevent the formation of tau pathology like tau αsynuclein is known to be modified with oglcnac moieties and iin vitroi these have been shown to prevent its aggregation and toxicity here we report the preclinical discovery and development of a novel small molecule oga inhibitor asn90 consistent with the substantial exposure of the drug and demonstrating target engagement in the brain the clinical oga inhibitor asn90 promoted the oglcnacylation of tau and αsynuclein in brains of transgenic mice after daily oral dosing across human tauopathy mouse models oral administration of asn90 prevented the development of tau pathology nft formation functional deficits in motor behavior and breathing and increased survival in addition asn90 slowed the progression of motor impairment and reduced astrogliosis in a frequently utilized αsynucleindependent preclinical rodent model of pd these findings provide a strong rationale for the development of oga inhibitors as diseasemodifying agents in both tauopathies and αsynucleinopathies since tau and αsynuclein pathologies frequently coexist in neurodegenerative diseases oga inhibitors represent unique multimodal drug candidates for further clinical development,"['neurodegenerative', 'proteinopathies', 'are', 'characterized', 'by', 'the', 'intracellular', 'formation', 'of', 'insoluble', 'and', 'toxic', 'protein', 'aggregates', 'in', 'the', 'brain', 'that', 'are', 'closely', 'linked', 'to', 'disease', 'progression', 'in', 'alzheimers', 'disease', 'and', 'in', 'rare', 'tauopathies', 'aggregation', 'of', 'the', 'microtubuleassociated', 'tau', 'protein', 'leads', 'to', 'the', 'formation', 'of', 'neurofibrillary', 'tangles', 'nft', 'in', 'parkinsons', 'disease', 'pd', 'and', 'other', 'αsynucleinopathies', 'intracellular', 'lewy', 'bodies', 'containing', 'aggregates', 'of', 'αsynuclein', 'constitute', 'the', 'pathological', 'hallmark', 'inhibition', 'of', 'the', 'glycoside', 'hydrolase', 'oglcnacase', 'oga', 'prevents', 'the', 'removal', 'of', 'olinked', 'iniacetyldglucosamine', 'oglcnac', 'moieties', 'from', 'intracellular', 'proteins', 'and', 'has', 'emerged', 'as', 'an', 'attractive', 'therapeutic', 'approach', 'to', 'prevent', 'the', 'formation', 'of', 'tau', 'pathology', 'like', 'tau', 'αsynuclein', 'is', 'known', 'to', 'be', 'modified', 'with', 'oglcnac', 'moieties', 'and', 'iin', 'vitroi', 'these', 'have', 'been', 'shown', 'to', 'prevent', 'its', 'aggregation', 'and', 'toxicity', 'here', 'we', 'report', 'the', 'preclinical', 'discovery', 'and', 'development', 'of', 'a', 'novel', 'small', 'molecule', 'oga', 'inhibitor', 'asn90', 'consistent', 'with', 'the', 'substantial', 'exposure', 'of', 'the', 'drug', 'and', 'demonstrating', 'target', 'engagement', 'in', 'the', 'brain', 'the', 'clinical', 'oga', 'inhibitor', 'asn90', 'promoted', 'the', 'oglcnacylation', 'of', 'tau', 'and', 'αsynuclein', 'in', 'brains', 'of', 'transgenic', 'mice', 'after', 'daily', 'oral', 'dosing', 'across', 'human', 'tauopathy', 'mouse', 'models', 'oral', 'administration', 'of', 'asn90', 'prevented', 'the', 'development', 'of', 'tau', 'pathology', 'nft', 'formation', 'functional', 'deficits', 'in', 'motor', 'behavior', 'and', 'breathing', 'and', 'increased', 'survival', 'in', 'addition', 'asn90', 'slowed', 'the', 'progression', 'of', 'motor', 'impairment', 'and', 'reduced', 'astrogliosis', 'in', 'a', 'frequently', 'utilized', 'αsynucleindependent', 'preclinical', 'rodent', 'model', 'of', 'pd', 'these', 'findings', 'provide', 'a', 'strong', 'rationale', 'for', 'the', 'development', 'of', 'oga', 'inhibitors', 'as', 'diseasemodifying', 'agents', 'in', 'both', 'tauopathies', 'and', 'αsynucleinopathies', 'since', 'tau', 'and', 'αsynuclein', 'pathologies', 'frequently', 'coexist', 'in', 'neurodegenerative', 'diseases', 'oga', 'inhibitors', 'represent', 'unique', 'multimodal', 'drug', 'candidates', 'for', 'further', 'clinical', 'development']","['neurodegenerative', 'proteinopathies', 'characterized', 'intracellular', 'formation', 'insoluble', 'toxic', 'protein', 'aggregates', 'brain', 'closely', 'linked', 'disease', 'progression', 'alzheimers', 'disease', 'rare', 'tauopathies', 'aggregation', 'microtubuleassociated', 'tau', 'protein', 'leads', 'formation', 'neurofibrillary', 'tangles', 'nft', 'parkinsons', 'disease', 'pd', 'αsynucleinopathies', 'intracellular', 'lewy', 'bodies', 'containing', 'aggregates', 'αsynuclein', 'constitute', 'pathological', 'hallmark', 'inhibition', 'glycoside', 'hydrolase', 'oglcnacase', 'oga', 'prevents', 'removal', 'olinked', 'iniacetyldglucosamine', 'oglcnac', 'moieties', 'intracellular', 'proteins', 'emerged', 'attractive', 'therapeutic', 'approach', 'prevent', 'formation', 'tau', 'pathology', 'like', 'tau', 'αsynuclein', 'known', 'modified', 'oglcnac', 'moieties', 'iin', 'vitroi', 'shown', 'prevent', 'aggregation', 'toxicity', 'report', 'preclinical', 'discovery', 'development', 'novel', 'small', 'molecule', 'oga', 'inhibitor', 'asn90', 'consistent', 'substantial', 'exposure', 'drug', 'demonstrating', 'target', 'engagement', 'brain', 'clinical', 'oga', 'inhibitor', 'asn90', 'promoted', 'oglcnacylation', 'tau', 'αsynuclein', 'brains', 'transgenic', 'mice', 'daily', 'oral', 'dosing', 'across', 'human', 'tauopathy', 'mouse', 'models', 'oral', 'administration', 'asn90', 'prevented', 'development', 'tau', 'pathology', 'nft', 'formation', 'functional', 'deficits', 'motor', 'behavior', 'breathing', 'increased', 'survival', 'addition', 'asn90', 'slowed', 'progression', 'motor', 'impairment', 'reduced', 'astrogliosis', 'frequently', 'utilized', 'αsynucleindependent', 'preclinical', 'rodent', 'model', 'pd', 'findings', 'provide', 'strong', 'rationale', 'development', 'oga', 'inhibitors', 'diseasemodifying', 'agents', 'tauopathies', 'αsynucleinopathies', 'since', 'tau', 'αsynuclein', 'pathologies', 'frequently', 'coexist', 'neurodegenerative', 'diseases', 'oga', 'inhibitors', 'represent', 'unique', 'multimodal', 'drug', 'candidates', 'clinical', 'development']","['proteinopathies', 'tau', 'tau', 'tau', 'tau', 'tau', 'tau']",['proteinopathies'],True,"['parkinson', 'alzheimer']"
35339985,Novel Small Molecule Fibroblast Growth Factor 23 Inhibitors Increase Serum Phosphate and Improve Skeletal Abnormalities in <i>Hyp</i> Mice.,"Excess fibroblast growth factor (FGF) 23 causes hereditary hypophosphatemic rickets, such as X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO). A small molecule that specifically binds to FGF23 to prevent activation of the fibroblast growth factor receptor/<i>α</i>-Klotho complex has potential advantages over the currently approved systemically administered FGF23 blocking antibody. Using structure-based drug design, we previously identified ZINC13407541 (N-[[2-(2-phenylethenyl)cyclopenten-1-yl]methylidene]hydroxylamine) as a small molecule antagonist for FGF23. Additional structure-activity studies developed a series of ZINC13407541 analogs with enhanced drug-like properties. In this study, we tested in a preclinical <i>Hyp</i> mouse homolog of XLH a direct connect analog [(<i>E</i>)-2-(4-(<i>tert</i>-butyl)phenyl)cyclopent-1-ene-1-carbaldehyde oxime] (<b>8n</b>), which exhibited the greatest stability in microsomal assays, and [(<i>E</i>)-2-((<i>E</i>)-4-methylstyryl)benzaldehyde oxime] (<b>13a</b>), which exhibited increased in vitro potency. Using cryo-electron microscopy structure and computational docking, we identified a key binding residue (Q156) of the FGF23 antagonists, ZINC13407541, and its analogs (<b>8n</b> and <b>13a</b>) in the N-terminal domain of FGF23 protein. Site-directed mutagenesis and bimolecular fluorescence complementation-fluorescence resonance energy transfer assay confirmed the binding site of these three antagonists. We found that pharmacological inhibition of FGF23 with either of these compounds blocked FGF23 signaling and increased serum phosphate and 1,25-dihydroxyvitamin D [1,25(OH)<sub>2</sub>D] concentrations in <i>Hyp</i> mice. Long-term parenteral treatment with <b>8n</b> or <b>13a</b> also enhanced linear bone growth, increased mineralization of bone, and narrowed the growth plate in <i>Hyp</i> mice. The more potent <b>13a</b> compound had greater therapeutic effects in <i>Hyp</i> mice. Further optimization of these FGF23 inhibitors may lead to versatile drugs to treat excess FGF23-mediated disorders. SIGNIFICANCE STATEMENT: This study used structure-based drug design and medicinal chemistry approaches to identify and optimize small molecules with different stability and potency, which antagonize excessive actions of fibroblast growth factor 23 (FGF23) in hereditary hypophosphatemic rickets. The findings confirmed that these antagonists bind to the N-terminus of FGF23 to inhibit its binding to and activation of the fibroblast growth factor receptors/α-Klotho signaling complex. Administration of these lead compounds improved phosphate homeostasis and abnormal skeletal phenotypes in a preclinical <i>Hyp</i> mouse model.",2022-03-26,excess fibroblast growth factor fgf 23 causes hereditary hypophosphatemic rickets such as xlinked hypophosphatemia xlh and tumorinduced osteomalacia tio a small molecule that specifically binds to fgf23 to prevent activation of the fibroblast growth factor receptoriαiklotho complex has potential advantages over the currently approved systemically administered fgf23 blocking antibody using structurebased drug design we previously identified zinc13407541 n22phenylethenylcyclopenten1ylmethylidenehydroxylamine as a small molecule antagonist for fgf23 additional structureactivity studies developed a series of zinc13407541 analogs with enhanced druglike properties in this study we tested in a preclinical ihypi mouse homolog of xlh a direct connect analog iei24itertibutylphenylcyclopent1ene1carbaldehyde oxime b8nb which exhibited the greatest stability in microsomal assays and iei2iei4methylstyrylbenzaldehyde oxime b13ab which exhibited increased in vitro potency using cryoelectron microscopy structure and computational docking we identified a key binding residue q156 of the fgf23 antagonists zinc13407541 and its analogs b8nb and b13ab in the nterminal domain of fgf23 protein sitedirected mutagenesis and bimolecular fluorescence complementationfluorescence resonance energy transfer assay confirmed the binding site of these three antagonists we found that pharmacological inhibition of fgf23 with either of these compounds blocked fgf23 signaling and increased serum phosphate and 125dihydroxyvitamin d 125ohsub2subd concentrations in ihypi mice longterm parenteral treatment with b8nb or b13ab also enhanced linear bone growth increased mineralization of bone and narrowed the growth plate in ihypi mice the more potent b13ab compound had greater therapeutic effects in ihypi mice further optimization of these fgf23 inhibitors may lead to versatile drugs to treat excess fgf23mediated disorders significance statement this study used structurebased drug design and medicinal chemistry approaches to identify and optimize small molecules with different stability and potency which antagonize excessive actions of fibroblast growth factor 23 fgf23 in hereditary hypophosphatemic rickets the findings confirmed that these antagonists bind to the nterminus of fgf23 to inhibit its binding to and activation of the fibroblast growth factor receptorsαklotho signaling complex administration of these lead compounds improved phosphate homeostasis and abnormal skeletal phenotypes in a preclinical ihypi mouse model,"['excess', 'fibroblast', 'growth', 'factor', 'fgf', '23', 'causes', 'hereditary', 'hypophosphatemic', 'rickets', 'such', 'as', 'xlinked', 'hypophosphatemia', 'xlh', 'and', 'tumorinduced', 'osteomalacia', 'tio', 'a', 'small', 'molecule', 'that', 'specifically', 'binds', 'to', 'fgf23', 'to', 'prevent', 'activation', 'of', 'the', 'fibroblast', 'growth', 'factor', 'receptoriαiklotho', 'complex', 'has', 'potential', 'advantages', 'over', 'the', 'currently', 'approved', 'systemically', 'administered', 'fgf23', 'blocking', 'antibody', 'using', 'structurebased', 'drug', 'design', 'we', 'previously', 'identified', 'zinc13407541', 'n22phenylethenylcyclopenten1ylmethylidenehydroxylamine', 'as', 'a', 'small', 'molecule', 'antagonist', 'for', 'fgf23', 'additional', 'structureactivity', 'studies', 'developed', 'a', 'series', 'of', 'zinc13407541', 'analogs', 'with', 'enhanced', 'druglike', 'properties', 'in', 'this', 'study', 'we', 'tested', 'in', 'a', 'preclinical', 'ihypi', 'mouse', 'homolog', 'of', 'xlh', 'a', 'direct', 'connect', 'analog', 'iei24itertibutylphenylcyclopent1ene1carbaldehyde', 'oxime', 'b8nb', 'which', 'exhibited', 'the', 'greatest', 'stability', 'in', 'microsomal', 'assays', 'and', 'iei2iei4methylstyrylbenzaldehyde', 'oxime', 'b13ab', 'which', 'exhibited', 'increased', 'in', 'vitro', 'potency', 'using', 'cryoelectron', 'microscopy', 'structure', 'and', 'computational', 'docking', 'we', 'identified', 'a', 'key', 'binding', 'residue', 'q156', 'of', 'the', 'fgf23', 'antagonists', 'zinc13407541', 'and', 'its', 'analogs', 'b8nb', 'and', 'b13ab', 'in', 'the', 'nterminal', 'domain', 'of', 'fgf23', 'protein', 'sitedirected', 'mutagenesis', 'and', 'bimolecular', 'fluorescence', 'complementationfluorescence', 'resonance', 'energy', 'transfer', 'assay', 'confirmed', 'the', 'binding', 'site', 'of', 'these', 'three', 'antagonists', 'we', 'found', 'that', 'pharmacological', 'inhibition', 'of', 'fgf23', 'with', 'either', 'of', 'these', 'compounds', 'blocked', 'fgf23', 'signaling', 'and', 'increased', 'serum', 'phosphate', 'and', '125dihydroxyvitamin', 'd', '125ohsub2subd', 'concentrations', 'in', 'ihypi', 'mice', 'longterm', 'parenteral', 'treatment', 'with', 'b8nb', 'or', 'b13ab', 'also', 'enhanced', 'linear', 'bone', 'growth', 'increased', 'mineralization', 'of', 'bone', 'and', 'narrowed', 'the', 'growth', 'plate', 'in', 'ihypi', 'mice', 'the', 'more', 'potent', 'b13ab', 'compound', 'had', 'greater', 'therapeutic', 'effects', 'in', 'ihypi', 'mice', 'further', 'optimization', 'of', 'these', 'fgf23', 'inhibitors', 'may', 'lead', 'to', 'versatile', 'drugs', 'to', 'treat', 'excess', 'fgf23mediated', 'disorders', 'significance', 'statement', 'this', 'study', 'used', 'structurebased', 'drug', 'design', 'and', 'medicinal', 'chemistry', 'approaches', 'to', 'identify', 'and', 'optimize', 'small', 'molecules', 'with', 'different', 'stability', 'and', 'potency', 'which', 'antagonize', 'excessive', 'actions', 'of', 'fibroblast', 'growth', 'factor', '23', 'fgf23', 'in', 'hereditary', 'hypophosphatemic', 'rickets', 'the', 'findings', 'confirmed', 'that', 'these', 'antagonists', 'bind', 'to', 'the', 'nterminus', 'of', 'fgf23', 'to', 'inhibit', 'its', 'binding', 'to', 'and', 'activation', 'of', 'the', 'fibroblast', 'growth', 'factor', 'receptorsαklotho', 'signaling', 'complex', 'administration', 'of', 'these', 'lead', 'compounds', 'improved', 'phosphate', 'homeostasis', 'and', 'abnormal', 'skeletal', 'phenotypes', 'in', 'a', 'preclinical', 'ihypi', 'mouse', 'model']","['excess', 'fibroblast', 'growth', 'factor', 'fgf', '23', 'causes', 'hereditary', 'hypophosphatemic', 'rickets', 'xlinked', 'hypophosphatemia', 'xlh', 'tumorinduced', 'osteomalacia', 'tio', 'small', 'molecule', 'specifically', 'binds', 'fgf23', 'prevent', 'activation', 'fibroblast', 'growth', 'factor', 'receptoriαiklotho', 'complex', 'potential', 'advantages', 'currently', 'approved', 'systemically', 'administered', 'fgf23', 'blocking', 'antibody', 'using', 'structurebased', 'drug', 'design', 'previously', 'identified', 'zinc13407541', 'n22phenylethenylcyclopenten1ylmethylidenehydroxylamine', 'small', 'molecule', 'antagonist', 'fgf23', 'additional', 'structureactivity', 'studies', 'developed', 'series', 'zinc13407541', 'analogs', 'enhanced', 'druglike', 'properties', 'study', 'tested', 'preclinical', 'ihypi', 'mouse', 'homolog', 'xlh', 'direct', 'connect', 'analog', 'iei24itertibutylphenylcyclopent1ene1carbaldehyde', 'oxime', 'b8nb', 'exhibited', 'greatest', 'stability', 'microsomal', 'assays', 'iei2iei4methylstyrylbenzaldehyde', 'oxime', 'b13ab', 'exhibited', 'increased', 'vitro', 'potency', 'using', 'cryoelectron', 'microscopy', 'structure', 'computational', 'docking', 'identified', 'key', 'binding', 'residue', 'q156', 'fgf23', 'antagonists', 'zinc13407541', 'analogs', 'b8nb', 'b13ab', 'nterminal', 'domain', 'fgf23', 'protein', 'sitedirected', 'mutagenesis', 'bimolecular', 'fluorescence', 'complementationfluorescence', 'resonance', 'energy', 'transfer', 'assay', 'confirmed', 'binding', 'site', 'three', 'antagonists', 'found', 'pharmacological', 'inhibition', 'fgf23', 'either', 'compounds', 'blocked', 'fgf23', 'signaling', 'increased', 'serum', 'phosphate', '125dihydroxyvitamin', '125ohsub2subd', 'concentrations', 'ihypi', 'mice', 'longterm', 'parenteral', 'treatment', 'b8nb', 'b13ab', 'also', 'enhanced', 'linear', 'bone', 'growth', 'increased', 'mineralization', 'bone', 'narrowed', 'growth', 'plate', 'ihypi', 'mice', 'potent', 'b13ab', 'compound', 'greater', 'therapeutic', 'effects', 'ihypi', 'mice', 'optimization', 'fgf23', 'inhibitors', 'may', 'lead', 'versatile', 'drugs', 'treat', 'excess', 'fgf23mediated', 'disorders', 'significance', 'statement', 'study', 'used', 'structurebased', 'drug', 'design', 'medicinal', 'chemistry', 'approaches', 'identify', 'optimize', 'small', 'molecules', 'different', 'stability', 'potency', 'antagonize', 'excessive', 'actions', 'fibroblast', 'growth', 'factor', '23', 'fgf23', 'hereditary', 'hypophosphatemic', 'rickets', 'findings', 'confirmed', 'antagonists', 'bind', 'nterminus', 'fgf23', 'inhibit', 'binding', 'activation', 'fibroblast', 'growth', 'factor', 'receptorsαklotho', 'signaling', 'complex', 'administration', 'lead', 'compounds', 'improved', 'phosphate', 'homeostasis', 'abnormal', 'skeletal', 'phenotypes', 'preclinical', 'ihypi', 'mouse', 'model']","['fgf', 'tio', 'fgf23', 'fgf23', 'fgf23', 'fgf23', 'fgf23', 'fgf23', 'fgf23', 'fgf23', 'fgf23', 'fgf23']","['fgf23', 'fgf23', 'fgf23', 'fgf23', 'fgf23', 'fgf23', 'fgf23', 'fgf23', 'fgf23', 'fgf23']",True,['tumor']
35260876,"Screening and identification of a novel antidiabetic peptide from collagen hydrolysates of Chinese giant salamander skin: network pharmacology, inhibition kinetics and protection of IR-HepG2 cells.","In this study, a novel peptide GPPGPA was screened from the collagen hydrolysates of Chinese giant salamander (<i>Andrias davidianus</i>) skin, and its anti-diabetes mechanism was predicted by network pharmacology, and an inhibitory effect on α-glycosidase and protective effect on IR (insulin resistance) and oxidative stress of IR-HepG2 cells were detected. Through network pharmacology screening, GPPGPA was found to have good drug-like properties, and 103 targets of GPPGPA overlap with T2DM targets. These targets were mainly enriched in the PI3K-Akt signaling pathway associated with T2DM, the AGE-RAGE signaling pathway in diabetic complications, the TNF signaling pathway, insulin resistance and so on. The core targets were identified as AKT1, MAPK8, MAPK10 and JUN by constructing a ""peptide-target-pathway"" network. The molecular docking results showed that GPPGPA was well bound to the core targets. These results suggested that GPPGPA had the potential to reduce T2DM. Further <i>in vitro</i> experiments showed that GPPGPA as a competitive inhibitor could effectively inhibit the activity of α-glucosidase. The results of the IR-HepG2 cell model experiments showed that GPPGPA was not toxic to HepG2 cells, and could reduce IR of HepG2 cells induced by high-glucose and high-insulin, improve glucose consumption, increase the activity of superoxide dismutase (SOD), and reduce the content of malondialdehyde (MDA). The above results suggested that GPPGPA could improve T2DM by reducing insulin resistance through a multi-target and multi-pathway mechanism. GPPGPA could be developed and utilized as a novel hyperglycemic inhibitor in functional food.",2022-03-21,in this study a novel peptide gppgpa was screened from the collagen hydrolysates of chinese giant salamander iandrias davidianusi skin and its antidiabetes mechanism was predicted by network pharmacology and an inhibitory effect on αglycosidase and protective effect on ir insulin resistance and oxidative stress of irhepg2 cells were detected through network pharmacology screening gppgpa was found to have good druglike properties and 103 targets of gppgpa overlap with t2dm targets these targets were mainly enriched in the pi3kakt signaling pathway associated with t2dm the agerage signaling pathway in diabetic complications the tnf signaling pathway insulin resistance and so on the core targets were identified as akt1 mapk8 mapk10 and jun by constructing a peptidetargetpathway network the molecular docking results showed that gppgpa was well bound to the core targets these results suggested that gppgpa had the potential to reduce t2dm further iin vitroi experiments showed that gppgpa as a competitive inhibitor could effectively inhibit the activity of αglucosidase the results of the irhepg2 cell model experiments showed that gppgpa was not toxic to hepg2 cells and could reduce ir of hepg2 cells induced by highglucose and highinsulin improve glucose consumption increase the activity of superoxide dismutase sod and reduce the content of malondialdehyde mda the above results suggested that gppgpa could improve t2dm by reducing insulin resistance through a multitarget and multipathway mechanism gppgpa could be developed and utilized as a novel hyperglycemic inhibitor in functional food,"['in', 'this', 'study', 'a', 'novel', 'peptide', 'gppgpa', 'was', 'screened', 'from', 'the', 'collagen', 'hydrolysates', 'of', 'chinese', 'giant', 'salamander', 'iandrias', 'davidianusi', 'skin', 'and', 'its', 'antidiabetes', 'mechanism', 'was', 'predicted', 'by', 'network', 'pharmacology', 'and', 'an', 'inhibitory', 'effect', 'on', 'αglycosidase', 'and', 'protective', 'effect', 'on', 'ir', 'insulin', 'resistance', 'and', 'oxidative', 'stress', 'of', 'irhepg2', 'cells', 'were', 'detected', 'through', 'network', 'pharmacology', 'screening', 'gppgpa', 'was', 'found', 'to', 'have', 'good', 'druglike', 'properties', 'and', '103', 'targets', 'of', 'gppgpa', 'overlap', 'with', 't2dm', 'targets', 'these', 'targets', 'were', 'mainly', 'enriched', 'in', 'the', 'pi3kakt', 'signaling', 'pathway', 'associated', 'with', 't2dm', 'the', 'agerage', 'signaling', 'pathway', 'in', 'diabetic', 'complications', 'the', 'tnf', 'signaling', 'pathway', 'insulin', 'resistance', 'and', 'so', 'on', 'the', 'core', 'targets', 'were', 'identified', 'as', 'akt1', 'mapk8', 'mapk10', 'and', 'jun', 'by', 'constructing', 'a', 'peptidetargetpathway', 'network', 'the', 'molecular', 'docking', 'results', 'showed', 'that', 'gppgpa', 'was', 'well', 'bound', 'to', 'the', 'core', 'targets', 'these', 'results', 'suggested', 'that', 'gppgpa', 'had', 'the', 'potential', 'to', 'reduce', 't2dm', 'further', 'iin', 'vitroi', 'experiments', 'showed', 'that', 'gppgpa', 'as', 'a', 'competitive', 'inhibitor', 'could', 'effectively', 'inhibit', 'the', 'activity', 'of', 'αglucosidase', 'the', 'results', 'of', 'the', 'irhepg2', 'cell', 'model', 'experiments', 'showed', 'that', 'gppgpa', 'was', 'not', 'toxic', 'to', 'hepg2', 'cells', 'and', 'could', 'reduce', 'ir', 'of', 'hepg2', 'cells', 'induced', 'by', 'highglucose', 'and', 'highinsulin', 'improve', 'glucose', 'consumption', 'increase', 'the', 'activity', 'of', 'superoxide', 'dismutase', 'sod', 'and', 'reduce', 'the', 'content', 'of', 'malondialdehyde', 'mda', 'the', 'above', 'results', 'suggested', 'that', 'gppgpa', 'could', 'improve', 't2dm', 'by', 'reducing', 'insulin', 'resistance', 'through', 'a', 'multitarget', 'and', 'multipathway', 'mechanism', 'gppgpa', 'could', 'be', 'developed', 'and', 'utilized', 'as', 'a', 'novel', 'hyperglycemic', 'inhibitor', 'in', 'functional', 'food']","['study', 'novel', 'peptide', 'gppgpa', 'screened', 'collagen', 'hydrolysates', 'chinese', 'giant', 'salamander', 'iandrias', 'davidianusi', 'skin', 'antidiabetes', 'mechanism', 'predicted', 'network', 'pharmacology', 'inhibitory', 'effect', 'αglycosidase', 'protective', 'effect', 'ir', 'insulin', 'resistance', 'oxidative', 'stress', 'irhepg2', 'cells', 'detected', 'network', 'pharmacology', 'screening', 'gppgpa', 'found', 'good', 'druglike', 'properties', '103', 'targets', 'gppgpa', 'overlap', 't2dm', 'targets', 'targets', 'mainly', 'enriched', 'pi3kakt', 'signaling', 'pathway', 'associated', 't2dm', 'agerage', 'signaling', 'pathway', 'diabetic', 'complications', 'tnf', 'signaling', 'pathway', 'insulin', 'resistance', 'core', 'targets', 'identified', 'akt1', 'mapk8', 'mapk10', 'jun', 'constructing', 'peptidetargetpathway', 'network', 'molecular', 'docking', 'results', 'showed', 'gppgpa', 'well', 'bound', 'core', 'targets', 'results', 'suggested', 'gppgpa', 'potential', 'reduce', 't2dm', 'iin', 'vitroi', 'experiments', 'showed', 'gppgpa', 'competitive', 'inhibitor', 'could', 'effectively', 'inhibit', 'activity', 'αglucosidase', 'results', 'irhepg2', 'cell', 'model', 'experiments', 'showed', 'gppgpa', 'toxic', 'hepg2', 'cells', 'could', 'reduce', 'ir', 'hepg2', 'cells', 'induced', 'highglucose', 'highinsulin', 'improve', 'glucose', 'consumption', 'increase', 'activity', 'superoxide', 'dismutase', 'sod', 'reduce', 'content', 'malondialdehyde', 'mda', 'results', 'suggested', 'gppgpa', 'could', 'improve', 't2dm', 'reducing', 'insulin', 'resistance', 'multitarget', 'multipathway', 'mechanism', 'gppgpa', 'could', 'developed', 'utilized', 'novel', 'hyperglycemic', 'inhibitor', 'functional', 'food']","['collagen', 'insulin', 'tnf', 'insulin', 'mapk8', 'jun', 'sod', 'insulin']",['mapk8'],True,['diabetes']
35251350,Inhibiting mutant KRAS G12D gene expression using novel peptide nucleic acid-based antisense: A potential new drug candidate for pancreatic cancer.,"KRAS mutations, which are the main cause of the pathogenesis of lethal pancreatic adenocarcinomas, impair the functioning of the GTPase subunit, thus rendering it constitutively active and signaling intracellular pathways that end with cell transformation. In the present study, the AsPC-1 cell line, which has a G12D-mutated KRAS gene sequence, was utilized as a cellular model to test peptide nucleic acid-based antisense technology. The use of peptide nucleic acids (PNAs) that are built to exhibit improved hybridization specificity and have an affinity for complementary RNA and DNA sequences, as well as a simple chemical structure and high biological stability that affords resistance to nucleases and proteases, enabled targeting of the KRAS-mutated gene to inhibit its expression at the translation level. Because PNA-based antisense molecules should be capable of binding to KRAS mRNA sequences, PNAs were utilized to target the mRNA of the mutated KRAS gene, a strategy that could lead to the development of a novel drug for pancreatic cancer. Moreover, it was demonstrated that introducing new PNA to cells inhibited the growth of cancer cells and induced apoptotic death and, notably, that it can inhibit G12D-mutated KRAS gene expression, as demonstrated by RT-PCR and western blotting. Altogether, these data strongly suggest that the use of PNA-based antisense agents is an attractive therapeutic approach to treating KRAS-driven cancers and may lead to the development of novel drugs that target the expression of other mutated genes.",2022-02-21,kras mutations which are the main cause of the pathogenesis of lethal pancreatic adenocarcinomas impair the functioning of the gtpase subunit thus rendering it constitutively active and signaling intracellular pathways that end with cell transformation in the present study the aspc1 cell line which has a g12dmutated kras gene sequence was utilized as a cellular model to test peptide nucleic acidbased antisense technology the use of peptide nucleic acids pnas that are built to exhibit improved hybridization specificity and have an affinity for complementary rna and dna sequences as well as a simple chemical structure and high biological stability that affords resistance to nucleases and proteases enabled targeting of the krasmutated gene to inhibit its expression at the translation level because pnabased antisense molecules should be capable of binding to kras mrna sequences pnas were utilized to target the mrna of the mutated kras gene a strategy that could lead to the development of a novel drug for pancreatic cancer moreover it was demonstrated that introducing new pna to cells inhibited the growth of cancer cells and induced apoptotic death and notably that it can inhibit g12dmutated kras gene expression as demonstrated by rtpcr and western blotting altogether these data strongly suggest that the use of pnabased antisense agents is an attractive therapeutic approach to treating krasdriven cancers and may lead to the development of novel drugs that target the expression of other mutated genes,"['kras', 'mutations', 'which', 'are', 'the', 'main', 'cause', 'of', 'the', 'pathogenesis', 'of', 'lethal', 'pancreatic', 'adenocarcinomas', 'impair', 'the', 'functioning', 'of', 'the', 'gtpase', 'subunit', 'thus', 'rendering', 'it', 'constitutively', 'active', 'and', 'signaling', 'intracellular', 'pathways', 'that', 'end', 'with', 'cell', 'transformation', 'in', 'the', 'present', 'study', 'the', 'aspc1', 'cell', 'line', 'which', 'has', 'a', 'g12dmutated', 'kras', 'gene', 'sequence', 'was', 'utilized', 'as', 'a', 'cellular', 'model', 'to', 'test', 'peptide', 'nucleic', 'acidbased', 'antisense', 'technology', 'the', 'use', 'of', 'peptide', 'nucleic', 'acids', 'pnas', 'that', 'are', 'built', 'to', 'exhibit', 'improved', 'hybridization', 'specificity', 'and', 'have', 'an', 'affinity', 'for', 'complementary', 'rna', 'and', 'dna', 'sequences', 'as', 'well', 'as', 'a', 'simple', 'chemical', 'structure', 'and', 'high', 'biological', 'stability', 'that', 'affords', 'resistance', 'to', 'nucleases', 'and', 'proteases', 'enabled', 'targeting', 'of', 'the', 'krasmutated', 'gene', 'to', 'inhibit', 'its', 'expression', 'at', 'the', 'translation', 'level', 'because', 'pnabased', 'antisense', 'molecules', 'should', 'be', 'capable', 'of', 'binding', 'to', 'kras', 'mrna', 'sequences', 'pnas', 'were', 'utilized', 'to', 'target', 'the', 'mrna', 'of', 'the', 'mutated', 'kras', 'gene', 'a', 'strategy', 'that', 'could', 'lead', 'to', 'the', 'development', 'of', 'a', 'novel', 'drug', 'for', 'pancreatic', 'cancer', 'moreover', 'it', 'was', 'demonstrated', 'that', 'introducing', 'new', 'pna', 'to', 'cells', 'inhibited', 'the', 'growth', 'of', 'cancer', 'cells', 'and', 'induced', 'apoptotic', 'death', 'and', 'notably', 'that', 'it', 'can', 'inhibit', 'g12dmutated', 'kras', 'gene', 'expression', 'as', 'demonstrated', 'by', 'rtpcr', 'and', 'western', 'blotting', 'altogether', 'these', 'data', 'strongly', 'suggest', 'that', 'the', 'use', 'of', 'pnabased', 'antisense', 'agents', 'is', 'an', 'attractive', 'therapeutic', 'approach', 'to', 'treating', 'krasdriven', 'cancers', 'and', 'may', 'lead', 'to', 'the', 'development', 'of', 'novel', 'drugs', 'that', 'target', 'the', 'expression', 'of', 'other', 'mutated', 'genes']","['kras', 'mutations', 'main', 'cause', 'pathogenesis', 'lethal', 'pancreatic', 'adenocarcinomas', 'impair', 'functioning', 'gtpase', 'subunit', 'thus', 'rendering', 'constitutively', 'active', 'signaling', 'intracellular', 'pathways', 'end', 'cell', 'transformation', 'present', 'study', 'aspc1', 'cell', 'line', 'g12dmutated', 'kras', 'gene', 'sequence', 'utilized', 'cellular', 'model', 'test', 'peptide', 'nucleic', 'acidbased', 'antisense', 'technology', 'use', 'peptide', 'nucleic', 'acids', 'pnas', 'built', 'exhibit', 'improved', 'hybridization', 'specificity', 'affinity', 'complementary', 'rna', 'dna', 'sequences', 'well', 'simple', 'chemical', 'structure', 'high', 'biological', 'stability', 'affords', 'resistance', 'nucleases', 'proteases', 'enabled', 'targeting', 'krasmutated', 'gene', 'inhibit', 'expression', 'translation', 'level', 'pnabased', 'antisense', 'molecules', 'capable', 'binding', 'kras', 'mrna', 'sequences', 'pnas', 'utilized', 'target', 'mrna', 'mutated', 'kras', 'gene', 'strategy', 'could', 'lead', 'development', 'novel', 'drug', 'pancreatic', 'cancer', 'moreover', 'demonstrated', 'introducing', 'new', 'pna', 'cells', 'inhibited', 'growth', 'cancer', 'cells', 'induced', 'apoptotic', 'death', 'notably', 'inhibit', 'g12dmutated', 'kras', 'gene', 'expression', 'demonstrated', 'rtpcr', 'western', 'blotting', 'altogether', 'data', 'strongly', 'suggest', 'use', 'pnabased', 'antisense', 'agents', 'attractive', 'therapeutic', 'approach', 'treating', 'krasdriven', 'cancers', 'may', 'lead', 'development', 'novel', 'drugs', 'target', 'expression', 'mutated', 'genes']",['gtpase'],['gtpase'],True,['cancer']
35245627,SS-4 is a highly selective small molecule inhibitor of STAT3 tyrosine phosphorylation that potently inhibits GBM tumorigenesis in vitro and in vivo.,"Glioblastoma (GBM) is a highly aggressive cancer with a dismal prognosis. Constitutively active STAT3 has a causal role in GBM progression and is associated with poor patient survival. We rationally designed a novel small molecule, SS-4, by computational modeling to specifically interact with STAT3. SS-4 strongly and selectively inhibited STAT3 tyrosine (Y)-705 phosphorylation in MT330 and LN229 GBM cells and inhibited their proliferation and induced apoptosis with an IC<sub>50</sub> of ∼100 nM. The antiproliferative and apoptotic actions of SS-4 were Y-705 phosphorylation dependent, as evidenced by its lack of effects on STAT3 knockout (STAT3<sup>KO</sup>) cells or STAT3<sup>KO</sup> cells that overexpressed a phospho-Y705 deficient (STAT3Y705F) mutant, and the recovery of effects when wild-type STAT3 or a phospho-serine (S)727 deficient mutant was expressed in STAT3<sup>KO</sup> cells. SS-4 increased the expression of STAT3 repressed genes, while decreasing the expression of STAT3 promoted genes. Importantly, SS-4 markedly reduced the growth of GBM intracranial tumor xenografts. These data together identify SS-4 as a potent STAT3 inhibitor that selectively blocks Y705-phosphorylation, induces apoptosis, and inhibits growth of human GBM models in vitro and in vivo.",2022-03-01,glioblastoma gbm is a highly aggressive cancer with a dismal prognosis constitutively active stat3 has a causal role in gbm progression and is associated with poor patient survival we rationally designed a novel small molecule ss4 by computational modeling to specifically interact with stat3 ss4 strongly and selectively inhibited stat3 tyrosine y705 phosphorylation in mt330 and ln229 gbm cells and inhibited their proliferation and induced apoptosis with an icsub50sub of 100 nm the antiproliferative and apoptotic actions of ss4 were y705 phosphorylation dependent as evidenced by its lack of effects on stat3 knockout stat3supkosup cells or stat3supkosup cells that overexpressed a phosphoy705 deficient stat3y705f mutant and the recovery of effects when wildtype stat3 or a phosphoserine s727 deficient mutant was expressed in stat3supkosup cells ss4 increased the expression of stat3 repressed genes while decreasing the expression of stat3 promoted genes importantly ss4 markedly reduced the growth of gbm intracranial tumor xenografts these data together identify ss4 as a potent stat3 inhibitor that selectively blocks y705phosphorylation induces apoptosis and inhibits growth of human gbm models in vitro and in vivo,"['glioblastoma', 'gbm', 'is', 'a', 'highly', 'aggressive', 'cancer', 'with', 'a', 'dismal', 'prognosis', 'constitutively', 'active', 'stat3', 'has', 'a', 'causal', 'role', 'in', 'gbm', 'progression', 'and', 'is', 'associated', 'with', 'poor', 'patient', 'survival', 'we', 'rationally', 'designed', 'a', 'novel', 'small', 'molecule', 'ss4', 'by', 'computational', 'modeling', 'to', 'specifically', 'interact', 'with', 'stat3', 'ss4', 'strongly', 'and', 'selectively', 'inhibited', 'stat3', 'tyrosine', 'y705', 'phosphorylation', 'in', 'mt330', 'and', 'ln229', 'gbm', 'cells', 'and', 'inhibited', 'their', 'proliferation', 'and', 'induced', 'apoptosis', 'with', 'an', 'icsub50sub', 'of', '100', 'nm', 'the', 'antiproliferative', 'and', 'apoptotic', 'actions', 'of', 'ss4', 'were', 'y705', 'phosphorylation', 'dependent', 'as', 'evidenced', 'by', 'its', 'lack', 'of', 'effects', 'on', 'stat3', 'knockout', 'stat3supkosup', 'cells', 'or', 'stat3supkosup', 'cells', 'that', 'overexpressed', 'a', 'phosphoy705', 'deficient', 'stat3y705f', 'mutant', 'and', 'the', 'recovery', 'of', 'effects', 'when', 'wildtype', 'stat3', 'or', 'a', 'phosphoserine', 's727', 'deficient', 'mutant', 'was', 'expressed', 'in', 'stat3supkosup', 'cells', 'ss4', 'increased', 'the', 'expression', 'of', 'stat3', 'repressed', 'genes', 'while', 'decreasing', 'the', 'expression', 'of', 'stat3', 'promoted', 'genes', 'importantly', 'ss4', 'markedly', 'reduced', 'the', 'growth', 'of', 'gbm', 'intracranial', 'tumor', 'xenografts', 'these', 'data', 'together', 'identify', 'ss4', 'as', 'a', 'potent', 'stat3', 'inhibitor', 'that', 'selectively', 'blocks', 'y705phosphorylation', 'induces', 'apoptosis', 'and', 'inhibits', 'growth', 'of', 'human', 'gbm', 'models', 'in', 'vitro', 'and', 'in', 'vivo']","['glioblastoma', 'gbm', 'highly', 'aggressive', 'cancer', 'dismal', 'prognosis', 'constitutively', 'active', 'stat3', 'causal', 'role', 'gbm', 'progression', 'associated', 'poor', 'patient', 'survival', 'rationally', 'designed', 'novel', 'small', 'molecule', 'ss4', 'computational', 'modeling', 'specifically', 'interact', 'stat3', 'ss4', 'strongly', 'selectively', 'inhibited', 'stat3', 'tyrosine', 'y705', 'phosphorylation', 'mt330', 'ln229', 'gbm', 'cells', 'inhibited', 'proliferation', 'induced', 'apoptosis', 'icsub50sub', '100', 'nm', 'antiproliferative', 'apoptotic', 'actions', 'ss4', 'y705', 'phosphorylation', 'dependent', 'evidenced', 'lack', 'effects', 'stat3', 'knockout', 'stat3supkosup', 'cells', 'stat3supkosup', 'cells', 'overexpressed', 'phosphoy705', 'deficient', 'stat3y705f', 'mutant', 'recovery', 'effects', 'wildtype', 'stat3', 'phosphoserine', 's727', 'deficient', 'mutant', 'expressed', 'stat3supkosup', 'cells', 'ss4', 'increased', 'expression', 'stat3', 'repressed', 'genes', 'decreasing', 'expression', 'stat3', 'promoted', 'genes', 'importantly', 'ss4', 'markedly', 'reduced', 'growth', 'gbm', 'intracranial', 'tumor', 'xenografts', 'data', 'together', 'identify', 'ss4', 'potent', 'stat3', 'inhibitor', 'selectively', 'blocks', 'y705phosphorylation', 'induces', 'apoptosis', 'inhibits', 'growth', 'human', 'gbm', 'models', 'vitro', 'vivo']","['stat3', 'stat3', 'stat3', 'stat3', 'stat3', 's727', 'stat3', 'stat3', 'stat3']",['s727'],True,"['tumor', 'cancer']"
35202743,Albumin metabolism targeted peptide-drug conjugate strategy for targeting pan-KRAS mutant cancer.,"Despite recent breakthroughs in the development of direct KRAS inhibitors and modulators, no drugs targeting pan-KRAS mutant cancers are clinically available. Here, we report a novel strategy to treat pan-KRAS cancers using a caspase-3 cleavable peptide-drug conjugate that exploits enhanced albumin metabolism in KRAS altered cancers to deliver a cytotoxic agent that can induce a widespread bystander killing effect in tumor cells. Increased albumin metabolism in KRAS mutant cancer cells induced apoptosis via the intracellular uptake of albumin-bound MPD1. This allowed caspase-3 upregulation activated MPD1 to release the payload and exert the non-selective killing of neighboring cancer cells. MPD1 exhibited potent and durable antitumor efficacy in mouse xenograft models with different KRAS genotypes. An augmentation of anti-cancer efficacy was achieved by the bystander killing effect derived from the caspase-3 mediated activation of MPD1. In summary, albumin metabolism-induced apoptosis, together with the bystander killing effect of MPD1 boosted by caspase-3 mediated activation, intensified the efficacy of MPD1 in KRAS mutant cancers. These findings suggest that this novel peptide-drug conjugate could be a promising breakthrough for the treatment in the targeting of pan-KRAS mutant cancers.",2022-02-22,despite recent breakthroughs in the development of direct kras inhibitors and modulators no drugs targeting pankras mutant cancers are clinically available here we report a novel strategy to treat pankras cancers using a caspase3 cleavable peptidedrug conjugate that exploits enhanced albumin metabolism in kras altered cancers to deliver a cytotoxic agent that can induce a widespread bystander killing effect in tumor cells increased albumin metabolism in kras mutant cancer cells induced apoptosis via the intracellular uptake of albuminbound mpd1 this allowed caspase3 upregulation activated mpd1 to release the payload and exert the nonselective killing of neighboring cancer cells mpd1 exhibited potent and durable antitumor efficacy in mouse xenograft models with different kras genotypes an augmentation of anticancer efficacy was achieved by the bystander killing effect derived from the caspase3 mediated activation of mpd1 in summary albumin metabolisminduced apoptosis together with the bystander killing effect of mpd1 boosted by caspase3 mediated activation intensified the efficacy of mpd1 in kras mutant cancers these findings suggest that this novel peptidedrug conjugate could be a promising breakthrough for the treatment in the targeting of pankras mutant cancers,"['despite', 'recent', 'breakthroughs', 'in', 'the', 'development', 'of', 'direct', 'kras', 'inhibitors', 'and', 'modulators', 'no', 'drugs', 'targeting', 'pankras', 'mutant', 'cancers', 'are', 'clinically', 'available', 'here', 'we', 'report', 'a', 'novel', 'strategy', 'to', 'treat', 'pankras', 'cancers', 'using', 'a', 'caspase3', 'cleavable', 'peptidedrug', 'conjugate', 'that', 'exploits', 'enhanced', 'albumin', 'metabolism', 'in', 'kras', 'altered', 'cancers', 'to', 'deliver', 'a', 'cytotoxic', 'agent', 'that', 'can', 'induce', 'a', 'widespread', 'bystander', 'killing', 'effect', 'in', 'tumor', 'cells', 'increased', 'albumin', 'metabolism', 'in', 'kras', 'mutant', 'cancer', 'cells', 'induced', 'apoptosis', 'via', 'the', 'intracellular', 'uptake', 'of', 'albuminbound', 'mpd1', 'this', 'allowed', 'caspase3', 'upregulation', 'activated', 'mpd1', 'to', 'release', 'the', 'payload', 'and', 'exert', 'the', 'nonselective', 'killing', 'of', 'neighboring', 'cancer', 'cells', 'mpd1', 'exhibited', 'potent', 'and', 'durable', 'antitumor', 'efficacy', 'in', 'mouse', 'xenograft', 'models', 'with', 'different', 'kras', 'genotypes', 'an', 'augmentation', 'of', 'anticancer', 'efficacy', 'was', 'achieved', 'by', 'the', 'bystander', 'killing', 'effect', 'derived', 'from', 'the', 'caspase3', 'mediated', 'activation', 'of', 'mpd1', 'in', 'summary', 'albumin', 'metabolisminduced', 'apoptosis', 'together', 'with', 'the', 'bystander', 'killing', 'effect', 'of', 'mpd1', 'boosted', 'by', 'caspase3', 'mediated', 'activation', 'intensified', 'the', 'efficacy', 'of', 'mpd1', 'in', 'kras', 'mutant', 'cancers', 'these', 'findings', 'suggest', 'that', 'this', 'novel', 'peptidedrug', 'conjugate', 'could', 'be', 'a', 'promising', 'breakthrough', 'for', 'the', 'treatment', 'in', 'the', 'targeting', 'of', 'pankras', 'mutant', 'cancers']","['despite', 'recent', 'breakthroughs', 'development', 'direct', 'kras', 'inhibitors', 'modulators', 'drugs', 'targeting', 'pankras', 'mutant', 'cancers', 'clinically', 'available', 'report', 'novel', 'strategy', 'treat', 'pankras', 'cancers', 'using', 'caspase3', 'cleavable', 'peptidedrug', 'conjugate', 'exploits', 'enhanced', 'albumin', 'metabolism', 'kras', 'altered', 'cancers', 'deliver', 'cytotoxic', 'agent', 'induce', 'widespread', 'bystander', 'killing', 'effect', 'tumor', 'cells', 'increased', 'albumin', 'metabolism', 'kras', 'mutant', 'cancer', 'cells', 'induced', 'apoptosis', 'via', 'intracellular', 'uptake', 'albuminbound', 'mpd1', 'allowed', 'caspase3', 'upregulation', 'activated', 'mpd1', 'release', 'payload', 'exert', 'nonselective', 'killing', 'neighboring', 'cancer', 'cells', 'mpd1', 'exhibited', 'potent', 'durable', 'antitumor', 'efficacy', 'mouse', 'xenograft', 'models', 'different', 'kras', 'genotypes', 'augmentation', 'anticancer', 'efficacy', 'achieved', 'bystander', 'killing', 'effect', 'derived', 'caspase3', 'mediated', 'activation', 'mpd1', 'summary', 'albumin', 'metabolisminduced', 'apoptosis', 'together', 'bystander', 'killing', 'effect', 'mpd1', 'boosted', 'caspase3', 'mediated', 'activation', 'intensified', 'efficacy', 'mpd1', 'kras', 'mutant', 'cancers', 'findings', 'suggest', 'novel', 'peptidedrug', 'conjugate', 'could', 'promising', 'breakthrough', 'treatment', 'targeting', 'pankras', 'mutant', 'cancers']","['caspase3', 'albumin', 'albumin', 'caspase3', 'caspase3', 'albumin', 'caspase3']","['caspase3', 'caspase3', 'caspase3', 'caspase3']",True,"['tumor', 'cancer']"
35200639,A Novel Peptide Derived from <i>Arca inflata</i> Induces Apoptosis in Colorectal Cancer Cells through Mitochondria and the p38 MAPK Pathway.,"Colorectal carcinoma (CRC) is one of the major causes of cancer-related incidence and deaths. Here, we identified a novel antitumor peptide, P6, with a molecular weight of 2794.8 Da from a marine Chinese medicine, <i>Arca inflata</i> Reeve. The full amino acid sequence and secondary structure of P6 were determined by tandem mass de novo sequencing and circular dichroism spectroscopy, respectively. P6 markedly inhibited cell proliferation and colony formation, and induced apoptosis in CRC cells. Mechanistically, transcriptomics analysis and a serial functional evaluation showed that P6 induced colon cancer cell apoptosis through the activation of the p38-MAPK signaling pathway. Moreover, it was demonstrated that P6 exhibited antitumor effects in a tumor xenograft model, and induced cell cycle arrest in CRC cells in a concentration-dependent mode. These findings provide the first line of indication that P6 could be a potential therapeutic agent for CRC treatment.",2022-01-29,colorectal carcinoma crc is one of the major causes of cancerrelated incidence and deaths here we identified a novel antitumor peptide p6 with a molecular weight of 27948 da from a marine chinese medicine iarca inflatai reeve the full amino acid sequence and secondary structure of p6 were determined by tandem mass de novo sequencing and circular dichroism spectroscopy respectively p6 markedly inhibited cell proliferation and colony formation and induced apoptosis in crc cells mechanistically transcriptomics analysis and a serial functional evaluation showed that p6 induced colon cancer cell apoptosis through the activation of the p38mapk signaling pathway moreover it was demonstrated that p6 exhibited antitumor effects in a tumor xenograft model and induced cell cycle arrest in crc cells in a concentrationdependent mode these findings provide the first line of indication that p6 could be a potential therapeutic agent for crc treatment,"['colorectal', 'carcinoma', 'crc', 'is', 'one', 'of', 'the', 'major', 'causes', 'of', 'cancerrelated', 'incidence', 'and', 'deaths', 'here', 'we', 'identified', 'a', 'novel', 'antitumor', 'peptide', 'p6', 'with', 'a', 'molecular', 'weight', 'of', '27948', 'da', 'from', 'a', 'marine', 'chinese', 'medicine', 'iarca', 'inflatai', 'reeve', 'the', 'full', 'amino', 'acid', 'sequence', 'and', 'secondary', 'structure', 'of', 'p6', 'were', 'determined', 'by', 'tandem', 'mass', 'de', 'novo', 'sequencing', 'and', 'circular', 'dichroism', 'spectroscopy', 'respectively', 'p6', 'markedly', 'inhibited', 'cell', 'proliferation', 'and', 'colony', 'formation', 'and', 'induced', 'apoptosis', 'in', 'crc', 'cells', 'mechanistically', 'transcriptomics', 'analysis', 'and', 'a', 'serial', 'functional', 'evaluation', 'showed', 'that', 'p6', 'induced', 'colon', 'cancer', 'cell', 'apoptosis', 'through', 'the', 'activation', 'of', 'the', 'p38mapk', 'signaling', 'pathway', 'moreover', 'it', 'was', 'demonstrated', 'that', 'p6', 'exhibited', 'antitumor', 'effects', 'in', 'a', 'tumor', 'xenograft', 'model', 'and', 'induced', 'cell', 'cycle', 'arrest', 'in', 'crc', 'cells', 'in', 'a', 'concentrationdependent', 'mode', 'these', 'findings', 'provide', 'the', 'first', 'line', 'of', 'indication', 'that', 'p6', 'could', 'be', 'a', 'potential', 'therapeutic', 'agent', 'for', 'crc', 'treatment']","['colorectal', 'carcinoma', 'crc', 'one', 'major', 'causes', 'cancerrelated', 'incidence', 'deaths', 'identified', 'novel', 'antitumor', 'peptide', 'p6', 'molecular', 'weight', '27948', 'da', 'marine', 'chinese', 'medicine', 'iarca', 'inflatai', 'reeve', 'full', 'amino', 'acid', 'sequence', 'secondary', 'structure', 'p6', 'determined', 'tandem', 'mass', 'de', 'novo', 'sequencing', 'circular', 'dichroism', 'spectroscopy', 'respectively', 'p6', 'markedly', 'inhibited', 'cell', 'proliferation', 'colony', 'formation', 'induced', 'apoptosis', 'crc', 'cells', 'mechanistically', 'transcriptomics', 'analysis', 'serial', 'functional', 'evaluation', 'showed', 'p6', 'induced', 'colon', 'cancer', 'cell', 'apoptosis', 'activation', 'p38mapk', 'signaling', 'pathway', 'moreover', 'demonstrated', 'p6', 'exhibited', 'antitumor', 'effects', 'tumor', 'xenograft', 'model', 'induced', 'cell', 'cycle', 'arrest', 'crc', 'cells', 'concentrationdependent', 'mode', 'findings', 'provide', 'first', 'line', 'indication', 'p6', 'could', 'potential', 'therapeutic', 'agent', 'crc', 'treatment']","['crc', 'crc', 'p38mapk', 'crc', 'crc']",['p38mapk'],True,"['tumor', 'cancer']"
35183936,"Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries.","Drug survival is an important proxy measure for effectiveness of treatments for inflammatory diseases such as rheumatoid arthritis (RA), axial spondyloarthritis (AxSpA), psoriatic arthritis (PsA), and psoriasis. The objective of this study was to examine the real-life drug survival of biologics and novel small-molecule therapies across various disease entities such as RA, AxSpA, PsA, and psoriasis.",2022-02-09,drug survival is an important proxy measure for effectiveness of treatments for inflammatory diseases such as rheumatoid arthritis ra axial spondyloarthritis axspa psoriatic arthritis psa and psoriasis the objective of this study was to examine the reallife drug survival of biologics and novel smallmolecule therapies across various disease entities such as ra axspa psa and psoriasis,"['drug', 'survival', 'is', 'an', 'important', 'proxy', 'measure', 'for', 'effectiveness', 'of', 'treatments', 'for', 'inflammatory', 'diseases', 'such', 'as', 'rheumatoid', 'arthritis', 'ra', 'axial', 'spondyloarthritis', 'axspa', 'psoriatic', 'arthritis', 'psa', 'and', 'psoriasis', 'the', 'objective', 'of', 'this', 'study', 'was', 'to', 'examine', 'the', 'reallife', 'drug', 'survival', 'of', 'biologics', 'and', 'novel', 'smallmolecule', 'therapies', 'across', 'various', 'disease', 'entities', 'such', 'as', 'ra', 'axspa', 'psa', 'and', 'psoriasis']","['drug', 'survival', 'important', 'proxy', 'measure', 'effectiveness', 'treatments', 'inflammatory', 'diseases', 'rheumatoid', 'arthritis', 'ra', 'axial', 'spondyloarthritis', 'axspa', 'psoriatic', 'arthritis', 'psa', 'psoriasis', 'objective', 'study', 'examine', 'reallife', 'drug', 'survival', 'biologics', 'novel', 'smallmolecule', 'therapies', 'across', 'various', 'disease', 'entities', 'ra', 'axspa', 'psa', 'psoriasis']","['ra', 'ra']","['ra', 'ra']",True,['arthritis']
35154362,Theta-Defensins to Counter COVID-19 as Furin Inhibitors: <i>In Silico</i> Efficiency Prediction and Novel Compound Design.,"Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was characterized as a pandemic by the World Health Organization (WHO) in Dec. 2019. SARS-CoV-2 binds to the cell membrane through spike proteins on its surface and infects the cell. Furin, a host-cell enzyme, possesses a binding site for the spike protein. Thus, molecules that block furin could potentially be a therapeutic solution. Defensins are antimicrobial peptides that can hypothetically inhibit furin because of their arginine-rich structure. Theta-defensins, a subclass of defensins, have attracted attention as drug candidates due to their small size, unique structure, and involvement in several defense mechanisms. Theta-defensins could be a potential treatment for COVID-19 through furin inhibition and an anti-inflammatory mechanism. Note that inflammatory events are a significant and deadly condition that could happen at the later stages of COVID-19 infection. Here, the potential of theta-defensins against SARS-CoV-2 infection was investigated through <i>in silico</i> approaches. Based on docking analysis results, theta-defensins can function as furin inhibitors. Additionally, a novel candidate peptide against COVID-19 with optimal properties regarding antigenicity, stability, electrostatic potential, and binding strength was proposed. Further <i>in vitro</i>/<i>in vivo</i> investigations could verify the efficiency of the designed novel peptide.",2022-02-09,coronavirus disease 2019 covid19 caused by severe acute respiratory syndrome coronavirus 2 sarscov2 was characterized as a pandemic by the world health organization who in dec 2019 sarscov2 binds to the cell membrane through spike proteins on its surface and infects the cell furin a hostcell enzyme possesses a binding site for the spike protein thus molecules that block furin could potentially be a therapeutic solution defensins are antimicrobial peptides that can hypothetically inhibit furin because of their argininerich structure thetadefensins a subclass of defensins have attracted attention as drug candidates due to their small size unique structure and involvement in several defense mechanisms thetadefensins could be a potential treatment for covid19 through furin inhibition and an antiinflammatory mechanism note that inflammatory events are a significant and deadly condition that could happen at the later stages of covid19 infection here the potential of thetadefensins against sarscov2 infection was investigated through iin silicoi approaches based on docking analysis results thetadefensins can function as furin inhibitors additionally a novel candidate peptide against covid19 with optimal properties regarding antigenicity stability electrostatic potential and binding strength was proposed further iin vitroiiin vivoi investigations could verify the efficiency of the designed novel peptide,"['coronavirus', 'disease', '2019', 'covid19', 'caused', 'by', 'severe', 'acute', 'respiratory', 'syndrome', 'coronavirus', '2', 'sarscov2', 'was', 'characterized', 'as', 'a', 'pandemic', 'by', 'the', 'world', 'health', 'organization', 'who', 'in', 'dec', '2019', 'sarscov2', 'binds', 'to', 'the', 'cell', 'membrane', 'through', 'spike', 'proteins', 'on', 'its', 'surface', 'and', 'infects', 'the', 'cell', 'furin', 'a', 'hostcell', 'enzyme', 'possesses', 'a', 'binding', 'site', 'for', 'the', 'spike', 'protein', 'thus', 'molecules', 'that', 'block', 'furin', 'could', 'potentially', 'be', 'a', 'therapeutic', 'solution', 'defensins', 'are', 'antimicrobial', 'peptides', 'that', 'can', 'hypothetically', 'inhibit', 'furin', 'because', 'of', 'their', 'argininerich', 'structure', 'thetadefensins', 'a', 'subclass', 'of', 'defensins', 'have', 'attracted', 'attention', 'as', 'drug', 'candidates', 'due', 'to', 'their', 'small', 'size', 'unique', 'structure', 'and', 'involvement', 'in', 'several', 'defense', 'mechanisms', 'thetadefensins', 'could', 'be', 'a', 'potential', 'treatment', 'for', 'covid19', 'through', 'furin', 'inhibition', 'and', 'an', 'antiinflammatory', 'mechanism', 'note', 'that', 'inflammatory', 'events', 'are', 'a', 'significant', 'and', 'deadly', 'condition', 'that', 'could', 'happen', 'at', 'the', 'later', 'stages', 'of', 'covid19', 'infection', 'here', 'the', 'potential', 'of', 'thetadefensins', 'against', 'sarscov2', 'infection', 'was', 'investigated', 'through', 'iin', 'silicoi', 'approaches', 'based', 'on', 'docking', 'analysis', 'results', 'thetadefensins', 'can', 'function', 'as', 'furin', 'inhibitors', 'additionally', 'a', 'novel', 'candidate', 'peptide', 'against', 'covid19', 'with', 'optimal', 'properties', 'regarding', 'antigenicity', 'stability', 'electrostatic', 'potential', 'and', 'binding', 'strength', 'was', 'proposed', 'further', 'iin', 'vitroiiin', 'vivoi', 'investigations', 'could', 'verify', 'the', 'efficiency', 'of', 'the', 'designed', 'novel', 'peptide']","['coronavirus', 'disease', '2019', 'covid19', 'caused', 'severe', 'acute', 'respiratory', 'syndrome', 'coronavirus', '2', 'sarscov2', 'characterized', 'pandemic', 'world', 'health', 'organization', 'dec', '2019', 'sarscov2', 'binds', 'cell', 'membrane', 'spike', 'proteins', 'surface', 'infects', 'cell', 'furin', 'hostcell', 'enzyme', 'possesses', 'binding', 'site', 'spike', 'protein', 'thus', 'molecules', 'block', 'furin', 'could', 'potentially', 'therapeutic', 'solution', 'defensins', 'antimicrobial', 'peptides', 'hypothetically', 'inhibit', 'furin', 'argininerich', 'structure', 'thetadefensins', 'subclass', 'defensins', 'attracted', 'attention', 'drug', 'candidates', 'due', 'small', 'size', 'unique', 'structure', 'involvement', 'several', 'defense', 'mechanisms', 'thetadefensins', 'could', 'potential', 'treatment', 'covid19', 'furin', 'inhibition', 'antiinflammatory', 'mechanism', 'note', 'inflammatory', 'events', 'significant', 'deadly', 'condition', 'could', 'happen', 'later', 'stages', 'covid19', 'infection', 'potential', 'thetadefensins', 'sarscov2', 'infection', 'investigated', 'iin', 'silicoi', 'approaches', 'based', 'docking', 'analysis', 'results', 'thetadefensins', 'function', 'furin', 'inhibitors', 'additionally', 'novel', 'candidate', 'peptide', 'covid19', 'optimal', 'properties', 'regarding', 'antigenicity', 'stability', 'electrostatic', 'potential', 'binding', 'strength', 'proposed', 'iin', 'vitroiiin', 'vivoi', 'investigations', 'could', 'verify', 'efficiency', 'designed', 'novel', 'peptide']","['furin', 'furin', 'furin', 'furin', 'furin']","['furin', 'furin', 'furin', 'furin', 'furin']",True,['infection']
35110393,"A Phase I, First-in-Human, Healthy Volunteer Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN424, a Novel G Protein-Coupled Receptor 6 Inverse Agonist for Parkinson's Disease.","CVN424 is a novel small molecule and first-in-class candidate therapeutic to selectively modulate GPR6, an orphan G-protein coupled receptor. Expression of GPR6 is largely confined to the subset of striatal projection neurons that give rise to the indirect (striatopallidal) pathway, important in the control of movement. CVN424 improves motor function in preclinical animal models of Parkinson's disease. Here, we report results of a phase 1, first-in-human study investigating the safety, tolerability, and pharmacokinetics of CVN424 in healthy volunteers. The study (NCT03657030) was randomized, double-blind, and placebo controlled. CVN424 was orally administered in ascending doses to successive cohorts as inpatients in a clinical research unit. Single doses ranged from 1 mg to 225 mg, and repeated (7 day) daily doses were 25, 75, or 150 mg. CVN424 peak plasma concentrations were reached within 2 h post-dose in the fasted state and increased with increasing dose. Dosing after a standardized high-fat meal reduced and delayed the peak plasma concentration, but total plasma exposure was similar. Mean terminal half-life ranged from 30 to 41 h. CVN424 was generally well tolerated: no serious or severe adverse effects were observed, and there were no clinically significant changes in vital signs or laboratory parameters. We conclude that CVN424, a nondopaminergic compound that modulates a novel therapeutic target, was safe and well tolerated. A phase 2 study in patients with Parkinson's disease is underway. SIGNIFICANCE STATEMENT: This is the first-in-human clinical study of a first-in-class candidate therapeutic. CVN424 modulates a novel drug target, GPR6, which is selectively expressed in a pathway in the brain that has been implicated in the motor dysfunction of patients with Parkinson's disease. This study paves the way for investigating this novel mechanism of action in patients with Parkinson's disease.",2022-02-02,cvn424 is a novel small molecule and firstinclass candidate therapeutic to selectively modulate gpr6 an orphan gprotein coupled receptor expression of gpr6 is largely confined to the subset of striatal projection neurons that give rise to the indirect striatopallidal pathway important in the control of movement cvn424 improves motor function in preclinical animal models of parkinsons disease here we report results of a phase 1 firstinhuman study investigating the safety tolerability and pharmacokinetics of cvn424 in healthy volunteers the study nct03657030 was randomized doubleblind and placebo controlled cvn424 was orally administered in ascending doses to successive cohorts as inpatients in a clinical research unit single doses ranged from 1 mg to 225 mg and repeated 7 day daily doses were 25 75 or 150 mg cvn424 peak plasma concentrations were reached within 2 h postdose in the fasted state and increased with increasing dose dosing after a standardized highfat meal reduced and delayed the peak plasma concentration but total plasma exposure was similar mean terminal halflife ranged from 30 to 41 h cvn424 was generally well tolerated no serious or severe adverse effects were observed and there were no clinically significant changes in vital signs or laboratory parameters we conclude that cvn424 a nondopaminergic compound that modulates a novel therapeutic target was safe and well tolerated a phase 2 study in patients with parkinsons disease is underway significance statement this is the firstinhuman clinical study of a firstinclass candidate therapeutic cvn424 modulates a novel drug target gpr6 which is selectively expressed in a pathway in the brain that has been implicated in the motor dysfunction of patients with parkinsons disease this study paves the way for investigating this novel mechanism of action in patients with parkinsons disease,"['cvn424', 'is', 'a', 'novel', 'small', 'molecule', 'and', 'firstinclass', 'candidate', 'therapeutic', 'to', 'selectively', 'modulate', 'gpr6', 'an', 'orphan', 'gprotein', 'coupled', 'receptor', 'expression', 'of', 'gpr6', 'is', 'largely', 'confined', 'to', 'the', 'subset', 'of', 'striatal', 'projection', 'neurons', 'that', 'give', 'rise', 'to', 'the', 'indirect', 'striatopallidal', 'pathway', 'important', 'in', 'the', 'control', 'of', 'movement', 'cvn424', 'improves', 'motor', 'function', 'in', 'preclinical', 'animal', 'models', 'of', 'parkinsons', 'disease', 'here', 'we', 'report', 'results', 'of', 'a', 'phase', '1', 'firstinhuman', 'study', 'investigating', 'the', 'safety', 'tolerability', 'and', 'pharmacokinetics', 'of', 'cvn424', 'in', 'healthy', 'volunteers', 'the', 'study', 'nct03657030', 'was', 'randomized', 'doubleblind', 'and', 'placebo', 'controlled', 'cvn424', 'was', 'orally', 'administered', 'in', 'ascending', 'doses', 'to', 'successive', 'cohorts', 'as', 'inpatients', 'in', 'a', 'clinical', 'research', 'unit', 'single', 'doses', 'ranged', 'from', '1', 'mg', 'to', '225', 'mg', 'and', 'repeated', '7', 'day', 'daily', 'doses', 'were', '25', '75', 'or', '150', 'mg', 'cvn424', 'peak', 'plasma', 'concentrations', 'were', 'reached', 'within', '2', 'h', 'postdose', 'in', 'the', 'fasted', 'state', 'and', 'increased', 'with', 'increasing', 'dose', 'dosing', 'after', 'a', 'standardized', 'highfat', 'meal', 'reduced', 'and', 'delayed', 'the', 'peak', 'plasma', 'concentration', 'but', 'total', 'plasma', 'exposure', 'was', 'similar', 'mean', 'terminal', 'halflife', 'ranged', 'from', '30', 'to', '41', 'h', 'cvn424', 'was', 'generally', 'well', 'tolerated', 'no', 'serious', 'or', 'severe', 'adverse', 'effects', 'were', 'observed', 'and', 'there', 'were', 'no', 'clinically', 'significant', 'changes', 'in', 'vital', 'signs', 'or', 'laboratory', 'parameters', 'we', 'conclude', 'that', 'cvn424', 'a', 'nondopaminergic', 'compound', 'that', 'modulates', 'a', 'novel', 'therapeutic', 'target', 'was', 'safe', 'and', 'well', 'tolerated', 'a', 'phase', '2', 'study', 'in', 'patients', 'with', 'parkinsons', 'disease', 'is', 'underway', 'significance', 'statement', 'this', 'is', 'the', 'firstinhuman', 'clinical', 'study', 'of', 'a', 'firstinclass', 'candidate', 'therapeutic', 'cvn424', 'modulates', 'a', 'novel', 'drug', 'target', 'gpr6', 'which', 'is', 'selectively', 'expressed', 'in', 'a', 'pathway', 'in', 'the', 'brain', 'that', 'has', 'been', 'implicated', 'in', 'the', 'motor', 'dysfunction', 'of', 'patients', 'with', 'parkinsons', 'disease', 'this', 'study', 'paves', 'the', 'way', 'for', 'investigating', 'this', 'novel', 'mechanism', 'of', 'action', 'in', 'patients', 'with', 'parkinsons', 'disease']","['cvn424', 'novel', 'small', 'molecule', 'firstinclass', 'candidate', 'therapeutic', 'selectively', 'modulate', 'gpr6', 'orphan', 'gprotein', 'coupled', 'receptor', 'expression', 'gpr6', 'largely', 'confined', 'subset', 'striatal', 'projection', 'neurons', 'give', 'rise', 'indirect', 'striatopallidal', 'pathway', 'important', 'control', 'movement', 'cvn424', 'improves', 'motor', 'function', 'preclinical', 'animal', 'models', 'parkinsons', 'disease', 'report', 'results', 'phase', '1', 'firstinhuman', 'study', 'investigating', 'safety', 'tolerability', 'pharmacokinetics', 'cvn424', 'healthy', 'volunteers', 'study', 'nct03657030', 'randomized', 'doubleblind', 'placebo', 'controlled', 'cvn424', 'orally', 'administered', 'ascending', 'doses', 'successive', 'cohorts', 'inpatients', 'clinical', 'research', 'unit', 'single', 'doses', 'ranged', '1', 'mg', '225', 'mg', 'repeated', '7', 'day', 'daily', 'doses', '25', '75', '150', 'mg', 'cvn424', 'peak', 'plasma', 'concentrations', 'reached', 'within', '2', 'h', 'postdose', 'fasted', 'state', 'increased', 'increasing', 'dose', 'dosing', 'standardized', 'highfat', 'meal', 'reduced', 'delayed', 'peak', 'plasma', 'concentration', 'total', 'plasma', 'exposure', 'similar', 'mean', 'terminal', 'halflife', 'ranged', '30', '41', 'h', 'cvn424', 'generally', 'well', 'tolerated', 'serious', 'severe', 'adverse', 'effects', 'observed', 'clinically', 'significant', 'changes', 'vital', 'signs', 'laboratory', 'parameters', 'conclude', 'cvn424', 'nondopaminergic', 'compound', 'modulates', 'novel', 'therapeutic', 'target', 'safe', 'well', 'tolerated', 'phase', '2', 'study', 'patients', 'parkinsons', 'disease', 'underway', 'significance', 'statement', 'firstinhuman', 'clinical', 'study', 'firstinclass', 'candidate', 'therapeutic', 'cvn424', 'modulates', 'novel', 'drug', 'target', 'gpr6', 'selectively', 'expressed', 'pathway', 'brain', 'implicated', 'motor', 'dysfunction', 'patients', 'parkinsons', 'disease', 'study', 'paves', 'way', 'investigating', 'novel', 'mechanism', 'action', 'patients', 'parkinsons', 'disease']","['gpr6', 'gpr6', 'gpr6']","['gpr6', 'gpr6', 'gpr6']",True,['parkinson']
35099767,Inducible Prostaglandin E Synthase as a Pharmacological Target for Ischemic Stroke.,"As the inducible terminal enzyme for prostaglandin E2 (PGE<sub>2</sub>) synthesis, microsomal PGE synthase-1 (mPGES-1) contributes to neuroinflammation and secondary brain injury after cerebral ischemia via producing excessive PGE<sub>2</sub>. However, a proof of concept that mPGES-1 is a therapeutic target for ischemic stroke has not been established by a pharmacological strategy mainly due to the lack of drug-like mPGES-1 inhibitors that can be used in relevant rodent models. To this end, we recently developed a series of novel small-molecule compounds that can inhibit both human and rodent mPGES-1. In this study, blockade of mPGES-1 by our several novel compounds abolished the lipopolysaccharide (LPS)-induced PGE<sub>2</sub> and pro-inflammatory cytokines interleukin 1β (IL-1β), IL-6, and tumor necrosis factor α (TNF-α) in mouse primary brain microglia. Inhibition of mPGES-1 also decreased PGE<sub>2</sub> produced by neuronal cells under oxygen-glucose deprivation (OGD) stress. Among the five enzymes for PGE<sub>2</sub> biosynthesis, mPGES-1 was the most induced one in cerebral ischemic lesions. Systemic treatment with our lead compound MPO-0063 (5 or 10 mg/kg, i.p.) in mice after transient middle cerebral artery occlusion (MCAO) improved post-stroke well-being, decreased infarction and edema, suppressed induction of brain cytokines (IL-1β, IL-6, and TNF-α), alleviated locomotor dysfunction and anxiety-like behavior, and reduced the long-term cognitive impairments. The therapeutic effects of MPO-0063 in this proof-of-concept study provide the first pharmacological evidence that mPGES-1 represents a feasible target for delayed, adjunct treatment - along with reperfusion therapies - for acute brain ischemia.",2022-01-31,as the inducible terminal enzyme for prostaglandin e2 pgesub2sub synthesis microsomal pge synthase1 mpges1 contributes to neuroinflammation and secondary brain injury after cerebral ischemia via producing excessive pgesub2sub however a proof of concept that mpges1 is a therapeutic target for ischemic stroke has not been established by a pharmacological strategy mainly due to the lack of druglike mpges1 inhibitors that can be used in relevant rodent models to this end we recently developed a series of novel smallmolecule compounds that can inhibit both human and rodent mpges1 in this study blockade of mpges1 by our several novel compounds abolished the lipopolysaccharide lpsinduced pgesub2sub and proinflammatory cytokines interleukin 1β il1β il6 and tumor necrosis factor α tnfα in mouse primary brain microglia inhibition of mpges1 also decreased pgesub2sub produced by neuronal cells under oxygenglucose deprivation ogd stress among the five enzymes for pgesub2sub biosynthesis mpges1 was the most induced one in cerebral ischemic lesions systemic treatment with our lead compound mpo0063 5 or 10 mgkg ip in mice after transient middle cerebral artery occlusion mcao improved poststroke wellbeing decreased infarction and edema suppressed induction of brain cytokines il1β il6 and tnfα alleviated locomotor dysfunction and anxietylike behavior and reduced the longterm cognitive impairments the therapeutic effects of mpo0063 in this proofofconcept study provide the first pharmacological evidence that mpges1 represents a feasible target for delayed adjunct treatment  along with reperfusion therapies  for acute brain ischemia,"['as', 'the', 'inducible', 'terminal', 'enzyme', 'for', 'prostaglandin', 'e2', 'pgesub2sub', 'synthesis', 'microsomal', 'pge', 'synthase1', 'mpges1', 'contributes', 'to', 'neuroinflammation', 'and', 'secondary', 'brain', 'injury', 'after', 'cerebral', 'ischemia', 'via', 'producing', 'excessive', 'pgesub2sub', 'however', 'a', 'proof', 'of', 'concept', 'that', 'mpges1', 'is', 'a', 'therapeutic', 'target', 'for', 'ischemic', 'stroke', 'has', 'not', 'been', 'established', 'by', 'a', 'pharmacological', 'strategy', 'mainly', 'due', 'to', 'the', 'lack', 'of', 'druglike', 'mpges1', 'inhibitors', 'that', 'can', 'be', 'used', 'in', 'relevant', 'rodent', 'models', 'to', 'this', 'end', 'we', 'recently', 'developed', 'a', 'series', 'of', 'novel', 'smallmolecule', 'compounds', 'that', 'can', 'inhibit', 'both', 'human', 'and', 'rodent', 'mpges1', 'in', 'this', 'study', 'blockade', 'of', 'mpges1', 'by', 'our', 'several', 'novel', 'compounds', 'abolished', 'the', 'lipopolysaccharide', 'lpsinduced', 'pgesub2sub', 'and', 'proinflammatory', 'cytokines', 'interleukin', '1β', 'il1β', 'il6', 'and', 'tumor', 'necrosis', 'factor', 'α', 'tnfα', 'in', 'mouse', 'primary', 'brain', 'microglia', 'inhibition', 'of', 'mpges1', 'also', 'decreased', 'pgesub2sub', 'produced', 'by', 'neuronal', 'cells', 'under', 'oxygenglucose', 'deprivation', 'ogd', 'stress', 'among', 'the', 'five', 'enzymes', 'for', 'pgesub2sub', 'biosynthesis', 'mpges1', 'was', 'the', 'most', 'induced', 'one', 'in', 'cerebral', 'ischemic', 'lesions', 'systemic', 'treatment', 'with', 'our', 'lead', 'compound', 'mpo0063', '5', 'or', '10', 'mgkg', 'ip', 'in', 'mice', 'after', 'transient', 'middle', 'cerebral', 'artery', 'occlusion', 'mcao', 'improved', 'poststroke', 'wellbeing', 'decreased', 'infarction', 'and', 'edema', 'suppressed', 'induction', 'of', 'brain', 'cytokines', 'il1β', 'il6', 'and', 'tnfα', 'alleviated', 'locomotor', 'dysfunction', 'and', 'anxietylike', 'behavior', 'and', 'reduced', 'the', 'longterm', 'cognitive', 'impairments', 'the', 'therapeutic', 'effects', 'of', 'mpo0063', 'in', 'this', 'proofofconcept', 'study', 'provide', 'the', 'first', 'pharmacological', 'evidence', 'that', 'mpges1', 'represents', 'a', 'feasible', 'target', 'for', 'delayed', 'adjunct', 'treatment', 'along', 'with', 'reperfusion', 'therapies', 'for', 'acute', 'brain', 'ischemia']","['inducible', 'terminal', 'enzyme', 'prostaglandin', 'e2', 'pgesub2sub', 'synthesis', 'microsomal', 'pge', 'synthase1', 'mpges1', 'contributes', 'neuroinflammation', 'secondary', 'brain', 'injury', 'cerebral', 'ischemia', 'via', 'producing', 'excessive', 'pgesub2sub', 'however', 'proof', 'concept', 'mpges1', 'therapeutic', 'target', 'ischemic', 'stroke', 'established', 'pharmacological', 'strategy', 'mainly', 'due', 'lack', 'druglike', 'mpges1', 'inhibitors', 'used', 'relevant', 'rodent', 'models', 'end', 'recently', 'developed', 'series', 'novel', 'smallmolecule', 'compounds', 'inhibit', 'human', 'rodent', 'mpges1', 'study', 'blockade', 'mpges1', 'several', 'novel', 'compounds', 'abolished', 'lipopolysaccharide', 'lpsinduced', 'pgesub2sub', 'proinflammatory', 'cytokines', 'interleukin', '1β', 'il1β', 'il6', 'tumor', 'necrosis', 'factor', 'α', 'tnfα', 'mouse', 'primary', 'brain', 'microglia', 'inhibition', 'mpges1', 'also', 'decreased', 'pgesub2sub', 'produced', 'neuronal', 'cells', 'oxygenglucose', 'deprivation', 'ogd', 'stress', 'among', 'five', 'enzymes', 'pgesub2sub', 'biosynthesis', 'mpges1', 'induced', 'one', 'cerebral', 'ischemic', 'lesions', 'systemic', 'treatment', 'lead', 'compound', 'mpo0063', '5', '10', 'mgkg', 'ip', 'mice', 'transient', 'middle', 'cerebral', 'artery', 'occlusion', 'mcao', 'improved', 'poststroke', 'wellbeing', 'decreased', 'infarction', 'edema', 'suppressed', 'induction', 'brain', 'cytokines', 'il1β', 'il6', 'tnfα', 'alleviated', 'locomotor', 'dysfunction', 'anxietylike', 'behavior', 'reduced', 'longterm', 'cognitive', 'impairments', 'therapeutic', 'effects', 'mpo0063', 'proofofconcept', 'study', 'provide', 'first', 'pharmacological', 'evidence', 'mpges1', 'represents', 'feasible', 'target', 'delayed', 'adjunct', 'treatment', 'along', 'reperfusion', 'therapies', 'acute', 'brain', 'ischemia']","['synthase1', 'interleukin']",['synthase1'],True,['tumor']
35025968,EBV+ tumors exploit tumor cell-intrinsic and -extrinsic mechanisms to produce regulatory T cell-recruiting chemokines CCL17 and CCL22.,"The Epstein-Barr Virus (EBV) is involved in the etiology of multiple hematologic and epithelial human cancers. EBV+ tumors employ multiple immune escape mechanisms, including the recruitment of immunosuppressive regulatory T cells (Treg). Here, we show some EBV+ tumor cells express high levels of the chemokines CCL17 and CCL22 both in vitro and in vivo and that this expression mirrors the expression levels of expression of the EBV LMP1 gene in vitro. Patient samples from lymphoblastic (Hodgkin lymphoma) and epithelial (nasopharyngeal carcinoma; NPC) EBV+ tumors revealed CCL17 and CCL22 expression of both tumor cell-intrinsic and -extrinsic origin, depending on tumor type. NPCs grown as mouse xenografts likewise showed both mechanisms of chemokine production. Single cell RNA-sequencing revealed in vivo tumor cell-intrinsic CCL17 and CCL22 expression combined with expression from infiltrating classical resident and migratory dendritic cells in a CT26 colon cancer mouse tumor engineered to express LMP1. These data suggest that EBV-driven tumors employ dual mechanisms for CCL17 and CCL22 production. Importantly, both in vitro and in vivo Treg migration was effectively blocked by a novel, small molecule antagonist of CCR4, CCR4-351. Antagonism of the CCR4 receptor may thus be an effective means of activating the immune response against a wide spectrum of EBV+ tumors.",2022-01-13,the epsteinbarr virus ebv is involved in the etiology of multiple hematologic and epithelial human cancers ebv tumors employ multiple immune escape mechanisms including the recruitment of immunosuppressive regulatory t cells treg here we show some ebv tumor cells express high levels of the chemokines ccl17 and ccl22 both in vitro and in vivo and that this expression mirrors the expression levels of expression of the ebv lmp1 gene in vitro patient samples from lymphoblastic hodgkin lymphoma and epithelial nasopharyngeal carcinoma npc ebv tumors revealed ccl17 and ccl22 expression of both tumor cellintrinsic and extrinsic origin depending on tumor type npcs grown as mouse xenografts likewise showed both mechanisms of chemokine production single cell rnasequencing revealed in vivo tumor cellintrinsic ccl17 and ccl22 expression combined with expression from infiltrating classical resident and migratory dendritic cells in a ct26 colon cancer mouse tumor engineered to express lmp1 these data suggest that ebvdriven tumors employ dual mechanisms for ccl17 and ccl22 production importantly both in vitro and in vivo treg migration was effectively blocked by a novel small molecule antagonist of ccr4 ccr4351 antagonism of the ccr4 receptor may thus be an effective means of activating the immune response against a wide spectrum of ebv tumors,"['the', 'epsteinbarr', 'virus', 'ebv', 'is', 'involved', 'in', 'the', 'etiology', 'of', 'multiple', 'hematologic', 'and', 'epithelial', 'human', 'cancers', 'ebv', 'tumors', 'employ', 'multiple', 'immune', 'escape', 'mechanisms', 'including', 'the', 'recruitment', 'of', 'immunosuppressive', 'regulatory', 't', 'cells', 'treg', 'here', 'we', 'show', 'some', 'ebv', 'tumor', 'cells', 'express', 'high', 'levels', 'of', 'the', 'chemokines', 'ccl17', 'and', 'ccl22', 'both', 'in', 'vitro', 'and', 'in', 'vivo', 'and', 'that', 'this', 'expression', 'mirrors', 'the', 'expression', 'levels', 'of', 'expression', 'of', 'the', 'ebv', 'lmp1', 'gene', 'in', 'vitro', 'patient', 'samples', 'from', 'lymphoblastic', 'hodgkin', 'lymphoma', 'and', 'epithelial', 'nasopharyngeal', 'carcinoma', 'npc', 'ebv', 'tumors', 'revealed', 'ccl17', 'and', 'ccl22', 'expression', 'of', 'both', 'tumor', 'cellintrinsic', 'and', 'extrinsic', 'origin', 'depending', 'on', 'tumor', 'type', 'npcs', 'grown', 'as', 'mouse', 'xenografts', 'likewise', 'showed', 'both', 'mechanisms', 'of', 'chemokine', 'production', 'single', 'cell', 'rnasequencing', 'revealed', 'in', 'vivo', 'tumor', 'cellintrinsic', 'ccl17', 'and', 'ccl22', 'expression', 'combined', 'with', 'expression', 'from', 'infiltrating', 'classical', 'resident', 'and', 'migratory', 'dendritic', 'cells', 'in', 'a', 'ct26', 'colon', 'cancer', 'mouse', 'tumor', 'engineered', 'to', 'express', 'lmp1', 'these', 'data', 'suggest', 'that', 'ebvdriven', 'tumors', 'employ', 'dual', 'mechanisms', 'for', 'ccl17', 'and', 'ccl22', 'production', 'importantly', 'both', 'in', 'vitro', 'and', 'in', 'vivo', 'treg', 'migration', 'was', 'effectively', 'blocked', 'by', 'a', 'novel', 'small', 'molecule', 'antagonist', 'of', 'ccr4', 'ccr4351', 'antagonism', 'of', 'the', 'ccr4', 'receptor', 'may', 'thus', 'be', 'an', 'effective', 'means', 'of', 'activating', 'the', 'immune', 'response', 'against', 'a', 'wide', 'spectrum', 'of', 'ebv', 'tumors']","['epsteinbarr', 'virus', 'ebv', 'involved', 'etiology', 'multiple', 'hematologic', 'epithelial', 'human', 'cancers', 'ebv', 'tumors', 'employ', 'multiple', 'immune', 'escape', 'mechanisms', 'including', 'recruitment', 'immunosuppressive', 'regulatory', 'cells', 'treg', 'show', 'ebv', 'tumor', 'cells', 'express', 'high', 'levels', 'chemokines', 'ccl17', 'ccl22', 'vitro', 'vivo', 'expression', 'mirrors', 'expression', 'levels', 'expression', 'ebv', 'lmp1', 'gene', 'vitro', 'patient', 'samples', 'lymphoblastic', 'hodgkin', 'lymphoma', 'epithelial', 'nasopharyngeal', 'carcinoma', 'npc', 'ebv', 'tumors', 'revealed', 'ccl17', 'ccl22', 'expression', 'tumor', 'cellintrinsic', 'extrinsic', 'origin', 'depending', 'tumor', 'type', 'npcs', 'grown', 'mouse', 'xenografts', 'likewise', 'showed', 'mechanisms', 'chemokine', 'production', 'single', 'cell', 'rnasequencing', 'revealed', 'vivo', 'tumor', 'cellintrinsic', 'ccl17', 'ccl22', 'expression', 'combined', 'expression', 'infiltrating', 'classical', 'resident', 'migratory', 'dendritic', 'cells', 'ct26', 'colon', 'cancer', 'mouse', 'tumor', 'engineered', 'express', 'lmp1', 'data', 'suggest', 'ebvdriven', 'tumors', 'employ', 'dual', 'mechanisms', 'ccl17', 'ccl22', 'production', 'importantly', 'vitro', 'vivo', 'treg', 'migration', 'effectively', 'blocked', 'novel', 'small', 'molecule', 'antagonist', 'ccr4', 'ccr4351', 'antagonism', 'ccr4', 'receptor', 'may', 'thus', 'effective', 'means', 'activating', 'immune', 'response', 'wide', 'spectrum', 'ebv', 'tumors']","['lmp1', 'lmp1']","['lmp1', 'lmp1']",True,"['tumor', 'cancer']"
35006491,Synthesis and Evaluation of Radioiodine-Labeled pH (Low) Insertion Peptide Variant 7-Like Peptide as a Noninvasive Tumor Microenvironment Imaging Agent in a Mouse MDA-MB-231 Triple-Negative Breast Cancer Model.,"The pH (low) insertion peptide (pHLIP) family can target the tumor microenvironment (TME). If pHLIP can be labeled with radioiodine, the imaging and treatment of tumors can be considered. However, tyrosine and tryptophan can bind with iodine in the insertion region of pHLIP, and radioiodine labeling may affect the formation of α-helix structures in acidic environments; therefore, it is necessary to adjust the structure of pHLIP. This study aims to develop an <sup>125</sup>I-labeled pH (low) insertion peptide variant 7-like peptide (pHLIP (Var7) LP) for imaging the TME in MDA-MB-231 triple-negative breast cancer (TNBC) xenograft tumor models.",2022-01-10,the ph low insertion peptide phlip family can target the tumor microenvironment tme if phlip can be labeled with radioiodine the imaging and treatment of tumors can be considered however tyrosine and tryptophan can bind with iodine in the insertion region of phlip and radioiodine labeling may affect the formation of αhelix structures in acidic environments therefore it is necessary to adjust the structure of phlip this study aims to develop an sup125supilabeled ph low insertion peptide variant 7like peptide phlip var7 lp for imaging the tme in mdamb231 triplenegative breast cancer tnbc xenograft tumor models,"['the', 'ph', 'low', 'insertion', 'peptide', 'phlip', 'family', 'can', 'target', 'the', 'tumor', 'microenvironment', 'tme', 'if', 'phlip', 'can', 'be', 'labeled', 'with', 'radioiodine', 'the', 'imaging', 'and', 'treatment', 'of', 'tumors', 'can', 'be', 'considered', 'however', 'tyrosine', 'and', 'tryptophan', 'can', 'bind', 'with', 'iodine', 'in', 'the', 'insertion', 'region', 'of', 'phlip', 'and', 'radioiodine', 'labeling', 'may', 'affect', 'the', 'formation', 'of', 'αhelix', 'structures', 'in', 'acidic', 'environments', 'therefore', 'it', 'is', 'necessary', 'to', 'adjust', 'the', 'structure', 'of', 'phlip', 'this', 'study', 'aims', 'to', 'develop', 'an', 'sup125supilabeled', 'ph', 'low', 'insertion', 'peptide', 'variant', '7like', 'peptide', 'phlip', 'var7', 'lp', 'for', 'imaging', 'the', 'tme', 'in', 'mdamb231', 'triplenegative', 'breast', 'cancer', 'tnbc', 'xenograft', 'tumor', 'models']","['ph', 'low', 'insertion', 'peptide', 'phlip', 'family', 'target', 'tumor', 'microenvironment', 'tme', 'phlip', 'labeled', 'radioiodine', 'imaging', 'treatment', 'tumors', 'considered', 'however', 'tyrosine', 'tryptophan', 'bind', 'iodine', 'insertion', 'region', 'phlip', 'radioiodine', 'labeling', 'may', 'affect', 'formation', 'αhelix', 'structures', 'acidic', 'environments', 'therefore', 'necessary', 'adjust', 'structure', 'phlip', 'study', 'aims', 'develop', 'sup125supilabeled', 'ph', 'low', 'insertion', 'peptide', 'variant', '7like', 'peptide', 'phlip', 'var7', 'lp', 'imaging', 'tme', 'mdamb231', 'triplenegative', 'breast', 'cancer', 'tnbc', 'xenograft', 'tumor', 'models']",['var7'],['var7'],True,"['tumor', 'cancer']"
34977908,Strategies to gain novel Alzheimer's disease diagnostics and therapeutics using modulators of ABCA transporters.,"Adenosine-triphosphate-(ATP)-binding cassette (ABC) transport proteins are ubiquitously present membrane-bound efflux pumps that distribute endo- and xenobiotics across intra- and intercellular barriers. Discovered over 40 years ago, ABC transporters have been identified as key players in various human diseases, such as multidrug-resistant cancer and atherosclerosis, but also neurodegenerative diseases, such as Alzheimer's disease (AD). Most prominent and well-studied are ABCB1, ABCC1, and ABCG2, not only due to their contribution to the multidrug resistance (MDR) phenotype in cancer, but also due to their contribution to AD. However, our understanding of other ABC transporters is limited, and most of the 49 human ABC transporters have been largely neglected as potential targets for novel small-molecule drugs. This is especially true for the ABCA subfamily, which contains several members known to play a role in AD initiation and progression. This review provides up-to-date information on the proposed functional background and pathological role of ABCA transporters in AD. We also provide an overview of small-molecules shown to interact with ABCA transporters as well as potential <i>in silico</i>, <i>in vitro</i>, and <i>in vivo</i> methodologies to gain novel templates for the development of innovative ABC transporter-targeting diagnostics and therapeutics.",2021-12-13,adenosinetriphosphateatpbinding cassette abc transport proteins are ubiquitously present membranebound efflux pumps that distribute endo and xenobiotics across intra and intercellular barriers discovered over 40 years ago abc transporters have been identified as key players in various human diseases such as multidrugresistant cancer and atherosclerosis but also neurodegenerative diseases such as alzheimers disease ad most prominent and wellstudied are abcb1 abcc1 and abcg2 not only due to their contribution to the multidrug resistance mdr phenotype in cancer but also due to their contribution to ad however our understanding of other abc transporters is limited and most of the 49 human abc transporters have been largely neglected as potential targets for novel smallmolecule drugs this is especially true for the abca subfamily which contains several members known to play a role in ad initiation and progression this review provides uptodate information on the proposed functional background and pathological role of abca transporters in ad we also provide an overview of smallmolecules shown to interact with abca transporters as well as potential iin silicoi iin vitroi and iin vivoi methodologies to gain novel templates for the development of innovative abc transportertargeting diagnostics and therapeutics,"['adenosinetriphosphateatpbinding', 'cassette', 'abc', 'transport', 'proteins', 'are', 'ubiquitously', 'present', 'membranebound', 'efflux', 'pumps', 'that', 'distribute', 'endo', 'and', 'xenobiotics', 'across', 'intra', 'and', 'intercellular', 'barriers', 'discovered', 'over', '40', 'years', 'ago', 'abc', 'transporters', 'have', 'been', 'identified', 'as', 'key', 'players', 'in', 'various', 'human', 'diseases', 'such', 'as', 'multidrugresistant', 'cancer', 'and', 'atherosclerosis', 'but', 'also', 'neurodegenerative', 'diseases', 'such', 'as', 'alzheimers', 'disease', 'ad', 'most', 'prominent', 'and', 'wellstudied', 'are', 'abcb1', 'abcc1', 'and', 'abcg2', 'not', 'only', 'due', 'to', 'their', 'contribution', 'to', 'the', 'multidrug', 'resistance', 'mdr', 'phenotype', 'in', 'cancer', 'but', 'also', 'due', 'to', 'their', 'contribution', 'to', 'ad', 'however', 'our', 'understanding', 'of', 'other', 'abc', 'transporters', 'is', 'limited', 'and', 'most', 'of', 'the', '49', 'human', 'abc', 'transporters', 'have', 'been', 'largely', 'neglected', 'as', 'potential', 'targets', 'for', 'novel', 'smallmolecule', 'drugs', 'this', 'is', 'especially', 'true', 'for', 'the', 'abca', 'subfamily', 'which', 'contains', 'several', 'members', 'known', 'to', 'play', 'a', 'role', 'in', 'ad', 'initiation', 'and', 'progression', 'this', 'review', 'provides', 'uptodate', 'information', 'on', 'the', 'proposed', 'functional', 'background', 'and', 'pathological', 'role', 'of', 'abca', 'transporters', 'in', 'ad', 'we', 'also', 'provide', 'an', 'overview', 'of', 'smallmolecules', 'shown', 'to', 'interact', 'with', 'abca', 'transporters', 'as', 'well', 'as', 'potential', 'iin', 'silicoi', 'iin', 'vitroi', 'and', 'iin', 'vivoi', 'methodologies', 'to', 'gain', 'novel', 'templates', 'for', 'the', 'development', 'of', 'innovative', 'abc', 'transportertargeting', 'diagnostics', 'and', 'therapeutics']","['adenosinetriphosphateatpbinding', 'cassette', 'abc', 'transport', 'proteins', 'ubiquitously', 'present', 'membranebound', 'efflux', 'pumps', 'distribute', 'endo', 'xenobiotics', 'across', 'intra', 'intercellular', 'barriers', 'discovered', '40', 'years', 'ago', 'abc', 'transporters', 'identified', 'key', 'players', 'various', 'human', 'diseases', 'multidrugresistant', 'cancer', 'atherosclerosis', 'also', 'neurodegenerative', 'diseases', 'alzheimers', 'disease', 'ad', 'prominent', 'wellstudied', 'abcb1', 'abcc1', 'abcg2', 'due', 'contribution', 'multidrug', 'resistance', 'mdr', 'phenotype', 'cancer', 'also', 'due', 'contribution', 'ad', 'however', 'understanding', 'abc', 'transporters', 'limited', '49', 'human', 'abc', 'transporters', 'largely', 'neglected', 'potential', 'targets', 'novel', 'smallmolecule', 'drugs', 'especially', 'true', 'abca', 'subfamily', 'contains', 'several', 'members', 'known', 'play', 'role', 'ad', 'initiation', 'progression', 'review', 'provides', 'uptodate', 'information', 'proposed', 'functional', 'background', 'pathological', 'role', 'abca', 'transporters', 'ad', 'also', 'provide', 'overview', 'smallmolecules', 'shown', 'interact', 'abca', 'transporters', 'well', 'potential', 'iin', 'silicoi', 'iin', 'vitroi', 'iin', 'vivoi', 'methodologies', 'gain', 'novel', 'templates', 'development', 'innovative', 'abc', 'transportertargeting', 'diagnostics', 'therapeutics']",['abcb1'],['abcb1'],True,"['cancer', 'alzheimer']"
34977169,The Novel Peptide AEDPPE Alleviates Trophoblast Cell Dysfunction Associated With Preeclampsia by Regulating the NF-κB Signaling Pathway.,"<b>Background:</b> Preeclampsia (PE) is a serious risk to the health of pregnant women and fetuses during pregnancy, and there is no effective treatment for this condition. Although many reports have confirmed the therapeutic effects of peptides in diseases, the role of peptides in PE remains poorly understood. <b>Methods:</b> A differentially expressed peptide in PE (AEDPPE) is derived from heat-shock protein beta-1 (HSPB1), amino acids 100 to 109 (DVNHFAPDEL), which we identified in a previous study. We synthesized AEDPPE and investigated its effect on HTR-8/SVneo cell function using a Cell Counting Kit-8, flow cytometric assay, and Transwell and wound-healing assays. Quantitative reverse transcription-PCR and ELISA were used to determine cytokine expression. Pull-down assay, mass spectrometry, Western blot analysis, and immunofluorescence were used to explore the potential targets and signaling pathways regulated by AEDPPE. Finally, we assessed the effect of AEDPPE in the lipopolysaccharide (LPS)-induced PE-like rat model. <b>Results:</b> AEDPPE significantly promoted the migration and invasion of HTR-8/SVneo cells, and it decreased the expression of interleukins 1 beta (IL-1β), interleukin 6 (IL-6), and interleukin 8 (IL-8). These functions performed by AEDPPE remained evident after injury to HTR-8/SVneo cells with tumor necrosis factor-alpha (TNF-α), and AEDPPE reversed the elevated sFlt-1/PlGF ratio induced by TNF-α. AEDPPE may exert these biological effects by binding to heat-shock protein 90β (HSP 90β) and, thus, affect the NF-κB signaling pathway. In an LPS-induced PE-like rat model, AEDPPE significantly improved PE symptoms and fetal rat outcomes. <b>Conclusion:</b> Our study showed that AEDPPE enhanced trophoblast migration and invasion and reduced inflammatory cytokine expression, and we hypothesized that these actions involved the NF-κB signaling pathway. The use of AEDPPE may thus develop into a novel modality in the treatment of PE.",2021-12-17,bbackgroundb preeclampsia pe is a serious risk to the health of pregnant women and fetuses during pregnancy and there is no effective treatment for this condition although many reports have confirmed the therapeutic effects of peptides in diseases the role of peptides in pe remains poorly understood bmethodsb a differentially expressed peptide in pe aedppe is derived from heatshock protein beta1 hspb1 amino acids 100 to 109 dvnhfapdel which we identified in a previous study we synthesized aedppe and investigated its effect on htr8svneo cell function using a cell counting kit8 flow cytometric assay and transwell and woundhealing assays quantitative reverse transcriptionpcr and elisa were used to determine cytokine expression pulldown assay mass spectrometry western blot analysis and immunofluorescence were used to explore the potential targets and signaling pathways regulated by aedppe finally we assessed the effect of aedppe in the lipopolysaccharide lpsinduced pelike rat model bresultsb aedppe significantly promoted the migration and invasion of htr8svneo cells and it decreased the expression of interleukins 1 beta il1β interleukin 6 il6 and interleukin 8 il8 these functions performed by aedppe remained evident after injury to htr8svneo cells with tumor necrosis factoralpha tnfα and aedppe reversed the elevated sflt1plgf ratio induced by tnfα aedppe may exert these biological effects by binding to heatshock protein 90β hsp 90β and thus affect the nfκb signaling pathway in an lpsinduced pelike rat model aedppe significantly improved pe symptoms and fetal rat outcomes bconclusionb our study showed that aedppe enhanced trophoblast migration and invasion and reduced inflammatory cytokine expression and we hypothesized that these actions involved the nfκb signaling pathway the use of aedppe may thus develop into a novel modality in the treatment of pe,"['bbackgroundb', 'preeclampsia', 'pe', 'is', 'a', 'serious', 'risk', 'to', 'the', 'health', 'of', 'pregnant', 'women', 'and', 'fetuses', 'during', 'pregnancy', 'and', 'there', 'is', 'no', 'effective', 'treatment', 'for', 'this', 'condition', 'although', 'many', 'reports', 'have', 'confirmed', 'the', 'therapeutic', 'effects', 'of', 'peptides', 'in', 'diseases', 'the', 'role', 'of', 'peptides', 'in', 'pe', 'remains', 'poorly', 'understood', 'bmethodsb', 'a', 'differentially', 'expressed', 'peptide', 'in', 'pe', 'aedppe', 'is', 'derived', 'from', 'heatshock', 'protein', 'beta1', 'hspb1', 'amino', 'acids', '100', 'to', '109', 'dvnhfapdel', 'which', 'we', 'identified', 'in', 'a', 'previous', 'study', 'we', 'synthesized', 'aedppe', 'and', 'investigated', 'its', 'effect', 'on', 'htr8svneo', 'cell', 'function', 'using', 'a', 'cell', 'counting', 'kit8', 'flow', 'cytometric', 'assay', 'and', 'transwell', 'and', 'woundhealing', 'assays', 'quantitative', 'reverse', 'transcriptionpcr', 'and', 'elisa', 'were', 'used', 'to', 'determine', 'cytokine', 'expression', 'pulldown', 'assay', 'mass', 'spectrometry', 'western', 'blot', 'analysis', 'and', 'immunofluorescence', 'were', 'used', 'to', 'explore', 'the', 'potential', 'targets', 'and', 'signaling', 'pathways', 'regulated', 'by', 'aedppe', 'finally', 'we', 'assessed', 'the', 'effect', 'of', 'aedppe', 'in', 'the', 'lipopolysaccharide', 'lpsinduced', 'pelike', 'rat', 'model', 'bresultsb', 'aedppe', 'significantly', 'promoted', 'the', 'migration', 'and', 'invasion', 'of', 'htr8svneo', 'cells', 'and', 'it', 'decreased', 'the', 'expression', 'of', 'interleukins', '1', 'beta', 'il1β', 'interleukin', '6', 'il6', 'and', 'interleukin', '8', 'il8', 'these', 'functions', 'performed', 'by', 'aedppe', 'remained', 'evident', 'after', 'injury', 'to', 'htr8svneo', 'cells', 'with', 'tumor', 'necrosis', 'factoralpha', 'tnfα', 'and', 'aedppe', 'reversed', 'the', 'elevated', 'sflt1plgf', 'ratio', 'induced', 'by', 'tnfα', 'aedppe', 'may', 'exert', 'these', 'biological', 'effects', 'by', 'binding', 'to', 'heatshock', 'protein', '90β', 'hsp', '90β', 'and', 'thus', 'affect', 'the', 'nfκb', 'signaling', 'pathway', 'in', 'an', 'lpsinduced', 'pelike', 'rat', 'model', 'aedppe', 'significantly', 'improved', 'pe', 'symptoms', 'and', 'fetal', 'rat', 'outcomes', 'bconclusionb', 'our', 'study', 'showed', 'that', 'aedppe', 'enhanced', 'trophoblast', 'migration', 'and', 'invasion', 'and', 'reduced', 'inflammatory', 'cytokine', 'expression', 'and', 'we', 'hypothesized', 'that', 'these', 'actions', 'involved', 'the', 'nfκb', 'signaling', 'pathway', 'the', 'use', 'of', 'aedppe', 'may', 'thus', 'develop', 'into', 'a', 'novel', 'modality', 'in', 'the', 'treatment', 'of', 'pe']","['bbackgroundb', 'preeclampsia', 'pe', 'serious', 'risk', 'health', 'pregnant', 'women', 'fetuses', 'pregnancy', 'effective', 'treatment', 'condition', 'although', 'many', 'reports', 'confirmed', 'therapeutic', 'effects', 'peptides', 'diseases', 'role', 'peptides', 'pe', 'remains', 'poorly', 'understood', 'bmethodsb', 'differentially', 'expressed', 'peptide', 'pe', 'aedppe', 'derived', 'heatshock', 'protein', 'beta1', 'hspb1', 'amino', 'acids', '100', '109', 'dvnhfapdel', 'identified', 'previous', 'study', 'synthesized', 'aedppe', 'investigated', 'effect', 'htr8svneo', 'cell', 'function', 'using', 'cell', 'counting', 'kit8', 'flow', 'cytometric', 'assay', 'transwell', 'woundhealing', 'assays', 'quantitative', 'reverse', 'transcriptionpcr', 'elisa', 'used', 'determine', 'cytokine', 'expression', 'pulldown', 'assay', 'mass', 'spectrometry', 'western', 'blot', 'analysis', 'immunofluorescence', 'used', 'explore', 'potential', 'targets', 'signaling', 'pathways', 'regulated', 'aedppe', 'finally', 'assessed', 'effect', 'aedppe', 'lipopolysaccharide', 'lpsinduced', 'pelike', 'rat', 'model', 'bresultsb', 'aedppe', 'significantly', 'promoted', 'migration', 'invasion', 'htr8svneo', 'cells', 'decreased', 'expression', 'interleukins', '1', 'beta', 'il1β', 'interleukin', '6', 'il6', 'interleukin', '8', 'il8', 'functions', 'performed', 'aedppe', 'remained', 'evident', 'injury', 'htr8svneo', 'cells', 'tumor', 'necrosis', 'factoralpha', 'tnfα', 'aedppe', 'reversed', 'elevated', 'sflt1plgf', 'ratio', 'induced', 'tnfα', 'aedppe', 'may', 'exert', 'biological', 'effects', 'binding', 'heatshock', 'protein', '90β', 'hsp', '90β', 'thus', 'affect', 'nfκb', 'signaling', 'pathway', 'lpsinduced', 'pelike', 'rat', 'model', 'aedppe', 'significantly', 'improved', 'pe', 'symptoms', 'fetal', 'rat', 'outcomes', 'bconclusionb', 'study', 'showed', 'aedppe', 'enhanced', 'trophoblast', 'migration', 'invasion', 'reduced', 'inflammatory', 'cytokine', 'expression', 'hypothesized', 'actions', 'involved', 'nfκb', 'signaling', 'pathway', 'use', 'aedppe', 'may', 'thus', 'develop', 'novel', 'modality', 'treatment', 'pe']","['beta1', 'hspb1', 'interleukins', 'beta', 'interleukin', 'interleukin', 'il8', 'factoralpha', 'hsp']",['hspb1'],True,['tumor']
34929517,"Design, synthesis and biological evaluation studies of novel small molecule ENPP1 inhibitors for cancer immunotherapy.","Ecto-nucleotide pyrophosphatase/phosphodiesterases 1 (ENPP1 or NPP1), is an attractive therapeutic target for various diseases, primarily cancer and mineralization disorders. The ecto-enzyme is located on the cell surface and has been implicated in the control of extracellular levels of nucleotide, nucleoside and (di) phosphate. Recently, it has emerged as a critical phosphodiesterase that hydrolyzes cyclic 2'3'- cGAMP, the endogenous ligand for STING (STimulator of INterferon Genes). STING plays an important role in innate immunity by activating type I interferon in response to cytosolic 2'3'-cGAMP. ENPP1 negatively regulates the STING pathway and hence its inhibition makes it an attractive therapeutic target for cancer immunotherapy. Herein, we describe the design, optimization and biological evaluation studies of a series of novel non-nucleotidic thioguanine based small molecule inhibitors of ENPP1. The lead compound 43 has shown good in vitro potency, stability in SGF/SIF/PBS, selectivity, ADME properties and pharmacokinetic profile and finally potent anti-tumor response in vivo. These compounds are a good starting point for the development of potentially effective cancer immunotherapy agents.",2021-12-11,ectonucleotide pyrophosphatasephosphodiesterases 1 enpp1 or npp1 is an attractive therapeutic target for various diseases primarily cancer and mineralization disorders the ectoenzyme is located on the cell surface and has been implicated in the control of extracellular levels of nucleotide nucleoside and di phosphate recently it has emerged as a critical phosphodiesterase that hydrolyzes cyclic 23 cgamp the endogenous ligand for sting stimulator of interferon genes sting plays an important role in innate immunity by activating type i interferon in response to cytosolic 23cgamp enpp1 negatively regulates the sting pathway and hence its inhibition makes it an attractive therapeutic target for cancer immunotherapy herein we describe the design optimization and biological evaluation studies of a series of novel nonnucleotidic thioguanine based small molecule inhibitors of enpp1 the lead compound 43 has shown good in vitro potency stability in sgfsifpbs selectivity adme properties and pharmacokinetic profile and finally potent antitumor response in vivo these compounds are a good starting point for the development of potentially effective cancer immunotherapy agents,"['ectonucleotide', 'pyrophosphatasephosphodiesterases', '1', 'enpp1', 'or', 'npp1', 'is', 'an', 'attractive', 'therapeutic', 'target', 'for', 'various', 'diseases', 'primarily', 'cancer', 'and', 'mineralization', 'disorders', 'the', 'ectoenzyme', 'is', 'located', 'on', 'the', 'cell', 'surface', 'and', 'has', 'been', 'implicated', 'in', 'the', 'control', 'of', 'extracellular', 'levels', 'of', 'nucleotide', 'nucleoside', 'and', 'di', 'phosphate', 'recently', 'it', 'has', 'emerged', 'as', 'a', 'critical', 'phosphodiesterase', 'that', 'hydrolyzes', 'cyclic', '23', 'cgamp', 'the', 'endogenous', 'ligand', 'for', 'sting', 'stimulator', 'of', 'interferon', 'genes', 'sting', 'plays', 'an', 'important', 'role', 'in', 'innate', 'immunity', 'by', 'activating', 'type', 'i', 'interferon', 'in', 'response', 'to', 'cytosolic', '23cgamp', 'enpp1', 'negatively', 'regulates', 'the', 'sting', 'pathway', 'and', 'hence', 'its', 'inhibition', 'makes', 'it', 'an', 'attractive', 'therapeutic', 'target', 'for', 'cancer', 'immunotherapy', 'herein', 'we', 'describe', 'the', 'design', 'optimization', 'and', 'biological', 'evaluation', 'studies', 'of', 'a', 'series', 'of', 'novel', 'nonnucleotidic', 'thioguanine', 'based', 'small', 'molecule', 'inhibitors', 'of', 'enpp1', 'the', 'lead', 'compound', '43', 'has', 'shown', 'good', 'in', 'vitro', 'potency', 'stability', 'in', 'sgfsifpbs', 'selectivity', 'adme', 'properties', 'and', 'pharmacokinetic', 'profile', 'and', 'finally', 'potent', 'antitumor', 'response', 'in', 'vivo', 'these', 'compounds', 'are', 'a', 'good', 'starting', 'point', 'for', 'the', 'development', 'of', 'potentially', 'effective', 'cancer', 'immunotherapy', 'agents']","['ectonucleotide', 'pyrophosphatasephosphodiesterases', '1', 'enpp1', 'npp1', 'attractive', 'therapeutic', 'target', 'various', 'diseases', 'primarily', 'cancer', 'mineralization', 'disorders', 'ectoenzyme', 'located', 'cell', 'surface', 'implicated', 'control', 'extracellular', 'levels', 'nucleotide', 'nucleoside', 'di', 'phosphate', 'recently', 'emerged', 'critical', 'phosphodiesterase', 'hydrolyzes', 'cyclic', '23', 'cgamp', 'endogenous', 'ligand', 'sting', 'stimulator', 'interferon', 'genes', 'sting', 'plays', 'important', 'role', 'innate', 'immunity', 'activating', 'type', 'interferon', 'response', 'cytosolic', '23cgamp', 'enpp1', 'negatively', 'regulates', 'sting', 'pathway', 'hence', 'inhibition', 'makes', 'attractive', 'therapeutic', 'target', 'cancer', 'immunotherapy', 'herein', 'describe', 'design', 'optimization', 'biological', 'evaluation', 'studies', 'series', 'novel', 'nonnucleotidic', 'thioguanine', 'based', 'small', 'molecule', 'inhibitors', 'enpp1', 'lead', 'compound', '43', 'shown', 'good', 'vitro', 'potency', 'stability', 'sgfsifpbs', 'selectivity', 'adme', 'properties', 'pharmacokinetic', 'profile', 'finally', 'potent', 'antitumor', 'response', 'vivo', 'compounds', 'good', 'starting', 'point', 'development', 'potentially', 'effective', 'cancer', 'immunotherapy', 'agents']",['ectonucleotide'],['ectonucleotide'],True,"['tumor', 'cancer']"
34900747,Inhibition of SREBP-1 Activation by a Novel Small-Molecule Inhibitor Enhances the Sensitivity of Hepatocellular Carcinoma Tissue to Radiofrequency Ablation.,"Radiofrequency ablation (RFA) is an important strategy for treatment of advanced hepatocellular carcinoma (HCC). However, the prognostic indicators of RFA therapy are not known, and there are few strategies for RFA sensitization. The transcription factor sterol regulatory element binding protein 1 (SREBP)-1 regulates fatty-acid synthesis but also promotes the proliferation or metastasis of HCC cells. Here, the clinical importance of SREBP-1 and potential application of knockdown of SREBP-1 expression in RFA of advanced HCC was elucidated. In patients with advanced HCC receiving RFA, a high level of endogenous SREBP-1 expression correlated to poor survival. Inhibition of SREBP-1 activation using a novel small-molecule inhibitor, SI-1, not only inhibited the aerobic glycolysis of HCC cells, it also enhanced the antitumor effects of RFA on xenograft tumors. Overall, our results: (i) revealed the correlation between SREBP-1 and HCC severity; (ii) indicated that inhibition of SREBP-1 activation could be a promising approach for treatment of advanced HCC.",2021-11-26,radiofrequency ablation rfa is an important strategy for treatment of advanced hepatocellular carcinoma hcc however the prognostic indicators of rfa therapy are not known and there are few strategies for rfa sensitization the transcription factor sterol regulatory element binding protein 1 srebp1 regulates fattyacid synthesis but also promotes the proliferation or metastasis of hcc cells here the clinical importance of srebp1 and potential application of knockdown of srebp1 expression in rfa of advanced hcc was elucidated in patients with advanced hcc receiving rfa a high level of endogenous srebp1 expression correlated to poor survival inhibition of srebp1 activation using a novel smallmolecule inhibitor si1 not only inhibited the aerobic glycolysis of hcc cells it also enhanced the antitumor effects of rfa on xenograft tumors overall our results i revealed the correlation between srebp1 and hcc severity ii indicated that inhibition of srebp1 activation could be a promising approach for treatment of advanced hcc,"['radiofrequency', 'ablation', 'rfa', 'is', 'an', 'important', 'strategy', 'for', 'treatment', 'of', 'advanced', 'hepatocellular', 'carcinoma', 'hcc', 'however', 'the', 'prognostic', 'indicators', 'of', 'rfa', 'therapy', 'are', 'not', 'known', 'and', 'there', 'are', 'few', 'strategies', 'for', 'rfa', 'sensitization', 'the', 'transcription', 'factor', 'sterol', 'regulatory', 'element', 'binding', 'protein', '1', 'srebp1', 'regulates', 'fattyacid', 'synthesis', 'but', 'also', 'promotes', 'the', 'proliferation', 'or', 'metastasis', 'of', 'hcc', 'cells', 'here', 'the', 'clinical', 'importance', 'of', 'srebp1', 'and', 'potential', 'application', 'of', 'knockdown', 'of', 'srebp1', 'expression', 'in', 'rfa', 'of', 'advanced', 'hcc', 'was', 'elucidated', 'in', 'patients', 'with', 'advanced', 'hcc', 'receiving', 'rfa', 'a', 'high', 'level', 'of', 'endogenous', 'srebp1', 'expression', 'correlated', 'to', 'poor', 'survival', 'inhibition', 'of', 'srebp1', 'activation', 'using', 'a', 'novel', 'smallmolecule', 'inhibitor', 'si1', 'not', 'only', 'inhibited', 'the', 'aerobic', 'glycolysis', 'of', 'hcc', 'cells', 'it', 'also', 'enhanced', 'the', 'antitumor', 'effects', 'of', 'rfa', 'on', 'xenograft', 'tumors', 'overall', 'our', 'results', 'i', 'revealed', 'the', 'correlation', 'between', 'srebp1', 'and', 'hcc', 'severity', 'ii', 'indicated', 'that', 'inhibition', 'of', 'srebp1', 'activation', 'could', 'be', 'a', 'promising', 'approach', 'for', 'treatment', 'of', 'advanced', 'hcc']","['radiofrequency', 'ablation', 'rfa', 'important', 'strategy', 'treatment', 'advanced', 'hepatocellular', 'carcinoma', 'hcc', 'however', 'prognostic', 'indicators', 'rfa', 'therapy', 'known', 'strategies', 'rfa', 'sensitization', 'transcription', 'factor', 'sterol', 'regulatory', 'element', 'binding', 'protein', '1', 'srebp1', 'regulates', 'fattyacid', 'synthesis', 'also', 'promotes', 'proliferation', 'metastasis', 'hcc', 'cells', 'clinical', 'importance', 'srebp1', 'potential', 'application', 'knockdown', 'srebp1', 'expression', 'rfa', 'advanced', 'hcc', 'elucidated', 'patients', 'advanced', 'hcc', 'receiving', 'rfa', 'high', 'level', 'endogenous', 'srebp1', 'expression', 'correlated', 'poor', 'survival', 'inhibition', 'srebp1', 'activation', 'using', 'novel', 'smallmolecule', 'inhibitor', 'si1', 'inhibited', 'aerobic', 'glycolysis', 'hcc', 'cells', 'also', 'enhanced', 'antitumor', 'effects', 'rfa', 'xenograft', 'tumors', 'overall', 'results', 'revealed', 'correlation', 'srebp1', 'hcc', 'severity', 'ii', 'indicated', 'inhibition', 'srebp1', 'activation', 'could', 'promising', 'approach', 'treatment', 'advanced', 'hcc']","['rfa', 'rfa', 'rfa', 'srebp1', 'srebp1', 'srebp1', 'rfa', 'rfa', 'srebp1', 'srebp1', 'rfa', 'srebp1', 'srebp1']","['srebp1', 'srebp1', 'srebp1', 'srebp1', 'srebp1', 'srebp1', 'srebp1']",True,['tumor']
34893553,"Post-Stroke Administration of the p75 Neurotrophin Receptor Modulator, LM11A-31, Attenuates Chronic Changes in Brain Metabolism, Increases Neurotransmitter Levels, and Improves Recovery.","The aim of this study was to test whether poststroke oral administration of a small molecule p75 neurotrophin receptor (p75<sup>NTR</sup>) modulator (LM11A-31) can augment neuronal survival and improve recovery in a mouse model of stroke. Mice were administered LM11A-31 for up to 12 weeks, beginning 1 week after stroke. Metabolomic analysis revealed that after 2 weeks of daily treatment, mice that received LM11A-31 were distinct from vehicle-treated mice by principal component analysis and had higher levels of serotonin, acetylcholine, and dopamine in their ipsilateral hemisphere. LM11A-31 treatment also improved redox homeostasis by restoring reduced glutathione. It also offset a stroke-induced reduction in glycolysis by increasing acetyl-CoA. There was no effect on cytokine levels in the infarct. At 13 weeks after stroke, adaptive immune cell infiltration in the infarct was unchanged in LM11A-31-treated mice, indicating that LM11A-31 does not alter the chronic inflammatory response to stroke at the site of the infarct. However, LM11A-31-treated mice had less brain atrophy, neurodegeneration, tau pathology, and microglial activation in other regions of the ipsilateral hemisphere. These findings correlated with improved recovery of motor function on a ladder test, improved sensorimotor and cognitive abilities on a nest construction test, and less impulsivity in an open field test. These data support small molecule modulation of the p75<sup>NTR</sup> for preserving neuronal health and function during stroke recovery. SIGNIFICANCE STATEMENT: The findings from this study introduce the p75 neurotrophin receptor as a novel small molecule target for promotion of stroke recovery. Given that LM11A-31 is in clinical trials as a potential therapy for Alzheimer's disease, it could be considered as a candidate for assessment in stroke or vascular dementia studies.",2021-12-10,the aim of this study was to test whether poststroke oral administration of a small molecule p75 neurotrophin receptor p75supntrsup modulator lm11a31 can augment neuronal survival and improve recovery in a mouse model of stroke mice were administered lm11a31 for up to 12 weeks beginning 1 week after stroke metabolomic analysis revealed that after 2 weeks of daily treatment mice that received lm11a31 were distinct from vehicletreated mice by principal component analysis and had higher levels of serotonin acetylcholine and dopamine in their ipsilateral hemisphere lm11a31 treatment also improved redox homeostasis by restoring reduced glutathione it also offset a strokeinduced reduction in glycolysis by increasing acetylcoa there was no effect on cytokine levels in the infarct at 13 weeks after stroke adaptive immune cell infiltration in the infarct was unchanged in lm11a31treated mice indicating that lm11a31 does not alter the chronic inflammatory response to stroke at the site of the infarct however lm11a31treated mice had less brain atrophy neurodegeneration tau pathology and microglial activation in other regions of the ipsilateral hemisphere these findings correlated with improved recovery of motor function on a ladder test improved sensorimotor and cognitive abilities on a nest construction test and less impulsivity in an open field test these data support small molecule modulation of the p75supntrsup for preserving neuronal health and function during stroke recovery significance statement the findings from this study introduce the p75 neurotrophin receptor as a novel small molecule target for promotion of stroke recovery given that lm11a31 is in clinical trials as a potential therapy for alzheimers disease it could be considered as a candidate for assessment in stroke or vascular dementia studies,"['the', 'aim', 'of', 'this', 'study', 'was', 'to', 'test', 'whether', 'poststroke', 'oral', 'administration', 'of', 'a', 'small', 'molecule', 'p75', 'neurotrophin', 'receptor', 'p75supntrsup', 'modulator', 'lm11a31', 'can', 'augment', 'neuronal', 'survival', 'and', 'improve', 'recovery', 'in', 'a', 'mouse', 'model', 'of', 'stroke', 'mice', 'were', 'administered', 'lm11a31', 'for', 'up', 'to', '12', 'weeks', 'beginning', '1', 'week', 'after', 'stroke', 'metabolomic', 'analysis', 'revealed', 'that', 'after', '2', 'weeks', 'of', 'daily', 'treatment', 'mice', 'that', 'received', 'lm11a31', 'were', 'distinct', 'from', 'vehicletreated', 'mice', 'by', 'principal', 'component', 'analysis', 'and', 'had', 'higher', 'levels', 'of', 'serotonin', 'acetylcholine', 'and', 'dopamine', 'in', 'their', 'ipsilateral', 'hemisphere', 'lm11a31', 'treatment', 'also', 'improved', 'redox', 'homeostasis', 'by', 'restoring', 'reduced', 'glutathione', 'it', 'also', 'offset', 'a', 'strokeinduced', 'reduction', 'in', 'glycolysis', 'by', 'increasing', 'acetylcoa', 'there', 'was', 'no', 'effect', 'on', 'cytokine', 'levels', 'in', 'the', 'infarct', 'at', '13', 'weeks', 'after', 'stroke', 'adaptive', 'immune', 'cell', 'infiltration', 'in', 'the', 'infarct', 'was', 'unchanged', 'in', 'lm11a31treated', 'mice', 'indicating', 'that', 'lm11a31', 'does', 'not', 'alter', 'the', 'chronic', 'inflammatory', 'response', 'to', 'stroke', 'at', 'the', 'site', 'of', 'the', 'infarct', 'however', 'lm11a31treated', 'mice', 'had', 'less', 'brain', 'atrophy', 'neurodegeneration', 'tau', 'pathology', 'and', 'microglial', 'activation', 'in', 'other', 'regions', 'of', 'the', 'ipsilateral', 'hemisphere', 'these', 'findings', 'correlated', 'with', 'improved', 'recovery', 'of', 'motor', 'function', 'on', 'a', 'ladder', 'test', 'improved', 'sensorimotor', 'and', 'cognitive', 'abilities', 'on', 'a', 'nest', 'construction', 'test', 'and', 'less', 'impulsivity', 'in', 'an', 'open', 'field', 'test', 'these', 'data', 'support', 'small', 'molecule', 'modulation', 'of', 'the', 'p75supntrsup', 'for', 'preserving', 'neuronal', 'health', 'and', 'function', 'during', 'stroke', 'recovery', 'significance', 'statement', 'the', 'findings', 'from', 'this', 'study', 'introduce', 'the', 'p75', 'neurotrophin', 'receptor', 'as', 'a', 'novel', 'small', 'molecule', 'target', 'for', 'promotion', 'of', 'stroke', 'recovery', 'given', 'that', 'lm11a31', 'is', 'in', 'clinical', 'trials', 'as', 'a', 'potential', 'therapy', 'for', 'alzheimers', 'disease', 'it', 'could', 'be', 'considered', 'as', 'a', 'candidate', 'for', 'assessment', 'in', 'stroke', 'or', 'vascular', 'dementia', 'studies']","['aim', 'study', 'test', 'whether', 'poststroke', 'oral', 'administration', 'small', 'molecule', 'p75', 'neurotrophin', 'receptor', 'p75supntrsup', 'modulator', 'lm11a31', 'augment', 'neuronal', 'survival', 'improve', 'recovery', 'mouse', 'model', 'stroke', 'mice', 'administered', 'lm11a31', '12', 'weeks', 'beginning', '1', 'week', 'stroke', 'metabolomic', 'analysis', 'revealed', '2', 'weeks', 'daily', 'treatment', 'mice', 'received', 'lm11a31', 'distinct', 'vehicletreated', 'mice', 'principal', 'component', 'analysis', 'higher', 'levels', 'serotonin', 'acetylcholine', 'dopamine', 'ipsilateral', 'hemisphere', 'lm11a31', 'treatment', 'also', 'improved', 'redox', 'homeostasis', 'restoring', 'reduced', 'glutathione', 'also', 'offset', 'strokeinduced', 'reduction', 'glycolysis', 'increasing', 'acetylcoa', 'effect', 'cytokine', 'levels', 'infarct', '13', 'weeks', 'stroke', 'adaptive', 'immune', 'cell', 'infiltration', 'infarct', 'unchanged', 'lm11a31treated', 'mice', 'indicating', 'lm11a31', 'alter', 'chronic', 'inflammatory', 'response', 'stroke', 'site', 'infarct', 'however', 'lm11a31treated', 'mice', 'less', 'brain', 'atrophy', 'neurodegeneration', 'tau', 'pathology', 'microglial', 'activation', 'regions', 'ipsilateral', 'hemisphere', 'findings', 'correlated', 'improved', 'recovery', 'motor', 'function', 'ladder', 'test', 'improved', 'sensorimotor', 'cognitive', 'abilities', 'nest', 'construction', 'test', 'less', 'impulsivity', 'open', 'field', 'test', 'data', 'support', 'small', 'molecule', 'modulation', 'p75supntrsup', 'preserving', 'neuronal', 'health', 'function', 'stroke', 'recovery', 'significance', 'statement', 'findings', 'study', 'introduce', 'p75', 'neurotrophin', 'receptor', 'novel', 'small', 'molecule', 'target', 'promotion', 'stroke', 'recovery', 'given', 'lm11a31', 'clinical', 'trials', 'potential', 'therapy', 'alzheimers', 'disease', 'could', 'considered', 'candidate', 'assessment', 'stroke', 'vascular', 'dementia', 'studies']","['p75', 'neurotrophin', 'serotonin', 'tau', 'p75', 'neurotrophin']","['neurotrophin', 'neurotrophin']",True,['alzheimer']
34816327,PIK3CA hotspot mutations p. H1047R and p. H1047L sensitize breast cancer cells to thymoquinone treatment by regulating the PI3K/Akt1 pathway.,"Nigella sativa (N. sativa) exhibits anti-inflammatory, antioxidant, antidiabetic, antimetastatic and antinociceptive effects and has been used to treat dozens of diseases. Thymoquinone (TQ) is an important and active component isolated from N. sativa seeds. Inhibition of cancer-associated activating PIK3CA mutations is a new prospective targeted therapy in personalized metastatic breast cancer (MBC). TQ is reported to be an effective inhibitor of the PI3K/Akt1 pathway in MBC. This study aimed to evaluate the in vitro antitumor effect of TQ in the context of two PIK3CA hotspot mutations, p. H1047R and p. H1047L.",2021-11-23,nigella sativa n sativa exhibits antiinflammatory antioxidant antidiabetic antimetastatic and antinociceptive effects and has been used to treat dozens of diseases thymoquinone tq is an important and active component isolated from n sativa seeds inhibition of cancerassociated activating pik3ca mutations is a new prospective targeted therapy in personalized metastatic breast cancer mbc tq is reported to be an effective inhibitor of the pi3kakt1 pathway in mbc this study aimed to evaluate the in vitro antitumor effect of tq in the context of two pik3ca hotspot mutations p h1047r and p h1047l,"['nigella', 'sativa', 'n', 'sativa', 'exhibits', 'antiinflammatory', 'antioxidant', 'antidiabetic', 'antimetastatic', 'and', 'antinociceptive', 'effects', 'and', 'has', 'been', 'used', 'to', 'treat', 'dozens', 'of', 'diseases', 'thymoquinone', 'tq', 'is', 'an', 'important', 'and', 'active', 'component', 'isolated', 'from', 'n', 'sativa', 'seeds', 'inhibition', 'of', 'cancerassociated', 'activating', 'pik3ca', 'mutations', 'is', 'a', 'new', 'prospective', 'targeted', 'therapy', 'in', 'personalized', 'metastatic', 'breast', 'cancer', 'mbc', 'tq', 'is', 'reported', 'to', 'be', 'an', 'effective', 'inhibitor', 'of', 'the', 'pi3kakt1', 'pathway', 'in', 'mbc', 'this', 'study', 'aimed', 'to', 'evaluate', 'the', 'in', 'vitro', 'antitumor', 'effect', 'of', 'tq', 'in', 'the', 'context', 'of', 'two', 'pik3ca', 'hotspot', 'mutations', 'p', 'h1047r', 'and', 'p', 'h1047l']","['nigella', 'sativa', 'n', 'sativa', 'exhibits', 'antiinflammatory', 'antioxidant', 'antidiabetic', 'antimetastatic', 'antinociceptive', 'effects', 'used', 'treat', 'dozens', 'diseases', 'thymoquinone', 'tq', 'important', 'active', 'component', 'isolated', 'n', 'sativa', 'seeds', 'inhibition', 'cancerassociated', 'activating', 'pik3ca', 'mutations', 'new', 'prospective', 'targeted', 'therapy', 'personalized', 'metastatic', 'breast', 'cancer', 'mbc', 'tq', 'reported', 'effective', 'inhibitor', 'pi3kakt1', 'pathway', 'mbc', 'study', 'aimed', 'evaluate', 'vitro', 'antitumor', 'effect', 'tq', 'context', 'two', 'pik3ca', 'hotspot', 'mutations', 'p', 'h1047r', 'p', 'h1047l']","['pik3ca', 'pik3ca']","['pik3ca', 'pik3ca']",True,"['tumor', 'cancer']"
34771675,Advances in Pancreatic Ductal Adenocarcinoma Treatment.,"Pancreatic Ductal Adenocarcinoma (PDAC) is one of the deadliest malignancies among all cancers. Despite curative intent, surgery and the use of standard cytotoxic chemotherapy and radiation therapy, PDAC remains treatment-resistant. In recent years, more contemporary treatment modalities such as immunotherapy via checkpoint inhibition have shown some promise in many other malignancies, yet PDAC still eludes an effective curative treatment. In investigating these phenomena, research has suggested that the significant desmoplastic and adaptive tumor microenvironment (TME) of PDAC promote the proliferation of immunosuppressive cells and act as major obstacles to treatment efficacy. In this review, we explore challenges associated with the treatment of PDAC, including its unique immunosuppressive TME. This review examines the role of surgery in PDAC, recent advances in surgical approaches and surgical optimization. We further focus on advances in immunotherapeutic approaches, including checkpoint inhibition, CD40 agonists, and discuss promising immune-based future strategies, such as therapeutic neoantigen cancer vaccines as means of overcoming the resistance mechanisms which underly the dense stroma and immune milieu of PDAC. We also explore unique signaling, TME and stromal targeting via novel small molecule inhibitors, which target KRAS, FAK, CCR2/CCR5, CXCR4, PARP and cancer-associated fibroblasts. This review also explores the most promising strategy for advancement in treatment of pancreatic cancer by reviewing contemporary combinatorial approaches in efforts to overcome the treatment refractory nature of PDAC.",2021-11-03,pancreatic ductal adenocarcinoma pdac is one of the deadliest malignancies among all cancers despite curative intent surgery and the use of standard cytotoxic chemotherapy and radiation therapy pdac remains treatmentresistant in recent years more contemporary treatment modalities such as immunotherapy via checkpoint inhibition have shown some promise in many other malignancies yet pdac still eludes an effective curative treatment in investigating these phenomena research has suggested that the significant desmoplastic and adaptive tumor microenvironment tme of pdac promote the proliferation of immunosuppressive cells and act as major obstacles to treatment efficacy in this review we explore challenges associated with the treatment of pdac including its unique immunosuppressive tme this review examines the role of surgery in pdac recent advances in surgical approaches and surgical optimization we further focus on advances in immunotherapeutic approaches including checkpoint inhibition cd40 agonists and discuss promising immunebased future strategies such as therapeutic neoantigen cancer vaccines as means of overcoming the resistance mechanisms which underly the dense stroma and immune milieu of pdac we also explore unique signaling tme and stromal targeting via novel small molecule inhibitors which target kras fak ccr2ccr5 cxcr4 parp and cancerassociated fibroblasts this review also explores the most promising strategy for advancement in treatment of pancreatic cancer by reviewing contemporary combinatorial approaches in efforts to overcome the treatment refractory nature of pdac,"['pancreatic', 'ductal', 'adenocarcinoma', 'pdac', 'is', 'one', 'of', 'the', 'deadliest', 'malignancies', 'among', 'all', 'cancers', 'despite', 'curative', 'intent', 'surgery', 'and', 'the', 'use', 'of', 'standard', 'cytotoxic', 'chemotherapy', 'and', 'radiation', 'therapy', 'pdac', 'remains', 'treatmentresistant', 'in', 'recent', 'years', 'more', 'contemporary', 'treatment', 'modalities', 'such', 'as', 'immunotherapy', 'via', 'checkpoint', 'inhibition', 'have', 'shown', 'some', 'promise', 'in', 'many', 'other', 'malignancies', 'yet', 'pdac', 'still', 'eludes', 'an', 'effective', 'curative', 'treatment', 'in', 'investigating', 'these', 'phenomena', 'research', 'has', 'suggested', 'that', 'the', 'significant', 'desmoplastic', 'and', 'adaptive', 'tumor', 'microenvironment', 'tme', 'of', 'pdac', 'promote', 'the', 'proliferation', 'of', 'immunosuppressive', 'cells', 'and', 'act', 'as', 'major', 'obstacles', 'to', 'treatment', 'efficacy', 'in', 'this', 'review', 'we', 'explore', 'challenges', 'associated', 'with', 'the', 'treatment', 'of', 'pdac', 'including', 'its', 'unique', 'immunosuppressive', 'tme', 'this', 'review', 'examines', 'the', 'role', 'of', 'surgery', 'in', 'pdac', 'recent', 'advances', 'in', 'surgical', 'approaches', 'and', 'surgical', 'optimization', 'we', 'further', 'focus', 'on', 'advances', 'in', 'immunotherapeutic', 'approaches', 'including', 'checkpoint', 'inhibition', 'cd40', 'agonists', 'and', 'discuss', 'promising', 'immunebased', 'future', 'strategies', 'such', 'as', 'therapeutic', 'neoantigen', 'cancer', 'vaccines', 'as', 'means', 'of', 'overcoming', 'the', 'resistance', 'mechanisms', 'which', 'underly', 'the', 'dense', 'stroma', 'and', 'immune', 'milieu', 'of', 'pdac', 'we', 'also', 'explore', 'unique', 'signaling', 'tme', 'and', 'stromal', 'targeting', 'via', 'novel', 'small', 'molecule', 'inhibitors', 'which', 'target', 'kras', 'fak', 'ccr2ccr5', 'cxcr4', 'parp', 'and', 'cancerassociated', 'fibroblasts', 'this', 'review', 'also', 'explores', 'the', 'most', 'promising', 'strategy', 'for', 'advancement', 'in', 'treatment', 'of', 'pancreatic', 'cancer', 'by', 'reviewing', 'contemporary', 'combinatorial', 'approaches', 'in', 'efforts', 'to', 'overcome', 'the', 'treatment', 'refractory', 'nature', 'of', 'pdac']","['pancreatic', 'ductal', 'adenocarcinoma', 'pdac', 'one', 'deadliest', 'malignancies', 'among', 'cancers', 'despite', 'curative', 'intent', 'surgery', 'use', 'standard', 'cytotoxic', 'chemotherapy', 'radiation', 'therapy', 'pdac', 'remains', 'treatmentresistant', 'recent', 'years', 'contemporary', 'treatment', 'modalities', 'immunotherapy', 'via', 'checkpoint', 'inhibition', 'shown', 'promise', 'many', 'malignancies', 'yet', 'pdac', 'still', 'eludes', 'effective', 'curative', 'treatment', 'investigating', 'phenomena', 'research', 'suggested', 'significant', 'desmoplastic', 'adaptive', 'tumor', 'microenvironment', 'tme', 'pdac', 'promote', 'proliferation', 'immunosuppressive', 'cells', 'act', 'major', 'obstacles', 'treatment', 'efficacy', 'review', 'explore', 'challenges', 'associated', 'treatment', 'pdac', 'including', 'unique', 'immunosuppressive', 'tme', 'review', 'examines', 'role', 'surgery', 'pdac', 'recent', 'advances', 'surgical', 'approaches', 'surgical', 'optimization', 'focus', 'advances', 'immunotherapeutic', 'approaches', 'including', 'checkpoint', 'inhibition', 'cd40', 'agonists', 'discuss', 'promising', 'immunebased', 'future', 'strategies', 'therapeutic', 'neoantigen', 'cancer', 'vaccines', 'means', 'overcoming', 'resistance', 'mechanisms', 'underly', 'dense', 'stroma', 'immune', 'milieu', 'pdac', 'also', 'explore', 'unique', 'signaling', 'tme', 'stromal', 'targeting', 'via', 'novel', 'small', 'molecule', 'inhibitors', 'target', 'kras', 'fak', 'ccr2ccr5', 'cxcr4', 'parp', 'cancerassociated', 'fibroblasts', 'review', 'also', 'explores', 'promising', 'strategy', 'advancement', 'treatment', 'pancreatic', 'cancer', 'reviewing', 'contemporary', 'combinatorial', 'approaches', 'efforts', 'overcome', 'treatment', 'refractory', 'nature', 'pdac']","['cd40', 'neoantigen', 'fak', 'cxcr4']",['neoantigen'],True,"['tumor', 'cancer']"
34765320,"Multiple functions of the DEAD-box RNA helicase, DDX5 (p68), make DDX5 a superior oncogenic biomarker and target for targeted cancer therapy.","DDX5 (p68) is a well-known multifunctional DEAD-box RNA helicase and a transcription cofactor. Since its initial discovery more than three decades ago, DDX5 is gradually recognized as a potential biomarker and target for the treatment of various cancer types. Studies over the years significantly expanded our understanding of the functional diversity of DDX5 in various cancer types and extended our knowledge of its Mechanism of Action (MOA). This provides a rationale for the development of novel cancer therapeutics by using DDX5 as a biomarker and a therapeutic target. However, while most of the published studies have found DDX5 to be an oncogenic target and a cancer treatment-resistant biomarker, a few studies have reported that in certain scenarios, DDX5 may act as a tumor suppressor. After careful review of all the available relevant studies in the literature, we found that the multiple functions of DDX5 make it both a superior independent oncogenic biomarker and target for targeted cancer therapy. In this article, we will summarize the relevant studies on DDX5 in literature with a careful analysis and discussion of any inconsistencies encountered, and then provide our conclusions with respect to understanding the MOA of FL118, a novel small molecule. We hope that such a review will stimulate further discussion on this topic and assist in developing better strategies to treat cancer by using DDX5 as both an oncogenic biomarker and therapeutic target.",2021-10-15,ddx5 p68 is a wellknown multifunctional deadbox rna helicase and a transcription cofactor since its initial discovery more than three decades ago ddx5 is gradually recognized as a potential biomarker and target for the treatment of various cancer types studies over the years significantly expanded our understanding of the functional diversity of ddx5 in various cancer types and extended our knowledge of its mechanism of action moa this provides a rationale for the development of novel cancer therapeutics by using ddx5 as a biomarker and a therapeutic target however while most of the published studies have found ddx5 to be an oncogenic target and a cancer treatmentresistant biomarker a few studies have reported that in certain scenarios ddx5 may act as a tumor suppressor after careful review of all the available relevant studies in the literature we found that the multiple functions of ddx5 make it both a superior independent oncogenic biomarker and target for targeted cancer therapy in this article we will summarize the relevant studies on ddx5 in literature with a careful analysis and discussion of any inconsistencies encountered and then provide our conclusions with respect to understanding the moa of fl118 a novel small molecule we hope that such a review will stimulate further discussion on this topic and assist in developing better strategies to treat cancer by using ddx5 as both an oncogenic biomarker and therapeutic target,"['ddx5', 'p68', 'is', 'a', 'wellknown', 'multifunctional', 'deadbox', 'rna', 'helicase', 'and', 'a', 'transcription', 'cofactor', 'since', 'its', 'initial', 'discovery', 'more', 'than', 'three', 'decades', 'ago', 'ddx5', 'is', 'gradually', 'recognized', 'as', 'a', 'potential', 'biomarker', 'and', 'target', 'for', 'the', 'treatment', 'of', 'various', 'cancer', 'types', 'studies', 'over', 'the', 'years', 'significantly', 'expanded', 'our', 'understanding', 'of', 'the', 'functional', 'diversity', 'of', 'ddx5', 'in', 'various', 'cancer', 'types', 'and', 'extended', 'our', 'knowledge', 'of', 'its', 'mechanism', 'of', 'action', 'moa', 'this', 'provides', 'a', 'rationale', 'for', 'the', 'development', 'of', 'novel', 'cancer', 'therapeutics', 'by', 'using', 'ddx5', 'as', 'a', 'biomarker', 'and', 'a', 'therapeutic', 'target', 'however', 'while', 'most', 'of', 'the', 'published', 'studies', 'have', 'found', 'ddx5', 'to', 'be', 'an', 'oncogenic', 'target', 'and', 'a', 'cancer', 'treatmentresistant', 'biomarker', 'a', 'few', 'studies', 'have', 'reported', 'that', 'in', 'certain', 'scenarios', 'ddx5', 'may', 'act', 'as', 'a', 'tumor', 'suppressor', 'after', 'careful', 'review', 'of', 'all', 'the', 'available', 'relevant', 'studies', 'in', 'the', 'literature', 'we', 'found', 'that', 'the', 'multiple', 'functions', 'of', 'ddx5', 'make', 'it', 'both', 'a', 'superior', 'independent', 'oncogenic', 'biomarker', 'and', 'target', 'for', 'targeted', 'cancer', 'therapy', 'in', 'this', 'article', 'we', 'will', 'summarize', 'the', 'relevant', 'studies', 'on', 'ddx5', 'in', 'literature', 'with', 'a', 'careful', 'analysis', 'and', 'discussion', 'of', 'any', 'inconsistencies', 'encountered', 'and', 'then', 'provide', 'our', 'conclusions', 'with', 'respect', 'to', 'understanding', 'the', 'moa', 'of', 'fl118', 'a', 'novel', 'small', 'molecule', 'we', 'hope', 'that', 'such', 'a', 'review', 'will', 'stimulate', 'further', 'discussion', 'on', 'this', 'topic', 'and', 'assist', 'in', 'developing', 'better', 'strategies', 'to', 'treat', 'cancer', 'by', 'using', 'ddx5', 'as', 'both', 'an', 'oncogenic', 'biomarker', 'and', 'therapeutic', 'target']","['ddx5', 'p68', 'wellknown', 'multifunctional', 'deadbox', 'rna', 'helicase', 'transcription', 'cofactor', 'since', 'initial', 'discovery', 'three', 'decades', 'ago', 'ddx5', 'gradually', 'recognized', 'potential', 'biomarker', 'target', 'treatment', 'various', 'cancer', 'types', 'studies', 'years', 'significantly', 'expanded', 'understanding', 'functional', 'diversity', 'ddx5', 'various', 'cancer', 'types', 'extended', 'knowledge', 'mechanism', 'action', 'moa', 'provides', 'rationale', 'development', 'novel', 'cancer', 'therapeutics', 'using', 'ddx5', 'biomarker', 'therapeutic', 'target', 'however', 'published', 'studies', 'found', 'ddx5', 'oncogenic', 'target', 'cancer', 'treatmentresistant', 'biomarker', 'studies', 'reported', 'certain', 'scenarios', 'ddx5', 'may', 'act', 'tumor', 'suppressor', 'careful', 'review', 'available', 'relevant', 'studies', 'literature', 'found', 'multiple', 'functions', 'ddx5', 'make', 'superior', 'independent', 'oncogenic', 'biomarker', 'target', 'targeted', 'cancer', 'therapy', 'article', 'summarize', 'relevant', 'studies', 'ddx5', 'literature', 'careful', 'analysis', 'discussion', 'inconsistencies', 'encountered', 'provide', 'conclusions', 'respect', 'understanding', 'moa', 'fl118', 'novel', 'small', 'molecule', 'hope', 'review', 'stimulate', 'discussion', 'topic', 'assist', 'developing', 'better', 'strategies', 'treat', 'cancer', 'using', 'ddx5', 'oncogenic', 'biomarker', 'therapeutic', 'target']","['ddx5', 'p68', 'deadbox', 'rna', 'ddx5', 'ddx5', 'ddx5', 'ddx5', 'ddx5', 'ddx5', 'ddx5', 'ddx5']","['ddx5', 'deadbox', 'ddx5', 'ddx5', 'ddx5', 'ddx5', 'ddx5', 'ddx5', 'ddx5', 'ddx5']",True,"['tumor', 'cancer']"
34717237,"Design, synthesis and binding mode of interaction of novel small molecule o-hydroxy benzamides as HDAC3-selective inhibitors with promising antitumor effects in 4T1-Luc breast cancer xenograft model.","Histone deacetylase 3 (HDAC3) is one of the most promising targets to develop anticancer therapeutics. In continuation of our quest for selective HDAC3 inhibitors, a series of small molecules having o-hydroxy benzamide as the novel zinc binding group (ZBG) has been introduced for the first time that can be able to produce good HDAC3-selectivity over other HDACs. The most promising HDAC3 inhibitors, 11a and 12b, displayed promising in vitro anticancer activities with less toxicity to normal kidney cells. These compounds significantly upregulate histone acetylation and induce apoptosis with a G2/M phase arrest in B16F10 cells. Compound 11a exhibited potent antitumor efficacy in 4T1-Luc breast cancer xenograft mouse model in female Balb/c mice. It also showed significant tumor growth suppression with no general toxicity and extended survival rates post-tumor resection. It significantly induced higher ROS generation, leading to apoptosis. No considerable toxicity was noticed in major organs isolated from the compound 11a-treated mice. Compound 11a also induced the upregulation of acH3K9, acH4K12, caspase-3 and caspase-7 as analyzed by immunoblotting with treated tumor tissue. Overall, HDAC3 selective inhibitor 11a might be a potential lead for the clinical translation as an emerging drug candidate.",2021-10-22,histone deacetylase 3 hdac3 is one of the most promising targets to develop anticancer therapeutics in continuation of our quest for selective hdac3 inhibitors a series of small molecules having ohydroxy benzamide as the novel zinc binding group zbg has been introduced for the first time that can be able to produce good hdac3selectivity over other hdacs the most promising hdac3 inhibitors 11a and 12b displayed promising in vitro anticancer activities with less toxicity to normal kidney cells these compounds significantly upregulate histone acetylation and induce apoptosis with a g2m phase arrest in b16f10 cells compound 11a exhibited potent antitumor efficacy in 4t1luc breast cancer xenograft mouse model in female balbc mice it also showed significant tumor growth suppression with no general toxicity and extended survival rates posttumor resection it significantly induced higher ros generation leading to apoptosis no considerable toxicity was noticed in major organs isolated from the compound 11atreated mice compound 11a also induced the upregulation of ach3k9 ach4k12 caspase3 and caspase7 as analyzed by immunoblotting with treated tumor tissue overall hdac3 selective inhibitor 11a might be a potential lead for the clinical translation as an emerging drug candidate,"['histone', 'deacetylase', '3', 'hdac3', 'is', 'one', 'of', 'the', 'most', 'promising', 'targets', 'to', 'develop', 'anticancer', 'therapeutics', 'in', 'continuation', 'of', 'our', 'quest', 'for', 'selective', 'hdac3', 'inhibitors', 'a', 'series', 'of', 'small', 'molecules', 'having', 'ohydroxy', 'benzamide', 'as', 'the', 'novel', 'zinc', 'binding', 'group', 'zbg', 'has', 'been', 'introduced', 'for', 'the', 'first', 'time', 'that', 'can', 'be', 'able', 'to', 'produce', 'good', 'hdac3selectivity', 'over', 'other', 'hdacs', 'the', 'most', 'promising', 'hdac3', 'inhibitors', '11a', 'and', '12b', 'displayed', 'promising', 'in', 'vitro', 'anticancer', 'activities', 'with', 'less', 'toxicity', 'to', 'normal', 'kidney', 'cells', 'these', 'compounds', 'significantly', 'upregulate', 'histone', 'acetylation', 'and', 'induce', 'apoptosis', 'with', 'a', 'g2m', 'phase', 'arrest', 'in', 'b16f10', 'cells', 'compound', '11a', 'exhibited', 'potent', 'antitumor', 'efficacy', 'in', '4t1luc', 'breast', 'cancer', 'xenograft', 'mouse', 'model', 'in', 'female', 'balbc', 'mice', 'it', 'also', 'showed', 'significant', 'tumor', 'growth', 'suppression', 'with', 'no', 'general', 'toxicity', 'and', 'extended', 'survival', 'rates', 'posttumor', 'resection', 'it', 'significantly', 'induced', 'higher', 'ros', 'generation', 'leading', 'to', 'apoptosis', 'no', 'considerable', 'toxicity', 'was', 'noticed', 'in', 'major', 'organs', 'isolated', 'from', 'the', 'compound', '11atreated', 'mice', 'compound', '11a', 'also', 'induced', 'the', 'upregulation', 'of', 'ach3k9', 'ach4k12', 'caspase3', 'and', 'caspase7', 'as', 'analyzed', 'by', 'immunoblotting', 'with', 'treated', 'tumor', 'tissue', 'overall', 'hdac3', 'selective', 'inhibitor', '11a', 'might', 'be', 'a', 'potential', 'lead', 'for', 'the', 'clinical', 'translation', 'as', 'an', 'emerging', 'drug', 'candidate']","['histone', 'deacetylase', '3', 'hdac3', 'one', 'promising', 'targets', 'develop', 'anticancer', 'therapeutics', 'continuation', 'quest', 'selective', 'hdac3', 'inhibitors', 'series', 'small', 'molecules', 'ohydroxy', 'benzamide', 'novel', 'zinc', 'binding', 'group', 'zbg', 'introduced', 'first', 'time', 'able', 'produce', 'good', 'hdac3selectivity', 'hdacs', 'promising', 'hdac3', 'inhibitors', '11a', '12b', 'displayed', 'promising', 'vitro', 'anticancer', 'activities', 'less', 'toxicity', 'normal', 'kidney', 'cells', 'compounds', 'significantly', 'upregulate', 'histone', 'acetylation', 'induce', 'apoptosis', 'g2m', 'phase', 'arrest', 'b16f10', 'cells', 'compound', '11a', 'exhibited', 'potent', 'antitumor', 'efficacy', '4t1luc', 'breast', 'cancer', 'xenograft', 'mouse', 'model', 'female', 'balbc', 'mice', 'also', 'showed', 'significant', 'tumor', 'growth', 'suppression', 'general', 'toxicity', 'extended', 'survival', 'rates', 'posttumor', 'resection', 'significantly', 'induced', 'higher', 'ros', 'generation', 'leading', 'apoptosis', 'considerable', 'toxicity', 'noticed', 'major', 'organs', 'isolated', 'compound', '11atreated', 'mice', 'compound', '11a', 'also', 'induced', 'upregulation', 'ach3k9', 'ach4k12', 'caspase3', 'caspase7', 'analyzed', 'immunoblotting', 'treated', 'tumor', 'tissue', 'overall', 'hdac3', 'selective', 'inhibitor', '11a', 'might', 'potential', 'lead', 'clinical', 'translation', 'emerging', 'drug', 'candidate']","['histone', 'deacetylase', 'ros', 'caspase3', 'caspase7']","['caspase3', 'caspase7']",True,"['tumor', 'cancer']"
34674294,"Design, synthesis, and evaluation of novel (E)-N'-(3-allyl-2-hydroxy)benzylidene-2-(4-oxoquinazolin-3(4H)-yl)acetohydrazides as antitumor agents.","In our continuing search for novel small-molecule anticancer agents, we designed and synthesized a series of novel (E)-N'-(3-allyl-2-hydroxy)benzylidene-2-(4-oxoquinazolin-3(4H)-yl)acetohydrazides (5), focusing on the modification of substitution in the quinazolin-4(3H)-one moiety. The biological evaluation showed that all 13 designed and synthesized compounds displayed significant cytotoxicity against three human cancer cell lines (SW620, colon cancer; PC-3, prostate cancer; NCI-H23, lung cancer). The most potent compound 5l displayed cytotoxicity up to 213-fold more potent than 5-fluorouracil and 87-fold more potent than PAC-1, the first procaspase-activating compound. Structure-activity relationship analysis revealed that substitution of either electron-withdrawing or electron-releasing groups at positions 6 or 7 on the quinazolin-4(3H)-4-one moiety increased the cytotoxicity of the compounds, but substitution at position 6 seemed to be more favorable. In the caspase activation assay, compound 5l was found to activate the caspase activity by 291% in comparison to PAC-1, which was used as a control. Further docking simulation also revealed that this compound may be a potent allosteric inhibitor of procaspase-3 through chelation of the inhibitory zinc ion. Physicochemical and ADMET calculations for 5l provided useful information of its suitable absorption profile and some toxicological effects that need further optimization to be developed as a promising anticancer agent.",2021-10-21,in our continuing search for novel smallmolecule anticancer agents we designed and synthesized a series of novel en3allyl2hydroxybenzylidene24oxoquinazolin34hylacetohydrazides 5 focusing on the modification of substitution in the quinazolin43hone moiety the biological evaluation showed that all 13 designed and synthesized compounds displayed significant cytotoxicity against three human cancer cell lines sw620 colon cancer pc3 prostate cancer ncih23 lung cancer the most potent compound 5l displayed cytotoxicity up to 213fold more potent than 5fluorouracil and 87fold more potent than pac1 the first procaspaseactivating compound structureactivity relationship analysis revealed that substitution of either electronwithdrawing or electronreleasing groups at positions 6 or 7 on the quinazolin43h4one moiety increased the cytotoxicity of the compounds but substitution at position 6 seemed to be more favorable in the caspase activation assay compound 5l was found to activate the caspase activity by 291 in comparison to pac1 which was used as a control further docking simulation also revealed that this compound may be a potent allosteric inhibitor of procaspase3 through chelation of the inhibitory zinc ion physicochemical and admet calculations for 5l provided useful information of its suitable absorption profile and some toxicological effects that need further optimization to be developed as a promising anticancer agent,"['in', 'our', 'continuing', 'search', 'for', 'novel', 'smallmolecule', 'anticancer', 'agents', 'we', 'designed', 'and', 'synthesized', 'a', 'series', 'of', 'novel', 'en3allyl2hydroxybenzylidene24oxoquinazolin34hylacetohydrazides', '5', 'focusing', 'on', 'the', 'modification', 'of', 'substitution', 'in', 'the', 'quinazolin43hone', 'moiety', 'the', 'biological', 'evaluation', 'showed', 'that', 'all', '13', 'designed', 'and', 'synthesized', 'compounds', 'displayed', 'significant', 'cytotoxicity', 'against', 'three', 'human', 'cancer', 'cell', 'lines', 'sw620', 'colon', 'cancer', 'pc3', 'prostate', 'cancer', 'ncih23', 'lung', 'cancer', 'the', 'most', 'potent', 'compound', '5l', 'displayed', 'cytotoxicity', 'up', 'to', '213fold', 'more', 'potent', 'than', '5fluorouracil', 'and', '87fold', 'more', 'potent', 'than', 'pac1', 'the', 'first', 'procaspaseactivating', 'compound', 'structureactivity', 'relationship', 'analysis', 'revealed', 'that', 'substitution', 'of', 'either', 'electronwithdrawing', 'or', 'electronreleasing', 'groups', 'at', 'positions', '6', 'or', '7', 'on', 'the', 'quinazolin43h4one', 'moiety', 'increased', 'the', 'cytotoxicity', 'of', 'the', 'compounds', 'but', 'substitution', 'at', 'position', '6', 'seemed', 'to', 'be', 'more', 'favorable', 'in', 'the', 'caspase', 'activation', 'assay', 'compound', '5l', 'was', 'found', 'to', 'activate', 'the', 'caspase', 'activity', 'by', '291', 'in', 'comparison', 'to', 'pac1', 'which', 'was', 'used', 'as', 'a', 'control', 'further', 'docking', 'simulation', 'also', 'revealed', 'that', 'this', 'compound', 'may', 'be', 'a', 'potent', 'allosteric', 'inhibitor', 'of', 'procaspase3', 'through', 'chelation', 'of', 'the', 'inhibitory', 'zinc', 'ion', 'physicochemical', 'and', 'admet', 'calculations', 'for', '5l', 'provided', 'useful', 'information', 'of', 'its', 'suitable', 'absorption', 'profile', 'and', 'some', 'toxicological', 'effects', 'that', 'need', 'further', 'optimization', 'to', 'be', 'developed', 'as', 'a', 'promising', 'anticancer', 'agent']","['continuing', 'search', 'novel', 'smallmolecule', 'anticancer', 'agents', 'designed', 'synthesized', 'series', 'novel', 'en3allyl2hydroxybenzylidene24oxoquinazolin34hylacetohydrazides', '5', 'focusing', 'modification', 'substitution', 'quinazolin43hone', 'moiety', 'biological', 'evaluation', 'showed', '13', 'designed', 'synthesized', 'compounds', 'displayed', 'significant', 'cytotoxicity', 'three', 'human', 'cancer', 'cell', 'lines', 'sw620', 'colon', 'cancer', 'pc3', 'prostate', 'cancer', 'ncih23', 'lung', 'cancer', 'potent', 'compound', '5l', 'displayed', 'cytotoxicity', '213fold', 'potent', '5fluorouracil', '87fold', 'potent', 'pac1', 'first', 'procaspaseactivating', 'compound', 'structureactivity', 'relationship', 'analysis', 'revealed', 'substitution', 'either', 'electronwithdrawing', 'electronreleasing', 'groups', 'positions', '6', '7', 'quinazolin43h4one', 'moiety', 'increased', 'cytotoxicity', 'compounds', 'substitution', 'position', '6', 'seemed', 'favorable', 'caspase', 'activation', 'assay', 'compound', '5l', 'found', 'activate', 'caspase', 'activity', '291', 'comparison', 'pac1', 'used', 'control', 'docking', 'simulation', 'also', 'revealed', 'compound', 'may', 'potent', 'allosteric', 'inhibitor', 'procaspase3', 'chelation', 'inhibitory', 'zinc', 'ion', 'physicochemical', 'admet', 'calculations', '5l', 'provided', 'useful', 'information', 'suitable', 'absorption', 'profile', 'toxicological', 'effects', 'need', 'optimization', 'developed', 'promising', 'anticancer', 'agent']","['pac1', 'caspase', 'caspase', 'pac1', 'procaspase3']",['procaspase3'],True,['cancer']
34669461,High-Throughput Screening Identifies Inhibitors for Parvovirus B19 Infection of Human Erythroid Progenitors.,"Parvovirus B19 (B19V) infection can cause hematological disorders and fetal hydrops during pregnancy. Currently, no antivirals or vaccines are available for the treatment or prevention of B19V infection. To identify novel small-molecule antivirals against B19V replication, we developed a high-throughput screening (HTS) assay, which is based on an <i>in vitro</i> nicking assay using recombinant N-terminal amino acids 1 to 176 of the viral large nonstructural protein (NS1N) and a fluorescently labeled DNA probe (<i>OriQ</i>) that spans the nicking site of the viral DNA replication origin. We collectively screened 17,040 compounds and identified 2,178 (12.78%) hits that possess >10% inhibition of the NS1 nicking activity, among which 84 hits were confirmed to inhibit nicking in a dose-dependent manner. Using <i>ex vivo</i>-expanded primary human erythroid progenitor cells (EPCs) infected by B19V, we validated 24 compounds that demonstrated >50% <i>in vivo</i> inhibition of B19V infection at 10 μM, which can be categorized into 7 structure scaffolds. Based on the therapeutic index (half-maximal cytotoxic concentration [CC<sub>50</sub>]/half-maximal effective concentration [EC<sub>50</sub>] ratio) in EPCs, the top 4 compounds were chosen to examine their inhibitions of B19V infection in EPCs at two times of the 90% maximal effective concentration (EC<sub>90</sub>). A purine derivative (P7) demonstrated an antiviral effect (EC<sub>50</sub> = 1.46 μM) without prominent cytotoxicity (CC<sub>50</sub> = 71.8 μM) in EPCs and exhibited 92% inhibition of B19V infection in EPCs at 3.32 μM, which can be used as the lead compound in future studies for the treatment of B19V infection-caused hematological disorders. <b>IMPORTANCE</b> B19V encodes a large nonstructural protein, NS1. Its N-terminal domain (NS1N) consisting of amino acids 1 to 176 binds to viral DNA and serves as an endonuclease to nick the viral DNA replication origins, which is a pivotal step in rolling-hairpin-dependent B19V DNA replication. For high-throughput screening (HTS) of anti-B19V antivirals, we miniaturized a fluorescence-based <i>in vitro</i> nicking assay, which employs a fluorophore-labeled probe spanning the terminal resolution site (<i>trs</i>) and the NS1N protein, into a 384-well-plate format. The HTS assay showed high reliability and capability in screening 17,040 compounds. Based on the therapeutic index (half-maximal cytotoxic concentration [CC<sub>50</sub>]/half-maximal effective concentration [EC<sub>50</sub>] ratio) in EPCs, a purine derivative demonstrated an antiviral effect of 92% inhibition of B19V infection in EPCs at 3.32 μM (two times the EC<sub>90</sub>). Our study demonstrated a robust HTS assay for screening antivirals against B19V infection.",2021-10-20,parvovirus b19 b19v infection can cause hematological disorders and fetal hydrops during pregnancy currently no antivirals or vaccines are available for the treatment or prevention of b19v infection to identify novel smallmolecule antivirals against b19v replication we developed a highthroughput screening hts assay which is based on an iin vitroi nicking assay using recombinant nterminal amino acids 1 to 176 of the viral large nonstructural protein ns1n and a fluorescently labeled dna probe ioriqi that spans the nicking site of the viral dna replication origin we collectively screened 17040 compounds and identified 2178 1278 hits that possess 10 inhibition of the ns1 nicking activity among which 84 hits were confirmed to inhibit nicking in a dosedependent manner using iex vivoiexpanded primary human erythroid progenitor cells epcs infected by b19v we validated 24 compounds that demonstrated 50 iin vivoi inhibition of b19v infection at 10 μm which can be categorized into 7 structure scaffolds based on the therapeutic index halfmaximal cytotoxic concentration ccsub50subhalfmaximal effective concentration ecsub50sub ratio in epcs the top 4 compounds were chosen to examine their inhibitions of b19v infection in epcs at two times of the 90 maximal effective concentration ecsub90sub a purine derivative p7 demonstrated an antiviral effect ecsub50sub  146 μm without prominent cytotoxicity ccsub50sub  718 μm in epcs and exhibited 92 inhibition of b19v infection in epcs at 332 μm which can be used as the lead compound in future studies for the treatment of b19v infectioncaused hematological disorders bimportanceb b19v encodes a large nonstructural protein ns1 its nterminal domain ns1n consisting of amino acids 1 to 176 binds to viral dna and serves as an endonuclease to nick the viral dna replication origins which is a pivotal step in rollinghairpindependent b19v dna replication for highthroughput screening hts of antib19v antivirals we miniaturized a fluorescencebased iin vitroi nicking assay which employs a fluorophorelabeled probe spanning the terminal resolution site itrsi and the ns1n protein into a 384wellplate format the hts assay showed high reliability and capability in screening 17040 compounds based on the therapeutic index halfmaximal cytotoxic concentration ccsub50subhalfmaximal effective concentration ecsub50sub ratio in epcs a purine derivative demonstrated an antiviral effect of 92 inhibition of b19v infection in epcs at 332 μm two times the ecsub90sub our study demonstrated a robust hts assay for screening antivirals against b19v infection,"['parvovirus', 'b19', 'b19v', 'infection', 'can', 'cause', 'hematological', 'disorders', 'and', 'fetal', 'hydrops', 'during', 'pregnancy', 'currently', 'no', 'antivirals', 'or', 'vaccines', 'are', 'available', 'for', 'the', 'treatment', 'or', 'prevention', 'of', 'b19v', 'infection', 'to', 'identify', 'novel', 'smallmolecule', 'antivirals', 'against', 'b19v', 'replication', 'we', 'developed', 'a', 'highthroughput', 'screening', 'hts', 'assay', 'which', 'is', 'based', 'on', 'an', 'iin', 'vitroi', 'nicking', 'assay', 'using', 'recombinant', 'nterminal', 'amino', 'acids', '1', 'to', '176', 'of', 'the', 'viral', 'large', 'nonstructural', 'protein', 'ns1n', 'and', 'a', 'fluorescently', 'labeled', 'dna', 'probe', 'ioriqi', 'that', 'spans', 'the', 'nicking', 'site', 'of', 'the', 'viral', 'dna', 'replication', 'origin', 'we', 'collectively', 'screened', '17040', 'compounds', 'and', 'identified', '2178', '1278', 'hits', 'that', 'possess', '10', 'inhibition', 'of', 'the', 'ns1', 'nicking', 'activity', 'among', 'which', '84', 'hits', 'were', 'confirmed', 'to', 'inhibit', 'nicking', 'in', 'a', 'dosedependent', 'manner', 'using', 'iex', 'vivoiexpanded', 'primary', 'human', 'erythroid', 'progenitor', 'cells', 'epcs', 'infected', 'by', 'b19v', 'we', 'validated', '24', 'compounds', 'that', 'demonstrated', '50', 'iin', 'vivoi', 'inhibition', 'of', 'b19v', 'infection', 'at', '10', 'μm', 'which', 'can', 'be', 'categorized', 'into', '7', 'structure', 'scaffolds', 'based', 'on', 'the', 'therapeutic', 'index', 'halfmaximal', 'cytotoxic', 'concentration', 'ccsub50subhalfmaximal', 'effective', 'concentration', 'ecsub50sub', 'ratio', 'in', 'epcs', 'the', 'top', '4', 'compounds', 'were', 'chosen', 'to', 'examine', 'their', 'inhibitions', 'of', 'b19v', 'infection', 'in', 'epcs', 'at', 'two', 'times', 'of', 'the', '90', 'maximal', 'effective', 'concentration', 'ecsub90sub', 'a', 'purine', 'derivative', 'p7', 'demonstrated', 'an', 'antiviral', 'effect', 'ecsub50sub', '146', 'μm', 'without', 'prominent', 'cytotoxicity', 'ccsub50sub', '718', 'μm', 'in', 'epcs', 'and', 'exhibited', '92', 'inhibition', 'of', 'b19v', 'infection', 'in', 'epcs', 'at', '332', 'μm', 'which', 'can', 'be', 'used', 'as', 'the', 'lead', 'compound', 'in', 'future', 'studies', 'for', 'the', 'treatment', 'of', 'b19v', 'infectioncaused', 'hematological', 'disorders', 'bimportanceb', 'b19v', 'encodes', 'a', 'large', 'nonstructural', 'protein', 'ns1', 'its', 'nterminal', 'domain', 'ns1n', 'consisting', 'of', 'amino', 'acids', '1', 'to', '176', 'binds', 'to', 'viral', 'dna', 'and', 'serves', 'as', 'an', 'endonuclease', 'to', 'nick', 'the', 'viral', 'dna', 'replication', 'origins', 'which', 'is', 'a', 'pivotal', 'step', 'in', 'rollinghairpindependent', 'b19v', 'dna', 'replication', 'for', 'highthroughput', 'screening', 'hts', 'of', 'antib19v', 'antivirals', 'we', 'miniaturized', 'a', 'fluorescencebased', 'iin', 'vitroi', 'nicking', 'assay', 'which', 'employs', 'a', 'fluorophorelabeled', 'probe', 'spanning', 'the', 'terminal', 'resolution', 'site', 'itrsi', 'and', 'the', 'ns1n', 'protein', 'into', 'a', '384wellplate', 'format', 'the', 'hts', 'assay', 'showed', 'high', 'reliability', 'and', 'capability', 'in', 'screening', '17040', 'compounds', 'based', 'on', 'the', 'therapeutic', 'index', 'halfmaximal', 'cytotoxic', 'concentration', 'ccsub50subhalfmaximal', 'effective', 'concentration', 'ecsub50sub', 'ratio', 'in', 'epcs', 'a', 'purine', 'derivative', 'demonstrated', 'an', 'antiviral', 'effect', 'of', '92', 'inhibition', 'of', 'b19v', 'infection', 'in', 'epcs', 'at', '332', 'μm', 'two', 'times', 'the', 'ecsub90sub', 'our', 'study', 'demonstrated', 'a', 'robust', 'hts', 'assay', 'for', 'screening', 'antivirals', 'against', 'b19v', 'infection']","['parvovirus', 'b19', 'b19v', 'infection', 'cause', 'hematological', 'disorders', 'fetal', 'hydrops', 'pregnancy', 'currently', 'antivirals', 'vaccines', 'available', 'treatment', 'prevention', 'b19v', 'infection', 'identify', 'novel', 'smallmolecule', 'antivirals', 'b19v', 'replication', 'developed', 'highthroughput', 'screening', 'hts', 'assay', 'based', 'iin', 'vitroi', 'nicking', 'assay', 'using', 'recombinant', 'nterminal', 'amino', 'acids', '1', '176', 'viral', 'large', 'nonstructural', 'protein', 'ns1n', 'fluorescently', 'labeled', 'dna', 'probe', 'ioriqi', 'spans', 'nicking', 'site', 'viral', 'dna', 'replication', 'origin', 'collectively', 'screened', '17040', 'compounds', 'identified', '2178', '1278', 'hits', 'possess', '10', 'inhibition', 'ns1', 'nicking', 'activity', 'among', '84', 'hits', 'confirmed', 'inhibit', 'nicking', 'dosedependent', 'manner', 'using', 'iex', 'vivoiexpanded', 'primary', 'human', 'erythroid', 'progenitor', 'cells', 'epcs', 'infected', 'b19v', 'validated', '24', 'compounds', 'demonstrated', '50', 'iin', 'vivoi', 'inhibition', 'b19v', 'infection', '10', 'μm', 'categorized', '7', 'structure', 'scaffolds', 'based', 'therapeutic', 'index', 'halfmaximal', 'cytotoxic', 'concentration', 'ccsub50subhalfmaximal', 'effective', 'concentration', 'ecsub50sub', 'ratio', 'epcs', 'top', '4', 'compounds', 'chosen', 'examine', 'inhibitions', 'b19v', 'infection', 'epcs', 'two', 'times', '90', 'maximal', 'effective', 'concentration', 'ecsub90sub', 'purine', 'derivative', 'p7', 'demonstrated', 'antiviral', 'effect', 'ecsub50sub', '146', 'μm', 'without', 'prominent', 'cytotoxicity', 'ccsub50sub', '718', 'μm', 'epcs', 'exhibited', '92', 'inhibition', 'b19v', 'infection', 'epcs', '332', 'μm', 'used', 'lead', 'compound', 'future', 'studies', 'treatment', 'b19v', 'infectioncaused', 'hematological', 'disorders', 'bimportanceb', 'b19v', 'encodes', 'large', 'nonstructural', 'protein', 'ns1', 'nterminal', 'domain', 'ns1n', 'consisting', 'amino', 'acids', '1', '176', 'binds', 'viral', 'dna', 'serves', 'endonuclease', 'nick', 'viral', 'dna', 'replication', 'origins', 'pivotal', 'step', 'rollinghairpindependent', 'b19v', 'dna', 'replication', 'highthroughput', 'screening', 'hts', 'antib19v', 'antivirals', 'miniaturized', 'fluorescencebased', 'iin', 'vitroi', 'nicking', 'assay', 'employs', 'fluorophorelabeled', 'probe', 'spanning', 'terminal', 'resolution', 'site', 'itrsi', 'ns1n', 'protein', '384wellplate', 'format', 'hts', 'assay', 'showed', 'high', 'reliability', 'capability', 'screening', '17040', 'compounds', 'based', 'therapeutic', 'index', 'halfmaximal', 'cytotoxic', 'concentration', 'ccsub50subhalfmaximal', 'effective', 'concentration', 'ecsub50sub', 'ratio', 'epcs', 'purine', 'derivative', 'demonstrated', 'antiviral', 'effect', '92', 'inhibition', 'b19v', 'infection', 'epcs', '332', 'μm', 'two', 'times', 'ecsub90sub', 'study', 'demonstrated', 'robust', 'hts', 'assay', 'screening', 'antivirals', 'b19v', 'infection']",['iex'],['iex'],True,['infection']
34583982,"Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity.","The protein arginine methyltransferase 5 (PRMT5) methylates a variety of proteins involved in splicing, multiple signal transduction pathways, epigenetic control of gene expression, and mechanisms leading to protein expression required for cellular proliferation. Dysregulation of PRMT5 is associated with clinical features of several cancers, including lymphomas, lung cancer, and breast cancer. Here, we describe the characterization of JNJ-64619178, a novel, selective, and potent PRMT5 inhibitor, currently in clinical trials for patients with advanced solid tumors, non-Hodgkin's lymphoma, and lower-risk myelodysplastic syndrome. JNJ-64619178 demonstrated a prolonged inhibition of PRMT5 and potent antiproliferative activity in subsets of cancer cell lines derived from various histologies, including lung, breast, pancreatic, and hematological malignancies. In primary acute myelogenous leukemia samples, the presence of splicing factor mutations correlated with a higher <i>ex vivo</i> sensitivity to JNJ-64619178. Furthermore, the potent and unique mechanism of inhibition of JNJ-64619178, combined with highly optimized pharmacological properties, led to efficient tumor growth inhibition and regression in several xenograft models <i>in vivo</i>, with once-daily or intermittent oral-dosing schedules. An increase in splicing burden was observed upon JNJ-64619178 treatment. Overall, these observations support the continued clinical evaluation of JNJ-64619178 in patients with aberrant PRMT5 activity-driven tumors.",2021-09-28,the protein arginine methyltransferase 5 prmt5 methylates a variety of proteins involved in splicing multiple signal transduction pathways epigenetic control of gene expression and mechanisms leading to protein expression required for cellular proliferation dysregulation of prmt5 is associated with clinical features of several cancers including lymphomas lung cancer and breast cancer here we describe the characterization of jnj64619178 a novel selective and potent prmt5 inhibitor currently in clinical trials for patients with advanced solid tumors nonhodgkins lymphoma and lowerrisk myelodysplastic syndrome jnj64619178 demonstrated a prolonged inhibition of prmt5 and potent antiproliferative activity in subsets of cancer cell lines derived from various histologies including lung breast pancreatic and hematological malignancies in primary acute myelogenous leukemia samples the presence of splicing factor mutations correlated with a higher iex vivoi sensitivity to jnj64619178 furthermore the potent and unique mechanism of inhibition of jnj64619178 combined with highly optimized pharmacological properties led to efficient tumor growth inhibition and regression in several xenograft models iin vivoi with oncedaily or intermittent oraldosing schedules an increase in splicing burden was observed upon jnj64619178 treatment overall these observations support the continued clinical evaluation of jnj64619178 in patients with aberrant prmt5 activitydriven tumors,"['the', 'protein', 'arginine', 'methyltransferase', '5', 'prmt5', 'methylates', 'a', 'variety', 'of', 'proteins', 'involved', 'in', 'splicing', 'multiple', 'signal', 'transduction', 'pathways', 'epigenetic', 'control', 'of', 'gene', 'expression', 'and', 'mechanisms', 'leading', 'to', 'protein', 'expression', 'required', 'for', 'cellular', 'proliferation', 'dysregulation', 'of', 'prmt5', 'is', 'associated', 'with', 'clinical', 'features', 'of', 'several', 'cancers', 'including', 'lymphomas', 'lung', 'cancer', 'and', 'breast', 'cancer', 'here', 'we', 'describe', 'the', 'characterization', 'of', 'jnj64619178', 'a', 'novel', 'selective', 'and', 'potent', 'prmt5', 'inhibitor', 'currently', 'in', 'clinical', 'trials', 'for', 'patients', 'with', 'advanced', 'solid', 'tumors', 'nonhodgkins', 'lymphoma', 'and', 'lowerrisk', 'myelodysplastic', 'syndrome', 'jnj64619178', 'demonstrated', 'a', 'prolonged', 'inhibition', 'of', 'prmt5', 'and', 'potent', 'antiproliferative', 'activity', 'in', 'subsets', 'of', 'cancer', 'cell', 'lines', 'derived', 'from', 'various', 'histologies', 'including', 'lung', 'breast', 'pancreatic', 'and', 'hematological', 'malignancies', 'in', 'primary', 'acute', 'myelogenous', 'leukemia', 'samples', 'the', 'presence', 'of', 'splicing', 'factor', 'mutations', 'correlated', 'with', 'a', 'higher', 'iex', 'vivoi', 'sensitivity', 'to', 'jnj64619178', 'furthermore', 'the', 'potent', 'and', 'unique', 'mechanism', 'of', 'inhibition', 'of', 'jnj64619178', 'combined', 'with', 'highly', 'optimized', 'pharmacological', 'properties', 'led', 'to', 'efficient', 'tumor', 'growth', 'inhibition', 'and', 'regression', 'in', 'several', 'xenograft', 'models', 'iin', 'vivoi', 'with', 'oncedaily', 'or', 'intermittent', 'oraldosing', 'schedules', 'an', 'increase', 'in', 'splicing', 'burden', 'was', 'observed', 'upon', 'jnj64619178', 'treatment', 'overall', 'these', 'observations', 'support', 'the', 'continued', 'clinical', 'evaluation', 'of', 'jnj64619178', 'in', 'patients', 'with', 'aberrant', 'prmt5', 'activitydriven', 'tumors']","['protein', 'arginine', 'methyltransferase', '5', 'prmt5', 'methylates', 'variety', 'proteins', 'involved', 'splicing', 'multiple', 'signal', 'transduction', 'pathways', 'epigenetic', 'control', 'gene', 'expression', 'mechanisms', 'leading', 'protein', 'expression', 'required', 'cellular', 'proliferation', 'dysregulation', 'prmt5', 'associated', 'clinical', 'features', 'several', 'cancers', 'including', 'lymphomas', 'lung', 'cancer', 'breast', 'cancer', 'describe', 'characterization', 'jnj64619178', 'novel', 'selective', 'potent', 'prmt5', 'inhibitor', 'currently', 'clinical', 'trials', 'patients', 'advanced', 'solid', 'tumors', 'nonhodgkins', 'lymphoma', 'lowerrisk', 'myelodysplastic', 'syndrome', 'jnj64619178', 'demonstrated', 'prolonged', 'inhibition', 'prmt5', 'potent', 'antiproliferative', 'activity', 'subsets', 'cancer', 'cell', 'lines', 'derived', 'various', 'histologies', 'including', 'lung', 'breast', 'pancreatic', 'hematological', 'malignancies', 'primary', 'acute', 'myelogenous', 'leukemia', 'samples', 'presence', 'splicing', 'factor', 'mutations', 'correlated', 'higher', 'iex', 'vivoi', 'sensitivity', 'jnj64619178', 'furthermore', 'potent', 'unique', 'mechanism', 'inhibition', 'jnj64619178', 'combined', 'highly', 'optimized', 'pharmacological', 'properties', 'led', 'efficient', 'tumor', 'growth', 'inhibition', 'regression', 'several', 'xenograft', 'models', 'iin', 'vivoi', 'oncedaily', 'intermittent', 'oraldosing', 'schedules', 'increase', 'splicing', 'burden', 'observed', 'upon', 'jnj64619178', 'treatment', 'overall', 'observations', 'support', 'continued', 'clinical', 'evaluation', 'jnj64619178', 'patients', 'aberrant', 'prmt5', 'activitydriven', 'tumors']",['iex'],['iex'],True,"['tumor', 'cancer', 'leukemia']"
34574082,AGL9: A Novel Hepatoprotective Peptide from the Larvae of Edible Insects Alleviates Obesity-Induced Hepatic Inflammation by Regulating AMPK/Nrf2 Signaling.,"In this study, we investigated the anti-obesity properties of the novel peptide Ala-Gly-Leu-Gln-Phe-Pro-Val-Gly-Arg (AGL9), isolated from the enzymatic hydrolysate of <i>Allomyrina</i><i>dichotoma</i> larvae. To investigate the preventive effects of AGL9 against hepatic steatosis and its possible mechanisms of action, we established an nonalcoholic fatty liver disease (NAFLD) model by feeding C57BL/6 mice a high-fat diet. NAFLD mice were administered 100 mg/kg AGL9 and 60 mg/kg orlistat via gavage (10 mL/kg) for 5 weeks, followed by the collection of blood and liver tissues. We found that AGL9 normalized the levels of serum alanine aminotransferase, aspartate aminotransferase, triglyceride, total cholesterol, high-density lipoprotein, very low-density lipoprotein (LDL)/LDL, adiponectin, and leptin in these mice. Additionally, AGL9 activated the protein-level expression of 5' AMP-activated protein kinase and acetyl-CoA carboxylase phosphorylation and the transcript-level expression of sterol regulatory element-binding protein-1c, fatty acid synthase, superoxide dismutase, glutathione peroxidase, glucocorticoid receptor, nuclear respiratory factor 2, tumor necrosis factor-α, interleukin-1β, interleukin-6, and monocyte chemoattractant protein-1 in hepatocytes. These results showed that AGL9 exhibited hepatoprotective effects by attenuating lipid deposition, oxidative stress, and inflammation via inhibition of AMPK/Nrf2 signaling, thereby reducing the production of hepatic proinflammatory mediators and indicating AGL9 as a potential therapeutic strategy for NAFLD.",2021-08-24,in this study we investigated the antiobesity properties of the novel peptide alaglyleuglnpheprovalglyarg agl9 isolated from the enzymatic hydrolysate of iallomyrinaiidichotomai larvae to investigate the preventive effects of agl9 against hepatic steatosis and its possible mechanisms of action we established an nonalcoholic fatty liver disease nafld model by feeding c57bl6 mice a highfat diet nafld mice were administered 100 mgkg agl9 and 60 mgkg orlistat via gavage 10 mlkg for 5 weeks followed by the collection of blood and liver tissues we found that agl9 normalized the levels of serum alanine aminotransferase aspartate aminotransferase triglyceride total cholesterol highdensity lipoprotein very lowdensity lipoprotein ldlldl adiponectin and leptin in these mice additionally agl9 activated the proteinlevel expression of 5 ampactivated protein kinase and acetylcoa carboxylase phosphorylation and the transcriptlevel expression of sterol regulatory elementbinding protein1c fatty acid synthase superoxide dismutase glutathione peroxidase glucocorticoid receptor nuclear respiratory factor 2 tumor necrosis factorα interleukin1β interleukin6 and monocyte chemoattractant protein1 in hepatocytes these results showed that agl9 exhibited hepatoprotective effects by attenuating lipid deposition oxidative stress and inflammation via inhibition of ampknrf2 signaling thereby reducing the production of hepatic proinflammatory mediators and indicating agl9 as a potential therapeutic strategy for nafld,"['in', 'this', 'study', 'we', 'investigated', 'the', 'antiobesity', 'properties', 'of', 'the', 'novel', 'peptide', 'alaglyleuglnpheprovalglyarg', 'agl9', 'isolated', 'from', 'the', 'enzymatic', 'hydrolysate', 'of', 'iallomyrinaiidichotomai', 'larvae', 'to', 'investigate', 'the', 'preventive', 'effects', 'of', 'agl9', 'against', 'hepatic', 'steatosis', 'and', 'its', 'possible', 'mechanisms', 'of', 'action', 'we', 'established', 'an', 'nonalcoholic', 'fatty', 'liver', 'disease', 'nafld', 'model', 'by', 'feeding', 'c57bl6', 'mice', 'a', 'highfat', 'diet', 'nafld', 'mice', 'were', 'administered', '100', 'mgkg', 'agl9', 'and', '60', 'mgkg', 'orlistat', 'via', 'gavage', '10', 'mlkg', 'for', '5', 'weeks', 'followed', 'by', 'the', 'collection', 'of', 'blood', 'and', 'liver', 'tissues', 'we', 'found', 'that', 'agl9', 'normalized', 'the', 'levels', 'of', 'serum', 'alanine', 'aminotransferase', 'aspartate', 'aminotransferase', 'triglyceride', 'total', 'cholesterol', 'highdensity', 'lipoprotein', 'very', 'lowdensity', 'lipoprotein', 'ldlldl', 'adiponectin', 'and', 'leptin', 'in', 'these', 'mice', 'additionally', 'agl9', 'activated', 'the', 'proteinlevel', 'expression', 'of', '5', 'ampactivated', 'protein', 'kinase', 'and', 'acetylcoa', 'carboxylase', 'phosphorylation', 'and', 'the', 'transcriptlevel', 'expression', 'of', 'sterol', 'regulatory', 'elementbinding', 'protein1c', 'fatty', 'acid', 'synthase', 'superoxide', 'dismutase', 'glutathione', 'peroxidase', 'glucocorticoid', 'receptor', 'nuclear', 'respiratory', 'factor', '2', 'tumor', 'necrosis', 'factorα', 'interleukin1β', 'interleukin6', 'and', 'monocyte', 'chemoattractant', 'protein1', 'in', 'hepatocytes', 'these', 'results', 'showed', 'that', 'agl9', 'exhibited', 'hepatoprotective', 'effects', 'by', 'attenuating', 'lipid', 'deposition', 'oxidative', 'stress', 'and', 'inflammation', 'via', 'inhibition', 'of', 'ampknrf2', 'signaling', 'thereby', 'reducing', 'the', 'production', 'of', 'hepatic', 'proinflammatory', 'mediators', 'and', 'indicating', 'agl9', 'as', 'a', 'potential', 'therapeutic', 'strategy', 'for', 'nafld']","['study', 'investigated', 'antiobesity', 'properties', 'novel', 'peptide', 'alaglyleuglnpheprovalglyarg', 'agl9', 'isolated', 'enzymatic', 'hydrolysate', 'iallomyrinaiidichotomai', 'larvae', 'investigate', 'preventive', 'effects', 'agl9', 'hepatic', 'steatosis', 'possible', 'mechanisms', 'action', 'established', 'nonalcoholic', 'fatty', 'liver', 'disease', 'nafld', 'model', 'feeding', 'c57bl6', 'mice', 'highfat', 'diet', 'nafld', 'mice', 'administered', '100', 'mgkg', 'agl9', '60', 'mgkg', 'orlistat', 'via', 'gavage', '10', 'mlkg', '5', 'weeks', 'followed', 'collection', 'blood', 'liver', 'tissues', 'found', 'agl9', 'normalized', 'levels', 'serum', 'alanine', 'aminotransferase', 'aspartate', 'aminotransferase', 'triglyceride', 'total', 'cholesterol', 'highdensity', 'lipoprotein', 'lowdensity', 'lipoprotein', 'ldlldl', 'adiponectin', 'leptin', 'mice', 'additionally', 'agl9', 'activated', 'proteinlevel', 'expression', '5', 'ampactivated', 'protein', 'kinase', 'acetylcoa', 'carboxylase', 'phosphorylation', 'transcriptlevel', 'expression', 'sterol', 'regulatory', 'elementbinding', 'protein1c', 'fatty', 'acid', 'synthase', 'superoxide', 'dismutase', 'glutathione', 'peroxidase', 'glucocorticoid', 'receptor', 'nuclear', 'respiratory', 'factor', '2', 'tumor', 'necrosis', 'factorα', 'interleukin1β', 'interleukin6', 'monocyte', 'chemoattractant', 'protein1', 'hepatocytes', 'results', 'showed', 'agl9', 'exhibited', 'hepatoprotective', 'effects', 'attenuating', 'lipid', 'deposition', 'oxidative', 'stress', 'inflammation', 'via', 'inhibition', 'ampknrf2', 'signaling', 'thereby', 'reducing', 'production', 'hepatic', 'proinflammatory', 'mediators', 'indicating', 'agl9', 'potential', 'therapeutic', 'strategy', 'nafld']","['fatty', 'adiponectin', 'leptin', 'fatty', 'peroxidase', 'interleukin6']","['adiponectin', 'peroxidase']",True,['tumor']
34573065,The Gasotransmitter Hydrogen Sulfide (H<sub>2</sub>S) Prevents Pathologic Calcification (PC) in Cartilage.,"Pathologic calcification (PC) is a painful and disabling condition whereby calcium-containing crystals deposit in tissues that do not physiologically calcify: cartilage, tendons, muscle, vessels and skin. In cartilage, compression and inflammation triggered by PC leads to cartilage degradation typical of osteoarthritis (OA). The PC process is poorly understood and treatments able to target the underlying mechanisms of the disease are lacking. Here we show a crucial role of the gasotransmitter hydrogen sulfide (H<sub>2</sub>S) and, in particular, of the H<sub>2</sub>S-producing enzyme cystathionine γ-lyase (CSE), in regulating PC in cartilage. Cse deficiency (Cse KO mice) exacerbated calcification in both surgically-induced (menisectomy) and spontaneous (aging) murine models of cartilage PC, and augmented PC was closely associated with cartilage degradation (OA). On the contrary, Cse overexpression (Cse tg mice) protected from these features. In vitro, Cse KO chondrocytes showed increased calcification, potentially via enhanced alkaline phosphatase (Alpl) expression and activity and increased IL-6 production. The opposite results were obtained in Cse tg chondrocytes. In cartilage samples from patients with OA, CSE expression inversely correlated with the degree of tissue calcification and disease severity. Increased cartilage degradation in murine and human tissues lacking or expressing low CSE levels may be accounted for by dysregulated catabolism. We found higher levels of matrix-degrading metalloproteases <i>Mmp-3</i> and <i>-13</i> in Cse KO chondrocytes, whereas the opposite results were obtained in Cse tg cells. Finally, by high-throughput screening, we identified a novel small molecule CSE positive allosteric modulator (PAM), and demonstrated that it was able to increase cellular H<sub>2</sub>S production, and decrease murine and human chondrocyte calcification and IL-6 secretion. Together, these data implicate impaired CSE-dependent H<sub>2</sub>S production by chondrocytes in the etiology of cartilage PC and worsening of secondary outcomes (OA). In this context, enhancing CSE expression and/or activity in chondrocytes could represent a potential strategy to inhibit PC.",2021-09-08,pathologic calcification pc is a painful and disabling condition whereby calciumcontaining crystals deposit in tissues that do not physiologically calcify cartilage tendons muscle vessels and skin in cartilage compression and inflammation triggered by pc leads to cartilage degradation typical of osteoarthritis oa the pc process is poorly understood and treatments able to target the underlying mechanisms of the disease are lacking here we show a crucial role of the gasotransmitter hydrogen sulfide hsub2subs and in particular of the hsub2subsproducing enzyme cystathionine γlyase cse in regulating pc in cartilage cse deficiency cse ko mice exacerbated calcification in both surgicallyinduced menisectomy and spontaneous aging murine models of cartilage pc and augmented pc was closely associated with cartilage degradation oa on the contrary cse overexpression cse tg mice protected from these features in vitro cse ko chondrocytes showed increased calcification potentially via enhanced alkaline phosphatase alpl expression and activity and increased il6 production the opposite results were obtained in cse tg chondrocytes in cartilage samples from patients with oa cse expression inversely correlated with the degree of tissue calcification and disease severity increased cartilage degradation in murine and human tissues lacking or expressing low cse levels may be accounted for by dysregulated catabolism we found higher levels of matrixdegrading metalloproteases immp3i and i13i in cse ko chondrocytes whereas the opposite results were obtained in cse tg cells finally by highthroughput screening we identified a novel small molecule cse positive allosteric modulator pam and demonstrated that it was able to increase cellular hsub2subs production and decrease murine and human chondrocyte calcification and il6 secretion together these data implicate impaired csedependent hsub2subs production by chondrocytes in the etiology of cartilage pc and worsening of secondary outcomes oa in this context enhancing cse expression andor activity in chondrocytes could represent a potential strategy to inhibit pc,"['pathologic', 'calcification', 'pc', 'is', 'a', 'painful', 'and', 'disabling', 'condition', 'whereby', 'calciumcontaining', 'crystals', 'deposit', 'in', 'tissues', 'that', 'do', 'not', 'physiologically', 'calcify', 'cartilage', 'tendons', 'muscle', 'vessels', 'and', 'skin', 'in', 'cartilage', 'compression', 'and', 'inflammation', 'triggered', 'by', 'pc', 'leads', 'to', 'cartilage', 'degradation', 'typical', 'of', 'osteoarthritis', 'oa', 'the', 'pc', 'process', 'is', 'poorly', 'understood', 'and', 'treatments', 'able', 'to', 'target', 'the', 'underlying', 'mechanisms', 'of', 'the', 'disease', 'are', 'lacking', 'here', 'we', 'show', 'a', 'crucial', 'role', 'of', 'the', 'gasotransmitter', 'hydrogen', 'sulfide', 'hsub2subs', 'and', 'in', 'particular', 'of', 'the', 'hsub2subsproducing', 'enzyme', 'cystathionine', 'γlyase', 'cse', 'in', 'regulating', 'pc', 'in', 'cartilage', 'cse', 'deficiency', 'cse', 'ko', 'mice', 'exacerbated', 'calcification', 'in', 'both', 'surgicallyinduced', 'menisectomy', 'and', 'spontaneous', 'aging', 'murine', 'models', 'of', 'cartilage', 'pc', 'and', 'augmented', 'pc', 'was', 'closely', 'associated', 'with', 'cartilage', 'degradation', 'oa', 'on', 'the', 'contrary', 'cse', 'overexpression', 'cse', 'tg', 'mice', 'protected', 'from', 'these', 'features', 'in', 'vitro', 'cse', 'ko', 'chondrocytes', 'showed', 'increased', 'calcification', 'potentially', 'via', 'enhanced', 'alkaline', 'phosphatase', 'alpl', 'expression', 'and', 'activity', 'and', 'increased', 'il6', 'production', 'the', 'opposite', 'results', 'were', 'obtained', 'in', 'cse', 'tg', 'chondrocytes', 'in', 'cartilage', 'samples', 'from', 'patients', 'with', 'oa', 'cse', 'expression', 'inversely', 'correlated', 'with', 'the', 'degree', 'of', 'tissue', 'calcification', 'and', 'disease', 'severity', 'increased', 'cartilage', 'degradation', 'in', 'murine', 'and', 'human', 'tissues', 'lacking', 'or', 'expressing', 'low', 'cse', 'levels', 'may', 'be', 'accounted', 'for', 'by', 'dysregulated', 'catabolism', 'we', 'found', 'higher', 'levels', 'of', 'matrixdegrading', 'metalloproteases', 'immp3i', 'and', 'i13i', 'in', 'cse', 'ko', 'chondrocytes', 'whereas', 'the', 'opposite', 'results', 'were', 'obtained', 'in', 'cse', 'tg', 'cells', 'finally', 'by', 'highthroughput', 'screening', 'we', 'identified', 'a', 'novel', 'small', 'molecule', 'cse', 'positive', 'allosteric', 'modulator', 'pam', 'and', 'demonstrated', 'that', 'it', 'was', 'able', 'to', 'increase', 'cellular', 'hsub2subs', 'production', 'and', 'decrease', 'murine', 'and', 'human', 'chondrocyte', 'calcification', 'and', 'il6', 'secretion', 'together', 'these', 'data', 'implicate', 'impaired', 'csedependent', 'hsub2subs', 'production', 'by', 'chondrocytes', 'in', 'the', 'etiology', 'of', 'cartilage', 'pc', 'and', 'worsening', 'of', 'secondary', 'outcomes', 'oa', 'in', 'this', 'context', 'enhancing', 'cse', 'expression', 'andor', 'activity', 'in', 'chondrocytes', 'could', 'represent', 'a', 'potential', 'strategy', 'to', 'inhibit', 'pc']","['pathologic', 'calcification', 'pc', 'painful', 'disabling', 'condition', 'whereby', 'calciumcontaining', 'crystals', 'deposit', 'tissues', 'physiologically', 'calcify', 'cartilage', 'tendons', 'muscle', 'vessels', 'skin', 'cartilage', 'compression', 'inflammation', 'triggered', 'pc', 'leads', 'cartilage', 'degradation', 'typical', 'osteoarthritis', 'oa', 'pc', 'process', 'poorly', 'understood', 'treatments', 'able', 'target', 'underlying', 'mechanisms', 'disease', 'lacking', 'show', 'crucial', 'role', 'gasotransmitter', 'hydrogen', 'sulfide', 'hsub2subs', 'particular', 'hsub2subsproducing', 'enzyme', 'cystathionine', 'γlyase', 'cse', 'regulating', 'pc', 'cartilage', 'cse', 'deficiency', 'cse', 'ko', 'mice', 'exacerbated', 'calcification', 'surgicallyinduced', 'menisectomy', 'spontaneous', 'aging', 'murine', 'models', 'cartilage', 'pc', 'augmented', 'pc', 'closely', 'associated', 'cartilage', 'degradation', 'oa', 'contrary', 'cse', 'overexpression', 'cse', 'tg', 'mice', 'protected', 'features', 'vitro', 'cse', 'ko', 'chondrocytes', 'showed', 'increased', 'calcification', 'potentially', 'via', 'enhanced', 'alkaline', 'phosphatase', 'alpl', 'expression', 'activity', 'increased', 'il6', 'production', 'opposite', 'results', 'obtained', 'cse', 'tg', 'chondrocytes', 'cartilage', 'samples', 'patients', 'oa', 'cse', 'expression', 'inversely', 'correlated', 'degree', 'tissue', 'calcification', 'disease', 'severity', 'increased', 'cartilage', 'degradation', 'murine', 'human', 'tissues', 'lacking', 'expressing', 'low', 'cse', 'levels', 'may', 'accounted', 'dysregulated', 'catabolism', 'found', 'higher', 'levels', 'matrixdegrading', 'metalloproteases', 'immp3i', 'i13i', 'cse', 'ko', 'chondrocytes', 'whereas', 'opposite', 'results', 'obtained', 'cse', 'tg', 'cells', 'finally', 'highthroughput', 'screening', 'identified', 'novel', 'small', 'molecule', 'cse', 'positive', 'allosteric', 'modulator', 'pam', 'demonstrated', 'able', 'increase', 'cellular', 'hsub2subs', 'production', 'decrease', 'murine', 'human', 'chondrocyte', 'calcification', 'il6', 'secretion', 'together', 'data', 'implicate', 'impaired', 'csedependent', 'hsub2subs', 'production', 'chondrocytes', 'etiology', 'cartilage', 'pc', 'worsening', 'secondary', 'outcomes', 'oa', 'context', 'enhancing', 'cse', 'expression', 'andor', 'activity', 'chondrocytes', 'could', 'represent', 'potential', 'strategy', 'inhibit', 'pc']",['alpl'],['alpl'],True,['arthritis']
34572040,A Preclinical Investigation of GBM-N019 as a Potential Inhibitor of Glioblastoma via Exosomal mTOR/CDK6/STAT3 Signaling.,"Glioblastoma (GBM) is one of the most aggressive brain malignancies with high incidences of developing treatment resistance, resulting in poor prognoses. Glioma stem cell (GSC)-derived exosomes are important players that contribute to GBM tumorigenesis and aggressive properties. Herein, we investigated the inhibitory roles of GBM-N019, a novel small molecule on the transfer of aggressive and invasive properties through the delivery of oncogene-loaded exosomes from GSCs to naïve and non-GSCs. Our results indicated that GBM-N019 significantly downregulated the expressions of the mammalian target of rapamycin (mTOR), signal transducer and activator of transcription 3 (STAT3), and cyclin-dependent kinase 6 (CDK6) signaling networks with concomitant inhibitory activities against viability, clonogenicity, and migratory abilities of U251 and U87MG cells. Treatments with GBM-N019 halted the exosomal transfer of protein kinase B (Akt), mTOR, p-mTOR, and Ras-related protein RAB27A to the naïve U251 and U87MG cells, and rescued the cells from invasive and stemness properties that were associated with activation of these oncogenes. GBM-N019 also synergized with and enhanced the anti-GBM activities of palbociclib in vitro and in vivo. In conclusion, our results suggested that GBM-N019 possesses good translational relevance as a potential anti-glioblastoma drug candidate worthy of consideration for clinical trials against recurrent glioblastomas.",2021-09-11,glioblastoma gbm is one of the most aggressive brain malignancies with high incidences of developing treatment resistance resulting in poor prognoses glioma stem cell gscderived exosomes are important players that contribute to gbm tumorigenesis and aggressive properties herein we investigated the inhibitory roles of gbmn019 a novel small molecule on the transfer of aggressive and invasive properties through the delivery of oncogeneloaded exosomes from gscs to naïve and nongscs our results indicated that gbmn019 significantly downregulated the expressions of the mammalian target of rapamycin mtor signal transducer and activator of transcription 3 stat3 and cyclindependent kinase 6 cdk6 signaling networks with concomitant inhibitory activities against viability clonogenicity and migratory abilities of u251 and u87mg cells treatments with gbmn019 halted the exosomal transfer of protein kinase b akt mtor pmtor and rasrelated protein rab27a to the naïve u251 and u87mg cells and rescued the cells from invasive and stemness properties that were associated with activation of these oncogenes gbmn019 also synergized with and enhanced the antigbm activities of palbociclib in vitro and in vivo in conclusion our results suggested that gbmn019 possesses good translational relevance as a potential antiglioblastoma drug candidate worthy of consideration for clinical trials against recurrent glioblastomas,"['glioblastoma', 'gbm', 'is', 'one', 'of', 'the', 'most', 'aggressive', 'brain', 'malignancies', 'with', 'high', 'incidences', 'of', 'developing', 'treatment', 'resistance', 'resulting', 'in', 'poor', 'prognoses', 'glioma', 'stem', 'cell', 'gscderived', 'exosomes', 'are', 'important', 'players', 'that', 'contribute', 'to', 'gbm', 'tumorigenesis', 'and', 'aggressive', 'properties', 'herein', 'we', 'investigated', 'the', 'inhibitory', 'roles', 'of', 'gbmn019', 'a', 'novel', 'small', 'molecule', 'on', 'the', 'transfer', 'of', 'aggressive', 'and', 'invasive', 'properties', 'through', 'the', 'delivery', 'of', 'oncogeneloaded', 'exosomes', 'from', 'gscs', 'to', 'naïve', 'and', 'nongscs', 'our', 'results', 'indicated', 'that', 'gbmn019', 'significantly', 'downregulated', 'the', 'expressions', 'of', 'the', 'mammalian', 'target', 'of', 'rapamycin', 'mtor', 'signal', 'transducer', 'and', 'activator', 'of', 'transcription', '3', 'stat3', 'and', 'cyclindependent', 'kinase', '6', 'cdk6', 'signaling', 'networks', 'with', 'concomitant', 'inhibitory', 'activities', 'against', 'viability', 'clonogenicity', 'and', 'migratory', 'abilities', 'of', 'u251', 'and', 'u87mg', 'cells', 'treatments', 'with', 'gbmn019', 'halted', 'the', 'exosomal', 'transfer', 'of', 'protein', 'kinase', 'b', 'akt', 'mtor', 'pmtor', 'and', 'rasrelated', 'protein', 'rab27a', 'to', 'the', 'naïve', 'u251', 'and', 'u87mg', 'cells', 'and', 'rescued', 'the', 'cells', 'from', 'invasive', 'and', 'stemness', 'properties', 'that', 'were', 'associated', 'with', 'activation', 'of', 'these', 'oncogenes', 'gbmn019', 'also', 'synergized', 'with', 'and', 'enhanced', 'the', 'antigbm', 'activities', 'of', 'palbociclib', 'in', 'vitro', 'and', 'in', 'vivo', 'in', 'conclusion', 'our', 'results', 'suggested', 'that', 'gbmn019', 'possesses', 'good', 'translational', 'relevance', 'as', 'a', 'potential', 'antiglioblastoma', 'drug', 'candidate', 'worthy', 'of', 'consideration', 'for', 'clinical', 'trials', 'against', 'recurrent', 'glioblastomas']","['glioblastoma', 'gbm', 'one', 'aggressive', 'brain', 'malignancies', 'high', 'incidences', 'developing', 'treatment', 'resistance', 'resulting', 'poor', 'prognoses', 'glioma', 'stem', 'cell', 'gscderived', 'exosomes', 'important', 'players', 'contribute', 'gbm', 'tumorigenesis', 'aggressive', 'properties', 'herein', 'investigated', 'inhibitory', 'roles', 'gbmn019', 'novel', 'small', 'molecule', 'transfer', 'aggressive', 'invasive', 'properties', 'delivery', 'oncogeneloaded', 'exosomes', 'gscs', 'naïve', 'nongscs', 'results', 'indicated', 'gbmn019', 'significantly', 'downregulated', 'expressions', 'mammalian', 'target', 'rapamycin', 'mtor', 'signal', 'transducer', 'activator', 'transcription', '3', 'stat3', 'cyclindependent', 'kinase', '6', 'cdk6', 'signaling', 'networks', 'concomitant', 'inhibitory', 'activities', 'viability', 'clonogenicity', 'migratory', 'abilities', 'u251', 'u87mg', 'cells', 'treatments', 'gbmn019', 'halted', 'exosomal', 'transfer', 'protein', 'kinase', 'b', 'akt', 'mtor', 'pmtor', 'rasrelated', 'protein', 'rab27a', 'naïve', 'u251', 'u87mg', 'cells', 'rescued', 'cells', 'invasive', 'stemness', 'properties', 'associated', 'activation', 'oncogenes', 'gbmn019', 'also', 'synergized', 'enhanced', 'antigbm', 'activities', 'palbociclib', 'vitro', 'vivo', 'conclusion', 'results', 'suggested', 'gbmn019', 'possesses', 'good', 'translational', 'relevance', 'potential', 'antiglioblastoma', 'drug', 'candidate', 'worthy', 'consideration', 'clinical', 'trials', 'recurrent', 'glioblastomas']","['stat3', 'cyclindependent', 'cdk6', 'akt']",['cdk6'],True,['tumor']
34512368,Targeting Autophagy with Natural Compounds in Cancer: A Renewed Perspective from Molecular Mechanisms to Targeted Therapy.,"Natural products are well-characterized to have pharmacological or biological activities that can be of therapeutic benefits for cancer therapy, which also provide an important source of inspiration for discovery of potential novel small-molecule drugs. In the past three decades, accumulating evidence has revealed that natural products can modulate a series of key autophagic signaling pathways and display therapeutic effects in different types of human cancers. In this review, we focus on summarizing some representative natural active compounds, mainly including curcumin, resveratrol, paclitaxel, Bufalin, and Ursolic acid that may ultimately trigger cancer cell death through the regulation of some key autophagic signaling pathways, such as RAS-RAF-MEK-ERK, PI3K-AKT-mTOR, AMPK, ULK1, Beclin-1, Atg5 and p53. Taken together, these inspiring findings would shed light on exploiting more natural compounds as candidate small-molecule drugs, by targeting the crucial pathways of autophagy for the future cancer therapy.",2021-08-26,natural products are wellcharacterized to have pharmacological or biological activities that can be of therapeutic benefits for cancer therapy which also provide an important source of inspiration for discovery of potential novel smallmolecule drugs in the past three decades accumulating evidence has revealed that natural products can modulate a series of key autophagic signaling pathways and display therapeutic effects in different types of human cancers in this review we focus on summarizing some representative natural active compounds mainly including curcumin resveratrol paclitaxel bufalin and ursolic acid that may ultimately trigger cancer cell death through the regulation of some key autophagic signaling pathways such as rasrafmekerk pi3kaktmtor ampk ulk1 beclin1 atg5 and p53 taken together these inspiring findings would shed light on exploiting more natural compounds as candidate smallmolecule drugs by targeting the crucial pathways of autophagy for the future cancer therapy,"['natural', 'products', 'are', 'wellcharacterized', 'to', 'have', 'pharmacological', 'or', 'biological', 'activities', 'that', 'can', 'be', 'of', 'therapeutic', 'benefits', 'for', 'cancer', 'therapy', 'which', 'also', 'provide', 'an', 'important', 'source', 'of', 'inspiration', 'for', 'discovery', 'of', 'potential', 'novel', 'smallmolecule', 'drugs', 'in', 'the', 'past', 'three', 'decades', 'accumulating', 'evidence', 'has', 'revealed', 'that', 'natural', 'products', 'can', 'modulate', 'a', 'series', 'of', 'key', 'autophagic', 'signaling', 'pathways', 'and', 'display', 'therapeutic', 'effects', 'in', 'different', 'types', 'of', 'human', 'cancers', 'in', 'this', 'review', 'we', 'focus', 'on', 'summarizing', 'some', 'representative', 'natural', 'active', 'compounds', 'mainly', 'including', 'curcumin', 'resveratrol', 'paclitaxel', 'bufalin', 'and', 'ursolic', 'acid', 'that', 'may', 'ultimately', 'trigger', 'cancer', 'cell', 'death', 'through', 'the', 'regulation', 'of', 'some', 'key', 'autophagic', 'signaling', 'pathways', 'such', 'as', 'rasrafmekerk', 'pi3kaktmtor', 'ampk', 'ulk1', 'beclin1', 'atg5', 'and', 'p53', 'taken', 'together', 'these', 'inspiring', 'findings', 'would', 'shed', 'light', 'on', 'exploiting', 'more', 'natural', 'compounds', 'as', 'candidate', 'smallmolecule', 'drugs', 'by', 'targeting', 'the', 'crucial', 'pathways', 'of', 'autophagy', 'for', 'the', 'future', 'cancer', 'therapy']","['natural', 'products', 'wellcharacterized', 'pharmacological', 'biological', 'activities', 'therapeutic', 'benefits', 'cancer', 'therapy', 'also', 'provide', 'important', 'source', 'inspiration', 'discovery', 'potential', 'novel', 'smallmolecule', 'drugs', 'past', 'three', 'decades', 'accumulating', 'evidence', 'revealed', 'natural', 'products', 'modulate', 'series', 'key', 'autophagic', 'signaling', 'pathways', 'display', 'therapeutic', 'effects', 'different', 'types', 'human', 'cancers', 'review', 'focus', 'summarizing', 'representative', 'natural', 'active', 'compounds', 'mainly', 'including', 'curcumin', 'resveratrol', 'paclitaxel', 'bufalin', 'ursolic', 'acid', 'may', 'ultimately', 'trigger', 'cancer', 'cell', 'death', 'regulation', 'key', 'autophagic', 'signaling', 'pathways', 'rasrafmekerk', 'pi3kaktmtor', 'ampk', 'ulk1', 'beclin1', 'atg5', 'p53', 'taken', 'together', 'inspiring', 'findings', 'would', 'shed', 'light', 'exploiting', 'natural', 'compounds', 'candidate', 'smallmolecule', 'drugs', 'targeting', 'crucial', 'pathways', 'autophagy', 'future', 'cancer', 'therapy']","['ulk1', 'beclin1', 'p53']","['ulk1', 'beclin1']",True,['cancer']
34481973,A novel small-molecule antagonist enhances the sensitivity of osteosarcoma to cabozantinib in vitro and in vivo by targeting DNMT-1 correlated with disease severity in human patients.,"Advanced osteosarcoma (OSA) is highly aggressive and can lead to distant metastasis or recurrence. Here, a novel small-molecule inhibitor/antagonist of DNA methyltransferase 1 (DNMT-1) named DI-1 (inhibitor of DNMT-1) was explored to enhance the antitumor effect of a molecular-targeted agent, cabozantinib, on OSA cell lines. In patients with OSA, expression of DNMT-1 was negatively related with that of microRNA (miR)-34a and associated with a poor prognosis. In OSA cell lines (OSA cell line U2OS and an OSA cell line U2OS<sup>R</sup> resistance to cabozantinib), DI-1 treatment enhanced miR-34a expression by inhibiting hypermethylation of the promoter region of miR-34a mediated by DNMT-1. DI-1 enhanced the sensitivity of OSA cells (U2OS, 143B and MG63) to cabozantinib and other molecular-targeted agents by enhancing miR-34a expression and repressing activation of the Notch pathway. Mechanistically, DI-1 repressed recruitment of DNMT-1 to the promoter region of miR-34a and, in turn, decreased the methylation rate in the promoter region of miR-34a in OSA cells. These results suggest that repressing DNMT-1 activation by DI-1 enhances miR-34a expression in OSA cells and could be a promising therapeutic strategy for OSA.",2021-09-03,advanced osteosarcoma osa is highly aggressive and can lead to distant metastasis or recurrence here a novel smallmolecule inhibitorantagonist of dna methyltransferase 1 dnmt1 named di1 inhibitor of dnmt1 was explored to enhance the antitumor effect of a moleculartargeted agent cabozantinib on osa cell lines in patients with osa expression of dnmt1 was negatively related with that of microrna mir34a and associated with a poor prognosis in osa cell lines osa cell line u2os and an osa cell line u2ossuprsup resistance to cabozantinib di1 treatment enhanced mir34a expression by inhibiting hypermethylation of the promoter region of mir34a mediated by dnmt1 di1 enhanced the sensitivity of osa cells u2os 143b and mg63 to cabozantinib and other moleculartargeted agents by enhancing mir34a expression and repressing activation of the notch pathway mechanistically di1 repressed recruitment of dnmt1 to the promoter region of mir34a and in turn decreased the methylation rate in the promoter region of mir34a in osa cells these results suggest that repressing dnmt1 activation by di1 enhances mir34a expression in osa cells and could be a promising therapeutic strategy for osa,"['advanced', 'osteosarcoma', 'osa', 'is', 'highly', 'aggressive', 'and', 'can', 'lead', 'to', 'distant', 'metastasis', 'or', 'recurrence', 'here', 'a', 'novel', 'smallmolecule', 'inhibitorantagonist', 'of', 'dna', 'methyltransferase', '1', 'dnmt1', 'named', 'di1', 'inhibitor', 'of', 'dnmt1', 'was', 'explored', 'to', 'enhance', 'the', 'antitumor', 'effect', 'of', 'a', 'moleculartargeted', 'agent', 'cabozantinib', 'on', 'osa', 'cell', 'lines', 'in', 'patients', 'with', 'osa', 'expression', 'of', 'dnmt1', 'was', 'negatively', 'related', 'with', 'that', 'of', 'microrna', 'mir34a', 'and', 'associated', 'with', 'a', 'poor', 'prognosis', 'in', 'osa', 'cell', 'lines', 'osa', 'cell', 'line', 'u2os', 'and', 'an', 'osa', 'cell', 'line', 'u2ossuprsup', 'resistance', 'to', 'cabozantinib', 'di1', 'treatment', 'enhanced', 'mir34a', 'expression', 'by', 'inhibiting', 'hypermethylation', 'of', 'the', 'promoter', 'region', 'of', 'mir34a', 'mediated', 'by', 'dnmt1', 'di1', 'enhanced', 'the', 'sensitivity', 'of', 'osa', 'cells', 'u2os', '143b', 'and', 'mg63', 'to', 'cabozantinib', 'and', 'other', 'moleculartargeted', 'agents', 'by', 'enhancing', 'mir34a', 'expression', 'and', 'repressing', 'activation', 'of', 'the', 'notch', 'pathway', 'mechanistically', 'di1', 'repressed', 'recruitment', 'of', 'dnmt1', 'to', 'the', 'promoter', 'region', 'of', 'mir34a', 'and', 'in', 'turn', 'decreased', 'the', 'methylation', 'rate', 'in', 'the', 'promoter', 'region', 'of', 'mir34a', 'in', 'osa', 'cells', 'these', 'results', 'suggest', 'that', 'repressing', 'dnmt1', 'activation', 'by', 'di1', 'enhances', 'mir34a', 'expression', 'in', 'osa', 'cells', 'and', 'could', 'be', 'a', 'promising', 'therapeutic', 'strategy', 'for', 'osa']","['advanced', 'osteosarcoma', 'osa', 'highly', 'aggressive', 'lead', 'distant', 'metastasis', 'recurrence', 'novel', 'smallmolecule', 'inhibitorantagonist', 'dna', 'methyltransferase', '1', 'dnmt1', 'named', 'di1', 'inhibitor', 'dnmt1', 'explored', 'enhance', 'antitumor', 'effect', 'moleculartargeted', 'agent', 'cabozantinib', 'osa', 'cell', 'lines', 'patients', 'osa', 'expression', 'dnmt1', 'negatively', 'related', 'microrna', 'mir34a', 'associated', 'poor', 'prognosis', 'osa', 'cell', 'lines', 'osa', 'cell', 'line', 'u2os', 'osa', 'cell', 'line', 'u2ossuprsup', 'resistance', 'cabozantinib', 'di1', 'treatment', 'enhanced', 'mir34a', 'expression', 'inhibiting', 'hypermethylation', 'promoter', 'region', 'mir34a', 'mediated', 'dnmt1', 'di1', 'enhanced', 'sensitivity', 'osa', 'cells', 'u2os', '143b', 'mg63', 'cabozantinib', 'moleculartargeted', 'agents', 'enhancing', 'mir34a', 'expression', 'repressing', 'activation', 'notch', 'pathway', 'mechanistically', 'di1', 'repressed', 'recruitment', 'dnmt1', 'promoter', 'region', 'mir34a', 'turn', 'decreased', 'methylation', 'rate', 'promoter', 'region', 'mir34a', 'osa', 'cells', 'results', 'suggest', 'repressing', 'dnmt1', 'activation', 'di1', 'enhances', 'mir34a', 'expression', 'osa', 'cells', 'could', 'promising', 'therapeutic', 'strategy', 'osa']",['microrna'],['microrna'],True,['tumor']
34440055,Development and Characterization of a Novel Peptide-Drug Conjugate with DM1 for Treatment of FGFR2-Positive Tumors.,"A maytansin derivative, DM1, is a promising therapeutic compound for treating tumors, but is also a highly poisonous substance with various side effects. For clinical expansion, we tried to develop novel peptide-drug conjugates (PDCs) with DM1. In the study, a one-bead one-compound (OBOC) platform was used to screen and identify a novel, highly stable, non-natural amino acid peptide targeting the tyrosine receptor FGFR2. Then, the identified peptide, named LLC2B, was conjugated with the cytotoxin DM1. Our results show that LLC2B has high affinity for the FGFR2 protein according to an isothermal titration calorimetry (ITC) test. LLC2B-Cy5.5 binding to FGFR2-positive cancer cells was confirmed by fluorescent microscopic imaging and flow cytometry in vitro. Using xenografted nude mouse models established with breast cancer MCF-7 cells and esophageal squamous cell carcinoma KYSE180 cells, respectively, LLC2B-Cy5.5 was observed to specifically target tumor tissues 24 h after tail vein injection. Incubation assays, both in aqueous solution at room temperature and in human plasma at 37 °C, suggested that LLC2B has high stability and strong anti-proteolytic ability. Then, we used two different linkers, one of molecular disulfide bonds and another of a maleimide group, to couple LLC2B to the toxin DM1. The novel peptide-drug conjugates (PDCs) inhibited tumor growth and significantly increased the maximum tolerated dose of DM1 in xenografted mice. In brief, our results suggest that LLC2B-DM1 can be developed into a potential PDC for tumor treatment in the future.",2021-07-21,a maytansin derivative dm1 is a promising therapeutic compound for treating tumors but is also a highly poisonous substance with various side effects for clinical expansion we tried to develop novel peptidedrug conjugates pdcs with dm1 in the study a onebead onecompound oboc platform was used to screen and identify a novel highly stable nonnatural amino acid peptide targeting the tyrosine receptor fgfr2 then the identified peptide named llc2b was conjugated with the cytotoxin dm1 our results show that llc2b has high affinity for the fgfr2 protein according to an isothermal titration calorimetry itc test llc2bcy55 binding to fgfr2positive cancer cells was confirmed by fluorescent microscopic imaging and flow cytometry in vitro using xenografted nude mouse models established with breast cancer mcf7 cells and esophageal squamous cell carcinoma kyse180 cells respectively llc2bcy55 was observed to specifically target tumor tissues 24 h after tail vein injection incubation assays both in aqueous solution at room temperature and in human plasma at 37 c suggested that llc2b has high stability and strong antiproteolytic ability then we used two different linkers one of molecular disulfide bonds and another of a maleimide group to couple llc2b to the toxin dm1 the novel peptidedrug conjugates pdcs inhibited tumor growth and significantly increased the maximum tolerated dose of dm1 in xenografted mice in brief our results suggest that llc2bdm1 can be developed into a potential pdc for tumor treatment in the future,"['a', 'maytansin', 'derivative', 'dm1', 'is', 'a', 'promising', 'therapeutic', 'compound', 'for', 'treating', 'tumors', 'but', 'is', 'also', 'a', 'highly', 'poisonous', 'substance', 'with', 'various', 'side', 'effects', 'for', 'clinical', 'expansion', 'we', 'tried', 'to', 'develop', 'novel', 'peptidedrug', 'conjugates', 'pdcs', 'with', 'dm1', 'in', 'the', 'study', 'a', 'onebead', 'onecompound', 'oboc', 'platform', 'was', 'used', 'to', 'screen', 'and', 'identify', 'a', 'novel', 'highly', 'stable', 'nonnatural', 'amino', 'acid', 'peptide', 'targeting', 'the', 'tyrosine', 'receptor', 'fgfr2', 'then', 'the', 'identified', 'peptide', 'named', 'llc2b', 'was', 'conjugated', 'with', 'the', 'cytotoxin', 'dm1', 'our', 'results', 'show', 'that', 'llc2b', 'has', 'high', 'affinity', 'for', 'the', 'fgfr2', 'protein', 'according', 'to', 'an', 'isothermal', 'titration', 'calorimetry', 'itc', 'test', 'llc2bcy55', 'binding', 'to', 'fgfr2positive', 'cancer', 'cells', 'was', 'confirmed', 'by', 'fluorescent', 'microscopic', 'imaging', 'and', 'flow', 'cytometry', 'in', 'vitro', 'using', 'xenografted', 'nude', 'mouse', 'models', 'established', 'with', 'breast', 'cancer', 'mcf7', 'cells', 'and', 'esophageal', 'squamous', 'cell', 'carcinoma', 'kyse180', 'cells', 'respectively', 'llc2bcy55', 'was', 'observed', 'to', 'specifically', 'target', 'tumor', 'tissues', '24', 'h', 'after', 'tail', 'vein', 'injection', 'incubation', 'assays', 'both', 'in', 'aqueous', 'solution', 'at', 'room', 'temperature', 'and', 'in', 'human', 'plasma', 'at', '37', 'c', 'suggested', 'that', 'llc2b', 'has', 'high', 'stability', 'and', 'strong', 'antiproteolytic', 'ability', 'then', 'we', 'used', 'two', 'different', 'linkers', 'one', 'of', 'molecular', 'disulfide', 'bonds', 'and', 'another', 'of', 'a', 'maleimide', 'group', 'to', 'couple', 'llc2b', 'to', 'the', 'toxin', 'dm1', 'the', 'novel', 'peptidedrug', 'conjugates', 'pdcs', 'inhibited', 'tumor', 'growth', 'and', 'significantly', 'increased', 'the', 'maximum', 'tolerated', 'dose', 'of', 'dm1', 'in', 'xenografted', 'mice', 'in', 'brief', 'our', 'results', 'suggest', 'that', 'llc2bdm1', 'can', 'be', 'developed', 'into', 'a', 'potential', 'pdc', 'for', 'tumor', 'treatment', 'in', 'the', 'future']","['maytansin', 'derivative', 'dm1', 'promising', 'therapeutic', 'compound', 'treating', 'tumors', 'also', 'highly', 'poisonous', 'substance', 'various', 'side', 'effects', 'clinical', 'expansion', 'tried', 'develop', 'novel', 'peptidedrug', 'conjugates', 'pdcs', 'dm1', 'study', 'onebead', 'onecompound', 'oboc', 'platform', 'used', 'screen', 'identify', 'novel', 'highly', 'stable', 'nonnatural', 'amino', 'acid', 'peptide', 'targeting', 'tyrosine', 'receptor', 'fgfr2', 'identified', 'peptide', 'named', 'llc2b', 'conjugated', 'cytotoxin', 'dm1', 'results', 'show', 'llc2b', 'high', 'affinity', 'fgfr2', 'protein', 'according', 'isothermal', 'titration', 'calorimetry', 'itc', 'test', 'llc2bcy55', 'binding', 'fgfr2positive', 'cancer', 'cells', 'confirmed', 'fluorescent', 'microscopic', 'imaging', 'flow', 'cytometry', 'vitro', 'using', 'xenografted', 'nude', 'mouse', 'models', 'established', 'breast', 'cancer', 'mcf7', 'cells', 'esophageal', 'squamous', 'cell', 'carcinoma', 'kyse180', 'cells', 'respectively', 'llc2bcy55', 'observed', 'specifically', 'target', 'tumor', 'tissues', '24', 'h', 'tail', 'vein', 'injection', 'incubation', 'assays', 'aqueous', 'solution', 'room', 'temperature', 'human', 'plasma', '37', 'c', 'suggested', 'llc2b', 'high', 'stability', 'strong', 'antiproteolytic', 'ability', 'used', 'two', 'different', 'linkers', 'one', 'molecular', 'disulfide', 'bonds', 'another', 'maleimide', 'group', 'couple', 'llc2b', 'toxin', 'dm1', 'novel', 'peptidedrug', 'conjugates', 'pdcs', 'inhibited', 'tumor', 'growth', 'significantly', 'increased', 'maximum', 'tolerated', 'dose', 'dm1', 'xenografted', 'mice', 'brief', 'results', 'suggest', 'llc2bdm1', 'developed', 'potential', 'pdc', 'tumor', 'treatment', 'future']","['fgfr2', 'fgfr2', 'toxin', 'pdc']","['fgfr2', 'fgfr2']",True,"['tumor', 'cancer']"
34411602,Inhibiting miR-129-5p alleviates inflammation and modulates autophagy by targeting ATG14 in fungal keratitis.,"To investigate the role of miR-129-5p in inflammation and autophagy in fungal keratitis, we established a keratitis mouse model infected with Fusarium solani (F. solani) and conducted experiments on corneal stromal cells infected with F. solani. The expression of miR-129-5p was detected via quantitative real-time polymerase chain reaction (PCR). The miR-129-5p antagomir was used to transfect cells and mice to study the regulatory role of miR-129-5p in autophagy and inflammation after fungal infection. The expression of Beclin1 and LC3B and colocalization of LC3B with lysosomes were detected via Western blotting and immunofluorescence. CCK-8 was used to determine the viability of corneal stromal cells. The expression of IL-1β were detected by ELISA. Bioinformatics software was used to predict the potential targets of miR-129-5p, which were verified by a luciferase reporter gene assay. RT-PCR showed that miR-129-5p expression in mouse corneas was significantly increased after infection with F. solani. Subconjunctival injection of the miR-129-5p antagomir significantly enhanced the proteins Beclin-1 and LC3B. At the same time, inhibiting miR-129-5p expression could reduce the inflammatory response in FK and significantly increase the viability of corneal stromal cells infected with F. solan. Moreover, the dual luciferase reporter assay indicated that Atg14 was a direct target of miR-129-5p. Our study shows that miR-129-5p is a novel small molecule that regulates autophagy by targeting Atg14, indicating that it may be a proinflammatory and therapeutic target for fungal keratitis.",2021-08-17,to investigate the role of mir1295p in inflammation and autophagy in fungal keratitis we established a keratitis mouse model infected with fusarium solani f solani and conducted experiments on corneal stromal cells infected with f solani the expression of mir1295p was detected via quantitative realtime polymerase chain reaction pcr the mir1295p antagomir was used to transfect cells and mice to study the regulatory role of mir1295p in autophagy and inflammation after fungal infection the expression of beclin1 and lc3b and colocalization of lc3b with lysosomes were detected via western blotting and immunofluorescence cck8 was used to determine the viability of corneal stromal cells the expression of il1β were detected by elisa bioinformatics software was used to predict the potential targets of mir1295p which were verified by a luciferase reporter gene assay rtpcr showed that mir1295p expression in mouse corneas was significantly increased after infection with f solani subconjunctival injection of the mir1295p antagomir significantly enhanced the proteins beclin1 and lc3b at the same time inhibiting mir1295p expression could reduce the inflammatory response in fk and significantly increase the viability of corneal stromal cells infected with f solan moreover the dual luciferase reporter assay indicated that atg14 was a direct target of mir1295p our study shows that mir1295p is a novel small molecule that regulates autophagy by targeting atg14 indicating that it may be a proinflammatory and therapeutic target for fungal keratitis,"['to', 'investigate', 'the', 'role', 'of', 'mir1295p', 'in', 'inflammation', 'and', 'autophagy', 'in', 'fungal', 'keratitis', 'we', 'established', 'a', 'keratitis', 'mouse', 'model', 'infected', 'with', 'fusarium', 'solani', 'f', 'solani', 'and', 'conducted', 'experiments', 'on', 'corneal', 'stromal', 'cells', 'infected', 'with', 'f', 'solani', 'the', 'expression', 'of', 'mir1295p', 'was', 'detected', 'via', 'quantitative', 'realtime', 'polymerase', 'chain', 'reaction', 'pcr', 'the', 'mir1295p', 'antagomir', 'was', 'used', 'to', 'transfect', 'cells', 'and', 'mice', 'to', 'study', 'the', 'regulatory', 'role', 'of', 'mir1295p', 'in', 'autophagy', 'and', 'inflammation', 'after', 'fungal', 'infection', 'the', 'expression', 'of', 'beclin1', 'and', 'lc3b', 'and', 'colocalization', 'of', 'lc3b', 'with', 'lysosomes', 'were', 'detected', 'via', 'western', 'blotting', 'and', 'immunofluorescence', 'cck8', 'was', 'used', 'to', 'determine', 'the', 'viability', 'of', 'corneal', 'stromal', 'cells', 'the', 'expression', 'of', 'il1β', 'were', 'detected', 'by', 'elisa', 'bioinformatics', 'software', 'was', 'used', 'to', 'predict', 'the', 'potential', 'targets', 'of', 'mir1295p', 'which', 'were', 'verified', 'by', 'a', 'luciferase', 'reporter', 'gene', 'assay', 'rtpcr', 'showed', 'that', 'mir1295p', 'expression', 'in', 'mouse', 'corneas', 'was', 'significantly', 'increased', 'after', 'infection', 'with', 'f', 'solani', 'subconjunctival', 'injection', 'of', 'the', 'mir1295p', 'antagomir', 'significantly', 'enhanced', 'the', 'proteins', 'beclin1', 'and', 'lc3b', 'at', 'the', 'same', 'time', 'inhibiting', 'mir1295p', 'expression', 'could', 'reduce', 'the', 'inflammatory', 'response', 'in', 'fk', 'and', 'significantly', 'increase', 'the', 'viability', 'of', 'corneal', 'stromal', 'cells', 'infected', 'with', 'f', 'solan', 'moreover', 'the', 'dual', 'luciferase', 'reporter', 'assay', 'indicated', 'that', 'atg14', 'was', 'a', 'direct', 'target', 'of', 'mir1295p', 'our', 'study', 'shows', 'that', 'mir1295p', 'is', 'a', 'novel', 'small', 'molecule', 'that', 'regulates', 'autophagy', 'by', 'targeting', 'atg14', 'indicating', 'that', 'it', 'may', 'be', 'a', 'proinflammatory', 'and', 'therapeutic', 'target', 'for', 'fungal', 'keratitis']","['investigate', 'role', 'mir1295p', 'inflammation', 'autophagy', 'fungal', 'keratitis', 'established', 'keratitis', 'mouse', 'model', 'infected', 'fusarium', 'solani', 'f', 'solani', 'conducted', 'experiments', 'corneal', 'stromal', 'cells', 'infected', 'f', 'solani', 'expression', 'mir1295p', 'detected', 'via', 'quantitative', 'realtime', 'polymerase', 'chain', 'reaction', 'pcr', 'mir1295p', 'antagomir', 'used', 'transfect', 'cells', 'mice', 'study', 'regulatory', 'role', 'mir1295p', 'autophagy', 'inflammation', 'fungal', 'infection', 'expression', 'beclin1', 'lc3b', 'colocalization', 'lc3b', 'lysosomes', 'detected', 'via', 'western', 'blotting', 'immunofluorescence', 'cck8', 'used', 'determine', 'viability', 'corneal', 'stromal', 'cells', 'expression', 'il1β', 'detected', 'elisa', 'bioinformatics', 'software', 'used', 'predict', 'potential', 'targets', 'mir1295p', 'verified', 'luciferase', 'reporter', 'gene', 'assay', 'rtpcr', 'showed', 'mir1295p', 'expression', 'mouse', 'corneas', 'significantly', 'increased', 'infection', 'f', 'solani', 'subconjunctival', 'injection', 'mir1295p', 'antagomir', 'significantly', 'enhanced', 'proteins', 'beclin1', 'lc3b', 'time', 'inhibiting', 'mir1295p', 'expression', 'could', 'reduce', 'inflammatory', 'response', 'fk', 'significantly', 'increase', 'viability', 'corneal', 'stromal', 'cells', 'infected', 'f', 'solan', 'moreover', 'dual', 'luciferase', 'reporter', 'assay', 'indicated', 'atg14', 'direct', 'target', 'mir1295p', 'study', 'shows', 'mir1295p', 'novel', 'small', 'molecule', 'regulates', 'autophagy', 'targeting', 'atg14', 'indicating', 'may', 'proinflammatory', 'therapeutic', 'target', 'fungal', 'keratitis']","['antagomir', 'beclin1', 'luciferase', 'antagomir', 'beclin1', 'luciferase']","['antagomir', 'beclin1', 'luciferase', 'antagomir', 'beclin1', 'luciferase']",True,['infection']
34389740,Potent antitumor activity of a glutamyltransferase-derived peptide via an activation of oncosis pathway.,"Hepatocellular carcinoma (HCC) still presents poor prognosis with high mortality rate, despite of the improvement in the management. The challenge for precision treatment was due to the fact that little targeted therapeutics are available for HCC. Recent studies show that metabolic and circulating peptides serve as endogenous switches for correcting aberrant cellular plasticity. Here we explored the antitumor activity of low molecular components in human umbilical serum and identified a high abundance peptide VI-13 by peptidome analysis, which was recognized as the part of glutamyltransferase signal peptide. We modified VI-13 by inserting four arginines and obtained an analog peptide VI-17 to improve its solubility. Our analyses showed that the peptide VI-17 induced rapid context-dependent cell death, and exhibited a higher sensitivity on hepatoma cells, which is attenuated by polyethylene glycol but not necrotic inhibitors such as z-VAD-fmk or necrostatin-1. Morphologically, VI-17 induced cell swelling, blebbing and membrane rupture with release of cellular ATP and LDH into extracellular media, which is hallmark of oncotic process. Mechanistically, VI-17 induced cell membrane pore formation, degradation of α-tubulin via influx of calcium ion. These results indicated that the novel peptide VI-17 induced oncosis in HCC cells, which could serve as a promising lead for development of therapeutic intervention of HCC.",2021-08-13,hepatocellular carcinoma hcc still presents poor prognosis with high mortality rate despite of the improvement in the management the challenge for precision treatment was due to the fact that little targeted therapeutics are available for hcc recent studies show that metabolic and circulating peptides serve as endogenous switches for correcting aberrant cellular plasticity here we explored the antitumor activity of low molecular components in human umbilical serum and identified a high abundance peptide vi13 by peptidome analysis which was recognized as the part of glutamyltransferase signal peptide we modified vi13 by inserting four arginines and obtained an analog peptide vi17 to improve its solubility our analyses showed that the peptide vi17 induced rapid contextdependent cell death and exhibited a higher sensitivity on hepatoma cells which is attenuated by polyethylene glycol but not necrotic inhibitors such as zvadfmk or necrostatin1 morphologically vi17 induced cell swelling blebbing and membrane rupture with release of cellular atp and ldh into extracellular media which is hallmark of oncotic process mechanistically vi17 induced cell membrane pore formation degradation of αtubulin via influx of calcium ion these results indicated that the novel peptide vi17 induced oncosis in hcc cells which could serve as a promising lead for development of therapeutic intervention of hcc,"['hepatocellular', 'carcinoma', 'hcc', 'still', 'presents', 'poor', 'prognosis', 'with', 'high', 'mortality', 'rate', 'despite', 'of', 'the', 'improvement', 'in', 'the', 'management', 'the', 'challenge', 'for', 'precision', 'treatment', 'was', 'due', 'to', 'the', 'fact', 'that', 'little', 'targeted', 'therapeutics', 'are', 'available', 'for', 'hcc', 'recent', 'studies', 'show', 'that', 'metabolic', 'and', 'circulating', 'peptides', 'serve', 'as', 'endogenous', 'switches', 'for', 'correcting', 'aberrant', 'cellular', 'plasticity', 'here', 'we', 'explored', 'the', 'antitumor', 'activity', 'of', 'low', 'molecular', 'components', 'in', 'human', 'umbilical', 'serum', 'and', 'identified', 'a', 'high', 'abundance', 'peptide', 'vi13', 'by', 'peptidome', 'analysis', 'which', 'was', 'recognized', 'as', 'the', 'part', 'of', 'glutamyltransferase', 'signal', 'peptide', 'we', 'modified', 'vi13', 'by', 'inserting', 'four', 'arginines', 'and', 'obtained', 'an', 'analog', 'peptide', 'vi17', 'to', 'improve', 'its', 'solubility', 'our', 'analyses', 'showed', 'that', 'the', 'peptide', 'vi17', 'induced', 'rapid', 'contextdependent', 'cell', 'death', 'and', 'exhibited', 'a', 'higher', 'sensitivity', 'on', 'hepatoma', 'cells', 'which', 'is', 'attenuated', 'by', 'polyethylene', 'glycol', 'but', 'not', 'necrotic', 'inhibitors', 'such', 'as', 'zvadfmk', 'or', 'necrostatin1', 'morphologically', 'vi17', 'induced', 'cell', 'swelling', 'blebbing', 'and', 'membrane', 'rupture', 'with', 'release', 'of', 'cellular', 'atp', 'and', 'ldh', 'into', 'extracellular', 'media', 'which', 'is', 'hallmark', 'of', 'oncotic', 'process', 'mechanistically', 'vi17', 'induced', 'cell', 'membrane', 'pore', 'formation', 'degradation', 'of', 'αtubulin', 'via', 'influx', 'of', 'calcium', 'ion', 'these', 'results', 'indicated', 'that', 'the', 'novel', 'peptide', 'vi17', 'induced', 'oncosis', 'in', 'hcc', 'cells', 'which', 'could', 'serve', 'as', 'a', 'promising', 'lead', 'for', 'development', 'of', 'therapeutic', 'intervention', 'of', 'hcc']","['hepatocellular', 'carcinoma', 'hcc', 'still', 'presents', 'poor', 'prognosis', 'high', 'mortality', 'rate', 'despite', 'improvement', 'management', 'challenge', 'precision', 'treatment', 'due', 'fact', 'little', 'targeted', 'therapeutics', 'available', 'hcc', 'recent', 'studies', 'show', 'metabolic', 'circulating', 'peptides', 'serve', 'endogenous', 'switches', 'correcting', 'aberrant', 'cellular', 'plasticity', 'explored', 'antitumor', 'activity', 'low', 'molecular', 'components', 'human', 'umbilical', 'serum', 'identified', 'high', 'abundance', 'peptide', 'vi13', 'peptidome', 'analysis', 'recognized', 'part', 'glutamyltransferase', 'signal', 'peptide', 'modified', 'vi13', 'inserting', 'four', 'arginines', 'obtained', 'analog', 'peptide', 'vi17', 'improve', 'solubility', 'analyses', 'showed', 'peptide', 'vi17', 'induced', 'rapid', 'contextdependent', 'cell', 'death', 'exhibited', 'higher', 'sensitivity', 'hepatoma', 'cells', 'attenuated', 'polyethylene', 'glycol', 'necrotic', 'inhibitors', 'zvadfmk', 'necrostatin1', 'morphologically', 'vi17', 'induced', 'cell', 'swelling', 'blebbing', 'membrane', 'rupture', 'release', 'cellular', 'atp', 'ldh', 'extracellular', 'media', 'hallmark', 'oncotic', 'process', 'mechanistically', 'vi17', 'induced', 'cell', 'membrane', 'pore', 'formation', 'degradation', 'αtubulin', 'via', 'influx', 'calcium', 'ion', 'results', 'indicated', 'novel', 'peptide', 'vi17', 'induced', 'oncosis', 'hcc', 'cells', 'could', 'serve', 'promising', 'lead', 'development', 'therapeutic', 'intervention', 'hcc']",['glutamyltransferase'],['glutamyltransferase'],True,['tumor']
34373735,Small-molecule inhibitor of AF9/ENL-DOT1L/AF4/AFF4 interactions suppresses malignant gene expression and tumor growth.,"Chromosome translocations involving mixed lineage leukemia (MLL) gene cause acute leukemia with a poor prognosis. MLL is frequently fused with transcription cofactors AF4 (~35%), AF9 (25%) or its paralog ENL (10%). The AHD domain of AF9/ENL binds to AF4, its paralog AFF4, or histone-H3 lysine-79 (H3K79) methyltransferase DOT1L. Formation of AF9/ENL/AF4/AFF4-containing super elongation complexes (SEC) and the catalytic activity of DOT1L are essential for MLL-rearranged leukemia. Protein-protein interactions (PPI) between AF9/ENL and DOT1L/AF4/AFF4 are therefore a potential drug target. <b>Methods</b>: Compound screening followed by medicinal chemistry was used to find inhibitors of such PPIs, which were examined for their biological activities against MLL-rearranged leukemia and other cancer cells. <b>Results</b>: Compound-<b>1</b> was identified to be a novel small-molecule inhibitor of the AF9/ENL-DOT1L/AF4/AFF4 interaction with IC50s of 0.9-3.5 µM. Pharmacological inhibition of the PPIs significantly reduced SEC and DOT1L-mediated H3K79 methylation in the leukemia cells. Gene profiling shows compound-<b>1</b> significantly suppressed the gene signatures related to onco-MLL, DOT1L, HoxA9 and Myc. It selectively inhibited proliferation of onco-MLL- or Myc-driven cancer cells and induced cell differentiation and apoptosis. Compound-<b>1</b> exhibited strong antitumor activity in a mouse model of MLL-rearranged leukemia. <b>Conclusions:</b> The AF9/ENL-DOT1L/AF4/AFF4 interactions are validated to be an anticancer target and compound-<b>1</b> is a useful in vivo probe for biological studies as well as a pharmacological lead for further drug development.",2021-07-13,chromosome translocations involving mixed lineage leukemia mll gene cause acute leukemia with a poor prognosis mll is frequently fused with transcription cofactors af4 35 af9 25 or its paralog enl 10 the ahd domain of af9enl binds to af4 its paralog aff4 or histoneh3 lysine79 h3k79 methyltransferase dot1l formation of af9enlaf4aff4containing super elongation complexes sec and the catalytic activity of dot1l are essential for mllrearranged leukemia proteinprotein interactions ppi between af9enl and dot1laf4aff4 are therefore a potential drug target bmethodsb compound screening followed by medicinal chemistry was used to find inhibitors of such ppis which were examined for their biological activities against mllrearranged leukemia and other cancer cells bresultsb compoundb1b was identified to be a novel smallmolecule inhibitor of the af9enldot1laf4aff4 interaction with ic50s of 0935 µm pharmacological inhibition of the ppis significantly reduced sec and dot1lmediated h3k79 methylation in the leukemia cells gene profiling shows compoundb1b significantly suppressed the gene signatures related to oncomll dot1l hoxa9 and myc it selectively inhibited proliferation of oncomll or mycdriven cancer cells and induced cell differentiation and apoptosis compoundb1b exhibited strong antitumor activity in a mouse model of mllrearranged leukemia bconclusionsb the af9enldot1laf4aff4 interactions are validated to be an anticancer target and compoundb1b is a useful in vivo probe for biological studies as well as a pharmacological lead for further drug development,"['chromosome', 'translocations', 'involving', 'mixed', 'lineage', 'leukemia', 'mll', 'gene', 'cause', 'acute', 'leukemia', 'with', 'a', 'poor', 'prognosis', 'mll', 'is', 'frequently', 'fused', 'with', 'transcription', 'cofactors', 'af4', '35', 'af9', '25', 'or', 'its', 'paralog', 'enl', '10', 'the', 'ahd', 'domain', 'of', 'af9enl', 'binds', 'to', 'af4', 'its', 'paralog', 'aff4', 'or', 'histoneh3', 'lysine79', 'h3k79', 'methyltransferase', 'dot1l', 'formation', 'of', 'af9enlaf4aff4containing', 'super', 'elongation', 'complexes', 'sec', 'and', 'the', 'catalytic', 'activity', 'of', 'dot1l', 'are', 'essential', 'for', 'mllrearranged', 'leukemia', 'proteinprotein', 'interactions', 'ppi', 'between', 'af9enl', 'and', 'dot1laf4aff4', 'are', 'therefore', 'a', 'potential', 'drug', 'target', 'bmethodsb', 'compound', 'screening', 'followed', 'by', 'medicinal', 'chemistry', 'was', 'used', 'to', 'find', 'inhibitors', 'of', 'such', 'ppis', 'which', 'were', 'examined', 'for', 'their', 'biological', 'activities', 'against', 'mllrearranged', 'leukemia', 'and', 'other', 'cancer', 'cells', 'bresultsb', 'compoundb1b', 'was', 'identified', 'to', 'be', 'a', 'novel', 'smallmolecule', 'inhibitor', 'of', 'the', 'af9enldot1laf4aff4', 'interaction', 'with', 'ic50s', 'of', '0935', 'µm', 'pharmacological', 'inhibition', 'of', 'the', 'ppis', 'significantly', 'reduced', 'sec', 'and', 'dot1lmediated', 'h3k79', 'methylation', 'in', 'the', 'leukemia', 'cells', 'gene', 'profiling', 'shows', 'compoundb1b', 'significantly', 'suppressed', 'the', 'gene', 'signatures', 'related', 'to', 'oncomll', 'dot1l', 'hoxa9', 'and', 'myc', 'it', 'selectively', 'inhibited', 'proliferation', 'of', 'oncomll', 'or', 'mycdriven', 'cancer', 'cells', 'and', 'induced', 'cell', 'differentiation', 'and', 'apoptosis', 'compoundb1b', 'exhibited', 'strong', 'antitumor', 'activity', 'in', 'a', 'mouse', 'model', 'of', 'mllrearranged', 'leukemia', 'bconclusionsb', 'the', 'af9enldot1laf4aff4', 'interactions', 'are', 'validated', 'to', 'be', 'an', 'anticancer', 'target', 'and', 'compoundb1b', 'is', 'a', 'useful', 'in', 'vivo', 'probe', 'for', 'biological', 'studies', 'as', 'well', 'as', 'a', 'pharmacological', 'lead', 'for', 'further', 'drug', 'development']","['chromosome', 'translocations', 'involving', 'mixed', 'lineage', 'leukemia', 'mll', 'gene', 'cause', 'acute', 'leukemia', 'poor', 'prognosis', 'mll', 'frequently', 'fused', 'transcription', 'cofactors', 'af4', '35', 'af9', '25', 'paralog', 'enl', '10', 'ahd', 'domain', 'af9enl', 'binds', 'af4', 'paralog', 'aff4', 'histoneh3', 'lysine79', 'h3k79', 'methyltransferase', 'dot1l', 'formation', 'af9enlaf4aff4containing', 'super', 'elongation', 'complexes', 'sec', 'catalytic', 'activity', 'dot1l', 'essential', 'mllrearranged', 'leukemia', 'proteinprotein', 'interactions', 'ppi', 'af9enl', 'dot1laf4aff4', 'therefore', 'potential', 'drug', 'target', 'bmethodsb', 'compound', 'screening', 'followed', 'medicinal', 'chemistry', 'used', 'find', 'inhibitors', 'ppis', 'examined', 'biological', 'activities', 'mllrearranged', 'leukemia', 'cancer', 'cells', 'bresultsb', 'compoundb1b', 'identified', 'novel', 'smallmolecule', 'inhibitor', 'af9enldot1laf4aff4', 'interaction', 'ic50s', '0935', 'µm', 'pharmacological', 'inhibition', 'ppis', 'significantly', 'reduced', 'sec', 'dot1lmediated', 'h3k79', 'methylation', 'leukemia', 'cells', 'gene', 'profiling', 'shows', 'compoundb1b', 'significantly', 'suppressed', 'gene', 'signatures', 'related', 'oncomll', 'dot1l', 'hoxa9', 'myc', 'selectively', 'inhibited', 'proliferation', 'oncomll', 'mycdriven', 'cancer', 'cells', 'induced', 'cell', 'differentiation', 'apoptosis', 'compoundb1b', 'exhibited', 'strong', 'antitumor', 'activity', 'mouse', 'model', 'mllrearranged', 'leukemia', 'bconclusionsb', 'af9enldot1laf4aff4', 'interactions', 'validated', 'anticancer', 'target', 'compoundb1b', 'useful', 'vivo', 'probe', 'biological', 'studies', 'well', 'pharmacological', 'lead', 'drug', 'development']","['mll', 'mll', 'af4', 'af4', 'hoxa9', 'myc']",['hoxa9'],True,"['tumor', 'cancer', 'leukemia']"
34325312,LC-MS/MS method for the quantification of the anti-cancer agent infigratinib: Application for estimation of metabolic stability in human liver microsomes.,"Infigratinib (INF) is a novel small molecule, administered orally, which acts as a human fibroblast growth factor receptors (FGFRs) inhibitor. FGFRs are a family of receptor tyrosine kinases (RTK) reported to be upregulated in various tumor cell types. In 1 December 2020, BridgeBio Pharma Inc. announced FDA approval of INF as a New Drug Application, granting it Priority Review for the treatment of cholangiocarcinoma (CCA). Thus, the current study aimed to establish a validated LC-MS/MS method to estimate the INF concentration in the HLM matrix. In silico prediction of INF metabolism was done using the StarDrop® WhichP450™ module to verify its metabolic stability. An accurate and efficient LC-MS/MS analytical method was developed for INF metabolic stability evaluation. INF and duvelisib (DVB) (internal standard; IS) were eluted using an isocratic mobile phase with a C<sub>18</sub> column as a stationary reversed phase. The established LC-MS/MS method showed a linear range over 5-500 ng/mL (r<sup>2</sup> ≥ 0.9998) in human liver microsomes (HLMs). The sensitivity of the method was confirmed at its limit of quantification (4.71 ng/mL), and reproducibility was indicated by inter- and intra-day accuracy and precision (within 7.3%). The evaluation of INF metabolic stability was assessed, which reflected an intrinsic clearance of 23.6 µL/min/mg and in vitro half-life of 29.4 min. The developed approach in the current study is the first LC-MS/MS method for INF metabolic stability assessment. Application of the developed method in HLM in vitro studies suggests that INF has a moderate extraction ratio, indicating relatively good predicted oral bioavailability.",2021-07-02,infigratinib inf is a novel small molecule administered orally which acts as a human fibroblast growth factor receptors fgfrs inhibitor fgfrs are a family of receptor tyrosine kinases rtk reported to be upregulated in various tumor cell types in 1 december 2020 bridgebio pharma inc announced fda approval of inf as a new drug application granting it priority review for the treatment of cholangiocarcinoma cca thus the current study aimed to establish a validated lcmsms method to estimate the inf concentration in the hlm matrix in silico prediction of inf metabolism was done using the stardrop whichp450 module to verify its metabolic stability an accurate and efficient lcmsms analytical method was developed for inf metabolic stability evaluation inf and duvelisib dvb internal standard is were eluted using an isocratic mobile phase with a csub18sub column as a stationary reversed phase the established lcmsms method showed a linear range over 5500 ngml rsup2sup  09998 in human liver microsomes hlms the sensitivity of the method was confirmed at its limit of quantification 471 ngml and reproducibility was indicated by inter and intraday accuracy and precision within 73 the evaluation of inf metabolic stability was assessed which reflected an intrinsic clearance of 236 µlminmg and in vitro halflife of 294 min the developed approach in the current study is the first lcmsms method for inf metabolic stability assessment application of the developed method in hlm in vitro studies suggests that inf has a moderate extraction ratio indicating relatively good predicted oral bioavailability,"['infigratinib', 'inf', 'is', 'a', 'novel', 'small', 'molecule', 'administered', 'orally', 'which', 'acts', 'as', 'a', 'human', 'fibroblast', 'growth', 'factor', 'receptors', 'fgfrs', 'inhibitor', 'fgfrs', 'are', 'a', 'family', 'of', 'receptor', 'tyrosine', 'kinases', 'rtk', 'reported', 'to', 'be', 'upregulated', 'in', 'various', 'tumor', 'cell', 'types', 'in', '1', 'december', '2020', 'bridgebio', 'pharma', 'inc', 'announced', 'fda', 'approval', 'of', 'inf', 'as', 'a', 'new', 'drug', 'application', 'granting', 'it', 'priority', 'review', 'for', 'the', 'treatment', 'of', 'cholangiocarcinoma', 'cca', 'thus', 'the', 'current', 'study', 'aimed', 'to', 'establish', 'a', 'validated', 'lcmsms', 'method', 'to', 'estimate', 'the', 'inf', 'concentration', 'in', 'the', 'hlm', 'matrix', 'in', 'silico', 'prediction', 'of', 'inf', 'metabolism', 'was', 'done', 'using', 'the', 'stardrop', 'whichp450', 'module', 'to', 'verify', 'its', 'metabolic', 'stability', 'an', 'accurate', 'and', 'efficient', 'lcmsms', 'analytical', 'method', 'was', 'developed', 'for', 'inf', 'metabolic', 'stability', 'evaluation', 'inf', 'and', 'duvelisib', 'dvb', 'internal', 'standard', 'is', 'were', 'eluted', 'using', 'an', 'isocratic', 'mobile', 'phase', 'with', 'a', 'csub18sub', 'column', 'as', 'a', 'stationary', 'reversed', 'phase', 'the', 'established', 'lcmsms', 'method', 'showed', 'a', 'linear', 'range', 'over', '5500', 'ngml', 'rsup2sup', '09998', 'in', 'human', 'liver', 'microsomes', 'hlms', 'the', 'sensitivity', 'of', 'the', 'method', 'was', 'confirmed', 'at', 'its', 'limit', 'of', 'quantification', '471', 'ngml', 'and', 'reproducibility', 'was', 'indicated', 'by', 'inter', 'and', 'intraday', 'accuracy', 'and', 'precision', 'within', '73', 'the', 'evaluation', 'of', 'inf', 'metabolic', 'stability', 'was', 'assessed', 'which', 'reflected', 'an', 'intrinsic', 'clearance', 'of', '236', 'µlminmg', 'and', 'in', 'vitro', 'halflife', 'of', '294', 'min', 'the', 'developed', 'approach', 'in', 'the', 'current', 'study', 'is', 'the', 'first', 'lcmsms', 'method', 'for', 'inf', 'metabolic', 'stability', 'assessment', 'application', 'of', 'the', 'developed', 'method', 'in', 'hlm', 'in', 'vitro', 'studies', 'suggests', 'that', 'inf', 'has', 'a', 'moderate', 'extraction', 'ratio', 'indicating', 'relatively', 'good', 'predicted', 'oral', 'bioavailability']","['infigratinib', 'inf', 'novel', 'small', 'molecule', 'administered', 'orally', 'acts', 'human', 'fibroblast', 'growth', 'factor', 'receptors', 'fgfrs', 'inhibitor', 'fgfrs', 'family', 'receptor', 'tyrosine', 'kinases', 'rtk', 'reported', 'upregulated', 'various', 'tumor', 'cell', 'types', '1', 'december', '2020', 'bridgebio', 'pharma', 'inc', 'announced', 'fda', 'approval', 'inf', 'new', 'drug', 'application', 'granting', 'priority', 'review', 'treatment', 'cholangiocarcinoma', 'cca', 'thus', 'current', 'study', 'aimed', 'establish', 'validated', 'lcmsms', 'method', 'estimate', 'inf', 'concentration', 'hlm', 'matrix', 'silico', 'prediction', 'inf', 'metabolism', 'done', 'using', 'stardrop', 'whichp450', 'module', 'verify', 'metabolic', 'stability', 'accurate', 'efficient', 'lcmsms', 'analytical', 'method', 'developed', 'inf', 'metabolic', 'stability', 'evaluation', 'inf', 'duvelisib', 'dvb', 'internal', 'standard', 'eluted', 'using', 'isocratic', 'mobile', 'phase', 'csub18sub', 'column', 'stationary', 'reversed', 'phase', 'established', 'lcmsms', 'method', 'showed', 'linear', 'range', '5500', 'ngml', 'rsup2sup', '09998', 'human', 'liver', 'microsomes', 'hlms', 'sensitivity', 'method', 'confirmed', 'limit', 'quantification', '471', 'ngml', 'reproducibility', 'indicated', 'inter', 'intraday', 'accuracy', 'precision', 'within', '73', 'evaluation', 'inf', 'metabolic', 'stability', 'assessed', 'reflected', 'intrinsic', 'clearance', '236', 'µlminmg', 'vitro', 'halflife', '294', 'min', 'developed', 'approach', 'current', 'study', 'first', 'lcmsms', 'method', 'inf', 'metabolic', 'stability', 'assessment', 'application', 'developed', 'method', 'hlm', 'vitro', 'studies', 'suggests', 'inf', 'moderate', 'extraction', 'ratio', 'indicating', 'relatively', 'good', 'predicted', 'oral', 'bioavailability']","['fgfrs', 'fgfrs', 'hlm', 'hlm']","['hlm', 'hlm']",True,['tumor']
34303079,Discovery and characterization of novel peptide inhibitors of the NRF2/MAFG/DNA ternary complex for the treatment of cancer.,"Pathway activating mutations of the transcription factor NRF2 and its negative regulator KEAP1 are strongly correlative with poor clinical outcome with pemetrexed/carbo(cis)platin/pembrolizumab (PCP) chemo-immunotherapy in lung cancer. Despite the strong genetic support and therapeutic potential for a NRF2 transcriptional inhibitor, currently there are no known direct inhibitors of the NRF2 protein or its complexes with MAF and/or DNA. Herein we describe the design of a novel and high-confidence homology model to guide a medicinal chemistry effort that resulted in the discovery of a series of peptides that demonstrate high affinity, selective binding to the Antioxidant Response Element (ARE) DNA and thereby displace NRF2-MAFG from its promoter, which is an inhibitory mechanism that to our knowledge has not been previously described. In addition to their activity in electrophoretic mobility shift (EMSA) and TR-FRET-based assays, we show significant dose-dependent ternary complex disruption of NRF2-MAFG binding to DNA by SPR, as well as cellular target engagement by thermal destabilization of HiBiT-tagged NRF2 in the NCI-H1944 NSCLC cell line upon digitonin permeabilization, and SAR studies leading to improved cellular stability. We report the characterization and unique profile of lead peptide 18, which we believe to be a useful in vitro tool to probe NRF2 biology in cancer cell lines and models, while also serving as an excellent starting point for additional in vivo optimization toward inhibition of NRF2-driven transcription to address a significant unmet medical need in non-small cell lung cancer (NSCLC).",2021-07-07,pathway activating mutations of the transcription factor nrf2 and its negative regulator keap1 are strongly correlative with poor clinical outcome with pemetrexedcarbocisplatinpembrolizumab pcp chemoimmunotherapy in lung cancer despite the strong genetic support and therapeutic potential for a nrf2 transcriptional inhibitor currently there are no known direct inhibitors of the nrf2 protein or its complexes with maf andor dna herein we describe the design of a novel and highconfidence homology model to guide a medicinal chemistry effort that resulted in the discovery of a series of peptides that demonstrate high affinity selective binding to the antioxidant response element are dna and thereby displace nrf2mafg from its promoter which is an inhibitory mechanism that to our knowledge has not been previously described in addition to their activity in electrophoretic mobility shift emsa and trfretbased assays we show significant dosedependent ternary complex disruption of nrf2mafg binding to dna by spr as well as cellular target engagement by thermal destabilization of hibittagged nrf2 in the ncih1944 nsclc cell line upon digitonin permeabilization and sar studies leading to improved cellular stability we report the characterization and unique profile of lead peptide 18 which we believe to be a useful in vitro tool to probe nrf2 biology in cancer cell lines and models while also serving as an excellent starting point for additional in vivo optimization toward inhibition of nrf2driven transcription to address a significant unmet medical need in nonsmall cell lung cancer nsclc,"['pathway', 'activating', 'mutations', 'of', 'the', 'transcription', 'factor', 'nrf2', 'and', 'its', 'negative', 'regulator', 'keap1', 'are', 'strongly', 'correlative', 'with', 'poor', 'clinical', 'outcome', 'with', 'pemetrexedcarbocisplatinpembrolizumab', 'pcp', 'chemoimmunotherapy', 'in', 'lung', 'cancer', 'despite', 'the', 'strong', 'genetic', 'support', 'and', 'therapeutic', 'potential', 'for', 'a', 'nrf2', 'transcriptional', 'inhibitor', 'currently', 'there', 'are', 'no', 'known', 'direct', 'inhibitors', 'of', 'the', 'nrf2', 'protein', 'or', 'its', 'complexes', 'with', 'maf', 'andor', 'dna', 'herein', 'we', 'describe', 'the', 'design', 'of', 'a', 'novel', 'and', 'highconfidence', 'homology', 'model', 'to', 'guide', 'a', 'medicinal', 'chemistry', 'effort', 'that', 'resulted', 'in', 'the', 'discovery', 'of', 'a', 'series', 'of', 'peptides', 'that', 'demonstrate', 'high', 'affinity', 'selective', 'binding', 'to', 'the', 'antioxidant', 'response', 'element', 'are', 'dna', 'and', 'thereby', 'displace', 'nrf2mafg', 'from', 'its', 'promoter', 'which', 'is', 'an', 'inhibitory', 'mechanism', 'that', 'to', 'our', 'knowledge', 'has', 'not', 'been', 'previously', 'described', 'in', 'addition', 'to', 'their', 'activity', 'in', 'electrophoretic', 'mobility', 'shift', 'emsa', 'and', 'trfretbased', 'assays', 'we', 'show', 'significant', 'dosedependent', 'ternary', 'complex', 'disruption', 'of', 'nrf2mafg', 'binding', 'to', 'dna', 'by', 'spr', 'as', 'well', 'as', 'cellular', 'target', 'engagement', 'by', 'thermal', 'destabilization', 'of', 'hibittagged', 'nrf2', 'in', 'the', 'ncih1944', 'nsclc', 'cell', 'line', 'upon', 'digitonin', 'permeabilization', 'and', 'sar', 'studies', 'leading', 'to', 'improved', 'cellular', 'stability', 'we', 'report', 'the', 'characterization', 'and', 'unique', 'profile', 'of', 'lead', 'peptide', '18', 'which', 'we', 'believe', 'to', 'be', 'a', 'useful', 'in', 'vitro', 'tool', 'to', 'probe', 'nrf2', 'biology', 'in', 'cancer', 'cell', 'lines', 'and', 'models', 'while', 'also', 'serving', 'as', 'an', 'excellent', 'starting', 'point', 'for', 'additional', 'in', 'vivo', 'optimization', 'toward', 'inhibition', 'of', 'nrf2driven', 'transcription', 'to', 'address', 'a', 'significant', 'unmet', 'medical', 'need', 'in', 'nonsmall', 'cell', 'lung', 'cancer', 'nsclc']","['pathway', 'activating', 'mutations', 'transcription', 'factor', 'nrf2', 'negative', 'regulator', 'keap1', 'strongly', 'correlative', 'poor', 'clinical', 'outcome', 'pemetrexedcarbocisplatinpembrolizumab', 'pcp', 'chemoimmunotherapy', 'lung', 'cancer', 'despite', 'strong', 'genetic', 'support', 'therapeutic', 'potential', 'nrf2', 'transcriptional', 'inhibitor', 'currently', 'known', 'direct', 'inhibitors', 'nrf2', 'protein', 'complexes', 'maf', 'andor', 'dna', 'herein', 'describe', 'design', 'novel', 'highconfidence', 'homology', 'model', 'guide', 'medicinal', 'chemistry', 'effort', 'resulted', 'discovery', 'series', 'peptides', 'demonstrate', 'high', 'affinity', 'selective', 'binding', 'antioxidant', 'response', 'element', 'dna', 'thereby', 'displace', 'nrf2mafg', 'promoter', 'inhibitory', 'mechanism', 'knowledge', 'previously', 'described', 'addition', 'activity', 'electrophoretic', 'mobility', 'shift', 'emsa', 'trfretbased', 'assays', 'show', 'significant', 'dosedependent', 'ternary', 'complex', 'disruption', 'nrf2mafg', 'binding', 'dna', 'spr', 'well', 'cellular', 'target', 'engagement', 'thermal', 'destabilization', 'hibittagged', 'nrf2', 'ncih1944', 'nsclc', 'cell', 'line', 'upon', 'digitonin', 'permeabilization', 'sar', 'studies', 'leading', 'improved', 'cellular', 'stability', 'report', 'characterization', 'unique', 'profile', 'lead', 'peptide', '18', 'believe', 'useful', 'vitro', 'tool', 'probe', 'nrf2', 'biology', 'cancer', 'cell', 'lines', 'models', 'also', 'serving', 'excellent', 'starting', 'point', 'additional', 'vivo', 'optimization', 'toward', 'inhibition', 'nrf2driven', 'transcription', 'address', 'significant', 'unmet', 'medical', 'need', 'nonsmall', 'cell', 'lung', 'cancer', 'nsclc']","['nrf2', 'keap1', 'pcp', 'nrf2', 'nrf2', 'maf', 'spr', 'nrf2', 'sar', 'nrf2']",['keap1'],True,['cancer']
34249447,Monepantel antitumor activity is mediated through inhibition of major cell cycle and tumor growth signaling pathways.,"In women, epithelial ovarian cancer is the leading cause of gynaecological malignancy-related deaths. Development of resistance to standard platinum and taxane based chemotherapy and recurrence of the disease necessitate development of novel drugs to halt disease progression. An established concept is to target molecular and signaling pathways that substantially contribute to development of drug resistance and disease progression. We have previously shown that, monepantel (MPL) a novel small molecule acetonitrile derivative is highly effective in suppressing growth, proliferation and colony formation of ovarian cancer cells. These effects are achieved through inhibition of the mTOR/p70S6K pathway in cancer cells. The present study was conducted to find in vivo corroboration and explore the effect of MPL om other growth stimulating putative signaling pathways. Here, female nude mice with subcutaneous OVCAR-3 xenografts were treated with 25 and 50 mg/kg doses of MPL administered (IP) three times weekly for 2 weeks. At the doses employed, MPL was modestly effective at suppressing tumor growth, but highly effective in inhibiting, mTOR, P70S6K and 4EBP1. There were also modest reductions in tumor cyclin D1 and retinoblastoma protein expression. Furthermore, it was found that MPL treatment causes down-regulation of IGF-1R, and c-MYC thus unveiling new dimensions to the growing antitumor actions of this potential anticancer drug. MPL treatment led to reduced tumor volume and weights without causing any detectable side effects. Coupled with the recent human safety data published on this molecule, expanded future trials are highly anticipated.",2021-06-15,in women epithelial ovarian cancer is the leading cause of gynaecological malignancyrelated deaths development of resistance to standard platinum and taxane based chemotherapy and recurrence of the disease necessitate development of novel drugs to halt disease progression an established concept is to target molecular and signaling pathways that substantially contribute to development of drug resistance and disease progression we have previously shown that monepantel mpl a novel small molecule acetonitrile derivative is highly effective in suppressing growth proliferation and colony formation of ovarian cancer cells these effects are achieved through inhibition of the mtorp70s6k pathway in cancer cells the present study was conducted to find in vivo corroboration and explore the effect of mpl om other growth stimulating putative signaling pathways here female nude mice with subcutaneous ovcar3 xenografts were treated with 25 and 50 mgkg doses of mpl administered ip three times weekly for 2 weeks at the doses employed mpl was modestly effective at suppressing tumor growth but highly effective in inhibiting mtor p70s6k and 4ebp1 there were also modest reductions in tumor cyclin d1 and retinoblastoma protein expression furthermore it was found that mpl treatment causes downregulation of igf1r and cmyc thus unveiling new dimensions to the growing antitumor actions of this potential anticancer drug mpl treatment led to reduced tumor volume and weights without causing any detectable side effects coupled with the recent human safety data published on this molecule expanded future trials are highly anticipated,"['in', 'women', 'epithelial', 'ovarian', 'cancer', 'is', 'the', 'leading', 'cause', 'of', 'gynaecological', 'malignancyrelated', 'deaths', 'development', 'of', 'resistance', 'to', 'standard', 'platinum', 'and', 'taxane', 'based', 'chemotherapy', 'and', 'recurrence', 'of', 'the', 'disease', 'necessitate', 'development', 'of', 'novel', 'drugs', 'to', 'halt', 'disease', 'progression', 'an', 'established', 'concept', 'is', 'to', 'target', 'molecular', 'and', 'signaling', 'pathways', 'that', 'substantially', 'contribute', 'to', 'development', 'of', 'drug', 'resistance', 'and', 'disease', 'progression', 'we', 'have', 'previously', 'shown', 'that', 'monepantel', 'mpl', 'a', 'novel', 'small', 'molecule', 'acetonitrile', 'derivative', 'is', 'highly', 'effective', 'in', 'suppressing', 'growth', 'proliferation', 'and', 'colony', 'formation', 'of', 'ovarian', 'cancer', 'cells', 'these', 'effects', 'are', 'achieved', 'through', 'inhibition', 'of', 'the', 'mtorp70s6k', 'pathway', 'in', 'cancer', 'cells', 'the', 'present', 'study', 'was', 'conducted', 'to', 'find', 'in', 'vivo', 'corroboration', 'and', 'explore', 'the', 'effect', 'of', 'mpl', 'om', 'other', 'growth', 'stimulating', 'putative', 'signaling', 'pathways', 'here', 'female', 'nude', 'mice', 'with', 'subcutaneous', 'ovcar3', 'xenografts', 'were', 'treated', 'with', '25', 'and', '50', 'mgkg', 'doses', 'of', 'mpl', 'administered', 'ip', 'three', 'times', 'weekly', 'for', '2', 'weeks', 'at', 'the', 'doses', 'employed', 'mpl', 'was', 'modestly', 'effective', 'at', 'suppressing', 'tumor', 'growth', 'but', 'highly', 'effective', 'in', 'inhibiting', 'mtor', 'p70s6k', 'and', '4ebp1', 'there', 'were', 'also', 'modest', 'reductions', 'in', 'tumor', 'cyclin', 'd1', 'and', 'retinoblastoma', 'protein', 'expression', 'furthermore', 'it', 'was', 'found', 'that', 'mpl', 'treatment', 'causes', 'downregulation', 'of', 'igf1r', 'and', 'cmyc', 'thus', 'unveiling', 'new', 'dimensions', 'to', 'the', 'growing', 'antitumor', 'actions', 'of', 'this', 'potential', 'anticancer', 'drug', 'mpl', 'treatment', 'led', 'to', 'reduced', 'tumor', 'volume', 'and', 'weights', 'without', 'causing', 'any', 'detectable', 'side', 'effects', 'coupled', 'with', 'the', 'recent', 'human', 'safety', 'data', 'published', 'on', 'this', 'molecule', 'expanded', 'future', 'trials', 'are', 'highly', 'anticipated']","['women', 'epithelial', 'ovarian', 'cancer', 'leading', 'cause', 'gynaecological', 'malignancyrelated', 'deaths', 'development', 'resistance', 'standard', 'platinum', 'taxane', 'based', 'chemotherapy', 'recurrence', 'disease', 'necessitate', 'development', 'novel', 'drugs', 'halt', 'disease', 'progression', 'established', 'concept', 'target', 'molecular', 'signaling', 'pathways', 'substantially', 'contribute', 'development', 'drug', 'resistance', 'disease', 'progression', 'previously', 'shown', 'monepantel', 'mpl', 'novel', 'small', 'molecule', 'acetonitrile', 'derivative', 'highly', 'effective', 'suppressing', 'growth', 'proliferation', 'colony', 'formation', 'ovarian', 'cancer', 'cells', 'effects', 'achieved', 'inhibition', 'mtorp70s6k', 'pathway', 'cancer', 'cells', 'present', 'study', 'conducted', 'find', 'vivo', 'corroboration', 'explore', 'effect', 'mpl', 'om', 'growth', 'stimulating', 'putative', 'signaling', 'pathways', 'female', 'nude', 'mice', 'subcutaneous', 'ovcar3', 'xenografts', 'treated', '25', '50', 'mgkg', 'doses', 'mpl', 'administered', 'ip', 'three', 'times', 'weekly', '2', 'weeks', 'doses', 'employed', 'mpl', 'modestly', 'effective', 'suppressing', 'tumor', 'growth', 'highly', 'effective', 'inhibiting', 'mtor', 'p70s6k', '4ebp1', 'also', 'modest', 'reductions', 'tumor', 'cyclin', 'd1', 'retinoblastoma', 'protein', 'expression', 'furthermore', 'found', 'mpl', 'treatment', 'causes', 'downregulation', 'igf1r', 'cmyc', 'thus', 'unveiling', 'new', 'dimensions', 'growing', 'antitumor', 'actions', 'potential', 'anticancer', 'drug', 'mpl', 'treatment', 'led', 'reduced', 'tumor', 'volume', 'weights', 'without', 'causing', 'detectable', 'side', 'effects', 'coupled', 'recent', 'human', 'safety', 'data', 'published', 'molecule', 'expanded', 'future', 'trials', 'highly', 'anticipated']","['p70s6k', '4ebp1', 'cyclin', 'igf1r']","['p70s6k', 'igf1r']",True,"['tumor', 'cancer']"
34246853,Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors.,"TGFβ is crucial for the homeostasis of epithelial and neural tissues, wound repair, and regulating immune responses. Its dysregulation is associated with a vast number of diseases, of which modifying the tumor microenvironment is one of vital clinical interest. Despite various attempts, there is still no FDA-approved therapy to inhibit the TGFβ pathway. Major mainstream approaches involve impairment of the TGFβ pathway via inhibition of the TGFβRI kinase. With the purpose to identify non-receptor kinase-based inhibitors to impair TGFβ signaling, an in-house chemical library was enriched, through a computational study, to eliminate TGFβRI kinase activity. Selected compounds were screened against a cell line engineered with a firefly luciferase gene under TGFβ-Smad-dependent transcriptional control. Results indicated moderate potency for a molecule with phthalazine core against TGFβ-Smad signaling. A series of phthalazine compounds were synthesized and evaluated for potency. The most promising compound (10p) exhibited an IC<sub>50</sub> of 0.11 ± 0.02 μM and was confirmed to be non-cytotoxic up to 12 μM, with a selectivity index of approximately 112-fold. Simultaneously, 10p was confirmed to reduce the Smad phosphorylation using Western blot without exhibiting inhibition on the TGFβRI enzyme. This study identified a novel small-molecule scaffold that targets the TGFβ pathway via a non-receptor-kinase mechanism.",2021-06-19,tgfβ is crucial for the homeostasis of epithelial and neural tissues wound repair and regulating immune responses its dysregulation is associated with a vast number of diseases of which modifying the tumor microenvironment is one of vital clinical interest despite various attempts there is still no fdaapproved therapy to inhibit the tgfβ pathway major mainstream approaches involve impairment of the tgfβ pathway via inhibition of the tgfβri kinase with the purpose to identify nonreceptor kinasebased inhibitors to impair tgfβ signaling an inhouse chemical library was enriched through a computational study to eliminate tgfβri kinase activity selected compounds were screened against a cell line engineered with a firefly luciferase gene under tgfβsmaddependent transcriptional control results indicated moderate potency for a molecule with phthalazine core against tgfβsmad signaling a series of phthalazine compounds were synthesized and evaluated for potency the most promising compound 10p exhibited an icsub50sub of 011  002 μm and was confirmed to be noncytotoxic up to 12 μm with a selectivity index of approximately 112fold simultaneously 10p was confirmed to reduce the smad phosphorylation using western blot without exhibiting inhibition on the tgfβri enzyme this study identified a novel smallmolecule scaffold that targets the tgfβ pathway via a nonreceptorkinase mechanism,"['tgfβ', 'is', 'crucial', 'for', 'the', 'homeostasis', 'of', 'epithelial', 'and', 'neural', 'tissues', 'wound', 'repair', 'and', 'regulating', 'immune', 'responses', 'its', 'dysregulation', 'is', 'associated', 'with', 'a', 'vast', 'number', 'of', 'diseases', 'of', 'which', 'modifying', 'the', 'tumor', 'microenvironment', 'is', 'one', 'of', 'vital', 'clinical', 'interest', 'despite', 'various', 'attempts', 'there', 'is', 'still', 'no', 'fdaapproved', 'therapy', 'to', 'inhibit', 'the', 'tgfβ', 'pathway', 'major', 'mainstream', 'approaches', 'involve', 'impairment', 'of', 'the', 'tgfβ', 'pathway', 'via', 'inhibition', 'of', 'the', 'tgfβri', 'kinase', 'with', 'the', 'purpose', 'to', 'identify', 'nonreceptor', 'kinasebased', 'inhibitors', 'to', 'impair', 'tgfβ', 'signaling', 'an', 'inhouse', 'chemical', 'library', 'was', 'enriched', 'through', 'a', 'computational', 'study', 'to', 'eliminate', 'tgfβri', 'kinase', 'activity', 'selected', 'compounds', 'were', 'screened', 'against', 'a', 'cell', 'line', 'engineered', 'with', 'a', 'firefly', 'luciferase', 'gene', 'under', 'tgfβsmaddependent', 'transcriptional', 'control', 'results', 'indicated', 'moderate', 'potency', 'for', 'a', 'molecule', 'with', 'phthalazine', 'core', 'against', 'tgfβsmad', 'signaling', 'a', 'series', 'of', 'phthalazine', 'compounds', 'were', 'synthesized', 'and', 'evaluated', 'for', 'potency', 'the', 'most', 'promising', 'compound', '10p', 'exhibited', 'an', 'icsub50sub', 'of', '011', '002', 'μm', 'and', 'was', 'confirmed', 'to', 'be', 'noncytotoxic', 'up', 'to', '12', 'μm', 'with', 'a', 'selectivity', 'index', 'of', 'approximately', '112fold', 'simultaneously', '10p', 'was', 'confirmed', 'to', 'reduce', 'the', 'smad', 'phosphorylation', 'using', 'western', 'blot', 'without', 'exhibiting', 'inhibition', 'on', 'the', 'tgfβri', 'enzyme', 'this', 'study', 'identified', 'a', 'novel', 'smallmolecule', 'scaffold', 'that', 'targets', 'the', 'tgfβ', 'pathway', 'via', 'a', 'nonreceptorkinase', 'mechanism']","['tgfβ', 'crucial', 'homeostasis', 'epithelial', 'neural', 'tissues', 'wound', 'repair', 'regulating', 'immune', 'responses', 'dysregulation', 'associated', 'vast', 'number', 'diseases', 'modifying', 'tumor', 'microenvironment', 'one', 'vital', 'clinical', 'interest', 'despite', 'various', 'attempts', 'still', 'fdaapproved', 'therapy', 'inhibit', 'tgfβ', 'pathway', 'major', 'mainstream', 'approaches', 'involve', 'impairment', 'tgfβ', 'pathway', 'via', 'inhibition', 'tgfβri', 'kinase', 'purpose', 'identify', 'nonreceptor', 'kinasebased', 'inhibitors', 'impair', 'tgfβ', 'signaling', 'inhouse', 'chemical', 'library', 'enriched', 'computational', 'study', 'eliminate', 'tgfβri', 'kinase', 'activity', 'selected', 'compounds', 'screened', 'cell', 'line', 'engineered', 'firefly', 'luciferase', 'gene', 'tgfβsmaddependent', 'transcriptional', 'control', 'results', 'indicated', 'moderate', 'potency', 'molecule', 'phthalazine', 'core', 'tgfβsmad', 'signaling', 'series', 'phthalazine', 'compounds', 'synthesized', 'evaluated', 'potency', 'promising', 'compound', '10p', 'exhibited', 'icsub50sub', '011', '002', 'μm', 'confirmed', 'noncytotoxic', '12', 'μm', 'selectivity', 'index', 'approximately', '112fold', 'simultaneously', '10p', 'confirmed', 'reduce', 'smad', 'phosphorylation', 'using', 'western', 'blot', 'without', 'exhibiting', 'inhibition', 'tgfβri', 'enzyme', 'study', 'identified', 'novel', 'smallmolecule', 'scaffold', 'targets', 'tgfβ', 'pathway', 'via', 'nonreceptorkinase', 'mechanism']","['firefly', 'luciferase', 'smad']","['firefly', 'luciferase', 'smad']",True,['tumor']
34223158,Recent advances in the development of AHR antagonists in immuno-oncology.,"The arylhydrocarbon receptor (AHR) is a ligand activated transcription factor that controls the expression of a number of immunosuppressive signaling molecules, including the immune checkpoint proteins PD-1/L1 and cytokine IL-10. AHR activation also stimulates the formation and recruitment of tolerogenic dendritic cells, tumor associated macrophages, and regulatory T cells in the tumor microenvironment, which restrains antitumoral immune response. Overexpression of AHR has been observed in a number of different types of cancer and suggested to contribute to immune dysfunction and cancer progression. One prominent endogenous ligand of AHR is the oncometabolite kynurenine, a product of tryptophan metabolism catalyzed by the dioxygenases IDO1 and TDO that are often aberrantly activated in cancer. AHR has gained significant interest as a drug target for the development of novel small molecule cancer immunotherapies, as evidenced by the advancement of two clinical candidates into phase 1 clinical trials in patients with advanced cancer. Discussed in this Review is a brief background of AHR in immuno-oncology and the recent progress in the discovery and development of AHR antagonists.",2021-04-06,the arylhydrocarbon receptor ahr is a ligand activated transcription factor that controls the expression of a number of immunosuppressive signaling molecules including the immune checkpoint proteins pd1l1 and cytokine il10 ahr activation also stimulates the formation and recruitment of tolerogenic dendritic cells tumor associated macrophages and regulatory t cells in the tumor microenvironment which restrains antitumoral immune response overexpression of ahr has been observed in a number of different types of cancer and suggested to contribute to immune dysfunction and cancer progression one prominent endogenous ligand of ahr is the oncometabolite kynurenine a product of tryptophan metabolism catalyzed by the dioxygenases ido1 and tdo that are often aberrantly activated in cancer ahr has gained significant interest as a drug target for the development of novel small molecule cancer immunotherapies as evidenced by the advancement of two clinical candidates into phase 1 clinical trials in patients with advanced cancer discussed in this review is a brief background of ahr in immunooncology and the recent progress in the discovery and development of ahr antagonists,"['the', 'arylhydrocarbon', 'receptor', 'ahr', 'is', 'a', 'ligand', 'activated', 'transcription', 'factor', 'that', 'controls', 'the', 'expression', 'of', 'a', 'number', 'of', 'immunosuppressive', 'signaling', 'molecules', 'including', 'the', 'immune', 'checkpoint', 'proteins', 'pd1l1', 'and', 'cytokine', 'il10', 'ahr', 'activation', 'also', 'stimulates', 'the', 'formation', 'and', 'recruitment', 'of', 'tolerogenic', 'dendritic', 'cells', 'tumor', 'associated', 'macrophages', 'and', 'regulatory', 't', 'cells', 'in', 'the', 'tumor', 'microenvironment', 'which', 'restrains', 'antitumoral', 'immune', 'response', 'overexpression', 'of', 'ahr', 'has', 'been', 'observed', 'in', 'a', 'number', 'of', 'different', 'types', 'of', 'cancer', 'and', 'suggested', 'to', 'contribute', 'to', 'immune', 'dysfunction', 'and', 'cancer', 'progression', 'one', 'prominent', 'endogenous', 'ligand', 'of', 'ahr', 'is', 'the', 'oncometabolite', 'kynurenine', 'a', 'product', 'of', 'tryptophan', 'metabolism', 'catalyzed', 'by', 'the', 'dioxygenases', 'ido1', 'and', 'tdo', 'that', 'are', 'often', 'aberrantly', 'activated', 'in', 'cancer', 'ahr', 'has', 'gained', 'significant', 'interest', 'as', 'a', 'drug', 'target', 'for', 'the', 'development', 'of', 'novel', 'small', 'molecule', 'cancer', 'immunotherapies', 'as', 'evidenced', 'by', 'the', 'advancement', 'of', 'two', 'clinical', 'candidates', 'into', 'phase', '1', 'clinical', 'trials', 'in', 'patients', 'with', 'advanced', 'cancer', 'discussed', 'in', 'this', 'review', 'is', 'a', 'brief', 'background', 'of', 'ahr', 'in', 'immunooncology', 'and', 'the', 'recent', 'progress', 'in', 'the', 'discovery', 'and', 'development', 'of', 'ahr', 'antagonists']","['arylhydrocarbon', 'receptor', 'ahr', 'ligand', 'activated', 'transcription', 'factor', 'controls', 'expression', 'number', 'immunosuppressive', 'signaling', 'molecules', 'including', 'immune', 'checkpoint', 'proteins', 'pd1l1', 'cytokine', 'il10', 'ahr', 'activation', 'also', 'stimulates', 'formation', 'recruitment', 'tolerogenic', 'dendritic', 'cells', 'tumor', 'associated', 'macrophages', 'regulatory', 'cells', 'tumor', 'microenvironment', 'restrains', 'antitumoral', 'immune', 'response', 'overexpression', 'ahr', 'observed', 'number', 'different', 'types', 'cancer', 'suggested', 'contribute', 'immune', 'dysfunction', 'cancer', 'progression', 'one', 'prominent', 'endogenous', 'ligand', 'ahr', 'oncometabolite', 'kynurenine', 'product', 'tryptophan', 'metabolism', 'catalyzed', 'dioxygenases', 'ido1', 'tdo', 'often', 'aberrantly', 'activated', 'cancer', 'ahr', 'gained', 'significant', 'interest', 'drug', 'target', 'development', 'novel', 'small', 'molecule', 'cancer', 'immunotherapies', 'evidenced', 'advancement', 'two', 'clinical', 'candidates', 'phase', '1', 'clinical', 'trials', 'patients', 'advanced', 'cancer', 'discussed', 'review', 'brief', 'background', 'ahr', 'immunooncology', 'recent', 'progress', 'discovery', 'development', 'ahr', 'antagonists']","['arylhydrocarbon', 'il10']",['arylhydrocarbon'],True,"['tumor', 'cancer']"
34158350,A Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy.,"The nuclear factor erythroid-2-related factor 2 (Nrf2)-Keap1-ARE pathway, a master regulator of oxidative stress, has emerged as a promising target for cancer therapy. Mutations in <i>NFE2L2, KEAP1</i>, and related genes have been found in many human cancers, especially lung cancer. These mutations lead to constitutive activation of the Nrf2 pathway, which promotes proliferation of cancer cells and their resistance to chemotherapies. Small molecules that inhibit the Nrf2 pathway are needed to arrest tumor growth and overcome chemoresistance in Nrf2-addicted cancers. Here, we identified a novel small molecule, MSU38225, which can suppress Nrf2 pathway activity. MSU38225 downregulates Nrf2 transcriptional activity and decreases the expression of Nrf2 downstream targets, including NQO1, GCLC, GCLM, AKR1C2, and UGT1A6. MSU38225 strikingly decreases the protein level of Nrf2, which can be blocked by the proteasome inhibitor MG132. Ubiquitination of Nrf2 is enhanced following treatment with MSU38225. By inhibiting production of antioxidants, MSU38225 increases the level of reactive oxygen species (ROS) when cells are stimulated with tert-butyl hydroperoxide (tBHP). MSU38225 also inhibits the growth of human lung cancer cells in both two-dimensional cell culture and soft agar. Cancer cells addicted to Nrf2 are more susceptible to MSU38225 for suppression of cell proliferation. MSU38225 also sensitizes human lung cancer cells to chemotherapies both <i>in vitro</i> and <i>in vivo</i> Our results suggest that MSU38225 is a novel Nrf2 pathway inhibitor that could potentially serve as an adjuvant therapy to enhance the response to chemotherapies in patients with lung cancer.",2021-06-22,the nuclear factor erythroid2related factor 2 nrf2keap1are pathway a master regulator of oxidative stress has emerged as a promising target for cancer therapy mutations in infe2l2 keap1i and related genes have been found in many human cancers especially lung cancer these mutations lead to constitutive activation of the nrf2 pathway which promotes proliferation of cancer cells and their resistance to chemotherapies small molecules that inhibit the nrf2 pathway are needed to arrest tumor growth and overcome chemoresistance in nrf2addicted cancers here we identified a novel small molecule msu38225 which can suppress nrf2 pathway activity msu38225 downregulates nrf2 transcriptional activity and decreases the expression of nrf2 downstream targets including nqo1 gclc gclm akr1c2 and ugt1a6 msu38225 strikingly decreases the protein level of nrf2 which can be blocked by the proteasome inhibitor mg132 ubiquitination of nrf2 is enhanced following treatment with msu38225 by inhibiting production of antioxidants msu38225 increases the level of reactive oxygen species ros when cells are stimulated with tertbutyl hydroperoxide tbhp msu38225 also inhibits the growth of human lung cancer cells in both twodimensional cell culture and soft agar cancer cells addicted to nrf2 are more susceptible to msu38225 for suppression of cell proliferation msu38225 also sensitizes human lung cancer cells to chemotherapies both iin vitroi and iin vivoi our results suggest that msu38225 is a novel nrf2 pathway inhibitor that could potentially serve as an adjuvant therapy to enhance the response to chemotherapies in patients with lung cancer,"['the', 'nuclear', 'factor', 'erythroid2related', 'factor', '2', 'nrf2keap1are', 'pathway', 'a', 'master', 'regulator', 'of', 'oxidative', 'stress', 'has', 'emerged', 'as', 'a', 'promising', 'target', 'for', 'cancer', 'therapy', 'mutations', 'in', 'infe2l2', 'keap1i', 'and', 'related', 'genes', 'have', 'been', 'found', 'in', 'many', 'human', 'cancers', 'especially', 'lung', 'cancer', 'these', 'mutations', 'lead', 'to', 'constitutive', 'activation', 'of', 'the', 'nrf2', 'pathway', 'which', 'promotes', 'proliferation', 'of', 'cancer', 'cells', 'and', 'their', 'resistance', 'to', 'chemotherapies', 'small', 'molecules', 'that', 'inhibit', 'the', 'nrf2', 'pathway', 'are', 'needed', 'to', 'arrest', 'tumor', 'growth', 'and', 'overcome', 'chemoresistance', 'in', 'nrf2addicted', 'cancers', 'here', 'we', 'identified', 'a', 'novel', 'small', 'molecule', 'msu38225', 'which', 'can', 'suppress', 'nrf2', 'pathway', 'activity', 'msu38225', 'downregulates', 'nrf2', 'transcriptional', 'activity', 'and', 'decreases', 'the', 'expression', 'of', 'nrf2', 'downstream', 'targets', 'including', 'nqo1', 'gclc', 'gclm', 'akr1c2', 'and', 'ugt1a6', 'msu38225', 'strikingly', 'decreases', 'the', 'protein', 'level', 'of', 'nrf2', 'which', 'can', 'be', 'blocked', 'by', 'the', 'proteasome', 'inhibitor', 'mg132', 'ubiquitination', 'of', 'nrf2', 'is', 'enhanced', 'following', 'treatment', 'with', 'msu38225', 'by', 'inhibiting', 'production', 'of', 'antioxidants', 'msu38225', 'increases', 'the', 'level', 'of', 'reactive', 'oxygen', 'species', 'ros', 'when', 'cells', 'are', 'stimulated', 'with', 'tertbutyl', 'hydroperoxide', 'tbhp', 'msu38225', 'also', 'inhibits', 'the', 'growth', 'of', 'human', 'lung', 'cancer', 'cells', 'in', 'both', 'twodimensional', 'cell', 'culture', 'and', 'soft', 'agar', 'cancer', 'cells', 'addicted', 'to', 'nrf2', 'are', 'more', 'susceptible', 'to', 'msu38225', 'for', 'suppression', 'of', 'cell', 'proliferation', 'msu38225', 'also', 'sensitizes', 'human', 'lung', 'cancer', 'cells', 'to', 'chemotherapies', 'both', 'iin', 'vitroi', 'and', 'iin', 'vivoi', 'our', 'results', 'suggest', 'that', 'msu38225', 'is', 'a', 'novel', 'nrf2', 'pathway', 'inhibitor', 'that', 'could', 'potentially', 'serve', 'as', 'an', 'adjuvant', 'therapy', 'to', 'enhance', 'the', 'response', 'to', 'chemotherapies', 'in', 'patients', 'with', 'lung', 'cancer']","['nuclear', 'factor', 'erythroid2related', 'factor', '2', 'nrf2keap1are', 'pathway', 'master', 'regulator', 'oxidative', 'stress', 'emerged', 'promising', 'target', 'cancer', 'therapy', 'mutations', 'infe2l2', 'keap1i', 'related', 'genes', 'found', 'many', 'human', 'cancers', 'especially', 'lung', 'cancer', 'mutations', 'lead', 'constitutive', 'activation', 'nrf2', 'pathway', 'promotes', 'proliferation', 'cancer', 'cells', 'resistance', 'chemotherapies', 'small', 'molecules', 'inhibit', 'nrf2', 'pathway', 'needed', 'arrest', 'tumor', 'growth', 'overcome', 'chemoresistance', 'nrf2addicted', 'cancers', 'identified', 'novel', 'small', 'molecule', 'msu38225', 'suppress', 'nrf2', 'pathway', 'activity', 'msu38225', 'downregulates', 'nrf2', 'transcriptional', 'activity', 'decreases', 'expression', 'nrf2', 'downstream', 'targets', 'including', 'nqo1', 'gclc', 'gclm', 'akr1c2', 'ugt1a6', 'msu38225', 'strikingly', 'decreases', 'protein', 'level', 'nrf2', 'blocked', 'proteasome', 'inhibitor', 'mg132', 'ubiquitination', 'nrf2', 'enhanced', 'following', 'treatment', 'msu38225', 'inhibiting', 'production', 'antioxidants', 'msu38225', 'increases', 'level', 'reactive', 'oxygen', 'species', 'ros', 'cells', 'stimulated', 'tertbutyl', 'hydroperoxide', 'tbhp', 'msu38225', 'also', 'inhibits', 'growth', 'human', 'lung', 'cancer', 'cells', 'twodimensional', 'cell', 'culture', 'soft', 'agar', 'cancer', 'cells', 'addicted', 'nrf2', 'susceptible', 'msu38225', 'suppression', 'cell', 'proliferation', 'msu38225', 'also', 'sensitizes', 'human', 'lung', 'cancer', 'cells', 'chemotherapies', 'iin', 'vitroi', 'iin', 'vivoi', 'results', 'suggest', 'msu38225', 'novel', 'nrf2', 'pathway', 'inhibitor', 'could', 'potentially', 'serve', 'adjuvant', 'therapy', 'enhance', 'response', 'chemotherapies', 'patients', 'lung', 'cancer']","['nrf2', 'nrf2', 'nrf2', 'nrf2', 'nrf2', 'nqo1', 'gclm', 'nrf2', 'nrf2', 'ros', 'nrf2', 'nrf2']","['nqo1', 'gclm']",True,"['tumor', 'cancer']"
34133900,TLR1/2 Agonist Enhances Reversal of HIV-1 Latency and Promotes NK Cell-Induced Suppression of HIV-1-Infected Autologous CD4<sup>+</sup> T Cells.,"The complete eradication of human immunodeficiency virus type 1 (HIV-1) is blocked by latent reservoirs in CD4<sup>+</sup> T cells and myeloid lineage cells. Toll-like receptors (TLRs) can induce the reversal of HIV-1 latency and trigger the innate immune response. To the best of our knowledge, there is little evidence showing the ""killing"" effect of TLR1/2 agonists but only a small ""shock"" potential. To identify a new approach for eradicating the HIV latent reservoir, we evaluated the effectiveness of SMU-Z1, a novel small-molecule TLR1/2 agonist, in the ""shock-and-kill"" strategy. The results showed that SMU-Z1 could enhance latent HIV-1 transcription not only <i>ex vivo</i> in peripheral blood mononuclear cells from aviremic HIV-1-infected donors receiving combined antiretroviral therapy but also <i>in vitro</i> in cells of myeloid-monocytic origin targeting the NF-κB and mitogen-activated protein kinase pathways. Interestingly, the activation marker CD69 was significantly upregulated in natural killer (NK) cells, B cells, and monocytes 48 h after SMU-Z1 treatment. Furthermore, SMU-Z1 was able to activate T cells without global T cell activation, as well as increasing NK cell degranulation and gamma interferon (IFN-γ) production, which further block HIV-1-infected CD4<sup>+</sup> lymphocytes. In summary, the present study found that SMU-Z1 can both enhance HIV-1 transcription and promote NK cell-mediated inhibition of HIV-1-infected autologous CD4<sup>+</sup> T cells. These findings indicate that the novel TLR1/2 agonist SMU-Z1 is a promising latency-reversing agent (LRA) for eradication of HIV-1 reservoirs. <b>IMPORTANCE</b> Multiple <i>in vivo</i> studies showed that many LRAs used in the shock-and-kill approach could activate viral transcription but could not induce killing effectively. Therefore, a dual-function LRA is needed for elimination of HIV-1 reservoirs. We previously developed a small-molecule TLR1/2 agonist, SMU-Z1, and demonstrated that it could upregulate NK cells and CD8<sup>+</sup> T cells with immune adjuvant and antitumor properties <i>in vivo</i>. In the present study, SMU-Z1 could activate innate immune cells without global T cell activation, induce production of proinflammatory and antiviral cytokines, and enhance the cytotoxic function of NK cells. We showed that SMU-Z1 displayed dual potential <i>ex vivo</i> in the shock of exposure of latently HIV-1-infected cells and in the kill of clearance of infected cells, which is critical for effective use in combination with therapeutic vaccines or broadly neutralizing antibody treatments aimed at curing AIDS.",2021-08-10,the complete eradication of human immunodeficiency virus type 1 hiv1 is blocked by latent reservoirs in cd4supsup t cells and myeloid lineage cells tolllike receptors tlrs can induce the reversal of hiv1 latency and trigger the innate immune response to the best of our knowledge there is little evidence showing the killing effect of tlr12 agonists but only a small shock potential to identify a new approach for eradicating the hiv latent reservoir we evaluated the effectiveness of smuz1 a novel smallmolecule tlr12 agonist in the shockandkill strategy the results showed that smuz1 could enhance latent hiv1 transcription not only iex vivoi in peripheral blood mononuclear cells from aviremic hiv1infected donors receiving combined antiretroviral therapy but also iin vitroi in cells of myeloidmonocytic origin targeting the nfκb and mitogenactivated protein kinase pathways interestingly the activation marker cd69 was significantly upregulated in natural killer nk cells b cells and monocytes 48 h after smuz1 treatment furthermore smuz1 was able to activate t cells without global t cell activation as well as increasing nk cell degranulation and gamma interferon ifnγ production which further block hiv1infected cd4supsup lymphocytes in summary the present study found that smuz1 can both enhance hiv1 transcription and promote nk cellmediated inhibition of hiv1infected autologous cd4supsup t cells these findings indicate that the novel tlr12 agonist smuz1 is a promising latencyreversing agent lra for eradication of hiv1 reservoirs bimportanceb multiple iin vivoi studies showed that many lras used in the shockandkill approach could activate viral transcription but could not induce killing effectively therefore a dualfunction lra is needed for elimination of hiv1 reservoirs we previously developed a smallmolecule tlr12 agonist smuz1 and demonstrated that it could upregulate nk cells and cd8supsup t cells with immune adjuvant and antitumor properties iin vivoi in the present study smuz1 could activate innate immune cells without global t cell activation induce production of proinflammatory and antiviral cytokines and enhance the cytotoxic function of nk cells we showed that smuz1 displayed dual potential iex vivoi in the shock of exposure of latently hiv1infected cells and in the kill of clearance of infected cells which is critical for effective use in combination with therapeutic vaccines or broadly neutralizing antibody treatments aimed at curing aids,"['the', 'complete', 'eradication', 'of', 'human', 'immunodeficiency', 'virus', 'type', '1', 'hiv1', 'is', 'blocked', 'by', 'latent', 'reservoirs', 'in', 'cd4supsup', 't', 'cells', 'and', 'myeloid', 'lineage', 'cells', 'tolllike', 'receptors', 'tlrs', 'can', 'induce', 'the', 'reversal', 'of', 'hiv1', 'latency', 'and', 'trigger', 'the', 'innate', 'immune', 'response', 'to', 'the', 'best', 'of', 'our', 'knowledge', 'there', 'is', 'little', 'evidence', 'showing', 'the', 'killing', 'effect', 'of', 'tlr12', 'agonists', 'but', 'only', 'a', 'small', 'shock', 'potential', 'to', 'identify', 'a', 'new', 'approach', 'for', 'eradicating', 'the', 'hiv', 'latent', 'reservoir', 'we', 'evaluated', 'the', 'effectiveness', 'of', 'smuz1', 'a', 'novel', 'smallmolecule', 'tlr12', 'agonist', 'in', 'the', 'shockandkill', 'strategy', 'the', 'results', 'showed', 'that', 'smuz1', 'could', 'enhance', 'latent', 'hiv1', 'transcription', 'not', 'only', 'iex', 'vivoi', 'in', 'peripheral', 'blood', 'mononuclear', 'cells', 'from', 'aviremic', 'hiv1infected', 'donors', 'receiving', 'combined', 'antiretroviral', 'therapy', 'but', 'also', 'iin', 'vitroi', 'in', 'cells', 'of', 'myeloidmonocytic', 'origin', 'targeting', 'the', 'nfκb', 'and', 'mitogenactivated', 'protein', 'kinase', 'pathways', 'interestingly', 'the', 'activation', 'marker', 'cd69', 'was', 'significantly', 'upregulated', 'in', 'natural', 'killer', 'nk', 'cells', 'b', 'cells', 'and', 'monocytes', '48', 'h', 'after', 'smuz1', 'treatment', 'furthermore', 'smuz1', 'was', 'able', 'to', 'activate', 't', 'cells', 'without', 'global', 't', 'cell', 'activation', 'as', 'well', 'as', 'increasing', 'nk', 'cell', 'degranulation', 'and', 'gamma', 'interferon', 'ifnγ', 'production', 'which', 'further', 'block', 'hiv1infected', 'cd4supsup', 'lymphocytes', 'in', 'summary', 'the', 'present', 'study', 'found', 'that', 'smuz1', 'can', 'both', 'enhance', 'hiv1', 'transcription', 'and', 'promote', 'nk', 'cellmediated', 'inhibition', 'of', 'hiv1infected', 'autologous', 'cd4supsup', 't', 'cells', 'these', 'findings', 'indicate', 'that', 'the', 'novel', 'tlr12', 'agonist', 'smuz1', 'is', 'a', 'promising', 'latencyreversing', 'agent', 'lra', 'for', 'eradication', 'of', 'hiv1', 'reservoirs', 'bimportanceb', 'multiple', 'iin', 'vivoi', 'studies', 'showed', 'that', 'many', 'lras', 'used', 'in', 'the', 'shockandkill', 'approach', 'could', 'activate', 'viral', 'transcription', 'but', 'could', 'not', 'induce', 'killing', 'effectively', 'therefore', 'a', 'dualfunction', 'lra', 'is', 'needed', 'for', 'elimination', 'of', 'hiv1', 'reservoirs', 'we', 'previously', 'developed', 'a', 'smallmolecule', 'tlr12', 'agonist', 'smuz1', 'and', 'demonstrated', 'that', 'it', 'could', 'upregulate', 'nk', 'cells', 'and', 'cd8supsup', 't', 'cells', 'with', 'immune', 'adjuvant', 'and', 'antitumor', 'properties', 'iin', 'vivoi', 'in', 'the', 'present', 'study', 'smuz1', 'could', 'activate', 'innate', 'immune', 'cells', 'without', 'global', 't', 'cell', 'activation', 'induce', 'production', 'of', 'proinflammatory', 'and', 'antiviral', 'cytokines', 'and', 'enhance', 'the', 'cytotoxic', 'function', 'of', 'nk', 'cells', 'we', 'showed', 'that', 'smuz1', 'displayed', 'dual', 'potential', 'iex', 'vivoi', 'in', 'the', 'shock', 'of', 'exposure', 'of', 'latently', 'hiv1infected', 'cells', 'and', 'in', 'the', 'kill', 'of', 'clearance', 'of', 'infected', 'cells', 'which', 'is', 'critical', 'for', 'effective', 'use', 'in', 'combination', 'with', 'therapeutic', 'vaccines', 'or', 'broadly', 'neutralizing', 'antibody', 'treatments', 'aimed', 'at', 'curing', 'aids']","['complete', 'eradication', 'human', 'immunodeficiency', 'virus', 'type', '1', 'hiv1', 'blocked', 'latent', 'reservoirs', 'cd4supsup', 'cells', 'myeloid', 'lineage', 'cells', 'tolllike', 'receptors', 'tlrs', 'induce', 'reversal', 'hiv1', 'latency', 'trigger', 'innate', 'immune', 'response', 'best', 'knowledge', 'little', 'evidence', 'showing', 'killing', 'effect', 'tlr12', 'agonists', 'small', 'shock', 'potential', 'identify', 'new', 'approach', 'eradicating', 'hiv', 'latent', 'reservoir', 'evaluated', 'effectiveness', 'smuz1', 'novel', 'smallmolecule', 'tlr12', 'agonist', 'shockandkill', 'strategy', 'results', 'showed', 'smuz1', 'could', 'enhance', 'latent', 'hiv1', 'transcription', 'iex', 'vivoi', 'peripheral', 'blood', 'mononuclear', 'cells', 'aviremic', 'hiv1infected', 'donors', 'receiving', 'combined', 'antiretroviral', 'therapy', 'also', 'iin', 'vitroi', 'cells', 'myeloidmonocytic', 'origin', 'targeting', 'nfκb', 'mitogenactivated', 'protein', 'kinase', 'pathways', 'interestingly', 'activation', 'marker', 'cd69', 'significantly', 'upregulated', 'natural', 'killer', 'nk', 'cells', 'b', 'cells', 'monocytes', '48', 'h', 'smuz1', 'treatment', 'furthermore', 'smuz1', 'able', 'activate', 'cells', 'without', 'global', 'cell', 'activation', 'well', 'increasing', 'nk', 'cell', 'degranulation', 'gamma', 'interferon', 'ifnγ', 'production', 'block', 'hiv1infected', 'cd4supsup', 'lymphocytes', 'summary', 'present', 'study', 'found', 'smuz1', 'enhance', 'hiv1', 'transcription', 'promote', 'nk', 'cellmediated', 'inhibition', 'hiv1infected', 'autologous', 'cd4supsup', 'cells', 'findings', 'indicate', 'novel', 'tlr12', 'agonist', 'smuz1', 'promising', 'latencyreversing', 'agent', 'lra', 'eradication', 'hiv1', 'reservoirs', 'bimportanceb', 'multiple', 'iin', 'vivoi', 'studies', 'showed', 'many', 'lras', 'used', 'shockandkill', 'approach', 'could', 'activate', 'viral', 'transcription', 'could', 'induce', 'killing', 'effectively', 'therefore', 'dualfunction', 'lra', 'needed', 'elimination', 'hiv1', 'reservoirs', 'previously', 'developed', 'smallmolecule', 'tlr12', 'agonist', 'smuz1', 'demonstrated', 'could', 'upregulate', 'nk', 'cells', 'cd8supsup', 'cells', 'immune', 'adjuvant', 'antitumor', 'properties', 'iin', 'vivoi', 'present', 'study', 'smuz1', 'could', 'activate', 'innate', 'immune', 'cells', 'without', 'global', 'cell', 'activation', 'induce', 'production', 'proinflammatory', 'antiviral', 'cytokines', 'enhance', 'cytotoxic', 'function', 'nk', 'cells', 'showed', 'smuz1', 'displayed', 'dual', 'potential', 'iex', 'vivoi', 'shock', 'exposure', 'latently', 'hiv1infected', 'cells', 'kill', 'clearance', 'infected', 'cells', 'critical', 'effective', 'use', 'combination', 'therapeutic', 'vaccines', 'broadly', 'neutralizing', 'antibody', 'treatments', 'aimed', 'curing', 'aids']","['iex', 'iex']","['iex', 'iex']",True,['tumor']
34116044,Novel small molecule inhibitors of the transcription factor ETS-1 and their antitumor activity against hepatocellular carcinoma.,"The transcription factor ETS-1 (E26 transformation specific sequence 1) is the key regulator for malignant tumor cell proliferation and invasion by mediating the transcription of the invasion/migration related factors, e.g. MMPs (matrix metalloproteinases). This work aims to identify the novel small molecule inhibitors of ETS-1 using a small molecule compound library and to study the inhibitors' antitumor activity against hepatocellular carcinoma (HCC). The luciferase reporter is used to examine the inhibition and activation of ETS-1's transcription factor activity in HCC cells, including a highly invasive HCC cell line, MHCC97-H, and five lines of patient-derived cells. The inhibition of the proliferation of HCC cells is examined using the MTT assay, while the invasion of HCC cells is examined using the transwell assay. The anti-tumor activity of the selected compound on HCC cells is also examined in a subcutaneous tumor model or intrahepatic tumor model in nude mice. The results show that for the first time, four compounds, EI1~EI-4, can inhibit the transcription factor activation of ETS-1 and the proliferation or invasion of HCC cells. Among the four compounds, EI-4 has the best activation. The results from this paper contribute to expanding our understanding of ETS-1 and provide alternative, the safer and more effective, HCC molecular therapy strategies.",2021-06-08,the transcription factor ets1 e26 transformation specific sequence 1 is the key regulator for malignant tumor cell proliferation and invasion by mediating the transcription of the invasionmigration related factors eg mmps matrix metalloproteinases this work aims to identify the novel small molecule inhibitors of ets1 using a small molecule compound library and to study the inhibitors antitumor activity against hepatocellular carcinoma hcc the luciferase reporter is used to examine the inhibition and activation of ets1s transcription factor activity in hcc cells including a highly invasive hcc cell line mhcc97h and five lines of patientderived cells the inhibition of the proliferation of hcc cells is examined using the mtt assay while the invasion of hcc cells is examined using the transwell assay the antitumor activity of the selected compound on hcc cells is also examined in a subcutaneous tumor model or intrahepatic tumor model in nude mice the results show that for the first time four compounds ei1ei4 can inhibit the transcription factor activation of ets1 and the proliferation or invasion of hcc cells among the four compounds ei4 has the best activation the results from this paper contribute to expanding our understanding of ets1 and provide alternative the safer and more effective hcc molecular therapy strategies,"['the', 'transcription', 'factor', 'ets1', 'e26', 'transformation', 'specific', 'sequence', '1', 'is', 'the', 'key', 'regulator', 'for', 'malignant', 'tumor', 'cell', 'proliferation', 'and', 'invasion', 'by', 'mediating', 'the', 'transcription', 'of', 'the', 'invasionmigration', 'related', 'factors', 'eg', 'mmps', 'matrix', 'metalloproteinases', 'this', 'work', 'aims', 'to', 'identify', 'the', 'novel', 'small', 'molecule', 'inhibitors', 'of', 'ets1', 'using', 'a', 'small', 'molecule', 'compound', 'library', 'and', 'to', 'study', 'the', 'inhibitors', 'antitumor', 'activity', 'against', 'hepatocellular', 'carcinoma', 'hcc', 'the', 'luciferase', 'reporter', 'is', 'used', 'to', 'examine', 'the', 'inhibition', 'and', 'activation', 'of', 'ets1s', 'transcription', 'factor', 'activity', 'in', 'hcc', 'cells', 'including', 'a', 'highly', 'invasive', 'hcc', 'cell', 'line', 'mhcc97h', 'and', 'five', 'lines', 'of', 'patientderived', 'cells', 'the', 'inhibition', 'of', 'the', 'proliferation', 'of', 'hcc', 'cells', 'is', 'examined', 'using', 'the', 'mtt', 'assay', 'while', 'the', 'invasion', 'of', 'hcc', 'cells', 'is', 'examined', 'using', 'the', 'transwell', 'assay', 'the', 'antitumor', 'activity', 'of', 'the', 'selected', 'compound', 'on', 'hcc', 'cells', 'is', 'also', 'examined', 'in', 'a', 'subcutaneous', 'tumor', 'model', 'or', 'intrahepatic', 'tumor', 'model', 'in', 'nude', 'mice', 'the', 'results', 'show', 'that', 'for', 'the', 'first', 'time', 'four', 'compounds', 'ei1ei4', 'can', 'inhibit', 'the', 'transcription', 'factor', 'activation', 'of', 'ets1', 'and', 'the', 'proliferation', 'or', 'invasion', 'of', 'hcc', 'cells', 'among', 'the', 'four', 'compounds', 'ei4', 'has', 'the', 'best', 'activation', 'the', 'results', 'from', 'this', 'paper', 'contribute', 'to', 'expanding', 'our', 'understanding', 'of', 'ets1', 'and', 'provide', 'alternative', 'the', 'safer', 'and', 'more', 'effective', 'hcc', 'molecular', 'therapy', 'strategies']","['transcription', 'factor', 'ets1', 'e26', 'transformation', 'specific', 'sequence', '1', 'key', 'regulator', 'malignant', 'tumor', 'cell', 'proliferation', 'invasion', 'mediating', 'transcription', 'invasionmigration', 'related', 'factors', 'eg', 'mmps', 'matrix', 'metalloproteinases', 'work', 'aims', 'identify', 'novel', 'small', 'molecule', 'inhibitors', 'ets1', 'using', 'small', 'molecule', 'compound', 'library', 'study', 'inhibitors', 'antitumor', 'activity', 'hepatocellular', 'carcinoma', 'hcc', 'luciferase', 'reporter', 'used', 'examine', 'inhibition', 'activation', 'ets1s', 'transcription', 'factor', 'activity', 'hcc', 'cells', 'including', 'highly', 'invasive', 'hcc', 'cell', 'line', 'mhcc97h', 'five', 'lines', 'patientderived', 'cells', 'inhibition', 'proliferation', 'hcc', 'cells', 'examined', 'using', 'mtt', 'assay', 'invasion', 'hcc', 'cells', 'examined', 'using', 'transwell', 'assay', 'antitumor', 'activity', 'selected', 'compound', 'hcc', 'cells', 'also', 'examined', 'subcutaneous', 'tumor', 'model', 'intrahepatic', 'tumor', 'model', 'nude', 'mice', 'results', 'show', 'first', 'time', 'four', 'compounds', 'ei1ei4', 'inhibit', 'transcription', 'factor', 'activation', 'ets1', 'proliferation', 'invasion', 'hcc', 'cells', 'among', 'four', 'compounds', 'ei4', 'best', 'activation', 'results', 'paper', 'contribute', 'expanding', 'understanding', 'ets1', 'provide', 'alternative', 'safer', 'effective', 'hcc', 'molecular', 'therapy', 'strategies']","['ets1', 'metalloproteinases', 'ets1', 'luciferase', 'ets1', 'ets1']","['ets1', 'ets1', 'luciferase', 'ets1', 'ets1']",True,['tumor']
34093983,A novel bioengineered fragment peptide of Vasostatin-1 exerts smooth muscle pharmacological activities and anti-angiogenic effects via blocking VEGFR signalling pathway.,"Chromogranin A (CgA) is a hydrophilic glycoprotein released by post-ganglionic sympathetic neurons. CgA consists of a single peptide chain containing numerous paired basic residues, which are typical cleavage sites in prohormones to generate bioactive peptides. It is recognized as a diagnostic and prognostic serum marker for neuroendocrine tumours. Vasostatin-1 is one of the most conserved regions of CgA and has diverse inhibitory biological activities. In this study, a novel peptide fragment that contains three typical functional structures of Vasostatin-1 was synthesized. This unique bioengineered Vasostatin-1 Derived Peptide (named V1DP) includes a highly conserved domain between vertebrate species in its N-terminal region, comprising a disulphide bridge formed by two cysteine residues at amino acid positions 17 and 38, respectively. Besides, V1DP contains two significant tripeptide recognition sequences: the amino acid triplets, RGD and KGD. Our data demonstrated that V1DP could induce a dose-dependent relaxation of rat arterial smooth muscle and also increase the contraction activity of rat uterus smooth muscle. More importantly, we found that V1DP inhibits cancer cell proliferation, modulate the HUVEC cell migration, and exhibit anti-angiogenesis effect both in <i>vitro</i> and in <i>vivo.</i> We further investigated the actual mechanism of V1DP, and our results confirmed that V1DP involves inhibiting the vascular endothelial growth factor receptor (VEGFR) signalling. We docked V1DP to the apo structures of VEGFR2 and examined the stability of the peptide in the protein pockets. Our simulation and free energy calculations results indicated that V1DP can bind to the catalytic domain and regulatory domain pockets, depending on whether the conformational state of the protein is JM-in or JM-out. Taken together, our data suggested that V1DP plays a role as the regulator of endothelial cell function and smooth muscle pharmacological homeostasis. V1DP is a water-soluble and biologically stable peptide and could further develop as an anti-angiogenic drug for cancer treatment.",2021-05-03,chromogranin a cga is a hydrophilic glycoprotein released by postganglionic sympathetic neurons cga consists of a single peptide chain containing numerous paired basic residues which are typical cleavage sites in prohormones to generate bioactive peptides it is recognized as a diagnostic and prognostic serum marker for neuroendocrine tumours vasostatin1 is one of the most conserved regions of cga and has diverse inhibitory biological activities in this study a novel peptide fragment that contains three typical functional structures of vasostatin1 was synthesized this unique bioengineered vasostatin1 derived peptide named v1dp includes a highly conserved domain between vertebrate species in its nterminal region comprising a disulphide bridge formed by two cysteine residues at amino acid positions 17 and 38 respectively besides v1dp contains two significant tripeptide recognition sequences the amino acid triplets rgd and kgd our data demonstrated that v1dp could induce a dosedependent relaxation of rat arterial smooth muscle and also increase the contraction activity of rat uterus smooth muscle more importantly we found that v1dp inhibits cancer cell proliferation modulate the huvec cell migration and exhibit antiangiogenesis effect both in ivitroi and in ivivoi we further investigated the actual mechanism of v1dp and our results confirmed that v1dp involves inhibiting the vascular endothelial growth factor receptor vegfr signalling we docked v1dp to the apo structures of vegfr2 and examined the stability of the peptide in the protein pockets our simulation and free energy calculations results indicated that v1dp can bind to the catalytic domain and regulatory domain pockets depending on whether the conformational state of the protein is jmin or jmout taken together our data suggested that v1dp plays a role as the regulator of endothelial cell function and smooth muscle pharmacological homeostasis v1dp is a watersoluble and biologically stable peptide and could further develop as an antiangiogenic drug for cancer treatment,"['chromogranin', 'a', 'cga', 'is', 'a', 'hydrophilic', 'glycoprotein', 'released', 'by', 'postganglionic', 'sympathetic', 'neurons', 'cga', 'consists', 'of', 'a', 'single', 'peptide', 'chain', 'containing', 'numerous', 'paired', 'basic', 'residues', 'which', 'are', 'typical', 'cleavage', 'sites', 'in', 'prohormones', 'to', 'generate', 'bioactive', 'peptides', 'it', 'is', 'recognized', 'as', 'a', 'diagnostic', 'and', 'prognostic', 'serum', 'marker', 'for', 'neuroendocrine', 'tumours', 'vasostatin1', 'is', 'one', 'of', 'the', 'most', 'conserved', 'regions', 'of', 'cga', 'and', 'has', 'diverse', 'inhibitory', 'biological', 'activities', 'in', 'this', 'study', 'a', 'novel', 'peptide', 'fragment', 'that', 'contains', 'three', 'typical', 'functional', 'structures', 'of', 'vasostatin1', 'was', 'synthesized', 'this', 'unique', 'bioengineered', 'vasostatin1', 'derived', 'peptide', 'named', 'v1dp', 'includes', 'a', 'highly', 'conserved', 'domain', 'between', 'vertebrate', 'species', 'in', 'its', 'nterminal', 'region', 'comprising', 'a', 'disulphide', 'bridge', 'formed', 'by', 'two', 'cysteine', 'residues', 'at', 'amino', 'acid', 'positions', '17', 'and', '38', 'respectively', 'besides', 'v1dp', 'contains', 'two', 'significant', 'tripeptide', 'recognition', 'sequences', 'the', 'amino', 'acid', 'triplets', 'rgd', 'and', 'kgd', 'our', 'data', 'demonstrated', 'that', 'v1dp', 'could', 'induce', 'a', 'dosedependent', 'relaxation', 'of', 'rat', 'arterial', 'smooth', 'muscle', 'and', 'also', 'increase', 'the', 'contraction', 'activity', 'of', 'rat', 'uterus', 'smooth', 'muscle', 'more', 'importantly', 'we', 'found', 'that', 'v1dp', 'inhibits', 'cancer', 'cell', 'proliferation', 'modulate', 'the', 'huvec', 'cell', 'migration', 'and', 'exhibit', 'antiangiogenesis', 'effect', 'both', 'in', 'ivitroi', 'and', 'in', 'ivivoi', 'we', 'further', 'investigated', 'the', 'actual', 'mechanism', 'of', 'v1dp', 'and', 'our', 'results', 'confirmed', 'that', 'v1dp', 'involves', 'inhibiting', 'the', 'vascular', 'endothelial', 'growth', 'factor', 'receptor', 'vegfr', 'signalling', 'we', 'docked', 'v1dp', 'to', 'the', 'apo', 'structures', 'of', 'vegfr2', 'and', 'examined', 'the', 'stability', 'of', 'the', 'peptide', 'in', 'the', 'protein', 'pockets', 'our', 'simulation', 'and', 'free', 'energy', 'calculations', 'results', 'indicated', 'that', 'v1dp', 'can', 'bind', 'to', 'the', 'catalytic', 'domain', 'and', 'regulatory', 'domain', 'pockets', 'depending', 'on', 'whether', 'the', 'conformational', 'state', 'of', 'the', 'protein', 'is', 'jmin', 'or', 'jmout', 'taken', 'together', 'our', 'data', 'suggested', 'that', 'v1dp', 'plays', 'a', 'role', 'as', 'the', 'regulator', 'of', 'endothelial', 'cell', 'function', 'and', 'smooth', 'muscle', 'pharmacological', 'homeostasis', 'v1dp', 'is', 'a', 'watersoluble', 'and', 'biologically', 'stable', 'peptide', 'and', 'could', 'further', 'develop', 'as', 'an', 'antiangiogenic', 'drug', 'for', 'cancer', 'treatment']","['chromogranin', 'cga', 'hydrophilic', 'glycoprotein', 'released', 'postganglionic', 'sympathetic', 'neurons', 'cga', 'consists', 'single', 'peptide', 'chain', 'containing', 'numerous', 'paired', 'basic', 'residues', 'typical', 'cleavage', 'sites', 'prohormones', 'generate', 'bioactive', 'peptides', 'recognized', 'diagnostic', 'prognostic', 'serum', 'marker', 'neuroendocrine', 'tumours', 'vasostatin1', 'one', 'conserved', 'regions', 'cga', 'diverse', 'inhibitory', 'biological', 'activities', 'study', 'novel', 'peptide', 'fragment', 'contains', 'three', 'typical', 'functional', 'structures', 'vasostatin1', 'synthesized', 'unique', 'bioengineered', 'vasostatin1', 'derived', 'peptide', 'named', 'v1dp', 'includes', 'highly', 'conserved', 'domain', 'vertebrate', 'species', 'nterminal', 'region', 'comprising', 'disulphide', 'bridge', 'formed', 'two', 'cysteine', 'residues', 'amino', 'acid', 'positions', '17', '38', 'respectively', 'besides', 'v1dp', 'contains', 'two', 'significant', 'tripeptide', 'recognition', 'sequences', 'amino', 'acid', 'triplets', 'rgd', 'kgd', 'data', 'demonstrated', 'v1dp', 'could', 'induce', 'dosedependent', 'relaxation', 'rat', 'arterial', 'smooth', 'muscle', 'also', 'increase', 'contraction', 'activity', 'rat', 'uterus', 'smooth', 'muscle', 'importantly', 'found', 'v1dp', 'inhibits', 'cancer', 'cell', 'proliferation', 'modulate', 'huvec', 'cell', 'migration', 'exhibit', 'antiangiogenesis', 'effect', 'ivitroi', 'ivivoi', 'investigated', 'actual', 'mechanism', 'v1dp', 'results', 'confirmed', 'v1dp', 'involves', 'inhibiting', 'vascular', 'endothelial', 'growth', 'factor', 'receptor', 'vegfr', 'signalling', 'docked', 'v1dp', 'apo', 'structures', 'vegfr2', 'examined', 'stability', 'peptide', 'protein', 'pockets', 'simulation', 'free', 'energy', 'calculations', 'results', 'indicated', 'v1dp', 'bind', 'catalytic', 'domain', 'regulatory', 'domain', 'pockets', 'depending', 'whether', 'conformational', 'state', 'protein', 'jmin', 'jmout', 'taken', 'together', 'data', 'suggested', 'v1dp', 'plays', 'role', 'regulator', 'endothelial', 'cell', 'function', 'smooth', 'muscle', 'pharmacological', 'homeostasis', 'v1dp', 'watersoluble', 'biologically', 'stable', 'peptide', 'could', 'develop', 'antiangiogenic', 'drug', 'cancer', 'treatment']","['chromogranin', 'vegfr', 'vegfr2']",['chromogranin'],True,['cancer']
34019908,Novel small molecule inhibitor of Kpnβ1 induces cell cycle arrest and apoptosis in cancer cells.,"Karyopherin beta 1 (Kpnβ1) is a major nuclear import receptor that mediates the import of cellular cargoes into the nucleus. Recently it has been shown that Kpnβ1 is highly expressed in several cancers, and its inhibition by siRNA induces apoptotic cancer cell death, while having little effect on non-cancer cells. This study investigated the effect of a novel small molecule, Inhibitor of Nuclear Import-60 (INI-60), on cancer cell biology, as well as nuclear import activities associated with Kpnβ1, and cancer progression in vivo using cervical and oesophageal cancer cell lines. INI-60 treatment resulted in the inhibition of cancer cell proliferation, colony formation, migration and invasion, and induced a G1/S cell cycle arrest, followed by cancer cell death via apoptosis. Non-cancer cells were minimally affected by INI-60 at concentrations that inhibited cancer cells. INI-60 treatment altered the localisation of Kpnβ1 and its cargoes, NFκB/p65, NFAT and AP-1, and the overexpression of Kpnβ1 reduced INI-60 cytotoxicity. INI-60 also inhibited KYSE 30 oesophageal cancer cell line growth in vivo. Taken together, these results show that INI-60 inhibits the nuclear import of Kpnβ1 cargoes and interferes with cancer cell biology. INI-60 presents as a potential therapeutic approach for cancers of different tissue origins and warrants further investigation as a novel anti-cancer agent.",2021-05-18,karyopherin beta 1 kpnβ1 is a major nuclear import receptor that mediates the import of cellular cargoes into the nucleus recently it has been shown that kpnβ1 is highly expressed in several cancers and its inhibition by sirna induces apoptotic cancer cell death while having little effect on noncancer cells this study investigated the effect of a novel small molecule inhibitor of nuclear import60 ini60 on cancer cell biology as well as nuclear import activities associated with kpnβ1 and cancer progression in vivo using cervical and oesophageal cancer cell lines ini60 treatment resulted in the inhibition of cancer cell proliferation colony formation migration and invasion and induced a g1s cell cycle arrest followed by cancer cell death via apoptosis noncancer cells were minimally affected by ini60 at concentrations that inhibited cancer cells ini60 treatment altered the localisation of kpnβ1 and its cargoes nfκbp65 nfat and ap1 and the overexpression of kpnβ1 reduced ini60 cytotoxicity ini60 also inhibited kyse 30 oesophageal cancer cell line growth in vivo taken together these results show that ini60 inhibits the nuclear import of kpnβ1 cargoes and interferes with cancer cell biology ini60 presents as a potential therapeutic approach for cancers of different tissue origins and warrants further investigation as a novel anticancer agent,"['karyopherin', 'beta', '1', 'kpnβ1', 'is', 'a', 'major', 'nuclear', 'import', 'receptor', 'that', 'mediates', 'the', 'import', 'of', 'cellular', 'cargoes', 'into', 'the', 'nucleus', 'recently', 'it', 'has', 'been', 'shown', 'that', 'kpnβ1', 'is', 'highly', 'expressed', 'in', 'several', 'cancers', 'and', 'its', 'inhibition', 'by', 'sirna', 'induces', 'apoptotic', 'cancer', 'cell', 'death', 'while', 'having', 'little', 'effect', 'on', 'noncancer', 'cells', 'this', 'study', 'investigated', 'the', 'effect', 'of', 'a', 'novel', 'small', 'molecule', 'inhibitor', 'of', 'nuclear', 'import60', 'ini60', 'on', 'cancer', 'cell', 'biology', 'as', 'well', 'as', 'nuclear', 'import', 'activities', 'associated', 'with', 'kpnβ1', 'and', 'cancer', 'progression', 'in', 'vivo', 'using', 'cervical', 'and', 'oesophageal', 'cancer', 'cell', 'lines', 'ini60', 'treatment', 'resulted', 'in', 'the', 'inhibition', 'of', 'cancer', 'cell', 'proliferation', 'colony', 'formation', 'migration', 'and', 'invasion', 'and', 'induced', 'a', 'g1s', 'cell', 'cycle', 'arrest', 'followed', 'by', 'cancer', 'cell', 'death', 'via', 'apoptosis', 'noncancer', 'cells', 'were', 'minimally', 'affected', 'by', 'ini60', 'at', 'concentrations', 'that', 'inhibited', 'cancer', 'cells', 'ini60', 'treatment', 'altered', 'the', 'localisation', 'of', 'kpnβ1', 'and', 'its', 'cargoes', 'nfκbp65', 'nfat', 'and', 'ap1', 'and', 'the', 'overexpression', 'of', 'kpnβ1', 'reduced', 'ini60', 'cytotoxicity', 'ini60', 'also', 'inhibited', 'kyse', '30', 'oesophageal', 'cancer', 'cell', 'line', 'growth', 'in', 'vivo', 'taken', 'together', 'these', 'results', 'show', 'that', 'ini60', 'inhibits', 'the', 'nuclear', 'import', 'of', 'kpnβ1', 'cargoes', 'and', 'interferes', 'with', 'cancer', 'cell', 'biology', 'ini60', 'presents', 'as', 'a', 'potential', 'therapeutic', 'approach', 'for', 'cancers', 'of', 'different', 'tissue', 'origins', 'and', 'warrants', 'further', 'investigation', 'as', 'a', 'novel', 'anticancer', 'agent']","['karyopherin', 'beta', '1', 'kpnβ1', 'major', 'nuclear', 'import', 'receptor', 'mediates', 'import', 'cellular', 'cargoes', 'nucleus', 'recently', 'shown', 'kpnβ1', 'highly', 'expressed', 'several', 'cancers', 'inhibition', 'sirna', 'induces', 'apoptotic', 'cancer', 'cell', 'death', 'little', 'effect', 'noncancer', 'cells', 'study', 'investigated', 'effect', 'novel', 'small', 'molecule', 'inhibitor', 'nuclear', 'import60', 'ini60', 'cancer', 'cell', 'biology', 'well', 'nuclear', 'import', 'activities', 'associated', 'kpnβ1', 'cancer', 'progression', 'vivo', 'using', 'cervical', 'oesophageal', 'cancer', 'cell', 'lines', 'ini60', 'treatment', 'resulted', 'inhibition', 'cancer', 'cell', 'proliferation', 'colony', 'formation', 'migration', 'invasion', 'induced', 'g1s', 'cell', 'cycle', 'arrest', 'followed', 'cancer', 'cell', 'death', 'via', 'apoptosis', 'noncancer', 'cells', 'minimally', 'affected', 'ini60', 'concentrations', 'inhibited', 'cancer', 'cells', 'ini60', 'treatment', 'altered', 'localisation', 'kpnβ1', 'cargoes', 'nfκbp65', 'nfat', 'ap1', 'overexpression', 'kpnβ1', 'reduced', 'ini60', 'cytotoxicity', 'ini60', 'also', 'inhibited', 'kyse', '30', 'oesophageal', 'cancer', 'cell', 'line', 'growth', 'vivo', 'taken', 'together', 'results', 'show', 'ini60', 'inhibits', 'nuclear', 'import', 'kpnβ1', 'cargoes', 'interferes', 'cancer', 'cell', 'biology', 'ini60', 'presents', 'potential', 'therapeutic', 'approach', 'cancers', 'different', 'tissue', 'origins', 'warrants', 'investigation', 'novel', 'anticancer', 'agent']","['karyopherin', 'beta', 'sirna']",['karyopherin'],True,['cancer']
33997269,Targeting glioblastoma using a novel peptide specific to a deglycosylated isoform of brevican.,"Glioblastoma multiforme (GBM) is the most common and deadliest form of brain tumor and remains amongst the most difficult cancers to treat. Brevican (Bcan), a central nervous system (CNS)-specific extracellular matrix protein, is upregulated in high-grade glioma cells, including GBM. A Bcan isoform lacking most glycosylation, dg-Bcan, is found only in GBM tissues. Here, dg-Bcan is explored as a molecular target for GBM. In this study, we screened a d-peptide library to identify a small 8-amino acid dg-<b>B</b>can-<b>T</b>argeting <b>P</b>eptide (BTP) candidate, called BTP-7 that binds dg-Bcan with high affinity and specificity. BTP-7 is preferentially internalized by dg-Bcan-expressing patient-derived GBM cells. To demonstrate GBM targeting, we radiolabeled BTP-7 with <sup>18</sup>F, a radioisotope of fluorine, and found increased radiotracer accumulation in intracranial GBM established in mice using positron emission tomography (PET) imaging. dg-Bcan is an attractive molecular target for GBM, and BTP-7 represents a promising lead candidate for further development into novel imaging agents and targeted therapeutics.",2021-01-20,glioblastoma multiforme gbm is the most common and deadliest form of brain tumor and remains amongst the most difficult cancers to treat brevican bcan a central nervous system cnsspecific extracellular matrix protein is upregulated in highgrade glioma cells including gbm a bcan isoform lacking most glycosylation dgbcan is found only in gbm tissues here dgbcan is explored as a molecular target for gbm in this study we screened a dpeptide library to identify a small 8amino acid dgbbbcanbtbargeting bpbeptide btp candidate called btp7 that binds dgbcan with high affinity and specificity btp7 is preferentially internalized by dgbcanexpressing patientderived gbm cells to demonstrate gbm targeting we radiolabeled btp7 with sup18supf a radioisotope of fluorine and found increased radiotracer accumulation in intracranial gbm established in mice using positron emission tomography pet imaging dgbcan is an attractive molecular target for gbm and btp7 represents a promising lead candidate for further development into novel imaging agents and targeted therapeutics,"['glioblastoma', 'multiforme', 'gbm', 'is', 'the', 'most', 'common', 'and', 'deadliest', 'form', 'of', 'brain', 'tumor', 'and', 'remains', 'amongst', 'the', 'most', 'difficult', 'cancers', 'to', 'treat', 'brevican', 'bcan', 'a', 'central', 'nervous', 'system', 'cnsspecific', 'extracellular', 'matrix', 'protein', 'is', 'upregulated', 'in', 'highgrade', 'glioma', 'cells', 'including', 'gbm', 'a', 'bcan', 'isoform', 'lacking', 'most', 'glycosylation', 'dgbcan', 'is', 'found', 'only', 'in', 'gbm', 'tissues', 'here', 'dgbcan', 'is', 'explored', 'as', 'a', 'molecular', 'target', 'for', 'gbm', 'in', 'this', 'study', 'we', 'screened', 'a', 'dpeptide', 'library', 'to', 'identify', 'a', 'small', '8amino', 'acid', 'dgbbbcanbtbargeting', 'bpbeptide', 'btp', 'candidate', 'called', 'btp7', 'that', 'binds', 'dgbcan', 'with', 'high', 'affinity', 'and', 'specificity', 'btp7', 'is', 'preferentially', 'internalized', 'by', 'dgbcanexpressing', 'patientderived', 'gbm', 'cells', 'to', 'demonstrate', 'gbm', 'targeting', 'we', 'radiolabeled', 'btp7', 'with', 'sup18supf', 'a', 'radioisotope', 'of', 'fluorine', 'and', 'found', 'increased', 'radiotracer', 'accumulation', 'in', 'intracranial', 'gbm', 'established', 'in', 'mice', 'using', 'positron', 'emission', 'tomography', 'pet', 'imaging', 'dgbcan', 'is', 'an', 'attractive', 'molecular', 'target', 'for', 'gbm', 'and', 'btp7', 'represents', 'a', 'promising', 'lead', 'candidate', 'for', 'further', 'development', 'into', 'novel', 'imaging', 'agents', 'and', 'targeted', 'therapeutics']","['glioblastoma', 'multiforme', 'gbm', 'common', 'deadliest', 'form', 'brain', 'tumor', 'remains', 'amongst', 'difficult', 'cancers', 'treat', 'brevican', 'bcan', 'central', 'nervous', 'system', 'cnsspecific', 'extracellular', 'matrix', 'protein', 'upregulated', 'highgrade', 'glioma', 'cells', 'including', 'gbm', 'bcan', 'isoform', 'lacking', 'glycosylation', 'dgbcan', 'found', 'gbm', 'tissues', 'dgbcan', 'explored', 'molecular', 'target', 'gbm', 'study', 'screened', 'dpeptide', 'library', 'identify', 'small', '8amino', 'acid', 'dgbbbcanbtbargeting', 'bpbeptide', 'btp', 'candidate', 'called', 'btp7', 'binds', 'dgbcan', 'high', 'affinity', 'specificity', 'btp7', 'preferentially', 'internalized', 'dgbcanexpressing', 'patientderived', 'gbm', 'cells', 'demonstrate', 'gbm', 'targeting', 'radiolabeled', 'btp7', 'sup18supf', 'radioisotope', 'fluorine', 'found', 'increased', 'radiotracer', 'accumulation', 'intracranial', 'gbm', 'established', 'mice', 'using', 'positron', 'emission', 'tomography', 'pet', 'imaging', 'dgbcan', 'attractive', 'molecular', 'target', 'gbm', 'btp7', 'represents', 'promising', 'lead', 'candidate', 'development', 'novel', 'imaging', 'agents', 'targeted', 'therapeutics']",['brevican'],['brevican'],True,"['tumor', 'cancer']"
33982891,Amelioration of Posttraumatic Osteoarthritis in Mice Using Intraarticular Silencing of Periostin via Nanoparticle-Based Small Interfering RNA.,"Recent evidence delineates an emerging role of periostin in osteoarthritis (OA), since its expression after knee injury is detrimental to the articular cartilage. We undertook this study to examine whether intraarticular (IA) knockdown of periostin would ameliorate posttraumatic OA in a murine model.",2021-10-28,recent evidence delineates an emerging role of periostin in osteoarthritis oa since its expression after knee injury is detrimental to the articular cartilage we undertook this study to examine whether intraarticular ia knockdown of periostin would ameliorate posttraumatic oa in a murine model,"['recent', 'evidence', 'delineates', 'an', 'emerging', 'role', 'of', 'periostin', 'in', 'osteoarthritis', 'oa', 'since', 'its', 'expression', 'after', 'knee', 'injury', 'is', 'detrimental', 'to', 'the', 'articular', 'cartilage', 'we', 'undertook', 'this', 'study', 'to', 'examine', 'whether', 'intraarticular', 'ia', 'knockdown', 'of', 'periostin', 'would', 'ameliorate', 'posttraumatic', 'oa', 'in', 'a', 'murine', 'model']","['recent', 'evidence', 'delineates', 'emerging', 'role', 'periostin', 'osteoarthritis', 'oa', 'since', 'expression', 'knee', 'injury', 'detrimental', 'articular', 'cartilage', 'undertook', 'study', 'examine', 'whether', 'intraarticular', 'ia', 'knockdown', 'periostin', 'would', 'ameliorate', 'posttraumatic', 'oa', 'murine', 'model']","['periostin', 'periostin']","['periostin', 'periostin']",False,['arthritis']
33967793,The Tetramethylpyrazine Derivative Statmp-151: A Novel Small Molecule Stat3 Inhibitor With Promising Activity Against Breast Cancer.,"Breast cancer is the most common malignancy in women and is a molecularly heterogeneous disease. Signal transducer and activator of transcription 3 (Stat3) is overexpressed and hyperactivated in a variety of human tumours, including breast cancer, thus representing a promising target for breast cancer treatment. In the present study, we evaluated the activities of a novel Stat3 inhibitor named Statmp-151 in the human breast cancer cell lines MCF-7 and MDA-MB-231 and the murine mammary carcinoma cell line 4T1. The <i>in vitro</i> results showed that Statmp-151 inhibited the proliferation of breast cancer cell lines in a dose- and time-dependent manner and suppressed the phosphorylation of Stat3 in a dose-dependent manner. Flow cytometry (FCM) assays revealed that Statmp-151 affected mitochondrial membrane potential and reactive oxygen species (ROS) production. Furthermore, Statmp-151 inhibited cell migration, as shown by analysis of the matrix metalloproteinases MMP2 and MMP9. Finally, in a 4T1 tumour-bearing mouse model, intraperitoneal injection of 30 mg/kg/day Statmp-151 significantly suppressed the growth of tumours without obvious toxicity. These results indicated that Statmp-151 might be a potential candidate for the treatment of breast cancer.",2021-04-15,breast cancer is the most common malignancy in women and is a molecularly heterogeneous disease signal transducer and activator of transcription 3 stat3 is overexpressed and hyperactivated in a variety of human tumours including breast cancer thus representing a promising target for breast cancer treatment in the present study we evaluated the activities of a novel stat3 inhibitor named statmp151 in the human breast cancer cell lines mcf7 and mdamb231 and the murine mammary carcinoma cell line 4t1 the iin vitroi results showed that statmp151 inhibited the proliferation of breast cancer cell lines in a dose and timedependent manner and suppressed the phosphorylation of stat3 in a dosedependent manner flow cytometry fcm assays revealed that statmp151 affected mitochondrial membrane potential and reactive oxygen species ros production furthermore statmp151 inhibited cell migration as shown by analysis of the matrix metalloproteinases mmp2 and mmp9 finally in a 4t1 tumourbearing mouse model intraperitoneal injection of 30 mgkgday statmp151 significantly suppressed the growth of tumours without obvious toxicity these results indicated that statmp151 might be a potential candidate for the treatment of breast cancer,"['breast', 'cancer', 'is', 'the', 'most', 'common', 'malignancy', 'in', 'women', 'and', 'is', 'a', 'molecularly', 'heterogeneous', 'disease', 'signal', 'transducer', 'and', 'activator', 'of', 'transcription', '3', 'stat3', 'is', 'overexpressed', 'and', 'hyperactivated', 'in', 'a', 'variety', 'of', 'human', 'tumours', 'including', 'breast', 'cancer', 'thus', 'representing', 'a', 'promising', 'target', 'for', 'breast', 'cancer', 'treatment', 'in', 'the', 'present', 'study', 'we', 'evaluated', 'the', 'activities', 'of', 'a', 'novel', 'stat3', 'inhibitor', 'named', 'statmp151', 'in', 'the', 'human', 'breast', 'cancer', 'cell', 'lines', 'mcf7', 'and', 'mdamb231', 'and', 'the', 'murine', 'mammary', 'carcinoma', 'cell', 'line', '4t1', 'the', 'iin', 'vitroi', 'results', 'showed', 'that', 'statmp151', 'inhibited', 'the', 'proliferation', 'of', 'breast', 'cancer', 'cell', 'lines', 'in', 'a', 'dose', 'and', 'timedependent', 'manner', 'and', 'suppressed', 'the', 'phosphorylation', 'of', 'stat3', 'in', 'a', 'dosedependent', 'manner', 'flow', 'cytometry', 'fcm', 'assays', 'revealed', 'that', 'statmp151', 'affected', 'mitochondrial', 'membrane', 'potential', 'and', 'reactive', 'oxygen', 'species', 'ros', 'production', 'furthermore', 'statmp151', 'inhibited', 'cell', 'migration', 'as', 'shown', 'by', 'analysis', 'of', 'the', 'matrix', 'metalloproteinases', 'mmp2', 'and', 'mmp9', 'finally', 'in', 'a', '4t1', 'tumourbearing', 'mouse', 'model', 'intraperitoneal', 'injection', 'of', '30', 'mgkgday', 'statmp151', 'significantly', 'suppressed', 'the', 'growth', 'of', 'tumours', 'without', 'obvious', 'toxicity', 'these', 'results', 'indicated', 'that', 'statmp151', 'might', 'be', 'a', 'potential', 'candidate', 'for', 'the', 'treatment', 'of', 'breast', 'cancer']","['breast', 'cancer', 'common', 'malignancy', 'women', 'molecularly', 'heterogeneous', 'disease', 'signal', 'transducer', 'activator', 'transcription', '3', 'stat3', 'overexpressed', 'hyperactivated', 'variety', 'human', 'tumours', 'including', 'breast', 'cancer', 'thus', 'representing', 'promising', 'target', 'breast', 'cancer', 'treatment', 'present', 'study', 'evaluated', 'activities', 'novel', 'stat3', 'inhibitor', 'named', 'statmp151', 'human', 'breast', 'cancer', 'cell', 'lines', 'mcf7', 'mdamb231', 'murine', 'mammary', 'carcinoma', 'cell', 'line', '4t1', 'iin', 'vitroi', 'results', 'showed', 'statmp151', 'inhibited', 'proliferation', 'breast', 'cancer', 'cell', 'lines', 'dose', 'timedependent', 'manner', 'suppressed', 'phosphorylation', 'stat3', 'dosedependent', 'manner', 'flow', 'cytometry', 'fcm', 'assays', 'revealed', 'statmp151', 'affected', 'mitochondrial', 'membrane', 'potential', 'reactive', 'oxygen', 'species', 'ros', 'production', 'furthermore', 'statmp151', 'inhibited', 'cell', 'migration', 'shown', 'analysis', 'matrix', 'metalloproteinases', 'mmp2', 'mmp9', 'finally', '4t1', 'tumourbearing', 'mouse', 'model', 'intraperitoneal', 'injection', '30', 'mgkgday', 'statmp151', 'significantly', 'suppressed', 'growth', 'tumours', 'without', 'obvious', 'toxicity', 'results', 'indicated', 'statmp151', 'might', 'potential', 'candidate', 'treatment', 'breast', 'cancer']","['stat3', 'stat3', 'stat3', 'ros', 'metalloproteinases', 'mmp2', 'mmp9']","['mmp2', 'mmp9']",True,['cancer']
33844495,Novel Peptide-Calix[4]arene Conjugate Inhibits Aβ Aggregation and Rescues Neurons from Aβ's Oligomers Cytotoxicity <i>In Vitro</i>.,"Alzheimer's disease (AD) is a progressive neurodegenerative condition affecting people in the elderly. Targeting aggregation of β-amyloid peptides (Aβ) is considered a promising approach for the therapeutic treatment of the disease. Peptide based inhibitors of β-amyloid fibrillation are emerging as safe drug candidates as well as interesting compounds for early diagnosis of AD. Peptide conjugation via covalent bond with functional moieties enables the resultant hybrid system to acquire desired functions. Here we report the synthesis, the structural characterization, and the Aβ<sub>42</sub> interaction of a <i>p</i>-amino-calix[4]arene derivative bearing a GPGKLVFF peptide pendant at the lower rim. We demonstrate that the <i>p</i>-amino-calix[4]arene-GPGKLVFF conjugate alters the Aβ<sub>42</sub> aggregation pathways by preventing Aβ<sub>42</sub>'s conformational transition from random coil to β-sheet with concomitant changes of the aggregation kinetic profile as evidenced by circular dichroism (CD), thioflavin T (ThT), and dynamic light scattering (DLS) measurements, respectively. High resolution mass spectrometry (HR-MS) confirmed a direct interaction of the <i>p</i>-amino-calix[4]arene-GPGKLVFF conjugate with Aβ<sub>42</sub> monomer which provided insight into a possible working mechanism, whereas the alteration of the Aβ<sub>42</sub>'s fibrillary architecture, by the calix-peptide conjugate, was further validated by atomic force microscopy (AFM) imaging. Finally, the herein proposed compound was shown to be effective against Aβ<sub>42</sub> oligomers' toxicity in differentiated neuroblastoma cells, SH-SY5Y.",2021-04-12,alzheimers disease ad is a progressive neurodegenerative condition affecting people in the elderly targeting aggregation of βamyloid peptides aβ is considered a promising approach for the therapeutic treatment of the disease peptide based inhibitors of βamyloid fibrillation are emerging as safe drug candidates as well as interesting compounds for early diagnosis of ad peptide conjugation via covalent bond with functional moieties enables the resultant hybrid system to acquire desired functions here we report the synthesis the structural characterization and the aβsub42sub interaction of a ipiaminocalix4arene derivative bearing a gpgklvff peptide pendant at the lower rim we demonstrate that the ipiaminocalix4arenegpgklvff conjugate alters the aβsub42sub aggregation pathways by preventing aβsub42subs conformational transition from random coil to βsheet with concomitant changes of the aggregation kinetic profile as evidenced by circular dichroism cd thioflavin t tht and dynamic light scattering dls measurements respectively high resolution mass spectrometry hrms confirmed a direct interaction of the ipiaminocalix4arenegpgklvff conjugate with aβsub42sub monomer which provided insight into a possible working mechanism whereas the alteration of the aβsub42subs fibrillary architecture by the calixpeptide conjugate was further validated by atomic force microscopy afm imaging finally the herein proposed compound was shown to be effective against aβsub42sub oligomers toxicity in differentiated neuroblastoma cells shsy5y,"['alzheimers', 'disease', 'ad', 'is', 'a', 'progressive', 'neurodegenerative', 'condition', 'affecting', 'people', 'in', 'the', 'elderly', 'targeting', 'aggregation', 'of', 'βamyloid', 'peptides', 'aβ', 'is', 'considered', 'a', 'promising', 'approach', 'for', 'the', 'therapeutic', 'treatment', 'of', 'the', 'disease', 'peptide', 'based', 'inhibitors', 'of', 'βamyloid', 'fibrillation', 'are', 'emerging', 'as', 'safe', 'drug', 'candidates', 'as', 'well', 'as', 'interesting', 'compounds', 'for', 'early', 'diagnosis', 'of', 'ad', 'peptide', 'conjugation', 'via', 'covalent', 'bond', 'with', 'functional', 'moieties', 'enables', 'the', 'resultant', 'hybrid', 'system', 'to', 'acquire', 'desired', 'functions', 'here', 'we', 'report', 'the', 'synthesis', 'the', 'structural', 'characterization', 'and', 'the', 'aβsub42sub', 'interaction', 'of', 'a', 'ipiaminocalix4arene', 'derivative', 'bearing', 'a', 'gpgklvff', 'peptide', 'pendant', 'at', 'the', 'lower', 'rim', 'we', 'demonstrate', 'that', 'the', 'ipiaminocalix4arenegpgklvff', 'conjugate', 'alters', 'the', 'aβsub42sub', 'aggregation', 'pathways', 'by', 'preventing', 'aβsub42subs', 'conformational', 'transition', 'from', 'random', 'coil', 'to', 'βsheet', 'with', 'concomitant', 'changes', 'of', 'the', 'aggregation', 'kinetic', 'profile', 'as', 'evidenced', 'by', 'circular', 'dichroism', 'cd', 'thioflavin', 't', 'tht', 'and', 'dynamic', 'light', 'scattering', 'dls', 'measurements', 'respectively', 'high', 'resolution', 'mass', 'spectrometry', 'hrms', 'confirmed', 'a', 'direct', 'interaction', 'of', 'the', 'ipiaminocalix4arenegpgklvff', 'conjugate', 'with', 'aβsub42sub', 'monomer', 'which', 'provided', 'insight', 'into', 'a', 'possible', 'working', 'mechanism', 'whereas', 'the', 'alteration', 'of', 'the', 'aβsub42subs', 'fibrillary', 'architecture', 'by', 'the', 'calixpeptide', 'conjugate', 'was', 'further', 'validated', 'by', 'atomic', 'force', 'microscopy', 'afm', 'imaging', 'finally', 'the', 'herein', 'proposed', 'compound', 'was', 'shown', 'to', 'be', 'effective', 'against', 'aβsub42sub', 'oligomers', 'toxicity', 'in', 'differentiated', 'neuroblastoma', 'cells', 'shsy5y']","['alzheimers', 'disease', 'ad', 'progressive', 'neurodegenerative', 'condition', 'affecting', 'people', 'elderly', 'targeting', 'aggregation', 'βamyloid', 'peptides', 'aβ', 'considered', 'promising', 'approach', 'therapeutic', 'treatment', 'disease', 'peptide', 'based', 'inhibitors', 'βamyloid', 'fibrillation', 'emerging', 'safe', 'drug', 'candidates', 'well', 'interesting', 'compounds', 'early', 'diagnosis', 'ad', 'peptide', 'conjugation', 'via', 'covalent', 'bond', 'functional', 'moieties', 'enables', 'resultant', 'hybrid', 'system', 'acquire', 'desired', 'functions', 'report', 'synthesis', 'structural', 'characterization', 'aβsub42sub', 'interaction', 'ipiaminocalix4arene', 'derivative', 'bearing', 'gpgklvff', 'peptide', 'pendant', 'lower', 'rim', 'demonstrate', 'ipiaminocalix4arenegpgklvff', 'conjugate', 'alters', 'aβsub42sub', 'aggregation', 'pathways', 'preventing', 'aβsub42subs', 'conformational', 'transition', 'random', 'coil', 'βsheet', 'concomitant', 'changes', 'aggregation', 'kinetic', 'profile', 'evidenced', 'circular', 'dichroism', 'cd', 'thioflavin', 'tht', 'dynamic', 'light', 'scattering', 'dls', 'measurements', 'respectively', 'high', 'resolution', 'mass', 'spectrometry', 'hrms', 'confirmed', 'direct', 'interaction', 'ipiaminocalix4arenegpgklvff', 'conjugate', 'aβsub42sub', 'monomer', 'provided', 'insight', 'possible', 'working', 'mechanism', 'whereas', 'alteration', 'aβsub42subs', 'fibrillary', 'architecture', 'calixpeptide', 'conjugate', 'validated', 'atomic', 'force', 'microscopy', 'afm', 'imaging', 'finally', 'herein', 'proposed', 'compound', 'shown', 'effective', 'aβsub42sub', 'oligomers', 'toxicity', 'differentiated', 'neuroblastoma', 'cells', 'shsy5y']","['thioflavin', 'fibrillary']",['fibrillary'],True,['alzheimer']
33805945,A 2-Benzylmalonate Derivative as STAT3 Inhibitor Suppresses Tumor Growth in Hepatocellular Carcinoma by Upregulating β-TrCP E3 Ubiquitin Ligase.,"The aberrant activation of a signal transducer and activator of transcription 3 (STAT3) restrains type I interferon (IFN) α/β-induced antiviral responses and is associated with the development of cancer. Designing specific STAT3 inhibitors will thus provide new options for use as IFN therapy. Herein, we identified a novel small molecule, dimethyl 2-(4-(2-(methyl(phenyl(p-tolyl)methyl)amino)ethoxy)benzyl)malonate (CIB-6), which can inhibit the IFN-α-induced interferon stimulated response element (ISRE) luciferase reporter (IC<sub>50</sub> value = 6.4 μM) and potentiate the antiproliferative effect of IFN-α in human hepatocellular carcinoma (HCC) cells. CIB-6 was found to bind to the STAT3 Src homology 2 (SH2) domain, thereby selectively inhibiting STAT3 phosphorylation without affecting Janus kinases and STAT1/2. CIB-6 also inhibited the migration and invasion of HCC cells by inhibiting the epithelial-mesenchymal transition (EMT) process. Mechanistically, CIB-6 reduced the expression of β-catenin (an EMT key protein) via upregulating β-transducin repeat-containing protein (β-TrCP) and curbed nuclear factor kappa-B (NF-κB) activation through restricting the phosphorylation of the inhibitor of NF-κB (IκB) kinase (IKK) via STAT3 inhibition. Treatment with CIB-6 significantly retarded tumor growth in nude mice with SK-HEP-1 xenografts. In addition, clinical sample analysis revealed that lower β-TrCP and higher β-catenin expression could affect the median survival time of HCC patients. Our findings suggest that CIB-6 could be a new therapeutic strategy for HCC therapy through STAT3-mediated β-TrCP/β-catenin/NF-κB axis.",2021-03-25,the aberrant activation of a signal transducer and activator of transcription 3 stat3 restrains type i interferon ifn αβinduced antiviral responses and is associated with the development of cancer designing specific stat3 inhibitors will thus provide new options for use as ifn therapy herein we identified a novel small molecule dimethyl 242methylphenylptolylmethylaminoethoxybenzylmalonate cib6 which can inhibit the ifnαinduced interferon stimulated response element isre luciferase reporter icsub50sub value  64 μm and potentiate the antiproliferative effect of ifnα in human hepatocellular carcinoma hcc cells cib6 was found to bind to the stat3 src homology 2 sh2 domain thereby selectively inhibiting stat3 phosphorylation without affecting janus kinases and stat12 cib6 also inhibited the migration and invasion of hcc cells by inhibiting the epithelialmesenchymal transition emt process mechanistically cib6 reduced the expression of βcatenin an emt key protein via upregulating βtransducin repeatcontaining protein βtrcp and curbed nuclear factor kappab nfκb activation through restricting the phosphorylation of the inhibitor of nfκb iκb kinase ikk via stat3 inhibition treatment with cib6 significantly retarded tumor growth in nude mice with skhep1 xenografts in addition clinical sample analysis revealed that lower βtrcp and higher βcatenin expression could affect the median survival time of hcc patients our findings suggest that cib6 could be a new therapeutic strategy for hcc therapy through stat3mediated βtrcpβcateninnfκb axis,"['the', 'aberrant', 'activation', 'of', 'a', 'signal', 'transducer', 'and', 'activator', 'of', 'transcription', '3', 'stat3', 'restrains', 'type', 'i', 'interferon', 'ifn', 'αβinduced', 'antiviral', 'responses', 'and', 'is', 'associated', 'with', 'the', 'development', 'of', 'cancer', 'designing', 'specific', 'stat3', 'inhibitors', 'will', 'thus', 'provide', 'new', 'options', 'for', 'use', 'as', 'ifn', 'therapy', 'herein', 'we', 'identified', 'a', 'novel', 'small', 'molecule', 'dimethyl', '242methylphenylptolylmethylaminoethoxybenzylmalonate', 'cib6', 'which', 'can', 'inhibit', 'the', 'ifnαinduced', 'interferon', 'stimulated', 'response', 'element', 'isre', 'luciferase', 'reporter', 'icsub50sub', 'value', '64', 'μm', 'and', 'potentiate', 'the', 'antiproliferative', 'effect', 'of', 'ifnα', 'in', 'human', 'hepatocellular', 'carcinoma', 'hcc', 'cells', 'cib6', 'was', 'found', 'to', 'bind', 'to', 'the', 'stat3', 'src', 'homology', '2', 'sh2', 'domain', 'thereby', 'selectively', 'inhibiting', 'stat3', 'phosphorylation', 'without', 'affecting', 'janus', 'kinases', 'and', 'stat12', 'cib6', 'also', 'inhibited', 'the', 'migration', 'and', 'invasion', 'of', 'hcc', 'cells', 'by', 'inhibiting', 'the', 'epithelialmesenchymal', 'transition', 'emt', 'process', 'mechanistically', 'cib6', 'reduced', 'the', 'expression', 'of', 'βcatenin', 'an', 'emt', 'key', 'protein', 'via', 'upregulating', 'βtransducin', 'repeatcontaining', 'protein', 'βtrcp', 'and', 'curbed', 'nuclear', 'factor', 'kappab', 'nfκb', 'activation', 'through', 'restricting', 'the', 'phosphorylation', 'of', 'the', 'inhibitor', 'of', 'nfκb', 'iκb', 'kinase', 'ikk', 'via', 'stat3', 'inhibition', 'treatment', 'with', 'cib6', 'significantly', 'retarded', 'tumor', 'growth', 'in', 'nude', 'mice', 'with', 'skhep1', 'xenografts', 'in', 'addition', 'clinical', 'sample', 'analysis', 'revealed', 'that', 'lower', 'βtrcp', 'and', 'higher', 'βcatenin', 'expression', 'could', 'affect', 'the', 'median', 'survival', 'time', 'of', 'hcc', 'patients', 'our', 'findings', 'suggest', 'that', 'cib6', 'could', 'be', 'a', 'new', 'therapeutic', 'strategy', 'for', 'hcc', 'therapy', 'through', 'stat3mediated', 'βtrcpβcateninnfκb', 'axis']","['aberrant', 'activation', 'signal', 'transducer', 'activator', 'transcription', '3', 'stat3', 'restrains', 'type', 'interferon', 'ifn', 'αβinduced', 'antiviral', 'responses', 'associated', 'development', 'cancer', 'designing', 'specific', 'stat3', 'inhibitors', 'thus', 'provide', 'new', 'options', 'use', 'ifn', 'therapy', 'herein', 'identified', 'novel', 'small', 'molecule', 'dimethyl', '242methylphenylptolylmethylaminoethoxybenzylmalonate', 'cib6', 'inhibit', 'ifnαinduced', 'interferon', 'stimulated', 'response', 'element', 'isre', 'luciferase', 'reporter', 'icsub50sub', 'value', '64', 'μm', 'potentiate', 'antiproliferative', 'effect', 'ifnα', 'human', 'hepatocellular', 'carcinoma', 'hcc', 'cells', 'cib6', 'found', 'bind', 'stat3', 'src', 'homology', '2', 'sh2', 'domain', 'thereby', 'selectively', 'inhibiting', 'stat3', 'phosphorylation', 'without', 'affecting', 'janus', 'kinases', 'stat12', 'cib6', 'also', 'inhibited', 'migration', 'invasion', 'hcc', 'cells', 'inhibiting', 'epithelialmesenchymal', 'transition', 'emt', 'process', 'mechanistically', 'cib6', 'reduced', 'expression', 'βcatenin', 'emt', 'key', 'protein', 'via', 'upregulating', 'βtransducin', 'repeatcontaining', 'protein', 'βtrcp', 'curbed', 'nuclear', 'factor', 'kappab', 'nfκb', 'activation', 'restricting', 'phosphorylation', 'inhibitor', 'nfκb', 'iκb', 'kinase', 'ikk', 'via', 'stat3', 'inhibition', 'treatment', 'cib6', 'significantly', 'retarded', 'tumor', 'growth', 'nude', 'mice', 'skhep1', 'xenografts', 'addition', 'clinical', 'sample', 'analysis', 'revealed', 'lower', 'βtrcp', 'higher', 'βcatenin', 'expression', 'could', 'affect', 'median', 'survival', 'time', 'hcc', 'patients', 'findings', 'suggest', 'cib6', 'could', 'new', 'therapeutic', 'strategy', 'hcc', 'therapy', 'stat3mediated', 'βtrcpβcateninnfκb', 'axis']","['stat3', 'stat3', 'luciferase', 'stat3', 'src', 'stat3', 'kappab', 'stat3']",['luciferase'],True,"['tumor', 'cancer']"
33805784,Moscatilin Inhibits Metastatic Behavior of Human Hepatocellular Carcinoma Cells: A Crucial Role of uPA Suppression via Akt/NF-κB-Dependent Pathway.,"Hepatocellular carcinoma (HCC) frequently shows early invasion into blood vessels as well as intrahepatic metastasis. Innovations of novel small-molecule agents to block HCC invasion and subsequent metastasis are urgently needed. Moscatilin is a bibenzyl derivative extracted from the stems of a traditional Chinese medicine, orchid <i>Dendrobium loddigesii</i>. Although moscatilin has been reported to suppress tumor angiogenesis and growth, the anti-metastatic property of moscatilin has not been elucidated. The present results revealed that moscatilin inhibited metastatic behavior of HCC cells without cytotoxic fashion in highly invasive human HCC cell lines. Furthermore, moscatilin significantly suppressed the activity of urokinase plasminogen activator (uPA), but not matrix metalloproteinase (MMP)-2 and MMP-9. Interestingly, moscatilin-suppressed uPA activity was through down-regulation the protein level of uPA, and did not impair the uPA receptor and uPA inhibitory molecule (PAI-1) expressions. Meanwhile, the mRNA expression of uPA was inhibited via moscatilin in a concentration-dependent manner. In addition, the expression of phosphorylated Akt, rather than ERK1/2, was inhibited by moscatilin treatment. The expression of phosphor-IκBα, and -p65, as well as κB-luciferase activity were also repressed after moscatilin treatment. Transfection of constitutively active Akt (Myr-Akt) obviously restored the moscatilin-inhibited the activation of NF-κB and uPA, and cancer invasion in HCC cells. Taken together, these results suggest that moscatilin impedes HCC invasion and uPA expression through the Akt/NF-κB signaling pathway. Moscatilin might serve as a potential anti-metastatic agent against the disease progression of human HCC.",2021-03-13,hepatocellular carcinoma hcc frequently shows early invasion into blood vessels as well as intrahepatic metastasis innovations of novel smallmolecule agents to block hcc invasion and subsequent metastasis are urgently needed moscatilin is a bibenzyl derivative extracted from the stems of a traditional chinese medicine orchid idendrobium loddigesiii although moscatilin has been reported to suppress tumor angiogenesis and growth the antimetastatic property of moscatilin has not been elucidated the present results revealed that moscatilin inhibited metastatic behavior of hcc cells without cytotoxic fashion in highly invasive human hcc cell lines furthermore moscatilin significantly suppressed the activity of urokinase plasminogen activator upa but not matrix metalloproteinase mmp2 and mmp9 interestingly moscatilinsuppressed upa activity was through downregulation the protein level of upa and did not impair the upa receptor and upa inhibitory molecule pai1 expressions meanwhile the mrna expression of upa was inhibited via moscatilin in a concentrationdependent manner in addition the expression of phosphorylated akt rather than erk12 was inhibited by moscatilin treatment the expression of phosphoriκbα and p65 as well as κbluciferase activity were also repressed after moscatilin treatment transfection of constitutively active akt myrakt obviously restored the moscatilininhibited the activation of nfκb and upa and cancer invasion in hcc cells taken together these results suggest that moscatilin impedes hcc invasion and upa expression through the aktnfκb signaling pathway moscatilin might serve as a potential antimetastatic agent against the disease progression of human hcc,"['hepatocellular', 'carcinoma', 'hcc', 'frequently', 'shows', 'early', 'invasion', 'into', 'blood', 'vessels', 'as', 'well', 'as', 'intrahepatic', 'metastasis', 'innovations', 'of', 'novel', 'smallmolecule', 'agents', 'to', 'block', 'hcc', 'invasion', 'and', 'subsequent', 'metastasis', 'are', 'urgently', 'needed', 'moscatilin', 'is', 'a', 'bibenzyl', 'derivative', 'extracted', 'from', 'the', 'stems', 'of', 'a', 'traditional', 'chinese', 'medicine', 'orchid', 'idendrobium', 'loddigesiii', 'although', 'moscatilin', 'has', 'been', 'reported', 'to', 'suppress', 'tumor', 'angiogenesis', 'and', 'growth', 'the', 'antimetastatic', 'property', 'of', 'moscatilin', 'has', 'not', 'been', 'elucidated', 'the', 'present', 'results', 'revealed', 'that', 'moscatilin', 'inhibited', 'metastatic', 'behavior', 'of', 'hcc', 'cells', 'without', 'cytotoxic', 'fashion', 'in', 'highly', 'invasive', 'human', 'hcc', 'cell', 'lines', 'furthermore', 'moscatilin', 'significantly', 'suppressed', 'the', 'activity', 'of', 'urokinase', 'plasminogen', 'activator', 'upa', 'but', 'not', 'matrix', 'metalloproteinase', 'mmp2', 'and', 'mmp9', 'interestingly', 'moscatilinsuppressed', 'upa', 'activity', 'was', 'through', 'downregulation', 'the', 'protein', 'level', 'of', 'upa', 'and', 'did', 'not', 'impair', 'the', 'upa', 'receptor', 'and', 'upa', 'inhibitory', 'molecule', 'pai1', 'expressions', 'meanwhile', 'the', 'mrna', 'expression', 'of', 'upa', 'was', 'inhibited', 'via', 'moscatilin', 'in', 'a', 'concentrationdependent', 'manner', 'in', 'addition', 'the', 'expression', 'of', 'phosphorylated', 'akt', 'rather', 'than', 'erk12', 'was', 'inhibited', 'by', 'moscatilin', 'treatment', 'the', 'expression', 'of', 'phosphoriκbα', 'and', 'p65', 'as', 'well', 'as', 'κbluciferase', 'activity', 'were', 'also', 'repressed', 'after', 'moscatilin', 'treatment', 'transfection', 'of', 'constitutively', 'active', 'akt', 'myrakt', 'obviously', 'restored', 'the', 'moscatilininhibited', 'the', 'activation', 'of', 'nfκb', 'and', 'upa', 'and', 'cancer', 'invasion', 'in', 'hcc', 'cells', 'taken', 'together', 'these', 'results', 'suggest', 'that', 'moscatilin', 'impedes', 'hcc', 'invasion', 'and', 'upa', 'expression', 'through', 'the', 'aktnfκb', 'signaling', 'pathway', 'moscatilin', 'might', 'serve', 'as', 'a', 'potential', 'antimetastatic', 'agent', 'against', 'the', 'disease', 'progression', 'of', 'human', 'hcc']","['hepatocellular', 'carcinoma', 'hcc', 'frequently', 'shows', 'early', 'invasion', 'blood', 'vessels', 'well', 'intrahepatic', 'metastasis', 'innovations', 'novel', 'smallmolecule', 'agents', 'block', 'hcc', 'invasion', 'subsequent', 'metastasis', 'urgently', 'needed', 'moscatilin', 'bibenzyl', 'derivative', 'extracted', 'stems', 'traditional', 'chinese', 'medicine', 'orchid', 'idendrobium', 'loddigesiii', 'although', 'moscatilin', 'reported', 'suppress', 'tumor', 'angiogenesis', 'growth', 'antimetastatic', 'property', 'moscatilin', 'elucidated', 'present', 'results', 'revealed', 'moscatilin', 'inhibited', 'metastatic', 'behavior', 'hcc', 'cells', 'without', 'cytotoxic', 'fashion', 'highly', 'invasive', 'human', 'hcc', 'cell', 'lines', 'furthermore', 'moscatilin', 'significantly', 'suppressed', 'activity', 'urokinase', 'plasminogen', 'activator', 'upa', 'matrix', 'metalloproteinase', 'mmp2', 'mmp9', 'interestingly', 'moscatilinsuppressed', 'upa', 'activity', 'downregulation', 'protein', 'level', 'upa', 'impair', 'upa', 'receptor', 'upa', 'inhibitory', 'molecule', 'pai1', 'expressions', 'meanwhile', 'mrna', 'expression', 'upa', 'inhibited', 'via', 'moscatilin', 'concentrationdependent', 'manner', 'addition', 'expression', 'phosphorylated', 'akt', 'rather', 'erk12', 'inhibited', 'moscatilin', 'treatment', 'expression', 'phosphoriκbα', 'p65', 'well', 'κbluciferase', 'activity', 'also', 'repressed', 'moscatilin', 'treatment', 'transfection', 'constitutively', 'active', 'akt', 'myrakt', 'obviously', 'restored', 'moscatilininhibited', 'activation', 'nfκb', 'upa', 'cancer', 'invasion', 'hcc', 'cells', 'taken', 'together', 'results', 'suggest', 'moscatilin', 'impedes', 'hcc', 'invasion', 'upa', 'expression', 'aktnfκb', 'signaling', 'pathway', 'moscatilin', 'might', 'serve', 'potential', 'antimetastatic', 'agent', 'disease', 'progression', 'human', 'hcc']","['urokinase', 'plasminogen', 'upa', 'mmp2', 'mmp9', 'upa', 'upa', 'upa', 'upa', 'upa', 'akt', 'p65', 'akt', 'upa', 'upa']","['mmp2', 'mmp9']",True,"['tumor', 'cancer']"
33788544,Novel Peptide-Based Magnetic Nanoparticle for Mesenchymal Circulating Tumor Cells Detection.,"The monitoring of circulating tumor cells (CTCs) has recently served as a promising approach for assessing prognosis and evaluating cancer treatment. We have already developed a CTCs enrichment platform by EpCAM recognition peptide-functionalized magnetic nanoparticles (EP@MNPs). However, considering heterogeneous CTCs generated through epithelial-mesenchymal transition (EMT), mesenchymal CTCs would be missed with this method. Notably, N-cadherin, overexpressed on mesenchymal CTCs, can facilitate the migration of cancer cells. Hence, we screened a novel peptide targeting N-cadherin, NP, and developed a new CTCs isolation approach via NP@MNPs to complement EpCAM methods' deficiencies. NP@MNPs had a high capture efficiency (about 85%) of mesenchymal CTCs from spiked human blood. Subsequently, CTCs were captured and sequenced at the single-cell level via NP@MNPs and EP@MNPs, RNA profiles of which showed that epithelial and mesenchymal subgroups could be distinguished. Here, a novel CTCs isolation platform laid the foundation for mesenchymal CTCs isolation and subsequent molecular analysis.",2021-03-31,the monitoring of circulating tumor cells ctcs has recently served as a promising approach for assessing prognosis and evaluating cancer treatment we have already developed a ctcs enrichment platform by epcam recognition peptidefunctionalized magnetic nanoparticles epmnps however considering heterogeneous ctcs generated through epithelialmesenchymal transition emt mesenchymal ctcs would be missed with this method notably ncadherin overexpressed on mesenchymal ctcs can facilitate the migration of cancer cells hence we screened a novel peptide targeting ncadherin np and developed a new ctcs isolation approach via npmnps to complement epcam methods deficiencies npmnps had a high capture efficiency about 85 of mesenchymal ctcs from spiked human blood subsequently ctcs were captured and sequenced at the singlecell level via npmnps and epmnps rna profiles of which showed that epithelial and mesenchymal subgroups could be distinguished here a novel ctcs isolation platform laid the foundation for mesenchymal ctcs isolation and subsequent molecular analysis,"['the', 'monitoring', 'of', 'circulating', 'tumor', 'cells', 'ctcs', 'has', 'recently', 'served', 'as', 'a', 'promising', 'approach', 'for', 'assessing', 'prognosis', 'and', 'evaluating', 'cancer', 'treatment', 'we', 'have', 'already', 'developed', 'a', 'ctcs', 'enrichment', 'platform', 'by', 'epcam', 'recognition', 'peptidefunctionalized', 'magnetic', 'nanoparticles', 'epmnps', 'however', 'considering', 'heterogeneous', 'ctcs', 'generated', 'through', 'epithelialmesenchymal', 'transition', 'emt', 'mesenchymal', 'ctcs', 'would', 'be', 'missed', 'with', 'this', 'method', 'notably', 'ncadherin', 'overexpressed', 'on', 'mesenchymal', 'ctcs', 'can', 'facilitate', 'the', 'migration', 'of', 'cancer', 'cells', 'hence', 'we', 'screened', 'a', 'novel', 'peptide', 'targeting', 'ncadherin', 'np', 'and', 'developed', 'a', 'new', 'ctcs', 'isolation', 'approach', 'via', 'npmnps', 'to', 'complement', 'epcam', 'methods', 'deficiencies', 'npmnps', 'had', 'a', 'high', 'capture', 'efficiency', 'about', '85', 'of', 'mesenchymal', 'ctcs', 'from', 'spiked', 'human', 'blood', 'subsequently', 'ctcs', 'were', 'captured', 'and', 'sequenced', 'at', 'the', 'singlecell', 'level', 'via', 'npmnps', 'and', 'epmnps', 'rna', 'profiles', 'of', 'which', 'showed', 'that', 'epithelial', 'and', 'mesenchymal', 'subgroups', 'could', 'be', 'distinguished', 'here', 'a', 'novel', 'ctcs', 'isolation', 'platform', 'laid', 'the', 'foundation', 'for', 'mesenchymal', 'ctcs', 'isolation', 'and', 'subsequent', 'molecular', 'analysis']","['monitoring', 'circulating', 'tumor', 'cells', 'ctcs', 'recently', 'served', 'promising', 'approach', 'assessing', 'prognosis', 'evaluating', 'cancer', 'treatment', 'already', 'developed', 'ctcs', 'enrichment', 'platform', 'epcam', 'recognition', 'peptidefunctionalized', 'magnetic', 'nanoparticles', 'epmnps', 'however', 'considering', 'heterogeneous', 'ctcs', 'generated', 'epithelialmesenchymal', 'transition', 'emt', 'mesenchymal', 'ctcs', 'would', 'missed', 'method', 'notably', 'ncadherin', 'overexpressed', 'mesenchymal', 'ctcs', 'facilitate', 'migration', 'cancer', 'cells', 'hence', 'screened', 'novel', 'peptide', 'targeting', 'ncadherin', 'np', 'developed', 'new', 'ctcs', 'isolation', 'approach', 'via', 'npmnps', 'complement', 'epcam', 'methods', 'deficiencies', 'npmnps', 'high', 'capture', 'efficiency', '85', 'mesenchymal', 'ctcs', 'spiked', 'human', 'blood', 'subsequently', 'ctcs', 'captured', 'sequenced', 'singlecell', 'level', 'via', 'npmnps', 'epmnps', 'rna', 'profiles', 'showed', 'epithelial', 'mesenchymal', 'subgroups', 'could', 'distinguished', 'novel', 'ctcs', 'isolation', 'platform', 'laid', 'foundation', 'mesenchymal', 'ctcs', 'isolation', 'subsequent', 'molecular', 'analysis']","['epcam', 'epcam']","['epcam', 'epcam']",True,"['tumor', 'cancer']"
33752129,Metabolomic analysis of a selective ABCA1 inducer in obesogenic challenge provides a rationale for therapeutic development.,"Therapeutic agents with novel mechanisms of action are needed to combat the growing epidemic of type 2 diabetes (T2D) and related metabolic syndromes. Liver X receptor (LXR) agonists possess preclinical efficacy yet produce side effects due to excessive lipogenesis. Anticipating that many beneficial and detrimental effects of LXR agonists are mediated by ABCA1 and SREPB1c expression, respectively, we hypothesized that a phenotypic optimization strategy prioritizing selective ABCA1 induction would identify an efficacious lead compound with an improved side effect profile over existing LXRβ agonists.",2021-03-19,therapeutic agents with novel mechanisms of action are needed to combat the growing epidemic of type 2 diabetes t2d and related metabolic syndromes liver x receptor lxr agonists possess preclinical efficacy yet produce side effects due to excessive lipogenesis anticipating that many beneficial and detrimental effects of lxr agonists are mediated by abca1 and srepb1c expression respectively we hypothesized that a phenotypic optimization strategy prioritizing selective abca1 induction would identify an efficacious lead compound with an improved side effect profile over existing lxrβ agonists,"['therapeutic', 'agents', 'with', 'novel', 'mechanisms', 'of', 'action', 'are', 'needed', 'to', 'combat', 'the', 'growing', 'epidemic', 'of', 'type', '2', 'diabetes', 't2d', 'and', 'related', 'metabolic', 'syndromes', 'liver', 'x', 'receptor', 'lxr', 'agonists', 'possess', 'preclinical', 'efficacy', 'yet', 'produce', 'side', 'effects', 'due', 'to', 'excessive', 'lipogenesis', 'anticipating', 'that', 'many', 'beneficial', 'and', 'detrimental', 'effects', 'of', 'lxr', 'agonists', 'are', 'mediated', 'by', 'abca1', 'and', 'srepb1c', 'expression', 'respectively', 'we', 'hypothesized', 'that', 'a', 'phenotypic', 'optimization', 'strategy', 'prioritizing', 'selective', 'abca1', 'induction', 'would', 'identify', 'an', 'efficacious', 'lead', 'compound', 'with', 'an', 'improved', 'side', 'effect', 'profile', 'over', 'existing', 'lxrβ', 'agonists']","['therapeutic', 'agents', 'novel', 'mechanisms', 'action', 'needed', 'combat', 'growing', 'epidemic', 'type', '2', 'diabetes', 't2d', 'related', 'metabolic', 'syndromes', 'liver', 'x', 'receptor', 'lxr', 'agonists', 'possess', 'preclinical', 'efficacy', 'yet', 'produce', 'side', 'effects', 'due', 'excessive', 'lipogenesis', 'anticipating', 'many', 'beneficial', 'detrimental', 'effects', 'lxr', 'agonists', 'mediated', 'abca1', 'srepb1c', 'expression', 'respectively', 'hypothesized', 'phenotypic', 'optimization', 'strategy', 'prioritizing', 'selective', 'abca1', 'induction', 'would', 'identify', 'efficacious', 'lead', 'compound', 'improved', 'side', 'effect', 'profile', 'existing', 'lxrβ', 'agonists']","['lxr', 'lxr', 'abca1', 'abca1']","['abca1', 'abca1']",True,['diabetes']
33747186,Protective effects of peptide FK18 against neuro-excitotoxicity in SH-SY5Y cells.,"Excitotoxic neuronal injury is associated with numerous acute and chronic neurological disorders, such as Alzheimer's disease and glaucoma. Neuroprotection is a direct and effective therapeutic approach, with small-molecule bioactive peptides displaying certain advantages, including high membrane permeability, low immunogenicity and convenient synthesis and modification. FK18 is a novel peptide derived from basic fibroblast growth factor, which is a protein with neuroprotective effects. The present study aims to evaluate the neuroprotective effect of FK18 against excitotoxic injury. For this purpose, cell viability was determined by the MTS assay, cell apoptosis was assessed by flow cytometry and the TUNEL assay; expression of antiapoptotic proteins Bcl-2, proapoptotic protein Bax and caspase-3 as well as the phosphorylation of Akt and Erk was estimated by western blotting. The results of the present study demonstrated that FK18 effectively increased the viability of, and attenuated glutamate-induced apoptosis of SH-SY5Y cells. In addition, FK18 significantly increased Akt phosphorylation and decreased Erk phosphorylation in SH-SY5Y cells. FK18 also increased the Bcl-2/Bax ratio and decreased the level of cleaved-caspase-3 in SY5Y cells, which was reversed by the Akt pathway inhibitor LY294002, but not by the Erk pathway inhibitor U0126. The findings of the present study suggested that FK18 may be a promising therapeutic agent for the inhibition of neuronal cell death in multiple neurological diseases involving excitotoxicity.",2021-03-01,excitotoxic neuronal injury is associated with numerous acute and chronic neurological disorders such as alzheimers disease and glaucoma neuroprotection is a direct and effective therapeutic approach with smallmolecule bioactive peptides displaying certain advantages including high membrane permeability low immunogenicity and convenient synthesis and modification fk18 is a novel peptide derived from basic fibroblast growth factor which is a protein with neuroprotective effects the present study aims to evaluate the neuroprotective effect of fk18 against excitotoxic injury for this purpose cell viability was determined by the mts assay cell apoptosis was assessed by flow cytometry and the tunel assay expression of antiapoptotic proteins bcl2 proapoptotic protein bax and caspase3 as well as the phosphorylation of akt and erk was estimated by western blotting the results of the present study demonstrated that fk18 effectively increased the viability of and attenuated glutamateinduced apoptosis of shsy5y cells in addition fk18 significantly increased akt phosphorylation and decreased erk phosphorylation in shsy5y cells fk18 also increased the bcl2bax ratio and decreased the level of cleavedcaspase3 in sy5y cells which was reversed by the akt pathway inhibitor ly294002 but not by the erk pathway inhibitor u0126 the findings of the present study suggested that fk18 may be a promising therapeutic agent for the inhibition of neuronal cell death in multiple neurological diseases involving excitotoxicity,"['excitotoxic', 'neuronal', 'injury', 'is', 'associated', 'with', 'numerous', 'acute', 'and', 'chronic', 'neurological', 'disorders', 'such', 'as', 'alzheimers', 'disease', 'and', 'glaucoma', 'neuroprotection', 'is', 'a', 'direct', 'and', 'effective', 'therapeutic', 'approach', 'with', 'smallmolecule', 'bioactive', 'peptides', 'displaying', 'certain', 'advantages', 'including', 'high', 'membrane', 'permeability', 'low', 'immunogenicity', 'and', 'convenient', 'synthesis', 'and', 'modification', 'fk18', 'is', 'a', 'novel', 'peptide', 'derived', 'from', 'basic', 'fibroblast', 'growth', 'factor', 'which', 'is', 'a', 'protein', 'with', 'neuroprotective', 'effects', 'the', 'present', 'study', 'aims', 'to', 'evaluate', 'the', 'neuroprotective', 'effect', 'of', 'fk18', 'against', 'excitotoxic', 'injury', 'for', 'this', 'purpose', 'cell', 'viability', 'was', 'determined', 'by', 'the', 'mts', 'assay', 'cell', 'apoptosis', 'was', 'assessed', 'by', 'flow', 'cytometry', 'and', 'the', 'tunel', 'assay', 'expression', 'of', 'antiapoptotic', 'proteins', 'bcl2', 'proapoptotic', 'protein', 'bax', 'and', 'caspase3', 'as', 'well', 'as', 'the', 'phosphorylation', 'of', 'akt', 'and', 'erk', 'was', 'estimated', 'by', 'western', 'blotting', 'the', 'results', 'of', 'the', 'present', 'study', 'demonstrated', 'that', 'fk18', 'effectively', 'increased', 'the', 'viability', 'of', 'and', 'attenuated', 'glutamateinduced', 'apoptosis', 'of', 'shsy5y', 'cells', 'in', 'addition', 'fk18', 'significantly', 'increased', 'akt', 'phosphorylation', 'and', 'decreased', 'erk', 'phosphorylation', 'in', 'shsy5y', 'cells', 'fk18', 'also', 'increased', 'the', 'bcl2bax', 'ratio', 'and', 'decreased', 'the', 'level', 'of', 'cleavedcaspase3', 'in', 'sy5y', 'cells', 'which', 'was', 'reversed', 'by', 'the', 'akt', 'pathway', 'inhibitor', 'ly294002', 'but', 'not', 'by', 'the', 'erk', 'pathway', 'inhibitor', 'u0126', 'the', 'findings', 'of', 'the', 'present', 'study', 'suggested', 'that', 'fk18', 'may', 'be', 'a', 'promising', 'therapeutic', 'agent', 'for', 'the', 'inhibition', 'of', 'neuronal', 'cell', 'death', 'in', 'multiple', 'neurological', 'diseases', 'involving', 'excitotoxicity']","['excitotoxic', 'neuronal', 'injury', 'associated', 'numerous', 'acute', 'chronic', 'neurological', 'disorders', 'alzheimers', 'disease', 'glaucoma', 'neuroprotection', 'direct', 'effective', 'therapeutic', 'approach', 'smallmolecule', 'bioactive', 'peptides', 'displaying', 'certain', 'advantages', 'including', 'high', 'membrane', 'permeability', 'low', 'immunogenicity', 'convenient', 'synthesis', 'modification', 'fk18', 'novel', 'peptide', 'derived', 'basic', 'fibroblast', 'growth', 'factor', 'protein', 'neuroprotective', 'effects', 'present', 'study', 'aims', 'evaluate', 'neuroprotective', 'effect', 'fk18', 'excitotoxic', 'injury', 'purpose', 'cell', 'viability', 'determined', 'mts', 'assay', 'cell', 'apoptosis', 'assessed', 'flow', 'cytometry', 'tunel', 'assay', 'expression', 'antiapoptotic', 'proteins', 'bcl2', 'proapoptotic', 'protein', 'bax', 'caspase3', 'well', 'phosphorylation', 'akt', 'erk', 'estimated', 'western', 'blotting', 'results', 'present', 'study', 'demonstrated', 'fk18', 'effectively', 'increased', 'viability', 'attenuated', 'glutamateinduced', 'apoptosis', 'shsy5y', 'cells', 'addition', 'fk18', 'significantly', 'increased', 'akt', 'phosphorylation', 'decreased', 'erk', 'phosphorylation', 'shsy5y', 'cells', 'fk18', 'also', 'increased', 'bcl2bax', 'ratio', 'decreased', 'level', 'cleavedcaspase3', 'sy5y', 'cells', 'reversed', 'akt', 'pathway', 'inhibitor', 'ly294002', 'erk', 'pathway', 'inhibitor', 'u0126', 'findings', 'present', 'study', 'suggested', 'fk18', 'may', 'promising', 'therapeutic', 'agent', 'inhibition', 'neuronal', 'cell', 'death', 'multiple', 'neurological', 'diseases', 'involving', 'excitotoxicity']","['bcl2', 'bax', 'caspase3', 'akt', 'erk', 'akt', 'erk', 'akt', 'erk']",['caspase3'],True,['alzheimer']
33671256,Identification and Characterization of Mortaparib<sup>Plus</sup>-A Novel Triazole Derivative That Targets Mortalin-p53 Interaction and Inhibits Cancer-Cell Proliferation by Wild-Type p53-Dependent and -Independent Mechanisms.,"p53 has an essential role in suppressing the carcinogenesis process by inducing cell cycle arrest/apoptosis/senescence. Mortalin/GRP75 is a member of the Hsp70 protein family that binds to p53 causing its sequestration in the cell cytoplasm. Hence, p53 cannot translocate to the nucleus to execute its canonical tumour suppression function as a transcription factor. Abrogation of mortalin-p53 interaction and subsequent reactivation of p53's tumour suppression function has been anticipated as a possible approach in developing a novel cancer therapeutic drug candidate. A chemical library was screened in a high-content screening system to identify potential mortalin-p53 interaction disruptors. By four rounds of visual assays for mortalin and p53, we identified a novel synthetic small-molecule triazole derivative (4-[(1E)-2-(2-phenylindol-3-yl)-1-azavinyl]-1,2,4-triazole, henceforth named Mortaparib<sup>Plus</sup>). Its activities were validated using multiple bioinformatics and experimental approaches in colorectal cancer cells possessing either wild-type (HCT116) or mutant (DLD-1) p53. Bioinformatics and computational analyses predicted the ability of Mortaparib<sup>Plus</sup> to competitively prevent the interaction of mortalin with p53 as it interacted with the p53 binding site of mortalin. Immunoprecipitation analyses demonstrated the abrogation of mortalin-p53 complex formation in Mortaparib<sup>Plus</sup>-treated cells that showed growth arrest and apoptosis mediated by activation of p21<sup>WAF1</sup>, or BAX and PUMA signalling, respectively. Furthermore, we demonstrate that Mortaparib<sup>Plus</sup>-induced cytotoxicity to cancer cells is mediated by multiple mechanisms that included the inhibition of PARP1, up-regulation of p73, and also the down-regulation of mortalin and CARF proteins that play critical roles in carcinogenesis. Mortaparib<sup>Plus</sup> is a novel multimodal candidate anticancer drug that warrants further experimental and clinical attention.",2021-02-17,p53 has an essential role in suppressing the carcinogenesis process by inducing cell cycle arrestapoptosissenescence mortalingrp75 is a member of the hsp70 protein family that binds to p53 causing its sequestration in the cell cytoplasm hence p53 cannot translocate to the nucleus to execute its canonical tumour suppression function as a transcription factor abrogation of mortalinp53 interaction and subsequent reactivation of p53s tumour suppression function has been anticipated as a possible approach in developing a novel cancer therapeutic drug candidate a chemical library was screened in a highcontent screening system to identify potential mortalinp53 interaction disruptors by four rounds of visual assays for mortalin and p53 we identified a novel synthetic smallmolecule triazole derivative 41e22phenylindol3yl1azavinyl124triazole henceforth named mortaparibsupplussup its activities were validated using multiple bioinformatics and experimental approaches in colorectal cancer cells possessing either wildtype hct116 or mutant dld1 p53 bioinformatics and computational analyses predicted the ability of mortaparibsupplussup to competitively prevent the interaction of mortalin with p53 as it interacted with the p53 binding site of mortalin immunoprecipitation analyses demonstrated the abrogation of mortalinp53 complex formation in mortaparibsupplussuptreated cells that showed growth arrest and apoptosis mediated by activation of p21supwaf1sup or bax and puma signalling respectively furthermore we demonstrate that mortaparibsupplussupinduced cytotoxicity to cancer cells is mediated by multiple mechanisms that included the inhibition of parp1 upregulation of p73 and also the downregulation of mortalin and carf proteins that play critical roles in carcinogenesis mortaparibsupplussup is a novel multimodal candidate anticancer drug that warrants further experimental and clinical attention,"['p53', 'has', 'an', 'essential', 'role', 'in', 'suppressing', 'the', 'carcinogenesis', 'process', 'by', 'inducing', 'cell', 'cycle', 'arrestapoptosissenescence', 'mortalingrp75', 'is', 'a', 'member', 'of', 'the', 'hsp70', 'protein', 'family', 'that', 'binds', 'to', 'p53', 'causing', 'its', 'sequestration', 'in', 'the', 'cell', 'cytoplasm', 'hence', 'p53', 'can', 'not', 'translocate', 'to', 'the', 'nucleus', 'to', 'execute', 'its', 'canonical', 'tumour', 'suppression', 'function', 'as', 'a', 'transcription', 'factor', 'abrogation', 'of', 'mortalinp53', 'interaction', 'and', 'subsequent', 'reactivation', 'of', 'p53s', 'tumour', 'suppression', 'function', 'has', 'been', 'anticipated', 'as', 'a', 'possible', 'approach', 'in', 'developing', 'a', 'novel', 'cancer', 'therapeutic', 'drug', 'candidate', 'a', 'chemical', 'library', 'was', 'screened', 'in', 'a', 'highcontent', 'screening', 'system', 'to', 'identify', 'potential', 'mortalinp53', 'interaction', 'disruptors', 'by', 'four', 'rounds', 'of', 'visual', 'assays', 'for', 'mortalin', 'and', 'p53', 'we', 'identified', 'a', 'novel', 'synthetic', 'smallmolecule', 'triazole', 'derivative', '41e22phenylindol3yl1azavinyl124triazole', 'henceforth', 'named', 'mortaparibsupplussup', 'its', 'activities', 'were', 'validated', 'using', 'multiple', 'bioinformatics', 'and', 'experimental', 'approaches', 'in', 'colorectal', 'cancer', 'cells', 'possessing', 'either', 'wildtype', 'hct116', 'or', 'mutant', 'dld1', 'p53', 'bioinformatics', 'and', 'computational', 'analyses', 'predicted', 'the', 'ability', 'of', 'mortaparibsupplussup', 'to', 'competitively', 'prevent', 'the', 'interaction', 'of', 'mortalin', 'with', 'p53', 'as', 'it', 'interacted', 'with', 'the', 'p53', 'binding', 'site', 'of', 'mortalin', 'immunoprecipitation', 'analyses', 'demonstrated', 'the', 'abrogation', 'of', 'mortalinp53', 'complex', 'formation', 'in', 'mortaparibsupplussuptreated', 'cells', 'that', 'showed', 'growth', 'arrest', 'and', 'apoptosis', 'mediated', 'by', 'activation', 'of', 'p21supwaf1sup', 'or', 'bax', 'and', 'puma', 'signalling', 'respectively', 'furthermore', 'we', 'demonstrate', 'that', 'mortaparibsupplussupinduced', 'cytotoxicity', 'to', 'cancer', 'cells', 'is', 'mediated', 'by', 'multiple', 'mechanisms', 'that', 'included', 'the', 'inhibition', 'of', 'parp1', 'upregulation', 'of', 'p73', 'and', 'also', 'the', 'downregulation', 'of', 'mortalin', 'and', 'carf', 'proteins', 'that', 'play', 'critical', 'roles', 'in', 'carcinogenesis', 'mortaparibsupplussup', 'is', 'a', 'novel', 'multimodal', 'candidate', 'anticancer', 'drug', 'that', 'warrants', 'further', 'experimental', 'and', 'clinical', 'attention']","['p53', 'essential', 'role', 'suppressing', 'carcinogenesis', 'process', 'inducing', 'cell', 'cycle', 'arrestapoptosissenescence', 'mortalingrp75', 'member', 'hsp70', 'protein', 'family', 'binds', 'p53', 'causing', 'sequestration', 'cell', 'cytoplasm', 'hence', 'p53', 'translocate', 'nucleus', 'execute', 'canonical', 'tumour', 'suppression', 'function', 'transcription', 'factor', 'abrogation', 'mortalinp53', 'interaction', 'subsequent', 'reactivation', 'p53s', 'tumour', 'suppression', 'function', 'anticipated', 'possible', 'approach', 'developing', 'novel', 'cancer', 'therapeutic', 'drug', 'candidate', 'chemical', 'library', 'screened', 'highcontent', 'screening', 'system', 'identify', 'potential', 'mortalinp53', 'interaction', 'disruptors', 'four', 'rounds', 'visual', 'assays', 'mortalin', 'p53', 'identified', 'novel', 'synthetic', 'smallmolecule', 'triazole', 'derivative', '41e22phenylindol3yl1azavinyl124triazole', 'henceforth', 'named', 'mortaparibsupplussup', 'activities', 'validated', 'using', 'multiple', 'bioinformatics', 'experimental', 'approaches', 'colorectal', 'cancer', 'cells', 'possessing', 'either', 'wildtype', 'hct116', 'mutant', 'dld1', 'p53', 'bioinformatics', 'computational', 'analyses', 'predicted', 'ability', 'mortaparibsupplussup', 'competitively', 'prevent', 'interaction', 'mortalin', 'p53', 'interacted', 'p53', 'binding', 'site', 'mortalin', 'immunoprecipitation', 'analyses', 'demonstrated', 'abrogation', 'mortalinp53', 'complex', 'formation', 'mortaparibsupplussuptreated', 'cells', 'showed', 'growth', 'arrest', 'apoptosis', 'mediated', 'activation', 'p21supwaf1sup', 'bax', 'puma', 'signalling', 'respectively', 'furthermore', 'demonstrate', 'mortaparibsupplussupinduced', 'cytotoxicity', 'cancer', 'cells', 'mediated', 'multiple', 'mechanisms', 'included', 'inhibition', 'parp1', 'upregulation', 'p73', 'also', 'downregulation', 'mortalin', 'carf', 'proteins', 'play', 'critical', 'roles', 'carcinogenesis', 'mortaparibsupplussup', 'novel', 'multimodal', 'candidate', 'anticancer', 'drug', 'warrants', 'experimental', 'clinical', 'attention']","['p53', 'hsp70', 'p53', 'p53', 'p53s', 'mortalin', 'p53', 'p53', 'mortalin', 'p53', 'p53', 'mortalin', 'bax', 'puma', 'parp1', 'p73', 'mortalin']","['hsp70', 'mortalin', 'mortalin', 'mortalin', 'mortalin']",True,['cancer']
33645410,Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells.,"The anti-proliferative effects of 5-methylquinolinium (5MQ) of nicotinamide N-methyltransferase (NNMT) have not been previously investigated on a cervical cancer cell line. NNMT is a metabolic enzyme that is correlated with tumour progression and metastasis. 5MQ is a small molecule inhibitor of NNMT. 0.1-500 μM of 5MQ was tested on the HeLa epithelial cervical cancer cell line. Cell viability was assessed with the MTT test. <i>TWIST, ZEB1, SERPIN1, SIRT1, CD16,</i> mRNA and various protein expression levels were analysed with Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) and Western Blotting, respectively. 5MQ significantly inhibited HeLa cell proliferation in a concentration and time-dependent manner. Increased cell shrinkage, loss of cellular adhesions and apoptotic bodies were observed in HeLa cells after 5MQ treatment. Following treatment with 5MQ, <i>ZEB1, SIRT1, CD16</i> mRNA levels were increased while <i>TWIST</i> and <i>SERPIN1</i> mRNA levels were reduced. Expressions of oncogenic proteins phospho-Akt and SIRT1 were decreased. 5MQ can effectively inhibit HeLa cell proliferation without apparently affecting HEK-293 cell proliferation.IMPACT STATEMENT<b>What is already known on this subject?</b> NNMT is a cytosolic enzyme involved in tumour progression, metastasis and treatment resistance. It was overexpressed in many human malignancies. 5-amino-1-methylquinolinium (5MQ) is a novel small molecule inhibitor of NNMT that has shown promising results in the treatment of obesity and in senescent muscle regeneration. 5MQ has not been tested on the HeLa cervical cancer cell line, previously.<b>What do the results of this study add?</b> In this study, 5MQ was tested on the HeLa cervical cancer cell line for the first time and the molecular changes associated with 5MQ treatment were analysed. 5MQ demonstrated significant anti-proliferative activity on HeLa cells, which displayed morphological signs of apoptosis. Treatment of HeLa cells with 5MQ led to an increase in <i>ZEB1, SIRT1</i> mRNA while <i>TWIST</i> mRNA was decreased. Phospho-Akt and Sirtuin1 protein expressions were decreased.<b>What are the implications of these findings for clinical practice and/or further research?</b> 5MQ can effectively inhibit HeLa cell proliferation without apparently affecting HEK-293 cell proliferation. 5MQ treatment was associated with a decrease in the expression of phospho-Akt and Sirtuin1 proteins, both of which have been reported to maintain tumour progression. 5MQ can further be investigated and modified for anti-cancer therapy.",2021-03-01,the antiproliferative effects of 5methylquinolinium 5mq of nicotinamide nmethyltransferase nnmt have not been previously investigated on a cervical cancer cell line nnmt is a metabolic enzyme that is correlated with tumour progression and metastasis 5mq is a small molecule inhibitor of nnmt 01500 μm of 5mq was tested on the hela epithelial cervical cancer cell line cell viability was assessed with the mtt test itwist zeb1 serpin1 sirt1 cd16i mrna and various protein expression levels were analysed with quantitative realtime polymerase chain reaction qrtpcr and western blotting respectively 5mq significantly inhibited hela cell proliferation in a concentration and timedependent manner increased cell shrinkage loss of cellular adhesions and apoptotic bodies were observed in hela cells after 5mq treatment following treatment with 5mq izeb1 sirt1 cd16i mrna levels were increased while itwisti and iserpin1i mrna levels were reduced expressions of oncogenic proteins phosphoakt and sirt1 were decreased 5mq can effectively inhibit hela cell proliferation without apparently affecting hek293 cell proliferationimpact statementbwhat is already known on this subjectb nnmt is a cytosolic enzyme involved in tumour progression metastasis and treatment resistance it was overexpressed in many human malignancies 5amino1methylquinolinium 5mq is a novel small molecule inhibitor of nnmt that has shown promising results in the treatment of obesity and in senescent muscle regeneration 5mq has not been tested on the hela cervical cancer cell line previouslybwhat do the results of this study addb in this study 5mq was tested on the hela cervical cancer cell line for the first time and the molecular changes associated with 5mq treatment were analysed 5mq demonstrated significant antiproliferative activity on hela cells which displayed morphological signs of apoptosis treatment of hela cells with 5mq led to an increase in izeb1 sirt1i mrna while itwisti mrna was decreased phosphoakt and sirtuin1 protein expressions were decreasedbwhat are the implications of these findings for clinical practice andor further researchb 5mq can effectively inhibit hela cell proliferation without apparently affecting hek293 cell proliferation 5mq treatment was associated with a decrease in the expression of phosphoakt and sirtuin1 proteins both of which have been reported to maintain tumour progression 5mq can further be investigated and modified for anticancer therapy,"['the', 'antiproliferative', 'effects', 'of', '5methylquinolinium', '5mq', 'of', 'nicotinamide', 'nmethyltransferase', 'nnmt', 'have', 'not', 'been', 'previously', 'investigated', 'on', 'a', 'cervical', 'cancer', 'cell', 'line', 'nnmt', 'is', 'a', 'metabolic', 'enzyme', 'that', 'is', 'correlated', 'with', 'tumour', 'progression', 'and', 'metastasis', '5mq', 'is', 'a', 'small', 'molecule', 'inhibitor', 'of', 'nnmt', '01500', 'μm', 'of', '5mq', 'was', 'tested', 'on', 'the', 'hela', 'epithelial', 'cervical', 'cancer', 'cell', 'line', 'cell', 'viability', 'was', 'assessed', 'with', 'the', 'mtt', 'test', 'itwist', 'zeb1', 'serpin1', 'sirt1', 'cd16i', 'mrna', 'and', 'various', 'protein', 'expression', 'levels', 'were', 'analysed', 'with', 'quantitative', 'realtime', 'polymerase', 'chain', 'reaction', 'qrtpcr', 'and', 'western', 'blotting', 'respectively', '5mq', 'significantly', 'inhibited', 'hela', 'cell', 'proliferation', 'in', 'a', 'concentration', 'and', 'timedependent', 'manner', 'increased', 'cell', 'shrinkage', 'loss', 'of', 'cellular', 'adhesions', 'and', 'apoptotic', 'bodies', 'were', 'observed', 'in', 'hela', 'cells', 'after', '5mq', 'treatment', 'following', 'treatment', 'with', '5mq', 'izeb1', 'sirt1', 'cd16i', 'mrna', 'levels', 'were', 'increased', 'while', 'itwisti', 'and', 'iserpin1i', 'mrna', 'levels', 'were', 'reduced', 'expressions', 'of', 'oncogenic', 'proteins', 'phosphoakt', 'and', 'sirt1', 'were', 'decreased', '5mq', 'can', 'effectively', 'inhibit', 'hela', 'cell', 'proliferation', 'without', 'apparently', 'affecting', 'hek293', 'cell', 'proliferationimpact', 'statementbwhat', 'is', 'already', 'known', 'on', 'this', 'subjectb', 'nnmt', 'is', 'a', 'cytosolic', 'enzyme', 'involved', 'in', 'tumour', 'progression', 'metastasis', 'and', 'treatment', 'resistance', 'it', 'was', 'overexpressed', 'in', 'many', 'human', 'malignancies', '5amino1methylquinolinium', '5mq', 'is', 'a', 'novel', 'small', 'molecule', 'inhibitor', 'of', 'nnmt', 'that', 'has', 'shown', 'promising', 'results', 'in', 'the', 'treatment', 'of', 'obesity', 'and', 'in', 'senescent', 'muscle', 'regeneration', '5mq', 'has', 'not', 'been', 'tested', 'on', 'the', 'hela', 'cervical', 'cancer', 'cell', 'line', 'previouslybwhat', 'do', 'the', 'results', 'of', 'this', 'study', 'addb', 'in', 'this', 'study', '5mq', 'was', 'tested', 'on', 'the', 'hela', 'cervical', 'cancer', 'cell', 'line', 'for', 'the', 'first', 'time', 'and', 'the', 'molecular', 'changes', 'associated', 'with', '5mq', 'treatment', 'were', 'analysed', '5mq', 'demonstrated', 'significant', 'antiproliferative', 'activity', 'on', 'hela', 'cells', 'which', 'displayed', 'morphological', 'signs', 'of', 'apoptosis', 'treatment', 'of', 'hela', 'cells', 'with', '5mq', 'led', 'to', 'an', 'increase', 'in', 'izeb1', 'sirt1i', 'mrna', 'while', 'itwisti', 'mrna', 'was', 'decreased', 'phosphoakt', 'and', 'sirtuin1', 'protein', 'expressions', 'were', 'decreasedbwhat', 'are', 'the', 'implications', 'of', 'these', 'findings', 'for', 'clinical', 'practice', 'andor', 'further', 'researchb', '5mq', 'can', 'effectively', 'inhibit', 'hela', 'cell', 'proliferation', 'without', 'apparently', 'affecting', 'hek293', 'cell', 'proliferation', '5mq', 'treatment', 'was', 'associated', 'with', 'a', 'decrease', 'in', 'the', 'expression', 'of', 'phosphoakt', 'and', 'sirtuin1', 'proteins', 'both', 'of', 'which', 'have', 'been', 'reported', 'to', 'maintain', 'tumour', 'progression', '5mq', 'can', 'further', 'be', 'investigated', 'and', 'modified', 'for', 'anticancer', 'therapy']","['antiproliferative', 'effects', '5methylquinolinium', '5mq', 'nicotinamide', 'nmethyltransferase', 'nnmt', 'previously', 'investigated', 'cervical', 'cancer', 'cell', 'line', 'nnmt', 'metabolic', 'enzyme', 'correlated', 'tumour', 'progression', 'metastasis', '5mq', 'small', 'molecule', 'inhibitor', 'nnmt', '01500', 'μm', '5mq', 'tested', 'hela', 'epithelial', 'cervical', 'cancer', 'cell', 'line', 'cell', 'viability', 'assessed', 'mtt', 'test', 'itwist', 'zeb1', 'serpin1', 'sirt1', 'cd16i', 'mrna', 'various', 'protein', 'expression', 'levels', 'analysed', 'quantitative', 'realtime', 'polymerase', 'chain', 'reaction', 'qrtpcr', 'western', 'blotting', 'respectively', '5mq', 'significantly', 'inhibited', 'hela', 'cell', 'proliferation', 'concentration', 'timedependent', 'manner', 'increased', 'cell', 'shrinkage', 'loss', 'cellular', 'adhesions', 'apoptotic', 'bodies', 'observed', 'hela', 'cells', '5mq', 'treatment', 'following', 'treatment', '5mq', 'izeb1', 'sirt1', 'cd16i', 'mrna', 'levels', 'increased', 'itwisti', 'iserpin1i', 'mrna', 'levels', 'reduced', 'expressions', 'oncogenic', 'proteins', 'phosphoakt', 'sirt1', 'decreased', '5mq', 'effectively', 'inhibit', 'hela', 'cell', 'proliferation', 'without', 'apparently', 'affecting', 'hek293', 'cell', 'proliferationimpact', 'statementbwhat', 'already', 'known', 'subjectb', 'nnmt', 'cytosolic', 'enzyme', 'involved', 'tumour', 'progression', 'metastasis', 'treatment', 'resistance', 'overexpressed', 'many', 'human', 'malignancies', '5amino1methylquinolinium', '5mq', 'novel', 'small', 'molecule', 'inhibitor', 'nnmt', 'shown', 'promising', 'results', 'treatment', 'obesity', 'senescent', 'muscle', 'regeneration', '5mq', 'tested', 'hela', 'cervical', 'cancer', 'cell', 'line', 'previouslybwhat', 'results', 'study', 'addb', 'study', '5mq', 'tested', 'hela', 'cervical', 'cancer', 'cell', 'line', 'first', 'time', 'molecular', 'changes', 'associated', '5mq', 'treatment', 'analysed', '5mq', 'demonstrated', 'significant', 'antiproliferative', 'activity', 'hela', 'cells', 'displayed', 'morphological', 'signs', 'apoptosis', 'treatment', 'hela', 'cells', '5mq', 'led', 'increase', 'izeb1', 'sirt1i', 'mrna', 'itwisti', 'mrna', 'decreased', 'phosphoakt', 'sirtuin1', 'protein', 'expressions', 'decreasedbwhat', 'implications', 'findings', 'clinical', 'practice', 'andor', 'researchb', '5mq', 'effectively', 'inhibit', 'hela', 'cell', 'proliferation', 'without', 'apparently', 'affecting', 'hek293', 'cell', 'proliferation', '5mq', 'treatment', 'associated', 'decrease', 'expression', 'phosphoakt', 'sirtuin1', 'proteins', 'reported', 'maintain', 'tumour', 'progression', '5mq', 'investigated', 'modified', 'anticancer', 'therapy']","['zeb1', 'serpin1', 'sirt1', 'sirt1', 'sirt1', 'sirtuin1', 'sirtuin1']","['zeb1', 'serpin1', 'sirtuin1', 'sirtuin1']",True,['cancer']
33645383,Emerging drugs for the treatment of gastrointestinal stromal tumors.,"Oncogenic activation of KIT or PDGFRA receptor tyrosine kinases is the crucial event in gastrointestinal stromal tumor (GIST) biology. Seminal works during the past two decades have underscored, first, the continuous relevance of KIT/PDGFRA oncogenic signaling after progression to targeted inhibition; second, the heterogeneity of KIT/PDGFRA acquired mutations, that cannot be efficiently suppressed by any given tyrosine kinase inhibitor (TKI); and third, the presence of specific mutants highly resistant to all approved therapies.",2021-03-10,oncogenic activation of kit or pdgfra receptor tyrosine kinases is the crucial event in gastrointestinal stromal tumor gist biology seminal works during the past two decades have underscored first the continuous relevance of kitpdgfra oncogenic signaling after progression to targeted inhibition second the heterogeneity of kitpdgfra acquired mutations that cannot be efficiently suppressed by any given tyrosine kinase inhibitor tki and third the presence of specific mutants highly resistant to all approved therapies,"['oncogenic', 'activation', 'of', 'kit', 'or', 'pdgfra', 'receptor', 'tyrosine', 'kinases', 'is', 'the', 'crucial', 'event', 'in', 'gastrointestinal', 'stromal', 'tumor', 'gist', 'biology', 'seminal', 'works', 'during', 'the', 'past', 'two', 'decades', 'have', 'underscored', 'first', 'the', 'continuous', 'relevance', 'of', 'kitpdgfra', 'oncogenic', 'signaling', 'after', 'progression', 'to', 'targeted', 'inhibition', 'second', 'the', 'heterogeneity', 'of', 'kitpdgfra', 'acquired', 'mutations', 'that', 'can', 'not', 'be', 'efficiently', 'suppressed', 'by', 'any', 'given', 'tyrosine', 'kinase', 'inhibitor', 'tki', 'and', 'third', 'the', 'presence', 'of', 'specific', 'mutants', 'highly', 'resistant', 'to', 'all', 'approved', 'therapies']","['oncogenic', 'activation', 'kit', 'pdgfra', 'receptor', 'tyrosine', 'kinases', 'crucial', 'event', 'gastrointestinal', 'stromal', 'tumor', 'gist', 'biology', 'seminal', 'works', 'past', 'two', 'decades', 'underscored', 'first', 'continuous', 'relevance', 'kitpdgfra', 'oncogenic', 'signaling', 'progression', 'targeted', 'inhibition', 'second', 'heterogeneity', 'kitpdgfra', 'acquired', 'mutations', 'efficiently', 'suppressed', 'given', 'tyrosine', 'kinase', 'inhibitor', 'tki', 'third', 'presence', 'specific', 'mutants', 'highly', 'resistant', 'approved', 'therapies']",['pdgfra'],['pdgfra'],True,['tumor']
33595876,A novel peptide isolated from garlic shows anticancer effect against leukemic cell lines via interaction with Bcl-2 family proteins.,"Leukemia is a group of cancer caused by the abnormal proliferation and differentiation of hematopoietic stem cells. Efforts geared toward effective therapeutic strategies with minimal side effects are underway. Peptides derived from natural resources have recently gained special attention as alternative chemotherapeutic agents due to their minimal adverse effects. In the present study, the aim was to isolate peptides from garlic (Allium sativum) and investigate their anticancer activity against leukemic cell lines. The protein extract of A. sativum was pepsin-digested to obtain protein hydrolysate followed by sequential purification methods. A novel anticancer peptide, VKLRSLLCS (VS-9), was identified and characterized by mass spectrometric analysis. The peptide was demonstrated to significantly inhibit the cell proliferation of MOLT-4 and K562 leukemic cell lines while exhibiting minimal inhibition against normal PBMC. Particularly, VS-9 could induce apoptosis and upregulate mRNA levels of caspase 3, caspase 8, caspase 9, and Bax while downregulating Bcl-2, Bcl-xL, and Bcl-w. Molecular docking of VS-9 with the anti-apoptotic Bcl-2 protein family suggested that VS-9 could bind the binding groove of the BH3 domain on target proteins. Protein-peptide interaction analysis by affinity chromatography and LC-MS/MS further showed that VS-9 could bind Bcl-2 proteins. Results suggest VS-9 as a potential garlic-derived novel anticancer peptide possessing apoptosis-inducing properties against leukemic cell lines via anti-apoptotic Bcl-2 protein family.",2021-03-01,leukemia is a group of cancer caused by the abnormal proliferation and differentiation of hematopoietic stem cells efforts geared toward effective therapeutic strategies with minimal side effects are underway peptides derived from natural resources have recently gained special attention as alternative chemotherapeutic agents due to their minimal adverse effects in the present study the aim was to isolate peptides from garlic allium sativum and investigate their anticancer activity against leukemic cell lines the protein extract of a sativum was pepsindigested to obtain protein hydrolysate followed by sequential purification methods a novel anticancer peptide vklrsllcs vs9 was identified and characterized by mass spectrometric analysis the peptide was demonstrated to significantly inhibit the cell proliferation of molt4 and k562 leukemic cell lines while exhibiting minimal inhibition against normal pbmc particularly vs9 could induce apoptosis and upregulate mrna levels of caspase 3 caspase 8 caspase 9 and bax while downregulating bcl2 bclxl and bclw molecular docking of vs9 with the antiapoptotic bcl2 protein family suggested that vs9 could bind the binding groove of the bh3 domain on target proteins proteinpeptide interaction analysis by affinity chromatography and lcmsms further showed that vs9 could bind bcl2 proteins results suggest vs9 as a potential garlicderived novel anticancer peptide possessing apoptosisinducing properties against leukemic cell lines via antiapoptotic bcl2 protein family,"['leukemia', 'is', 'a', 'group', 'of', 'cancer', 'caused', 'by', 'the', 'abnormal', 'proliferation', 'and', 'differentiation', 'of', 'hematopoietic', 'stem', 'cells', 'efforts', 'geared', 'toward', 'effective', 'therapeutic', 'strategies', 'with', 'minimal', 'side', 'effects', 'are', 'underway', 'peptides', 'derived', 'from', 'natural', 'resources', 'have', 'recently', 'gained', 'special', 'attention', 'as', 'alternative', 'chemotherapeutic', 'agents', 'due', 'to', 'their', 'minimal', 'adverse', 'effects', 'in', 'the', 'present', 'study', 'the', 'aim', 'was', 'to', 'isolate', 'peptides', 'from', 'garlic', 'allium', 'sativum', 'and', 'investigate', 'their', 'anticancer', 'activity', 'against', 'leukemic', 'cell', 'lines', 'the', 'protein', 'extract', 'of', 'a', 'sativum', 'was', 'pepsindigested', 'to', 'obtain', 'protein', 'hydrolysate', 'followed', 'by', 'sequential', 'purification', 'methods', 'a', 'novel', 'anticancer', 'peptide', 'vklrsllcs', 'vs9', 'was', 'identified', 'and', 'characterized', 'by', 'mass', 'spectrometric', 'analysis', 'the', 'peptide', 'was', 'demonstrated', 'to', 'significantly', 'inhibit', 'the', 'cell', 'proliferation', 'of', 'molt4', 'and', 'k562', 'leukemic', 'cell', 'lines', 'while', 'exhibiting', 'minimal', 'inhibition', 'against', 'normal', 'pbmc', 'particularly', 'vs9', 'could', 'induce', 'apoptosis', 'and', 'upregulate', 'mrna', 'levels', 'of', 'caspase', '3', 'caspase', '8', 'caspase', '9', 'and', 'bax', 'while', 'downregulating', 'bcl2', 'bclxl', 'and', 'bclw', 'molecular', 'docking', 'of', 'vs9', 'with', 'the', 'antiapoptotic', 'bcl2', 'protein', 'family', 'suggested', 'that', 'vs9', 'could', 'bind', 'the', 'binding', 'groove', 'of', 'the', 'bh3', 'domain', 'on', 'target', 'proteins', 'proteinpeptide', 'interaction', 'analysis', 'by', 'affinity', 'chromatography', 'and', 'lcmsms', 'further', 'showed', 'that', 'vs9', 'could', 'bind', 'bcl2', 'proteins', 'results', 'suggest', 'vs9', 'as', 'a', 'potential', 'garlicderived', 'novel', 'anticancer', 'peptide', 'possessing', 'apoptosisinducing', 'properties', 'against', 'leukemic', 'cell', 'lines', 'via', 'antiapoptotic', 'bcl2', 'protein', 'family']","['leukemia', 'group', 'cancer', 'caused', 'abnormal', 'proliferation', 'differentiation', 'hematopoietic', 'stem', 'cells', 'efforts', 'geared', 'toward', 'effective', 'therapeutic', 'strategies', 'minimal', 'side', 'effects', 'underway', 'peptides', 'derived', 'natural', 'resources', 'recently', 'gained', 'special', 'attention', 'alternative', 'chemotherapeutic', 'agents', 'due', 'minimal', 'adverse', 'effects', 'present', 'study', 'aim', 'isolate', 'peptides', 'garlic', 'allium', 'sativum', 'investigate', 'anticancer', 'activity', 'leukemic', 'cell', 'lines', 'protein', 'extract', 'sativum', 'pepsindigested', 'obtain', 'protein', 'hydrolysate', 'followed', 'sequential', 'purification', 'methods', 'novel', 'anticancer', 'peptide', 'vklrsllcs', 'vs9', 'identified', 'characterized', 'mass', 'spectrometric', 'analysis', 'peptide', 'demonstrated', 'significantly', 'inhibit', 'cell', 'proliferation', 'molt4', 'k562', 'leukemic', 'cell', 'lines', 'exhibiting', 'minimal', 'inhibition', 'normal', 'pbmc', 'particularly', 'vs9', 'could', 'induce', 'apoptosis', 'upregulate', 'mrna', 'levels', 'caspase', '3', 'caspase', '8', 'caspase', '9', 'bax', 'downregulating', 'bcl2', 'bclxl', 'bclw', 'molecular', 'docking', 'vs9', 'antiapoptotic', 'bcl2', 'protein', 'family', 'suggested', 'vs9', 'could', 'bind', 'binding', 'groove', 'bh3', 'domain', 'target', 'proteins', 'proteinpeptide', 'interaction', 'analysis', 'affinity', 'chromatography', 'lcmsms', 'showed', 'vs9', 'could', 'bind', 'bcl2', 'proteins', 'results', 'suggest', 'vs9', 'potential', 'garlicderived', 'novel', 'anticancer', 'peptide', 'possessing', 'apoptosisinducing', 'properties', 'leukemic', 'cell', 'lines', 'via', 'antiapoptotic', 'bcl2', 'protein', 'family']","['caspase', 'caspase', 'caspase', 'bax', 'bcl2', 'bclxl', 'bcl2', 'bcl2', 'bcl2']",['bclxl'],True,"['cancer', 'leukemia']"
33586590,A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome.,"Bromodomain and extra-terminal (BET) proteins can drive carcinogenesis and therapy resistance. RO6870810 (RO) is a novel, small-molecule BET inhibitor. We conducted a study in 32 patients with relapsed/refractory acute myeloid leukemia and hypomethylating agent-refractory myelodysplastic syndrome (NCT02308761). Pharmacodynamic assessments showed decreases in CD11b in peripheral blood mononuclear cells at RO concentrations above 120 ng/mL. Treatment emergent adverse events were generally mild and the most frequent were fatigue, injection site reactions, diarrhea, decreased appetite and nausea. There were no treatment-related deaths. Potential drug-related dose limiting toxicities included decreased appetite, congestive cardiac failure, hypertension, fatigue, increased conjugated bilirubin and increased gamma glutamyltransferase. One AML patient achieved complete remission after withdrawal from study. Eleven AML patients experienced SD. For AML, the median OS was 72.0 days. For MDS, two patients experienced SD. Further development of RO as monotherapy was discontinued due to lack of efficacy, but combinations with other agents are under consideration.",2021-02-13,bromodomain and extraterminal bet proteins can drive carcinogenesis and therapy resistance ro6870810 ro is a novel smallmolecule bet inhibitor we conducted a study in 32 patients with relapsedrefractory acute myeloid leukemia and hypomethylating agentrefractory myelodysplastic syndrome nct02308761 pharmacodynamic assessments showed decreases in cd11b in peripheral blood mononuclear cells at ro concentrations above 120 ngml treatment emergent adverse events were generally mild and the most frequent were fatigue injection site reactions diarrhea decreased appetite and nausea there were no treatmentrelated deaths potential drugrelated dose limiting toxicities included decreased appetite congestive cardiac failure hypertension fatigue increased conjugated bilirubin and increased gamma glutamyltransferase one aml patient achieved complete remission after withdrawal from study eleven aml patients experienced sd for aml the median os was 720 days for mds two patients experienced sd further development of ro as monotherapy was discontinued due to lack of efficacy but combinations with other agents are under consideration,"['bromodomain', 'and', 'extraterminal', 'bet', 'proteins', 'can', 'drive', 'carcinogenesis', 'and', 'therapy', 'resistance', 'ro6870810', 'ro', 'is', 'a', 'novel', 'smallmolecule', 'bet', 'inhibitor', 'we', 'conducted', 'a', 'study', 'in', '32', 'patients', 'with', 'relapsedrefractory', 'acute', 'myeloid', 'leukemia', 'and', 'hypomethylating', 'agentrefractory', 'myelodysplastic', 'syndrome', 'nct02308761', 'pharmacodynamic', 'assessments', 'showed', 'decreases', 'in', 'cd11b', 'in', 'peripheral', 'blood', 'mononuclear', 'cells', 'at', 'ro', 'concentrations', 'above', '120', 'ngml', 'treatment', 'emergent', 'adverse', 'events', 'were', 'generally', 'mild', 'and', 'the', 'most', 'frequent', 'were', 'fatigue', 'injection', 'site', 'reactions', 'diarrhea', 'decreased', 'appetite', 'and', 'nausea', 'there', 'were', 'no', 'treatmentrelated', 'deaths', 'potential', 'drugrelated', 'dose', 'limiting', 'toxicities', 'included', 'decreased', 'appetite', 'congestive', 'cardiac', 'failure', 'hypertension', 'fatigue', 'increased', 'conjugated', 'bilirubin', 'and', 'increased', 'gamma', 'glutamyltransferase', 'one', 'aml', 'patient', 'achieved', 'complete', 'remission', 'after', 'withdrawal', 'from', 'study', 'eleven', 'aml', 'patients', 'experienced', 'sd', 'for', 'aml', 'the', 'median', 'os', 'was', '720', 'days', 'for', 'mds', 'two', 'patients', 'experienced', 'sd', 'further', 'development', 'of', 'ro', 'as', 'monotherapy', 'was', 'discontinued', 'due', 'to', 'lack', 'of', 'efficacy', 'but', 'combinations', 'with', 'other', 'agents', 'are', 'under', 'consideration']","['bromodomain', 'extraterminal', 'bet', 'proteins', 'drive', 'carcinogenesis', 'therapy', 'resistance', 'ro6870810', 'ro', 'novel', 'smallmolecule', 'bet', 'inhibitor', 'conducted', 'study', '32', 'patients', 'relapsedrefractory', 'acute', 'myeloid', 'leukemia', 'hypomethylating', 'agentrefractory', 'myelodysplastic', 'syndrome', 'nct02308761', 'pharmacodynamic', 'assessments', 'showed', 'decreases', 'cd11b', 'peripheral', 'blood', 'mononuclear', 'cells', 'ro', 'concentrations', '120', 'ngml', 'treatment', 'emergent', 'adverse', 'events', 'generally', 'mild', 'frequent', 'fatigue', 'injection', 'site', 'reactions', 'diarrhea', 'decreased', 'appetite', 'nausea', 'treatmentrelated', 'deaths', 'potential', 'drugrelated', 'dose', 'limiting', 'toxicities', 'included', 'decreased', 'appetite', 'congestive', 'cardiac', 'failure', 'hypertension', 'fatigue', 'increased', 'conjugated', 'bilirubin', 'increased', 'gamma', 'glutamyltransferase', 'one', 'aml', 'patient', 'achieved', 'complete', 'remission', 'withdrawal', 'study', 'eleven', 'aml', 'patients', 'experienced', 'sd', 'aml', 'median', 'os', '720', 'days', 'mds', 'two', 'patients', 'experienced', 'sd', 'development', 'ro', 'monotherapy', 'discontinued', 'due', 'lack', 'efficacy', 'combinations', 'agents', 'consideration']","['cd11b', 'glutamyltransferase']","['cd11b', 'glutamyltransferase']",True,['leukemia']
33582407,P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9.,"A long-term goal in the cancer-field has been to develop strategies for treating p53-mutated tumors. A novel small-molecule, PG3-Oc, restores p53 pathway-signaling in tumor cells with mutant-p53, independently of p53/p73. PG3-Oc partially upregulates the p53-transcriptome (13.7% of public p53 target-gene dataset; 15.2% of in-house dataset) and p53-proteome (18%, HT29; 16%, HCT116-p53<sup>-/-</sup>). Bioinformatic analysis indicates critical p53-effectors of growth-arrest (p21), apoptosis (PUMA, DR5, Noxa), autophagy (DRAM1), and metastasis-suppression (NDRG1) are induced by PG3-Oc. ERK1/2- and CDK9-kinases are required to upregulate ATF4 by PG3-Oc which restores p53 transcriptomic-targets in cells without functional-p53. PG3-Oc represses MYC (ATF4-independent), and upregulates PUMA (ATF4-dependent) in mediating cell death. With largely nonoverlapping transcriptomes, induced-ATF4 restores p53 transcriptomic targets in drug-treated cells including functionally important mediators such as PUMA and DR5. Our results demonstrate novel p53-independent drug-induced molecular reprogramming involving ERK1/2, CDK9, and ATF4 to restore upregulation of p53 effector genes required for cell death and tumor suppression.",2021-02-11,a longterm goal in the cancerfield has been to develop strategies for treating p53mutated tumors a novel smallmolecule pg3oc restores p53 pathwaysignaling in tumor cells with mutantp53 independently of p53p73 pg3oc partially upregulates the p53transcriptome 137 of public p53 targetgene dataset 152 of inhouse dataset and p53proteome 18 ht29 16 hct116p53supsup bioinformatic analysis indicates critical p53effectors of growtharrest p21 apoptosis puma dr5 noxa autophagy dram1 and metastasissuppression ndrg1 are induced by pg3oc erk12 and cdk9kinases are required to upregulate atf4 by pg3oc which restores p53 transcriptomictargets in cells without functionalp53 pg3oc represses myc atf4independent and upregulates puma atf4dependent in mediating cell death with largely nonoverlapping transcriptomes inducedatf4 restores p53 transcriptomic targets in drugtreated cells including functionally important mediators such as puma and dr5 our results demonstrate novel p53independent druginduced molecular reprogramming involving erk12 cdk9 and atf4 to restore upregulation of p53 effector genes required for cell death and tumor suppression,"['a', 'longterm', 'goal', 'in', 'the', 'cancerfield', 'has', 'been', 'to', 'develop', 'strategies', 'for', 'treating', 'p53mutated', 'tumors', 'a', 'novel', 'smallmolecule', 'pg3oc', 'restores', 'p53', 'pathwaysignaling', 'in', 'tumor', 'cells', 'with', 'mutantp53', 'independently', 'of', 'p53p73', 'pg3oc', 'partially', 'upregulates', 'the', 'p53transcriptome', '137', 'of', 'public', 'p53', 'targetgene', 'dataset', '152', 'of', 'inhouse', 'dataset', 'and', 'p53proteome', '18', 'ht29', '16', 'hct116p53supsup', 'bioinformatic', 'analysis', 'indicates', 'critical', 'p53effectors', 'of', 'growtharrest', 'p21', 'apoptosis', 'puma', 'dr5', 'noxa', 'autophagy', 'dram1', 'and', 'metastasissuppression', 'ndrg1', 'are', 'induced', 'by', 'pg3oc', 'erk12', 'and', 'cdk9kinases', 'are', 'required', 'to', 'upregulate', 'atf4', 'by', 'pg3oc', 'which', 'restores', 'p53', 'transcriptomictargets', 'in', 'cells', 'without', 'functionalp53', 'pg3oc', 'represses', 'myc', 'atf4independent', 'and', 'upregulates', 'puma', 'atf4dependent', 'in', 'mediating', 'cell', 'death', 'with', 'largely', 'nonoverlapping', 'transcriptomes', 'inducedatf4', 'restores', 'p53', 'transcriptomic', 'targets', 'in', 'drugtreated', 'cells', 'including', 'functionally', 'important', 'mediators', 'such', 'as', 'puma', 'and', 'dr5', 'our', 'results', 'demonstrate', 'novel', 'p53independent', 'druginduced', 'molecular', 'reprogramming', 'involving', 'erk12', 'cdk9', 'and', 'atf4', 'to', 'restore', 'upregulation', 'of', 'p53', 'effector', 'genes', 'required', 'for', 'cell', 'death', 'and', 'tumor', 'suppression']","['longterm', 'goal', 'cancerfield', 'develop', 'strategies', 'treating', 'p53mutated', 'tumors', 'novel', 'smallmolecule', 'pg3oc', 'restores', 'p53', 'pathwaysignaling', 'tumor', 'cells', 'mutantp53', 'independently', 'p53p73', 'pg3oc', 'partially', 'upregulates', 'p53transcriptome', '137', 'public', 'p53', 'targetgene', 'dataset', '152', 'inhouse', 'dataset', 'p53proteome', '18', 'ht29', '16', 'hct116p53supsup', 'bioinformatic', 'analysis', 'indicates', 'critical', 'p53effectors', 'growtharrest', 'p21', 'apoptosis', 'puma', 'dr5', 'noxa', 'autophagy', 'dram1', 'metastasissuppression', 'ndrg1', 'induced', 'pg3oc', 'erk12', 'cdk9kinases', 'required', 'upregulate', 'atf4', 'pg3oc', 'restores', 'p53', 'transcriptomictargets', 'cells', 'without', 'functionalp53', 'pg3oc', 'represses', 'myc', 'atf4independent', 'upregulates', 'puma', 'atf4dependent', 'mediating', 'cell', 'death', 'largely', 'nonoverlapping', 'transcriptomes', 'inducedatf4', 'restores', 'p53', 'transcriptomic', 'targets', 'drugtreated', 'cells', 'including', 'functionally', 'important', 'mediators', 'puma', 'dr5', 'results', 'demonstrate', 'novel', 'p53independent', 'druginduced', 'molecular', 'reprogramming', 'involving', 'erk12', 'cdk9', 'atf4', 'restore', 'upregulation', 'p53', 'effector', 'genes', 'required', 'cell', 'death', 'tumor', 'suppression']","['p53', 'p53', 'p21', 'puma', 'dr5', 'noxa', 'ndrg1', 'atf4', 'p53', 'myc', 'puma', 'p53', 'puma', 'dr5', 'cdk9', 'atf4', 'p53']","['ndrg1', 'atf4', 'atf4']",False,"['tumor', 'cancer']"
33510636,"The Anti-Inflammatory Effect of KS23, A Novel Peptide Derived From Globular Adiponectin, on Endotoxin-Induced Uveitis in Rats.","<b>Purpose:</b> Adiponectin has been shown to exert potent anti-inflammatory activities in a range of systemic inflammatory diseases. This study aimed to investigate the potential therapeutic effects of KS23, a globular adiponectin-derived peptide, on endotoxin-induced uveitis (EIU) in rats and lipopolysaccharide (LPS)-stimulated mouse macrophage-like RAW 264.7 cells. <b>Methods:</b> EIU was induced in Lewis rats by subcutaneous injection of LPS into a single footpad. KS23 or phosphate-buffered saline (PBS) was administered immediately after LPS induction via intravitreal injection. Twenty-four hours later, clinical and histopathological scores were evaluated, and the aqueous humor (AqH) was collected to determine the infiltrating cells, protein concentration, and levels of inflammatory cytokines. <i>In vitro</i>, cultured RAW 264.7 cells were stimulated with LPS in the presence or absence of KS23, inflammatory cytokine levels in the supernatant, nuclear translocation of nuclear factor kappa B (NF-κB) subunit p65, and the expression of NF-kB signaling pathway components were analyzed. <b>Results:</b> KS23 treatment significantly ameliorated the clinical and histopathological scores of EIU rats and reduced the levels of infiltration cells, protein, tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in the aqueous humor. Consistently, KS23 decreased the expression of TNF-α and IL-6 in the supernatant of LPS-stimulated RAW 264.7 cells and inhibited the LPS-induced nuclear translocation of NF-κB p65 and the phosphorylation of IKKα/β/IκBα/NF-κB. <b>Conclusion:</b> The <i>in vivo</i> and <i>in vitro</i> results demonstrated the anti-inflammatory effects of the peptide KS23 and suggested that KS23 is a compelling, novel therapeutic candidate for the treatment of ocular inflammation.",2021-01-12,bpurposeb adiponectin has been shown to exert potent antiinflammatory activities in a range of systemic inflammatory diseases this study aimed to investigate the potential therapeutic effects of ks23 a globular adiponectinderived peptide on endotoxininduced uveitis eiu in rats and lipopolysaccharide lpsstimulated mouse macrophagelike raw 2647 cells bmethodsb eiu was induced in lewis rats by subcutaneous injection of lps into a single footpad ks23 or phosphatebuffered saline pbs was administered immediately after lps induction via intravitreal injection twentyfour hours later clinical and histopathological scores were evaluated and the aqueous humor aqh was collected to determine the infiltrating cells protein concentration and levels of inflammatory cytokines iin vitroi cultured raw 2647 cells were stimulated with lps in the presence or absence of ks23 inflammatory cytokine levels in the supernatant nuclear translocation of nuclear factor kappa b nfκb subunit p65 and the expression of nfkb signaling pathway components were analyzed bresultsb ks23 treatment significantly ameliorated the clinical and histopathological scores of eiu rats and reduced the levels of infiltration cells protein tumor necrosis factorα tnfα and interleukin6 il6 in the aqueous humor consistently ks23 decreased the expression of tnfα and il6 in the supernatant of lpsstimulated raw 2647 cells and inhibited the lpsinduced nuclear translocation of nfκb p65 and the phosphorylation of ikkαβiκbαnfκb bconclusionb the iin vivoi and iin vitroi results demonstrated the antiinflammatory effects of the peptide ks23 and suggested that ks23 is a compelling novel therapeutic candidate for the treatment of ocular inflammation,"['bpurposeb', 'adiponectin', 'has', 'been', 'shown', 'to', 'exert', 'potent', 'antiinflammatory', 'activities', 'in', 'a', 'range', 'of', 'systemic', 'inflammatory', 'diseases', 'this', 'study', 'aimed', 'to', 'investigate', 'the', 'potential', 'therapeutic', 'effects', 'of', 'ks23', 'a', 'globular', 'adiponectinderived', 'peptide', 'on', 'endotoxininduced', 'uveitis', 'eiu', 'in', 'rats', 'and', 'lipopolysaccharide', 'lpsstimulated', 'mouse', 'macrophagelike', 'raw', '2647', 'cells', 'bmethodsb', 'eiu', 'was', 'induced', 'in', 'lewis', 'rats', 'by', 'subcutaneous', 'injection', 'of', 'lps', 'into', 'a', 'single', 'footpad', 'ks23', 'or', 'phosphatebuffered', 'saline', 'pbs', 'was', 'administered', 'immediately', 'after', 'lps', 'induction', 'via', 'intravitreal', 'injection', 'twentyfour', 'hours', 'later', 'clinical', 'and', 'histopathological', 'scores', 'were', 'evaluated', 'and', 'the', 'aqueous', 'humor', 'aqh', 'was', 'collected', 'to', 'determine', 'the', 'infiltrating', 'cells', 'protein', 'concentration', 'and', 'levels', 'of', 'inflammatory', 'cytokines', 'iin', 'vitroi', 'cultured', 'raw', '2647', 'cells', 'were', 'stimulated', 'with', 'lps', 'in', 'the', 'presence', 'or', 'absence', 'of', 'ks23', 'inflammatory', 'cytokine', 'levels', 'in', 'the', 'supernatant', 'nuclear', 'translocation', 'of', 'nuclear', 'factor', 'kappa', 'b', 'nfκb', 'subunit', 'p65', 'and', 'the', 'expression', 'of', 'nfkb', 'signaling', 'pathway', 'components', 'were', 'analyzed', 'bresultsb', 'ks23', 'treatment', 'significantly', 'ameliorated', 'the', 'clinical', 'and', 'histopathological', 'scores', 'of', 'eiu', 'rats', 'and', 'reduced', 'the', 'levels', 'of', 'infiltration', 'cells', 'protein', 'tumor', 'necrosis', 'factorα', 'tnfα', 'and', 'interleukin6', 'il6', 'in', 'the', 'aqueous', 'humor', 'consistently', 'ks23', 'decreased', 'the', 'expression', 'of', 'tnfα', 'and', 'il6', 'in', 'the', 'supernatant', 'of', 'lpsstimulated', 'raw', '2647', 'cells', 'and', 'inhibited', 'the', 'lpsinduced', 'nuclear', 'translocation', 'of', 'nfκb', 'p65', 'and', 'the', 'phosphorylation', 'of', 'ikkαβiκbαnfκb', 'bconclusionb', 'the', 'iin', 'vivoi', 'and', 'iin', 'vitroi', 'results', 'demonstrated', 'the', 'antiinflammatory', 'effects', 'of', 'the', 'peptide', 'ks23', 'and', 'suggested', 'that', 'ks23', 'is', 'a', 'compelling', 'novel', 'therapeutic', 'candidate', 'for', 'the', 'treatment', 'of', 'ocular', 'inflammation']","['bpurposeb', 'adiponectin', 'shown', 'exert', 'potent', 'antiinflammatory', 'activities', 'range', 'systemic', 'inflammatory', 'diseases', 'study', 'aimed', 'investigate', 'potential', 'therapeutic', 'effects', 'ks23', 'globular', 'adiponectinderived', 'peptide', 'endotoxininduced', 'uveitis', 'eiu', 'rats', 'lipopolysaccharide', 'lpsstimulated', 'mouse', 'macrophagelike', 'raw', '2647', 'cells', 'bmethodsb', 'eiu', 'induced', 'lewis', 'rats', 'subcutaneous', 'injection', 'lps', 'single', 'footpad', 'ks23', 'phosphatebuffered', 'saline', 'pbs', 'administered', 'immediately', 'lps', 'induction', 'via', 'intravitreal', 'injection', 'twentyfour', 'hours', 'later', 'clinical', 'histopathological', 'scores', 'evaluated', 'aqueous', 'humor', 'aqh', 'collected', 'determine', 'infiltrating', 'cells', 'protein', 'concentration', 'levels', 'inflammatory', 'cytokines', 'iin', 'vitroi', 'cultured', 'raw', '2647', 'cells', 'stimulated', 'lps', 'presence', 'absence', 'ks23', 'inflammatory', 'cytokine', 'levels', 'supernatant', 'nuclear', 'translocation', 'nuclear', 'factor', 'kappa', 'b', 'nfκb', 'subunit', 'p65', 'expression', 'nfkb', 'signaling', 'pathway', 'components', 'analyzed', 'bresultsb', 'ks23', 'treatment', 'significantly', 'ameliorated', 'clinical', 'histopathological', 'scores', 'eiu', 'rats', 'reduced', 'levels', 'infiltration', 'cells', 'protein', 'tumor', 'necrosis', 'factorα', 'tnfα', 'interleukin6', 'il6', 'aqueous', 'humor', 'consistently', 'ks23', 'decreased', 'expression', 'tnfα', 'il6', 'supernatant', 'lpsstimulated', 'raw', '2647', 'cells', 'inhibited', 'lpsinduced', 'nuclear', 'translocation', 'nfκb', 'p65', 'phosphorylation', 'ikkαβiκbαnfκb', 'bconclusionb', 'iin', 'vivoi', 'iin', 'vitroi', 'results', 'demonstrated', 'antiinflammatory', 'effects', 'peptide', 'ks23', 'suggested', 'ks23', 'compelling', 'novel', 'therapeutic', 'candidate', 'treatment', 'ocular', 'inflammation']","['adiponectin', 'p65', 'nfkb', 'interleukin6', 'p65']",['adiponectin'],True,['tumor']
36262318,Solubility Measurements and Correlation of MBQ-167 in Neat and Binary Solvent Mixtures.,"MBQ-167 is a novel, small-molecule dual inhibitor of Rac and Cdc42, small GTPases that are involved in cytoskeletal organization, cell cycle progression, and cell migration. In an <i>in vivo</i> mouse model, MBQ-167 has been shown to significantly reduce mammary tumor growth and metastasis and is currently undergoing preclinical studies for the treatment of metastatic cancer. To date, no solubility data have been reported for this compound. For this reason, the present study aims to determine the solubility of this compound in eight neat solvents (acetonitrile, 1-butanol, 2-butanol, ethanol, ethyl acetate, methanol, 1-propanol, and 2-propanol) and two binary solvent mixtures [ethyl acetate (2) + heptane (3) and ethanol (2) + water (3)] between the temperatures of 278.15 and 333.15 K. The results obtained employing the polythermal method show that the solubility of MBQ-167 increases with an increase in temperature in all neat solvents used within this study. Moreover, in the two binary solvent mixtures, the solubility of this compound increases with increasing temperature and decreases with an increasing mass fraction of the antisolvent (heptane or water). The experimental solubility data were correlated using the modified Apelblat and <i>λ</i>h model equations. The predicted solubility data acquired from the Apelblat and <i>λ</i>h model equations correlate well with the experimental solubility data as indicated by the low ARD % (≤1.8304 and ≤6.5366, respectively). No solvent-mediated polymorphic phase transitions were observed while performing the solubility studies, and no other solid forms were detected after the recrystallization in the solvents and solvent mixtures. The solubility data determined here can offer pathways to develop pharmaceutical crystallization processes that can further the translation of MBQ-167 into a clinical setting.",2020-12-10,mbq167 is a novel smallmolecule dual inhibitor of rac and cdc42 small gtpases that are involved in cytoskeletal organization cell cycle progression and cell migration in an iin vivoi mouse model mbq167 has been shown to significantly reduce mammary tumor growth and metastasis and is currently undergoing preclinical studies for the treatment of metastatic cancer to date no solubility data have been reported for this compound for this reason the present study aims to determine the solubility of this compound in eight neat solvents acetonitrile 1butanol 2butanol ethanol ethyl acetate methanol 1propanol and 2propanol and two binary solvent mixtures ethyl acetate 2  heptane 3 and ethanol 2  water 3 between the temperatures of 27815 and 33315 k the results obtained employing the polythermal method show that the solubility of mbq167 increases with an increase in temperature in all neat solvents used within this study moreover in the two binary solvent mixtures the solubility of this compound increases with increasing temperature and decreases with an increasing mass fraction of the antisolvent heptane or water the experimental solubility data were correlated using the modified apelblat and iλih model equations the predicted solubility data acquired from the apelblat and iλih model equations correlate well with the experimental solubility data as indicated by the low ard  18304 and 65366 respectively no solventmediated polymorphic phase transitions were observed while performing the solubility studies and no other solid forms were detected after the recrystallization in the solvents and solvent mixtures the solubility data determined here can offer pathways to develop pharmaceutical crystallization processes that can further the translation of mbq167 into a clinical setting,"['mbq167', 'is', 'a', 'novel', 'smallmolecule', 'dual', 'inhibitor', 'of', 'rac', 'and', 'cdc42', 'small', 'gtpases', 'that', 'are', 'involved', 'in', 'cytoskeletal', 'organization', 'cell', 'cycle', 'progression', 'and', 'cell', 'migration', 'in', 'an', 'iin', 'vivoi', 'mouse', 'model', 'mbq167', 'has', 'been', 'shown', 'to', 'significantly', 'reduce', 'mammary', 'tumor', 'growth', 'and', 'metastasis', 'and', 'is', 'currently', 'undergoing', 'preclinical', 'studies', 'for', 'the', 'treatment', 'of', 'metastatic', 'cancer', 'to', 'date', 'no', 'solubility', 'data', 'have', 'been', 'reported', 'for', 'this', 'compound', 'for', 'this', 'reason', 'the', 'present', 'study', 'aims', 'to', 'determine', 'the', 'solubility', 'of', 'this', 'compound', 'in', 'eight', 'neat', 'solvents', 'acetonitrile', '1butanol', '2butanol', 'ethanol', 'ethyl', 'acetate', 'methanol', '1propanol', 'and', '2propanol', 'and', 'two', 'binary', 'solvent', 'mixtures', 'ethyl', 'acetate', '2', 'heptane', '3', 'and', 'ethanol', '2', 'water', '3', 'between', 'the', 'temperatures', 'of', '27815', 'and', '33315', 'k', 'the', 'results', 'obtained', 'employing', 'the', 'polythermal', 'method', 'show', 'that', 'the', 'solubility', 'of', 'mbq167', 'increases', 'with', 'an', 'increase', 'in', 'temperature', 'in', 'all', 'neat', 'solvents', 'used', 'within', 'this', 'study', 'moreover', 'in', 'the', 'two', 'binary', 'solvent', 'mixtures', 'the', 'solubility', 'of', 'this', 'compound', 'increases', 'with', 'increasing', 'temperature', 'and', 'decreases', 'with', 'an', 'increasing', 'mass', 'fraction', 'of', 'the', 'antisolvent', 'heptane', 'or', 'water', 'the', 'experimental', 'solubility', 'data', 'were', 'correlated', 'using', 'the', 'modified', 'apelblat', 'and', 'iλih', 'model', 'equations', 'the', 'predicted', 'solubility', 'data', 'acquired', 'from', 'the', 'apelblat', 'and', 'iλih', 'model', 'equations', 'correlate', 'well', 'with', 'the', 'experimental', 'solubility', 'data', 'as', 'indicated', 'by', 'the', 'low', 'ard', '18304', 'and', '65366', 'respectively', 'no', 'solventmediated', 'polymorphic', 'phase', 'transitions', 'were', 'observed', 'while', 'performing', 'the', 'solubility', 'studies', 'and', 'no', 'other', 'solid', 'forms', 'were', 'detected', 'after', 'the', 'recrystallization', 'in', 'the', 'solvents', 'and', 'solvent', 'mixtures', 'the', 'solubility', 'data', 'determined', 'here', 'can', 'offer', 'pathways', 'to', 'develop', 'pharmaceutical', 'crystallization', 'processes', 'that', 'can', 'further', 'the', 'translation', 'of', 'mbq167', 'into', 'a', 'clinical', 'setting']","['mbq167', 'novel', 'smallmolecule', 'dual', 'inhibitor', 'rac', 'cdc42', 'small', 'gtpases', 'involved', 'cytoskeletal', 'organization', 'cell', 'cycle', 'progression', 'cell', 'migration', 'iin', 'vivoi', 'mouse', 'model', 'mbq167', 'shown', 'significantly', 'reduce', 'mammary', 'tumor', 'growth', 'metastasis', 'currently', 'undergoing', 'preclinical', 'studies', 'treatment', 'metastatic', 'cancer', 'date', 'solubility', 'data', 'reported', 'compound', 'reason', 'present', 'study', 'aims', 'determine', 'solubility', 'compound', 'eight', 'neat', 'solvents', 'acetonitrile', '1butanol', '2butanol', 'ethanol', 'ethyl', 'acetate', 'methanol', '1propanol', '2propanol', 'two', 'binary', 'solvent', 'mixtures', 'ethyl', 'acetate', '2', 'heptane', '3', 'ethanol', '2', 'water', '3', 'temperatures', '27815', '33315', 'k', 'results', 'obtained', 'employing', 'polythermal', 'method', 'show', 'solubility', 'mbq167', 'increases', 'increase', 'temperature', 'neat', 'solvents', 'used', 'within', 'study', 'moreover', 'two', 'binary', 'solvent', 'mixtures', 'solubility', 'compound', 'increases', 'increasing', 'temperature', 'decreases', 'increasing', 'mass', 'fraction', 'antisolvent', 'heptane', 'water', 'experimental', 'solubility', 'data', 'correlated', 'using', 'modified', 'apelblat', 'iλih', 'model', 'equations', 'predicted', 'solubility', 'data', 'acquired', 'apelblat', 'iλih', 'model', 'equations', 'correlate', 'well', 'experimental', 'solubility', 'data', 'indicated', 'low', 'ard', '18304', '65366', 'respectively', 'solventmediated', 'polymorphic', 'phase', 'transitions', 'observed', 'performing', 'solubility', 'studies', 'solid', 'forms', 'detected', 'recrystallization', 'solvents', 'solvent', 'mixtures', 'solubility', 'data', 'determined', 'offer', 'pathways', 'develop', 'pharmaceutical', 'crystallization', 'processes', 'translation', 'mbq167', 'clinical', 'setting']","['rac', 'cdc42']",['cdc42'],True,"['tumor', 'cancer']"
33436007,"Novel pharmacotherapy: NNI-362, an allosteric p70S6 kinase stimulator, reverses cognitive and neural regenerative deficits in models of aging and disease.","Aging is known to slow the neurogenic capacity of the hippocampus, one of only two mammalian adult neurogenic niches. The reduction of adult-born neurons with age may initiate cognitive decline progression which is exacerbated in chronic neurodegenerative disorders, e.g., Alzheimer's disease (AD). With physiologic neurogenesis diminished, but still viable in aging, non-invasive therapeutic modulation of this neuron regeneration process remains possible. The discovery of truly novel neuron regenerative therapies could be identified through phenotypic screening of small molecules that promote adult-born neurons from human neural progenitor cells (hNPCs). By identifying neuron-generating therapeutics and potentially novel mechanism of actions, therapeutic benefit could be confirmed through in vivo proof-of-concept studies. The key aging and longevity mTOR/p70S6 kinase axis, a commonly targeted pathway, is substrate for potential selective kinase modulators to promote new hippocampal neurons from NPCs. The highly regulated downstream substrate of mTOR, p70S6 kinase, directly controls pleiotropic cellular activities, including translation and cell growth. Stimulating this kinase, selectively in an adult neurogenic niche, should promote NPC proliferation, and cell growth and survival in the hippocampus. Studies of kinase profiling and immunocytochemistry of human progenitor neurogenesis suggest that the novel small molecule NNI-362 stimulates p70S6 kinase phosphorylation, which, in turn, promotes proliferation and differentiation of NPCs to neurons. NNI-362 promoted the associative reversal of age- and disease-related cognitive deficits in aged mice and Down syndrome-modeled mice. This oral, allosteric modulator may ultimately be beneficial for age-related neurodegenerative disorders involving hippocampal-dependent cognitive impairment, specifically AD, by promoting endogenous hippocampal regeneration.",2021-01-13,aging is known to slow the neurogenic capacity of the hippocampus one of only two mammalian adult neurogenic niches the reduction of adultborn neurons with age may initiate cognitive decline progression which is exacerbated in chronic neurodegenerative disorders eg alzheimers disease ad with physiologic neurogenesis diminished but still viable in aging noninvasive therapeutic modulation of this neuron regeneration process remains possible the discovery of truly novel neuron regenerative therapies could be identified through phenotypic screening of small molecules that promote adultborn neurons from human neural progenitor cells hnpcs by identifying neurongenerating therapeutics and potentially novel mechanism of actions therapeutic benefit could be confirmed through in vivo proofofconcept studies the key aging and longevity mtorp70s6 kinase axis a commonly targeted pathway is substrate for potential selective kinase modulators to promote new hippocampal neurons from npcs the highly regulated downstream substrate of mtor p70s6 kinase directly controls pleiotropic cellular activities including translation and cell growth stimulating this kinase selectively in an adult neurogenic niche should promote npc proliferation and cell growth and survival in the hippocampus studies of kinase profiling and immunocytochemistry of human progenitor neurogenesis suggest that the novel small molecule nni362 stimulates p70s6 kinase phosphorylation which in turn promotes proliferation and differentiation of npcs to neurons nni362 promoted the associative reversal of age and diseaserelated cognitive deficits in aged mice and down syndromemodeled mice this oral allosteric modulator may ultimately be beneficial for agerelated neurodegenerative disorders involving hippocampaldependent cognitive impairment specifically ad by promoting endogenous hippocampal regeneration,"['aging', 'is', 'known', 'to', 'slow', 'the', 'neurogenic', 'capacity', 'of', 'the', 'hippocampus', 'one', 'of', 'only', 'two', 'mammalian', 'adult', 'neurogenic', 'niches', 'the', 'reduction', 'of', 'adultborn', 'neurons', 'with', 'age', 'may', 'initiate', 'cognitive', 'decline', 'progression', 'which', 'is', 'exacerbated', 'in', 'chronic', 'neurodegenerative', 'disorders', 'eg', 'alzheimers', 'disease', 'ad', 'with', 'physiologic', 'neurogenesis', 'diminished', 'but', 'still', 'viable', 'in', 'aging', 'noninvasive', 'therapeutic', 'modulation', 'of', 'this', 'neuron', 'regeneration', 'process', 'remains', 'possible', 'the', 'discovery', 'of', 'truly', 'novel', 'neuron', 'regenerative', 'therapies', 'could', 'be', 'identified', 'through', 'phenotypic', 'screening', 'of', 'small', 'molecules', 'that', 'promote', 'adultborn', 'neurons', 'from', 'human', 'neural', 'progenitor', 'cells', 'hnpcs', 'by', 'identifying', 'neurongenerating', 'therapeutics', 'and', 'potentially', 'novel', 'mechanism', 'of', 'actions', 'therapeutic', 'benefit', 'could', 'be', 'confirmed', 'through', 'in', 'vivo', 'proofofconcept', 'studies', 'the', 'key', 'aging', 'and', 'longevity', 'mtorp70s6', 'kinase', 'axis', 'a', 'commonly', 'targeted', 'pathway', 'is', 'substrate', 'for', 'potential', 'selective', 'kinase', 'modulators', 'to', 'promote', 'new', 'hippocampal', 'neurons', 'from', 'npcs', 'the', 'highly', 'regulated', 'downstream', 'substrate', 'of', 'mtor', 'p70s6', 'kinase', 'directly', 'controls', 'pleiotropic', 'cellular', 'activities', 'including', 'translation', 'and', 'cell', 'growth', 'stimulating', 'this', 'kinase', 'selectively', 'in', 'an', 'adult', 'neurogenic', 'niche', 'should', 'promote', 'npc', 'proliferation', 'and', 'cell', 'growth', 'and', 'survival', 'in', 'the', 'hippocampus', 'studies', 'of', 'kinase', 'profiling', 'and', 'immunocytochemistry', 'of', 'human', 'progenitor', 'neurogenesis', 'suggest', 'that', 'the', 'novel', 'small', 'molecule', 'nni362', 'stimulates', 'p70s6', 'kinase', 'phosphorylation', 'which', 'in', 'turn', 'promotes', 'proliferation', 'and', 'differentiation', 'of', 'npcs', 'to', 'neurons', 'nni362', 'promoted', 'the', 'associative', 'reversal', 'of', 'age', 'and', 'diseaserelated', 'cognitive', 'deficits', 'in', 'aged', 'mice', 'and', 'down', 'syndromemodeled', 'mice', 'this', 'oral', 'allosteric', 'modulator', 'may', 'ultimately', 'be', 'beneficial', 'for', 'agerelated', 'neurodegenerative', 'disorders', 'involving', 'hippocampaldependent', 'cognitive', 'impairment', 'specifically', 'ad', 'by', 'promoting', 'endogenous', 'hippocampal', 'regeneration']","['aging', 'known', 'slow', 'neurogenic', 'capacity', 'hippocampus', 'one', 'two', 'mammalian', 'adult', 'neurogenic', 'niches', 'reduction', 'adultborn', 'neurons', 'age', 'may', 'initiate', 'cognitive', 'decline', 'progression', 'exacerbated', 'chronic', 'neurodegenerative', 'disorders', 'eg', 'alzheimers', 'disease', 'ad', 'physiologic', 'neurogenesis', 'diminished', 'still', 'viable', 'aging', 'noninvasive', 'therapeutic', 'modulation', 'neuron', 'regeneration', 'process', 'remains', 'possible', 'discovery', 'truly', 'novel', 'neuron', 'regenerative', 'therapies', 'could', 'identified', 'phenotypic', 'screening', 'small', 'molecules', 'promote', 'adultborn', 'neurons', 'human', 'neural', 'progenitor', 'cells', 'hnpcs', 'identifying', 'neurongenerating', 'therapeutics', 'potentially', 'novel', 'mechanism', 'actions', 'therapeutic', 'benefit', 'could', 'confirmed', 'vivo', 'proofofconcept', 'studies', 'key', 'aging', 'longevity', 'mtorp70s6', 'kinase', 'axis', 'commonly', 'targeted', 'pathway', 'substrate', 'potential', 'selective', 'kinase', 'modulators', 'promote', 'new', 'hippocampal', 'neurons', 'npcs', 'highly', 'regulated', 'downstream', 'substrate', 'mtor', 'p70s6', 'kinase', 'directly', 'controls', 'pleiotropic', 'cellular', 'activities', 'including', 'translation', 'cell', 'growth', 'stimulating', 'kinase', 'selectively', 'adult', 'neurogenic', 'niche', 'promote', 'npc', 'proliferation', 'cell', 'growth', 'survival', 'hippocampus', 'studies', 'kinase', 'profiling', 'immunocytochemistry', 'human', 'progenitor', 'neurogenesis', 'suggest', 'novel', 'small', 'molecule', 'nni362', 'stimulates', 'p70s6', 'kinase', 'phosphorylation', 'turn', 'promotes', 'proliferation', 'differentiation', 'npcs', 'neurons', 'nni362', 'promoted', 'associative', 'reversal', 'age', 'diseaserelated', 'cognitive', 'deficits', 'aged', 'mice', 'syndromemodeled', 'mice', 'oral', 'allosteric', 'modulator', 'may', 'ultimately', 'beneficial', 'agerelated', 'neurodegenerative', 'disorders', 'involving', 'hippocampaldependent', 'cognitive', 'impairment', 'specifically', 'ad', 'promoting', 'endogenous', 'hippocampal', 'regeneration']","['p70s6', 'p70s6']","['p70s6', 'p70s6']",True,['alzheimer']
33431496,Targeting the p300/CBP Axis in Lethal Prostate Cancer.,"Resistance to androgen receptor (AR) blockade in castration-resistant prostate cancer (CRPC) is associated with sustained AR signaling, including through alternative splicing of AR (AR-SV). Inhibitors of transcriptional coactivators that regulate AR activity, including the paralog histone acetyltransferase proteins p300 and CBP, are attractive therapeutic targets for lethal prostate cancer. Herein, we validate targeting p300/CBP as a therapeutic strategy for lethal prostate cancer and describe CCS1477, a novel small-molecule inhibitor of the p300/CBP conserved bromodomain. We show that CCS1477 inhibits cell proliferation in prostate cancer cell lines and decreases AR- and C-MYC-regulated gene expression. In AR-SV-driven models, CCS1477 has antitumor activity, regulating AR and C-MYC signaling. Early clinical studies suggest that CCS1477 modulates KLK3 blood levels and regulates CRPC biopsy biomarker expression. Overall, CCS1477 shows promise for the treatment of patients with advanced prostate cancer. SIGNIFICANCE: Treating CRPC remains challenging due to persistent AR signaling. Inhibiting transcriptional AR coactivators is an attractive therapeutic strategy. CCS1477, an inhibitor of p300/CBP, inhibits growth and AR activity in CRPC models, and can affect metastatic CRPC target expression in serial clinical biopsies.<i>See related commentary by Rasool et al., p. 1011</i>.<i>This article is highlighted in the In This Issue feature, p. 995</i>.",2021-01-11,resistance to androgen receptor ar blockade in castrationresistant prostate cancer crpc is associated with sustained ar signaling including through alternative splicing of ar arsv inhibitors of transcriptional coactivators that regulate ar activity including the paralog histone acetyltransferase proteins p300 and cbp are attractive therapeutic targets for lethal prostate cancer herein we validate targeting p300cbp as a therapeutic strategy for lethal prostate cancer and describe ccs1477 a novel smallmolecule inhibitor of the p300cbp conserved bromodomain we show that ccs1477 inhibits cell proliferation in prostate cancer cell lines and decreases ar and cmycregulated gene expression in arsvdriven models ccs1477 has antitumor activity regulating ar and cmyc signaling early clinical studies suggest that ccs1477 modulates klk3 blood levels and regulates crpc biopsy biomarker expression overall ccs1477 shows promise for the treatment of patients with advanced prostate cancer significance treating crpc remains challenging due to persistent ar signaling inhibiting transcriptional ar coactivators is an attractive therapeutic strategy ccs1477 an inhibitor of p300cbp inhibits growth and ar activity in crpc models and can affect metastatic crpc target expression in serial clinical biopsiesisee related commentary by rasool et al p 1011iithis article is highlighted in the in this issue feature p 995i,"['resistance', 'to', 'androgen', 'receptor', 'ar', 'blockade', 'in', 'castrationresistant', 'prostate', 'cancer', 'crpc', 'is', 'associated', 'with', 'sustained', 'ar', 'signaling', 'including', 'through', 'alternative', 'splicing', 'of', 'ar', 'arsv', 'inhibitors', 'of', 'transcriptional', 'coactivators', 'that', 'regulate', 'ar', 'activity', 'including', 'the', 'paralog', 'histone', 'acetyltransferase', 'proteins', 'p300', 'and', 'cbp', 'are', 'attractive', 'therapeutic', 'targets', 'for', 'lethal', 'prostate', 'cancer', 'herein', 'we', 'validate', 'targeting', 'p300cbp', 'as', 'a', 'therapeutic', 'strategy', 'for', 'lethal', 'prostate', 'cancer', 'and', 'describe', 'ccs1477', 'a', 'novel', 'smallmolecule', 'inhibitor', 'of', 'the', 'p300cbp', 'conserved', 'bromodomain', 'we', 'show', 'that', 'ccs1477', 'inhibits', 'cell', 'proliferation', 'in', 'prostate', 'cancer', 'cell', 'lines', 'and', 'decreases', 'ar', 'and', 'cmycregulated', 'gene', 'expression', 'in', 'arsvdriven', 'models', 'ccs1477', 'has', 'antitumor', 'activity', 'regulating', 'ar', 'and', 'cmyc', 'signaling', 'early', 'clinical', 'studies', 'suggest', 'that', 'ccs1477', 'modulates', 'klk3', 'blood', 'levels', 'and', 'regulates', 'crpc', 'biopsy', 'biomarker', 'expression', 'overall', 'ccs1477', 'shows', 'promise', 'for', 'the', 'treatment', 'of', 'patients', 'with', 'advanced', 'prostate', 'cancer', 'significance', 'treating', 'crpc', 'remains', 'challenging', 'due', 'to', 'persistent', 'ar', 'signaling', 'inhibiting', 'transcriptional', 'ar', 'coactivators', 'is', 'an', 'attractive', 'therapeutic', 'strategy', 'ccs1477', 'an', 'inhibitor', 'of', 'p300cbp', 'inhibits', 'growth', 'and', 'ar', 'activity', 'in', 'crpc', 'models', 'and', 'can', 'affect', 'metastatic', 'crpc', 'target', 'expression', 'in', 'serial', 'clinical', 'biopsiesisee', 'related', 'commentary', 'by', 'rasool', 'et', 'al', 'p', '1011iithis', 'article', 'is', 'highlighted', 'in', 'the', 'in', 'this', 'issue', 'feature', 'p', '995i']","['resistance', 'androgen', 'receptor', 'ar', 'blockade', 'castrationresistant', 'prostate', 'cancer', 'crpc', 'associated', 'sustained', 'ar', 'signaling', 'including', 'alternative', 'splicing', 'ar', 'arsv', 'inhibitors', 'transcriptional', 'coactivators', 'regulate', 'ar', 'activity', 'including', 'paralog', 'histone', 'acetyltransferase', 'proteins', 'p300', 'cbp', 'attractive', 'therapeutic', 'targets', 'lethal', 'prostate', 'cancer', 'herein', 'validate', 'targeting', 'p300cbp', 'therapeutic', 'strategy', 'lethal', 'prostate', 'cancer', 'describe', 'ccs1477', 'novel', 'smallmolecule', 'inhibitor', 'p300cbp', 'conserved', 'bromodomain', 'show', 'ccs1477', 'inhibits', 'cell', 'proliferation', 'prostate', 'cancer', 'cell', 'lines', 'decreases', 'ar', 'cmycregulated', 'gene', 'expression', 'arsvdriven', 'models', 'ccs1477', 'antitumor', 'activity', 'regulating', 'ar', 'cmyc', 'signaling', 'early', 'clinical', 'studies', 'suggest', 'ccs1477', 'modulates', 'klk3', 'blood', 'levels', 'regulates', 'crpc', 'biopsy', 'biomarker', 'expression', 'overall', 'ccs1477', 'shows', 'promise', 'treatment', 'patients', 'advanced', 'prostate', 'cancer', 'significance', 'treating', 'crpc', 'remains', 'challenging', 'due', 'persistent', 'ar', 'signaling', 'inhibiting', 'transcriptional', 'ar', 'coactivators', 'attractive', 'therapeutic', 'strategy', 'ccs1477', 'inhibitor', 'p300cbp', 'inhibits', 'growth', 'ar', 'activity', 'crpc', 'models', 'affect', 'metastatic', 'crpc', 'target', 'expression', 'serial', 'clinical', 'biopsiesisee', 'related', 'commentary', 'rasool', 'et', 'al', 'p', '1011iithis', 'article', 'highlighted', 'issue', 'feature', 'p', '995i']","['coactivators', 'acetyltransferase', 'p300', 'coactivators']","['coactivators', 'coactivators']",True,"['tumor', 'cancer']"
33314617,Selection of a new peptide homing SK-BR-3 breast cancer cells.,"Breast cancer diagnosis remains a challenge, mostly due to its heterogeneity. This reality translates in delayed treatments, increasing treatment aggressiveness and lower chances of overall survival. The conventional detection techniques, although becoming increasingly sophisticated each year, still lack the ability to provide reliable conclusions without being time consuming, expensive, and uncomfortable for the patients. The identification of novel biomarkers for breast cancer research is therefore of utmost relevance for an early diagnosis. Moreover, breast cancer-specific peptide moieties can be used to develop novel targeted drug delivery systems. In this work, we used phage display to identify a novel peptide with specificity to the SK-BR-3 breast cancer cell line. Cytometry assays confirmed its specificity, while bioinformatics and docking studies predicted the potential biomarkers at the SK-BR-3 cells' surface. These findings can be potentially useful in the clinical context, contributing to more specific and targeted therapeutic solutions against HER2-positive breast cancer subtypes.",2020-12-25,breast cancer diagnosis remains a challenge mostly due to its heterogeneity this reality translates in delayed treatments increasing treatment aggressiveness and lower chances of overall survival the conventional detection techniques although becoming increasingly sophisticated each year still lack the ability to provide reliable conclusions without being time consuming expensive and uncomfortable for the patients the identification of novel biomarkers for breast cancer research is therefore of utmost relevance for an early diagnosis moreover breast cancerspecific peptide moieties can be used to develop novel targeted drug delivery systems in this work we used phage display to identify a novel peptide with specificity to the skbr3 breast cancer cell line cytometry assays confirmed its specificity while bioinformatics and docking studies predicted the potential biomarkers at the skbr3 cells surface these findings can be potentially useful in the clinical context contributing to more specific and targeted therapeutic solutions against her2positive breast cancer subtypes,"['breast', 'cancer', 'diagnosis', 'remains', 'a', 'challenge', 'mostly', 'due', 'to', 'its', 'heterogeneity', 'this', 'reality', 'translates', 'in', 'delayed', 'treatments', 'increasing', 'treatment', 'aggressiveness', 'and', 'lower', 'chances', 'of', 'overall', 'survival', 'the', 'conventional', 'detection', 'techniques', 'although', 'becoming', 'increasingly', 'sophisticated', 'each', 'year', 'still', 'lack', 'the', 'ability', 'to', 'provide', 'reliable', 'conclusions', 'without', 'being', 'time', 'consuming', 'expensive', 'and', 'uncomfortable', 'for', 'the', 'patients', 'the', 'identification', 'of', 'novel', 'biomarkers', 'for', 'breast', 'cancer', 'research', 'is', 'therefore', 'of', 'utmost', 'relevance', 'for', 'an', 'early', 'diagnosis', 'moreover', 'breast', 'cancerspecific', 'peptide', 'moieties', 'can', 'be', 'used', 'to', 'develop', 'novel', 'targeted', 'drug', 'delivery', 'systems', 'in', 'this', 'work', 'we', 'used', 'phage', 'display', 'to', 'identify', 'a', 'novel', 'peptide', 'with', 'specificity', 'to', 'the', 'skbr3', 'breast', 'cancer', 'cell', 'line', 'cytometry', 'assays', 'confirmed', 'its', 'specificity', 'while', 'bioinformatics', 'and', 'docking', 'studies', 'predicted', 'the', 'potential', 'biomarkers', 'at', 'the', 'skbr3', 'cells', 'surface', 'these', 'findings', 'can', 'be', 'potentially', 'useful', 'in', 'the', 'clinical', 'context', 'contributing', 'to', 'more', 'specific', 'and', 'targeted', 'therapeutic', 'solutions', 'against', 'her2positive', 'breast', 'cancer', 'subtypes']","['breast', 'cancer', 'diagnosis', 'remains', 'challenge', 'mostly', 'due', 'heterogeneity', 'reality', 'translates', 'delayed', 'treatments', 'increasing', 'treatment', 'aggressiveness', 'lower', 'chances', 'overall', 'survival', 'conventional', 'detection', 'techniques', 'although', 'becoming', 'increasingly', 'sophisticated', 'year', 'still', 'lack', 'ability', 'provide', 'reliable', 'conclusions', 'without', 'time', 'consuming', 'expensive', 'uncomfortable', 'patients', 'identification', 'novel', 'biomarkers', 'breast', 'cancer', 'research', 'therefore', 'utmost', 'relevance', 'early', 'diagnosis', 'moreover', 'breast', 'cancerspecific', 'peptide', 'moieties', 'used', 'develop', 'novel', 'targeted', 'drug', 'delivery', 'systems', 'work', 'used', 'phage', 'display', 'identify', 'novel', 'peptide', 'specificity', 'skbr3', 'breast', 'cancer', 'cell', 'line', 'cytometry', 'assays', 'confirmed', 'specificity', 'bioinformatics', 'docking', 'studies', 'predicted', 'potential', 'biomarkers', 'skbr3', 'cells', 'surface', 'findings', 'potentially', 'useful', 'clinical', 'context', 'contributing', 'specific', 'targeted', 'therapeutic', 'solutions', 'her2positive', 'breast', 'cancer', 'subtypes']",['cancerspecific'],['cancerspecific'],True,['cancer']
33268144,"Discovery of 4H-chromeno[2,3-d]pyrimidin-4-one derivatives as senescence inducers and their senescence-associated antiproliferative activities on cancer cells using advanced phenotypic assay.","Current research suggests therapy-induced senescence (TIS) of cancer cells characterized by distinct morphological and biochemical phenotypic changes represent a novel functional target that may enhance the effectiveness of cancer therapy. In order to identify novel small-molecule inducers of cellular senescence and determine the potential to be used for the treatment of melanoma, a new method of high-throughput screening (HTS) and high-contents screening (HCS) based on the detection of morphological changes was designed. This image-based and whole cell-based technology was applied to screen and select a novel class of antiproliferative agents on cancer cells, 4H-chromeno[2,3-d]pyrimidin-4-one derivatives, which induced senescence-like phenotypic changes in human melanoma A375 cells without serious cytotoxicity against normal cells. To evaluate structure-activity relationship (SAR) study of 4H-chromeno[2,3-d]pyrimidin-4-one scaffold starting from hit 3, a focused library containing diversely modified analogues was constructed and which led to the identification of 38, a novel compound to have remarkable anti-melanoma activity in vitro with good metabolic stability.",2020-07-19,current research suggests therapyinduced senescence tis of cancer cells characterized by distinct morphological and biochemical phenotypic changes represent a novel functional target that may enhance the effectiveness of cancer therapy in order to identify novel smallmolecule inducers of cellular senescence and determine the potential to be used for the treatment of melanoma a new method of highthroughput screening hts and highcontents screening hcs based on the detection of morphological changes was designed this imagebased and whole cellbased technology was applied to screen and select a novel class of antiproliferative agents on cancer cells 4hchromeno23dpyrimidin4one derivatives which induced senescencelike phenotypic changes in human melanoma a375 cells without serious cytotoxicity against normal cells to evaluate structureactivity relationship sar study of 4hchromeno23dpyrimidin4one scaffold starting from hit 3 a focused library containing diversely modified analogues was constructed and which led to the identification of 38 a novel compound to have remarkable antimelanoma activity in vitro with good metabolic stability,"['current', 'research', 'suggests', 'therapyinduced', 'senescence', 'tis', 'of', 'cancer', 'cells', 'characterized', 'by', 'distinct', 'morphological', 'and', 'biochemical', 'phenotypic', 'changes', 'represent', 'a', 'novel', 'functional', 'target', 'that', 'may', 'enhance', 'the', 'effectiveness', 'of', 'cancer', 'therapy', 'in', 'order', 'to', 'identify', 'novel', 'smallmolecule', 'inducers', 'of', 'cellular', 'senescence', 'and', 'determine', 'the', 'potential', 'to', 'be', 'used', 'for', 'the', 'treatment', 'of', 'melanoma', 'a', 'new', 'method', 'of', 'highthroughput', 'screening', 'hts', 'and', 'highcontents', 'screening', 'hcs', 'based', 'on', 'the', 'detection', 'of', 'morphological', 'changes', 'was', 'designed', 'this', 'imagebased', 'and', 'whole', 'cellbased', 'technology', 'was', 'applied', 'to', 'screen', 'and', 'select', 'a', 'novel', 'class', 'of', 'antiproliferative', 'agents', 'on', 'cancer', 'cells', '4hchromeno23dpyrimidin4one', 'derivatives', 'which', 'induced', 'senescencelike', 'phenotypic', 'changes', 'in', 'human', 'melanoma', 'a375', 'cells', 'without', 'serious', 'cytotoxicity', 'against', 'normal', 'cells', 'to', 'evaluate', 'structureactivity', 'relationship', 'sar', 'study', 'of', '4hchromeno23dpyrimidin4one', 'scaffold', 'starting', 'from', 'hit', '3', 'a', 'focused', 'library', 'containing', 'diversely', 'modified', 'analogues', 'was', 'constructed', 'and', 'which', 'led', 'to', 'the', 'identification', 'of', '38', 'a', 'novel', 'compound', 'to', 'have', 'remarkable', 'antimelanoma', 'activity', 'in', 'vitro', 'with', 'good', 'metabolic', 'stability']","['current', 'research', 'suggests', 'therapyinduced', 'senescence', 'tis', 'cancer', 'cells', 'characterized', 'distinct', 'morphological', 'biochemical', 'phenotypic', 'changes', 'represent', 'novel', 'functional', 'target', 'may', 'enhance', 'effectiveness', 'cancer', 'therapy', 'order', 'identify', 'novel', 'smallmolecule', 'inducers', 'cellular', 'senescence', 'determine', 'potential', 'used', 'treatment', 'melanoma', 'new', 'method', 'highthroughput', 'screening', 'hts', 'highcontents', 'screening', 'hcs', 'based', 'detection', 'morphological', 'changes', 'designed', 'imagebased', 'whole', 'cellbased', 'technology', 'applied', 'screen', 'select', 'novel', 'class', 'antiproliferative', 'agents', 'cancer', 'cells', '4hchromeno23dpyrimidin4one', 'derivatives', 'induced', 'senescencelike', 'phenotypic', 'changes', 'human', 'melanoma', 'a375', 'cells', 'without', 'serious', 'cytotoxicity', 'normal', 'cells', 'evaluate', 'structureactivity', 'relationship', 'sar', 'study', '4hchromeno23dpyrimidin4one', 'scaffold', 'starting', 'hit', '3', 'focused', 'library', 'containing', 'diversely', 'modified', 'analogues', 'constructed', 'led', 'identification', '38', 'novel', 'compound', 'remarkable', 'antimelanoma', 'activity', 'vitro', 'good', 'metabolic', 'stability']","['hcs', 'a375', 'sar']",['a375'],True,['cancer']
33205861,The novel peptide NbPPI1 identified from Nicotiana benthamiana triggers immune responses and enhances resistance against Phytophthora pathogens.,"In plants, recognition of small secreted peptides, such as damage/danger-associated molecular patterns (DAMPs), regulates diverse processes, including stress and immune responses. Here, we identified an SGPS (Ser-Gly-Pro-Ser) motif-containing peptide, Nicotiana tabacum NtPROPPI, and its two homologs in Nicotiana benthamiana, NbPROPPI1 and NbPROPPI2. Phytophthora parasitica infection and salicylic acid (SA) treatment induced NbPROPPI1/2 expression. Moreover, SignalP predicted that the 89-amino acid NtPROPPI includes a 24-amino acid N-terminal signal peptide and NbPROPPI1/2-GFP fusion proteins were mainly localized to the periplasm. Transient expression of NbPROPPI1/2 inhibited P. parasitica colonization, and NbPROPPI1/2 knockdown rendered plants more susceptible to P. parasitica. An eight-amino-acid segment in the NbPROPPI1 C-terminus was essential for its immune function and a synthetic 20-residue peptide, NbPPI1, derived from the C-terminus of NbPROPPI1 provoked significant immune responses in N. benthamiana. These responses led to enhanced accumulation of reactive oxygen species, activation of mitogen-activated protein kinases, and up-regulation of the defense genes Flg22-induced receptor-like kinase (FRK) and WRKY DNA-binding protein 33 (WRKY33). The NbPPI1-induced defense responses require Brassinosteroid insensitive 1-associated receptor kinase 1 (BAK1). These results suggest that NbPPI1 functions as a DAMP in N. benthamiana; this novel DAMP provides a potentially useful target for improving plant resistance to Pytophthora pathogens.",2021-03-15,in plants recognition of small secreted peptides such as damagedangerassociated molecular patterns damps regulates diverse processes including stress and immune responses here we identified an sgps serglyproser motifcontaining peptide nicotiana tabacum ntproppi and its two homologs in nicotiana benthamiana nbproppi1 and nbproppi2 phytophthora parasitica infection and salicylic acid sa treatment induced nbproppi12 expression moreover signalp predicted that the 89amino acid ntproppi includes a 24amino acid nterminal signal peptide and nbproppi12gfp fusion proteins were mainly localized to the periplasm transient expression of nbproppi12 inhibited p parasitica colonization and nbproppi12 knockdown rendered plants more susceptible to p parasitica an eightaminoacid segment in the nbproppi1 cterminus was essential for its immune function and a synthetic 20residue peptide nbppi1 derived from the cterminus of nbproppi1 provoked significant immune responses in n benthamiana these responses led to enhanced accumulation of reactive oxygen species activation of mitogenactivated protein kinases and upregulation of the defense genes flg22induced receptorlike kinase frk and wrky dnabinding protein 33 wrky33 the nbppi1induced defense responses require brassinosteroid insensitive 1associated receptor kinase 1 bak1 these results suggest that nbppi1 functions as a damp in n benthamiana this novel damp provides a potentially useful target for improving plant resistance to pytophthora pathogens,"['in', 'plants', 'recognition', 'of', 'small', 'secreted', 'peptides', 'such', 'as', 'damagedangerassociated', 'molecular', 'patterns', 'damps', 'regulates', 'diverse', 'processes', 'including', 'stress', 'and', 'immune', 'responses', 'here', 'we', 'identified', 'an', 'sgps', 'serglyproser', 'motifcontaining', 'peptide', 'nicotiana', 'tabacum', 'ntproppi', 'and', 'its', 'two', 'homologs', 'in', 'nicotiana', 'benthamiana', 'nbproppi1', 'and', 'nbproppi2', 'phytophthora', 'parasitica', 'infection', 'and', 'salicylic', 'acid', 'sa', 'treatment', 'induced', 'nbproppi12', 'expression', 'moreover', 'signalp', 'predicted', 'that', 'the', '89amino', 'acid', 'ntproppi', 'includes', 'a', '24amino', 'acid', 'nterminal', 'signal', 'peptide', 'and', 'nbproppi12gfp', 'fusion', 'proteins', 'were', 'mainly', 'localized', 'to', 'the', 'periplasm', 'transient', 'expression', 'of', 'nbproppi12', 'inhibited', 'p', 'parasitica', 'colonization', 'and', 'nbproppi12', 'knockdown', 'rendered', 'plants', 'more', 'susceptible', 'to', 'p', 'parasitica', 'an', 'eightaminoacid', 'segment', 'in', 'the', 'nbproppi1', 'cterminus', 'was', 'essential', 'for', 'its', 'immune', 'function', 'and', 'a', 'synthetic', '20residue', 'peptide', 'nbppi1', 'derived', 'from', 'the', 'cterminus', 'of', 'nbproppi1', 'provoked', 'significant', 'immune', 'responses', 'in', 'n', 'benthamiana', 'these', 'responses', 'led', 'to', 'enhanced', 'accumulation', 'of', 'reactive', 'oxygen', 'species', 'activation', 'of', 'mitogenactivated', 'protein', 'kinases', 'and', 'upregulation', 'of', 'the', 'defense', 'genes', 'flg22induced', 'receptorlike', 'kinase', 'frk', 'and', 'wrky', 'dnabinding', 'protein', '33', 'wrky33', 'the', 'nbppi1induced', 'defense', 'responses', 'require', 'brassinosteroid', 'insensitive', '1associated', 'receptor', 'kinase', '1', 'bak1', 'these', 'results', 'suggest', 'that', 'nbppi1', 'functions', 'as', 'a', 'damp', 'in', 'n', 'benthamiana', 'this', 'novel', 'damp', 'provides', 'a', 'potentially', 'useful', 'target', 'for', 'improving', 'plant', 'resistance', 'to', 'pytophthora', 'pathogens']","['plants', 'recognition', 'small', 'secreted', 'peptides', 'damagedangerassociated', 'molecular', 'patterns', 'damps', 'regulates', 'diverse', 'processes', 'including', 'stress', 'immune', 'responses', 'identified', 'sgps', 'serglyproser', 'motifcontaining', 'peptide', 'nicotiana', 'tabacum', 'ntproppi', 'two', 'homologs', 'nicotiana', 'benthamiana', 'nbproppi1', 'nbproppi2', 'phytophthora', 'parasitica', 'infection', 'salicylic', 'acid', 'sa', 'treatment', 'induced', 'nbproppi12', 'expression', 'moreover', 'signalp', 'predicted', '89amino', 'acid', 'ntproppi', 'includes', '24amino', 'acid', 'nterminal', 'signal', 'peptide', 'nbproppi12gfp', 'fusion', 'proteins', 'mainly', 'localized', 'periplasm', 'transient', 'expression', 'nbproppi12', 'inhibited', 'p', 'parasitica', 'colonization', 'nbproppi12', 'knockdown', 'rendered', 'plants', 'susceptible', 'p', 'parasitica', 'eightaminoacid', 'segment', 'nbproppi1', 'cterminus', 'essential', 'immune', 'function', 'synthetic', '20residue', 'peptide', 'nbppi1', 'derived', 'cterminus', 'nbproppi1', 'provoked', 'significant', 'immune', 'responses', 'n', 'benthamiana', 'responses', 'led', 'enhanced', 'accumulation', 'reactive', 'oxygen', 'species', 'activation', 'mitogenactivated', 'protein', 'kinases', 'upregulation', 'defense', 'genes', 'flg22induced', 'receptorlike', 'kinase', 'frk', 'wrky', 'dnabinding', 'protein', '33', 'wrky33', 'nbppi1induced', 'defense', 'responses', 'require', 'brassinosteroid', 'insensitive', '1associated', 'receptor', 'kinase', '1', 'bak1', 'results', 'suggest', 'nbppi1', 'functions', 'damp', 'n', 'benthamiana', 'novel', 'damp', 'provides', 'potentially', 'useful', 'target', 'improving', 'plant', 'resistance', 'pytophthora', 'pathogens']",['receptorlike'],['receptorlike'],True,['infection']
33183172,LRH-1 (liver receptor homolog-1) derived affinity peptide ligand to inhibit interactions between β-catenin and LRH-1 in pancreatic cancer cells: from computational design to experimental validation.,"Poor prognosis, rapid progression and the lack of an effective treatment make pancreatic cancer one of the most lethal malignancies. Recent studies point to a role for liver receptor homolog-1 (LRH-1) in pathogenesis of pancreatic cancer and suggest prevention of the β-catenin/LRH-1 complex formation as a potential strategy for inhibition of the pancreas cancer cells progression. In the current investigation, we have followed a biomimetic strategy and designed an affinity peptide with sequence DEMEEPQQTE to inhibit formation of the β-catenin/LRH-1 complex. Quantitative real-time PCR experiments on the AsPC-1 pancreatic metastatic cells showed that the peptide has an inhibitory effect on the Wnt signaling proliferation line by reducing the expression levels of the <i>CCND1</i>, <i>CCNE1</i>, and <i>MYC</i> genes. Furthermore, the increased expression level of <i>BAX</i> gene showed that AsPC-1 cells were directed to the apoptosis pathway. At last, <i>POU5F1</i>, <i>KLF4</i>, and <i>CD44</i> gene expression levels suggested that the peptide has an inhibitory effect on the stemness feature of the AsPC-1 cells. Here, we introduced a novel peptide inhibitor targeting an important protein-protein interaction, the β-catenin/LRH-1 complex, which may provide highly promising starting points for subsequent drug design. Communicated by Ramaswamy H. Sarma.",2020-11-13,poor prognosis rapid progression and the lack of an effective treatment make pancreatic cancer one of the most lethal malignancies recent studies point to a role for liver receptor homolog1 lrh1 in pathogenesis of pancreatic cancer and suggest prevention of the βcateninlrh1 complex formation as a potential strategy for inhibition of the pancreas cancer cells progression in the current investigation we have followed a biomimetic strategy and designed an affinity peptide with sequence demeepqqte to inhibit formation of the βcateninlrh1 complex quantitative realtime pcr experiments on the aspc1 pancreatic metastatic cells showed that the peptide has an inhibitory effect on the wnt signaling proliferation line by reducing the expression levels of the iccnd1i iccne1i and imyci genes furthermore the increased expression level of ibaxi gene showed that aspc1 cells were directed to the apoptosis pathway at last ipou5f1i iklf4i and icd44i gene expression levels suggested that the peptide has an inhibitory effect on the stemness feature of the aspc1 cells here we introduced a novel peptide inhibitor targeting an important proteinprotein interaction the βcateninlrh1 complex which may provide highly promising starting points for subsequent drug design communicated by ramaswamy h sarma,"['poor', 'prognosis', 'rapid', 'progression', 'and', 'the', 'lack', 'of', 'an', 'effective', 'treatment', 'make', 'pancreatic', 'cancer', 'one', 'of', 'the', 'most', 'lethal', 'malignancies', 'recent', 'studies', 'point', 'to', 'a', 'role', 'for', 'liver', 'receptor', 'homolog1', 'lrh1', 'in', 'pathogenesis', 'of', 'pancreatic', 'cancer', 'and', 'suggest', 'prevention', 'of', 'the', 'βcateninlrh1', 'complex', 'formation', 'as', 'a', 'potential', 'strategy', 'for', 'inhibition', 'of', 'the', 'pancreas', 'cancer', 'cells', 'progression', 'in', 'the', 'current', 'investigation', 'we', 'have', 'followed', 'a', 'biomimetic', 'strategy', 'and', 'designed', 'an', 'affinity', 'peptide', 'with', 'sequence', 'demeepqqte', 'to', 'inhibit', 'formation', 'of', 'the', 'βcateninlrh1', 'complex', 'quantitative', 'realtime', 'pcr', 'experiments', 'on', 'the', 'aspc1', 'pancreatic', 'metastatic', 'cells', 'showed', 'that', 'the', 'peptide', 'has', 'an', 'inhibitory', 'effect', 'on', 'the', 'wnt', 'signaling', 'proliferation', 'line', 'by', 'reducing', 'the', 'expression', 'levels', 'of', 'the', 'iccnd1i', 'iccne1i', 'and', 'imyci', 'genes', 'furthermore', 'the', 'increased', 'expression', 'level', 'of', 'ibaxi', 'gene', 'showed', 'that', 'aspc1', 'cells', 'were', 'directed', 'to', 'the', 'apoptosis', 'pathway', 'at', 'last', 'ipou5f1i', 'iklf4i', 'and', 'icd44i', 'gene', 'expression', 'levels', 'suggested', 'that', 'the', 'peptide', 'has', 'an', 'inhibitory', 'effect', 'on', 'the', 'stemness', 'feature', 'of', 'the', 'aspc1', 'cells', 'here', 'we', 'introduced', 'a', 'novel', 'peptide', 'inhibitor', 'targeting', 'an', 'important', 'proteinprotein', 'interaction', 'the', 'βcateninlrh1', 'complex', 'which', 'may', 'provide', 'highly', 'promising', 'starting', 'points', 'for', 'subsequent', 'drug', 'design', 'communicated', 'by', 'ramaswamy', 'h', 'sarma']","['poor', 'prognosis', 'rapid', 'progression', 'lack', 'effective', 'treatment', 'make', 'pancreatic', 'cancer', 'one', 'lethal', 'malignancies', 'recent', 'studies', 'point', 'role', 'liver', 'receptor', 'homolog1', 'lrh1', 'pathogenesis', 'pancreatic', 'cancer', 'suggest', 'prevention', 'βcateninlrh1', 'complex', 'formation', 'potential', 'strategy', 'inhibition', 'pancreas', 'cancer', 'cells', 'progression', 'current', 'investigation', 'followed', 'biomimetic', 'strategy', 'designed', 'affinity', 'peptide', 'sequence', 'demeepqqte', 'inhibit', 'formation', 'βcateninlrh1', 'complex', 'quantitative', 'realtime', 'pcr', 'experiments', 'aspc1', 'pancreatic', 'metastatic', 'cells', 'showed', 'peptide', 'inhibitory', 'effect', 'wnt', 'signaling', 'proliferation', 'line', 'reducing', 'expression', 'levels', 'iccnd1i', 'iccne1i', 'imyci', 'genes', 'furthermore', 'increased', 'expression', 'level', 'ibaxi', 'gene', 'showed', 'aspc1', 'cells', 'directed', 'apoptosis', 'pathway', 'last', 'ipou5f1i', 'iklf4i', 'icd44i', 'gene', 'expression', 'levels', 'suggested', 'peptide', 'inhibitory', 'effect', 'stemness', 'feature', 'aspc1', 'cells', 'introduced', 'novel', 'peptide', 'inhibitor', 'targeting', 'important', 'proteinprotein', 'interaction', 'βcateninlrh1', 'complex', 'may', 'provide', 'highly', 'promising', 'starting', 'points', 'subsequent', 'drug', 'design', 'communicated', 'ramaswamy', 'h', 'sarma']","['homolog1', 'wnt']",['homolog1'],True,['cancer']
33114206,Crystal Structure of the Kinase Domain of MerTK in Complex with AZD7762 Provides Clues for Structure-Based Drug Development.,"Aberrant tyrosine-protein kinase Mer (MerTK) expression triggers prosurvival signaling and contributes to cell survival, invasive motility, and chemoresistance in many kinds of cancers. In addition, recent reports suggested that MerTK could be a primary target for abnormal platelet aggregation. Consequently, MerTK inhibitors may promote cancer cell death, sensitize cells to chemotherapy, and act as new antiplatelet agents. We screened an inhouse chemical library to discover novel small-molecule MerTK inhibitors, and identified AZD7762, which is known as a checkpoint-kinase (Chk) inhibitor. The inhibition of MerTK by AZD7762 was validated using an in vitro homogeneous time-resolved fluorescence (HTRF) assay and through monitoring the decrease in phosphorylated MerTK in two lung cancer cell lines. We also determined the crystal structure of the MerTK:AZD7762 complex and revealed the binding mode of AZD7762 to MerTK. Structural information from the MerTK:AZD7762 complex and its comparison with other MerTK:inhibitor structures gave us new insights for optimizing the development of inhibitors targeting MerTK.",2020-10-23,aberrant tyrosineprotein kinase mer mertk expression triggers prosurvival signaling and contributes to cell survival invasive motility and chemoresistance in many kinds of cancers in addition recent reports suggested that mertk could be a primary target for abnormal platelet aggregation consequently mertk inhibitors may promote cancer cell death sensitize cells to chemotherapy and act as new antiplatelet agents we screened an inhouse chemical library to discover novel smallmolecule mertk inhibitors and identified azd7762 which is known as a checkpointkinase chk inhibitor the inhibition of mertk by azd7762 was validated using an in vitro homogeneous timeresolved fluorescence htrf assay and through monitoring the decrease in phosphorylated mertk in two lung cancer cell lines we also determined the crystal structure of the mertkazd7762 complex and revealed the binding mode of azd7762 to mertk structural information from the mertkazd7762 complex and its comparison with other mertkinhibitor structures gave us new insights for optimizing the development of inhibitors targeting mertk,"['aberrant', 'tyrosineprotein', 'kinase', 'mer', 'mertk', 'expression', 'triggers', 'prosurvival', 'signaling', 'and', 'contributes', 'to', 'cell', 'survival', 'invasive', 'motility', 'and', 'chemoresistance', 'in', 'many', 'kinds', 'of', 'cancers', 'in', 'addition', 'recent', 'reports', 'suggested', 'that', 'mertk', 'could', 'be', 'a', 'primary', 'target', 'for', 'abnormal', 'platelet', 'aggregation', 'consequently', 'mertk', 'inhibitors', 'may', 'promote', 'cancer', 'cell', 'death', 'sensitize', 'cells', 'to', 'chemotherapy', 'and', 'act', 'as', 'new', 'antiplatelet', 'agents', 'we', 'screened', 'an', 'inhouse', 'chemical', 'library', 'to', 'discover', 'novel', 'smallmolecule', 'mertk', 'inhibitors', 'and', 'identified', 'azd7762', 'which', 'is', 'known', 'as', 'a', 'checkpointkinase', 'chk', 'inhibitor', 'the', 'inhibition', 'of', 'mertk', 'by', 'azd7762', 'was', 'validated', 'using', 'an', 'in', 'vitro', 'homogeneous', 'timeresolved', 'fluorescence', 'htrf', 'assay', 'and', 'through', 'monitoring', 'the', 'decrease', 'in', 'phosphorylated', 'mertk', 'in', 'two', 'lung', 'cancer', 'cell', 'lines', 'we', 'also', 'determined', 'the', 'crystal', 'structure', 'of', 'the', 'mertkazd7762', 'complex', 'and', 'revealed', 'the', 'binding', 'mode', 'of', 'azd7762', 'to', 'mertk', 'structural', 'information', 'from', 'the', 'mertkazd7762', 'complex', 'and', 'its', 'comparison', 'with', 'other', 'mertkinhibitor', 'structures', 'gave', 'us', 'new', 'insights', 'for', 'optimizing', 'the', 'development', 'of', 'inhibitors', 'targeting', 'mertk']","['aberrant', 'tyrosineprotein', 'kinase', 'mer', 'mertk', 'expression', 'triggers', 'prosurvival', 'signaling', 'contributes', 'cell', 'survival', 'invasive', 'motility', 'chemoresistance', 'many', 'kinds', 'cancers', 'addition', 'recent', 'reports', 'suggested', 'mertk', 'could', 'primary', 'target', 'abnormal', 'platelet', 'aggregation', 'consequently', 'mertk', 'inhibitors', 'may', 'promote', 'cancer', 'cell', 'death', 'sensitize', 'cells', 'chemotherapy', 'act', 'new', 'antiplatelet', 'agents', 'screened', 'inhouse', 'chemical', 'library', 'discover', 'novel', 'smallmolecule', 'mertk', 'inhibitors', 'identified', 'azd7762', 'known', 'checkpointkinase', 'chk', 'inhibitor', 'inhibition', 'mertk', 'azd7762', 'validated', 'using', 'vitro', 'homogeneous', 'timeresolved', 'fluorescence', 'htrf', 'assay', 'monitoring', 'decrease', 'phosphorylated', 'mertk', 'two', 'lung', 'cancer', 'cell', 'lines', 'also', 'determined', 'crystal', 'structure', 'mertkazd7762', 'complex', 'revealed', 'binding', 'mode', 'azd7762', 'mertk', 'structural', 'information', 'mertkazd7762', 'complex', 'comparison', 'mertkinhibitor', 'structures', 'gave', 'us', 'new', 'insights', 'optimizing', 'development', 'inhibitors', 'targeting', 'mertk']",['chk'],['chk'],True,['cancer']
33087513,"ASR490, a Small Molecule, Overrides Aberrant Expression of <i>Notch1</i> in Colorectal Cancer.","<i>Notch1</i> activation triggers significant oncogenic signaling that manifests as enhanced metastatic potential and tumorigenesis in colorectal cancer. Novel small-molecule inhibitors, mainly plant-derived analogs, have low toxicity profiles and higher bioavailability. In this study, we have developed a small molecule, ASR490, by modifying structure of naturally occurring compound Withaferin A. ASR490 showed a growth-inhibitory potential by downregulating <i>Notch1</i> signaling in HCT116 and SW620 cell lines. Docking studies and thermal shift assays confirmed that ASR490 binds to <i>Notch1</i>, whereas no changes in <i>Notch2</i> and <i>Notch3</i> expression were seen in colorectal cancer cells. <i>Notch1</i> governs epithelial-to-mesenchymal transition signaling and is responsible for metastasis, which was abolished by ASR490 treatment. To further confirm the therapeutic potential of ASR490, we stably overexpressed <i>Notch1</i> in HCT-116 cells and determined its inhibitory potential in transfected colorectal cancer (Notch1/HCT116) cells. ASR490 effectively prevented cell growth in both the vector (<i>P</i> = 0.005) and <i>Notch1</i> (<i>P</i> = 0.05) transfectants. The downregulation of <i>Notch1</i> signaling was evident, which corresponded with downregulation of mesenchymal markers, including <i>N-cadherin</i> and <i>β-catenin</i> and induction of <i>E-cadherin</i> in HCT-116 transfectants. Intraperitoneal administration of a 1% MTD dose of ASR490 (5 mg/kg) effectively suppressed the tumor growth in control (pCMV/HCT116) and Notch1/HCT116 in xenotransplanted mice. In addition, downregulation of <i>Notch1</i> and survival signaling in ASR-treated tumors confirmed the <i>in vitro</i> results. In conclusion, ASR490 appears to be a potent agent that can inhibit <i>Notch1</i> signaling in colorectal cancer.",2020-10-21,inotch1i activation triggers significant oncogenic signaling that manifests as enhanced metastatic potential and tumorigenesis in colorectal cancer novel smallmolecule inhibitors mainly plantderived analogs have low toxicity profiles and higher bioavailability in this study we have developed a small molecule asr490 by modifying structure of naturally occurring compound withaferin a asr490 showed a growthinhibitory potential by downregulating inotch1i signaling in hct116 and sw620 cell lines docking studies and thermal shift assays confirmed that asr490 binds to inotch1i whereas no changes in inotch2i and inotch3i expression were seen in colorectal cancer cells inotch1i governs epithelialtomesenchymal transition signaling and is responsible for metastasis which was abolished by asr490 treatment to further confirm the therapeutic potential of asr490 we stably overexpressed inotch1i in hct116 cells and determined its inhibitory potential in transfected colorectal cancer notch1hct116 cells asr490 effectively prevented cell growth in both the vector ipi  0005 and inotch1i ipi  005 transfectants the downregulation of inotch1i signaling was evident which corresponded with downregulation of mesenchymal markers including incadherini and iβcatenini and induction of iecadherini in hct116 transfectants intraperitoneal administration of a 1 mtd dose of asr490 5 mgkg effectively suppressed the tumor growth in control pcmvhct116 and notch1hct116 in xenotransplanted mice in addition downregulation of inotch1i and survival signaling in asrtreated tumors confirmed the iin vitroi results in conclusion asr490 appears to be a potent agent that can inhibit inotch1i signaling in colorectal cancer,"['inotch1i', 'activation', 'triggers', 'significant', 'oncogenic', 'signaling', 'that', 'manifests', 'as', 'enhanced', 'metastatic', 'potential', 'and', 'tumorigenesis', 'in', 'colorectal', 'cancer', 'novel', 'smallmolecule', 'inhibitors', 'mainly', 'plantderived', 'analogs', 'have', 'low', 'toxicity', 'profiles', 'and', 'higher', 'bioavailability', 'in', 'this', 'study', 'we', 'have', 'developed', 'a', 'small', 'molecule', 'asr490', 'by', 'modifying', 'structure', 'of', 'naturally', 'occurring', 'compound', 'withaferin', 'a', 'asr490', 'showed', 'a', 'growthinhibitory', 'potential', 'by', 'downregulating', 'inotch1i', 'signaling', 'in', 'hct116', 'and', 'sw620', 'cell', 'lines', 'docking', 'studies', 'and', 'thermal', 'shift', 'assays', 'confirmed', 'that', 'asr490', 'binds', 'to', 'inotch1i', 'whereas', 'no', 'changes', 'in', 'inotch2i', 'and', 'inotch3i', 'expression', 'were', 'seen', 'in', 'colorectal', 'cancer', 'cells', 'inotch1i', 'governs', 'epithelialtomesenchymal', 'transition', 'signaling', 'and', 'is', 'responsible', 'for', 'metastasis', 'which', 'was', 'abolished', 'by', 'asr490', 'treatment', 'to', 'further', 'confirm', 'the', 'therapeutic', 'potential', 'of', 'asr490', 'we', 'stably', 'overexpressed', 'inotch1i', 'in', 'hct116', 'cells', 'and', 'determined', 'its', 'inhibitory', 'potential', 'in', 'transfected', 'colorectal', 'cancer', 'notch1hct116', 'cells', 'asr490', 'effectively', 'prevented', 'cell', 'growth', 'in', 'both', 'the', 'vector', 'ipi', '0005', 'and', 'inotch1i', 'ipi', '005', 'transfectants', 'the', 'downregulation', 'of', 'inotch1i', 'signaling', 'was', 'evident', 'which', 'corresponded', 'with', 'downregulation', 'of', 'mesenchymal', 'markers', 'including', 'incadherini', 'and', 'iβcatenini', 'and', 'induction', 'of', 'iecadherini', 'in', 'hct116', 'transfectants', 'intraperitoneal', 'administration', 'of', 'a', '1', 'mtd', 'dose', 'of', 'asr490', '5', 'mgkg', 'effectively', 'suppressed', 'the', 'tumor', 'growth', 'in', 'control', 'pcmvhct116', 'and', 'notch1hct116', 'in', 'xenotransplanted', 'mice', 'in', 'addition', 'downregulation', 'of', 'inotch1i', 'and', 'survival', 'signaling', 'in', 'asrtreated', 'tumors', 'confirmed', 'the', 'iin', 'vitroi', 'results', 'in', 'conclusion', 'asr490', 'appears', 'to', 'be', 'a', 'potent', 'agent', 'that', 'can', 'inhibit', 'inotch1i', 'signaling', 'in', 'colorectal', 'cancer']","['inotch1i', 'activation', 'triggers', 'significant', 'oncogenic', 'signaling', 'manifests', 'enhanced', 'metastatic', 'potential', 'tumorigenesis', 'colorectal', 'cancer', 'novel', 'smallmolecule', 'inhibitors', 'mainly', 'plantderived', 'analogs', 'low', 'toxicity', 'profiles', 'higher', 'bioavailability', 'study', 'developed', 'small', 'molecule', 'asr490', 'modifying', 'structure', 'naturally', 'occurring', 'compound', 'withaferin', 'asr490', 'showed', 'growthinhibitory', 'potential', 'downregulating', 'inotch1i', 'signaling', 'hct116', 'sw620', 'cell', 'lines', 'docking', 'studies', 'thermal', 'shift', 'assays', 'confirmed', 'asr490', 'binds', 'inotch1i', 'whereas', 'changes', 'inotch2i', 'inotch3i', 'expression', 'seen', 'colorectal', 'cancer', 'cells', 'inotch1i', 'governs', 'epithelialtomesenchymal', 'transition', 'signaling', 'responsible', 'metastasis', 'abolished', 'asr490', 'treatment', 'confirm', 'therapeutic', 'potential', 'asr490', 'stably', 'overexpressed', 'inotch1i', 'hct116', 'cells', 'determined', 'inhibitory', 'potential', 'transfected', 'colorectal', 'cancer', 'notch1hct116', 'cells', 'asr490', 'effectively', 'prevented', 'cell', 'growth', 'vector', 'ipi', '0005', 'inotch1i', 'ipi', '005', 'transfectants', 'downregulation', 'inotch1i', 'signaling', 'evident', 'corresponded', 'downregulation', 'mesenchymal', 'markers', 'including', 'incadherini', 'iβcatenini', 'induction', 'iecadherini', 'hct116', 'transfectants', 'intraperitoneal', 'administration', '1', 'mtd', 'dose', 'asr490', '5', 'mgkg', 'effectively', 'suppressed', 'tumor', 'growth', 'control', 'pcmvhct116', 'notch1hct116', 'xenotransplanted', 'mice', 'addition', 'downregulation', 'inotch1i', 'survival', 'signaling', 'asrtreated', 'tumors', 'confirmed', 'iin', 'vitroi', 'results', 'conclusion', 'asr490', 'appears', 'potent', 'agent', 'inhibit', 'inotch1i', 'signaling', 'colorectal', 'cancer']",['mtd'],['mtd'],True,"['tumor', 'cancer']"
33077662,Small-Molecule Antibiotics Inhibiting tRNA-Regulated Gene Expression Is a Viable Strategy for Targeting Gram-Positive Bacteria.,"Bacterial infections and the rise of antibiotic resistance, especially multidrug resistance, have generated a clear need for discovery of novel therapeutics. We demonstrated that a small-molecule drug, PKZ18, targets the T-box mechanism and inhibits bacterial growth. The T-box is a structurally conserved riboswitch-like gene regulator in the 5' untranslated region (UTR) of numerous essential genes of Gram-positive bacteria. T-boxes are stabilized by cognate, unacylated tRNA ligands, allowing the formation of an antiterminator hairpin in the mRNA that enables transcription of the gene. In the absence of an unacylated cognate tRNA, transcription is halted due to the formation of a thermodynamically more stable terminator hairpin. PKZ18 targets the site of the codon-anticodon interaction of the conserved stem I and reduces T-box-controlled gene expression. Here, we show that novel analogs of PKZ18 have improved MICs, bactericidal effects against methicillin-resistant <i>Staphylococcus aureus</i> (MRSA), and increased efficacy in nutrient-limiting conditions. The analogs have reduced cytotoxicity against eukaryotic cells compared to PKZ18. The PKZ18 analogs acted synergistically with aminoglycosides to significantly enhance the efficacy of the analogs and aminoglycosides, further increasing their therapeutic windows. RNA sequencing showed that the analog PKZ18-22 affects expression of 8 of 12 T-box controlled genes in a statistically significant manner, but not other 5'-UTR regulated genes in MRSA. Very low levels of resistance further support the existence of multiple T-box targets for PKZ18 analogs in the cell. Together, the multiple targets, low resistance, and synergy make PKZ18 analogs promising drugs for development and future clinical applications.",2020-12-16,bacterial infections and the rise of antibiotic resistance especially multidrug resistance have generated a clear need for discovery of novel therapeutics we demonstrated that a smallmolecule drug pkz18 targets the tbox mechanism and inhibits bacterial growth the tbox is a structurally conserved riboswitchlike gene regulator in the 5 untranslated region utr of numerous essential genes of grampositive bacteria tboxes are stabilized by cognate unacylated trna ligands allowing the formation of an antiterminator hairpin in the mrna that enables transcription of the gene in the absence of an unacylated cognate trna transcription is halted due to the formation of a thermodynamically more stable terminator hairpin pkz18 targets the site of the codonanticodon interaction of the conserved stem i and reduces tboxcontrolled gene expression here we show that novel analogs of pkz18 have improved mics bactericidal effects against methicillinresistant istaphylococcus aureusi mrsa and increased efficacy in nutrientlimiting conditions the analogs have reduced cytotoxicity against eukaryotic cells compared to pkz18 the pkz18 analogs acted synergistically with aminoglycosides to significantly enhance the efficacy of the analogs and aminoglycosides further increasing their therapeutic windows rna sequencing showed that the analog pkz1822 affects expression of 8 of 12 tbox controlled genes in a statistically significant manner but not other 5utr regulated genes in mrsa very low levels of resistance further support the existence of multiple tbox targets for pkz18 analogs in the cell together the multiple targets low resistance and synergy make pkz18 analogs promising drugs for development and future clinical applications,"['bacterial', 'infections', 'and', 'the', 'rise', 'of', 'antibiotic', 'resistance', 'especially', 'multidrug', 'resistance', 'have', 'generated', 'a', 'clear', 'need', 'for', 'discovery', 'of', 'novel', 'therapeutics', 'we', 'demonstrated', 'that', 'a', 'smallmolecule', 'drug', 'pkz18', 'targets', 'the', 'tbox', 'mechanism', 'and', 'inhibits', 'bacterial', 'growth', 'the', 'tbox', 'is', 'a', 'structurally', 'conserved', 'riboswitchlike', 'gene', 'regulator', 'in', 'the', '5', 'untranslated', 'region', 'utr', 'of', 'numerous', 'essential', 'genes', 'of', 'grampositive', 'bacteria', 'tboxes', 'are', 'stabilized', 'by', 'cognate', 'unacylated', 'trna', 'ligands', 'allowing', 'the', 'formation', 'of', 'an', 'antiterminator', 'hairpin', 'in', 'the', 'mrna', 'that', 'enables', 'transcription', 'of', 'the', 'gene', 'in', 'the', 'absence', 'of', 'an', 'unacylated', 'cognate', 'trna', 'transcription', 'is', 'halted', 'due', 'to', 'the', 'formation', 'of', 'a', 'thermodynamically', 'more', 'stable', 'terminator', 'hairpin', 'pkz18', 'targets', 'the', 'site', 'of', 'the', 'codonanticodon', 'interaction', 'of', 'the', 'conserved', 'stem', 'i', 'and', 'reduces', 'tboxcontrolled', 'gene', 'expression', 'here', 'we', 'show', 'that', 'novel', 'analogs', 'of', 'pkz18', 'have', 'improved', 'mics', 'bactericidal', 'effects', 'against', 'methicillinresistant', 'istaphylococcus', 'aureusi', 'mrsa', 'and', 'increased', 'efficacy', 'in', 'nutrientlimiting', 'conditions', 'the', 'analogs', 'have', 'reduced', 'cytotoxicity', 'against', 'eukaryotic', 'cells', 'compared', 'to', 'pkz18', 'the', 'pkz18', 'analogs', 'acted', 'synergistically', 'with', 'aminoglycosides', 'to', 'significantly', 'enhance', 'the', 'efficacy', 'of', 'the', 'analogs', 'and', 'aminoglycosides', 'further', 'increasing', 'their', 'therapeutic', 'windows', 'rna', 'sequencing', 'showed', 'that', 'the', 'analog', 'pkz1822', 'affects', 'expression', 'of', '8', 'of', '12', 'tbox', 'controlled', 'genes', 'in', 'a', 'statistically', 'significant', 'manner', 'but', 'not', 'other', '5utr', 'regulated', 'genes', 'in', 'mrsa', 'very', 'low', 'levels', 'of', 'resistance', 'further', 'support', 'the', 'existence', 'of', 'multiple', 'tbox', 'targets', 'for', 'pkz18', 'analogs', 'in', 'the', 'cell', 'together', 'the', 'multiple', 'targets', 'low', 'resistance', 'and', 'synergy', 'make', 'pkz18', 'analogs', 'promising', 'drugs', 'for', 'development', 'and', 'future', 'clinical', 'applications']","['bacterial', 'infections', 'rise', 'antibiotic', 'resistance', 'especially', 'multidrug', 'resistance', 'generated', 'clear', 'need', 'discovery', 'novel', 'therapeutics', 'demonstrated', 'smallmolecule', 'drug', 'pkz18', 'targets', 'tbox', 'mechanism', 'inhibits', 'bacterial', 'growth', 'tbox', 'structurally', 'conserved', 'riboswitchlike', 'gene', 'regulator', '5', 'untranslated', 'region', 'utr', 'numerous', 'essential', 'genes', 'grampositive', 'bacteria', 'tboxes', 'stabilized', 'cognate', 'unacylated', 'trna', 'ligands', 'allowing', 'formation', 'antiterminator', 'hairpin', 'mrna', 'enables', 'transcription', 'gene', 'absence', 'unacylated', 'cognate', 'trna', 'transcription', 'halted', 'due', 'formation', 'thermodynamically', 'stable', 'terminator', 'hairpin', 'pkz18', 'targets', 'site', 'codonanticodon', 'interaction', 'conserved', 'stem', 'reduces', 'tboxcontrolled', 'gene', 'expression', 'show', 'novel', 'analogs', 'pkz18', 'improved', 'mics', 'bactericidal', 'effects', 'methicillinresistant', 'istaphylococcus', 'aureusi', 'mrsa', 'increased', 'efficacy', 'nutrientlimiting', 'conditions', 'analogs', 'reduced', 'cytotoxicity', 'eukaryotic', 'cells', 'compared', 'pkz18', 'pkz18', 'analogs', 'acted', 'synergistically', 'aminoglycosides', 'significantly', 'enhance', 'efficacy', 'analogs', 'aminoglycosides', 'increasing', 'therapeutic', 'windows', 'rna', 'sequencing', 'showed', 'analog', 'pkz1822', 'affects', 'expression', '8', '12', 'tbox', 'controlled', 'genes', 'statistically', 'significant', 'manner', '5utr', 'regulated', 'genes', 'mrsa', 'low', 'levels', 'resistance', 'support', 'existence', 'multiple', 'tbox', 'targets', 'pkz18', 'analogs', 'cell', 'together', 'multiple', 'targets', 'low', 'resistance', 'synergy', 'make', 'pkz18', 'analogs', 'promising', 'drugs', 'development', 'future', 'clinical', 'applications']","['pkz18', 'pkz18', 'pkz18', 'pkz18', 'pkz18', 'pkz18', 'pkz18']","['pkz18', 'pkz18', 'pkz18', 'pkz18', 'pkz18', 'pkz18', 'pkz18']",True,['infection']
33075488,"Design, synthesis, and biological evaluation of N-arylpiperazine derivatives as interferon inducers.","Type I Interferon (IFN) signaling plays an important role in the immune defense system against virus infection and in the innate immune response, thus IFNs are widely used as anti-viral agents and treatment for immune disorder or cancer. However, there is a growing demand for novel small-molecule IFN inducer due to tolerance, toxicity, or short duration of action following direct administration of IFNs. In this study, we assessed arylpiperazine (ARP) as a new core skeleton of IFN inducer. To investigate structure-activity relationship, we designed and synthesized a series of ARP analogues and evaluated the ability to stimulate IFN response in THP-1 human monocyte cells. Compound 5i was identified as a potent type I IFN inducer as it significantly increased cytokine secretion and increased expression of various IFN-stimulating genes which are representative biomarkers of type I IFN pathway. Our results suggested a beneficial therapeutic potential of 5i as an anti-viral agent.",2020-10-16,type i interferon ifn signaling plays an important role in the immune defense system against virus infection and in the innate immune response thus ifns are widely used as antiviral agents and treatment for immune disorder or cancer however there is a growing demand for novel smallmolecule ifn inducer due to tolerance toxicity or short duration of action following direct administration of ifns in this study we assessed arylpiperazine arp as a new core skeleton of ifn inducer to investigate structureactivity relationship we designed and synthesized a series of arp analogues and evaluated the ability to stimulate ifn response in thp1 human monocyte cells compound 5i was identified as a potent type i ifn inducer as it significantly increased cytokine secretion and increased expression of various ifnstimulating genes which are representative biomarkers of type i ifn pathway our results suggested a beneficial therapeutic potential of 5i as an antiviral agent,"['type', 'i', 'interferon', 'ifn', 'signaling', 'plays', 'an', 'important', 'role', 'in', 'the', 'immune', 'defense', 'system', 'against', 'virus', 'infection', 'and', 'in', 'the', 'innate', 'immune', 'response', 'thus', 'ifns', 'are', 'widely', 'used', 'as', 'antiviral', 'agents', 'and', 'treatment', 'for', 'immune', 'disorder', 'or', 'cancer', 'however', 'there', 'is', 'a', 'growing', 'demand', 'for', 'novel', 'smallmolecule', 'ifn', 'inducer', 'due', 'to', 'tolerance', 'toxicity', 'or', 'short', 'duration', 'of', 'action', 'following', 'direct', 'administration', 'of', 'ifns', 'in', 'this', 'study', 'we', 'assessed', 'arylpiperazine', 'arp', 'as', 'a', 'new', 'core', 'skeleton', 'of', 'ifn', 'inducer', 'to', 'investigate', 'structureactivity', 'relationship', 'we', 'designed', 'and', 'synthesized', 'a', 'series', 'of', 'arp', 'analogues', 'and', 'evaluated', 'the', 'ability', 'to', 'stimulate', 'ifn', 'response', 'in', 'thp1', 'human', 'monocyte', 'cells', 'compound', '5i', 'was', 'identified', 'as', 'a', 'potent', 'type', 'i', 'ifn', 'inducer', 'as', 'it', 'significantly', 'increased', 'cytokine', 'secretion', 'and', 'increased', 'expression', 'of', 'various', 'ifnstimulating', 'genes', 'which', 'are', 'representative', 'biomarkers', 'of', 'type', 'i', 'ifn', 'pathway', 'our', 'results', 'suggested', 'a', 'beneficial', 'therapeutic', 'potential', 'of', '5i', 'as', 'an', 'antiviral', 'agent']","['type', 'interferon', 'ifn', 'signaling', 'plays', 'important', 'role', 'immune', 'defense', 'system', 'virus', 'infection', 'innate', 'immune', 'response', 'thus', 'ifns', 'widely', 'used', 'antiviral', 'agents', 'treatment', 'immune', 'disorder', 'cancer', 'however', 'growing', 'demand', 'novel', 'smallmolecule', 'ifn', 'inducer', 'due', 'tolerance', 'toxicity', 'short', 'duration', 'action', 'following', 'direct', 'administration', 'ifns', 'study', 'assessed', 'arylpiperazine', 'arp', 'new', 'core', 'skeleton', 'ifn', 'inducer', 'investigate', 'structureactivity', 'relationship', 'designed', 'synthesized', 'series', 'arp', 'analogues', 'evaluated', 'ability', 'stimulate', 'ifn', 'response', 'thp1', 'human', 'monocyte', 'cells', 'compound', '5i', 'identified', 'potent', 'type', 'ifn', 'inducer', 'significantly', 'increased', 'cytokine', 'secretion', 'increased', 'expression', 'various', 'ifnstimulating', 'genes', 'representative', 'biomarkers', 'type', 'ifn', 'pathway', 'results', 'suggested', 'beneficial', 'therapeutic', 'potential', '5i', 'antiviral', 'agent']",['thp1'],['thp1'],True,"['infection', 'cancer']"
33072093,Strategies for Targeting SARS CoV-2: Small Molecule Inhibitors-The Current Status.,"Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2) induced Coronavirus Disease - 19 (COVID-19) cases have been increasing at an alarming rate (7.4 million positive cases as on June 11 2020), causing high mortality (4,17,956 deaths as on June 11 2020) and economic loss (a 3.2% shrink in global economy in 2020) across 212 countries globally. The clinical manifestations of this disease are pneumonia, lung injury, inflammation, and severe acute respiratory syndrome (SARS). Currently, there is no vaccine or effective pharmacological agents available for the prevention/treatment of SARS-CoV2 infections. Moreover, development of a suitable vaccine is a challenging task due to antibody-dependent enhancement (ADE) and Th-2 immunopathology, which aggravates infection with SARS-CoV-2. Furthermore, the emerging SARS-CoV-2 strain exhibits several distinct genomic and structural patterns compared to other coronavirus strains, making the development of a suitable vaccine even more difficult. Therefore, the identification of novel small molecule inhibitors (NSMIs) that can interfere with viral entry or viral propagation is of special interest and is vital in managing already infected cases. SARS-CoV-2 infection is mediated by the binding of viral Spike proteins (S-protein) to human cells through a 2-step process, which involves Angiotensin Converting Enzyme-2 (ACE2) and Transmembrane Serine Protease (TMPRSS)-2. Therefore, the development of novel inhibitors of ACE2/TMPRSS2 is likely to be beneficial in combating SARS-CoV-2 infections. However, the usage of ACE-2 inhibitors to block the SARS-CoV-2 viral entry requires additional studies as there are conflicting findings and severe health complications reported for these inhibitors in patients. Hence, the current interest is shifted toward the development of NSMIs, which includes natural antiviral phytochemicals and Nrf-2 activators to manage a SARS-CoV-2 infection. It is imperative to investigate the efficacy of existing antiviral phytochemicals and Nrf-2 activators to mitigate the SARS-CoV-2-mediated oxidative stress. Therefore, in this review, we have reviewed structural features of SARS-CoV-2 with special emphasis on key molecular targets and their known modulators that can be considered for the development of NSMIs.",2020-09-18,severe acute respiratory syndromecorona virus2 sarscov2 induced coronavirus disease  19 covid19 cases have been increasing at an alarming rate 74 million positive cases as on june 11 2020 causing high mortality 417956 deaths as on june 11 2020 and economic loss a 32 shrink in global economy in 2020 across 212 countries globally the clinical manifestations of this disease are pneumonia lung injury inflammation and severe acute respiratory syndrome sars currently there is no vaccine or effective pharmacological agents available for the preventiontreatment of sarscov2 infections moreover development of a suitable vaccine is a challenging task due to antibodydependent enhancement ade and th2 immunopathology which aggravates infection with sarscov2 furthermore the emerging sarscov2 strain exhibits several distinct genomic and structural patterns compared to other coronavirus strains making the development of a suitable vaccine even more difficult therefore the identification of novel small molecule inhibitors nsmis that can interfere with viral entry or viral propagation is of special interest and is vital in managing already infected cases sarscov2 infection is mediated by the binding of viral spike proteins sprotein to human cells through a 2step process which involves angiotensin converting enzyme2 ace2 and transmembrane serine protease tmprss2 therefore the development of novel inhibitors of ace2tmprss2 is likely to be beneficial in combating sarscov2 infections however the usage of ace2 inhibitors to block the sarscov2 viral entry requires additional studies as there are conflicting findings and severe health complications reported for these inhibitors in patients hence the current interest is shifted toward the development of nsmis which includes natural antiviral phytochemicals and nrf2 activators to manage a sarscov2 infection it is imperative to investigate the efficacy of existing antiviral phytochemicals and nrf2 activators to mitigate the sarscov2mediated oxidative stress therefore in this review we have reviewed structural features of sarscov2 with special emphasis on key molecular targets and their known modulators that can be considered for the development of nsmis,"['severe', 'acute', 'respiratory', 'syndromecorona', 'virus2', 'sarscov2', 'induced', 'coronavirus', 'disease', '19', 'covid19', 'cases', 'have', 'been', 'increasing', 'at', 'an', 'alarming', 'rate', '74', 'million', 'positive', 'cases', 'as', 'on', 'june', '11', '2020', 'causing', 'high', 'mortality', '417956', 'deaths', 'as', 'on', 'june', '11', '2020', 'and', 'economic', 'loss', 'a', '32', 'shrink', 'in', 'global', 'economy', 'in', '2020', 'across', '212', 'countries', 'globally', 'the', 'clinical', 'manifestations', 'of', 'this', 'disease', 'are', 'pneumonia', 'lung', 'injury', 'inflammation', 'and', 'severe', 'acute', 'respiratory', 'syndrome', 'sars', 'currently', 'there', 'is', 'no', 'vaccine', 'or', 'effective', 'pharmacological', 'agents', 'available', 'for', 'the', 'preventiontreatment', 'of', 'sarscov2', 'infections', 'moreover', 'development', 'of', 'a', 'suitable', 'vaccine', 'is', 'a', 'challenging', 'task', 'due', 'to', 'antibodydependent', 'enhancement', 'ade', 'and', 'th2', 'immunopathology', 'which', 'aggravates', 'infection', 'with', 'sarscov2', 'furthermore', 'the', 'emerging', 'sarscov2', 'strain', 'exhibits', 'several', 'distinct', 'genomic', 'and', 'structural', 'patterns', 'compared', 'to', 'other', 'coronavirus', 'strains', 'making', 'the', 'development', 'of', 'a', 'suitable', 'vaccine', 'even', 'more', 'difficult', 'therefore', 'the', 'identification', 'of', 'novel', 'small', 'molecule', 'inhibitors', 'nsmis', 'that', 'can', 'interfere', 'with', 'viral', 'entry', 'or', 'viral', 'propagation', 'is', 'of', 'special', 'interest', 'and', 'is', 'vital', 'in', 'managing', 'already', 'infected', 'cases', 'sarscov2', 'infection', 'is', 'mediated', 'by', 'the', 'binding', 'of', 'viral', 'spike', 'proteins', 'sprotein', 'to', 'human', 'cells', 'through', 'a', '2step', 'process', 'which', 'involves', 'angiotensin', 'converting', 'enzyme2', 'ace2', 'and', 'transmembrane', 'serine', 'protease', 'tmprss2', 'therefore', 'the', 'development', 'of', 'novel', 'inhibitors', 'of', 'ace2tmprss2', 'is', 'likely', 'to', 'be', 'beneficial', 'in', 'combating', 'sarscov2', 'infections', 'however', 'the', 'usage', 'of', 'ace2', 'inhibitors', 'to', 'block', 'the', 'sarscov2', 'viral', 'entry', 'requires', 'additional', 'studies', 'as', 'there', 'are', 'conflicting', 'findings', 'and', 'severe', 'health', 'complications', 'reported', 'for', 'these', 'inhibitors', 'in', 'patients', 'hence', 'the', 'current', 'interest', 'is', 'shifted', 'toward', 'the', 'development', 'of', 'nsmis', 'which', 'includes', 'natural', 'antiviral', 'phytochemicals', 'and', 'nrf2', 'activators', 'to', 'manage', 'a', 'sarscov2', 'infection', 'it', 'is', 'imperative', 'to', 'investigate', 'the', 'efficacy', 'of', 'existing', 'antiviral', 'phytochemicals', 'and', 'nrf2', 'activators', 'to', 'mitigate', 'the', 'sarscov2mediated', 'oxidative', 'stress', 'therefore', 'in', 'this', 'review', 'we', 'have', 'reviewed', 'structural', 'features', 'of', 'sarscov2', 'with', 'special', 'emphasis', 'on', 'key', 'molecular', 'targets', 'and', 'their', 'known', 'modulators', 'that', 'can', 'be', 'considered', 'for', 'the', 'development', 'of', 'nsmis']","['severe', 'acute', 'respiratory', 'syndromecorona', 'virus2', 'sarscov2', 'induced', 'coronavirus', 'disease', '19', 'covid19', 'cases', 'increasing', 'alarming', 'rate', '74', 'million', 'positive', 'cases', 'june', '11', '2020', 'causing', 'high', 'mortality', '417956', 'deaths', 'june', '11', '2020', 'economic', 'loss', '32', 'shrink', 'global', 'economy', '2020', 'across', '212', 'countries', 'globally', 'clinical', 'manifestations', 'disease', 'pneumonia', 'lung', 'injury', 'inflammation', 'severe', 'acute', 'respiratory', 'syndrome', 'sars', 'currently', 'vaccine', 'effective', 'pharmacological', 'agents', 'available', 'preventiontreatment', 'sarscov2', 'infections', 'moreover', 'development', 'suitable', 'vaccine', 'challenging', 'task', 'due', 'antibodydependent', 'enhancement', 'ade', 'th2', 'immunopathology', 'aggravates', 'infection', 'sarscov2', 'furthermore', 'emerging', 'sarscov2', 'strain', 'exhibits', 'several', 'distinct', 'genomic', 'structural', 'patterns', 'compared', 'coronavirus', 'strains', 'making', 'development', 'suitable', 'vaccine', 'even', 'difficult', 'therefore', 'identification', 'novel', 'small', 'molecule', 'inhibitors', 'nsmis', 'interfere', 'viral', 'entry', 'viral', 'propagation', 'special', 'interest', 'vital', 'managing', 'already', 'infected', 'cases', 'sarscov2', 'infection', 'mediated', 'binding', 'viral', 'spike', 'proteins', 'sprotein', 'human', 'cells', '2step', 'process', 'involves', 'angiotensin', 'converting', 'enzyme2', 'ace2', 'transmembrane', 'serine', 'protease', 'tmprss2', 'therefore', 'development', 'novel', 'inhibitors', 'ace2tmprss2', 'likely', 'beneficial', 'combating', 'sarscov2', 'infections', 'however', 'usage', 'ace2', 'inhibitors', 'block', 'sarscov2', 'viral', 'entry', 'requires', 'additional', 'studies', 'conflicting', 'findings', 'severe', 'health', 'complications', 'reported', 'inhibitors', 'patients', 'hence', 'current', 'interest', 'shifted', 'toward', 'development', 'nsmis', 'includes', 'natural', 'antiviral', 'phytochemicals', 'nrf2', 'activators', 'manage', 'sarscov2', 'infection', 'imperative', 'investigate', 'efficacy', 'existing', 'antiviral', 'phytochemicals', 'nrf2', 'activators', 'mitigate', 'sarscov2mediated', 'oxidative', 'stress', 'therefore', 'review', 'reviewed', 'structural', 'features', 'sarscov2', 'special', 'emphasis', 'key', 'molecular', 'targets', 'known', 'modulators', 'considered', 'development', 'nsmis']","['th2', 'enzyme2', 'nrf2', 'nrf2']",['enzyme2'],True,['infection']
33043190,Novel Small-Molecule Inhibitor for the Oncogenic Tyrosine Phosphatase SHP2 with Anti-Breast Cancer Cell Effects.,"The oncogenic property of the Src homology phosphotyrosine phosphatase 2 (SHP2) is well-known, but developing specific inhibitors has been very difficult. Based on our previous reports that showed the importance of acidic residues surrounding SHP2 substrate phosphotyrosines for specific recognition, we have rationally designed and chemically synthesized a small-molecule SHP2 inhibitor named 4,4'-(4'-carboxy)-4-nonyloxy-[1,1'-biphenyl]-3,5-diyl)dibutanoic acid (CNBDA). Molecular modeling predicted that CNBDA packs well into the SHP2 active site and makes extended interactions primarily with positively charged and polar amino acids surrounding the active site. <i>In vitro</i> PTPase assays showed that CNBDA inhibits SHP2 with an IC<sub>50</sub> of 5 μM. However, the IC<sub>50</sub> of CNBDA toward SHP1, the close structural homologue of SHP2, was 125 μM, suggesting an approximately 25-fold effectiveness against SHP2 than SHP1. Because SHP2 is known for its positive role in breast cancer (BC) cell biology, we tested the effect of SHP2 inhibition with CNBDA in HER2-positive BC cells. Treatment with CNBDA suppressed cell proliferation in 2D culture, anchorage-independent growth in soft agar, and mammosphere (tumorisphere) formation in suspension cultures in a concentration-dependent manner. Furthermore, CNBDA inhibited EGF-induced signaling and expression of HER2 by inhibiting the PTPase activity of SHP2 in BC cells. These findings suggest that CNBDA is a promising anti-SHP2 lead compound with anti-BC cell effects.",2020-09-25,the oncogenic property of the src homology phosphotyrosine phosphatase 2 shp2 is wellknown but developing specific inhibitors has been very difficult based on our previous reports that showed the importance of acidic residues surrounding shp2 substrate phosphotyrosines for specific recognition we have rationally designed and chemically synthesized a smallmolecule shp2 inhibitor named 444carboxy4nonyloxy11biphenyl35diyldibutanoic acid cnbda molecular modeling predicted that cnbda packs well into the shp2 active site and makes extended interactions primarily with positively charged and polar amino acids surrounding the active site iin vitroi ptpase assays showed that cnbda inhibits shp2 with an icsub50sub of 5 μm however the icsub50sub of cnbda toward shp1 the close structural homologue of shp2 was 125 μm suggesting an approximately 25fold effectiveness against shp2 than shp1 because shp2 is known for its positive role in breast cancer bc cell biology we tested the effect of shp2 inhibition with cnbda in her2positive bc cells treatment with cnbda suppressed cell proliferation in 2d culture anchorageindependent growth in soft agar and mammosphere tumorisphere formation in suspension cultures in a concentrationdependent manner furthermore cnbda inhibited egfinduced signaling and expression of her2 by inhibiting the ptpase activity of shp2 in bc cells these findings suggest that cnbda is a promising antishp2 lead compound with antibc cell effects,"['the', 'oncogenic', 'property', 'of', 'the', 'src', 'homology', 'phosphotyrosine', 'phosphatase', '2', 'shp2', 'is', 'wellknown', 'but', 'developing', 'specific', 'inhibitors', 'has', 'been', 'very', 'difficult', 'based', 'on', 'our', 'previous', 'reports', 'that', 'showed', 'the', 'importance', 'of', 'acidic', 'residues', 'surrounding', 'shp2', 'substrate', 'phosphotyrosines', 'for', 'specific', 'recognition', 'we', 'have', 'rationally', 'designed', 'and', 'chemically', 'synthesized', 'a', 'smallmolecule', 'shp2', 'inhibitor', 'named', '444carboxy4nonyloxy11biphenyl35diyldibutanoic', 'acid', 'cnbda', 'molecular', 'modeling', 'predicted', 'that', 'cnbda', 'packs', 'well', 'into', 'the', 'shp2', 'active', 'site', 'and', 'makes', 'extended', 'interactions', 'primarily', 'with', 'positively', 'charged', 'and', 'polar', 'amino', 'acids', 'surrounding', 'the', 'active', 'site', 'iin', 'vitroi', 'ptpase', 'assays', 'showed', 'that', 'cnbda', 'inhibits', 'shp2', 'with', 'an', 'icsub50sub', 'of', '5', 'μm', 'however', 'the', 'icsub50sub', 'of', 'cnbda', 'toward', 'shp1', 'the', 'close', 'structural', 'homologue', 'of', 'shp2', 'was', '125', 'μm', 'suggesting', 'an', 'approximately', '25fold', 'effectiveness', 'against', 'shp2', 'than', 'shp1', 'because', 'shp2', 'is', 'known', 'for', 'its', 'positive', 'role', 'in', 'breast', 'cancer', 'bc', 'cell', 'biology', 'we', 'tested', 'the', 'effect', 'of', 'shp2', 'inhibition', 'with', 'cnbda', 'in', 'her2positive', 'bc', 'cells', 'treatment', 'with', 'cnbda', 'suppressed', 'cell', 'proliferation', 'in', '2d', 'culture', 'anchorageindependent', 'growth', 'in', 'soft', 'agar', 'and', 'mammosphere', 'tumorisphere', 'formation', 'in', 'suspension', 'cultures', 'in', 'a', 'concentrationdependent', 'manner', 'furthermore', 'cnbda', 'inhibited', 'egfinduced', 'signaling', 'and', 'expression', 'of', 'her2', 'by', 'inhibiting', 'the', 'ptpase', 'activity', 'of', 'shp2', 'in', 'bc', 'cells', 'these', 'findings', 'suggest', 'that', 'cnbda', 'is', 'a', 'promising', 'antishp2', 'lead', 'compound', 'with', 'antibc', 'cell', 'effects']","['oncogenic', 'property', 'src', 'homology', 'phosphotyrosine', 'phosphatase', '2', 'shp2', 'wellknown', 'developing', 'specific', 'inhibitors', 'difficult', 'based', 'previous', 'reports', 'showed', 'importance', 'acidic', 'residues', 'surrounding', 'shp2', 'substrate', 'phosphotyrosines', 'specific', 'recognition', 'rationally', 'designed', 'chemically', 'synthesized', 'smallmolecule', 'shp2', 'inhibitor', 'named', '444carboxy4nonyloxy11biphenyl35diyldibutanoic', 'acid', 'cnbda', 'molecular', 'modeling', 'predicted', 'cnbda', 'packs', 'well', 'shp2', 'active', 'site', 'makes', 'extended', 'interactions', 'primarily', 'positively', 'charged', 'polar', 'amino', 'acids', 'surrounding', 'active', 'site', 'iin', 'vitroi', 'ptpase', 'assays', 'showed', 'cnbda', 'inhibits', 'shp2', 'icsub50sub', '5', 'μm', 'however', 'icsub50sub', 'cnbda', 'toward', 'shp1', 'close', 'structural', 'homologue', 'shp2', '125', 'μm', 'suggesting', 'approximately', '25fold', 'effectiveness', 'shp2', 'shp1', 'shp2', 'known', 'positive', 'role', 'breast', 'cancer', 'bc', 'cell', 'biology', 'tested', 'effect', 'shp2', 'inhibition', 'cnbda', 'her2positive', 'bc', 'cells', 'treatment', 'cnbda', 'suppressed', 'cell', 'proliferation', '2d', 'culture', 'anchorageindependent', 'growth', 'soft', 'agar', 'mammosphere', 'tumorisphere', 'formation', 'suspension', 'cultures', 'concentrationdependent', 'manner', 'furthermore', 'cnbda', 'inhibited', 'egfinduced', 'signaling', 'expression', 'her2', 'inhibiting', 'ptpase', 'activity', 'shp2', 'bc', 'cells', 'findings', 'suggest', 'cnbda', 'promising', 'antishp2', 'lead', 'compound', 'antibc', 'cell', 'effects']","['src', 'phosphotyrosines', 'shp1', 'shp1', 'her2']",['phosphotyrosines'],True,"['tumor', 'cancer']"
33039566,Androstano-arylpyrimidines: Novel small molecule inhibitors of MDR1 for sensitizing multidrug-resistant breast cancer cells.,"Apart from the numerous physiological functions of MDR1, it is widely known for its role in granting multidrug resistance to cancer cells. This ATP-driven transmembrane protein exports a wide range of chemotherapeutic agents from cancer cells, thereby deterring drugs to reach effective intracellular concentrations. Thus, inhibition of MDR1 expression or function would be a viable option to enhance the accumulation of cytotoxic agents in cancer cells which in turn could improve significantly the success rate of chemotherapy. Although, several pharmacological inhibitors have been designed and tested in the past, due to their unsuccessful translation to clinical application, there is still ongoing research to find suitable compounds to manipulate MDR1 function and potentially overturn multidrug resistance. In the present study, we demonstrate that novel DHT-derived A-ring-fused arylpyrimidinone derivatives, based on their acetylation status, can inhibit MDR1 efflux activity in MDR1 overexpressing multidrug-resistant breast adenocarcinoma cells. Strikingly, all derivatives carrying an acetoxy group on the sterane d-ring were highly potent in hindering Rhodamine 123 export via MDR1, however deacetylated molecules were not capable to exert a similar effect on multidrug resistant cancer cells. The possible molecular and cellular mechanisms underlying the efflux pump inhibiting function of acetylated derivatives were dissected using the most potent MDR1 inhibitor, compound 10g and its deacetylated counterpart (11g). Importantly, molecule 10g was able to sensitize drug resistant cells to doxorubicin-induced apoptosis, further verifying the highly advantageous nature of efflux pump inhibition upon chemotherapy. Our experiments also revealed that neither mitochondrial damage, nor MDR1 gene regulation could lay behind the MDR1 inhibitory function of compound 10g. Molecular docking studies were carried out to analyze the interactions of 10g and 11g with MDR1, however no significant differences in their binding properties were observed. Nevertheless, our results indicate that the ER stress inducing potential of molecule 10g might be the fundamental mechanism behind its inhibitory action on MDR1. With additional studies, our work can yield a structural platform for a new generation of small molecule MDR1 inhibitors to sensitize drug resistant cancer cells and at the same time it elucidates the exemplary involvement of endoplasmic reticulum stress in the molecular events to defeat multidrug resistance.",2020-10-08,apart from the numerous physiological functions of mdr1 it is widely known for its role in granting multidrug resistance to cancer cells this atpdriven transmembrane protein exports a wide range of chemotherapeutic agents from cancer cells thereby deterring drugs to reach effective intracellular concentrations thus inhibition of mdr1 expression or function would be a viable option to enhance the accumulation of cytotoxic agents in cancer cells which in turn could improve significantly the success rate of chemotherapy although several pharmacological inhibitors have been designed and tested in the past due to their unsuccessful translation to clinical application there is still ongoing research to find suitable compounds to manipulate mdr1 function and potentially overturn multidrug resistance in the present study we demonstrate that novel dhtderived aringfused arylpyrimidinone derivatives based on their acetylation status can inhibit mdr1 efflux activity in mdr1 overexpressing multidrugresistant breast adenocarcinoma cells strikingly all derivatives carrying an acetoxy group on the sterane dring were highly potent in hindering rhodamine 123 export via mdr1 however deacetylated molecules were not capable to exert a similar effect on multidrug resistant cancer cells the possible molecular and cellular mechanisms underlying the efflux pump inhibiting function of acetylated derivatives were dissected using the most potent mdr1 inhibitor compound 10g and its deacetylated counterpart 11g importantly molecule 10g was able to sensitize drug resistant cells to doxorubicininduced apoptosis further verifying the highly advantageous nature of efflux pump inhibition upon chemotherapy our experiments also revealed that neither mitochondrial damage nor mdr1 gene regulation could lay behind the mdr1 inhibitory function of compound 10g molecular docking studies were carried out to analyze the interactions of 10g and 11g with mdr1 however no significant differences in their binding properties were observed nevertheless our results indicate that the er stress inducing potential of molecule 10g might be the fundamental mechanism behind its inhibitory action on mdr1 with additional studies our work can yield a structural platform for a new generation of small molecule mdr1 inhibitors to sensitize drug resistant cancer cells and at the same time it elucidates the exemplary involvement of endoplasmic reticulum stress in the molecular events to defeat multidrug resistance,"['apart', 'from', 'the', 'numerous', 'physiological', 'functions', 'of', 'mdr1', 'it', 'is', 'widely', 'known', 'for', 'its', 'role', 'in', 'granting', 'multidrug', 'resistance', 'to', 'cancer', 'cells', 'this', 'atpdriven', 'transmembrane', 'protein', 'exports', 'a', 'wide', 'range', 'of', 'chemotherapeutic', 'agents', 'from', 'cancer', 'cells', 'thereby', 'deterring', 'drugs', 'to', 'reach', 'effective', 'intracellular', 'concentrations', 'thus', 'inhibition', 'of', 'mdr1', 'expression', 'or', 'function', 'would', 'be', 'a', 'viable', 'option', 'to', 'enhance', 'the', 'accumulation', 'of', 'cytotoxic', 'agents', 'in', 'cancer', 'cells', 'which', 'in', 'turn', 'could', 'improve', 'significantly', 'the', 'success', 'rate', 'of', 'chemotherapy', 'although', 'several', 'pharmacological', 'inhibitors', 'have', 'been', 'designed', 'and', 'tested', 'in', 'the', 'past', 'due', 'to', 'their', 'unsuccessful', 'translation', 'to', 'clinical', 'application', 'there', 'is', 'still', 'ongoing', 'research', 'to', 'find', 'suitable', 'compounds', 'to', 'manipulate', 'mdr1', 'function', 'and', 'potentially', 'overturn', 'multidrug', 'resistance', 'in', 'the', 'present', 'study', 'we', 'demonstrate', 'that', 'novel', 'dhtderived', 'aringfused', 'arylpyrimidinone', 'derivatives', 'based', 'on', 'their', 'acetylation', 'status', 'can', 'inhibit', 'mdr1', 'efflux', 'activity', 'in', 'mdr1', 'overexpressing', 'multidrugresistant', 'breast', 'adenocarcinoma', 'cells', 'strikingly', 'all', 'derivatives', 'carrying', 'an', 'acetoxy', 'group', 'on', 'the', 'sterane', 'dring', 'were', 'highly', 'potent', 'in', 'hindering', 'rhodamine', '123', 'export', 'via', 'mdr1', 'however', 'deacetylated', 'molecules', 'were', 'not', 'capable', 'to', 'exert', 'a', 'similar', 'effect', 'on', 'multidrug', 'resistant', 'cancer', 'cells', 'the', 'possible', 'molecular', 'and', 'cellular', 'mechanisms', 'underlying', 'the', 'efflux', 'pump', 'inhibiting', 'function', 'of', 'acetylated', 'derivatives', 'were', 'dissected', 'using', 'the', 'most', 'potent', 'mdr1', 'inhibitor', 'compound', '10g', 'and', 'its', 'deacetylated', 'counterpart', '11g', 'importantly', 'molecule', '10g', 'was', 'able', 'to', 'sensitize', 'drug', 'resistant', 'cells', 'to', 'doxorubicininduced', 'apoptosis', 'further', 'verifying', 'the', 'highly', 'advantageous', 'nature', 'of', 'efflux', 'pump', 'inhibition', 'upon', 'chemotherapy', 'our', 'experiments', 'also', 'revealed', 'that', 'neither', 'mitochondrial', 'damage', 'nor', 'mdr1', 'gene', 'regulation', 'could', 'lay', 'behind', 'the', 'mdr1', 'inhibitory', 'function', 'of', 'compound', '10g', 'molecular', 'docking', 'studies', 'were', 'carried', 'out', 'to', 'analyze', 'the', 'interactions', 'of', '10g', 'and', '11g', 'with', 'mdr1', 'however', 'no', 'significant', 'differences', 'in', 'their', 'binding', 'properties', 'were', 'observed', 'nevertheless', 'our', 'results', 'indicate', 'that', 'the', 'er', 'stress', 'inducing', 'potential', 'of', 'molecule', '10g', 'might', 'be', 'the', 'fundamental', 'mechanism', 'behind', 'its', 'inhibitory', 'action', 'on', 'mdr1', 'with', 'additional', 'studies', 'our', 'work', 'can', 'yield', 'a', 'structural', 'platform', 'for', 'a', 'new', 'generation', 'of', 'small', 'molecule', 'mdr1', 'inhibitors', 'to', 'sensitize', 'drug', 'resistant', 'cancer', 'cells', 'and', 'at', 'the', 'same', 'time', 'it', 'elucidates', 'the', 'exemplary', 'involvement', 'of', 'endoplasmic', 'reticulum', 'stress', 'in', 'the', 'molecular', 'events', 'to', 'defeat', 'multidrug', 'resistance']","['apart', 'numerous', 'physiological', 'functions', 'mdr1', 'widely', 'known', 'role', 'granting', 'multidrug', 'resistance', 'cancer', 'cells', 'atpdriven', 'transmembrane', 'protein', 'exports', 'wide', 'range', 'chemotherapeutic', 'agents', 'cancer', 'cells', 'thereby', 'deterring', 'drugs', 'reach', 'effective', 'intracellular', 'concentrations', 'thus', 'inhibition', 'mdr1', 'expression', 'function', 'would', 'viable', 'option', 'enhance', 'accumulation', 'cytotoxic', 'agents', 'cancer', 'cells', 'turn', 'could', 'improve', 'significantly', 'success', 'rate', 'chemotherapy', 'although', 'several', 'pharmacological', 'inhibitors', 'designed', 'tested', 'past', 'due', 'unsuccessful', 'translation', 'clinical', 'application', 'still', 'ongoing', 'research', 'find', 'suitable', 'compounds', 'manipulate', 'mdr1', 'function', 'potentially', 'overturn', 'multidrug', 'resistance', 'present', 'study', 'demonstrate', 'novel', 'dhtderived', 'aringfused', 'arylpyrimidinone', 'derivatives', 'based', 'acetylation', 'status', 'inhibit', 'mdr1', 'efflux', 'activity', 'mdr1', 'overexpressing', 'multidrugresistant', 'breast', 'adenocarcinoma', 'cells', 'strikingly', 'derivatives', 'carrying', 'acetoxy', 'group', 'sterane', 'dring', 'highly', 'potent', 'hindering', 'rhodamine', '123', 'export', 'via', 'mdr1', 'however', 'deacetylated', 'molecules', 'capable', 'exert', 'similar', 'effect', 'multidrug', 'resistant', 'cancer', 'cells', 'possible', 'molecular', 'cellular', 'mechanisms', 'underlying', 'efflux', 'pump', 'inhibiting', 'function', 'acetylated', 'derivatives', 'dissected', 'using', 'potent', 'mdr1', 'inhibitor', 'compound', '10g', 'deacetylated', 'counterpart', '11g', 'importantly', 'molecule', '10g', 'able', 'sensitize', 'drug', 'resistant', 'cells', 'doxorubicininduced', 'apoptosis', 'verifying', 'highly', 'advantageous', 'nature', 'efflux', 'pump', 'inhibition', 'upon', 'chemotherapy', 'experiments', 'also', 'revealed', 'neither', 'mitochondrial', 'damage', 'mdr1', 'gene', 'regulation', 'could', 'lay', 'behind', 'mdr1', 'inhibitory', 'function', 'compound', '10g', 'molecular', 'docking', 'studies', 'carried', 'analyze', 'interactions', '10g', '11g', 'mdr1', 'however', 'significant', 'differences', 'binding', 'properties', 'observed', 'nevertheless', 'results', 'indicate', 'er', 'stress', 'inducing', 'potential', 'molecule', '10g', 'might', 'fundamental', 'mechanism', 'behind', 'inhibitory', 'action', 'mdr1', 'additional', 'studies', 'work', 'yield', 'structural', 'platform', 'new', 'generation', 'small', 'molecule', 'mdr1', 'inhibitors', 'sensitize', 'drug', 'resistant', 'cancer', 'cells', 'time', 'elucidates', 'exemplary', 'involvement', 'endoplasmic', 'reticulum', 'stress', 'molecular', 'events', 'defeat', 'multidrug', 'resistance']","['mdr1', 'mdr1', 'mdr1', 'mdr1', 'mdr1', 'mdr1', 'mdr1', 'mdr1', 'mdr1', 'mdr1', 'mdr1', 'mdr1']","['mdr1', 'mdr1', 'mdr1', 'mdr1', 'mdr1', 'mdr1', 'mdr1', 'mdr1', 'mdr1', 'mdr1', 'mdr1', 'mdr1']",True,['cancer']
33002342,New small-molecule compound Hu-17 inhibits estrogen biosynthesis by aromatase in human ovarian granulosa cancer cells.,"Estrogen-dependent cancers (breast, endometrial, and ovarian) are among the leading causes of morbidity and mortality in women worldwide. Aromatase is the main enzyme that catalyzes the biosynthesis of estrogen, which drives proliferation, and antiestrogens can inhibit the growth of these estrogen-dependent cancers. Hu-17, an aromatase inhibitor, is a novel small-molecule compound that suppresses viability of and promotes apoptosis in ovarian cancer cells. Therefore, this study aimed to predict targets of Hu-17 and assess its intracellular signaling in ovarian cancer cells. Using the Similarity Ensemble Approach software to predict the potential mechanism of Hu-17 and combining phospho-proteome arrays with western blot analysis, we observed that Hu-17 could inhibit the ERK pathway, resulting in reduced estrogen synthesis in KGN cells, a cell line derived from a patient with invasive ovarian granulosa cell carcinoma. Hu-17 reduced the expression of CYP19A1 mRNA, responsible for producing aromatase, by suppressing the phosphorylation of cAMP response element binding-1. Hu-17 also accelerated aromatase protein degradation but had no effect on aromatase activity. Therefore, Hu-17 could serve as a potential treatment for estrogen-dependent cancers albeit further investigation is warranted.",2020-10-01,estrogendependent cancers breast endometrial and ovarian are among the leading causes of morbidity and mortality in women worldwide aromatase is the main enzyme that catalyzes the biosynthesis of estrogen which drives proliferation and antiestrogens can inhibit the growth of these estrogendependent cancers hu17 an aromatase inhibitor is a novel smallmolecule compound that suppresses viability of and promotes apoptosis in ovarian cancer cells therefore this study aimed to predict targets of hu17 and assess its intracellular signaling in ovarian cancer cells using the similarity ensemble approach software to predict the potential mechanism of hu17 and combining phosphoproteome arrays with western blot analysis we observed that hu17 could inhibit the erk pathway resulting in reduced estrogen synthesis in kgn cells a cell line derived from a patient with invasive ovarian granulosa cell carcinoma hu17 reduced the expression of cyp19a1 mrna responsible for producing aromatase by suppressing the phosphorylation of camp response element binding1 hu17 also accelerated aromatase protein degradation but had no effect on aromatase activity therefore hu17 could serve as a potential treatment for estrogendependent cancers albeit further investigation is warranted,"['estrogendependent', 'cancers', 'breast', 'endometrial', 'and', 'ovarian', 'are', 'among', 'the', 'leading', 'causes', 'of', 'morbidity', 'and', 'mortality', 'in', 'women', 'worldwide', 'aromatase', 'is', 'the', 'main', 'enzyme', 'that', 'catalyzes', 'the', 'biosynthesis', 'of', 'estrogen', 'which', 'drives', 'proliferation', 'and', 'antiestrogens', 'can', 'inhibit', 'the', 'growth', 'of', 'these', 'estrogendependent', 'cancers', 'hu17', 'an', 'aromatase', 'inhibitor', 'is', 'a', 'novel', 'smallmolecule', 'compound', 'that', 'suppresses', 'viability', 'of', 'and', 'promotes', 'apoptosis', 'in', 'ovarian', 'cancer', 'cells', 'therefore', 'this', 'study', 'aimed', 'to', 'predict', 'targets', 'of', 'hu17', 'and', 'assess', 'its', 'intracellular', 'signaling', 'in', 'ovarian', 'cancer', 'cells', 'using', 'the', 'similarity', 'ensemble', 'approach', 'software', 'to', 'predict', 'the', 'potential', 'mechanism', 'of', 'hu17', 'and', 'combining', 'phosphoproteome', 'arrays', 'with', 'western', 'blot', 'analysis', 'we', 'observed', 'that', 'hu17', 'could', 'inhibit', 'the', 'erk', 'pathway', 'resulting', 'in', 'reduced', 'estrogen', 'synthesis', 'in', 'kgn', 'cells', 'a', 'cell', 'line', 'derived', 'from', 'a', 'patient', 'with', 'invasive', 'ovarian', 'granulosa', 'cell', 'carcinoma', 'hu17', 'reduced', 'the', 'expression', 'of', 'cyp19a1', 'mrna', 'responsible', 'for', 'producing', 'aromatase', 'by', 'suppressing', 'the', 'phosphorylation', 'of', 'camp', 'response', 'element', 'binding1', 'hu17', 'also', 'accelerated', 'aromatase', 'protein', 'degradation', 'but', 'had', 'no', 'effect', 'on', 'aromatase', 'activity', 'therefore', 'hu17', 'could', 'serve', 'as', 'a', 'potential', 'treatment', 'for', 'estrogendependent', 'cancers', 'albeit', 'further', 'investigation', 'is', 'warranted']","['estrogendependent', 'cancers', 'breast', 'endometrial', 'ovarian', 'among', 'leading', 'causes', 'morbidity', 'mortality', 'women', 'worldwide', 'aromatase', 'main', 'enzyme', 'catalyzes', 'biosynthesis', 'estrogen', 'drives', 'proliferation', 'antiestrogens', 'inhibit', 'growth', 'estrogendependent', 'cancers', 'hu17', 'aromatase', 'inhibitor', 'novel', 'smallmolecule', 'compound', 'suppresses', 'viability', 'promotes', 'apoptosis', 'ovarian', 'cancer', 'cells', 'therefore', 'study', 'aimed', 'predict', 'targets', 'hu17', 'assess', 'intracellular', 'signaling', 'ovarian', 'cancer', 'cells', 'using', 'similarity', 'ensemble', 'approach', 'software', 'predict', 'potential', 'mechanism', 'hu17', 'combining', 'phosphoproteome', 'arrays', 'western', 'blot', 'analysis', 'observed', 'hu17', 'could', 'inhibit', 'erk', 'pathway', 'resulting', 'reduced', 'estrogen', 'synthesis', 'kgn', 'cells', 'cell', 'line', 'derived', 'patient', 'invasive', 'ovarian', 'granulosa', 'cell', 'carcinoma', 'hu17', 'reduced', 'expression', 'cyp19a1', 'mrna', 'responsible', 'producing', 'aromatase', 'suppressing', 'phosphorylation', 'camp', 'response', 'element', 'binding1', 'hu17', 'also', 'accelerated', 'aromatase', 'protein', 'degradation', 'effect', 'aromatase', 'activity', 'therefore', 'hu17', 'could', 'serve', 'potential', 'treatment', 'estrogendependent', 'cancers', 'albeit', 'investigation', 'warranted']","['erk', 'cyp19a1', 'binding1']","['cyp19a1', 'binding1']",True,['cancer']
32947941,Inhibition of DNA Repair Pathways and Induction of ROS Are Potential Mechanisms of Action of the Small Molecule Inhibitor BOLD-100 in Breast Cancer.,"BOLD-100, a ruthenium-based complex, sodium trans-[tetrachloridobis (1H-indazole) ruthenate (III)] (also known as IT-139, NKP1339 or KP1339), is a novel small molecule drug that demonstrated a manageable safety profile at the maximum tolerated dose and modest antitumor activity in a phase I clinical trial. BOLD-100 has been reported to inhibit the upregulation of the endoplasmic reticulum stress sensing protein GRP78. However, response to BOLD-100 varies in different cancer models and the precise mechanism of action in high-response versus low-response cancer cells remains unclear. In vitro studies have indicated that BOLD-100 induces cytostatic rather than cytotoxic effects as a monotherapy. To understand BOLD-100-mediated signaling mechanism in breast cancer cells, we used estrogen receptor positive (ER+) MCF7 breast cancer cells to obtain gene-metabolite integrated models. At 100 μM, BOLD-100 significantly reduced cell proliferation and expression of genes involved in the DNA repair pathway. BOLD-100 also induced reactive oxygen species (ROS) and phosphorylation of histone H2AX, gamma-H2AX (Ser139), suggesting disruption of proper DNA surveillance. In estrogen receptor negative (ER-) breast cancer cells, combination of BOLD-100 with a PARP inhibitor, olaparib, induced significant inhibition of cell growth and xenografts and increased gamma-H2AX. Thus, BOLD-100 is a novel DNA repair pathway targeting agent and can be used with other chemotherapies in ER- breast cancer.",2020-09-16,bold100 a rutheniumbased complex sodium transtetrachloridobis 1hindazole ruthenate iii also known as it139 nkp1339 or kp1339 is a novel small molecule drug that demonstrated a manageable safety profile at the maximum tolerated dose and modest antitumor activity in a phase i clinical trial bold100 has been reported to inhibit the upregulation of the endoplasmic reticulum stress sensing protein grp78 however response to bold100 varies in different cancer models and the precise mechanism of action in highresponse versus lowresponse cancer cells remains unclear in vitro studies have indicated that bold100 induces cytostatic rather than cytotoxic effects as a monotherapy to understand bold100mediated signaling mechanism in breast cancer cells we used estrogen receptor positive er mcf7 breast cancer cells to obtain genemetabolite integrated models at 100 μm bold100 significantly reduced cell proliferation and expression of genes involved in the dna repair pathway bold100 also induced reactive oxygen species ros and phosphorylation of histone h2ax gammah2ax ser139 suggesting disruption of proper dna surveillance in estrogen receptor negative er breast cancer cells combination of bold100 with a parp inhibitor olaparib induced significant inhibition of cell growth and xenografts and increased gammah2ax thus bold100 is a novel dna repair pathway targeting agent and can be used with other chemotherapies in er breast cancer,"['bold100', 'a', 'rutheniumbased', 'complex', 'sodium', 'transtetrachloridobis', '1hindazole', 'ruthenate', 'iii', 'also', 'known', 'as', 'it139', 'nkp1339', 'or', 'kp1339', 'is', 'a', 'novel', 'small', 'molecule', 'drug', 'that', 'demonstrated', 'a', 'manageable', 'safety', 'profile', 'at', 'the', 'maximum', 'tolerated', 'dose', 'and', 'modest', 'antitumor', 'activity', 'in', 'a', 'phase', 'i', 'clinical', 'trial', 'bold100', 'has', 'been', 'reported', 'to', 'inhibit', 'the', 'upregulation', 'of', 'the', 'endoplasmic', 'reticulum', 'stress', 'sensing', 'protein', 'grp78', 'however', 'response', 'to', 'bold100', 'varies', 'in', 'different', 'cancer', 'models', 'and', 'the', 'precise', 'mechanism', 'of', 'action', 'in', 'highresponse', 'versus', 'lowresponse', 'cancer', 'cells', 'remains', 'unclear', 'in', 'vitro', 'studies', 'have', 'indicated', 'that', 'bold100', 'induces', 'cytostatic', 'rather', 'than', 'cytotoxic', 'effects', 'as', 'a', 'monotherapy', 'to', 'understand', 'bold100mediated', 'signaling', 'mechanism', 'in', 'breast', 'cancer', 'cells', 'we', 'used', 'estrogen', 'receptor', 'positive', 'er', 'mcf7', 'breast', 'cancer', 'cells', 'to', 'obtain', 'genemetabolite', 'integrated', 'models', 'at', '100', 'μm', 'bold100', 'significantly', 'reduced', 'cell', 'proliferation', 'and', 'expression', 'of', 'genes', 'involved', 'in', 'the', 'dna', 'repair', 'pathway', 'bold100', 'also', 'induced', 'reactive', 'oxygen', 'species', 'ros', 'and', 'phosphorylation', 'of', 'histone', 'h2ax', 'gammah2ax', 'ser139', 'suggesting', 'disruption', 'of', 'proper', 'dna', 'surveillance', 'in', 'estrogen', 'receptor', 'negative', 'er', 'breast', 'cancer', 'cells', 'combination', 'of', 'bold100', 'with', 'a', 'parp', 'inhibitor', 'olaparib', 'induced', 'significant', 'inhibition', 'of', 'cell', 'growth', 'and', 'xenografts', 'and', 'increased', 'gammah2ax', 'thus', 'bold100', 'is', 'a', 'novel', 'dna', 'repair', 'pathway', 'targeting', 'agent', 'and', 'can', 'be', 'used', 'with', 'other', 'chemotherapies', 'in', 'er', 'breast', 'cancer']","['bold100', 'rutheniumbased', 'complex', 'sodium', 'transtetrachloridobis', '1hindazole', 'ruthenate', 'iii', 'also', 'known', 'it139', 'nkp1339', 'kp1339', 'novel', 'small', 'molecule', 'drug', 'demonstrated', 'manageable', 'safety', 'profile', 'maximum', 'tolerated', 'dose', 'modest', 'antitumor', 'activity', 'phase', 'clinical', 'trial', 'bold100', 'reported', 'inhibit', 'upregulation', 'endoplasmic', 'reticulum', 'stress', 'sensing', 'protein', 'grp78', 'however', 'response', 'bold100', 'varies', 'different', 'cancer', 'models', 'precise', 'mechanism', 'action', 'highresponse', 'versus', 'lowresponse', 'cancer', 'cells', 'remains', 'unclear', 'vitro', 'studies', 'indicated', 'bold100', 'induces', 'cytostatic', 'rather', 'cytotoxic', 'effects', 'monotherapy', 'understand', 'bold100mediated', 'signaling', 'mechanism', 'breast', 'cancer', 'cells', 'used', 'estrogen', 'receptor', 'positive', 'er', 'mcf7', 'breast', 'cancer', 'cells', 'obtain', 'genemetabolite', 'integrated', 'models', '100', 'μm', 'bold100', 'significantly', 'reduced', 'cell', 'proliferation', 'expression', 'genes', 'involved', 'dna', 'repair', 'pathway', 'bold100', 'also', 'induced', 'reactive', 'oxygen', 'species', 'ros', 'phosphorylation', 'histone', 'h2ax', 'gammah2ax', 'ser139', 'suggesting', 'disruption', 'proper', 'dna', 'surveillance', 'estrogen', 'receptor', 'negative', 'er', 'breast', 'cancer', 'cells', 'combination', 'bold100', 'parp', 'inhibitor', 'olaparib', 'induced', 'significant', 'inhibition', 'cell', 'growth', 'xenografts', 'increased', 'gammah2ax', 'thus', 'bold100', 'novel', 'dna', 'repair', 'pathway', 'targeting', 'agent', 'used', 'chemotherapies', 'er', 'breast', 'cancer']","['grp78', 'ros']",['grp78'],True,"['tumor', 'cancer']"
32923118,Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide.,"Triple-negative breast cancer (TNBC) is a highly metastatic and aggressive disease with limited treatment options. Recently, the combination of the immune checkpoint inhibitor (ICI) atezolizumab (anti-PD-L1) with nab-paclitaxel was approved following a clinical trial that showed response rates in at least 43% of patients. While this approval marks a major advance in the treatment of TNBC it may be possible to improve the efficacy of ICI therapies through further modulation of the suppressive tumor immune microenvironment (TIME). Several factors may limit immune response in TNBC including aberrant growth factor signaling, such as VEGFR2 and cMet signaling, inefficient vascularization, poor delivery of drugs and immune cells, and the skewing of immune cell populations toward immunosuppressive phenotypes. Here we investigate the immune-modulating properties of AXT201, a novel 20 amino-acid integrin-binding peptide in two syngeneic mouse TNBC models: 4T1-BALB/c and NT4-FVB. AXT201 treatment improved survival in the NT4 model by 20% and inhibited the growth of 4T1 tumors by 47% over 22 days post-inoculation. Subsequent immunohistochemical analyses of 4T1 tumors also showed a 53% reduction in vascular density and a 184% increase in pericyte coverage following peptide treatment. Flow cytometry analyses demonstrated evidence of a more favorable anti-tumor immune microenvironment following treatment with AXT201, including significant decreases in the populations of T regulatory cells, monocytic myeloid-derived suppressor cells, and PD-L1 expressing cells and increased expression of T cell functional markers. Together, these findings demonstrate immune-activating properties of AXT201 that could be developed in combination with other immunomodulatory agents in the treatment of TNBC.",2020-05-14,triplenegative breast cancer tnbc is a highly metastatic and aggressive disease with limited treatment options recently the combination of the immune checkpoint inhibitor ici atezolizumab antipdl1 with nabpaclitaxel was approved following a clinical trial that showed response rates in at least 43 of patients while this approval marks a major advance in the treatment of tnbc it may be possible to improve the efficacy of ici therapies through further modulation of the suppressive tumor immune microenvironment time several factors may limit immune response in tnbc including aberrant growth factor signaling such as vegfr2 and cmet signaling inefficient vascularization poor delivery of drugs and immune cells and the skewing of immune cell populations toward immunosuppressive phenotypes here we investigate the immunemodulating properties of axt201 a novel 20 aminoacid integrinbinding peptide in two syngeneic mouse tnbc models 4t1balbc and nt4fvb axt201 treatment improved survival in the nt4 model by 20 and inhibited the growth of 4t1 tumors by 47 over 22 days postinoculation subsequent immunohistochemical analyses of 4t1 tumors also showed a 53 reduction in vascular density and a 184 increase in pericyte coverage following peptide treatment flow cytometry analyses demonstrated evidence of a more favorable antitumor immune microenvironment following treatment with axt201 including significant decreases in the populations of t regulatory cells monocytic myeloidderived suppressor cells and pdl1 expressing cells and increased expression of t cell functional markers together these findings demonstrate immuneactivating properties of axt201 that could be developed in combination with other immunomodulatory agents in the treatment of tnbc,"['triplenegative', 'breast', 'cancer', 'tnbc', 'is', 'a', 'highly', 'metastatic', 'and', 'aggressive', 'disease', 'with', 'limited', 'treatment', 'options', 'recently', 'the', 'combination', 'of', 'the', 'immune', 'checkpoint', 'inhibitor', 'ici', 'atezolizumab', 'antipdl1', 'with', 'nabpaclitaxel', 'was', 'approved', 'following', 'a', 'clinical', 'trial', 'that', 'showed', 'response', 'rates', 'in', 'at', 'least', '43', 'of', 'patients', 'while', 'this', 'approval', 'marks', 'a', 'major', 'advance', 'in', 'the', 'treatment', 'of', 'tnbc', 'it', 'may', 'be', 'possible', 'to', 'improve', 'the', 'efficacy', 'of', 'ici', 'therapies', 'through', 'further', 'modulation', 'of', 'the', 'suppressive', 'tumor', 'immune', 'microenvironment', 'time', 'several', 'factors', 'may', 'limit', 'immune', 'response', 'in', 'tnbc', 'including', 'aberrant', 'growth', 'factor', 'signaling', 'such', 'as', 'vegfr2', 'and', 'cmet', 'signaling', 'inefficient', 'vascularization', 'poor', 'delivery', 'of', 'drugs', 'and', 'immune', 'cells', 'and', 'the', 'skewing', 'of', 'immune', 'cell', 'populations', 'toward', 'immunosuppressive', 'phenotypes', 'here', 'we', 'investigate', 'the', 'immunemodulating', 'properties', 'of', 'axt201', 'a', 'novel', '20', 'aminoacid', 'integrinbinding', 'peptide', 'in', 'two', 'syngeneic', 'mouse', 'tnbc', 'models', '4t1balbc', 'and', 'nt4fvb', 'axt201', 'treatment', 'improved', 'survival', 'in', 'the', 'nt4', 'model', 'by', '20', 'and', 'inhibited', 'the', 'growth', 'of', '4t1', 'tumors', 'by', '47', 'over', '22', 'days', 'postinoculation', 'subsequent', 'immunohistochemical', 'analyses', 'of', '4t1', 'tumors', 'also', 'showed', 'a', '53', 'reduction', 'in', 'vascular', 'density', 'and', 'a', '184', 'increase', 'in', 'pericyte', 'coverage', 'following', 'peptide', 'treatment', 'flow', 'cytometry', 'analyses', 'demonstrated', 'evidence', 'of', 'a', 'more', 'favorable', 'antitumor', 'immune', 'microenvironment', 'following', 'treatment', 'with', 'axt201', 'including', 'significant', 'decreases', 'in', 'the', 'populations', 'of', 't', 'regulatory', 'cells', 'monocytic', 'myeloidderived', 'suppressor', 'cells', 'and', 'pdl1', 'expressing', 'cells', 'and', 'increased', 'expression', 'of', 't', 'cell', 'functional', 'markers', 'together', 'these', 'findings', 'demonstrate', 'immuneactivating', 'properties', 'of', 'axt201', 'that', 'could', 'be', 'developed', 'in', 'combination', 'with', 'other', 'immunomodulatory', 'agents', 'in', 'the', 'treatment', 'of', 'tnbc']","['triplenegative', 'breast', 'cancer', 'tnbc', 'highly', 'metastatic', 'aggressive', 'disease', 'limited', 'treatment', 'options', 'recently', 'combination', 'immune', 'checkpoint', 'inhibitor', 'ici', 'atezolizumab', 'antipdl1', 'nabpaclitaxel', 'approved', 'following', 'clinical', 'trial', 'showed', 'response', 'rates', 'least', '43', 'patients', 'approval', 'marks', 'major', 'advance', 'treatment', 'tnbc', 'may', 'possible', 'improve', 'efficacy', 'ici', 'therapies', 'modulation', 'suppressive', 'tumor', 'immune', 'microenvironment', 'time', 'several', 'factors', 'may', 'limit', 'immune', 'response', 'tnbc', 'including', 'aberrant', 'growth', 'factor', 'signaling', 'vegfr2', 'cmet', 'signaling', 'inefficient', 'vascularization', 'poor', 'delivery', 'drugs', 'immune', 'cells', 'skewing', 'immune', 'cell', 'populations', 'toward', 'immunosuppressive', 'phenotypes', 'investigate', 'immunemodulating', 'properties', 'axt201', 'novel', '20', 'aminoacid', 'integrinbinding', 'peptide', 'two', 'syngeneic', 'mouse', 'tnbc', 'models', '4t1balbc', 'nt4fvb', 'axt201', 'treatment', 'improved', 'survival', 'nt4', 'model', '20', 'inhibited', 'growth', '4t1', 'tumors', '47', '22', 'days', 'postinoculation', 'subsequent', 'immunohistochemical', 'analyses', '4t1', 'tumors', 'also', 'showed', '53', 'reduction', 'vascular', 'density', '184', 'increase', 'pericyte', 'coverage', 'following', 'peptide', 'treatment', 'flow', 'cytometry', 'analyses', 'demonstrated', 'evidence', 'favorable', 'antitumor', 'immune', 'microenvironment', 'following', 'treatment', 'axt201', 'including', 'significant', 'decreases', 'populations', 'regulatory', 'cells', 'monocytic', 'myeloidderived', 'suppressor', 'cells', 'pdl1', 'expressing', 'cells', 'increased', 'expression', 'cell', 'functional', 'markers', 'together', 'findings', 'demonstrate', 'immuneactivating', 'properties', 'axt201', 'could', 'developed', 'combination', 'immunomodulatory', 'agents', 'treatment', 'tnbc']","['vegfr2', 'cmet']",['cmet'],True,"['tumor', 'cancer']"
32905903,Adaptable antigen matrix platforms for peptide vaccination strategies and T cell-mediated anti-tumor immunity.,"Injection of antigenic peptides has been widely used as a vaccine strategy to boost T cell immunity. However, the poor immunogenicity of single peptides can potentially be strengthened through modification of the tertiary structure and the selection of the accompanying adjuvant. Here, we generated antigenic peptides into non-linear trimers by solid phase peptide synthesis, thereby enhancing antigen presentation by dendritic cells to CD8<sup>+</sup> T cells in vitro and in vivo. CD8<sup>+</sup> T cells from mice vaccinated with trimers showed an KLRG1<sup>+</sup> effector phenotype and were able to recognize and kill antigen-expressing tumor cells ex vivo. Importantly, trimers outperformed synthetic long peptide in terms of T cell response even when equal number of epitopes were used for immunization. To improve the synthesis of trimers containing difficult peptide sequences, we developed a novel small molecule that functions as conjugation platform for synthetic long peptides. This platform , termed Antigen MAtriX (AMAX) improved yield, purity and solubility of trimers over conventional solid phase synthesis strategies. AMAX outperformed synthetic long peptides in terms of both CD8<sup>+</sup> and CD4<sup>+</sup> T cell responses and allowed functionalization with DC-SIGN-binding carbohydrates for in vivo dendritic cell targeting strategies, boosting T cell responses even further. Moreover, we show that agonistic CD40 antibody combined with MF59 (AddaVax) emulsion synergistically improves the antigen-specific T cell response of the AMAX in vivo. Also, tumor-associated antigens and neo-antigens could be incorporated in AMAX for tumor-specific CD8<sup>+</sup> T cell responses. Importantly, immunization with a mix of neoantigen AMAX could reduce tumor growth in a pre-clinical syngeneic mouse model. Hence, we provide pre-clinical support for the induction of effector CD8<sup>+</sup> T cells through the adaptable AMAX platform as easy implementable peptidic vaccination strategy against any antigen of choice, including neoantigens for anti-tumor immunity.",2020-08-28,injection of antigenic peptides has been widely used as a vaccine strategy to boost t cell immunity however the poor immunogenicity of single peptides can potentially be strengthened through modification of the tertiary structure and the selection of the accompanying adjuvant here we generated antigenic peptides into nonlinear trimers by solid phase peptide synthesis thereby enhancing antigen presentation by dendritic cells to cd8supsup t cells in vitro and in vivo cd8supsup t cells from mice vaccinated with trimers showed an klrg1supsup effector phenotype and were able to recognize and kill antigenexpressing tumor cells ex vivo importantly trimers outperformed synthetic long peptide in terms of t cell response even when equal number of epitopes were used for immunization to improve the synthesis of trimers containing difficult peptide sequences we developed a novel small molecule that functions as conjugation platform for synthetic long peptides this platform  termed antigen matrix amax improved yield purity and solubility of trimers over conventional solid phase synthesis strategies amax outperformed synthetic long peptides in terms of both cd8supsup and cd4supsup t cell responses and allowed functionalization with dcsignbinding carbohydrates for in vivo dendritic cell targeting strategies boosting t cell responses even further moreover we show that agonistic cd40 antibody combined with mf59 addavax emulsion synergistically improves the antigenspecific t cell response of the amax in vivo also tumorassociated antigens and neoantigens could be incorporated in amax for tumorspecific cd8supsup t cell responses importantly immunization with a mix of neoantigen amax could reduce tumor growth in a preclinical syngeneic mouse model hence we provide preclinical support for the induction of effector cd8supsup t cells through the adaptable amax platform as easy implementable peptidic vaccination strategy against any antigen of choice including neoantigens for antitumor immunity,"['injection', 'of', 'antigenic', 'peptides', 'has', 'been', 'widely', 'used', 'as', 'a', 'vaccine', 'strategy', 'to', 'boost', 't', 'cell', 'immunity', 'however', 'the', 'poor', 'immunogenicity', 'of', 'single', 'peptides', 'can', 'potentially', 'be', 'strengthened', 'through', 'modification', 'of', 'the', 'tertiary', 'structure', 'and', 'the', 'selection', 'of', 'the', 'accompanying', 'adjuvant', 'here', 'we', 'generated', 'antigenic', 'peptides', 'into', 'nonlinear', 'trimers', 'by', 'solid', 'phase', 'peptide', 'synthesis', 'thereby', 'enhancing', 'antigen', 'presentation', 'by', 'dendritic', 'cells', 'to', 'cd8supsup', 't', 'cells', 'in', 'vitro', 'and', 'in', 'vivo', 'cd8supsup', 't', 'cells', 'from', 'mice', 'vaccinated', 'with', 'trimers', 'showed', 'an', 'klrg1supsup', 'effector', 'phenotype', 'and', 'were', 'able', 'to', 'recognize', 'and', 'kill', 'antigenexpressing', 'tumor', 'cells', 'ex', 'vivo', 'importantly', 'trimers', 'outperformed', 'synthetic', 'long', 'peptide', 'in', 'terms', 'of', 't', 'cell', 'response', 'even', 'when', 'equal', 'number', 'of', 'epitopes', 'were', 'used', 'for', 'immunization', 'to', 'improve', 'the', 'synthesis', 'of', 'trimers', 'containing', 'difficult', 'peptide', 'sequences', 'we', 'developed', 'a', 'novel', 'small', 'molecule', 'that', 'functions', 'as', 'conjugation', 'platform', 'for', 'synthetic', 'long', 'peptides', 'this', 'platform', 'termed', 'antigen', 'matrix', 'amax', 'improved', 'yield', 'purity', 'and', 'solubility', 'of', 'trimers', 'over', 'conventional', 'solid', 'phase', 'synthesis', 'strategies', 'amax', 'outperformed', 'synthetic', 'long', 'peptides', 'in', 'terms', 'of', 'both', 'cd8supsup', 'and', 'cd4supsup', 't', 'cell', 'responses', 'and', 'allowed', 'functionalization', 'with', 'dcsignbinding', 'carbohydrates', 'for', 'in', 'vivo', 'dendritic', 'cell', 'targeting', 'strategies', 'boosting', 't', 'cell', 'responses', 'even', 'further', 'moreover', 'we', 'show', 'that', 'agonistic', 'cd40', 'antibody', 'combined', 'with', 'mf59', 'addavax', 'emulsion', 'synergistically', 'improves', 'the', 'antigenspecific', 't', 'cell', 'response', 'of', 'the', 'amax', 'in', 'vivo', 'also', 'tumorassociated', 'antigens', 'and', 'neoantigens', 'could', 'be', 'incorporated', 'in', 'amax', 'for', 'tumorspecific', 'cd8supsup', 't', 'cell', 'responses', 'importantly', 'immunization', 'with', 'a', 'mix', 'of', 'neoantigen', 'amax', 'could', 'reduce', 'tumor', 'growth', 'in', 'a', 'preclinical', 'syngeneic', 'mouse', 'model', 'hence', 'we', 'provide', 'preclinical', 'support', 'for', 'the', 'induction', 'of', 'effector', 'cd8supsup', 't', 'cells', 'through', 'the', 'adaptable', 'amax', 'platform', 'as', 'easy', 'implementable', 'peptidic', 'vaccination', 'strategy', 'against', 'any', 'antigen', 'of', 'choice', 'including', 'neoantigens', 'for', 'antitumor', 'immunity']","['injection', 'antigenic', 'peptides', 'widely', 'used', 'vaccine', 'strategy', 'boost', 'cell', 'immunity', 'however', 'poor', 'immunogenicity', 'single', 'peptides', 'potentially', 'strengthened', 'modification', 'tertiary', 'structure', 'selection', 'accompanying', 'adjuvant', 'generated', 'antigenic', 'peptides', 'nonlinear', 'trimers', 'solid', 'phase', 'peptide', 'synthesis', 'thereby', 'enhancing', 'antigen', 'presentation', 'dendritic', 'cells', 'cd8supsup', 'cells', 'vitro', 'vivo', 'cd8supsup', 'cells', 'mice', 'vaccinated', 'trimers', 'showed', 'klrg1supsup', 'effector', 'phenotype', 'able', 'recognize', 'kill', 'antigenexpressing', 'tumor', 'cells', 'ex', 'vivo', 'importantly', 'trimers', 'outperformed', 'synthetic', 'long', 'peptide', 'terms', 'cell', 'response', 'even', 'equal', 'number', 'epitopes', 'used', 'immunization', 'improve', 'synthesis', 'trimers', 'containing', 'difficult', 'peptide', 'sequences', 'developed', 'novel', 'small', 'molecule', 'functions', 'conjugation', 'platform', 'synthetic', 'long', 'peptides', 'platform', 'termed', 'antigen', 'matrix', 'amax', 'improved', 'yield', 'purity', 'solubility', 'trimers', 'conventional', 'solid', 'phase', 'synthesis', 'strategies', 'amax', 'outperformed', 'synthetic', 'long', 'peptides', 'terms', 'cd8supsup', 'cd4supsup', 'cell', 'responses', 'allowed', 'functionalization', 'dcsignbinding', 'carbohydrates', 'vivo', 'dendritic', 'cell', 'targeting', 'strategies', 'boosting', 'cell', 'responses', 'even', 'moreover', 'show', 'agonistic', 'cd40', 'antibody', 'combined', 'mf59', 'addavax', 'emulsion', 'synergistically', 'improves', 'antigenspecific', 'cell', 'response', 'amax', 'vivo', 'also', 'tumorassociated', 'antigens', 'neoantigens', 'could', 'incorporated', 'amax', 'tumorspecific', 'cd8supsup', 'cell', 'responses', 'importantly', 'immunization', 'mix', 'neoantigen', 'amax', 'could', 'reduce', 'tumor', 'growth', 'preclinical', 'syngeneic', 'mouse', 'model', 'hence', 'provide', 'preclinical', 'support', 'induction', 'effector', 'cd8supsup', 'cells', 'adaptable', 'amax', 'platform', 'easy', 'implementable', 'peptidic', 'vaccination', 'strategy', 'antigen', 'choice', 'including', 'neoantigens', 'antitumor', 'immunity']","['cd40', 'neoantigen']",['neoantigen'],False,['tumor']
32867384,"A Novel Peptide Antibiotic, Pro10-1D, Designed from Insect Defensin Shows Antibacterial and Anti-Inflammatory Activities in Sepsis Models.","Owing to the challenges faced by conventional therapeutics, novel peptide antibiotics against multidrug-resistant (MDR) gram-negative bacteria need to be urgently developed. We had previously designed Pro9-3 and Pro9-3D from the defensin of beetle <i>Protaetia brevitarsis</i>; they showed high antimicrobial activity with cytotoxicity. Here, we aimed to develop peptide antibiotics with bacterial cell selectivity and potent antibacterial activity against gram-negative bacteria. We designed 10-meric peptides with increased cationicity by adding Arg to the N-terminus of Pro9-3 (Pro10-1) and its D-enantiomeric alteration (Pro10-1D). Among all tested peptides, the newly designed Pro10-1D showed the strongest antibacterial activity against <i>Escherichia coli</i>, <i>Acinetobacter baumannii</i>, and MDR strains with resistance against protease digestion. Pro10-1D can act as a novel potent peptide antibiotic owing to its outstanding inhibitory activities against bacterial film formation with high bacterial cell selectivity. Dye leakage and scanning electron microscopy revealed that Pro10-1D targets the bacterial membrane. Pro10-1D inhibited inflammation via Toll Like Receptor 4 (TLR4)/Nuclear factor-κB (NF-κB) signaling pathways in lipopolysaccharide (LPS)-stimulated RAW264.7 cells. Furthermore, Pro10-1D ameliorated multiple-organ damage and attenuated systemic infection-associated inflammation in an <i>E. coli</i> K1-induced sepsis mouse model. Overall, our results suggest that Pro10-1D can potentially serve as a novel peptide antibiotic for the treatment of gram-negative sepsis.",2020-08-27,owing to the challenges faced by conventional therapeutics novel peptide antibiotics against multidrugresistant mdr gramnegative bacteria need to be urgently developed we had previously designed pro93 and pro93d from the defensin of beetle iprotaetia brevitarsisi they showed high antimicrobial activity with cytotoxicity here we aimed to develop peptide antibiotics with bacterial cell selectivity and potent antibacterial activity against gramnegative bacteria we designed 10meric peptides with increased cationicity by adding arg to the nterminus of pro93 pro101 and its denantiomeric alteration pro101d among all tested peptides the newly designed pro101d showed the strongest antibacterial activity against iescherichia colii iacinetobacter baumanniii and mdr strains with resistance against protease digestion pro101d can act as a novel potent peptide antibiotic owing to its outstanding inhibitory activities against bacterial film formation with high bacterial cell selectivity dye leakage and scanning electron microscopy revealed that pro101d targets the bacterial membrane pro101d inhibited inflammation via toll like receptor 4 tlr4nuclear factorκb nfκb signaling pathways in lipopolysaccharide lpsstimulated raw2647 cells furthermore pro101d ameliorated multipleorgan damage and attenuated systemic infectionassociated inflammation in an ie colii k1induced sepsis mouse model overall our results suggest that pro101d can potentially serve as a novel peptide antibiotic for the treatment of gramnegative sepsis,"['owing', 'to', 'the', 'challenges', 'faced', 'by', 'conventional', 'therapeutics', 'novel', 'peptide', 'antibiotics', 'against', 'multidrugresistant', 'mdr', 'gramnegative', 'bacteria', 'need', 'to', 'be', 'urgently', 'developed', 'we', 'had', 'previously', 'designed', 'pro93', 'and', 'pro93d', 'from', 'the', 'defensin', 'of', 'beetle', 'iprotaetia', 'brevitarsisi', 'they', 'showed', 'high', 'antimicrobial', 'activity', 'with', 'cytotoxicity', 'here', 'we', 'aimed', 'to', 'develop', 'peptide', 'antibiotics', 'with', 'bacterial', 'cell', 'selectivity', 'and', 'potent', 'antibacterial', 'activity', 'against', 'gramnegative', 'bacteria', 'we', 'designed', '10meric', 'peptides', 'with', 'increased', 'cationicity', 'by', 'adding', 'arg', 'to', 'the', 'nterminus', 'of', 'pro93', 'pro101', 'and', 'its', 'denantiomeric', 'alteration', 'pro101d', 'among', 'all', 'tested', 'peptides', 'the', 'newly', 'designed', 'pro101d', 'showed', 'the', 'strongest', 'antibacterial', 'activity', 'against', 'iescherichia', 'colii', 'iacinetobacter', 'baumanniii', 'and', 'mdr', 'strains', 'with', 'resistance', 'against', 'protease', 'digestion', 'pro101d', 'can', 'act', 'as', 'a', 'novel', 'potent', 'peptide', 'antibiotic', 'owing', 'to', 'its', 'outstanding', 'inhibitory', 'activities', 'against', 'bacterial', 'film', 'formation', 'with', 'high', 'bacterial', 'cell', 'selectivity', 'dye', 'leakage', 'and', 'scanning', 'electron', 'microscopy', 'revealed', 'that', 'pro101d', 'targets', 'the', 'bacterial', 'membrane', 'pro101d', 'inhibited', 'inflammation', 'via', 'toll', 'like', 'receptor', '4', 'tlr4nuclear', 'factorκb', 'nfκb', 'signaling', 'pathways', 'in', 'lipopolysaccharide', 'lpsstimulated', 'raw2647', 'cells', 'furthermore', 'pro101d', 'ameliorated', 'multipleorgan', 'damage', 'and', 'attenuated', 'systemic', 'infectionassociated', 'inflammation', 'in', 'an', 'ie', 'colii', 'k1induced', 'sepsis', 'mouse', 'model', 'overall', 'our', 'results', 'suggest', 'that', 'pro101d', 'can', 'potentially', 'serve', 'as', 'a', 'novel', 'peptide', 'antibiotic', 'for', 'the', 'treatment', 'of', 'gramnegative', 'sepsis']","['owing', 'challenges', 'faced', 'conventional', 'therapeutics', 'novel', 'peptide', 'antibiotics', 'multidrugresistant', 'mdr', 'gramnegative', 'bacteria', 'need', 'urgently', 'developed', 'previously', 'designed', 'pro93', 'pro93d', 'defensin', 'beetle', 'iprotaetia', 'brevitarsisi', 'showed', 'high', 'antimicrobial', 'activity', 'cytotoxicity', 'aimed', 'develop', 'peptide', 'antibiotics', 'bacterial', 'cell', 'selectivity', 'potent', 'antibacterial', 'activity', 'gramnegative', 'bacteria', 'designed', '10meric', 'peptides', 'increased', 'cationicity', 'adding', 'arg', 'nterminus', 'pro93', 'pro101', 'denantiomeric', 'alteration', 'pro101d', 'among', 'tested', 'peptides', 'newly', 'designed', 'pro101d', 'showed', 'strongest', 'antibacterial', 'activity', 'iescherichia', 'colii', 'iacinetobacter', 'baumanniii', 'mdr', 'strains', 'resistance', 'protease', 'digestion', 'pro101d', 'act', 'novel', 'potent', 'peptide', 'antibiotic', 'owing', 'outstanding', 'inhibitory', 'activities', 'bacterial', 'film', 'formation', 'high', 'bacterial', 'cell', 'selectivity', 'dye', 'leakage', 'scanning', 'electron', 'microscopy', 'revealed', 'pro101d', 'targets', 'bacterial', 'membrane', 'pro101d', 'inhibited', 'inflammation', 'via', 'toll', 'like', 'receptor', '4', 'tlr4nuclear', 'factorκb', 'nfκb', 'signaling', 'pathways', 'lipopolysaccharide', 'lpsstimulated', 'raw2647', 'cells', 'furthermore', 'pro101d', 'ameliorated', 'multipleorgan', 'damage', 'attenuated', 'systemic', 'infectionassociated', 'inflammation', 'ie', 'colii', 'k1induced', 'sepsis', 'mouse', 'model', 'overall', 'results', 'suggest', 'pro101d', 'potentially', 'serve', 'novel', 'peptide', 'antibiotic', 'treatment', 'gramnegative', 'sepsis']","['pro101d', 'pro101d', 'pro101d', 'pro101d', 'pro101d', 'pro101d', 'pro101d']","['pro101d', 'pro101d', 'pro101d', 'pro101d', 'pro101d', 'pro101d', 'pro101d']",True,['infection']
32766160,"The Design, Characterizations, and Tumor Angiogenesis Inhibition of a Multi-Epitope Peptibody With bFGF/VEGFA.","Tumor angiogenesis is dependent on growth factors, and inhibition of their pathways is one of the promising strategies in cancer therapy. However, resistance to single pathway has been a great concern in clinical trials so that it necessitates multiple targetable factors for developing tumor angiogenesis inhibitors. Moreover, the strategy of Fc fusion protein is an attractive platform for novel peptide agents, which gains increasing importance with FDA approval because of better immunogenicity and stability. Here, we applied the Fc fusion protein concept to bFGF/VEGFA pathways and designed a multi-epitope Peptibody with immunogenic peptides derived from human bFGF and VEGFA sequences. Immunization with Peptibody could elicit high-titer anti-bFGF and anti-VEGFA antibodies, activate T cells, and induce Th1/Th2-type cytokines. In <i>in vitro</i> experiments, the isolated anti-Peptibody antibody inhibited the proliferation and migration of A549 cells and human umbilical vein endothelial cells (HUVECs) by decreasing the MAPK/Akt/mTOR signal pathways. In the murine tumor model, pre-immunization with Peptibody suppressed the tumor growth and neovascularization of lung cancer by decreasing the production of bFGF/VEGFA/PDGF, the MAPK/Akt/mTOR signal pathways, and the activation of suppressive cells in tumor sites. Further, the biological characterizations of the recombinant Peptibody were investigated systematically, including protein primary structure, secondary structure, stability, and toxicity. Collectively, the results highlighted the strategy of bFGF/VEGFA pathways and Fc fusion protein in suppressing tumor progression and angiogenesis, which emphasized the potential of multiple targetable factors for producing enduring clinical responses in tumor patients.",2020-07-17,tumor angiogenesis is dependent on growth factors and inhibition of their pathways is one of the promising strategies in cancer therapy however resistance to single pathway has been a great concern in clinical trials so that it necessitates multiple targetable factors for developing tumor angiogenesis inhibitors moreover the strategy of fc fusion protein is an attractive platform for novel peptide agents which gains increasing importance with fda approval because of better immunogenicity and stability here we applied the fc fusion protein concept to bfgfvegfa pathways and designed a multiepitope peptibody with immunogenic peptides derived from human bfgf and vegfa sequences immunization with peptibody could elicit hightiter antibfgf and antivegfa antibodies activate t cells and induce th1th2type cytokines in iin vitroi experiments the isolated antipeptibody antibody inhibited the proliferation and migration of a549 cells and human umbilical vein endothelial cells huvecs by decreasing the mapkaktmtor signal pathways in the murine tumor model preimmunization with peptibody suppressed the tumor growth and neovascularization of lung cancer by decreasing the production of bfgfvegfapdgf the mapkaktmtor signal pathways and the activation of suppressive cells in tumor sites further the biological characterizations of the recombinant peptibody were investigated systematically including protein primary structure secondary structure stability and toxicity collectively the results highlighted the strategy of bfgfvegfa pathways and fc fusion protein in suppressing tumor progression and angiogenesis which emphasized the potential of multiple targetable factors for producing enduring clinical responses in tumor patients,"['tumor', 'angiogenesis', 'is', 'dependent', 'on', 'growth', 'factors', 'and', 'inhibition', 'of', 'their', 'pathways', 'is', 'one', 'of', 'the', 'promising', 'strategies', 'in', 'cancer', 'therapy', 'however', 'resistance', 'to', 'single', 'pathway', 'has', 'been', 'a', 'great', 'concern', 'in', 'clinical', 'trials', 'so', 'that', 'it', 'necessitates', 'multiple', 'targetable', 'factors', 'for', 'developing', 'tumor', 'angiogenesis', 'inhibitors', 'moreover', 'the', 'strategy', 'of', 'fc', 'fusion', 'protein', 'is', 'an', 'attractive', 'platform', 'for', 'novel', 'peptide', 'agents', 'which', 'gains', 'increasing', 'importance', 'with', 'fda', 'approval', 'because', 'of', 'better', 'immunogenicity', 'and', 'stability', 'here', 'we', 'applied', 'the', 'fc', 'fusion', 'protein', 'concept', 'to', 'bfgfvegfa', 'pathways', 'and', 'designed', 'a', 'multiepitope', 'peptibody', 'with', 'immunogenic', 'peptides', 'derived', 'from', 'human', 'bfgf', 'and', 'vegfa', 'sequences', 'immunization', 'with', 'peptibody', 'could', 'elicit', 'hightiter', 'antibfgf', 'and', 'antivegfa', 'antibodies', 'activate', 't', 'cells', 'and', 'induce', 'th1th2type', 'cytokines', 'in', 'iin', 'vitroi', 'experiments', 'the', 'isolated', 'antipeptibody', 'antibody', 'inhibited', 'the', 'proliferation', 'and', 'migration', 'of', 'a549', 'cells', 'and', 'human', 'umbilical', 'vein', 'endothelial', 'cells', 'huvecs', 'by', 'decreasing', 'the', 'mapkaktmtor', 'signal', 'pathways', 'in', 'the', 'murine', 'tumor', 'model', 'preimmunization', 'with', 'peptibody', 'suppressed', 'the', 'tumor', 'growth', 'and', 'neovascularization', 'of', 'lung', 'cancer', 'by', 'decreasing', 'the', 'production', 'of', 'bfgfvegfapdgf', 'the', 'mapkaktmtor', 'signal', 'pathways', 'and', 'the', 'activation', 'of', 'suppressive', 'cells', 'in', 'tumor', 'sites', 'further', 'the', 'biological', 'characterizations', 'of', 'the', 'recombinant', 'peptibody', 'were', 'investigated', 'systematically', 'including', 'protein', 'primary', 'structure', 'secondary', 'structure', 'stability', 'and', 'toxicity', 'collectively', 'the', 'results', 'highlighted', 'the', 'strategy', 'of', 'bfgfvegfa', 'pathways', 'and', 'fc', 'fusion', 'protein', 'in', 'suppressing', 'tumor', 'progression', 'and', 'angiogenesis', 'which', 'emphasized', 'the', 'potential', 'of', 'multiple', 'targetable', 'factors', 'for', 'producing', 'enduring', 'clinical', 'responses', 'in', 'tumor', 'patients']","['tumor', 'angiogenesis', 'dependent', 'growth', 'factors', 'inhibition', 'pathways', 'one', 'promising', 'strategies', 'cancer', 'therapy', 'however', 'resistance', 'single', 'pathway', 'great', 'concern', 'clinical', 'trials', 'necessitates', 'multiple', 'targetable', 'factors', 'developing', 'tumor', 'angiogenesis', 'inhibitors', 'moreover', 'strategy', 'fc', 'fusion', 'protein', 'attractive', 'platform', 'novel', 'peptide', 'agents', 'gains', 'increasing', 'importance', 'fda', 'approval', 'better', 'immunogenicity', 'stability', 'applied', 'fc', 'fusion', 'protein', 'concept', 'bfgfvegfa', 'pathways', 'designed', 'multiepitope', 'peptibody', 'immunogenic', 'peptides', 'derived', 'human', 'bfgf', 'vegfa', 'sequences', 'immunization', 'peptibody', 'could', 'elicit', 'hightiter', 'antibfgf', 'antivegfa', 'antibodies', 'activate', 'cells', 'induce', 'th1th2type', 'cytokines', 'iin', 'vitroi', 'experiments', 'isolated', 'antipeptibody', 'antibody', 'inhibited', 'proliferation', 'migration', 'a549', 'cells', 'human', 'umbilical', 'vein', 'endothelial', 'cells', 'huvecs', 'decreasing', 'mapkaktmtor', 'signal', 'pathways', 'murine', 'tumor', 'model', 'preimmunization', 'peptibody', 'suppressed', 'tumor', 'growth', 'neovascularization', 'lung', 'cancer', 'decreasing', 'production', 'bfgfvegfapdgf', 'mapkaktmtor', 'signal', 'pathways', 'activation', 'suppressive', 'cells', 'tumor', 'sites', 'biological', 'characterizations', 'recombinant', 'peptibody', 'investigated', 'systematically', 'including', 'protein', 'primary', 'structure', 'secondary', 'structure', 'stability', 'toxicity', 'collectively', 'results', 'highlighted', 'strategy', 'bfgfvegfa', 'pathways', 'fc', 'fusion', 'protein', 'suppressing', 'tumor', 'progression', 'angiogenesis', 'emphasized', 'potential', 'multiple', 'targetable', 'factors', 'producing', 'enduring', 'clinical', 'responses', 'tumor', 'patients']","['bfgf', 'vegfa']",['bfgf'],True,"['tumor', 'cancer']"
32747027,Identification of a peptide targeting CD56.,"Neural cell adhesion molecule 1 (NCAM1/CD56) is expressed on immune cells, myoblasts, and malignant cells, and there is a growing demand for the genetic detection of CD56 and CD56-targeted therapy. In the present study, we developed a novel peptide ligand (designated Natein) that binds to human CD56 by using T7 phage display technology. Natein recognized the extracellular region of CD56 and could bind to natural killer (NK) cells and CD56-positive (CD56<sup>+</sup>) cancer cells. CD56<sup>+</sup> cells enriched from human peripheral blood mononuclear cells (PBMCs) using biotinylated Natein-conjugated microbeads, similarly to CD56 antibody-isolated cells, demonstrated functional cytotoxicity against K562 cells. In addition, Natein could be used to stain CD56<sup>+</sup> lymphoma cells in nasal-type extranodal NK/T-cell lymphoma tissues similarly to a CD56 antibody. These findings suggest that Natein has the potential to be alternative to CD56 antibody that could be used for peptide-based cell isolation and diagnosis.",2020-07-06,neural cell adhesion molecule 1 ncam1cd56 is expressed on immune cells myoblasts and malignant cells and there is a growing demand for the genetic detection of cd56 and cd56targeted therapy in the present study we developed a novel peptide ligand designated natein that binds to human cd56 by using t7 phage display technology natein recognized the extracellular region of cd56 and could bind to natural killer nk cells and cd56positive cd56supsup cancer cells cd56supsup cells enriched from human peripheral blood mononuclear cells pbmcs using biotinylated nateinconjugated microbeads similarly to cd56 antibodyisolated cells demonstrated functional cytotoxicity against k562 cells in addition natein could be used to stain cd56supsup lymphoma cells in nasaltype extranodal nktcell lymphoma tissues similarly to a cd56 antibody these findings suggest that natein has the potential to be alternative to cd56 antibody that could be used for peptidebased cell isolation and diagnosis,"['neural', 'cell', 'adhesion', 'molecule', '1', 'ncam1cd56', 'is', 'expressed', 'on', 'immune', 'cells', 'myoblasts', 'and', 'malignant', 'cells', 'and', 'there', 'is', 'a', 'growing', 'demand', 'for', 'the', 'genetic', 'detection', 'of', 'cd56', 'and', 'cd56targeted', 'therapy', 'in', 'the', 'present', 'study', 'we', 'developed', 'a', 'novel', 'peptide', 'ligand', 'designated', 'natein', 'that', 'binds', 'to', 'human', 'cd56', 'by', 'using', 't7', 'phage', 'display', 'technology', 'natein', 'recognized', 'the', 'extracellular', 'region', 'of', 'cd56', 'and', 'could', 'bind', 'to', 'natural', 'killer', 'nk', 'cells', 'and', 'cd56positive', 'cd56supsup', 'cancer', 'cells', 'cd56supsup', 'cells', 'enriched', 'from', 'human', 'peripheral', 'blood', 'mononuclear', 'cells', 'pbmcs', 'using', 'biotinylated', 'nateinconjugated', 'microbeads', 'similarly', 'to', 'cd56', 'antibodyisolated', 'cells', 'demonstrated', 'functional', 'cytotoxicity', 'against', 'k562', 'cells', 'in', 'addition', 'natein', 'could', 'be', 'used', 'to', 'stain', 'cd56supsup', 'lymphoma', 'cells', 'in', 'nasaltype', 'extranodal', 'nktcell', 'lymphoma', 'tissues', 'similarly', 'to', 'a', 'cd56', 'antibody', 'these', 'findings', 'suggest', 'that', 'natein', 'has', 'the', 'potential', 'to', 'be', 'alternative', 'to', 'cd56', 'antibody', 'that', 'could', 'be', 'used', 'for', 'peptidebased', 'cell', 'isolation', 'and', 'diagnosis']","['neural', 'cell', 'adhesion', 'molecule', '1', 'ncam1cd56', 'expressed', 'immune', 'cells', 'myoblasts', 'malignant', 'cells', 'growing', 'demand', 'genetic', 'detection', 'cd56', 'cd56targeted', 'therapy', 'present', 'study', 'developed', 'novel', 'peptide', 'ligand', 'designated', 'natein', 'binds', 'human', 'cd56', 'using', 't7', 'phage', 'display', 'technology', 'natein', 'recognized', 'extracellular', 'region', 'cd56', 'could', 'bind', 'natural', 'killer', 'nk', 'cells', 'cd56positive', 'cd56supsup', 'cancer', 'cells', 'cd56supsup', 'cells', 'enriched', 'human', 'peripheral', 'blood', 'mononuclear', 'cells', 'pbmcs', 'using', 'biotinylated', 'nateinconjugated', 'microbeads', 'similarly', 'cd56', 'antibodyisolated', 'cells', 'demonstrated', 'functional', 'cytotoxicity', 'k562', 'cells', 'addition', 'natein', 'could', 'used', 'stain', 'cd56supsup', 'lymphoma', 'cells', 'nasaltype', 'extranodal', 'nktcell', 'lymphoma', 'tissues', 'similarly', 'cd56', 'antibody', 'findings', 'suggest', 'natein', 'potential', 'alternative', 'cd56', 'antibody', 'could', 'used', 'peptidebased', 'cell', 'isolation', 'diagnosis']","['cd56', 'cd56', 'cd56', 'cd56', 'cd56', 'cd56']","['cd56', 'cd56', 'cd56', 'cd56', 'cd56', 'cd56']",False,['cancer']
32731448,Predicted Hotspot Residues Involved in Allosteric Signal Transmission in Pro-Apoptotic Peptide-Mcl1 Complexes.,"Mcl1 is a primary member of the Bcl-2 family-anti-apoptotic proteins (AAP)-that is overexpressed in several cancer pathologies. The apoptotic regulation is mediated through the binding of pro-apoptotic peptides (PAPs) (e.g., Bak and Bid) at the canonical hydrophobic binding groove (CBG) of Mcl1. Although all PAPs form amphipathic α-helices, their amino acid sequences vary to different degree. This sequence variation exhibits a central role in the binding partner selectivity towards different AAPs. Thus, constructing a novel peptide or small organic molecule with the ability to mimic the natural regulatory process of PAP is essential to inhibit various AAPs. Previously reported experimental binding free energies (BFEs) were utilized in the current investigation aimed to understand the mechanistic basis of different PAPs targeted to mMcl1. Molecular dynamics (MD) simulations used to estimate BFEs between mMcl1-PAP complexes using Molecular Mechanics-Generalized Born Solvent Accessible (MMGBSA) approach with multiple parameters. Predicted BFE values showed an excellent agreement with the experiment (<i>R</i><sup>2</sup> = 0.92). The van-der Waals (ΔG<sub>vdw</sub>) and electrostatic (ΔG<sub>ele</sub>) energy terms found to be the main energy components that drive heterodimerization of mMcl1-PAP complexes. Finally, the dynamic network analysis predicted the allosteric signal transmission pathway involves more favorable energy contributing residues. In total, the results obtained from the current investigation may provide valuable insights for the synthesis of a novel peptide or small organic inhibitor targeting Mcl1.",2020-07-28,mcl1 is a primary member of the bcl2 familyantiapoptotic proteins aapthat is overexpressed in several cancer pathologies the apoptotic regulation is mediated through the binding of proapoptotic peptides paps eg bak and bid at the canonical hydrophobic binding groove cbg of mcl1 although all paps form amphipathic αhelices their amino acid sequences vary to different degree this sequence variation exhibits a central role in the binding partner selectivity towards different aaps thus constructing a novel peptide or small organic molecule with the ability to mimic the natural regulatory process of pap is essential to inhibit various aaps previously reported experimental binding free energies bfes were utilized in the current investigation aimed to understand the mechanistic basis of different paps targeted to mmcl1 molecular dynamics md simulations used to estimate bfes between mmcl1pap complexes using molecular mechanicsgeneralized born solvent accessible mmgbsa approach with multiple parameters predicted bfe values showed an excellent agreement with the experiment irisup2sup  092 the vander waals δgsubvdwsub and electrostatic δgsubelesub energy terms found to be the main energy components that drive heterodimerization of mmcl1pap complexes finally the dynamic network analysis predicted the allosteric signal transmission pathway involves more favorable energy contributing residues in total the results obtained from the current investigation may provide valuable insights for the synthesis of a novel peptide or small organic inhibitor targeting mcl1,"['mcl1', 'is', 'a', 'primary', 'member', 'of', 'the', 'bcl2', 'familyantiapoptotic', 'proteins', 'aapthat', 'is', 'overexpressed', 'in', 'several', 'cancer', 'pathologies', 'the', 'apoptotic', 'regulation', 'is', 'mediated', 'through', 'the', 'binding', 'of', 'proapoptotic', 'peptides', 'paps', 'eg', 'bak', 'and', 'bid', 'at', 'the', 'canonical', 'hydrophobic', 'binding', 'groove', 'cbg', 'of', 'mcl1', 'although', 'all', 'paps', 'form', 'amphipathic', 'αhelices', 'their', 'amino', 'acid', 'sequences', 'vary', 'to', 'different', 'degree', 'this', 'sequence', 'variation', 'exhibits', 'a', 'central', 'role', 'in', 'the', 'binding', 'partner', 'selectivity', 'towards', 'different', 'aaps', 'thus', 'constructing', 'a', 'novel', 'peptide', 'or', 'small', 'organic', 'molecule', 'with', 'the', 'ability', 'to', 'mimic', 'the', 'natural', 'regulatory', 'process', 'of', 'pap', 'is', 'essential', 'to', 'inhibit', 'various', 'aaps', 'previously', 'reported', 'experimental', 'binding', 'free', 'energies', 'bfes', 'were', 'utilized', 'in', 'the', 'current', 'investigation', 'aimed', 'to', 'understand', 'the', 'mechanistic', 'basis', 'of', 'different', 'paps', 'targeted', 'to', 'mmcl1', 'molecular', 'dynamics', 'md', 'simulations', 'used', 'to', 'estimate', 'bfes', 'between', 'mmcl1pap', 'complexes', 'using', 'molecular', 'mechanicsgeneralized', 'born', 'solvent', 'accessible', 'mmgbsa', 'approach', 'with', 'multiple', 'parameters', 'predicted', 'bfe', 'values', 'showed', 'an', 'excellent', 'agreement', 'with', 'the', 'experiment', 'irisup2sup', '092', 'the', 'vander', 'waals', 'δgsubvdwsub', 'and', 'electrostatic', 'δgsubelesub', 'energy', 'terms', 'found', 'to', 'be', 'the', 'main', 'energy', 'components', 'that', 'drive', 'heterodimerization', 'of', 'mmcl1pap', 'complexes', 'finally', 'the', 'dynamic', 'network', 'analysis', 'predicted', 'the', 'allosteric', 'signal', 'transmission', 'pathway', 'involves', 'more', 'favorable', 'energy', 'contributing', 'residues', 'in', 'total', 'the', 'results', 'obtained', 'from', 'the', 'current', 'investigation', 'may', 'provide', 'valuable', 'insights', 'for', 'the', 'synthesis', 'of', 'a', 'novel', 'peptide', 'or', 'small', 'organic', 'inhibitor', 'targeting', 'mcl1']","['mcl1', 'primary', 'member', 'bcl2', 'familyantiapoptotic', 'proteins', 'aapthat', 'overexpressed', 'several', 'cancer', 'pathologies', 'apoptotic', 'regulation', 'mediated', 'binding', 'proapoptotic', 'peptides', 'paps', 'eg', 'bak', 'bid', 'canonical', 'hydrophobic', 'binding', 'groove', 'cbg', 'mcl1', 'although', 'paps', 'form', 'amphipathic', 'αhelices', 'amino', 'acid', 'sequences', 'vary', 'different', 'degree', 'sequence', 'variation', 'exhibits', 'central', 'role', 'binding', 'partner', 'selectivity', 'towards', 'different', 'aaps', 'thus', 'constructing', 'novel', 'peptide', 'small', 'organic', 'molecule', 'ability', 'mimic', 'natural', 'regulatory', 'process', 'pap', 'essential', 'inhibit', 'various', 'aaps', 'previously', 'reported', 'experimental', 'binding', 'free', 'energies', 'bfes', 'utilized', 'current', 'investigation', 'aimed', 'understand', 'mechanistic', 'basis', 'different', 'paps', 'targeted', 'mmcl1', 'molecular', 'dynamics', 'md', 'simulations', 'used', 'estimate', 'bfes', 'mmcl1pap', 'complexes', 'using', 'molecular', 'mechanicsgeneralized', 'born', 'solvent', 'accessible', 'mmgbsa', 'approach', 'multiple', 'parameters', 'predicted', 'bfe', 'values', 'showed', 'excellent', 'agreement', 'experiment', 'irisup2sup', '092', 'vander', 'waals', 'δgsubvdwsub', 'electrostatic', 'δgsubelesub', 'energy', 'terms', 'found', 'main', 'energy', 'components', 'drive', 'heterodimerization', 'mmcl1pap', 'complexes', 'finally', 'dynamic', 'network', 'analysis', 'predicted', 'allosteric', 'signal', 'transmission', 'pathway', 'involves', 'favorable', 'energy', 'contributing', 'residues', 'total', 'results', 'obtained', 'current', 'investigation', 'may', 'provide', 'valuable', 'insights', 'synthesis', 'novel', 'peptide', 'small', 'organic', 'inhibitor', 'targeting', 'mcl1']","['mcl1', 'bcl2', 'bak', 'mcl1', 'bfe', 'mcl1']",['bfe'],True,['cancer']
32707527,Discovery of novel small molecule inhibitors of S100P with in vitro anti-metastatic effects on pancreatic cancer cells.,"S100P, a calcium-binding protein, is known to advance tumor progression and metastasis in pancreatic and several other cancers. Herein is described the in silico identification of a putative binding pocket of S100P to identify, synthesize and evaluate novel small molecules with the potential to selectively bind S100P and inhibit its activation of cell survival and metastatic pathways. The virtual screening of a drug-like database against the S100P model led to the identification of over 100 clusters of diverse scaffolds. A representative test set identified a number of structurally unrelated hits that inhibit S100P-RAGE interaction, measured by ELISA, and reduce in vitro cell invasion selectively in S100P-expressing pancreatic cancer cells at 10 μM. This study establishes a proof of concept in the potential for rational design of small molecule S100P inhibitors for drug candidate development.",2020-07-15,s100p a calciumbinding protein is known to advance tumor progression and metastasis in pancreatic and several other cancers herein is described the in silico identification of a putative binding pocket of s100p to identify synthesize and evaluate novel small molecules with the potential to selectively bind s100p and inhibit its activation of cell survival and metastatic pathways the virtual screening of a druglike database against the s100p model led to the identification of over 100 clusters of diverse scaffolds a representative test set identified a number of structurally unrelated hits that inhibit s100prage interaction measured by elisa and reduce in vitro cell invasion selectively in s100pexpressing pancreatic cancer cells at 10 μm this study establishes a proof of concept in the potential for rational design of small molecule s100p inhibitors for drug candidate development,"['s100p', 'a', 'calciumbinding', 'protein', 'is', 'known', 'to', 'advance', 'tumor', 'progression', 'and', 'metastasis', 'in', 'pancreatic', 'and', 'several', 'other', 'cancers', 'herein', 'is', 'described', 'the', 'in', 'silico', 'identification', 'of', 'a', 'putative', 'binding', 'pocket', 'of', 's100p', 'to', 'identify', 'synthesize', 'and', 'evaluate', 'novel', 'small', 'molecules', 'with', 'the', 'potential', 'to', 'selectively', 'bind', 's100p', 'and', 'inhibit', 'its', 'activation', 'of', 'cell', 'survival', 'and', 'metastatic', 'pathways', 'the', 'virtual', 'screening', 'of', 'a', 'druglike', 'database', 'against', 'the', 's100p', 'model', 'led', 'to', 'the', 'identification', 'of', 'over', '100', 'clusters', 'of', 'diverse', 'scaffolds', 'a', 'representative', 'test', 'set', 'identified', 'a', 'number', 'of', 'structurally', 'unrelated', 'hits', 'that', 'inhibit', 's100prage', 'interaction', 'measured', 'by', 'elisa', 'and', 'reduce', 'in', 'vitro', 'cell', 'invasion', 'selectively', 'in', 's100pexpressing', 'pancreatic', 'cancer', 'cells', 'at', '10', 'μm', 'this', 'study', 'establishes', 'a', 'proof', 'of', 'concept', 'in', 'the', 'potential', 'for', 'rational', 'design', 'of', 'small', 'molecule', 's100p', 'inhibitors', 'for', 'drug', 'candidate', 'development']","['s100p', 'calciumbinding', 'protein', 'known', 'advance', 'tumor', 'progression', 'metastasis', 'pancreatic', 'several', 'cancers', 'herein', 'described', 'silico', 'identification', 'putative', 'binding', 'pocket', 's100p', 'identify', 'synthesize', 'evaluate', 'novel', 'small', 'molecules', 'potential', 'selectively', 'bind', 's100p', 'inhibit', 'activation', 'cell', 'survival', 'metastatic', 'pathways', 'virtual', 'screening', 'druglike', 'database', 's100p', 'model', 'led', 'identification', '100', 'clusters', 'diverse', 'scaffolds', 'representative', 'test', 'set', 'identified', 'number', 'structurally', 'unrelated', 'hits', 'inhibit', 's100prage', 'interaction', 'measured', 'elisa', 'reduce', 'vitro', 'cell', 'invasion', 'selectively', 's100pexpressing', 'pancreatic', 'cancer', 'cells', '10', 'μm', 'study', 'establishes', 'proof', 'concept', 'potential', 'rational', 'design', 'small', 'molecule', 's100p', 'inhibitors', 'drug', 'candidate', 'development']","['s100p', 's100p', 's100p', 's100p', 's100p']","['s100p', 's100p', 's100p', 's100p', 's100p']",True,"['tumor', 'cancer']"
32673674,Discovery of a novel small molecule PT109 with multi-targeted effects against Alzheimer's disease in vitro and in vivo.,"Alzheimer's disease (AD), which is characterized by impairment of cognitive functions, is a chronic neurodegenerative disease that mainly affects the elderly. Currently available anti-AD drugs can only offer limited symptom-relieving effects. ""One-compound-Multitargeted Strategy"" have been recognized as the promising way to win the war against AD. Herein we report a potential anti-AD agent PT109 with multi-functions. First, an 81-kinase screening was carried out and results showed that PT109 potently inhibited c-Jun N-terminal kinases and Serum and glucocorticoid-inducible kinase 1, which are the important signaling molecules involved in neurogenesis, neuroprotection and neuroinflammation and mildly inhibit glycogen synthase kinase-3β as well as protein kinase C gamma, both are involved in AD pathological processes. In addition, invitro studies of immunofluorescent staining and Western blot showed that PT109 might promote the neurogenesis of C17.2 cells and induce synaptogenesis in primary cultured rat hippocampal neurons. We detected and confirmed the neuroprotective effect of PT109 in cultured HT22 cells by MTT assay, dehydrogenase assay, glutathione assay and reactive oxygen species assay. Furthermore, the results of Western blot, ELISA assay and immunofluorescent staining indicated that PT109 attenuated lipopolysaccharide-induced inflammation in BV2 cells and primary astrocytes. The results of Morris water maze and Step-through test indicated that PT109 improved the spatial learning ability in APP/PS1 mice. More importantly, the invivo pharmacokinetic parameters indicated that PT109 had better medicinal properties. Taken together, our findings suggest that PT109 may be a promising candidate for treating AD through multiple targets although further studies are ought to be conducted.",2020-07-13,alzheimers disease ad which is characterized by impairment of cognitive functions is a chronic neurodegenerative disease that mainly affects the elderly currently available antiad drugs can only offer limited symptomrelieving effects onecompoundmultitargeted strategy have been recognized as the promising way to win the war against ad herein we report a potential antiad agent pt109 with multifunctions first an 81kinase screening was carried out and results showed that pt109 potently inhibited cjun nterminal kinases and serum and glucocorticoidinducible kinase 1 which are the important signaling molecules involved in neurogenesis neuroprotection and neuroinflammation and mildly inhibit glycogen synthase kinase3β as well as protein kinase c gamma both are involved in ad pathological processes in addition invitro studies of immunofluorescent staining and western blot showed that pt109 might promote the neurogenesis of c172 cells and induce synaptogenesis in primary cultured rat hippocampal neurons we detected and confirmed the neuroprotective effect of pt109 in cultured ht22 cells by mtt assay dehydrogenase assay glutathione assay and reactive oxygen species assay furthermore the results of western blot elisa assay and immunofluorescent staining indicated that pt109 attenuated lipopolysaccharideinduced inflammation in bv2 cells and primary astrocytes the results of morris water maze and stepthrough test indicated that pt109 improved the spatial learning ability in appps1 mice more importantly the invivo pharmacokinetic parameters indicated that pt109 had better medicinal properties taken together our findings suggest that pt109 may be a promising candidate for treating ad through multiple targets although further studies are ought to be conducted,"['alzheimers', 'disease', 'ad', 'which', 'is', 'characterized', 'by', 'impairment', 'of', 'cognitive', 'functions', 'is', 'a', 'chronic', 'neurodegenerative', 'disease', 'that', 'mainly', 'affects', 'the', 'elderly', 'currently', 'available', 'antiad', 'drugs', 'can', 'only', 'offer', 'limited', 'symptomrelieving', 'effects', 'onecompoundmultitargeted', 'strategy', 'have', 'been', 'recognized', 'as', 'the', 'promising', 'way', 'to', 'win', 'the', 'war', 'against', 'ad', 'herein', 'we', 'report', 'a', 'potential', 'antiad', 'agent', 'pt109', 'with', 'multifunctions', 'first', 'an', '81kinase', 'screening', 'was', 'carried', 'out', 'and', 'results', 'showed', 'that', 'pt109', 'potently', 'inhibited', 'cjun', 'nterminal', 'kinases', 'and', 'serum', 'and', 'glucocorticoidinducible', 'kinase', '1', 'which', 'are', 'the', 'important', 'signaling', 'molecules', 'involved', 'in', 'neurogenesis', 'neuroprotection', 'and', 'neuroinflammation', 'and', 'mildly', 'inhibit', 'glycogen', 'synthase', 'kinase3β', 'as', 'well', 'as', 'protein', 'kinase', 'c', 'gamma', 'both', 'are', 'involved', 'in', 'ad', 'pathological', 'processes', 'in', 'addition', 'invitro', 'studies', 'of', 'immunofluorescent', 'staining', 'and', 'western', 'blot', 'showed', 'that', 'pt109', 'might', 'promote', 'the', 'neurogenesis', 'of', 'c172', 'cells', 'and', 'induce', 'synaptogenesis', 'in', 'primary', 'cultured', 'rat', 'hippocampal', 'neurons', 'we', 'detected', 'and', 'confirmed', 'the', 'neuroprotective', 'effect', 'of', 'pt109', 'in', 'cultured', 'ht22', 'cells', 'by', 'mtt', 'assay', 'dehydrogenase', 'assay', 'glutathione', 'assay', 'and', 'reactive', 'oxygen', 'species', 'assay', 'furthermore', 'the', 'results', 'of', 'western', 'blot', 'elisa', 'assay', 'and', 'immunofluorescent', 'staining', 'indicated', 'that', 'pt109', 'attenuated', 'lipopolysaccharideinduced', 'inflammation', 'in', 'bv2', 'cells', 'and', 'primary', 'astrocytes', 'the', 'results', 'of', 'morris', 'water', 'maze', 'and', 'stepthrough', 'test', 'indicated', 'that', 'pt109', 'improved', 'the', 'spatial', 'learning', 'ability', 'in', 'appps1', 'mice', 'more', 'importantly', 'the', 'invivo', 'pharmacokinetic', 'parameters', 'indicated', 'that', 'pt109', 'had', 'better', 'medicinal', 'properties', 'taken', 'together', 'our', 'findings', 'suggest', 'that', 'pt109', 'may', 'be', 'a', 'promising', 'candidate', 'for', 'treating', 'ad', 'through', 'multiple', 'targets', 'although', 'further', 'studies', 'are', 'ought', 'to', 'be', 'conducted']","['alzheimers', 'disease', 'ad', 'characterized', 'impairment', 'cognitive', 'functions', 'chronic', 'neurodegenerative', 'disease', 'mainly', 'affects', 'elderly', 'currently', 'available', 'antiad', 'drugs', 'offer', 'limited', 'symptomrelieving', 'effects', 'onecompoundmultitargeted', 'strategy', 'recognized', 'promising', 'way', 'win', 'war', 'ad', 'herein', 'report', 'potential', 'antiad', 'agent', 'pt109', 'multifunctions', 'first', '81kinase', 'screening', 'carried', 'results', 'showed', 'pt109', 'potently', 'inhibited', 'cjun', 'nterminal', 'kinases', 'serum', 'glucocorticoidinducible', 'kinase', '1', 'important', 'signaling', 'molecules', 'involved', 'neurogenesis', 'neuroprotection', 'neuroinflammation', 'mildly', 'inhibit', 'glycogen', 'synthase', 'kinase3β', 'well', 'protein', 'kinase', 'c', 'gamma', 'involved', 'ad', 'pathological', 'processes', 'addition', 'invitro', 'studies', 'immunofluorescent', 'staining', 'western', 'blot', 'showed', 'pt109', 'might', 'promote', 'neurogenesis', 'c172', 'cells', 'induce', 'synaptogenesis', 'primary', 'cultured', 'rat', 'hippocampal', 'neurons', 'detected', 'confirmed', 'neuroprotective', 'effect', 'pt109', 'cultured', 'ht22', 'cells', 'mtt', 'assay', 'dehydrogenase', 'assay', 'glutathione', 'assay', 'reactive', 'oxygen', 'species', 'assay', 'furthermore', 'results', 'western', 'blot', 'elisa', 'assay', 'immunofluorescent', 'staining', 'indicated', 'pt109', 'attenuated', 'lipopolysaccharideinduced', 'inflammation', 'bv2', 'cells', 'primary', 'astrocytes', 'results', 'morris', 'water', 'maze', 'stepthrough', 'test', 'indicated', 'pt109', 'improved', 'spatial', 'learning', 'ability', 'appps1', 'mice', 'importantly', 'invivo', 'pharmacokinetic', 'parameters', 'indicated', 'pt109', 'better', 'medicinal', 'properties', 'taken', 'together', 'findings', 'suggest', 'pt109', 'may', 'promising', 'candidate', 'treating', 'ad', 'multiple', 'targets', 'although', 'studies', 'ought', 'conducted']",['cjun'],['cjun'],False,['alzheimer']
32591930,Design and in vitro analysis of SIRT2 inhibitor targeting Parkinson's disease.,"Inhibition of Sirtuin2 (SIRT2) protein rescues the α-synuclein toxicity in vitro and in vivo models of Parkinson's disease (PD). Thioacetyl group can structurally mimic the acetyl group and restrain the deacetylating p53 reaction by SIRT2. This work evaluated the biological activity of designed pentapeptides inhibitor containing N-thioacetyl-lysine against SIRT2. Pentapeptide by introducing thioacetyl-lysine as an inhibitor of SIRT2 was screened by molecular docking and synthesized by solid phase method. The inhibition of pure recombinant SIRT2 as well as SIRT2 in serum of PD patients by peptide was done by fluorescent activity assay. The inhibition of SIRT2 was assessed in PC12 cell line by measuring acetylated α-tubulin level. The peptide YKK(ε-thioAc)AM and HRK(ε-thioAc)AM were found to be SIRT2 inhibitors by molecular docking. However, YKK(ε-thioAc)AM was more specific towards SIRT2 than SIRT1 (Sirtuin1). It inhibited recombinant SIRT2 by IC<sub>50</sub> value of 0.15 µM and KD values 9.92 × 10<sup>-8</sup>/M. It also inhibited serum SIRT2 of PD. It increased the acetylation of α-tubulin in PC12 neuroblastoma cells which is essential for maintaining the microtubular cell functions of brain. It can be concluded that novel peptide YKK(ε-thioAc)AM may be a platform for therapeutic agent for Parkinson's disease targeting SIRT2.",2020-06-26,inhibition of sirtuin2 sirt2 protein rescues the αsynuclein toxicity in vitro and in vivo models of parkinsons disease pd thioacetyl group can structurally mimic the acetyl group and restrain the deacetylating p53 reaction by sirt2 this work evaluated the biological activity of designed pentapeptides inhibitor containing nthioacetyllysine against sirt2 pentapeptide by introducing thioacetyllysine as an inhibitor of sirt2 was screened by molecular docking and synthesized by solid phase method the inhibition of pure recombinant sirt2 as well as sirt2 in serum of pd patients by peptide was done by fluorescent activity assay the inhibition of sirt2 was assessed in pc12 cell line by measuring acetylated αtubulin level the peptide ykkεthioacam and hrkεthioacam were found to be sirt2 inhibitors by molecular docking however ykkεthioacam was more specific towards sirt2 than sirt1 sirtuin1 it inhibited recombinant sirt2 by icsub50sub value of 015 µm and kd values 992  10sup8supm it also inhibited serum sirt2 of pd it increased the acetylation of αtubulin in pc12 neuroblastoma cells which is essential for maintaining the microtubular cell functions of brain it can be concluded that novel peptide ykkεthioacam may be a platform for therapeutic agent for parkinsons disease targeting sirt2,"['inhibition', 'of', 'sirtuin2', 'sirt2', 'protein', 'rescues', 'the', 'αsynuclein', 'toxicity', 'in', 'vitro', 'and', 'in', 'vivo', 'models', 'of', 'parkinsons', 'disease', 'pd', 'thioacetyl', 'group', 'can', 'structurally', 'mimic', 'the', 'acetyl', 'group', 'and', 'restrain', 'the', 'deacetylating', 'p53', 'reaction', 'by', 'sirt2', 'this', 'work', 'evaluated', 'the', 'biological', 'activity', 'of', 'designed', 'pentapeptides', 'inhibitor', 'containing', 'nthioacetyllysine', 'against', 'sirt2', 'pentapeptide', 'by', 'introducing', 'thioacetyllysine', 'as', 'an', 'inhibitor', 'of', 'sirt2', 'was', 'screened', 'by', 'molecular', 'docking', 'and', 'synthesized', 'by', 'solid', 'phase', 'method', 'the', 'inhibition', 'of', 'pure', 'recombinant', 'sirt2', 'as', 'well', 'as', 'sirt2', 'in', 'serum', 'of', 'pd', 'patients', 'by', 'peptide', 'was', 'done', 'by', 'fluorescent', 'activity', 'assay', 'the', 'inhibition', 'of', 'sirt2', 'was', 'assessed', 'in', 'pc12', 'cell', 'line', 'by', 'measuring', 'acetylated', 'αtubulin', 'level', 'the', 'peptide', 'ykkεthioacam', 'and', 'hrkεthioacam', 'were', 'found', 'to', 'be', 'sirt2', 'inhibitors', 'by', 'molecular', 'docking', 'however', 'ykkεthioacam', 'was', 'more', 'specific', 'towards', 'sirt2', 'than', 'sirt1', 'sirtuin1', 'it', 'inhibited', 'recombinant', 'sirt2', 'by', 'icsub50sub', 'value', 'of', '015', 'µm', 'and', 'kd', 'values', '992', '10sup8supm', 'it', 'also', 'inhibited', 'serum', 'sirt2', 'of', 'pd', 'it', 'increased', 'the', 'acetylation', 'of', 'αtubulin', 'in', 'pc12', 'neuroblastoma', 'cells', 'which', 'is', 'essential', 'for', 'maintaining', 'the', 'microtubular', 'cell', 'functions', 'of', 'brain', 'it', 'can', 'be', 'concluded', 'that', 'novel', 'peptide', 'ykkεthioacam', 'may', 'be', 'a', 'platform', 'for', 'therapeutic', 'agent', 'for', 'parkinsons', 'disease', 'targeting', 'sirt2']","['inhibition', 'sirtuin2', 'sirt2', 'protein', 'rescues', 'αsynuclein', 'toxicity', 'vitro', 'vivo', 'models', 'parkinsons', 'disease', 'pd', 'thioacetyl', 'group', 'structurally', 'mimic', 'acetyl', 'group', 'restrain', 'deacetylating', 'p53', 'reaction', 'sirt2', 'work', 'evaluated', 'biological', 'activity', 'designed', 'pentapeptides', 'inhibitor', 'containing', 'nthioacetyllysine', 'sirt2', 'pentapeptide', 'introducing', 'thioacetyllysine', 'inhibitor', 'sirt2', 'screened', 'molecular', 'docking', 'synthesized', 'solid', 'phase', 'method', 'inhibition', 'pure', 'recombinant', 'sirt2', 'well', 'sirt2', 'serum', 'pd', 'patients', 'peptide', 'done', 'fluorescent', 'activity', 'assay', 'inhibition', 'sirt2', 'assessed', 'pc12', 'cell', 'line', 'measuring', 'acetylated', 'αtubulin', 'level', 'peptide', 'ykkεthioacam', 'hrkεthioacam', 'found', 'sirt2', 'inhibitors', 'molecular', 'docking', 'however', 'ykkεthioacam', 'specific', 'towards', 'sirt2', 'sirt1', 'sirtuin1', 'inhibited', 'recombinant', 'sirt2', 'icsub50sub', 'value', '015', 'µm', 'kd', 'values', '992', '10sup8supm', 'also', 'inhibited', 'serum', 'sirt2', 'pd', 'increased', 'acetylation', 'αtubulin', 'pc12', 'neuroblastoma', 'cells', 'essential', 'maintaining', 'microtubular', 'cell', 'functions', 'brain', 'concluded', 'novel', 'peptide', 'ykkεthioacam', 'may', 'platform', 'therapeutic', 'agent', 'parkinsons', 'disease', 'targeting', 'sirt2']","['sirt2', 'p53', 'sirt2', 'sirt2', 'sirt2', 'sirt2', 'sirt2', 'sirt2', 'sirt2', 'sirt2', 'sirt1', 'sirtuin1', 'sirt2', 'sirt2', 'sirt2']","['sirt2', 'sirt2', 'sirt2', 'sirt2', 'sirt2', 'sirt2', 'sirt2', 'sirt2', 'sirt2', 'sirtuin1', 'sirt2', 'sirt2', 'sirt2']",True,['parkinson']
32566012,"ASR488, a novel small molecule, activates an mRNA binding protein, CPEB1, and inhibits the growth of bladder cancer.","Due to a lack of mechanistic insights, muscle-invasive bladder cancer (MIBC) remains incurable and is one of the most lethal types of cancer in the United States. The present study investigated changes in the molecular signatures of MIBC cells (TCCSUP and HT1376) after treatment with a novel small molecule, ASR488, to gain knowledge of the mechanisms that inhibited MIBC cell growth. ASR488 treatment initiated apoptotic signaling in MIBC cells. Pathway enrichment analysis was used to analyze the changes in function of differentially expressed genes. Gene Ontology analysis, as well as Kyoto Encyclopedia of Genes and Genomes analysis, was also performed. These analyses along with reactome pathway enrichment analyses indicated that the genes upregulated in the ASR488-treated cells are involved in focal adhesion, neurotrophin signaling, p53 signaling, endoplasmic reticulum functioning in terms of protein processing, and pathways related to bladder cancer. The genes downregulated in ASR488-treated MIBC cells were mainly involved in DNA replication, mismatch repair, RNA degradation, nucleotide excision repair and TGFβ signaling (P<0.05). Furthermore, reverse transcription-quantitative PCR analysis revealed an increase in transcripts of the most upregulated genes in ASR 488-treated MIBC cells: <i>CPEB1</i> (36-fold), <i>IL11</i> (30-fold), <i>SFN</i> (20.12-fold) and <i>CYP4F11</i> (15.8-fold). In conclusion, the analysis of biological functions of the most differentially expressed genes revealed possible mechanisms that may be associated with the aggressiveness of MIBC.",2020-05-07,due to a lack of mechanistic insights muscleinvasive bladder cancer mibc remains incurable and is one of the most lethal types of cancer in the united states the present study investigated changes in the molecular signatures of mibc cells tccsup and ht1376 after treatment with a novel small molecule asr488 to gain knowledge of the mechanisms that inhibited mibc cell growth asr488 treatment initiated apoptotic signaling in mibc cells pathway enrichment analysis was used to analyze the changes in function of differentially expressed genes gene ontology analysis as well as kyoto encyclopedia of genes and genomes analysis was also performed these analyses along with reactome pathway enrichment analyses indicated that the genes upregulated in the asr488treated cells are involved in focal adhesion neurotrophin signaling p53 signaling endoplasmic reticulum functioning in terms of protein processing and pathways related to bladder cancer the genes downregulated in asr488treated mibc cells were mainly involved in dna replication mismatch repair rna degradation nucleotide excision repair and tgfβ signaling p005 furthermore reverse transcriptionquantitative pcr analysis revealed an increase in transcripts of the most upregulated genes in asr 488treated mibc cells icpeb1i 36fold iil11i 30fold isfni 2012fold and icyp4f11i 158fold in conclusion the analysis of biological functions of the most differentially expressed genes revealed possible mechanisms that may be associated with the aggressiveness of mibc,"['due', 'to', 'a', 'lack', 'of', 'mechanistic', 'insights', 'muscleinvasive', 'bladder', 'cancer', 'mibc', 'remains', 'incurable', 'and', 'is', 'one', 'of', 'the', 'most', 'lethal', 'types', 'of', 'cancer', 'in', 'the', 'united', 'states', 'the', 'present', 'study', 'investigated', 'changes', 'in', 'the', 'molecular', 'signatures', 'of', 'mibc', 'cells', 'tccsup', 'and', 'ht1376', 'after', 'treatment', 'with', 'a', 'novel', 'small', 'molecule', 'asr488', 'to', 'gain', 'knowledge', 'of', 'the', 'mechanisms', 'that', 'inhibited', 'mibc', 'cell', 'growth', 'asr488', 'treatment', 'initiated', 'apoptotic', 'signaling', 'in', 'mibc', 'cells', 'pathway', 'enrichment', 'analysis', 'was', 'used', 'to', 'analyze', 'the', 'changes', 'in', 'function', 'of', 'differentially', 'expressed', 'genes', 'gene', 'ontology', 'analysis', 'as', 'well', 'as', 'kyoto', 'encyclopedia', 'of', 'genes', 'and', 'genomes', 'analysis', 'was', 'also', 'performed', 'these', 'analyses', 'along', 'with', 'reactome', 'pathway', 'enrichment', 'analyses', 'indicated', 'that', 'the', 'genes', 'upregulated', 'in', 'the', 'asr488treated', 'cells', 'are', 'involved', 'in', 'focal', 'adhesion', 'neurotrophin', 'signaling', 'p53', 'signaling', 'endoplasmic', 'reticulum', 'functioning', 'in', 'terms', 'of', 'protein', 'processing', 'and', 'pathways', 'related', 'to', 'bladder', 'cancer', 'the', 'genes', 'downregulated', 'in', 'asr488treated', 'mibc', 'cells', 'were', 'mainly', 'involved', 'in', 'dna', 'replication', 'mismatch', 'repair', 'rna', 'degradation', 'nucleotide', 'excision', 'repair', 'and', 'tgfβ', 'signaling', 'p005', 'furthermore', 'reverse', 'transcriptionquantitative', 'pcr', 'analysis', 'revealed', 'an', 'increase', 'in', 'transcripts', 'of', 'the', 'most', 'upregulated', 'genes', 'in', 'asr', '488treated', 'mibc', 'cells', 'icpeb1i', '36fold', 'iil11i', '30fold', 'isfni', '2012fold', 'and', 'icyp4f11i', '158fold', 'in', 'conclusion', 'the', 'analysis', 'of', 'biological', 'functions', 'of', 'the', 'most', 'differentially', 'expressed', 'genes', 'revealed', 'possible', 'mechanisms', 'that', 'may', 'be', 'associated', 'with', 'the', 'aggressiveness', 'of', 'mibc']","['due', 'lack', 'mechanistic', 'insights', 'muscleinvasive', 'bladder', 'cancer', 'mibc', 'remains', 'incurable', 'one', 'lethal', 'types', 'cancer', 'united', 'states', 'present', 'study', 'investigated', 'changes', 'molecular', 'signatures', 'mibc', 'cells', 'tccsup', 'ht1376', 'treatment', 'novel', 'small', 'molecule', 'asr488', 'gain', 'knowledge', 'mechanisms', 'inhibited', 'mibc', 'cell', 'growth', 'asr488', 'treatment', 'initiated', 'apoptotic', 'signaling', 'mibc', 'cells', 'pathway', 'enrichment', 'analysis', 'used', 'analyze', 'changes', 'function', 'differentially', 'expressed', 'genes', 'gene', 'ontology', 'analysis', 'well', 'kyoto', 'encyclopedia', 'genes', 'genomes', 'analysis', 'also', 'performed', 'analyses', 'along', 'reactome', 'pathway', 'enrichment', 'analyses', 'indicated', 'genes', 'upregulated', 'asr488treated', 'cells', 'involved', 'focal', 'adhesion', 'neurotrophin', 'signaling', 'p53', 'signaling', 'endoplasmic', 'reticulum', 'functioning', 'terms', 'protein', 'processing', 'pathways', 'related', 'bladder', 'cancer', 'genes', 'downregulated', 'asr488treated', 'mibc', 'cells', 'mainly', 'involved', 'dna', 'replication', 'mismatch', 'repair', 'rna', 'degradation', 'nucleotide', 'excision', 'repair', 'tgfβ', 'signaling', 'p005', 'furthermore', 'reverse', 'transcriptionquantitative', 'pcr', 'analysis', 'revealed', 'increase', 'transcripts', 'upregulated', 'genes', 'asr', '488treated', 'mibc', 'cells', 'icpeb1i', '36fold', 'iil11i', '30fold', 'isfni', '2012fold', 'icyp4f11i', '158fold', 'conclusion', 'analysis', 'biological', 'functions', 'differentially', 'expressed', 'genes', 'revealed', 'possible', 'mechanisms', 'may', 'associated', 'aggressiveness', 'mibc']","['neurotrophin', 'p53', 'p005', 'asr']","['neurotrophin', 'p005']",True,['cancer']
32560222,Preclinical Evaluation of the Novel Small-Molecule MSI-N1014 for Treating Drug-Resistant Colon Cancer via the LGR5/β-catenin/miR-142-3p Network and Reducing Cancer-Associated Fibroblast Transformation.,"Colorectal cancer represents one of the most prevalent malignancies globally, with an estimated 140,000 new cases in the United States alone in 2019. Despite advancements in interventions, drug resistance occurs in virtually all patients diagnosed with late stages of colon cancer. Amplified epidermal growth factor receptor (EGFR) signaling is one of the most prevalent oncogenic drivers in patients and induces increased Janus kinase (JAK)/signal transduction and activator of transcription (STAT) and β-catenin functions, all of which facilitate disease progression. Equally important, cancer-associated fibroblasts (CAFs) transformed by cancer cells within the tumor microenvironment (TME) further facilitate malignancy by secreting interleukin (IL)-6 and augmenting STAT3 signaling in colon cancer cells and promoting the generation of cancer stem-like cells (CSCs). Based on these premises, single-targeted therapeutics have proven ineffective for treating malignant colon cancer, and alternative multiple-targeting agents should be explored. Herein, we synthesized a tetracyclic heterocyclic azathioxanthone, MSI-N1014, and demonstrated its therapeutic potential both in vitro and in vivo. First, we used a co-culture system to demonstrate that colon cancer cells co-cultured with CAFs resulted in heightened 5-fluorouracil (5-FU) resistance and tumor sphere-forming ability and increased side populations, accompanied by elevated expression of cluster of differentiation 44 (CD44), β-catenin, leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5), and ATP-binding cassette super-family G member 2 (ABCG2). MSI-N1014 suppressed cell viability, colony formation, and migration in both DLD1 and HCT116 cells. MSI-N1014 treatment led to decreased expressions of oncogenic markers, including mammalian target of rapamycin (mTOR), EGFR, and IL-6 and stemness markers such as CD44, β-catenin, and LGR5. More importantly, MSI-N1014 treatment suppressed the transformation of CAFs, and was associated with decreased secretion of IL-6 and vascular endothelial growth factor (VEGF) by CAFs. Furthermore, MSI-N1014 treatment resulted in significantly reduced oncogenic properties, namely the migratory ability, tumor-sphere generation, and resistance against 5-FU. Notably, an increased level of the tumor suppressor, miR-142-3p, whose targets include LGR5, IL-6, and ABCG2, was detected in association with MSI-N1014 treatment. Finally, we demonstrated the therapeutic potential of MSI-N1014 in vivo<i>,</i> where combined treatment with MSI-N1014 and 5-FU led to the lowest tumor growth, followed by MSI-N1014 only, 5-FU, and the vehicle control. Tumor samples from the MSI-N1014 group showed markedly reduced expressions of LGR5, β-catenin, IL-6, and mTOR, but increased expression of the tumor suppressor, miR-142-3p, according to qRT-PCR analysis. Collectively, we present preclinical support for the application of MSI-N1014 in treating 5-FU-resistant colon cancer cells. Further investigation is warranted to translate these findings into clinical settings.",2020-06-16,colorectal cancer represents one of the most prevalent malignancies globally with an estimated 140000 new cases in the united states alone in 2019 despite advancements in interventions drug resistance occurs in virtually all patients diagnosed with late stages of colon cancer amplified epidermal growth factor receptor egfr signaling is one of the most prevalent oncogenic drivers in patients and induces increased janus kinase jaksignal transduction and activator of transcription stat and βcatenin functions all of which facilitate disease progression equally important cancerassociated fibroblasts cafs transformed by cancer cells within the tumor microenvironment tme further facilitate malignancy by secreting interleukin il6 and augmenting stat3 signaling in colon cancer cells and promoting the generation of cancer stemlike cells cscs based on these premises singletargeted therapeutics have proven ineffective for treating malignant colon cancer and alternative multipletargeting agents should be explored herein we synthesized a tetracyclic heterocyclic azathioxanthone msin1014 and demonstrated its therapeutic potential both in vitro and in vivo first we used a coculture system to demonstrate that colon cancer cells cocultured with cafs resulted in heightened 5fluorouracil 5fu resistance and tumor sphereforming ability and increased side populations accompanied by elevated expression of cluster of differentiation 44 cd44 βcatenin leucinerich repeatcontaining gproteincoupled receptor 5 lgr5 and atpbinding cassette superfamily g member 2 abcg2 msin1014 suppressed cell viability colony formation and migration in both dld1 and hct116 cells msin1014 treatment led to decreased expressions of oncogenic markers including mammalian target of rapamycin mtor egfr and il6 and stemness markers such as cd44 βcatenin and lgr5 more importantly msin1014 treatment suppressed the transformation of cafs and was associated with decreased secretion of il6 and vascular endothelial growth factor vegf by cafs furthermore msin1014 treatment resulted in significantly reduced oncogenic properties namely the migratory ability tumorsphere generation and resistance against 5fu notably an increased level of the tumor suppressor mir1423p whose targets include lgr5 il6 and abcg2 was detected in association with msin1014 treatment finally we demonstrated the therapeutic potential of msin1014 in vivoii where combined treatment with msin1014 and 5fu led to the lowest tumor growth followed by msin1014 only 5fu and the vehicle control tumor samples from the msin1014 group showed markedly reduced expressions of lgr5 βcatenin il6 and mtor but increased expression of the tumor suppressor mir1423p according to qrtpcr analysis collectively we present preclinical support for the application of msin1014 in treating 5furesistant colon cancer cells further investigation is warranted to translate these findings into clinical settings,"['colorectal', 'cancer', 'represents', 'one', 'of', 'the', 'most', 'prevalent', 'malignancies', 'globally', 'with', 'an', 'estimated', '140000', 'new', 'cases', 'in', 'the', 'united', 'states', 'alone', 'in', '2019', 'despite', 'advancements', 'in', 'interventions', 'drug', 'resistance', 'occurs', 'in', 'virtually', 'all', 'patients', 'diagnosed', 'with', 'late', 'stages', 'of', 'colon', 'cancer', 'amplified', 'epidermal', 'growth', 'factor', 'receptor', 'egfr', 'signaling', 'is', 'one', 'of', 'the', 'most', 'prevalent', 'oncogenic', 'drivers', 'in', 'patients', 'and', 'induces', 'increased', 'janus', 'kinase', 'jaksignal', 'transduction', 'and', 'activator', 'of', 'transcription', 'stat', 'and', 'βcatenin', 'functions', 'all', 'of', 'which', 'facilitate', 'disease', 'progression', 'equally', 'important', 'cancerassociated', 'fibroblasts', 'cafs', 'transformed', 'by', 'cancer', 'cells', 'within', 'the', 'tumor', 'microenvironment', 'tme', 'further', 'facilitate', 'malignancy', 'by', 'secreting', 'interleukin', 'il6', 'and', 'augmenting', 'stat3', 'signaling', 'in', 'colon', 'cancer', 'cells', 'and', 'promoting', 'the', 'generation', 'of', 'cancer', 'stemlike', 'cells', 'cscs', 'based', 'on', 'these', 'premises', 'singletargeted', 'therapeutics', 'have', 'proven', 'ineffective', 'for', 'treating', 'malignant', 'colon', 'cancer', 'and', 'alternative', 'multipletargeting', 'agents', 'should', 'be', 'explored', 'herein', 'we', 'synthesized', 'a', 'tetracyclic', 'heterocyclic', 'azathioxanthone', 'msin1014', 'and', 'demonstrated', 'its', 'therapeutic', 'potential', 'both', 'in', 'vitro', 'and', 'in', 'vivo', 'first', 'we', 'used', 'a', 'coculture', 'system', 'to', 'demonstrate', 'that', 'colon', 'cancer', 'cells', 'cocultured', 'with', 'cafs', 'resulted', 'in', 'heightened', '5fluorouracil', '5fu', 'resistance', 'and', 'tumor', 'sphereforming', 'ability', 'and', 'increased', 'side', 'populations', 'accompanied', 'by', 'elevated', 'expression', 'of', 'cluster', 'of', 'differentiation', '44', 'cd44', 'βcatenin', 'leucinerich', 'repeatcontaining', 'gproteincoupled', 'receptor', '5', 'lgr5', 'and', 'atpbinding', 'cassette', 'superfamily', 'g', 'member', '2', 'abcg2', 'msin1014', 'suppressed', 'cell', 'viability', 'colony', 'formation', 'and', 'migration', 'in', 'both', 'dld1', 'and', 'hct116', 'cells', 'msin1014', 'treatment', 'led', 'to', 'decreased', 'expressions', 'of', 'oncogenic', 'markers', 'including', 'mammalian', 'target', 'of', 'rapamycin', 'mtor', 'egfr', 'and', 'il6', 'and', 'stemness', 'markers', 'such', 'as', 'cd44', 'βcatenin', 'and', 'lgr5', 'more', 'importantly', 'msin1014', 'treatment', 'suppressed', 'the', 'transformation', 'of', 'cafs', 'and', 'was', 'associated', 'with', 'decreased', 'secretion', 'of', 'il6', 'and', 'vascular', 'endothelial', 'growth', 'factor', 'vegf', 'by', 'cafs', 'furthermore', 'msin1014', 'treatment', 'resulted', 'in', 'significantly', 'reduced', 'oncogenic', 'properties', 'namely', 'the', 'migratory', 'ability', 'tumorsphere', 'generation', 'and', 'resistance', 'against', '5fu', 'notably', 'an', 'increased', 'level', 'of', 'the', 'tumor', 'suppressor', 'mir1423p', 'whose', 'targets', 'include', 'lgr5', 'il6', 'and', 'abcg2', 'was', 'detected', 'in', 'association', 'with', 'msin1014', 'treatment', 'finally', 'we', 'demonstrated', 'the', 'therapeutic', 'potential', 'of', 'msin1014', 'in', 'vivoii', 'where', 'combined', 'treatment', 'with', 'msin1014', 'and', '5fu', 'led', 'to', 'the', 'lowest', 'tumor', 'growth', 'followed', 'by', 'msin1014', 'only', '5fu', 'and', 'the', 'vehicle', 'control', 'tumor', 'samples', 'from', 'the', 'msin1014', 'group', 'showed', 'markedly', 'reduced', 'expressions', 'of', 'lgr5', 'βcatenin', 'il6', 'and', 'mtor', 'but', 'increased', 'expression', 'of', 'the', 'tumor', 'suppressor', 'mir1423p', 'according', 'to', 'qrtpcr', 'analysis', 'collectively', 'we', 'present', 'preclinical', 'support', 'for', 'the', 'application', 'of', 'msin1014', 'in', 'treating', '5furesistant', 'colon', 'cancer', 'cells', 'further', 'investigation', 'is', 'warranted', 'to', 'translate', 'these', 'findings', 'into', 'clinical', 'settings']","['colorectal', 'cancer', 'represents', 'one', 'prevalent', 'malignancies', 'globally', 'estimated', '140000', 'new', 'cases', 'united', 'states', 'alone', '2019', 'despite', 'advancements', 'interventions', 'drug', 'resistance', 'occurs', 'virtually', 'patients', 'diagnosed', 'late', 'stages', 'colon', 'cancer', 'amplified', 'epidermal', 'growth', 'factor', 'receptor', 'egfr', 'signaling', 'one', 'prevalent', 'oncogenic', 'drivers', 'patients', 'induces', 'increased', 'janus', 'kinase', 'jaksignal', 'transduction', 'activator', 'transcription', 'stat', 'βcatenin', 'functions', 'facilitate', 'disease', 'progression', 'equally', 'important', 'cancerassociated', 'fibroblasts', 'cafs', 'transformed', 'cancer', 'cells', 'within', 'tumor', 'microenvironment', 'tme', 'facilitate', 'malignancy', 'secreting', 'interleukin', 'il6', 'augmenting', 'stat3', 'signaling', 'colon', 'cancer', 'cells', 'promoting', 'generation', 'cancer', 'stemlike', 'cells', 'cscs', 'based', 'premises', 'singletargeted', 'therapeutics', 'proven', 'ineffective', 'treating', 'malignant', 'colon', 'cancer', 'alternative', 'multipletargeting', 'agents', 'explored', 'herein', 'synthesized', 'tetracyclic', 'heterocyclic', 'azathioxanthone', 'msin1014', 'demonstrated', 'therapeutic', 'potential', 'vitro', 'vivo', 'first', 'used', 'coculture', 'system', 'demonstrate', 'colon', 'cancer', 'cells', 'cocultured', 'cafs', 'resulted', 'heightened', '5fluorouracil', '5fu', 'resistance', 'tumor', 'sphereforming', 'ability', 'increased', 'side', 'populations', 'accompanied', 'elevated', 'expression', 'cluster', 'differentiation', '44', 'cd44', 'βcatenin', 'leucinerich', 'repeatcontaining', 'gproteincoupled', 'receptor', '5', 'lgr5', 'atpbinding', 'cassette', 'superfamily', 'g', 'member', '2', 'abcg2', 'msin1014', 'suppressed', 'cell', 'viability', 'colony', 'formation', 'migration', 'dld1', 'hct116', 'cells', 'msin1014', 'treatment', 'led', 'decreased', 'expressions', 'oncogenic', 'markers', 'including', 'mammalian', 'target', 'rapamycin', 'mtor', 'egfr', 'il6', 'stemness', 'markers', 'cd44', 'βcatenin', 'lgr5', 'importantly', 'msin1014', 'treatment', 'suppressed', 'transformation', 'cafs', 'associated', 'decreased', 'secretion', 'il6', 'vascular', 'endothelial', 'growth', 'factor', 'vegf', 'cafs', 'furthermore', 'msin1014', 'treatment', 'resulted', 'significantly', 'reduced', 'oncogenic', 'properties', 'namely', 'migratory', 'ability', 'tumorsphere', 'generation', 'resistance', '5fu', 'notably', 'increased', 'level', 'tumor', 'suppressor', 'mir1423p', 'whose', 'targets', 'include', 'lgr5', 'il6', 'abcg2', 'detected', 'association', 'msin1014', 'treatment', 'finally', 'demonstrated', 'therapeutic', 'potential', 'msin1014', 'vivoii', 'combined', 'treatment', 'msin1014', '5fu', 'led', 'lowest', 'tumor', 'growth', 'followed', 'msin1014', '5fu', 'vehicle', 'control', 'tumor', 'samples', 'msin1014', 'group', 'showed', 'markedly', 'reduced', 'expressions', 'lgr5', 'βcatenin', 'il6', 'mtor', 'increased', 'expression', 'tumor', 'suppressor', 'mir1423p', 'according', 'qrtpcr', 'analysis', 'collectively', 'present', 'preclinical', 'support', 'application', 'msin1014', 'treating', '5furesistant', 'colon', 'cancer', 'cells', 'investigation', 'warranted', 'translate', 'findings', 'clinical', 'settings']","['egfr', 'interleukin', 'stat3', 'cd44', 'lgr5', 'egfr', 'cd44', 'lgr5', 'vegf', 'lgr5', 'lgr5']","['cd44', 'lgr5', 'cd44', 'lgr5', 'lgr5', 'lgr5']",True,"['tumor', 'cancer']"
32528880,Positive Allosteric Modulation of CD11b as a Novel Therapeutic Strategy Against Lung Cancer.,"Lung cancer is one of the leading causes of cancer-related deaths in the United States. A major hurdle for improved therapies is immune suppression mediated by the tumor and its microenvironment. The lung tumor microenvironment (TME) contains large numbers of tumor-associated macrophages (TAMs), which suppress the adaptive immune response, increase neo-vascularization of the tumor, and provide pro-tumor factors to promote tumor growth. CD11b is highly expressed on myeloid cells, including TAMs, where it forms a heterodimeric integrin receptor with CD18 (known as CD11b/CD18, Mac-1, CR3, and αMβ2), and plays an important role in recruitment and biological functions of these cells, and is a validated therapeutic target. Here, we describe our pre-clinical studies targeting CD11b in the context of lung cancer, using pharmacologic and genetic approaches that work via positive allosteric modulation of CD11b function. GB1275 is a novel small molecule modulator of CD11b that is currently in Phase 1/2 clinical development. We assess GB1275 treatment effects on tumor growth and immune infiltrates in the murine Lewis Lung Carcinoma (LLC) syngeneic tumor model. Additionally, as an orthogonal approach to determine mechanisms of action, we utilize our recently developed novel CD11b knock-in (KI) mouse that constitutively expresses CD11b containing an activating isoleucine to glycine substitution at residue 332 in the ligand binding CD11b A-domain (I332G) that acts as a positive allosteric modulator of CD11b activity. We report that pharmacologic modulation of CD11b with GB1275 significantly reduces LLC tumor growth. CD11b KI mice similarly show significant reduction in both the size and rate of LLC tumor growth, as compared to WT mice, mimicking our observed treatment effects with GB1275. Tumor profiling revealed a significant reduction in TAM infiltration in GB1275-treated and in CD11b KI mice, increase in the ratio of M1/M2-like TAMs, and concomitant increase in cytotoxic T cells. The profiling also showed a significant decrease in CCL2 levels and a concomitant reduction in Ly6C<sup>hi</sup> monocytes in circulation in both groups. These findings suggest that positive allosteric modulation of CD11b reduces TAM density and reprograms them to enhance the adaptive immune response and is a novel therapeutic strategy against lung cancer.",2020-05-21,lung cancer is one of the leading causes of cancerrelated deaths in the united states a major hurdle for improved therapies is immune suppression mediated by the tumor and its microenvironment the lung tumor microenvironment tme contains large numbers of tumorassociated macrophages tams which suppress the adaptive immune response increase neovascularization of the tumor and provide protumor factors to promote tumor growth cd11b is highly expressed on myeloid cells including tams where it forms a heterodimeric integrin receptor with cd18 known as cd11bcd18 mac1 cr3 and αmβ2 and plays an important role in recruitment and biological functions of these cells and is a validated therapeutic target here we describe our preclinical studies targeting cd11b in the context of lung cancer using pharmacologic and genetic approaches that work via positive allosteric modulation of cd11b function gb1275 is a novel small molecule modulator of cd11b that is currently in phase 12 clinical development we assess gb1275 treatment effects on tumor growth and immune infiltrates in the murine lewis lung carcinoma llc syngeneic tumor model additionally as an orthogonal approach to determine mechanisms of action we utilize our recently developed novel cd11b knockin ki mouse that constitutively expresses cd11b containing an activating isoleucine to glycine substitution at residue 332 in the ligand binding cd11b adomain i332g that acts as a positive allosteric modulator of cd11b activity we report that pharmacologic modulation of cd11b with gb1275 significantly reduces llc tumor growth cd11b ki mice similarly show significant reduction in both the size and rate of llc tumor growth as compared to wt mice mimicking our observed treatment effects with gb1275 tumor profiling revealed a significant reduction in tam infiltration in gb1275treated and in cd11b ki mice increase in the ratio of m1m2like tams and concomitant increase in cytotoxic t cells the profiling also showed a significant decrease in ccl2 levels and a concomitant reduction in ly6csuphisup monocytes in circulation in both groups these findings suggest that positive allosteric modulation of cd11b reduces tam density and reprograms them to enhance the adaptive immune response and is a novel therapeutic strategy against lung cancer,"['lung', 'cancer', 'is', 'one', 'of', 'the', 'leading', 'causes', 'of', 'cancerrelated', 'deaths', 'in', 'the', 'united', 'states', 'a', 'major', 'hurdle', 'for', 'improved', 'therapies', 'is', 'immune', 'suppression', 'mediated', 'by', 'the', 'tumor', 'and', 'its', 'microenvironment', 'the', 'lung', 'tumor', 'microenvironment', 'tme', 'contains', 'large', 'numbers', 'of', 'tumorassociated', 'macrophages', 'tams', 'which', 'suppress', 'the', 'adaptive', 'immune', 'response', 'increase', 'neovascularization', 'of', 'the', 'tumor', 'and', 'provide', 'protumor', 'factors', 'to', 'promote', 'tumor', 'growth', 'cd11b', 'is', 'highly', 'expressed', 'on', 'myeloid', 'cells', 'including', 'tams', 'where', 'it', 'forms', 'a', 'heterodimeric', 'integrin', 'receptor', 'with', 'cd18', 'known', 'as', 'cd11bcd18', 'mac1', 'cr3', 'and', 'αmβ2', 'and', 'plays', 'an', 'important', 'role', 'in', 'recruitment', 'and', 'biological', 'functions', 'of', 'these', 'cells', 'and', 'is', 'a', 'validated', 'therapeutic', 'target', 'here', 'we', 'describe', 'our', 'preclinical', 'studies', 'targeting', 'cd11b', 'in', 'the', 'context', 'of', 'lung', 'cancer', 'using', 'pharmacologic', 'and', 'genetic', 'approaches', 'that', 'work', 'via', 'positive', 'allosteric', 'modulation', 'of', 'cd11b', 'function', 'gb1275', 'is', 'a', 'novel', 'small', 'molecule', 'modulator', 'of', 'cd11b', 'that', 'is', 'currently', 'in', 'phase', '12', 'clinical', 'development', 'we', 'assess', 'gb1275', 'treatment', 'effects', 'on', 'tumor', 'growth', 'and', 'immune', 'infiltrates', 'in', 'the', 'murine', 'lewis', 'lung', 'carcinoma', 'llc', 'syngeneic', 'tumor', 'model', 'additionally', 'as', 'an', 'orthogonal', 'approach', 'to', 'determine', 'mechanisms', 'of', 'action', 'we', 'utilize', 'our', 'recently', 'developed', 'novel', 'cd11b', 'knockin', 'ki', 'mouse', 'that', 'constitutively', 'expresses', 'cd11b', 'containing', 'an', 'activating', 'isoleucine', 'to', 'glycine', 'substitution', 'at', 'residue', '332', 'in', 'the', 'ligand', 'binding', 'cd11b', 'adomain', 'i332g', 'that', 'acts', 'as', 'a', 'positive', 'allosteric', 'modulator', 'of', 'cd11b', 'activity', 'we', 'report', 'that', 'pharmacologic', 'modulation', 'of', 'cd11b', 'with', 'gb1275', 'significantly', 'reduces', 'llc', 'tumor', 'growth', 'cd11b', 'ki', 'mice', 'similarly', 'show', 'significant', 'reduction', 'in', 'both', 'the', 'size', 'and', 'rate', 'of', 'llc', 'tumor', 'growth', 'as', 'compared', 'to', 'wt', 'mice', 'mimicking', 'our', 'observed', 'treatment', 'effects', 'with', 'gb1275', 'tumor', 'profiling', 'revealed', 'a', 'significant', 'reduction', 'in', 'tam', 'infiltration', 'in', 'gb1275treated', 'and', 'in', 'cd11b', 'ki', 'mice', 'increase', 'in', 'the', 'ratio', 'of', 'm1m2like', 'tams', 'and', 'concomitant', 'increase', 'in', 'cytotoxic', 't', 'cells', 'the', 'profiling', 'also', 'showed', 'a', 'significant', 'decrease', 'in', 'ccl2', 'levels', 'and', 'a', 'concomitant', 'reduction', 'in', 'ly6csuphisup', 'monocytes', 'in', 'circulation', 'in', 'both', 'groups', 'these', 'findings', 'suggest', 'that', 'positive', 'allosteric', 'modulation', 'of', 'cd11b', 'reduces', 'tam', 'density', 'and', 'reprograms', 'them', 'to', 'enhance', 'the', 'adaptive', 'immune', 'response', 'and', 'is', 'a', 'novel', 'therapeutic', 'strategy', 'against', 'lung', 'cancer']","['lung', 'cancer', 'one', 'leading', 'causes', 'cancerrelated', 'deaths', 'united', 'states', 'major', 'hurdle', 'improved', 'therapies', 'immune', 'suppression', 'mediated', 'tumor', 'microenvironment', 'lung', 'tumor', 'microenvironment', 'tme', 'contains', 'large', 'numbers', 'tumorassociated', 'macrophages', 'tams', 'suppress', 'adaptive', 'immune', 'response', 'increase', 'neovascularization', 'tumor', 'provide', 'protumor', 'factors', 'promote', 'tumor', 'growth', 'cd11b', 'highly', 'expressed', 'myeloid', 'cells', 'including', 'tams', 'forms', 'heterodimeric', 'integrin', 'receptor', 'cd18', 'known', 'cd11bcd18', 'mac1', 'cr3', 'αmβ2', 'plays', 'important', 'role', 'recruitment', 'biological', 'functions', 'cells', 'validated', 'therapeutic', 'target', 'describe', 'preclinical', 'studies', 'targeting', 'cd11b', 'context', 'lung', 'cancer', 'using', 'pharmacologic', 'genetic', 'approaches', 'work', 'via', 'positive', 'allosteric', 'modulation', 'cd11b', 'function', 'gb1275', 'novel', 'small', 'molecule', 'modulator', 'cd11b', 'currently', 'phase', '12', 'clinical', 'development', 'assess', 'gb1275', 'treatment', 'effects', 'tumor', 'growth', 'immune', 'infiltrates', 'murine', 'lewis', 'lung', 'carcinoma', 'llc', 'syngeneic', 'tumor', 'model', 'additionally', 'orthogonal', 'approach', 'determine', 'mechanisms', 'action', 'utilize', 'recently', 'developed', 'novel', 'cd11b', 'knockin', 'ki', 'mouse', 'constitutively', 'expresses', 'cd11b', 'containing', 'activating', 'isoleucine', 'glycine', 'substitution', 'residue', '332', 'ligand', 'binding', 'cd11b', 'adomain', 'i332g', 'acts', 'positive', 'allosteric', 'modulator', 'cd11b', 'activity', 'report', 'pharmacologic', 'modulation', 'cd11b', 'gb1275', 'significantly', 'reduces', 'llc', 'tumor', 'growth', 'cd11b', 'ki', 'mice', 'similarly', 'show', 'significant', 'reduction', 'size', 'rate', 'llc', 'tumor', 'growth', 'compared', 'wt', 'mice', 'mimicking', 'observed', 'treatment', 'effects', 'gb1275', 'tumor', 'profiling', 'revealed', 'significant', 'reduction', 'tam', 'infiltration', 'gb1275treated', 'cd11b', 'ki', 'mice', 'increase', 'ratio', 'm1m2like', 'tams', 'concomitant', 'increase', 'cytotoxic', 'cells', 'profiling', 'also', 'showed', 'significant', 'decrease', 'ccl2', 'levels', 'concomitant', 'reduction', 'ly6csuphisup', 'monocytes', 'circulation', 'groups', 'findings', 'suggest', 'positive', 'allosteric', 'modulation', 'cd11b', 'reduces', 'tam', 'density', 'reprograms', 'enhance', 'adaptive', 'immune', 'response', 'novel', 'therapeutic', 'strategy', 'lung', 'cancer']","['cd11b', 'integrin', 'cd18', 'cd11b', 'cd11b', 'cd11b', 'cd11b', 'cd11b', 'cd11b', 'cd11b', 'cd11b', 'cd11b', 'cd11b', 'ccl2', 'cd11b']","['cd11b', 'cd11b', 'cd11b', 'cd11b', 'cd11b', 'cd11b', 'cd11b', 'cd11b', 'cd11b', 'cd11b', 'cd11b', 'cd11b']",True,"['tumor', 'cancer']"
32440095,"Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.","Tenosynovial giant cell tumor (TGCT) is a rare benign tumor that involves the synovium, bursa, and tendon sheath, resulting in reduced mobility of the affected joint or limb. The current standard of care for TGCT is surgical resection. However, some patients have tumor recurrence, present with unresectable tumors, or have tumors that are in locations where resection could result in amputations or significant debility. Therefore, the development of systemic agents with activity against TGCT to expand treatment options is a highly unmet medical need. Pathologically, TGCT is characterized by the overexpression of colony﻿-stimulating factor 1 (CSF-1), which leads to the recruitment of colony﻿-stimulating factor-1 receptor (CSF-1R) expressing macrophages that make up the primary cell type within these giant cell tumors. The binding of CSF-1 and CSF-1R controls cell survival and proliferation of monocytes and the switch from a monocytic to macrophage phenotype contributing to the growth and inflammation within these tumors. Therefore, molecules that target CSF-1/CSF-1R have emerged as potential systemic agents for the treatment of TGCT. Given the role of macrophages in regulating tumorigenesis, CSF1/CSF1R-targeting agents have emerged as attractive therapeutic targets for solid tumors. Pexidartinib is an orally bioavailable and potent inhibitor of CSF-1R which is one of the most clinically used agents. In this review, we discuss the biology of TGCT and review the pre-clinical and clinical development of pexidartinib which ultimately led to the FDA approval of this agent for the treatment of TGCT as well as ongoing clinical studies utilizing pexidartinib in the setting of cancer.",2020-05-04,tenosynovial giant cell tumor tgct is a rare benign tumor that involves the synovium bursa and tendon sheath resulting in reduced mobility of the affected joint or limb the current standard of care for tgct is surgical resection however some patients have tumor recurrence present with unresectable tumors or have tumors that are in locations where resection could result in amputations or significant debility therefore the development of systemic agents with activity against tgct to expand treatment options is a highly unmet medical need pathologically tgct is characterized by the overexpression of colonystimulating factor 1 csf1 which leads to the recruitment of colonystimulating factor1 receptor csf1r expressing macrophages that make up the primary cell type within these giant cell tumors the binding of csf1 and csf1r controls cell survival and proliferation of monocytes and the switch from a monocytic to macrophage phenotype contributing to the growth and inflammation within these tumors therefore molecules that target csf1csf1r have emerged as potential systemic agents for the treatment of tgct given the role of macrophages in regulating tumorigenesis csf1csf1rtargeting agents have emerged as attractive therapeutic targets for solid tumors pexidartinib is an orally bioavailable and potent inhibitor of csf1r which is one of the most clinically used agents in this review we discuss the biology of tgct and review the preclinical and clinical development of pexidartinib which ultimately led to the fda approval of this agent for the treatment of tgct as well as ongoing clinical studies utilizing pexidartinib in the setting of cancer,"['tenosynovial', 'giant', 'cell', 'tumor', 'tgct', 'is', 'a', 'rare', 'benign', 'tumor', 'that', 'involves', 'the', 'synovium', 'bursa', 'and', 'tendon', 'sheath', 'resulting', 'in', 'reduced', 'mobility', 'of', 'the', 'affected', 'joint', 'or', 'limb', 'the', 'current', 'standard', 'of', 'care', 'for', 'tgct', 'is', 'surgical', 'resection', 'however', 'some', 'patients', 'have', 'tumor', 'recurrence', 'present', 'with', 'unresectable', 'tumors', 'or', 'have', 'tumors', 'that', 'are', 'in', 'locations', 'where', 'resection', 'could', 'result', 'in', 'amputations', 'or', 'significant', 'debility', 'therefore', 'the', 'development', 'of', 'systemic', 'agents', 'with', 'activity', 'against', 'tgct', 'to', 'expand', 'treatment', 'options', 'is', 'a', 'highly', 'unmet', 'medical', 'need', 'pathologically', 'tgct', 'is', 'characterized', 'by', 'the', 'overexpression', 'of', 'colonystimulating', 'factor', '1', 'csf1', 'which', 'leads', 'to', 'the', 'recruitment', 'of', 'colonystimulating', 'factor1', 'receptor', 'csf1r', 'expressing', 'macrophages', 'that', 'make', 'up', 'the', 'primary', 'cell', 'type', 'within', 'these', 'giant', 'cell', 'tumors', 'the', 'binding', 'of', 'csf1', 'and', 'csf1r', 'controls', 'cell', 'survival', 'and', 'proliferation', 'of', 'monocytes', 'and', 'the', 'switch', 'from', 'a', 'monocytic', 'to', 'macrophage', 'phenotype', 'contributing', 'to', 'the', 'growth', 'and', 'inflammation', 'within', 'these', 'tumors', 'therefore', 'molecules', 'that', 'target', 'csf1csf1r', 'have', 'emerged', 'as', 'potential', 'systemic', 'agents', 'for', 'the', 'treatment', 'of', 'tgct', 'given', 'the', 'role', 'of', 'macrophages', 'in', 'regulating', 'tumorigenesis', 'csf1csf1rtargeting', 'agents', 'have', 'emerged', 'as', 'attractive', 'therapeutic', 'targets', 'for', 'solid', 'tumors', 'pexidartinib', 'is', 'an', 'orally', 'bioavailable', 'and', 'potent', 'inhibitor', 'of', 'csf1r', 'which', 'is', 'one', 'of', 'the', 'most', 'clinically', 'used', 'agents', 'in', 'this', 'review', 'we', 'discuss', 'the', 'biology', 'of', 'tgct', 'and', 'review', 'the', 'preclinical', 'and', 'clinical', 'development', 'of', 'pexidartinib', 'which', 'ultimately', 'led', 'to', 'the', 'fda', 'approval', 'of', 'this', 'agent', 'for', 'the', 'treatment', 'of', 'tgct', 'as', 'well', 'as', 'ongoing', 'clinical', 'studies', 'utilizing', 'pexidartinib', 'in', 'the', 'setting', 'of', 'cancer']","['tenosynovial', 'giant', 'cell', 'tumor', 'tgct', 'rare', 'benign', 'tumor', 'involves', 'synovium', 'bursa', 'tendon', 'sheath', 'resulting', 'reduced', 'mobility', 'affected', 'joint', 'limb', 'current', 'standard', 'care', 'tgct', 'surgical', 'resection', 'however', 'patients', 'tumor', 'recurrence', 'present', 'unresectable', 'tumors', 'tumors', 'locations', 'resection', 'could', 'result', 'amputations', 'significant', 'debility', 'therefore', 'development', 'systemic', 'agents', 'activity', 'tgct', 'expand', 'treatment', 'options', 'highly', 'unmet', 'medical', 'need', 'pathologically', 'tgct', 'characterized', 'overexpression', 'colonystimulating', 'factor', '1', 'csf1', 'leads', 'recruitment', 'colonystimulating', 'factor1', 'receptor', 'csf1r', 'expressing', 'macrophages', 'make', 'primary', 'cell', 'type', 'within', 'giant', 'cell', 'tumors', 'binding', 'csf1', 'csf1r', 'controls', 'cell', 'survival', 'proliferation', 'monocytes', 'switch', 'monocytic', 'macrophage', 'phenotype', 'contributing', 'growth', 'inflammation', 'within', 'tumors', 'therefore', 'molecules', 'target', 'csf1csf1r', 'emerged', 'potential', 'systemic', 'agents', 'treatment', 'tgct', 'given', 'role', 'macrophages', 'regulating', 'tumorigenesis', 'csf1csf1rtargeting', 'agents', 'emerged', 'attractive', 'therapeutic', 'targets', 'solid', 'tumors', 'pexidartinib', 'orally', 'bioavailable', 'potent', 'inhibitor', 'csf1r', 'one', 'clinically', 'used', 'agents', 'review', 'discuss', 'biology', 'tgct', 'review', 'preclinical', 'clinical', 'development', 'pexidartinib', 'ultimately', 'led', 'fda', 'approval', 'agent', 'treatment', 'tgct', 'well', 'ongoing', 'clinical', 'studies', 'utilizing', 'pexidartinib', 'setting', 'cancer']","['csf1', 'factor1', 'csf1r', 'csf1', 'csf1r', 'csf1r']","['csf1r', 'csf1r', 'csf1r']",True,"['tumor', 'cancer']"
32423862,Identification and functional characterization of ribosomal protein S23 as a new member of antimicrobial protein.,"Previous studies show that some ribosomal proteins possess antimicrobial peptide (AMP) activity. However, information as such remains rather fragmentary and rather limited. We showed here for the first time that amphioxus RPS23, BjRPS23, was a previously uncharacterized AMP. It not only acted as a pattern recognition receptor, capable of identifying LPS, LTA and PGN, but also an effector, capable of killing the Gram-negative and -positive bacteria. We also showed that the residues positioned at 67-84 formed the core region for the antimicrobial activity of BjRPS23, and its orthologues Verrucomicrobia RPS12<sub>68-85</sub> and Thermotoga RPS12<sub>65-82</sub> similarly displayed some antibacterial activities. BjRPS23 functioned by a combined action of membranolytic mechanisms including interaction with bacterial membrane via LPS, LTA and PGN, and membrane depolarization. BjRPS23 also stimulated production of intracellular ROS in bacteria. Moreover, we demonstrated that RPS23 existed across widely separated taxa, and might play a universal role in protection against bacterial infection in different animals. In addition, we found that neither BjRPS23 nor its truncated form BjRPS23<sub>67-84</sub> were cytotoxic to mammalian cells, making them promising lead molecules for the design of novel peptide antibiotics against bacteria. Collectively, these indicate that RPS23 is a new member of AMP with ancient origin and high conservation.",2020-05-11,previous studies show that some ribosomal proteins possess antimicrobial peptide amp activity however information as such remains rather fragmentary and rather limited we showed here for the first time that amphioxus rps23 bjrps23 was a previously uncharacterized amp it not only acted as a pattern recognition receptor capable of identifying lps lta and pgn but also an effector capable of killing the gramnegative and positive bacteria we also showed that the residues positioned at 6784 formed the core region for the antimicrobial activity of bjrps23 and its orthologues verrucomicrobia rps12sub6885sub and thermotoga rps12sub6582sub similarly displayed some antibacterial activities bjrps23 functioned by a combined action of membranolytic mechanisms including interaction with bacterial membrane via lps lta and pgn and membrane depolarization bjrps23 also stimulated production of intracellular ros in bacteria moreover we demonstrated that rps23 existed across widely separated taxa and might play a universal role in protection against bacterial infection in different animals in addition we found that neither bjrps23 nor its truncated form bjrps23sub6784sub were cytotoxic to mammalian cells making them promising lead molecules for the design of novel peptide antibiotics against bacteria collectively these indicate that rps23 is a new member of amp with ancient origin and high conservation,"['previous', 'studies', 'show', 'that', 'some', 'ribosomal', 'proteins', 'possess', 'antimicrobial', 'peptide', 'amp', 'activity', 'however', 'information', 'as', 'such', 'remains', 'rather', 'fragmentary', 'and', 'rather', 'limited', 'we', 'showed', 'here', 'for', 'the', 'first', 'time', 'that', 'amphioxus', 'rps23', 'bjrps23', 'was', 'a', 'previously', 'uncharacterized', 'amp', 'it', 'not', 'only', 'acted', 'as', 'a', 'pattern', 'recognition', 'receptor', 'capable', 'of', 'identifying', 'lps', 'lta', 'and', 'pgn', 'but', 'also', 'an', 'effector', 'capable', 'of', 'killing', 'the', 'gramnegative', 'and', 'positive', 'bacteria', 'we', 'also', 'showed', 'that', 'the', 'residues', 'positioned', 'at', '6784', 'formed', 'the', 'core', 'region', 'for', 'the', 'antimicrobial', 'activity', 'of', 'bjrps23', 'and', 'its', 'orthologues', 'verrucomicrobia', 'rps12sub6885sub', 'and', 'thermotoga', 'rps12sub6582sub', 'similarly', 'displayed', 'some', 'antibacterial', 'activities', 'bjrps23', 'functioned', 'by', 'a', 'combined', 'action', 'of', 'membranolytic', 'mechanisms', 'including', 'interaction', 'with', 'bacterial', 'membrane', 'via', 'lps', 'lta', 'and', 'pgn', 'and', 'membrane', 'depolarization', 'bjrps23', 'also', 'stimulated', 'production', 'of', 'intracellular', 'ros', 'in', 'bacteria', 'moreover', 'we', 'demonstrated', 'that', 'rps23', 'existed', 'across', 'widely', 'separated', 'taxa', 'and', 'might', 'play', 'a', 'universal', 'role', 'in', 'protection', 'against', 'bacterial', 'infection', 'in', 'different', 'animals', 'in', 'addition', 'we', 'found', 'that', 'neither', 'bjrps23', 'nor', 'its', 'truncated', 'form', 'bjrps23sub6784sub', 'were', 'cytotoxic', 'to', 'mammalian', 'cells', 'making', 'them', 'promising', 'lead', 'molecules', 'for', 'the', 'design', 'of', 'novel', 'peptide', 'antibiotics', 'against', 'bacteria', 'collectively', 'these', 'indicate', 'that', 'rps23', 'is', 'a', 'new', 'member', 'of', 'amp', 'with', 'ancient', 'origin', 'and', 'high', 'conservation']","['previous', 'studies', 'show', 'ribosomal', 'proteins', 'possess', 'antimicrobial', 'peptide', 'amp', 'activity', 'however', 'information', 'remains', 'rather', 'fragmentary', 'rather', 'limited', 'showed', 'first', 'time', 'amphioxus', 'rps23', 'bjrps23', 'previously', 'uncharacterized', 'amp', 'acted', 'pattern', 'recognition', 'receptor', 'capable', 'identifying', 'lps', 'lta', 'pgn', 'also', 'effector', 'capable', 'killing', 'gramnegative', 'positive', 'bacteria', 'also', 'showed', 'residues', 'positioned', '6784', 'formed', 'core', 'region', 'antimicrobial', 'activity', 'bjrps23', 'orthologues', 'verrucomicrobia', 'rps12sub6885sub', 'thermotoga', 'rps12sub6582sub', 'similarly', 'displayed', 'antibacterial', 'activities', 'bjrps23', 'functioned', 'combined', 'action', 'membranolytic', 'mechanisms', 'including', 'interaction', 'bacterial', 'membrane', 'via', 'lps', 'lta', 'pgn', 'membrane', 'depolarization', 'bjrps23', 'also', 'stimulated', 'production', 'intracellular', 'ros', 'bacteria', 'moreover', 'demonstrated', 'rps23', 'existed', 'across', 'widely', 'separated', 'taxa', 'might', 'play', 'universal', 'role', 'protection', 'bacterial', 'infection', 'different', 'animals', 'addition', 'found', 'neither', 'bjrps23', 'truncated', 'form', 'bjrps23sub6784sub', 'cytotoxic', 'mammalian', 'cells', 'making', 'promising', 'lead', 'molecules', 'design', 'novel', 'peptide', 'antibiotics', 'bacteria', 'collectively', 'indicate', 'rps23', 'new', 'member', 'amp', 'ancient', 'origin', 'high', 'conservation']","['thermotoga', 'ros']",['thermotoga'],False,['infection']
32381104,"Sur-X, a novel peptide, kills colorectal cancer cells by targeting survivin-XIAP complex.","Survivin and XIAP are two important members of the inhibitor of apoptosis protein family and have been considered as potential targets for cancer treatment due to their overexpression in large variety of cancers including colorectal cancer. It has been reported that survivin and XIAP can synergistically inhibit apoptosis by forming survivin-XIAP complex. In this study, we aimed to design a peptide that targets the survivin-XIAP complex and elucidate its anticancer mechanisms in colorectal cancer cells.",2020-05-07,survivin and xiap are two important members of the inhibitor of apoptosis protein family and have been considered as potential targets for cancer treatment due to their overexpression in large variety of cancers including colorectal cancer it has been reported that survivin and xiap can synergistically inhibit apoptosis by forming survivinxiap complex in this study we aimed to design a peptide that targets the survivinxiap complex and elucidate its anticancer mechanisms in colorectal cancer cells,"['survivin', 'and', 'xiap', 'are', 'two', 'important', 'members', 'of', 'the', 'inhibitor', 'of', 'apoptosis', 'protein', 'family', 'and', 'have', 'been', 'considered', 'as', 'potential', 'targets', 'for', 'cancer', 'treatment', 'due', 'to', 'their', 'overexpression', 'in', 'large', 'variety', 'of', 'cancers', 'including', 'colorectal', 'cancer', 'it', 'has', 'been', 'reported', 'that', 'survivin', 'and', 'xiap', 'can', 'synergistically', 'inhibit', 'apoptosis', 'by', 'forming', 'survivinxiap', 'complex', 'in', 'this', 'study', 'we', 'aimed', 'to', 'design', 'a', 'peptide', 'that', 'targets', 'the', 'survivinxiap', 'complex', 'and', 'elucidate', 'its', 'anticancer', 'mechanisms', 'in', 'colorectal', 'cancer', 'cells']","['survivin', 'xiap', 'two', 'important', 'members', 'inhibitor', 'apoptosis', 'protein', 'family', 'considered', 'potential', 'targets', 'cancer', 'treatment', 'due', 'overexpression', 'large', 'variety', 'cancers', 'including', 'colorectal', 'cancer', 'reported', 'survivin', 'xiap', 'synergistically', 'inhibit', 'apoptosis', 'forming', 'survivinxiap', 'complex', 'study', 'aimed', 'design', 'peptide', 'targets', 'survivinxiap', 'complex', 'elucidate', 'anticancer', 'mechanisms', 'colorectal', 'cancer', 'cells']","['survivin', 'xiap', 'survivin', 'xiap']","['survivin', 'xiap', 'survivin', 'xiap']",True,['cancer']
32358047,"Effects of a Novel Psychomotor Stabilizer, IRL790, on Biochemical Measures of Synaptic Markers and Neurotransmission.","The novel small-molecule psychomotor stabilizer, IRL790, is currently in clinical trial for treatment of levodopa-induced dyskinesia and psychosis in patients with Parkinson disease. Here, we used naïve mice to investigate the effects of acute systemic administration of IRL790 on protein levels and phosphorylation states of proteins relevant for synaptic plasticity and transmission. IRL790 increased pro-brain-derived neurotrophic factor protein levels and phosphorylation at Ser1303 of the N-methyl-D-aspartate (NMDA) subtype 2B glutamate receptor (NR2B) in prefrontal cortex. IRL790 also increased the phosphorylation states at Ser19, Ser31, and Ser40, respectively, of tyrosine hydroxylase in striatum. IRL790 reduced protein levels of the NR2B receptor in striatum but not in prefrontal cortex. Taken together, we report that systemically administered IRL790 rapidly elicits changes in protein level and phosphorylation state of proteins associated with a beneficial effect on synaptic markers and neurotransmission. SIGNIFICANCE STATEMENT: The novel small-molecule psychomotor stabilizer, IRL790, is currently in clinical trial for treatment of levodopa-induced dyskinesia and psychosis in patients with Parkinson disease. In this study, we report that systemically administered IRL790 rapidly elicits changes in protein level and phosphorylation state of proteins associated with a beneficial effect on synaptic markers and neurotransmission.",2020-05-01,the novel smallmolecule psychomotor stabilizer irl790 is currently in clinical trial for treatment of levodopainduced dyskinesia and psychosis in patients with parkinson disease here we used naïve mice to investigate the effects of acute systemic administration of irl790 on protein levels and phosphorylation states of proteins relevant for synaptic plasticity and transmission irl790 increased probrainderived neurotrophic factor protein levels and phosphorylation at ser1303 of the nmethyldaspartate nmda subtype 2b glutamate receptor nr2b in prefrontal cortex irl790 also increased the phosphorylation states at ser19 ser31 and ser40 respectively of tyrosine hydroxylase in striatum irl790 reduced protein levels of the nr2b receptor in striatum but not in prefrontal cortex taken together we report that systemically administered irl790 rapidly elicits changes in protein level and phosphorylation state of proteins associated with a beneficial effect on synaptic markers and neurotransmission significance statement the novel smallmolecule psychomotor stabilizer irl790 is currently in clinical trial for treatment of levodopainduced dyskinesia and psychosis in patients with parkinson disease in this study we report that systemically administered irl790 rapidly elicits changes in protein level and phosphorylation state of proteins associated with a beneficial effect on synaptic markers and neurotransmission,"['the', 'novel', 'smallmolecule', 'psychomotor', 'stabilizer', 'irl790', 'is', 'currently', 'in', 'clinical', 'trial', 'for', 'treatment', 'of', 'levodopainduced', 'dyskinesia', 'and', 'psychosis', 'in', 'patients', 'with', 'parkinson', 'disease', 'here', 'we', 'used', 'naïve', 'mice', 'to', 'investigate', 'the', 'effects', 'of', 'acute', 'systemic', 'administration', 'of', 'irl790', 'on', 'protein', 'levels', 'and', 'phosphorylation', 'states', 'of', 'proteins', 'relevant', 'for', 'synaptic', 'plasticity', 'and', 'transmission', 'irl790', 'increased', 'probrainderived', 'neurotrophic', 'factor', 'protein', 'levels', 'and', 'phosphorylation', 'at', 'ser1303', 'of', 'the', 'nmethyldaspartate', 'nmda', 'subtype', '2b', 'glutamate', 'receptor', 'nr2b', 'in', 'prefrontal', 'cortex', 'irl790', 'also', 'increased', 'the', 'phosphorylation', 'states', 'at', 'ser19', 'ser31', 'and', 'ser40', 'respectively', 'of', 'tyrosine', 'hydroxylase', 'in', 'striatum', 'irl790', 'reduced', 'protein', 'levels', 'of', 'the', 'nr2b', 'receptor', 'in', 'striatum', 'but', 'not', 'in', 'prefrontal', 'cortex', 'taken', 'together', 'we', 'report', 'that', 'systemically', 'administered', 'irl790', 'rapidly', 'elicits', 'changes', 'in', 'protein', 'level', 'and', 'phosphorylation', 'state', 'of', 'proteins', 'associated', 'with', 'a', 'beneficial', 'effect', 'on', 'synaptic', 'markers', 'and', 'neurotransmission', 'significance', 'statement', 'the', 'novel', 'smallmolecule', 'psychomotor', 'stabilizer', 'irl790', 'is', 'currently', 'in', 'clinical', 'trial', 'for', 'treatment', 'of', 'levodopainduced', 'dyskinesia', 'and', 'psychosis', 'in', 'patients', 'with', 'parkinson', 'disease', 'in', 'this', 'study', 'we', 'report', 'that', 'systemically', 'administered', 'irl790', 'rapidly', 'elicits', 'changes', 'in', 'protein', 'level', 'and', 'phosphorylation', 'state', 'of', 'proteins', 'associated', 'with', 'a', 'beneficial', 'effect', 'on', 'synaptic', 'markers', 'and', 'neurotransmission']","['novel', 'smallmolecule', 'psychomotor', 'stabilizer', 'irl790', 'currently', 'clinical', 'trial', 'treatment', 'levodopainduced', 'dyskinesia', 'psychosis', 'patients', 'parkinson', 'disease', 'used', 'naïve', 'mice', 'investigate', 'effects', 'acute', 'systemic', 'administration', 'irl790', 'protein', 'levels', 'phosphorylation', 'states', 'proteins', 'relevant', 'synaptic', 'plasticity', 'transmission', 'irl790', 'increased', 'probrainderived', 'neurotrophic', 'factor', 'protein', 'levels', 'phosphorylation', 'ser1303', 'nmethyldaspartate', 'nmda', 'subtype', '2b', 'glutamate', 'receptor', 'nr2b', 'prefrontal', 'cortex', 'irl790', 'also', 'increased', 'phosphorylation', 'states', 'ser19', 'ser31', 'ser40', 'respectively', 'tyrosine', 'hydroxylase', 'striatum', 'irl790', 'reduced', 'protein', 'levels', 'nr2b', 'receptor', 'striatum', 'prefrontal', 'cortex', 'taken', 'together', 'report', 'systemically', 'administered', 'irl790', 'rapidly', 'elicits', 'changes', 'protein', 'level', 'phosphorylation', 'state', 'proteins', 'associated', 'beneficial', 'effect', 'synaptic', 'markers', 'neurotransmission', 'significance', 'statement', 'novel', 'smallmolecule', 'psychomotor', 'stabilizer', 'irl790', 'currently', 'clinical', 'trial', 'treatment', 'levodopainduced', 'dyskinesia', 'psychosis', 'patients', 'parkinson', 'disease', 'study', 'report', 'systemically', 'administered', 'irl790', 'rapidly', 'elicits', 'changes', 'protein', 'level', 'phosphorylation', 'state', 'proteins', 'associated', 'beneficial', 'effect', 'synaptic', 'markers', 'neurotransmission']","['neurotrophic', 'nmda', 'ser19', 'ser31', 'ser40']","['ser19', 'ser31', 'ser40']",True,['parkinson']
32341035,"Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis.","Metastasis is the major cause of mortality for patients with cancer, and dysregulation of developmental signaling pathways can significantly contribute to the metastatic process. The Sine oculis homeobox homolog 1 (SIX1)/eyes absent (EYA) transcriptional complex plays a critical role in the development of multiple organs and is typically downregulated after development is complete. In breast cancer, aberrant expression of SIX1 has been demonstrated to stimulate metastasis through activation of TGFβ signaling and subsequent induction of epithelial-mesenchymal transition (EMT). In addition, SIX1 can induce metastasis via non-cell autonomous means, including activation of GLI-signaling in neighboring tumor cells and activation of VEGFC-induced lymphangiogenesis. Thus, targeting SIX1 would be expected to inhibit metastasis while conferring limited side effects. However, transcription factors are notoriously difficult to target, and thus novel approaches to inhibit their action must be taken. Here we identified a novel small molecule compound, NCGC00378430 (abbreviated as 8430), that reduces the SIX1/EYA2 interaction. 8430 partially reversed transcriptional and metabolic profiles mediated by SIX1 overexpression and reversed SIX1-induced TGFβ signaling and EMT. 8430 was well tolerated when delivered to mice and significantly suppressed breast cancer-associated metastasis <i>in vivo</i> without significantly altering primary tumor growth. Thus, we have demonstrated for the first time that pharmacologic inhibition of the SIX1/EYA2 complex and associated phenotypes is sufficient to suppress breast cancer metastasis. SIGNIFICANCE: These findings identify and characterize a novel inhibitor of the SIX1/EYA2 complex that reverses EMT phenotypes suppressing breast cancer metastasis.",2020-04-27,metastasis is the major cause of mortality for patients with cancer and dysregulation of developmental signaling pathways can significantly contribute to the metastatic process the sine oculis homeobox homolog 1 six1eyes absent eya transcriptional complex plays a critical role in the development of multiple organs and is typically downregulated after development is complete in breast cancer aberrant expression of six1 has been demonstrated to stimulate metastasis through activation of tgfβ signaling and subsequent induction of epithelialmesenchymal transition emt in addition six1 can induce metastasis via noncell autonomous means including activation of glisignaling in neighboring tumor cells and activation of vegfcinduced lymphangiogenesis thus targeting six1 would be expected to inhibit metastasis while conferring limited side effects however transcription factors are notoriously difficult to target and thus novel approaches to inhibit their action must be taken here we identified a novel small molecule compound ncgc00378430 abbreviated as 8430 that reduces the six1eya2 interaction 8430 partially reversed transcriptional and metabolic profiles mediated by six1 overexpression and reversed six1induced tgfβ signaling and emt 8430 was well tolerated when delivered to mice and significantly suppressed breast cancerassociated metastasis iin vivoi without significantly altering primary tumor growth thus we have demonstrated for the first time that pharmacologic inhibition of the six1eya2 complex and associated phenotypes is sufficient to suppress breast cancer metastasis significance these findings identify and characterize a novel inhibitor of the six1eya2 complex that reverses emt phenotypes suppressing breast cancer metastasis,"['metastasis', 'is', 'the', 'major', 'cause', 'of', 'mortality', 'for', 'patients', 'with', 'cancer', 'and', 'dysregulation', 'of', 'developmental', 'signaling', 'pathways', 'can', 'significantly', 'contribute', 'to', 'the', 'metastatic', 'process', 'the', 'sine', 'oculis', 'homeobox', 'homolog', '1', 'six1eyes', 'absent', 'eya', 'transcriptional', 'complex', 'plays', 'a', 'critical', 'role', 'in', 'the', 'development', 'of', 'multiple', 'organs', 'and', 'is', 'typically', 'downregulated', 'after', 'development', 'is', 'complete', 'in', 'breast', 'cancer', 'aberrant', 'expression', 'of', 'six1', 'has', 'been', 'demonstrated', 'to', 'stimulate', 'metastasis', 'through', 'activation', 'of', 'tgfβ', 'signaling', 'and', 'subsequent', 'induction', 'of', 'epithelialmesenchymal', 'transition', 'emt', 'in', 'addition', 'six1', 'can', 'induce', 'metastasis', 'via', 'noncell', 'autonomous', 'means', 'including', 'activation', 'of', 'glisignaling', 'in', 'neighboring', 'tumor', 'cells', 'and', 'activation', 'of', 'vegfcinduced', 'lymphangiogenesis', 'thus', 'targeting', 'six1', 'would', 'be', 'expected', 'to', 'inhibit', 'metastasis', 'while', 'conferring', 'limited', 'side', 'effects', 'however', 'transcription', 'factors', 'are', 'notoriously', 'difficult', 'to', 'target', 'and', 'thus', 'novel', 'approaches', 'to', 'inhibit', 'their', 'action', 'must', 'be', 'taken', 'here', 'we', 'identified', 'a', 'novel', 'small', 'molecule', 'compound', 'ncgc00378430', 'abbreviated', 'as', '8430', 'that', 'reduces', 'the', 'six1eya2', 'interaction', '8430', 'partially', 'reversed', 'transcriptional', 'and', 'metabolic', 'profiles', 'mediated', 'by', 'six1', 'overexpression', 'and', 'reversed', 'six1induced', 'tgfβ', 'signaling', 'and', 'emt', '8430', 'was', 'well', 'tolerated', 'when', 'delivered', 'to', 'mice', 'and', 'significantly', 'suppressed', 'breast', 'cancerassociated', 'metastasis', 'iin', 'vivoi', 'without', 'significantly', 'altering', 'primary', 'tumor', 'growth', 'thus', 'we', 'have', 'demonstrated', 'for', 'the', 'first', 'time', 'that', 'pharmacologic', 'inhibition', 'of', 'the', 'six1eya2', 'complex', 'and', 'associated', 'phenotypes', 'is', 'sufficient', 'to', 'suppress', 'breast', 'cancer', 'metastasis', 'significance', 'these', 'findings', 'identify', 'and', 'characterize', 'a', 'novel', 'inhibitor', 'of', 'the', 'six1eya2', 'complex', 'that', 'reverses', 'emt', 'phenotypes', 'suppressing', 'breast', 'cancer', 'metastasis']","['metastasis', 'major', 'cause', 'mortality', 'patients', 'cancer', 'dysregulation', 'developmental', 'signaling', 'pathways', 'significantly', 'contribute', 'metastatic', 'process', 'sine', 'oculis', 'homeobox', 'homolog', '1', 'six1eyes', 'absent', 'eya', 'transcriptional', 'complex', 'plays', 'critical', 'role', 'development', 'multiple', 'organs', 'typically', 'downregulated', 'development', 'complete', 'breast', 'cancer', 'aberrant', 'expression', 'six1', 'demonstrated', 'stimulate', 'metastasis', 'activation', 'tgfβ', 'signaling', 'subsequent', 'induction', 'epithelialmesenchymal', 'transition', 'emt', 'addition', 'six1', 'induce', 'metastasis', 'via', 'noncell', 'autonomous', 'means', 'including', 'activation', 'glisignaling', 'neighboring', 'tumor', 'cells', 'activation', 'vegfcinduced', 'lymphangiogenesis', 'thus', 'targeting', 'six1', 'would', 'expected', 'inhibit', 'metastasis', 'conferring', 'limited', 'side', 'effects', 'however', 'transcription', 'factors', 'notoriously', 'difficult', 'target', 'thus', 'novel', 'approaches', 'inhibit', 'action', 'must', 'taken', 'identified', 'novel', 'small', 'molecule', 'compound', 'ncgc00378430', 'abbreviated', '8430', 'reduces', 'six1eya2', 'interaction', '8430', 'partially', 'reversed', 'transcriptional', 'metabolic', 'profiles', 'mediated', 'six1', 'overexpression', 'reversed', 'six1induced', 'tgfβ', 'signaling', 'emt', '8430', 'well', 'tolerated', 'delivered', 'mice', 'significantly', 'suppressed', 'breast', 'cancerassociated', 'metastasis', 'iin', 'vivoi', 'without', 'significantly', 'altering', 'primary', 'tumor', 'growth', 'thus', 'demonstrated', 'first', 'time', 'pharmacologic', 'inhibition', 'six1eya2', 'complex', 'associated', 'phenotypes', 'sufficient', 'suppress', 'breast', 'cancer', 'metastasis', 'significance', 'findings', 'identify', 'characterize', 'novel', 'inhibitor', 'six1eya2', 'complex', 'reverses', 'emt', 'phenotypes', 'suppressing', 'breast', 'cancer', 'metastasis']","['homeobox', 'eya', 'six1', 'six1', 'six1', 'six1']","['homeobox', 'eya', 'six1', 'six1', 'six1', 'six1']",True,"['tumor', 'cancer']"
32313651,Targeting Toll-like receptor-4 to tackle preterm birth and fetal inflammatory injury.,"Every year, 15 million pregnancies end prematurely, resulting in more than 1 million infant deaths and long-term health consequences for many children. The physiological processes of labour and birth involve essential roles for immune cells and pro-inflammatory cytokines in gestational tissues. There is compelling evidence that the mechanisms underlying spontaneous preterm birth are initiated when a premature and excessive inflammatory response is triggered by infection or other causes. Exposure to pro-inflammatory mediators is emerging as a major factor in the 'fetal inflammatory response syndrome' that often accompanies preterm birth, where unscheduled effects in fetal tissues interfere with normal development and predispose to neonatal morbidity. Toll-like receptors (TLRs) are critical upstream gatekeepers of inflammatory activation. TLR4 is prominently involved through its ability to sense and integrate signals from a range of microbial and endogenous triggers to provoke and perpetuate inflammation. Preclinical studies have identified TLR4 as an attractive pharmacological target to promote uterine quiescence and protect the fetus from inflammatory injury. Novel small-molecule inhibitors of TLR4 signalling, specifically the non-opioid receptor antagonists (+)-naloxone and (+)-naltrexone, are proving highly effective in animal models for preventing preterm birth induced by bacterial mimetic LPS, heat-killed <i>Escherichia coli</i>, or the TLR4-dependent pro-inflammatory lipid, platelet-activating factor (PAF). Here, we summarise the rationale for targeting TLR4 as a master regulator of inflammation in fetal and gestational tissues, and the potential utility of TLR4 antagonists as candidates for preventative and therapeutic application in preterm delivery and fetal inflammatory injury.",2020-04-14,every year 15 million pregnancies end prematurely resulting in more than 1 million infant deaths and longterm health consequences for many children the physiological processes of labour and birth involve essential roles for immune cells and proinflammatory cytokines in gestational tissues there is compelling evidence that the mechanisms underlying spontaneous preterm birth are initiated when a premature and excessive inflammatory response is triggered by infection or other causes exposure to proinflammatory mediators is emerging as a major factor in the fetal inflammatory response syndrome that often accompanies preterm birth where unscheduled effects in fetal tissues interfere with normal development and predispose to neonatal morbidity tolllike receptors tlrs are critical upstream gatekeepers of inflammatory activation tlr4 is prominently involved through its ability to sense and integrate signals from a range of microbial and endogenous triggers to provoke and perpetuate inflammation preclinical studies have identified tlr4 as an attractive pharmacological target to promote uterine quiescence and protect the fetus from inflammatory injury novel smallmolecule inhibitors of tlr4 signalling specifically the nonopioid receptor antagonists naloxone and naltrexone are proving highly effective in animal models for preventing preterm birth induced by bacterial mimetic lps heatkilled iescherichia colii or the tlr4dependent proinflammatory lipid plateletactivating factor paf here we summarise the rationale for targeting tlr4 as a master regulator of inflammation in fetal and gestational tissues and the potential utility of tlr4 antagonists as candidates for preventative and therapeutic application in preterm delivery and fetal inflammatory injury,"['every', 'year', '15', 'million', 'pregnancies', 'end', 'prematurely', 'resulting', 'in', 'more', 'than', '1', 'million', 'infant', 'deaths', 'and', 'longterm', 'health', 'consequences', 'for', 'many', 'children', 'the', 'physiological', 'processes', 'of', 'labour', 'and', 'birth', 'involve', 'essential', 'roles', 'for', 'immune', 'cells', 'and', 'proinflammatory', 'cytokines', 'in', 'gestational', 'tissues', 'there', 'is', 'compelling', 'evidence', 'that', 'the', 'mechanisms', 'underlying', 'spontaneous', 'preterm', 'birth', 'are', 'initiated', 'when', 'a', 'premature', 'and', 'excessive', 'inflammatory', 'response', 'is', 'triggered', 'by', 'infection', 'or', 'other', 'causes', 'exposure', 'to', 'proinflammatory', 'mediators', 'is', 'emerging', 'as', 'a', 'major', 'factor', 'in', 'the', 'fetal', 'inflammatory', 'response', 'syndrome', 'that', 'often', 'accompanies', 'preterm', 'birth', 'where', 'unscheduled', 'effects', 'in', 'fetal', 'tissues', 'interfere', 'with', 'normal', 'development', 'and', 'predispose', 'to', 'neonatal', 'morbidity', 'tolllike', 'receptors', 'tlrs', 'are', 'critical', 'upstream', 'gatekeepers', 'of', 'inflammatory', 'activation', 'tlr4', 'is', 'prominently', 'involved', 'through', 'its', 'ability', 'to', 'sense', 'and', 'integrate', 'signals', 'from', 'a', 'range', 'of', 'microbial', 'and', 'endogenous', 'triggers', 'to', 'provoke', 'and', 'perpetuate', 'inflammation', 'preclinical', 'studies', 'have', 'identified', 'tlr4', 'as', 'an', 'attractive', 'pharmacological', 'target', 'to', 'promote', 'uterine', 'quiescence', 'and', 'protect', 'the', 'fetus', 'from', 'inflammatory', 'injury', 'novel', 'smallmolecule', 'inhibitors', 'of', 'tlr4', 'signalling', 'specifically', 'the', 'nonopioid', 'receptor', 'antagonists', 'naloxone', 'and', 'naltrexone', 'are', 'proving', 'highly', 'effective', 'in', 'animal', 'models', 'for', 'preventing', 'preterm', 'birth', 'induced', 'by', 'bacterial', 'mimetic', 'lps', 'heatkilled', 'iescherichia', 'colii', 'or', 'the', 'tlr4dependent', 'proinflammatory', 'lipid', 'plateletactivating', 'factor', 'paf', 'here', 'we', 'summarise', 'the', 'rationale', 'for', 'targeting', 'tlr4', 'as', 'a', 'master', 'regulator', 'of', 'inflammation', 'in', 'fetal', 'and', 'gestational', 'tissues', 'and', 'the', 'potential', 'utility', 'of', 'tlr4', 'antagonists', 'as', 'candidates', 'for', 'preventative', 'and', 'therapeutic', 'application', 'in', 'preterm', 'delivery', 'and', 'fetal', 'inflammatory', 'injury']","['every', 'year', '15', 'million', 'pregnancies', 'end', 'prematurely', 'resulting', '1', 'million', 'infant', 'deaths', 'longterm', 'health', 'consequences', 'many', 'children', 'physiological', 'processes', 'labour', 'birth', 'involve', 'essential', 'roles', 'immune', 'cells', 'proinflammatory', 'cytokines', 'gestational', 'tissues', 'compelling', 'evidence', 'mechanisms', 'underlying', 'spontaneous', 'preterm', 'birth', 'initiated', 'premature', 'excessive', 'inflammatory', 'response', 'triggered', 'infection', 'causes', 'exposure', 'proinflammatory', 'mediators', 'emerging', 'major', 'factor', 'fetal', 'inflammatory', 'response', 'syndrome', 'often', 'accompanies', 'preterm', 'birth', 'unscheduled', 'effects', 'fetal', 'tissues', 'interfere', 'normal', 'development', 'predispose', 'neonatal', 'morbidity', 'tolllike', 'receptors', 'tlrs', 'critical', 'upstream', 'gatekeepers', 'inflammatory', 'activation', 'tlr4', 'prominently', 'involved', 'ability', 'sense', 'integrate', 'signals', 'range', 'microbial', 'endogenous', 'triggers', 'provoke', 'perpetuate', 'inflammation', 'preclinical', 'studies', 'identified', 'tlr4', 'attractive', 'pharmacological', 'target', 'promote', 'uterine', 'quiescence', 'protect', 'fetus', 'inflammatory', 'injury', 'novel', 'smallmolecule', 'inhibitors', 'tlr4', 'signalling', 'specifically', 'nonopioid', 'receptor', 'antagonists', 'naloxone', 'naltrexone', 'proving', 'highly', 'effective', 'animal', 'models', 'preventing', 'preterm', 'birth', 'induced', 'bacterial', 'mimetic', 'lps', 'heatkilled', 'iescherichia', 'colii', 'tlr4dependent', 'proinflammatory', 'lipid', 'plateletactivating', 'factor', 'paf', 'summarise', 'rationale', 'targeting', 'tlr4', 'master', 'regulator', 'inflammation', 'fetal', 'gestational', 'tissues', 'potential', 'utility', 'tlr4', 'antagonists', 'candidates', 'preventative', 'therapeutic', 'application', 'preterm', 'delivery', 'fetal', 'inflammatory', 'injury']","['tlr4', 'tlr4', 'tlr4', 'tlr4', 'tlr4']","['tlr4', 'tlr4', 'tlr4', 'tlr4', 'tlr4']",True,['infection']
32269074,Targeting Opsin4/Melanopsin with a Novel Small Molecule Suppresses PKC/RAF/MEK/ERK Signaling and Inhibits Lung Adenocarcinoma Progression.,"The identification of oncogenic biomolecules as drug targets is an unmet need for the development of clinically effective novel anticancer therapies. In this study, we report for the first time that opsin 4/melanopsin (OPN4) plays a critical role in the pathogenesis of non-small cell lung cancer (NSCLC) and is a potential drug target. Our study has revealed that OPN4 is overexpressed in human lung cancer tissues and cells, and is inversely correlated with patient survival probability. Knocking down expression of OPN4 suppressed cells growth and induced apoptosis in lung cancer cells. We have also found that OPN4, a G protein-coupled receptor, interacted with Gα11 and triggered the PKC/BRAF/MEK/ERKs signaling pathway in lung adenocarcinoma cells. Genetic ablation of <i>OPN4</i> attenuated the multiplicity and the volume of urethane-induced lung tumors in mice. Importantly, our study provides the first report of AE 51310 (1-[(2,5-dichloro-4-methoxyphenyl)sulfonyl]-3-methylpiperidine) as a small-molecule inhibitor of OPN4, suppressed the anchorage-independent growth of lung cancer cells and the growth of patient-derived xenograft tumors in mice. IMPLICATIONS: Overall, this study unveils the role of OPN4 in NSCLC and suggests that targeting OPN4 with small molecules, such as AE 51310 would be interesting to develop novel anticancer therapies for lung adenocarcinoma.",2020-04-08,the identification of oncogenic biomolecules as drug targets is an unmet need for the development of clinically effective novel anticancer therapies in this study we report for the first time that opsin 4melanopsin opn4 plays a critical role in the pathogenesis of nonsmall cell lung cancer nsclc and is a potential drug target our study has revealed that opn4 is overexpressed in human lung cancer tissues and cells and is inversely correlated with patient survival probability knocking down expression of opn4 suppressed cells growth and induced apoptosis in lung cancer cells we have also found that opn4 a g proteincoupled receptor interacted with gα11 and triggered the pkcbrafmekerks signaling pathway in lung adenocarcinoma cells genetic ablation of iopn4i attenuated the multiplicity and the volume of urethaneinduced lung tumors in mice importantly our study provides the first report of ae 51310 125dichloro4methoxyphenylsulfonyl3methylpiperidine as a smallmolecule inhibitor of opn4 suppressed the anchorageindependent growth of lung cancer cells and the growth of patientderived xenograft tumors in mice implications overall this study unveils the role of opn4 in nsclc and suggests that targeting opn4 with small molecules such as ae 51310 would be interesting to develop novel anticancer therapies for lung adenocarcinoma,"['the', 'identification', 'of', 'oncogenic', 'biomolecules', 'as', 'drug', 'targets', 'is', 'an', 'unmet', 'need', 'for', 'the', 'development', 'of', 'clinically', 'effective', 'novel', 'anticancer', 'therapies', 'in', 'this', 'study', 'we', 'report', 'for', 'the', 'first', 'time', 'that', 'opsin', '4melanopsin', 'opn4', 'plays', 'a', 'critical', 'role', 'in', 'the', 'pathogenesis', 'of', 'nonsmall', 'cell', 'lung', 'cancer', 'nsclc', 'and', 'is', 'a', 'potential', 'drug', 'target', 'our', 'study', 'has', 'revealed', 'that', 'opn4', 'is', 'overexpressed', 'in', 'human', 'lung', 'cancer', 'tissues', 'and', 'cells', 'and', 'is', 'inversely', 'correlated', 'with', 'patient', 'survival', 'probability', 'knocking', 'down', 'expression', 'of', 'opn4', 'suppressed', 'cells', 'growth', 'and', 'induced', 'apoptosis', 'in', 'lung', 'cancer', 'cells', 'we', 'have', 'also', 'found', 'that', 'opn4', 'a', 'g', 'proteincoupled', 'receptor', 'interacted', 'with', 'gα11', 'and', 'triggered', 'the', 'pkcbrafmekerks', 'signaling', 'pathway', 'in', 'lung', 'adenocarcinoma', 'cells', 'genetic', 'ablation', 'of', 'iopn4i', 'attenuated', 'the', 'multiplicity', 'and', 'the', 'volume', 'of', 'urethaneinduced', 'lung', 'tumors', 'in', 'mice', 'importantly', 'our', 'study', 'provides', 'the', 'first', 'report', 'of', 'ae', '51310', '125dichloro4methoxyphenylsulfonyl3methylpiperidine', 'as', 'a', 'smallmolecule', 'inhibitor', 'of', 'opn4', 'suppressed', 'the', 'anchorageindependent', 'growth', 'of', 'lung', 'cancer', 'cells', 'and', 'the', 'growth', 'of', 'patientderived', 'xenograft', 'tumors', 'in', 'mice', 'implications', 'overall', 'this', 'study', 'unveils', 'the', 'role', 'of', 'opn4', 'in', 'nsclc', 'and', 'suggests', 'that', 'targeting', 'opn4', 'with', 'small', 'molecules', 'such', 'as', 'ae', '51310', 'would', 'be', 'interesting', 'to', 'develop', 'novel', 'anticancer', 'therapies', 'for', 'lung', 'adenocarcinoma']","['identification', 'oncogenic', 'biomolecules', 'drug', 'targets', 'unmet', 'need', 'development', 'clinically', 'effective', 'novel', 'anticancer', 'therapies', 'study', 'report', 'first', 'time', 'opsin', '4melanopsin', 'opn4', 'plays', 'critical', 'role', 'pathogenesis', 'nonsmall', 'cell', 'lung', 'cancer', 'nsclc', 'potential', 'drug', 'target', 'study', 'revealed', 'opn4', 'overexpressed', 'human', 'lung', 'cancer', 'tissues', 'cells', 'inversely', 'correlated', 'patient', 'survival', 'probability', 'knocking', 'expression', 'opn4', 'suppressed', 'cells', 'growth', 'induced', 'apoptosis', 'lung', 'cancer', 'cells', 'also', 'found', 'opn4', 'g', 'proteincoupled', 'receptor', 'interacted', 'gα11', 'triggered', 'pkcbrafmekerks', 'signaling', 'pathway', 'lung', 'adenocarcinoma', 'cells', 'genetic', 'ablation', 'iopn4i', 'attenuated', 'multiplicity', 'volume', 'urethaneinduced', 'lung', 'tumors', 'mice', 'importantly', 'study', 'provides', 'first', 'report', 'ae', '51310', '125dichloro4methoxyphenylsulfonyl3methylpiperidine', 'smallmolecule', 'inhibitor', 'opn4', 'suppressed', 'anchorageindependent', 'growth', 'lung', 'cancer', 'cells', 'growth', 'patientderived', 'xenograft', 'tumors', 'mice', 'implications', 'overall', 'study', 'unveils', 'role', 'opn4', 'nsclc', 'suggests', 'targeting', 'opn4', 'small', 'molecules', 'ae', '51310', 'would', 'interesting', 'develop', 'novel', 'anticancer', 'therapies', 'lung', 'adenocarcinoma']","['opn4', 'opn4', 'opn4', 'opn4', 'opn4', 'opn4', 'opn4']","['opn4', 'opn4', 'opn4', 'opn4', 'opn4', 'opn4', 'opn4']",True,"['tumor', 'cancer']"
32219501,A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial.,"This phase I study aimed to evaluate the safety, peptide-specific immune responses, and anti-tumor effects of a novel vaccination therapy comprising multi-HLA-binding heat shock protein (HSP) 70/glypican-3 (GPC3) peptides and a novel adjuvant combination of hLAG-3Ig and Poly-ICLC against metastatic gastrointestinal cancers.",2020-03-26,this phase i study aimed to evaluate the safety peptidespecific immune responses and antitumor effects of a novel vaccination therapy comprising multihlabinding heat shock protein hsp 70glypican3 gpc3 peptides and a novel adjuvant combination of hlag3ig and polyiclc against metastatic gastrointestinal cancers,"['this', 'phase', 'i', 'study', 'aimed', 'to', 'evaluate', 'the', 'safety', 'peptidespecific', 'immune', 'responses', 'and', 'antitumor', 'effects', 'of', 'a', 'novel', 'vaccination', 'therapy', 'comprising', 'multihlabinding', 'heat', 'shock', 'protein', 'hsp', '70glypican3', 'gpc3', 'peptides', 'and', 'a', 'novel', 'adjuvant', 'combination', 'of', 'hlag3ig', 'and', 'polyiclc', 'against', 'metastatic', 'gastrointestinal', 'cancers']","['phase', 'study', 'aimed', 'evaluate', 'safety', 'peptidespecific', 'immune', 'responses', 'antitumor', 'effects', 'novel', 'vaccination', 'therapy', 'comprising', 'multihlabinding', 'heat', 'shock', 'protein', 'hsp', '70glypican3', 'gpc3', 'peptides', 'novel', 'adjuvant', 'combination', 'hlag3ig', 'polyiclc', 'metastatic', 'gastrointestinal', 'cancers']","['hsp', 'gpc3']",['gpc3'],False,"['tumor', 'cancer']"
32217770,"Pharmacokinetic-Pharmacodynamic-Efficacy Modeling of ONO-7579, a Novel Pan-Tropomyosin Receptor Kinase Inhibitor, in a Murine Xenograft Tumor Model.","The orally available and novel small molecule ONO-7579 (<i>N</i>-{2-[4-(2-amino-5-chloropyridin-3-yl)phenoxy]pyrimidin-5-yl}-<i>N</i>'-[2-(methanesulfonyl)-5-(trifluoromethyl)phenyl]urea) is a highly potent and selective pan-tropomyosin receptor kinase (TRK) inhibitor. The objective of the present study was to characterize the pharmacokinetic (PK), pharmacodynamic (PD), and antitumor efficacy relationships of ONO-7579 in mice xenografted with a human colorectal cancer cell line, KM12 (harboring the tropomyosin 3 <i>(TPM3)</i> <i>-</i>neurotrophic tyrosine receptor kinase 1 fusion gene), via a PK/PD modeling approach. Plasma and tumor concentrations of ONO-7579, tumor levels of phosphorylated TPM3-TRKA (pTRKA), and tumor volumes in the murine model were measured with a single or multiple dose of ONO-7579 (0.06-0.60 mg/kg) administered once daily. The PK/PD/efficacy models were developed in a sequential manner. Changes in plasma concentrations of ONO-7579 were described with an oral one-compartment model. Tumor concentrations of ONO-7579 were higher than plasma concentrations, and changes in ONO-7579 tumor concentrations were described with an additional tumor compartment that had no influence on plasma concentrations. pTRKA in tumors was described with a direct E<sub>max</sub> model, and the tumor ONO-7579 concentration causing 50% of the maximum effect was estimated to be 17.6 ng/g. In addition, a pTRKA-driven tumor growth inhibition model indicated that ONO-7579 started to sharply increase the antitumor effect at pTRKA inhibition rates >60% and required >91.5% to reduce tumors. In conclusion, the developed PK/PD/efficacy models revealed a ""switch-like"" relationship between pTRKA inhibition rate and antitumor effect in a murine KM12 xenograft model, demonstrating that pTRKA in tumors could serve as an effective biomarker for scheduling the dose regimen in early-stage clinical studies. SIGNIFICANCE STATEMENT: In recent years, clinical development of TRK inhibitors in patients with neurotrophic tyrosine receptor kinase fusion-positive solid tumors has been accelerated. This research found that phosphorylated TRKA was a useful biomarker for explaining the antitumor efficacy of TRK inhibitors using a pharmacokinetic/pharmacodynamic modeling approach in xenograft mice. This finding suggests a rational dosing regimen in early-stage clinical studies for ONO-7579 (<i>N</i>-{2-[4-(2-amino-5-chloropyridin-3-yl)phenoxy]pyrimidin-5-yl}-<i>N</i>'-[2-(methanesulfonyl)-5-(trifluoromethyl)phenyl]urea), a novel pan-TRK inhibitor.",2020-03-26,the orally available and novel small molecule ono7579 ini242amino5chloropyridin3ylphenoxypyrimidin5ylini2methanesulfonyl5trifluoromethylphenylurea is a highly potent and selective pantropomyosin receptor kinase trk inhibitor the objective of the present study was to characterize the pharmacokinetic pk pharmacodynamic pd and antitumor efficacy relationships of ono7579 in mice xenografted with a human colorectal cancer cell line km12 harboring the tropomyosin 3 itpm3i iineurotrophic tyrosine receptor kinase 1 fusion gene via a pkpd modeling approach plasma and tumor concentrations of ono7579 tumor levels of phosphorylated tpm3trka ptrka and tumor volumes in the murine model were measured with a single or multiple dose of ono7579 006060 mgkg administered once daily the pkpdefficacy models were developed in a sequential manner changes in plasma concentrations of ono7579 were described with an oral onecompartment model tumor concentrations of ono7579 were higher than plasma concentrations and changes in ono7579 tumor concentrations were described with an additional tumor compartment that had no influence on plasma concentrations ptrka in tumors was described with a direct esubmaxsub model and the tumor ono7579 concentration causing 50 of the maximum effect was estimated to be 176 ngg in addition a ptrkadriven tumor growth inhibition model indicated that ono7579 started to sharply increase the antitumor effect at ptrka inhibition rates 60 and required 915 to reduce tumors in conclusion the developed pkpdefficacy models revealed a switchlike relationship between ptrka inhibition rate and antitumor effect in a murine km12 xenograft model demonstrating that ptrka in tumors could serve as an effective biomarker for scheduling the dose regimen in earlystage clinical studies significance statement in recent years clinical development of trk inhibitors in patients with neurotrophic tyrosine receptor kinase fusionpositive solid tumors has been accelerated this research found that phosphorylated trka was a useful biomarker for explaining the antitumor efficacy of trk inhibitors using a pharmacokineticpharmacodynamic modeling approach in xenograft mice this finding suggests a rational dosing regimen in earlystage clinical studies for ono7579 ini242amino5chloropyridin3ylphenoxypyrimidin5ylini2methanesulfonyl5trifluoromethylphenylurea a novel pantrk inhibitor,"['the', 'orally', 'available', 'and', 'novel', 'small', 'molecule', 'ono7579', 'ini242amino5chloropyridin3ylphenoxypyrimidin5ylini2methanesulfonyl5trifluoromethylphenylurea', 'is', 'a', 'highly', 'potent', 'and', 'selective', 'pantropomyosin', 'receptor', 'kinase', 'trk', 'inhibitor', 'the', 'objective', 'of', 'the', 'present', 'study', 'was', 'to', 'characterize', 'the', 'pharmacokinetic', 'pk', 'pharmacodynamic', 'pd', 'and', 'antitumor', 'efficacy', 'relationships', 'of', 'ono7579', 'in', 'mice', 'xenografted', 'with', 'a', 'human', 'colorectal', 'cancer', 'cell', 'line', 'km12', 'harboring', 'the', 'tropomyosin', '3', 'itpm3i', 'iineurotrophic', 'tyrosine', 'receptor', 'kinase', '1', 'fusion', 'gene', 'via', 'a', 'pkpd', 'modeling', 'approach', 'plasma', 'and', 'tumor', 'concentrations', 'of', 'ono7579', 'tumor', 'levels', 'of', 'phosphorylated', 'tpm3trka', 'ptrka', 'and', 'tumor', 'volumes', 'in', 'the', 'murine', 'model', 'were', 'measured', 'with', 'a', 'single', 'or', 'multiple', 'dose', 'of', 'ono7579', '006060', 'mgkg', 'administered', 'once', 'daily', 'the', 'pkpdefficacy', 'models', 'were', 'developed', 'in', 'a', 'sequential', 'manner', 'changes', 'in', 'plasma', 'concentrations', 'of', 'ono7579', 'were', 'described', 'with', 'an', 'oral', 'onecompartment', 'model', 'tumor', 'concentrations', 'of', 'ono7579', 'were', 'higher', 'than', 'plasma', 'concentrations', 'and', 'changes', 'in', 'ono7579', 'tumor', 'concentrations', 'were', 'described', 'with', 'an', 'additional', 'tumor', 'compartment', 'that', 'had', 'no', 'influence', 'on', 'plasma', 'concentrations', 'ptrka', 'in', 'tumors', 'was', 'described', 'with', 'a', 'direct', 'esubmaxsub', 'model', 'and', 'the', 'tumor', 'ono7579', 'concentration', 'causing', '50', 'of', 'the', 'maximum', 'effect', 'was', 'estimated', 'to', 'be', '176', 'ngg', 'in', 'addition', 'a', 'ptrkadriven', 'tumor', 'growth', 'inhibition', 'model', 'indicated', 'that', 'ono7579', 'started', 'to', 'sharply', 'increase', 'the', 'antitumor', 'effect', 'at', 'ptrka', 'inhibition', 'rates', '60', 'and', 'required', '915', 'to', 'reduce', 'tumors', 'in', 'conclusion', 'the', 'developed', 'pkpdefficacy', 'models', 'revealed', 'a', 'switchlike', 'relationship', 'between', 'ptrka', 'inhibition', 'rate', 'and', 'antitumor', 'effect', 'in', 'a', 'murine', 'km12', 'xenograft', 'model', 'demonstrating', 'that', 'ptrka', 'in', 'tumors', 'could', 'serve', 'as', 'an', 'effective', 'biomarker', 'for', 'scheduling', 'the', 'dose', 'regimen', 'in', 'earlystage', 'clinical', 'studies', 'significance', 'statement', 'in', 'recent', 'years', 'clinical', 'development', 'of', 'trk', 'inhibitors', 'in', 'patients', 'with', 'neurotrophic', 'tyrosine', 'receptor', 'kinase', 'fusionpositive', 'solid', 'tumors', 'has', 'been', 'accelerated', 'this', 'research', 'found', 'that', 'phosphorylated', 'trka', 'was', 'a', 'useful', 'biomarker', 'for', 'explaining', 'the', 'antitumor', 'efficacy', 'of', 'trk', 'inhibitors', 'using', 'a', 'pharmacokineticpharmacodynamic', 'modeling', 'approach', 'in', 'xenograft', 'mice', 'this', 'finding', 'suggests', 'a', 'rational', 'dosing', 'regimen', 'in', 'earlystage', 'clinical', 'studies', 'for', 'ono7579', 'ini242amino5chloropyridin3ylphenoxypyrimidin5ylini2methanesulfonyl5trifluoromethylphenylurea', 'a', 'novel', 'pantrk', 'inhibitor']","['orally', 'available', 'novel', 'small', 'molecule', 'ono7579', 'ini242amino5chloropyridin3ylphenoxypyrimidin5ylini2methanesulfonyl5trifluoromethylphenylurea', 'highly', 'potent', 'selective', 'pantropomyosin', 'receptor', 'kinase', 'trk', 'inhibitor', 'objective', 'present', 'study', 'characterize', 'pharmacokinetic', 'pk', 'pharmacodynamic', 'pd', 'antitumor', 'efficacy', 'relationships', 'ono7579', 'mice', 'xenografted', 'human', 'colorectal', 'cancer', 'cell', 'line', 'km12', 'harboring', 'tropomyosin', '3', 'itpm3i', 'iineurotrophic', 'tyrosine', 'receptor', 'kinase', '1', 'fusion', 'gene', 'via', 'pkpd', 'modeling', 'approach', 'plasma', 'tumor', 'concentrations', 'ono7579', 'tumor', 'levels', 'phosphorylated', 'tpm3trka', 'ptrka', 'tumor', 'volumes', 'murine', 'model', 'measured', 'single', 'multiple', 'dose', 'ono7579', '006060', 'mgkg', 'administered', 'daily', 'pkpdefficacy', 'models', 'developed', 'sequential', 'manner', 'changes', 'plasma', 'concentrations', 'ono7579', 'described', 'oral', 'onecompartment', 'model', 'tumor', 'concentrations', 'ono7579', 'higher', 'plasma', 'concentrations', 'changes', 'ono7579', 'tumor', 'concentrations', 'described', 'additional', 'tumor', 'compartment', 'influence', 'plasma', 'concentrations', 'ptrka', 'tumors', 'described', 'direct', 'esubmaxsub', 'model', 'tumor', 'ono7579', 'concentration', 'causing', '50', 'maximum', 'effect', 'estimated', '176', 'ngg', 'addition', 'ptrkadriven', 'tumor', 'growth', 'inhibition', 'model', 'indicated', 'ono7579', 'started', 'sharply', 'increase', 'antitumor', 'effect', 'ptrka', 'inhibition', 'rates', '60', 'required', '915', 'reduce', 'tumors', 'conclusion', 'developed', 'pkpdefficacy', 'models', 'revealed', 'switchlike', 'relationship', 'ptrka', 'inhibition', 'rate', 'antitumor', 'effect', 'murine', 'km12', 'xenograft', 'model', 'demonstrating', 'ptrka', 'tumors', 'could', 'serve', 'effective', 'biomarker', 'scheduling', 'dose', 'regimen', 'earlystage', 'clinical', 'studies', 'significance', 'statement', 'recent', 'years', 'clinical', 'development', 'trk', 'inhibitors', 'patients', 'neurotrophic', 'tyrosine', 'receptor', 'kinase', 'fusionpositive', 'solid', 'tumors', 'accelerated', 'research', 'found', 'phosphorylated', 'trka', 'useful', 'biomarker', 'explaining', 'antitumor', 'efficacy', 'trk', 'inhibitors', 'using', 'pharmacokineticpharmacodynamic', 'modeling', 'approach', 'xenograft', 'mice', 'finding', 'suggests', 'rational', 'dosing', 'regimen', 'earlystage', 'clinical', 'studies', 'ono7579', 'ini242amino5chloropyridin3ylphenoxypyrimidin5ylini2methanesulfonyl5trifluoromethylphenylurea', 'novel', 'pantrk', 'inhibitor']","['trk', 'trk', 'neurotrophic', 'trka', 'trk']",['trka'],True,"['tumor', 'cancer']"
32141766,OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma.,"Melflufen is a novel peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells. It has emerged as a potential new multiple myeloma treatment, particularly for late-stage forms of the disease. Here we describe the rationale and design of OCEAN (NCT03151811), a randomized, head-to-head, superiority, open-label, global, Phase III study evaluating the efficacy and safety of melflufen + dexamethasone versus pomalidomide + dexamethasone. Eligible patients with relapsed refractory multiple myeloma have received 2-4 previous treatments and are refractory to both lenalidomide and their last treatment. Patients are excluded if they have previously received pomalidomide. The primary endpoint is progression-free survival, and key secondary endpoints include overall response rate, duration of response and overall survival.",2020-03-06,melflufen is a novel peptidedrug conjugate that rapidly delivers a cytotoxic payload into tumor cells it has emerged as a potential new multiple myeloma treatment particularly for latestage forms of the disease here we describe the rationale and design of ocean nct03151811 a randomized headtohead superiority openlabel global phase iii study evaluating the efficacy and safety of melflufen  dexamethasone versus pomalidomide  dexamethasone eligible patients with relapsed refractory multiple myeloma have received 24 previous treatments and are refractory to both lenalidomide and their last treatment patients are excluded if they have previously received pomalidomide the primary endpoint is progressionfree survival and key secondary endpoints include overall response rate duration of response and overall survival,"['melflufen', 'is', 'a', 'novel', 'peptidedrug', 'conjugate', 'that', 'rapidly', 'delivers', 'a', 'cytotoxic', 'payload', 'into', 'tumor', 'cells', 'it', 'has', 'emerged', 'as', 'a', 'potential', 'new', 'multiple', 'myeloma', 'treatment', 'particularly', 'for', 'latestage', 'forms', 'of', 'the', 'disease', 'here', 'we', 'describe', 'the', 'rationale', 'and', 'design', 'of', 'ocean', 'nct03151811', 'a', 'randomized', 'headtohead', 'superiority', 'openlabel', 'global', 'phase', 'iii', 'study', 'evaluating', 'the', 'efficacy', 'and', 'safety', 'of', 'melflufen', 'dexamethasone', 'versus', 'pomalidomide', 'dexamethasone', 'eligible', 'patients', 'with', 'relapsed', 'refractory', 'multiple', 'myeloma', 'have', 'received', '24', 'previous', 'treatments', 'and', 'are', 'refractory', 'to', 'both', 'lenalidomide', 'and', 'their', 'last', 'treatment', 'patients', 'are', 'excluded', 'if', 'they', 'have', 'previously', 'received', 'pomalidomide', 'the', 'primary', 'endpoint', 'is', 'progressionfree', 'survival', 'and', 'key', 'secondary', 'endpoints', 'include', 'overall', 'response', 'rate', 'duration', 'of', 'response', 'and', 'overall', 'survival']","['melflufen', 'novel', 'peptidedrug', 'conjugate', 'rapidly', 'delivers', 'cytotoxic', 'payload', 'tumor', 'cells', 'emerged', 'potential', 'new', 'multiple', 'myeloma', 'treatment', 'particularly', 'latestage', 'forms', 'disease', 'describe', 'rationale', 'design', 'ocean', 'nct03151811', 'randomized', 'headtohead', 'superiority', 'openlabel', 'global', 'phase', 'iii', 'study', 'evaluating', 'efficacy', 'safety', 'melflufen', 'dexamethasone', 'versus', 'pomalidomide', 'dexamethasone', 'eligible', 'patients', 'relapsed', 'refractory', 'multiple', 'myeloma', 'received', '24', 'previous', 'treatments', 'refractory', 'lenalidomide', 'last', 'treatment', 'patients', 'excluded', 'previously', 'received', 'pomalidomide', 'primary', 'endpoint', 'progressionfree', 'survival', 'key', 'secondary', 'endpoints', 'include', 'overall', 'response', 'rate', 'duration', 'response', 'overall', 'survival']",['latestage'],['latestage'],True,['tumor']
32127468,Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis-Initiating Cells.,"The development of efficacious therapies targeting metastatic spread of breast cancer to the brain represents an unmet clinical need. Accordingly, an improved understanding of the molecular underpinnings of central nervous system spread and progression of breast cancer brain metastases (BCBM) is required. In this study, the clinical burden of disease in BCBM was investigated, as well as the role of aldehyde dehydrogenase 1A3 (ALDH1A3) in the metastatic cascade leading to BCBM development. Initial analysis of clinical survival trends for breast cancer and BCBM determined improvement of breast cancer survival rates; however, this has failed to positively affect the prognostic milestones of triple-negative breast cancer (TNBC) brain metastases (BM). ALDH1A3 and a representative epithelial-mesenchymal transition (EMT) gene signature (mesenchymal markers, CD44 or Vimentin) were compared in tumors derived from BM, lung metastases (LM), or bone metastases (BoM) of patients as well as mice after injection of TNBC cells. Selective elevation of the EMT signature and ALDH1A3 were observed in BM, unlike LM and BoM, especially in the tumor edge. Furthermore, ALDH1A3 was determined to play a role in BCBM establishment via regulation of circulating tumor cell adhesion and migration phases in the BCBM cascade. Validation through genetic and pharmacologic inhibition of ALDH1A3 via lentiviral shRNA knockdown and a novel small-molecule inhibitor demonstrated selective inhibition of BCBM formation with prolonged survival of tumor-bearing mice. Given the survival benefits via targeting ALDH1A3, it may prove an effective therapeutic strategy for BCBM prevention and/or treatment.",2020-03-03,the development of efficacious therapies targeting metastatic spread of breast cancer to the brain represents an unmet clinical need accordingly an improved understanding of the molecular underpinnings of central nervous system spread and progression of breast cancer brain metastases bcbm is required in this study the clinical burden of disease in bcbm was investigated as well as the role of aldehyde dehydrogenase 1a3 aldh1a3 in the metastatic cascade leading to bcbm development initial analysis of clinical survival trends for breast cancer and bcbm determined improvement of breast cancer survival rates however this has failed to positively affect the prognostic milestones of triplenegative breast cancer tnbc brain metastases bm aldh1a3 and a representative epithelialmesenchymal transition emt gene signature mesenchymal markers cd44 or vimentin were compared in tumors derived from bm lung metastases lm or bone metastases bom of patients as well as mice after injection of tnbc cells selective elevation of the emt signature and aldh1a3 were observed in bm unlike lm and bom especially in the tumor edge furthermore aldh1a3 was determined to play a role in bcbm establishment via regulation of circulating tumor cell adhesion and migration phases in the bcbm cascade validation through genetic and pharmacologic inhibition of aldh1a3 via lentiviral shrna knockdown and a novel smallmolecule inhibitor demonstrated selective inhibition of bcbm formation with prolonged survival of tumorbearing mice given the survival benefits via targeting aldh1a3 it may prove an effective therapeutic strategy for bcbm prevention andor treatment,"['the', 'development', 'of', 'efficacious', 'therapies', 'targeting', 'metastatic', 'spread', 'of', 'breast', 'cancer', 'to', 'the', 'brain', 'represents', 'an', 'unmet', 'clinical', 'need', 'accordingly', 'an', 'improved', 'understanding', 'of', 'the', 'molecular', 'underpinnings', 'of', 'central', 'nervous', 'system', 'spread', 'and', 'progression', 'of', 'breast', 'cancer', 'brain', 'metastases', 'bcbm', 'is', 'required', 'in', 'this', 'study', 'the', 'clinical', 'burden', 'of', 'disease', 'in', 'bcbm', 'was', 'investigated', 'as', 'well', 'as', 'the', 'role', 'of', 'aldehyde', 'dehydrogenase', '1a3', 'aldh1a3', 'in', 'the', 'metastatic', 'cascade', 'leading', 'to', 'bcbm', 'development', 'initial', 'analysis', 'of', 'clinical', 'survival', 'trends', 'for', 'breast', 'cancer', 'and', 'bcbm', 'determined', 'improvement', 'of', 'breast', 'cancer', 'survival', 'rates', 'however', 'this', 'has', 'failed', 'to', 'positively', 'affect', 'the', 'prognostic', 'milestones', 'of', 'triplenegative', 'breast', 'cancer', 'tnbc', 'brain', 'metastases', 'bm', 'aldh1a3', 'and', 'a', 'representative', 'epithelialmesenchymal', 'transition', 'emt', 'gene', 'signature', 'mesenchymal', 'markers', 'cd44', 'or', 'vimentin', 'were', 'compared', 'in', 'tumors', 'derived', 'from', 'bm', 'lung', 'metastases', 'lm', 'or', 'bone', 'metastases', 'bom', 'of', 'patients', 'as', 'well', 'as', 'mice', 'after', 'injection', 'of', 'tnbc', 'cells', 'selective', 'elevation', 'of', 'the', 'emt', 'signature', 'and', 'aldh1a3', 'were', 'observed', 'in', 'bm', 'unlike', 'lm', 'and', 'bom', 'especially', 'in', 'the', 'tumor', 'edge', 'furthermore', 'aldh1a3', 'was', 'determined', 'to', 'play', 'a', 'role', 'in', 'bcbm', 'establishment', 'via', 'regulation', 'of', 'circulating', 'tumor', 'cell', 'adhesion', 'and', 'migration', 'phases', 'in', 'the', 'bcbm', 'cascade', 'validation', 'through', 'genetic', 'and', 'pharmacologic', 'inhibition', 'of', 'aldh1a3', 'via', 'lentiviral', 'shrna', 'knockdown', 'and', 'a', 'novel', 'smallmolecule', 'inhibitor', 'demonstrated', 'selective', 'inhibition', 'of', 'bcbm', 'formation', 'with', 'prolonged', 'survival', 'of', 'tumorbearing', 'mice', 'given', 'the', 'survival', 'benefits', 'via', 'targeting', 'aldh1a3', 'it', 'may', 'prove', 'an', 'effective', 'therapeutic', 'strategy', 'for', 'bcbm', 'prevention', 'andor', 'treatment']","['development', 'efficacious', 'therapies', 'targeting', 'metastatic', 'spread', 'breast', 'cancer', 'brain', 'represents', 'unmet', 'clinical', 'need', 'accordingly', 'improved', 'understanding', 'molecular', 'underpinnings', 'central', 'nervous', 'system', 'spread', 'progression', 'breast', 'cancer', 'brain', 'metastases', 'bcbm', 'required', 'study', 'clinical', 'burden', 'disease', 'bcbm', 'investigated', 'well', 'role', 'aldehyde', 'dehydrogenase', '1a3', 'aldh1a3', 'metastatic', 'cascade', 'leading', 'bcbm', 'development', 'initial', 'analysis', 'clinical', 'survival', 'trends', 'breast', 'cancer', 'bcbm', 'determined', 'improvement', 'breast', 'cancer', 'survival', 'rates', 'however', 'failed', 'positively', 'affect', 'prognostic', 'milestones', 'triplenegative', 'breast', 'cancer', 'tnbc', 'brain', 'metastases', 'bm', 'aldh1a3', 'representative', 'epithelialmesenchymal', 'transition', 'emt', 'gene', 'signature', 'mesenchymal', 'markers', 'cd44', 'vimentin', 'compared', 'tumors', 'derived', 'bm', 'lung', 'metastases', 'lm', 'bone', 'metastases', 'bom', 'patients', 'well', 'mice', 'injection', 'tnbc', 'cells', 'selective', 'elevation', 'emt', 'signature', 'aldh1a3', 'observed', 'bm', 'unlike', 'lm', 'bom', 'especially', 'tumor', 'edge', 'furthermore', 'aldh1a3', 'determined', 'play', 'role', 'bcbm', 'establishment', 'via', 'regulation', 'circulating', 'tumor', 'cell', 'adhesion', 'migration', 'phases', 'bcbm', 'cascade', 'validation', 'genetic', 'pharmacologic', 'inhibition', 'aldh1a3', 'via', 'lentiviral', 'shrna', 'knockdown', 'novel', 'smallmolecule', 'inhibitor', 'demonstrated', 'selective', 'inhibition', 'bcbm', 'formation', 'prolonged', 'survival', 'tumorbearing', 'mice', 'given', 'survival', 'benefits', 'via', 'targeting', 'aldh1a3', 'may', 'prove', 'effective', 'therapeutic', 'strategy', 'bcbm', 'prevention', 'andor', 'treatment']","['cd44', 'vimentin']","['cd44', 'vimentin']",True,"['tumor', 'cancer']"
32082974,"PCC0208017, a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression <i>in vitro</i> and <i>in vivo</i>.","Gliomas are the most common primary intracranial neoplasms among all brain malignancies, and the microtubule affinity regulating kinases (MARKs) have become potential drug targets for glioma. Here, we report a novel dual small-molecule inhibitor of MARK3 and MARK4, designated as PCC0208017. <i>In vitro,</i> PCC0208017 strongly inhibited kinase activity against MARK3 and MARK4, and strongly reduced proliferation in three glioma cell lines. This compound attenuated glioma cell migration, glioma cell invasion, and angiogenesis. Molecular mechanism studies revealed that PCC0208017 decreased the phosphorylation of Tau, disrupted microtubule dynamics, and induced a G2/M phase cell cycle arrest. In an <i>in vivo</i> glioma model, PCC0208017 showed robust anti-tumor activity, blood-brain barrier permeability, and a good oral pharmacokinetic profile. Molecular docking studies showed that PCC0208017 exhibited high binding affinity to MARK3 and MARK4. Taken together, our study describes for the first time that PCC0208017, a novel MARK3/MARK4 inhibitor, might be a promising lead compound for treatment of glioma.",2019-09-18,gliomas are the most common primary intracranial neoplasms among all brain malignancies and the microtubule affinity regulating kinases marks have become potential drug targets for glioma here we report a novel dual smallmolecule inhibitor of mark3 and mark4 designated as pcc0208017 iin vitroi pcc0208017 strongly inhibited kinase activity against mark3 and mark4 and strongly reduced proliferation in three glioma cell lines this compound attenuated glioma cell migration glioma cell invasion and angiogenesis molecular mechanism studies revealed that pcc0208017 decreased the phosphorylation of tau disrupted microtubule dynamics and induced a g2m phase cell cycle arrest in an iin vivoi glioma model pcc0208017 showed robust antitumor activity bloodbrain barrier permeability and a good oral pharmacokinetic profile molecular docking studies showed that pcc0208017 exhibited high binding affinity to mark3 and mark4 taken together our study describes for the first time that pcc0208017 a novel mark3mark4 inhibitor might be a promising lead compound for treatment of glioma,"['gliomas', 'are', 'the', 'most', 'common', 'primary', 'intracranial', 'neoplasms', 'among', 'all', 'brain', 'malignancies', 'and', 'the', 'microtubule', 'affinity', 'regulating', 'kinases', 'marks', 'have', 'become', 'potential', 'drug', 'targets', 'for', 'glioma', 'here', 'we', 'report', 'a', 'novel', 'dual', 'smallmolecule', 'inhibitor', 'of', 'mark3', 'and', 'mark4', 'designated', 'as', 'pcc0208017', 'iin', 'vitroi', 'pcc0208017', 'strongly', 'inhibited', 'kinase', 'activity', 'against', 'mark3', 'and', 'mark4', 'and', 'strongly', 'reduced', 'proliferation', 'in', 'three', 'glioma', 'cell', 'lines', 'this', 'compound', 'attenuated', 'glioma', 'cell', 'migration', 'glioma', 'cell', 'invasion', 'and', 'angiogenesis', 'molecular', 'mechanism', 'studies', 'revealed', 'that', 'pcc0208017', 'decreased', 'the', 'phosphorylation', 'of', 'tau', 'disrupted', 'microtubule', 'dynamics', 'and', 'induced', 'a', 'g2m', 'phase', 'cell', 'cycle', 'arrest', 'in', 'an', 'iin', 'vivoi', 'glioma', 'model', 'pcc0208017', 'showed', 'robust', 'antitumor', 'activity', 'bloodbrain', 'barrier', 'permeability', 'and', 'a', 'good', 'oral', 'pharmacokinetic', 'profile', 'molecular', 'docking', 'studies', 'showed', 'that', 'pcc0208017', 'exhibited', 'high', 'binding', 'affinity', 'to', 'mark3', 'and', 'mark4', 'taken', 'together', 'our', 'study', 'describes', 'for', 'the', 'first', 'time', 'that', 'pcc0208017', 'a', 'novel', 'mark3mark4', 'inhibitor', 'might', 'be', 'a', 'promising', 'lead', 'compound', 'for', 'treatment', 'of', 'glioma']","['gliomas', 'common', 'primary', 'intracranial', 'neoplasms', 'among', 'brain', 'malignancies', 'microtubule', 'affinity', 'regulating', 'kinases', 'marks', 'become', 'potential', 'drug', 'targets', 'glioma', 'report', 'novel', 'dual', 'smallmolecule', 'inhibitor', 'mark3', 'mark4', 'designated', 'pcc0208017', 'iin', 'vitroi', 'pcc0208017', 'strongly', 'inhibited', 'kinase', 'activity', 'mark3', 'mark4', 'strongly', 'reduced', 'proliferation', 'three', 'glioma', 'cell', 'lines', 'compound', 'attenuated', 'glioma', 'cell', 'migration', 'glioma', 'cell', 'invasion', 'angiogenesis', 'molecular', 'mechanism', 'studies', 'revealed', 'pcc0208017', 'decreased', 'phosphorylation', 'tau', 'disrupted', 'microtubule', 'dynamics', 'induced', 'g2m', 'phase', 'cell', 'cycle', 'arrest', 'iin', 'vivoi', 'glioma', 'model', 'pcc0208017', 'showed', 'robust', 'antitumor', 'activity', 'bloodbrain', 'barrier', 'permeability', 'good', 'oral', 'pharmacokinetic', 'profile', 'molecular', 'docking', 'studies', 'showed', 'pcc0208017', 'exhibited', 'high', 'binding', 'affinity', 'mark3', 'mark4', 'taken', 'together', 'study', 'describes', 'first', 'time', 'pcc0208017', 'novel', 'mark3mark4', 'inhibitor', 'might', 'promising', 'lead', 'compound', 'treatment', 'glioma']","['mark3', 'mark3', 'tau', 'mark3']","['mark3', 'mark3', 'mark3']",True,['tumor']
